FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Guo, L
Liu, F
Chen, S
Yang, X
Huang, J
He, J
Jaquish, CE
Zhao, Q
Gu, CC
Hixson, JE
Gu, D
AF Guo, L.
Liu, F.
Chen, S.
Yang, X.
Huang, J.
He, J.
Jaquish, C. E.
Zhao, Q.
Gu, C. C.
Hixson, J. E.
Gu, D.
TI Common variants in the Na+-coupled bicarbonate transporter genes and
salt sensitivity of blood pressure: the GenSalt study
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article
ID DIETARY-SODIUM; CARDIOVASCULAR-DISEASE; METABOLIC-ACIDOSIS; BASE-LINE;
HYPERTENSION; COTRANSPORTER; SYSTEM; POLYMORPHISMS; ASSOCIATION;
POTASSIUM
AB The current study comprehensively examined the association between common variants in the Na+-coupled bicarbonate transporter (NCBT) genes and blood pressure (BP) responses to dietary sodium intervention. A 7-day low-sodium followed by a 7-day high-sodium dietary intervention was conducted among 1906 Han participants from rural areas of northern China. Nine BP measurements were obtained at baseline and each intervention using a random-zero sphygmomanometer. A mixed-effect model was used to assess the additive associations of 76 common variants in five NCBT genes, including SLC4A4, SLC4A5, SLC4A7, SLC4A8 and SLC4A10, with salt sensitivity phenotypes. The Bonferroni method was used to adjust for multiple testing. SLC4A4 marker rs4254735 was significantly associated with diastolic BP (DBP) response to low-sodium intervention (P = 5.05 x 10(-4)), with mean (95% confidence interval (CI)) response of -2.91 (-3.21, -2.61) and -0.40 (-1.84, 1.05) mmHg for genotype AA and AG, respectively. In addition, BP responses to high-sodium intervention significantly increased with the number of minor C alleles of SLC4A4 marker rs10022637. Mean systolic BP responses among those with genotypes TT, CT and CC were 4.62 (4.29, 4.99), 5.94 (5.31, 6.58) and 6.00 (3.57, 8.43) mmHg (P = 1.14 x 10(-4)); mean DBP responses were 1.72 (1.41, 2.03), 3.22 (2.52, 3.92) and 3.94 (1.88, 5.99) mmHg (P = 2.26 x 10(-5)) and mean arterial pressure responses were 2.69 (2.40, 2.97), 4.13 (3.57, 4.70) and 4.61 (2.51, 6.71) mmHg (P = 2.07 x 10(-6)), respectively. In brief, the present study indicated that common variants in the SLC4A4 gene might contribute to the variation of BP responses to dietary sodium intake in Han Chinese population.
C1 [Guo, L.; Liu, F.; Chen, S.; Yang, X.; Huang, J.; Gu, D.] Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Dept Epidemiol, Fuwai Hosp,Natl Ctr Cardiovasc Dis, Beijing, Peoples R China.
[Guo, L.; Liu, F.; Chen, S.; Yang, X.; Huang, J.; Gu, D.] Peking Union Med Coll, 167 Beilishi Rd, Beijing 100037, Peoples R China.
[He, J.; Zhao, Q.] Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.
[Jaquish, C. E.] NHLBI, Div Prevent & Populat Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Gu, C. C.] Washington Univ, St Louis Sch Med, Div Biostat, St Louis, MO USA.
[Hixson, J. E.] Univ Texas Houston, Sch Publ Hlth, Dept Epidemiol, Houston, TX USA.
RP Gu, D (reprint author), Peking Union Med Coll, 167 Beilishi Rd, Beijing 100037, Peoples R China.; Gu, D (reprint author), Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, State Key Lab Cardiovasc Dis, 167 Beilishi Rd, Beijing 100037, Peoples R China.
EM gudongfeng@vip.sina.com
FU National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, MD, USA [U01HL072507, R01HL087263, R01HL090682];
High-Tech Research and Development Program of China (863 Plan) from the
Ministry of Science and Technology of China [2012AA02A516]
FX The Genetic Epidemiology Network of Salt Sensitivity (GenSalt) is
supported by research grants (U01HL072507, R01HL087263 and R01HL090682)
from the National Heart, Lung, and Blood Institute, National Institutes
of Health, Bethesda, MD, USA. This study is also funded by a research
grant (2012AA02A516) from the High-Tech Research and Development Program
of China (863 Plan) from the Ministry of Science and Technology of
China.
NR 33
TC 2
Z9 2
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9240
EI 1476-5527
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
PD SEP
PY 2016
VL 30
IS 9
BP 543
EP 548
DI 10.1038/jhh.2015.113
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DT2OA
UT WOS:000381318500005
PM 26582410
ER
PT J
AU Perera, AP
Mehta, GU
Pratt, D
Quezado, MM
Gilbert, MR
Heiss, JD
AF Perera, Andrea P.
Mehta, Gautam U.
Pratt, Drew
Quezado, Martha M.
Gilbert, Mark R.
Heiss, John D.
TI Diagnosis of a growing radiation-induced skull lesion in a patient: an
unusual scar
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE fibroblast; lesion; skull; radiotherapy; oncology
ID INDUCED FIBROSIS; CRANIAL FASCIITIS; DIFFERENTIATION; RADIOTHERAPY
AB New lesions arising from within an area of previous irradiation often present a diagnostic dilemma, with new malignancy or metastasis of particular concern. The authors report a case of reactive fibroblast proliferation emerging from a previous radiation field and presenting as a growing lesion of the frontal and parietal skull. Following complete gross resection of the skull lesion and histopathological analysis, it was discovered that this lesion consisted of dense fibroblast proliferation with areas of osteonecrosis. This unusual reactive phenomenon offers a novel differential diagnosis for a new contrast-enhancing lesion in a region of previous radiation.
C1 [Perera, Andrea P.] Queen Mary Univ London, Barts & London SMD, London, England.
[Perera, Andrea P.; Mehta, Gautam U.; Heiss, John D.] NINDS, Surg Neurol Branch, 10 Ctr Dr,Rm 3D20,MSC 1414, Bethesda, MD 20892 USA.
[Pratt, Drew; Quezado, Martha M.] NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Gilbert, Mark R.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Heiss, JD (reprint author), NINDS, NIH, Surg Neurol Branch, 10 Ctr Dr,Rm 3D20,MSC 1414, Bethesda, MD 20892 USA.
EM heissj@ninds.nih.gov
OI Heiss, John/0000-0002-3890-0165
FU Intramural Research Program at the National Institute of Neurological
Disorders; Stroke (NINDS) at the National Institutes of Health (NIH)
FX This work was supported by the Intramural Research Program at the
National Institute of Neurological Disorders and Stroke (NINDS) at the
National Institutes of Health (NIH).
NR 14
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD SEP
PY 2016
VL 125
IS 3
BP 561
EP 564
DI 10.3171/2015.7.JNS15989
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA DT8YS
UT WOS:000381782300005
PM 26684773
ER
PT J
AU Mertan, FV
Greer, MD
Shih, JH
George, AK
Kongnyuy, M
Muthigi, A
Merino, MJ
Wood, BJ
Pinto, PA
Choyke, PL
Turkbey, B
AF Mertan, Francesca V.
Greer, Matthew D.
Shih, Joanna H.
George, Arvin K.
Kongnyuy, Michael
Muthigi, Akhil
Merino, Maria J.
Wood, Bradford J.
Pinto, Peter A.
Choyke, Peter L.
Turkbey, Baris
TI Prospective Evaluation of the Prostate Imaging Reporting and Data System
Version 2 for Prostate Cancer Detection
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostate; magnetic resonance imaging; diffusion magnetic resonance
imaging
ID PI-RADS; BIOPSY; GUIDELINES; DIAGNOSIS; FUSION
AB Purpose: Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) was developed to standardize the interpretation and reporting of multiparametric prostate magnetic resonance imaging and provide guidelines for biopsy of multiparametric magnetic resonance imaging findings. We prospectively evaluated the cancer detection rate at each overall PI-RADSv2 score.
Materials and Methods: This prospective study included 62 consecutive patients with 116 lesions who underwent multiparametric prostate magnetic resonance imaging at 3T with PI-RADSv2 evaluation and subsequent targeted magnetic resonance imaging/transrectal ultrasound fusion guided biopsy and concurrent 12-core systematic prostate biopsy between May and September 2015. Median patient age and prostate specific antigen values were 65.5 years( range 50.3 to 76.6) and 7.10 ng/ml( range 0.47 to 863.0), respectively. Mean lesion size was 12.7 mm overall. Lesion based cancer detection rates for all tumors and for Gleason 3+4 or greater tumors at each PI-RADSv2 score were calculated. Univariate analysis was performed to assess differences in the cancer detection rate among PI-RADSv2 scores.
Results: A total of 116 lesions in 62 patients were evaluated prospectively ( 0 PI-RADS 1, 18 PI-RADS 2, 19 PI-RADS 3, 47 PI-RADS 4, 32 PI-RADS 5), and the patients underwent magnetic resonance/transrectal ultrasound fusion guided biopsy and systematic biopsy. Histopathology revealed 55 of 116( 47.4%) cancers( 17 Gleason 3+3, 16 Gleason 3+4, 6 Gleason 4+3, 12 Gleason 4+4, 3 Gleason 4+5 and 1 Gleason 5+4). Based on targeted biopsy on a per lesion basis, the overall cancer detection rates of PI-RADS 2, 3, 4 and 5 scores for all tumors was 22.2%, 15.8%, 29.8% and 78.1%, respectively. The cancer detection rate of PI-RADS 2, 3, 4 and 5 scores for Gleason 3_4 or greater tumors was 5.6%, 0%, 21.3% and 75%, respectively. Differences in the cancer detection rate between overall PI-RADS 4 and 5 scores were significant( p < 0.001 for Gleason greater than 3+3 and Gleason 3+4 or greater cancers).
Conclusions: A PI-RADS score of 5 had the highest prospective cancer detection rate (78%). A PI-RADS score of 4 had only a 30% cancer detection rate, which is lower than expected. Surprisingly, no or few significant cancers were detected at a PI-RADS score of 3 (16%). These early prospective data suggest that current criteria result in a high false-positive rate that lowers the cancer detection rate. Therefore, stricter criteria may be needed in the future to decrease false-positives and increase the cancer detection rate for PI-RADS scores of 3, 4 and 5.
C1 [Mertan, Francesca V.; Greer, Matthew D.; Choyke, Peter L.; Turkbey, Baris] NCI, Mol Imaging Program, 10 Ctr Dr,MSC 1182,Bldg 10,Room B3B85, Bethesda, MD 20892 USA.
[George, Arvin K.; Kongnyuy, Michael; Muthigi, Akhil; Pinto, Peter A.] NCI, Urol Oncol Branch, Bethesda, MD 20892 USA.
[Merino, Maria J.] NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA.
[Wood, Bradford J.] NCI, Ctr Intervent Oncol, Bethesda, MD 20892 USA.
[Wood, Bradford J.] NIH, Ctr Clin, Radiol & Imaging Sci, Bethesda, MD 20892 USA.
[Shih, Joanna H.] NCI, Div Canc Treatment & Diag, Biometr Res Program, NIH, Rockville, MD USA.
RP Turkbey, B (reprint author), NCI, Mol Imaging Program, 10 Ctr Dr,MSC 1182,Bldg 10,Room B3B85, Bethesda, MD 20892 USA.
EM turkbeyi@mail.nih.gov
OI Greer, Matthew/0000-0003-4409-4398
NR 14
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 2016
VL 196
IS 3
BP 690
EP 696
DI 10.1016/j.juro.2016.04.057
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DT1WF
UT WOS:000381272100019
PM 27101772
ER
PT J
AU Turkbey, B
Pinto, PA
AF Turkbey, Baris
Pinto, Peter A.
TI Serial Anatomical Prostate Ultrasound during Prostate Cancer Active
Surveillance
SO JOURNAL OF UROLOGY
LA English
DT Editorial Material
C1 [Turkbey, Baris; Pinto, Peter A.] NCI, NIH, Bethesda, MD 20892 USA.
RP Turkbey, B (reprint author), NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 2016
VL 196
IS 3
BP 733
EP 733
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA DT1WF
UT WOS:000381272100029
PM 27264350
ER
PT J
AU Chai, TC
Moalli, PA
Richter, HE
Lake, AG
Kim, HY
Nager, CW
Sirls, LT
Brubaker, L
Kusek, JW
AF Chai, Toby C.
Moalli, Pamela A.
Richter, Holly E.
Lake, AeuMuro G.
Kim, Hae-Young
Nager, Charles W.
Sirls, Larry T.
Brubaker, Linda
Kusek, John W.
TI Preoperative Urodynamic Parameters (Valsalva Leak Point Pressure and
Maximum Urethral Closure Pressure), Urinary Collagen and Plasma Vitamin
D Levels as Predictors of Mid Urethral Sling Surgery Outcome
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urethra; suburethral sling; urodynamics; biomarkers; outcome assessment
(health care)
ID NUTRITION-EXAMINATION-SURVEY; NATIONAL-HEALTH; N-TELOPEPTIDE; WOMEN;
INCONTINENCE
AB Purpose: To determine the best predictor of the mid urethral sling outcome we calculated the AUC of ROC curves of preoperative parameters, including Valsalva leak point pressure, maximum urethral closure pressure, urinary NTx (N-telopeptide of crosslinked type I collagen) and plasma vitamin D values (D2, D3 and D2 plus D3).
Materials and Methods: This was an ancillary study of TOMUS (Trial of Mid-urethral Slings) and the ValUE (Value of Urodynamics Evaluation) trial in which subjects underwent mid urethral sling surgery for stress urinary incontinence. Valsalva leak point pressure and maximum urethral closure pressure were measured in 427 subjects, whereas NTx, vitamin D2, vitamin D3 and vitamin D2 plus D3 levels were obtained from 150, 116, 115 and 116 subjects respectively. Outcome success was defined using identical outcome (subjective and objective) variables for all subjects. ROC curves with corresponding AUC values were compared.
Results: TOMUS and ValUE subjects were significantly different in age, body mass index, UDI (Urogenital Distress Inventory) scores. TOMUS subjects had a lower surgical success rate compared to ValUE subjects (66.3% vs 76.0%, p = 0.03). The AUC values of Valsalva leak point pressure, maximum urethral closure pressure, NTx, and vitamins D2, D3 and D2 plus D3 were 0.542, 0.561, 0.702, 0.627, 0.645 and 0.640, respectively. The AUC of NTx was significantly higher than the AUCs of Valsalva leak point pressure and maximum urethral closure pressure (p = 0.02 and 0.03, respectively).
Conclusions: Urinary NTx was the best predictor of the mid urethral sling outcome. This test is not only noninvasive, it is also modifiable. Finding ideal modifiable risk factors prior to mid urethral sling surgery should be subject to future investigations.
C1 [Chai, Toby C.; Lake, AeuMuro G.] Yale Univ, Sch Med, Dept Urol, 789 Howard Ave,FMP 309,POB 208058, New Haven, CT 06520 USA.
[Chai, Toby C.; Lake, AeuMuro G.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.
[Moalli, Pamela A.] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA.
[Richter, Holly E.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA.
[Kim, Hae-Young] New England Res Inst, 9 Galen St, Watertown, MA 02172 USA.
[Nager, Charles W.] Univ Calif San Diego, Dept Reprod Med, San Diego, CA 92103 USA.
[Sirls, Larry T.] Beaumont Hosp, Dept Urol, Royal Oak, MI USA.
[Brubaker, Linda] Loyola Univ, Chicago, IL 60611 USA.
[Kusek, John W.] NIDDK, Bethesda, MD 20892 USA.
RP Chai, TC (reprint author), Yale Univ, Sch Med, Dept Urol, 789 Howard Ave,FMP 309,POB 208058, New Haven, CT 06520 USA.
EM toby.chai@yale.edu
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases [U01-DK058229]
FX Supported by National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Diseases U01-DK058229.
NR 13
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 2016
VL 196
IS 3
BP 819
EP 823
DI 10.1016/j.juro.2016.03.177
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA DT1WF
UT WOS:000381272100065
PM 27113967
ER
PT J
AU Garcia-Beltran, WF
Holzemer, A
Martrus, G
Chung, AW
Pacheco, Y
Simoneau, CR
Rucevic, M
Lamothe-Molina, PA
Pertel, T
Kim, TE
Dugan, H
Alter, G
Dechanet-Merville, J
Jost, S
Carrington, M
Altfeld, M
AF Garcia-Beltran, Wilfredo F.
Hoelzemer, Angelique
Martrus, Gloria
Chung, Amy W.
Pacheco, Yovana
Simoneau, Camille R.
Rucevic, Marijana
Lamothe-Molina, Pedro A.
Pertel, Thomas
Kim, Tae-Eun
Dugan, Haley
Alter, Galit
Dechanet-Merville, Julie
Jost, Stephanie
Carrington, Mary
Altfeld, Marcus
TI Open conformers of HLA-F are high-affinity ligands of the activating
NK-cell receptor KIR3DS1
SO NATURE IMMUNOLOGY
LA English
DT Article
ID IMMUNOGLOBULIN-LIKE RECEPTOR; NATURAL-KILLER-CELL; MHC-I MOLECULES;
CUTTING EDGE; DISEASE PROGRESSION; SURFACE EXPRESSION; PROTEIN; HIV-1;
ANTIBODIES; COMPLEX
AB The activating natural killer (NK)-cell receptor KIR3DS1 has been linked to the outcome of various human diseases, including delayed progression of disease caused by human immunodeficiency virus type 1 (HIV-1), yet a ligand that would account for its biological effects has remained unknown. We screened 100 HLA class I proteins and found that KIR3DS1 bound to HLA-F, a result we confirmed biochemically and functionally. Primary human KIR3DS1(+) NK cells degranulated and produced antiviral cytokines after encountering HLA-F and inhibited HIV-1 replication in vitro. Activation of CD4(+) T cells triggered the transcription and surface expression of HLA-F mRNA and HLA-F protein, respectively, and induced binding of KIR3DS1. HIV-1 infection further increased the transcription of HLA-F mRNA but decreased the binding of KIR3DS1, indicative of a mechanism for evading recognition by KIR3DS1(+) NK cells. Thus, we have established HLA-F as a ligand of KIR3DS1 and have demonstrated cell-context-dependent expression of HLA-F that might explain the widespread influence of KIR3DS1 in human disease.
C1 [Garcia-Beltran, Wilfredo F.; Hoelzemer, Angelique; Chung, Amy W.; Pacheco, Yovana; Simoneau, Camille R.; Rucevic, Marijana; Lamothe-Molina, Pedro A.; Kim, Tae-Eun; Dugan, Haley; Alter, Galit; Jost, Stephanie; Carrington, Mary; Altfeld, Marcus] MGH MIT & Harvard, Ragon Inst, Cambridge, MA USA.
[Hoelzemer, Angelique; Martrus, Gloria; Altfeld, Marcus] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany.
[Hoelzemer, Angelique] Univ Med Ctr Eppendorf, Dept Internal Med 1, Hamburg, Germany.
[Pacheco, Yovana] Univ Nuestra Senora Rosario, Fac Ciencias, Dept Maternat, Bogota, Colombia.
[Pertel, Thomas] Harvard Med Sch, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA USA.
[Dechanet-Merville, Julie] Univ Bordeaux, CNRS, UMR 5164, Bordeaux, France.
[Carrington, Mary] Frederick Natl Lab Canc Res, Canc & Inflammat Program, Expt Immunol Lab, Leidos Biomed Res, Frederick, MD USA.
RP Altfeld, M (reprint author), MGH MIT & Harvard, Ragon Inst, Cambridge, MA USA.; Altfeld, M (reprint author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany.
EM marcus.altfeld@hpi.uni-hamburg.de
FU Ragon Institute Flow Cytometry Core and Virology Core; US National
Institutes of Health [R01-AI067031-08, P01-AI104715, F31AI116366]; US
National Institutes of Health (Intramural Research Program, Frederick
National Lab, Center for Cancer Research); National Institute of General
Medical Sciences [T32GM007753]; Ragon Institute of MGH; Ragon Institute
of MIT; Ragon Institute of Harvard; Frederick National Laboratory for
Cancer Research [HHSN261200800001E]; Heinrich-Pette Institute-Leibniz
Institute for Experimental Virology (Program Area Antiviral Targets and
Strategies); German Center for Infection Research
FX We thank C. Korner and A. Crespo for advice and discussions; D. Campana
(St. Jude Children's Research Hospital) for K562 cells expressing
mbIL-15 and CD137L; C. Brander (Ragon Institute of MGH, MIT, and
Harvard) for 721.221 cells transduced to express HLA; J. Strominger
(Harvard University) for 721.221-HLA-G cells; F. Zhang (Broad Institute
of MIT and Harvard) for the lentiCas9-Blast plasmid; L. Ferreira
(Harvard University) and T. Meissner (Harvard University) for
beta2m-targeting single-guide RNA plasmid; and the Ragon
Institute Flow Cytometry Core and Virology Core for support and
assistance. Supported by the US National Institutes of Health
(R01-AI067031-08 and P01-AI104715; F31AI116366 to W.F.G.-B.; the
Intramural Research Program, Frederick National Lab, Center for Cancer
Research), the National Institute of General Medical Sciences
(T32GM007753), the Ragon Institute of MGH, MIT and Harvard, the
Frederick National Laboratory for Cancer Research (HHSN261200800001E),
the Heinrich-Pette Institute-Leibniz Institute for Experimental Virology
(Program Area Antiviral Targets and Strategies) and the German Center
for Infection Research. The content is solely the responsibility of the
authors and does not necessarily represent the official views or
policies of the National Institute of General Medical Sciences, the
National Institutes of Health, or the Department of Health and Human
Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the US Government.
NR 50
TC 6
Z9 6
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD SEP
PY 2016
VL 17
IS 9
BP 1067
EP 1074
DI 10.1038/ni.3513
PG 8
WC Immunology
SC Immunology
GA DT9OO
UT WOS:000381832000010
PM 27455421
ER
PT J
AU Heilig, M
Epstein, DH
Nader, MA
Shaham, Y
AF Heilig, Markus
Epstein, David H.
Nader, Michael A.
Shaham, Yavin
TI Time to connect: bringing social context into addiction neuroscience
SO NATURE REVIEWS NEUROSCIENCE
LA English
DT Review
ID OPIOID-RECEPTOR GENE; CORTICOTROPIN-RELEASING-FACTOR; PLACEBO-CONTROLLED
TRIAL; RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS;
ALCOHOL-DEPENDENCE; DRUG-ADDICTION; ANIMAL-MODELS; DOUBLE-BLIND;
ATTACHMENT BEHAVIOR
AB Research on the neural substrates of drug reward, withdrawal and relapse has yet to be translated into significant advances in the treatment of addiction. One potential reason is that this research has not captured a common feature of human addiction: progressive social exclusion and marginalization. We propose that research aimed at understanding the neural mechanisms that link these processes to drug seeking and drug taking would help to make addiction neuroscience research more clinically relevant.
C1 [Heilig, Markus] Linkoping Univ, Ctr Social & Affect Neurosci, Dept Clin & Expt Med IKE, SE-58183 Linkoping, Sweden.
[Epstein, David H.; Shaham, Yavin] NIDA, Intramural Res Program, NIH, Baltimore, MD 21044 USA.
[Nader, Michael A.] Wake Forest Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.
RP Heilig, M (reprint author), Linkoping Univ, Ctr Social & Affect Neurosci, Dept Clin & Expt Med IKE, SE-58183 Linkoping, Sweden.
EM markus.heilig@liu.se
FU Swedish Research Council; Intramural Research Program of the US National
Institutes of Health; US National Institute on Drug Abuse [DA010584,
DA017763]
FX The writing of this article was supported in part by a grant from the
Swedish Research Council (M.H.), the Intramural Research Program of the
US National Institutes of Health and the US National Institute on Drug
Abuse (D.H.E. and Y.S.) and grants DA010584 and DA017763 (M.A.N.). The
authors are grateful to S. N. Haber at the University of Rochester, New
York, USA, and her co-workers for producing and providing Figure 3. The
authors apologize to their many friends and colleagues for not citing
many reviews and empirical papers relevant to the topic of their paper,
owing to format restrictions.
NR 127
TC 4
Z9 4
U1 11
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-003X
EI 1471-0048
J9 NAT REV NEUROSCI
JI Nat. Rev. Neurosci.
PD SEP
PY 2016
VL 17
IS 9
BP 592
EP 599
DI 10.1038/nrn.2016.67
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA DU5MK
UT WOS:000382255600012
PM 27277868
ER
PT J
AU Bandres-Ciga, S
Price, TR
Barrero, FJ
Escamilla-Sevilla, F
Pelegrina, J
Arepalli, S
Hernandez, D
Gutierrez, B
Cervilla, J
Rivera, M
Rivera, A
Ding, JH
Vives, F
Nalls, M
Singleton, A
Duran, R
AF Bandres-Ciga, Sara
Price, Timothy Ryan
Barrero, Francisco Javier
Escamilla-Sevilla, Francisco
Pelegrina, Javier
Arepalli, Sampath
Hernandez, Dena
Gutierrez, Blanca
Cervilla, Jorge
Rivera, Margarita
Rivera, Alberto
Ding, Jing-hui
Vives, Francisco
Nalls, Michael
Singleton, Andrew
Duran, Raquel
TI Genome-wide assessment of Parkinson's disease in a Southern Spanish
population
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Parkinson's disease; Genetics; GWAS; Southern Spain
ID RISK LOCI; GENETIC RISK; MUTATIONS; ASSOCIATION; ONSET; METAANALYSIS;
AGE; IDENTIFICATION; VARIANTS; COMPLEX
AB Here, we set out to study the genetic architecture of Parkinson's disease (PD) through a Genome-Wide Association Study in a Southern Spanish population. About 240 PD cases and 192 controls were geno-typed on the NeuroX array. We estimated genetic variation associated with PD risk and age at onset (AAO). Risk profile analyses for PD and AAO were performed using a weighted genetic risk score. Total heritability was estimated by genome-wide complex trait analysis. Rare variants were screened with single-variant and burden tests. We also screened for variation in known PD genes. Finally, we explored runs of homozygosity and structural genomic variations. We replicate PD association (uncorrected p-value < 0.05) at the following loci: ACMSD/TMEM163, MAPT, STK39, MIR4697, and SREBF/RAI1. Subjects in the highest genetic risk score quintile showed significantly increased risk of PD versus the lowest quintile (odds ratio - 3.6, p-value < 4e(-7)), but no significant difference in AAO. We found evidence of runs of homozygosity in 2 PD-associated regions: one intersecting the HLA-DQB1 gene in 6 patients and 1 control; and another intersecting the GBA-SYT11 gene in PD case. The GBA N370S and the LRRK2 G2019S variants were found in 8 and 7 cases, respectively, replicating previous work. A structural variant was found in 1 case in the PARK2 gene locus. This current work represents a comprehensive assessment at a genome-wide level characterizing a novel population in PD genetics. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Bandres-Ciga, Sara; Vives, Francisco; Duran, Raquel] Univ Granada, Ctr Invest Biomed CIBM, Dept Physiol, Granada 18016, Spain.
[Bandres-Ciga, Sara; Gutierrez, Blanca; Cervilla, Jorge; Rivera, Margarita; Vives, Francisco; Duran, Raquel] Univ Granada, Ctr Invest Biomed CIBM, Inst Neurosci Federico Oloriz, Granada 18016, Spain.
[Price, Timothy Ryan; Arepalli, Sampath; Hernandez, Dena; Rivera, Alberto; Ding, Jing-hui; Nalls, Michael; Singleton, Andrew] NIA, Neurogenet Lab, NIH, Bethesda, MD USA.
[Barrero, Francisco Javier; Pelegrina, Javier] Univ Hosp San Cecilio, Movement Disorders Unit, Granada, Spain.
[Escamilla-Sevilla, Francisco] Univ Hosp Virgen Nieves, Inst Invest Biosanitaria IBS, Dept Neurol, Movement Disorders Unit, Granada, Spain.
[Gutierrez, Blanca; Cervilla, Jorge; Rivera, Margarita] Univ Granada, Ctr Invest Biomed CIBM, Dept Psychiat, Granada, Spain.
[Gutierrez, Blanca; Cervilla, Jorge; Rivera, Margarita] Univ Granada, CIBER Salud Mental CIBERSAM, Granada, Spain.
RP Duran, R (reprint author), Univ Granada, Ctr Invest Biomed CIBM, Dept Physiol, Granada 18016, Spain.; Duran, R (reprint author), Univ Granada, Ctr Invest Biomed CIBM, Inst Neurosci Federico Oloriz, Granada 18016, Spain.
EM rduran@ugr.es
RI Cervilla, Jorge/O-2106-2016; DURAN , RAQUEL/D-7784-2016;
OI Cervilla, Jorge/0000-0001-6891-1992; DURAN , RAQUEL/0000-0002-5749-8968;
Bandres Ciga, Sara/0000-0003-0056-1361
FU Intramural Research Program of the National Institute on Aging, National
Institutes of Health, Department of Health and Human Services [ZO1
AG000949]; Junta de Andalucia [PI0322/2009]; Andalusian Society of
Neurology; FPU fellowship [FPU12-01885]; Spanish Ministry of Education
and Science [EST14/0061]; [CVI-6476]; [PSI2014-57643]
FX The authors are grateful to the participants in this study without whom
this work would not have been possible. Sara Bandres Ciga and Timothy
Ryan Price contributed equally to this work. Andrew Singleton, Michael
Nalls, Dena Hernandez, Raquel Duran, and Francisco Vives contributed to
study concept, design, revision, and critique. Sampath Arepalli and Sara
Bandres Ciga contributed for execution of the laboratory work. Timothy
Ryan Price, Sara Bandres Ciga, Alberto Rivera, and Jing-Hui Ding
contributed for data analysis. Francisco Barrero-Hernandez, Francisco
Escamilla-Sevilla, Javier Pelegrina, Blanca Gutierrez, Jorge Cervilla,
and Margarita Rivera contributed to neurological-clinical assessment,
patient and control recruitment, and sample collection. This work was
supported in part by the Intramural Research Program of the National
Institute on Aging, National Institutes of Health, part of the
Department of Health and Human Services (project ZO1 AG000949), the
following grants from the Junta de Andalucia; PI0322/2009 to the group
CTS-6682; CVI-6476 and PSI2014-57643 to the CTS-438 group, and a
research award from the Andalusian Society of Neurology. Sara Bandres
Ciga held an FPU fellowship FPU12-01885 and a short-term stay grant
EST14/0061 from the Spanish Ministry of Education and Science.
NR 45
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD SEP
PY 2016
VL 45
AR 213.e3
DI 10.1016/j.neurobiolaging.2016.06.001
PG 7
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA DS9HF
UT WOS:000381092900026
PM 27393345
ER
PT J
AU Padayatty, SJ
Levine, M
AF Padayatty, S. J.
Levine, M.
TI Vitamin C: the known and the unknown and Goldilocks
SO ORAL DISEASES
LA English
DT Review
DE vitamin C; dehydroascorbic acid; vitamin C transport; scurvy;
dose-concentration relationship; recommended dietary allowance
ID L-ASCORBIC-ACID; HYPOXIA-INDUCIBLE FACTOR; RECOMMENDED DIETARY
ALLOWANCE; CHRONIC GRANULOMATOUS-DISEASE; PAROXYSMAL-NOCTURNAL
HEMOGLOBINURIA; ENDOTHELIUM-DEPENDENT VASODILATION; PERFORMANCE
LIQUID-CHROMATOGRAPHY; HUMAN ERYTHROCYTE-MEMBRANES; ACUTE
MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL
AB Vitamin C (Ascorbic Acid), the antiscorbutic vitamin, cannot be synthesized by humans and other primates, and has to be obtained from diet. Ascorbic acid is an electron donor and acts as a cofactor for fifteen mammalian enzymes. Two sodium-dependent transporters are specific for ascorbic acid, and its oxidation product dehydroascorbic acid is transported by glucose transporters. Ascorbic acid is differentially accumulated by most tissues and body fluids. Plasma and tissue vitamin C concentrations are dependent on amount consumed, bioavailability, renal excretion, and utilization. To be biologically meaningful or to be clinically relevant, in vitro and in vivo studies of vitamin C actions have to take into account physiologic concentrations of the vitamin. In this paper, we review vitamin C physiology; the many phenomena involving vitamin C where new knowledge has accrued or where understanding remains limited; raise questions about the vitamin that remain to be answered; and explore lines of investigations that are likely to be fruitful.
C1 [Padayatty, S. J.; Levine, M.] NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Room 4D52,MSC 1372, Bethesda, MD 20892 USA.
RP Padayatty, SJ (reprint author), NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Room 4D52,MSC 1372, Bethesda, MD 20892 USA.
EM sebastianp@intra.niddk.nih.gov
FU Intramural Research Program, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health
[1ZIADK053211-08]
FX This work was supported by the Intramural Research Program, National
Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health (Project no: 1ZIADK053211-08). SJP thanks Drs.
Michael Espey, Peter Eck, and Nermi Parrow for helpful suggestions; Dr.
Eck for information on SVCT SNPs deposited in databases; and Ethan
Tyler, NIH Medical Arts, for new and modified illustrations.
NR 331
TC 1
Z9 1
U1 23
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1354-523X
EI 1601-0825
J9 ORAL DIS
JI Oral Dis.
PD SEP
PY 2016
VL 22
IS 6
BP 463
EP 493
DI 10.1111/odi.12446
PG 31
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DS8PB
UT WOS:000381044200003
PM 26808119
ER
PT J
AU Arimbasseri, AG
Iben, J
Wei, FY
Rijal, K
Tomizawa, K
Hafner, M
Maraia, RJ
AF Arimbasseri, Aneeshkumar G.
Iben, James
Wei, Fan-Yan
Rijal, Keshab
Tomizawa, Kazuhito
Hafner, Markus
Maraia, Richard J.
TI Evolving specificity of tRNA 3-methyl-cytidine-32 (m(3)C32)
modification: a subset of tRNAs(Ser) requires N-6-isopentenylation of
A37
SO RNA
LA English
DT Article
DE anticodon loop; isopentenylation; tRNA-HySeq
ID MULTIPLE SEQUENCE ALIGNMENT; TRNA(PHE) ANTICODON LOOP; BINDING PROTEIN
ABP140; SERINE TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE;
THERMUS-THERMOPHILUS; NUCLEOTIDE-SEQUENCES; HIGH-THROUGHPUT; BOVINE
LIVER; LA PROTEIN
AB Post-transcriptional modifications of anticodon loop (ACL) nucleotides impact tRNA structure, affinity for the ribosome, and decoding activity, and these activities can be fine-tuned by interactions between nucleobases on either side of the anticodon. A recently discovered ACL modification circuit involving positions 32, 34, and 37 is disrupted by a human disease-associated mutation to the gene encoding a tRNA modification enzyme. We used tRNA-HydroSeq (-HySeq) to examine (3)methyl-cytidine-32 (m(3)C32), which is found in yeast only in the ACLs of tRNAs(Ser) and tRNAs(Thr). In contrast to that reported for Saccharomyces cerevisiae in which all m(3)C32 depends on a single gene, TRM140, the m(3)C32 of tRNAs(Ser) and tRNAs(Thr) of the fission yeast S. pombe, are each dependent on one of two related genes, trm140(+) and trm141(+), homologs of which are found in higher eukaryotes. Interestingly, mammals and other vertebrates contain a third homolog and also contain m(3)C at new sites, positions 32 on tRNAs(Arg) and C47:3 in the variable arm of tRNAs(Ser). More significantly, by examining S. pombe mutants deficient for other modifications, we found that m(3)C32 on the three tRNAs(Ser) that contain anticodon base A36, requires N-6-isopentenyl modification of A37 (i(6)A37). This new C32 A37 ACL circuitry indicates that i(6)A37 is a pre- or corequisite for m(3)C32 on these tRNAs. Examination of the tRNA database suggests that such circuitry may be more expansive than observed here. The results emphasize two contemporary themes, that tRNA modifications are interconnected, and that some specific modifications on tRNAs of the same anticodon identity are species-specific.
C1 [Arimbasseri, Aneeshkumar G.; Iben, James; Rijal, Keshab] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Wei, Fan-Yan; Tomizawa, Kazuhito] Kumamoto Univ, Dept Mol Physiol, Fac Life Sci, Kumamoto 8600862, Japan.
[Hafner, Markus] NIAMSD, Natl Inst Hlth, Bethesda, MD 20892 USA.
[Maraia, Richard J.] US PHS, Commissioned Corps, Washington, DC 20201 USA.
[Arimbasseri, Aneeshkumar G.] North Carolina State Univ, Dept Biomol & Chem Engn, Raleigh, NC 27606 USA.
RP Maraia, RJ (reprint author), US PHS, Commissioned Corps, Washington, DC 20201 USA.
EM maraiar@mail.nih.gov
OI Arimbasseri, Gopalakrishnan Aneeshkumar/0000-0001-5266-2688
FU Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development; National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of
Health
FX A.G.A. thanks S. Mattijssen for cell lines and advice with tissue
culture, and M. Blum for media preparation. This work was supported by
the Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, and National Institute
of Arthritis and Musculoskeletal and Skin Diseases, National Institutes
of Health.
NR 57
TC 1
Z9 1
U1 0
U2 1
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1355-8382
EI 1469-9001
J9 RNA
JI RNA
PD SEP
PY 2016
VL 22
IS 9
BP 1400
EP 1410
DI 10.1261/rna.056259.116
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DU1GV
UT WOS:000381957100011
PM 27354703
ER
PT J
AU Koob, GF
AF Koob, George F.
TI Corticotropin-Releasing Factor From Rodents to Primates: Translational
Hope Expresses Itself, Pun Intended
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID STRESS; BEHAVIORS; CRF
C1 [Koob, George F.] NIAAA, NIH, Bethesda, MD USA.
RP Koob, GF (reprint author), NIAAA, 5635 Fishers Lane,Room 2001,Suite 2000, Rockville, MD 20852 USA.
EM george.koob@nih.gov
RI koob, george/P-8791-2016
NR 10
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD SEP 1
PY 2016
VL 80
IS 5
BP 340
EP 342
DI 10.1016/j.biopsych.2016.06.015
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DS5RR
UT WOS:000380840500004
PM 27499011
ER
PT J
AU Grillon, C
Ernst, M
AF Grillon, Christian
Ernst, Monique
TI Gain in Translation: Is It Time for Thigmotaxis Studies in Humans?
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID PROGRESS; ANXIETY; MODEL
C1 [Grillon, Christian; Ernst, Monique] NIMH, Sect Neurobiol Fear & Anxiety, NIH, Bethesda, MD 20892 USA.
RP Grillon, C (reprint author), NIMH, MAP, 15K North Dr,Bldg 15K,Room 203,MSC 2670, Bethesda, MD 20892 USA.
EM christian.grillon@nih.gov
FU Intramural NIH HHS [Z01 MH002798-07]; NIMH NIH HHS [Z01 MH002798]
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD SEP 1
PY 2016
VL 80
IS 5
BP 343
EP 344
DI 10.1016/j.biopsych.2016.07.003
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DS5RR
UT WOS:000380840500005
PM 27499012
ER
PT J
AU Lansford, JE
Bornstein, MH
Deater-Deckard, K
Dodge, KA
Al-Hassan, SM
Bacchini, D
Bombi, AS
Chang, L
Chen, BB
Di Giunta, L
Malone, PS
Oburu, P
Pastorelli, C
Skinner, AT
Sorbring, E
Steinberg, L
Tapanya, S
Alampay, LP
Tirado, LMU
Zelli, A
AF Lansford, Jennifer E.
Bornstein, Marc H.
Deater-Deckard, Kirby
Dodge, Kenneth A.
Al-Hassan, Suha M.
Bacchini, Dario
Bombi, Anna Silvia
Chang, Lei
Chen, Bin-Bin
Di Giunta, Laura
Malone, Patrick S.
Oburu, Paul
Pastorelli, Concetta
Skinner, Ann T.
Sorbring, Emma
Steinberg, Laurence
Tapanya, Sombat
Alampay, Liane P.
Uribe Tirado, Liliana M.
Zelli, Arnaldo
TI How International Research on Parenting Advances Understanding of Child
Development
SO CHILD DEVELOPMENT PERSPECTIVES
LA English
DT Article
DE child development; culture; international research; parenting
ID 9 COUNTRIES; ACCEPTANCE-REJECTION; ADJUSTMENT; DISCIPLINE;
NORMATIVENESS; ASSOCIATIONS; AMERICAN; CULTURE; CHINESE; WARMTH
AB International research on parenting and child development can advance our understanding of similarities and differences in how parenting is related to children's development across countries. Challenges to conducting international research include operationalizing culture, disentangling effects within and between countries, and balancing emic and etic perspectives. Benefits of international research include testing whether findings regarding parenting and child development replicate across diverse samples, incorporating cultural and contextual diversity to foster more inclusive and representative research samples and investigators than has typically occurred, and understanding how children develop in proximal parenting and family and distal international contexts.
C1 [Lansford, Jennifer E.; Dodge, Kenneth A.; Malone, Patrick S.; Skinner, Ann T.] Duke Univ, Durham, NC 27706 USA.
[Bornstein, Marc H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Deater-Deckard, Kirby] Univ Massachusetts, Amherst, MA 01003 USA.
[Al-Hassan, Suha M.] Hashemite Univ, Zarqa, Jordan.
[Al-Hassan, Suha M.] Emirates Coll Adv Educ, Abu Dhabi, U Arab Emirates.
[Bacchini, Dario] Univ Naples 2, Naples, Italy.
[Bombi, Anna Silvia; Di Giunta, Laura; Pastorelli, Concetta] Univ Roma La Sapienza, Rome, Italy.
[Chang, Lei] Univ Macau, Zhuhai, Peoples R China.
[Chen, Bin-Bin] Fudan Univ, Shanghai, Peoples R China.
[Oburu, Paul] Maseno Univ, Kisumu, Kenya.
[Sorbring, Emma] Univ West, Trollhattan, Sweden.
[Steinberg, Laurence] Temple Univ, Philadelphia, PA 19122 USA.
[Steinberg, Laurence] King Abdulaziz Univ, Jeddah, Saudi Arabia.
[Tapanya, Sombat] Chiang Mai Univ, Chiang Mai, Thailand.
[Alampay, Liane P.] Ateneo Manila Univ, Quezon City, Philippines.
[Uribe Tirado, Liliana M.] Univ San Buenaventura, Cali, Colombia.
[Zelli, Arnaldo] Univ Rome Foro Italico, Rome, Italy.
RP Lansford, JE (reprint author), Duke Univ, Ctr Child & Family Policy, Box 90545, Durham, NC 27708 USA.
EM lansford@duke.edu
OI ZELLI, Arnaldo/0000-0003-4020-8159
FU Jacobs Foundation; Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD) [RO1-HD054805]; Fogarty
International Center [RO3-TW008141]; National Institute on Drug Abuse
[K01DA024116, 2K05 DA015226]; Intramural Research Program of the
National Institutes of Health/NICHD
FX This article was prepared, in part, during a Marbach Residence Program
funded by the Jacobs Foundation. The research featured in this article
was funded by the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD; Grant RO1-HD054805) and the Fogarty
International Center (Grant RO3-TW008141). Patrick S. Malone is
supported by Grant K01DA024116 from the National Institute on Drug
Abuse. Kenneth A. Dodge is supported by Senior Scientist award 2K05
DA015226 from the National Institute on Drug Abuse. This research also
was supported by the Intramural Research Program of the National
Institutes of Health/NICHD. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
NIH or NICHD.
NR 42
TC 0
Z9 0
U1 7
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1750-8592
EI 1750-8606
J9 CHILD DEV PERSPECT
JI Child Develop. Perspect.
PD SEP
PY 2016
VL 10
IS 3
BP 202
EP 207
DI 10.1111/cdep.12186
PG 6
WC Psychology, Developmental
SC Psychology
GA DS7GV
UT WOS:000380952100011
PM 27725843
ER
PT J
AU Vergallo, R
Xing, L
Minami, Y
Soeda, T
Ong, DS
Gao, L
Lee, H
Guagliumi, G
Biasucci, LM
Crea, F
Yu, B
Uemura, S
O'Donnell, CJ
Jang, IK
AF Vergallo, Rocco
Xing, Lei
Minami, Yoshiyasu
Soeda, Tsunenari
Ong, Daniel S.
Gao, Lei
Lee, Hang
Guagliumi, Giulio
Biasucci, Luigi M.
Crea, Filippo
Yu, Bo
Uemura, Shiro
O'Donnell, Christopher J.
Jang, Ik-Kyung
TI Associations between the Framingham Risk Score and coronary plaque
characteristics as assessed by three-vessel optical coherence tomography
SO CORONARY ARTERY DISEASE
LA English
DT Article
DE coronary artery disease; Framingham Risk Score; optical coherence
tomography
ID INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; HEART-DISEASE;
ETHNIC-GROUPS; PROGRESSION; ARTERY; CALCIFICATION; BURDEN; VALIDATION;
PREDICTION
AB Objectives This study sought to explore the association between the Framingham Risk Score (FRS) and coronary plaque characteristics assessed by optical coherence tomography (OCT) imaging.
Background Clinical prediction models are useful for identifying high-risk patients. However, coronary events often occur in individuals estimated to be at low risk.
Methods A total of 254 patients with coronary artery disease who underwent three-vessel OCT were divided into tertiles according to FRS. Nonculprit plaque characteristics were compared among the three groups.
Results A total of 663 plaques were analyzed. FRS was significantly associated with calcification [37% (low FRS) vs. 46% (intermediate FRS) vs. 70% (high FRS); P<0.001] and neovascularization [39% (low FRS) vs. 41% (intermediate FRS) vs. 56% (high FRS); P<0.001], but not with lipid-rich plaques or thin-cap fibroatheroma (TCFA). On multivariate analysis, FRS was an independent predictor of the presence of both calcification and neovascularization. There were no deaths, two acute myocardial infarctions, and 15 nontarget lesion revascularizations at the 1-year followup. The event rate increased progressively across FRS tertiles [2.4% (low FRS) vs. 7.1% (intermediate FRS) vs. 8.6% (high FRS); P=0.186]. The c-statistic for FRS to predict future clinical events was 0.628 (95% confidence interval, 0.500-0.757). The addition of both calcification and TCFA to FRS provided incremental prognostic value [c-statistics: 0.761 (95% confidence interval, 0.631-0.890)].
Conclusion The present study showed significant associations between FRS and the presence of coronary calcification and neovascularization in nonculprit plaques. The combination of FRS and OCT-detected calcifications and TCFA provides improved prognostic ability in identifying patients with known coronary artery disease who are at risk of recurrent events. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Vergallo, Rocco; Xing, Lei; Minami, Yoshiyasu; Soeda, Tsunenari; Ong, Daniel S.; Gao, Lei; O'Donnell, Christopher J.; Jang, Ik-Kyung] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, GRB 800,55 Fruit St, Boston, MA 02114 USA.
[Lee, Hang] Harvard Med Sch, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA.
[O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Xing, Lei; Yu, Bo] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 2, Harbin, Peoples R China.
[Guagliumi, Giulio] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy.
[Biasucci, Luigi M.; Crea, Filippo] Univ Cattolica Sacro Cuore, Dept Cardiovasc Med, Rome, Italy.
[Uemura, Shiro] Nara Med Univ, Dept Cardiol, Nara, Japan.
[Jang, Ik-Kyung] Kyung Hee Univ, Div Cardiol, Seoul, South Korea.
RP Jang, IK (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, GRB 800,55 Fruit St, Boston, MA 02114 USA.
EM ijang@mgh.harvard.edu
FU Michael and Kathryn Park; Gill and Allan Gray; St Jude Medical; Italian
Society of Cardiology Award for Research Abroad and the 'Enrico ed
Enrica Sovena' Foundation, Rome, Italy
FX Dr Jang's research was supported by Michael and Kathryn Park, and by
Gill and Allan Gray. Dr Jang has received grants and consulting fees
from St Jude Medical. Dr Vergallo was supported by the 2013 Italian
Society of Cardiology Award for Research Abroad and the 'Enrico ed
Enrica Sovena' Foundation, Rome, Italy. For the remaining authors there
are no conflicts of interest.
NR 28
TC 0
Z9 0
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0954-6928
EI 1473-5830
J9 CORONARY ARTERY DIS
JI Coronary Artery Dis.
PD SEP
PY 2016
VL 27
IS 6
BP 460
EP 466
DI 10.1097/MCA.0000000000000383
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DS5FI
UT WOS:000380806300005
PM 27218146
ER
PT J
AU Lewandowski, LB
Kaplan, MJ
AF Lewandowski, Laura B.
Kaplan, Mariana J.
TI Update on cardiovascular disease in lupus
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE atherosclerosis; cardiovascular disease; interferons; neutrophil
extracellular traps; systemic lupus erythematosus
ID NEUTROPHIL EXTRACELLULAR TRAPS; INTERNATIONAL INCEPTION COHORT;
LOW-DENSITY-LIPOPROTEIN; 25-HYDROXYVITAMIN D DEFICIENCY;
POPULATION-BASED COHORT; CORONARY-HEART-DISEASE; RISK-FACTORS;
SUBCLINICAL ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; METABOLIC SYNDROME
AB Purpose of review
Atherosclerotic cardiovascular disease confers significant morbidity and mortality in patients with systemic lupus erythematosus (SLE) and cannot be fully explained by traditional cardiovascular risk factors. Recent immunologic discoveries have outlined putative pathways in SLE that may also accelerate the development of atherosclerosis.
Recent findings
Aberrant innate and adaptive immune responses implicated in lupus pathogenesis may also contribute to the development of accelerated atherosclerosis in these patients. Defective apoptosis, abnormal lipoprotein function, autoantibodies, aberrant neutrophil responses, and a dysregulated type I interferon pathway likely contribute to endothelial dysfunction. SLE macrophages have an inflammatory phenotype that may drive progression of plaque.
Summary
Recent discoveries have placed increased emphasis on the immunology of atherosclerotic cardiovascular disease. Understanding the factors that drive the increased risk for cardiovascular disease in SLE patients may provide selective therapeutic targets for reducing inflammation and improving outcomes in atherosclerosis.
C1 [Lewandowski, Laura B.; Kaplan, Mariana J.] NIAMSD, Syst Autoimmun Branch, NIH, Bethesda, MD 20892 USA.
RP Kaplan, MJ (reprint author), NIAMS, Syst Autoimmun Branch, NIH, 10 Ctr Dr,6D47C, Bethesda, MD 20892 USA.
EM Mariana.kaplan@nih.gov
FU NIAMS/NIH; Lupus Research Institute
FX This work was supported by the Intramural Research Program, NIAMS/NIH
and the Lupus Research Institute.
NR 114
TC 0
Z9 0
U1 10
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8711
EI 1531-6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD SEP
PY 2016
VL 28
IS 5
BP 460
EP 468
DI 10.1097/BOR.0000000000000307
PG 9
WC Rheumatology
SC Rheumatology
GA DS5AS
UT WOS:000380793500002
ER
PT J
AU Janssen, I
Chen, CC
Millo, CM
Ling, A
Taieb, D
Lin, FI
Adams, KT
Wolf, KI
Herscovitch, P
Fojo, AT
Buchmann, I
Kebebew, E
Pacak, K
AF Janssen, Ingo
Chen, Clara C.
Millo, Corina M.
Ling, Alexander
Taieb, David
Lin, Frank I.
Adams, Karen T.
Wolf, Katherine I.
Herscovitch, Peter
Fojo, Antonio T.
Buchmann, Inga
Kebebew, Electron
Pacak, Karel
TI PET/CT comparing Ga-68-DOTATATE and other radiopharmaceuticals and in
comparison with CT/MRI for the localization of sporadic metastatic
pheochromocytoma and paraganglioma
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE Ga-68-DOTATATE; F-18-FDG; Pheochromocytoma; Paraganglioma; Metastatic
ID POSITRON-EMISSION-TOMOGRAPHY; I-123-MIBG SPECT; TUMORS; SDHB; DIAGNOSIS;
CANCER; HEAD; NEUROENDOCRINE; METAANALYSIS; SUPERIORITY
AB Pheochromocytomas/paragangliomas (PPGLs) and their metastases are tumors that predominantly express somatostatin receptor 2 (SSR2). Ga-68-DOTA(0)-Tyr(3)-octreotate (Ga-68-DOTATATE) is a PET radiopharmaceutical with both high and selective affinity for SSRs. The purpose of this study was to evaluate the utility of Ga-68-DOTATATE in comparison with other specific and nonspecific radiopharmaceuticals recommended in the current guidelines for the localization of metastatic sporadic PPGL by PET/CT.
This prospective study included 22 patients (15 men, 7 women; aged 50.0 +/- 13.9 years) with confirmed metastatic PPGL, a negative family history for PPGL, and negative genetic testing, who underwent Ga-68-DOTATATE, F-18-fluoro-2-deoxy-D-glucose (F-18-FDG) PET/CT, and CT/MRI. Only 12 patients underwent an additional F-18-fluorodihydroxyphenylalanine (F-18-FDOPA) PET/CT scan and only 11 patients underwent an additional F-18-fluorodopamine (F-18-FDA) PET/CT scan. The rates of detection of metastatic lesions were compared among all the imaging studies. A composite of all functional and anatomical imaging studies served as the imaging comparator.
Ga-68-DOTATATE PET/CT showed a lesion-based detection rate of 97.6 % (95 % confidence interval, CI, 95.8 - 98.7 %). F-18-FDG PET/CT, F-18-FDOPA PET/CT, F-18-FDA PET/CT, and CT/MRI showed detection rates of 49.2 % (CI 44.5 - 53.6 %; p < 0.01), 74.8 % (CI 69.0 - 79.9 %); p < 0.01), 77.7 % (CI 71.5 - 82.8 %; p < 0.01), and 81.6 % (CI 77.8 - 84.8 %; p < 0.01), respectively.
The results of this study demonstrate the superiority of Ga-68-DOTATATE PET/CT in the localization of sporadic metastatic PPGLs compared to all other functional and anatomical imaging modalities, and suggest modification of future guidelines towards this new imaging modality.
C1 [Janssen, Ingo; Adams, Karen T.; Wolf, Katherine I.; Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Adult & Reprod Endocrinol, NIH, Bldg 10,CRC,Room 1E-3140,10 Ctr Dr MSC 1109, Bethesda, MD 20892 USA.
[Janssen, Ingo; Buchmann, Inga] Univ Hosp Schleswig Holstein, Nucl Med Sect, Dept Radiol & Nucl Med, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.
[Chen, Clara C.] NIH, Nucl Med Div Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA.
[Millo, Corina M.; Herscovitch, Peter] NIH, Positron Emiss Tomog Dept, Ctr Clin, Bethesda, MD 20892 USA.
[Ling, Alexander] NIH, Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA.
[Taieb, David] Aix Marseille Univ, La Timone Univ Hosp, Dept Nucl Med, CERIMED, Marseille, France.
[Lin, Frank I.] NCI, Canc Imaging Program, NIH, Bethesda, MD 20892 USA.
[Fojo, Antonio T.] NCI, Endocrine Oncol Branch, Bethesda, MD 20892 USA.
[Kebebew, Electron] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Pacak, K (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Adult & Reprod Endocrinol, NIH, Bldg 10,CRC,Room 1E-3140,10 Ctr Dr MSC 1109, Bethesda, MD 20892 USA.
EM karel@mail.nih.gov
FU Intramural Research Program of the National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child Health and Human Development
FX This work was supported, in part, by the Intramural Research Program of
the National Institutes of Health, Eunice Kennedy Shriver National
Institute of Child Health and Human Development.
NR 37
TC 2
Z9 2
U1 8
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD SEP
PY 2016
VL 43
IS 10
BP 1784
EP 1791
DI 10.1007/s00259-016-3357-x
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DS3RJ
UT WOS:000380700100005
PM 26996779
ER
PT J
AU Melo, DR
Miller, DL
Chang, L
Moroz, B
Linet, MS
Simon, SL
AF Melo, Dunstana R.
Miller, Donald L.
Chang, Lienard
Moroz, Brian
Linet, Martha S.
Simon, Steven L.
TI ORGAN DOSES FROM DIAGNOSTIC MEDICAL RADIOGRAPHY-TRENDS OVER EIGHT
DECADES (1930 TO 2010)
SO HEALTH PHYSICS
LA English
DT Article
DE diagnostic radiology; dose; absorbed; epidemiology; radiation; medical
ID X-RAY EXAMINATIONS; ACTIVE BONE-MARROW; COMPUTED RADIOGRAPHY; CHEST
RADIOGRAPHY; NATIONWIDE EVALUATION; PATIENT DOSIMETRY; RADIATION RISKS;
UNITED-STATES; RADIOLOGY; POPULATION
AB This study provides a retrospective assessment of doses to 13 organs for the most common radiographic examinations conducted between the 1930s and 2010, taking into account typical technical parameters used for radiography during those years. This study is intended to be a resource on changes in medical diagnostic radiation exposure over time with a specific purpose of supporting retrospective epidemiological studies of radiation health risks. The authors derived organ doses to the brain, esophagus, thyroid, red bone marrow, lungs, breast, heart, stomach, liver, colon, urinary bladder, ovaries, and testes based on 14 common radiographic procedures and compared, when possible, with doses reported in the literature. These dose estimates were based on radiographic exposure parameters described in textbooks widely used by radiologic technologists in training from 1939 to 2010. The derived estimated doses presented here are believed to be representative of typical organs for an average-size adult who might be considered to be similar to the reference person. There were large variations in organ doses noted among the different types of radiographic examinations. Doses were highest in organs within the area imaged and next highest in organs in close proximity to the area imaged. Estimated organ doses have declined substantially [overall 22-fold (+/- 38)] over time as a consequence of changes in technology, imaging protocols and protective measures. For some examinations, only slight differences were observed in doses for the decades of the 1960s, 1970s, and 1980s due to minor changes in technical parameters. Substantial dose reductions were observed in the 1990s and 2000s.
C1 [Melo, Dunstana R.] NCI, DCEG, NIH, Bethesda, MD 20892 USA.
[Melo, Dunstana R.] Melohill Technol, Rockville, MD USA.
[Miller, Donald L.] US FDA, Silver Spring, MD USA.
[Chang, Lienard; Moroz, Brian; Linet, Martha S.; Simon, Steven L.] NCI, DCEG, Bethesda, MD 20892 USA.
RP Melo, DR (reprint author), 1 Res Court,Suite 450, Rockville, MD 20850 USA.
EM dunstana.melo@melohilltech.com
FU Intramural Research Program of the National Cancer Institute, National
Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Cancer Institute, National Institutes of Health. We express our
appreciation to Alice Sigurdson (NCI, retired) for encouragement,
insight and support and to Charles Myers of the Division of Radiological
Health, Center for Devices and Radiological Health, Food and Drug
Administration for his assistance in defining radiography fields for
examinations conducted in past decades.
NR 75
TC 0
Z9 0
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD SEP
PY 2016
VL 111
IS 3
BP 235
EP 255
DI 10.1097/HP.0000000000000524
PG 21
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA DS4PX
UT WOS:000380764100001
PM 27472750
ER
PT J
AU Wiener, L
Viola, A
Kearney, J
Mullins, LL
Sherman-Bien, S
Zadeh, S
Farkas-Patenaude, A
Pao, M
AF Wiener, Lori
Viola, Adrienne
Kearney, Julia
Mullins, Larry L.
Sherman-Bien, Sandra
Zadeh, Sima
Farkas-Patenaude, Andrea
Pao, Maryland
CA Lone Parent Study Grp
TI Impact of Caregiving for a Child With Cancer on Parental Health
Behaviors, Relationship Quality, and Spiritual Faith: Do Lone Parents
Fare Worse?
SO JOURNAL OF PEDIATRIC ONCOLOGY NURSING
LA English
DT Article
DE health behavior; pediatric cancer; caregivers; psychosocial; spiritual
faith; relationships
ID PEDIATRIC CANCER; MOTHERS; STRESS; SINGLE; LIFE; FATHERS; CARE
AB Caregiving stress has been associated with changes in the psychological and physical health of parents of children with cancer, including both partnered and single parents. While parents who indicate single on a demographic checklist are typically designated as single parents, a parent can be legally single and still have considerable support caring for an ill child. Correspondingly, an individual can be married/partnered and feel alone when caring for a child with serious illness. In the current study, we report the results from our exploratory analyses of parent self-reports of behavior changes during their child's treatment. Parents (N = 263) of children diagnosed with cancer were enrolled at 10 cancer centers. Parents reported significant worsening of all their own health behaviors surveyed, including poorer diet and nutrition, decreased physical activity, and less time spent engaged in enjoyable activities 6 to 18 months following their child's diagnosis. More partnered parents found support from friends increased or stayed the same since their child's diagnosis, whereas a higher proportion of lone parents reported relationships with friends getting worse. More lone parents reported that the quality of their relationship with the ill child's siblings had gotten worse since their child's diagnosis. Spiritual faith increased for all parents.
C1 [Wiener, Lori; Viola, Adrienne; Zadeh, Sima] NCI, Pediat Oncol Branch, Bldg 10,Room 1-6466, Bethesda, MD 20892 USA.
[Viola, Adrienne] Rutgers Robert Wood Johnson Med Sch, Newark, NJ USA.
[Kearney, Julia] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Mullins, Larry L.] Oklahoma State Univ, Coll Arts & Sci, Dept Psychol, Psychol, Stillwater, OK 74078 USA.
[Mullins, Larry L.] Oklahoma State Univ, Coll Arts & Sci, Res, Stillwater, OK 74078 USA.
[Sherman-Bien, Sandra] Miller Childrens Hosp, Jonathan Jaques Childrens Canc Ctr, Long Beach, CA USA.
[Farkas-Patenaude, Andrea] Dana Farber Canc Inst, Psychol Res Serv, Boston, MA 02115 USA.
[Farkas-Patenaude, Andrea] Dana Farber Canc Inst, Clin Serv, Boston, MA 02115 USA.
[Pao, Maryland] NIMH, Bethesda, MD 20892 USA.
RP Wiener, L (reprint author), NCI, Pediat Oncol Branch, Bldg 10,Room 1-6466, Bethesda, MD 20892 USA.
EM wienerl@nih.gov
FU National Cancer Institute; National Institute of Mental Health
intramural programs of the National Institutes of Health
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
is supported [in part] by the National Cancer Institute and the National
Institute of Mental Health intramural programs of the National
Institutes of Health. This funding supported the design and conduct of
the study; the collection, management, analysis, and interpretation of
the data; preparation, review, and approval of the article; and the
decision to submit the article for publication. The Andre Sobel River of
Life Foundation contributed the gift cards for the study
participants.hD; and Sean Phipps, PhD.
NR 24
TC 0
Z9 0
U1 5
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1043-4542
EI 1532-8457
J9 J PEDIATR ONCOL NURS
JI J. Pediatr. Oncol. Nurs.
PD SEP-OCT
PY 2016
VL 33
IS 5
BP 378
EP 386
DI 10.1177/1043454215616610
PG 9
WC Oncology; Nursing
SC Oncology; Nursing
GA DS7JV
UT WOS:000380960700007
PM 26668211
ER
PT J
AU Saposnik, G
Cohen, LG
Mamdani, M
Pooyania, S
Ploughman, M
Cheung, D
Shaw, J
Hall, J
Nord, P
Dukelow, S
Nilanont, Y
De los Rios, F
Olmos, L
Levin, M
Teasell, R
Cohen, A
Thorpe, K
Laupacis, A
Bayley, M
AF Saposnik, Gustavo
Cohen, Leonardo G.
Mamdani, Muhammad
Pooyania, Sepideth
Ploughman, Michelle
Cheung, Donna
Shaw, Jennifer
Hall, Judith
Nord, Peter
Dukelow, Sean
Nilanont, Yongchai
De los Rios, Felipe
Olmos, Lisandro
Levin, Mindy
Teasell, Robert
Cohen, Ashley
Thorpe, Kevin
Laupacis, Andreas
Bayley, Mark
CA Stroke Outcomes Res Canada
TI Efficacy and safety of non-immersive virtual reality exercising in
stroke rehabilitation (EVREST): a randomised, multicentre, single-blind,
controlled trial
SO LANCET NEUROLOGY
LA English
DT Article
ID MOTOR FUNCTION-TEST; UPPER-LIMB; REGIONAL BURDEN; CLINICAL-TRIAL; GLOBAL
BURDEN; SURVIVORS; RECOVERY; IMPAIRMENT; MOVEMENT; DISEASE
AB Background Non-immersive virtual reality is an emerging strategy to enhance motor performance for stroke rehabilitation. There has been rapid adoption of non-immersive virtual reality as a rehabilitation strategy despite the limited evidence about its safety and effectiveness. Our aim was to compare the safety and efficacy of virtual reality with recreational therapy on motor recovery in patients after an acute ischaemic stroke.
Methods In this randomised, controlled, single-blind, parallel-group trial we enrolled adults (aged 18-85 years) who had a first-ever ischaemic stroke and a motor deficit of the upper extremity score of 3 or more (measured with the Chedoke-McMaster scale) within 3 months of randomisation from 14 in-patient stroke rehabilitation units from four countries (Canada [11], Argentina [1], Peru [1], and Thailand [1]). Participants were randomly allocated (1: 1) by a computer-generated assignment at enrolment to receive a programme of structured, task-oriented, upper extremity sessions (ten sessions, 60 min each) of either non-immersive virtual reality using the Nintendo Wii gaming system (VRWii) or simple recreational activities (playing cards, bingo, Jenga, or ball game) as add-on therapies to conventional rehabilitation over a 2 week period. All investigators assessing outcomes were masked to treatment assignment. The primary outcome was upper extremity motor performance measured by total time to complete the Wolf Motor Function Test (WMFT) at the end of the 2 week intervention period, analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NTC01406912.
Findings The study was done between May 12, 2012, and Oct 1, 2015. We randomly assigned 141 patients: 71 received VRWii therapy and 70 received recreational activity. 121 (86%) patients (59 in the VRWii group and 62 in the recreational activity group) completed the final assessment and were included in the primary analysis. Each group improved WMFT performance time relative to baseline (decrease in median time from 43.7 s [IQR 26.1-68.0] to 29.7 s [21.4-45.2], 32.0% reduction for VRWii vs 38.0 s [IQR 28.0-64.1] to 27.1 s [21.2-45.5], 28.7% reduction for recreational activity). Mean time of conventional rehabilitation during the trial was similar between groups (VRWii, 373 min [SD 322] vs recreational activity, 397 min [345]; p=0.70) as was the total duration of study intervention (VRWii, 528 min [SD 155] vs recreational activity, 541 min [142]; p=0.60). Multivariable analysis adjusted for baseline WMFT score, age, sex, baseline Chedoke-McMaster, and stroke severity revealed no signifi cant diff erence between groups in the primary outcome (adjusted mean estimate of diff erence in WMFT: 4.1 s, 95% CI -14.4 to 22.6). There were three serious adverse events during the trial, all deemed to be unrelated to the interventions (seizure after discharge and intracerebral haemorrhage in the recreational activity group and heart attack in the VRWii group). Overall incidences of adverse events and serious adverse events were similar between treatment groups.
Interpretation In patients who had a stroke within the 3 months before enrolment and had mild-to-moderate upper extremity motor impairment, non-immersive virtual reality as an add-on therapy to conventional rehabilitation was not superior to a recreational activity intervention in improving motor function, as measured by WMFT. Our study suggests that the type of task used in motor rehabilitation post-stroke might be less relevant, as long as it is intensive enough and task-specifi c. Simple, low-cost, and widely available recreational activities might be as eff ective as innovative non-immersive virtual reality technologies.
C1 [Saposnik, Gustavo] Univ Toronto, St Michaels Hosp, Div Neurol, Toronto, ON M5C 1R6, Canada.
[Saposnik, Gustavo; Cheung, Donna] Univ Toronto, St Michaels Hosp, Stroke Program, Toronto, ON M5C 1R6, Canada.
[Cohen, Leonardo G.] NINDS, Human Cort Physiol & Stroke Neurorehabil Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Saposnik, Gustavo; Mamdani, Muhammad; Hall, Judith; Cohen, Ashley; Thorpe, Kevin; Laupacis, Andreas] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
[Pooyania, Sepideth] Riverview Hlth Ctr, Winnipeg, MB, Canada.
[Ploughman, Michelle] Mem Univ, Miller Ctr, St John, NF, Canada.
[Shaw, Jennifer; Bayley, Mark] Univ Toronto, UHN Toronto Rehabil Inst, Toronto, ON M5C 1R6, Canada.
[Nord, Peter] Providence Healthcare, Toronto, ON, Canada.
[Dukelow, Sean] Foothills Med Ctr, Calgary, AB, Canada.
[Nilanont, Yongchai] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand.
[De los Rios, Felipe] Hosp Nacl Cayetano Heredia, Lima, Peru.
[Olmos, Lisandro] Escobar, FLENI Rehabil Inst, Buenos Aires, DF, Argentina.
[Levin, Mindy] McGill Univ, CRIR Res Ctr, Jewish Rehabil Hosp, Montreal, PQ, Canada.
[Teasell, Robert] Univ Western Ontario, Parkwood Inst, London, ON, Canada.
RP Saposnik, G (reprint author), Univ Toronto, Stroke Outcomes Res & Virtual Real Ctr, Stroke Outcome Res Canada Working Grp, St Michaels Hosp,Dept Med, 55 Queen St E, Toronto, ON M5C 1R6, Canada.
EM saposnikg@smh.ca
OI Dukelow, Sean/0000-0002-0609-981X
FU South East Toronto Stroke Network
FX The authors are indebted to all participants of the EVREST trial. We are
very grateful to allied health members at each site who were
instrumental for the successful implementation of EVREST. The authors
would like to thank co-operative students at Li Ka Shing Knowledge
Institute for their assistance with database development and data entry.
The authors thank Sarah Blanton and Steven Wolf for the facilitation of
the training video and suggestions regarding the analysis of the WMFT.
The authors are most grateful for the initial funding provided by South
East Toronto Stroke Network and to Jacqueline Willems for the
unconditional support with the early organisation of the study design
and coordination.
NR 34
TC 2
Z9 2
U1 20
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
EI 1474-4465
J9 LANCET NEUROL
JI Lancet Neurol.
PD SEP
PY 2016
VL 15
IS 10
BP 1019
EP 1027
DI 10.1016/S1474-4422(16)30121-1
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA DT1ZJ
UT WOS:000381280300018
PM 27365261
ER
PT J
AU Goldstein, DS
Jinsmaa, Y
Sullivan, P
Holmes, C
Kopin, IJ
Sharabi, Y
AF Goldstein, David S.
Jinsmaa, Yunden
Sullivan, Patti
Holmes, Courtney
Kopin, Irwin J.
Sharabi, Yehonatan
TI 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in
Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in
PC12 Cells
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE Hydroxytyrosol; DOPET; DOPAL; Cysteinyl-dopamine; Monoamine oxidase;
Parkinson's disease
ID OLIVE OIL; RED WINE; DISEASES; ADDUCTS; DAMAGE
AB The catecholaldehyde hypothesis predicts that monoamine oxidase (MAO) inhibition should slow the progression of Parkinson's disease, by decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). Inhibiting MAO, however, diverts the fate of cytoplasmic dopamine toward potentially harmful spontaneous oxidation products, indicated by increased 5-S-cysteinyl-dopamine (Cys-DA) levels. 3,4-Dihydroxyphenylethanol (hydroxytyrosol) is an abundant anti-oxidant phenol in constituents of the Mediterranean diet. Whether hydroxytyrosol alters enzymatic or spontaneous oxidation of dopamine has been unknown. Rat pheochromocytoma PC12 cells were incubated with hydroxytyrosol (10 A mu M, 180 min) alone or with the MAO-A inhibitor clorgyline (1 nM) or the MAO-B inhibitors rasagiline or selegiline (0.5 A mu M). Hydroxytyrosol decreased levels of DOPAL by 30 % and Cys-DA by 49 % (p < 0.0001 each). Co-incubation with hydroxytyrosol prevented the increases in Cys-DA seen with all 3 MAO inhibitors. Hydroxytyrosol therefore inhibits both enzymatic and spontaneous oxidation of endogenous dopamine and mitigates the increase in spontaneous oxidation during MAO inhibition.
C1 [Goldstein, David S.; Jinsmaa, Yunden; Sullivan, Patti; Holmes, Courtney; Kopin, Irwin J.; Sharabi, Yehonatan] NINDS, Clin Neurocardiol Sect, CNP, DIR,NIH, 9000 Rockville Pike,Bldg 10 Rm 5N220, Bethesda, MD 20892 USA.
[Sharabi, Yehonatan] Chaim Sheba Med Ctr, Sackler Fac Med, Tel Aviv, Israel.
[Sharabi, Yehonatan] Tel Aviv Univ, Tel Aviv, Israel.
RP Goldstein, DS (reprint author), NINDS, Clin Neurocardiol Sect, CNP, DIR,NIH, 9000 Rockville Pike,Bldg 10 Rm 5N220, Bethesda, MD 20892 USA.
EM goldsteind@ninds.nih.gov
FU Intramural NIH HHS [ZIA NS003125-06, ZIA NS003034-10, Z99 NS999999]
NR 20
TC 1
Z9 1
U1 7
U2 7
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD SEP
PY 2016
VL 41
IS 9
BP 2173
EP 2178
DI 10.1007/s11064-016-1959-0
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DS3XV
UT WOS:000380716900001
PM 27220335
ER
PT J
AU Bolanos-Guzman, CA
Zarate, CA
AF Bolanos-Guzman, Carlos A.
Zarate, Carlos A., Jr.
TI Underrepresented Minorities in Science: ACNP Strives to Increase
Minority Representation and Inclusion
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Editorial Material
ID ACADEMIC MEDICINE; DISPARITIES; FACULTY
C1 [Bolanos-Guzman, Carlos A.] Texas A&M Univ, Dept Psychol, 3245 TAMU, College Stn, TX 77843 USA.
[Zarate, Carlos A., Jr.] NIMH, Expt Therapeut & Pathophysiol Branch, Bethesda, MD USA.
[Zarate, Carlos A., Jr.] NIMH, Div Intramural Res Program, Sect Neurobiol & Treatment Mood Disorders, Bethesda, MD USA.
RP Bolanos-Guzman, CA (reprint author), Texas A&M Univ, Dept Psychol, 3245 TAMU, College Stn, TX 77843 USA.
EM bolanos-guzman@tamu.edu
NR 17
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD SEP
PY 2016
VL 41
IS 10
BP 2421
EP 2423
DI 10.1038/npp.2016.71
PG 3
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DT7FV
UT WOS:000381653400001
PM 27510298
ER
PT J
AU Fedota, JR
Matous, AL
Salmeron, BJ
Gu, H
Ross, TJ
Stein, EA
AF Fedota, John R.
Matous, Allison L.
Salmeron, Betty Jo
Gu, Hong
Ross, Thomas J.
Stein, Elliot A.
TI Insula Demonstrates a Non-Linear Response to Varying Demand for
Cognitive Control and Weaker Resting Connectivity With the Executive
Control Network in Smokers
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
ID FMRI GROUP-ANALYSIS; SMOKING CUES; FUNCTIONAL CONNECTIVITY;
CIGARETTE-SMOKING; PREFRONTAL CORTEX; DEFAULT-MODE; BRAIN; ADDICTION;
NICOTINE; CONFLICT
AB Deficits in cognitive control processes are a primary characteristic of nicotine addiction. However, while network-based connectivity measures of dysfunction have frequently been observed, empirical evidence of task-based dysfunction in these processes has been inconsistent. Here, in a sample of smokers (n = 35) and non-smokers (n = 21), a previously validated parametric flanker task is employed to characterize addiction-related alterations in responses to varying (ie, high, intermediate, and low) demands for cognitive control. This approach yields a demand-response curve that aims to characterize potential non-linear responses to increased demand for control, including insensitivities or lags in fully activating the cognitive control network. We further used task-based differences in activation between groups as seeds for resting-state analysis of network dysfunction in an effort to more closely link prior inconsistencies in task-related activation with evidence of impaired network connectivity in smokers. For both smokers and non-smokers, neuroimaging results showed similar increases in activation in brain areas associated with cognitive control. However, reduced activation in right insula was seen only in smokers and only when processing intermediate demand for cognitive control. Further, in smokers, this task-modulated right insula showed weaker functional connectivity with the superior frontal gyros, a component of the task-positive executive control network These results demonstrate that the neural instantiation of salience attribution in smokers is both more effortful to fully activate and has more difficulty communicating with the exogenous, task-positive, executive control network. Together, these findings further articulate the cognitive control dysfunction associated with smoking and illustrate a specific brain circuit potentially responsible.
C1 [Fedota, John R.; Matous, Allison L.; Salmeron, Betty Jo; Gu, Hong; Ross, Thomas J.; Stein, Elliot A.] NIDA, Neuroimaging Res Branch, Intramural Res Program, NIH, 251 Bayview Blvd, Baltimore, MD 21224 USA.
RP Fedota, JR (reprint author), NIDA, Neuroimaging Res Branch, Intramural Res Program, NIH, 251 Bayview Blvd, Baltimore, MD 21224 USA.
EM john.fedota@nih.gov
RI Salmeron, Betty Jo/M-1793-2016;
OI Salmeron, Betty Jo/0000-0003-1699-9333; Ross, Thomas/0000-0002-7745-3572
FU National Institute on Drug Abuse (NIDA), Intramural Research Program;
FDA grant [NDA13001-001-00000]
FX This study was supported by the National Institute on Drug Abuse (NIDA),
Intramural Research Program and FDA grant NDA13001-001-00000 to EAS. The
authors declare no conflict of interest.
NR 53
TC 1
Z9 1
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD SEP
PY 2016
VL 41
IS 10
BP 2557
EP 2565
DI 10.1038/npp.2016.62
PG 9
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DT7FV
UT WOS:000381653400014
PM 27112116
ER
PT J
AU Wiers, CE
Shokri-Kojori, E
Wong, CT
Abi-Dargham, A
Demiral, SB
Tomasi, D
Wang, GJ
Volkow, ND
AF Wiers, Corinde E.
Shokri-Kojori, Ehsan
Wong, Christopher T.
Abi-Dargham, Anissa
Demiral, Sukru B.
Tomasi, Dardo
Wang, Gene-Jack
Volkow, Nora D.
TI Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a
Stimulant Challenge in Females but not in Males
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; NATIONAL EPIDEMIOLOGIC SURVEY;
GLUCOSE-METABOLISM; GENDER-DIFFERENCES; COCAINE ABUSERS; DOPAMINE
TRANSPORTER; RECEPTOR AVAILABILITY; ORBITOFRONTAL CORTEX; ORAL
METHYLPHENIDATE; PREFRONTAL CORTEX
AB The extent to which cannabis is deleterious to the human brain is not well understood. Here, we test whether cannabis abusers (CA) have impaired frontal function and reactivity to dopaminergic signaling, which are fundamental to relapse in addiction. We measured brain glucose metabolism using PET and [F-18]FDG both at baseline (placebo) and after challenge with methylphenidate (MP), a dopamine enhancing drug, in 24 active CA (50% female) and 24 controls (HC; 50% female). Results show that (i) CA had lower baseline glucose metabolism than HC in frontal cortex including anterior cingulate, which was associated with negative emotionality. (ii) MP increased whole-brain glucose metabolism in HC but not in CA; and group by challenge effects were most profound in putamen, caudate, midbrain, thalamus, and cerebellum. In CA, MP-induced metabolic increases in putamen correlated negatively with addiction severity. (id) There were significant gender effects, such that both the group differences at baseline in frontal metabolism and the attenuated regional brain metabolic responses to MP were observed in female CA but not in male CA. As for other drug addictions, reduced baseline frontal metabolism is likely to contribute to relapse in CA. The attenuated responses to MP in midbrain and striatum are consistent with decreased brain reactivity to dopamine stimulation and might contribute to addictive behaviors in CA. The gender differences suggest that females are more sensitive than males to the adverse effects of cannabis in brain.
C1 [Wiers, Corinde E.; Shokri-Kojori, Ehsan; Wong, Christopher T.; Demiral, Sukru B.; Tomasi, Dardo; Wang, Gene-Jack; Volkow, Nora D.] NIAAA, NIH, Bethesda, MD USA.
[Abi-Dargham, Anissa] Columbia Univ, Dept Psychiat, Div Translat Imaging, New York, NY USA.
[Abi-Dargham, Anissa] New York State Psychiat Inst & Hosp, New York, NY USA.
[Volkow, Nora D.] NIDA, NIH, Bethesda, MD USA.
RP Wiers, CE; Volkow, ND (reprint author), NIAAA, Lab Neuroimaging, NIH, 10 Ctr Dr,Room B2L 124, Bethesda, MD 20892 USA.
EM corinde.wiers@nih.gov; nvolkow@nida.nih.gov
FU NIH/NIAAA intramural grant [Y1AA-3009]; German Research Foundation
FX We thank Karen Torres, Barbara Hubbard, Millard Jayne, Yana Studentsova,
Payton King, Pauline Carter, Donald Warner, Joanna Fowler, and Ruben
Baler for their contributions. The work was supported by NIH/NIAAA
intramural grant Y1AA-3009 to NDV. CEW received a scholarship from the
German Research Foundation.
NR 62
TC 3
Z9 3
U1 6
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD SEP
PY 2016
VL 41
IS 10
BP 2596
EP 2605
DI 10.1038/npp.2016.67
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DT7FV
UT WOS:000381653400018
PM 27156854
ER
PT J
AU Alonso, N
Nebreda, AD
Monczor, F
Gutkind, JS
Davio, C
Fernandez, N
Shayo, C
AF Alonso, Natalia
Diaz Nebreda, Antonela
Monczor, Federico
Silvio Gutkind, J.
Davio, Carlos
Fernandez, Natalia
Shayo, Carina
TI PI3K pathway is involved in ERK signaling cascade activation by
histamine H2R agonist in HEK293T cells
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE Histamine H2 receptor; ERK; PI3K; Cell proliferation; Cell signaling
ID BETA-GAMMA-SUBUNITS; LEYDIG TUMOR-CELLS; STRUCTURAL INSTABILITY;
CONSTITUTIVE ACTIVITY; INTERNATIONAL UNION; KINASE ACTIVATION;
COLORECTAL-CANCER; REGULATED KINASES; BREAST-CANCER; RAP GTPASES
AB Background: Histamine, through histamine H2 receptor (H2R), modulates different biological processes, involving the modulation of PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways. Many evidences have demonstrated the existence and importance of the crossregulation between these two signaling pathways. The aim of the present work was to determine the molecular mechanisms leading to PI3K and ERK pathways modulation induced by the H2R agonist amthamine and to evaluate the possible interplay between them.
Methods: Phosphorylation levels of ERK and Akt were examined by Western blot in HEK293T cells expressing the human H2R, in the presence of H2R agonist and dominant negative mutants or pharmacological inhibitors of different proteins/pathways. Transcriptional activity assays were assessed to determine SRE activity. Amthamine-mediated cellular proliferation was investigated in MA-10A cells in the presence of PI3K inhibitor.
Results: H2R agonist inhibits PI3K/Akt/mTOR and stimulates Ras/MEK/ERK pathways. Moreover, PI3K/Akt/mTOR signaling inhibition is necessary to achieve H2R mediated ERK activation. In the presence of a constitutive active mutant of Akt, amthamine is not able to mediate ERK activation. This crosstalk affects classical ERK downstream targets such as Elk1 phosphorylation and the transcriptional activity of the SRE, classically associated to proliferation. We further demonstrate that amthamine-induced proliferation in Leydig MA-10 tumor cells, is enhanced by LY294002, a PI3K inhibitor.
Conclusions: These results describe a crosstalk between PI3K/AKT/mTOR and Ras/MEK/ERK pathways induced by H2R stimulation with implications in cell proliferation.
General significance: This work indicates that the modulation of PI3K/AKT/mTOR pathway by H2R in turn regulates Ras/MEK/ERK activation conditioning the proliferative capacity of the cells. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Alonso, Natalia; Diaz Nebreda, Antonela; Shayo, Carina] Consejo Nacl Invest Cient & Tecn, Lab Patol & Farmacol Mol, IBYME, Buenos Aires, DF, Argentina.
[Monczor, Federico; Davio, Carlos; Fernandez, Natalia] Univ Buenos Aires, Fac Farm & Bioquim, Catedra Quim Med, Buenos Aires, DF, Argentina.
[Monczor, Federico; Davio, Carlos; Fernandez, Natalia] UBA CONICET, Fac Farm & Bioquim, Inst Invest Farmacol, ININFA, Junin 956, Buenos Aires, DF, Argentina.
[Silvio Gutkind, J.] NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
[Alonso, Natalia] Ctr Invest Ciencias Vet & Agron, Inst Biotecnol, Inst Nacl Tecnol Agr, Buenos Aires, DF, Argentina.
[Silvio Gutkind, J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
RP Shayo, C (reprint author), Inst Biol & Med Expt, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.
EM carinashayo@hotmail.com
FU Agencia Nacional de Promotion Cientifica y Tecnologica [PICT2013-0495,
PICT2013-2050]; CONICET [PIP 2013-562]; Fundacion Rene Baron [002/2016]
FX This work was supported by grants from the Agencia Nacional de Promotion
Cientifica y Tecnologica (PICT2013-0495, -2050), and from CONICET (PIP
2013-562), as well as from Fundacion Rene Baron (002/2016).
NR 53
TC 2
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD SEP
PY 2016
VL 1860
IS 9
BP 1998
EP 2007
DI 10.1016/j.bbagen.2016.06.016
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DS2LQ
UT WOS:000380601400018
PM 27316323
ER
PT J
AU Schade, A
Walliser, C
Wist, M
Haas, J
Vatter, P
Kraus, JM
Filingeri, D
Havenith, G
Kestler, HA
Milner, JD
Gierschik, P
AF Schade, Anja
Walliser, Claudia
Wist, Martin
Haas, Jennifer
Vatter, Petra
Kraus, Johann M.
Filingeri, Davide
Havenith, George
Kestler, Hans A.
Milner, Joshua D.
Gierschik, Peter
TI Cool-temperature-mediated activation of phospholipase C-gamma(2) in the
human hereditary disease PLAID
SO CELLULAR SIGNALLING
LA English
DT Article
DE Phospholipase C-gamma(2); lnositol phospholipid; Rac2 GTPase; Split PH
domain; Autoinhibition; Cold temperature sensitivity
ID GAIN-OF-FUNCTION; B-CELL RECEPTOR; PHOSPHORYLATION-INDUCED ACTIVATION;
COMMON VARIABLE IMMUNODEFICIENCY; PLECKSTRIN HOMOLOGY DOMAIN; C-GAMMA
ISOZYMES; CA2+ ENTRY; SIGNALING COMPLEX; FUNCTION MUTATION; MAST-CELLS
AB Deletions in the gene encoding signal-transducing inositol phospholipid-specific phospholipase C-gamma(2) (PLC gamma(2)) are associated with the novel human hereditary disease PLAID (PLC gamma(2)-associated antibody deficiency and immune dysregulation). PLAID is characterized by a rather puzzling concurrence of augmented and diminished functions of the immune system, such as cold urticaria triggered by only minimal decreases in temperature, autoimmunity, and immunodeficiency. Understanding of the functional effects of the genomic alterations at the level of the affected enzyme, PLC gamma(2), is currently lacking. PLC gamma(2) is critically involved in coupling various cell surface receptors to regulation of important functions of immune cells such as mast cells, B cells, monocytes/macrophages, and neutrophils. PLC gamma(2) is unique by carrying three Src (SH) and one split pleckstrin homology domain (spPH) between the two catalytic subdomains (spPHn-SH2n-SH2c-SH3-spPHc). Prevailing evidence suggests that activation of PLC gamma(2) is primarily due to loss of SH-region-mediated autoinhibition and/or enhanced plasma membrane trans location. Here, we show that the two PLAID PLC gamma(2) mutants lacking portions of the SH region are strongly (>100-fold), rapidly, and reversibly activated by cooling by only a few degrees. We found that the mechanism(s) underlying PLCy gamma(2) PLAID mutant activation by cool temperatures is distinct from a mere loss of SH-region-mediated autoinhibition and dependent on both the integrity and the pliability of the spPH domain. The results suggest a new mechanism of PLC gamma activation with unique thermodynamic features and assign a novel regulatory role to its spPH domain. Involvement of this mechanism in other human disease states associated with cooling such as exertional asthma and certain acute coronary events appears an intriguing possibility. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Schade, Anja; Walliser, Claudia; Wist, Martin; Haas, Jennifer; Vatter, Petra; Gierschik, Peter] Univ Ulm, Med Ctr, Inst Pharmacol & Toxicol, D-89070 Ulm, Germany.
[Kraus, Johann M.; Kestler, Hans A.] Univ Ulm, Inst Med Syst Biol, D-89081 Ulm, Germany.
[Filingeri, Davide; Havenith, George] Univ Loughborough, Environm Ergon Res Ctr, Loughborough LE11 3TU, Leics, England.
[Milner, Joshua D.] NIAID, Allerg Inflammat Unit, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA.
[Filingeri, Davide] Univ Calif Berkeley, Ctr Environm Design Res, Berkeley, CA 94720 USA.
RP Gierschik, P (reprint author), Univ Ulm, Med Ctr, Inst Pharmacol & Toxicol, Albert Einstein Allee 11, D-89081 Ulm, Germany.
EM peter.gierschik@uni-ulm.de
FU Deutsche Forschungsgemeinschaft (DFG) [SFB 1074, TP A8]; SFB [1074]; DFG
Research Training Group [GRK1041]; International Graduate School in
Molecular Medicine Ulm (IGradU) within the Excellence Initiative of the
German Federal and State Governments [GSC 279]
FX Work in P.G.'s laboratory is funded by grants from the Deutsche
Forschungsgemeinschaft (DFG) (SFB 1074, TP A8). The contribution of J.K.
and H.K. was supported by project Z1 of SFB 1074. A.S. was a fellow of
the DFG Research Training Group GRK1041 and the International Graduate
School in Molecular Medicine Ulm (IGradU) funded within the Excellence
Initiative of the German Federal and State Governments (GSC 279).
NR 66
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD SEP
PY 2016
VL 28
IS 9
BP 1237
EP 1251
DI 10.1016/j.cellsig.2016.05.010
PG 15
WC Cell Biology
SC Cell Biology
GA DS2JJ
UT WOS:000380595500011
PM 27196803
ER
PT J
AU Singh, N
Kumar, R
Engwerda, C
Sacks, D
Nylen, S
Sundar, S
AF Singh, Neetu
Kumar, Rajiv
Engwerda, Christian
Sacks, David
Nylen, Susanne
Sundar, Shyam
TI Tumor necrosis factor alpha neutralization has no direct effect on
parasite burden, but causes impaired IFN-gamma production by spleen
cells from human visceral leishmaniasis patients
SO CYTOKINE
LA English
DT Article
DE Visceral leishmaniasis; TNF-alpha; Enbrel; IL-10; Splenic aspirate;
Whole blood assay
ID OF-THE-LITERATURE; MICE LACKING TNF; CUTANEOUS LEISHMANIASIS; T-CELLS;
RHEUMATOID-ARTHRITIS; INFECTIOUS-DISEASES; FACTOR THERAPY; RECEPTOR P55;
NITRIC-OXIDE; IN-VIVO
AB The pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha has an important role in control of experimental Leishmania donovani infection. Less is known about the role of TNF-alpha in human visceral leishmaniasis (VL). Evidence for a protective role is primarily based on case reports of VL development in individuals treated with TNF-alpha neutralizing antibody. In this study, we have evaluated how TNF-alpha neutralization affects parasite replication and cytokine production in ex vivo splenic aspirates (SA) from active VL patients. The effect of TNF-alpha neutralization on cell mediated antigen specific responses were also evaluated using whole blood cultures. Neutralization of TNF-alpha did not affect parasite numbers in SA cultures. Interferon (IFN)-gamma levels were significantly reduced, but interleukin (IL)-10 levels were unchanged in these cultures. Leishmania antigen stimulated SA produced significant TNF-alpha which suggests that TNF-alpha is actively produced in VL spleen. Further it stimulates IFN-gamma production, but no direct effect on parasite replication. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Singh, Neetu; Sundar, Shyam] Banaras Hindu Univ, Dept Med, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India.
[Kumar, Rajiv] Netaji Subhas Inst Technol, Div Biotechnol, New Delhi 110078, India.
[Engwerda, Christian] QIMR Berghofer Med Res Inst, Immunol & Infect Lab, Herston, Qld 4006, Australia.
[Sacks, David] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Nylen, Susanne] Karolinska Inst, Dept Microbiol, Stockholm, Sweden.
[Kumar, Rajiv] Banaras Hindu Univ, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
RP Sundar, S (reprint author), Banaras Hindu Univ, Dept Med, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India.; Kumar, R (reprint author), Banaras Hindu Univ, Dept Biochem, Varanasi 221005, Uttar Pradesh, India.
EM rajiv082@yahoo.com; drshyamsundar@hotmail.com
FU Extramural Research Program of the National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH)
Tropical Medicine Research Centers [TMRC Grant] [IP50 AI074321];
UGC-CSIR, New Delhi, India
FX This work was supported by the Extramural Research Program of the
National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH) Tropical Medicine Research Centers [TMRC
Grant No. IP50 AI074321]. Neetu Singh is funded by UGC-CSIR, New Delhi,
India.
NR 46
TC 0
Z9 0
U1 3
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD SEP
PY 2016
VL 85
BP 184
EP 190
DI 10.1016/j.cyto.2016.06.013
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA DS2JO
UT WOS:000380596000029
PM 27372917
ER
PT J
AU Jackson, JP
Li, LH
Chamberlain, ED
Wang, HB
Ferguson, SS
AF Jackson, Jonathan P.
Li, Linhou
Chamberlain, Erica D.
Wang, Hongbing
Ferguson, Stephen S.
TI Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell
Cultures
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID-X-RECEPTOR; SALT EXPORT
PUMP; IN-VITRO; CYTOCHROME-P450 ISOFORMS; HEPG2 CELLS; NUCLEAR
TRANSLOCATION; INTRINSIC CLEARANCE; DRUG-METABOLISM; RAT HEPATOCYTES
AB Over the last decade HepaRG cells have emerged as a promising alternative to primary human hepatocytes (PHH) and have been featured in over 300 research publications. Most of these reports employed freshly differentiated HepaRG cells that require time-consuming culture (similar to 28 days) for full differentiation. Recently, a cryopreserved, predifferentiated format of HepaRG cells (termed here "cryo-HepaRG") has emerged as a new model that improves global availability and experimental flexibility; however, it is largely unknown whether HepaRG cells in this format fully retain their hepatic characteristics. Therefore, we systematically investigated the hepatocyte functionality of cryo-HepaRG cultures in context with the range of interindividual variation observed with PHH in both sandwich-culture and suspension formats. These evaluations uncovered a novel adaptation period for the cryo-HepaRG format and demonstrated the impact of extracellular matrix on cryo-HepaRG functionality. Pharmacologically important drug-metabolizing alleles were genotyped in HepaRG cells and poor metabolizer alleles for CYP2D6, CYP2C9, and CYP3A5 were identified and consistent with higher frequency alleles found in individuals of Caucasian decent. We observed liver enzyme inducibility with aryl hydrocarbon receptor, constitutive androstane receptor (CAR), and pregnane X receptor activators comparable to that of sandwich-cultured PHH. Finally, we show for the first time that cryo-HepaRG supports proper CAR cytosolic sequestration and translocation to hepatocyte nuclei in response to phenobarbital treatment. Taken together, these data reveal important considerations for the use of this cell model and demonstrate that cryo-HepaRG are suitable for metabolism and toxicology screening.
C1 [Jackson, Jonathan P.; Chamberlain, Erica D.; Ferguson, Stephen S.] ADME Tox, Cell Syst Div, Life Technol, Durham, NC USA.
[Li, Linhou; Wang, Hongbing] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
[Jackson, Jonathan P.] QTS, Durham, NC USA.
[Chamberlain, Erica D.] QPS, Newark, DE USA.
[Ferguson, Stephen S.] NIEHS, Natl Toxicol Program Div, Bethesda, MD USA.
RP Ferguson, SS (reprint author), 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
EM stephen.ferguson@nih.gov
FU Life Technologies (Thermo Fisher) research and development
FX The laboratory research was funded by Life Technologies (Thermo Fisher)
research and development. Resources for data analysis and manuscript
preparation were supported by the National Institutes of Health,
National Institute of Environmental Health Sciences, the National
Toxicology Program Division, and by Qualyst Transporter Solutions, Inc.
NR 43
TC 1
Z9 1
U1 7
U2 9
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0090-9556
EI 1521-009X
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD SEP
PY 2016
VL 44
IS 9
BP 1463
EP 1479
DI 10.1124/dmd.116.069831
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DS4IA
UT WOS:000380743500005
PM 27338863
ER
PT J
AU Purdue, MP
Silverman, DT
AF Purdue, Mark P.
Silverman, Debra T.
TI Clearing the Air: Summarizing the Smoking-related Relative Risks of
Bladder and Kidney Cancer
SO EUROPEAN UROLOGY
LA English
DT Editorial Material
C1 [Purdue, Mark P.; Silverman, Debra T.] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Purdue, MP (reprint author), NCI, 9609 Med Ctr Dr,Room 6E602, Rockville, MD 20850 USA.
EM purduem@mail.nih.gov
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD SEP
PY 2016
VL 70
IS 3
BP 467
EP 468
DI 10.1016/j.eururo.2016.04.009
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA DS4MA
UT WOS:000380754000023
PM 27130147
ER
PT J
AU Krakow, M
Rogers, B
AF Krakow, Melinda
Rogers, Brian
TI Collateral Damage and Critical Turning Points: Public Health
Implications of HPV Vaccine News Coverage for Boys and Men in 2011
SO HEALTH COMMUNICATION
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS VACCINATION; PROMISCUITY; NEWSPAPERS; CANCER;
SAMPLE
AB In 2009, the Food and Drug Administration (FDA) officially expanded approval of the Gardasil vaccine to include human papillomavirus (HPV) vaccination for boys and men, and in 2011, the Centers for Disease Control and Prevention (CDC) issued a formal recommendation for routine vaccination for this population. Despite these efforts, HPV vaccination rates for boys and men continue to fall short of public health targets. While news was breaking about the benefits of the HPV vaccine for boys and men, public attention shifted as a result of political debates concerning the vaccine. This study examines a pivotal time period for public health in which the vaccine became officially recommended for boys and men and at the same time became the center of political controversies in the lead-up to the 2012 presidential campaign. The current study extends previous research and presents a content analysis of newspaper articles (N=154) about the HPV vaccine for the year 2011. Results indicate that the lack of comprehensive coverage of HPV and the HPV vaccine found in previous studies continued in this year. Results shed light on key political events that may have functioned to overshadow the recommendation of the HPV vaccine for boys and men. The implications of this pattern of news coverage can inform public health efforts to address low rates of HPV vaccination uptake among boys and men in present day.
C1 [Krakow, Melinda] NCI, Canc Prevent Fellowship Program, 9609 Med Ctr Dr,Room 2W-136, Rockville, MD 20850 USA.
[Rogers, Brian] Univ Utah, Dept Commun, Salt Lake City, UT 84112 USA.
RP Krakow, M (reprint author), NCI, Canc Prevent Fellowship Program, 9609 Med Ctr Dr,Room 2W-136, Rockville, MD 20850 USA.
EM melinda.krakow@nih.gov
NR 21
TC 1
Z9 1
U1 17
U2 17
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1041-0236
EI 1532-7027
J9 HEALTH COMMUN
JI Health Commun.
PD SEP
PY 2016
VL 31
IS 9
BP 1081
EP 1088
DI 10.1080/10410236.2015.1038773
PG 8
WC Communication; Health Policy & Services
SC Communication; Health Care Sciences & Services
GA DR8LG
UT WOS:000380148800004
PM 26799666
ER
PT J
AU Stolze, BR
Gounden, V
Gu, JH
Elliott, EA
Masika, LS
Abel, BS
Merke, DP
Skarulis, MC
Soldin, SJ
AF Stolze, Brian R.
Gounden, Verena
Gu, Jianghong
Elliott, Elizabeth A.
Masika, Likhona S.
Abel, Brent S.
Merke, Deborah P.
Skarulis, Monica C.
Soldin, Steven J.
TI An improved micro-method for the measurement of steroid profiles by
APPI-LC-MS/MS and its use in assessing diurnal effects on steroid
concentrations and optimizing the diagnosis and treatment of adrenal
insufficiency and CAH
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Review
DE Micro-method atmospheric pressure; photoionization LC-MS/MS; Steroids;
Diurnal variation; Dehydroepiandrosterone
ID TANDEM MASS-SPECTROMETRY; LIQUID-CHROMATOGRAPHY; TESTOSTERONE; MEN;
HORMONES; SERUM; HYPERPLASIA; CORTISOL;
5-ALPHA-ANDROSTANE-3-ALPHA,17-BETA-DIOL; RADIOIMMUNOASSAY
AB Our goals were to (1) develop an improved micro-method usable for neonates for steroid profile measurements and a method to measure androsterone, a key steroid in the recently described androgen backdoor pathway together, with dehydroepiandrosterone and (2) to assess if dehydroepiandrosterone diurnal concentration fluctuations exist potentially necessitating strict adherence to time of blood sample draw and requirement of separate time-dependent reference intervals. Liquid chromatography tandem mass spectrometry was performed with an atmospheric pressure photoionization source [1]. For each sample 50 mu L (100 mu L for the backdoor pathway) of serum was deproteinized by adding 75 mu L (150 mu L for the backdoor pathway) of acetonitrile containing the internal standards. After centrifugation, 75 mu L (150 mu L for the backdoor pathway) of supernatant was diluted with 250 mu L of water and injected onto a Poroshell 120 EC-C8 column (SB-C8 column for the backdoor pathway). Within-run coefficients of variation ranged from 2.4 to 10.4% and between-day coefficients of variation from 2.9 to 11.2%. Comparison studies yielded correlation coefficient between 0.97 and 1.00 with recoveries of 90% or greater. Our methods analyze a 9 steroid profile and an additional 2 steroid profile (backdoor pathway) with minimal sample volume (usable in neonates optimizing early diagnosis of endocrinopathies and genetic diseases). Low limits of quantitation make these methods ideal for steroid measurement in women and prepubertal children. As diurnal variations of dehydroepiandrosterone and other steroids [2] concentrations are clinically significant we recommend that separate reference intervals be developed for 8 am, 8 pm, and midnight sample draws. The use of this approach in improving the diagnosis of patients with adrenal insufficiency and congenital adrenal hyperplasia is discussed. Published by Elsevier Ltd.
C1 [Stolze, Brian R.; Gounden, Verena; Gu, Jianghong; Elliott, Elizabeth A.; Masika, Likhona S.; Soldin, Steven J.] NIH, Dept Lab Med, 10 Ctr Dr,Bldg 10,Room 2C-306, Bethesda, MD 20814 USA.
[Abel, Brent S.; Skarulis, Monica C.] NIDDK, NIH, 10Ctr Dr,Bldg 10,Room 6-3940, Bethesda, MD 20814 USA.
[Soldin, Steven J.] Georgetown Univ, Div Endocrinol & Metab, Dept Med, 3700 O St NW, Washington, DC 20057 USA.
[Merke, Deborah P.] NIH, Ctr Clin, 10 Ctr Dr,Bldg 10,Room 1-2740, Bethesda, MD 20814 USA.
[Merke, Deborah P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, 10 Ctr Dr,Bldg 10,Room 1-2740, Bethesda, MD 20814 USA.
RP Soldin, SJ (reprint author), NIH, Dept Lab Med, 10 Ctr Dr,Bldg 10,Room 2C-306, Bethesda, MD 20814 USA.
EM steven.soldin@nih.gov
OI Elliott, Elizabeth/0000-0001-7743-4526
FU Intramural program of the NIH
FX This research has been supported (in part) by the Intramural program of
the NIH.
NR 32
TC 1
Z9 1
U1 4
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD SEP
PY 2016
VL 162
SI SI
BP 110
EP 116
DI 10.1016/j.jsbmb.2015.12.024
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA DS1XM
UT WOS:000380418500010
PM 26721696
ER
PT J
AU Tetrault, JM
Tate, JP
Edelman, EJ
Gordon, AJ
Lo Re, V
Lim, JK
Rimland, D
Goulet, J
Crystal, S
Gaither, JR
Gibert, CL
Rodriguez-Barradas, MC
Fiellin, LE
Bryant, K
Justice, AC
Fiellin, DA
AF Tetrault, Jeanette M.
Tate, Janet P.
Edelman, E. Jennifer
Gordon, Adam J.
Lo Re, Vincent, III
Lim, Joseph K.
Rimland, David
Goulet, Joseph
Crystal, Stephen
Gaither, Julie R.
Gibert, Cynthia L.
Rodriguez-Barradas, Maria C.
Fiellin, Lynn E.
Bryant, Kendall
Justice, Amy C.
Fiellin, David A.
TI Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients
With Opioid Use Disorder: The Role of HCV-Infection
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Buprenorphine; HIV; Hepatitis C; Drug induced liver injury
ID LIVER-ENZYME ELEVATION; DEPENDENT PATIENTS; NALOXONE TREATMENT;
INDIVIDUALS; THERAPY; HEALTH; TRIAL; RISK
AB Introduction: Individuals with HIV and hepatitis C (HCV) infection, alcohol use disorder, or who are prescribed potentially hepatotoxic medications may be at increased risk for buprenorphine (BUP) associated hepatotoxicity.
Materials and methods: We examined a cohort of HIV-infected and uninfected patients receiving an initial BUP prescription between 2003 and 2012. We compared changes in alanine and aspartate aminotransferases (ALT and AST) and total bilirubin (TB) stratified by HIV status. We identified cases of liver enzyme elevation (LEE), TB elevation (TBE), and conducted chart review to assess for cases of drug induced liver injury (DILI) and death. We examined associations between age, sex, race, HIV-infection, HCV-infection, alcohol use disorder, and prescription of other potentially heptatotoxic medications with the composite endpoint of LEE, TBE, and DILI.
Results: Of 666 patients prescribed BUP, 36% were HIV-infected, 98% were male, 60% had RNA-confirmed HCV infection, 50% had a recent diagnosis of alcohol use disorder, and 64% were prescribed other potentially hepatotoxic medications. No clinically significant changes were observed in median ALT, AST and TB and these changes did not differ between HIV-infected and uninfected patients. Compared with uninfected patients, HIV-infected (OR 73, 95% CI 2.1-26.1, p = 0.002), HCV-infected (OR 4.9 95% CI 1.6-15.2, p = 0.007) or HIV/HCV co-infected patients (OR 6.9, 95%CI 2.1-22.2, p = 0.001) were more likely to have the composite endpoint of LEE, TB elevation or DILI, in analyses that excluded 60 patients with evidence of pre-existing liver injury. 31 patients had LEE, 14/187 HIV-infected and 17/340 uninfected (p = 0.25); 11 had TBE, including 9/186 HIV-infected and 2/329 uninfected (p = 0.002); 8 experienced DILI, 4/202 HIV-infected and 4/204 uninfected (p = 0.45). There were no significant associations with alcohol use disorder or prescription of other potentially hepatotoxic medications after adjustment for HIV/HCV status.
Conclusions: Liver enzymes and TB are rarely elevated in HIV-infected and uninfected patients receiving BUP. Risk of hepatotoxicity was greater in individuals infected with HIV, HCV, or HIV/HCV co-infection, who may benefit from increased monitoring. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tetrault, Jeanette M.; Tate, Janet P.; Edelman, E. Jennifer; Lim, Joseph K.; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] VA Connecticut Hlth Care Syst, West Haven, CT USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA.
[Lo Re, Vincent, III] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Rimland, David] VA Med Ctr, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Goulet, Joseph] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Crystal, Stephen] Rutgers State Univ, Inst Hlth, Ctr Hlth Serv Res, New Brunswick, NJ USA.
[Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA.
[Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia L.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll, Sch Med, Houston, TX USA.
[Bryant, Kendall] NIAAA, Bethesda, MD USA.
RP Tetrault, JM (reprint author), 367 Cedar St,Suite 305, New Haven, CT 06510 USA.
EM jeanette.tetrault@yale.edu
OI Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X
FU Department of Veterans Affairs, Veterans Health Administration, and
Office of Research and Development; [U10 AA013566]; [U24 AA020794];
[U01 AA020790]; [U19 HS021112]; [R01 HS018372]
FX This material is based upon work supported by the Department of Veterans
Affairs, Veterans Health Administration, and Office of Research and
Development We must disclaim that the views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs.; Supported by. U10
AA013566, U24 AA020794, U01 AA020790, U19 HS021112, R01 HS018372
NR 25
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD SEP
PY 2016
VL 68
BP 62
EP 67
DI 10.1016/j.jsat.2016.06.002
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA DS2GB
UT WOS:000380579300008
PM 27431048
ER
PT J
AU Strickland, J
Zang, QD
Kleinstreuer, N
Paris, M
Lehmann, DM
Choksi, N
Matheson, J
Jacobs, A
Lowit, A
Allen, D
Casey, W
AF Strickland, Judy
Zang, Qingda
Kleinstreuer, Nicole
Paris, Michael
Lehmann, David M.
Choksi, Neepa
Matheson, Joanna
Jacobs, Abigail
Lowit, Anna
Allen, David
Casey, Warren
TI Integrated decision strategies for skin sensitization hazard
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Article
DE skin sensitization; allergic contact dermatitis; integrated decision
strategy; machine learning; LLNA; DPRA; KeratinoSens; h-CLAT; support
vector machine
ID LYMPH-NODE ASSAY; LINE ACTIVATION TEST; TEST H-CLAT; SCREENING CONTACT
ALLERGENS; PEPTIDE REACTIVITY ASSAY; NONANIMAL TEST METHODS; PIG
MAXIMIZATION TEST; RISK-ASSESSMENT MODEL; IN-VITRO METHODS; PREDICTIVE
PERFORMANCE
AB One of the top priorities of the Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM) is the identification and evaluation of non-animal alternatives for skin sensitization testing. Although skin sensitization is a complex process, the key biological events of the process have been well characterized in an adverse outcome pathway (AOP) proposed by the Organisation for Economic Co-operation and Development (OECD). Accordingly, ICCVAM is working to develop integrated decision strategies based on the AOP using in vitro, in chemico and in silico information. Data were compiled for 120 substances tested in the murine local lymph node assay (LLNA), direct peptide reactivity assay (DPRA), human cell line activation test (h-CLAT) and KeratinoSens assay. Data for six physicochemical properties, which may affect skin penetration, were also collected, and skin sensitization read-across predictions were performed using OECD QSAR Toolbox. All data were combined into a variety of potential integrated decision strategies to predict LLNA outcomes using a training set of 94 substances and an external test set of 26 substances. Fifty-four models were built using multiple combinations of machine learning approaches and predictor variables. The seven models with the highest accuracy (89-96% for the test set and 96-99% for the training set) for predicting LLNA outcomes used a support vector machine (SVM) approach with different combinations of predictor variables. The performance statistics of the SVM models were higher than any of the non-animal tests alone and higher than simple test battery approaches using these methods. These data suggest that computational approaches are promising tools to effectively integrate data sources to identify potential skin sensitizers without animal testing. Published 2016. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
The Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM) evaluated a non-animal decision strategies to predict skin sensitization. Machine learning approaches integrated in vitro, in chemico and in silico data and six physicochemical properties for 120 substances to predict murine local lymph node assay (LLNA) outcomes. The seven models with the highest accuracy used a support vector machine with different combinations of predictor variables. The models outperformed individual non-animal methods and test batteries. This suggests that computational approaches are promising tools to effectively integrate data to identify potential skin sensitizers without animal testing.
C1 [Strickland, Judy; Zang, Qingda; Kleinstreuer, Nicole; Paris, Michael; Choksi, Neepa; Allen, David] ILS, Res Triangle Pk, NC 27709 USA.
[Lehmann, David M.] US EPA, NHEERL, EPHD, CIB, Res Triangle Pk, NC 27709 USA.
[Matheson, Joanna] US Consumer Prod Safety Commiss, Bethesda, MD 20814 USA.
[Jacobs, Abigail] US FDA, CDER, Silver Spring, MD 20993 USA.
[Lowit, Anna] US EPA, OCSPP, OPP, HED, Washington, DC 20460 USA.
[Casey, Warren] NIEHS, NIH, DNTP, NICEATM, Res Triangle Pk, NC 27709 USA.
RP Casey, W (reprint author), NIEHS, NIH, DNTP, NICEATM, POB 12233, Res Triangle Pk, NC 27709 USA.
EM warren.casey@nih.gov
OI Kleinstreuer, Nicole/0000-0002-7914-3682
FU federal funds from the NIEHS, NIH of NICEATM [HHSN273201500010C]
FX The authors thank Drs D. Germolec, B.A. Merrick, R. Luebke and M. Ward
for their thoughtful critical review of this manuscript. This project
was funded in whole or in part with federal funds from the NIEHS, NIH
under contract HHSN273201500010C to ILS in support of NICEATM.
NR 77
TC 8
Z9 8
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0260-437X
EI 1099-1263
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD SEP
PY 2016
VL 36
IS 9
BP 1150
EP 1162
DI 10.1002/jat.3281
PG 13
WC Toxicology
SC Toxicology
GA DR5PD
UT WOS:000379954000008
PM 26851134
ER
PT J
AU He, ZJ
Wan, XM
Schulz, A
Bludau, H
Dobrovolskaia, MA
Stern, ST
Montgomery, SA
Yuan, H
Li, ZB
Alakhova, D
Sokolsky, M
Darr, DB
Perou, CM
Jordan, R
Luxenhofer, R
Kabanov, AV
AF He, Zhijian
Wan, Xiaomeng
Schulz, Anita
Bludau, Herdis
Dobrovolskaia, Marina A.
Stern, Stephan T.
Montgomery, Stephanie A.
Yuan, Hong
Li, Zibo
Alakhova, Dania
Sokolsky, Marina
Darr, David B.
Perou, Charles M.
Jordan, Rainer
Luxenhofer, Robert
Kabanov, Alexander V.
TI A high capacity polymeric micelle of paclitaxel: Implication of high
dose drug therapy to safety and in vivo anti-cancer activity
SO BIOMATERIALS
LA English
DT Article
DE Polyoxazolines; Paclitaxel nanoformulation; In vitro; In vivo; Efficacy;
Multi-drug resistant cancer
ID BREAST-CANCER; DELIVERY-SYSTEMS; NANOPARTICLE FORMULATION;
CREMOPHOR-FREE; PHASE-II; POLY(2-OXAZOLINE); EFFICACY; TUMORS; NK105;
TAXOL
AB The poor solubility of paclitaxel (PTX), the commercially most successful anticancer drug, has long been hampering the development of suitable formulations. Here, we present translational evaluation of a nanoformulation of PTX, which is characterized by a facile preparation, extraordinary high drug loading of 50% wt. and PTX solubility of up to 45 g/L, excellent shelf stability and controllable, sub-100 nm size. We observe favorable in vitro and in vivo safety profiles and a higher maximum tolerated dose compared to clinically approved formulations. Pharmacokinetic analysis reveals that the higher dose administered leads to a higher exposure of the tumor to PTX. As a result, we observed improved therapeutic outcome in orthotopic tumor models including particularly faithful and aggressive "T11" mouse claudin-low breast cancer orthotopic, syngeneic transplants. The promising preclinical data on the presented PTX nanoformulation showcase the need to investigate new excipients and is a robust basis to translate into clinical trials. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [He, Zhijian; Wan, Xiaomeng; Alakhova, Dania; Sokolsky, Marina; Kabanov, Alexander V.] Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Genet Med Bldg,Room 1094,Campus Box 7362, Chapel Hill, NC 27599 USA.
[He, Zhijian; Wan, Xiaomeng; Alakhova, Dania; Sokolsky, Marina; Kabanov, Alexander V.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
[Schulz, Anita; Bludau, Herdis; Jordan, Rainer] Tech Univ Dresden, Dept Chem, Makromol Chem, Mommsenstr 4, D-01069 Dresden, Germany.
[Dobrovolskaia, Marina A.; Stern, Stephan T.] Leidos Biomed Res Inc, Nanotechnol Characterizat Lab, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Montgomery, Stephanie A.] Univ N Carolina, Dept Pathol & Lab Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Yuan, Hong; Li, Zibo] Univ N Carolina, Sch Med, Dept Radiol, Chapel Hill, NC 27599 USA.
[Darr, David B.; Perou, Charles M.] Univ N Carolina, Anim Study Core, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Luxenhofer, Robert] Univ Wurzburg, Funct Polymer Mat, Chair Chem Technol Mat Synth, Rontgenring 11, D-97070 Wurzburg, Germany.
[Kabanov, Alexander V.] Moscow MV Lomonosov State Univ, Lab Chem Design Bionanomat, Fac Chem, Moscow, Russia.
RP Kabanov, AV (reprint author), Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Genet Med Bldg,Room 1094,Campus Box 7362, Chapel Hill, NC 27599 USA.; Luxenhofer, R (reprint author), Univ Wurzburg, Funct Polymer Mat, Chair Chem Technol Mat Synth, Rontgenring 11, D-97070 Wurzburg, Germany.
EM robert.luxenhofer@uni-wuerzburg.de; kabanov@email.unc.edu
RI Jordan, Rainer/B-6542-2008; Nanotechnology Characterization Lab,
NCL/K-8454-2012; Luxenhofer, Robert/C-2825-2008
OI Jordan, Rainer/0000-0002-9414-1597; Luxenhofer,
Robert/0000-0001-5567-7404
FU Cancer Nanotechnology Platform Partnership grant of the National Cancer
Institute Alliance for Nanotechnology in Cancer [U01 CA116591]; UNC
Eshelman School of Pharmacy; University Cancer Research Fund through the
Lineberger Comprehensive Cancer Center; NCI Breast SPORE program
[P50-CA58223-09A1]; [RO1-CA148761]
FX This work was supported by a Cancer Nanotechnology Platform Partnership
grant (U01 CA116591) of the National Cancer Institute Alliance for
Nanotechnology in Cancer awarded to A.V.K. and the The Carolina
Partnership, a strategic partnership between the, UNC Eshelman School of
Pharmacy and The University Cancer Research Fund through the Lineberger
Comprehensive Cancer Center. C.M.P was supported by NCI Breast SPORE
program (P50-CA58223-09A1), and RO1-CA148761.
NR 45
TC 6
Z9 6
U1 44
U2 96
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2016
VL 101
BP 296
EP 309
DI 10.1016/j.biomaterials.2016.06.002
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DR0YJ
UT WOS:000379632500027
PM 27315213
ER
PT J
AU Liu, LJ
Fissel, JA
Tasnim, A
Borzan, J
Gocke, A
Calabresi, PA
Farah, MH
AF Liu, Lijuan
Fissel, John A.
Tasnim, Aniqa
Borzan, Jasenka
Gocke, Anne
Calabresi, Peter A.
Farah, Mohamed H.
TI Increased TNFR1 expression and signaling in injured peripheral nerves of
mice with reduced BACE1 activity
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Neuroinflammation; Macrophages in the PNS; Nervous system injury
ID NECROSIS-FACTOR-ALPHA; MOUSE SCIATIC-NERVE; IMMUNE-MEDIATED
DEMYELINATION; CHRONIC CONSTRICTION INJURY; AMYLOID PRECURSOR PROTEIN;
BETA-SECRETASE BACE1; WALLERIAN DEGENERATION; FUNCTIONAL RECOVERY;
CYTOKINE EXPRESSION; AXON REGENERATION
AB Hematogenous macrophages remove myelin debris from injured peripheral nerves to provide a micro environment conducive to axonal regeneration. Previously, we observed that injured peripheral nerves from Beta-site APP Cleaving Enzyme 1 (BACE1) knockout (KO) mice displayed earlier influx of and enhanced phagocytosis by macrophages when compared to wild-type (WT) mice. These observations suggest that BACE1 might regulate macrophage influx into distal stumps of injured nerves. To determine through which pathway BACE1 influences macrophage influx, we used a mouse inflammation antibody array to assay the expression of inflammation-related proteins in injured nerves of BACE1 KO and WT mice. The most significant change was in expression of tumor necrosis factor receptor 1 (TNFR1) in the distal stump of injured BACE1 KO nerves. Western blotting of protein extracts confirmed increased expression of TNFR1 and its downstream transcriptional factor NF kappa B in the BACE1 KO distal stumps. Additionally, treatment of WT mice with a BACE1 inhibitor resulted in increased TNFR1 expression and signaling in the distal stump of injured nerves. Exogenous TNF alpha increased nuclear translocation of p65 NF kappa B in BACE1 KO tissue and cultured fibroblasts compared with control WT. BACE1 regulates TNFR1 expression at the level of gene expression and not through proteolytic processing. The accelerated macrophage influx in injured nerves of BACE1 KO mice correlates with increased expression and signaling via TNFR1, indicating a link between BACE1 activity and TNFR1 expression/signaling that might contribute to repair of the injured nervous system. (C) 2016 Elsevier Inc All rights reserved.
C1 [Liu, Lijuan; Fissel, John A.; Tasnim, Aniqa; Gocke, Anne; Calabresi, Peter A.; Farah, Mohamed H.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Borzan, Jasenka] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.
[Tasnim, Aniqa] Harvard Univ, Cambridge, MA 02138 USA.
[Borzan, Jasenka] NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Farah, MH (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurol, Neuromuscular Div, John G Rangos Sr Bldg,Room 239,855 N Wolfe St, Baltimore, MD 21205 USA.
EM mfarah2@jhmi.edu
FU Muscular Dystrophy Association [MDA 254860]; National Institutes of
Neurological Disease and Stroke of the National Institutes of Health
[R01NS079339]
FX This work was supported by the Muscular Dystrophy Association (MDA
254860) and R01NS079339 from the National Institutes of Neurological
Disease and Stroke of the National Institutes of Health. We thank Carol
Cooke, Justin Glenn, Lori Lebson, Zoe Rammelkamp, and Parisa
Moghaddam-Taaheri for technical assistance.
NR 53
TC 1
Z9 1
U1 7
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
EI 1095-953X
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD SEP
PY 2016
VL 93
BP 21
EP 27
DI 10.1016/j.nbd.2016.04.002
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA DQ8IE
UT WOS:000379452600003
PM 27080468
ER
PT J
AU Srivastava, S
Reid, BJ
Ghosh, S
Kramer, BS
AF Srivastava, Sudhir
Reid, Brian J.
Ghosh, Sharmistha
Kramer, Barnett S.
TI Research Needs for Understanding the Biology of Overdiagnosis in Cancer
Screening
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
ID PROSTATE-CANCER; BREAST-CANCER; FOLLOW-UP; BARRETTS-ESOPHAGUS;
EVOLUTION; MUTATIONS; CELLS; ADENOCARCINOMA; KERATINOCYTES; MAMMOGRAPHY
AB Many cancers offer an extended window of opportunity for early detection and therapeutic intervention that could lead to a reduction in cause-specific mortality. The pursuit of early detection in screening settings has resulted in decreased incidence and mortality for some cancers (e.g., colon and cervical cancers), and increased incidence with only modest or no effect on cause-specific mortality in others (e.g., breast and prostate). Whereas highly sensitive screening technologies are better at detecting a number of suspected "cancers" that are indolent and likely to remain clinically unimportant in the lifetime of a patient, defined as overdiagnosis, they often miss cancers that are aggressive and tend to present clinically between screenings, known as interval cancers. Unrecognized overdiagnosis leads to overtreatment with its attendant (often long-lasting) side effects, anxiety, and substantial financial harm. Existing methods often cannot differentiate indolent lesions from aggressive ones or understand the dynamics of neoplastic progression. To correctly identify the population that would benefit the most from screening and identify the lesions that would benefit most from treatment, the evolving genomic and molecular profiles of individual cancers during the clinical course of progression or indolence must be investigated, while taking into account an individual's genetic susceptibility, clinical and environmental risk factors, and the tumor microenvironment. Practical challenges lie not only in the lack of access to tissue specimens that are appropriate for the study of natural history, but also in the absence of targeted research strategies. This commentary summarizes the recommendations from a diverse group of scientists with expertise in basic biology, translational research, clinical research, statistics, and epidemiology and public health professionals convened to discuss research directions. (C) 2015 Wiley Periodicals, Inc.
C1 [Srivastava, Sudhir; Ghosh, Sharmistha; Kramer, Barnett S.] NCI, Canc Prevent Div, NIH, 9609 Med Ctr Dr, Bethesda, MD 20892 USA.
[Reid, Brian J.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Genome Sci, Div Human Biol, Seattle, WA 98195 USA.
[Reid, Brian J.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Genome Sci, Div Publ Hlth Sci, Seattle, WA 98195 USA.
[Reid, Brian J.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Human Biol, Seattle, WA 98195 USA.
Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Publ Hlth Sci, Seattle, WA 98195 USA.
RP Srivastava, S (reprint author), NCI, Canc Prevent Div, NIH, 9609 Med Ctr Dr, Bethesda, MD 20892 USA.
EM srivasts@mail.nih.gov
FU NCI NIH HHS [P01 CA091955]
NR 51
TC 3
Z9 3
U1 3
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2016
VL 231
IS 9
BP 1870
EP 1875
DI 10.1002/jcp.25227
PG 6
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA DQ4FJ
UT WOS:000379159100004
PM 26505642
ER
PT J
AU Salinas, AG
Davis, MI
Lovinger, DM
Mateo, Y
AF Salinas, Armando G.
Davis, Margaret I.
Lovinger, David M.
Mateo, Yolanda
TI Dopamine dynamics and cocaine sensitivity differ between striosome and
matrix compartments of the striatum
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Patch; Voltammetry; Nucleus accumbens; Dopamine transporter; Dopamine D2
receptor
ID SIZED SPINY NEURONS; CAT CAUDATE-NUCLEUS; RAT STRIATUM; DORSAL STRIATUM;
CHOLINERGIC INTERNEURONS; PROJECTION SYSTEMS; SINGLE-AXON; RELEASE;
ACCUMBENS; HETEROGENEITY
AB The striatum is typically classified according to its major output pathways, which consist of dopamine D1 and D2 receptor-expressing neurons. The striatum is also divided into striosome and matrix compartments, based on the differential expression of a number of proteins, including the mu opioid receptor, dopamine transporter (DAT), and Nr4a1 (nuclear receptor subfamily 4, group A, member 1). Numerous functional differences between the striosome and matrix compartments are implicated in dopamine related neurological disorders including Parkinson's disease and addiction. Using Nr4a1-eGFP mice, we provide evidence that electrically evoked dopamine release differs between the striosome and matrix compartments in a regionally-distinct manner. We further demonstrate that this difference is not due to differences in inhibition of dopamine release by dopamine autoreceptors or nicotinic acetylcholine receptors. Furthermore, cocaine enhanced extracellular dopamine in striosomes to a greater degree than in the matrix and concomitantly inhibited dopamine uptake in the matrix to a greater degree than in striosomes. Importantly, these compartment differences in cocaine sensitivity were limited to the dorsal striatum. These findings demonstrate a level of exquisite microanatomical regulation of dopamine by the DAT in striosomes relative to the matrix. Published by Elsevier Ltd.
C1 [Salinas, Armando G.] George Mason Univ, Krasnow Inst Adv Study, Fairfax, VA 22030 USA.
[Salinas, Armando G.; Davis, Margaret I.; Lovinger, David M.; Mateo, Yolanda] NIAAA, Lab Integrat Neurosci, Sect Synapt Pharmacol, Rockville, MD 20852 USA.
RP Mateo, Y (reprint author), NIAAA, Lab Integrat Neurosci, Sect Synapt Pharmacol, NIH, 5625 Fishers Lane, Rockville, MD 20852 USA.
EM mateoy@mail.nih.gov
FU NIAAA [R01 AA016022]; National Institutes of Health, National Institute
on Alcohol Abuse and Alcoholism, Division of Intramural Clinical and
Biomedical Research [ZIA AA000407]
FX This work was supported by NIAAA R01 AA016022 (AGS) and the National
Institutes of Health, National Institute on Alcohol Abuse and
Alcoholism, Division of Intramural Clinical and Biomedical Research
(MID, YM, and DML) (Grant Number: ZIA AA000407).
NR 59
TC 4
Z9 4
U1 4
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD SEP
PY 2016
VL 108
BP 275
EP 283
DI 10.1016/j.neuropharm.2016.03.049
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DQ1IA
UT WOS:000378953500027
PM 27036891
ER
PT J
AU Kocarnik, JM
Chan, AT
Slattery, ML
Potter, JD
Meyerhardt, J
Phipps, A
Nan, HM
Harrison, T
Rohan, TE
Qi, LH
Hou, LF
Caan, B
Kroenke, CH
Strickler, H
Hayes, RB
Schoen, RE
Chong, DQ
White, E
Berndt, SI
Peters, U
Newcomb, PA
AF Kocarnik, Jonathan M.
Chan, Andrew T.
Slattery, Martha L.
Potter, John D.
Meyerhardt, Jeffrey
Phipps, Amanda
Nan, Hongmei
Harrison, Tabitha
Rohan, Thomas E.
Qi, Lihong
Hou, Lifang
Caan, Bette
Kroenke, Candyce H.
Strickler, Howard
Hayes, Richard B.
Schoen, Robert E.
Chong, Dawn Q.
White, Emily
Berndt, Sonja I.
Peters, Ulrike
Newcomb, Polly A.
TI Relationship of prediagnostic body mass index with survival after
colorectal cancer: Stage-specific associations
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE body mass index (BMI); cancer stage; colorectal cancer (CRC); mortality;
survival
ID OBESITY PARADOX; WOMENS HEALTH; COLON-CANCER; SUSCEPTIBILITY LOCI;
PROSPECTIVE COHORT; PHYSICAL-ACTIVITY; MORTALITY; DIAGNOSIS; OVERWEIGHT;
DEATH
AB Higher body mass index (BMI) is a well-established risk factor for colorectal cancer (CRC), but is inconsistently associated with CRC survival. In 6 prospective studies participating in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), 2,249 non-Hispanic white CRC cases were followed for a median 4.5 years after diagnosis, during which 777 died, 554 from CRC-related causes. Associations between prediagnosis BMI and survival (overall and CRC-specific) were evaluated using Cox regression models adjusted for age at diagnosis, sex, study and smoking status (current/former/never). The association between BMI category and CRC survival varied by cancer stage at diagnosis (I-IV) for both all-cause (p-interaction=0.03) and CRC-specific mortality (p-interaction=0.04). Compared to normal BMI (18.5-24.9 kg/m(2)), overweight (BMI 25.0-29.9) was associated with increased mortality among those with Stage I disease, and decreased mortality among those with Stages II-IV disease. Similarly, obesity (BMI >= 30) was associated with increased mortality among those with Stages I-II disease, and decreased mortality among those with Stages III-IV disease. These results suggest the relationship between BMI and survival after CRC diagnosis differs by stage at diagnosis, and may emphasize the importance of adequate metabolic reserves for colorectal cancer survival in patients with late-stage disease.
C1 [Kocarnik, Jonathan M.; Phipps, Amanda; White, Emily; Peters, Ulrike; Newcomb, Polly A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Kocarnik, Jonathan M.; Potter, John D.; Phipps, Amanda; Harrison, Tabitha; White, Emily; Peters, Ulrike; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
[Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Chan, Andrew T.; Chong, Dawn Q.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Slattery, Martha L.] Univ Utah, Dept Internal Med, Hlth Sci Ctr, Salt Lake City, UT 84112 USA.
[Meyerhardt, Jeffrey] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Meyerhardt, Jeffrey] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Nan, Hongmei] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46204 USA.
[Nan, Hongmei] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
[Rohan, Thomas E.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Qi, Lihong] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA.
[Hou, Lifang] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Hou, Lifang] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Caan, Bette; Kroenke, Candyce H.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Hayes, Richard B.] NYU, Div Epidemiol, Sch Med, New York, NY USA.
[Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Med & Epidemiol, Pittsburgh, PA USA.
[Chong, Dawn Q.] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore.
[Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Kocarnik, JM (reprint author), Kocarnik 1100 Fairview Ave N Mailstop M4-B402, Seattle, WA 98199 USA.
EM jkocarni@fredhutch.org
OI Hayes, Richard/0000-0002-0918-661X; Kocarnik,
Jonathan/0000-0001-8084-1608
FU National Center for Advancing Translational Sciences (National
Institutes of Health) [KL2 TR000421]; National Cancer Institute [K05
CA152715, T32 CA 09168, U01 CA137088, R01 CA059045, P01 CA055075, UM1
CA167552, R01 CA137178, R01 CA151993, P50 CA127003, UM1 CA186107, P01
CA87969, R01 CA042182, K05 CA154337]; Division of Cancer Epidemiology;
Division of Cancer Prevention (PLCO); National Heart, Lung, and Blood
Institute, National Institutes of Health [HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, HHSN271201100004C]
FX Grant sponsor: National Center for Advancing Translational Sciences
(National Institutes of Health); Grant number: KL2 TR000421; Grant
sponsor: National Cancer Institute; Grant numbers: K05 CA152715, T32 CA
09168; U01 CA137088 and R01 CA059045 (GECCO); P01 CA055075, UM1
CA167552, R01 CA137178, R01 CA151993 and P50 CA127003 (HPFS); UM1
CA186107, R01 CA137178, P01 CA87969, R01 CA151993 and P50 CA127003
(NHS); R01 CA042182 (PHS); K05 CA154337 (VITAL); Intramural Research
Program of the Division of Cancer Epidemiology and contracts from the
Division of Cancer Prevention (PLCO); Grant sponsor: National Heart,
Lung, and Blood Institute, National Institutes of Health; Grant numbers:
HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C and HHSN271201100004C (WHI)
NR 47
TC 2
Z9 2
U1 2
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2016
VL 139
IS 5
BP 1065
EP 1072
DI 10.1002/ijc.30163
PG 8
WC Oncology
SC Oncology
GA DP3TR
UT WOS:000378418800011
PM 27121247
ER
PT J
AU Xi, LF
Schiffman, M
Koutsky, LA
Hughes, JP
Hulbert, A
Shen, ZP
Galloway, DA
Kiviat, NB
AF Xi, Long Fu
Schiffman, Mark
Koutsky, Laura A.
Hughes, James P.
Hulbert, Ayaka
Shen, Zhenping
Galloway, Denise A.
Kiviat, Nancy B.
TI Variant-specific persistence of infections with human papillomavirus
Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial
neoplasia
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE human papillomavirus; variants; persistence; cervical intraepithelial
neoplasia
ID NATURAL-HISTORY; YOUNG-WOMEN; LESIONS; HPV; POLYMORPHISM; POPULATION;
CANCER; COHORT; CLASSIFICATION
AB In our previous study of the etiologic role of oncogenic human papillomavirus (HPV) types other than HPV16 and 18, we observed a significantly higher risk of cervical intraepithelial neoplasia Grades 2-3 (CIN2/3) associated with certain lineages of HPV types 31/33/45/56/58 [called high-risk (HR) variants] compared with non-HR variants. This study was to examine whether these intra-type variants differ in persistence of the infection and persistence-associated risk of CIN2/3. Study subjects were women who had any of HPV types 31/33/45/56/58 newly detected during a 2-year follow-up with 6-month intervals. For each type, the first positive sample was used for variant characterization. The association of reverting-to-negativity with group of the variants and CIN2/3 with length of positivity was assessed using discrete Cox regression and logistic regression, respectively. Of the 598 newly detected, type-specific HPV infections, 312 became undetectable during follow-up. Infections with HR, compared with non-HR, variants were marginally more likely to become negative [adjusted hazard ratio=1.3; 95% confidence interval (CI), 0.9-1.8]. The adjusted odds ratio associating with the development of CIN2/3 was 3.0 (95% CI, 1.2-7.4) for persistent infections with HR variants for 6 months and 10.0 (95% CI, 3.8-38.0) for persistent infections with HR variants for 12-18 months as compared with the first positive detection of HR variants. Among women with non-HR variants, there were no appreciable differences in risk of CIN2/3 by length of positivity. Findings suggest that the lineage-associated risk of CIN2/3 was not mediated through a prolonged persistent infection, but oncogenic heterogeneity of the variants.
C1 [Xi, Long Fu; Hulbert, Ayaka; Shen, Zhenping; Kiviat, Nancy B.] Univ Washington, Sch Med, Dept Pathol, NJB Ste 1187,325 9th Ave, Seattle, WA 98104 USA.
[Xi, Long Fu; Koutsky, Laura A.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, NJB Ste 1187,325 9th Ave, Seattle, WA 98104 USA.
[Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Hughes, James P.] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, NJB Ste 1187,325 9th Ave, Seattle, WA 98104 USA.
[Galloway, Denise A.] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.
RP Xi, LF (reprint author), Univ Washington, Harborview Med Ctr, Dept Pathol, NJB Ste 1187,325 9th Ave, Seattle, WA 98104 USA.
EM longfu@u.washington.edu
FU National Cancer Institute of the National Institutes of Health
[CA133569]
FX This study was part of the project ancillary to the ALTS clinical trial
but does not represent the views of the ALTS Group. The authors would
like to thank the ALTS Group Investigators for their planning and
conducting the trial and for providing the biological specimens and data
to the present study. We also thank Information Management Services,
Calverton, MD for data management and programming support. The research
reported in this publication was supported by National Cancer Institute
of the National Institutes of Health under award number CA133569. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health. All authors have no commercial or other associations that might
pose a conflict of interest.
NR 38
TC 0
Z9 0
U1 7
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2016
VL 139
IS 5
BP 1098
EP 1105
DI 10.1002/ijc.30164
PG 8
WC Oncology
SC Oncology
GA DP3TR
UT WOS:000378418800015
PM 27121353
ER
PT J
AU Liow, JS
Zoghbi, SS
Hu, S
Hall, MD
Hines, CS
Shetty, HU
Araneta, MD
Page, EM
Pike, VW
Kreisl, WC
Herscovitch, P
Gottesman, MM
Theodore, WH
Innis, RB
AF Liow, Jeih-San
Zoghbi, Sami S.
Hu, Shuo
Hall, Matthew D.
Hines, Christina S.
Shetty, H. Umesha
Araneta, Maria D.
Page, Emily M.
Pike, Victor W.
Kreisl, William C.
Herscovitch, Peter
Gottesman, Michael M.
Theodore, William H.
Innis, Robert B.
TI F-18-FCWAY, a serotonin 1A receptor radioligand, is a substrate for
efflux transport at the human blood-brain barrier
SO NEUROIMAGE
LA English
DT Article
DE PET; Efflux transporter; P-gp; Blood brain barrier; 5-HT1A
ID TEMPORAL-LOBE EPILEPSY; P-GLYCOPROTEIN; 5-HT1A RECEPTORS; RODENT BRAIN;
PET; DEFLUORINATION; METABOLITES; INHIBITION; WAY-100635; EXPRESSION
AB Efflux transporters at the blood-brain barrier can decrease the entry of drugs and increase the removal of those molecules able to bypass the transporter. We previously hypothesized that F-18-FCWAY, a radioligand for the serotonin 5-HT1A receptor, is a weak substrate for permeability glycoprotein (P-gp) based on its very early peak and rapid washout from human brain. To determine whether F-18-FCWAY is a substrate for P-gp, breast cancer resistance protein (BCRP), and multidrug resistance protein (MRP1) - the three most prevalent efflux transporters at the blood-brain barrier - we performed three sets of experiments. In vitro, we conducted fluorescence-activated cell sorting (FACS) flow cytometry studies in cells over-expressing P-gp, BCRP, and MRP1 treated with inhibitors specific to each transporter and with FCWAY. Ex vivo, we measured F-18-FCWAY concentration in plasma and brain homogenate of transporter knockout mice using gamma-counter and radio-HPLC. In vivo, we conducted positron emission tomography (PET) studies to assess changes in humans who received F-18-FCWAY during an infusion of tariquidar (2-4mg/kg iv), a potent and selective P-gp inhibitor. In vitro studies showed that FCWAY allowed fluorescent substrates to get into the cell by competitive inhibition of all three transporters at the cell membrane. Ex vivo measurements in knockout mice indicate that F-18-FCWAY is a substrate only for P-gp and not BCRP. In vivo, tariquidar increased F-18-FCWAY brain uptake in seven of eight subjects by 60-100% compared to each person's baseline. Tariquidar did not increase brain uptake via some peripheral mechanism, given that it did not significantly alter concentrations in plasma of the parent radioligand F-18-FCWAY or its brain-penetrant radiometabolite F-18-FC. These results show that F-18-FCWAY is a weak substrate for efflux transport at the blood-brain barrier; some radioligand can enter brain, but its removal is hastened by P-gp. Although F-18-FCWAY is not ideal for measuring 5-HT1A receptors, it demonstrates that weak substrate radioligands can be useful for measuring both increased and decreased function of efflux transporters, which is not possible with currently available radioligands such as C-11-loperamide and C-11-verapamil that are avid substrates for transporters. Published by Elsevier Inc.
C1 [Liow, Jeih-San; Zoghbi, Sami S.; Shetty, H. Umesha; Araneta, Maria D.; Page, Emily M.; Pike, Victor W.; Innis, Robert B.] NIMH, Mol Imaging Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
[Hu, Shuo] Cent S Univ, Xiang Ya Hosp, PET Ctr, Changsha, Hunan, Peoples R China.
[Hall, Matthew D.] NCATS Chem Genom Ctr, Rockville, MD USA.
[Hines, Christina S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Kreisl, William C.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA.
[Herscovitch, Peter] NIH, PET Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Gottesman, Michael M.] NCI, Multidrug Resistance Sect, NIH, Bethesda, MD 20892 USA.
[Theodore, William H.] NINDS, Clin Epilepsy Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Liow, JS (reprint author), NIMH, Mol Imaging Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
EM liowj@mail.nih.gov
FU Intramural Research Program of the National Institute Mental Health, NIH
[ZIAMH002852, ZIAMH002793, NCT01386476]
FX This study was funded by the Intramural Research Program of the National
Institute Mental Health, NIH: projects ZIAMH002852 and ZIAMH002793,
under clinical protocol NCT01386476. All authors have no conflicts of
interest to disclose.
NR 25
TC 0
Z9 0
U1 6
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD SEP
PY 2016
VL 138
BP 134
EP 140
DI 10.1016/j.neuroimage.2016.05.045
PG 7
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DP5ET
UT WOS:000378519500011
PM 27211474
ER
PT J
AU Huo, Y
Plassard, AJ
Carass, A
Resnick, SM
Pham, DL
Prince, JL
Landman, BA
AF Huo, Yuankai
Plassard, Andrew J.
Carass, Aaron
Resnick, Susan M.
Pham, Dzung L.
Prince, Jerry L.
Landman, Bennett A.
TI Consistent cortical reconstruction and multi-atlas brain segmentation
SO NEUROIMAGE
LA English
DT Article
DE Multi-atlas segmentation; Magnetic resonance imaging; Cerebral cortex;
Cortical reconstruction
ID HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; AUTOMATED 3-D
EXTRACTION; SURFACE-BASED ANALYSIS; TISSUE CLASSIFICATION; COORDINATE
SYSTEM; OLDER-ADULTS; LABEL FUSION; MR-IMAGES; THICKNESS
AB Whole brain segmentation and cortical surface reconstruction are two essential techniques for investigating the human brain. Spatial inconsistences, which can hinder further integrated analyses of brain structure, can result due to these two tasks typically being conducted independently of each other. FreeSurfer obtains selfconsistent whole brain segmentations and cortical surfaces. It starts with subcortical segmentation, then carries out cortical surface reconstruction, and ends with cortical segmentation and labeling. However, this "segmentation to surface to parcellation" strategy has shown limitations in various cohorts such as older populations with large ventricles. In this work, we propose a novel "multi-atlas segmentation to surface" method calledMulti-atlas CRUISE (MaCRUISE), which achieves self-consistent whole brain segmentations and cortical surfaces by combining multi-atlas segmentation with the cortical reconstruction method CRUISE. A modification called MaCRUISE(+) is designed to perform well when white matter lesions are present. Comparing to the benchmarks CRUISE and FreeSurfer, the surface accuracy of MaCRUISE and MaCRUISE+ is validated using two independent datasets with expertly placed cortical landmarks. A third independent dataset with expertly delineated volumetric labels is employed to compare segmentation performance. Finally, 200MR volumetric images from an older adult sample are used to assess the robustness of MaCRUISE and FreeSurfer. The advantages of MaCRUISE are: (1) MaCRUISE constructs self-consistent voxelwise segmentations and cortical surfaces, while MaCRUISE(+) is robust to white matter pathology. (2) MaCRUISE achieves more accurate whole brain segmentations than independently conducting the multi-atlas segmentation. (3) MaCRUISE is comparable in accuracy to FreeSurfer (when FreeSurfer does not exhibit global failures) while achieving greater robustness across an older adult population. MaCRUISE has been made freely available in open source. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Huo, Yuankai; Landman, Bennett A.] Vanderbilt Univ, Elect Engn, EECS 2301,Vanderbilt Pl,POB 351679 Stn B, Nashville, TN 37235 USA.
[Plassard, Andrew J.; Landman, Bennett A.] Vanderbilt Univ, Comp Sci, EECS 2301,Vanderbilt Pl,POB 351679 Stn B, Nashville, TN 37235 USA.
[Carass, Aaron; Prince, Jerry L.] Johns Hopkins Univ, Image Anal & Commun Lab, Baltimore, MD USA.
[Resnick, Susan M.] Natl Inst Aging, Lab Behav Neurosci, Baltimore, MD USA.
[Pham, Dzung L.] Henry Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD USA.
[Landman, Bennett A.] Vanderbilt Univ, Inst Imaging Sci, EECS 2301,Vanderbilt Pl,POB 351679 Stn B, Nashville, TN 37235 USA.
[Landman, Bennett A.] Vanderbilt Univ, Radiol & Radiol Sci, EECS 2301,Vanderbilt Pl,POB 351679 Stn B, Nashville, TN 37235 USA.
RP Huo, Y (reprint author), Vanderbilt Univ, EECS 2301,Vanderbilt Pl,POB 351679 Stn B, Nashville, TN 37235 USA.
EM yuankai.huo@vanderbilt.edu
OI Huo, Yuankai/0000-0002-2096-8065; Carass, Aaron/0000-0003-4939-5085
FU NSF CAREER [1452485]; NIH [5R21EY024036, 1R21NS064534, 1R01NS070906,
5R01NS056307, 1R21NS096497, 2R01EB006136, 1R03EB012461, R01EB006193,
5R21NS082891]; Intramural Research Program, National Institute on Aging,
NIH; National MS Society [RG-1507-05243]; Advanced Computing Center for
Research and Education (ACCRE) at Vanderbilt University, Nashville, TN;
ViSE/VICTR [VR3029]; National Center for Research Resources [UL1
RR024975-01]; National Center for Advancing Translational Sciences [2
UL1 TR000445-06]; Department of Defense in the Center for Neuroscience
and Regenerative Medicine
FX This research was supported by NSF CAREER 1452485 (Landman), NIH grants
5R21EY024036 (Landman), 1R21NS064534 (Prince/Landman), 1R01NS070906
(Pham), 5R01NS056307 (Prince), 1R21NS096497 (Prince), 2R01EB006136
(Dawant), 1R03EB012461 (Landman) and R01EB006193 (Dawant). This research
was conducted with the support from Intramural Research Program,
National Institute on Aging, NIH. This research was supported by
National MS Society RG-1507-05243 (Pham). This study was also supported
by NIH 5R01NS056307, 5R21NS082891 and in part using the resources of the
Advanced Computing Center for Research and Education (ACCRE) at
Vanderbilt University, Nashville, TN. This project was supported in part
by ViSE/VICTR VR3029 and the National Center for Research Resources,
Grant UL1 RR024975-01, and is now at the National Center for Advancing
Translational Sciences, Grant 2 UL1 TR000445-06. Support for this work
included funding from the Department of Defense in the Center for
Neuroscience and Regenerative Medicine. The authors are responsible for
the content. The content does not necessarily represent the official
views of the NIH. We are grateful for the assistance of Naresh
Nandakumar in helping prepare this manuscript.
NR 92
TC 1
Z9 1
U1 6
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD SEP
PY 2016
VL 138
BP 197
EP 210
DI 10.1016/j.neuroimage.2016.05.030
PG 14
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DP5ET
UT WOS:000378519500017
PM 27184203
ER
PT J
AU Guo, AL
Xu, YF
Mowery, J
Nagy, A
Bauchan, G
Nou, XW
AF Guo, Ailing
Xu, Yunfeng
Mowery, Joseph
Nagy, Attila
Bauchan, Gary
Nou, Xiangwu
TI Ralstonia insidiosa induces cell aggregation of Listeria monocytogenes
SO FOOD CONTROL
LA English
DT Article
DE Listeria monocytogenes; Ralstonia insidiosa; Cell aggregation; Biofilms;
TEM
ID ESCHERICHIA-COLI O157H7; BIOFILM FORMATION; STRAINS; COAGGREGATION;
PREVALENCE; CANTALOUPE; PICKETTII; OUTBREAK; GROWTH; LEVEL
AB Biofilm formation is an important strategy for foodborne bacterial pathogens to survive in stressful environments such as fresh produce processing facilities. Bacterial cell aggregation strongly promotes the initiation of microcolonies and the formation of biofilms on abiological surfaces. We previously showed that Ralstonia insidiosa, an environmental bacterial species frequently isolated from fresh produce facilities, may serve as a "bridge bacterium" that strongly enhanced the incorporation of several foodborne bacterial pathogens into dual species biofilms. While the R. insidiosa strain exhibited moderate cell aggregation in liquid culture, co-culturing Listeria monocytogenes with R. insidiosa resulted in significant augmentation of cell aggregation. Electron microscopy indicated that L. monocytogenes cells were initially attracted to the R. insidiosa aggregates and formed large dual species aggregates that were predominately composed of L. monocytogenes cells. The predominant presence of L. monocytogenes in the dual species aggregates was also confirmed by differential plating. These findings suggest that bridge bacteria such as R. insidiosa play critical roles in the survival of foodborne bacterial pathogens, such as L. monocytogenes and Escherichia coli, by promoting multispecies biofilm formation. The implications of such bridge bacteria on food safety need to be further evaluated. Published by Elsevier Ltd.
C1 [Guo, Ailing] Huazhong Agr Univ, Natl Res & Dev Ctr Egg Proc, Wuhan 430070, Peoples R China.
[Xu, Yunfeng; Nagy, Attila; Nou, Xiangwu] ARS, Environm Microbial & Food Safety Lab, Beltsville Agr Res Ctr, USDA, Beltsville, MD 20705 USA.
[Mowery, Joseph; Bauchan, Gary] ARS, Electron & Confocal Microscopy Unit, Beltsville Agr Res Ctr, USDA, Beltsville, MD 20705 USA.
[Nagy, Attila] NIAID, NIH, Vaccine Res Ctr, Gaithersburg, MD 20878 USA.
RP Nou, XW (reprint author), ARS, Environm Microbial & Food Safety Lab, Beltsville Agr Res Ctr, USDA, Beltsville, MD 20705 USA.
EM Xiangwu.nou@ars.usda.gov
FU Huazhong Agricultural University; China Scholarship Council
FX Authors wish to thank Dr. T. Ward for providing L.monocytogenes strains
used in this study. Ailing Guo was a visiting scientist to USDA ARS
EMFSL from and supported by Huazhong Agricultural University, and
Yunfeng Xu is predoctoral student from Northwest A&F University, China,
and is supported by China Scholarship Council.
NR 37
TC 0
Z9 0
U1 6
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-7135
EI 1873-7129
J9 FOOD CONTROL
JI Food Control
PD SEP
PY 2016
VL 67
BP 303
EP 309
DI 10.1016/j.foodcont.2016.03.006
PG 7
WC Food Science & Technology
SC Food Science & Technology
GA DK8FY
UT WOS:000375163800039
ER
PT J
AU Wang, YC
Chin, KH
Tu, ZL
He, J
Jones, CJ
Sanchez, DZ
Yildiz, FH
Galperin, MY
Chou, SH
AF Wang, Yu-Chuan
Chin, Ko-Hsin
Tu, Zhi-Le
He, Jin
Jones, Christopher J.
Sanchez, David Zamorano
Yildiz, Fitnat H.
Galperin, Michael Y.
Chou, Shan-Ho
TI Nucleotide binding by the widespread high-affinity cyclic di-GMP
receptor MshEN domain
SO NATURE COMMUNICATIONS
LA English
DT Article
ID II SECRETION SYSTEM; MOLECULAR DISCRIMINATION; MECHANISTIC INSIGHTS;
STRUCTURAL BASIS; YDAO RIBOSWITCH; PILZ-DOMAIN; PROTEIN; DATABASE; AMP;
2ND-MESSENGER
AB C-di-GMP is a bacterial second messenger regulating various cellular functions. Many bacteria contain c-di-GMP-metabolizing enzymes but lack known c-di-GMP receptors. Recently, two MshE-type ATPases associated with bacterial type II secretion system and type IV pilus formation were shown to specifically bind c-di-GMP. Here we report crystal structure of the MshE N-terminal domain (MshEN(1-145)) from Vibrio cholerae in complex with c-di-GMP at a 1.37 resolution. This structure reveals a unique c-di-GMP-binding mode, featuring a tandem array of two highly conserved binding motifs, each comprising a 24-residue sequence RLGxx(L/V/I)(L/V/I)xxG(L/V/I)(L/V/I)xxxxLxxxLxxQ that binds half of the c-di-GMP molecule, primarily through hydrophobic interactions. Mutating these highly conserved residues markedly reduces c-di-GMP binding and biofilm formation by V. cholerae. This c-di-GMP-binding motif is present in diverse bacterial proteins exhibiting binding affinities ranging from 0.5 mu M to as low as 14 nM. The MshEN domain contains the longest nucleotide-binding motif reported to date.
C1 [Wang, Yu-Chuan; Tu, Zhi-Le; Chou, Shan-Ho] Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.
[Chin, Ko-Hsin; Chou, Shan-Ho] Natl Chung Hsing Univ, Agr Biotechnol Ctr, Taichung 40227, Taiwan.
[He, Jin] Huazhong Agr Univ, Coll Life Sci & Technol, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
[Jones, Christopher J.; Sanchez, David Zamorano; Yildiz, Fitnat H.] Univ Calif Santa Cruz, Dept Microbiol & Environm Toxicol, Santa Cruz, CA 95064 USA.
[Galperin, Michael Y.] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
RP Chou, SH (reprint author), Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.; Chou, SH (reprint author), Natl Chung Hsing Univ, Agr Biotechnol Ctr, Taichung 40227, Taiwan.
EM shchou@nchu.edu.tw
OI Galperin, Michael/0000-0002-2265-5572
FU Ministry of Education, Taiwan, ROC under the ATU plan; Ministry of
Science and Technology, Taiwan, ROC [102-2113-M-005 -006 -MY3]; NIH [RO1
AI102584]; NIH Intramural Research Program at the US National Library of
Medicine
FX This work was supported in part by the Ministry of Education, Taiwan,
ROC under the ATU plan, and by the Ministry of Science and Technology,
Taiwan, ROC (102-2113-M-005 -006 -MY3) to S.-H.C. and NIH award RO1
AI102584 to F.H.Y. M.Y.G. was supported by the NIH Intramural Research
Program at the US National Library of Medicine. We would also like to
thank the National Synchrotron Radiation Research Center (NSRRC) in
Taiwan, and the SPring-8 Synchrotron facility in Japan for assistance of
the X-ray data collections.
NR 51
TC 2
Z9 2
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 31
PY 2016
VL 7
AR 12481
DI 10.1038/ncomms12481
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH6FY
UT WOS:000391869500001
PM 27578558
ER
PT J
AU Wen, PJ
Grenklo, S
Arpino, G
Tan, XY
Liao, HS
Heureaux, J
Peng, SY
Chiang, HC
Hamid, E
Zhao, WD
Shin, W
Nareoja, T
Evergren, E
Jin, YH
Karlsson, R
Ebert, SN
Jin, A
Liu, AP
Shupliakov, O
Wu, LG
AF Wen, Peter J.
Grenklo, Staffan
Arpino, Gianvito
Tan, Xinyu
Liao, Hsien-Shun
Heureaux, Johanna
Peng, Shi-Yong
Chiang, Hsueh-Cheng
Hamid, Edaeni
Zhao, Wei-Dong
Shin, Wonchul
Naereoja, Tuomas
Evergren, Emma
Jin, Yinghui
Karlsson, Roger
Ebert, Steven N.
Jin, Albert
Liu, Allen P.
Shupliakov, Oleg
Wu, Ling-Gang
TI Actin dynamics provides membrane tension to merge fusing vesicles into
the plasma membrane
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ADRENAL CHROMAFFIN CELLS; KISS-AND-RUN; CROSS-LINKED PROFILIN;
DENSE-CORE VESICLES; REGULATED EXOCYTOSIS; F-ACTIN; COMPENSATORY
ENDOCYTOSIS; NEUROENDOCRINE CELLS; STRUCTURAL-CHANGES; SYNAPTIC VESICLES
AB Vesicle fusion is executed via formation of an Omega-shaped structure (Omega-profile), followed by closure (kiss-and-run) or merging of the Omega-profile into the plasma membrane (full fusion). Although Omega-profile closure limits release but recycles vesicles economically, Omega-profile merging facilitates release but couples to classical endocytosis for recycling. Despite its crucial role in determining exocytosis/endocytosis modes, how Omega-profile merging is mediated is poorly understood in endocrine cells and neurons containing small similar to 30-300 nm vesicles. Here, using confocal and super-resolution STED imaging, force measurements, pharmacology and gene knockout, we show that dynamic assembly of filamentous actin, involving ATP hydrolysis, N-WASP and formin, mediates Omega-profile merging by providing sufficient plasma membrane tension to shrink the Omega-profile in neuroendocrine chromaffin cells containing similar to 300 nm vesicles. Actin-directed compounds also induce Omega-profile accumulation at lamprey synaptic active zones, suggesting that actin may mediate Omega-profile merging at synapses. These results uncover molecular and biophysical mechanisms underlying Omega-profile merging.
C1 [Wen, Peter J.; Arpino, Gianvito; Peng, Shi-Yong; Chiang, Hsueh-Cheng; Hamid, Edaeni; Zhao, Wei-Dong; Shin, Wonchul; Jin, Yinghui; Wu, Ling-Gang] Natl Inst Neurol Disorders & Stroke, 35 Convent Dr,Bldg 35,Room 2B 1012, Bethesda, MD 20892 USA.
[Grenklo, Staffan; Arpino, Gianvito; Naereoja, Tuomas; Evergren, Emma; Shupliakov, Oleg] Karolinska Inst, Ctr Excellence Dev Biol, Dept Neurosci, S-17177 Stockholm, Sweden.
[Grenklo, Staffan; Karlsson, Roger] Stockholm Univ, WGI, Dept Cell Biol, S-10691 Stockholm, Sweden.
[Tan, Xinyu; Heureaux, Johanna; Liu, Allen P.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA.
[Liao, Hsien-Shun; Jin, Albert] NIBIB, Bethesda, MD 20892 USA.
[Ebert, Steven N.] Univ Cent Florida, Burnett Sch Biomed Sci, Coll Med, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.
[Shupliakov, Oleg] St Petersburg State Univ, Inst Translat Biomed, St Petersburg 199034, Russia.
[Chiang, Hsueh-Cheng] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 701, Taiwan.
[Evergren, Emma] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7AE, Antrim, North Ireland.
RP Wu, LG (reprint author), Natl Inst Neurol Disorders & Stroke, 35 Convent Dr,Bldg 35,Room 2B 1012, Bethesda, MD 20892 USA.; Shupliakov, O (reprint author), Karolinska Inst, Ctr Excellence Dev Biol, Dept Neurosci, S-17177 Stockholm, Sweden.; Shupliakov, O (reprint author), St Petersburg State Univ, Inst Translat Biomed, St Petersburg 199034, Russia.
EM oleg.shupliakov@ki.se; wul@ninds.nih.gov
RI Nareoja, Tuomas/K-3800-2014
OI Nareoja, Tuomas/0000-0002-2174-4434
FU National Institute of Neurological Disorders and Stroke Intramural
Research Program [ZIA NS003009-13, ZIA NS003105-08]; Swedish Research
Council [13473]; Parkinsonfonden; Hjarnfonden; Russian Science
Foundation [16-15-10273]
FX We thank Dr James Ervasti for providing Actbloxp mice. This work was
supported by the National Institute of Neurological Disorders and Stroke
Intramural Research Program (ZIA NS003009-13 and ZIA NS003105-08) to
L.G.W. and by grants from the Swedish Research Council (project 13473),
Parkinsonfonden, Hjarnfonden and the Russian Science Foundation (project
number 16-15-10273) to O.S.
NR 67
TC 2
Z9 2
U1 6
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 31
PY 2016
VL 7
AR 12604
DI 10.1038/ncomms12604
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH6GO
UT WOS:000391871100001
PM 27576662
ER
PT J
AU Zaslavsky, L
Ciufo, S
Fedorov, B
Tatusova, T
AF Zaslavsky, Leonid
Ciufo, Stacy
Fedorov, Boris
Tatusova, Tatiana
TI Clustering analysis of proteins from microbial genomes at multiple
levels of resolution
SO BMC BIOINFORMATICS
LA English
DT Article; Proceedings Paper
CT 11th International Symposium on Bioinformatics Research and Applications
(ISBRA)
CY JUN 07-10, 2015
CL Old Domin Univ, Norfolk, VA
HO Old Domin Univ
DE Protein; Cluster; Clustering; Microbial; Procaryotic; Core-periphery;
Multiscale; Multiresolution; Knowledge discovery; Data mining; Parallel
processing; Parallel computing
ID BACTERIAL PAN-GENOME; PARALLEL ALGORITHMS; SEARCH; ORTHOLOGS; ALIGNMENT;
BLAST
AB Background: Microbial genomes at the National Center for Biotechnology Information (NCBI) represent a large collection of more than 35,000 assemblies. There are several complexities associated with the data: a great variation in sampling density since human pathogens are densely sampled while other bacteria are less represented; different protein families occur in annotations with different frequencies; and the quality of genome annotation varies greatly. In order to extract useful information from these sophisticated data, the analysis needs to be performed at multiple levels of phylogenomic resolution and protein similarity, with an adequate sampling strategy.
Results: Protein clustering is used to construct meaningful and stable groups of similar proteins to be used for analysis and functional annotation. Our approach is to create protein clusters at three levels. First, tight clusters in groups of closely-related genomes (species-level clades) are constructed using a combined approach that takes into account both sequence similarity and genome context. Second, clustroids of conservative in-clade clusters are organized into seed global clusters. Finally, global protein clusters are built around the the seed clusters. We propose filtering strategies that allow limiting the protein set included in global clustering. The in-clade clustering procedure, subsequent selection of clustroids and organization into seed global clusters provides a robust representation and high rate of compression. Seed protein clusters are further extended by adding related proteins. Extended seed clusters include a significant part of the data and represent all major known cell machinery. The remaining part, coming from either non-conservative (unique) or rapidly evolving proteins, from rare genomes, or resulting from low-quality annotation, does not group together well. Processing these proteins requires significant computational resources and results in a large number of questionable clusters.
Conclusion: The developed filtering strategies allow to identify and exclude such peripheral proteins limiting the protein dataset in global clustering. Overall, the proposed methodology allows the relevant data at different levels of details to be obtained and data redundancy eliminated while keeping biologically interesting variations.
C1 [Zaslavsky, Leonid; Ciufo, Stacy; Fedorov, Boris; Tatusova, Tatiana] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
RP Zaslavsky, L (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
EM zaslavsk@ncbi.nlm.nih.gov
NR 43
TC 0
Z9 0
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD AUG 31
PY 2016
VL 17
SU 8
AR 276
DI 10.1186/s12859-016-1112-8
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA DW5AV
UT WOS:000383655300001
PM 27586436
ER
PT J
AU Kim, DA
Benjamin, EJ
Fowler, JH
Christakis, NA
AF Kim, David A.
Benjamin, Emelia J.
Fowler, James H.
Christakis, Nicholas A.
TI Social connectedness is associated with fibrinogen level in a human
social network
SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE social networks; social epidemiology; fibrinogen; social hierarchy;
stress response
ID CORONARY-HEART-DISEASE; MORTALITY; HEALTH; DETERMINANTS; SPREAD;
LONELINESS; INEQUALITY; FRIENDSHIP; DYNAMICS; WOMEN
AB Socially isolated individuals face elevated rates of illness and death. Conventional measures of social connectedness reflect an individual's perceived network and can be subject to bias and variation in reporting. In this study of a large human social network, we find that greater indegree, a sociocentric measure of friendship and familial ties identified by a subject's social connections rather than by the subject, predicts significantly lower concentrations of fibrinogen (a biomarker of inflammation and cardiac risk), after adjusting for demographics, education, medical history and known predictors of cardiac risk. The association between fibrinogen and social isolation, as measured by low indegree, is comparable to the effect of smoking, and greater than that of low education, a conventional measure of socioeconomic disadvantage. By contrast, outdegree, which reflects an individual's perceived connectedness, displays a significantly weaker association with fibrinogen concentrations.
C1 [Kim, David A.] Stanford Univ, Dept Emergency Med, 300 Pasteur Dr MC 5119, Stanford, CA 94305 USA.
[Benjamin, Emelia J.] Natl Heart Lung & Blood Inst, 73 Mt Wayte Ave, Framingham, MA 01702 USA.
[Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, 73 Mt Wayte Ave, Framingham, MA 01702 USA.
[Fowler, James H.] Univ Calif San Diego, Dept Med, 9500 Gilman Dr 0521, La Jolla, CA 92093 USA.
[Fowler, James H.] Univ Calif San Diego, Dept Polit Sci, 9500 Gilman Dr 0521, La Jolla, CA 92093 USA.
[Christakis, Nicholas A.] Yale Univ, Dept Med, POB 208263, New Haven, CT 06520 USA.
[Christakis, Nicholas A.] Yale Univ, Dept Ecol & Evolutionary Biol, POB 208263, New Haven, CT 06520 USA.
[Christakis, Nicholas A.] Yale Univ, Dept Sociol, POB 208263, New Haven, CT 06520 USA.
RP Christakis, NA (reprint author), Yale Univ, Dept Med, POB 208263, New Haven, CT 06520 USA.; Christakis, NA (reprint author), Yale Univ, Dept Ecol & Evolutionary Biol, POB 208263, New Haven, CT 06520 USA.; Christakis, NA (reprint author), Yale Univ, Dept Sociol, POB 208263, New Haven, CT 06520 USA.
EM nicholas.christakis@yale.edu
OI Kim, David/0000-0003-0151-5121
FU NIH [P01AG31093]; National Institute on Aging; Canadian Institutes of
Health Research; [HHSN268201500001I]; [N01-HC 25195]
FX This work was supported by NIH grant no. P01AG31093 and by the National
Institute on Aging. D.A.K. was supported by the Canadian Institutes of
Health Research. The FHS is supported by HHSN268201500001I and N01-HC
25195.
NR 48
TC 0
Z9 0
U1 5
U2 5
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8452
EI 1471-2954
J9 P ROY SOC B-BIOL SCI
JI Proc. R. Soc. B-Biol. Sci.
PD AUG 31
PY 2016
VL 283
IS 1837
AR 20160958
DI 10.1098/rspb.2016.0958
PG 7
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
Ecology; Evolutionary Biology
GA DY4FY
UT WOS:000385055600018
ER
PT J
AU Pugacheva, EM
Teplyakov, E
Wu, QF
Li, JJ
Chen, C
Meng, CC
Liu, J
Robinson, S
Loukinov, D
Boukaba, A
Hutchins, AP
Lobanenkov, V
Strunnikov, A
AF Pugacheva, Elena M.
Teplyakov, Evgeny
Wu, Qiongfang
Li, Jingjing
Chen, Cheng
Meng, Chengcheng
Liu, Jian
Robinson, Susan
Loukinov, Dmitry
Boukaba, Abdelhalim
Hutchins, Andrew Paul
Lobanenkov, Victor
Strunnikov, Alexander
TI The cancer-associated CTCFL/BORIS protein targets multiple classes of
genomic repeats, with a distinct binding and functional preference for
humanoid-specific SVA transposable elements
SO EPIGENETICS & CHROMATIN
LA English
DT Article
ID DNA METHYLATION; CTCF BINDING; SOMATIC RETROTRANSPOSITION; ENDOGENOUS
RETROVIRUSES; EXPANSION DISORDERS; PLURIPOTENT CELLS; GENE PROMOTERS;
FACTOR BORIS; STEM-CELLS; EXPRESSION
AB Background: A common aberration in cancer is the activation of germline-specific proteins. The DNA-binding proteins among them could generate novel chromatin states, not found in normal cells. The germline-specific transcription factor BORIS/CTCFL, a paralog of chromatin architecture protein CTCF, is often erroneously activated in cancers and rewires the epigenome for the germline-like transcription program. Another common feature of malignancies is the changed expression and epigenetic states of genomic repeats, which could alter the transcription of neighboring genes and cause somatic mutations upon transposition. The role of BORIS in transposable elements and other repeats has never been assessed.
Results: The investigation of BORIS and CTCF binding to DNA repeats in the K562 cancer cells dependent on BORIS for self-renewal by ChIP-chip and ChIP-seq revealed three classes of occupancy by these proteins: elements cohabited by BORIS and CTCF, CTCF-only bound, or BORIS-only bound. The CTCF-only enrichment is characteristic for evolutionary old and inactive repeat classes, while BORIS and CTCF co-binding predominately occurs at uncharacterized tandem repeats. These repeats form staggered cluster binding sites, which are a prerequisite for CTCF and BORIS co-binding. At the same time, BORIS preferentially occupies a specific subset of the evolutionary young, transcribed, and mobile genomic repeat family, SVA. Unlike CTCF, BORIS prominently binds to the VNTR region of the SVA repeats in vivo. This suggests a role of BORIS in SVA expression regulation. RNA-seq analysis indicates that BORIS largely serves as a repressor of SVA expression, alongside DNA and histone methylation, with the exception of promoter capture by SVA.
Conclusions: Thus, BORIS directly binds to, and regulates SVA repeats, which are essentially movable CpG islands, via clusters of BORIS binding sites. This finding uncovers a new function of the global germline-specific transcriptional regulator BORIS in regulating and repressing the newest class of transposable elements that are actively transposed in human genome when activated. This function of BORIS in cancer cells is likely a reflection of its roles in the germline.
C1 [Teplyakov, Evgeny; Wu, Qiongfang; Li, Jingjing; Chen, Cheng; Meng, Chengcheng; Liu, Jian; Boukaba, Abdelhalim; Strunnikov, Alexander] Guangzhou Inst Biomed & Hlth, Mol Epigenet Lab, Guangzhou 510530, Guangdong, Peoples R China.
[Pugacheva, Elena M.; Robinson, Susan; Loukinov, Dmitry; Lobanenkov, Victor] NIAID, Lab Immunogenet, NIH, Rockville, MD 20852 USA.
[Hutchins, Andrew Paul] Southern Univ Sci & Technol China, Dept Biol, Shenzhen 518055, Guangdong, Peoples R China.
RP Strunnikov, A (reprint author), Guangzhou Inst Biomed & Hlth, Mol Epigenet Lab, Guangzhou 510530, Guangdong, Peoples R China.
EM alex@gibh.org
FU PRC government's "1000 Talents Program" grant; Guangdong provincial
government's "Guangdong High Talent" award; Intramural Program of the
National Institute of Allergy and Infectious Diseases
FX This work was supported by the PRC government's "1000 Talents Program"
grant to AS, the Guangdong provincial government's "Guangdong High
Talent" award to AS, and the Intramural Program of the National
Institute of Allergy and Infectious Diseases for VL.
NR 117
TC 1
Z9 1
U1 10
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD AUG 31
PY 2016
VL 9
AR 35
DI 10.1186/s13072-016-0084-2
PG 20
WC Genetics & Heredity
SC Genetics & Heredity
GA DV8CR
UT WOS:000383165600001
PM 27588042
ER
PT J
AU Yu, LD
Ham, K
Gao, XH
Castro, L
Yan, YT
Kissling, GE
Tucker, CJ
Flagler, N
Dong, R
Archer, TK
Dixon, D
AF Yu, Linda
Ham, Kyle
Gao, Xiaohua
Castro, Lysandra
Yan, Yitang
Kissling, Grace E.
Tucker, Charles J.
Flagler, Norris
Dong, Ray
Archer, Trevor K.
Dixon, Darlene
TI Epigenetic regulation of transcription factor promoter regions by
low-dose genistein through mitogen-activated protein kinase and
mitogen-and-stress activated kinase 1 nongenomic signaling
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Epigenetic; Histone H3; Leiomyoma; MAPK(p44/42); MSK1
ID HISTONE H3 PHOSPHORYLATION; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER
CELLS; HUMAN UTERINE LEIOMYOMAS; MATCHED MYOMETRIUM; GROWTH-FACTORS;
ER-ALPHA; PATHWAY; CHROMATIN; TRANSDUCTION
AB Background: The phytoestrogen, genistein at low doses nongenomically activates mitogen-activated protein kinase p44/42 (MAPK(p44/42)) via estrogen receptor alpha (ER alpha) leading to proliferation of human uterine leiomyoma cells. In this study, we evaluated if MAPK(p44/42) could activate downstream effectors such as mitogen-and stress-activated protein kinase 1 (MSK1), which could then epigenetically modify histone H3 by phosphorylation following a low dose (1 mu g/ml) of genistein.
Results: Using hormone-responsive immortalized human uterine leiomyoma (ht-UtLM) cells, we found that genistein activated MAPK(p44/42) and MSK1, and also increased phosphorylation of histone H3 at serine10 (H3S10ph) in ht-UtLM cells. Colocalization of phosphorylated MSK1 and H3S10ph was evident by confocal microscopy in ht-UtLM cells (r = 0.8533). Phosphorylation of both MSK1 and H3S10ph was abrogated by PD98059 (PD), a MEK1 kinase inhibitor, thereby supporting genistein's activation of MSK1 and Histone H3 was downstream of MAPK(p44/42). In proliferative (estrogenic) phase human uterine fibroid tissues, phosphorylated MSK1 and H3S10ph showed increased immunoexpression compared to normal myometrial tissues, similar to results observed in in vitro studies following low-dose genistein administration. Real-time RT-PCR arrays showed induction of growth-related transcription factor genes, EGR1, Elk1, ID1, and MYB (cMyb) with confirmation by western blot, downstream of MAPK in response to low-dose genistein in ht-UtLM cells. Additionally, genistein induced associations of promoter regions of the above transcription factors with H3S10ph as evidenced by Chromatin Immunoprecipitation (ChIP) assays, which were inhibited by PD. Therefore, genistein epigenetically modified histone H3 by phosphorylation of serine 10, which was regulated by MSK1 and MAPK activation.
Conclusion: Histone H3 phosphorylation possibly represents a mechanism whereby increased transcriptional activation occurs following low-dose genistein exposure.
C1 [Yu, Linda; Ham, Kyle; Gao, Xiaohua; Castro, Lysandra; Yan, Yitang; Dong, Ray; Dixon, Darlene] NIEHS, Mol Pathogenesis Grp, Toxicol Program NTP Lab, Div NTP DNTP,NIH,US Dept Hlth & Human Serv HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
[Kissling, Grace E.] NIEHS, Biostat & Computat Biol Branch, DIR, NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
[Tucker, Charles J.] NIEHS, Signal Transduct Lab, DIR, NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
[Flagler, Norris] NIEHS, Cellular & Mol Pathol Branch, DNTP, NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
[Archer, Trevor K.] NIEHS, Chromatin & Gene Express Grp, Epigenet & Stem Cell Biol Lab, DIR,NIH,HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
RP Dixon, D (reprint author), NIEHS, Mol Pathogenesis Grp, Toxicol Program NTP Lab, Div NTP DNTP,NIH,US Dept Hlth & Human Serv HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
EM dixon@niehs.nih.gov
FU Intramural Research Program of the NIH; NIEHS; DNTP
FX The authors kindly thank Drs. Wei Qu and Kyathanahalli Janardhan for
their critical review of this manuscript. The authors would also like to
thank Alicia B. Moore for her excellent assistance with formatting the
manuscript. This research was supported by the Intramural Research
Program of the NIH, NIEHS and DNTP.
NR 44
TC 0
Z9 0
U1 4
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD AUG 31
PY 2016
VL 14
AR 18
DI 10.1186/s12964-016-0141-2
PG 13
WC Cell Biology
SC Cell Biology
GA DV3IV
UT WOS:000382815400001
PM 27582276
ER
PT J
AU Segade, F
Cota, C
Famiglietti, A
Cha, A
Davidson, B
AF Segade, Fernando
Cota, Christina
Famiglietti, Amber
Cha, Anna
Davidson, Brad
TI Fibronectin contributes to notochord intercalation in the invertebrate
chordate, Ciona intestinalis
SO EVODEVO
LA English
DT Article
DE Chordate evolution; Tunicates; Extracellular matrix; Fibronectin;
Notochord; Convergent extension
ID GENE REGULATORY NETWORK; CONVERGENT EXTENSION; TRANSCRIPTION FACTORS;
EXTRACELLULAR-MATRIX; FUNCTIONAL GENOMICS; ASCIDIAN NOTOCHORD; TISSUE
MECHANICS; CELL MOTILITY; EVOLUTION; HEART
AB Background: Genomic analysis has upended chordate phylogeny, placing the tunicates as the sister group to the vertebrates. This taxonomic rearrangement raises questions about the emergence of a tunicate/vertebrate ancestor.
Results: Characterization of developmental genes uniquely shared by tunicates and vertebrates is one promising approach for deciphering developmental shifts underlying acquisition of novel, ancestral traits. The matrix glycoprotein Fibronectin (FN) has long been considered a vertebrate-specific gene, playing a major instructive role in vertebrate embryonic development. However, the recent computational prediction of an orthologous "vertebrate-like" Fn gene in the genome of a tunicate, Ciona savignyi, challenges this viewpoint suggesting that Fn may have arisen in the shared tunicate/vertebrate ancestor. Here we verify the presence of a tunicate Fn ortholog. Transgenic reporter analysis was used to characterize a Ciona Fn enhancer driving expression in the notochord. Targeted knockdown in the notochord lineage indicates that FN is required for proper convergent extension.
Conclusions: These findings suggest that acquisition of Fn was associated with altered notochord morphogenesis in the vertebrate/tunicate ancestor.
C1 [Segade, Fernando] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA.
[Cota, Christina; Davidson, Brad] Swarthmore Coll, Dept Biol, 500 Coll Ave, Swarthmore, PA 19081 USA.
[Famiglietti, Amber] Natl Inst Dent & Craniofacial Res, Sect Biol Chem, NIH, Bethesda, MD 20892 USA.
[Cha, Anna] Harvard Med Sch, Dept Syst Biol, Boston, MA USA.
RP Davidson, B (reprint author), Swarthmore Coll, Dept Biol, 500 Coll Ave, Swarthmore, PA 19081 USA.
EM bdavids1@swarthmore.edu
OI Cota, Christina/0000-0003-1307-903X
FU Swarthmore College; NIH [1R01HL091027, R15 HD080525-01]; American Heart
Association Postdoctoral Award [16POST27250075]
FX Funding was also provided by Swarthmore College and the NIH
(1R01HL091027, R15 HD080525-01). CC was supported by an American Heart
Association Postdoctoral Award (16POST27250075).
NR 83
TC 0
Z9 0
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2041-9139
J9 EVODEVO
JI EvoDevo
PD AUG 31
PY 2016
VL 7
AR 21
DI 10.1186/s13227-016-0056-4
PG 16
WC Evolutionary Biology; Developmental Biology
SC Evolutionary Biology; Developmental Biology
GA DU7ZX
UT WOS:000382434200001
PM 27583126
ER
PT J
AU Vargas-Inchaustegui, DA
Ying, O
Demberg, T
Robert-Guroff, M
AF Vargas-Inchaustegui, Diego A.
Ying, Olivia
Demberg, Thorsten
Robert-Guroff, Marjorie
TI Evaluation of Functional NK Cell Responses in Vaccinated and
SIV-Infected Rhesus Macaques
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE NK cell; SIV; rhesus macaque; cytokine; cytotoxicity
ID NATURAL-KILLER-CELLS; IMMUNODEFICIENCY-VIRUS-INFECTION; VIREMIC HIV-1
INFECTION; EXPRESSION; INNATE; INTERLEUKIN-15; MEMORY; CYTOTOXICITY;
INDIVIDUALS; ACTIVATION
AB NK cells are crucial components of the innate immune system due to their capacity to exert rapid cytotoxic and immunomodulatory function in the absence of prior sensitization. NK cells can become activated by exposure to target cells and/or by cytokines produced by antigen-presenting cells. In this study, we examined the effects of a simian immunodeficiency virus (SIV) vaccine regimen and subsequent SIV infection on the cytotoxic and immunomodulatory functions of circulatory NK cells. While vaccination did not significantly impact the capacity of NK cells to kill MHC-devoid 721.221 target cells, Sly-infection led to a significant decrease in target cell killing. NK cells from uninfected macaques were responsive to a low dose (5 ng/ml) of IL-15 pre-activation, leading to significant increases in their cytotoxic potential, however, NK cells from SIV-infected macaques required a higher dose (50 ng/ml) of IL-15 pre-activation in order to significantly increase their cytotoxic potential. By contrast, no differences were observed in the capacity of NK cells from vaccinated and SIV-infected macaques to respond to IL-12 and IL-18. Similarly, NK cells both before and after infection exhibited equivalent responses to Fc-mediated activation. Collectively, our results show that early SIV-infection impairs the natural cytotoxic capacity of circulatory NK cells without affecting Fc-mediated or cytokine-producing function.
C1 [Vargas-Inchaustegui, Diego A.; Ying, Olivia; Demberg, Thorsten; Robert-Guroff, Marjorie] NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Vargas-Inchaustegui, Diego A.] NIAID, Mol Struct Sect, Viral Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Vargas-Inchaustegui, DA; Robert-Guroff, M (reprint author), NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM vargasinchausda@mail.nih.gov; guroffm@mail.nih.gov
FU Intramural Research Program of the NIH, National Cancer Institute
FX We gratefully acknowledge the animal caretakers at Advanced BioScience
Laboratories, Inc. We thank Katherine McKinnon and Sophia Brown (Vaccine
Branch Flow Core, NCI) for expert advice in Flow Cytometry; the
NIIA/NCRR Resource for Non-human Primate Immune Reagents (Emory
University, Atlanta, GA, USA) for the macaque recombinant proteins; and
Dr. Bernard A. P. Lafont (Laboratory of Molecular Microbiology, MAID)
for providing 721.221 cells. The following reagent was obtained through
the NIH Non-human Primate Reagent Resource: QD0t605 anti-CD4. This
research was supported by the Intramural Research Program of the NIH,
National Cancer Institute.
NR 41
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 31
PY 2016
VL 7
AR 340
DI 10.3389/fimmu.2016.00340
PG 10
WC Immunology
SC Immunology
GA DU5DO
UT WOS:000382232600001
PM 27630641
ER
PT J
AU Lehmann, ML
Cooper, HA
Maric, D
Herkenham, M
AF Lehmann, Michael L.
Cooper, Hannah A.
Maric, Dragan
Herkenham, Miles
TI Social defeat induces depressive-like states and microglial activation
without involvement of peripheral macrophages
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Stress; Microglia; Depression; Neuroimmune; Macrophage; Microglial
proliferation
ID ANXIETY-LIKE BEHAVIOR; BLOOD-BRAIN-BARRIER; MEDIAL PREFRONTAL CORTEX;
MARROW-DERIVED MICROGLIA; CENTRAL-NERVOUS-SYSTEM; ENVIRONMENTAL
ENRICHMENT; NEUROTROPHIC FACTOR; IMMUNE INTERACTIONS; ADULT
NEUROGENESIS; RAT-BRAIN
AB Background: We are interested in the causal interactions between psychological stress and activity within different compartments of the immune system. Psychosocial stress has been reported to not only alter microglia morphology but also produce anxiety-like and depressive-like effects by triggering CNS infiltration of macrophages from the periphery. We sought to test these phenomena in a somewhat different but standardized model of chronic social defeat (SD) stress.
Methods: We used a paradigm of dyadic home pairing of dominant and subordinate mice that has been validated to induce powerful anxiety-like and depressive-like effects manifested by behavior assessed in social tasks. We administered the SD stress for 3 days (acute SD) or 14 days (chronic SD) and looked for monocyte entry into the brain by three independent means, including CD45 activation states assessed by flow cytometry and tracking fluorescently tagged peripheral cells from Ccr2(wt/rfp) and Ubc(gfp/gfp) reporter mice. We further characterized the effects of SD stress on microglia using quantitative morphometric analysis, ex vivo phagocytosis assays, flow cytometry, and immunochemistry.
Results: We saw no evidence of stress-induced macrophage entry after acute or chronic defeat stress. In comparison, brain infiltration of peripheral cells did occur after endotoxin administration. Furthermore, mutant mice lacking infiltrating macrophages due to CCR2 knockout developed the same degree of chronic SD-induced depressive behavior as wildtype mice. We therefore focused more closely on the intrinsic immune cells, the microglia. Using Cx3cr1(wt/gpf) microglial reporter mice, we saw by quantitative methods that microglial morphology was not altered by stress at either time point. However, chronic SD mice had elevated numbers of CD68(hi) microglia examined by flow cytometry. CD68 is a marker for phagocytic activity. Indeed, these cells ex vivo showed elevated phagocytosis, confirming the increased activation status of chronic SD microglia. Finally, acute SD but not chronic SD increased microglial proliferation, which occurred selectively in telencephalic stress-related brain areas.
Conclusions: In the SD paradigm, changes in CNS-resident microglia numbers and activation states might represent the main immunological component of the psychosocial stress-induced depressive state.
C1 [Lehmann, Michael L.; Cooper, Hannah A.; Herkenham, Miles] NIMH, Funct Neuroanat Sect, Intramural Res Program, NIH, Bldg 35,Rm 1C911, Bethesda, MD 20892 USA.
[Maric, Dragan] NINDS, Flow Cytometry Core Facil, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Lehmann, ML (reprint author), NIMH, Funct Neuroanat Sect, Intramural Res Program, NIH, Bldg 35,Rm 1C911, Bethesda, MD 20892 USA.
EM michael.lehmann@nih.gov
FU NIMH Intramural Research Program [ZIA MH001090]
FX The work was supported by the NIMH Intramural Research Program, ZIA
MH001090.
NR 89
TC 0
Z9 0
U1 9
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD AUG 31
PY 2016
VL 13
AR 224
DI 10.1186/s12974-016-0672-x
PG 19
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DV4EX
UT WOS:000382879300001
PM 27581371
ER
PT J
AU Puppala, AK
French, RL
Matthies, D
Baxa, U
Subramaniam, S
Simonovic, M
AF Puppala, Anupama K.
French, Rachel L.
Matthies, Doreen
Baxa, Ulrich
Subramaniam, Sriram
Simonovic, Miljan
TI Structural basis for early-onset neurological disorders caused by
mutations in human selenocysteine synthase
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROGRESSIVE CEREBELLOCEREBRAL ATROPHY; CAUSE PONTOCEREBELLAR HYPOPLASIA;
SCATTERING DATA-ANALYSIS; SELENOPROTEIN BIOSYNTHESIS; RNA; SYSTEM; GENE;
DIFFRACTION; CLEARANCE; MECHANISM
AB Selenocysteine synthase (SepSecS) catalyzes the terminal reaction of selenocysteine, and is vital for human selenoproteome integrity. Autosomal recessive inheritance of mutations in SepSecS-Ala239Thr, Thr325Ser, Tyr334Cys and Tyr429*-induced severe, early-onset, neurological disorders in distinct human populations. Although harboring different mutant alleles, patients presented remarkably similar phenotypes typified by cerebellar and cerebral atrophy, seizures, irritability, ataxia, and extreme spasticity. However, it has remained unclear how these genetic alterations affected the structure of SepSecS and subsequently elicited the development of a neurological pathology. Herein, our biophysical and structural characterization demonstrates that, with the exception of Tyr429*, pathogenic mutations decrease protein stability and trigger protein misfolding. We propose that the reduced stability and increased propensity towards misfolding are the main causes for the loss of SepSecS activity in afflicted patients, and that these factors contribute to disease progression. We also suggest that misfolding of enzymes regulating protein synthesis should be considered in the diagnosis and study of childhood neurological disorders.
C1 [Puppala, Anupama K.; French, Rachel L.; Simonovic, Miljan] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA.
[Matthies, Doreen; Baxa, Ulrich; Subramaniam, Sriram] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
[French, Rachel L.] St Louis Univ, Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
RP Simonovic, M (reprint author), Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA.
EM msimon5@uic.edu
RI ID, BioCAT/D-2459-2012
FU National Institute of General Medical Sciences of the National
Institutes of Health [R01 GM097042, P41 GM103622]; National Cancer
Institute, NIH; DOE Office of Science [DE-AC02-06CH11357]; Michigan
Economic Development Corporation; Michigan Technology Tri-Corridor
[085P1000817]
FX We are grateful to the staff of LS-CAT beam line at APS-ANL for their
help during X-ray data collection and processing, and Dr. Srinivas
Chakravarthy for help during SAXS data collection and processing. We
thank Kaitlyn Holman for help with protein purification. This work was
supported by a grant from the National Institute of General Medical
Sciences of the National Institutes of Health R01 GM097042 (to MS) and
from the intramural program of the National Cancer Institute, NIH (to
SS). This research used resources of the Advanced Photon Source, a U.S.
Department of Energy (DOE) Office of Science User Facility operated for
the DOE Office of Science by Argonne National Laboratory under Contract
No. DE-AC02-06CH11357. BioCAT is supported by grant from the National
Institute of General Medical Sciences of the National Institutes of
Health (P41 GM103622). Use of the LS-CAT Sector 21 is supported by the
Michigan Economic Development Corporation and the Michigan Technology
Tri-Corridor (Grant 085P1000817).
NR 42
TC 0
Z9 0
U1 3
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 31
PY 2016
VL 6
AR 32563
DI 10.1038/srep32563
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU5JD
UT WOS:000382247100001
PM 27576344
ER
PT J
AU Pavlatou, MG
Remaley, AT
Gold, PW
AF Pavlatou, M. G.
Remaley, A. T.
Gold, P. W.
TI Klotho: a humeral mediator in CSF and plasma that influences longevity
and susceptibility to multiple complex disorders, including depression
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Review
ID VITAMIN-D METABOLISM; CORONARY-ARTERY-DISEASE; CHRONIC KIDNEY-DISEASE;
CHRONIC-RENAL-FAILURE; ENDOTHELIAL DYSFUNCTION; ALPHA-KLOTHO;
PARATHYROID-HORMONE; FUNCTIONAL VARIANT; BLOOD-PRESSURE; MUTANT MICE
AB Klotho is a hormone secreted into human cerebrospinal fluid (CSF), plasma and urine that promotes longevity and influences the onset of several premature senescent phenotypes in mice and humans, including atherosclerosis, cardiovascular disease, stroke and osteoporosis. Preliminary studies also suggest that Klotho possesses tumor suppressor properties. Klotho's roles in these phenomena were first suggested by studies demonstrating that a defect in the Klotho gene in mice results in a significant decrease in lifespan. The Klotho-deficient mouse dies prematurely at 8-9 weeks of age. At 4-5 weeks of age, a syndrome resembling human ageing emerges consisting of atherosclerosis, osteoporosis, cognitive disturbances and alterations of hippocampal architecture. Several deficits in Klotho-deficient mice are likely to contribute to these phenomena. These include an inability to defend against oxidative stress in the central nervous system and periphery, decreased capacity to generate nitric oxide to sustain normal endothelial reactivity, defective Klotho-related mediation of glycosylation and ion channel regulation, increased insulin/insulin-like growth factor signaling and a disturbed calcium and phosphate homeostasis accompanied by altered vitamin D levels and ectopic calcification. Identifying the mechanisms by which Klotho influences multiple important pathways is an emerging field in human biology that will contribute significantly to understanding basic physiologic processes and targets for the treatment of complex diseases. Because many of the phenomena seen in Klotho-deficient mice occur in depressive illness, major depression and bipolar disorder represent illnesses potentially associated with Klotho dysregulation. Klotho's presence in CSF, blood and urine should facilitate its study in clinical populations.
C1 [Pavlatou, M. G.; Gold, P. W.] NIMH, Clin Neuroendocrinol Branch, NIH, Bethesda, MD 20892 USA.
[Remaley, A. T.] Natl Inst Heart Lung & Blood Inst, Lipoprotein Metab Sect, Cardiovasc & Pulm Branch, Bethesda, MD USA.
RP Gold, PW (reprint author), NIMH, Intramural NIH Res Program, NIH, Ctr Clin, Bldg 10,Room 2D-46,10 Ctr Dr MSC 1284, Bethesda, MD 20892 USA.
EM philipgold@mail.nih.gov
NR 110
TC 0
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD AUG 30
PY 2016
VL 6
AR e876
DI 10.1038/tp.2016.135
PG 9
WC Psychiatry
SC Psychiatry
GA DW1SR
UT WOS:000383423400002
PM 27576165
ER
PT J
AU Ha, HL
Kwon, T
Bak, IS
Erikson, RL
Kim, BY
Yu, DY
AF Ha, Hye-Lin
Kwon, Taeho
Bak, In Seon
Erikson, Raymond L.
Kim, Bo Yeon
Yu, Dae-Yeul
TI IGF-II induced by hepatitis B virus X protein regulates EMT via SUMO
mediated loss of E- cadherin in mice
SO ONCOTARGET
LA English
DT Article
DE hepatocellular carcinoma; hepatitis B virus X protein; IGF-II;
epithelial-mesenchymal transition; SUMOylation
ID GROWTH-FACTOR-II; EPITHELIAL-MESENCHYMAL TRANSITION;
HEPATOCELLULAR-CARCINOMA; CANCER CELLS; GENE-EXPRESSION; BREAST-CANCER;
IN-VITRO; EXTRACELLULAR CLEAVAGE; MOLECULAR-MECHANISMS; TUMOR
PROGRESSION
AB Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer mortality. Prognosis of this disease largely depends on its stage. An Enlarged liver, due to dysplasia, may be a critical point in the multi-step progression to HCC. The mechanism underlying hepatomegaly in human and mouse models are poorly understood. We previously reported we observed enlarged liver in hepatitis B virus X protein (HBx) expressing mice (HBx mice). Here we identify the critical role of HBx induced IGF-II in hepatomegaly in mice and abnormal cell growth in human hepatoma cells. We found that HBx induced IGF-II is essential to induce epithelial-mesenchymal transition (EMT) through loss of E-cadherin. In mouse liver, loss of E-cadherin was mediated by post-translational regulation, at least in part, by protease and SUMOylation not by transcriptional regulation. In contrast, in hepatoma cell line (HepG2 cells) Akt signal pathway controls the mRNA expression level of EMT-related transcription factors, especially Twist, in addition to post-translational modification through SUMOylation. Thus, IGF-II-mediated loss of E-cadherin is central in developing hepatomegaly in mice and abnormal cell growth in the hepatoma cell line. HBx induced IGF-II represents a potential biomarker, which is also a therapeutic target in HCC.
C1 [Ha, Hye-Lin; Kwon, Taeho; Bak, In Seon; Yu, Dae-Yeul] Korea Res Inst Biosci & Biotechnol, Genome Editing Res Ctr, Dis Model Res Lab, Daejeon, South Korea.
[Ha, Hye-Lin; Yu, Dae-Yeul] Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea.
[Erikson, Raymond L.] Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.
[Kim, Bo Yeon] Korea Res Inst Biosci & Biotechnol, Anticanc Agents Res Ctr, Ochang, Cheongwon, South Korea.
[Ha, Hye-Lin] NIAID, Immune Activat Sect, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Yu, DY (reprint author), Korea Res Inst Biosci & Biotechnol, Genome Editing Res Ctr, Dis Model Res Lab, Daejeon, South Korea.; Yu, DY (reprint author), Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea.; Kim, BY (reprint author), Korea Res Inst Biosci & Biotechnol, Anticanc Agents Res Ctr, Ochang, Cheongwon, South Korea.
EM bykim@kribb.re.kr; dyyu10@kribb.re.kr
FU R&D Convergence Program of the National Research Council of Science &
Technology (NST) of the Republic of Korea [CAP-15-03-KRIBB,
CAP-16-03-KRIBB]; Bio and Medical Technology Development Program of the
Ministry of Science, ICT and Future Planning (MSIP) of Korea
[NRF-2014M3A9B5073938]
FX The authors thank Dr. SM Kim for meaningful discussion. This work was
supported by the R&D Convergence Program (CAP-15-03-KRIBB and
CAP-16-03-KRIBB) of the National Research Council of Science &
Technology (NST) of the Republic of Korea and by the Bio and Medical
Technology Development Program (NRF-2014M3A9B5073938) of the Ministry of
Science, ICT and Future Planning (MSIP) of Korea.
NR 55
TC 0
Z9 0
U1 2
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 30
PY 2016
VL 7
IS 35
BP 56944
EP 56957
DI 10.18632/oncotarget.10922
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA EA8TL
UT WOS:000386911600080
PM 27486970
ER
PT J
AU Hannah-Shmouni, F
Faucz, FR
Stratakis, CA
AF Hannah-Shmouni, Fady
Faucz, Fabio R.
Stratakis, Constantine A.
TI Alterations of Phosphodiesterases in Adrenocortical Tumors
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Review
DE phosphodiesterases; adrenocortical tumors; adrenal hyperplasia; Cushing
syndrome; genetics; Carney complex; cAMP
ID MACRONODULAR ADRENAL-HYPERPLASIA; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES;
MCCUNE-ALBRIGHT-SYNDROME; CUSHINGS-SYNDROME; CARNEY COMPLEX;
GENETIC-HETEROGENEITY; ACTIVATING MUTATIONS; MOLECULAR-GENETICS;
SEQUENCE VARIANTS; 11A4 PDE11A
AB Alterations in the cyclic (c) AMP-dependent signaling pathway have been implicated in the majority of benign adrenocortical tumors (ACTs) causing Cushing syndrome (CS). Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including cyclic adenosine monophosphate (cAMP). Inactivating mutations and other functional variants in PDE11A and PDE8B, two cAMP-binding PDEs, predispose to ACTs. The involvement of these two genes in ACTs was initially revealed by a genome-wide association study in patients with micronodular bilateral adrenocortical hyperplasia. Thereafter, PDE11A or PDE8B genetic variants have been found in other ACTs, including macronodular adrenocortical hyperplasias and cortisol-producing adenomas. In addition, downregulation of PDE11A expression and inactivating variants of the gene have been found in hereditary and sporadic testicular germ cell tumors, as well as in prostatic cancer. PDEs confer an increased risk of ACT formation probably through, primarily, their action on cAMP levels, but other actions might be possible. In this report, we review what is known to date about PDE11A and PDE8B and their involvement in the predisposition to ACTs.
C1 [Hannah-Shmouni, Fady; Faucz, Fabio R.; Stratakis, Constantine A.] NICHD, Program Dev Endocrinol & Genet PDEGEN, Sect Endocrinol & Genet SEGEN, NIH, Bethesda, MD 20817 USA.
RP Stratakis, CA (reprint author), NICHD, Program Dev Endocrinol & Genet PDEGEN, Sect Endocrinol & Genet SEGEN, NIH, Bethesda, MD 20817 USA.
EM fady.hannah-shmouni@nih.gov; stratakc@mail.nih.gov
FU intramural program of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, National Institutes of Health (NIH)
[HD008920]
FX This work was supported by the intramural program of the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
National Institutes of Health (NIH), protocol HD008920.
NR 58
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD AUG 30
PY 2016
VL 7
AR 111
DI 10.3389/fendo.2016.00111
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DY7ML
UT WOS:000385313300001
PM 27625633
ER
PT J
AU Smith, A
Calley, J
Mathur, S
Qian, HR
Wu, H
Farmen, M
Caiment, F
Bushel, PR
Li, JY
Fisher, C
Kirby, P
Koenig, E
Hall, DG
Watson, DE
AF Smith, Aaron
Calley, John
Mathur, Sachin
Qian, Hui-Rong
Wu, Han
Farmen, Mark
Caiment, Florian
Bushel, Pierre R.
Li, Jianying
Fisher, Craig
Kirby, Patrick
Koenig, Erik
Hall, David G.
Watson, David E.
TI The Rat microRNA body atlas; Evaluation of the microRNA content of rat
organs through deep sequencing and characterization of pancreas enriched
miRNAs as biomarkers of pancreatic toxicity in the rat and dog
SO BMC GENOMICS
LA English
DT Article
DE microRNA; Biomarkers; Deep sequencing; Tissue specific; Tissue enriched;
Pancreatic toxicity
AB Background: MicroRNAs (miRNA) are similar to 19-25 nucleotide long RNA molecules that fine tune gene expression through the inhibition of translation or degradation of the mRNA through incorporation into the RNA induced silencing complex (RISC). MicroRNAs are stable in the serum and plasma, are detectable in a wide variety of body fluids, are conserved across veterinary species and humans and are expressed in a tissue specific manner. They can be detected at low concentrations in circulation in animals and humans, generating interest in the utilization of miRNAs as serum and/or plasma based biomarkers of tissue injury. MicroRNA tissue profiling in rodents has been published, but sample an insufficient number of organs of toxicologic interest using microarray or qPCR technologies for miRNA detection. Here we impart an improved rat microRNA body atlas consisting of 21 and 23 tissues of toxicologic interest from male and female Sprague Dawley rats respectively, using Illumina miRNA sequencing. Several of the authors created a dog miRNA body atlas and we collaborated to test miRNAs conserved in rat and dog pancreas in caerulein toxicity studies utilizing both species.
Results: A rich data set is presented that more robustly defines the tissue specificity and enrichment profiles of previously published and undiscovered rat miRNAs. We generated 1,927 sequences that mapped to mature miRNAs in rat, mouse and human from miRBase and discovered an additional 1,162 rat miRNAs as compared to the current number of rat miRNAs in miRBase version 21. Tissue specific and enriched miRNAs were identified and a subset of these miRNAs were validated by qPCR for tissue specificity or enrichment. As an example of the power of this approach, we have conducted rat and dog pancreas toxicity studies and examined the levels of some tissue specific and enriched miRNAs conserved between rat and dog in the serum of each species. The studies demonstrate that conserved tissue specific/ enriched miRs-216a-5p, 375-3p, 148a-3p, 216b-5p and 141-3p are candidate biomarkers of pancreatic injury in the rat and dog.
Conclusions: A microRNA body atlas for rat and dog was useful in identifying new candidate miRNA biomarkers of organ toxicity in 2 toxicologically relevant species.
C1 [Smith, Aaron; Watson, David E.] Lilly Corp Ctr, Dept Investigat Toxicol Non Clin Safety Assessmen, Lilly Res Labs, Indianapolis, IN 46285 USA.
[Calley, John; Mathur, Sachin] Lilly Corp Ctr, Dept TTX Bioinformat, Lilly Res Labs, Indianapolis, IN 46285 USA.
[Qian, Hui-Rong; Wu, Han; Farmen, Mark] Lilly Corp Ctr, Dept Discovery & Dev Stat, Lilly Res Labs, Indianapolis, IN 46285 USA.
[Caiment, Florian] Maastricht Univ, Univ Single, Dept Toxicogen, Maastricht, Netherlands.
[Bushel, Pierre R.] NIEHS, Biostat Branch, Durham, NC USA.
[Li, Jianying] Kelly Govt Solut, Durham, NC 27709 USA.
[Fisher, Craig; Kirby, Patrick] Takeda Pharmaceut Int Co, Drug Safety Evaluat, Deerfield, IL USA.
[Koenig, Erik] Takeda Pharmaceut Int Co, Mol Pathol, Deerfield, IL USA.
[Hall, David G.] Lilly Corp Ctr, Dept Investigat Pathol, Lilly Res Labs, Indianapolis, IN 46285 USA.
RP Smith, A (reprint author), Lilly Corp Ctr, Dept Investigat Toxicol Non Clin Safety Assessmen, Lilly Res Labs, Indianapolis, IN 46285 USA.
EM smithat@lilly.com
FU Intramural Research Program of the National Institutes of Health (NIH),
National Institute of Environmental Health Sciences (NIEHS); HESI
FX This research was supported, in part, by the Intramural Research Program
of the National Institutes of Health (NIH), National Institute of
Environmental Health Sciences (NIEHS).; This HESI scientific initiative
is primarily supported by in-kind contributions (from public and private
sector participants) of time, expertise, and experimental effort. These
contributions are supplemented by direct funding (that largely supports
program infrastructure and management) that was provided by HESI's
corporate sponsors. A list of supporting organizations (public and
private) is available at
http://www.hesiglobal.org/i4a/pages/index.cfm?pageid=3311.
NR 45
TC 1
Z9 1
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 30
PY 2016
VL 17
AR 694
DI 10.1186/s12864-016-2956-z
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DY3HG
UT WOS:000384980800008
PM 27576563
ER
PT J
AU Woo, HJ
Yu, CG
Kumar, K
Gold, B
Reifman, J
AF Woo, Hyung Jun
Yu, Chenggang
Kumar, Kamal
Gold, Bert
Reifman, Jaques
TI Genotype distribution-based inference of collective effects in
genome-wide association studies: insights to age-related macular
degeneration disease mechanism
SO BMC GENOMICS
LA English
DT Article
DE Genome-wide association; Machine learning; Epistasis; Single-nucleotide
polymorphism; Age-related macular degeneration
ID COMPLEMENT FACTOR-H; PENALIZED LOGISTIC-REGRESSION;
DISCRIMINANT-ANALYSIS; VARIABLE SELECTION; GENE INTERACTIONS; CANDIDATE
GENE; BREAST-CANCER; SUSCEPTIBILITY; EPISTASIS; APOPTOSIS
AB Background: Genome-wide association studies provide important insights to the genetic component of disease risks. However, an existing challenge is how to incorporate collective effects of interactions beyond the level of independent single nucleotide polymorphism (SNP) tests. While methods considering each SNP pair separately have provided insights, a large portion of expected heritability may reside in higher-order interaction effects.
Results: We describe an inference approach (discrete discriminant analysis; DDA) designed to probe collective interactions while treating both genotypes and phenotypes as random variables. The genotype distributions in case and control groups are modeled separately based on empirical allele frequency and covariance data, whose differences yield disease risk parameters. We compared pairwise tests and collective inference methods, the latter based both on DDA and logistic regression. Analyses using simulated data demonstrated that significantly higher sensitivity and specificity can be achieved with collective inference in comparison to pairwise tests, and with DDA in comparison to logistic regression. Using age-related macular degeneration (AMD) data, we demonstrated two possible applications of DDA. In the first application, a genome-wide SNP set is reduced into a small number (similar to 100) of variants via filtering and SNP pairs with significant interactions are identified. We found that interactions between SNPs with highest AMD association were epigenetically active in the liver, adipocytes, and mesenchymal stem cells. In the other application, multiple groups of SNPs were formed from the genome-wide data and their relative strengths of association were compared using cross-validation. This analysis allowed us to discover novel collections of loci for which interactions between SNPs play significant roles in their disease association. In particular, we considered pathway-based groups of SNPs containing up to similar to 10,000 variants in each group. In addition to pathways related to complement activation, our collective inference pointed to pathway groups involved in phospholipid synthesis, oxidative stress, and apoptosis, consistent with the AMD pathogenesis mechanism where the dysfunction of retinal pigment epithelium cells plays central roles.
Conclusions: The simultaneous inference of collective interaction effects within a set of SNPs has the potential to reveal novel aspects of disease association.
C1 [Woo, Hyung Jun; Yu, Chenggang; Kumar, Kamal; Reifman, Jaques] US Army Med Res & Mat Command, Biotechnol High Performance Comp Software Applica, Telemed & Adv Technol Res Ctr, Ft Detrick, MD 21702 USA.
[Gold, Bert] NCI, Lab Genom Div, Frederick, MD 21701 USA.
RP Reifman, J (reprint author), US Army Med Res & Mat Command, Biotechnol High Performance Comp Software Applica, Telemed & Adv Technol Res Ctr, Ft Detrick, MD 21702 USA.
EM jaques.reifman.civ@mail.mil
OI Kumar, Kamal/0000-0002-9470-6682
FU U.S. Army Medical Research and Materiel Command (Ft. Detrick, Maryland)
FX This work was supported by the U.S. Army Medical Research and Materiel
Command (Ft. Detrick, Maryland). The opinions and assertions contained
herein are the private views of the authors and are not to be construed
as official or as reflecting the views of the U.S. Army or of the U.S.
Department of Defense. This paper has been approved for public release
with unlimited distribution.
NR 71
TC 1
Z9 1
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 30
PY 2016
VL 17
AR 695
DI 10.1186/s12864-016-2871-3
PG 20
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DY3HG
UT WOS:000384980800009
PM 27576376
ER
PT J
AU Vaid, R
Dev, K
Lichten, M
Sourirajan, A
AF Vaid, Rajni
Dev, Kamal
Lichten, Michael
Sourirajan, Anuradha
TI Generation of an inducible system to express polo-like kinase, Cdc5 as
TAP fusion protein during meiosis in Saccharomyces cerevisiae
SO 3 BIOTECH
LA English
DT Article
DE Tandem affinity purification; Fusion protein; Saccharomyces cerevisiae;
Meiosis; Polo-like kinase; Cdc5; Kinase dead; Estrogen inducible;
Pachytene; Meiotic recombination; Joint molecules (JM); Substrates
ID BUDDING YEAST; SEGREGATION; DIVISION; GENE; RECOMBINATION; PURIFICATION;
CHROMOSOMES; MECHANISMS; REGULATORS; PACHYTENE
AB Tandem affinity purification (TAP) is a highly efficient method for isolation of protein complexes from endogenous biological macromolecules. TAP system consists of dual affinity tags that facilitates the sequential purification of the desired proteins expressed at their low levels in vivo. Polo-like kinases (PLK) are serine/threonine protein kinases that are the crucial regulators of cell cycle. Cdc5, the solitary PLK in budding yeast Saccharomyces cerevisiae, has diverse array of targets in cell cycle. The present study was undertaken to construct an estrogen-inducible system for expression of Cdc5-TAP to isolate the substrates of Cdc5 during meiosis, particularly, pachytene stage of meiosis I. Two yeast strains were constructed CDC5-IN (ndt80 Delta pGAL1-CDC5-TAP) and Cdc5-kinase inactive mutant (ndt80 Delta pGAL1-cdc5-N209A-TAP). The estrogen-inducible expression of Cdc5-TAP and cdc5-N209A-TAP was validated by Western analysis. The systems would serve as a valuable tool for purification of substrates binding to Cdc5-TAP by TAP affinity chromatography.
C1 [Vaid, Rajni; Dev, Kamal; Sourirajan, Anuradha] Shoolini Univ, Fac Appl Sci & Biotechnol, Solan 173212, Himachal Prades, India.
[Lichten, Michael] NCI, Lab Biochem & Mol Biol, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Sourirajan, A (reprint author), Shoolini Univ, Fac Appl Sci & Biotechnol, Solan 173212, Himachal Prades, India.
EM mlichten@helix.nih.gov; asourirajan@gmail.com
FU Department of Biotechnology (DBT), Government of India
[BT/Bio-CARe/01/616]
FX We thank Dr. Wolfgang Zachariae, Max Planck Institute of Molecular Cell
Biology and Genetics, Germany for providing genomic-tagged CDC5-TAP
yeast strains. We acknowledge the research funding to Dr. Sourirajan and
research fellowship to Ms. Vaid provided by the Department of
Biotechnology (DBT), Government of India under the project
BT/Bio-CARe/01/616. The authors would like to acknowledge Shoolini
University for infrastructural support in the research work.
NR 29
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-5738
EI 2190-572X
J9 3 BIOTECH
JI 3 Biotech
PD AUG 30
PY 2016
VL 6
AR 185
DI 10.1007/s13205-016-0503-x
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DV0YR
UT WOS:000382647200001
PM 28330257
ER
PT J
AU St Laurent, B
Oy, K
Miller, B
Gasteiger, EB
Lee, E
Sovannaroth, S
Gwadz, RW
Anderson, JM
Fairhurst, RM
AF St Laurent, Brandyce
Oy, Kolthida
Miller, Becky
Gasteiger, Elizabeth B.
Lee, Eunjae
Sovannaroth, Siv
Gwadz, Robert W.
Anderson, Jennifer M.
Fairhurst, Rick M.
TI Cow-baited tents are highly effective in sampling diverse Anopheles
malaria vectors in Cambodia
SO MALARIA JOURNAL
LA English
DT Article
DE Anopheles; Cambodia; Trap; Outdoor transmission; Malaria; Vector
ID PLASMODIUM-FALCIPARUM MALARIA; HUMAN LANDING CATCHES; MOSQUITOS DIPTERA;
WESTERN THAILAND; SOUTHEAST-ASIA; ENDEMIC AREA; IDENTIFICATION;
TRANSMISSION; POPULATIONS; RESISTANCE
AB Background: The accurate monitoring and evaluation of malaria vectors requires efficient sampling. The objective of this study was to compare methods for sampling outdoor-biting Anopheles mosquitoes in Cambodia.
Methods: In the Cambodian provinces of Pursat, Preah Vihear, and Ratanakiri, six different mosquito trapping methods were evaluated: human landing collection (HLC), human-baited tent (HBT), cow-baited tent (CBT), CDC miniature light trap (LT), CDC miniature light trap baited with molasses and yeast (LT-M), and barrier fence (F) in a Latin square design during four or six consecutive nights at the height of the malaria transmission season.
Results: Using all traps, a total of 507, 1175, and 615 anophelines were collected in Pursat, Preah Vihear, and Ratanakiri, respectively. CBTs captured 10- to 20-fold more anophelines per night than the other five sampling methods. All 2297 Anopheles mosquitoes were morphologically identified and molecularly typed using standard morphological keys and sequencing the rDNA ITS2 region to distinguish cryptic species, respectively. Overall, an extremely diverse set of 27 known Anopheles species was sampled. CBTs captured the same molecular species that HLCs and the other four traps did, as well as additional species. Nine specimens representing five Anopheles species (Anopheles hyrcanus, Anopheles barbirostris sensu stricto, Anopheles barbirostris clade III, Anopheles nivipes, and Anopheles peditaeniatus) were infected with Plasmodium falciparum and were exclusively captured in CBTs.
Conclusions: These data indicate that cow-baited tents are highly effective in sampling diverse Anopheles malaria vectors in Cambodia. This sampling method captured high numbers of anophelines with limited sampling effort and greatly reduced human exposure to mosquito bites compared to the gold-standard human landing collection.
C1 [St Laurent, Brandyce; Miller, Becky; Gasteiger, Elizabeth B.; Lee, Eunjae; Gwadz, Robert W.; Anderson, Jennifer M.; Fairhurst, Rick M.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
[Oy, Kolthida; Sovannaroth, Siv] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh 12101, Cambodia.
RP St Laurent, B; Fairhurst, RM (reprint author), NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
EM brandyce.stlaurent@nih.gov; rfairhurst@niaid.nih.gov
OI St. Laurent, Brandyce/0000-0002-2957-5364
FU Intramural Research Program, National Institute of Allergy and
Infectious Diseases, US National Institutes of Health
FX This study was funded by the Intramural Research Program, National
Institute of Allergy and Infectious Diseases, US National Institutes of
Health.
NR 34
TC 0
Z9 0
U1 3
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 30
PY 2016
VL 15
AR 440
DI 10.1186/s12936-016-1488-y
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU9KM
UT WOS:000382535900001
PM 27577697
ER
PT J
AU Langenfurth, A
Gu, S
Bautze, V
Zhang, CY
Neumann, JE
Schuller, U
Stock, K
Wolf, SA
Maier, AM
Mastrella, G
Pak, A
Cheng, HW
Kalin, RE
Holmbeck, K
Strotmann, J
Kettenmann, H
Glass, R
AF Langenfurth, Anika
Gu, Song
Bautze, Verena
Zhang, Caiyi
Neumann, Julia E.
Schueller, Ulrich
Stock, Kristin
Wolf, Susanne A.
Maier, Anna-Maria
Mastrella, Giorgia
Pak, Andrew
Cheng, Hongwei
Kaelin, Roland E.
Holmbeck, Kenn
Strotmann, Joerg
Kettenmann, Helmut
Glass, Rainer
TI Decreased demand for olfactory periglomerular cells impacts on neural
precursor cell viability in the rostral migratory stream
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ADULT MAMMALIAN BRAIN; SUBVENTRICULAR ZONE; BULB NEUROGENESIS;
STEM-CELLS; MICE; RAT; HIPPOCAMPAL; DEATH; PLASTICITY; NEURONS
AB The subventricular zone (SVZ) provides a constant supply of new neurons to the olfactory bulb (OB). Different studies have investigated the role of olfactory sensory input to neural precursor cell (NPC) turnover in the SVZ but it was not addressed if a reduced demand specifically for periglomerular neurons impacts on NPC-traits in the rostral migratory stream (RMS). We here report that membrane type-1 matrix metalloproteinase (MT1-MMP) deficient mice have reduced complexity of the nasal turbinates, decreased sensory innervation of the OB, reduced numbers of olfactory glomeruli and reduced OB-size without alterations in SVZ neurogenesis. Large parts of the RMS were fully preserved in MT1-MMP-deficient mice, but we detected an increase in cell death-levels and a decrease in SVZ-derived neuroblasts in the distal RMS, as compared to controls. BrdU-tracking experiments showed that homing of NPCs specifically to the glomerular layer was reduced in MT1-MMP-deficient mice in contrast to controls while numbers of tracked cells remained equal in other OB-layers throughout all experimental groups. Altogether, our data show the demand for olfactory interneurons in the glomerular layer modulates cell turnover in the RMS, but has no impact on subventricular neurogenesis.
C1 [Langenfurth, Anika; Stock, Kristin; Wolf, Susanne A.; Kettenmann, Helmut] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Cellular Neurosci, Robert Rossle Str 10, Berlin, Germany.
[Langenfurth, Anika] Charite, Dept Psychiat & Psychotherapy Neuropsychiat, Charitepl 1, Berlin, Germany.
[Gu, Song; Zhang, Caiyi; Mastrella, Giorgia; Kaelin, Roland E.; Glass, Rainer] Univ Munich, Neurosurg Res, Marchioninistr 15, Munich, Germany.
[Gu, Song; Cheng, Hongwei] Anhui Med Univ, Affiliated Hosp 1, Dept Neurosurg, Hefei 230022, Anhui, Peoples R China.
[Bautze, Verena; Maier, Anna-Maria; Strotmann, Joerg] Univ Hohenheim, Inst Physiol, Garbenstr 30, Hohenheim, Germany.
[Neumann, Julia E.; Schueller, Ulrich] Univ Munich, Ctr Neuropathol, Feodor Lynen Str 23, Munich, Germany.
[Neumann, Julia E.; Schueller, Ulrich] Univ Med Ctr, Inst Neuropathol, Hamburg, Germany.
[Neumann, Julia E.; Schueller, Ulrich] Res Inst Childrens Canc Ctr, Hamburg, Germany.
[Schueller, Ulrich] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, D-20264 Hamburg, Germany.
[Pak, Andrew; Holmbeck, Kenn] NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Glass, R (reprint author), Univ Munich, Neurosurg Res, Marchioninistr 15, Munich, Germany.
EM rainer.glass@med.uni-muenchen.de
FU Klinisches Ausbildungsprogramm (KAP); Neurocure; DFG [Str 619/5-1,
SPP1392, GL691/2, SFB824]; Wilhelm Sander Stiftung; Anni-Hofmann
Stiftung; Verein zur Forderung von Wissenschaft und Forschung an der
Medizinischen Fakultat (WiFoMed) der LMU Munchen; Curt Bohnewandt Fonds;
Friedrich-Baur-Stiftung; Familie Mehdorn Stiftung
FX We are thankful to Kazuaki Yoshikawa (Osaka University, Osaka, Japan)
for providing us with the guinea pig anti-Dlx2 antibody. A.L. was
supported by a scholarship from the "Klinisches Ausbildungsprogramm
(KAP)". This research was supported by Neurocure. J.S. R.G. and R.E.K.
gratefully acknowledge funding by the DFG (Str 619/5-1; SPP1392;
GL691/2; SFB824), the Wilhelm Sander Stiftung, the Anni-Hofmann
Stiftung, Verein zur Forderung von Wissenschaft und Forschung an der
Medizinischen Fakultat (WiFoMed) der LMU Munchen, the Curt Bohnewandt
Fonds, the Friedrich-Baur-Stiftung and the Familie Mehdorn Stiftung.
NR 45
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 30
PY 2016
VL 6
AR 32203
DI 10.1038/srep32203
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU5PH
UT WOS:000382263300001
PM 27573347
ER
PT J
AU van der Laan, SW
Fall, T
Soumare, A
Teumer, A
Sedaghat, S
Baumert, J
Zabaneh, D
van Setten, J
Isgum, I
Galesloot, TE
Arpegard, J
Amouyel, P
Trompet, S
Waldenberger, M
Dorr, M
Magnusson, PK
Giedraitis, V
Larsson, A
Morris, AP
Felix, JF
Morrison, AC
Franceschini, N
Bis, JC
Kavousi, M
O'Donnell, C
Drenos, F
Tragante, V
Munroe, PB
Malik, R
Dichgans, M
Worrall, BB
Erdmann, J
Nelson, CP
Samani, NJ
Schunkert, H
Marchini, J
Patel, RS
Hingorani, AD
Lind, L
Pedersen, NL
de Graaf, J
Kiemeney, LALM
Baumeister, SE
Franco, OH
Hofman, A
Uitterlinden, AG
Koenig, W
Meisinger, C
Peters, A
Thorand, B
Jukema, JW
Eriksen, BO
Toft, I
Wilsgaard, T
Onland-Moret, NC
van der Schouw, YT
Debette, S
Kumari, M
Svensson, P
van der Harst, P
Kivimaki, M
Keating, BJ
Sattar, N
Dehghan, A
Reiner, AP
Ingelsson, E
den Ruijter, HM
de Bakker, PIW
Pasterkamp, G
Arnlov, J
Holmes, MV
Asselbergs, FW
AF van der Laan, Sander W.
Fall, Tove
Soumare, Aicha
Teumer, Alexander
Sedaghat, Sanaz
Baumert, Jens
Zabaneh, Delilah
van Setten, Jessica
Isgum, Ivana
Galesloot, Tessel E.
Arpegard, Johannes
Amouyel, Philippe
Trompet, Stella
Waldenberger, Melanie
Doerr, Marcus
Magnusson, Patrik K.
Giedraitis, Vilmantas
Larsson, Anders
Morris, Andrew P.
Felix, Janine F.
Morrison, Alanna C.
Franceschini, Nora
Bis, Joshua C.
Kavousi, Maryam
O'Donnell, Christopher
Drenos, Fotios
Tragante, Vinicius
Munroe, Patricia B.
Malik, Rainer
Dichgans, Martin
Worrall, Bradford B.
Erdmann, Jeanette
Nelson, Christopher P.
Samani, Nilesh J.
Schunkert, Heribert
Marchini, Jonathan
Patel, Riyaz S.
Hingorani, Aroon D.
Lind, Lars
Pedersen, Nancy L.
de Graaf, Jacqueline
Kiemeney, Lambertus A. L. M.
Baumeister, Sebastian E.
Franco, Oscar H.
Hofman, Albert
Uitterlinden, Andre G.
Koenig, Wolfgang
Meisinger, Christa
Peters, Annette
Thorand, Barbara
Jukema, J. Wouter
Eriksen, Bjorn Odvar
Toft, Ingrid
Wilsgaard, Tom
Onland-Moret, N. Charlotte
van der Schouw, Yvonne T.
Debette, Stephanie
Kumari, Meena
Svensson, Per
van der Harst, Pim
Kivimaki, Mika
Keating, Brendan J.
Sattar, Naveed
Dehghan, Abbas
Reiner, Alex P.
Ingelsson, Erik
den Ruijter, Hester M.
de Bakker, Paul I. W.
Pasterkamp, Gerard
Arnlov, Johan
Holmes, Michael V.
Asselbergs, Folkert W.
TI Cystatin C and Cardiovascular Disease A Mendelian Randomization Study
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE coronary heart disease; genetics; heart failure; ischemic stroke
ID CHRONIC KIDNEY-DISEASE; GENOME-WIDE ASSOCIATION;
CORONARY-ARTERY-DISEASE; INCIDENT HEART-FAILURE; BODY-MASS INDEX;
SUSCEPTIBILITY LOCI; CHARGE CONSORTIUM; COMMON VARIANTS;
ISCHEMIC-STROKE; RISK
AB BACKGROUND Epidemiological studies show that high circulating cystatin C is associated with risk of cardiovascular disease (CVD), independent of creatinine-based renal function measurements. It is unclear whether this relationship is causal, arises from residual confounding, and/or is a consequence of reverse causation.
OBJECTIVES The aim of this study was to use Mendelian randomization to investigate whether cystatin C is causally related to CVD in the general population.
METHODS We incorporated participant data from 16 prospective cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 252,216) with 63,292 CVD events. We used the common variant rs911119 in CST3 as an instrumental variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, ischemic stroke, and heart failure.
RESULTS Cystatin C concentrations were associated with CVD risk after adjusting for age, sex, and traditional risk factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13; p = 2.12 x 10(-14)). The minor allele of rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p = 5.95 x 10(-211)), explaining 2.8% of the observed variation in cystatin C. Mendelian randomization analysis did not provide evidence fora causal role of cystatin C, with a causal relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0,994), which was statistically different from the observational estimate (p = 1.6 x 10(-5)). A causal effect of cystatin C was not detected for any individual component of CVD.
CONCLUSIONS Mendelian randomization analyses did not support a causal role of cystatin C in the etiology of CVD. As such, therapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CVD. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license.
C1 [van der Laan, Sander W.; van Setten, Jessica; den Ruijter, Hester M.; Pasterkamp, Gerard] Univ Med Ctr Utrecht, Div Heart & Lungs, Lab Expt Cardiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
[Fall, Tove; Arnlov, Johan] Uppsala Univ, Dept Med Sci, Cardiovasc Epidemiol, Uppsala, Sweden.
[Soumare, Aicha; Debette, Stephanie] Univ Bordeaux, INSERM, U1219, Team Vintage, Bordeaux, France.
[Teumer, Alexander; Baumeister, Sebastian E.] Univ Med Greifswald, Inst Community Med, Dept SHIP KEF, Greifswald, Germany.
[Teumer, Alexander; Doerr, Marcus; Koenig, Wolfgang; Peters, Annette] German Ctr Cardiovasc Res, DZHK, Partner Site, Greifswald, Germany.
[Sedaghat, Sanaz; Felix, Janine F.; Kavousi, Maryam; Franco, Oscar H.; Hofman, Albert; Dehghan, Abbas] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
[Baumert, Jens; Waldenberger, Melanie; Meisinger, Christa; Peters, Annette; Thorand, Barbara] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany.
[Zabaneh, Delilah] UCL, Dept Genet Environm & Evolut, London, England.
[Zabaneh, Delilah] UCL, Genet Inst, London, England.
[Isgum, Ivana] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands.
[Galesloot, Tessel E.; de Graaf, Jacqueline; Kiemeney, Lambertus A. L. M.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands.
[Arpegard, Johannes; Svensson, Per] Karolinska Univ Hosp Solna, Dept Emergency Med, Stockholm, Sweden.
[Arpegard, Johannes; Svensson, Per] Karolinska Inst, Dept Med Solna, Stockholm, Sweden.
[Amouyel, Philippe] Univ Lille, INSERM, Lille, France.
[Amouyel, Philippe] Inst Pasteur, Lille, France.
[Trompet, Stella; Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol P C5, Leiden, Netherlands.
[Trompet, Stella] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands.
[Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany.
[Doerr, Marcus] Univ Med Greifswald, Dept Internal Med B, Greifswald, Germany.
[Magnusson, Patrik K.; Pedersen, Nancy L.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Giedraitis, Vilmantas] Uppsala Univ, Dept Publ Health Geriatr, Uppsala, Sweden.
[Larsson, Anders; Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England.
[Morris, Andrew P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Morrison, Alanna C.] Univ Texas Hlth Sci Ctr Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
[Franceschini, Nora] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[O'Donnell, Christopher] Boston Vet Adm Healthcare, Dept Cardiol, West Roxbury, MA USA.
[O'Donnell, Christopher] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Drenos, Fotios] UCL, Inst Cardiovasc Sci, Ctr Cardiovasc Genet, London, England.
[Drenos, Fotios] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
[Tragante, Vinicius; Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
[Munroe, Patricia B.] Queen Mary Univ London, William Harvey Res Inst, Natl Inst Hlth Res, Cardiovasc Biomed Res Unit, London, England.
[Malik, Rainer; Dichgans, Martin] Univ Munich, Klinikum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany.
[Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany.
[Worrall, Bradford B.] Univ Virginia, Dept Neurol, Charlottesville, VA USA.
[Worrall, Bradford B.] Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA.
[Erdmann, Jeanette] Univ Lubeck, Inst Integrat & Expt Genom, Lubeck, Germany.
[Nelson, Christopher P.; Samani, Nilesh J.] Univ Leicester, Glenfield Hosp, British Heart Fdn Cardiovasc, Res Ctr,Dept Cardiovasc Sci, Leicester, Leics, England.
[Nelson, Christopher P.; Samani, Nilesh J.] Glenfield Hosp, Natl Inst Hlth Res Leicester, Cardiovasc Biomed Res Unit, Leicester, Leics, England.
[Schunkert, Heribert; Koenig, Wolfgang] Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany.
[Schunkert, Heribert] German Ctr Cardiovasc Res, DZHK, Munich Heart Alliance, Partner Site, Munich, Germany.
[Marchini, Jonathan] Univ Oxford, Dept Stat, Oxford, England.
[Patel, Riyaz S.; Hingorani, Aroon D.] UCL, Inst Cardiovasc Sci, Genet Epidemiol Res Grp, London, England.
[Patel, Riyaz S.] Barts Heart Ctr, London, England.
[Patel, Riyaz S.] UCL, Farr Inst Hlth Informat, London, England.
[de Graaf, Jacqueline] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.
[Baumeister, Sebastian E.] Univ Regensburg, Inst Epidemiol & Prevent Med, Regensburg, Germany.
[Uitterlinden, Andre G.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
[Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, Ulm, Germany.
[Jukema, J. Wouter; van der Harst, Pim; Asselbergs, Folkert W.] ICIN Netherlands Heart Inst, Durrer Ctr Cardiogenet Res, Utrecht, Netherlands.
[Eriksen, Bjorn Odvar] UiT Arctic Univ Norway, Metab & Renal Res Grp, Tromso, Norway.
[Eriksen, Bjorn Odvar; Toft, Ingrid] Univ Hosp North Norway, Nephrol Sect, Tromso, Norway.
[Wilsgaard, Tom] UiT Arctic Univ Norway, Dept Community Med, Tromso, Norway.
[Onland-Moret, N. Charlotte; van der Schouw, Yvonne T.; de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
[Kumari, Meena] Univ Essex, Biol & Social Epidemiol, Inst Social & Econ Res, Colchester CO4 3SQ, Essex, England.
[van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[Kivimaki, Mika] UCL, Dept Epidemiol & Publ Hlth, London, England.
[Keating, Brendan J.] Univ Penn, Dept Surg, Div Transplantat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Sattar, Naveed] Univ Glasgow, Glasgow, Lanark, Scotland.
[Reiner, Alex P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Ingelsson, Erik] Uppsala Univ, Mol Epidemiol & Sci Life Lab, Dept Med Sci, Uppsala, Sweden.
[Ingelsson, Erik] Stanford Univ, Dept Med, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA.
[de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Med Genet, Utrecht, Netherlands.
[Pasterkamp, Gerard] Univ Med Ctr Utrecht, Div Labs & Pharm, Lab Clin Chem & Hematol, Utrecht, Netherlands.
[Holmes, Michael V.] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.
[Holmes, Michael V.] Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit CTSU, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.
[Asselbergs, Folkert W.] UCL, Fac Populat Hlth Sci, Inst Cardiovasc Sci, London, England.
RP van der Laan, SW (reprint author), Univ Med Ctr Utrecht, Div Heart & Lungs, Lab Expt Cardiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.; Asselbergs, FW (reprint author), Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.; Holmes, MV (reprint author), Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.; Holmes, MV (reprint author), Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit CTSU, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.
EM s.w.vanderlaan-2@umcutrecht.nl; michael.holmes@ndph.ox.ac.uk;
f.w.asselbergs@umcutrecht.nl
RI Waldenberger, Melanie/B-5355-2014; Peters, Annette/A-6117-2011;
Onland-Moret, N. Charlotte/G-9185-2011; Magnusson, Patrik/C-4458-2017;
OI Waldenberger, Melanie/0000-0003-0583-5093; van der Laan, Sander
W./0000-0001-6888-1404; Kumari, Meena/0000-0001-9716-1035; Svensson,
Per/0000-0003-0372-6272; Peters, Annette/0000-0001-6645-0985
FU Pie Medical Imaging; 3Mensio Medical Imaging B.V.; NWO and Foundation
for Technological Sciences [12726]; Stockholm County Council (combined
clinical residency and PhD training program); Servier; Hoffman Laroche;
Total; Genoscreen; Alzprotect; Fondation Plan Alzheimer; Takeda;
Wellcome Trust Senior Fellow in Basic Biomedical Science [WT098017];
National Institute of Neurological Disorders and Stroke [U-01 N5069208];
National Human Genome Research Institute [U-01 HG005160]; British Heart
Foundation (BHF); National Institute for Health Research Senior
Investigator; BHF; Nestle Nutrition (Nestec Ltd.); Metagenics Inc.; AXA;
BHF Intermediate Fellowship; NGFNplus [01GS0834]; Abbott; Roche
Diagnostics; Beckmann; Singulex; Netherlands Heart Foundation [2001 D
032]; Swedish Society of Medicine [SLS-412071]; Medical Research Council
[K013351]; Economic and Social Research Council; National Institutes of
Health [HL36310]; Netherlands Organization for Scientific Research (NWO)
[916.12.154]; EUR Fellowship; Goran Gustafsson Foundation; Swedish
Heart-Lung Foundation [20140422]; Knut and Alice Wallenberg Foundation;
European Research Council [ERC-StG-335395]; Swedish Diabetes Foundation
(Diabetesfonden) [2013-024]; Swedish Research Council [2012-1397,
2012-1727, 2012-2215]; Swedish Heart-Lung Foundation; Thureus
Foundation; Marianne and Marcus Wallenberg Foundation; Dalarna
University; Uppsala University; Dekker scholarship-Junior Staff Member
[2014T001]; European Union Seventh Framework Programme FP7
[HEALTH-F2-2013-601456]; Netherlands Heart Foundation; UCL Hospitals
National Institute for Health Research Biomedical Research Centre
FX The individual study sponsor(s) had no role in the study design; in the
collection, analysis, and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication. Dr.
Isgum is supported by research grants from Pie Medical Imaging, 3Mensio
Medical Imaging B.V., the NWO and Foundation for Technological Sciences
under Project 12726, The Netherlands Organization for Health Research
and Development, and the Dutch Cancer Society. Dr. Arpegard has received
funding through the Stockholm County Council (combined clinical
residency and PhD training program). Dr. Amouyel has received personal
fees from Servier, Hoffman Laroche, Total, Genoscreen, Alzprotect,
Fondation Plan Alzheimer, and Takeda outside of the submitted work; and
has shares in Genoscreen. Dr. Morris is a Wellcome Trust Senior Fellow
in Basic Biomedical Science under grant number WT098017. Dr. Worrall has
received compensation for his role as deputy editor of the Journal of
Neurology; and has received National Institutes of Health funding
through the National Institute of Neurological Disorders and Stroke
(U-01 N5069208) and National Human Genome Research Institute (U-01
HG005160). Dr. Samani is supported by the British Heart Foundation
(BHF); and is a National Institute for Health Research Senior
Investigator. Dr. Nelson is supported by the BHF. Dr. Franco works in
ErasmusAGE, a center for aging research across the life course funded by
Nestle Nutrition (Nestec Ltd.), Metagenics Inc., and AXA; Nestle
Nutrition (Nestec Ltd.), Metagenics Inc., and AXA had no role in design
and conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript. Dr. Patel is supported by a BHF Intermediate Fellowship. Dr.
Koenig has received funds through NGFNplus, project number 01GS0834; has
received research grants from Abbott, Roche Diagnostics, Beckmann, and
Singulex; has received honorarium for lectures from AstraZeneca,
Novartis, Merck Sharp & Dohme, Amgen, and Actavis; and has served as a
consultant for Novartis, Pfizer, The Medicines Company, Amgen,
AstraZeneca, Merck Sharp & Dohme, and GlaxoSmithKline. Dr. Jukema is an
Established Clinical Investigator of the Netherlands Heart Foundation
(grant 2001 D 032). Dr. Svensson has received a grant from the Swedish
Society of Medicine (SLS-412071). Dr. Kivimaki has received funding
through the Medical Research Council (K013351), Economic and Social
Research Council, and National Institutes of Health (HL36310). Dr.
Dehghan is supported by a Netherlands Organization for Scientific
Research (NWO) grant (VENI, 916.12.154) and the EUR Fellowship; and has
received consultancy and research support from Metagenics Inc. (outside
the scope of this work). Dr. Ingelsson is supported by grants from Goran
Gustafsson Foundation, Swedish Heart-Lung Foundation (20140422), Knut
and Alice Wallenberg Foundation (Knut och Alice Wallenbergs Stiftelse),
European Research Council (ERC-StG-335395), Swedish Diabetes Foundation
(Diabetesfonden; grant no. 2013-024), and the Swedish Research Council
(VR; grant no. 2012-1397). Dr. de Bakker is an employee of Vertex
Pharmaceuticals. Dr. Arnlov was funded by the Swedish Research Council
(2012-1727, 2012-2215), Swedish Heart-Lung Foundation, Thureus
Foundation, the Marianne and Marcus Wallenberg Foundation, Dalarna
University, and Uppsala University. Dr.; Asselbergs is supported by a
Dekker scholarship-Junior Staff Member 2014T001-Netherlands Heart
Foundation and UCL Hospitals National Institute for Health Research
Biomedical Research Centre. The research leading to these results has
received funding from the European Union Seventh Framework Programme
FP7/2007-2013 under grant agreement no HEALTH-F2-2013-601456
(CVgenes-at-target). All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
NR 46
TC 1
Z9 1
U1 10
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD AUG 30
PY 2016
VL 68
IS 9
BP 934
EP 945
DI 10.1016/j.jacc.2016.05.092
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DU6GS
UT WOS:000382312900009
PM 27561768
ER
PT J
AU Nugent, AC
Robinson, SE
Coppola, R
Zarate, CA
AF Nugent, Allison C.
Robinson, Stephen E.
Coppola, Richard
Zarate, Carlos A., Jr.
TI Preliminary differences in resting state MEG functional connectivity
pre- and post-ketamine in major depressive disorder
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Magnetoencephalography (MEG); Depression; Ketamine; Resting state;
Connectivity; Independent components analysis (ICA)
ID RAPID ANTIDEPRESSANT RESPONSE; TREATMENT-RESISTANT DEPRESSION; DEFAULT
MODE NETWORK; ACTING ANTIDEPRESSANTS; HEALTHY-VOLUNTEERS; NEURAL
ACTIVITY; CINGULATE; GLUTAMATE; CORTEX; FMRI
AB Functional neuroimaging techniques including magnetoencephalography (MEG) have demonstrated that the brain is organized into networks displaying correlated activity. Group connectivity differences between healthy controls and participants with major depressive disorder (MDD) can be detected using temporal independent components analysis (ICA) on beta-bandpass filtered Hilbert envelope MEG data. However, the response of these networks to treatment is unknown. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, exerts rapid antidepressant effects. We obtained MEG recordings before and after open-label infusion of 0.5mg/kg ketamine in MDD subjects (N=13) and examined networks previously shown to differ between healthy individuals and those with MDD. Connectivity between the amygdala and an insulo-temporal component decreased post-ketamine in MDD subjects towards that observed in control subjects at baseline. Decreased baseline connectivity of the subgenual anterior cingulate cortex (sgACC) with a bilateral precentral network had previously been observed in MDD compared to healthy controls, and the change in connectivity post-ketamine was proportional to the change in sgACC glucose metabolism in a subset (N=8) of subjects receiving [11F]FDG-PET imaging. Ketamine appeared to reduce connectivity, regardless of whether connectivity was abnormally high or low compared to controls at baseline. These preliminary findings suggest that sgACC connectivity may be directly related to glutamate levels. Published by Elsevier Ireland Ltd.
C1 [Nugent, Allison C.; Zarate, Carlos A., Jr.] NIMH, Expt Therapeut & Pathophysiol Branch, NIH, 9000 Rockville Pike,MSC 1030, Bethesda, MD 20892 USA.
[Robinson, Stephen E.; Coppola, Richard] NIMH, NIMH Magnetoencephalog Core Facil, NIH, Bethesda, MD 20892 USA.
RP Nugent, AC (reprint author), NIMH, Expt Therapeut & Pathophysiol Branch, NIH, 9000 Rockville Pike,MSC 1030, Bethesda, MD 20892 USA.
EM nugenta@mail.nih.gov
FU Intramural Research Program at the National Institute of Mental Health;
National Institutes of Health (IRP-NIMH-NIH) [ZIA-MH002927-04]; Brain &
Behavior Mood Disorders Research Award
FX Funding for this work was supported by the Intramural Research Program
at the National Institute of Mental Health, National Institutes of
Health (IRP-NIMH-NIH; Clinical Trials Identifier: NCT00024635
(ZIA-MH002927-04)), by a NARSAD Independent Investigator to Dr. Zarate,
and by a Brain & Behavior Mood Disorders Research Award to Dr. Zarate.
The authors thank the 7SE research unit and staff for their support.
loline Henter, MA (NIMH) provided invaluable editorial assistance.
NR 66
TC 3
Z9 3
U1 5
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
EI 1872-7506
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD AUG 30
PY 2016
VL 254
BP 56
EP 66
DI 10.1016/j.pscychresns.2016.06.006
PG 11
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DU6HU
UT WOS:000382316000009
PM 27362845
ER
PT J
AU Szczepanik, J
Nugent, AC
Drevets, WC
Khanna, A
Zarate, CA
Furey, ML
AF Szczepanik, Joanna
Nugent, Allison C.
Drevets, Wayne C.
Khanna, Ashish
Zarate, Carlos A., Jr.
Furey, Maura L.
TI Amygdala response to explicit sad face stimuliat baseline predicts
antidepressant treatment response to scopolamine in major depressive
disorder
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Major depressive disorder; Amygdala; Rapid-acting antidepressants;
Scopolamine; Stimulus processing; Functional magnetic resonance imaging
(fMRI)
ID EMOTIONAL FACES; MOOD-STATE; PERSONALIZED MEDICINE; SELECTIVE ATTENTION;
FEARFUL FACES; BIOMARKERS; FMRI; SUPERSENSITIVITY; PATHOPHYSIOLOGY;
ACETYLCHOLINE
AB The muscarinic antagonist scopolamine produces rapid antidepressant effects in individuals with major depressive disorder (MDD). In healthy subjects, manipulation of acetyl-cholinergic transmission modulates attention in a stimulus-dependent manner. This study tested the hypothesis that baseline amygdalar activity in response to emotional stimuli correlates with antidepressant treatment response to scopolamine and could thus potentially predict treatment outcome. MDD patients and healthy controls performed an attention shifting task involving emotional faces while undergoing functional magnetic resonance imaging (fMRI). We found that blood oxygenation level dependent (BOLD) signal in the amygdala acquired while MDD patients processed sad face stimuli correlated positively with antidepressant response to scopolamine. Amygdalar response to sad faces in MDD patients who did not respond to scopolamine did not differ from that of healthy controls. This suggests that the pre-treatment task elicited amygdalar activity that may constitute a biomarker of antidepressant treatment response to scopolamine. Furthermore, in MDD patients who responded to scopolamine, we observed a post-scopolamine stimulus processing shift towards a pattern demonstrated by healthy controls, indicating a change in stimulus-dependent neural response potentially driven by attenuated cholinergic activity in the amygdala. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Szczepanik, Joanna; Nugent, Allison C.; Zarate, Carlos A., Jr.; Furey, Maura L.] NIMH, Expt Therapeut & Pathophysiol Branch, NIH, Bldg 10 CRC,Rm 7-5565, Bethesda, MD 20892 USA.
[Drevets, Wayne C.] Johnson & Johnson Inc, Janssen Pharmaceut LLC, Titusville, NJ USA.
[Khanna, Ashish] Brooklyn Hosp Ctr, Jewish Med Ctr, Phys Med & Rehabil, Brooklyn, NY USA.
[Furey, Maura L.] Janssen Res & Dev, Neurosci Biomarkers Div, San Diego, CA USA.
RP Szczepanik, J (reprint author), NIMH, Expt Therapeut & Pathophysiol Branch, NIH, Bldg 10 CRC,Rm 7-5565, Bethesda, MD 20892 USA.
EM szczepaj@mail.nih.gov
FU Intramural Research Program at the National Institute of Mental Health;
National Institutes of Health (IRP-NIMH-NIH) [NCT00369915, ZIA
MH002927]; NARSAD Independent Investigator; Brain & Behavior Mood
Disorders Research Award
FX Funding for this work was supported in part by the Intramural Research
Program at the National Institute of Mental Health, National Institutes
of Health (IRP-NIMH-NIH; NCT00369915, ZIA MH002927), by a NARSAD
Independent Investigator to Dr. Zarate, and by a Brain & Behavior Mood
Disorders Research Award to Dr. Zarate. These funding sources had no
further role in study design; in the collection, analysis, or
interpretation of data; in the writing of the report; or in the decision
to submit the paper for publication. Dr. Zarate is listed as a
co-inventor on a patent application for the use of ketamine and its
metabolites in major depression, and Dr. Furey is identified as a
co-inventor on a patent application for the use of scopolamine in mood
disorders. Drs. Zarate and Furey have assigned their rights in these
patents to the U.S. government but will share a percentage of any
royalties that may be received by the government. Dr. Furey was a
full-time employee of the NIMH at the time this study was conducted. All
other authors have no conflict of interest to disclose, financial or
otherwise.
NR 53
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
EI 1872-7506
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD AUG 30
PY 2016
VL 254
BP 67
EP 73
DI 10.1016/j.pscychresns.2016.06.005
PG 7
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DU6HU
UT WOS:000382316000010
PM 27366831
ER
PT J
AU Cai, XY
Li, HY
Liu, AY
AF Cai, Xiaoyu
Li, Huiyun
Liu, Aiyi
TI A marginal rank-based inverse normal transformation approach to
comparing multiple clinical trial endpoints
SO STATISTICS IN MEDICINE
LA English
DT Article
DE clinical trials; multiple endpoints; power of test; rank-based
transformation; ratio of dependent variables; type I error
ID FUNCTIONAL LINEAR-MODELS; QUANTITATIVE TRAITS; FAMILY; ASSOCIATION;
QUALITY; INDEX
AB The increase in incidence of obesity and chronic diseases and their health care costs have raised the importance of quality diet on the health policy agendas. The healthy eating index is an important measure for diet quality which consists of 12 components derived from ratios of dependent variables with distributions hard to specify, measurement errors and excessive zero observations difficult to model parametrically. Hypothesis testing involving data of such nature poses challenges because the widely used multiple comparison procedures such as Hotelling's T-2 test and Bonferroni correction may suffer from substantial loss of efficiency. We propose a marginal rank-based inverse normal transformation approach to normalizing the marginal distribution of the data before employing a multivariate test procedure. Extensive simulation was conducted to demonstrate the ability of the proposed approach to adequately control the type I error rate as well as increase the power of the test, with data particularly from non-symmetric or heavy-tailed distributions. The methods are exemplified with data from a dietary intervention study for type I diabetic children. Published 2016. This article is a U.S. Government work and is in the public domain in the USA
C1 [Cai, Xiaoyu] George Washington Univ, Dept Stat, Washington, DC 20052 USA.
[Li, Huiyun] Beijing Inst Technol, Sch Management & Econ, Beijing 100081, Peoples R China.
[Liu, Aiyi] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Rockville, MD 20852 USA.
RP Liu, AY (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Rockville, MD 20852 USA.
EM liua@mail.nih.gov
OI Liu, Aiyi/0000-0002-6618-5082
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development Intramural Research Program [HHSN267200703434C,
HHSN2752008000031/HHSN275002]
FX Research of A. Liu was supported by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development Intramural Research
Program (contract #HHSN267200703434C and #HHSN2752008000031/HHSN275002).
The authors thank Drs. Ruzong Fan for helpful discussions and Tonja
Nansel for providing the dietary quality data from the CHEF study. The
authors thank two anonymous referees for their constructive comments
that helped improve the manuscript.
NR 15
TC 0
Z9 0
U1 5
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD AUG 30
PY 2016
VL 35
IS 19
BP 3259
EP 3271
DI 10.1002/sim.6928
PG 13
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA DS0YS
UT WOS:000380323400002
PM 26990442
ER
PT J
AU Wu, MX
Shu, Y
Li, ZH
Liu, AY
AF Wu, Mixia
Shu, Yu
Li, Zhaohai
Liu, Aiyi
TI Repeated significance tests of linear combinations of sensitivity and
specificity of a diagnostic biomarker
SO STATISTICS IN MEDICINE
LA English
DT Article
DE expected sample size; inference upon early stopping; sensitivity;
sequential testing; specificity; two-stage designs; type I error;
Youden's index
ID II CLINICAL-TRIALS; SEQUENTIAL EVALUATION; 2-STAGE DESIGNS; ACCURACY;
PREVALENCE; EFFICIENT; BIAS
AB A sequential design is proposed to test whether the accuracy of a binary diagnostic biomarker meets the minimal level of acceptance. The accuracy of a binary diagnostic biomarker is a linear combination of the marker's sensitivity and specificity. The objective of the sequential method is to minimize the maximum expected sample size under the null hypothesis that the marker's accuracy is below the minimal level of acceptance. The exact results of two-stage designs based on Youden's index and efficiency indicate that the maximum expected sample sizes are smaller than the sample sizes of the fixed designs. Exact methods are also developed for estimation, confidence interval and p-value concerning the proposed accuracy index upon termination of the sequential testing. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Wu, Mixia] Beijing Univ Technol, Coll Appl Sci, Beijing 100124, Peoples R China.
[Shu, Yu] Abbott Labs Vasc Div, 3200 Lakeside Dr, Santa Clara, CA 95054 USA.
[Li, Zhaohai] George Washington Univ, Dept Stat, 801 22nd St NW, Washington, DC 20052 USA.
[Liu, Aiyi] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, 6100 Execut Blvd, Rockville, MD 20852 USA.
RP Liu, AY (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, 6100 Execut Blvd, Rockville, MD 20852 USA.
EM liua@mail.nih.gov
OI Liu, Aiyi/0000-0002-6618-5082
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD), National Institutes of Health (NIH)
FX Research of A. Liu is supported by the Intramural Research Program of
the Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD), the National Institutes of Health (NIH). The
authors thank two anonymous referees and an associate editor for their
constructive comments that resulted in an improved manuscript.
NR 31
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD AUG 30
PY 2016
VL 35
IS 19
BP 3397
EP 3412
DI 10.1002/sim.6932
PG 16
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA DS0YS
UT WOS:000380323400011
PM 26947768
ER
PT J
AU Shaw, PA
Fay, MP
AF Shaw, Pamela A.
Fay, Michael P.
TI A rank test for bivariate time-to-event outcomes when one event is a
surrogate
SO STATISTICS IN MEDICINE
LA English
DT Article
DE bivariate survival; composite outcome; interval censoring;
semi-competing risks; surrogate endpoints; survival analysis
ID INTERVAL-CENSORED-DATA; MULTIPLE END-POINTS; CLINICAL-TRIALS; SURVIVAL;
FAILURE; NPMLE
AB In many clinical settings, improving patient survival is of interest but a practical surrogate, such as time to disease progression, is instead used as a clinical trial's primary endpoint. A time-to-first endpoint (e.g., death or disease progression) is commonly analyzed but may not be adequate to summarize patient outcomes if a subsequent event contains important additional information. We consider a surrogate outcome very generally as one correlated with the true endpoint of interest. Settings of interest include those where the surrogate indicates a beneficial outcome so that the usual time-to-first endpoint of death or surrogate event is nonsensical. We present a new two-sample test for bivariate, interval-censored time-to-event data, where one endpoint is a surrogate for the second, less frequently observed endpoint of true interest. This test examines whether patient groups have equal clinical severity. If the true endpoint rarely occurs, the proposed test acts like a weighted logrank test on the surrogate; if it occurs for most individuals, then our test acts like a weighted logrank test on the true endpoint. If the surrogate is a useful statistical surrogate, our test can have better power than tests based on the surrogate that naively handles the true endpoint. In settings where the surrogate is not valid (treatment affects the surrogate but not the true endpoint), our test incorporates the information regarding the lack of treatment effect from the observed true endpoints and hence is expected to have a dampened treatment effect compared with tests based on the surrogate alone. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Shaw, Pamela A.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Fay, Michael P.] NIAID, Biostat Res Branch, Rockville, MD USA.
RP Shaw, PA (reprint author), Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
EM shawp@upenn.edu
OI Fay, Michael P./0000-0002-8643-9625
FU Intramural NIH HHS [Z99 AI999999]
NR 24
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD AUG 30
PY 2016
VL 35
IS 19
BP 3413
EP 3423
DI 10.1002/sim.6950
PG 11
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA DS0YS
UT WOS:000380323400012
PM 27059817
ER
PT J
AU Brooks, AT
Krumlauf, M
Fryer, CS
Beck, KH
Yang, L
Ramchandani, VA
Wallen, GR
AF Brooks, Alyssa Todaro
Krumlauf, Michael
Fryer, Craig S.
Beck, Kenneth H.
Yang, Li
Ramchandani, Vijay A.
Wallen, Gwenyth R.
TI Critical Transitions: A Mixed Methods Examination of Sleep from
Inpatient Alcohol Rehabilitation Treatment to the Community
SO PLOS ONE
LA English
DT Article
ID QUALITY INDEX; DAYTIME SLEEPINESS; DEPENDENT PATIENTS; INSOMNIA; SCALE;
ABSTINENCE; DRINKING; DURATION; RELAPSE; DEPRESSION
AB Aims
This prospective, repeated measures study utilized a convergent parallel mixed methods approach to assess sleep experiences among individuals who were alcohol-dependent undergoing inpatient detoxification and treatment at a clinical research facility across the transition periods associated with the rehabilitation process: the initial adjustment to becoming an inpatient and the transition from inpatient to outpatient status.
Methods
This study included individual semi-structured interviews and quantitative measures relating to psychological distress, sleep quality, daytime sleepiness, and sleep-related beliefs and behavior (n = 33; 66.7% male). Interviews were conducted and questionnaires were administered within one week of participants' scheduled discharge date and again four to six weeks post-discharge when they returned for a follow-up visit (or via phone).
Results
Participants self-reported significant sleep disturbances at both study time points. Of those participants with valid data at both time points (n = 28), there were no significant changes in mean scores from pre- to post-discharge with the exception of self-efficacy for sleep (SE-S) being significantly higher post-discharge. Preliminary qualitative findings suggested differences between those with ongoing sleep disturbances, those whose sleep disturbances had resolved, and those with no sleep disturbances at either time point.
Conclusions
This analysis highlights individual variation in sleep throughout the process of inpatient treatment and transition to outpatient aftercare in individuals with alcohol dependence. Collecting quantitative and qualitative data concurrently and combining emerging themes from qualitative data with quantitative analyses allowed for a more thorough examination of this relatively novel area of research and provided information that can be utilized to inform future behavioral sleep interventions.
C1 [Brooks, Alyssa Todaro; Krumlauf, Michael; Yang, Li; Wallen, Gwenyth R.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Brooks, Alyssa Todaro; Ramchandani, Vijay A.] NIAAA, Bethesda, MD 20892 USA.
[Fryer, Craig S.; Beck, Kenneth H.] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA.
RP Brooks, AT (reprint author), NIH, Ctr Clin, Bethesda, MD 20892 USA.; Brooks, AT (reprint author), NIAAA, Bethesda, MD 20892 USA.
EM todaroad@mail.nih.gov; gwallen@cc.nih.gov
FU National Institutes of Health, Clinical Center intramural research
program
FX This project has been funded in whole or in part with federal funds from
the National Institutes of Health, Clinical Center intramural research
program. The content of this publication does not necessarily reflect
the views or policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products, or organizations
imply endorsement by the U.S. government.
NR 49
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2016
VL 11
IS 8
AR e0161725
DI 10.1371/journal.pone.0161725
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV4DZ
UT WOS:000382876700030
PM 27571353
ER
PT J
AU Martinez, NJ
Rai, G
Yasgar, A
Lea, WA
Sun, HM
Wang, YH
Luci, DK
Yang, SM
Nishihara, K
Takeda, S
Sagor, M
Earnshaw, I
Okada, T
Mori, K
Wilson, K
Riggins, GJ
Xia, MH
Grimaldi, M
Jadhav, A
Maloney, DJ
Simeonov, A
AF Martinez, Natalia J.
Rai, Ganesha
Yasgar, Adam
Lea, Wendy A.
Sun, Hongmao
Wang, Yuhong
Luci, Diane K.
Yang, Shyh-Ming
Nishihara, Kana
Takeda, Shunichi
Sagor, Mohiuddin
Earnshaw, Irina
Okada, Tetsuya
Mori, Kazutoshi
Wilson, Kelli
Riggins, Gregory J.
Xia, Menghang
Grimaldi, Maurizio
Jadhav, Ajit
Maloney, David J.
Simeonov, Anton
TI A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as
Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic
Activity in 3D Glioma Cell Models
SO PLOS ONE
LA English
DT Article
ID UNFOLDED-PROTEIN RESPONSE; ER STRESS; MALIGNANT GLIOMA; DEATH; CA2+;
CANCER; ACTIVATION; GRP78/BIP; AUTOPHAGY; XBP1
AB The endoplasmic reticulum (ER) is involved in Ca2+ signaling and protein folding. ER Ca2+ depletion and accumulation of unfolded proteins activate the molecular chaperone GRP78 (glucose-regulated protein 78) which in turn triggers the ER stress response (ERSR) pathway aimed to restore ER homeostasis. Failure to adapt to stress, however, results in apoptosis. We and others have shown that malignant cells are more susceptible to ERSR-induced apoptosis than their normal counterparts, implicating the ERSR as a potential target for cancer therapeutics. Predicated on these findings, we developed an assay that uses a GRP78 biosensor to identify small molecule activators of ERSR in glioma cells. We performed a quantitative high-throughput screen (qHTS) against a collection of similar to 425,000 compounds and a comprehensive panel of orthogonal secondary assays was formulated for stringent compound validation. We identified novel activators of ERSR, including a compound with a 2,9-diazaspiro[5.5]undecane core, which depletes intracellular Ca2+ stores and induces apoptosis-mediated cell death in several cancer cell lines, including patient-derived and 3D cultures of glioma cells. This study demonstrates that our screening platform enables the identification and profiling of ERSR inducers with cytotoxic activity and advocates for characterization of these compound in in vivo models.
C1 [Martinez, Natalia J.; Rai, Ganesha; Yasgar, Adam; Lea, Wendy A.; Sun, Hongmao; Wang, Yuhong; Luci, Diane K.; Yang, Shyh-Ming; Nishihara, Kana; Wilson, Kelli; Xia, Menghang; Jadhav, Ajit; Maloney, David J.; Simeonov, Anton] NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
[Nishihara, Kana; Sagor, Mohiuddin; Earnshaw, Irina] Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan.
[Okada, Tetsuya; Mori, Kazutoshi] Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.
[Takeda, Shunichi; Wilson, Kelli; Riggins, Gregory J.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21231 USA.
[Grimaldi, Maurizio] Southern Res Inst, Dept Biochem & Mol Biol, Neuropharmacol Lab, Birmingham, AL 35205 USA.
RP Maloney, DJ; Simeonov, A (reprint author), NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
EM maloneyd@mail.nih.gov; asimeono@mail.nih.gov
OI Earnshaw, Irina/0000-0002-9546-6641
FU National Center for Advancing Translational Sciences; Molecular
Libraries Initiative of the National Institutes of Health Roadmap for
Medical Research [U54MH084681, DA031669]
FX NJM, GR, AY, WAL, HS, YW, DKL, SMY, MX, AJ, DJM and AS were supported by
the intramural research program of the National Center for Advancing
Translational Sciences and the Molecular Libraries Initiative of the
National Institutes of Health Roadmap for Medical Research (U54MH084681
and DA031669).
NR 45
TC 1
Z9 1
U1 5
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2016
VL 11
IS 8
AR e0161486
DI 10.1371/journal.pone.0161486
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV4DZ
UT WOS:000382876700021
PM 27570969
ER
PT J
AU Zhao, WT
Pang, Q
Xu, RX
Liu, JW
Liu, SF
Li, J
Su, XZ
AF Zhao, Wenting
Pang, Qin
Xu, Ruixue
Liu, Jianwen
Liu, Shengfa
Li, Jian
Su, Xin-zhuan
TI Monitoring the Prevalence of Leucocytozoon sabrazesi in Southern China
and Testing Tricyclic Compounds against Gametocytes
SO PLOS ONE
LA English
DT Article
ID AVIAN BLOOD PARASITES; PCR-BASED DETECTION; HAEMOPROTEUS; PLASMODIUM;
INFECTION; CHICKENS; SIMONDI; MALARIA; BIRDS; OWLS
AB Leucocytozoon parasites infect many species of avian hosts, including domestic chicken, and can inflict heavy economic loss on the poultry industry. Two major species of Leucocytozoon parasites have been reported in China, L. sabrazesi and L. caulleryi, although L. sabrazesi appears to be more widespread than L. caulleryi in southern China. The traditional method for detecting Leucocytozoon infection is microscopic examination of blood smears for the presence of mature gametocytes in circulation, which may miss infections with low parasitemia (gametocytemia) or immature gametocytes. Here we developed a PCR-based method to monitor L. sabrazesi infections at seven sites in four provinces of China after testing two PCR primer pairs based on parasite mitochondrial cytochrome b (cytb) and cytochrome c oxidase III (coxIII) genes. We compared the results of PCR detection with those of microscopic observation. As expected, the PCR assays were more sensitive than microscope examination in detecting L. sabrazesi infection and were able to detect parasite DNA after gametocytes disappeared in the blood stream. Using these methods, we investigated monthly dynamics of L. sabrazesi in chickens from a free-range farm in Xiamen, Fujian province of China, over one year. Our results showed that chickens were infected with L. sabrazesi year-round in southern China. Finally, we tested several compounds for potential treatment of Leucocytozoon infections, including primaquine, ketotifen, clomipramine hydrochloride, desipramine hydrochloride, sulfaquinoxaline, and pyrimethamine. Only primaquine had activity against L. sabrazesi gametocytes. Our results provide important information for controlling parasite transmission in southern China and disease management.
C1 [Zhao, Wenting; Pang, Qin; Xu, Ruixue; Liu, Jianwen; Liu, Shengfa; Li, Jian; Su, Xin-zhuan] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.
[Su, Xin-zhuan] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
RP Li, J; Su, XZ (reprint author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.; Su, XZ (reprint author), NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
EM jianli_204@xmu.edu.cn; xsu@niaid.nih.gov
OI Su, Xinzhuan/0000-0003-3246-3248
FU National Natural Science Foundation of China [81220108019, 81271858,
81572017]; Fundamental Research Funds for the Central Universities
[20720160057]; Project 111 of the State Bureau of Foreign Experts and
Ministry of Education of China [B06016]; Division of Intramural
Research, National Institute of Allergy and Infectious Diseases,
National Institutes of Health
FX This work was supported by the National Natural Science Foundation of
China #81220108019, #81271858, and #81572017, by Fundamental Research
Funds for the Central Universities (20720160057), by Project 111 of the
State Bureau of Foreign Experts and Ministry of Education of China
(B06016), and by the Division of Intramural Research, National Institute
of Allergy and Infectious Diseases, National Institutes of Health. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 42
TC 0
Z9 0
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2016
VL 11
IS 8
AR e0161869
DI 10.1371/journal.pone.0161869
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV4DZ
UT WOS:000382876700038
PM 27571513
ER
PT J
AU Banadyga, L
Dolan, MA
Ebihara, H
AF Banadyga, Logan
Dolan, Michael A.
Ebihara, Hideki
TI Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Review
DE Filovirus; Ebola virus; Marburg virus; rodent adaptation; pathogenesis
ID EBOLA-VIRUS VP24; MARBURG HEMORRHAGIC-FEVER; REVERSE GENETICS SYSTEM;
SYRIAN GOLDEN-HAMSTER; VERVET MONKEY DISEASE; MATRIX PROTEIN VP40;
DOUBLE-STRANDED-RNA; OUTBRED GUINEA-PIG; MOUSE MODEL; INTERFERON
ANTAGONISM
AB Ebola, Marburg, and Ravn viruses, all filoviruses, are the causative agents of severe hemorrhagic fever. Much of what we understand about the pathogenesis of filovirus disease is derived from work with animal models, including nonhuman primates, which are considered the "gold standard" filovirus model since they faithfully recapitulate the clinical hallmarks of filovirus disease. However, rodent models, including the mouse, guinea pig, and hamster, also exist for Ebola, Marburg, and Ravn viruses, and although they may not reproduce all the clinical signs of filovirus disease, thanks to their relative ease of use and low cost, they are often the first choice for initial descriptions of virus pathogenesis and evaluation of antiviral prophylactics and therapeutics. Since filoviruses do not cause significant disease in adult, immunocompetent rodents, these models rely on "rodent-adapted" viruses that have been passaged several times through their host until virulence and lethality are achieved. In the process of adaptation, the viruses acquire numerous nucleotide/amino acid mutations that contribute to virulence in their rodent host. Interestingly, virus protein 24 (VP24) and nucleoprotein (NP) appear to be major virulence factors for ebolaviruses in rodents, whereas VP40 appears to be the major virulence factor for marburgviruses. By characterizing these mutations and understanding the molecular mechanisms that lead to the acquisition of virulence, we can gain better insight into the pathogenic processes that underlie filovirus disease in humans. These processes, and the viral and/or cellular proteins that contribute to them, will make attractive targets for the development of novel therapeutics and counter-measures. Published by Elsevier Ltd.
C1 [Banadyga, Logan; Ebihara, Hideki] NIAID, Virol Lab, Div Intramural Res, NIH, Hamilton, MT 59840 USA.
[Dolan, Michael A.] NIAID, Bioinformat & Computat Biosci Branch, NIH, Bethesda, MD 20892 USA.
RP Ebihara, H (reprint author), 903 South 4th St, Hamilton, MT 59840 USA.
EM ebiharah@niaid.nih.gov
FU Division of Intramural Research, NIAID, NIH
FX The authors are grateful to Ryan Kissinger and Austin Athman (Visual
Medical Arts, Rocky Mountain Laboratories) for their technical
assistance in preparing Fig. 2. We thank Heinz Feldmann for his critical
review of this manuscript. The authors are supported by the Division of
Intramural Research, NIAID, NIH. Opinions, interpretations, conclusions,
and recommendations are those of the authors and are not necessarily
endorsed by the NIH.
NR 136
TC 3
Z9 3
U1 6
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 28
PY 2016
VL 428
IS 17
SI SI
BP 3449
EP 3466
DI 10.1016/j.jmb.2016.05.008
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DW0FD
UT WOS:000383315400008
PM 27189922
ER
PT J
AU Du, C
Pusey, BN
Adams, CJ
Lau, CC
Bone, WP
Gahl, WA
Markello, TC
Adams, DR
AF Du, Chen
Pusey, Barbara N.
Adams, Christopher J.
Lau, C. Christopher
Bone, William P.
Gahl, William A.
Markello, Thomas C.
Adams, David R.
TI Explorations to improve the completeness of exome sequencing
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Clinical exome sequencing; Analytical quality; Performance enhancement;
Clinical genomics; Rare diseases; Completeness problem; False negative
results
ID HUMAN PHENOTYPE ONTOLOGY; UNDIAGNOSED DISEASES; HUMAN GENOME; INTRONIC
MUTATION; CLINICAL EXOME; FRAMEWORK; VARIANTS; PROGRAM; POPULATION;
DISCOVERY
AB Background: Exome sequencing has advanced to clinical practice and proven useful for obtaining molecular diagnoses in rare diseases. In approximately 75 % of cases, however, a clinical exome study does not produce a definitive molecular diagnosis. These residual cases comprise a new diagnostic challenge for the genetics community. The Undiagnosed Diseases Program of the National Institutes of Health routinely utilizes exome sequencing for refractory clinical cases. Our preliminary data suggest that disease-causing variants may be missed by current standard-of-care clinical exome analysis. Such false negatives reflect limitations in experimental design, technical performance, and data analysis.
Results: We present examples from our datasets to quantify the analytical performance associated with current practices, and explore strategies to improve the completeness of data analysis. In particular, we focus on patient ascertainment, exome capture, inclusion of intronic variants, and evaluation of medium-sized structural variants.
Conclusions: The strategies we present may recover previously-missed, disease causing variants in second-pass exome analysis. Understanding the limitations of the current clinical exome search space provides a rational basis to improve methods for disease variant detection using genome-scale sequencing techniques.
C1 [Du, Chen; Pusey, Barbara N.; Adams, Christopher J.; Lau, C. Christopher; Bone, William P.; Gahl, William A.; Markello, Thomas C.; Adams, David R.] NHGRI, Undiagnosed Dis Program, Common Fund, NIH, Bethesda, MD 20892 USA.
RP Adams, DR (reprint author), NHGRI, Undiagnosed Dis Program, Common Fund, NIH, Bethesda, MD 20892 USA.
EM dadams1@mail.nih.gov
FU Intramural Research Program of the National Human Genome Research
Institute; Common Fund of the National Institutes of Health
FX This research is supported by the Intramural Research Program of the
National Human Genome Research Institute and the Common Fund of the
National Institutes of Health.
NR 64
TC 0
Z9 0
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD AUG 27
PY 2016
VL 9
AR 56
DI 10.1186/s12920-016-0216-3
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA DU4XE
UT WOS:000382215400001
PM 27568008
ER
PT J
AU Freedhoff, Y
Hall, KD
AF Freedhoff, Yoni
Hall, Kevin D.
TI Weight loss diet studies: we need help not hype
SO LANCET
LA English
DT Editorial Material
ID RANDOMIZED CONTROLLED-TRIAL; LOW-FAT DIET; METAANALYSIS; ADHERENCE;
OUTCOMES; ADULTS
C1 [Freedhoff, Yoni] Bariatr Med Inst, Ottawa, ON, Canada.
[Hall, Kevin D.] NIDDK, Integrat Physiol Sect, Lab Biol Modeling, Bethesda, MD 20892 USA.
RP Hall, KD (reprint author), NIDDK, Integrat Physiol Sect, Lab Biol Modeling, Bethesda, MD 20892 USA.
EM kevinh@niddk.nih.gov
NR 13
TC 2
Z9 2
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 27
PY 2016
VL 388
IS 10047
BP 849
EP 851
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU0RI
UT WOS:000381911800008
PM 27597452
ER
PT J
AU Zhao, YP
Zhang, T
Huo, HH
Ye, YH
Liu, YF
AF Zhao, Yupeng
Zhang, Ting
Huo, Huanhuan
Ye, Yihong
Liu, Yanfen
TI Lunapark Is a Component of a Ubiquitin Ligase Complex Localized to the
Endoplasmic Reticulum Three-way Junctions
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE endoplasmic-reticulum-associated protein degradation (ERAD); protein
misfolding; ubiquitin; ubiquitin ligase; ubiquitin-conjugating enzyme
(E2 enzyme); Atlastin; ER three-way junction; Lunapark; Lnp; gp78;
misfolded
ID ER-ASSOCIATED DEGRADATION; MEMBRANE-PROTEINS; POLYUBIQUITIN CHAINS;
GP78; REQUIRES; CYTOSOL; GENERATION; MORPHOLOGY; NETWORK; ENZYMES
AB The endoplasmic reticulum (ER) network comprises sheets and tubules that are connected by dynamic three-way junctions. Lunapark (Lnp) localizes to and stabilizes ER three-way junctions by antagonizing the small GTPase Atlastin, but how Lnp shapes the ER network is unclear. Here, we used an affinity purification approach and mass spectrometry to identify Lnp as an interacting partner of the ER protein quality control ubiquitin ligase gp78. Accordingly, Lnp purified from mammalian cells has a ubiquitin ligase activity in vitro. Intriguingly, biochemical analyses show that this activity can be attributed not only to associated ubiquitin ligase, but also to an intrinsic ubiquitin ligase activity borne by Lnp itself. This activity is contained in the N-terminal 45 amino acids of Lnp although this segment does not share homology to any known ubiquitin ligase motifs. Despite its interaction with gp78, Lnp does not seem to have a broad function in degradation of misfolded ER proteins. On the other hand, the N-terminal ubiquitin ligase-bearing motif is required for the ER three-way junction localization of Lnp. Our study identifies a new type of ubiquitin ligase and reveals a potential link between ubiquitin and ER morphology regulation.
C1 [Zhao, Yupeng; Huo, Huanhuan; Liu, Yanfen] ShanghaiTech Univ, Sch Life Sci & Technol, 100 Haike Rd, Shanghai 201210, Peoples R China.
[Zhang, Ting; Ye, Yihong] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Liu, YF (reprint author), ShanghaiTech Univ, Sch Life Sci & Technol, 100 Haike Rd, Shanghai 201210, Peoples R China.; Ye, YH (reprint author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
EM yihongy@mail.nih.gov; liuyf@shanghaitech.edu.cn
FU National Institutes of Health Intramural Research Program NIDDK Grant
[1ZIADK033008-06]; National Natural Science Foundation of China
[31570781]
FX This work was supported, in whole or in part, by National Institutes of
Health Intramural Research Program NIDDK Grant 1ZIADK033008-06 and
National Natural Science Foundation of China Grant 31570781. The authors
declare no conflict of interest with the contents of this article. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health.
NR 48
TC 1
Z9 1
U1 3
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 26
PY 2016
VL 291
IS 35
BP 18252
EP 18262
DI 10.1074/jbc.M116.737783
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV9EC
UT WOS:000383241800018
PM 27387505
ER
PT J
AU Rosas-Hernandez, H
Cuevas, E
Lantz, SM
Rice, KC
Gannon, BM
Fantegrossi, WE
Gonzalez, C
Paule, MG
Ali, SF
AF Rosas-Hernandez, Hector
Cuevas, Elvis
Lantz, Susan M.
Rice, Kenner C.
Gannon, Brenda M.
Fantegrossi, William E.
Gonzalez, Carmen
Paule, Merle G.
Ali, Syed F.
TI Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and
3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic
effects in bovine brain microvessel endothelial cells
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Methamphetamine; MDMA; MDPV; Blood-brain barrier; Cytotoxicity
ID BARRIER DISRUPTION; OXIDATIVE STRESS; DOPAMINE TRANSPORTER; IN-VITRO;
HYPERTHERMIA; ECSTASY; COCAINE; METHYLENEDIOXYPYROVALERONE;
NEUROINFLAMMATION; VASOCONSTRICTION
AB Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. In addition to methamphetamine (METH), these drugs include 3,4-methylenedioxy-methamphetamine (MDMA) and commercial preparations of synthetic cathinones including 3,4-methylenedioxypyrovalerone (MDPV), typically referred to as "bath salts." These psychostimulants exert neurotoxic effects by altering monoamine systems in the brain. Additionally, METH and MDMA adversely affect the integrity of the blood-brain barrier (BBB): there are no current reports on the effects of MDPV on the BBB. The aim of this study was to compare the effects of METH, MDMA and MDPV on bovine brain microvessel endothelial cells (bBMVECs), an accepted in vitro model of the BBB. Confluent bBMVEC monolayers were treated with METH, MDMA and MDPV (0.5 mM-2.5 mM) for 24 h. METH and MDMA increased lactate dehydrogenase release only at the highest concentration (2.5 mM), whereas MDPV induced cytotoxicity at all concentrations. MDMA and METH decreased cellular proliferation only at 2.5 mM, with similar effects observed after MDPV exposures starting at 1 mM. Only MDPV increased reactive oxygen species production at all concentrations tested whereas all 3 drugs increased nitric oxide production. Morphological analysis revealed different patterns of compound-induced cell damage. METH induced vacuole formation at 1 mM and disruption of the monolayer at 2.5 mM. MDMA induced disruption of the endothelial monolayer from 1 mM without vacuolization. On the other hand, MDPV induced monolayer disruption at doses >= 0.5 mM without vacuole formation; at 2.5 mM, the few remaining cells lacked endothelial morphology. These data suggest that even though these synthetic psychostimulants altermonoaminergic systems, they each induce BBB toxicity by different mechanisms with MDPV being the most toxic. Published by Elsevier Ireland Ltd.
C1 [Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Paule, Merle G.; Ali, Syed F.] US FDA, Neurochem Lab, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Rice, Kenner C.] NIAAA, Drug Design & Synth Sect, Mol Targets & Medicat Discovery Branch, NIDA, Bethesda, MD USA.
[Gannon, Brenda M.; Fantegrossi, William E.] UAMS, Dept Pharmacol & Toxicol, Little Rock, AR USA.
[Gonzalez, Carmen] UASLP, Fac Ciencias Quim, Slp, Mexico.
RP Ali, SF (reprint author), US FDA, Neurochem Lab, Div Neurotoxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
EM Syed.Ali@fda.hhs.gov
FU U.S. Department of Energy; U.S. Food and Drug Administration; Intramural
Research Programs of the National Institute on Drug Abuse; National
Institute on Alcoholism and Alcohol Abuse
FX This research was supported in part by an appointment (H. R-H.) to the
Research Participation Program at the National Center for Toxicological
Research administered by the Oak Ridge Institute for Science and
Education through an interagency agreement between the U.S. Department
of Energy and the U.S. Food and Drug Administration. A portion of this
work was supported by the Intramural Research Programs of the National
Institute on Drug Abuse and the National Institute on Alcoholism and
Alcohol Abuse. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the US. Food
and Drug Administration, the National Institute on Drug Abuse, the
National Institute of Alcohol Abuse and Alcoholism, or the National
Institutes of Health.
NR 45
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD AUG 26
PY 2016
VL 629
BP 125
EP 130
DI 10.1016/j.neulet.2016.06.029
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA DU7QF
UT WOS:000382409000023
PM 27320055
ER
PT J
AU Dellibovi-Ragheb, TA
AF Dellibovi-Ragheb, Teegan A.
TI Next Gen PhD A Guide to Career Paths in Science
SO SCIENCE
LA English
DT Book Review
C1 [Dellibovi-Ragheb, Teegan A.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Dellibovi-Ragheb, TA (reprint author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM teegan.dellibovi-ragheb@nih.gov
NR 1
TC 0
Z9 0
U1 4
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 26
PY 2016
VL 353
IS 6302
BP 877
EP 877
DI 10.1126/science.aah3463
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU0CA
UT WOS:000381867700023
ER
PT J
AU Sherman, ME
Ichikawa, L
Pfeiffer, RM
Miglioretti, DL
Kerlikowske, K
Tice, J
Vacek, PM
Gierach, GL
AF Sherman, Mark E.
Ichikawa, Laura
Pfeiffer, Ruth M.
Miglioretti, Diana L.
Kerlikowske, Karla
Tice, Jeffery
Vacek, Pamela M.
Gierach, Gretchen L.
TI Relationship of Predicted Risk of Developing Invasive Breast Cancer, as
Assessed with Three Models, and Breast Cancer Mortality among Breast
Cancer Patients
SO PLOS ONE
LA English
DT Article
ID HORMONE-RECEPTOR STATUS; POSTMENOPAUSAL WOMEN; SCREENING-PROGRAM;
MAMMOGRAPHY; VALIDATION; CONSORTIUM; PREVENTION; REDUCTION; PROGNOSIS;
ONCOLOGY
AB Purpose
Breast cancer risk prediction models are used to plan clinical trials and counsel women; however, relationships of predicted risks of breast cancer incidence and prognosis after breast cancer diagnosis are unknown.
Methods
Using largely pre-diagnostic information from the Breast Cancer Surveillance Consortium (BCSC) for 37,939 invasive breast cancers (1996-2007), we estimated 5-year breast cancer risk (< 1%; 1-1.66%; >= 1.67%) with three models: BCSC 1-year risk model (BCSC-1; adapted to 5-year predictions); Breast Cancer Risk Assessment Tool (BCRAT); and BCSC 5-year risk model (BCSC-5). Breast cancer-specific mortality post-diagnosis (range: 1-13 years; median: 5.4-5.6 years) was related to predicted risk of developing breast cancer using unadjusted Cox proportional hazards models, and in age-stratified (35-44; 45-54; 55-69; 70-89 years) models adjusted for continuous age, BCSC registry, calendar period, income, mode of presentation, stage and treatment. Mean age at diagnosis was 60 years.
Results
Of 6,021 deaths, 2,993 (49.7%) were ascribed to breast cancer. In unadjusted case-only analyses, predicted breast cancer risk >= 1.67% versus < 1.0% was associated with lower risk of breast cancer death; BCSC-1: hazard ratio (HR) = 0.82 (95% CI = 0.75-0.90); BCRAT: HR = 0.72 (95% CI = 0.65-0.81) and BCSC-5: HR = 0.84 (95% CI = 0.75-0.94). Age-stratified, adjusted models showed similar, although mostly non-significant HRs. Among women ages 55-69 years, HRs approximated 1.0. Generally, higher predicted risk was inversely related to percentages of cancers with unfavorable prognostic characteristics, especially among women 35-44 years.
Conclusions
Among cases assessed with three models, higher predicted risk of developing breast cancer was not associated with greater risk of breast cancer death; thus, these models would have limited utility in planning studies to evaluate breast cancer mortality reduction strategies. Further, when offering women counseling, it may be useful to note that high predicted risk of developing breast cancer does not imply that if cancer develops it will behave aggressively.
C1 [Sherman, Mark E.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
[Sherman, Mark E.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Ichikawa, Laura; Miglioretti, Diana L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Pfeiffer, Ruth M.; Gierach, Gretchen L.] Div Canc Epidemiol & Genet, Bethesda, MD USA.
[Miglioretti, Diana L.] Univ Calif Davis, Dept Publ Hlth, Davis, CA 95616 USA.
[Kerlikowske, Karla; Tice, Jeffery] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol Biostat, San Francisco, CA 94143 USA.
[Vacek, Pamela M.] Univ Vermont, Sch Med, Dept Med Biostat, Burlington, VT 05405 USA.
RP Sherman, ME (reprint author), NCI, Canc Prevent Div, Bethesda, MD 20892 USA.; Sherman, ME (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
EM ShermanM@mail.nih.gov
RI Gierach, Gretchen/E-1817-2016
OI Gierach, Gretchen/0000-0002-0165-5522
FU Intramural Research Program of the National Cancer Institute
[HHSN261201100031C]; several state public health departments and cancer
registries throughout the US
FX This was funded in part by the Intramural Research Program of the
National Cancer Institute (HHSN261201100031C). The collection of cancer
and vital status data used in this study was supported in part by
several state public health departments and cancer registries throughout
the US. For a full description of these sources, please see:
http://breastscreening.cancer.gov/work/acknowledgement.html. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 39
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 25
PY 2016
VL 11
IS 8
AR e0160966
DI 10.1371/journal.pone.0160966
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU5NN
UT WOS:000382258600021
PM 27560501
ER
PT J
AU Lo, B
Fritz, JM
Su, HC
Uzel, G
Jordan, MB
Lenardo, MJ
AF Lo, Bernice
Fritz, Jill M.
Su, Helen C.
Uzel, Gulbu
Jordan, Michael B.
Lenardo, Michael J.
TI CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
SO BLOOD
LA English
DT Article
ID REGULATORY T-CELLS; IMMUNE DYSREGULATION; LRBA MUTATION;
RHEUMATOID-ARTHRITIS; FOLLICULAR HELPER; DEFICIENCY; RESPONSES; PATIENT;
HYDROXYCHLOROQUINE; TRANSPLANTATION
AB CTLA-4 is a critical inhibitory "checkpoint" molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatment-induced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.
C1 [Lo, Bernice] Sidra Med & Res Ctr, Div Translat Med, POB 26999, Doha, Qatar.
[Lo, Bernice; Fritz, Jill M.; Lenardo, Michael J.] NIAID, Mol Dev, Immune Syst Sect, Immunol Lab,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Lo, Bernice; Fritz, Jill M.; Su, Helen C.; Lenardo, Michael J.] NIAID, Clin Genom Program, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Su, Helen C.] NIAID, Human Immunol Dis Sect, Lab Host Defenses, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Uzel, Gulbu] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Jordan, Michael B.] Univ Cincinnati, Dept Pediat, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Jordan, Michael B.] Univ Cincinnati, Div Immunobiol, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
RP Lo, B (reprint author), Sidra Med & Res Ctr, Div Translat Med, POB 26999, Doha, Qatar.; Lenardo, MJ (reprint author), Immunol Lab, 10 Ctr Dr,Bldg 10,Room 11D14, Bethesda, MD 20892 USA.
EM blo@sidra.org; lenardo@nih.gov
OI Lo, Bernice/0000-0002-1087-6845
FU Intramural Research Program of the National Institute of Allergy and
Infectious Diseases, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health.
NR 48
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 25
PY 2016
VL 128
IS 8
BP 1037
EP 1042
DI 10.1182/blood-2016-04-712612
PG 6
WC Hematology
SC Hematology
GA DW7LT
UT WOS:000383832900010
PM 27418640
ER
PT J
AU Alvarnas, JC
Le Rademacher, J
Wang, YL
Little, RF
Akpek, G
Ayala, E
Devine, S
Baiocchi, R
Lozanski, G
Kaplan, L
Noy, A
Popat, U
Hsu, J
Morris, LE
Thompson, J
Horowitz, MM
Mendizabal, A
Levine, A
Krishnan, A
Forman, SJ
Navarro, WH
Ambinder, R
AF Alvarnas, Joseph C.
Le Rademacher, Jennifer
Wang, Yanli
Little, Richard F.
Akpek, Gorgun
Ayala, Ernesto
Devine, Steven
Baiocchi, Robert
Lozanski, Gerard
Kaplan, Lawrence
Noy, Ariela
Popat, Uday
Hsu, Jack
Morris, Lawrence E., Jr.
Thompson, Jason
Horowitz, Mary M.
Mendizabal, Adam
Levine, Alexandra
Krishnan, Amrita
Forman, Stephen J.
Navarro, Willis H.
Ambinder, Richard
TI Autologous hematopoietic cell transplantation for HIV-related lymphoma:
results of the BMT CTN 0803/AMC 071 trial
SO BLOOD
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-DOSE THERAPY; ACTIVE ANTIRETROVIRAL
THERAPY; AIDS-RELATED LYMPHOMA; NON-HODGKINS-LYMPHOMA;
PROGNOSTIC-FACTORS; SALVAGE TREATMENT; INFECTION; DISEASE; CHEMOTHERAPY
AB Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is largely limited to centers with HIV-specific expertise. The Blood and Marrow Transplant Clinical Trials Network 0803/AIDS Malignancy Consortium 071 trial is a multicenter phase 2 study of AHCT for patients with HIV-related lymphoma (HRL). Eligible patients had chemotherapy-sensitive relapsed/persistent HRL, were >15 years of age, and had treatable HIV infection. Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and received consistent management of peritransplant antiretroviral treatment. The primary endpoint was 1-year overall survival. Forty-three patients were enrolled; 40 underwent AHCT. Pretransplant HIV viral load was undetectable (<50 copies/mL) in 32 patients (80%); the median CD4 count was 249/mu L (range, 39-797). At a median follow-up of 24.8 months, 1-year and 2-year overall survival probabilities were 87.3% (95% confidence interval [CI], 72.1-94.5) and82%(95% CI, 65.9-91), respectively. The probability of 2-year progression-free survival was 79.8% (95% CI, 63.7-89.4). One-year transplant-related mortality was 5.2%. Median time to neutrophil and platelet recovery was 11 days and 18 days, respectively. Nine patients experienced a total of 13 unexpected grade 3-5 adverse events posttransplant (10 grade 3 and 3 grade 4 events). Twenty-two patients had at least 1 infectious episode posttransplant. At 1 year post-AHCT, median CD4(+) T-cell count was 280.3 (range, 28.8-1148.0); 82.6% had an undetectable HIV viral load. Trial patients were compared with 151 matched Center for International Bone Marrow Transplant Research controls. Outcomes between HIV-infected patients and controls were not statistically significantly different. HRL patients should be considered candidates for AHCT if they meet standard transplant criteria. The trial was registered at www.clinicaltrials.gov as #NCT01141712.
C1 [Alvarnas, Joseph C.; Krishnan, Amrita; Forman, Stephen J.] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.
[Le Rademacher, Jennifer; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Wang, Yanli; Thompson, Jason; Mendizabal, Adam] Emmes Corp, Rockville, MD USA.
[Little, Richard F.] NCI, Canc Therapy Evaluat Program, Rockville, MD USA.
[Akpek, Gorgun] Univ Maryland Med Syst, Greenebaum Canc Ctr, Baltimore, MD USA.
[Ayala, Ernesto] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.
[Devine, Steven; Baiocchi, Robert; Lozanski, Gerard] Ohio State Univ, Arthur G James Canc Ctr Hosp, Dept Hematol, Columbus, OH 43210 USA.
[Kaplan, Lawrence] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA.
[Noy, Ariela] Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, 1275 York Ave, New York, NY 10021 USA.
[Popat, Uday] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
[Hsu, Jack] Univ Florida, Hlth Canc Ctr, Bone Marrow Transplant Program, Gainesville, FL USA.
[Morris, Lawrence E., Jr.] Northside Hosp Canc Inst, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.
[Levine, Alexandra] City Hope Natl Med Ctr, 1500 E Duarte Rd,MOB3001, Duarte, CA 91010 USA.
[Navarro, Willis H.] Natl Marrow Donor Program, Minneapolis, MN USA.
[Ambinder, Richard] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA.
RP Alvarnas, JC (reprint author), City Hope Natl Med Ctr, 1500 E Duarte Rd,MOB3001, Duarte, CA 91010 USA.
EM jalvarnas@coh.org
FU National Institutes of Health National Cancer Institute (NCI)
[HHSN21200622012C-009]; AMC through NCI [U01CA121947]; National Heart,
Lung, and Blood Institute; NCI [U10HL069294]
FX This work is supported by grants from the National Institutes of Health
National Cancer Institute (NCI; grant HHSN21200622012C-009) and the AMC
through NCI (grant U01CA121947). The Blood and Marrow Transplant
Clinical Trials Network infrastructure is supported in part by the
National Heart, Lung, and Blood Institute and NCI (grant U10HL069294).
NR 41
TC 5
Z9 5
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 25
PY 2016
VL 128
IS 8
BP 1050
EP 1058
DI 10.1182/blood-2015-08-664706
PG 9
WC Hematology
SC Hematology
GA DW7LT
UT WOS:000383832900012
PM 27297790
ER
PT J
AU Schmidt, J
Gong, SY
Marafioti, T
Mankel, B
Gonzalez-Farre, B
Balague, O
Mozos, A
Cabecadas, J
van der Walt, J
Hoehn, D
Rosenwald, A
Ott, G
Dojcinov, S
Egan, C
Nadeu, F
Ramis-Zaldivar, JE
Clot, G
Barcena, C
Perez-Alonso, V
Endris, V
Penzel, R
Lome-Maldonado, C
Bonzheim, I
Fend, F
Campo, E
Jaffe, ES
Salaverria, I
Quintanilla-Martinez, L
AF Schmidt, Janine
Gong, Shunyou
Marafioti, Teresa
Mankel, Barbara
Gonzalez-Farre, Blanca
Balague, Olga
Mozos, Ana
Cabecadas, Jose
van der Walt, Jon
Hoehn, Daniela
Rosenwald, Andreas
Ott, German
Dojcinov, Stefan
Egan, Caoimhe
Nadeu, Ferran
Ramis-Zaldivar, Joan Enric
Clot, Guillem
Barcena, Carmen
Perez-Alonso, Vanesa
Endris, Volker
Penzel, Roland
Lome-Maldonado, Carmen
Bonzheim, Irina
Fend, Falko
Campo, Elias
Jaffe, Elaine S.
Salaverria, Itziar
Quintanilla-Martinez, Leticia
TI Genome-wide analysis of pediatric-type follicular lymphoma reveals low
genetic complexity and recurrent alterations of TNFRSF14 gene
SO BLOOD
LA English
DT Article
ID LYMPHOCYTIC-LEUKEMIA; CLINICAL-FEATURES; NODULAR LYMPHOMA; YOUNG-ADULTS;
MUTATIONS; EXPRESSION; CHILDREN; RECEPTOR; BTLA; TRANSLOCATION
AB Pediatric-type follicular lymphoma (PTFL) is a variant of follicular lymphoma (FL) with distinctive clinicopathological features. Patients are predominantly young males presenting with localized lymphadenopathy; the tumor shows high-grade cytology and lacks both BCL2 expression and t(14; 18) translocation. The genetic alterations involved in the pathogenesis of PTFL are unknown. Therefore, 42 PTFL (40 males and 2 females; mean age, 16 years; range, 5-31) were genetically characterized. For comparison, 11 cases of conventional t(14: 18)(-) FL in adults were investigated. Morphologically, PTFL cases had follicular growth pattern without diffuse areas and characteristic immunophenotype. All cases showed monoclonal immunoglobulin (IG) rearrangement. PTFL displays low genomic complexity when compared with t(14; 18)(-) FL (mean, 0.77 vs 9 copy number alterations per case; P <.001). Both groups presented 1p36 alterations including TNFRSF14, but copy-number neutral loss of heterozygosity (CNN-LOH) of this locus was more frequently observed in PTFL (40% vs 9%; P =.075). TNFRSF14 was the most frequently affected gene in PTFL (21 mutations and 2 deletions), identified in 54% of cases, followed by KMT2D mutations in 16%. Other histone-modifying genes were rarely affected. In contrast, t(14; 18)(-) FL displayed a mutational profile similar to t(14; 18)(+) FL. In 8 PTFL cases (19%), no genetic alterations were identified beyond IG monoclonal rearrangement. The genetic landscape of PTFL suggests that TNFRSF14 mutations accompanied by CNN-LOH of the 1p36 locus in over 70% of mutated cases, as additional selection mechanism, might play a key role in the pathogenesis of this disease. The genetic profiles of PTFL and t(14; 18)(-) FL in adults indicate that these are two different disorders.
C1 [Schmidt, Janine; Mankel, Barbara; Bonzheim, Irina; Fend, Falko; Quintanilla-Martinez, Leticia] Univ Tubingen, Inst Pathol & Neuropathol, Tubingen, Germany.
[Schmidt, Janine; Mankel, Barbara; Bonzheim, Irina; Fend, Falko; Quintanilla-Martinez, Leticia] Univ Hosp Tubingen, Ctr Comprehens Canc, Tubingen, Germany.
[Gong, Shunyou; Egan, Caoimhe; Jaffe, Elaine S.] NCI, Hematopathol Sect, Pathol Lab, Bethesda, MD 20892 USA.
[Marafioti, Teresa] Barts & London NHS Trust, Dept Cellular Pathol, London, England.
[Gonzalez-Farre, Blanca; Balague, Olga; Nadeu, Ferran; Ramis-Zaldivar, Joan Enric; Clot, Guillem; Campo, Elias; Salaverria, Itziar] Hosp Clin Barcelona, Hematopathol Unit, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.
[Mozos, Ana] Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona, Spain.
[Cabecadas, Jose] Inst Portugues Oncol Francisco Gentil, Dept Pathol, Lisbon, Portugal.
[van der Walt, Jon] Guys & St Thomas Hosp, Dept Histopathol, London, England.
[Hoehn, Daniela] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY USA.
[Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany.
[Rosenwald, Andreas] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.
[Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany.
[Ott, German] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
[Dojcinov, Stefan] Univ Wales Hosp, Dept Pathol, All Wales Lymphoma Panel, Cardiff, S Glam, Wales.
[Barcena, Carmen; Perez-Alonso, Vanesa] Hosp Univ 12 Octubre, Madrid, Spain.
[Endris, Volker; Penzel, Roland] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
[Lome-Maldonado, Carmen] Inst Nacl Cancerol, Dept Pathol, Mexico City, DF, Mexico.
RP Quintanilla-Martinez, L (reprint author), Univ Tubingen, Inst Pathol, Univ Hosp Tubingen, Liebermeisterstr 8, D-72076 Tubingen, Germany.; Quintanilla-Martinez, L (reprint author), Ctr Comprehens Canc, Liebermeisterstr 8, D-72076 Tubingen, Germany.; Salaverria, I (reprint author), IDIBAPS, Rossello 153, Barcelona 08036, Spain.
EM isalaver@clinic.ub.es; leticia.quintanilla-fend@med.uni-tuebingen.de
RI Campo, elias/O-7192-2016;
OI Campo, elias/0000-0001-9850-9793; Cabecadas, Jose/0000-0001-6232-1596
FU Fondo de Investigaciones Sanitarias; Instituto de Salud Carlos III
(Miguel Servet) [CP13/00159, PI15/00580]; Generalitat de Catalunya
Suport Grups de Recerca [2013-SGR-378]; European Regional Development
Fund "Una manera de fer Europa"; Wilhelm-Sander-Stiftung [2015.058.1]
FX This work was supported by Fondo de Investigaciones Sanitarias,
Instituto de Salud Carlos III (Miguel Servet contract CP13/00159 and
PI15/00580), Generalitat de Catalunya Suport Grups de Recerca
(2013-SGR-378), the European Regional Development Fund "Una manera de
fer Europa" and the Wilhelm-Sander-Stiftung (2015.058.1; L.Q.-M. and
F.F.). This work was partially developed at the Centro Esther Koplowitz,
Barcelona, Spain.
NR 41
TC 1
Z9 1
U1 5
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 25
PY 2016
VL 128
IS 8
BP 1101
EP 1111
DI 10.1182/blood-2016-03-703819
PG 11
WC Hematology
SC Hematology
GA DW7LT
UT WOS:000383832900018
PM 27257180
ER
PT J
AU Gopich, IV
Szabo, A
AF Gopich, Irina V.
Szabo, Attila
TI Reversible Stochastically Gated Diffusion-Influenced Reactions
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID ASSOCIATION-DISSOCIATION REACTION; DEPENDENT RATE COEFFICIENTS;
MICHAELIS-MENTEN KINETICS; INTEGRAL ENCOUNTER THEORY; MANY-PARTICLE
TREATMENT; LONG-TIME ASYMPTOTICS; BIMOLECULAR REACTIONS; MULTISTAGE
REACTIONS; LIQUID SOLUTIONS; REACTION-RATES
AB An approximate but accurate theory is developed for the kinetics of reversible binding of a ligand to a macromolecule when either can stochastically fluctuate between reactive and unreactive conformations. The theory is based on a set of reaction-diffusion equations for the deviations of the pair distributions from their bulk values. The concentrations are shown to satisfy non-Markovian rate equations with memory kernels that are obtained by solving an irreversible geminate (i.e., two-particle) problem. The relaxation to equilibrium is not exponential but rather a power law. In the Markovian limit, the theory reduces to a set of ordinary rate equations with renormalized rate constants.
C1 [Gopich, Irina V.; Szabo, Attila] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Szabo, A (reprint author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
EM attilas@niddk.nih.gov
RI Szabo, Attila/H-3867-2012
FU Intramural Research Program of the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health.
NR 53
TC 1
Z9 1
U1 4
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD AUG 25
PY 2016
VL 120
IS 33
BP 8080
EP 8089
DI 10.1021/acs.jpcb.6b00152
PG 10
WC Chemistry, Physical
SC Chemistry
GA DU4JZ
UT WOS:000382180200004
PM 26956646
ER
PT J
AU Zhang, X
Xiao, WX
Acencio, ML
Lemke, N
Wang, XJ
AF Zhang, Xue
Xiao, Wangxin
Acencio, Marcio Luis
Lemke, Ney
Wang, Xujing
TI An ensemble framework for identifying essential proteins
SO BMC BIOINFORMATICS
LA English
DT Article
DE Essential protein; Protein-protein interaction networks; Centrality
measure; Ensemble learning; Gene expression
ID SACCHAROMYCES-CEREVISIAE GENOME; ESSENTIAL GENE IDENTIFICATION;
INTERACTION NETWORKS; PPI NETWORK; CENTRALITY; YEAST; DATABASE;
INTEGRATION; EXPRESSION; DISCOVERY
AB Background: Many centrality measures have been proposed to mine and characterize the correlations between network topological properties and protein essentiality. However, most of them show limited prediction accuracy, and the number of common predicted essential proteins by different methods is very small.
Results: In this paper, an ensemble framework is proposed which integrates gene expression data and protein-protein interaction networks (PINs). It aims to improve the prediction accuracy of basic centrality measures. The idea behind this ensemble framework is that different protein-protein interactions (PPIs) may show different contributions to protein essentiality. Five standard centrality measures (degree centrality, betweenness centrality, closeness centrality, eigenvector centrality, and subgraph centrality) are integrated into the ensemble framework respectively. We evaluated the performance of the proposed ensemble framework using yeast PINs and gene expression data. The results show that it can considerably improve the prediction accuracy of the five centrality measures individually. It can also remarkably increase the number of common predicted essential proteins among those predicted by each centrality measure individually and enable each centrality measure to find more low-degree essential proteins.
Conclusions: This paper demonstrates that it is valuable to differentiate the contributions of different PPIs for identifying essential proteins based on network topological characteristics. The proposed ensemble framework is a successful paradigm to this end.
C1 [Zhang, Xue; Wang, Xujing] NHLBI, Syst Biol Core, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Xiao, Wangxin] XiangNan Univ, Dept Comp Sci, Eastern Wangxian Pk, Chenzhou 423000, Hunan, Peoples R China.
[Acencio, Marcio Luis; Lemke, Ney] UNESP Sao Paulo State Univ, Dept Phys & Biophys, Inst Biosci Botucatu, BR-18618970 Botucatu, SP, Brazil.
[Acencio, Marcio Luis] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, PB 8905, N-7491 Trondheim, Norway.
RP Wang, XJ (reprint author), NHLBI, Syst Biol Core, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Xiao, WX (reprint author), XiangNan Univ, Dept Comp Sci, Eastern Wangxian Pk, Chenzhou 423000, Hunan, Peoples R China.
EM xiaozhangdoctor@126.com; xujing.wang@nih.gov
RI Acencio, Marcio/D-9264-2012
OI Acencio, Marcio/0000-0002-8278-240X
FU Intramural Research Program of the NIH, NHLBI; National Natural Science
Foundation of China [61402423, 51378243, 61502343]
FX This work was partially supported by the Intramural Research Program of
the NIH, NHLBI; the National Natural Science Foundation of China under
Grants No.61402423, No.51378243, and No. 61502343.
NR 46
TC 0
Z9 0
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD AUG 25
PY 2016
VL 17
AR 322
DI 10.1186/s12859-016-1166-7
PG 17
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA DV3OJ
UT WOS:000382831900001
ER
PT J
AU Freed, EO
AF Freed, Eric O.
TI Getting IN on Viral RNA Condensation and Virion Maturation
SO CELL
LA English
DT Editorial Material
ID HIV-1 INTEGRASE
AB The retroviral enzyme integrase plays an essential role in the virus replication cycle by catalyzing the covalent insertion of newly synthesized viral DNA into the host cell chromosome early after infection. Now, Kessl et al. report a second function of integrase: binding to the viral RNA genome in virion particles late in the virus replication cycle to promote particle maturation.
C1 [Freed, Eric O.] NCI, Virus Cell Interact Sect, HIV Dynam & Replicat Program, Ctr Canc Res, Frederick, MD 21702 USA.
RP Freed, EO (reprint author), NCI, Virus Cell Interact Sect, HIV Dynam & Replicat Program, Ctr Canc Res, Frederick, MD 21702 USA.
EM efreed@nih.gov
NR 10
TC 0
Z9 0
U1 10
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 25
PY 2016
VL 166
IS 5
BP 1082
EP 1083
DI 10.1016/j.cell.2016.08.013
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DU5NW
UT WOS:000382259500008
PM 27565339
ER
PT J
AU Clever, D
Roychoudhuri, R
Constantinides, MG
Askenase, MH
Sukumar, M
Klebanoff, CA
Eil, RL
Hickman, HD
Yu, ZY
Pan, JH
Palmer, DC
Phan, AT
Goulding, J
Gattinoni, L
Goldrath, AW
Belkaid, Y
Restifo, NP
AF Clever, David
Roychoudhuri, Rahul
Constantinides, Michael G.
Askenase, Michael H.
Sukumar, Madhusudhanan
Klebanoff, Christopher A.
Eil, Robert L.
Hickman, Heather D.
Yu, Zhiya
Pan, Jenny H.
Palmer, Douglas C.
Phan, Anthony T.
Goulding, John
Gattinoni, Luca
Goldrath, Ananda W.
Belkaid, Yasmine
Restifo, Nicholas P.
TI Oxygen Sensing by T Cells Establishes an Immunologically Tolerant
Metastatic Niche
SO CELL
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TRANSCRIPTION FACTOR;
RESPIRATORY-TRACT; DENDRITIC CELLS; REG-CELLS; PROLYL HYDROXYLATION;
METABOLIC CHECKPOINT; EXPRESSION; DIFFERENTIATION; INFLAMMATION
AB Cancer cells must evade immune responses at distant sites to establish metastases. The lung is a frequent site for metastasis. We hypothesized that lung-specific immunoregulatory mechanisms create an immunologically permissive environment for tumor colonization. We found that T-cell-intrinsic expression of the oxygen-sensing prolyl-hydroxylase (PHD) proteins is required to maintain local tolerance against innocuous antigens in the lung but powerfully licenses colonization by circulating tumor cells. PHD proteins limit pulmonary type helper (Th)-1 responses, promote CD4(+)-regulatory T (Treg) cell induction, and restrain CD8(+) T cell effector function. Tumor colonization is accompanied by PHD-protein-dependent induction of pulmonary Treg cells and suppression of IFN-g-dependent tumor clearance. T-cell-intrinsic deletion or pharmacological inhibition of PHD proteins limits tumor colonization of the lung and improves the efficacy of adoptive cell transfer immunotherapy. Collectively, PHD proteins function in T cells to coordinate distinct immunoregulatory programs within the lung that are permissive to cancer metastasis.
C1 [Clever, David; Roychoudhuri, Rahul; Sukumar, Madhusudhanan; Klebanoff, Christopher A.; Eil, Robert L.; Yu, Zhiya; Pan, Jenny H.; Palmer, Douglas C.; Restifo, Nicholas P.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA.
[Clever, David] Ohio State Univ, Coll Med, Med Scientist Training Program, Columbus, OH 43210 USA.
[Roychoudhuri, Rahul] Babraham Inst, Lab Lymphocyte Signaling & Dev, Cambridge CB22 3AT, England.
[Constantinides, Michael G.; Askenase, Michael H.; Belkaid, Yasmine] NIAID, Mucosal Immunol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
[Belkaid, Yasmine] NIAID, NIAID Microbiome Program Initiat, NIH, Bethesda, MD 20892 USA.
[Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10065 USA.
[Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
[Hickman, Heather D.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
[Phan, Anthony T.; Goulding, John; Goldrath, Ananda W.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.
[Gattinoni, Luca] NCI, Expt Transplantat Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Restifo, Nicholas P.] NCI, Ctr Cell Based Therapy, NIH, Bethesda, MD 20892 USA.
RP Clever, D; Restifo, NP (reprint author), NCI, Surg Branch, NIH, Bethesda, MD 20892 USA.; Clever, D (reprint author), Ohio State Univ, Coll Med, Med Scientist Training Program, Columbus, OH 43210 USA.; Restifo, NP (reprint author), NCI, Ctr Cell Based Therapy, NIH, Bethesda, MD 20892 USA.
EM david.clever@osumc.edu; restifo@nih.gov
RI Gattinoni, Luca/A-2281-2008; Roychoudhuri, Rahul/A-7442-2010
OI Gattinoni, Luca/0000-0003-2239-3282; Roychoudhuri,
Rahul/0000-0002-5392-1853
FU NCI; NIAID; Wellcome Trust/Royal Society [105663/Z/14/Z]; UK
Biotechnology and Biological Sciences Research Council [BB/N007794/1];
Cancer Research Institute
FX This research was supported by the Intramural Research Programs of the
NCI and NIAID and by charitable gifts from Li Jinyuan and the Tiens
Charitable Foundation and the Milstein Family Foundation. R.R. was
supported by the Wellcome Trust/Royal Society (grant 105663/Z/14/Z) and
the UK Biotechnology and Biological Sciences Research Council (grant
BB/N007794/1). M.G.C. is a Cancer Research Institute Irvington Fellow
supported by the Cancer Research Institute. We thank G.H. Fong for
providing Egln1-3fl/fl mice, D. Haines for pathologic
analysis of H&E-stained tissues, R. Johnson, A. Palazon, and P. Tyrakis
for technical advice.
NR 50
TC 9
Z9 9
U1 27
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 25
PY 2016
VL 166
IS 5
BP 1117
EP +
DI 10.1016/j.cell.2016.07.032
PG 29
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DU5NW
UT WOS:000382259500011
PM 27565342
ER
PT J
AU Ryan, JF
Schnitzler, CE
Tamm, SL
AF Ryan, Joseph F.
Schnitzler, Christine E.
Tamm, Sidney L.
TI Meeting report of Ctenopalooza: the first international meeting of
ctenophorologists
SO EVODEVO
LA English
DT Article
DE Ctenophora; Ctenophore; Ctenopalooza
ID MNEMIOPSIS-LEIDYI; CTENOPHORES; FERTILIZATION; INVASION; ANIMALS;
SYSTEMS; SUCCESS; ORIGIN
AB Here we present a report on Ctenopalooza: A meeting of ctenophorologists held at the Whitney Laboratory for Marine Bioscience in St. Augustine, FL, USA, on March 14-15, 2016. In this report, we provide a summary of each of the sessions that occurred during this two-day meeting, which touched on most of the relevant areas of ctenophore biology. The report includes some major themes regarding the future of ctenophore research that emerged during Ctenopalooza. More information can be found at the meeting Web site: http://ctenopalooza.whitney.ufl.edu.
C1 [Ryan, Joseph F.; Schnitzler, Christine E.] Univ Florida, Whitney Lab Marine Biosci, St Augustine, FL 32080 USA.
[Ryan, Joseph F.; Schnitzler, Christine E.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA.
[Schnitzler, Christine E.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Tamm, Sidney L.] Marine Biol Lab, Bell Ctr, Woods Hole, MA 02543 USA.
RP Ryan, JF (reprint author), Univ Florida, Whitney Lab Marine Biosci, St Augustine, FL 32080 USA.
EM joseph.ryan@whitney.ufl.edu
FU National Science Foundation's Division of Integrative Organismal Systems
[1619712]; University of Florida's Office of Research to Joseph Ryan
[00075235]; Whitney Laboratory for Marine Bioscience
FX Ctenopalooza was sponsored by a grant from the National Science
Foundation's Division of Integrative Organismal Systems to Joseph Ryan
(#1619712). We also acknowledge funding was provided by a grant from the
University of Florida's Office of Research to Joseph Ryan (Project
#00075235). Additional funding was provided by The Whitney Laboratory
for Marine Bioscience. Student and Postdoc prizes were provided by
Harvard University Press. EvoDevo generously waived open-access fees for
this report.
NR 41
TC 0
Z9 0
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2041-9139
J9 EVODEVO
JI EvoDevo
PD AUG 25
PY 2016
VL 7
AR 19
DI 10.1186/s13227-016-0057-3
PG 6
WC Evolutionary Biology; Developmental Biology
SC Evolutionary Biology; Developmental Biology
GA DU7ZV
UT WOS:000382434000001
ER
PT J
AU Kumar, V
Bonifazi, A
Ellenberger, MP
Keck, TM
Pommier, E
Rais, R
Slusher, BS
Gardner, E
You, ZB
Xi, ZX
Newman, AH
AF Kumar, Vivek
Bonifazi, Alessandro
Ellenberger, Michael P.
Keck, Thomas M.
Pommier, Elie
Rais, Rana
Slusher, Barbara S.
Gardner, Eliot
You, Zhi-Bing
Xi, Zheng-Xiong
Newman, Amy Hauck
TI Highly Selective Dopamine D-3 Receptor (D3R) Antagonists and Partial
Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads
for Opioid Dependence Treatment
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID CONDITIONED PLACE PREFERENCE; FUNCTIONALIZED LINKING CHAINS; KNOCKOUT
MICE; BEHAVIORAL SENSITIZATION; HIGH-AFFINITY; ADDICTION; COCAINE; RATS;
DISCOVERY; POTENT
AB The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D-3 receptor (D3R) as a target for therapeutic intervention. Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clinical use for cocaine abuse. Herein, we report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies. Lead compound 19 was selected based on its in vitro profile: D3R K-i= 6.84 nM, 1700-fold D3R versus D2R binding selectivity, and its metabolic stability in mouse microsomes. Compound 19 inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization. In addition, pretreatment with 19 also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats. These findings support the D3R as a target for opioid dependence treatment and compound 19 as a new lead molecule for development.
C1 [Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck] NIDA, Mol Targets & Medicat Discovery Branch, Intramural Res Program, NIH, 333 Cassell Dr, Baltimore, MD 21224 USA.
[Keck, Thomas M.] Rowan Univ, Coll Sci & Math, Dept Biomed & Translat Sci, Dept Chem & Biochem, 201 Mullica Hill Rd, Glassboro, NJ 08028 USA.
[Pommier, Elie; Rais, Rana; Slusher, Barbara S.] Johns Hopkins Univ, Sch Med, Johns Hopkins Drug Discovery, Dept Neurol, 855 North Wolfe St, Baltimore, MD 21205 USA.
RP Newman, AH (reprint author), NIDA, Mol Targets & Medicat Discovery Branch, Intramural Res Program, NIH, 333 Cassell Dr, Baltimore, MD 21224 USA.
EM anewman@intra.nida.nih.gov
FU National Institute on Drug Abuse - Intramural Research Program; NIDA
Addiction Treatment Discovery Program [ADA151001]; Oregon Health &
Science University; Johns Hopkins Drug Discovery [P30MH075673]
FX Support for this research was provided by the National Institute on Drug
Abuse - Intramural Research Program, NIDA Addiction Treatment Discovery
Program contract (ADA151001) with Oregon Health & Science University and
Johns Hopkins Drug Discovery (P30MH075673 to BSS). We thank Dr.
Anerbasha Shaik for help with the TOC Graphic.
NR 56
TC 2
Z9 2
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 25
PY 2016
VL 59
IS 16
BP 7634
EP 7650
DI 10.1021/acs.jmedchem.6b00860
PG 17
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DU4JP
UT WOS:000382179200020
PM 27508895
ER
PT J
AU Huynh, L
Kusnadi, A
Park, SH
Murata, K
Park-Min, KH
Ivashkiv, LB
AF Huynh, Linda
Kusnadi, Anthony
Park, Sung Ho
Murata, Koichi
Park-Min, Kyung-Hyun
Ivashkiv, Lionel B.
TI Opposing regulation of the late phase TNF response by mTORC1-IL-10
signaling and hypoxia in human macrophages
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; INNATE IMMUNE-RESPONSES; RHEUMATOID-ARTHRITIS;
GENE-EXPRESSION; LISTERIA-MONOCYTOGENES; METABOLIC CHECKPOINT; IL-10
PRODUCTION; CUTTING EDGE; I INTERFERON; MICE LACKING
AB Tumor necrosis factor (TNF) is best known for inducing a rapid but transient NF-kappa B-mediated inflammatory response. We investigated later phases of TNF signaling, after the initial transient induction of inflammatory genes has subsided, in primary human macrophages. TNF signaling induced expression of late response genes, including inhibitors of NF-kappa B and TLR signaling, with delayed and sustained kinetics 6-24 hr after TNF stimulation. A subset of late phase genes was expressed in rheumatoid arthritis synovial macrophages, confirming their expression under chronic inflammatory conditions in vivo. Expression of a subset of late phase genes was mediated by autocrine IL-10, which activated STAT3 with delayed kinetics. Hypoxia, which occurs at sites of infection or inflammation where TNF is expressed, suppressed this IL-10-STAT3 autocrine loop and expression of late phase genes. TNF-induced expression of IL-10 and downstream genes was also dependent on signaling by mTORC1, which senses the metabolic state of cells and is modulated by hypoxia. These results reveal an mTORC1-dependent IL-10- mediated late phase response to TNF by primary human macrophages, and identify suppression of IL-10 responses as a new mechanism by which hypoxia can promote inflammation. Thus, hypoxic and metabolic pathways may modulate TNF responses during chronic inflammation.
C1 [Huynh, Linda; Kusnadi, Anthony; Ivashkiv, Lionel B.] Weill Cornell Grad Sch Med Sci, Grad Program Immunol & Microbial Pathogenesis, 1300 York Ave, New York, NY 10021 USA.
[Huynh, Linda; Kusnadi, Anthony; Park, Sung Ho; Murata, Koichi; Park-Min, Kyung-Hyun; Ivashkiv, Lionel B.] Hosp Special Surg, Arthrit & Tissue Degenerat Program, 535 East 70th St, New York, NY 10021 USA.
[Huynh, Linda; Kusnadi, Anthony; Park, Sung Ho; Murata, Koichi; Park-Min, Kyung-Hyun; Ivashkiv, Lionel B.] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, 535 East 70th St, New York, NY 10021 USA.
[Huynh, Linda] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, 31 Ctr Dr,Bldg 31, Bethesda, MD 20892 USA.
RP Ivashkiv, LB (reprint author), Weill Cornell Grad Sch Med Sci, Grad Program Immunol & Microbial Pathogenesis, 1300 York Ave, New York, NY 10021 USA.; Ivashkiv, LB (reprint author), Hosp Special Surg, Arthrit & Tissue Degenerat Program, 535 East 70th St, New York, NY 10021 USA.; Ivashkiv, LB (reprint author), Hosp Special Surg, David Z Rosensweig Genom Res Ctr, 535 East 70th St, New York, NY 10021 USA.
EM ivashkivl@hss.edu
FU NIH [T32 AI007621]
FX We thank Carl Nathan and Amy Cunningham Bussel for access to tissue
culture incubators in which oxygen tension can be regulated. We also
thank Rachael Gordon for pilot experiments showing IL-10 production
downstream of TNF signaling, and Galina Grigoriev and Angela Lee for
processing samples from RA synovial fluids. We thank Laura Donlin for
helpful discussions and critical reading of the manuscript. This work
was supported by grants from the NIH (to L.B.I.). L.H. was supported by
the NIH Grant T32 AI007621 (to the Graduate Program in Immunology and
Microbial Pathogenesis, Weill Cornell Graduate School of Medical
Sciences).
NR 68
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 25
PY 2016
VL 6
AR 31959
DI 10.1038/srep31959
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU0KI
UT WOS:000381891900001
PM 27558590
ER
PT J
AU Kim, MK
Caplen, N
Chakka, S
Hernandez, L
House, C
Pongas, G
Jordan, E
Annunziata, CM
AF Kim, Marianne K.
Caplen, Natasha
Chakka, Sirisha
Hernandez, Lidia
House, Carrie
Pongas, Georgios
Jordan, Elizabeth
Annunziata, Christina M.
TI Identification of therapeutic targets applicable to clinical strategies
in ovarian cancer
SO BMC CANCER
LA English
DT Article
DE Ovarian cancer; PLK1; MAP3K7/TAK1; WEE1
ID GYNECOLOGIC-ONCOLOGY-GROUP; CARCINOMA; CELLS; ACTIVATION; INHIBITOR;
SURVIVAL; CD133
AB Background: shRNA-mediated lethality screening is a useful tool to identify essential targets in cancer biology. Ovarian cancer (OC) is extremely heterogeneous and most cases are advanced stages at diagnosis. OC has a high response rate initially, but becomes resistant to standard chemotherapy. We previously employed high throughput global shRNA sensitization screens to identify NF-kB related pathways. Here, we re-analyzed our previous shRNA screens in an unbiased manner to identify clinically applicable molecular targets.
Methods: We proceeded with siRNA lethality screening using the top 55 genes in an expanded set of 6 OC cell lines. We investigated clinical relevance of candidate targets in The Cancer Genome Atlas OC dataset. To move these findings towards the clinic, we chose four pharmacological inhibitors to recapitulate the top siRNA effects: Oxozeaenol (for MAP3K7/TAK1), BI6727 (PLK1), MK1775 (WEE1), and Lapatinib (ERBB2). Cytotoxic effects were measured by cellular viability assay, as single agents and in 2-way combinations. Co-treatments were evaluated in either sequential or simultaneous exposure to drug for short term and extended periods to simulate different treatment strategies.
Results: Loss-of-function shRNA screens followed by short-term siRNA validation screens identified therapeutic targets in OC cells. Candidate genes were dysregulated in a subset of TCGA OCs although the alterations of these genes showed no statistical significance to overall survival. Pharmacological inhibitors such as Oxozeaenol, BI6727, and MK1775 showed cytotoxic effects in OC cells regardless of cisplatin responsiveness, while all OC cells tested were cytostatic to Lapatinib. Co-treatment with BI6727 and MK1775 at sub-lethal concentrations was equally potent to BI6727 alone at lethal concentrations without cellular re-growth after the drugs were washed off, suggesting the co-inhibition at reduced dosages may be more efficacious than maximal single-agent cytotoxic concentrations.
Conclusions: Loss-of-function screen followed by in vitro target validation using chemical inhibitors identified clinically relevant targets. This approach has the potential to systematically refine therapeutic strategies in OC. These molecular target-driven strategies may provide additional therapeutic options for women whose tumors have become refractory to standard chemotherapy.
C1 [Kim, Marianne K.; Hernandez, Lidia; House, Carrie; Pongas, Georgios; Jordan, Elizabeth; Annunziata, Christina M.] NCI, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Caplen, Natasha; Chakka, Sirisha] NCI, Gene Silencing Sect, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Annunziata, Christina M.] Natl Canc Inst, Womens Malignancies Branch, Ctr Canc Res, 10 Ctr Dr,Room 4B54, Bethesda, MD 20892 USA.
RP Annunziata, CM (reprint author), NCI, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA.; Annunziata, CM (reprint author), Natl Canc Inst, Womens Malignancies Branch, Ctr Canc Res, 10 Ctr Dr,Room 4B54, Bethesda, MD 20892 USA.
EM annunzic@mail.nih.gov
OI Annunziata, Christina/0000-0003-2033-6532
FU Foundation of Women's cancer-Amgen Ovarian Cancer Research Grant;
Intramural Research Program of the National Cancer Institute
FX This work was supported by the Foundation of Women's cancer-Amgen
Ovarian Cancer Research Grant (MK) and the Intramural Research Program
of the National Cancer Institute (CMA).
NR 21
TC 0
Z9 0
U1 2
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 24
PY 2016
VL 16
AR 678
DI 10.1186/s12885-016-2675-5
PG 13
WC Oncology
SC Oncology
GA DX2JR
UT WOS:000384195500001
PM 27558154
ER
PT J
AU Antignani, A
Griner, LM
Guha, R
Simon, N
Pasetto, M
Keller, J
Huang, M
Angelus, E
Pastan, I
Ferrer, M
FitzGerald, DJ
Thomas, CJ
AF Antignani, Antonella
Griner, Lesley Mathews
Guha, Rajarshi
Simon, Nathan
Pasetto, Matteo
Keller, Jonathan
Huang, Manjie
Angelus, Evan
Pastan, Ira
Ferrer, Marc
FitzGerald, David J.
Thomas, Craig J.
TI Chemical Screens Identify Drugs that Enhance or Mitigate Cellular
Responses to Antibody-Toxin Fusion Proteins
SO PLOS ONE
LA English
DT Article
ID PHASE-I TRIAL; IMMUNOTOXIN RFB4(DSFV)-PE38 BL22; ADP-RIBOSYLATING
TOXINS; ANTIMESOTHELIN IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; CANCER-CELLS;
CLINICAL-EXPERIENCE; BREAST-CANCER; SS1P; COMBINATION
AB The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium. However, very little is known about how to combine them in optimal ways. Immunotoxins are antibody-toxin gene fusion proteins engineered to target cancer cells via antibody binding to surface antigens. For fusion proteins derived from Pseudomonas exotoxin (PE), potency relies on the enzymatic domain of the toxin which catalyzes the ADP-ribosylation of EF2 causing inhibition of protein synthesis leading to cell death. Candidate immunotoxins have demonstrated clear value in clinical trials but generally have not been curative as single agents. Therefore we undertook three screens to discover effective combinations that could act synergistically. From the MIPE-3 library of compounds we identified various enhancers of immunotoxin action and at least one major class of inhibitor. Follow-up experiments confirmed the screening data and suggested that immunotoxins when administered with everolimus or nilotinib exhibit favorable combinatory activity and would be candidates for preclinical development. Mechanistic studies revealed that everolimus-immunotoxin combinations acted synergistically on elements of the protein synthetic machinery, including S61 kinase and 4E-BP1 of the mTORC1 pathway. Conversely, PARP inhibitors antagonized immunotoxins and also blocked the toxicity due to native ADP-ribosylating toxins. Thus, our goal of investigating a chemical library was justified based on the identification of several approved compounds that could be developed preclinically as 'enhancers' and at least one class of mitigator to be avoided.
C1 [Antignani, Antonella; Simon, Nathan; Pasetto, Matteo; Huang, Manjie; Angelus, Evan; Pastan, Ira; FitzGerald, David J.] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
[Griner, Lesley Mathews; Guha, Rajarshi; Keller, Jonathan; Ferrer, Marc; Thomas, Craig J.] NIH, Div Preclin Innovat, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
[Pasetto, Matteo] Univ Verona, Dept Pathol, Verona, Italy.
RP FitzGerald, DJ (reprint author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.; Thomas, CJ (reprint author), NIH, Div Preclin Innovat, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
EM fitzgerd@helix.nih.gov; craigt@mail.nih.gov
FU National Cancer Institute; National Center for Advancing Translational
Sciences
FX This work was funded by the intramural programs of the National Cancer
Institute and the National Center for Advancing Translational Sciences.
There are no grant or award numbers as the funding is "in-house".
NR 38
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 24
PY 2016
VL 11
IS 8
AR e0161415
DI 10.1371/journal.pone.0161415
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU5NI
UT WOS:000382258100040
PM 27556570
ER
PT J
AU Horne, HN
Chung, CC
Zhang, H
Yu, K
Prokunina-Olsson, L
Michailidou, K
Bolla, MK
Wang, Q
Dennis, J
Hopper, JL
Southey, MC
Schmidt, MK
Broeks, A
Muir, K
Lophatananon, A
Fasching, PA
Beckmann, MW
Fletcher, O
Johnson, N
Sawyer, EJ
Tomlinson, I
Burwinkel, B
Marme, F
Guenel, P
Truong, T
Bojesen, SE
Flyger, H
Benitez, J
Gonzalez-Neira, A
Anton-Culver, H
Neuhausen, SL
Brenner, H
Arndt, V
Meindl, A
Schmutzler, RK
Brauch, H
Hamann, U
Nevanlinna, H
Khan, S
Matsuo, K
Iwata, H
Dork, T
Bogdanova, NV
Lindblom, A
Margolin, S
Mannermaa, A
Kosma, VM
Chenevix-Trench, G
Wu, AH
den Berg, DV
Smeets, A
Zhao, H
Chang-Claude, J
Rudolph, A
Radice, P
Barile, M
Couch, FJ
Vachon, C
Giles, GG
Milne, RL
Haiman, CA
Le Marchand, L
Goldberg, MS
Teo, SH
Taib, NAM
Kristensen, V
Borresen-Dale, AL
Zheng, W
Shrubsole, M
Winqvist, R
Jukkola-Vuorinen, A
Andrulis, IL
Knight, JA
Devilee, P
Seynaeve, C
Garcia-Closas, M
Czene, K
Darabi, H
Hollestelle, A
Martens, JWM
Li, JM
Lu, W
Shu, XO
Cox, A
Cross, SS
Blot, W
Cai, QY
Shah, M
Luccarini, C
Baynes, C
Harrington, P
Kang, D
Choi, JY
Hartman, M
Chia, KS
Kabisch, M
Torres, D
Jakubowska, A
Lubinski, J
Sangrajrang, S
Brennan, P
Slager, S
Yannoukakos, D
Shen, CY
Hou, MF
Swerdlow, A
Orr, N
Simard, J
Hall, P
Pharoah, PDP
Easton, DF
Chanock, SJ
Dunning, AM
Figueroa, JD
AF Horne, Hisani N.
Chung, Charles C.
Zhang, Han
Yu, Kai
Prokunina-Olsson, Ludmila
Michailidou, Kyriaki
Bolla, Manjeet K.
Wang, Qin
Dennis, Joe
Hopper, John L.
Southey, Melissa C.
Schmidt, Marjanka K.
Broeks, Annegien
Muir, Kenneth
Lophatananon, Artitaya
Fasching, Peter A.
Beckmann, Matthias W.
Fletcher, Olivia
Johnson, Nichola
Sawyer, Elinor J.
Tomlinson, Ian
Burwinkel, Barbara
Marme, Frederik
Guenel, Pascal
Truong, Therese
Bojesen, Stig E.
Flyger, Henrik
Benitez, Javier
Gonzalez-Neira, Anna
Anton-Culver, Hoda
Neuhausen, Susan L.
Brenner, Hermann
Arndt, Volker
Meindl, Alfons
Schmutzler, Rita K.
Brauch, Hiltrud
Hamann, Ute
Nevanlinna, Heli
Khan, Sofia
Matsuo, Keitaro
Iwata, Hiroji
Dork, Thilo
Bogdanova, Natalia V.
Lindblom, Annika
Margolin, Sara
Mannermaa, Arto
Kosma, Veli-Matti
Chenevix-Trench, Georgia
Wu, Anna H.
den Berg, David Ven
Smeets, Ann
Zhao, Hui
Chang-Claude, Jenny
Rudolph, Anja
Radice, Paolo
Barile, Monica
Couch, Fergus J.
Vachon, Celine
Giles, Graham G.
Milne, Roger L.
Haiman, Christopher A.
Le Marchand, Loic
Goldberg, Mark S.
Teo, Soo H.
Taib, Nur A. M.
Kristensen, Vessela
Borresen-Dale, Anne-Lise
Zheng, Wei
Shrubsole, Martha
Winqvist, Robert
Jukkola-Vuorinen, Arja
Andrulis, Irene L.
Knight, Julia A.
Devilee, Peter
Seynaeve, Caroline
Garcia-Closas, Montserrat
Czene, Kamila
Darabi, Hatef
Hollestelle, Antoinette
Martens, John W. M.
Li, Jingmei
Lu, Wei
Shu, Xiao-Ou
Cox, Angela
Cross, Simon S.
Blot, William
Cai, Qiuyin
Shah, Mitul
Luccarini, Craig
Baynes, Caroline
Harrington, Patricia
Kang, Daehee
Choi, Ji-Yeob
Hartman, Mikael
Chia, Kee Seng
Kabisch, Maria
Torres, Diana
Jakubowska, Anna
Lubinski, Jan
Sangrajrang, Suleeporn
Brennan, Paul
Slager, Susan
Yannoukakos, Drakoulis
Shen, Chen-Yang
Hou, Ming-Feng
Swerdlow, Anthony
Orr, Nick
Simard, Jacques
Hall, Per
Pharoah, Paul D. P.
Easton, Douglas F.
Chanock, Stephen J.
Dunning, Alison M.
Figueroa, Jonine D.
CA kConFab AOCS Investigators
TI Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMMON VARIANTS; CONFER SUSCEPTIBILITY;
GENETIC-VARIATION; 14Q24.1 RAD51L1; RISK; HETEROGENEITY; ALLELES;
DISEASE
AB The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, we genotyped 92 SNPs in a 900kb region (120,505,799-121,481,132) flanking rs11249433 in 45,276 breast cancer cases and 48,998 controls of European, Asian and African ancestry from 50 studies in the Breast Cancer Association Consortium. Genotyping was done using iCOGS, a custom-built array. Due to the complicated nature of the region on chr1p11.2: 120,300,000-120,505,798, that lies near the centromere and contains seven duplicated genomic segments, we restricted analyses to 429 SNPs excluding the duplicated regions (42 genotyped and 387 imputed). Perallelic associations with breast cancer risk were estimated using logistic regression models adjusting for study and ancestry-specific principal components. The strongest association observed was with the original identified index SNP rs11249433 (minor allele frequency (MAF) 0.402; per-allele odds ratio (OR) = 1.10, 95% confidence interval (CI) 1.08-1.13, P = 1.49 x 10(-21)). The association for rs11249433 was limited to ER-positive breast cancers (test for heterogeneity P <= 8.41 x 10(-5)). Additional analyses by other tumor characteristics showed stronger associations with moderately/well differentiated tumors and tumors of lobular histology. Although no significant eQTL associations were observed, in silico analyses showed that rs11249433 was located in a region that is likely a weak enhancer/promoter. Fine-mapping analysis of the 1p11.2 breast cancer susceptibility locus confirms this region to be limited to risk to cancers that are ER-positive.
C1 [Horne, Hisani N.; Chung, Charles C.; Zhang, Han; Yu, Kai; Prokunina-Olsson, Ludmila; Garcia-Closas, Montserrat; Chanock, Stephen J.; Figueroa, Jonine D.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Horne, Hisani N.] US FDA, Silver Spring, MD USA.
[Michailidou, Kyriaki; Bolla, Manjeet K.; Wang, Qin; Dennis, Joe; Pharoah, Paul D. P.; Easton, Douglas F.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England.
[Hopper, John L.; Giles, Graham G.; Milne, Roger L.] Univ Melbourne, Ctr Epidemiol & Biostat, Sch Populat & Global Hlth, Melbourne, Vic, Australia.
[Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
[Schmidt, Marjanka K.; Broeks, Annegien] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
[Muir, Kenneth; Lophatananon, Artitaya] Univ Warwick, Div Hlth Sci, Warwick Med Sch, Coventry, W Midlands, England.
[Muir, Kenneth] Univ Manchester, Inst Populat Hlth, Manchester, Lancs, England.
[Fasching, Peter A.; Beckmann, Matthias W.] Univ Erlangen Nurnberg, Dept Obstet & Gynaecol, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Fletcher, Olivia; Johnson, Nichola; Orr, Nick] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London, England.
[Fletcher, Olivia; Johnson, Nichola; Swerdlow, Anthony] Inst Canc Res, Div Breast Canc Res, London, England.
[Sawyer, Elinor J.] Kings Coll London, Res Oncol, Guys Hosp, London, England.
[Tomlinson, Ian] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Tomlinson, Ian] Univ Oxford, Oxford Biomed Res Ctr, Oxford, England.
[Burwinkel, Barbara; Marme, Frederik] Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, Heidelberg, Germany.
[Marme, Frederik] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany.
[Guenel, Pascal; Truong, Therese] INSERM, Environm Epidemiol Canc, Ctr Res Epidemiol & Populat Hlth, Villejuif, France.
[Guenel, Pascal; Truong, Therese] Univ Paris 11, Villejuif, France.
[Bojesen, Stig E.] Copenhagen Univ Hosp, Copenhagen Gen Populat Study, Herlev Hosp, Herlev, Denmark.
[Bojesen, Stig E.] Copenhagen Univ Hosp, Dept Clin Biochem, Herlev Hosp, Herlev, Denmark.
[Bojesen, Stig E.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
[Flyger, Henrik] Copenhagen Univ Hosp, Dept Breast Surg, Herlev Hosp, Herlev, Denmark.
[Benitez, Javier; Gonzalez-Neira, Anna] Spanish Natl Canc Res Ctr, Human Canc Genet Program, Madrid, Spain.
[Benitez, Javier] Ctr Invest Red Enfermedades Raras, Valencia, Spain.
[Anton-Culver, Hoda] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA.
[Neuhausen, Susan L.] Beckman Res Inst City Hope, Duarte, CA USA.
[Brenner, Hermann; Arndt, Volker] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Brenner, Hermann] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.
[Brenner, Hermann; Brauch, Hiltrud] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.
[Meindl, Alfons] Tech Univ Munich, Div Gynaecol & Obstet, Munich, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Dept Obstet & Gynaecol, Div Mol Gynecooncol, Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Ctr Familial Breast & Ovarian Canc, Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Ctr Mol Med, Cologne, Germany.
[Brauch, Hiltrud] Dr Margarete Fischer Bosch Institute Clin Pharmac, Stuttgart, Germany.
[Brauch, Hiltrud] Univ Tubingen, Tubingen, Germany.
[Hamann, Ute; Kabisch, Maria; Torres, Diana] German Canc Res Ctr, Mol Genet Breast Canc, Heidelberg, Germany.
[Nevanlinna, Heli; Khan, Sofia] Univ Helsinki, Helsinki Univ Hosp, Dept Obstet & Gynecol, Helsinki, Finland.
[Matsuo, Keitaro] Kyushu Univ, Dept Prevent Med, Fac Med Sci, Fukuoka, Japan.
[Iwata, Hiroji] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan.
[Dork, Thilo] Hannover Med Sch, Gynaecol Res Unit, Hannover, Germany.
[Bogdanova, Natalia V.] Hannover Med Sch, Dept Radiat Oncol, Hannover, Germany.
[Lindblom, Annika] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
[Margolin, Sara] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
[Mannermaa, Arto; Kosma, Veli-Matti] Kuopio Univ Hosp, Ctr Canc, Kuopio, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti] Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, Kuopio, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti] Kuopio Univ Hosp, Imaging Ctr, Dept Clin Pathol, Kuopio, Finland.
[Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Dept Genet, Brisbane, Qld, Australia.
[kConFab AOCS Investigators] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Wu, Anna H.; den Berg, David Ven; Haiman, Christopher A.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
[Smeets, Ann] Univ Hosp Gashuisberg, Leuven, Belgium.
[Zhao, Hui] Vesalius Res Ctr, Leuven, Belgium.
[Zhao, Hui] Univ Leuven, Lab Translat Genet, Dept Oncol, Leuven, Belgium.
[Chang-Claude, Jenny; Rudolph, Anja] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Chang-Claude, Jenny] Univ Med Ctr Hamburg Eppendorf, UCCH, Hamburg, Germany.
[Radice, Paolo] Ist Nazl Tumori, Unit Mol Bases Genet Risk & Genet Testing, Dept Prevent & Predict Med, Fdn IRCCS Ist Ricovero & Cura Carattere Sci, Milan, Italy.
[Barile, Monica] Ist Europeo Oncol, Div Canc Prevent & Genet, Milan, Italy.
[Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Vachon, Celine; Slager, Susan] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Giles, Graham G.; Milne, Roger L.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
[Goldberg, Mark S.] McGill Univ, Dept Med, Montreal, PQ, Canada.
[Goldberg, Mark S.] McGill Univ, Div Clin Epidemiol, Royal Victoria Hosp, Montreal, PQ, Canada.
[Teo, Soo H.] Canc Res Initiat Fdn, Subang Jaya, Selangor, Malaysia.
[Teo, Soo H.; Taib, Nur A. M.] Univ Malaya, Med Ctr, Breast Canc Res Unit, Canc Res Inst, Kuala Lumpur, Malaysia.
[Kristensen, Vessela; Borresen-Dale, Anne-Lise] Oslo Univ Hosp, Dept Genet, Inst Canc Res, Radiumhosp, Oslo, Norway.
[Kristensen, Vessela; Borresen-Dale, Anne-Lise] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
[Kristensen, Vessela] Univ Oslo, Oslo Univ Hosp, Dept Clin Mol Biol, Oslo, Norway.
[Zheng, Wei; Shrubsole, Martha; Shu, Xiao-Ou; Blot, William; Cai, Qiuyin] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Epidemiol,Dept Med, Nashville, TN 37212 USA.
[Winqvist, Robert] Univ Oulu, Lab Canc Genet & Tumor Biol, Dept Clin Chem, Oulu, Finland.
[Winqvist, Robert] Univ Oulu, Bioctr Oulu, Oulu, Finland.
[Winqvist, Robert] Northern Finland Lab Ctr NordLab, Lab Canc Genet & Tumor Biol, Oulu, Finland.
[Jukkola-Vuorinen, Arja] Univ Oulu, Dept Oncol, Oulu Univ Hosp, Oulu, Finland.
[Andrulis, Irene L.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
[Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Knight, Julia A.] Mt Sinai Hosp, Prosserman Ctr Hlth Res, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
[Knight, Julia A.] Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
[Devilee, Peter] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands.
[Devilee, Peter] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands.
[Seynaeve, Caroline; Hollestelle, Antoinette; Martens, John W. M.] Erasmus MC Canc Inst, Dept Med Oncol, Family Canc Clin, Rotterdam, Netherlands.
[Garcia-Closas, Montserrat; Swerdlow, Anthony] Inst Canc Res, Div Genet & Epidemiol, London, England.
[Czene, Kamila; Darabi, Hatef; Li, Jingmei; Hall, Per] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Lu, Wei] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China.
[Cox, Angela] Univ Sheffield, Sheffield Canc Res, Dept Oncol, Sheffield, S Yorkshire, England.
[Cross, Simon S.] Univ Sheffield, Acad Unit Pathol, Dept Neurosci, Sheffield, S Yorkshire, England.
[Blot, William] Int Epidemiol Inst, Rockville, MD USA.
[Shah, Mitul; Luccarini, Craig; Baynes, Caroline; Harrington, Patricia; Pharoah, Paul D. P.; Easton, Douglas F.; Dunning, Alison M.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England.
[Kang, Daehee] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
[Kang, Daehee; Choi, Ji-Yeob] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
[Kang, Daehee; Choi, Ji-Yeob] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.
[Hartman, Mikael; Chia, Kee Seng] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
[Hartman, Mikael] Natl Univ Hlth Syst, Dept Surg, Singapore, Singapore.
[Torres, Diana] Pontificia Univ Javeriana, Inst Human Genet, Bogota, Colombia.
[Jakubowska, Anna; Lubinski, Jan] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland.
[Sangrajrang, Suleeporn] Natl Canc Inst, Bangkok, Thailand.
[Brennan, Paul] Int Agcy Res Canc, Lyon, France.
[Yannoukakos, Drakoulis] Natl Ctr Sci Res Demokritos, Mol Diagnost Lab, IRRP, Athens, Greece.
[Shen, Chen-Yang] China Med Univ, Sch Publ Hlth, Taichung, Taiwan.
[Shen, Chen-Yang] Acad Sinica, Taiwan Biobank, Inst Biomed Sci, Taipei, Taiwan.
[Hou, Ming-Feng] Kaohsiung Med Univ, Ctr Canc, Chung Ho Mem Hosp, Kaohsiung, Taiwan.
[Hou, Ming-Feng] Kaohsiung Med Univ, Dept Surg, Chung Ho Mem Hosp, Kaohsiung, Taiwan.
[Simard, Jacques] Univ Laval, Ctr Hosp Univ Quebec, Res Ctr, Quebec City, PQ, Canada.
[Figueroa, Jonine D.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
[Figueroa, Jonine D.] Univ Edinburgh, Edinburgh Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
RP Figueroa, JD (reprint author), NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.; Figueroa, JD (reprint author), Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.; Figueroa, JD (reprint author), Univ Edinburgh, Edinburgh Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
EM jonine.figueroa@ed.ac.uk
RI Knight, Julia/A-6843-2012; Zheng, Wei/O-3351-2013; Dork,
Thilo/J-8620-2012; Zhang, Han/K-2118-2016; Li, Jingmei/I-2904-2012;
Brenner, Hermann/B-4627-2017;
OI Zheng, Wei/0000-0003-1226-070X; Zhang, Han/0000-0001-7977-9616; Li,
Jingmei/0000-0001-8587-7511; Brenner, Hermann/0000-0002-6129-1572; Khan,
Sofia/0000-0003-4185-8882; Matsuo, Keitaro/0000-0003-1761-6314;
Yannoukakos, Drakoulis/0000-0001-7509-3510; Dunning, Alison
Margaret/0000-0001-6651-7166
FU Cancer Research UK [10124]; NCI NIH HHS [R01 CA176785]
NR 43
TC 1
Z9 1
U1 6
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 24
PY 2016
VL 11
IS 8
AR e0160316
DI 10.1371/journal.pone.0160316
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DU5NI
UT WOS:000382258100011
PM 27556229
ER
PT J
AU Tunstall, BJ
Carmack, SA
AF Tunstall, Brendan J.
Carmack, Stephanie A.
TI Social Stress-Induced Alterations in CRF Signaling in the VTA Facilitate
the Emergence of Addiction-like Behavior
SO JOURNAL OF NEUROSCIENCE
LA English
DT Editorial Material
ID CORTICOTROPIN-RELEASING-FACTOR; VENTRAL TEGMENTAL AREA; COCAINE SEEKING;
BINDING-PROTEIN; INDUCED RELAPSE; FACTOR NEURONS; DOPAMINE; RATS;
VASOPRESSIN; RECEPTORS
C1 [Tunstall, Brendan J.; Carmack, Stephanie A.] NIDA, NIH, Baltimore, MD 21224 USA.
RP Tunstall, BJ (reprint author), NIDA, Intramural Res Program, 251 Bayview Blvd,BRC 08A406-17, Baltimore, MD 21224 USA.
EM brendan.tunstall@nih.gov
NR 29
TC 0
Z9 0
U1 3
U2 3
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 24
PY 2016
VL 36
IS 34
BP 8780
EP 8782
DI 10.1523/JNEUROSCI.1815-16.2016
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA DW9SW
UT WOS:000384004000002
PM 27559161
ER
PT J
AU Henriksen, S
Read, JCA
Cumming, BG
AF Henriksen, Sid
Read, Jenny C. A.
Cumming, Bruce G.
TI Neurons in Striate Cortex Signal Disparity in Half-Matched Random-Dot
Stereograms
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE binocular; correspondence problem; disparity; half-matched; random dot
stereogram; stereopsis
ID STEREOSCOPIC DEPTH-PERCEPTION; SINGLE-NEURON; V1 NEURONS;
HORIZONTAL-DISPARITY; BINOCULAR DISPARITY; VISUAL-CORTEX; AWAKE MONKEYS;
ENERGY-MODEL; RESPONSES; MACAQUE
AB Human stereopsis can operate in dense "cyclopean" images containing no monocular objects. This is believed to depend on the computation of binocular correlation by neurons in primary visual cortex (V1). The observation that humans perceive depth in half-matched random-dot stereograms, although these stimuli have no net correlation, has led to the proposition that human depth perception in these stimuli depends on a distinct "matching" computation possibly performed in extrastriate cortex. However, recording from disparity-selective neurons in V1 of fixating monkeys, we found that they are in fact able to signal disparity in half-matched stimuli. We present a simple model that explains these results. This reinstates the view that disparity-selective neurons in V1 provide the initial substrate for perception in dense cyclopean stimuli, and strongly suggests that separate correlation and matching computations are not necessary to explain existing data on mixed correlation stereograms.
C1 [Henriksen, Sid; Read, Jenny C. A.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Henriksen, Sid; Cumming, Bruce G.] NEI, Lab Sensorimotor Res, NIH, Bethesda, MD 20892 USA.
RP Henriksen, S (reprint author), NIH, 49 Convent Dr, Bethesda, MD 20892 USA.
EM sid.henriksen@gmail.com
OI Read, Jenny/0000-0002-9029-5185
FU Wellcome Trust/National Institutes of Health joint PhD Studentship
[100931/Z/13/Z]; Intramural Research Program at the National Eye
Institute/National Institutes of Health
FX This work was supported by a Wellcome Trust/National Institutes of
Health joint PhD Studentship (100931/Z/13/Z) to S.H., and by the
Intramural Research Program at the National Eye Institute/National
Institutes of Health to B.G.C.
NR 37
TC 0
Z9 0
U1 1
U2 1
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 24
PY 2016
VL 36
IS 34
BP 8967
EP 8976
DI 10.1523/JNEUROSCI.0642-16.2016
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA DW9SW
UT WOS:000384004000018
PM 27559177
ER
PT J
AU Serra-Musach, J
Mateo, F
Capdevila-Busquets, E
de Garibay, GR
Zhang, XH
Guha, R
Thomas, CJ
Grueso, J
Villanueva, A
Jaeger, S
Heyn, H
Vizoso, M
Perez, H
Cordero, A
Gonzalez-Suarez, E
Esteller, M
Moreno-Bueno, G
Tjarnberg, A
Lazaro, C
Serra, V
Arribas, J
Benson, M
Gustafsson, M
Ferrer, M
Aloy, P
Pujana, MA
AF Serra-Musach, Jordi
Mateo, Francesca
Capdevila-Busquets, Eva
de Garibay, Gorka Ruiz
Zhang, Xiaohu
Guha, Raj
Thomas, Craig J.
Grueso, Judit
Villanueva, Alberto
Jaeger, Samira
Heyn, Holger
Vizoso, Miguel
Perez, Hector
Cordero, Alex
Gonzalez-Suarez, Eva
Esteller, Manel
Moreno-Bueno, Gema
Tjaernberg, Andreas
Lazaro, Conxi
Serra, Violeta
Arribas, Joaquin
Benson, Mikael
Gustafsson, Mika
Ferrer, Marc
Aloy, Patrick
Pujana, Miquel Angel
TI Cancer network activity associated with therapeutic response and
synergism
SO GENOME MEDICINE
LA English
DT Article
DE Cancer; Network; Therapy; Synergy
ID PROTEIN-INTERACTION NETWORKS; BREAST-CANCER; DRUG-RESISTANCE; SIGNALING
ENTROPY; SYSTEMS BIOLOGY; CELLS; COMBINATION; SENSITIVITY; ROBUSTNESS;
EXPRESSION
AB Background: Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. We reasoned that network analysis of omic data could help to achieve this goal.
Methods: A measure of "cancer network activity" (CNA) was implemented based on a previously defined network feature of communicability. The network nodes and edges corresponded to human proteins and experimentally identified interactions, respectively. The edges were weighted proportionally to the expression of the genes encoding for the corresponding proteins and relative to the number of direct interactors. The gene expression data corresponded to the basal conditions of 595 human cancer cell lines. Therapeutic responses corresponded to the impairment of cell viability measured by the half maximal inhibitory concentration (IC50) of 130 drugs approved or under clinical development. Gene ontology, signaling pathway, and transcription factor-binding annotations were taken from public repositories. Predicted synergies were assessed by determining the viability of four breast cancer cell lines and by applying two different analytical methods.
Results: The effects of drug classes were associated with CNAs formed by different cell lines. CNAs also differentiate target families and effector pathways. Proteins that occupy a central position in the network largely contribute to CNA. Known key cancer-associated biological processes, signaling pathways, and master regulators also contribute to CNA. Moreover, the major cancer drivers frequently mediate CNA and therapeutic differences. Cell-based assays centered on these differences and using uncorrelated drug effects reveals novel synergistic combinations for the treatment of breast cancer dependent on PI3K-mTOR signaling.
Conclusions: Cancer therapeutic responses can be predicted on the basis of a systems-level analysis of molecular interactions and gene expression. Fundamental cancer processes, pathways, and drivers contribute to this feature, which can also be exploited to predict precise synergistic drug combinations.
C1 [Zhang, Xiaohu; Guha, Raj; Thomas, Craig J.; Ferrer, Marc] NIH, NCATS, Div Preclin Innovat, 9800 Med Ctr Dr Rockville, Bethesda, MD 20850 USA.
[Capdevila-Busquets, Eva; Jaeger, Samira; Aloy, Patrick] Barcelona Inst Sci & Technol, IRB Barcelona, Joint IRB BSC CRG Program Computat Biol, Baldiri Reixac 10, Barcelona 08028, Catalonia, Spain.
[Serra-Musach, Jordi; Mateo, Francesca; de Garibay, Gorka Ruiz; Villanueva, Alberto; Pujana, Miquel Angel] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol ICO, Program Canc Therapeut Resistance ProCURE, Breast Canc & Syst Biol Lab, Gran Via 199,Lhosp Llobregat, Barcelona 08908, Catalonia, Spain.
[Grueso, Judit; Serra, Violeta] VHIO, Cellex Ctr, Expt Therapeut Grp, Natzaret 115-117, Barcelona 08035, Catalonia, Spain.
[Heyn, Holger; Vizoso, Miguel; Perez, Hector; Cordero, Alex; Gonzalez-Suarez, Eva; Esteller, Manel] IDIBELL, Cancer Epigenet & Biol Program PEBC, Gran Via 199, Barcelona 08908, Catalonia, Spain.
[Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Feixa Llarga S-N, Barcelona 08908, Catalonia, Spain.
[Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Feixa Llarga S-N, Barcelona 08010, Catalonia, Spain.
[Esteller, Manel; Arribas, Joaquin; Aloy, Patrick] ICREA, Passeig Lluis Companys 23, Barcelona 08010, Catalonia, Spain.
[Moreno-Bueno, Gema] Autonomous Univ Madrid, Biomed Res Inst Alberto Sols, Spanish Natl Res Council CSIC, Hosp La Paz Inst Hlth Res IdiPAZ,Dept Biochem, Arzobispo Morcillo 4, E-28029 Madrid, Spain.
[Moreno-Bueno, Gema] MD Anderson Int Fdn, Arturo Soria 270, Madrid 28033, Spain.
[Tjaernberg, Andreas; Benson, Mikael; Gustafsson, Mika] Linkoping Univ, Ctr Individualized Med, Dept Clin & Expt Med, S-58183 Linkoping, Sweden.
[Lazaro, Conxi] IDIBELL, ICO, Hereditary Canc Program, Gran Via 199, Barcelona 08908, Catalonia, Spain.
[Arribas, Joaquin] VHIO, Cellex Ctr, Preclin Res Program, Natzaret 115-117, Barcelona 08035, Catalonia, Spain.
[Arribas, Joaquin] Autonomous Univ Barcelona, Med Sch Bldg M, Dept Biochem & Mol Biol, Bellaterra 08193, Catalonia, Spain.
RP Ferrer, M (reprint author), NIH, NCATS, Div Preclin Innovat, 9800 Med Ctr Dr Rockville, Bethesda, MD 20850 USA.; Aloy, P (reprint author), Barcelona Inst Sci & Technol, IRB Barcelona, Joint IRB BSC CRG Program Computat Biol, Baldiri Reixac 10, Barcelona 08028, Catalonia, Spain.; Pujana, MA (reprint author), Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol ICO, Program Canc Therapeut Resistance ProCURE, Breast Canc & Syst Biol Lab, Gran Via 199,Lhosp Llobregat, Barcelona 08908, Catalonia, Spain.; Aloy, P (reprint author), ICREA, Passeig Lluis Companys 23, Barcelona 08010, Catalonia, Spain.
EM marc.ferrer@nih.gov; paloy@irbbarcelona.org; mapujana@iconcologia.net
RI Moreno-Bueno, Gema/K-9354-2016; Mateo, Francesca/K-7746-2015;
OI Moreno-Bueno, Gema/0000-0002-5030-6687; Mateo,
Francesca/0000-0002-2342-7010; Heyn, Holger/0000-0002-3276-1889
FU Generalitat de Catalunya AGAUR SGR [364]; Spanish Ministry of Health
ISCIII [PI12/01528, PI15/00854, RTICC RD12/0036/0007, 0008]; Spanish
Ministry of Science and Innovation "Fondo Europeo de Desarrollo Regional
(FEDER), una manera de hacer Europa" [PIE13/00022-ONCOPROFILE];
Telemaraton "Todos Somos Raros, Todos Somos Unicos" [P35]
FX This study was supported by Generalitat de Catalunya AGAUR SGR 2014
grant 364, Spanish Ministry of Health ISCIII grants PI12/01528,
PI15/00854, RTICC RD12/0036/0007 and 0008, and PIE13/00022-ONCOPROFILE,
Spanish Ministry of Science and Innovation "Fondo Europeo de Desarrollo
Regional (FEDER), una manera de hacer Europa", and the Telemaraton 2014
"Todos Somos Raros, Todos Somos Unicos" grant P35.
NR 59
TC 1
Z9 1
U1 7
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD AUG 24
PY 2016
VL 8
AR 88
DI 10.1186/s13073-016-0340-x
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA DU8HR
UT WOS:000382454400002
PM 27553366
ER
PT J
AU Francis, WR
Christianson, LM
Powers, ML
Schnitzler, CE
Haddock, SHD
AF Francis, Warren R.
Christianson, Lynne M.
Powers, Meghan L.
Schnitzler, Christine E.
Haddock, Steven H. D.
TI Non-excitable fluorescent protein orthologs found in ctenophores
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article
DE Fluorescent protein; Ctenophore; Siphonophore; Transcriptome;
Fluorescence; Haeckelia
ID GFP-LIKE PROTEINS; GENOMIC ORGANIZATION; EVOLUTION; AEQUOREA; CORAL;
SEA; BIOLUMINESCENCE; EXPRESSION; VERSION; FAMILY
AB Background: Fluorescent proteins are optically active proteins found across many clades in metazoans. A fluorescent protein was recently identified in a ctenophore, but this has been suggested to derive from a cnidarian, raising again the question of origins of this group of proteins.
Results: Through analysis of transcriptome data from 30 ctenophores, we identified a member of an orthologous group of proteins similar to fluorescent proteins in each of them, as well as in the genome of Mnemiopsis leidyi. These orthologs lack canonical residues involved in chromophore formation, suggesting another function.
Conclusions: The phylogenetic position of the ctenophore protein family among fluorescent proteins suggests that this gene was present in the common ancestor of all ctenophores and that the fluorescent protein previously found in a ctenophore actually derives from a siphonophore.
C1 [Francis, Warren R.; Christianson, Lynne M.; Powers, Meghan L.; Haddock, Steven H. D.] Monterey Bay Aquarium Res Inst, 7700 Sandholdt Rd, Moss Landing, CA 95039 USA.
[Schnitzler, Christine E.] NHGRI, NIH, 50 South Dr, Bethesda, MD 20892 USA.
[Francis, Warren R.] Univ Munich, Munich, Germany.
[Schnitzler, Christine E.] Univ Florida, Whitney Lab Marine Biosci, St Augustine, FL 32080 USA.
RP Haddock, SHD (reprint author), Monterey Bay Aquarium Res Inst, 7700 Sandholdt Rd, Moss Landing, CA 95039 USA.
EM haddock@mbari.org
FU David and Lucile Packard Foundation; National Institute of General
Medical Sciences at the National Institutes of Health
[NIGMS:5-R01-GM087198]; Intramural Research Program of the National
Human Genome Research Institute, National Institutes of Health
FX This work was supported by the David and Lucile Packard Foundation and
funded by the National Institute of General Medical Sciences at the
National Institutes of Health (NIGMS:5-R01-GM087198) to SHDH. This work
was also supported in part by the Intramural Research Program of the
National Human Genome Research Institute, National Institutes of Health
to CES.
NR 49
TC 0
Z9 0
U1 14
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2148
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD AUG 24
PY 2016
VL 16
AR 167
DI 10.1186/s12862-016-0738-5
PG 8
WC Evolutionary Biology; Genetics & Heredity
SC Evolutionary Biology; Genetics & Heredity
GA DT9JG
UT WOS:000381814600002
PM 27557948
ER
PT J
AU Liu, JF
Huang, SG
Su, XZ
Song, JP
Lu, FL
AF Liu, Jinfeng
Huang, Shiguang
Su, Xin-zhuan
Song, Jianping
Lu, Fangli
TI Blockage of Galectin-receptor Interactions by alpha-lactose Exacerbates
Plasmodium berghei-induced Pulmonary Immunopathology
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROTEIN DISULFIDE-ISOMERASE; ENTERICA SEROVAR TYPHIMURIUM; REGULATORY
T-CELLS; ACUTE LUNG INJURY; MALARIA INFECTIONS; CEREBRAL MALARIA;
MACROPHAGES; INFLAMMATION; TIM-3; INTERFERONS
AB Malaria-associated acute lung injury (ALI) is a frequent complication of severe malaria that is often caused by "excessive" immune responses. To better understand the mechanism of ALI in malaria infection, here we investigated the roles of galectin (Gal)-1, 3, 8, 9 and the receptors of Gal-9 (Tim-3, CD44, CD137, and PDI) in malaria-induced ALI. We injected alpha (alpha)-lactose into mice-infected with Plasmodium berghei ANKA (PbANKA) to block galectins and found significantly elevated total proteins in bronchoalveolar lavage fluid, higher parasitemia and tissue parasite burden, and increased numbers of CD68(+) alveolar macrophages as well as apoptotic cells in the lungs after blockage. Additionally, mRNA levels of Gal-9, Tim-3, CD44, CD137, and PDI were significantly increased in the lungs at day 5 after infection, and the levels of CD137, IFN-alpha, IFN-beta, IFN-gamma, IL-4, and IL-10 in the lungs were also increased after alpha-lactose treatment. Similarly, the levels of Gal-9, Tim-3, IFN-alpha, IFN-beta, IFN-gamma, and IL-10 were all significantly increased in murine peritoneal macrophages co-cultured with PbANKA-infected red blood cells in vitro; but only IFN-alpha and IFN-beta were significantly increased after alpha-lactose treatment. Our data indicate that Gal-9 interaction with its multiple receptors play an important role in murine malaria-associated ALI.
C1 [Liu, Jinfeng; Lu, Fangli] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Parasitol, Guangzhou 510080, Guangdong, Peoples R China.
[Liu, Jinfeng; Lu, Fangli] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China.
[Huang, Shiguang] Jinan Univ, Sch Med, Guangzhou 510632, Guangdong, Peoples R China.
[Su, Xin-zhuan] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
[Su, Xin-zhuan] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.
[Song, Jianping] Guangzhou Univ Chinese Med, Inst Sci & Technol, 436 Chentai Rd, Guangzhou 510445, Guangdong, Peoples R China.
RP Lu, FL (reprint author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Parasitol, Guangzhou 510080, Guangdong, Peoples R China.; Lu, FL (reprint author), Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China.; Su, XZ (reprint author), NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.; Su, XZ (reprint author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.
EM xsu@niaid.nih.gov; fanglilu@yahoo.com
FU Natural Science Foundation of China [81271854, 81471973, 81273643];
Science and Technology Planning Project of Guangdong Province, China
[2014A020212108, 2013B021800043, 2014A020212212, 2014B050502013];
Project 111 of the State Bureau of Foreign Experts and Ministry of
Education of China [B06016]; Division of Intramural Research at the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health; Natural Science Foundation of Guangdong Province,
China [S2013010016736]
FX Research reported in this publication was supported in part by the
Natural Science Foundation of China (Nos 81271854 and 81471973), the
Science and Technology Planning Project of Guangdong Province, China
(No. 2014A020212108), and the Project 111 of the State Bureau of Foreign
Experts and Ministry of Education of China (B06016) (F. Lu); by the
Division of Intramural Research at the National Institute of Allergy and
Infectious Diseases, National Institutes of Health (X.-z. Su); by the
Science and Technology Planning Project of Guangdong Province, China
(Nos 2013B021800043 and 2014A020212212) (S. Huang); by the Natural
Science Foundation of China (No. 81273643); the Natural Science
Foundation of Guangdong Province, China (No. S2013010016736), and the
Science and Technology Planning Project of Guangdong Province, China
(No. 2014B050502013) (J. Song). The authors thank Cindy Clark, NIH
Library Writing Center, for manuscript editing assistance.
NR 59
TC 0
Z9 0
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 24
PY 2016
VL 6
AR 32024
DI 10.1038/srep32024
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT9WM
UT WOS:000381853000002
PM 27554340
ER
PT J
AU Hsu, DC
Ma, YF
Hur, S
Li, D
Rupert, A
Scherzer, R
Kalapus, SC
Deeks, S
Sereti, I
Hsue, PY
AF Hsu, Denise C.
Ma, Yi Fei
Hur, Sophia
Li, Danny
Rupert, Adam
Scherzer, Rebecca
Kalapus, S. C.
Deeks, Steven
Sereti, Irini
Hsue, Priscilla Y.
TI Plasma IL-6 levels are independently associated with atherosclerosis and
mortality in HIV-infected individuals on suppressive antiretroviral
therapy
SO AIDS
LA English
DT Article
DE atherosclerosis; CCR5; HIV; IL-6; immune activation
ID INTIMA-MEDIA THICKNESS; CORONARY-HEART-DISEASE; T-CELL-ACTIVATION;
SUBCLINICAL VASCULAR-DISEASE; CARDIOVASCULAR RISK-FACTORS; CAROTID
ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS;
INFLAMMATORY MARKERS; MONOCYTE-ACTIVATION
AB Objective: To determine the associations of markers of immune activation with atherosclerosis and mortality, in participants with treated and suppressed HIV infection.
Design: Observational study of 149 HIV-infected participants with virologic suppression on antiretroviral therapy.
Methods: Cryopreserved mononuclear cells and plasma were used to evaluate markers of T cell and monocyte activation, inflammation and coagulopathy. Carotid artery intima-media thickness (CIMT) was measured by high-resolution ultrasound at the common, bifurcation and internal carotid regions. Associations of immunologic markers with CIMT and all-cause mortality were assessed using multivariable linear regression and Cox proportional hazards regression.
Results: The majority of participants were men (93%) and white (67%), median age of 48.5 years and median CD4(+) T-cell count of 522 cells/mu l. The median baseline IMT was 1.0 mm. Over a median of 8.3-year follow-up, 12 deaths occurred. In multivariate analysis, adjusted for traditional cardiovascular risk factors, higher monocyte C-C motif chemokine receptor 5 (CCR5) expression [5.4%, P = 0.001] was associated with greater common CIMT. Higher plasma IL-6 was associated with greater bifurcation [8.0%, P = 0.007] and overall mean IMT [5.2%, P = 0.026]. Finally, higher plasma IL-6 [hazard ratio 1.9, P = 0.030], internal carotid [hazard ratio 4.1, P = 0.022] and mean IMT [hazard ratio 5.2, P = 0.026] were individually associated with all-cause mortality.
Conclusion: Higher monocyte CCR5 expression and plasma IL-6 were associated with atherosclerosis, independent of traditional cardiovascular risk factors. IL-6 and CIMT were individually associated with all-cause mortality. The impact of therapies targeting immune activation in cardiovascular disease in treated HIV infection merits additional investigation. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Hsu, Denise C.; Sereti, Irini] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Ma, Yi Fei; Hur, Sophia; Li, Danny; Kalapus, S. C.; Deeks, Steven; Hsue, Priscilla Y.] Univ Calif San Francisco, Room 5G1 Cardiol SFGH,1001 Potrero Ave, San Francisco, CA 94110 USA.
[Rupert, Adam] Leidos Biomed Res Inc, Frederick, MD USA.
[Scherzer, Rebecca] Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
RP Hsue, PY (reprint author), Univ Calif San Francisco, Room 5G1 Cardiol SFGH,1001 Potrero Ave, San Francisco, CA 94110 USA.
EM Priscilla.Hsue@ucsf.edu
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; National Institute of Allergy and Infectious
Diseases [K24AI112393]; NIAID/NIH; NIAID [K24AI069994]; UCSF/Gladstone
Institute of Virology & Immunology CFAR [P30 AI027763]; UCSF Clinical
and Translational Research Institute Clinical Research Center [UL1
RR024131]; CFAR Network of Integrated Systems [R24 AI067039]
FX The project has been funded in part with Federal funds from the National
Cancer Institute, National Institutes of Health, under contract no.
HHSN261200800001E (A.R.) and by the National Institute of Allergy and
Infectious Diseases K24AI112393 (P.Y.H.). This project has also been
funded in part by the intramural program of NIAID/NIH. The SCOPE cohort
was supported in part by the NIAID (K24AI069994), the UCSF/Gladstone
Institute of Virology & Immunology CFAR (P30 AI027763), the UCSF
Clinical and Translational Research Institute Clinical Research Center
(UL1 RR024131) and the CFAR Network of Integrated Systems (R24
AI067039). The content of this publication does not necessarily reflect
the views or policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products or organizations
imply endorsement by the U.S. Government.
NR 76
TC 2
Z9 2
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD AUG 24
PY 2016
VL 30
IS 13
BP 2065
EP 2074
DI 10.1097/QAD.0000000000001149
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DS5HN
UT WOS:000380812400007
PM 27177313
ER
PT J
AU Chan, ES
Landay, AL
Brown, TT
Ribaudo, HJ
Mirmonsef, P
Ofotokun, I
Weitzmann, MN
Martinson, J
Klingman, KL
Eron, JJ
Fichtenbaum, CJ
Plants, J
Taiwo, BO
AF Chan, Ellen S.
Landay, Alan L.
Brown, Todd T.
Ribaudo, Heather J.
Mirmonsef, Paria
Ofotokun, Igho
Weitzmann, M. Neale
Martinson, Jeffrey
Klingman, Karin L.
Eron, Joseph J.
Fichtenbaum, Carl J.
Plants, Jill
Taiwo, Babafemi O.
TI Differential CD4(+) cell count increase and CD4(+): CD8(+) ratio
normalization with maraviroc compared with tenofovir
SO AIDS
LA English
DT Article
DE CD4 lymphocyte count; CD4: CD8 ratio; HIV; inflammation; maraviroc;
tenofovir
ID ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; CLINICAL-TRIALS; HIV;
INFLAMMATION; SUPPRESSION; INDIVIDUALS; RECOVERY; MARKERS; EVENTS
AB Objective: Studies exploring the immunologic effects of maraviroc (MVC) have produced mixed results; hence, it remains unclear whether MVC has unique immunologic effects in comparison with other antiretroviral drugs. We sought to determine whether MVC has differential effects compared with tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy.
Design: Prospective study in AIDS Clinical Trials Group A5303, a double-blind, placebo-controlled trial (N = 262) of MVC vs. TDF, each combined with boosted darunavir and emtricitabine.
Methods: A total of 31 cellular and soluble biomarkers were assayed at weeks 0 and 48. Polychromatic flow cytometry was performed on cryopreserved peripheral blood mononuclear cells. Soluble markers were assayed in plasma using ELISA kits. Analyses were as treated.
Results: Analyses included 230 participants (119 in MVC arm and 111 in TDF arm). Over 48 weeks of treatment, no significant differences were detected in declines in markers of inflammation and activation with MVC vs. TDF. A greater CD4(+) T-cell count increase (median +234 vs. +188 cells/mu l, P = 0.036), a smaller CD8(+) T-cell count decrease (-6 vs. -109 cells/mu l, P = 0.008), and a smaller CD4(+) : CD8(+) ratio increase (0.26 vs. 0.39, P = 0.003) occurred with MVC. Among participants with a baseline CD4(+) : CD8(+) ratio less than 1, a smaller proportion of MVC group normalized to a ratio greater than 1 at week 48 (15 and 36%, P < 0.001).
Conclusion: MVC resulted in less improvement in the CD4(+) : CD8(+) ratio driven by greater increase in CD4(+) cell count but smaller decline in CD8(+) cell count. Changes in soluble or cellular biomarkers of inflammation and immune activation were not different between MVC and TDF. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Chan, Ellen S.; Ribaudo, Heather J.] Harvard Chan Sch Publ Hlth, Stat & Data Anal Ctr, 651 Huntington Ave,FXB 539, Boston, MA 02115 USA.
[Landay, Alan L.; Mirmonsef, Paria; Martinson, Jeffrey; Plants, Jill] Rush Univ, Med Ctr, Dept Immunol & Microbiol, Chicago, IL 60612 USA.
[Brown, Todd T.] Johns Hopkins Univ, Div Endocrinol Diabet & Metab, Baltimore, MD USA.
[Ofotokun, Igho] Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA.
[Weitzmann, M. Neale] Emory Univ, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
[Weitzmann, M. Neale] Atlanta VA Med Ctr, Decatur, GA USA.
[Klingman, Karin L.] NIAID, HIV Res Branch, Div Aids, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Eron, Joseph J.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA.
[Fichtenbaum, Carl J.] Univ Cincinnati, Div Infect Dis, Cincinnati, OH USA.
[Taiwo, Babafemi O.] Northwestern Univ, Div Infect Dis, Chicago, IL 60611 USA.
RP Chan, ES (reprint author), Harvard Chan Sch Publ Hlth, Stat & Data Anal Ctr, 651 Huntington Ave,FXB 539, Boston, MA 02115 USA.
EM echan@sdac.harvard.edu; echan@sdac.harvard.edu; echan@sdac.harvard.edu
FU National Institute of Allergy and Infectious Diseases [U01AI068636];
National Institute of Mental Health (NIMH), National Institute of Dental
and Craniofacial Research (NIDCR); NIH [AI068634, AI068636, AI69439, UM1
AI069496, 5UM1AI069412, UM1 AI069423, 1UL1TR001111, P30 AI50410,
2UMIA1069423-08, 2UM1AI069418-08, 2P30 AI 50409-10, UL1TR000454]; NIH
(National Center for Advancing Translational Sciences/NIH) [UMAI069494,
UMAI069432, UM1AI 069471, UM1AI069452, UM1 AI069501, 2UM1AI069432, UL1
TR001082, 1U01AI069477-01, P30AI073961, 5UM1 AI068636, 2UM1AI069503, UM1
AI069471, 2UM1AI06943908, UL1 TR000445]; National Institute of Health
[AI069501, 5UM1AI069415-10, 2UM1AI069412-08, AI069424, UL1 RR025780,
2UM1-AI069470-08, UM1AI069472, 2UMAI069432, AI 69501, UM1AI069471, UM1A
068636-09, 5 P30 AI-045008-15, U01AI069447, NO1-HD-3-3345, UMI AI069511,
UM1 AI069465, UL1TR001079, UL1 RR024160, UL1 TR000042]
FX This work was supported by (Award Number U01AI068636) from the National
Institute of Allergy and Infectious Diseases and supported by National
Institute of Mental Health (NIMH), National Institute of Dental and
Craniofacial Research (NIDCR). The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institute of Allergy and Infectious Diseases or the
National Institutes of Health. This work was also supported by grants
from the NIH [(grant numbers AI068634 and AI068636) to the ACTG
Statistical Data Analysis Center (to E.S.C. and H.J.R.), (grant number
AI068636) to the Rush University Medical Center (to A.L.L., P.M,J.M, and
J.P.), and to the research sites that participated in the study (grant
numbers UMAI069494, UMAI069432, UM1AI 069471, UM1AI069452, UM1 AI069501,
2UM1AI069432, UL1 TR001082, 1U01AI069477-01, P30AI073961, 5UM1 AI068636,
2UM1AI069503, UM1 AI069471, 2UM1AI06943908, and UL1 TR000445 from the
National Center for Advancing Translational Sciences/NIH, AI69439, UM1
AI069496, 5UM1AI069412, UM1 AI069423, 1UL1TR001111, P30 AI50410,
2UMIA1069423-08, 2UM1AI069418-08, 2P30 AI 50409-10, UL1TR000454,
AI069501, 5UM1AI069415-10, 2UM1AI069412-08, AI069424, UL1 RR025780,
2UM1-AI069470-08, UM1AI069472, 2UMAI069432, AI 69501, UM1AI069471, UM1A
068636-09, 5 P30 AI-045008-15, U01AI069447, NO1-HD-3-3345, UMI AI069511,
UM1 AI069465, UL1TR001079, UL1 RR024160, and UL1 TR000042)]. ViiV,
Gilead, and AbbVie provided study drugs. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 14
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD AUG 24
PY 2016
VL 30
IS 13
BP 2091
EP 2097
DI 10.1097/QAD.0000000000001181
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DS5HN
UT WOS:000380812400010
PM 27281061
ER
PT J
AU Khatami, M
AF Khatami, Mahin
TI Is cancer a severe delayed hypersensitivity reaction and histamine a
blueprint?
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE Aging; Allergy; Angiogenesis; Branched amino acids; Bioenergetics;
Cancer; Fetal growth; Histamine; Hypersensitivity; Immune-privileged and
immune-responsive tissues; Mitochondria; Placenta; Taurine; Yin and Yang
of inflammation
ID SMALL-CELL-CARCINOMA; AGE-RELATED-CHANGES; NECROSIS-FACTOR-ALPHA; L-DOPA
DECARBOXYLASE; MAST-CELLS; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS;
AORTIC STIFFNESS; BLOOD-PRESSURE; IMMUNE-SYSTEM
AB Longevity and accumulation of multiple context-dependent signaling pathways of long-standing inflammation (antigen-load or oxidative stress) are the results of decreased/altered regulation of immunity and loss of control switch mechanisms that we defined as Yin and Yang of acute inflammation or immune surveillance. Chronic inflammation is initiated by immune disruptors-induced progressive changes in physiology and function of susceptible host tissues that lead to increased immune suppression and multistep disease processes including carcinogenesis. The interrelated multiple hypotheses that are presented for the first time in this article are extension of author's earlier series of 'accidental' discoveries on the role of inflammation in developmental stages of immune dysfunction toward tumorigenesis and angiogenesis. Detailed analyses of data on chronic diseases suggest that nearly all age-associated illnesses, generally categorized as 'mild' (e.g., increased allergies), 'moderate' (e.g., hypertension, colitis, gastritis, pancreatitis, emphysema) or 'severe' (e.g., accelerated neurodegenerative and autoimmune diseases or site-specific cancers and metastasis) are variations of hypersensitivity responses of tissues that are manifested as different diseases in immune-responsive or immune-privileged tissues. Continuous release/presence of low level histamine (subclinical) in circulation could contribute to sustained oxidative stress and induction of 'mild' or 'moderate' or 'severe' (immune tsunami) immune disorders in susceptible tissues. Site-specific cancers are proposed to be 'severe' (irreversible) forms of cumulative delayed hypersensitivity responses that would induce immunological chaos in favor of tissue growth in target tissues. Shared or special features of growth from fetus development into adulthood and aging processes and carcinogenesis are briefly compared with regard to energy requirements of highly complex function of Yin and Yang. Features of Yang (growth-promoting) arm of acute inflammation during fetus and cancer growth will be compared for consuming low energy from glycolysis (Warburg effect). Growth of fetus and cancer cells under hypoxic conditions and impaired mitochondrial energy requirements of tissues including metabolism of essential branched amino acids (e.g., val, leu, isoleu) will be compared for proposing a working model for future systematic research on cancer biology, prevention and therapy. Presentation of a working model provides insightful clues into bioenergetics that are required for fetus growth (absence of external threat and lack of high energy-demands of Yin events and parasite-like survival in host), normal growth in adulthood (balance in Yin and Yang processes) or disease processes and carcinogenesis (loss of balance in Yin-Yang). Future studies require focusing on dynamics and promotion of natural/inherent balance between Yin (tumoricidal) and Yang (tumorigenic) of effective immunity that develop after birth. Lawless growth of cancerous cells and loss of cell contact inhibition could partially be due to impaired mitochondria (mitophagy) that influence metabolism of branched chain amino acids for biosynthesis of structural proteins. The author invites interested scientists with diverse expertise to provide comments, confirm, dispute and question and/or expand and collaborate on many components of the proposed working model with the goal to better understand cancer biology for future designs of cost-effective research and clinical trials and prevention of cancer.
Initial events during oxidative stress-induced damages to DNA/RNA repair mechanisms and inappropriate expression of inflammatory mediators are potentially correctable, preventable or druggable, if future studies were to focus on systematic understanding of early altered immune response dynamics toward multistep chronic diseases and carcinogenesis.
C1 [Khatami, Mahin] NCI, NIH, Bethesda, MD 20892 USA.
RP Khatami, M (reprint author), NCI, NIH, Bethesda, MD 20892 USA.
EM mkgoodness@aol.com
FU National Eye Institute-NEI
FX The experimental studies on models of acute and chronic ocular
inflammatory diseases were established at the University of
Pennsylvania, School of Medicine, Department of Ophthalmology, Scheie
Eye Institute, laboratory of John H. Rockey, MD, Ph.D. with a supportive
team of scientists, funded by National Eye Institute-NEI. Analyses of
original data and recent hypotheses on the extension of our 'accidental'
discoveries were developed at the National Cancer Institute (NCI), the
National Institutes of Health (NIH) since 1998, despite heavy opposition
and denial of NCI decision makers to support the studies. Opinions
presented in this article are the author's views and not those of the
cancer establishment at NCI/NIH.
NR 224
TC 1
Z9 1
U1 8
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD AUG 23
PY 2016
VL 5
AR 35
DI 10.1186/s40169-016-0108-3
PG 23
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EH7KH
UT WOS:000391951200001
PM 27558401
ER
PT J
AU Venugopalan, A
Lee, MJ
Niu, G
Medina-Echeverz, J
Tomita, Y
Lizak, MJ
Cultraro, CM
Simpson, RM
Chen, XY
Trepel, JB
Guha, U
AF Venugopalan, Abhilash
Lee, Min-Jung
Niu, Gang
Medina-Echeverz, Jose
Tomita, Yusuke
Lizak, Martin J.
Cultraro, Constance M.
Simpson, Robert Mark
Chen, Xiaoyuan
Trepel, Jane B.
Guha, Udayan
TI EGFR-targeted therapy results in dramatic early lung tumor regression
accompanied by imaging response and immune infiltration in EGFR mutant
transgenic mouse models
SO ONCOTARGET
LA English
DT Article
DE lung cancer; EGFR; TKI; imaging; immune-infiltration
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; RANDOMIZED-TRIAL;
PHASE-III; CANCER; GEFITINIB; MUTATIONS; ADENOCARCINOMAS; CHEMOTHERAPY;
ERLOTINIB
AB Lung adenocarcinoma patients harboring kinase domain mutations in Epidermal growth factor receptor (EGFR) have significant clinical benefit from EGFR-targeted tyrosine kinase inhibitors (TKIs). Although a majority of patients experience clinical symptomatic benefit immediately, an objective response can only be demonstrated after 6-8 weeks of treatment. Evaluation of patient response by imaging shows that 30-40% of patients do not respond due to intrinsic resistance to these TKIs. We investigated immediate-early effects of EGFR-TKI treatment in mutant EGFR-driven transgenic mouse models by FDG-PET and MRI and correlated the effects on the tumor and the tumor microenvironment. Within 24 hours of erlotinib treatment we saw approximately 65% tumor regression in mice with TKI-sensitive EGFR(L858R) lung adenocarcinoma. However, mice with EGFR(L858R/T790M)-driven tumors did not respond to either erlotinib or afatinib monotherapy, but did show a significant tumor response to afatinib-cetuximab combination treatment. The imaging responses correlated with the inhibition of downstream EGFR signaling, increased apoptosis, and decreased proliferation in the tumor tissues. In EGFR(L858R)-driven tumors, we saw a significant increase in CD45(+) leukocytes, NK cells, dendritic cells, macrophages and lymphocytes, particularly CD8(+) T cells. In response to erlotinib, these dendritic cells and macrophages had significantly higher MHC class II expression, indicating increased antigen-presenting capabilities. Together, results of our study provide novel insight into the immediate-early therapeutic response to EGFR TKIs in vivo.
C1 [Venugopalan, Abhilash; Medina-Echeverz, Jose; Cultraro, Constance M.; Guha, Udayan] NCI, Thorac & Gastrointestinal Oncol Branch, Bethesda, MD 20892 USA.
[Lee, Min-Jung; Tomita, Yusuke; Trepel, Jane B.] NCI, Dev Therapeut Branch, Bethesda, MD 20892 USA.
[Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, Bethesda, MD USA.
[Lizak, Martin J.] NINDS, Mouse Imaging Facil, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Simpson, Robert Mark] NCI, Lab Canc Biol & Genet, Bethesda, MD 20892 USA.
RP Guha, U (reprint author), NCI, Thorac & Gastrointestinal Oncol Branch, Bethesda, MD 20892 USA.
EM udayan.guha@nih.gov
FU Intramural Research Program of the NIH / NCI / Center for Cancer
Research (CCR); Lung Cancer Research Foundation (LCRF)
FX This research was supported by the Intramural Research Program of the
NIH / NCI / Center for Cancer Research (CCR) and a Lung Cancer Research
Foundation (LCRF) grant (U. Guha).
NR 51
TC 2
Z9 2
U1 3
U2 3
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 23
PY 2016
VL 7
IS 34
BP 54137
EP 54156
DI 10.18632/oncotarget.11021
PG 20
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY9DY
UT WOS:000385435000005
PM 27494838
ER
PT J
AU Inaguma, S
Wang, ZF
Lasota, JP
Miettinen, MM
AF Inaguma, Shingo
Wang, Zengfeng
Lasota, Jerzy P.
Miettinen, Markku M.
TI Expression of neural cell adhesion molecule L1 (CD171) in
neuroectodermal and other tumors. An immunohistochemical study of 5155
tumors and critical evaluation of CD171 prognostic value in
gastrointestinal stromal tumors
SO ONCOTARGET
LA English
DT Article
DE CD171 (NCAM-L1, L1CAM); immunohistochemistry; neuroectodermal tumor;
gastrointestinal stromal tumor; mismatch repair deficiency
ID IMMUNOGLOBULIN SUPERFAMILY; ENDOMETRIAL CARCINOMAS; RECOGNITION
MOLECULES; MEDIATED RELEASE; AXON GUIDANCE; L1CAM; CANCER; L1-CAM;
NEUROBLASTOMA; RECEPTOR
AB The neural cell adhesion molecule L1 (CD171) is a multidomain type 1 membrane glycoprotein of the immunoglobulin superfamily important in the nervous system development, kidney morphogenesis, and maintenance of the immune system. Recent studies reported CD171 expression being associated with adverse clinical outcome in different types of cancer and there has been a growing interest in targeting this cell membrane molecule on neoplastic cells by chimeric antigen receptor redirected T lymphocytes or specific antibodies. Nevertheless, conflicting results regarding the prognostic value of CD171 expression in renal cell carcinomas and gastrointestinal stromal tumors were published. In this study, CD171 expression was immunohistochemically analyzed in 5155 epithelial, mesenchymal, melanocytic, and lymphohematopoietic tumors to assess its utility in diagnostic pathology and to pinpoint potential targets for CD171-targeting therapy. A newly developed anti-CD171 rabbit monoclonal antibody, clone 014, was selected from the panel of commercially available CD171 antibodies. Immunohistochemistry was performed using Leica Bond Max automation and multitumor blocks containing up to 60 tumor samples. CD171 was constitutively and strongly expressed in neuroectodermal tumors such as schwannoma, neuroblastoma, and paraganglioma, whereas other mesenchymal tumors including schwannoma mimics showed only rarely CD171 positivity. Frequent CD171-expression was also detected in ovarian serous carcinoma, malignant mesothelioma, and testicular embryonal carcinoma. CD171 immunohistochemistry may have some role in immunophenotypic differential diagnosis of neurogenic tumors and pinpointing potential candidates for anti-CD171 therapy. Though, because of its rare expression and lack of predictive value, CD171 is neither a diagnostic nor prognostic marker for gastrointestinal stromal tumors.
C1 [Inaguma, Shingo; Wang, Zengfeng; Lasota, Jerzy P.; Miettinen, Markku M.] NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA.
[Inaguma, Shingo] Aichi Med Univ, Dept Pathol, Sch Med, Nagakute, Aichi, Japan.
RP Inaguma, S (reprint author), NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA.; Inaguma, S (reprint author), Aichi Med Univ, Dept Pathol, Sch Med, Nagakute, Aichi, Japan.
EM inaguma@aichi-med-u.ac.jp
FU National Cancer Institute's intramural research program
FX This study was supported as a part of National Cancer Institute's
intramural research program. The authors have disclosed that they have
no relationships with, or financial interest in, any commercial
companies pertaining to this article.
NR 41
TC 0
Z9 0
U1 2
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 23
PY 2016
VL 7
IS 34
BP 55276
EP 55289
DI 10.18632/oncotarget.10527
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY9DY
UT WOS:000385435000093
PM 27419370
ER
PT J
AU Fenerty, KE
Folio, LR
Patronas, NJ
Marte, JL
Gulley, JL
Heery, CR
AF Fenerty, Kathleen E.
Folio, Les R.
Patronas, Nicholas J.
Marte, Jennifer L.
Gulley, James L.
Heery, Christopher R.
TI Predicting clinical outcomes in chordoma patients receiving
immunotherapy: a comparison between volumetric segmentation and RECIST
SO BMC CANCER
LA English
DT Article
DE Chordoma; Volumetric; RECIST; Radiologic; Response criteria
ID RADIATION-THERAPY; RESPONSE CRITERIA; TUMOR RESPONSE; SOLID TUMORS; CT;
LESIONS; FRONTS
AB Background: The Response Evaluation Criteria in Solid Tumors (RECIST) are the current standard for evaluating disease progression or therapy response in patients with solid tumors. RECIST 1.1 calls for axial, longest-diameter (or perpendicular short axis of lymph nodes) measurements of a maximum of five tumors, which limits clinicians' ability to adequately measure disease burden, especially in patients with irregularly shaped tumors. This is especially problematic in chordoma, a disease for which RECIST does not always adequately capture disease burden because chordoma tumors are typically irregularly shaped and slow-growing. Furthermore, primary chordoma tumors tend to be adjacent to vital structures in the skull or sacrum that, when compressed, lead to significant clinical consequences.
Methods: Volumetric segmentation is a newer technology that allows tumor burden to be measured in three dimensions on either MR or CT. Here, we compared the ability of RECIST measurements and tumor volumes to predict clinical outcomes in a cohort of 21 chordoma patients receiving immunotherapy.
Results: There was a significant difference in radiologic time to progression Kaplan-Meier curves between clinical outcome groups using volumetric segmentation (P = 0.012) but not RECIST (P = 0.38). In several cases, changes in volume were earlier and more sensitive reflections of clinical status.
Conclusion: RECIST is a useful evaluation method when obvious changes are occurring in patients with chordoma. However, in many cases, RECIST does not detect small changes, and volumetric assessment was capable of detecting changes and predicting clinical outcome earlier than RECIST. Although this study was small and retrospective, we believe our results warrant further research in this area.
C1 [Fenerty, Kathleen E.; Heery, Christopher R.] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, 10 Ctr Dr,Room 13N208, Bethesda, MD 20892 USA.
[Folio, Les R.; Patronas, Nicholas J.] NCI, Canc Imaging Program, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
[Marte, Jennifer L.; Gulley, James L.] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA.
RP Heery, CR (reprint author), NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, 10 Ctr Dr,Room 13N208, Bethesda, MD 20892 USA.
EM heerycr@mail.nih.gov
FU Intramural Research Program of the Center for Cancer Research, National
Cancer Institute, National Institutes of Health
FX This research was supported by the Intramural Research Program of the
Center for Cancer Research, National Cancer Institute, National
Institutes of Health.
NR 18
TC 1
Z9 1
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 23
PY 2016
VL 16
AR 672
DI 10.1186/s12885-016-2699-x
PG 9
WC Oncology
SC Oncology
GA DX2JL
UT WOS:000384194700001
PM 27553491
ER
PT J
AU Felix, AS
Lenz, P
Pfeiffer, RM
Hewitt, SM
Morris, J
Patel, DA
Geller, B
Vacek, PM
Weaver, DL
Chicoine, RE
Shepherd, J
Mahmoudzadeh, AP
Wang, J
Fan, B
Malkov, S
Herschorn, SD
Johnson, JM
Cora, RL
Brinton, LA
Sherman, ME
Gierach, GL
AF Felix, Ashley S.
Lenz, Petra
Pfeiffer, Ruth M.
Hewitt, Stephen M.
Morris, Jennifer
Patel, Deesha A.
Geller, Berta
Vacek, Pamela M.
Weaver, Donald L.
Chicoine, Rachael E.
Shepherd, John
Mahmoudzadeh, Amir Pasha
Wang, Jeff
Fan, Bo
Malkov, Serghei
Herschorn, Sally D.
Johnson, Jason M.
Cora, Renata L.
Brinton, Louise A.
Sherman, Mark E.
Gierach, Gretchen L.
TI Relationships between mammographic density, tissue microvessel density,
and breast biopsy diagnosis
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Mammographic density; Breast neoplasms; Angiogenesis; Pathology;
Lesional density
ID BACKGROUND PARENCHYMAL ENHANCEMENT; CANCER RISK; FIBROGLANDULAR TISSUE;
LOBULAR INVOLUTION; ADIPOSE-TISSUE; IN-SITU; ANGIOGENESIS; MRI; DISEASE;
IMPACT
AB Background: Women with high levels of mammographic density (MD) have a four-to six-fold increased risk of developing breast cancer; however, most neither have a prevalent tumor nor will they develop one. Magnetic resonance imaging (MRI) studies suggest that background parenchymal enhancement, an indicator of vascularity, is related to increased breast cancer risk. Correlations of microvessel density (MVD) in tissue, MD and biopsy diagnosis have not been defined, and we investigated these relationships among 218 women referred for biopsy.
Methods: MVD was determined by counting CD31-positive vessels in whole sections of breast biopsies in three representative areas; average MVD was transformed to approximate normality. Using digital mammograms, we quantified MD volume with single X-ray absorptiometry. We used linear regression to evaluate associations between MVD and MD adjusted for age and body mass index (BMI) overall, and stratified by biopsy diagnosis: cases (in situ or invasive cancer, n = 44) versus non-cases (non-proliferative or proliferative benign breast disease, n = 174). Logistic regression adjusted for age, BMI, and MD was used to calculate odds ratios (ORs) and 95 % confidence intervals (CIs) for associations between MVD and biopsy diagnosis. We also assessed whether the MVD-breast cancer association varied by MD.
Results: MVD and MD were not consistently associated. Higher MVD was significantly associated with higher odds of in situ/invasive disease (ORAdjusted = 1.69, 95 % CI = 1.17-2.44). MVD-breast cancer associations were strongest among women with greater non-dense volume.
Conclusions: Increased MVD in tissues is associated with breast cancer, independently of MD, consistent with MRI findings suggestive of its possible value as a radiological cancer biomarker.
C1 [Felix, Ashley S.; Pfeiffer, Ruth M.; Patel, Deesha A.; Cora, Renata L.; Brinton, Louise A.; Gierach, Gretchen L.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Felix, Ashley S.] NCI, Canc Prevent Fellowship Program, Canc Prevent Div, NIH, Bethesda, MD 20892 USA.
[Felix, Ashley S.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, 1841 Neil Ave,300C Cunz Hall, Columbus, OH 43210 USA.
[Lenz, Petra] Leidos Biomed Res Inc, Clin Res Directorate, Clin Monitoring Res Program, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Hewitt, Stephen M.; Morris, Jennifer] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Geller, Berta] Univ Vermont, Dept Family Med, Burlington, VT USA.
[Vacek, Pamela M.; Weaver, Donald L.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA.
[Chicoine, Rachael E.] Univ Vermont, Off Hlth Promot Res, Burlington, VT USA.
[Shepherd, John; Mahmoudzadeh, Amir Pasha; Wang, Jeff; Fan, Bo; Malkov, Serghei] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wang, Jeff] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.
[Herschorn, Sally D.] Univ Vermont, Dept Radiol, Burlington, VT USA.
[Johnson, Jason M.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Neuroradiol Sect, Houston, TX 77030 USA.
[Sherman, Mark E.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA.
RP Felix, AS (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.; Felix, AS (reprint author), NCI, Canc Prevent Fellowship Program, Canc Prevent Div, NIH, Bethesda, MD 20892 USA.; Felix, AS (reprint author), Ohio State Univ, Coll Publ Hlth, Div Epidemiol, 1841 Neil Ave,300C Cunz Hall, Columbus, OH 43210 USA.
EM Felix.20@osu.edu
RI Gierach, Gretchen/E-1817-2016
OI Gierach, Gretchen/0000-0002-0165-5522
FU NCI NIH HHS [R01 CA166945]
NR 38
TC 0
Z9 0
U1 2
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD AUG 23
PY 2016
VL 18
AR 88
DI 10.1186/s13058-016-0746-9
PG 12
WC Oncology
SC Oncology
GA DW1VK
UT WOS:000383430900001
PM 27552842
ER
PT J
AU Cossio, P
Hummer, G
Szabo, A
AF Cossio, Pilar
Hummer, Gerhard
Szabo, Attila
TI Kinetic Ductility and Force-Spike Resistance of Proteins from
Single-Molecule Force Spectroscopy
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID DYNAMICS SIMULATIONS; UNFOLDING PATHWAYS; ENERGY LANDSCAPES; ADHESION
BONDS; TITIN; DOMAIN; DEFORMATION; MICROSCOPY; DIFFUSION; UBIQUITIN
AB Ductile materials can absorb spikes in mechanical force, whereas brittle ones fail catastrophically. Here we develop a theory to quantify the kinetic ductility of single molecules from force spectroscopy experiments, relating force-spike resistance to the differential responses of the intact protein and the unfolding transition state to an applied mechanical force. We introduce a class of unistable one-dimensional potential surfaces that encompass previous models as special cases and continuously cover the entire range from ductile to brittle. Compact analytic expressions for force-dependent rates and rupture-force distributions allow us to analyze force-clamp and force-ramp pulling experiments. We find that the force-transmitting protein domains of filamin and titin are kinetically ductile when pulled from their two termini, making them resistant to force spikes. For the mechanostable muscle protein titin, a highly ductile model reconciles data over 10 orders of magnitude in force loading rate from experiment and simulation.
C1 [Cossio, Pilar; Hummer, Gerhard] Max Planck Inst Biophys, Dept Theoret Biophys, Frankfurt, Germany.
[Szabo, Attila] Natl Inst Diabet & Digest & Kidney Dis, Lab Chem Phys, NIH, Bethesda, MD USA.
RP Hummer, G (reprint author), Max Planck Inst Biophys, Dept Theoret Biophys, Frankfurt, Germany.
EM gerhard.hummer@biophys.mpg.de
RI Hummer, Gerhard/A-2546-2013; Szabo, Attila/H-3867-2012
OI Hummer, Gerhard/0000-0001-7768-746X;
FU Max Planck Society; Intramural Research Program of the National
Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health
FX P.C. and G.H. were supported by the Max Planck Society; and A.S. was
supported by the Intramural Research Program of the National Institute
of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health.
NR 47
TC 0
Z9 0
U1 8
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD AUG 23
PY 2016
VL 111
IS 4
BP 832
EP 840
DI 10.1016/j.bpj.2016.05.054
PG 9
WC Biophysics
SC Biophysics
GA DU3GR
UT WOS:000382099300016
PM 27558726
ER
PT J
AU Manago, F
Mereu, M
Mastwal, S
Mastrogiacomo, R
Scheggia, D
Emanuele, M
De Luca, MA
Weinberger, DR
Wang, KH
Papaleo, F
AF Manago, Francesca
Mereu, Maddalena
Mastwal, Surjeet
Mastrogiacomo, Rosa
Scheggia, Diego
Emanuele, Marco
De Luca, Maria A.
Weinberger, Daniel R.
Wang, Kuan Hong
Papaleo, Francesco
TI Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine
and Neurobehavioral Phenotypes Related to Schizophrenia
SO CELL REPORTS
LA English
DT Article
ID VENTRAL TEGMENTAL AREA; AMPHETAMINE-INDUCED ACTIVITY; MEDIAL PREFRONTAL
CORTEX; IMMEDIATE-EARLY GENE; TEMPORAL-ORDER; PREPULSE INHIBITION;
SYNAPTIC PLASTICITY; RECOGNITION MEMORY; NUCLEUS-ACCUMBENS; PYRAMIDAL
NEURONS
AB Human genetic studies have recently suggested that the postsynaptic activity-regulated cytoskeleton-associated protein (Arc) complex is a convergence signal for several genes implicated in schizophrenia. However, the functional significance of Arc in schizophrenia-related neurobehavioral phenotypes and brain circuits is unclear. Here, we find that, consistent with schizophrenia-related phenotypes, disruption of Arc in mice produces deficits in sensorimotor gating, cognitive functions, social behaviors, and amphetamine-induced psychomotor responses. Furthermore, genetic disruption of Arc leads to concomitant hypoactive mesocortical and hyperactive mesostriatal dopamine pathways. Application of a D1 agonist to the prefrontal cortex or a D2 antagonist in the ventral striatumrescues Arc-dependent cognitive or psychomotor abnormalities, respectively. Our findings demonstrate a role for Arc in the regulation of dopaminergic neurotransmission and related behaviors. The results also provide initial biological support implicating Arc in dopaminergic and behavioral abnormalities related to schizophrenia.
C1 [Manago, Francesca; Mastrogiacomo, Rosa; Scheggia, Diego; Emanuele, Marco; Papaleo, Francesco] Ist Italiano Tecnol, Dept Neurosci & Brain Technol, Via Morego 30, I-16163 Genoa, Italy.
[Mereu, Maddalena] Univ Padua, Dipartimento Sci Farmaco, Largo Meneghetti 2, I-35131 Padua, Italy.
[Mastwal, Surjeet; Wang, Kuan Hong] NIMH, Unit Neural Circuits & Adapt Behav, Clin & Translat Neurosci Branch, Bethesda, MD 20892 USA.
[De Luca, Maria A.] Univ Cagliari, Dept Biomed Sci, I-09124 Cagliari, Italy.
[Weinberger, Daniel R.] Johns Hopkins Univ, Lieber Inst Brain Dev, Med Campus, Baltimore, MD 21205 USA.
[Weinberger, Daniel R.] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.
[Weinberger, Daniel R.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Weinberger, Daniel R.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
[Weinberger, Daniel R.] Johns Hopkins Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
RP Papaleo, F (reprint author), Ist Italiano Tecnol, Dept Neurosci & Brain Technol, Via Morego 30, I-16163 Genoa, Italy.; Wang, KH (reprint author), NIMH, Unit Neural Circuits & Adapt Behav, Clin & Translat Neurosci Branch, Bethesda, MD 20892 USA.
EM wkuan@mail.nih.gov; francesco.papaleo@iit.it
RI Wang, Kuan Hong/J-1150-2016;
OI Wang, Kuan Hong/0000-0002-2249-5417; Papaleo,
Francesco/0000-0002-6326-0657
FU Istituto Italiano di Tecnologia, Marie Curie grant [268247]; Italian
Ministry of Health [GR-2010-2315883]; NARSAD Independent Investigator
grant [23234]; Intramural Research Program of the National Institute of
Mental Health [ZIA MH002897]
FX We thank Dr. G. Tanda, Dr. R. Gainetdinov, Dr. M. Morini, D. Cantatore,
and C. Chiabrera for suggestions and technical assistance. We thank Dr.
S. Tonegawa for donating the Arc mutant breeders. This research was
supported by the Istituto Italiano di Tecnologia, Marie Curie grant
268247, Italian Ministry of Health grant GR-2010-2315883, and 2015
NARSAD Independent Investigator grant 23234 (to F.P.) and by the
Intramural Research Program of the National Institute of Mental Health
(ZIA MH002897 to D.R.W. and K.H.W.).
NR 72
TC 1
Z9 1
U1 6
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD AUG 23
PY 2016
VL 16
IS 8
BP 2116
EP 2128
DI 10.1016/j.celrep.2016.07.044
PG 13
WC Cell Biology
SC Cell Biology
GA DU6FQ
UT WOS:000382310100009
PM 27524619
ER
PT J
AU Casagrande, SS
Menke, A
Cowie, CC
AF Casagrande, Sarah S.
Menke, Andy
Cowie, Catherine C.
TI Cardiovascular Risk Factors of Adults Age 20-49 Years in the United
States, 1971-2012: A Series of Cross-Sectional Studies
SO PLOS ONE
LA English
DT Article
ID OBESITY; HEALTH; ASSOCIATION; BALTIMORE; EPIDEMIC; MARYLAND; TRENDS; BMI
AB Background
The health of younger adults in the U.S. has important public health and economic-related implications. However, previous literature is insufficient to fully understand how the health of this group has changed over time. This study examined generational differences in cardiovascular risk factors of younger adults over the past 40 years.
Methods
Data were from 6 nationally representative cross-sectional National Health and Nutrition Examination Surveys (1971-2012; N = 44,670). Participants were adults age 20-49 years who self-reported sociodemographic characteristics and health conditions, and had examination/laboratory measures for hypertension, hyperlipidemia, diabetes, obesity, and chronic kidney disease. Prevalences of sociodemographic characteristics and health status were determined by study period. Logistic regression was used to determine the odds [odds ratio (OR), 95% confidence interval] of health conditions by study period: models adjusted only for age, sex, and race, and fully adjusted models additionally adjusted for socioeconomic characteristics, smoking, BMI, diabetes, and/or hypertension (depending on the outcome) were assessed.
Results
Participants in 2009-2012 were significantly more likely to be obese and have diabetes compared to those in 1971-1975 (OR = 4.98, 3.57-6.97; OR = 3.49, 1.59-7.65, respectively, fully adjusted). Participants in 2009-2012 vs. 1988-1994 were significantly more likely to have had hypertension but uncontrolled hypertension was significantly less likely (OR = 0.67, 0.52-0.86, fully adjusted). There was no difference over time for high cholesterol, but uncontrolled high cholesterol was significantly less likely in 2009-2012 vs. 1988-1994 (OR = 0.80, 0.68-0.94, fully adjusted). The use of hypertensive and cholesterol medications increased while chronic kidney and cardiovascular diseases were relatively stable.
Conclusions
Cardiovascular risk factors of younger U.S. adults have worsened over the past 40 years, but treatment for hypertension and high cholesterol has improved. The sub-optimal and worsening health in younger adults may have a substantial impact on health care utilization and costs, and should be considered when developing health care practices.
C1 [Casagrande, Sarah S.; Menke, Andy] Social & Sci Syst Inc, Publ Hlth Res, Silver Spring, MD 20910 USA.
[Cowie, Catherine C.] NIDDK, Div Diabet Endocrinol & Metab Dis, Bethesda, MD 20892 USA.
RP Casagrande, SS (reprint author), Social & Sci Syst Inc, Publ Hlth Res, Silver Spring, MD 20910 USA.
EM scasagrande@s-3.com
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[GS-10F-0381L]
FX The National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) (GS-10F-0381L) funded NHANES and oversaw its conduct and
reporting with regard to diabetes-related data. As employees NIDDK (C.
Cowie) or contractors of NIDDK (Social & Scientific Systems, Inc.; S.
Casagrande, A. Menke), the authors had a direct role in the design and
interpretation of the secondary analysis and the decision to submit the
manuscript for publication.
NR 51
TC 0
Z9 0
U1 15
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 23
PY 2016
VL 11
IS 8
AR e0161770
DI 10.1371/journal.pone.0161770
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT8TR
UT WOS:000381768800075
PM 27552151
ER
PT J
AU Liberman, Z
Woodward, AL
Sullivan, KR
Kinzler, KD
AF Liberman, Zoe
Woodward, Amanda L.
Sullivan, Kathleen R.
Kinzler, Katherine D.
TI Early emerging system for reasoning about the social nature of food
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE food; social cognition; infancy; cognitive development; disgust
ID CHILDS CONCEPTION; CONTAMINATION SENSITIVITY; INDUCTIVE INFERENCES;
INFANTS GENERALIZE; SHAPE SIMILARITY; YOUNG-CHILDREN; SHARED LABELS;
PREFERENCES; EAT; CONSUMPTION
AB Selecting appropriate foods is a complex and evolutionarily ancient problem, yet past studies have revealed little evidence of adaptations present in infancy that support sophisticated reasoning about perceptual properties of food. We propose that humans have an early-emerging system for reasoning about the social nature of food selection. Specifically, infants' reasoning about food choice is tied to their thinking about agents' intentions and social relationships. Whereas infants do not expect people to like the same objects, infants view food preferences as meaningfully shared across individuals. Infants' reasoning about food preferences is fundamentally social: They generalize food preferences across individuals who affiliate, or who speak a common language, but not across individuals who socially disengage or who speak different languages. Importantly, infants' reasoning about food preferences is flexibly calibrated to their own experiences: Tests of bilingual babies reveal that an infant's sociolinguistic background influences whether she will constrain her generalization of food preferences to people who speak the same language. Additionally, infants' systems for reasoning about food is differentially responsive to positive and negative information. Infants generalize information about food disgust across all people, regardless of those people's social identities. Thus, whereas food preferences are seen as embedded within social groups, disgust is interpreted as socially universal, which could help infants avoid potentially dangerous foods. These studies reveal an early-emerging system for thinking about food that incorporates social reasoning about agents and their relationships, and allows infants to make abstract, flexible, adaptive inferences to interpret others' food choices.
C1 [Liberman, Zoe; Woodward, Amanda L.; Sullivan, Kathleen R.; Kinzler, Katherine D.] Univ Chicago, Dept Psychol, Chicago, IL 60642 USA.
[Sullivan, Kathleen R.] NIH, Off Res Womens Hlth, Bldg 10, Bethesda, MD 20892 USA.
[Kinzler, Katherine D.] Cornell Univ, Dept Psychol, Ithaca, NY 14853 USA.
[Kinzler, Katherine D.] Cornell Univ, Dept Human Dev, Ithaca, NY 14853 USA.
RP Liberman, Z (reprint author), Univ Chicago, Dept Psychol, Chicago, IL 60642 USA.
EM zoeliberman@uchicago.edu
FU NIH [R01 HD070890]; National Science Foundation Graduate Research
Fellowship Program
FX We thank Kristin Shutts for extremely helpful conversations about the
intellectual direction of this project, and Alex Shaw and Susan
Goldin-Meadow for comments on a previous version of this manuscript.
This research was supported by NIH Grant R01 HD070890 (to K.D.K.) and by
a National Science Foundation Graduate Research Fellowship Program (to
Z.L.).
NR 85
TC 0
Z9 0
U1 5
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 23
PY 2016
VL 113
IS 34
BP 9480
EP 9485
DI 10.1073/pnas.1605456113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT9ZK
UT WOS:000381860800042
PM 27503878
ER
PT J
AU Wang, W
Nguyen, LTT
Burlak, C
Chegini, F
Guo, F
Chataway, T
Ju, SL
Fisher, OS
Miller, DW
Datta, D
Wu, F
Wu, CX
Landeru, A
Wells, JA
Cookson, MR
Boxer, MB
Thomas, CJ
Gai, WP
Ringe, D
Petsko, GA
Hoang, QQ
AF Wang, Wei
Nguyen, Linh T. T.
Burlak, Christopher
Chegini, Fariba
Guo, Feng
Chataway, Tim
Ju, Shulin
Fisher, Oriana S.
Miller, David W.
Datta, Debajyoti
Wu, Fang
Wu, Chun-Xiang
Landeru, Anuradha
Wells, James A.
Cookson, Mark R.
Boxer, Matthew B.
Thomas, Craig J.
Gai, Wei Ping
Ringe, Dagmar
Petsko, Gregory A.
Hoang, Quyen Q.
TI Caspase-1 causes truncation and aggregation of the Parkinson's
disease-associated protein alpha-synuclein
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE synuclein; Parkinson's disease; caspase; inflammasome; aggregation
ID TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MOUSE
MODEL; IN-VIVO; NEURODEGENERATION; INTERLEUKIN-1-BETA;
NEUROINFLAMMATION; INFLAMMATION; PATHOGENESIS
AB The aggregation of alpha-synuclein (aSyn) leading to the formation of Lewy bodies is the defining pathological hallmark of Parkinson's disease (PD). Rare familial PD-associated mutations in aSyn render it aggregation-prone; however, PD patients carrying wild type (WT) aSyn also have aggregated aSyn in Lewy bodies. The mechanisms by which WT aSyn aggregates are unclear. Here, we report that inflammation can play a role in causing the aggregation of WT aSyn. We show that activation of the inflammasome with known stimuli results in the aggregation of aSyn in a neuronal cell model of PD. The insoluble aggregates are enriched with truncated aSyn as found in Lewy bodies of the PD brain. Inhibition of the inflammasome enzyme caspase-1 by chemical inhibition or genetic knockdown with shRNA abated aSyn truncation. In vitro characterization confirmed that caspase-1 directly cleaves aSyn, generating a highly aggregation-prone species. The truncation-induced aggregation of aSyn is toxic to neuronal culture, and inhibition of caspase-1 by shRNA or a specific chemical inhibitor improved the survival of a neuronal PD cell model. This study provides a molecular link for the role of inflammation in aSyn aggregation, and perhaps in the pathogenesis of sporadic PD as well.
C1 [Wang, Wei; Nguyen, Linh T. T.; Wu, Chun-Xiang; Landeru, Anuradha; Hoang, Quyen Q.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
[Wang, Wei; Nguyen, Linh T. T.; Wu, Chun-Xiang; Landeru, Anuradha; Hoang, Quyen Q.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.
[Burlak, Christopher] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Box 242 UMHC, Minneapolis, MN 55455 USA.
[Chegini, Fariba; Guo, Feng; Chataway, Tim; Gai, Wei Ping] Flinders Univ S Australia, Dept Human Physiol, Ctr Neurosci, Adelaide, SA 5001, Australia.
[Ju, Shulin; Fisher, Oriana S.; Wu, Fang; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Chem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.
[Ju, Shulin; Fisher, Oriana S.; Wu, Fang; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Biochem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.
[Miller, David W.; Cookson, Mark R.] NIH, Neurogenet Lab, Bldg 10, Bethesda, MD 20892 USA.
[Datta, Debajyoti; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
[Wells, James A.] Univ Calif San Francisco, Dept Cellular & Mol Physiol, San Francisco, CA 94143 USA.
[Boxer, Matthew B.; Thomas, Craig J.] NIH, Natl Ctr Adv Translat Sci, Chem Genom Ctr, Bldg 10, Bethesda, MD 20892 USA.
[Ringe, Dagmar; Petsko, Gregory A.] Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA.
[Ringe, Dagmar; Petsko, Gregory A.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02116 USA.
[Hoang, Quyen Q.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.
[Ju, Shulin] Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.
[Fisher, Oriana S.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA.
[Wu, Fang; Petsko, Gregory A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Calif Inst Quantitat Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
[Petsko, Gregory A.; Hoang, Quyen Q.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.
RP Hoang, QQ (reprint author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Hoang, QQ (reprint author), Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.; Petsko, GA (reprint author), Brandeis Univ, Dept Chem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.; Petsko, GA (reprint author), Brandeis Univ, Dept Biochem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.; Petsko, GA (reprint author), Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA.; Petsko, GA (reprint author), Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02116 USA.; Hoang, QQ (reprint author), Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.; Petsko, GA (reprint author), Univ Calif Berkeley, Dept Mol & Cell Biol, Calif Inst Quantitat Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.; Petsko, GA; Hoang, QQ (reprint author), Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.
EM gpetsko@med.cornell.edu; qqhoang@iu.edu
RI Wells, Jim/O-9854-2016
FU Community Fast Track grant from Michael J. Fox Foundation; National
Institutes of Health Grants [1R21NS079881-01, 5R01GM111639]; Indiana
University School of Medicine Biomedical Research Grant; Indiana
University-Purdue University Indianapolis Research Support Funds Grant;
Fidelity Biosciences Research Initiative; Ellison Medical Foundation;
McKnight Endowment for Neuroscience; Molecular Libraries Initiative of
the National Institutes of Health Roadmap for Medical Research;
Intramural Research Program of the National Human Genome Research
Institute, National Institutes of Health; Intramural Research Program of
the National Institute on Aging, National Institutes of Health
FX We thank S. Lindquist for the yeast expression vectors of aSyn, and Z.
Y. Z. Zhang and L. Chen for their generous support and access to the
Chemical Genomics Core Facility at Indiana University. Q.Q.H., D.R., and
G.A.P. were supported through a Community Fast Track grant from the
Michael J. Fox Foundation. Q.Q.H. was also supported by National
Institutes of Health Grants 1R21NS079881-01 and 5R01GM111639, an Indiana
University School of Medicine Biomedical Research Grant, and an Indiana
University-Purdue University Indianapolis Research Support Funds Grant.
D.R. and G.A.P. also acknowledge support from the Fidelity Biosciences
Research Initiative (with much useful discussion from Dr. S. Weninger)
and early support from the Ellison Medical Foundation and the McKnight
Endowment for Neuroscience. M.B.B. and C.J.T. acknowledge support from
the Molecular Libraries Initiative of the National Institutes of Health
Roadmap for Medical Research and the Intramural Research Program of the
National Human Genome Research Institute, National Institutes of Health.
This research was supported in part by the Intramural Research Program
of the National Institute on Aging, National Institutes of Health.
NR 50
TC 0
Z9 0
U1 8
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 23
PY 2016
VL 113
IS 34
BP 9587
EP 9592
DI 10.1073/pnas.1610099113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT9ZK
UT WOS:000381860800060
ER
PT J
AU Brinkmeyer-Langford, C
Balog-Alvarez, C
Cai, JJ
Davis, BW
Kornegay, JN
AF Brinkmeyer-Langford, Candice
Balog-Alvarez, Cynthia
Cai, James J.
Davis, Brian W.
Kornegay, Joe N.
TI Genome-wide association study to identify potential genetic modifiers in
a canine model for Duchenne muscular dystrophy
SO BMC GENOMICS
LA English
DT Article
DE Muscular dystrophy; Duchenne muscular dystrophy; DMD; Golden retriever
muscular dystrophy; GRMD; Modifier; Linear mixed-model analysis; Gene
expression
ID READING-FRAME RULE; NONSENSE MUTATION; POPULATION STRATIFICATION;
MESSENGER-RNA; DOGS; DISEASE; EXPRESSION; MUSCLE; DMD; EXON
AB Background: Duchenne muscular dystrophy (DMD) causes progressive muscle degeneration, cardiomyopathy and respiratory failure in approximately 1/5,000 boys. Golden Retriever muscular dystrophy (GRMD) resembles DMD both clinically and pathologically. Like DMD, GRMD exhibits remarkable phenotypic variation among affected dogs, suggesting the influence of modifiers. Understanding the role(s) of genetic modifiers of GRMD may identify genes and pathways that also modify phenotypes in DMD and reveal novel therapies. Therefore, our objective in this study was to identify genetic modifiers that affect discrete GRMD phenotypes.
Results: We performed a linear mixed-model (LMM) analysis using 16 variably-affected dogs from our GRMD colony (8 dystrophic, 8 non-dystrophic). All of these dogs were either full or half-siblings, and phenotyped for 19 objective, quantitative biomarkers at ages 6 and 12 months. Each biomarker was individually assessed. Gene expression profiles of 59 possible candidate genes were generated for two muscle types: the cranial tibialis and medial head of the gastrocnemius. SNPs significantly associated with GRMD biomarkers were identified on multiple chromosomes (including the X chromosome). Gene expression levels for candidate genes located near these SNPs correlated with biomarker values, suggesting possible roles as GRMD modifiers.
Conclusions: The results of this study enhance our understanding of GRMD pathology and represent a first step toward the characterization of GRMD modifiers that may be relevant to DMD pathology. Such modifiers are likely to be useful for DMD treatment development based on their relationships to GRMD phenotypes.
C1 [Brinkmeyer-Langford, Candice; Balog-Alvarez, Cynthia; Cai, James J.; Kornegay, Joe N.] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA.
[Davis, Brian W.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
RP Brinkmeyer-Langford, C (reprint author), Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX USA.
EM cbrinkmeyer@cvm.tamu.edu
OI Cai, James/0000-0002-8081-6725
FU NINDS grant [1U24NS059696-01A1]; Co-operative Program in Translational
Research: Proposal for Establishment of the National Center for Canine
Models of Duchenne Muscular Dystrophy; Muscular Dystrophy Association
Infrastructure grant
FX NINDS grant 1U24NS059696-01A1, the Co-operative Program in Translational
Research: Proposal for Establishment of the National Center for Canine
Models of Duchenne Muscular Dystrophy, and a Muscular Dystrophy
Association Infrastructure grant to the Translational Research Advisory
Committee (J.N.K.).
NR 82
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 22
PY 2016
VL 17
AR 665
DI 10.1186/s12864-016-2948-z
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DY3GT
UT WOS:000384979500002
PM 27549615
ER
PT J
AU Guerard, F
Lee, YS
Baidoo, K
Gestin, JF
Brechbiel, MW
AF Guerard, Francois
Lee, Yong-Sok
Baidoo, Kwamena
Gestin, Jean-Francois
Brechbiel, Martin W.
TI Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic
Substitution of Aryliodonium Salts
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE astatine; halogenation; iodonium salts; nucleophilic substitution;
radiopharmaceuticals
ID DIARYLIODONIUM SALTS; RADIOFLUORINATION; CHEMISTRY; THERAPY; TOSYLATES;
SOLVENTS; ARENES; IODINE; ARYL
AB Aryliodonium salts have become precursors of choice for the synthesis of F-18-labeled tracers for nuclear imaging. However, little is known on the reactivity of these compounds with heavy halides, that is, radioiodide and astatide, at the radiotracer scale. In the first comparative study of radiohalogenation of aryliodonium salts with I-125(-) and At-211(-), initial experiments on a model compound highlight the higher reactivity of astatide compared to iodide, which could not be anticipated from the trends previously observed within the halogen series. Kinetic studies indicate a significant difference in activation energy (E-a=23.5 and 17.1kcalmol(-1) with I-125(-) and At-211(-), respectively). Quantum chemical calculations suggest that astatination occurs via the monomeric form of an iodonium complex whereas iodination occurs via a heterodimeric iodonium intermediate. The good to excellent regioselectivity of halogenation and high yields achieved with diversely substituted aryliodonium salts indicate that this class of compounds is a promising alternative to the stannane chemistry currently used for heavy radiohalogen labeling of tracers in nuclear medicine.
C1 [Guerard, Francois; Baidoo, Kwamena; Brechbiel, Martin W.] NCI, Radioimmune & Inorgan Chem Sect, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA.
[Guerard, Francois; Gestin, Jean-Francois] Univ Nantes, INSERM, U892, CNRS,UMR6299, Nantes, France.
[Lee, Yong-Sok] NIH, Ctr Mol Modeling, Div Computat Biosci, Ctr Informat Technol, Bldg 10, Bethesda, MD 20892 USA.
RP Guerard, F (reprint author), NCI, Radioimmune & Inorgan Chem Sect, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA.; Guerard, F (reprint author), Univ Nantes, INSERM, U892, CNRS,UMR6299, Nantes, France.
EM francois.guerard@univ-nantes.fr
OI Guerard, Francois/0000-0001-9795-2785
FU Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research and Center for Information Technology; French
National Agency for Research, called "Investissements d'Avenir" IRON
Labex [ANR-11-LABX-0018-01]; ArronaxPlus Equipex [ANR-11-EQPX-0004]
FX This research was supported by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research and Center
for Information Technology and in part by grants from the French
National Agency for Research, called "Investissements d'Avenir" IRON
Labex (no. ANR-11-LABX-0018-01) and ArronaxPlus Equipex (no.
ANR-11-EQPX-0004). The quantum chemical study utilized PC/linux clusters
at the center for Molecular Modeling of the National Institutes of
Health (http://cit.nih.gov). Lawrence Szajek, NIH, CC is thanked for his
cyclotron operations and irradiation of bismuth targets for the
production of 211At. Professor Vanelle is thanked for the
input on radical mechanism investigations.
NR 49
TC 0
Z9 0
U1 9
U2 9
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD AUG 22
PY 2016
VL 22
IS 35
BP 12332
EP 12339
DI 10.1002/chem.201600922
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA DV4DX
UT WOS:000382876500017
PM 27305065
ER
PT J
AU Hager, A
Wu, MX
Wang, HC
Brown, NW
Shears, SB
Veiga, N
Fiedler, D
AF Hager, Anastasia
Wu, Mingxuan
Wang, Huanchen
Brown, Nathaniel W., Jr.
Shears, Stephen B.
Veiga, Nicolas
Fiedler, Dorothea
TI Cellular Cations Control Conformational Switching of Inositol
Pyrophosphate Analogues
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE biological activity; conformation analysis; phosphorylation;
protonation; signal transduction
ID DIPHOSPHOINOSITOL-POLYPHOSPHATE PHOSPHOHYDROLASES; MYOINOSITOL
HEXAKISPHOSPHATE; P-31 NMR; PROTEIN PYROPHOSPHORYLATION;
SACCHAROMYCES-CEREVISIAE; PH MICRODOMAINS; TELOMERE LENGTH; KINASE;
PENTAKISPHOSPHATE; METABOLISM
AB The inositol pyrophosphate messengers (PP-InsPs) are emerging as an important class of cellular regulators. These molecules have been linked to numerous biological processes, including insulin secretion and cancer cell migration, but how they trigger such a wide range of cellular responses has remained unanswered in many cases. Here, we show that the PP-InsPs exhibit complex speciation behaviour and propose that a unique conformational switching mechanism could contribute to their multifunctional effects. We synthesised non-hydrolysable bisphosphonate analogues and crystallised the analogues in complex with mammalian PPIP5K2 kinase. Subsequently, the bisphosphonate analogues were used to investigate the protonation sequence, metal-coordination properties, and conformation in solution. Remarkably, the presence of potassium and magnesium ions enabled the analogues to adopt two different conformations near physiological pH. Understanding how the intrinsic chemical properties of the PP-InsPs can contribute to their complex signalling outputs will be essential to elucidate their regulatory functions.
C1 [Brown, Nathaniel W., Jr.; Fiedler, Dorothea] Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.
[Hager, Anastasia; Wu, Mingxuan; Brown, Nathaniel W., Jr.; Fiedler, Dorothea] Princeton Univ, Dept Chem, Washington Rd, Princeton, NJ 08544 USA.
[Wang, Huanchen; Shears, Stephen B.] NIH, Inositol Signaling Grp, Res Triangle Pk, NC 27709 USA.
[Veiga, Nicolas] Univ Republica, Fac Quim, Catedra Quim Inorgan, Dept Estrella Campos, CC 1157, Montevideo, Uruguay.
RP Fiedler, D (reprint author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.; Fiedler, D (reprint author), Princeton Univ, Dept Chem, Washington Rd, Princeton, NJ 08544 USA.; Veiga, N (reprint author), Univ Republica, Fac Quim, Catedra Quim Inorgan, Dept Estrella Campos, CC 1157, Montevideo, Uruguay.
EM nveiga@fq.edu.uy; fiedler@fmp-berlin.de
FU Deutsche Forschungsgemeinschaft (DFG); NIH [DP2 CA186753]; Sidney Kimmel
Foundation; Rita Allen Foundation; Princeton University
FX We thank Dr. Istvan Pelczer, Ken Conover, and Dr. Peter Schmieder for
guidance with the NMR experiments, and their helpful suggestions. We
also thank Laura Wilson from Lotus Separations for assistance with the
chiral SFC. Anastasia Hager gratefully acknowledges the Deutsche
Forschungsgemeinschaft (DFG) for her postdoctoral fellowship. D.F.
received funding from the NIH (DP2 CA186753), the Sidney Kimmel
Foundation, the Rita Allen Foundation, and Princeton University.
NR 63
TC 2
Z9 2
U1 4
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD AUG 22
PY 2016
VL 22
IS 35
BP 12406
EP 12414
DI 10.1002/chem.201601754
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA DV4DX
UT WOS:000382876500026
PM 27460418
ER
PT J
AU Maul, RW
MacCarthy, T
Frank, EG
Donigan, KA
McLenigan, MP
Yang, W
Saribasak, H
Huston, DE
Lange, SS
Woodgate, R
Gearhart, PJ
AF Maul, Robert W.
MacCarthy, Thomas
Frank, Ekaterina G.
Donigan, Katherine A.
McLenigan, Mary P.
Yang, William
Saribasak, Huseyin
Huston, Donald E.
Lange, Sabine S.
Woodgate, Roger
Gearhart, Patricia J.
TI DNA polymerase iota functions in the generation of tandem mutations
during somatic hypermutation of antibody genes
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID CLASS-SWITCH RECOMBINATION; IMMUNOGLOBULIN GENES; DEFICIENT MICE; ZETA;
ETA; MOUSE; CELLS; EXPRESSION; PROTEINS; FIDELITY
AB DNA polymerase iota (Pol iota) is an attractive candidate for somatic hypermutation in antibody genes because of its low fidelity. To identify a role for Pol iota, we analyzed mutations in two strains of mice with deficiencies in the enzyme: 129 mice with negligible expression of truncated Pol iota, and knock-in mice that express full-length Pol iota that is catalytically inactive. Both strains had normal frequencies and spectra of mutations in the variable region, indicating that loss of Pol iota did not change overall mutagenesis. We next examined if Pol iota affected tandem mutations generated by another error-prone polymerase, Pol zeta. The frequency of contiguous mutations was analyzed using a novel computational model to determine if they occur during a single DNA transaction or during two independent events. Analyses of 2,000 mutations from both strains indicated that Pol iota-compromised mice lost the tandem signature, whereas C57BL/6 mice accumulated significant amounts of double mutations. The results support a model where Pol iota occasionally accesses the replication fork to generate a first mutation, and Pol zeta extends the mismatch with a second mutation.
C1 [Maul, Robert W.; Yang, William; Saribasak, Huseyin; Gearhart, Patricia J.] NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA.
[MacCarthy, Thomas] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
[Frank, Ekaterina G.; Donigan, Katherine A.; McLenigan, Mary P.; Huston, Donald E.; Woodgate, Roger] NICHHD, Lab Genom Integr, NIH, Rockville, MD 20850 USA.
[Lange, Sabine S.] Univ Texas MD Anderson Canc Ctr, Dept Mol Carcinogenesis, Sci Pk, Smithville, TX 78957 USA.
RP Gearhart, PJ (reprint author), NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA.
EM gearhartp@mail.nih.gov
FU National Institutes of Health (NIH) [GM111741]; Intramural Research
Programs of the National Institute of Child Health and Human
Development; National Institute on Aging
FX This work was supported in part by National Institutes of Health (NIH)
grant GM111741 to T. MacCarthy, and the Intramural Research Programs of
the National Institute of Child Health and Human Development to R.
Woodgate, and National Institute on Aging to P.J. Gearhart.
NR 36
TC 3
Z9 3
U1 5
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD AUG 22
PY 2016
VL 213
IS 9
BP 1675
EP 1683
DI 10.1084/jem.20151227
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DU9FE
UT WOS:000382520900004
PM 27455952
ER
PT J
AU Liu, Y
Betts, MJ
Lei, J
Wei, GC
Bao, QY
Kehl, T
Russell, RB
Lochelt, M
AF Liu, Yang
Betts, Matthew J.
Lei, Janet
Wei, Guochao
Bao, Qiuying
Kehl, Timo
Russell, Robert B.
Loechelt, Martin
TI Mutagenesis of N-terminal residues of feline foamy virus Gag reveals
entirely distinct functions during capsid formation, particle assembly,
Gag processing and budding
SO RETROVIROLOGY
LA English
DT Article
DE Foamy virus; Feline foamy virus; Gag; Mutagenesis; Capsid formation;
Assembly; Genome packaging; Particle budding and maturation;
Transmission
ID ENV LEADER PROTEIN; TARGETING-RETENTION SIGNAL; PERICENTRIOLAR REGION;
VIRAL INFECTIVITY; POL POLYPROTEIN; RETROVIRAL GAG; HUMAN-CELLS;
C-TERMINUS; DOMAIN; IDENTIFICATION
AB Background: Foamy viruses (FVs) of the Spumaretrovirinae subfamily are distinct retroviruses, with many features of their molecular biology and replication strategy clearly different from those of the Orthoretroviruses, such as human immunodeficiency, murine leukemia, and human T cell lymphotropic viruses. The FV Gag N-terminal region is responsible for capsid formation and particle budding via interaction with Env. However, the critical residues or motifs in this region and their functional interaction are currently ill-defined, especially in non-primate FVs.
Results: Mutagenesis of N-terminal Gag residues of feline FV (FFV) reveals key residues essential for either capsid assembly and/or viral budding via interaction with the FFV Env leader protein (Elp). In an in vitro Gag-Elp interaction screen, Gag mutations abolishing particle assembly also interfered with Elp binding, indicating that Gag assembly is a prerequisite for this highly specific interaction. Gradient sedimentation analyses of cytosolic proteins indicate that wild-type Gag is mostly assembled into virus capsids. Moreover, proteolytic processing of Gag correlates with capsid assembly and is mostly, if not completely, independent from particle budding. In addition, Gag processing correlates with the presence of packaging-competent FFV genomic RNA suggesting that Pol encapsidation via genomic RNA is a prerequisite for Gag processing. Though an appended heterogeneous myristoylation signal rescues Gag particle budding of mutants unable to form capsids or defective in interacting with Elp, it fails to generate infectious particles that co-package Pol, as evidenced by a lack of Gag processing.
Conclusions: Changes in proteolytic Gag processing, intracellular capsid assembly, particle budding and infectivity of defined N-terminal Gag mutants highlight their essential, distinct and only partially overlapping roles during viral assembly and budding. Discussion of these findings will be based on a recent model developed for Gag-Elp interactions in prototype FV.
C1 [Liu, Yang; Lei, Janet; Wei, Guochao; Bao, Qiuying; Kehl, Timo; Loechelt, Martin] German Canc Res Ctr, Dept Mol Diagnost Oncogen Infect, Res Program Infect & Canc, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.
[Betts, Matthew J.; Russell, Robert B.] Heidelberg Univ, CellNetworks, Bioquant, Neuenheimer Feld 267, D-69120 Heidelberg, Germany.
[Russell, Robert B.] BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.
[Liu, Yang] NCI, Ctr Canc Res, Frederick, MD 21701 USA.
[Lei, Janet] Univ Oxford, Dept Oncol, Oxford, England.
[Bao, Qiuying] East China Normal Univ, Dept Biol, Shanghai, Peoples R China.
RP Lochelt, M (reprint author), German Canc Res Ctr, Dept Mol Diagnost Oncogen Infect, Res Program Infect & Canc, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.
EM m.loechelt@dkfz.de
FU German Cancer Research Center, Heidelberg, Germany; Chinese Scholarship
Council; Helmholtz International Graduate School for Cancer Research
FX This work was funded in part by the German Cancer Research Center,
Heidelberg, Germany. YL, GW, and QB are supported by PhD stipends from
the Chinese Scholarship Council. JL is supported by a PhD stipend from
the Helmholtz International Graduate School for Cancer Research. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 57
TC 0
Z9 0
U1 4
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD AUG 22
PY 2016
VL 13
AR 57
DI 10.1186/s12977-016-0291-8
PG 20
WC Virology
SC Virology
GA DT8OR
UT WOS:000381751000001
PM 27549192
ER
PT J
AU Thokala, R
Olivares, S
Mi, TJ
Maiti, S
Deniger, D
Huls, H
Torikai, H
Singh, H
Champlin, RE
Laskowski, T
McNamara, G
Cooper, LJN
AF Thokala, Radhika
Olivares, Simon
Mi, Tiejuan
Maiti, Sourindra
Deniger, Drew
Huls, Helen
Torikai, Hiroki
Singh, Harjeet
Champlin, Richard E.
Laskowski, Tamara
McNamara, George
Cooper, Laurence J. N.
TI Redirecting Specificity of T cells Using the Sleeping Beauty System to
Express Chimeric Antigen Receptors by Mix-and-Matching of V-L and V-H
Domains Targeting CD123(+) Tumors
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; TOXIN-INTERLEUKIN-3 FUSION PROTEIN; ACUTE
MYELOGENOUS LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; INTERLEUKIN-3 RECEPTOR;
CD28 COSTIMULATION; PHASE-I; VENOOCCLUSIVE DISEASE; CYTOTOXIC
LYMPHOCYTES; ANTITUMOR EFFICACY
AB Adoptive immunotherapy infusing T cells with engineered specificity for CD19 expressed on B-cell malignancies is generating enthusiasm to extend this approach to other hematological malignancies, such as acute myelogenous leukemia (AML). CD123, or interleukin 3 receptor alpha, is overexpressed on most AML and some lymphoid malignancies, such as acute lymphocytic leukemia (ALL), and has been an effective target for T cells expressing chimeric antigen receptors (CARs). The prototypical CAR encodes a V-H and V-L from one monoclonal antibody (mAb), coupled to a transmembrane domain and one or more cytoplasmic signaling domains. Previous studies showed that treatment of an experimental AML model with CD123-specific CAR T cells was therapeutic, but at the cost of impaired myelopoiesis, highlighting the need for systems to define the antigen threshold for CAR recognition. Here, we show that CARs can be engineered using V-H and V-L chains derived from different CD123-specific mAbs to generate a panel of CAR(+) T cells. While all CARs exhibited specificity to CD123, one V-H and V-L combination had reduced lysis of normal hematopoietic stem cells. This CAR's in vivo anti-tumor activity was similar whether signaling occurred via chimeric CD28 or CD137, prolonging survival in both AML and ALL models. Co-expression of inducible caspase 9 eliminated CAR(+) T cells. These data help support the use of CD123-specific CARs for treatment of CD123(+) hematologic malignancies.
C1 [Thokala, Radhika; Olivares, Simon; Mi, Tiejuan; Maiti, Sourindra; Deniger, Drew; Torikai, Hiroki; Singh, Harjeet; Laskowski, Tamara; McNamara, George; Cooper, Laurence J. N.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA.
[Thokala, Radhika] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA.
[Champlin, Richard E.] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
[Cooper, Laurence J. N.] Ziopharm Oncol Inc, Boston, MA 02129 USA.
[Huls, Helen] Intrexon Corp, Germantown, MD USA.
[Deniger, Drew] NCI, Surg Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Cooper, LJN (reprint author), Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA.; Cooper, LJN (reprint author), Ziopharm Oncol Inc, Boston, MA 02129 USA.
EM ljncooper@ziopharm.com
FU Cancer Center Core Grant [CA16672]; SPORES [CA100632, CA136411,
CA00632]; Albert J Ward Foundation; Alex's Lemonade Stand Foundation;
Burroughs Wellcome Fund; Cancer Prevention and Research Institute of
Texas; Charles B. Goddard Foundation of Texas; CLL Global Research
Foundation; Energy Transfer Partners; Estate of Noelan L. Bibler;
Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund for
Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation; Kleberg
Foundation; Leukemia and Lymphoma Society; Lymphoma Research Foundation;
Miller Foundation; National Foundation for Cancer Research; Pediatric
Cancer Research Foundation; Sheikh Khalifa Bin Zayed Al Nahyan Institute
for Personalized Cancer Therapy; University of Texas MD Anderson Cancer
Center Sister Institution Network Fund; University of Texas MD Anderson
Cancer Center Moon Shot Fund; William Lawrence and Blanche Hughes
Children's Foundation; [CA124782]; [CA120956]; [CA141303];
[CA148600]
FX This work was supported by: Cancer Center Core Grant (CA16672); RO1
(CA124782, CA120956, CA141303; CA141303); P01 (CA148600); SPORES
(CA100632, CA136411, CA00632); Albert J Ward Foundation; Alex's Lemonade
Stand Foundation; Burroughs Wellcome Fund; Cancer Prevention and
Research Institute of Texas; Charles B. Goddard Foundation of Texas; CLL
Global Research Foundation; Energy Transfer Partners; Estate of Noelan
L. Bibler; Gillson Longenbaugh Foundation; Harry T. Mangurian, Jr., Fund
for Leukemia Immunotherapy; Khalifa Bin Zayed Al Nahyan Foundation;
Kleberg Foundation; Leukemia and Lymphoma Society; Lymphoma Research
Foundation; Miller Foundation; Mr. Herb Simons; Mr. and Mrs. Joe H.
Scales; Mr. Thomas Scott; National Foundation for Cancer Research;
Pediatric Cancer Research Foundation; Sheikh Khalifa Bin Zayed Al Nahyan
Institute for Personalized Cancer Therapy; University of Texas MD
Anderson Cancer Center Sister Institution Network Fund and Moon Shot
Fund; William Lawrence and Blanche Hughes Children's Foundation. Dr.
Cooper receives a salary as CEO of Ziopharm. The specific roles of the
authors are articulated in the 'author contributions' section. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 70
TC 3
Z9 3
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2016
VL 11
IS 8
AR e0159477
DI 10.1371/journal.pone.0159477
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT8TP
UT WOS:000381768400006
PM 27548616
ER
PT J
AU Tong, X
Srivatsan, A
Jacobson, O
Wang, Y
Wang, ZT
Yang, XY
Niu, G
Kiesewetter, DO
Zheng, HR
Chen, XY
AF Tong, Xiao
Srivatsan, Avinash
Jacobson, Orit
Wang, Yu
Wang, Zhantong
Yang, Xiangyu
Niu, Gang
Kiesewetter, Dale O.
Zheng, Hairong
Chen, Xiaoyuan
TI Monitoring Tumor Hypoxia Using F-18-FMISO PET and Pharmacokinetics
Modeling after Photodynamic Therapy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IN-VITRO; F-18 FLUOROMISONIDAZOLE; F-18-FLUOROMISONIDAZOLE PET;
NECK-CANCER; MICROENVIRONMENT; RESPONSIVENESS; VASCULATURE; DETERMINES;
HEAD; PDT
AB Photodynamic therapy (PDT) is an efficacious treatment for some types of cancers. However, PDT-induced tumor hypoxia as a result of oxygen consumption and vascular damage can reduce the efficacy of this therapy. Measuring and monitoring intrinsic and PDT-induced tumor hypoxia in vivo during PDT is of high interest for prognostic and treatment evaluation. In the present study, static and dynamic F-18-FMISO PET were performed with mice bearing either U87MG or MDA-MB-435 tumor xenografts immediately before and after PDT at different time points. Significant difference in tumor hypoxia in response to PDT over time was found between the U87MG and MDA-MB-435 tumors in both static and dynamic PET. Dynamic PET with pharmacokinetics modeling further monitored the kinetics of F-18-FMISO retention to hypoxic sites after treatment. The K-i and k(3) parametric analysis provided information on tumor hypoxia by distinction of the specific tracer retention in hypoxic sites from its non-specific distribution in tumor. Dynamic F-18-FMISO PET with pharmacokinetics modeling, complementary to static PET analysis, provides a potential imaging tool for more detailed and more accurate quantification of tumor hypoxia during PDT.
C1 [Tong, Xiao; Srivatsan, Avinash; Jacobson, Orit; Wang, Yu; Wang, Zhantong; Yang, Xiangyu; Niu, Gang; Kiesewetter, Dale O.; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
[Tong, Xiao; Zheng, Hairong] Chinese Acad Sci, Shenzhen Inst Adv Technol, Paul C Lauterbur Res Ctr Biomed Imaging, Inst Biomed & Hlth Engn, Shenzhen 518055, Peoples R China.
RP Chen, XY (reprint author), Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.; Zheng, HR (reprint author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Paul C Lauterbur Res Ctr Biomed Imaging, Inst Biomed & Hlth Engn, Shenzhen 518055, Peoples R China.
EM hr.zheng@siat.ac.cn; shawn.chen@nih.gov
FU Intramural Research Program of the National Institute of Biomedical
Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH);
National High Technology Research and Development Program of China
[2014AA020503]
FX This work was supported by the Intramural Research Program of the
National Institute of Biomedical Imaging and Bioengineering (NIBIB),
National Institutes of Health (NIH), and the National High Technology
Research and Development Program of China (2014AA020503).
NR 38
TC 0
Z9 0
U1 13
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 22
PY 2016
VL 6
AR 31551
DI 10.1038/srep31551
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT7WZ
UT WOS:000381700300001
PM 27546160
ER
PT J
AU Zheng, G
Zhang, W
Xu, JF
Yuan, A
Li, QZ
Gastwirth, JL
AF Zheng, Gang
Zhang, Wei
Xu, Jinfeng
Yuan, Ao
Li, Qizhai
Gastwirth, Joseph L.
TI Genetic risks and genetic model specification
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Case-control design; Genetic model; Genetic risk; Hardy-Weinberg
equilibrium
ID CASE-CONTROL ASSOCIATION; HARDY-WEINBERG DISEQUILIBRIUM; SAMPLE-SIZE;
TREND TESTS; POWER; APPROXIMATIONS; SELECTION; GENOTYPES; MARKERS; MAX
AB Genetic risks and genetic models are often used in design and analysis of genetic epidemiology studies. A genetic model is defined in terms of two genetic risk measures: genotype relative risk and odds ratio. The impacts of choosing a risk measure on the resulting genetic models are studied in the power to detect association and deviation from Hardy Weinberg equilibrium in cases using genetic relative risk. Extensive simulations demonstrate that the power of a study to detect associations using odds ratio is lower than that using relative risk with the same value when other parameters are fixed. When the Hardy Weinberg equilibrium holds in the general population, the genetic model can be inferred by the deviation from Hardy Weinberg equilibrium in only cases. Furthermore, it is more efficient than that based on the deviation from Hardy-Weinberg equilibrium in all cases and controls. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Zheng, Gang] NHLBI, Bldg 10, Bethesda, MD 20892 USA.
[Zhang, Wei; Li, Qizhai] Chinese Acad Sci, Acad Math & Syst Sci, Key Lab Syst & Control, Beijing, Peoples R China.
[Xu, Jinfeng] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
[Yuan, Ao] Georgetown Univ, Washington, DC 20057 USA.
[Gastwirth, Joseph L.] George Washington Univ, Washington, DC USA.
RP Yuan, A (reprint author), Georgetown Univ, Washington, DC 20057 USA.
EM yuanao@hotmail.com
FU National Science Foundation of China [11371353, 61134013]; Chinese
Academy of Sciences [XDB13040600]
FX We would like to thank three anonymous reviewers for their careful
reading and thoughtful comments, which greatly improved our manuscript.
The authors would like to thank Ryo Yamada for some helpful discussions.
Q. Li was supported in part by the National Science Foundation of China,
(Grant nos. 11371353 and 61134013) and the Breakthrough Project of
Strategic Priority Program of the Chinese Academy of Sciences, Grant no.
XDB13040600.
NR 19
TC 1
Z9 1
U1 5
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD AUG 21
PY 2016
VL 403
BP 68
EP 74
DI 10.1016/j.jtbi.2016.05.016
PG 7
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
Biology
GA DQ1UY
UT WOS:000378987100008
PM 27181372
ER
PT J
AU Lazarus, HM
Pavletic, SZ
AF Lazarus, Hillard M.
Pavletic, Steven Z.
TI Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing
Chronic Graft-Versus-Host Disease After Haploidentical Transplantation:
Just Another Labor-Intensive Strategy, or Showing the Way?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID HEMATOLOGIC MALIGNANCY PATIENTS; ACUTE MYELOID-LEUKEMIA;
NATURAL-KILLER-CELLS; STEM-CELLS; COTRANSPLANTATION
C1 [Lazarus, Hillard M.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Pavletic, Steven Z.] Natl Inst Hlth, Bethesda, MD USA.
RP Lazarus, HM (reprint author), Case Western Reserve Univ, Cleveland, OH 44106 USA.
NR 18
TC 0
Z9 1
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 20
PY 2016
VL 34
IS 24
BP 2812
EP +
DI 10.1200/JCO.2016.67.7344
PG 4
WC Oncology
SC Oncology
GA DU8MZ
UT WOS:000382469100003
PM 27400943
ER
PT J
AU Lengacher, CA
Reich, RR
Paterson, CL
Ramesar, S
Park, JY
Alinat, C
Johnson-Mallard, V
Moscoso, M
Budhrani-Shani, P
Miladinovic, B
Jacobsen, PB
Cox, CE
Goodman, M
Kip, KE
AF Lengacher, Cecile A.
Reich, Richard R.
Paterson, Carly L.
Ramesar, Sophia
Park, Jong Y.
Alinat, Carissa
Johnson-Mallard, Versie
Moscoso, Manolete
Budhrani-Shani, Pinky
Miladinovic, Branko
Jacobsen, Paul B.
Cox, Charles E.
Goodman, Matthew
Kip, Kevin E.
TI Examination of Broad Symptom Improvement Resulting From
Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A
Randomized Controlled Trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; OLDER WOMEN; LONG-TERM; FOLLOW-UP; MEDITATION;
RECURRENCE; FATIGUE; SLEEP; PREVALENCE; THERAPY
AB Purpose
The purpose of this randomized trial was to evaluate the efficacy of the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR[BC]) program in improving psychological and physical symptoms and quality of life among breast cancer survivors (BCSs) who completed treatment. Outcomes were assessed immediately after 6 weeks of MBSR(BC) training and 6 weeks later to test efficacy over an extended timeframe.
Patients and Methods
A total of 322 BCSs were randomly assigned to either a 6-week MBSR(BC) program (n = 155) or a usual care group (n = 167). Psychological (depression, anxiety, stress, and fear of recurrence) and physical symptoms (fatigue and pain) and quality of life (as related to health) were assessed at baseline and at 6 and 12 weeks. Linear mixed models were used to assess MBSR(BC) effects over time, and participant characteristics at baseline were also tested as moderators of MBSR(BC) effects.
Results
Results demonstrated extended improvement for the MBSR(BC) group compared with usual care in both psychological symptoms of anxiety, fear of recurrence overall, and fear of recurrence problems and physical symptoms of fatigue severity and fatigue interference (P < .01). Overall effect sizes were largest for fear of recurrence problems (d = 0.35) and fatigue severity (d = 0.27). Moderation effects showed BCSs with the highest levels of stress at baseline experienced the greatest benefit from MBSR(BC).
Conclusion
The MBSR(BC) program significantly improved a broad range of symptoms among BCSs up to 6 weeks after MBSR(BC) training, with generally small to moderate overall effect sizes.
C1 [Lengacher, Cecile A.; Ramesar, Sophia; Alinat, Carissa; Moscoso, Manolete; Kip, Kevin E.] Univ S Florida, Coll Nursing, MDC 22,12901 Bruce B Downs Blvd, Tampa, FL 33620 USA.
[Park, Jong Y.; Jacobsen, Paul B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Miladinovic, Branko; Cox, Charles E.] Univ S Florida, Morsani Coll Med, Tampa, FL USA.
[Reich, Richard R.] Univ S Florida, Sarasota, FL USA.
[Johnson-Mallard, Versie] Univ Florida, Coll Nursing, Gainesville, FL 32611 USA.
[Paterson, Carly L.] NCI, Rockville, MD USA.
[Budhrani-Shani, Pinky] Texas Womans Univ, Nelda C Stark Coll Nursing, Houston, TX USA.
[Goodman, Matthew] Univ Virginia, Charlottesville, VA USA.
RP Lengacher, CA (reprint author), Univ S Florida, Coll Nursing, MDC 22,12901 Bruce B Downs Blvd, Tampa, FL 33620 USA.
EM clengach@health.usf.edu
FU National Cancer Institute [1R01CA131080-01A2]; Survey Methods Core
Facility at the H. Lee Moffitt Cancer Center and Research Institute
FX Supported by Award No. 1R01CA131080-01A2 from the National Cancer
Institute and in part by the Survey Methods Core Facility at the H. Lee
Moffitt Cancer Center and Research Institute.
NR 43
TC 3
Z9 3
U1 10
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 20
PY 2016
VL 34
IS 24
BP 2827
EP +
DI 10.1200/JCO.2015.65.7874
PG 9
WC Oncology
SC Oncology
GA DU8MZ
UT WOS:000382469100006
PM 27247219
ER
PT J
AU Wentzensen, N
Poole, EM
Trabert, B
White, E
Arslan, AA
Patel, AV
Setiawan, VW
Visvanathan, K
Weiderpass, E
Adami, HO
Black, A
Bernstein, L
Brinton, LA
Buring, J
Butler, LM
Chamosa, S
Clendenen, TV
Dossus, L
Fortner, R
Gapstur, SM
Gaudet, MM
Gram, IT
Hartge, P
Hoffman-Bolton, J
Idahl, A
Jones, M
Kaaks, R
Kirsh, V
Koh, WP
Lacey, JV
Lee, IM
Lundin, E
Merritt, MA
Onland-Moret, NC
Peters, U
Poynter, JN
Rinaldi, S
Robien, K
Rohan, T
Sandler, DP
Schairer, C
Schouten, LJ
Sjoholm, LK
Sieri, S
Swerdlow, A
Tjonneland, A
Travis, R
Trichopoulou, A
van den Brandt, PA
Wilkens, L
Wolk, A
Yang, HP
Zeleniuch-Jacquotte, A
Tworoger, SS
AF Wentzensen, Nicolas
Poole, Elizabeth M.
Trabert, Britton
White, Emily
Arslan, Alan A.
Patel, Alpa V.
Setiawan, V. Wendy
Visvanathan, Kala
Weiderpass, Elisabete
Adami, Hans-Olov
Black, Amanda
Bernstein, Leslie
Brinton, Louise A.
Buring, Julie
Butler, Lesley M.
Chamosa, Saioa
Clendenen, Tess V.
Dossus, Laure
Fortner, Renee
Gapstur, Susan M.
Gaudet, Mia M.
Gram, Inger T.
Hartge, Patricia
Hoffman-Bolton, Judith
Idahl, Annika
Jones, Michael
Kaaks, Rudolf
Kirsh, Victoria
Koh, Woon-Puay
Lacey, James V., Jr.
Lee, I-Min
Lundin, Eva
Merritt, Melissa A.
Onland-Moret, N. Charlotte
Peters, Ulrike
Poynter, Jenny N.
Rinaldi, Sabina
Robien, Kim
Rohan, Thomas
Sandler, Dale P.
Schairer, Catherine
Schouten, Leo J.
Sjoholm, Louise K.
Sieri, Sabina
Swerdlow, Anthony
Tjonneland, Anna
Travis, Ruth
Trichopoulou, Antonia
van den Brandt, Piet A.
Wilkens, Lynne
Wolk, Alicja
Yang, Hannah P.
Zeleniuch-Jacquotte, Anne
Tworoger, Shelley S.
TI Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the
Ovarian Cancer Cohort Consortium
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID INDIVIDUAL PARTICIPANT METAANALYSIS; RANDOMIZED CONTROLLED-TRIAL;
ASSOCIATION CONSORTIUM; POOLED ANALYSIS; WOMEN; PATHOGENESIS;
INFLAMMATION; MORTALITY; PROSTATE; SMOKING
AB Purpose
An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3).
Patients and Methods
Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other). By using competing risks Cox proportional hazards regression stratified by study and birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all invasive cancers by histology. Heterogeneity was evaluated by likelihood ratio test.
Results
Most risk factors exhibited significant heterogeneity by histology. Higher parity was most strongly associated with endometrioid (relative risk [RR] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) carcinomas (P value for heterogeneity [P-het] < .001). Similarly, age at menopause, endometriosis, and tubal ligation were only associated with endometrioid and clear cell tumors (P-het <= .01). Family history of breast cancer (P-het = .008) had modest heterogeneity. Smoking was associated with an increased risk of mucinous (RR per 20 pack-years, 1.26; 95% CI, 1.08 to 1.46) but a decreased risk of clear cell (RR, 0.72; 95% CI, 0.55 to 0.94) tumors (P-het = .004). Unsupervised clustering by risk factors separated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous carcinomas.
Conclusion
The heterogeneous associations of risk factors with ovarian cancer subtypes emphasize the importance of conducting etiologic studies by ovarian cancer subtypes. Most established risk factors were more strongly associated with nonserous carcinomas, which demonstrate challenges for risk prediction of serous cancers, the most fatal subtype. (C) 2016 by American Society of Clinical Oncology
C1 [Wentzensen, Nicolas; Poole, Elizabeth M.; Trabert, Britton; Black, Amanda; Brinton, Louise A.; Hartge, Patricia; Schairer, Catherine; Yang, Hannah P.] NCI, Bethesda, MD 20892 USA.
[Sandler, Dale P.] NIEHS, Bethesda, MD USA.
[Poole, Elizabeth M.; Buring, Julie; Lee, I-Min; Tworoger, Shelley S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Poole, Elizabeth M.; Adami, Hans-Olov; Buring, Julie; Lee, I-Min; Tworoger, Shelley S.] Harvard Univ, Boston, MA 02115 USA.
[White, Emily; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Arslan, Alan A.; Clendenen, Tess V.; Zeleniuch-Jacquotte, Anne] NYU, Sch Med, New York, NY 10003 USA.
[Rohan, Thomas] Albert Einstein Coll Med, New York, NY USA.
[Patel, Alpa V.; Gapstur, Susan M.; Gaudet, Mia M.] Amer Canc Soc, Atlanta, GA 30329 USA.
[Setiawan, V. Wendy] Univ Southern Calif, Los Angeles, CA USA.
[Bernstein, Leslie; Lacey, James V., Jr.] City Hope Natl Med Ctr, Duarte, CA USA.
[Visvanathan, Kala; Hoffman-Bolton, Judith] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Weiderpass, Elisabete; Gram, Inger T.] Univ Tromso Arctic Univ Norway, Tromso, Norway.
[Weiderpass, Elisabete] Canc Registry Norway, Oslo, Norway.
[Weiderpass, Elisabete; Adami, Hans-Olov; Sjoholm, Louise K.; Wolk, Alicja] Karolinska Inst, Stockholm, Sweden.
[Idahl, Annika; Lundin, Eva] Umea Univ, Umea, Sweden.
[Weiderpass, Elisabete] Folkhalsan Res Ctr, Helsinki, Finland.
[Butler, Lesley M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Chamosa, Saioa] BioDonostia Res Inst, San Sebastian, Spain.
[Dossus, Laure] French Inst Hlth & Med Res, Paris, France.
[Rinaldi, Sabina] Int Agcy Res Canc, Lyon, France.
[Fortner, Renee; Kaaks, Rudolf] German Canc Res Ctr, Heidelberg, Germany.
[Jones, Michael; Swerdlow, Anthony] Inst Canc Res, Sutton, Surrey, England.
[Merritt, Melissa A.] Imperial Coll London, London, England.
[Travis, Ruth] Univ Oxford, Oxford, England.
[Kirsh, Victoria] Univ Toronto, Toronto, ON, Canada.
[Koh, Woon-Puay] Duke Univ, Singapore, Singapore.
[Onland-Moret, N. Charlotte] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Schouten, Leo J.; van den Brandt, Piet A.] Maastricht Univ, Maastricht, Netherlands.
[Poynter, Jenny N.] Univ Minnesota, Minneapolis, MN USA.
[Robien, Kim] George Washington Univ, Washington, DC USA.
[Sieri, Sabina] Natl Canc Inst, Rome, Italy.
[Tjonneland, Anna] Danish Canc Soc, Copenhagen, Denmark.
[Trichopoulou, Antonia] Hellenic Hlth Fdn, Athens, Greece.
[Wilkens, Lynne] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
RP Wentzensen, N (reprint author), NCI, Div Canc Epidemiol & Genet, Room 7-E114,9609 Med Ctr Dr, Bethesda, MD 20892 USA.
EM wentzenn@mail.nih.gov
RI Weiderpass, Elisabete/M-4029-2016; Trabert, Britton/F-8051-2015;
Onland-Moret, N. Charlotte/G-9185-2011;
OI Weiderpass, Elisabete/0000-0003-2237-0128; Fortner,
Renee/0000-0002-1426-8505; Robien, Kim/0000-0002-2120-2280; Sandler,
Dale/0000-0002-6776-0018; Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303
FU Department of Defense Ovarian Cancer Research Program
[W81XWH-12-1-0561]; Breakthrough Breast Cancer; Institute of Cancer
Research; National Health Service; National Cancer Institute (NCI) [K05
CA154337]; Office of Dietary Supplements (VITAL [Vitamins and Lifestyle
study cohort]); Iowa Women's Health Study [R01 CA39742]; National
Institutes of Health/NCI grant [UM1 CA182876, CA047988, HL043851,
HL080467, HL099355, CA164973, R01 CA77398, UM1 CA169417, UM1 CA186107,
P01 CA87969, UM1 CA176726, R01 CA67262]; Swedish Cancer Society; Swedish
Research Council; Intramural Research Program of the American Cancer
Society; NCI Intramural Research Program; Intramural Research Program of
the National Institutes of Health; National Institute of Environmental
Health Sciences [Z01ES044005]; European Commission (DG-SANCO);
International Agency for Research on Cancer; Danish Cancer Society
(Denmark); Ligue Contre le Cancer (France); Institut Gustave Roussy
(France); Mutuelle Generale de l'Education Nationale (France); Institut
National de la Sante et de la Recherche Medicale (France); German Cancer
Aid (Germany); German Cancer Research Center (Germany); Federal Ministry
of Education and Research (Germany); Hellenic Health Foundation
(Greece); Associazione Italiana per la Ricerca sul Cancro-Italy;
National Research Council (Italy); Dutch Ministry of Public Health,
Welfare and Sports (the Netherlands); Netherlands Cancer Registry (the
Netherlands); LK Research Funds (the Netherlands); Dutch Prevention
Funds (the Netherlands); Dutch Zorg Onderzoek Nederland (the
Netherlands); World Cancer Research Fund (the Netherlands); Statistics
Netherlands (the Netherlands); Nordic Centre of Excellence Programme on
Food, Nutrition and Health (Norway); Health Research Fund (Spain)
[PI13/00061]; Instituto San Carlos III Las Redes Tematicas de
Investigacion Cooperativa en Salud (Spain) [RD06/0020]; regional
government of Spain (Andalucia); regional government of Spain
(Asturias); regional government of Spain (Basque Country); regional
government of Spain (Murcia) [6236]; regional government of Spain
(Navarra); Swedish Cancer Society (Sweden); Swedish Scientific Council
(Sweden); County Council of Skane (Sweden); County Council of
Vasterbotten (Sweden); Cancer Research UK (United Kingdom) [14136,
C570/A16491]; Medical Research Council (United Kingdom) [1000143]
FX Supported by Department of Defense Ovarian Cancer Research Program Grant
No. W81XWH-12-1-0561. The UK Breakthrough Generations Study is supported
by Breakthrough Breast Cancer and the Institute of Cancer Research. The
Institute for Cancer Research is supported by National Health Service
funding to the National Institute for Health Research Biomedical
Research Centre. Also supported by K05 CA154337 from the National Cancer
Institute (NCI) and Office of Dietary Supplements (VITAL [Vitamins and
Lifestyle study cohort]); R01 CA39742 (Iowa Women's Health Study);
National Institutes of Health/NCI grant UM1 CA182876 (Singapore Chinese
Health Study); CA047988, HL043851, HL080467, and HL099355 (Women's
Health Study); CA164973 (Multiethnic Cohort); R01 CA77398 and UM1
CA169417 (California Teachers Study); UM1 CA186107, P01 CA87969, UM1
CA176726, and R01 CA67262 (Nurses' Health Study, Nurses' Health Study
II); grants from the Swedish Cancer Society and Swedish Research Council
(Swedish Women's Lifestyle and Health cohort study); and the Swedish
Research Council (Swedish Mammography Cohort). All aspects of the Cancer
Prevention Study II were funded by the Intramural Research Program of
the American Cancer Society and by the NCI Intramural Research Program,
Intramural Research Program of the National Institutes of Health, and
National Institute of Environmental Health Sciences (Z01ES044005; Sister
Study). The coordination of European Prospective Investigation Into
Cancer (EPIC) is supported by the European Commission (DG-SANCO) and the
International Agency for Research on Cancer. The national cohorts are
supported by the Danish Cancer Society (Denmark); Ligue Contre le
Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education
Nationale, and Institut National de la Sante et de la Recherche Medicale
(France); German Cancer Aid, German Cancer Research Center, and Federal
Ministry of Education and Research (Germany); Hellenic Health Foundation
(Greece); Associazione Italiana per la Ricerca sul Cancro-Italy and
National Research Council (Italy); Dutch Ministry of Public Health,
Welfare and Sports, Netherlands Cancer Registry, LK Research Funds,
Dutch Prevention Funds, Dutch Zorg Onderzoek Nederland, World Cancer
Research Fund, and Statistics Netherlands (the Netherlands); Nordic
Centre of Excellence Programme on Food, Nutrition and Health (Norway);
Health Research Fund, PI13/00061 to Granada, regional governments of
Spain (Andalucia, Asturias, Basque Country, Murcia [No. 6236], and
Navarra), and Instituto San Carlos III Las Redes Tematicas de
Investigacion Cooperativa en Salud (RD06/0020; Spain); Swedish Cancer
Society, Swedish Scientific Council, and County Councils of Skane and
Vasterbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk,
C570/A16491 to EPIC-Oxford) and Medical Research Council (1000143 to
EPIC-Norfolk; United Kingdom).
NR 38
TC 4
Z9 4
U1 13
U2 14
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 20
PY 2016
VL 34
IS 24
BP 2888
EP +
DI 10.1200/JCO.2016.66.8178
PG 19
WC Oncology
SC Oncology
GA DU8MZ
UT WOS:000382469100014
PM 27325851
ER
PT J
AU Wu, YC
Chandris, P
Winter, PW
Kim, EY
Jaumouille, V
Kumar, A
Guo, M
Leung, JM
Smith, C
Rey-Suarez, I
Liu, HF
Waterman, CM
Ramamurthi, KS
La Riviere, PJ
Shroff, H
AF Wu, Yicong
Chandris, Panagiotis
Winter, Peter W.
Kim, Edward Y.
Jaumouille, Valentin
Kumar, Abhishek
Guo, Min
Leung, Jacqueline M.
Smith, Corey
Rey-Suarez, Ivan
Liu, Huafeng
Waterman, Clare M.
Ramamurthi, Kumaran S.
La Riviere, Patrick J.
Shroff, Hari
TI Simultaneous multiview capture and fusion improves spatial resolution in
wide-field and light-sheet microscopy
SO OPTICA
LA English
DT Article
ID PLANE ILLUMINATION MICROSCOPY; TOXOPLASMA-GONDII; BACILLUS-SUBTILIS;
FLUORESCENCE MICROSCOPY; DECONVOLUTION; LOCALIZATION; SPORULATION;
PROTEIN; 3D
AB Most fluorescence microscopes are inefficient, collecting only a small fraction of the emitted light at any instant. Besides wasting valuable signal, this inefficiency also reduces spatial resolution and causes imaging volumes to exhibit significant resolution anisotropy. We describe microscopic and computational techniques that address these problems by simultaneously capturing and subsequently fusing and deconvolving multiple specimen views. Unlike previous methods that serially capture multiple views, our approach improves spatial resolution without introducing any additional illumination dose or compromising temporal resolution relative to conventional imaging. When applying our methods to single-view wide-field or dual-view light-sheet microscopy, we achieve a twofold improvement in volumetric resolution (similar to 235 nm x 235 nm x 340 nm) as demonstrated on a variety of samples including microtubules in Toxoplasma gondii, SpoVM in sporulating Bacillus subtilis, and multiple protein distributions and organelles in eukaryotic cells. In every case, spatial resolution is improved with no drawback by harnessing previously unused fluorescence. (C) 2016 Optical Society of America
C1 [Wu, Yicong; Chandris, Panagiotis; Winter, Peter W.; Kumar, Abhishek; Guo, Min; Rey-Suarez, Ivan; Shroff, Hari] Natl Inst Biomed Imaging & Bioengn, Sect High Resolut Opt Imaging, NIH, Bethesda, MD 20892 USA.
[Kim, Edward Y.; Ramamurthi, Kumaran S.] NCI, Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.
[Jaumouille, Valentin; Waterman, Clare M.] NHLBI, Cell Biol & Physiol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Guo, Min; Liu, Huafeng] Zhejiang Univ, State Key Lab Modern Opt Instrumentat, Coll Opt Sci & Engn, Hangzhou 310027, Peoples R China.
[Leung, Jacqueline M.] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.
[Smith, Corey; La Riviere, Patrick J.] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
[La Riviere, Patrick J.; Shroff, Hari] Marine Biol Lab, Whitman Ctr, Woods Hole, MA 02543 USA.
RP Wu, YC (reprint author), Natl Inst Biomed Imaging & Bioengn, Sect High Resolut Opt Imaging, NIH, Bethesda, MD 20892 USA.
EM yicong.wu@nih.gov
FU National Institute of Biomedical Imaging and Bioengineering (NIBIB);
National Cancer Institute (NCI); National Heart, Lung, and Blood
Institute (NHLBI); Marine Biological Laboratory (MBL) MBL-UChicago
Exploratory Research Fund Research Award; National Institute of General
Medical Sciences (NIGMS) [R25GM109439]; National Natural Science
Foundation of China (NSFC) [61427807, 61271083, 61525106];
Colciencias-Fulbright Scholarship; March of Dimes Foundation (MODF)
[6-FY15-198]
FX National Institute of Biomedical Imaging and Bioengineering (NIBIB);
National Cancer Institute (NCI); National Heart, Lung, and Blood
Institute (NHLBI); Marine Biological Laboratory (MBL) MBL-UChicago
Exploratory Research Fund Research Award; National Institute of General
Medical Sciences (NIGMS) (R25GM109439); National Natural Science
Foundation of China (NSFC) (61427807, 61271083, 61525106);
Colciencias-Fulbright Scholarship; March of Dimes Foundation (MODF)
(6-FY15-198).
NR 40
TC 2
Z9 2
U1 17
U2 17
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2334-2536
J9 OPTICA
JI Optica
PD AUG 20
PY 2016
VL 3
IS 8
BP 897
EP 910
DI 10.1364/OPTICA.3.000897
PG 14
WC Optics
SC Optics
GA DU1YU
UT WOS:000382007700019
PM 27761486
ER
PT J
AU Dacks, PA
Armstrong, JJ
Brannan, SK
Carman, AJ
Green, AM
Kirkman, MS
Krakoff, LR
Kuller, LH
Launer, LJ
Lovestone, S
Merikle, E
Neumann, PJ
Rockwood, K
Shineman, DW
Stefanacci, RG
Velentgas, P
Viswanathan, A
Whitmer, RA
Williamson, JD
Fillit, HM
AF Dacks, Penny A.
Armstrong, Joshua J.
Brannan, Stephen K.
Carman, Aaron J.
Green, Allan M.
Kirkman, M. Sue
Krakoff, Lawrence R.
Kuller, Lewis H.
Launer, Lenore J.
Lovestone, Simon
Merikle, Elizabeth
Neumann, Peter J.
Rockwood, Kenneth
Shineman, Diana W.
Stefanacci, Richard G.
Velentgas, Priscilla
Viswanathan, Anand
Whitmer, Rachel A.
Williamson, Jeff D.
Fillit, Howard M.
TI A call for comparative effectiveness research to learn whether routine
clinical care decisions can protect from dementia and cognitive decline
SO ALZHEIMERS RESEARCH & THERAPY
LA English
DT Review
DE Comparative effectiveness; Dementia; Alzheimer's; Prevention; Cognitive
decline; Cognitive aging; Comorbidity; Repurposing; Hypertension;
Diabetes
ID CALCIUM-CHANNEL BLOCKERS; ALZHEIMERS-DISEASE; ANTIHYPERTENSIVE DRUGS;
HYPERTENSIVE PATIENTS; PROSPECTIVE COHORT; BLOOD-PRESSURE;
HEART-FAILURE; OLDER-ADULTS; IMPAIRMENT; PREVENTION
AB Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.
C1 [Dacks, Penny A.; Carman, Aaron J.; Shineman, Diana W.; Fillit, Howard M.] Alzheimers Drug Discovery Fdn, 57 West 57th St Suite 901, New York, NY 10019 USA.
[Armstrong, Joshua J.; Rockwood, Kenneth] Dalhousie Univ, Dept Med, Geriatr Med Res Unit, Halifax, NS, Canada.
[Brannan, Stephen K.; Merikle, Elizabeth] Takeda Pharmaceut, Deerfield, IL USA.
[Green, Allan M.] Attorney Law, Cambridge, MA USA.
[Kirkman, M. Sue] Univ N Carolina, Div Endocrinol & Metab, Dept Med, Sch Med, Chapel Hill, NC USA.
[Krakoff, Lawrence R.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Launer, Lenore J.] NIA, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Lovestone, Simon] Univ Oxford, Dept Psychiat, Oxford, England.
[Neumann, Peter J.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA.
[Rockwood, Kenneth] DGI Clin, Halifax, NS, Canada.
[Rockwood, Kenneth] Nova Scotia Hlth Author, Halifax, NS, Canada.
[Stefanacci, Richard G.] Thomas Jefferson Coll Populat Hlth, Access Grp, Philadelphia, PA USA.
[Velentgas, Priscilla] Quintiles Real World Late Phase Res, Sci Affairs, Cambridge, MA USA.
[Viswanathan, Anand] Amer Heart Assoc, Boston, MA USA.
[Viswanathan, Anand] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Stroke Res, Dept Neurol,Hemorrhag Stroke Res Program, Boston, MA USA.
[Whitmer, Rachel A.] Kaiser Permanente Div Res Populat Sci & Brain Agi, Oakland, CA USA.
[Williamson, Jeff D.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA.
RP Dacks, PA (reprint author), Alzheimers Drug Discovery Fdn, 57 West 57th St Suite 901, New York, NY 10019 USA.
EM pdacks@alzdiscovery.org
FU Alzheimer's Drug Discovery Foundation; Canadian Consortium on
Neurodegeneration in Aging; Intramural Research Program, National
Institute on Aging, NIH; NIH-NIA grants [K23 AG028726, R01AG047975]
FX This position paper and the corresponding advisory panel were funded by
the Alzheimer's Drug Discovery Foundation. Support for authors' time was
provided by the Canadian Consortium on Neurodegeneration in Aging (JJA);
the Intramural Research Program, National Institute on Aging, NIH (LJL);
NIH-NIA grants K23 AG028726 and R01AG047975 (AV). Takeda Pharmaceuticals
provided some support for the advisory panel; the American Heart
Association supported the cost of travel for their representative (AV).
NR 68
TC 0
Z9 0
U1 8
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-9193
J9 ALZHEIMERS RES THER
JI Alzheimers Res. Ther.
PD AUG 20
PY 2016
VL 8
AR 33
DI 10.1186/s13195-016-0200-3
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DU9FR
UT WOS:000382522300001
PM 27543171
ER
PT J
AU Berrigan, D
Troiano, RP
Graubard, BI
AF Berrigan, David
Troiano, Richard P.
Graubard, Barry I.
TI BMI and mortality: the limits of epidemiological evidence
SO LANCET
LA English
DT Editorial Material
ID BODY-MASS INDEX; ADULTS; INTERVENTIONS; DISEASE; LIFE
C1 [Berrigan, David; Troiano, Richard P.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Graubard, Barry I.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
RP Berrigan, D (reprint author), NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
EM berrigad@mail.nih.gov
NR 15
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 20
PY 2016
VL 388
IS 10046
BP 734
EP 736
DI 10.1016/S0140-6736(16)30949-7
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT6UH
UT WOS:000381619200005
PM 27423263
ER
PT J
AU Di Angelantonio, E
Bhupathiraju, SN
Wormser, D
Gao, P
Kaptoge, S
de Gonzalez, AB
Cairns, BJ
Huxley, R
Jackson, CL
Joshy, G
Lewington, S
Manson, JE
Murphy, N
Patel, AV
Samet, JM
Woodward, M
Zheng, W
Zhou, M
Bansal, N
Barricarte, A
Carter, B
Cerhan, JR
Collins, R
Smith, GD
Fang, X
Franco, OH
Green, J
Halsey, J
Hildebrand, JS
Jung, KJ
Korda, RJ
McLerran, DF
Moore, SC
O'Keeff, LM
Paige, E
Ramond, A
Reeves, GK
Rolland, B
Sacerdote, C
Sattar, N
Sofianopoulou, E
Stevens, J
Thun, M
Ueshima, H
Yang, L
Yun, YD
Willeit, P
Banks, E
Beral, V
Chen, Z
Gapstur, SM
Gunter, MJ
Hartge, P
Jee, SH
Lam, TH
Peto, R
Potter, JD
Willett, WC
Thompson, SG
Danesh, J
Hu, FB
AF Di Angelantonio, Emanuele
Bhupathiraju, Shilpa N.
Wormser, David
Gao, Pei
Kaptoge, Stephen
de Gonzalez, Amy Berrington
Cairns, Benjamin J.
Huxley, Rachel
Jackson, Chandra L.
Joshy, Grace
Lewington, Sarah
Manson, JoAnn E.
Murphy, Neil
Patel, Alpa V.
Samet, Jonathan M.
Woodward, Mark
Zheng, Wei
Zhou, Maigen
Bansal, Narinder
Barricarte, Aurelio
Carter, Brian
Cerhan, James R.
Collins, Rory
Smith, George Davey
Fang, Xianghua
Franco, Oscar H.
Green, Jane
Halsey, Jim
Hildebrand, Janet S.
Jung, Keum Ji
Korda, Rosemary J.
McLerran, Dale F.
Moore, Steven C.
O'Keeff, Linda M.
Paige, Ellie
Ramond, Anna
Reeves, Gillian K.
Rolland, Betsy
Sacerdote, Carlotta
Sattar, Naveed
Sofianopoulou, Eleni
Stevens, June
Thun, Michael
Ueshima, Hirotsugu
Yang, Ling
Yun, Young Duk
Willeit, Peter
Banks, Emily
Beral, Valerie
Chen, Zhengming
Gapstur, Susan M.
Gunter, Marc J.
Hartge, Patricia
Jee, Sun Ha
Lam, Tai-Hing
Peto, Richard
Potter, John D.
Willett, Walter C.
Thompson, Simon G.
Danesh, John
Hu, Frank B.
CA Global BMI Mortality Collaboration
TI Body-mass index and all-cause mortality: individual-participant-data
meta-analysis of 239 prospective studies in four continents
SO LANCET
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; ABDOMINAL ADIPOSITY; RISK-FACTORS; OBESITY;
ASSOCIATION; POPULATION; OVERWEIGHT; METHODOLOGY; TRENDS; COHORT
AB Background Overweight and obesity are increasing worldwide. To help assess their relevance to mortality in different populations we conducted individual-participant data meta-analyses of prospective studies of body-mass index (BMI), limiting confounding and reverse causality by restricting analyses to never-smokers and excluding pre-existing disease and the first 5 years of follow-up.
Methods Of 10 625 411 participants in Asia, Australia and New Zealand, Europe, and North America from 239 prospective studies (median follow-up 13.7 years, IQR 11.4-14.7), 3 951 455 people in 189 studies were never-smokers without chronic diseases at recruitment who survived 5 years, of whom 385 879 died. The primary analyses are of these deaths, and study, age, and sex adjusted hazard ratios (HRs), relative to BMI 22.5-<25.0 kg/m(2).
Findings All-cause mortality was minimal at 20.0-25.0 kg/m(2) (HR 1.00, 95% CI 0.98-1.02 for BMI 20.0-<22.5 kg/m(2); 1.00, 0.99-1.01 for BMI 22.5-<25.0 kg/m(2)), and increased significantly both just below this range (1.13, 1.09-1.17 for BMI 18.5-<20.0 kg/m(2); 1.51, 1.43-1.59 for BMI 15.0-<18.5) and throughout the overweight range (1.07, 1.07-1.08 for BMI 25.0-<27.5 kg/m(2); 1.20, 1.18-1.22 for BMI 27.5-<30.0 kg/m(2)). The HR for obesity grade 1 (BMI 30.0-<35.0 kg/m(2)) was 1.45, 95% CI 1.41-1.48; the HR for obesity grade 2 (35.0-<40.0 kg/m(2)) was 1.94, 1.87-2.01; and the HR for obesity grade 3 (40.0-<60.0 kg/m(2)) was 2.76, 2.60-2.92. For BMI over 25.0 kg/m(2), mortality increased approximately log-linearly with BMI; the HR per 5 kg/m(2) units higher BMI was 1.39 (1.34-1.43) in Europe, 1.29 (1.26-1.32) in North America, 1.39 (1.34-1.44) in east Asia, and 1.31 (1.27-1.35) in Australia and New Zealand. This HR per 5 kg/m(2) units higher BMI (for BMI over 25 kg/m(2)) was greater in younger than older people (1.52, 95% CI 1.47-1.56, for BMI measured at 35-49 years vs 1.21, 1.17-1.25, for BMI measured at 70-89 years; p(heterogeneity) < 0.0001), greater in men than women (1.51, 1.46-1.56, vs 1.30, 1.26-1.33; p(heterogeneity) < 0.0001), but similar in studies with self-reported and measured BMI.
Interpretation The associations of both overweight and obesity with higher all-cause mortality were broadly consistent in four continents. This finding supports strategies to combat the entire spectrum of excess adiposity in many populations.
C1 [Di Angelantonio, Emanuele; Wormser, David; Gao, Pei; Kaptoge, Stephen; Bansal, Narinder; O'Keeff, Linda M.; Paige, Ellie; Ramond, Anna; Sofianopoulou, Eleni; Willeit, Peter; Thompson, Simon G.; Danesh, John] Univ Cambridge, Cambridge, England.
[Bhupathiraju, Shilpa N.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Gao, Pei] Peking Univ, Beijing 100871, Peoples R China.
[de Gonzalez, Amy Berrington; Hartge, Patricia] Natl Canc Inst, Bethesda, MD USA.
[Cairns, Benjamin J.; Lewington, Sarah; Woodward, Mark; Collins, Rory; Green, Jane; Halsey, Jim; Reeves, Gillian K.; Yang, Ling; Beral, Valerie; Chen, Zhengming; Peto, Richard] Univ Oxford, S Parks Rd, Oxford, England.
[Huxley, Rachel] Curtin Univ, Perth, WA 6845, Australia.
[Jackson, Chandra L.] Harvard Univ, Sch Med, Boston, MA USA.
[Joshy, Grace] Australian Natl Univ, GPO Box 4, Canberra, ACT, Australia.
[Manson, JoAnn E.] Harvard Univ, Sch Med, Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
[Murphy, Neil] Imperial Coll London, London, England.
[Patel, Alpa V.; Carter, Brian; Hildebrand, Janet S.; Thun, Michael; Gapstur, Susan M.] Amer Canc Soc, Atlanta, GA 30329 USA.
[Samet, Jonathan M.] Univ So Calif, Los Angeles, CA USA.
[Woodward, Mark] Univ Sydney, Sydney, NSW, Australia.
[Woodward, Mark] Johns Hopkins Univ, Baltimore, MD USA.
[Zheng, Wei] Vanderbilt Univ Sch Med, Nashville, TN USA.
[Zhou, Maigen] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
[Barricarte, Aurelio] Consortium Biomed Res Epidemiol & Publ Hlth, Navarre Publ Hlth Inst, Pamplona, Spain.
[Cerhan, James R.] Mayo Clin, Rochester, MN USA.
[Smith, George Davey] Univ Bristol, Bristol, Avon, England.
[Fang, Xianghua] Capital Med Univ, Beijing, Peoples R China.
[Franco, Oscar H.] Univ Med Ctr Rotterdam, Rotterdam, Netherlands.
[Jung, Keum Ji; Jee, Sun Ha] Yonsei Univ, Seoul 120749, South Korea.
[Korda, Rosemary J.] Australian Natl Univ, GPO Box 4, Canberra, ACT, Australia.
[McLerran, Dale F.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Moore, Steven C.; Rolland, Betsy] Natl Canc Inst, Bethesda, MD USA.
[Sacerdote, Carlotta] Univ Turin, Ctr Canc Prevent, Turin, Italy.
[Sattar, Naveed] Univ Glasgow, Glasgow, Lanark, Scotland.
[Stevens, June] Univ N Carolina, Chapel Hill, NC USA.
[Ueshima, Hirotsugu] Shiga Univ, Med Sci, Shiga, Japan.
[Yun, Young Duk] Hlth Insurance Policy Res Inst, Seoul, South Korea.
[Willeit, Peter] Med Univ Innsbruck, A-6020 Innsbruck, Austria.
[Banks, Emily] Australian Natl Univ Canberra, Canberra, ACT, Australia.
[Gunter, Marc J.] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.
[Lam, Tai-Hing] Univ Hong Kong, Hong Kong, Peoples R China.
[Potter, John D.] Massey Univ, Wellington, New Zealand.
[Willett, Walter C.; Hu, Frank B.] Harvard Univ, Sch Med, Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
RP Di Angelantonio, E (reprint author), Univ Cambridge, Cambridge, England.
RI Huxley, Rachel/C-7032-2013; Zheng, Wei/O-3351-2013; Woodward,
Mark/D-8492-2015; Moore, Steven/D-8760-2016; Jackson,
Chandra/A-6291-2017; Murphy, Neil/E-1189-2017; Ulmer, Hanno/C-3488-2011;
OI Huxley, Rachel/0000-0002-2705-6616; Zheng, Wei/0000-0003-1226-070X;
Davey Smith, George/0000-0002-1407-8314; Moore,
Steven/0000-0002-8169-1661; Jackson, Chandra/0000-0002-0915-8272;
Murphy, Neil/0000-0003-3347-8249; Ulmer, Hanno/0000-0001-5911-1002;
Ramond, Anna/0000-0002-9958-3693
FU UK Medical Research Council; British Heart Foundation; National
Institute for Health Research; US National Institutes of Health
FX UK Medical Research Council, British Heart Foundation, National
Institute for Health Research, US National Institutes of Health.
NR 43
TC 3
Z9 3
U1 11
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 20
PY 2016
VL 388
IS 10046
BP 776
EP 786
DI 10.1016/S0140-6736(16)30175-1
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT6UH
UT WOS:000381619200026
ER
PT J
AU Koonin, EV
AF Koonin, Eugene V.
TI Viruses and mobile elements as drivers of evolutionary transitions
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Review
DE evolutionary transitions; mobile genetic elements; parasites; viruses;
antivirus defence; host-parasite coevolution
ID RESTRICTION-MODIFICATION SYSTEMS; TOXIN-ANTITOXIN SYSTEMS; PROGRAMMED
CELL-DEATH; CRISPR-CAS SYSTEMS; TRANSPOSABLE ELEMENTS; GENE-TRANSFER;
AGGREGATIVE MULTICELLULARITY; REVERSE-TRANSCRIPTASE; DELETERIOUS
MUTATIONS; COMPARATIVE GENOMICS
AB The history of life is punctuated by evolutionary transitions which engender emergence of new levels of biological organization that involves selection acting at increasingly complex ensembles of biological entities. Major evolutionary transitions include the origin of prokaryotic and then eukaryotic cells, multicellular organisms and eusocial animals. All or nearly all cellular life forms are hosts to diverse selfish genetic elements with various levels of autonomy including plasmids, transposons and viruses. I present evidence that, at least up to and including the origin of multicellularity, evolutionary transitions are driven by the coevolution of hosts with these genetic parasites along with sharing of 'public goods'. Selfish elements drive evolutionary transitions at two distinct levels. First, mathematical modelling of evolutionary processes, such as evolution of primitive replicator populations or unicellular organisms, indicates that only increasing organizational complexity, e.g. emergence ofmulticellular aggregates, can prevent the collapse of the host-parasite system under the pressure of parasites. Second, comparative genomic analysis reveals numerous cases of recruitment of genes with essential functions in cellular life forms, including those that enable evolutionary transitions.
This article is part of the themed issue 'The major synthetic evolutionary transitions'.
C1 [Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
RP Koonin, EV (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
EM koonin@ncbi.nlm.nih.gov
FU US Department of Health and Human Services
FX This research is supported by intramural funds of the US Department of
Health and Human Services (to the National Library of Medicine).
NR 189
TC 2
Z9 2
U1 20
U2 20
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD AUG 19
PY 2016
VL 371
IS 1701
AR 20150442
DI 10.1098/rstb.2015.0442
PG 13
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DX5ZF
UT WOS:000384460600005
ER
PT J
AU Corona, A
Desantis, J
Massari, S
Distinto, S
Masaoka, T
Sabatini, S
Esposito, F
Manfroni, G
Maccioni, E
Cecchetti, V
Pannecouque, C
Le Grice, SFJ
Tramontano, E
Tabarrini, O
AF Corona, Angela
Desantis, Jenny
Massari, Serena
Distinto, Simona
Masaoka, Takashi
Sabatini, Stefano
Esposito, Francesca
Manfroni, Giuseppe
Maccioni, Elias
Cecchetti, Violetta
Pannecouque, Christophe
Le Grice, Stuart F. J.
Tramontano, Enzo
Tabarrini, Oriana
TI Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric
HIV-1 RibonucleaseH Inhibitors
SO CHEMMEDCHEM
LA English
DT Article; Proceedings Paper
CT 23rd National Meeting of the Medicinal-Chemistry-Division of the
Italian-Chemical-Society (DCF-SCI)
CY 2015
CL Salerno, ITALY
SP Italian Chem Soc, Med Chem Div
DE allosterism antiviral agents inhibitors medicinal chemistry
ribonucleases
ID DIKETO ACID-DERIVATIVES; RNASE-H FUNCTION; IMMUNODEFICIENCY-VIRUS
TYPE-1; REVERSE-TRANSCRIPTASE; DUAL INHIBITORS; COLORIMETRIC ASSAY;
DNA-POLYMERASE; ACTIVE-SITE; IDENTIFICATION; RESIDUES
AB Despite the significant progress achieved with combination antiretroviral therapy in the fight against human immunodeficiency virus (HIV) infection, the difficulty to eradicate the virus together with the rapid emergence of multidrug-resistant strains clearly underline a pressing need for innovative agents, possibly endowed with novel mechanisms of action. In this context, owing to its essential role in HIV genome replication, the reverse transcriptase associated ribonucleaseH (RNaseH) has proven to be an appealing target. To identify new RNaseH inhibitors, an in-house cycloheptathiophene-3-carboxamide library was screened; this led to compounds endowed with inhibitory activity, the structural optimization of which led to the catechol derivative 2-(3,4-dihydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (compound 33) with an IC50 value on the RNaseH activity in the nanomolar range. Mechanistic studies suggested selective inhibition of the RNaseH through binding to an innovative allosteric site, which could be further exploited to enrich this class of inhibitors.
C1 [Corona, Angela; Distinto, Simona; Esposito, Francesca; Maccioni, Elias; Tramontano, Enzo] Cittadella Univ Monserrato, Dipartimento Sci Vita & Ambiente, SS554, I-09042 Monserrato, Italy.
[Desantis, Jenny; Massari, Serena; Sabatini, Stefano; Manfroni, Giuseppe; Cecchetti, Violetta; Tabarrini, Oriana] Univ Perugia, Dipartimento Sci Farmaceut, Via Liceo 1, I-06123 Perugia, Italy.
[Masaoka, Takashi; Le Grice, Stuart F. J.] NCI, Basic Res Lab, Frederick, MD 21702 USA.
[Pannecouque, Christophe] Katholieke Univ Leuven, Lab Virol & Chemotherapy, Dept Microbiol & Immunol, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Leuven, Belgium.
RP Tramontano, E (reprint author), Cittadella Univ Monserrato, Dipartimento Sci Vita & Ambiente, SS554, I-09042 Monserrato, Italy.; Tabarrini, O (reprint author), Univ Perugia, Dipartimento Sci Farmaceut, Via Liceo 1, I-06123 Perugia, Italy.
EM tramon@unica.it; oriana.tabarrini@unipg.it
RI Esposito, Francesca/I-8879-2012;
OI Esposito, Francesca/0000-0001-9725-7977; Corona,
Angela/0000-0002-6630-8636
NR 52
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD AUG 19
PY 2016
VL 11
IS 16
SI SI
BP 1709
EP 1720
DI 10.1002/cmdc.201600015
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DW3YT
UT WOS:000383579700007
PM 26990134
ER
PT J
AU Mammoli, V
Bonifazi, A
Dal Ben, D
Giannella, M
Giorgioni, G
Piergentili, A
Pigini, M
Quaglia, W
Thomas, A
Newman, AH
Ferre, S
Sanchez-Soto, M
Keck, TM
Del Bello, F
AF Mammoli, Valerio
Bonifazi, Alessandro
Dal Ben, Diego
Giannella, Mario
Giorgioni, Gianfabio
Piergentili, Alessandro
Pigini, Maria
Quaglia, Wilma
Thomas, Ajiroghene
Newman, Amy H.
Ferre, Sergi
Sanchez-Soto, Marta
Keck, Thomas M.
Del Bello, Fabio
TI A Novel Class of Dopamine D-4 Receptor Ligands Bearing an Imidazoline
Nucleus
SO CHEMMEDCHEM
LA English
DT Article; Proceedings Paper
CT 23rd National Meeting of the Medicinal-Chemistry-Division of the
Italian-Chemical-Society (DCF-SCI)
CY 2015
CL Salerno, ITALY
SP Italian Chem Soc, Med Chem Div
DE D4 receptor antagonists; dopamine; drug design; imidazolines; privileged
structures
ID D3 RECEPTOR; PSYCHIATRIC-DISORDERS; PRIVILEGED STRUCTURES; ERECTILE
DYSFUNCTION; CURRENT PERSPECTIVES; MORPHINE-DEPENDENCE; FORCE-FIELD;
RATS; AGONIST; ANTAGONIST
AB Over the years, the 2-substituted imidazoline nucleus has been demonstrated to be a bioversatile structural motif. In this study, novel imidazoline derivatives bearing a 3- and/or 4-hydroxy- or methoxy-substituted phenyl ring, linked by an ethylene bridge to position2 of an N-benzyl- or N-phenethyl-substituted imidazoline nucleus, were prepared and studied against D-2-like receptor subtypes. Binding studies highlighted that a set of N-phenethylimidazoline compounds are selective for D-4 over D-2 and D-3 receptors. In functional assays, the 3-methoxy-substituted derivative, endowed with the highest D-4 affinity value, and its 3-hydroxy analogue behaved as partial agonists with low intrinsic efficacy and as competitive D-4 antagonists when tested in the presence of the D-2-like receptor agonist quinpirole. Molecular docking analysis, performed using a homology model of the human D-4 receptor developed using the X-ray crystal structure of the antagonist-bound human D-3 receptor as a template, was in accordance with the binding results and provided useful information for the design of novel imidazoline D-4 receptor ligands based on this new scaffold.
C1 [Mammoli, Valerio; Bonifazi, Alessandro; Dal Ben, Diego; Giannella, Mario; Giorgioni, Gianfabio; Piergentili, Alessandro; Pigini, Maria; Quaglia, Wilma; Thomas, Ajiroghene; Del Bello, Fabio] Univ Camerino, Sch Pharm, Med Chem Unit, Via S Agostino 1, I-62032 Camerino, Italy.
[Bonifazi, Alessandro; Newman, Amy H.; Keck, Thomas M.] NIDA, Med Chem Sect, Mol Targets & Medicat Discovery Branch, Intramural Res Program, 333 Cassell Dr, Baltimore, MD 21224 USA.
[Ferre, Sergi; Sanchez-Soto, Marta] NIDA, Integrat Neurobiol Sect, Mol Targets & Medicat Discovery Branch, Intramural Res Program, 333 Cassell Dr, Baltimore, MD 21224 USA.
[Keck, Thomas M.] Rowan Univ, Dept Chem & Biochem, Dept Biomed & Translat Sci, Coll Sci & Math, 201 Mullica Hill Rd, Glassboro, NJ 08028 USA.
RP Del Bello, F (reprint author), Univ Camerino, Sch Pharm, Med Chem Unit, Via S Agostino 1, I-62032 Camerino, Italy.
EM fabio.delbello@unicam.it
RI Ferre, Sergi/K-6115-2014;
OI Ferre, Sergi/0000-0002-1747-1779; Thomas, Ajiroghene/0000-0003-1852-6716
FU Intramural NIH HHS [ZIA DA000424-17]
NR 54
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD AUG 19
PY 2016
VL 11
IS 16
SI SI
BP 1819
EP 1828
DI 10.1002/cmdc.201600022
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DW3YT
UT WOS:000383579700018
PM 26990230
ER
PT J
AU Lauer, MS
AF Lauer, Michael S.
TI Heart Rate Recovery: Coming Back Full-Circle to the Baroreceptor Reflex
SO CIRCULATION RESEARCH
LA English
DT Editorial Material
DE Editorials; blood pressure; cohort studies; dogs; heart rate; myocardial
infarction
ID TREADMILL EXERCISE; SUDDEN-DEATH; MORTALITY; PREDICTOR; DISEASE
C1 [Lauer, Michael S.] NIH, Off Extramural Res, One Ctr Dr,Bldg 1,Room 144, Bethesda, MD 20892 USA.
RP Lauer, MS (reprint author), NIH, Off Extramural Res, One Ctr Dr,Bldg 1,Room 144, Bethesda, MD 20892 USA.
EM michael.lauer@nih.gov
FU Intramural NIH HHS [Z99 OD999999]
NR 13
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD AUG 19
PY 2016
VL 119
IS 5
BP 582
EP 583
DI 10.1161/CIRCRESAHA.116.309392
PG 2
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA DV9RN
UT WOS:000383279000005
PM 27539969
ER
PT J
AU Maric-Bilkan, C
Galis, ZS
AF Maric-Bilkan, Christine
Galis, Zorina S.
TI Trends in NHLBI-Funded Research on Sex Differences in Hypertension
SO CIRCULATION RESEARCH
LA English
DT Article
DE blood pressure; cardiovascular disease; hypertension; research; sex
hormones
ID AMERICAN-HEART-ASSOCIATION; II-INDUCED HYPERTENSION; T-CELL; DISEASE;
UPDATE
AB Although sex differences in blood pressure levels and the prevalence of hypertension are well recognized, the mechanisms responsible for this sexual dimorphism remain poorly understood. To gain a better understanding of the research funding trends in the field of sex differences related to hypertension and the main research topics funded by the National Heart, Lung, and Blood Institute (NHLBI), we analyzed the entire NHLBI award portfolio between fiscal years (FYs) 1991 to 2014. Using specific search terms to define "sex differences," we interrogated the publicly available list of NHLBI-funded awards active in FY1991 to FY2014 in the National Institutes of Health (NIH) Research Portfolio Online Reporting (RePORTER) database. We further analyzed and categorized awards according to a disease focus and whether each award was directly focused on comparing males versus females, or examining the effects of sex hormones in either sex. The number of NHLBI awards related to " sex differences in hypertension" progressively increased from FY1991 to FY2014, for a cumulative total of 486 awards during the entire period analyzed. The overall dollar investment has also progressively increased from $0.5 million (FY1991) to $18.3 million (FY2014), for a cumulative total of $187 million during FY1991 to FY2014. When compared with global funding trends, NHLBI seems to be the largest funder of research on " sex differences in hypertension" in the world. Importantly, the increased NHLBI investment in sex differences in hypertension research has enabled the investigation of an increased diversity of scientific topics. Although NHLBI is funding an increasing number of awards related to " sex differences in hypertension," there are still many unanswered questions related to the mechanisms underlying this disparity.
C1 [Maric-Bilkan, Christine; Galis, Zorina S.] NHLBI, NIH, Div Cardiovasc Sci, Vasc Biol & Hypertens Branch, 6701 Rockledge Dr,Room 8110, Bethesda, MD 20892 USA.
RP Maric-Bilkan, C (reprint author), NHLBI, NIH, Div Cardiovasc Sci, Vasc Biol & Hypertens Branch, 6701 Rockledge Dr,Room 8110, Bethesda, MD 20892 USA.
EM christine.maric-bilkan@nih.gov
NR 12
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD AUG 19
PY 2016
VL 119
IS 5
BP 591
EP 595
DI 10.1161/CIRCRESAHA.116.308963
PG 5
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA DV9RN
UT WOS:000383279000008
PM 27539972
ER
PT J
AU Schmidt, T
Ye, F
Situ, AJ
An, W
Ginsberg, MH
Ulmer, TS
AF Schmidt, Thomas
Ye, Feng
Situ, Alan J.
An, Woojin
Ginsberg, Mark H.
Ulmer, Tobias S.
TI A Conserved Ectodomain-Transmembrane Domain Linker Motif Tunes the
Allosteric Regulation of Cell Surface Receptors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE allosteric regulation; cytokine; integrin; isothermal titration
calorimetry (ITC); nuclear magnetic resonance (NMR); protein dynamics;
receptor signaling; transmembrane cell surface receptors
ID GROWTH-FACTOR RECEPTOR; INTEGRIN ACTIVATION; DIPOLAR COUPLINGS; PROTEIN
STRUCTURES; MEMBRANE-PROTEINS; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY;
CHEMICAL-SHIFTS; ALPHA-SUBUNIT; COMPLEX
AB In many families of cell surface receptors, a single transmembrane (TM) -helix separates ecto- and cytosolic domains. A defined coupling of ecto- and TM domains must be essential to allosteric receptor regulation but remains little understood. Here, we characterize the linker structure, dynamics, and resulting ecto-TM domain coupling of integrin IIb in model constructs and relate it to other integrin subunits by mutagenesis. Cellular integrin activation assays subsequently validate the findings in intact receptors. Our results indicate a flexible yet carefully tuned ecto-TM coupling that modulates the signaling threshold of integrin receptors. Interestingly, a proline at the N-terminal TM helix border, termed NBP, is critical to linker flexibility in integrins. NBP is further predicted in 21% of human single-pass TM proteins and validated in cytokine receptors by the TM domain structure of the cytokine receptor common subunit and its P441A-substituted variant. Thus, NBP is a conserved uncoupling motif of the ecto-TM domain transition and the degree of ecto-TM domain coupling represents an important parameter in the allosteric regulation of diverse cell surface receptors.
C1 [Schmidt, Thomas; Situ, Alan J.; Ulmer, Tobias S.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
[Schmidt, Thomas; Situ, Alan J.; Ulmer, Tobias S.] Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA.
[Ye, Feng; Ginsberg, Mark H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[An, Woojin] Univ Southern Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
[An, Woojin] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
[Schmidt, Thomas] NIDDK, Chem Phys Lab, NIH, Bldg 2, Bethesda, MD 20892 USA.
RP Ulmer, TS (reprint author), 1501 San Pablo St,ZNI 111, Los Angeles, CA 90033 USA.
EM tulmer@usc.edu
FU American Heart Association [15GRNT23200010]; National Institutes of
Health [HL31950, HL078784, HL117807]
FX This work was supported by American Heart Association Grant
15GRNT23200010 (to T. S. U.) and National Institutes of Health Grants
HL31950, HL078784, and HL117807 (to M. H. G.). The authors declare that
they have no conflicts of interest with the contents of this article.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health.
NR 60
TC 3
Z9 3
U1 3
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 19
PY 2016
VL 291
IS 34
BP 17536
EP 17546
DI 10.1074/jbc.M116.733683
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV9DX
UT WOS:000383241300006
PM 27365391
ER
PT J
AU Zhou, BY
Ritt, DA
Morrison, DK
Der, CJ
Cox, AD
AF Zhou, Bingying
Ritt, Daniel A.
Morrison, Deborah K.
Der, Channing J.
Cox, Adrienne D.
TI Protein Kinase CK2 Maintains Extracellular Signal-regulated Kinase (ERK)
Activity in a CK2 Kinase-independent Manner to Promote Resistance to
Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE drug resistance; dual specificity phosphoprotein phosphatase;
extracellular signal-regulated kinase (ERK); melanoma; Ras protein; CK2;
kinase suppressor of RAS 1 (KSR1)
ID PANCREATIC-CANCER; ACTIVATION; CK2-ALPHA; CELLS; PHOSPHORYLATES;
CARCINOMA; SURVIVAL; LEUKEMIA; COMPLEX
AB The protein kinase casein kinase 2 (CK2) is a pleiotropic and constitutively active kinase that plays crucial roles in cellular proliferation and survival. Overexpression of CK2, particularly the catalytic subunit (CK2, CSNK2A1), has been implicated in a wide variety of cancers and is associated with poorer survival and resistance to both conventional and targeted anticancer therapies. Here, we found that CK2 protein is elevated in melanoma cell lines compared with normal human melanocytes. We then tested the involvement of CK2 in drug resistance to Food and Drug Administration-approved single agent targeted therapies for melanoma. In BRAF mutant melanoma cells, ectopic CK2 decreased sensitivity to vemurafenib (BRAF inhibitor), dabrafenib (BRAF inhibitor), and trametinib (MEK inhibitor) by a mechanism distinct from that of mutant NRAS. Conversely, knockdown of CK2 sensitized cells to inhibitor treatment. CK2-mediated RAF-MEK kinase inhibitor resistance was tightly linked to its maintenance of ERK phosphorylation. We found that CK2 post-translationally regulates the ERK-specific phosphatase dual specificity phosphatase 6 (DUSP6) in a kinase dependent-manner, decreasing its abundance. However, we unexpectedly showed, by using a kinase-inactive mutant of CK2, that RAF-MEK inhibitor resistance did not rely on CK2 kinase catalytic function, and both wild-type and kinase-inactive CK2 maintained ERK phosphorylation upon inhibition of BRAF or MEK. That both wild-type and kinase-inactive CK2 bound equally well to the RAF-MEK-ERK scaffold kinase suppressor of Ras 1 (KSR1) suggested that CK2 increases KSR facilitation of ERK phosphorylation. Accordingly, CK2 did not cause resistance to direct inhibition of ERK by the ERK1/2-selective inhibitor SCH772984. Our findings support a kinase-independent scaffolding function of CK2 that promotes resistance to RAF- and MEK-targeted therapies.
C1 [Zhou, Bingying; Der, Channing J.; Cox, Adrienne D.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
[Der, Channing J.; Cox, Adrienne D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Cox, Adrienne D.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
[Ritt, Daniel A.; Morrison, Deborah K.] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
RP Cox, AD (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
EM adrienne_cox@med.unc.edu
FU National Institutes of Health [CA042978, CA179193, CA199235]; NCI [ZIA
BC 010329]; Pancreatic Cancer Action Network-American Association for
Cancer Research
FX This work was supported by National Institutes of Health Grants
CA042978, CA179193, and CA199235 (to A. D. C. and C. J. D.) and ZIA BC
010329 from the NCI (to D. K. M. and D. A. R.) and by the Pancreatic
Cancer Action Network-American Association for Cancer Research (to A. D.
C. and C. J. D.). The authors declare that they have no conflicts of
interest with the contents of this article. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.
NR 40
TC 0
Z9 0
U1 7
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 19
PY 2016
VL 291
IS 34
BP 17804
EP 17815
DI 10.1074/jbc.M115.712885
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV9DX
UT WOS:000383241300027
PM 27226552
ER
PT J
AU Atwood, BL
Woolnough, JL
Lefevre, GM
Ribeiro, MS
Felsenfeld, G
Giles, KE
AF Atwood, Blake L.
Woolnough, Jessica L.
Lefevre, Gaelle M.
Ribeiro, Mariana Saint Just
Felsenfeld, Gary
Giles, Keith E.
TI Human Argonaute 2 Is Tethered to Ribosomal RNA through MicroRNA
Interactions
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Argonaute; ChIP-sequencing (ChIP-seq); Dicer; microRNA (miRNA);
ribosomal ribonucleic acid (rRNA) (ribosomal RNA); miRNA; par-clip; rRNA
ID HUMAN-CELLS; GENE-EXPRESSION; BINDING-SITES; POLYMERASE I; PAR-CLIP;
TARGET; NUCLEOLUS; PROTEIN; HETEROCHROMATIN; DICER
AB The primary role of the RNAi machinery is to promote mRNA degradation within the cytoplasm in a microRNA-dependent manner. However, both Dicer and the Argonaute protein family have expanded roles in gene regulation within the nucleus. To further our understanding of this role, we have identified chromatin binding sites for AGO2 throughout the 45S region of the human rRNA gene. The location of these sites was mirrored by the positions of AGO2 cross-linking sites identified via PAR-CLIP-seq. AGO2 binding to the rRNA within the nucleus was confirmed by RNA immunoprecipitation and quantitative-PCR. To explore a possible mechanism by which AGO2 could be recruited to the rRNA, we identified 1174 regions within the 45S rRNA transcript that have the ability to form a perfect duplex with position 2-6 (seed sequence) of each microRNA expressed in HEK293T cells. Of these potential AGO2 binding sites, 479 occurred within experimentally verified AGO2-rRNA cross-linking sites. The ability of AGO2 to cross-link to rRNA was almost completely lost in a DICER knock-out cell line. The transfection of miR-92a-2-3p into the noDICE cell line facilitated AGO2 cross-linking at a region of the rRNA that has a perfect seed match at positions 3-8, including a single G-U base pair. Knockdown of AGO2 within HEK293T cells causes a slight, but statistically significant increase in the overall rRNA synthesis rate but did not impact the ratio of processing intermediates or the recruitment of the Pol I transcription factor UBTF.
C1 [Atwood, Blake L.; Woolnough, Jessica L.; Ribeiro, Mariana Saint Just; Giles, Keith E.] Univ Alabama Birmingham, UAB Stem Cell Inst, Dept Biochem & Mol Genet, Birmingham, AL 35209 USA.
[Lefevre, Gaelle M.; Felsenfeld, Gary] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Giles, KE (reprint author), Univ Alabama Birmingham, UAB Stem Cell Inst, Dept Biochem & Mol Genet, Birmingham, AL 35209 USA.
EM kegiles@uab.edu
FU National Institutes of Health, NIDDK Intramural Research Program
FX This work was supported in part by the National Institutes of Health,
NIDDK Intramural Research Program. The authors declare that they have no
conflicts of interest with the contents of this article. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
NR 60
TC 0
Z9 0
U1 6
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 19
PY 2016
VL 291
IS 34
BP 17919
EP 17928
DI 10.1074/jbc.M116.725051
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV9DX
UT WOS:000383241300035
PM 27288410
ER
PT J
AU Tatusova, T
DiCuccio, M
Badretdin, A
Chetvernin, V
Nawrocki, EP
Zaslavsky, L
Lomsadze, A
Pruitt, K
Borodovsky, M
Ostell, J
AF Tatusova, Tatiana
DiCuccio, Michael
Badretdin, Azat
Chetvernin, Vyacheslav
Nawrocki, Eric P.
Zaslavsky, Leonid
Lomsadze, Alexandre
Pruitt, Kimd.
Borodovsky, Mark
Ostell, James
TI NCBI prokaryotic genome annotation pipeline
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID MICROBIAL GENOMES; PAN-GENOME; DATABASE; PREDICTION; CLASSIFICATION;
RESOURCES
AB Recent technological advances have opened unprecedented opportunities for large-scale sequencing and analysis of populations of pathogenic species in disease outbreaks, as well as for large-scale diversity studies aimed at expanding our knowledge across the whole domain of prokaryotes. To meet the challenge of timely interpretation of structure, function and meaning of this vast genetic information, a comprehensive approach to automatic genome annotation is critically needed. In collaboration with Georgia Tech, NCBI has developed a new approach to genome annotation that combines alignment based methods with methods of predicting protein-coding and RNA genes and other functional elements directly from sequence. A new gene finding tool, GeneMarkS+, uses the combined evidence of protein and RNA placement by homology as an initial map of annotation to generate and modify ab initio gene predictions across the whole genome. Thus, the new NCBI's Prokaryotic Genome Annotation Pipeline (PGAP) relies more on sequence similarity when confident comparative data are available, while it relies more on statistical predictions in the absence of external evidence. The pipeline provides a framework for generation and analysis of annotation on the full breadth of prokaryotic taxonomy. For additional information on PGAP see https://www.ncbi.nlm.nih.gov/genome/annotation prok/ and the NCBI Handbook, https://www.ncbi.nlm.nih.gov/books/NBK174280/.
C1 [Tatusova, Tatiana; DiCuccio, Michael; Badretdin, Azat; Chetvernin, Vyacheslav; Nawrocki, Eric P.; Zaslavsky, Leonid; Pruitt, Kimd.; Ostell, James] US Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA.
[Lomsadze, Alexandre; Borodovsky, Mark] Georgia Tech, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
[Borodovsky, Mark] Georgia Tech, Sch Computat Sci & Engn, Atlanta, GA 30332 USA.
RP Borodovsky, M (reprint author), Georgia Tech, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.; Borodovsky, M (reprint author), Georgia Tech, Sch Computat Sci & Engn, Atlanta, GA 30332 USA.
EM borodovsky@gatech.edu
FU Intramural Research Program of the NIH National Library of Medicine; NIH
[HG000783]
FX Intramural Research Program of the NIH National Library of Medicine (in
part); the work of M.B. and A.L. was supported in part by NIH grant
HG000783 to M.B. Funding for open access charge: Intramural Research
Program of the NIH National Library of Medicine.
NR 36
TC 15
Z9 15
U1 6
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG 19
PY 2016
VL 44
IS 14
BP 6614
EP 6624
DI 10.1093/nar/gkw569
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV5VX
UT WOS:000382999900013
PM 27342282
ER
PT J
AU Arbel-Goren, R
Tal, A
Parasar, B
Dym, A
Costantino, N
Munoz-Garcia, J
Court, DL
Stavans, J
AF Arbel-Goren, Rinat
Tal, Asaf
Parasar, Bibudha
Dym, Alvah
Costantino, Nina
Munoz-Garcia, Javier
Court, Donald L.
Stavans, Joel
TI Transcript degradation and noise of small RNA-controlled genes in a
switch activated network in Escherichia coli
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID BACTERIAL SMALL RNAS; RYHB SMALL RNA; SMALL REGULATORY RNAS;
MESSENGER-RNA; NONCODING RNA; PHENOTYPIC NOISE; IRON HOMEOSTASIS;
HFQ-BINDING; EXPRESSION; TARGETS
AB Post-transcriptional regulatory processes may change transcript levels and affect cell-to-cell variability or noise. We study small-RNA downregulation to elucidate its effects on noise in the iron homeostasis network of Escherichia coli. In this network, the small-RNA RyhB undergoes stoichiometric degradation with the transcripts of target genes in response to iron stress. Using single-molecule fluorescence in situ hybridization, we measured transcript numbers of the RyhB-regulated genes sodB and fumA in individual cells as a function of iron deprivation. We observed a monotonic increase of noise with iron stress but no evidence of theoretically predicted, enhanced stoichiometric fluctuations in transcript numbers, nor of bistable behavior in transcript distributions. Direct detection of RyhB in individual cells shows that its noise is much smaller than that of these two targets, when RyhB production is significant. A generalized two-state model of bursty transcription that neglects RyhB fluctuations describes quantitatively the dependence of noise and transcript distributions on iron deprivation, enabling extraction of in vivo RyhB-mediated transcript degradation rates. The transcripts' threshold-linear behavior indicates that the effective in vivo interaction strength between RyhB and its two target transcripts is comparable. Strikingly, the bacterial cell response exhibits Furdependent, switch-like activation instead of a graded response to iron deprivation.
C1 [Arbel-Goren, Rinat; Tal, Asaf; Parasar, Bibudha; Dym, Alvah; Munoz-Garcia, Javier; Stavans, Joel] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.
[Costantino, Nina; Court, Donald L.] NCI, Gene Regulat & Chromosome Biol Lab, Frederick, MD 21702 USA.
[Munoz-Garcia, Javier] Univ Carlos III Madrid, Dept Matemat, Ave Univ 30, Madrid 28911, Spain.
[Munoz-Garcia, Javier] Univ Carlos III Madrid, GISC, Ave Univ 30, Madrid 28911, Spain.
RP Stavans, J (reprint author), Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.; Court, DL (reprint author), NCI, Gene Regulat & Chromosome Biol Lab, Frederick, MD 21702 USA.
EM courtd@mail.nih.gov; joel.stavans@weizmann.ac.il
RI Munoz-Garcia, Javier/C-1135-2011
OI Munoz-Garcia, Javier/0000-0002-7594-9507
FU Israel Science Foundation [514415]; Feinberg Foundation Visiting Faculty
Program; MICINN (Spain) [FIS2012-32349]; Intramural Research Program of
the National Institutes of Health; National Cancer Institute; Center for
Cancer Research; Siegfried and Irma Ullman Professorial Chair
FX Israel Science Foundation [514415 to J.S.]; Feinberg Foundation Visiting
Faculty Program (to J.M.-G.); MICINN (Spain) [FIS2012-32349 to J.M.-G.];
Intramural Research Program of the National Institutes of Health (to
D.L.C.); National Cancer Institute (to D.L.C.); Center for Cancer
Research (to D.L.C.); Siegfried and Irma Ullman Professorial Chair (to
J.S.). Funding for open access charge: Israel Science Foundation.
NR 73
TC 1
Z9 1
U1 5
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG 19
PY 2016
VL 44
IS 14
BP 6707
EP 6720
DI 10.1093/nar/gkw273
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV5VX
UT WOS:000382999900020
PM 27085802
ER
PT J
AU Ni, T
Yang, WJ
Han, M
Zhang, YB
Shen, T
Nie, HB
Zhou, ZH
Dai, YL
Yang, YQ
Liu, PC
Cui, KR
Zeng, ZH
Tian, Y
Zhou, B
Wei, G
Zhao, KJ
Peng, WQ
Zhu, J
AF Ni, Ting
Yang, Wenjing
Han, Miao
Zhang, Yubo
Shen, Ting
Nie, Hongbo
Zhou, Zhihui
Dai, Yalei
Yang, Yanqin
Liu, Poching
Cui, Kairong
Zeng, Zhouhao
Tian, Yi
Zhou, Bin
Wei, Gang
Zhao, Keji
Peng, Weiqun
Zhu, Jun
TI Global intron retention mediated gene regulation during CD4(+) T cell
activation
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CO-TRANSCRIPTIONAL REGULATION; HUMAN GENOME; DNA METHYLATION;
COORDINATED REGULATION; HISTONE MODIFICATION; CHROMATIN-STATE; RNA;
DIFFERENTIATION; EXPRESSION; PATHWAYS
AB T cell activation is a well-established model for studying cellular responses to exogenous stimulation. Using strand-specific RNA-seq, we observed that intron retention is prevalent in polyadenylated transcripts in resting CD4(+) T cells and is significantly reduced upon T cell activation. Several lines of evidence suggest that intron-retained transcripts are less stable than fully spliced transcripts. Strikingly, the decrease in intron retention (IR) levels correlate with the increase in steady-state mRNA levels. Further, the majority of the genes upregulated in activated T cells are accompanied by a significant reduction in IR. Of these 1583 genes, 185 genes are predominantly regulated at the IR level, and highly enriched in the proteasome pathway, which is essential for proper T cell proliferation and cytokine release. These observations were corroborated in both human and mouse CD4(+) T cells. Our study revealed a novel post-transcriptional regulatory mechanism that may potentially contribute to coordinated and/or quick cellular responses to extracellular stimuli such as an acute infection.
C1 [Ni, Ting; Han, Miao; Shen, Ting; Nie, Hongbo; Zhou, Bin; Wei, Gang] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.
[Ni, Ting; Han, Miao; Shen, Ting; Nie, Hongbo; Zhou, Bin; Wei, Gang] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, MOE Key Lab Contemporary Anthropol, Shanghai 200438, Peoples R China.
[Yang, Wenjing; Zhang, Yubo; Yang, Yanqin; Liu, Poching; Cui, Kairong; Zhao, Keji; Zhu, Jun] NHLBI, Syst Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Zhou, Zhihui; Dai, Yalei] Tongji Univ, Sch Med, Dept Immunol, Shanghai 200092, Peoples R China.
[Zeng, Zhouhao; Tian, Yi; Peng, Weiqun] George Washington Univ, Dept Phys, Washington, DC 20052 USA.
[Tian, Yi] Third Mil Med Univ, PLA, Inst Immunol, Chongqing 400038, Peoples R China.
RP Ni, T (reprint author), Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.; Ni, T (reprint author), Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, MOE Key Lab Contemporary Anthropol, Shanghai 200438, Peoples R China.; Zhu, J (reprint author), NHLBI, Syst Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.; Peng, WQ (reprint author), George Washington Univ, Dept Phys, Washington, DC 20052 USA.
EM tingni@fudan.edu.cn; wpeng@gwu.edu; jun.zhu@nih.gov
FU National Institute of Health (NIH) [Division of Intramural Research of
National Heart Lung and Blood Institute] [1R21AI113806]; National Key
Basic Research Program of China [973 programs] [2013CB530700,
2015CB943000, 2012CB518700]; National Science Foundation of China
[31271348, 31471192]; Innovation Project of Shanghai Municipal Education
Commission [14ZZ007]; Thousand Talents Plan of China; 111 Project of
China [B13016]
FX National Institute of Health (NIH) [Division of Intramural Research of
National Heart Lung and Blood Institute to K. Z. and J. Z.; 1R21AI113806
to W. P.]; National Key Basic Research Program of China [973 programs:
2013CB530700 and 2015CB943000 to T. N., 2012CB518700 to Y. D.]; National
Science Foundation of China [31271348 and 31471192 to T. N.]; Innovation
Project of Shanghai Municipal Education Commission [14ZZ007 to T. N.];
Thousand Talents Plan of China and the 111 Project of China (B13016).
NR 61
TC 2
Z9 2
U1 8
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG 19
PY 2016
VL 44
IS 14
BP 6817
EP 6829
DI 10.1093/nar/gkw591
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV5VX
UT WOS:000382999900029
PM 27369383
ER
PT J
AU Metifiot, M
Johnson, BC
Kiselev, E
Marler, L
Zhao, XZ
Burke, TR
Marchand, C
Hughes, SH
Pommier, Y
AF Metifiot, Mathieu
Johnson, Barry C.
Kiselev, Evgeny
Marler, Laura
Zhao, Xue Zhi
Burke, Terrence R., Jr.
Marchand, Christophe
Hughes, Stephen H.
Pommier, Yves
TI Selectivity for strand-transfer over 3 '-processing and susceptibility
to clinical resistance of HIV-1 integrase inhibitors are driven by key
enzyme-DNA interactions in the active site
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID VIRAL-DNA; MOLECULAR-DYNAMICS; CROSS-RESISTANCE; FLEXIBLE LOOP;
IN-VITRO; RALTEGRAVIR; ELVITEGRAVIR; BINDING; MUTANTS; DOLUTEGRAVIR
AB Integrase strand transfer inhibitors (INSTIs) are highly effective against HIV infections. Co-crystal structures of the prototype foamy virus intasome have shown that all three FDA-approved drugs, raltegravir (RAL), elvitegravir and dolutegravir (DTG), act as interfacial inhibitors during the strand transfer (ST) integration step. However, these structures give only a partial sense for the limited inhibition of the 3'-processing reaction by INSTIs and how INSTIs can be modified to overcome drug resistance, notably against the G140S-Q148H double mutation. Based on biochemical experiments with modified oligonucleotides, we demonstrate that both the viral DNA + 1 and -1 bases, which flank the 3'-processing site, play a critical role for 3'-processing efficiency and inhibition by RAL and DTG. In addition, the G140S-Q148H (SH) mutant integrase, which has a reduced 3'-processing activity, becomes more active and more resistant to inhibition of 3'-processing by RAL and DTG in the absence of the -1 and + 1 bases. Molecular modeling of HIV-1 integrase, together with biochemical data, indicate that the conserved residue Q146 in the flexible loop of HIV-1 integrase is critical for productive viral DNA binding through specific contacts with the virus DNA ends in the 3'-processing and ST reactions. The potency of integrase inhibitors against 3'-processing and their ability to overcome resistance is discussed.
C1 [Metifiot, Mathieu; Kiselev, Evgeny; Marler, Laura; Marchand, Christophe; Pommier, Yves] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, 37 Convent Dr, Bethesda, MD 20892 USA.
[Metifiot, Mathieu; Kiselev, Evgeny; Marler, Laura; Marchand, Christophe; Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr, Bethesda, MD 20892 USA.
[Johnson, Barry C.; Hughes, Stephen H.] NCI, HIV Dynam & Replicat Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
[Zhao, Xue Zhi; Burke, Terrence R., Jr.] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
[Metifiot, Mathieu] Univ Bordeaux, Lab Microbiol Fondamentale & Pathogen, CNRS UMR 5234, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
RP Metifiot, M; Pommier, Y (reprint author), NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, 37 Convent Dr, Bethesda, MD 20892 USA.; Metifiot, M; Pommier, Y (reprint author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr, Bethesda, MD 20892 USA.; Metifiot, M (reprint author), Univ Bordeaux, Lab Microbiol Fondamentale & Pathogen, CNRS UMR 5234, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM mathieu.metifiot@u-bordeaux.fr; pommier@nih.gov
FU Intramural Program of the National Cancer Institute; Center for Cancer
Research [Z01 BC 007333, ZIA BC 007363]; Intramural AIDS Targeted
Antiviral Program (IATAP); National Institutes of Health; Developmental
Therapeutics Branch; Laboratory of Molecular Pharmacology; CCR/NCI/NIH
FX Intramural Program of the National Cancer Institute; Center for Cancer
Research [Z01 BC 007333, ZIA BC 007363]; Intramural AIDS Targeted
Antiviral Program (IATAP); National Institutes of Health. Funding for
open access charge: Developmental Therapeutics Branch; Laboratory of
Molecular Pharmacology; CCR/NCI/NIH.
NR 47
TC 0
Z9 0
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG 19
PY 2016
VL 44
IS 14
BP 6896
EP 6906
DI 10.1093/nar/gkw592
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV5VX
UT WOS:000382999900035
PM 27369381
ER
PT J
AU Lee, HJ
Gottesman, S
AF Lee, Hyun-Jung
Gottesman, Susan
TI sRNA roles in regulating transcriptional regulators: Lrp and SoxS
regulation by sRNAs
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID TRANSPORTER MESSENGER-RNAS; OXIDATIVE STRESS REGULON; BINDING SMALL
RNAS; GCVB SMALL RNA; COLI CRP GENE; ESCHERICHIA-COLI; H-NS; GLOBAL
REGULATOR; LIPOPOLYSACCHARIDE MODIFICATION; POSTTRANSCRIPTIONAL
REGULATION
AB Post-transcriptional regulation of transcription factors contributes to regulatory circuits. We created translational reporter fusions for multiple central regulators in Escherichia coli and examined the effect of Hfq-dependent non-coding RNAs on these fusions. This approach yields an 'RNA landscape,' identifying Hfq-dependent sRNAs that regulate a given fusion. No significant sRNA regulation of crp or fnr was detected. hns was regulated only by DsrA, as previously reported. Lrp and SoxS were both found to be regulated post-transcriptionally. Lrp, 'leucineresponsive regulatory protein,' regulates genes involved in amino acid biosynthesis and catabolism and other cellular functions. sRNAs DsrA, MicF and GcvB each independently downregulate thelrp translational fusion, confirming previous reports for MicF and GcvB. MicF and DsrA interact with an overlapping site early in the lrp ORF, while GcvB acts upstream at two independent sites in the long lrp leader. Surprisingly, GcvB was found to be responsible for significant downregulation of lrp after oxidative stress; MicF also contributed. SoxS, an activator of genes used to combat oxidative stress, is negatively regulated by sRNA MgrR. This study demonstrates that while not all global regulators are subject to sRNA regulation, post-transcriptional control by sRNAs allows multiple environmental signals to affect synthesis of the transcriptional regulator.
C1 [Lee, Hyun-Jung; Gottesman, Susan] NCI, Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.
[Lee, Hyun-Jung] Ajou Univ, Sch Med, Dept Biomed Sci, Suwon 443380, South Korea.
RP Gottesman, S (reprint author), NCI, Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM Gottesms@helix.nih.gov
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Center for Cancer Research
FX Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Center for Cancer Research. Funding for open
access charge: Center for Cancer Research intramural funding.
NR 83
TC 4
Z9 4
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG 19
PY 2016
VL 44
IS 14
BP 6907
EP 6923
DI 10.1093/nar/gkw358
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV5VX
UT WOS:000382999900036
PM 27137887
ER
PT J
AU Hao, Y
Updegrove, TB
Livingston, NN
Storz, G
AF Hao, Yue
Updegrove, Taylor B.
Livingston, Natasha N.
Storz, Gisela
TI Protection against deleterious nitrogen compounds: role of
sigma(S)-dependent small RNAs encoded adjacent to sdiA
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID SMALL NONCODING RNA; ESCHERICHIA-COLI; MESSENGER-RNA; SOLUBLE-RNA;
OUTER-MEMBRANE; REGULATORY RNAS; GENE-EXPRESSION; E. COLI; HFQ; RPOS
AB Here, we report the characterization of a set of small, regulatory RNAs (sRNAs) expressed from an Escherichia coli locus we have denoted sdsN located adjacent to the LuxR-homolog gene sdiA. Two longer sRNAs, SdsN(137) and SdsN(178) are transcribed from two sigma(S)-dependent promoters but share the same terminator. Low temperature, rich nitrogen sources and the Crl and NarP transcription factors differentially affect the levels of the SdsN transcripts. Whole genome expression analysis after pulse overexpression of SdsN(137) and assays of lacZ fusions revealed that the SdsN(137) directly represses the synthesis of the nitroreductase NfsA, which catalyzes the reduction of the nitrogroup (NO2) in nitroaromatic compounds and the flavohemoglobin HmpA, which has aerobic nitric oxide (NO) dioxygenase activity. Consistent with this regulation, SdsN(137) confers resistance to nitrofurans. In addition, SdsN(137) negatively regulates synthesis of NarP. Interestingly, SdsN(178) is defective at regulating the above targets due to unusual binding to the Hfq protein, but cleavage leads to a shorter form, SdsN(124), able to repress nfsA and hmpA.
C1 [Hao, Yue; Updegrove, Taylor B.; Livingston, Natasha N.; Storz, Gisela] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Mol & Cellular Biol, Bethesda, MD 20892 USA.
[Hao, Yue] Chinese Acad Agr Sci, Inst Apicultural Res, Beijing 100093, Peoples R China.
[Updegrove, Taylor B.] NCI, Mol Biol Lab, Bldg 37, Bethesda, MD 20892 USA.
[Livingston, Natasha N.] US FDA, Ctr Tobacco Prod, Silver Spring, MD 20993 USA.
RP Storz, G (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Mol & Cellular Biol, Bethesda, MD 20892 USA.
EM storz@helix.nih.gov
FU Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development; ZIA [HD001608]
FX Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development. Funding for open access
charge: ZIA [HD001608].
NR 51
TC 2
Z9 2
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG 19
PY 2016
VL 44
IS 14
BP 6935
EP 6948
DI 10.1093/nar/gkw404
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DV5VX
UT WOS:000382999900038
PM 27166377
ER
PT J
AU Agrawal, AS
Ying, TL
Tao, XR
Garron, T
Algaissi, A
Wang, YP
Wang, LL
Peng, BH
Jiang, SB
Dimitrov, DS
Tseng, CTK
AF Agrawal, Anurodh Shankar
Ying, Tianlei
Tao, Xinrong
Garron, Tania
Algaissi, Abdullah
Wang, Yanping
Wang, Lili
Peng, Bi-Hung
Jiang, Shibo
Dimitrov, Dimiter S.
Tseng, Chien-Te K.
TI Passive Transfer of A Germline-like Neutralizing Human Monoclonal
Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory
Syndrome Coronavirus Infection
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; PIPISTRELLUS BAT CORONAVIRUS; MERS-COV
INFECTION; SPIKE PROTEIN; MOUSE MODEL; POSTEXPOSURE EFFICACY; DROMEDARY
CAMELS; SAUDI-ARABIA; BETACORONAVIRUS; TRANSMISSION
AB Middle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian Peninsula. To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV infections. Several neutralizing human monoclonal antibodies (mAbs), including m336, a germline-like human mAb, have been chosen as promising MCM for MERS-CoV. However, their clinical development has been hindered by the lack of a robust animal model that recapitulate the morbidity and mortality of human infections. We assessed the prophylactic and therapeutic efficacy of m336 by using well-characterized transgenic mice shown to be highly sensitive to MERS-CoV infection and disease. We found that mice treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to control mice which sufferered from profound weight loss and uniform death within days after infection. Taken together, these results support further development of m336 and other human monoclonal antibodies as potential therapeutics for MERS-CoV infection.
C1 [Agrawal, Anurodh Shankar; Tao, Xinrong; Garron, Tania; Algaissi, Abdullah; Tseng, Chien-Te K.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
[Ying, Tianlei] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol, Minist Educ, Shanghai 200032, Peoples R China.
[Ying, Tianlei] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol, Minist Hlth, Shanghai 200032, Peoples R China.
[Algaissi, Abdullah; Jiang, Shibo] Jazan Univ, Dept Med Labs Technol, Coll Appl Med Sci, Jazan, Saudi Arabia.
[Wang, Yanping; Wang, Lili; Dimitrov, Dimiter S.] NCI, Prot Interact Sect, Canc & Inflammat Program, Ctr Canc Res,NIH, Frederick, MD 21702 USA.
[Peng, Bi-Hung] Univ Texas Med Branch, Neurosci & Cell Biol, Galveston, TX 77555 USA.
RP Tseng, CTK (reprint author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
EM sktseng@utmb.edu
FU National Institutes of Health Grant [R21AI113206-01]; Center for
Biodefense and Emerging Infectious Diseases and from the Galveston
National Laboratory [5UC7AI094660-05]; University of Texas Medical
Branch, Galveston, TX; NCI; National Natural Science Foundation of China
[31570936]; T32 Biodefense Training Program by NIH [5 T32 AI 60549-12]
FX We thank Dr. Heinz Feldmann, National Institute of Health at Hamilton,
Montana, and Dr. Ron A. Fouchier, Erasmus Medical Center at Rotterdam,
The Netherlands for the MERS-CoV. This research was supported in part by
a National Institutes of Health Grant, R21AI113206-01 (to C-T.K.T), and
pilot grants from the Center for Biodefense and Emerging Infectious
Diseases and from the Galveston National Laboratory (Grant Number:
5UC7AI094660-05. Project Title: National Biocontainment Laboratories
(NBLs) Operations Support), University of Texas Medical Branch,
Galveston, TX (to C-T.K.T.), intramural funding of NCI (to DSD), and the
National Natural Science Foundation of China (#31570936 to SJ, #31570936
to TY). T.G was supported in part by a T32 Biodefense Training Program
(5 T32 AI 60549-12) awarded to UTMB by NIH.
NR 46
TC 3
Z9 3
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 19
PY 2016
VL 6
AR 31629
DI 10.1038/srep31629
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT7KX
UT WOS:000381666600001
PM 27538452
ER
PT J
AU Ghazizadeh, A
Griggs, W
Hikosaka, O
AF Ghazizadeh, Ali
Griggs, Whitney
Hikosaka, Okihide
TI Ecological Origins of Object Salience: Reward, Uncertainty,
Aversiveness, and Novelty
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE object salience; reward; uncertainty; aversiveness; novelty
ID BASAL GANGLIA CIRCUITS; LONG-TERM-MEMORY; RECOGNITION MEMORY; DOPAMINE
NEURONS; ORBITOFRONTAL CORTEX; ATTENTIONAL CAPTURE; SIGNALS;
INFORMATION; MONKEYS; STIMULI
AB Among many objects around us, some are more salient than others (i.e., attract our attention automatically). Some objects may be inherently salient (e.g., brighter), while others may become salient by virtue of their ecological relevance through experience. However, the role of ecological experience in automatic attention has not been studied systematically. To address this question, we let subjects (macaque monkeys) view a large number of complex objects (>300), each experienced repeatedly (>5 days) with rewarding, aversive or no outcome association (mere-perceptual exposure). Test of salience was done on separate days using free viewing with no outcome. We found that gaze was biased among the objects from the outset, affecting saccades to objects or fixations within objects. When the outcome was rewarding, gaze preference was stronger (i.e., positive) for objects with larger or equal but uncertain rewards. The effects of aversive outcomes were variable. Gaze preference was positive for some outcome associations airpuff), but negative for others (e.g., time-out), possibly due to differences in threat levels. Finally, novel objects attracted gaze, but mere perceptual exposure of objects reduced their salience (learned negative salience). Our results show that, in primates, object salience is strongly influenced by previous ecological experience and is supported by a large memory capacity. Owing to such high capacity for learned salience, the ability to rapidly choose important objects can grow during the entire life to promote biological fitness.
C1 [Ghazizadeh, Ali; Griggs, Whitney; Hikosaka, Okihide] NEI, Sensorimotor Res Lab, Natl Inst Hlth Bethesda, Bldg 10, Bethesda, MD 20892 USA.
[Hikosaka, Okihide] NIDA, NIH, Baltimore, MD USA.
RP Ghazizadeh, A (reprint author), NEI, Sensorimotor Res Lab, Natl Inst Hlth Bethesda, Bldg 10, Bethesda, MD 20892 USA.
EM alieghazizadeh@gmail.com
FU Intramural Research Program at the National Institutes of Health,
National Eye Institute
FX This research was supported by the Intramural Research Program at the
National Institutes of Health, National Eye Institute. We thank H. Kim,
H. Amita, D. McMahon for valuable discussions and S. Hong for providing
technical assistance. We thank O. Dal Monte for providing the monkey
face library.
NR 69
TC 1
Z9 1
U1 9
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD AUG 19
PY 2016
VL 10
AR 378
DI 10.3389/fnins.2016.00378
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA DT9FO
UT WOS:000381801500002
PM 27594825
ER
PT J
AU Speer, SD
Pierson, TC
AF Speer, Scott D.
Pierson, Theodore C.
TI Diagnostics for Zika virus on the horizon
SO SCIENCE
LA English
DT Editorial Material
ID WEST-NILE-VIRUS; INFECTION; ANTIBODY
C1 [Speer, Scott D.; Pierson, Theodore C.] NIAID, Viral Pathogenesis Sect, Bethesda, MD 20892 USA.
RP Pierson, TC (reprint author), NIAID, Viral Pathogenesis Sect, Bethesda, MD 20892 USA.
EM piersontc@niaid.nih.gov
FU Intramural NIH HHS
NR 15
TC 2
Z9 3
U1 71
U2 84
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 19
PY 2016
VL 353
IS 6301
BP 750
EP 751
DI 10.1126/science.aah6187
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5ZE
UT WOS:000381561400020
PM 27540152
ER
PT J
AU Russo, MV
McGavern, DB
AF Russo, Matthew V.
McGavern, Dorian B.
TI Inflammatory neuroprotection following traumatic brain injury
SO SCIENCE
LA English
DT Editorial Material
ID SPINAL-CORD; T-CELLS
AB Traumatic brain injury (TBI) elicits an inflammatory response in the central nervous system (CNS) that involves both resident and peripheral immune cells. Neuroinflammation can persist for years following a single TBI and may contribute to neurodegeneration. However, administration of anti-inflammatory drugs shortly after injury was not effective in the treatment of TBI patients. Some components of the neuroinflammatory response seem to play a beneficial role in the acute phase of TBI. Indeed, following CNS injury, early inflammation can set the stage for proper tissue regeneration and recovery, which can, perhaps, explain why general immunosuppression in TBI patients is disadvantageous. Here, we discuss some positive attributes of neuroinflammation and propose that inflammation be therapeutically guided in TBI patients rather than globally suppressed.
C1 [Russo, Matthew V.; McGavern, Dorian B.] NINDS, Viral Immunol & Intravital Imaging Sect, NIH, Bethesda, MD 20852 USA.
RP McGavern, DB (reprint author), NINDS, Viral Immunol & Intravital Imaging Sect, NIH, Bethesda, MD 20852 USA.
EM mcgavernd@mail.nih.gov
FU Intramural NIH HHS [, ZIA NS003112-07]
NR 15
TC 3
Z9 4
U1 14
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 19
PY 2016
VL 353
IS 6301
BP 783
EP 785
DI 10.1126/science.aaf6260
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5ZE
UT WOS:000381561400036
PM 27540166
ER
PT J
AU Malecki, M
Sabo, C
Foorohar, A
Tombokan, X
AF Malecki, Marek
Sabo, Chelsea
Foorohar, Afsoon
Tombokan, Xenia
TI Novel paradigm for immunotherapy of breast cancer by engaging
prophylactic immunity against hepatitis B
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE Breast cancer; Immunotherapy; Trastuzumab; Cancer; Vaccine; HER-2;
Erb-B2; Mimotope; Hepatitis B
ID VIRUS SURFACE-ANTIGEN; MECHANISM; CELLS; IMMUNOASSAY; ANTIBODIES;
HERCEPTIN; SURVIVAL; SINGLE; YEAST
AB Background: Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing (HER-2(+)) breast cancers with the anti-HER-2 antibodies results in increase of the patients' overall survival. However, no prophylactic vaccine is available against HER-2+ breast cancers. Although, prophylactic vaccine for human hepatitis B virus (HBV) is very effective.
Specific aim: The specific aim of this work was to design, synthesize, and test bio-molecules which would engage prophylactic immunity against hepatitis B virus towards killing breast cancers cells.
Methods and Results: By biomolecular engineering, we have created a novel family of biomolecules: antibody (anti-HER-2) x vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 x HBsAg). These biomolecules were utilized for redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted against HBV as therapeutic immunity, newly targeted against HER-2+ breast cancers. Treatment of the HER-2+ breast cancer cells with AVEC: anti-HER-2 x HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy of killing of HER-2+ breast cancer cells over that attained with the naked anti-HER-2 antibodies.
Conclusion: Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying of prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2+ breast cancer. We currently streamline this novel therapeutic paradigm into clinical trials of breast and other cancers.
C1 [Malecki, Marek] Phoenix Biomol Engn Fdn, San Francisco, CA 94119 USA.
[Malecki, Marek] Univ Wisconsin, Madison, WI 53706 USA.
[Malecki, Marek] NIH, Madison, WI 20892 USA.
[Sabo, Chelsea] Sutter Hlth Ctr, San Francisco, CA USA.
[Foorohar, Afsoon] Univ Sheffield, Sheffield, S Yorkshire, England.
[Tombokan, Xenia] Bruker Corp, The Woodlands, TX USA.
RP Malecki, M (reprint author), Phoenix Biomol Engn Fdn, San Francisco, CA 94119 USA.; Malecki, M (reprint author), Univ Wisconsin, Madison, WI 53706 USA.; Malecki, M (reprint author), NIH, Madison, WI 20892 USA.
EM mm@pbmef.org
FU PBMEF [2006070101]; NSF [9420056, 9522771, 9902020, 0094016]; NIH [P41
RR000570, P41 RR002301]
FX Parts of this work were supported by the funds from the PBMEF
(2006070101), the NSF (9420056, 9522771, 9902020, and 0094016), the NIH
(P41 RR000570 and P41 RR002301); to Marek Malecki MD Ph.D.-the principal
investigator. Administrators of the funding institutions had no
influence on the data acquisition and the IP.
NR 22
TC 0
Z9 0
U1 6
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD AUG 18
PY 2016
VL 5
AR 32
DI 10.1186/s40169-016-0111-8
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EH7KG
UT WOS:000391951100001
PM 27539579
ER
PT J
AU Ferre, EMN
Rose, SR
Rosenzweig, SD
Burbelo, PD
Romito, KR
Niemela, JE
Rosen, LB
Break, TJ
Gu, WJ
Hunsberger, S
Browne, SK
Hsu, AP
Rampertaap, S
Swamydas, M
Collar, AL
Kong, HH
Lee, CCR
Chascsa, D
Simcox, T
Pham, A
Bondici, A
Natarajan, M
Monsale, J
Kleiner, DE
Quezado, M
Alevizos, I
Moutsopoulos, NM
Yockey, L
Frein, C
Soldatos, A
Calvo, KR
Adjemian, J
Similuk, MN
Lang, DM
Stone, KD
Uzel, G
Kopp, JB
Bishop, RJ
Holland, SM
Olivier, KN
Fleisher, TA
Heller, T
Winer, KK
Lionakis, MS
AF Ferre, Elise M. N.
Rose, Stacey R.
Rosenzweig, Sergio D.
Burbelo, Peter D.
Romito, Kimberly R.
Niemela, Julie E.
Rosen, Lindsey B.
Break, Timothy J.
Gu, Wenjuan
Hunsberger, Sally
Browne, Sarah K.
Hsu, Amy P.
Rampertaap, Shakuntala
Swamydas, Muthulekha
Collar, Amanda L.
Kong, Heidi H.
Lee, Chyi-Chia Richard
Chascsa, David
Simcox, Thomas
Pham, Angela
Bondici, Anamaria
Natarajan, Mukil
Monsale, Joseph
Kleiner, David E.
Quezado, Martha
Alevizos, Ilias
Moutsopoulos, Niki M.
Yockey, Lynne
Frein, Cathleen
Soldatos, Ariane
Calvo, Katherine R.
Adjemian, Jennifer
Similuk, Morgan N.
Lang, David M.
Stone, Kelly D.
Uzel, Gulbu
Kopp, Jeffrey B.
Bishop, Rachel J.
Holland, Steven M.
Olivier, Kenneth N.
Fleisher, Thomas A.
Heller, Theo
Winer, Karen K.
Lionakis, Michail S.
TI Redefined clinical features and diagnostic criteria in autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
SO JCI INSIGHT
LA English
DT Article
ID SYNDROME TYPE-I; CHRONIC MUCOCUTANEOUS CANDIDIASIS; COMMON VARIABLE
IMMUNODEFICIENCY; POLYGLANDULAR SYNDROME TYPE-1; B-CELL POPULATION;
ADDISONS-DISEASE; REGULATOR GENE; PERIPHERAL-BLOOD; APS-I;
AUTOANTIBODIES
AB Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare primary immunodeficiency disorder typically caused by homozygous AIRE mutations. It classically presents with chronic mucocutaneous candidiasis and autoimmunity that primarily targets endocrine tissues; hypoparathyroidism and adrenal insufficiency are most common. Developing any two of these classic triad manifestations establishes the diagnosis. Although widely recognized in Europe, where nonendocrine autoimmune manifestations are uncommon, APECED is less defined in patients from the Western Hemisphere. We enrolled 35 consecutive American APECED patients (33 from the US) in a prospective observational natural history study and systematically examined their genetic, clinical, autoantibody, and immunological characteristics. Most patients were compound heterozygous; the most common AIRE mutation was c.967_979del13. All but one patient had anti-IFN-omega autoantibodies, including 4 of 5 patients without biallelic AIRE mutations. Urticarial eruption, hepatitis, gastritis, intestinal dysfunction, pneumonitis, and Sjogren's-like syndrome, uncommon entities in European APECED cohorts, affected 40%-80% of American cases. Development of a classic diagnostic dyad was delayed at mean 7.38 years. Eighty percent of patients developed a median of 3 non-triad manifestations before a diagnostic dyad. Only 20% of patients had their first two manifestations among the classic triad. Urticarial eruption, intestinal dysfunction, and enamel hypoplasia were prominent among early manifestations. Patients exhibited expanded peripheral CD4(+) T cells and CD21(lo)CD38(lo) B lymphocytes. In summary, American APECED patients develop a diverse syndrome, with dramatic enrichment in organ-specific nonendocrine manifestations starting early in life, compared with European patients. Incorporation of these new manifestations into American diagnostic criteria would accelerate diagnosis by approximately 4 years and potentially prevent life-threatening endocrine complications.
C1 [Ferre, Elise M. N.; Rose, Stacey R.; Break, Timothy J.; Swamydas, Muthulekha; Collar, Amanda L.; Pham, Angela; Bondici, Anamaria; Natarajan, Mukil; Yockey, Lynne; Lionakis, Michail S.] NIAID, Fungal Pathogenesis Unit, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Rosenzweig, Sergio D.; Romito, Kimberly R.; Niemela, Julie E.; Rampertaap, Shakuntala; Monsale, Joseph; Fleisher, Thomas A.] NIH, Serv Immunol, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Burbelo, Peter D.] Natl Inst Dent & Craniofacial Res, Dent Clin Res Core, Bethesda, MD USA.
[Rosen, Lindsey B.; Browne, Sarah K.; Hsu, Amy P.; Yockey, Lynne; Uzel, Gulbu; Holland, Steven M.] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Gu, Wenjuan; Frein, Cathleen] Natl Canc Inst NCI Campus Frederick, Clin Res Directorate, Clin Monitoring Res Program, Leidos Biomed Res Inc, Frederick, MD USA.
[Hunsberger, Sally] NIAID, Biostat Res Branch, Div Clin Res, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Kong, Heidi H.; Kleiner, David E.; Quezado, Martha] NCI, Dermatol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.
[Lee, Chyi-Chia Richard] NCI, Pathol Lab, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.
[Chascsa, David; Simcox, Thomas; Heller, Theo] NIDDK, Translat Hepatol Unit, Liver Dis Branch, Bethesda, MD 20892 USA.
[Alevizos, Ilias] Natl Inst Dent & Craniofacial Res, Sjogrens Syndrome & Salivary Gland Dysfunct Unit, NIH, Bethesda, MD USA.
[Moutsopoulos, Niki M.] Natl Inst Dent & Craniofacial Res, Oral Immun & Inflammat Unit, NIH, Bethesda, MD USA.
[Soldatos, Ariane] NIH, Undiag Dis Program, Common Fund, Off Director, Bldg 10, Bethesda, MD 20892 USA.
[Soldatos, Ariane] NHGRI, Bethesda, MD 20892 USA.
[Calvo, Katherine R.] NIH, Hematol Sect, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Adjemian, Jennifer] NIAID, Epidemiol Unit, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Similuk, Morgan N.] NIAID, Immunol Lab, Bldg 10, Bethesda, MD 20892 USA.
[Lang, David M.] NIH, Pediat Consult Serv, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Stone, Kelly D.] NIAID, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Kopp, Jeffrey B.] NIDDK, Kidney Dis Branch, Bethesda, MD 20892 USA.
[Bishop, Rachel J.] NEI, Consult Serv Sect, Bethesda, MD 20892 USA.
[Olivier, Kenneth N.] NHLBI, Cardiovasc & Pulm Branch, Bldg 10, Bethesda, MD 20892 USA.
[Winer, Karen K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Growth & Nutr Branch, NIH, Bethesda, MD USA.
[Rose, Stacey R.] Baylor Coll Med, Div Infect Dis, Houston, TX 77030 USA.
[Browne, Sarah K.] US FDA, Div Vaccines & Related Prod Applicat, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
RP Lionakis, MS (reprint author), NIAID, Fungal Pathogenesis Unit, LCID, NIH, 9000 Rockville Pike,Bldg 10,Room 11C102, Bethesda, MD 20892 USA.
EM lionakism@mail.nih.gov
NR 63
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD AUG 18
PY 2016
VL 1
IS 13
DI 10.1172/jci.insight.88782
PG 18
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EB1NO
UT WOS:000387119700010
ER
PT J
AU Johnson, AD
AF Johnson, Andrew D.
TI Pairing megakaryopoiesis methylation with PEAR1
SO BLOOD
LA English
DT Editorial Material
ID PLATELET AGGREGABILITY; AGGREGATION; ACTIVATION; VARIANT; GENE
C1 [Johnson, Andrew D.] NHLBI, Bldg 10, Bethesda, MD 20892 USA.
RP Johnson, AD (reprint author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 18
PY 2016
VL 128
IS 7
BP 890
EP 892
DI 10.1182/blood-2016-06-723940
PG 5
WC Hematology
SC Hematology
GA DW7ML
UT WOS:000383834800006
PM 27539998
ER
PT J
AU Lama, JR
Karuna, ST
Grant, SP
Swann, EM
Ganoza, C
Segura, P
Montano, SM
Lacherre, M
De Rosa, SC
Buchbinder, S
Sanchez, J
McElrath, MJ
Lemos, MP
AF Lama, Javier R.
Karuna, Shelly T.
Grant, Shannon P.
Swann, Edith M.
Ganoza, Carmela
Segura, Patricia
Montano, Silvia M.
Lacherre, Martin
De Rosa, Stephen C.
Buchbinder, Susan
Sanchez, Jorge
McElrath, M. Juliana
Lemos, Maria P.
CA HVTN 914 Study Team
TI Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or
Circumcision in a Cohort Study of MSM at Risk of HIV Infection
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; VIRUS-INFECTION; MEN; SEX; VACCINE; TRIAL;
ACQUISITION; PREVENTION; SAFETY; PERU
AB Background
Rectal and genital sampling in HIV prevention trials permits assessments at the site of HIV entry. Yet the safety and acceptability of circumcision and sigmoidoscopy (and associated abstinence recommendations) are unknown in uncircumcised men who have sex with men (MSM) at high risk of HIV infection.
Methods
Twenty-nine HIV-seronegative high-risk Peruvian MSM agreed to elective sigmoidoscopy biopsy collections (weeks 2 and 27) and circumcision (week 4) in a 28-week cohort study designed to mimic an HIV vaccine study mucosal collection protocol. We monitored adherence to abstinence recommendations, procedure-related complications, HIV infections, peripheral immune activation, and retention.
Results
Twenty-three (79.3%) underwent a first sigmoidoscopy, 21 (72.4%) were circumcised, and 16 (55.2%) completed a second sigmoidoscopy during the study period. All who underwent procedures completed the associated follow-up safety visits. Those completing the procedures reported they were well tolerated, and complication rates were similar to those reported in the literature. Immune activation was detected during the healing period (1 week post-sigmoidoscopy, 6 weeks post-circumcision), including increases in CCR5(+)CD4(+)T cells and alpha 4 beta 7(+)CD4(+)T cells. Most participants adhered to post-circumcision abstinence recommendations whereas reduced adherence occurred post-sigmoidoscopy.
Conclusion
Rectosigmoid mucosal and genital tissue collections were safe in high-risk MSM. Although the clinical implications of the post-procedure increase in peripheral immune activation markers are unknown, they reinforce the need to provide ongoing risk reduction counseling and support for post-procedure abstinence recommendations. Future HIV vaccine studies should also consider the effects of mucosal and tissue collections on peripheral blood endpoints in trial design and analysis.
C1 [Lama, Javier R.; Ganoza, Carmela; Segura, Patricia; Lacherre, Martin; Sanchez, Jorge] Asociac Civil Impacta Salud & Educ, Lima, Peru.
[Karuna, Shelly T.; Grant, Shannon P.; De Rosa, Stephen C.; McElrath, M. Juliana; Lemos, Maria P.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
[Swann, Edith M.] NIAID, Vaccine Clin Res Branch, Div AIDS, US NIH, Bethesda, MD USA.
[Montano, Silvia M.] US Naval Med Res Unit 6, Callao, Peru.
[De Rosa, Stephen C.; Sanchez, Jorge] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
[McElrath, M. Juliana] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[McElrath, M. Juliana] Univ Washington, Dept Med, Seattle, WA USA.
[Buchbinder, Susan] San Francisco Dept Hlth, San Francisco, CA USA.
RP Lemos, MP (reprint author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
EM mlemos@fredhutch.org
FU National Institute of Allergy and Infectious Diseases of the National
Institutes of Health [UM1AI068614, UM1AI068618, UM1AI068635,
UM1AI069438]; National Institute of Allergy and Infectious Diseases of
the U.S. National Institutes of Health
FX Research reported in this publication was supported by the National
Institute of Allergy and Infectious Diseases of the National Institutes
of Health under award numbers UM1AI068614, UM1AI068618, UM1AI068635, and
UM1AI069438. The content is the responsibility of the authors and does
not necessarily represent the official views, policy or position of the
U.S. National Institutes of Health, Department of the Navy, Department
of Defense, or U.S. Government. Silvia Montano and Edith Swann are
employees of the U.S. Government, who contributed to this work as part
of their official duties. No copyright protection is available for their
work as defined by Title 17 U.S.C. 105 and 101.; Research reported in
this publication was supported by the National Institute of Allergy and
Infectious Diseases of the U.S. National Institutes of Health. The
content is the responsibility of the authors and does not necessarily
represent the official views, policy or position of the U.S. National
Institutes of Health, the Department of the Navy, the Department of
Defense, or the U.S. Government. Silvia Montano and Edith Swann are
employees of the U.S. Government who contributed to this work as part of
her official duties. No copyright protection is available for their work
as defined by Titles 17 U.S.C. 105 and 101.
NR 47
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2016
VL 11
IS 8
AR e0160487
DI 10.1371/journal.pone.0160487
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT6ES
UT WOS:000381577000022
PM 27536938
ER
PT J
AU Sathyanarayana, BK
Li, P
Lin, JX
Leonard, WJ
Lee, B
AF Sathyanarayana, Bangalore K.
Li, Peng
Lin, Jian-Xin
Leonard, Warren J.
Lee, Byungkook
TI Molecular Models of STAT5A Tetramers Complexed to DNA Predict Relative
GenomeWide Frequencies of the Spacing between the Two Dimer Binding
Motifs of the Tetramer Binding Sites
SO PLOS ONE
LA English
DT Article
ID TRANSACTIVATION DOMAINS; GENE; TRANSCRIPTION; RECRUITMENT; ACTIVATION;
INDUCTION; GROWTH; CELLS
AB STAT proteins bind DNA as dimers and tetramers to control cellular development, differentiation, survival, and expansion. The tetramer binding sites are comprised of two dimer-binding sites repeated in tandem. The genome-wide distribution of the spacings between the dimer binding sites shows a distinctive, non-random pattern. Here, we report on estimating the feasibility of building possible molecular models of STAT5A tetramers bound to a DNA double helix with all possible spacings between the dimer binding sites. We found that the calculated feasibility estimates correlated well with the experimentally measured frequency of tetramer-binding sites. This suggests that the feasibility of forming the tetramer complex was a major factor in the evolution of this DNA sequence variation.
C1 [Sathyanarayana, Bangalore K.; Lee, Byungkook] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Li, Peng; Lin, Jian-Xin; Leonard, Warren J.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.
[Li, Peng; Lin, Jian-Xin; Leonard, Warren J.] NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA.
RP Lee, B (reprint author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Leonard, WJ (reprint author), NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.; Leonard, WJ (reprint author), NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA.
EM leonardw@nhlbi.nih.gov; BKLee@mail.nih.gov
OI Lee, Byungkook/0000-0002-3339-4582
FU Intramural Research Program of the NIH; National Cancer Institute;
Center for Cancer Research; Division of Intramural Research, National
Heart, Lung, and Blood Institute; National Institutes of Health
(National Center for Research Resources) [2P41RR001081]; National
Institutes of Health (National Institute of General Medical Sciences)
[9P41GM103311]
FX This research was supported by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research and the
Division of Intramural Research, National Heart, Lung, and Blood
Institute. The Chimera software we used was developed by the Resource
for Biocomputing, Visualization, and Informatics at the University of
California, San Francisco, with support from the National Institutes of
Health (National Center for Research Resources grant 2P41RR001081,
National Institute of General Medical Sciences grant 9P41GM103311). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 24
TC 0
Z9 0
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2016
VL 11
IS 8
AR e0160339
DI 10.1371/journal.pone.0160339
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT6ES
UT WOS:000381577000017
PM 27537504
ER
PT J
AU Shukla, A
Yang, YH
Madanikia, S
Ho, Y
Li, MM
Sanchez, V
Cataisson, C
Huang, J
Yuspa, SH
AF Shukla, Anjali
Yang, Yihan
Madanikia, Sara
Ho, Yan
Li, Mangmang
Sanchez, Vanesa
Cataisson, Christophe
Huang, Jing
Yuspa, Stuart H.
TI Elevating CLIC4 in Multiple Cell Types Reveals a TGF-Dependent Induction
of a Dominant Negative Smad7 Splice Variant
SO PLOS ONE
LA English
DT Article
ID BETA SUPERFAMILY; SKIN CARCINOGENESIS; TUMOR-SUPPRESSOR; GROWTH;
INHIBITION; PROLIFERATION; KERATINOCYTES; NUCLEUS; DISEASE; CANCER
AB CLIC4 (Chloride intracellular channel 4) belongs to a family of putative intracellular chloride channel proteins expressed ubiquitously in multiple tissues. CLIC4 is predominantly soluble and traffics between the cytoplasm and nucleus and participates in cell cycle control and differentiation. Transforming growth factor beta (TGF-beta) elevates CLIC4, which enhances TGF-beta signaling through CLIC4 mediated stabilization of phospho-Smad2/3. CLIC4 is essential for TGF-beta induced conversion of fibroblasts to myofibroblasts and expression of matrix proteins, signaling via the p38MAPK pathway. Therefore, regulation of TGF-beta signaling is a major mechanism by which CLIC4 modifies normal growth and differentiation. We now report that elevated CLIC4 alters Smad7 function, a feedback inhibitor of the TGF-beta pathway. Overexpression of CLIC4 in keratinocytes, mouse embryonic fibroblasts and other mouse and human cell types increases the expression of Smad7 Delta, a novel truncated form of Smad7. The alternatively spliced Smad7 Delta variant is missing 94bp in exon 4 of Smad 7 and is conserved between mouse and human cells. The deletion is predicted to lack the TGF-beta signaling inhibitory MH2 domain of Smad7. Treatment with exogenous TGF-beta 1 also enhances expression of Smad7 Delta that is amplified in the presence of CLIC4. While Smad7 expression inhibits TGF-beta signaling, exogenously expressed Smad7 Delta does not inhibit TGF-beta signaling as determined by TGF-beta dependent proliferation, reporter assays and phosphorylation of Smad proteins. Instead, exogenous Smad7 Delta acts as a dominant negative inhibitor of Smad7, thus increasing TGF-beta signaling. This discovery adds another dimension to the myriad ways by which CLIC4 modifies TGF-beta signaling.
C1 [Shukla, Anjali; Yang, Yihan; Madanikia, Sara; Ho, Yan; Li, Mangmang; Sanchez, Vanesa; Cataisson, Christophe; Huang, Jing; Yuspa, Stuart H.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Yuspa, SH (reprint author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA.
EM yuspas@mail.nih.gov
FU NCI, CCR intramural program [BC005445-30]
FX This work was conducted with funding to SHY from the NCI, CCR intramural
program under project BC005445-30.
NR 36
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2016
VL 11
IS 8
AR e0161410
DI 10.1371/journal.pone.0161410
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT6ES
UT WOS:000381577000102
PM 27536941
ER
PT J
AU Silson, EH
Steel, AD
Baker, CI
AF Silson, Edward H.
Steel, Adam D.
Baker, Chris I.
TI Scene-Selectivity and Retinotopy in Medial Parietal Cortex
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE retinotopy; population receptive fields; scene-selectivity;
resting-state functional connectivity; memory
ID HUMAN RETROSPLENIAL CORTEX; BOLD-CONTRAST SENSITIVITY; LATERAL OCCIPITAL
CORTEX; HUMAN VISUAL-CORTEX; OCCIPITOTEMPORAL CORTEX; PLACE AREA; FMRI;
PARAHIPPOCAMPAL; CONNECTIVITY; REGIONS
AB Functional imaging studies in human reliably identify a trio of scene-selective regions, one on each of the lateral [occipital place area (OPA)], ventral [parahippocampal place area (PPA)], and medial [retrosplenial complex (RSC)] cortical surfaces. Recently, we demonstrated differential retinotopic biases for the contralateral lower and upper visual fields within OPA and PPA, respectively. Here, using functional magnetic resonance imaging, we combine detailed mapping of both population receptive fields (pRF) and category-selectivity, with independently acquired resting-state functional connectivity analyses, to examine scene and retinotopic processing within medial parietal cortex. We identified a medial scene-selective region, which was contained largely within the posterior and ventral bank of the parieto-occipital sulcus (POS). While this region is typically referred to as RSC, the spatial extent of our scene-selective region typically did not extend into retrosplenial cortex, and thus we adopt the term medial place area (MPA) to refer to this visually defined scene-selective region. Intriguingly MPA co-localized with a region identified solely on the basis of retinotopic sensitivity using pRF analyses. We found that MPA demonstrates a significant contralateral visual field bias, coupled with large pRF sizes. Unlike OPA and PPA. MPA did not show a consistent bias to a single visual quadrant. MPA also co-localized with a region identified by strong differential functional connectivity with PPA and the human face-selective fusiform face area (FFA), commensurate with its functional selectivity. Functional connectivity with OPA was much weaker than with PPA, and similar to that with face-selective occipital face area (OFA), suggesting a closer link with ventral than lateral cortex. Consistent with prior research, we also observed differential functional connectivity in medial parietal cortex for anterior over posterior PPA, as well as a region on the lateral surface, the caudal inferior parietal lobule (cIPL). However, the differential connectivity in medial parietal cortex was found principally anterior of MPA. We suggest that there is posterior anterior gradient within medial parietal cortex, with posterior regions in the POS showing retinotopically based scene-selectivity and more anterior regions showing connectivity that may be more reflective of abstract, navigationally pertinent and possibly mnemonic representations.
C1 [Silson, Edward H.; Steel, Adam D.; Baker, Chris I.] NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA.
[Steel, Adam D.] Univ Oxford, John Radcliffe Hosp, Physiol Neuroimaging Grp, FMRIB Ctr, Oxford, England.
RP Silson, EH (reprint author), NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA.
EM ed.silson@nih.gov
OI Steel, Adam/0000-0001-8876-933X
FU Intramural Research Program of the National Institutes of Health -
National Institute of Mental Health Clinical Study Protocol
[ZIAMH002909, 93-M-0170, NCT00001360]
FX This work was supported by the Intramural Research Program (ZIAMH002909)
of the National Institutes of Health - National Institute of Mental
Health Clinical Study Protocol 93-M-0170, NCT00001360.
NR 54
TC 3
Z9 3
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD AUG 18
PY 2016
VL 10
AR 412
DI 10.3389/fnhum.2016.00412
PG 17
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA DT6LR
UT WOS:000381596200001
PM 27588001
ER
PT J
AU Reichert, MC
Brown, HE
Evans, TA
AF Reichert, Marie C.
Brown, Haley E.
Evans, Timothy A.
TI In vivo functional analysis of Drosophila Robo1 immunoglobulin-like
domains
SO NEURAL DEVELOPMENT
LA English
DT Article
DE Drosophila; Slit; Robo; Axon guidance; Midline crossing;
Immunoglobulin-like domain
ID COMMISSURAL AXON GUIDANCE; GROWTH CONE GUIDANCE; CNS MIDLINE; ROUNDABOUT
RECEPTOR; DISTINCT ROLES; SLIT BINDING; REPULSION; EXPRESSION; NEURONS;
SYSTEM
AB Background: In animals with bilateral symmetry, midline crossing of axons in the developing central nervous system is regulated by Slit ligands and their neuronal Roundabout (Robo) receptors. Multiple structural domains are present in an evolutionarily conserved arrangement in Robo family proteins, but our understanding of the functional importance of individual domains for midline repulsive signaling is limited.
Methods: We have examined the functional importance of each of the five conserved immunoglobulin-like (Ig) domains within the Drosophila Robo1 receptor. We generated a series of Robo1 variants, each lacking one of the five Ig domains (Ig1-5), and tested each for their ability to bind Slit when expressed in cultured Drosophila cells. We used a transgenic approach to express each variant in robo1's normal expression pattern in wild-type and robo1 mutant embryos, and examined the effects of deleting each domain on receptor expression, axonal localization, regulation, and midline repulsive signaling in vivo.
Results: We show that individual deletion of Ig domains 2-5 does not interfere with Robo1's ability to bind Slit, while deletion of Ig1 strongly disrupts Slit binding. None of the five Ig domains (Ig1-5) are individually required for proper expression of Robo1 in embryonic neurons, for exclusion from commissural axon segments in wild-type embryos, or for downregulation by Commissureless (Comm), a negative regulator of Slit-Robo repulsion in Drosophila. Each of the Robo1 Ig deletion variants (with the exception of Robo1 Delta Ig1) were able to restore midline crossing in robo1 mutant embryos to nearly the same extent as full-length Robo1, indicating that Ig domains 2-5 are individually dispensable for midline repulsive signaling in vivo.
Conclusions: Our findings indicate that four of the five Ig domains within Drosophila Robo1 are dispensable for its role in midline repulsion, despite their strong evolutionary conservation, and highlight a unique requirement for the Slit-binding Ig1 domain in the regulation of midline crossing.
C1 [Reichert, Marie C.; Brown, Haley E.; Evans, Timothy A.] Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA.
[Reichert, Marie C.] NHGRI, Intramural Res Training Program, Bethesda, MD 20892 USA.
RP Evans, TA (reprint author), Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA.
EM evanst@uark.edu
OI Evans, Timothy/0000-0002-2756-8064
FU University of Arkansas
FX This work was supported by funds from the University of Arkansas. The
funders had no role in the design of the study, collection, analysis,
and interpretation of data, decision to publish, or preparation of the
manuscript.
NR 57
TC 0
Z9 0
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-8104
J9 NEURAL DEV
JI Neural Dev.
PD AUG 18
PY 2016
VL 11
AR 15
DI 10.1186/s13064-016-0071-0
PG 11
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA DU9EV
UT WOS:000382520000001
PM 27539083
ER
PT J
AU Sato, K
Sato, N
Xu, BY
Nakamura, Y
Nagaya, T
Choyke, PL
Hasegawa, Y
Kobayashi, H
AF Sato, Kazuhide
Sato, Noriko
Xu, Biying
Nakamura, Yuko
Nagaya, Tadanobu
Choyke, Peter L.
Hasegawa, Yoshinori
Kobayashi, Hisataka
TI Spatially selective depletion of tumor-associated regulatory T cells
with near-infrared photoimmunotherapy
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID IMMUNE CHECKPOINT BLOCKADE; CANCER-IMMUNOTHERAPY; IN-VIVO; REJECTION;
IMMUNOLOGY; METASTASES; MECHANISM; RECEPTOR; THERAPY; GROWTH
AB Current immunotherapies for cancer seek to modulate the balance among different immune cell populations, thereby promoting antitumor immune responses. However, because these are systemic therapies, they often cause treatment-limiting autoimmune adverse effects. It would be ideal to manipulate the balance between suppressor and effector cells within the tumor without disturbing homeostasis elsewhere in the body. CD4(+)CD25(+)Foxp3(+) regulatory T cells (T-regs) are well-known immunosuppressor cells that play a key role in tumor immunoevasion and have been the target of systemic immunotherapies. We used CD25-targeted near-infrared photoimmunotherapy (NIR-PIT) to selectively deplete T-regs, thus activating CD8 T and natural killer cells and restoring local antitumor immunity. This not only resulted in regression of the treated tumor but also induced responses in separate untreated tumors of the same cell line derivation. We conclude that CD25-targeted NIR-PIT causes spatially selective depletion of T-regs, thereby providing an alternative approach to cancer immunotherapy.
C1 [Sato, Kazuhide; Sato, Noriko; Nakamura, Yuko; Nagaya, Tadanobu; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Sato, Kazuhide; Hasegawa, Yoshinori] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4668550, Japan.
[Xu, Biying] NHLBI, Image Probe Dev Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Kobayashi, H (reprint author), NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM kobayash@mail.nih.gov
FU Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research
FX This research was supported by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research.
NR 43
TC 1
Z9 1
U1 6
U2 6
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 17
PY 2016
VL 8
IS 352
AR 352ra110
DI 10.1126/scitranslmed.aaf6843
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA DW9WP
UT WOS:000384013700004
ER
PT J
AU Saethang, T
Payne, DM
Avihingsanon, Y
Pisitkun, T
AF Saethang, Thammakorn
Payne, D. Michael
Avihingsanon, Yingyos
Pisitkun, Trairak
TI A machine learning strategy for predicting localization of
post-translational modification sites in protein-protein interacting
regions
SO BMC BIOINFORMATICS
LA English
DT Article
DE Post-translational modification; Protein-protein interacting region;
Machine learning; AAindex
ID PAIRWISE CONTACT POTENTIALS; DATA SETS; PHOSPHORYLATION; BINDING;
CLASSIFICATION; RESOURCE; GLYCOSYLATION; DATABASE
AB Background: One very important functional domain of proteins is the protein-protein interacting region (PPIR), which forms the binding interface between interacting polypeptide chains. Post-translational modifications (PTMs) that occur in the PPIR can either interfere with or facilitate the interaction between proteins. The ability to predict whether sites of protein modifications are inside or outside of PPIRs would be useful in further elucidating the regulatory mechanisms by which modifications of specific proteins regulate their cellular functions.
Results: Using two of the comprehensive databases for protein-protein interaction and protein modification site data (PDB and PhosphoSitePlus, respectively), we created new databases that map PTMs to their locations inside or outside of PPIRs. The mapped PTMs represented only 5 % of all known PTMs. Thus, in order to predict localization within or outside of PPIRs for the vast majority of PTMs, a machine learning strategy was used to generate predictive models from these mapped databases. For the three mapped PTM databases which had sufficient numbers of modification sites for generating models (acetylation, phosphorylation, and ubiquitylation), the resulting models yielded high overall predictive performance as judged by a combined performance score (CPS). Among the multiple properties of amino acids that were used in the classification tasks, hydrophobicity was found to contribute substantially to the performance of the final predictive models. Compared to the other classifiers we also evaluated, the SVM provided the best performance overall.
Conclusions: These models are the first to predict whether PTMs are located inside or outside of PPIRs, as demonstrated by their high predictive performance. The models and data presented here should be useful in prioritizing both known and newly identified PTMs for further studies to determine the functional relationship between specific PTMs and protein-protein interactions. The implemented R package is available online (http://sysbio.chula.ac.th/PtmPPIR).
C1 [Saethang, Thammakorn; Payne, D. Michael; Pisitkun, Trairak] Chulalongkorn Univ, Syst Biol Ctr, Res Affairs, Fac Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand.
[Avihingsanon, Yingyos] Chulalongkorn Univ, Div Nephrol, Dept Med, Fac Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand.
[Pisitkun, Trairak] NHLBI, Epithelial Syst Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Pisitkun, T (reprint author), Chulalongkorn Univ, Syst Biol Ctr, Res Affairs, Fac Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand.; Avihingsanon, Y (reprint author), Chulalongkorn Univ, Div Nephrol, Dept Med, Fac Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand.; Pisitkun, T (reprint author), NHLBI, Epithelial Syst Biol Lab, NIH, Bethesda, MD 20892 USA.
EM fmedyah@md.chula.ac.th; pisitkut@nhlbi.nih.gov
OI Pisitkun, Trairak/0000-0001-6677-2271
FU Chulalongkorn Academic Advancement into Its 2nd Century Project
(CUAASC); Grants for Development of New Faculty Staff
Ratchadaphiseksomphot Endowment Fund; Post-Doctoral Scholarship,
Chulalongkorn University Ratchadaphiseksomphot Fund
FX This work was supported by the Chulalongkorn Academic Advancement into
Its 2nd Century Project (CUAASC) (TP), and the Grants for Development of
New Faculty Staff Ratchadaphiseksomphot Endowment Fund (TS). TS was also
supported by Post-Doctoral Scholarship, Chulalongkorn University
Ratchadaphiseksomphot Fund.
NR 54
TC 0
Z9 0
U1 8
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD AUG 17
PY 2016
VL 17
AR 307
DI 10.1186/s12859-016-1165-8
PG 15
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA DV3NR
UT WOS:000382829900002
PM 27534850
ER
PT J
AU Funk, D
Coen, K
Tamadon, S
Hope, BT
Shaham, Y
Le, AD
AF Funk, Douglas
Coen, Kathleen
Tamadon, Sahar
Hope, Bruce T.
Shaham, Yavin
Le, A. D.
TI Role of Central Amygdala Neuronal Ensembles in Incubation of Nicotine
Craving
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE central amygdala; Daun02; Fos; incubation of craving; nicotine;
orbitofrontal cortex
ID ADULT MALE RATS; MEDIAL PREFRONTAL CORTEX; TIME-DEPENDENT CHANGES;
PROTEIN-KINASE-A; NUCLEUS-ACCUMBENS; DRUG RELAPSE; COCAINE-SEEKING;
INDUCED REINSTATEMENT; SMOKING-CESSATION; SIGNALING PATHWAY
AB The craving response to smoking-associated cues in humans or to intravenous nicotine-associated cues in adult rats progressively increases or incubates after withdrawal. Here, we further characterized incubation of nicotine craving in the rat model by determining whether this incubation is observed after adolescent-onset nicotine self-administration. We also used the neuronal activity marker Fos and the Daun02 chemogenetic inactivation procedure to identify cue-activated neuronal ensembles that mediate incubation of nicotine craving. Wetrained adolescent and adult male rats to self-administer nicotine (2 h/d for 12 d) and assessed cue-induced nicotine seeking in extinction tests (1 h) after 1, 7, 14, or 28 withdrawal days. In both adult and adolescent rats, nicotine seeking in the relapse tests followed an inverted U-shaped curve, with maximal responding on withdrawal day 14. Independent of the withdrawal day, nicotine seeking in the relapse tests was higher in adult than in adolescent rats. Analysis of Fos expression in different brain areas of adolescent and adult rats on withdrawal days 1 and 14 showed time-dependent increases in the number of Fos-positive neurons in central and basolateral amygdala, orbitofrontal cortex, ventral and dorsal medial prefrontal cortex, and nucleus accumbens core and shell. In adult Fos-lacZ transgenic rats, selective inactivation of nicotine-cue-activated Fos neurons in central amygdala, but not orbitofrontal cortex, decreased "incubated" nicotine seeking on withdrawal day 14. Our results demonstrate that incubation of nicotine craving occurs after adolescent-onset nicotine self-administration and that neuronal ensembles in central amygdala play a critical role in this incubation.
C1 [Funk, Douglas; Coen, Kathleen; Tamadon, Sahar; Le, A. D.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Neurobiol Alcohol Lab, 33 Russell St, Toronto, ON M5S 2S1, Canada.
[Le, A. D.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada.
[Le, A. D.] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A8, Canada.
[Hope, Bruce T.; Shaham, Yavin] NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
RP Funk, D (reprint author), Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Neurobiol Alcohol Lab, 33 Russell St, Toronto, ON M5S 2S1, Canada.
EM Douglas.Funk@camh.ca
RI Hope, Bruce/A-9223-2010
OI Hope, Bruce/0000-0001-5804-7061
FU National Institute on Drug Abuse-National Institutes of Health
[R21DA034394]; National Institute on Drug Abuse-National Institutes of
Health (Intramural Research Program grant)
FX This work was supported by the National Institute on Drug Abuse-National
Institutes of Health (Grant R21DA034394 to A.D.L. and Intramural
Research Program grant to Y.S. and B.T.H.).
NR 76
TC 1
Z9 1
U1 2
U2 2
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 17
PY 2016
VL 36
IS 33
BP 8612
EP 8623
DI 10.1523/JNEUROSCI.1505-16.2016
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA DU6GW
UT WOS:000382313400009
PM 27535909
ER
PT J
AU Kaufman, DJ
Baker, R
Milner, LC
Devaney, S
Hudson, KL
AF Kaufman, David J.
Baker, Rebecca
Milner, Lauren C.
Devaney, Stephanie
Hudson, Kathy L.
TI A Survey of U.S Adults' Opinions about Conduct of a Nationwide Precision
Medicine Initiative (R) Cohort Study of Genes and Environment
SO PLOS ONE
LA English
DT Article
ID DATABASE; BIOBANK; HEART
AB Objectives
A survey of a population-based sample of U.S adults was conducted to measure their attitudes about, and inform the design of the Precision Medicine Initiative's planned national cohort study.
Methods
An online survey was conducted by GfK between May and June of 2015. The influence of different consent models on willingness to share data was examined by randomizing participants to one of eight consent scenarios.
Results
Of 4,777 people invited to take the survey, 2,706 responded and 2,601 (54% response rate) provided valid responses. Most respondents (79%) supported the proposed study, and 54% said they would definitely or probably participate if asked. Support for and willingness to participate in the study varied little among demographic groups; younger respondents, LGBT respondents, and those with more years of education were significantly more likely to take part if asked. The most important study incentive that the survey asked about was learning about one's own health information. Willingness to share data and samples under broad, study-by-study, menu and dynamic consent models was similar when a statement about transparency was included in the consent scenarios. Respondents were generally interested in taking part in several governance functions of the cohort study.
Conclusions
A large majority of the U.S. adults who responded to the survey supported a large national cohort study. Levels of support for the study and willingness to participate were both consistent across most demographic groups. The opportunity to learn health information about one's self from the study appears to be a strong motivation to participate.
C1 [Kaufman, David J.] NHGRI, Div Genom & Soc, NIH, Rockville, MD 20852 USA.
[Baker, Rebecca; Milner, Lauren C.; Devaney, Stephanie; Hudson, Kathy L.] NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA.
RP Kaufman, DJ (reprint author), NHGRI, Div Genom & Soc, NIH, Rockville, MD 20852 USA.
EM dave.kaufman@nih.gov
FU Foundation for the National Institutes of Health
FX The authors wish to thank the Foundation for the National Institutes of
Health, which funded this survey. The authors would also like to thank
Vence Bonham, Laura Rodriguez, Alex Lee and the members of the Consent,
Education, Regulation and Consultation Working Group of the eMERGE
research consortium for their contributions to the survey and manuscript
development.; The Foundation for National Institutes of Health directly
paid for GfK to field the survey. The authors themselves received no
specific funding for the work. FNIH did not participate in data
collection, analysis, decisions to publish or preparation of the
manuscript. They were involved in discussions about the logistics of
study design but did not influence survey content.
NR 25
TC 3
Z9 3
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 17
PY 2016
VL 11
IS 8
AR e0160461
DI 10.1371/journal.pone.0160461
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT4YN
UT WOS:000381487600031
ER
PT J
AU Frew, PM
Parker, K
Vo, L
Haley, D
O'Leary, A
Diallo, DD
Golin, CE
Kuo, I
Soto-Torres, L
Wang, J
Adimora, AA
Randall, LA
del Rio, C
Hodder, S
AF Frew, Paula M.
Parker, Kimberly
Vo, Linda
Haley, Danielle
O'Leary, Ann
Diallo, Dazon Dixon
Golin, Carol E.
Kuo, Irene
Soto-Torres, Lydia
Wang, Jing
Adimora, Adaora A.
Randall, Laura A.
del Rio, Carlos
Hodder, Sally
CA HIV Prevention Trials Network 064
TI Socioecological factors influencing women's HIV risk in the United
States: qualitative findings from the women's HIV SeroIncidence study
(HPTN 064)
SO BMC PUBLIC HEALTH
LA English
DT Article
DE HIV/AIDS; Sexual health; Socioecological model; Women; Minorities; HIV
risk reduction
ID SEXUALLY-TRANSMITTED INFECTIONS; INTIMATE PARTNER VIOLENCE;
AFRICAN-AMERICAN WOMEN; PREVENTION TRIALS NETWORK; NEIGHBORHOOD
DISADVANTAGE; DRUG-USERS; PERCEIVED DISCRIMINATION; DEPRESSIVE SYMPTOMS;
PHYSICAL HEALTH; SUBSTANCE-ABUSE
AB Background: We sought to understand the multilevel syndemic factors that are concurrently contributing to the HIV epidemic among women living in the US. We specifically examined community, network, dyadic, and individual factors to explain HIV vulnerability within a socioecological framework.
Methods: We gathered qualitative data (120 interviews and 31 focus groups) from a subset of women ages 18-44 years (N = 2,099) enrolled in the HPTN 064 HIV seroincidence estimation study across 10 US communities. We analyzed data from 4 diverse locations: Atlanta, New York City (the Bronx), Raleigh, and Washington, DC. Data were thematically coded using grounded theory methodology. Intercoder reliability was assessed to evaluate consistency of team-based coding practices.
Results: The following themes were identified at 4 levels including 1) exosystem (community): poverty prevalence, discrimination, gender imbalances, community violence, and housing challenges; 2) mesosystem (network): organizational social support and sexual concurrency; 3) microsystem (dyadic): sex exchange, interpersonal social support, intimate partner violence; and 4) individual: HIV/STI awareness, risk taking, and substance use. A strong theme emerged with over 80 % of responses linked to the fundamental role of financial insecurity underlying risktaking behavioral pathways.
Conclusions: Multilevel syndemic factors contribute to women's vulnerability to HIV in the US. Financial insecurity is a predominant theme, suggesting the need for tailored programming for women to reduce HIV risk.
C1 [Frew, Paula M.; Vo, Linda; Randall, Laura A.; del Rio, Carlos] Emory Univ, Div Infect Dis, Dept Med, Sch Med, 1760 Haygood Rd,Suite 300, Atlanta, GA 30322 USA.
[Frew, Paula M.; Haley, Danielle] Emory Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
[Frew, Paula M.; del Rio, Carlos] Emory Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE, Atlanta, GA 30329 USA.
[Frew, Paula M.; del Rio, Carlos] Emory Univ, Emory Ctr AIDS Res, 1518 Clifton Rd NE,Suite 8050, Atlanta, GA 30322 USA.
[Parker, Kimberly] Texas Womans Univ, Dept Hlth Studies, CFO Bldg 1007,POB 425499, Denton, TX 76204 USA.
[O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
[Diallo, Dazon Dixon] SisterLove Inc, 3709 Bakers Ferry Rd SW, Atlanta, GA 30331 USA.
[Golin, Carol E.; Adimora, Adaora A.] Univ N Carolina, Sch Med, Dept Med, 130 Mason Farm Rd, Chapel Hill, NC 27599 USA.
[Kuo, Irene] George Washington Univ, Milken Inst, Sch Publ Hlth, 950 New Hampshire Ave NW,Suite 500, Washington, DC 20052 USA.
[Soto-Torres, Lydia] NIAID, Washington, DC USA.
[Wang, Jing] Fred Hutchinson Canc Res Ctr, SCHARP, 1124 Columbia St, Seattle, WA 98104 USA.
[Hodder, Sally] West Virginia Univ, Sch Med, One Med Ctr Dr,HSC South 2244, Morgantown, WV 26506 USA.
RP Frew, PM (reprint author), Emory Univ, Div Infect Dis, Dept Med, Sch Med, 1760 Haygood Rd,Suite 300, Atlanta, GA 30322 USA.; Frew, PM (reprint author), Emory Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.; Frew, PM (reprint author), Emory Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE, Atlanta, GA 30329 USA.; Frew, PM (reprint author), Emory Univ, Emory Ctr AIDS Res, 1518 Clifton Rd NE,Suite 8050, Atlanta, GA 30322 USA.
EM pfrew@emory.edu
RI del Rio, Carlos/B-3763-2012;
OI del Rio, Carlos/0000-0002-0153-3517; Frew, Paula/0000-0002-3078-9124
FU National Institute of Allergy and Infectious Diseases, National
Institute on Drug Abuse, and National Institute of Mental Health [UM1
AI068619, U01-AI068613, UM1-AI068613]; Centers for Innovative Research
to Control AIDS, Mailman School of Public Health, Columbia University
[5U1Al069466]; University of North Carolina Clinical Trials Unit
[AI069423]; University of North Carolina Clinical Trials Research Center
of the Clinical and Translational Science Award [RR 025747]; University
of North Carolina Center for AIDS Research [AI050410]; Emory University
HIV/AIDS Clinical Trials Unit [5UO1AI069418]; Center for AIDS Research
[P30 AI050409]; Clinical and Translational Science Award [UL1 RR025008];
Terry Beirn Community Programs for Clinical Research on AIDS Clinical
Trials Unit [5 UM1 AI069503-07]; Johns Hopkins Adult AIDS Clinical Trial
Unit [AI069465]; Johns Hopkins Clinical and Translational Science Award
[UL1 RR 25005]
FX Grant support provided by the National Institute of Allergy and
Infectious Diseases, National Institute on Drug Abuse, and National
Institute of Mental Health [UM1 AI068619, U01-AI068613, and
UM1-AI068613]; Centers for Innovative Research to Control AIDS, Mailman
School of Public Health, Columbia University [5U1Al069466]; University
of North Carolina Clinical Trials Unit [AI069423]; University of North
Carolina Clinical Trials Research Center of the Clinical and
Translational Science Award [RR 025747]; University of North Carolina
Center for AIDS Research [AI050410]; Emory University HIV/AIDS Clinical
Trials Unit [5UO1AI069418], Center for AIDS Research [P30 AI050409], and
Clinical and Translational Science Award [UL1 RR025008]; The Terry Beirn
Community Programs for Clinical Research on AIDS Clinical Trials Unit [5
UM1 AI069503-07], and; The Johns Hopkins Adult AIDS Clinical Trial Unit
[AI069465] and The Johns Hopkins Clinical and Translational Science
Award [UL1 RR 25005].
NR 95
TC 1
Z9 1
U1 9
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 17
PY 2016
VL 16
AR 803
DI 10.1186/s12889-016-3364-7
PG 18
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DT5UV
UT WOS:000381549400004
PM 27530401
ER
PT J
AU Maachani, UB
Tandle, A
Shankavaram, U
Kramp, T
Camphausen, K
AF Maachani, Uday B.
Tandle, Anita
Shankavaram, Uma
Kramp, Tamalee
Camphausen, Kevin
TI Modulation of miR-21 signaling by MPS1 in human glioblastoma
SO ONCOTARGET
LA English
DT Article
DE glioblastoma multiforme; MPS1; MiR21; PDCD4; MSH2; TGF-beta/SMAD
signaling
ID TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; MITOTIC CHECKPOINT;
COLORECTAL-CANCER; MICRORNA MATURATION; DIFFERENTIAL ROLES; PDCD4
EXPRESSION; RENAL FIBROSIS; PROTEIN; KINASE
AB Monopolar spindle 1 (MPS1) is an essential spindle assembly checkpoint (SAC) kinase involved in determining spindle integrity. Beyond its mitotic functions, it has been implicated in several other signaling pathways. Our earlier studies have elaborated on role of MPS1 in glioblastoma (GBM) radiosensitization. In this study using reverse phase protein arrays (RPPAs), we assessed MPS1 mediated cell signaling pathways and demonstrated that inhibiting MPS1 could upregulate the expression of the tumor suppressor PDCD4 and MSH2 genes, by down regulating micro RNA-21 (miR-21). In GBMs miR-21 expression is significantly elevated and is associated with chemo and radioresistance. Both MPS1 and miR-21 depletion suppressed GBM cell proliferation, whereas, ectopic expression of miR-21 rescued GBM cell growth from MPS1 inhibition. Further, we demonstrate that MPS1 mediates phosphorylation of SMAD3 but not SMAD2 in GBM cells; A possible mechanism behind miR-21 modulation by MPS1. Collectively, our results shed light onto an important role of MPS1 in TGF-beta/SMAD signaling via miR-21 regulation. We also, show the prognostic effect of miR-21, PDCD4 and MSH2 levels to patient survival across different GBM molecular subtypes. This scenario in which miR-21 is modulated by MPS1 inhibition may be exploited as a potential target for effective GBM therapy.
C1 [Maachani, Uday B.; Tandle, Anita; Shankavaram, Uma; Kramp, Tamalee; Camphausen, Kevin] NCI, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Camphausen, K (reprint author), NCI, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA.
EM camphauk@mail.nih.gov
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute
FX This research was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute.
NR 54
TC 0
Z9 0
U1 3
U2 3
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 16
PY 2016
VL 7
IS 33
BP 52912
EP 52927
DI 10.18632/oncotarget.4143
PG 16
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY9DG
UT WOS:000385433000024
PM 25991676
ER
PT J
AU Wang, J
He, PJ
Gaida, M
Yang, SH
Schetter, AJ
Gaedcke, J
Ghadimi, BM
Ried, T
Yfantis, H
Lee, D
Weiss, JM
Stauffer, J
Hanna, N
Alexander, HR
Hussain, SP
AF Wang, Jian
He, Peijun
Gaida, Matthias
Yang, Shouhui
Schetter, Aaron J.
Gaedcke, Jochen
Ghadimi, B. Michael
Ried, Thomas
Yfantis, Harris
Lee, Dong
Weiss, Jonathan M.
Stauffer, Jimmy
Hanna, Nader
Alexander, H. Richard
Hussain, S. Perwez
TI Inducible nitric oxide synthase enhances disease aggressiveness in
pancreatic cancer
SO ONCOTARGET
LA English
DT Article
DE NOS2; NO; PDAC; KPC mouse model
ID FORKHEAD TRANSCRIPTION FACTOR; DUCTAL ADENOCARCINOMA; BREAST-CANCER;
INFLAMMATION; SURVIVAL; TUMORIGENESIS; INVASION; GROWTH; FOXOS; CELLS
AB Pancreatic cancer is one of the most lethal malignancies and is refractory to the available treatments. Pancreatic ductal adenocarcinoma (PDAC) expresses high level of inducible nitric oxide synthase (NOS2), which causes sustained production of nitric oxide (NO). We tested the hypothesis that an aberrantly increased NO-release enhances the development and progression of PDAC. Enhanced NOS2 expression in tumors significantly associated with poor survival in PDAC patients (N = 107) with validation in independent cohorts. We then genetically targeted NOS2 in an autochthonous mouse model of PDAC to examine the effect of NOS2-deficiency on disease progression and survival. Genetic ablation of NOS2 significantly prolonged survival and reduced tumor severity in LSL-Kras(G12D/+); LSL-Trp53(R172H/+); Pdx-1-Cre (KPC) mice. Primary tumor cells isolated from NOS2-deficient KPC (NKPC) mice showed decreased proliferation and invasiveness as compared to those from KPC mice. Furthermore, NKPC tumors showed reduced expression of pERK, a diminished inactivation of Forkhead box transcription factor O (FOXO3), a tumor suppressor, and a decrease in the expression of oncomir-21, when compared with tumors in KPC mice. Taken together, these findings showed that NOS2 is a predictor of prognosis in early stage, resected PDAC patients, and provide proof-of-principle that targeting NOS2 may have potential therapeutic value in this lethal malignancy.
C1 [Wang, Jian; He, Peijun; Yang, Shouhui; Hussain, S. Perwez] NCI, Pancreat Canc Unit, Human Carcinogenesis Lab, CCR, Bethesda, MD 20892 USA.
[Gaida, Matthias] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
[Schetter, Aaron J.] US FDA, Silver Spring, MD USA.
[Gaedcke, Jochen; Ghadimi, B. Michael] Univ Med, Dept Gen Visceral & Pediat Surg, Gottingen, Germany.
[Ried, Thomas] NCI, Genet Branch, CCR, Baltimore Vet Affairs Med Ctr, Baltimore, MD USA.
[Yfantis, Harris; Lee, Dong] Baltimore Vet Affairs Med Ctr, Pathol & Lab Med, Baltimore, MD USA.
[Weiss, Jonathan M.] NCI, Canc & Inflammat Program, CCR, Frederick, MD 21701 USA.
[Stauffer, Jimmy] NCI, Lab Cell & Dev Signaling, Frederick, MD 21701 USA.
[Hanna, Nader; Alexander, H. Richard] Univ Maryland, Sch Med, Div Surg Oncol, Baltimore, MD 21201 USA.
RP Hussain, SP (reprint author), NCI, Pancreat Canc Unit, Human Carcinogenesis Lab, CCR, Bethesda, MD 20892 USA.
EM hussainp@mail.nih.gov
FU Intramural Research Program of Center for Cancer Research, National
Cancer Institute, NIH
FX Intramural Research Program of the Center for Cancer Research, National
Cancer Institute, NIH.
NR 45
TC 0
Z9 0
U1 2
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 16
PY 2016
VL 7
IS 33
BP 52993
EP 53004
DI 10.18632/oncotarget.10323
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY9DG
UT WOS:000385433000029
PM 27367029
ER
PT J
AU Fu, SW
Kirolikar, SP
Ginsburg, E
Tan, XH
Schwartz, A
Simmens, SJ
Man, YG
Pinzone, JJ
Teal, C
Awate, S
Vonderhaar, BK
Berg, PE
AF Fu, Sidney W.
Kirolikar, Saurabh P.
Ginsburg, Erika
Tan, Xiaohui
Schwartz, Arnold
Simmens, Samuel J.
Man, Yan-gao
Pinzone, Joseph J.
Teal, Christine
Awate, Sanket
Vonderhaar, Barbara K.
Berg, Patricia E.
TI Beta protein 1 homeoprotein induces cell growth and estrogen-independent
tumorigenesis by binding to the estrogen receptor in breast cancer
SO ONCOTARGET
LA English
DT Article
DE homeobox gene; BP1; estrogen receptor; tamoxifen resistance;
tumorigenesis
ID GENOME-WIDE ANALYSIS; HOMEOBOX GENE; ER-ALPHA; TAMOXIFEN RESISTANCE;
BRCA1 INHIBITION; EXPRESSION; BP1; TUMORS; CARCINOMA; SURVIVAL
AB Expression of Beta Protein 1 (BP1), a homeotic transcription factor, increases during breast cancer progression and may be associated with tumor aggressiveness. In our present work, we investigate the influence of BP1 on breast tumor formation and size in vitro and in vivo. Cells overexpressing BP1 showed higher viability when grown in the absence of serum (p < 0.05), greater invasive potential (p < 0.05) and formed larger colonies (p < 0.004) compared with the controls. To determine the influence of BP1 overexpression on tumor characteristics, MCF-7 cells transfected with either empty vector (V1) or overexpressor plasmids (O2 and O4) were injected into the fat pads of athymic nude mice. Tumors grew larger in mice receiving O2 or O4 cells than in mice receiving V1 cells. Moreover, BP1 mRNA expression levels were positively correlated with tumor size in patients (p = 0.01). Interestingly, 20% of mice injected with O2 or O4 cells developed tumors in the absence of estrogen, while no mice receiving V1 cells developed tumors. Several mechanisms of estrogen independent tumor formation related to BP1 were established. These data are consistent with the fact that expression of breast cancer anti-estrogen resistance 1 (BCAR1) was increased in O2 compared to V1 cells (p < 0.01). Importantly, O2 cells exhibited increased proliferation when treated with tamoxifen, while V1 cells showed growth inhibition. Overall, BP1 overexpresssion in MCF-7 breast cancer cells leads to increased cell growth, estrogen-independent tumor formation, and increased proliferation. These findings suggest that BP1 may be an important biomarker and therapeutic target in ER positive breast cancer.
C1 [Fu, Sidney W.; Tan, Xiaohui] George Washington Univ, Dept Med, Div Genom Med, Washington, DC 20037 USA.
[Kirolikar, Saurabh P.; Awate, Sanket; Berg, Patricia E.] George Washington Univ, Dept Biochem & Mol Med, Washington, DC 20037 USA.
[Ginsburg, Erika; Vonderhaar, Barbara K.] NCI, Mammary Biol & Tumorigenesis Lab, NIH, Bethesda, MD 20892 USA.
[Schwartz, Arnold] George Washington Univ, Med Ctr, Dept Pathol, Washington, DC 20037 USA.
[Simmens, Samuel J.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Epidemiol & Biostat, Washington, DC 20037 USA.
[Man, Yan-gao] Armed Forces Inst Pathol, Dept Gynecol & Breast Pathol, Washington, DC 20306 USA.
[Pinzone, Joseph J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Teal, Christine] George Washington Univ, Dept Surg, Washington, DC 20037 USA.
RP Berg, PE (reprint author), George Washington Univ, Dept Biochem & Mol Med, Washington, DC 20037 USA.
EM peb@gwu.edu
FU Intramural Research Program of the NIH; Center for Cancer Research; NCI;
Elaine H. Snyder Cancer Research Award (SWF); Katherine Birch McCormick
Foundation (PEB); [K08 CA102875]
FX Portions of this research were supported by grant K08 CA102875 (JJP), by
the Intramural Research Program of the NIH, Center for Cancer Research,
NCI (E.G. and B.K.V.), the Elaine H. Snyder Cancer Research Award (SWF)
and by the Katherine Birch McCormick Foundation (PEB).
NR 53
TC 0
Z9 0
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 16
PY 2016
VL 7
IS 33
BP 53204
EP 53216
DI 10.18632/oncotarget.10633
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY9DG
UT WOS:000385433000045
PM 27449292
ER
PT J
AU Cousin, SF
Kaderavek, P
Haddou, B
Charlier, C
Marquardsen, T
Tyburn, JM
Bovier, PA
Engelke, F
Maas, W
Bodenhausen, G
Pelupessy, P
Ferrage, F
AF Cousin, Samuel F.
Kaderavek, Pavel
Haddou, Baptiste
Charlier, Cyril
Marquardsen, Thorsten
Tyburn, Jean-Max
Bovier, Pierre-Alain
Engelke, Frank
Maas, Werner
Bodenhausen, Geoffrey
Pelupessy, Philippe
Ferrage, Fabien
TI Recovering Invisible Signals by Two-Field NMR Spectroscopy
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE chemical exchange; high-field NMR spectroscopy; kinetics; nuclear
magnetic resonance; low-field NMR spectroscopy
ID MAGNETIC-RELAXATION DISPERSION; MOLECULAR-WEIGHT PROTEINS; FIELD-CYCLING
DEVICE; CONTRAST AGENTS; MOLTEN GLOBULE; RESOLUTION; DYNAMICS;
RELAXOMETRY; RESONANCE; NANOSECOND
AB Nuclear magnetic resonance (NMR) studies have benefited tremendously from the steady increase in the strength of magnetic fields. Spectacular improvements in both sensitivity and resolution have enabled the investigation of molecular systems of rising complexity. At very high fields, this progress may be jeopardized by line broadening, which is due to chemical exchange or relaxation by chemical shift anisotropy. In this work, we introduce a two-field NMR spectrometer designed for both excitation and observation of nuclear spins in two distinct magnetic fields in a single experiment. NMR spectra of several small molecules as well as a protein were obtained, with two dimensions acquired at vastly different magnetic fields. Resonances of exchanging groups that are broadened beyond recognition at high field can be sharpened to narrow peaks in the low-field dimension. Two-field NMR spectroscopy enables the measurement of chemical shifts at optimal fields and the study of molecular systems that suffer from internal dynamics, and opens new avenues for NMR spectroscopy at very high magnetic fields.
C1 [Cousin, Samuel F.; Kaderavek, Pavel; Haddou, Baptiste; Charlier, Cyril; Bodenhausen, Geoffrey; Pelupessy, Philippe; Ferrage, Fabien] PSL Res Univ, Ecole Normale Super, Dept Chem, 24 Rue Lhomond, F-75005 Paris, France.
[Cousin, Samuel F.; Kaderavek, Pavel; Haddou, Baptiste; Charlier, Cyril; Bodenhausen, Geoffrey; Pelupessy, Philippe; Ferrage, Fabien] Univ Paris 06, Sorbonne Univ, LBM 4 Pl Jussieu, F-75005 Paris, France.
[Cousin, Samuel F.; Kaderavek, Pavel; Charlier, Cyril; Bodenhausen, Geoffrey; Pelupessy, Philippe; Ferrage, Fabien] CNRS, UMR LBM 7203, F-75005 Paris, France.
[Haddou, Baptiste] CNRS, UMR Pasteur 8640, F-75005 Paris, France.
[Marquardsen, Thorsten; Engelke, Frank] Bruker BioSpin GmbH, Silberstreifen 4, D-76287 Rheinstetten, Germany.
[Tyburn, Jean-Max] Bruker BioSpin, 34 Rue Ind BP 10002, F-67166 Wissembourg, France.
[Bovier, Pierre-Alain] Bruker BioSpin AG, Ind Str 26, CH-8117 Fallanden, Switzerland.
[Maas, Werner] Bruker BioSpin, Billerica, MA 01821 USA.
[Charlier, Cyril] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Ferrage, F (reprint author), PSL Res Univ, Ecole Normale Super, Dept Chem, 24 Rue Lhomond, F-75005 Paris, France.; Ferrage, F (reprint author), Univ Paris 06, Sorbonne Univ, LBM 4 Pl Jussieu, F-75005 Paris, France.; Ferrage, F (reprint author), CNRS, UMR LBM 7203, F-75005 Paris, France.
EM Fabien.Ferrage@ens.fr
RI Kaderavek, Pavel/D-7670-2012
FU European Research Council (ERC) under the European Community Seventh
Framework Program [279519 (2F4BIODYN)]
FX We thank Kaushik Dutta (New York Structural Biology Center) for the
ubiquitin plasmid as well as Lei Bruschweiler-Li and Rafael Bruschweiler
(the Ohio State University) for the method for ubiquitin purification.
This work was funded by the European Research Council (ERC) under the
European Community Seventh Framework Program (FP7/2007-2013), ERC Grant
Agreement 279519 (2F4BIODYN).
NR 48
TC 1
Z9 1
U1 22
U2 22
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD AUG 16
PY 2016
VL 55
IS 34
BP 9886
EP 9889
DI 10.1002/anie.201602978
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA DW0ZT
UT WOS:000383373000009
PM 27417269
ER
PT J
AU Ahlawat, S
Fayad, LM
Khan, MS
Bredella, MA
Harris, GJ
Evans, DG
Farschtschi, S
Jacobs, MA
Chhabra, A
Salamon, JM
Wenzel, R
Mautner, VF
Dombi, E
Cai, WL
Plotkin, SR
Blakeley, JO
AF Ahlawat, Shivani
Fayad, Laura M.
Khan, Muhammad Shayan
Bredella, Miriam A.
Harris, Gordon J.
Evans, D. Gareth
Farschtschi, Said
Jacobs, Michael A.
Chhabra, Avneesh
Salamon, Johannes M.
Wenzel, Ralph
Mautner, Victor F.
Dombi, Eva
Cai, Wenli
Plotkin, Scott R.
Blakeley, Jaishri O.
CA Whole Body MRI Comm REiNS
TI Current whole-body MRI applications in the neurofibromatoses NF1, NF2,
and schwannomatosis
SO NEUROLOGY
LA English
DT Article
ID NERVE SHEATH TUMORS; PLEXIFORM NEUROFIBROMAS; INTRAOBSERVER VARIABILITY;
DIAGNOSTIC-CRITERIA; METASTATIC-DISEASE; BURDEN; TYPE-1; GROWTH;
INTEROBSERVER; FEASIBILITY
AB Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials.
Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy.
Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection of WB tumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility.
Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.
C1 [Ahlawat, Shivani; Fayad, Laura M.; Jacobs, Michael A.] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA.
[Jacobs, Michael A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
[Khan, Muhammad Shayan] Khyber Med Coll, Peshawar, Pakistan.
[Bredella, Miriam A.; Harris, Gordon J.; Cai, Wenli] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
Harvard Med Sch, Boston, MA USA.
[Evans, D. Gareth] Univ Manchester, Manchester Acad Hlth Sci Ctr, Genom Med, Manchester M13 9PL, Lancs, England.
[Farschtschi, Said; Mautner, Victor F.] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany.
[Chhabra, Avneesh] Univ Texas Southwestern Med Ctr Dallas, Radiol & Orthoped Surg, Dallas, TX 75390 USA.
[Salamon, Johannes M.] Univ Hosp Hamburg Eppendorf, Dept Diagnost & Intervent Radiol, Hamburg, Germany.
[Wenzel, Ralph] Radiol Practice Altona, Hamburg, Germany.
[Dombi, Eva] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Ahlawat, S (reprint author), Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA.
EM sahlawa1@jhmi.edu
RI North, Kathryn/K-6476-2012;
OI North, Kathryn/0000-0003-0841-8009; Evans, Gareth/0000-0002-8482-5784
FU NICHD NIH HHS [U54 HD090255]
NR 37
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 16
PY 2016
VL 87
SU 1
BP S31
EP S39
DI 10.1212/WNL.0000000000002929
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6MD
UT WOS:000382328100006
PM 27527647
ER
PT J
AU Hanemann, CO
Blakeley, JO
Nunes, FP
Robertson, K
Stemmer-Rachamimov, A
Mautner, V
Kurtz, A
Ferguson, M
Widemann, BC
Evans, DG
Ferner, R
Carroll, SL
Korf, B
Wolkenstein, P
Knight, P
Plotkin, SR
AF Hanemann, C. Oliver
Blakeley, Jaishri O.
Nunes, Fabio P.
Robertson, Kent
Stemmer-Rachamimov, Anat
Mautner, Victor
Kurtz, Andreas
Ferguson, Michael
Widemann, Brigitte C.
Evans, D. Gareth
Ferner, Rosalie
Carroll, Steven L.
Korf, Bruce
Wolkenstein, Pierre
Knight, Pamela
Plotkin, Scott R.
CA REiNS Int Collaboration
TI Current status and recommendations for biomarkers and biobanking in
neurofibromatosis
SO NEUROLOGY
LA English
DT Article
ID NERVE-SHEATH TUMORS; CLINICAL-TRIALS; TYPE-1; SERUM; MANAGEMENT;
EXPRESSION; DIAGNOSIS; CONSENSUS
AB Objective: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs).
Methods: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and on biobanking efforts outside these diseases via literature search, defined the need for biomarkers in NF, and developed recommendations in a series of consensus meetings.
Results: We describe existing biomarkers in NF and report consensus recommendations for SOP and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and SWN in decentralized biobanks.
Conclusions: These recommendations are intended to provide clinicians and researchers with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for NF1, NF2, and SWN.
C1 [Hanemann, C. Oliver] Univ Plymouth, Peninsula Sch Med & Dent, Inst Translat & Stratified Med, Plymouth, Devon, England.
[Blakeley, Jaishri O.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Nunes, Fabio P.] Indiana Univ, Dept Pediat, Bloomington, IN 47405 USA.
[Robertson, Kent; Ferguson, Michael] Indiana Univ, Dept Pediat, Sch Med, Bloomington, IN 47405 USA.
[Nunes, Fabio P.] Eli Lilly & Co, Tailored Therapeut, Indianapolis, IN 46285 USA.
[Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Plotkin, Scott R.] Massachusetts Gen Hosp, Neurooncol, Boston, MA 02114 USA.
[Mautner, Victor] Uniklin Eppendorf, Neurol Klin, Hamburg, Germany.
[Kurtz, Andreas] Charite, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.
[Kurtz, Andreas] Seoul Natl Univ, Coll Vet Med, Seoul, South Korea.
[Kurtz, Andreas] Seoul Natl Univ, Res Inst Vet Sci, Seoul, South Korea.
[Widemann, Brigitte C.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Evans, D. Gareth] Univ Manchester, Genom Med, Manchester M13 9PL, Lancs, England.
[Ferner, Rosalie] Guys & St Thomas NHS Fdn Trust, Dept Neurol, Natl Neurofibromatosis Serv, London, England.
[Carroll, Steven L.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Korf, Bruce] Univ Alabama Birmingham, Heflin Ctr Genom Sci, Birmingham, AL USA.
GHU Henri Mondor, Paris, France.
[Knight, Pamela] Childrens Tumor Fdn, New York, NY USA.
RP Hanemann, CO (reprint author), Univ Plymouth, Peninsula Sch Med & Dent, Inst Translat & Stratified Med, Plymouth, Devon, England.
EM Oliver.Hanemann@plymouth.ac.uk
RI North, Kathryn/K-6476-2012;
OI North, Kathryn/0000-0003-0841-8009; Hanemann, Clemens
Oliver/0000-0002-1951-1025; Evans, Gareth/0000-0002-8482-5784
FU NICHD NIH HHS [U54 HD090255]
NR 22
TC 1
Z9 1
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 16
PY 2016
VL 87
SU 1
BP S40
EP S48
DI 10.1212/WNL.0000000000002932
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6MD
UT WOS:000382328100007
PM 27527649
ER
PT J
AU Plotkin, SR
Davis, SD
Robertson, KA
Akshintala, S
Allen, J
Fisher, MJ
Blakeley, JO
Widemann, BC
Ferner, RE
Marcus, CL
AF Plotkin, Scott R.
Davis, Stephanie D.
Robertson, Kent A.
Akshintala, Srivandana
Allen, Julian
Fisher, Michael J.
Blakeley, Jaishri O.
Widemann, Brigitte C.
Ferner, Rosalie E.
Marcus, Carole L.
CA REiNS Int Collaboration
TI Sleep and pulmonary outcomes for clinical trials of airway plexiform
neurofibromas in NF1
SO NEUROLOGY
LA English
DT Article
ID PHASE-I TRIAL; APNEA SYNDROME; REFERENCE VALUES; RESPIRATORY
INDICATIONS; PRACTICE PARAMETERS; CYSTIC-FIBROSIS; CPAP TREATMENT;
CHILDREN; POLYSOMNOGRAPHY; SPIROMETRY
AB Objective: Plexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%-50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction are uncommon but clinically important. Because improvement in sleep quality or airway function represents direct clinical benefit, measures of sleep and pulmonary function may be more meaningful than tumor size as endpoints in therapeutic clinical trials targeting airway PN.
Methods: The Response Evaluation in Neurofibromatosis and Schwannomatosis functional outcomes group reviewed currently available endpoints for sleep and pulmonary outcomes and developed consensus recommendations for response evaluation in NF clinical trials.
Results: For patients with airway PNs, polysomnography, impulse oscillometry, and spirometry should be performed to identify abnormal function that will be targeted by the agent under clinical investigation. The functional group endorsed the use of the apnea hypopnea index (AHI) as the primary sleep endpoint, and pulmonary resistance at 10 Hz (R-10) or forced expiratory volume in 1 or 0.75 seconds (FEV1 or FEV0.75) as primary pulmonary endpoints. The group defined minimum changes in AHI, R-10, and FEV1 or FEV0.75 for response criteria. Secondary sleep outcomes include desaturation and hypercapnia during sleep and arousal index. Secondary pulmonary outcomes include pulmonary resistance and reactance measurements at 5, 10, and 20 Hz; forced vital capacity; peak expiratory flow; and forced expiratory flows.
Conclusions: These recommended sleep and pulmonary evaluations are intended to provide researchers with a standardized set of clinically meaningful endpoints for response evaluation in trials of NF1-related airway PNs.
C1 [Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Davis, Stephanie D.] Indiana Univ Sch Med, Riley Childrens Hosp, Sect Pediat Pulmonol Allergy & Sleep Med, Indianapolis, IN 46202 USA.
[Robertson, Kent A.] Indiana Univ Sch Med, Riley Childrens Hosp, Stem Cell Transplantat Program, Indianapolis, IN 46202 USA.
[Akshintala, Srivandana; Widemann, Brigitte C.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Allen, Julian] Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA.
[Fisher, Michael J.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
[Marcus, Carole L.] Childrens Hosp Philadelphia, Sleep Ctr, Philadelphia, PA 19104 USA.
[Fisher, Michael J.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Marcus, Carole L.] Univ Penn, Sleep Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Allen, Julian] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Blakeley, Jaishri O.] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA.
[Ferner, Rosalie E.] Guys & St Thomas NHS Fdn Trust, Dept Neurol, London, England.
Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Plotkin, SR (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
EM splotkin@partners.org
RI North, Kathryn/K-6476-2012;
OI North, Kathryn/0000-0003-0841-8009; Evans, Gareth/0000-0002-8482-5784
FU NICHD NIH HHS [U54 HD090255]
NR 42
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 16
PY 2016
VL 87
SU 1
BP S13
EP S20
DI 10.1212/WNL.0000000000002933
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6MD
UT WOS:000382328100004
PM 27527645
ER
PT J
AU Walsh, KS
Janusz, J
Wolters, PL
Martin, S
Klein-Tasman, BP
Toledo-Tamula, MA
Thompson, HL
Payne, JM
Hardy, KK
de Blank, P
Semerjian, C
Gray, LS
Solomon, SE
Ullrich, N
AF Walsh, Karin S.
Janusz, Jennifer
Wolters, Pamela L.
Martin, Staci
Klein-Tasman, Bonita P.
Toledo-Tamula, Mary Anne
Thompson, Heather L.
Payne, Jonathan M.
Hardy, Kristina K.
de Blank, Peter
Semerjian, Claire
Gray, Laura Schaffner
Solomon, Sondra E.
Ullrich, Nicole
CA REiNS Int Collaboration
TI Neurocognitive outcomes in neurofibromatosis clinical trials
Recommendations for the domain of attention
SO NEUROLOGY
LA English
DT Article
ID CONSENSUS COGNITIVE BATTERY; DEFICIT/HYPERACTIVITY DISORDER; TYPE-1;
CHILDREN; ADHD; DEFICITS; NF1; SPAN; METHYLPHENIDATE; COMPLICATION
AB Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact everyday functioning of children, adolescents, and adults with this disease. However, there is little agreement regarding measures to use as cognitive endpoints in clinical trials. This article describes the work of the Neurocognitive Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration. The goal of this committee is to identify standardized and specific cognitive assessment tools for use in NF clinical trials. The committee first identified cognitive domains relevant to NF1 and prioritized attention as the first domain of focus given prior and current trends in NF1 cognitive clinical trials. Performance measures and behavioral rating questionnaires of attention were reviewed by the group using established criteria to assess patient characteristics, psychometric properties, and feasibility. The highest rated tests underwent side-by-side comparison. The Digit Span subtest from the Wechsler scales was given the highest ratings of the performance measures due to its good psychometrics, feasibility, utility across a wide age range, and extensive use in previous research. The Conners scales achieved the highest ratings of the behavioral questionnaires for similar reasons. Future articles will focus on other cognitive domains, with the ultimate goal of achieving agreement for cognitive endpoints that can be used across NF clinical trials.
C1 [Walsh, Karin S.; Hardy, Kristina K.] George Washington Sch Med, Childrens Natl Hlth Syst, Washington, DC 20052 USA.
[Janusz, Jennifer] Univ Colorado, Sch Med, Childrens Hosp Colorado, Aurora, CO USA.
[Wolters, Pamela L.; Martin, Staci] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Klein-Tasman, Bonita P.] Univ Wisconsin, Milwaukee, WI 53201 USA.
[Toledo-Tamula, Mary Anne] NCI, Clin Res Directorate, Clin Monitoring Res Program, Leidos Biomed Res Inc, Frederick, MD 21701 USA.
[Thompson, Heather L.] Calif State Univ Sacramento, Sacramento, CA 95819 USA.
[Payne, Jonathan M.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
[de Blank, Peter] Rainbow Babies & Childrens Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA.
[Semerjian, Claire] Roosevelt Univ, Chicago, IL 60605 USA.
[Gray, Laura Schaffner; Ullrich, Nicole] Boston Childrens Hosp, Boston, MA USA.
[Solomon, Sondra E.] Univ Vermont, Burlington, VT 05405 USA.
RP Walsh, KS (reprint author), George Washington Sch Med, Childrens Natl Hlth Syst, Washington, DC 20052 USA.
EM kwalsh@childrensnational.org
RI North, Kathryn/K-6476-2012;
OI North, Kathryn/0000-0003-0841-8009; Payne, Jonathan/0000-0001-9565-3845;
Evans, Gareth/0000-0002-8482-5784
FU NICHD NIH HHS [U54 HD090255]
NR 50
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 16
PY 2016
VL 87
SU 1
BP S21
EP S30
DI 10.1212/WNL.0000000000002928
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6MD
UT WOS:000382328100005
PM 27527646
ER
PT J
AU Widemann, BC
Plotkin, SR
AF Widemann, Brigitte C.
Plotkin, Scott R.
TI Consensus for NF clinical trials Recommendations of the REiNS
collaboration (Supplement II) INTRODUCTION
SO NEUROLOGY
LA English
DT Editorial Material
ID PROGRESSIVE VESTIBULAR SCHWANNOMAS; INTERNATIONAL COLLABORATION;
NEUROFIBROMATOSIS TYPE-2; PHASE-II; OUTCOMES
AB The neurofibromatoses (NFs) can result in substantial morbidity in affected patients. In order to accelerate the development of effective therapies for NF-related tumor and nontumor manifestations, the development of standardized meaningful outcome measures for clinical trials is critical. The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established with the goal to develop consensus recommendations for outcome measures and endpoints in future NF trials and provided the first set of recommendations in a Neurology (R) supplement in 2013. This second supplement updates on clinical trials that have incorporated the recommended measures and provides new recommendations for (1) standardized and specific cognitive assessment tools for use in NF clinical trials, (2) patient-reported outcome measures including pain and physical functioning, (3) functional outcome measures for airway plexiform neurofibromas, (4) the use of whole-body MRI in NF, and (5) the development of biomarkers in NF and guidelines for collection of biospecimens and establishment of biobanks for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis. Through engagement of the NF research community, regulatory agencies, NF advocacy groups, industry, and patients with NF, REiNS will provide a framework for comprehensive review of these recommendations, continue development of outcome measures relevant to patients, and compare results of trials, which use identical outcome measures.
C1 [Widemann, Brigitte C.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Widemann, BC (reprint author), NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
EM widemanb@mail.nih.gov
NR 14
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 16
PY 2016
VL 87
SU 1
BP S1
EP S3
DI 10.1212/WNL.0000000000002930
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6MD
UT WOS:000382328100001
ER
PT J
AU Wolters, PL
Martin, S
Merker, VL
Tonsgard, JH
Solomon, SE
Baldwin, A
Bergner, AL
Walsh, K
Thompson, HL
Gardner, KL
Hingtgen, CM
Schorry, E
Dudley, WN
Franklin, B
AF Wolters, Pamela L.
Martin, Staci
Merker, Vanessa L.
Tonsgard, James H.
Solomon, Sondra E.
Baldwin, Andrea
Bergner, Amanda L.
Walsh, Karin
Thompson, Heather L.
Gardner, Kathy L.
Hingtgen, Cynthia M.
Schorry, Elizabeth
Dudley, William N.
Franklin, Barbara
CA REiNS Int Collaboration
TI Patient-reported outcomes of pain and physical functioning in
neurofibromatosis clinical trials
SO NEUROLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; PROMISA(R) PEDIATRIC SCALES; INFORMATION-SYSTEM PROMIS;
ITEM RESPONSE THEORY; PLEXIFORM NEUROFIBROMAS; INTERFERENCE INDEX;
CHILDREN; TYPE-1; HEALTH; VALIDATION
AB Objective: Tumors and other disease complications of neurofibromatosis (NF) can cause pain and negatively affect physical functioning. To document the clinical benefit of treatment in NF trials targeting these manifestations, patient-reported outcomes (PROs) assessing pain and physical functioning should be included as study endpoints. Currently, there is no consensus on the selection and use of such measures in the NF population. This article presents the recommendations of the PRO group of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration for assessing the domains of pain and physical functioning for NF clinical trials.
Methods: The REiNS PRO group reviewed and rated existing PRO measures assessing pain intensity, pain interference, and physical functioning using their systematic method. Final recommendations are based primarily on 4 main criteria: patient characteristics, item content, psychometric properties, and feasibility for clinical trials.
Results: The REiNS PRO group chose the Numeric Rating Scale-11 (>= 8 years) to assess pain intensity, the Pain Interference Index (6-24 years) and the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Interference Scale (>= 18 years) to evaluate pain interference, and the PROMIS Physical Functioning Scale to measure upper extremity function and mobility (>= 5 years) for NF clinical trials.
Conclusions: The REiNS Collaboration currently recommends these PRO measures to assess the domains of pain and physical functioning for NF clinical trials; however, further research is needed to evaluate their use in individuals with NF. A final consensus recommendation for the pain interference measure will be disseminated in a future publication based on findings from additional published research.
C1 [Wolters, Pamela L.; Martin, Staci; Baldwin, Andrea] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.
[Merker, Vanessa L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Merker, Vanessa L.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Tonsgard, James H.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
[Solomon, Sondra E.] Univ Vermont, Dept Psychol Sci, Burlington, VT 05405 USA.
[Bergner, Amanda L.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
[Bergner, Amanda L.] Johns Hopkins Univ, Dept Genet, Baltimore, MD USA.
[Walsh, Karin] Childrens Natl Hlth Syst, Washington, DC USA.
[Walsh, Karin] George Washington Sch Med, Washington, DC USA.
[Thompson, Heather L.] Calif State Univ Sacramento, Dept Speech Pathol & Audiol, Sacramento, CA 95819 USA.
[Gardner, Kathy L.] Vet Adm Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gardner, Kathy L.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Hingtgen, Cynthia M.] Michigan State Univ, Dept Clin Neurosci, Spectrum Hlth Med Grp, E Lansing, MI 48824 USA.
[Hingtgen, Cynthia M.] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
[Schorry, Elizabeth] Cincinnati Childrens Hosp, Div Human Genet, Cincinnati, OH USA.
[Dudley, William N.] Univ N Carolina, Sch Hlth & Human Sci, Dept Publ Hlth Educ, Greensboro, NC USA.
[Franklin, Barbara] Advocure NF2 Inc, Los Angeles, CA USA.
RP Wolters, PL (reprint author), NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.
EM woltersp@mail.nih.gov
RI North, Kathryn/K-6476-2012;
OI North, Kathryn/0000-0003-0841-8009; Merker, Vanessa/0000-0002-4542-5227;
Evans, Gareth/0000-0002-8482-5784
FU NICHD NIH HHS [U54 HD090255]
NR 44
TC 2
Z9 2
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 16
PY 2016
VL 87
SU 1
BP S4
EP S12
DI 10.1212/WNL.0000000000002927
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6MD
UT WOS:000382328100002
PM 27527648
ER
PT J
AU Rosario, AM
Perez-Stable, EJ
AF Rosario, Adelaida M.
Perez-Stable, Eliseo J.
TI Making Neighborhoods Good for Your Health
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; atherosclerosis; cardiovascular diseases; health status
disparities; outcome assessment (health care); residence characteristics
ID UNITED-STATES; ATHEROSCLEROSIS; ENVIRONMENT; IMPACT; COUNTY
C1 [Rosario, Adelaida M.] Natl Inst Minor Hlth & Hlth Dispar, Div Sci Programs, NIH, Bethesda, MD USA.
[Perez-Stable, Eliseo J.] Natl Inst Minor Hlth & Hlth Dispar, Off Director, NIH, Bethesda, MD USA.
RP Perez-Stable, EJ (reprint author), 6707 Democracy Blvd,Suite 800, Bethesda, MD 20892 USA.
EM eliseo.perez-stable@nih.gov
NR 14
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 16
PY 2016
VL 134
IS 7
BP 514
EP 516
DI 10.1161/CIRCULATIONAHA.116.024158
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DU5XC
UT WOS:000382286000006
PM 27528646
ER
PT J
AU Simon, R
AF Simon, Richard
TI Genomic Alteration-Driven Clinical Trial Designs in Oncology
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID PHASE-II TRIALS; LUNG-CANCER; VEMURAFENIB; THERAPY; PARADIGM; MEDICINE
AB The established molecular heterogeneity of human cancers necessitates the development of new paradigms to serve as a reliable basis for precision medicine. The assumptions underlying some of the conventional approaches to clinical trial design and analysis are no longer appropriate because of the molecular heterogeneity of tumors of a given primary site. This article reviews some clinical trial designs that have been actively applied in the codevelopment of therapeutics and predictive biomarkers to inform their use in oncology. These include the enrichment design, the basket design, and the umbrella design. Oncology leads most other therapeutic areas in development of personalized or precision medicine. Personalized or precision medicine is practiced daily in oncology on the basis of tumor genomics and may evolve in other therapeutic areas as it has in oncology, rather than according to inherited polymorphisms as so often imagined. Consequently, some of the clinical trial designs described here may serve as a possible blueprint for therapeutic development in fields other than oncology.
C1 [Simon, Richard] NCI, Rockville, MD 20892 USA.
RP Simon, R (reprint author), NCI, Div Canc Treatment & Diag, Biometr Res Program, 9609 Med Ctr Dr, Rockville, MD 20892 USA.
EM rsimon@nih.gov
NR 27
TC 1
Z9 1
U1 2
U2 4
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD AUG 16
PY 2016
VL 165
IS 4
BP 270
EP U114
DI 10.7326/M15-2413
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT1UI
UT WOS:000381267200016
PM 27214515
ER
PT J
AU Chertow, DS
Nath, A
Suffredini, AF
Danner, RL
Reich, DS
Bishop, RJ
Childs, RW
Arai, AE
Palmore, TN
Lane, HC
Fauci, AS
Davey, RT
AF Chertow, Daniel S.
Nath, Avindra
Suffredini, Anthony F.
Danner, Robert L.
Reich, Daniel S.
Bishop, Rachel J.
Childs, Richard W.
Arai, Andrew E.
Palmore, Tara N.
Lane, H. Clifford
Fauci, Anthony S.
Davey, Richard T.
TI Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case
Report
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Chertow, Daniel S.; Suffredini, Anthony F.; Danner, Robert L.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.
[Nath, Avindra; Reich, Daniel S.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Bishop, Rachel J.] NEI, NIH, Bethesda, MD 20892 USA.
[Childs, Richard W.; Arai, Andrew E.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Palmore, Tara N.] NIH, Hosp Epidemiol Serv, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Lane, H. Clifford; Fauci, Anthony S.; Davey, Richard T.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Chertow, DS (reprint author), NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.
FU Intramural NIH HHS [Z99 CL999999]
NR 6
TC 5
Z9 5
U1 2
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD AUG 16
PY 2016
VL 165
IS 4
BP 301
EP 304
DI 10.7326/M15-3066
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT1UI
UT WOS:000381267200030
PM 27043004
ER
PT J
AU Crompton, PD
Pierce, SK
AF Crompton, Peter D.
Pierce, Susan K.
TI PD-L2 Elbows out PD-L1 to Rescue T Cell Immunity to Malaria
SO IMMUNITY
LA English
DT Editorial Material
AB How early interactions between innate and adaptive immune cells influence outcomes of acute infections is incompletely understood. In this issue of Immunity, Karunarathne et al. (2016) show that dendritic cells help CD4(+) T helper 1 cell immunity against malaria through PD-L2' s competition with PD-L1.
C1 [Crompton, Peter D.] NIAID, Malaria Infect Biol & Immun Unit, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
[Pierce, Susan K.] NIAID, Lymphocyte Activat Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
RP Pierce, SK (reprint author), NIAID, Lymphocyte Activat Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
EM spierce@nih.gov
RI Crompton, Peter/N-1130-2016
NR 10
TC 0
Z9 0
U1 4
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD AUG 16
PY 2016
VL 45
IS 2
BP 231
EP 233
DI 10.1016/j.immuni.2016.08.001
PG 4
WC Immunology
SC Immunology
GA DU5QV
UT WOS:000382267300004
PM 27533008
ER
PT J
AU Hess, C
Kemper, C
AF Hess, Christoph
Kemper, Claudia
TI Complement-Mediated Regulation of Metabolism and Basic Cellular
Processes
SO IMMUNITY
LA English
DT Review
ID NLRP3 INFLAMMASOME ACTIVATION; ADIPOSE-TISSUE INFLAMMATION; TOLL-LIKE
RECEPTORS; CD4(+) T-CELLS; INSULIN-RESISTANCE; GLYCOLYTIC SWITCH;
INDUCED APOPTOSIS; HUMAN MONOCYTES; INDUCED INJURY; GLUCOSE-UPTAKE
AB Complement is well appreciated as a critical arm of innate immunity. It is required for the removal of invading pathogens and works by directly destroying them through the activation of innate and adaptive immune cells. However, complement activation and function is not confined to the extracellular space but also occurs within cells. Recent work indicates that complement activation regulates key metabolic pathways and thus can impact fundamental cellular processes, such as survival, proliferation, and autophagy. Newly identified functions of complement include a key role in shaping metabolic reprogramming, which underlies T cell effector differentiation, and a role as a nexus for interactions with other effector systems, in particular the inflammasome and Notch transcription-factor networks. This review focuses on the contributions of complement to basic processes of the cell, in particular the integration of complement with cellular metabolism and the potential implications in infection and other disease settings.
C1 [Hess, Christoph] Univ Basel, Dept Biomed, Immunobiol, 20 Hebelstr, CH-4031 Basel, Switzerland.
[Kemper, Claudia] Kings Coll London, Guys Hosp, Div Transplant Immunol & Mucosal Biol, Med Res Council,Ctr Transplantat, London SE1 9RT, England.
[Kemper, Claudia] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.
[Kemper, Claudia] NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA.
RP Hess, C (reprint author), Univ Basel, Dept Biomed, Immunobiol, 20 Hebelstr, CH-4031 Basel, Switzerland.; Kemper, C (reprint author), Kings Coll London, Guys Hosp, Div Transplant Immunol & Mucosal Biol, Med Res Council,Ctr Transplantat, London SE1 9RT, England.; Kemper, C (reprint author), NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.; Kemper, C (reprint author), NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA.
EM chess@uhbs.ch; claudia.kemper@kcl.ac.uk
FU MRC Centre grant [MR/J006742/1]; EU-funded Innovative Medicines
Initiative BTCURE; Wellcome Trust Investigator Award; King's Bioscience
Institute at King's College London; National Institute for Health
Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas'
NHS Foundation Trust; King's College London; Division of Intramural
Research of the National Heart, Lung, and Blood Institute at the NIH;
intramural research program of NIAID, NIH; Swiss National Science
Foundation [310030_154059, CRSII_160766]; Gebert-Ruf Foundation
[GER-058/14]; Swiss Cancer League [KFS-3773-08-2015]
FX Work in the Hess and Kemper laboratories is supported by MRC Centre
grant MR/J006742/1, an EU-funded Innovative Medicines Initiative BTCURE
(C.K.), a Wellcome Trust Investigator Award (C.K.), the King's
Bioscience Institute at King's College London (G.A.), the National
Institute for Health Research (NIHR) Biomedical Research Centre based at
Guy's and St Thomas' NHS Foundation Trust and King's College London, the
Division of Intramural Research of the National Heart, Lung, and Blood
Institute at the NIH, the intramural research program of NIAID, NIH, the
Swiss National Science Foundation (310030_154059 and CRSII_160766)
(C.H.), the Gebert-Ruf Foundation (GER-058/14), and the Swiss Cancer
League (KFS-3773-08-2015).
NR 150
TC 1
Z9 1
U1 16
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD AUG 16
PY 2016
VL 45
IS 2
BP 240
EP 254
DI 10.1016/j.immuni.2016.08.003
PG 15
WC Immunology
SC Immunology
GA DU5QV
UT WOS:000382267300008
PM 27533012
ER
PT J
AU Krishnamurty, AT
Thouvenel, CD
Portugal, S
Keitany, GJ
Kim, KS
Holder, A
Crompton, PD
Rawlings, DJ
Pepper, M
AF Krishnamurty, Akshay T.
Thouvenel, Christopher D.
Portugal, Silvia
Keitany, Gladys J.
Kim, Karen S.
Holder, Anthony
Crompton, Peter D.
Rawlings, David J.
Pepper, Marion
TI Somatically Hypermutated Plasmodium-Specific IgM(+) Memory B Cells Are
Rapid, Plastic, Early Responders upon Malaria Rechallenge
SO IMMUNITY
LA English
DT Article
ID MEROZOITE SURFACE PROTEIN-1; CD4(+) T-CELLS; PLASMA-CELLS; IMMUNOLOGICAL
MEMORY; PARASITE DEVELOPMENT; IMMUNE-RESPONSES; ANTIBODY-LEVELS;
IN-VITRO; FALCIPARUM; ANTIGEN
AB Humoral immunity consists of pre-existing antibodies expressed by long-lived plasma cells and rapidly reactive memory B cells (MBC). Recent studies of MBC development and function after protein immunization have uncovered significant MBC heterogeneity. To clarify functional roles for distinct MBC subsets during malaria infection, we generated tetramers that identify Plasmodium-specific MBCs in both humans and mice. Long-lived murine Plasmodium-specific MBCs consisted of three populations: somatically hypermutated immunoglobulin M+ (IgM +) and IgG(+) MBC subsets and an unmutated IgD(+) MBC population. Rechallenge experiments revealed that high affinity, somatically hypermutated Plasmodium-specific IgM(+) MBCs proliferated and gave rise to antibody-secreting cells that dominated the early secondary response to parasite rechallenge. IgM (+) MBCs also gave rise to T cell-dependent IgM(+) and IgG(+) B220(+) CD138(+) plasmablasts or T cell-independent B220-CD138(+) IgM(+) plasma cells. Thus, even in competition with IgG(+) MBCs, IgM(+) MBCs are rapid, plastic, early responders to a secondary Plasmodium rechallenge and should be targeted by vaccine strategies.
C1 [Krishnamurty, Akshay T.; Keitany, Gladys J.; Kim, Karen S.; Rawlings, David J.; Pepper, Marion] Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98109 USA.
[Thouvenel, Christopher D.; Rawlings, David J.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA 98101 USA.
[Portugal, Silvia; Crompton, Peter D.] NIAID, Immunogenet Lab, NIH, Rockville, MD 20892 USA.
[Holder, Anthony] Francis Crick Inst, Mill Hill Lab, Ridgeway,Mill Hill, London NW7 1AA, England.
RP Pepper, M (reprint author), Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98109 USA.
EM mpepper@uw.edu
RI Holder, Anthony/A-7554-2013; Crompton, Peter/N-1130-2016
OI Holder, Anthony/0000-0002-8490-6058;
FU NIH [T32-AI10667701]; [R01AI108626-01A-A87299]
FX We thank Dr. J. Langhorne and D. Perez-Mazliah for providing recombinant
MSP1 constructs and technical assistance, Dr. J. Rayner for providing P.
falciparum AMA1 protein, and Drs. M. Bevan and B. Hondowicz for
reviewing the manuscript and providing valuable discussion. We also
thank Drs. O. Doumbo and B. Traore and the residents of Kambila, Mali,
for helping acquire human PBMC samples. This work was supported by
grants to M.P. (NIH R01AI108626-01A-A87299), A.T.K. (NIH
T32-AI10667701), D.J.R. (Seattle Children's Research Institute, Center
for Immunity and Immunotherapies [CIIT]; the CIIT, Program for Cell and
Gene Therapy; and the Benaroya Family Gift Fund) and P.D.C. (NIH,
Division of Intramural Research, National Institute of Allergy and
Infectious Diseases).
NR 57
TC 1
Z9 1
U1 3
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD AUG 16
PY 2016
VL 45
IS 2
BP 402
EP 414
DI 10.1016/j.immuni.2016.06.014
PG 13
WC Immunology
SC Immunology
GA DU5QV
UT WOS:000382267300020
PM 27473412
ER
PT J
AU Rosenberg, HF
Druey, KM
AF Rosenberg, Helene F.
Druey, Kirk M.
TI Eosinophils, galectins, and a reason to breathe
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Editorial Material
ID GLYCAN INTERACTIONS; MURINE MODEL; ASTHMA; INFLAMMATION;
HYPERRESPONSIVENESS; MEPOLIZUMAB; PROTEIN; HEALTH; LECTIN; CELLS
C1 [Rosenberg, Helene F.] NIH, Inflammat Immunobiol Sect, Lab Allerg Dis, Bethesda, MD 20892 USA.
[Druey, Kirk M.] NIH, Mol Signal Transduct Sect, Lab Allerg Dis, Bethesda, MD 20892 USA.
RP Rosenberg, HF (reprint author), NIH, Inflammat Immunobiol Sect, Lab Allerg Dis, Bethesda, MD 20892 USA.
EM hrosenberg@niaid.nih.gov
FU NIAID NIH HHS [Z01 AI000746, Z01 AI000939, Z01 AI000941, Z01 AI000943]
NR 25
TC 0
Z9 0
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2016
VL 113
IS 33
BP 9139
EP 9141
DI 10.1073/pnas.1610644113
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3RS
UT WOS:000381399200030
PM 27496328
ER
PT J
AU Nolte-'t Hoen, E
Cremer, T
Gallo, RC
Margolis, LB
AF Nolte-'t Hoen, Esther
Cremer, Tom
Gallo, Robert C.
Margolis, Leonid B.
TI Extracellular vesicles and viruses: Are they close relatives?
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE extracellular vesicles; exosomes; viruses; defective viruses; infection
ID EXOSOMAL TRANSFER; DENDRITIC CELLS; RECIPIENT CELLS; INNATE IMMUNITY;
HIV-1; INFECTION; RNA; SECRETION; MICROVESICLES; MECHANISM
AB Extracellular vesicles (EVs) released by various cells are small phospholipid membrane-enclosed entities that can carry miRNA. They are now central to research in many fields of biology because they seem to constitute a new system of cell-cell communication. Physical and chemical characteristics of many EVs, as well as their biogenesis pathways, resemble those of retroviruses. Moreover, EVs generated by virus-infected cells can incorporate viral proteins and fragments of viral RNA, being thus indistinguishable from defective (noninfectious) retroviruses. EVs, depending on the proteins and genetic material incorporated in them, play a significant role in viral infection, both facilitating and suppressing it. Deciphering the mechanisms of EV-cell interactions may facilitate the design of EVs that inhibit viral infection and can be used as vehicles for targeted drug delivery.
C1 [Nolte-'t Hoen, Esther; Cremer, Tom] Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3584 CM Utrecht, Netherlands.
[Gallo, Robert C.] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA.
[Margolis, Leonid B.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Intercellular Interact, NIH, Bethesda, MD 20892 USA.
RP Gallo, RC (reprint author), Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA.
EM rgallo@ihv.umaryland.edu
FU European Research Council (ERC) under the European Union's Seventh
Framework Programme (FP)/ERC grant [337581]; National Institute of Child
Health and Human Development/NIH Intramural Program; Gates Foundation;
National Institute of Allergy and Infectious Diseases; University of
Maryland School of Medicine
FX E.N.-t.H. receives funding from the European Research Council (ERC)
under the European Union's Seventh Framework Programme
(FP/2007-2013)/ERC grant agreement 337581; the work of L.B.M. is funded
by the National Institute of Child Health and Human Development/NIH
Intramural Program; the work of R.C.G. is funded by the Gates
Foundation, the National Institute of Allergy and Infectious Diseases,
and the University of Maryland School of Medicine.
NR 63
TC 2
Z9 2
U1 14
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2016
VL 113
IS 33
BP 9155
EP 9161
DI 10.1073/pnas.1605146113
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3RS
UT WOS:000381399200034
PM 27432966
ER
PT J
AU Salie, ZL
Kirby, KA
Michailidis, E
Marchand, B
Singh, K
Rohan, LC
Kodama, EN
Mitsuya, H
Parniak, MA
Sarafianos, SG
AF Salie, Zhe Li
Kirby, Karen A.
Michailidis, Eleftherios
Marchand, Bruno
Singh, Kamalendra
Rohan, Lisa C.
Kodama, Eiichi N.
Mitsuya, Hiroaki
Parniak, Michael A.
Sarafianos, Stefan G.
TI Structural basis of HIV inhibition by translocation-defective RT
inhibitor 4 '-ethynyl-2-fluoro-2 '-deoxyadenosine (EFdA)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE EFdA; HIV-1 reverse transcriptase; inhibitors; NRTIs; X-ray
crystallography
ID REVERSE-TRANSCRIPTASE INHIBITOR; IMMUNODEFICIENCY-VIRUS TYPE-1;
HEPATITIS-B; DRUG-RESISTANCE; NUCLEOSIDE EFDA; POTENT; DNA; SOFOSBUVIR;
ENTECAVIR; SOFTWARE
AB 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent nucleoside analog inhibitor of HIV reverse transcriptase (RT). It retains a 3'-OH yet acts as a chain-terminating agent by diminishing translocation from the pretranslocation nucleotide-binding site (N site) to the posttranslocation primer-binding site (P site). Also, facile misincorporation of EFdA-monophosphate (MP) results in difficult-to-extend mismatched primers. To understand the high potency and unusual inhibition mechanism of EFdA, we solved RT crystal structures (resolutions from 2.4 to 2.9 angstrom) that include inhibition intermediates (i) before inhibitor incorporation (catalytic complex, RT/DNA/EFdA-triphosphate), (ii) after incorporation of EFdA-MP followed by dT-MP (RT/DNA(EFdA-MPP center dot dT-MPN)), or (iii) after incorporation of two EFdA-MPs (RT/DNA(EFdA-MPP center dot EFdA-MPN)); (iv) the latter was also solved with EFdA-MP mismatched at the N site (RT/DNA(EFdA-MPP center dot EFdA-MP*N)). We report that the inhibition mechanism and potency of EFdA stem from interactions of its 4'-ethynyl at a previously unexploited conserved hydrophobic pocket in the polymerase active site. The high resolution of the catalytic complex structure revealed a network of ordered water molecules at the polymerase active site that stabilize enzyme interactions with nucleotide and DNA substrates. Finally, decreased translocation results from favorable interactions of primer-terminating EFdA-MP at the pretranslocation site and unfavorable posttranslocation interactions that lead to observed localized primer distortions.
C1 [Salie, Zhe Li; Sarafianos, Stefan G.] Univ Missouri, Dept Biochem, CS Bond Life Sci Ctr, Columbia, MO 65211 USA.
[Kirby, Karen A.; Michailidis, Eleftherios; Marchand, Bruno; Singh, Kamalendra; Sarafianos, Stefan G.] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, CS Bond Life Sci Ctr, Columbia, MO 65211 USA.
[Rohan, Lisa C.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Rohan, Lisa C.] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
[Kodama, Eiichi N.] Tohoku Univ, Div Infect Dis, Sendai, Miyagi 9808575, Japan.
[Kodama, Eiichi N.] Tohoku Med Megabank Org, Sendai, Miyagi 9808575, Japan.
[Mitsuya, Hiroaki] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA.
[Mitsuya, Hiroaki] Kumamoto Univ, Grad Sch Med Sci, Dept Infect Dis, Kumamoto 8608556, Japan.
[Mitsuya, Hiroaki] Kumamoto Univ, Grad Sch Med Sci, Dept Hematol, Kumamoto 8608556, Japan.
[Mitsuya, Hiroaki] Natl Ctr Global Hlth & Med, Res Inst, Tokyo 1628655, Japan.
[Mitsuya, Hiroaki] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Tokyo 1628655, Japan.
[Parniak, Michael A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15219 USA.
RP Sarafianos, SG (reprint author), Univ Missouri, Dept Biochem, CS Bond Life Sci Ctr, Columbia, MO 65211 USA.; Sarafianos, SG (reprint author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, CS Bond Life Sci Ctr, Columbia, MO 65211 USA.
EM sarafianoss@missouri.edu
RI Kodama, Eiichi /C-4032-2009;
OI Kodama, Eiichi /0000-0002-6622-2752; Li, Zhe/0000-0003-2063-1013;
Sarafianos, Stefan G/0000-0002-5840-154X; Kirby, Karen
A./0000-0003-2468-4796
FU Office of Science, Office of Basic Energy Sciences, of the US Department
of Energy (DOE) [DE-AC02-05CH11231]; US DOE [DE-AC02-06CH11357];
National Institutes of Health [AI076119, AI099284, AI100890, AI120860,
GM103368, GM118012]; Mizzou Advantage; Trail to a Cure
FX We thank Jay Nix of Advanced Light Source beamline 4.2.2 for support.
The ALS is supported by the Director, Office of Science, Office of Basic
Energy Sciences, of the US Department of Energy (DOE) under Contract
DE-AC02-05CH11231. We also acknowledge the Advanced Photon Source. Use
of the Advanced Photon Source, an Office of Science User Facility
operated for the US DOE Office of Science by Argonne National
Laboratory, was supported by the US DOE under Contract
DE-AC02-06CH11357. This work was supported in part by grants from the
National Institutes of Health (AI076119, AI099284, AI100890, AI120860,
GM103368, and GM118012), Mizzou Advantage, and Trail to a Cure.
NR 26
TC 1
Z9 1
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2016
VL 113
IS 33
BP 9274
EP 9279
DI 10.1073/pnas.1605223113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3RS
UT WOS:000381399200054
PM 27489345
ER
PT J
AU Levine, ME
Lu, AT
Chen, BH
Hernandez, DG
Singleton, AB
Ferrucci, L
Bandinelli, S
Salfati, E
Manson, JE
Quach, A
Kusters, CDJ
Kuh, D
Wong, A
Teschendorff, AE
Widschwendter, M
Ritz, BR
Absher, D
Assimes, TL
Horvath, S
AF Levine, Morgan E.
Lu, Ake T.
Chen, Brian H.
Hernandez, Dena G.
Singleton, Andrew B.
Ferrucci, Luigi
Bandinelli, Stefania
Salfati, Elias
Manson, JoAnn E.
Quach, Austin
Kusters, Cynthia D. J.
Kuh, Diana
Wong, Andrew
Teschendorff, Andrew E.
Widschwendter, Martin
Ritz, Beate R.
Absher, Devin
Assimes, Themistocles L.
Horvath, Steve
TI Menopause accelerates biological aging
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE menopause; DNA methylation; aging; WHI; epigenetic clock
ID BRITISH BIRTH COHORT; DNA METHYLATION AGE; NATURAL MENOPAUSE; EPIGENETIC
AGE; PARKINSONS-DISEASE; PREFRONTAL CORTEX; LIFE-SPAN; BLOOD; MORTALITY;
EPIDEMIOLOGY
AB Although epigenetic processes have been linked to aging and disease in other systems, it is not yet known whether they relate to reproductive aging. Recently, we developed a highly accurate epigenetic biomarker of age (known as the "epigenetic clock"), which is based on DNA methylation levels. Here we carry out an epigenetic clock analysis of blood, saliva, and buccal epithelium using data from four large studies: the Women's Health Initiative (n = 1,864); Invec-chiare nel Chianti (n = 200); Parkinson's disease, Environment, and Genes (n = 256); and the United Kingdom Medical Research Council National Survey of Health and Development (n = 790). We find that increased epigenetic age acceleration in blood is significantly associated with earlier menopause (P = 0.00091), bilateral oophorectomy (P = 0.0018), and a longer time since menopause (P = 0.017). Conversely, epigenetic age acceleration in buccal epithelium and saliva do not relate to age at menopause; however, a higher epigenetic age in saliva is exhibited in women who undergo bilateral oophorectomy (P = 0.0079), while a lower epigenetic age in buccal epithelium was found for women who underwent menopausal hormone therapy (P = 0.00078). Using genetic data, we find evidence of coheritability between age at menopause and epigenetic age acceleration in blood. Using Mendelian randomization analysis, we find that two SNPs that are highly associated with age at menopause exhibit a significant association with epigenetic age acceleration. Overall, our Mendelian randomization approach and other lines of evidence suggest that menopause accelerates epigenetic aging of blood, but mechanistic studies will be needed to dissect cause-and-effect relationships further.
C1 [Levine, Morgan E.; Lu, Ake T.; Quach, Austin; Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
[Levine, Morgan E.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Los Angeles, CA 90095 USA.
[Chen, Brian H.; Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Bethesda, MD 20892 USA.
[Hernandez, Dena G.; Singleton, Andrew B.] NIA, Lab Neurogenet, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Bandinelli, Stefania] Azienda Sanit Firenze, Geriatr Unit, I-50100 Florence, Italy.
[Salfati, Elias; Assimes, Themistocles L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
[Manson, JoAnn E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Kusters, Cynthia D. J.; Ritz, Beate R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
[Kuh, Diana; Wong, Andrew] UCL, Unit Lifelong Hlth & Ageing, Med Res Council, London WC1B 5JU, England.
[Teschendorff, Andrew E.; Widschwendter, Martin] UCL, Dept Womens Canc, London WC1 6BT, England.
[Teschendorff, Andrew E.] UCL, Inst Canc, London WC1 6BT, England.
[Teschendorff, Andrew E.] UCL, Inst Canc, Stat Genom Grp, London WC1E 6DD, England.
[Teschendorff, Andrew E.] Chinese Acad Sci, Shanghai Inst Biol, Chinese Acad Sci Max Planck Soc Partner Inst Comp, Key Lab Computat Biol, Shanghai 200031, Peoples R China.
[Absher, Devin] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.
[Horvath, Steve] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
RP Horvath, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.; Horvath, S (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
EM shorvath@mednet.ucla.edu
RI Assimes, Themistocles/D-9696-2015; Wong, Andrew/M-8899-2016
OI Assimes, Themistocles/0000-0003-2349-0009; Wong,
Andrew/0000-0003-2079-4779
FU NIH/NHLBI Grant [60442456 BAA23]; NIH/National Institute on Aging Grant
[1U34AG051425-01]; NIH/National Institute of Neurological Disorders and
Stroke Grant [T32NS048004]; NHLBI of the NIH, US Department of Health
and Human Services [HHSN268201100046C, HHSN268201100001C,
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C,
HHSN271201100004C]; Eve Appeal; Department of Health National Institute
for Health Research Biomedical Research Centres funding scheme; UK
Medical Research Council Grant [MC_UU_12019/1]; NIH/National Institute
of Environmental Health Sciences Grants [R21-ES024356, R01-ES10544]
FX This study was supported by NIH/NHLBI Grant 60442456 BAA23 (to T.L.A.,
D.A., and S.H.), NIH/National Institute on Aging Grant 1U34AG051425-01
(to S.H.), and NIH/National Institute of Neurological Disorders and
Stroke Grant T32NS048004 (to M.E.L.). The WHI program is funded by the
NHLBI of the NIH, US Department of Health and Human Services through
Contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. Part of
this work was funded by the Eve Appeal (https://www.eveappeal.org.uk/)
and was done at University College London Hospital/University College
London, which received a proportion of its funding from the Department
of Health National Institute for Health Research Biomedical Research
Centres funding scheme (M.W.). The NSHD is funded by UK Medical Research
Council Grant MC_UU_12019/1. The PEG study was funded by NIH/National
Institute of Environmental Health Sciences Grants R21-ES024356 (to S.H.
and B.R.R.) and R01-ES10544 (to B.R.R.).
NR 47
TC 7
Z9 7
U1 11
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2016
VL 113
IS 33
BP 9327
EP 9332
DI 10.1073/pnas.1604558113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3RS
UT WOS:000381399200063
PM 27457926
ER
PT J
AU Yim, KH
Prince, TL
Qu, SW
Bai, F
Jennings, PA
Onuchic, JN
Theodorakis, EA
Neckers, L
AF Yim, Kendrick H.
Prince, Thomas L.
Qu, Shiwei
Bai, Fang
Jennings, Patricia A.
Onuchic, Jose N.
Theodorakis, Emmanuel A.
Neckers, Leonard
TI Gambogic acid identifies an isoform-specific druggable pocket in the
middle domain of Hsp90 beta
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE molecular chaperone; heat-shock protein 90; isoform-specific inhibitor;
molecular docking; caged xanthone
ID SHOCK-PROTEIN 90; POTENT ANTITUMOR-ACTIVITY; CAGED GARCINIA XANTHONES;
MOLECULAR CHAPERONE; BINDING-SITE; CANCER-CELLS; DOWN-REGULATION; ATOMIC
CHARGES; BREAST-CANCER; TUMOR-GROWTH
AB Because of their importance in maintaining protein homeostasis, molecular chaperones, including heat-shock protein 90 (Hsp90), represent attractive drug targets. Although a number of Hsp90 inhibitors are in preclinical/clinical development, none strongly differentiate between constitutively expressed Hsp90 beta and stress-induced Hsp90 alpha, the two cytosolic paralogs of this molecular chaperone. Thus, the importance of inhibiting one or the other paralog in different disease states remains unknown. We show that the natural product, gambogic acid (GBA), binds selectively to a site in the middle domain of Hsp90 beta, identifying GBA as an Hsp90 beta-specific Hsp90 inhibitor. Furthermore, using computational and medicinal chemistry, we identified a GBA analog, referred to as DAP-19, which binds potently and selectively to Hsp90 beta. Because of its unprecedented selectivity for Hsp90 beta among all Hsp90 paralogs, GBA thus provides a new chemical tool to study the unique biological role of this abundantly expressed molecular chaperone in health and disease.
C1 [Yim, Kendrick H.; Prince, Thomas L.; Neckers, Leonard] NCI, Urol Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Qu, Shiwei; Jennings, Patricia A.; Theodorakis, Emmanuel A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
[Bai, Fang; Onuchic, Jose N.] Rice Univ, Ctr Theoret Biol Phys, Houston, TX 77005 USA.
[Onuchic, Jose N.] Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA.
[Onuchic, Jose N.] Rice Univ, Dept Chem, Houston, TX 77005 USA.
[Onuchic, Jose N.] Rice Univ, Dept Biosci, Houston, TX 77005 USA.
RP Neckers, L (reprint author), NCI, Urol Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM neckersl@mail.nih.gov
FU Intramural Research Program, Center for Cancer Research, National Cancer
Institute Grant [Z01 SC010074-12]; National Institutes of Health Grants
[CA 133002, GM101467]; Cancer Research Coordinating Committee
[CRC-15-380737]; National Science Foundation [PHY-1427654, MCB-1214457];
Cancer Prevention and Research Institute of Texas; Welch Foundation
Grant [C-1792]
FX This work was supported in part by the Intramural Research Program,
Center for Cancer Research, National Cancer Institute Grant Z01
SC010074-12 (to L.N.); National Institutes of Health Grants CA 133002
(to E.A.T.) and GM101467 (to P.A.J.); and a grant from the Cancer
Research Coordinating Committee (CRC-15-380737) (to E.A.T.). Work at the
Center for Theoretical Biological Physics was sponsored by the National
Science Foundation (Grants PHY-1427654 and MCB-1214457) and the Cancer
Prevention and Research Institute of Texas. F.B. was also supported by
Welch Foundation Grant C-1792.
NR 66
TC 2
Z9 2
U1 11
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2016
VL 113
IS 33
BP E4801
EP E4809
DI 10.1073/pnas.1606655113
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3RS
UT WOS:000381399200009
PM 27466407
ER
PT J
AU Warnick, EP
Dupuis, RJ
Piro, NA
Kassel, WS
Nataro, C
AF Warnick, Eugene P.
Dupuis, Ryan J.
Piro, Nicholas A.
Kassel, W. Scott
Nataro, Chip
TI Compounds containing weak, non-covalent interactions to the metal in the
backbone of 1,1 '-bis(phosphino)metallocene ligands
SO POLYHEDRON
LA English
DT Article
DE Halide abstraction; Chloride-bridged dimer; Weak non-covalent
interaction; X-ray crystal structure; Cyclic voltammetry
ID SYMMETRICALLY DISUBSTITUTED FERROCENES; X-RAY STRUCTURES;
1,1'-BIS(DIPHENYLPHOSPHINO)FERROCENE DPPF; MOLECULAR-STRUCTURES;
CRYSTAL-STRUCTURE; ROOM-TEMPERATURE; COMPLEXES; PALLADIUM; CHEMISTRY;
PHOSPHINE
AB The reactions of Na[BArF] (BArF = tetrakis(3,5-bis(trifluoromethyl)phenyl)borate) with a series of [Pd(dpEMc)Cl-2] (dpEMc = 1,1'-bis(diphenylphosphino)ruthenocene (dppr), 1,1'-bis(diphenylphosphino)osmocene (dppo) or 1,1'-bis(diphenylarsino)ferrocene (dpaf)) compounds were examined. The reaction of Na[BArF] with [Pd(dppMc)Cl-2] (dppMc = dppr or dppo) resulted in the formation of the corresponding chloride-bridged dimers, [Pd(dppMc)(mu-Cl)](2)(2+), which were structurally characterized. However, these dimers appear to be unstable in CH2Cl2 and partially (Ru) or fully (Os) convert into the corresponding monomers, [Pd(dppMc)Cl](+), which are proposed to have a weak, non-covalent M-Pd (M = Ru or Os) interaction. Similar compounds, [Pd(dppo)PPh3](2+) and [Pt(dppMc)PPh3](2+) (M = Fe (1,1'-bis(diphenylphosphino)ferrocene (dppf)) or Os (dppo)), were also prepared and structurally characterized. These compound also exhibit weak, non-covalent M-Pd/Pt interactions. In addition, the electrochemical properties of these compounds were examined by cyclic voltammetry. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Warnick, Eugene P.; Dupuis, Ryan J.; Nataro, Chip] Dept Chem, Lafayette Coll, Easton, PA 18042 USA.
[Piro, Nicholas A.; Kassel, W. Scott] Villanova Univ, Dept Chem, Villanova, PA 19085 USA.
[Warnick, Eugene P.] NIH, Bethesda, MD 20892 USA.
RP Nataro, C (reprint author), Dept Chem, Lafayette Coll, Easton, PA 18042 USA.
EM nataroc@lafayette.edu
OI Nataro, Chip/0000-0003-0439-9218
FU Academic Research Committee at Lafayette College
FX E.P.W., R.J.D. and C.N. thank Kresge Foundation for the purchase of the
JEOL NMR, and the Academic Research Committee at Lafayette College for
funding EXCEL scholars.
NR 48
TC 0
Z9 0
U1 3
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-5387
J9 POLYHEDRON
JI Polyhedron
PD AUG 16
PY 2016
VL 114
SI SI
BP 156
EP 164
DI 10.1016/j.poly.2015.11.025
PG 9
WC Chemistry, Inorganic & Nuclear; Crystallography
SC Chemistry; Crystallography
GA DQ9YE
UT WOS:000379564400023
ER
PT J
AU Ma, B
Xu, LY
Pan, XD
Sun, LX
Ding, JH
Xie, CS
Koliatsos, VE
Cai, HB
AF Ma, Bo
Xu, Leyan
Pan, Xiaodong
Sun, Lixin
Ding, Jinhui
Xie, Chengsong
Koliatsos, Vassilis E.
Cai, Huaibin
TI LRRK2 modulates microglial activity through regulation of chemokine
(C-X3-C) receptor 1-mediated signalling pathways
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PARKINSONS-DISEASE; FRACTALKINE RECEPTOR; CULTURED MICROGLIA;
ALPHA-SYNUCLEIN; MOUSE MODEL; KINASE; CELLS; ACTIVATION; CX3CL1;
PHOSPHORYLATION
AB Multiple missense mutations in Leucine-rich repeat kinase 2 (LRRK2) have been linked to Parkinson's disease (PD), the most common degenerative movement disorder. LRRK2 is expressed by both neurons and microglia, the residential immune cells in the brain. Increasing evidence supports a role of LRRK2 in modulating microglial activity, of which Lrrk2-null rodent microglia display less inflammatory response to endotoxin lipopolysaccharide (LPS). The underlying molecular mechanism, however, remains elusive. Chemokine (C-X3-C) receptor 1 (CX3CR1), predominantly expressed by microglia, suppresses microglial inflammation while promotes migration. Using whole-genome microarray screening, we found that Cx3cr1 mRNA levels were substantially higher in microglia derived from Lrrk2 knockout (Lrrk2(-/-)) mice. The total and cell surface levels of CX3CR1 proteins were also remarkably increased. In correlation with the enhanced CX3CR1 expression, Lrrk2-null microglia migrated faster and travelled longer distance toward the source of fractalkine (CX3CL1), an endogenous ligand of CX3CR1. To investigate the impact of CX3CR1 elevation in vivo, we compared LPS-induced inflammation in the striatum of Lrrk2(-/-) knockout mice with Cx3cr1 heterozygous and homozygous knockout background. We found that a complete loss of Cx3cr1 restored the responsiveness of Lrrk2(-/-) microglia to LPS stimulation. In conclusion, our findings reveal a previously unknown regulatory role for LRRK2 in CX3CR1 signalling and suggest that an increase of CX3CR1 activity contributes to the attenuated inflammatory responses in Lrrk2-null microglia.
C1 [Ma, Bo; Pan, Xiaodong; Sun, Lixin; Xie, Chengsong; Cai, Huaibin] NIA, Transgen Sect, Neurogenet Lab, NIH, Bldg 35,Room 1A112,MSC 3707,35 Convent Dr, Bethesda, MD 20892 USA.
[Xu, Leyan; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA.
[Ding, Jinhui] NIA, Bioinformat Core, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.
[Ma, Bo] Univ Florida, Coll Med, Dept Anesthesiol, Ctr Translat Res Neurodegenerat Dis, 1275 Ctr Dr,Biomed Sci J448, Gainesville, FL 32610 USA.
[Pan, Xiaodong] Fujian Med Univ, Union Hosp, Dept Neurol, 29 Xinquan Rd, Fuzhou 350001, Peoples R China.
RP Cai, HB (reprint author), NIA, Transgen Sect, Neurogenet Lab, NIH, Bldg 35,Room 1A112,MSC 3707,35 Convent Dr, Bethesda, MD 20892 USA.
EM caih@mail.nih.gov
FU intramural research programs of the National Institutes of Health
(NIH)-National Institute on Aging [AG000928, AG000944]; National Natural
Science Grant of China [81571257]
FX This work was supported in part by the intramural research programs of
the National Institutes of Health (NIH)-National Institute on Aging
(Grants AG000928 and AG000944 to H.C.), and National Natural Science
Grant of China (No. 81571257 to XD P.).
NR 43
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2016
VL 25
IS 16
BP 3515
EP 3523
DI 10.1093/hmg/ddw194
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EJ4IO
UT WOS:000393180400011
PM 27378696
ER
PT J
AU Permuth, JB
Pirie, A
Chen, YA
Lin, HY
Reid, BM
Chen, ZH
Monteiro, A
Dennis, J
Mendoza-Fandino, G
Anton-Culver, H
Bandera, EV
Bisogna, M
Brinton, L
Brooks-Wilson, A
Carney, ME
Chenevix-Trench, G
Cook, LS
Cramer, DW
Cunningham, JM
Cybulski, C
D'Aloisio, AA
Doherty, JA
Earp, M
Edwards, RP
Fridley, BL
Gayther, SA
Gentry-Maharaj, A
Goodman, MT
Gronwald, J
Hogdall, E
Iversen, ES
Jakubowska, A
Jensen, A
Karlan, BY
Kelemen, LE
Kjaer, SK
Kraft, P
Le, ND
Levine, DA
Lissowska, J
Lubinski, J
Matsuo, K
Menon, U
Modugno, R
Moysich, KB
Nakanishi, T
Ness, RB
Olson, S
Orlow, I
Pearce, CL
Pejovic, T
Poole, EM
Ramus, SJ
Rossing, MA
Sandler, DP
Shu, XO
Song, H
Taylor, JA
Teo, SH
Terry, KL
Thompson, PJ
Tworoger, SS
Webb, PM
Wentzensen, N
Wilkens, LR
Winham, S
Woo, YL
Wu, AH
Yang, H
Zheng, W
Ziogas, A
Phelan, CM
Schildkraut, JM
Berchuck, A
Goode, EL
Pharoah, PDP
Sellers, TA
AF Permuth, Jennifer B.
Pirie, Ailith
Chen, Y. Ann
Lin, Hui-Yi
Reid, Brett M.
Chen, Zhihua
Monteiro, Alvaro
Dennis, Joe
Mendoza-Fandino, Gustavo
Anton-Culver, Hoda
Bandera, Elisa V.
Bisogna, Maria
Brinton, Louise
Brooks-Wilson, Angela
Carney, Michael E.
Chenevix-Trench, Georgia
Cook, Linda S.
Cramer, Daniel W.
Cunningham, Julie M.
Cybulski, Cezary
D'Aloisio, Aimee A.
Doherty, Jennifer Anne
Earp, Madalene
Edwards, Robert P.
Fridley, Brooke L.
Gayther, Simon A.
Gentry-Maharaj, Aleksandra
Goodman, Marc T.
Gronwald, Jacek
Hogdall, Estrid
Iversen, Edwin S.
Jakubowska, Anna
Jensen, Allan
Karlan, Beth Y.
Kelemen, Linda E.
Kjaer, Suzanne K.
Kraft, Peter
Le, Nhu D.
Levine, Douglas A.
Lissowska, Jolanta
Lubinski, Jan
Matsuo, Keitaro
Menon, Usha
Modugno, Rosemary
Moysich, Kirsten B.
Nakanishi, Toru
Ness, Roberta B.
Olson, Sara
Orlow, Irene
Pearce, Celeste L.
Pejovic, Tanja
Poole, Elizabeth M.
Ramus, Susan J.
Rossing, Mary Anne
Sandler, Dale P.
Shu, Xiao-Ou
Song, Honglin
Taylor, Jack A.
Teo, Soo-Hwang
Terry, Kathryn L.
Thompson, Pamela J.
Tworoger, Shelley S.
Webb, Penelope M.
Wentzensen, Nicolas
Wilkens, Lynne R.
Winham, Stacey
Woo, Yin-Ling
Wu, Anna H.
Yang, Hannah
Zheng, Wei
Ziogas, Argyrios
Phelan, Catherine M.
Schildkraut, Joellen M.
Berchuck, Andrew
Goode, Ellen L.
Pharoah, Paul D. P.
Sellers, Thomas A.
CA AOCS Study Grp
Australian Canc Study Ovarian Canc
Ovarian Canc Assoc Consortium
TI Exome genotyping arrays to identify rare and low frequency variants
associated with epithelial ovarian cancer risk
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MAXIMUM-LIKELIHOOD TEST; SUSCEPTIBILITY LOCI;
GENE-EXPRESSION; BREAST-CANCER; CUSHINGS-SYNDROME; PROSTATE-CANCER;
COMPLEX DISEASE; IDENTIFICATION; CARCINOMA
AB Rare and low frequency variants are not well covered in most germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium (OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium (LD) with previously-identified signals at established loci reached traditional thresholds for exome-wide significance (P < 5.0 x 10(-7)). One of the most significant signals (P-all histologies = 1.01 x 10(-13);P-serous = 3.54 x 10(-14)) occurred at 3q25.31 for rs62273959, a missense variant mapping to the LEKR1 gene that is in LD (r(2) = 0.90) with a previously identified 'best hit' (rs7651446) mapping to an intron of TIPARP. Suggestive associations (5.0 x 10(-5) > P >= 5.0 x10(-7)) were detected for rare and low-frequency variants at 16 novel loci. Four rare missense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR = 9.66). Genes most strongly associated with EOC risk included ACTBL2 (P-AML = 3.23 x 10(-5); PSKAT-o = 9.23 x 10(-4)) and KRT13 (PAML = 1.67 x 10(-4); PSKAT-o = 1.07 x 10(-5)), reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes that may contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease
C1 [Permuth, Jennifer B.; Reid, Brett M.; Monteiro, Alvaro; Mendoza-Fandino, Gustavo; Phelan, Catherine M.; Sellers, Thomas A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA.
[Pirie, Ailith; Dennis, Joe; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Cambridge, England.
[Chen, Y. Ann; Lin, Hui-Yi; Chen, Zhihua] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA.
[Chenevix-Trench, Georgia; AOCS Study Grp; Australian Canc Study Ovarian Canc] QIMR Berghofer Med Res Inst, Genet & Computat Biol Dept, Brisbane, Qld, Australia.
[Anton-Culver, Hoda] Univ Calif Irvine, UCI Sch Med, Dept Epidemiol, Genet Epidemiol Res Inst, Irvine, CA USA.
[Bandera, Elisa V.] Rutgers Canc Inst New Jersey, Canc Prevent & Control Program, New Brunswick, NJ USA.
[Bisogna, Maria; Levine, Douglas A.] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA.
[Brinton, Louise] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Brooks-Wilson, Angela] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada.
[Brooks-Wilson, Angela] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC, Canada.
[Carney, Michael E.] Univ Hawaii, John A Burns Sch Med, Dept Obstet & Gynecol, Honolulu, HI 96822 USA.
[Cook, Linda S.] Univ New Mexico, Dept Internal Med, Div Epidemiol & Biostat, Albuquerque, NM 87131 USA.
[Cramer, Daniel W.; Terry, Kathryn L.] Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, 75 Francis St, Boston, MA 02115 USA.
[Cunningham, Julie M.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Cybulski, Cezary; Gronwald, Jacek; Jakubowska, Anna; Lubinski, Jan] Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Szczecin, Poland.
[D'Aloisio, Aimee A.] Social & Sci Syst Inc, Durham, NC USA.
[Doherty, Jennifer Anne] Dartmouth Coll, Geisel Sch Med, Dept Epidemiol, Hanover, NY USA.
[Earp, Madalene; Goode, Ellen L.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA.
[Edwards, Robert P.; Modugno, Rosemary] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, Pittsburgh, PA USA.
[Edwards, Robert P.; Modugno, Rosemary] Magee Womens Res Inst, Womens Canc Res Program, Ovarian Canc Ctr Excellence, Pittsburgh, PA USA.
[Edwards, Robert P.; Modugno, Rosemary] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Fridley, Brooke L.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA.
[Gayther, Simon A.; Pearce, Celeste L.; Ramus, Susan J.; Wu, Anna H.] Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
[Gentry-Maharaj, Aleksandra; Menon, Usha] UCL, Womens Canc Inst Womens Hlth, London, England.
[Goodman, Marc T.] Cedars Sinai Med Ctr, Samuel Oshin Comprehens Canc Inst, Canc Prevent & Control, Los Angeles, CA 90048 USA.
[Goodman, Marc T.] Cedars Sinai Med Ctr, Dept Biomed Sci, Community & Populat Hlth Res Inst, Los Angeles, CA 90048 USA.
[Hogdall, Estrid; Jensen, Allan; Kjaer, Suzanne K.] Danish Canc Soc, Res Ctr, Dept Virus Lifestyle & Genes, Copenhagen, Denmark.
[Hogdall, Estrid] Univ Copenhagen, Herlev Hosp, Dept Pathol, Mol Unit, Copenhagen, Denmark.
[Iversen, Edwin S.] Duke Univ, Dept Stat Sci, Durham, NC USA.
[Karlan, Beth Y.; Thompson, Pamela J.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA.
[Kelemen, Linda E.] Med Univ South Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC USA.
[Kjaer, Suzanne K.] Univ Copenhagen, Rigshosp, Dept Gynaecol, Copenhagen, Denmark.
[Kraft, Peter] Harvard TH Chan Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Boston, MA USA.
[Le, Nhu D.] BC Canc Agcy, Canc Control Res, Vancouver, BC, Canada.
[Lissowska, Jolanta] Maria Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland.
[Matsuo, Keitaro] Aichi Canc Ctr, Res Inst, Div Mol Med, Nagoya, Aichi, Japan.
[Modugno, Rosemary] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Moysich, Kirsten B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
[Nakanishi, Toru] Aichi Canc Ctr, Cent Hosp, Dept Gynecol Oncol, Nagoya, Aichi, Japan.
[Ness, Roberta B.] Univ Texas Sch Publ Hlth, Houston, TX USA.
[Olson, Sara; Orlow, Irene] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Pearce, Celeste L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Pejovic, Tanja] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA.
[Pejovic, Tanja] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Poole, Elizabeth M.; Tworoger, Shelley S.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Poole, Elizabeth M.; Tworoger, Shelley S.] Harvard Med Sch, Boston, MA USA.
[Poole, Elizabeth M.; Tworoger, Shelley S.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Rossing, Mary Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1124 Columbia St, Seattle, WA 98104 USA.
[Rossing, Mary Anne] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Sandler, Dale P.; Taylor, Jack A.] NIEHS, Epidemiol Branch, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA.
[Shu, Xiao-Ou] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Song, Honglin; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Dept Oncol, Cambridge, England.
[Teo, Soo-Hwang] Canc Res Malaysia, Subang Jaya, Malaysia.
[Teo, Soo-Hwang] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia.
[Webb, Penelope M.] QIMR Berghofer Med Res Inst, Populat Hlth Dept, Herston, Qld, Australia.
[Wentzensen, Nicolas; Yang, Hannah] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Wilkens, Lynne R.] Univ Hawaii, Ctr Canc, Canc Epidemiol Program, Honolulu, HI 96822 USA.
[Winham, Stacey] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA.
[Woo, Yin-Ling] Univ Malaya, Med Ctr, Dept Obstet & Gynaecol, Kuala Lumpur, Malaysia.
[Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Nashville, TN 37212 USA.
[Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
[Ziogas, Argyrios] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA.
[Schildkraut, Joellen M.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC USA.
[Schildkraut, Joellen M.] Duke Canc Inst, Canc Control & Populat Sci, Durham, NC USA.
[Berchuck, Andrew] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
RP Sellers, TA (reprint author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.
RI Gronwald, Jacek/A-4576-2017; Brooks-Wilson, Angela/E-9399-2012;
OI Gronwald, Jacek/0000-0002-3643-2871; Brooks-Wilson,
Angela/0000-0003-1009-6408; taylor, jack/0000-0001-5303-6398; Sandler,
Dale/0000-0002-6776-0018; Matsuo, Keitaro/0000-0003-1761-6314; Winham,
Stacey/0000-0002-8492-9102
FU National Institute of Health; Genetic Associations and Mechanisms in
Oncology (GAME-ON), a NCI Cancer Post-GWAS Initiative [U19-CA148112];
NHMRC; Medical Research Council studentship; U.S. National Institutes of
Health [R01-CA112523, R01-CA87538, R01- CA58598, N01-CN-55424,
N01-PC-67001]; DOD [DAMD17-02-1-0669]; NCI [K07-CA080668, R01-CA95023,
P50-CA159981]; NIH/National Center for Research Resources/General
Clinical Research Center grant [M01-RR000056, R01-CA126841]; Ministry of
Health, Labour and Welfare; American Cancer Society Early Detection
Professorship [SIOP-06-258-01-COUN]; L & S Milken Foundation; National
Cancer Institute, Bethesda, MD [R01- CA61107]; Danish Cancer Society,
Copenhagen, Denmark [94 222 52]; Mermaid I project; National Institutes
of Health [R01-CA122443, P30-CA15083, P50-CA136393, R01-CA76016,
R01-CA54419, P50-CA105009, P01-CA87696, R01-CA49449]; Mayo Foundation;
Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen
Foundation; Malaysian Ministry of Higher Education [UM.C/HIR/MOHE/06];
Cancer Research Initiatives Foundation; Department of Defense
[DAMD17-02-1-0666, W81XWH- 10-1-02802]; OHSU Foundation; Pomeranian
Medical University; National Cancer Institute [NIH-K07 CA095666,
R01-CA83918, NIH-K22-CA138563, P30-CA072720]; Cancer Institute of New
Jersey; NCI CCSG award [P30- CA008748]; Intramural Research Program of
the NCI; Cancer Research UK [C490/A10119 C490/A10124]; UK National
Institute for Health Research Biomedical Research Centres at the
University of Cambridge, SEARCH team; National Institute of
Environmental Health Sciences [Z01ES044005]; National Institute for
Health [R37-CA070867]; Eve Appeal (The Oak Foundation); National
Institute for Health Research University College London Hospitals
Biomedical Research Centre; Lon V Smith Foundation [LVS-39420];
California Cancer Research Program [00-01389V-20170, 2II0200];
Biostatistics and Cancer Informatics Core Facilities at the H. Lee
Moffitt Cancer Center & Research Institute, an NCI designated
Comprehensive Cancer Center [P30-CA076292]; [MOP-86727]; [MSH-87734]
FX Funding for this study was supported by the National Institute of Health
and the Genetic Associations and Mechanisms in Oncology (GAME-ON), a NCI
Cancer Post-GWAS Initiative (U19-CA148112). In addition, we acknowledge
the following: AUS: U.S. Army Medical Research and Materiel Command
(DAMD17-01-1-0729), National Health & Medical Research Council of
Australia, Cancer Councils of New South Wales, Victoria, Queensland,
South Australia and Tasmania, Cancer Foundation of Western Australia;
National Health and Medical Research Council of Australia (199600 and
400281). The Australian Ovarian Cancer Study Management Group (D.
Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb)
and ACS Investigators (A. Green, P. Parsons, N. Hayward, P. Webb, D.
Whiteman) thank all the clinical and scientific collaborators (see
http://www.aocstudy.org/) and the women for their contribution. GCT & PW
are supported by Fellowships from NHMRC; AP is funded by a Medical
Research Council studentship; DOV: U.S. National Institutes of Health
R01-CA112523 and R01-CA87538; HAW: U.S. National Institutes of Health
(R01- CA58598, N01-CN-55424 and N01-PC-67001); HOP: DOD DAMD17-02-1-0669
and NCI K07-CA080668, R01-CA95023, P50-CA159981; NIH/National Center for
Research Resources/General Clinical Research Center grant M01-RR000056;
R01-CA126841; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year
Strategy for Cancer Control from the Ministry of Health, Labour and
Welfare; LAX: American Cancer Society Early Detection Professorship
(SIOP-06-258-01-COUN) and the L & S Milken Foundation; MAL: Funding for
this study was provided by research grant R01- CA61107 from the National
Cancer Institute, Bethesda, MD; research grant 94 222 52 from the Danish
Cancer Society, Copenhagen, Denmark; and the Mermaid I project.; MAC and
MAY: National Institutes of Health (R01-CA122443, P30-CA15083,
P50-CA136393), Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred
C. and Katherine B. Andersen Foundation; MAS: Malaysian Ministry of
Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives
Foundation; NCO: National Institutes of Health (R01-CA76016) and the
Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of
Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-
10-1-02802; NHS: National Institute of Health (P01-CA87696 and
R01-CA49449); ORE: OHSU Foundation; POC: Pomeranian Medical University;
NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918,
NIH-K22-CA138563, and P30-CA072720), the Cancer Institute of New Jersey,
and NCI CCSG award (P30- CA008748). POL: Intramural Research Program of
the NCI; RMH: Cancer Research UK (no grant number is available); OVA:
(MOP-86727, MSH-87734; SEA: Cancer Research UK (C490/A10119
C490/A10124); UK National Institute for Health Research Biomedical
Research Centres at the University of Cambridge, SEARCH team, Craig
Luccarini, Caroline Baynes, Don Conroy; SIS: National Institute of
Environmental Health Sciences, (Z01ES044005); SWH: National Institute
for Health (R37-CA070867); UKO: The UKOPS study was funded by The Eve
Appeal (The Oak Foundation) and supported by the National Institute for
Health Research University College London Hospitals Biomedical Research
Centre. We particularly thank I. Jacobs, M. Widschwendter, E. Wozniak,
A. Ryan, J. Ford and N.; Balogun for their contribution to the study;
UCI: NIH R01-CA058860, NIH R01-CA092044, US Public Health Service
PSA-042205, and the Lon V Smith Foundation grant LVS-39420; USC:
P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, R03-CA113148,
R03-CA115195, N01-CN025403, and California Cancer Research Program
(00-01389V-20170, 2II0200). This study was also supported in part by the
Biostatistics and Cancer Informatics Core Facilities at the H. Lee
Moffitt Cancer Center & Research Institute, an NCI designated
Comprehensive Cancer Center (P30-CA076292).
NR 56
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2016
VL 25
IS 16
BP 3600
EP 3612
DI 10.1093/hmg/ddw196
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EJ4IO
UT WOS:000393180400018
PM 27378695
ER
PT J
AU Mohile, SG
Hurria, A
Cohen, HJ
Rowland, JH
Leach, CR
Arora, NK
Canin, B
Muss, HB
Magnuson, A
Flannery, M
Lowenstein, L
Allore, HG
Mustian, KM
Demark-Wahnefried, W
Extermann, M
Ferrell, B
Inouye, SK
Studenski, SA
Dale, W
AF Mohile, Supriya G.
Hurria, Arti
Cohen, Harvey J.
Rowland, Julia H.
Leach, Corinne R.
Arora, Neeraj K.
Canin, Beverly
Muss, Hyman B.
Magnuson, Allison
Flannery, Marie
Lowenstein, Lisa
Allore, Heather G.
Mustian, Karen M.
Demark-Wahnefried, Wendy
Extermann, Martine
Ferrell, Betty
Inouye, Sharon K.
Studenski, Stephanie A.
Dale, William
TI Improving the Quality of Survivorship for Older Adults With Cancer
SO CANCER
LA English
DT Review
DE aging; elderly; quality of life; research priorities; survivorship
ID COMPREHENSIVE GERIATRIC ASSESSMENT; ELDERLY-PATIENTS; AGING RESEARCH;
CHEMOTHERAPY TOXICITY; INTERNATIONAL SOCIETY; ONCOLOGY RESEARCH;
CONTROLLED-TRIAL; CLINICAL-TRIALS; CARE; MULTICENTER
AB In May 2015, the Cancer and Aging Research Group, in collaboration with the National Cancer Institute and the National Institute on Aging through a U13 grant, convened a conference to identify research priorities to help design and implement intervention studies to improve the quality of life and survivorship of older, frailer adults with cancer. Conference attendees included researchers with multidisciplinary expertise and advocates. It was concluded that future intervention trials for older adults with cancer should: 1) rigorously test interventions to prevent the decline of or improve health status, especially interventions focused on optimizing physical performance, nutritional status, and cognition while undergoing cancer treatment; 2) use standardized care plans based on geriatric assessment findings to guide targeted interventions; and 3) incorporate the principles of geriatrics into survivorship care plans. Also highlighted was the need to integrate the expertise of interdisciplinary team members into geriatric oncology research, improve funding mechanisms to support geriatric oncology research, and disseminate high-impact results to the research and clinical community. In conjunction with the 2 prior U13 meetings, this conference provided the framework for future research to improve the evidence base for the clinical care of older adults with cancer. (C) 2016 American Cancer Society.
C1 [Mohile, Supriya G.] Univ Rochester, Dept Med, Rochester, NY 14642 USA.
[Hurria, Arti] City Hope Natl Med Ctr, Med Oncol & Expt Therapeut, 1500 E Duarte Rd, Duarte, CA 91010 USA.
[Cohen, Harvey J.] Duke Univ, Ctr Study Aging & Human Dev, Durham, NC USA.
[Rowland, Julia H.; Leach, Corinne R.] NCI, Off Canc Survivorship, Bethesda, MD 20892 USA.
[Arora, Neeraj K.] Patient Ctr Outcomes Res Inst, Washington, DC USA.
[Canin, Beverly] SCOREboard Advocacy Grp, Rochester, NY USA.
[Muss, Hyman B.] Univ N Carolina, Breast Canc, Geriatr Oncol Program, Sch Med, Chapel Hill, NC USA.
[Magnuson, Allison] Univ Rochester, Div Med Oncol, 601 Elmwood Ave, Rochester, NY 14642 USA.
[Flannery, Marie; Mustian, Karen M.] Univ Rochester, Dept Surg, 601 Elmwood Ave, Rochester, NY 14642 USA.
[Lowenstein, Lisa] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA.
[Allore, Heather G.] Yale Univ, Dept Med & Publ Hlth Serv, New Haven, CT USA.
[Demark-Wahnefried, Wendy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Extermann, Martine] H Lee Moffitt Canc Ctr & Res Inst, Senior Adult Oncol Program, Tampa, FL USA.
[Ferrell, Betty] City Hope Natl Med Ctr, Dept Nursing, 1500 E Duarte Rd, Duarte, CA 91010 USA.
[Inouye, Sharon K.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Hebrew SeniorLife, Inst Aging Res, Boston, MA USA.
[Studenski, Stephanie A.] NIA, Bethesda, MD 20892 USA.
[Dale, William] Univ Chicago, Dept Med, Div Geriatr, 5841 S Maryland Ave, Chicago, IL 60637 USA.
RP Mohile, SG (reprint author), Univ Rochester, Med Ctr, Dept Med, 601 Elmwood Ave,Box 704, Rochester, NY 14642 USA.
EM Supriya_mohile@urmc.rochester.edu
OI Allore, Heather/0000-0001-7685-8175
FU National Institute on Aging [U13 AG038151]; American Cancer Society;
Patient-Centered Outcomes Research Institute [4634]; James Wilmot Cancer
Institute; Alliance for Clinical Trials in Oncology (National Cancer
Institute of the National Institutes of Health) [U10CA18082,
1UG1CA189823]; National Cancer Institute [UG1 CA189961]
FX Funded by grant U13 AG038151 from the National Institute on Aging. The
current study also was funded by the American Cancer Society and a
Patient-Centered Outcomes Research Institute Program contract (4634).
The work received support from the James Wilmot Cancer Institute, the
Alliance for Clinical Trials in Oncology (National Cancer Institute of
the National Institutes of Health under awards U10CA18082 and
1UG1CA189823), and grant UG1 CA189961 from the National Cancer
Institute. This work was made possible by the generous donors to the
James Wilmot Cancer Institute geriatric oncology philanthropy fund. All
statements in this report, including its findings and conclusions, are
solely those of the authors; do not necessarily represent the official
views of the funding agencies; and do not necessarily represent the
views of the Patient-Centered Outcomes Research Institute, its Board of
Governors, or Methodology Committee.
NR 47
TC 1
Z9 1
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD AUG 15
PY 2016
VL 122
IS 16
BP 2459
EP 2468
DI 10.1002/cncr.30053
PG 10
WC Oncology
SC Oncology
GA DW4MG
UT WOS:000383616600005
PM 27172129
ER
PT J
AU Siskind, RL
Andrasik, M
Karuna, ST
Broder, GB
Collins, C
Liu, A
Lucas, JP
Harper, GW
Renzullo, PO
AF Siskind, Rona L.
Andrasik, Michele
Karuna, Shelly T.
Broder, Gail B.
Collins, Clare
Liu, Albert
Lucas, Jonathan Paul
Harper, Gary W.
Renzullo, Philip O.
TI Engaging Transgender People in NIH-Funded HIV/AIDS Clinical Trials
Research
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE transgender; HIV; AIDS; clinical trials; research; NIH
ID PARTICIPANTS; HVTN
AB In 2009, the National Institutes of Health recognized the need to expand knowledge of lesbian, gay, bisexual, and transgender (LGBT) health and commissioned the Institute of Medicine to report on the health of these populations in the United States. The resulting Institute of Medicine publication called for more knowledge of the health of LGBT populations, as well as improved methodologies to reach them, more LGBT-focused research, and enhanced training programs and cultural competency of physicians and researchers. Several of the National Institutes of Health-funded HIV/AIDS clinical trials networks, including the Adolescent Medicine Trials Network for HIV/AIDS Interventions, HIV Prevention Trials Network, HIV Vaccine Trials Network, and Microbicide Trials Network, have focused attention on engaging transgender (TG) individuals in research. They have identified issues that transcend the nature of research (ie, treatment or prevention, adult or adolescent) and have adopted various approaches to effectively engage the TG community. Each network has recognized the importance of developing partner-ships to build trust with and seek input from TG individuals on research plans and policies. They have established standing advisory groups and convened consultations for this purpose. To ensure that trial data are reflective of the participants they are seeking to enroll, they have reviewed and revised data collection forms to incorporate the 2-step method of collecting sex at birth and gender identity as 2 independent variables, and some have also revised research protocol templates and policies for concept development to ensure that they are appropriate for the inclusion of TG participants. The networks have also initiated trainings to enhance cultural sensitivity and developed a range of materials and resources for network and clinical research site staff. They continue to identify TG-specific research needs in an effort to be more responsive to and improve the health of TG individuals, particularly related to HIV/AIDS.
C1 [Siskind, Rona L.; Renzullo, Philip O.] NIAID, Div Aids, NIH, 5601 Fishers Lane,Room 8D28A, Bethesda, MD 20852 USA.
[Andrasik, Michele; Karuna, Shelly T.; Broder, Gail B.] Fred Hutchinson Canc Res Ctr, HIV Vaccine Trials Network, 1124 Columbia St, Seattle, WA 98104 USA.
[Collins, Clare] Microbicide Trials Network, Pittsburgh, PA USA.
[Liu, Albert] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
[Lucas, Jonathan Paul] FHI360, HIV Prevent Trials Network, Durham, NC USA.
[Harper, Gary W.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
RP Siskind, RL (reprint author), NIAID, Div Aids, NIH, 5601 Fishers Lane,Room 8D28A, Bethesda, MD 20852 USA.
EM rsiskind@niaid.nih.gov
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD); National Institute on Drug Abuse (NIDA); National
Institute of Mental Health (NIMH) [U01HD040533, U01HD040474]; National
Institute of Allergy and Infectious Diseases (NIAID); NIMH; NIDA
[UM1AI068619, UM1AI068617, UM1AI068613]; NIAID [UM1AI68614, UM1AI68618,
UM1AI68635]; NICHD; NIMH [UM1AI068633, UM1AI068615, UM1AI106707]
FX Overall support for the Adolescent Medicine Trials Network for HIV/AIDS
Interventions is funded by Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD) with supplemental funding
from the National Institute on Drug Abuse (NIDA) and the National
Institute of Mental Health (NIMH) (U01HD040533 and U01HD040474); support
for the HIV Prevention Trials Network is provided by the National
Institute of Allergy and Infectious Diseases (NIAID), NIMH, and NIDA
(UM1AI068619, UM1AI068617, and UM1AI068613); support for the HIV Vaccine
Trials Network is provided by NIAID (UM1AI68614, UM1AI68618, and
UM1AI68635); support for the Microbicides Trials Network (MTN) is
provided by NIAID with co-funding from NICHD and the NIMH (UM1AI068633,
UM1AI068615, and UM1AI106707). The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the NIAID, NICHD, NIDA, NIMH, or the National Institutes of Health.
NR 14
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2016
VL 72
SU 3
BP S243
EP S247
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YM
UT WOS:000385275700007
PM 27429190
ER
PT J
AU Naradikian, MS
Myles, A
Beiting, DP
Roberts, KJ
Dawson, L
Herati, RS
Bengsch, B
Linderman, SL
Stelekati, E
Spolski, R
Wherry, EJ
Hunter, C
Hensley, SE
Leonard, WJ
Cancro, MP
AF Naradikian, Martin S.
Myles, Arpita
Beiting, Daniel P.
Roberts, Kenneth J.
Dawson, Lucas
Herati, Ramin Sedaghat
Bengsch, Bertram
Linderman, Susanne L.
Stelekati, Erietta
Spolski, Rosanne
Wherry, E. John
Hunter, Christopher
Hensley, Scott E.
Leonard, Warren J.
Cancro, Michael P.
TI Cutting Edge: IL-4, IL-21, and IFN-gamma Interact To Govern T-bet and
CD11c Expression in TLR-Activated B Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID FOLLICULAR HELPER-CELLS; AUTOANTIBODY PRODUCTION; TRANSCRIPTION FACTOR;
AGED MICE; MEMORY; EXPANSION; RESPONSES; RECEPTOR; INFECTION; ANTIGEN
AB T-bet and CD11c expression in B cells is linked with IgG(2c) isotype switching, virus-specific immune responses, and humoral autoimmunity. However, the activation requisites and regulatory cues governing T-bet and CD11c expression in B cells remain poorly defined. In this article, we reveal a relationship among TLR engagement, IL-4, IL-21, and IFN-gamma that regulates T-bet expression in B cells. We find that IL-21 or IFN-gamma directly promote T-bet expression in the context of TLR engagement. Further, IL-4 antagonizes T-bet induction. Finally, IL-21, but not IFN-gamma, promotes CD11c expression independent of T-bet. Using influenza virus and Heligmosomoides polygyrus infections, we show that these interactions function in vivo to determine whether T-bet(+) and CD11c(+) B cells are formed. These findings suggest that T-bet(+) B cells seen in health and disease share the common initiating features of TLR-driven activation within this circumscribed cytokine milieu.
C1 [Naradikian, Martin S.; Myles, Arpita; Roberts, Kenneth J.; Cancro, Michael P.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Naradikian, Martin S.; Myles, Arpita; Beiting, Daniel P.; Dawson, Lucas; Herati, Ramin Sedaghat; Bengsch, Bertram; Linderman, Susanne L.; Stelekati, Erietta; Wherry, E. John; Hunter, Christopher; Hensley, Scott E.; Cancro, Michael P.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.
[Beiting, Daniel P.; Dawson, Lucas; Hunter, Christopher] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA.
[Herati, Ramin Sedaghat] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Bengsch, Bertram; Linderman, Susanne L.; Stelekati, Erietta; Wherry, E. John; Hensley, Scott E.] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
[Linderman, Susanne L.; Hensley, Scott E.] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
[Spolski, Rosanne; Leonard, Warren J.] NHLBI, Lab Mol Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Spolski, Rosanne; Leonard, Warren J.] NHLBI, Ctr Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Cancro, MP (reprint author), Univ Penn, Perelman Sch Med, 284 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.
EM cancro@mail.med.upenn.edu
FU NCI NIH HHS [T32 CA009171]; NIA NIH HHS [R01 AG030227]; NIAID NIH HHS
[R01 AI118691, K08 AI114852, R01 AI108686, R01 AI113047, T32 AI055428]
NR 31
TC 2
Z9 2
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2016
VL 197
IS 4
BP 1023
EP 1028
DI 10.4049/jimmunol.1600522
PG 6
WC Immunology
SC Immunology
GA DY3NB
UT WOS:000384999100003
PM 27430719
ER
PT J
AU Su, P
Chen, S
Zheng, YH
Zhou, HY
Yan, CH
Yu, F
Zhang, YG
He, L
Zhang, Y
Wang, YM
Wu, L
Wu, XA
Yu, BK
Ma, LY
Yang, ZR
Wang, JH
Zhao, GX
Zhu, JF
Wu, ZY
Sun, B
AF Su, Pan
Chen, Sheng
Zheng, Yu Han
Zhou, Hai Yan
Yan, Cheng Hua
Yu, Fang
Zhang, Ya Guang
He, Lan
Zhang, Yuan
Wang, Yanming
Wu, Lei
Wu, Xiaoai
Yu, Bingke
Ma, Li Yan
Yang, Zhiru
Wang, Jianhua
Zhao, Guixian
Zhu, Jinfang
Wu, Zhi-Ying
Sun, Bing
TI Novel Function of Extracellular Matrix Protein 1 in Suppressing Th17
Cell Development in Experimental Autoimmune Encephalomyelitis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY T-CELLS; GROWTH-FACTOR-BETA; TGF-BETA; MULTIPLE-SCLEROSIS;
DENDRITIC CELLS; HUMAN SKIN; DIFFERENTIATION; ACTIVATION; EXPRESSION;
RESPONSES
AB Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS characterized by demyelination and axonal damage. Experimental autoimmune encephalomyelitis (EAE) is a well-established animal model for human MS. Although Th17 cells are important for disease induction, Th2 cells are inhibitory in this process. In this article, we report the effect of a Th2 cell product, extracellular matrix protein 1 (ECM1), on the differentiation of Th17 cells and the development of EAE. Our results demonstrated that ECM1 administration from day 1 to day 7 following the EAE induction could ameliorate the Th17 cell responses and EAE development in vivo. Further study of the mechanism revealed that ECM1 could interact with alpha v integrin on dendritic cells and block the alpha v integrin-mediated activation of latent TGF-beta, resulting in an inhibition of Th17 cell differentiation at an early stage of EAE induction. Furthermore, overexpression of ECM1 in vivo significantly inhibited the Th17 cell response and EAE induction in ECM1 transgenic mice. Overall, our work has identified a novel function of ECM1 in inhibiting Th17 cell differentiation in the EAE model, suggesting that ECM1 may have the potential to be used in clinical applications for understanding the pathogenesis of MS and its diagnosis.
C1 [Su, Pan; Zheng, Yu Han; Zhou, Hai Yan; Yan, Cheng Hua; Zhang, Ya Guang; He, Lan; Zhang, Yuan; Wang, Yanming; Ma, Li Yan; Sun, Bing] Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci, Inst Biochem & Cell Biol,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.
[Chen, Sheng; Wu, Lei; Wu, Zhi-Ying] Zhejiang Univ, Sch Med, Dept Neurol, Hangzhou 310058, Zhejiang, Peoples R China.
[Chen, Sheng; Wu, Lei; Wu, Zhi-Ying] Zhejiang Univ, Sch Med, Res Ctr Neurol, Affiliated Hosp 2, Hangzhou 310058, Zhejiang, Peoples R China.
[Chen, Sheng; Wu, Lei; Wu, Zhi-Ying] Zhejiang Univ, Sch Med, Collaborat Innovat Ctr Brain Sci, Hangzhou 310058, Zhejiang, Peoples R China.
[Chen, Sheng] Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, Fuzhou 350004, Peoples R China.
[Chen, Sheng] Fujian Med Univ, Affiliated Hosp 1, Inst Neurol, Fuzhou 350004, Peoples R China.
[Yu, Fang] NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Wu, Xiaoai; Yu, Bingke; Yang, Zhiru] Novo Nordisk Res Ctr, Beijing 100000, Peoples R China.
[Wang, Jianhua] Chinese Acad Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China.
[Zhao, Guixian] Fudan Univ, Dept Neurol, Shanghai Med Coll, Huashan Hosp, Shanghai 200032, Peoples R China.
[Zhao, Guixian] Fudan Univ, Inst Neurol, Shanghai Med Coll, Huashan Hosp, Shanghai 200032, Peoples R China.
RP Sun, B (reprint author), Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci, Inst Biochem & Cell Biol,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.; Zhu, JF; Wu, ZY; Sun, B (reprint author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.
EM jfZhu@niaid.nih.gov; zhiyingwu@zju.edu.cn; bsun@sibs.ac.cn
RI Zhu, Jinfang/B-7574-2012
FU Intramural NIH HHS [ZIA AI001169-04]
NR 50
TC 0
Z9 0
U1 3
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2016
VL 197
IS 4
BP 1054
EP 1064
DI 10.4049/jimmunol.1502457
PG 11
WC Immunology
SC Immunology
GA DY3NB
UT WOS:000384999100007
PM 27316685
ER
PT J
AU Cao, X
Lu, Y
Zhang, XY
Kovalovsky, D
AF Cao, Xin
Lu, Ying
Zhang, Xianyu
Kovalovsky, Damian
TI Zbtb1 Safeguards Genome Integrity and Prevents p53-Mediated Apoptosis in
Proliferating Lymphoid Progenitors
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CD8(+) T-CELLS; ZINC-FINGER; PLZF CONTROLS; CHK1; REPLICATION;
PHOSPHORYLATION; LINEAGE; REPAIR; BCL-2; ATR
AB Expression of the transcription factor Zbtb1 is required for normal lymphoid development. We report in the present study that Zbtb1 maintains genome integrity in immune progenitors, without which cells undergo increased DNA damage and p53-mediated apoptosis during replication and differentiation. Increased DNA damage in Zbtb1-mutant (ScanT) progenitors was due to increased sensitivity to replication stress, which was a consequence of inefficient activation of the S-phase checkpoint response. Increased p53-mediated apoptosis affected not only lymphoid but also myeloid development in competitive bone marrow chimeras, and prevention of apoptosis by transgenic Bcl2 expression and p53 deficiency rescued lymphoid as well as myeloid development from Zbtb1-mutant progenitors. Interestingly, however, protection from apoptosis rescued only the early stages of T cell development, and thymocytes remained arrested at the double-negative 3 developmental stage, indicating a strict requirement of Zbtb1 at later T cell developmental stages. Collectively, these results indicate that Zbtb1 prevents DNA damage in replicating immune progenitors, allowing the generation of B cells, T cells, and myeloid cells.
C1 [Cao, Xin] Northwest Univ Nationalities, Coll Life Sci & Engn, Lanzhou 730030, Peoples R China.
[Cao, Xin; Lu, Ying; Zhang, Xianyu; Kovalovsky, Damian] NCI, Expt Immunol Branch, NIH, 9000 Rockville Pike,Bldg 10-4B17, Bethesda, MD 20892 USA.
RP Kovalovsky, D (reprint author), NCI, Expt Immunol Branch, NIH, 9000 Rockville Pike,Bldg 10-4B17, Bethesda, MD 20892 USA.
EM kovalovskyd@mail.nih.gov
FU Intramural NIH HHS [ZIA BC011429-02, ZIA BC011429-01, Z99 CA999999, ZIA
BC011429-03, ZIA BC011429-04]; NCI NIH HHS [ZIA BC011429]
NR 36
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2016
VL 197
IS 4
BP 1199
EP 1211
DI 10.4049/jimmunol.1600013
PG 13
WC Immunology
SC Immunology
GA DY3NB
UT WOS:000384999100020
PM 27402700
ER
PT J
AU Seedhom, MO
Hickman, HD
Wei, JJ
David, A
Yewdell, JW
AF Seedhom, Mina O.
Hickman, Heather D.
Wei, Jiajie
David, Alexandre
Yewdell, Jonathan W.
TI Protein Translation Activity: A New Measure of Host Immune Cell
Activation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CD8(+) T-CELLS; MEMORY PHENOTYPE; LYMPH-NODES; ANTIGEN; STIMULATION;
INNATE
AB We describe the in vivo ribopuromycylation (RPM) method, which uses a puromycin-specific Ab to fluorescently label ribosome-bound puromycylated nascent chains, enabling measurement of translational activity via immunohistochemistry or flow cytometry. Tissue staining provides a unique view of virus-induced activation of adaptive, innate, and stromal immune cells. RPM flow precisely quantitates virus-induced activation of lymphocytes and innate immune cells, and it provides a unique measure of immune cell deactivation and quiescence. Using RPM we find that high endothelial cells in draining lymph nodes rapidly increase translation in the first day of vaccinia virus infection. We also find a population of constitutively activated splenic T cells in naive mice and further that most bone marrow T cells activate 3 d after vaccinia virus infection. Bone marrow T cell activation is nonspecific, IL-12-dependent, and induces innate memory T cell phenotypic markers. Thus, RPM measures translational activity to uniquely identify cell populations that participate in the immune response to pathogens, other foreign substances, and autoantigens.
C1 [Seedhom, Mina O.; Hickman, Heather D.; Wei, Jiajie; David, Alexandre; Yewdell, Jonathan W.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
[David, Alexandre] Inst Genom Fonct, Montpellier, France.
RP Yewdell, JW (reprint author), NIAID, NIH, 33 North Dr,Room 2E13C-1,Bldg 33, Bethesda, MD 20892 USA.
EM jyewdell@niaid.nih.gov
FU Intramural NIH HHS [ZIA AI000814-16]
NR 22
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2016
VL 197
IS 4
BP 1498
EP 1506
DI 10.4049/jimmunol.1600088
PG 9
WC Immunology
SC Immunology
GA DY3NB
UT WOS:000384999100048
PM 27385780
ER
PT J
AU Doritchamou, JYA
Herrera, R
Aebig, JA
Morrison, R
Nguyen, V
Reiter, K
Shimp, RL
MacDonald, NJ
Narum, DL
Fried, M
Duffy, PE
AF Doritchamou, Justin Yai Alamou
Herrera, Raul
Aebig, Joan A.
Morrison, Robert
Vu Nguyen
Reiter, Karine
Shimp, Richard L.
MacDonald, Nicholas J.
Narum, David L.
Fried, Michal
Duffy, Patrick E.
TI VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional
Antibodies to Plasmodium falciparum Placental Malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE malaria; pregnancy; multigravidae; VAR2CSA; DBL domains; functional
antibody; vaccine
ID CHONDROITIN-SULFATE-A; ADHESION-INHIBITORY ANTIBODIES; APICAL MEMBRANE
ANTIGEN-1; VARIANT SURFACE-ANTIGENS; INFECTED ERYTHROCYTES;
PREGNANT-WOMEN; BLOCKING ANTIBODIES; PARASITE ADHESION; VACCINE
CANDIDATE; MATERNAL MALARIA
AB Background. Placental malaria is caused by Plasmodium falciparum infected erythrocytes (IEs) that surface-express VAR2CSA and bind chondroitin sulfate A. The inflammatory response to placenta-sequestered parasites is associated with poor pregnancy outcomes, and protection may be mediated in part by VAR2CSA antibodies that block placental IE adhesion.
Methods. In this study, we used a new approach to assess VAR2CSA domains for functional epitopes recognized by naturally acquired antibodies. Antigen-specific immunoglobulin (Ig) G targeting Duffy binding like (DBL) domains from different alleles were sequentially purified from plasma pooled from multigravid women and then characterized using enzyme-linked immunosorbent assay, flow cytometry, and antiadhesion assays.
Results. Different DBL domain-specific IgGs could react to homologous as well as heterologous antigens and parasites, suggesting that conserved epitopes are shared between allelic variants. Homologous blocking of IE binding was observed with ID1-DBL2-ID2a-, DBL4-, and DBL5-specific IgG (range, 42%-75%), whereas partial cross-inhibition activity was observed with purified IgG specific to ID1-DBL2-ID2a and DBL4 antigens. Plasma retained broadly neutralizing activity after complete depletion of these VAR2CSA specificities.
Conclusions. Broadly neutralizing antibodies of multigravidae are not depleted on VAR2CSA recombinant antigens, and hence development of VAR2CSA vaccines based on a single construct and variant might induce antibodies with limited broadly neutralizing activity.
C1 [Doritchamou, Justin Yai Alamou; Herrera, Raul; Aebig, Joan A.; Morrison, Robert; Vu Nguyen; Reiter, Karine; Shimp, Richard L.; MacDonald, Nicholas J.; Narum, David L.; Fried, Michal; Duffy, Patrick E.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, Twinbrook 1,Rm 1111,5640 Fishers Ln, Rockville, MD 20852 USA.
[Morrison, Robert] Seattle Biomed Res Inst, MOMS Project, 4 Nickerson St, Seattle, WA 98109 USA.
RP Duffy, PE (reprint author), NIAID, Lab Malaria Immunol & Vaccinol, NIH, Twinbrook 1,Rm 1111,5640 Fishers Ln, Rockville, MD 20852 USA.
EM patrick.duffy@nih.gov
FU Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health
FX This work was supported by the Division of Intramural Research, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health.
NR 49
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 15
PY 2016
VL 214
IS 4
BP 577
EP 586
DI 10.1093/infdis/jiw197
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DY1JB
UT WOS:000384849600010
PM 27190180
ER
PT J
AU Powers, JH
Howard, K
Saretsky, T
Clifford, S
Hoffmann, S
Llorens, L
Talbot, G
AF Powers, John H., III
Howard, Kellee
Saretsky, Todd
Clifford, Sarah
Hoffmann, Steve
Llorens, Lily
Talbot, George
TI Patient-Reported Outcome Assessments as Endpoints in Studies in
Infectious Diseases
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE infectious diseases; clinical trials; patient-reported outcomes;
endpoints; clinical practice
ID CONTROLLED SERIES; CYSTIC-FIBROSIS; CLINICAL-TRIALS; SYMPTOMS;
FOUNDATION; QUESTIONNAIRE; SULFANILAMIDE; RELIABILITY; ERYSIPELAS;
PNEUMONIA
AB The goal of administering medical interventions is to help patients live longer or live better. In keeping with this goal, there has been increasing interest in taking the "voice" of the patient into account during the development process, specifically in the evaluation of treatment benefits of medical interventions, and use of patient-centered outcome data to justify reimbursement. Patient-reported outcomes (PROs) are outcome assessments (OAs) used to define endpoints that can provide direct evidence of treatment benefit on how patients feel or function. When PROs are appropriately developed, they can increase the efficiency and clinical relevance of clinical trials. Several PROs have been developed for OA in specific infectious diseases indications, and more are under development. PROs also hold promise for use in evaluating adherence, adverse effects, satisfaction with care, and routine clinical practice.
C1 [Powers, John H., III] George Washington Univ, Sch Med, Washington, DC 20052 USA.
[Howard, Kellee; Saretsky, Todd; Clifford, Sarah] ICON PLC, San Francisco, CA USA.
[Hoffmann, Steve] Fdn Natl Inst Hlth, Bethesda, MD USA.
[Llorens, Lily] Llorens Consulting, Bay Village, OH USA.
[Talbot, George] Talbot Advisors LLC, Anna Maria, FL USA.
RP Powers, JH (reprint author), 15915 Emory Lane, Rockville, MD 20853 USA.
EM jpowers3@aol.com
FU Clinical Trials Transformation Initiative
FX This article appears as part of the supplement "Facilitating
Antibacterial Drug Development in a Time of Great Need," sponsored by
the Clinical Trials Transformation Initiative.
NR 44
TC 2
Z9 2
U1 3
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
SU 2
BP S52
EP S56
DI 10.1093/cid/ciw317
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QX
UT WOS:000383202700007
PM 27481954
ER
PT J
AU Chen, HM
Larson, DR
AF Chen, Huimin
Larson, Daniel R.
TI What have single-molecule studies taught us about gene expression?
SO GENES & DEVELOPMENT
LA English
DT Review
DE fluorescence; single molecule; splicing; transcription
ID RNA-POLYMERASE-II; PRE-MESSENGER-RNA; TRANSCRIPTION FACTOR-BINDING;
START-SITE SELECTION; EMBRYONIC STEM-CELLS; U4/U6.U5 TRI-SNRNP;
REAL-TIME ANALYSIS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; IN-VIVO
AB The production of a single mRNA is the result of many sequential steps, from docking of transcription factors to polymerase initiation, elongation, splicing, and, finally, termination. Much of our knowledge about the fundamentals of RNA synthesis and processing come from ensemble in vitro biochemical measurements. Single-molecule approaches are very much in this same reductionist tradition but offer exquisite sensitivity in space and time along with the ability to observe heterogeneous behavior and actually manipulate macromolecules. These techniques can also be applied in vivo, allowing one to address questions in living cells that were previously restricted to reconstituted systems. In this review, we examine the unique insights that single-molecule techniques have yielded on the mechanisms of gene expression.
C1 [Chen, Huimin; Larson, Daniel R.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Larson, DR (reprint author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM dan.larson@nih.gov
RI Larson, Daniel/B-9829-2008
OI Larson, Daniel/0000-0001-9253-3055
FU Intramural Research Program of the National Cancer Institute
FX We acknowledge Maxime Dahan, Timothee Lionnet, Aaron Hoskins, Tineke
Lenstra, and Murali Palangat for critical comments on the manuscript. In
addition, both anonymous referees provided advice that greatly improved
the final review. This work was supported by the Intramural Research
Program of the National Cancer Institute.
NR 153
TC 1
Z9 1
U1 14
U2 14
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD AUG 15
PY 2016
VL 30
IS 16
BP 1796
EP 1810
DI 10.1101/gad.281725.116
PG 15
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA DW6CJ
UT WOS:000383733700003
PM 27601529
ER
PT J
AU Patterson, TF
Thompson, GR
Denning, DW
Fishman, JA
Hadley, S
Herbrecht, R
Kontoyiannis, DP
Marr, KA
Morrison, VA
Nguyen, MH
Segal, BH
Steinbach, WJ
Stevens, DA
Walsh, TJ
Wingard, JR
Young, JAH
Bennett, JE
AF Patterson, Thomas F.
Thompson, George R., III
Denning, David W.
Fishman, Jay A.
Hadley, Susan
Herbrecht, Raoul
Kontoyiannis, Dimitrios P.
Marr, Kieren A.
Morrison, Vicki A.
Nguyen, M. Hong
Segal, Brahm H.
Steinbach, William J.
Stevens, David A.
Walsh, Thomas J.
Wingard, John R.
Young, Jo-Anne H.
Bennett, John E.
TI Practice Guidelines for the Diagnosis and Management of Aspergillosis:
2016 Update by the Infectious Diseases Society of America
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE aspergillosis; invasive aspergillosis; allergic aspergillosis; chronic
aspergillosis; fungal diagnostics; azoles; echniocandins; amphotericin
AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
C1 [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Thompson, George R., III] Univ Calif Davis, Davis, CA 95616 USA.
[Denning, David W.] Univ Manchester, Univ South Manchester Hosp, Natl Aspergillosis Ctr, Manchester M13 9PL, Lancs, England.
[Fishman, Jay A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fishman, Jay A.] Harvard Med Sch, Boston, MA USA.
[Hadley, Susan] Tufts Med Ctr, Boston, MA USA.
[Herbrecht, Raoul] Univ Strasbourg, Strasbourg, France.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Marr, Kieren A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Marr, Kieren A.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Morrison, Vicki A.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Morrison, Vicki A.; Young, Jo-Anne H.] Univ Minnesota, Minneapolis, MN USA.
[Nguyen, M. Hong] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Segal, Brahm H.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.
[Segal, Brahm H.] Roswell Pk Canc Inst, New York, NY USA.
[Steinbach, William J.] Duke Univ, Med Ctr, Durham, NC USA.
[Stevens, David A.] Calif Inst Med Res, San Jose, CA 95128 USA.
[Walsh, Thomas J.] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA.
[Wingard, John R.] Univ Florida, Gainesville, FL USA.
[Bennett, John E.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio Ctr Med Mycol, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA.
EM patterson@uthscsa.edu
FU IDSA
FX Support for this guideline was provided by the IDSA.
NR 1
TC 9
Z9 9
U1 6
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP 433
EP 442
DI 10.1093/cid/ciw444
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400002
PM 27481947
ER
PT J
AU Xie, YDL
Chen, RY
Sereti, I
Zerbe, CS
Holland, SM
Browne, SK
AF Xie, Yingda L.
Chen, Ray Y.
Sereti, Irini
Zerbe, Christa S.
Holland, Steven M.
Browne, Sarah K.
TI Neutralizing Anti-Interferon-Gamma Autoantibody Levels May Not Correlate
With Clinical Course of Disease Reply
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Xie, Yingda L.; Chen, Ray Y.; Zerbe, Christa S.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Sereti, Irini] NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Browne, Sarah K.] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
RP Holland, SM (reprint author), CRC B3-4141 MSC 1684, Bethesda, MD 20892 USA.
EM smh@nih.gov
NR 5
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP 573
EP 574
DI 10.1093/cid/ciw352
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400026
PM 27225244
ER
PT J
AU Patterson, TF
Thompson, GR
Denning, DW
Fishman, JA
Hadley, S
Herbrecht, R
Kontoyiannis, DP
Marr, KA
Morrison, VA
Nguyen, MH
Segal, BH
Steinbach, WJ
Stevens, DA
Walsh, TJ
Wingard, JR
Young, JAH
Bennett, JE
AF Patterson, Thomas F.
Thompson, George R., III
Denning, David W.
Fishman, Jay A.
Hadley, Susan
Herbrecht, Raoul
Kontoyiannis, Dimitrios P.
Marr, Kieren A.
Morrison, Vicki A.
Nguyen, M. Hong
Segal, Brahm H.
Steinbach, William J.
Stevens, David A.
Walsh, Thomas J.
Wingard, John R.
Young, Jo-Anne H.
Bennett, John E.
TI Practice Guidelines for the Diagnosis and Management of Aspergillosis:
2016 Update by the Infectious Diseases Society of America
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE aspergillosis; invasive aspergillosis; allergic aspergillosis; chronic
aspergillosis; fungal diagnostics; azoles; echniocandins; amphotericin
ID INVASIVE FUNGAL-INFECTIONS; CELL TRANSPLANT RECIPIENTS; LIPOSOMAL
AMPHOTERICIN-B; CHRONIC PULMONARY ASPERGILLOSIS; ALLERGIC
BRONCHOPULMONARY ASPERGILLOSIS; CENTRAL-NERVOUS-SYSTEM; BRONCHOALVEOLAR
LAVAGE FLUID; CHRONIC GRANULOMATOUS-DISEASE; RANDOMIZED
CONTROLLED-TRIAL; SOLID-ORGAN TRANSPLANT
AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
C1 [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Thompson, George R., III] Univ Calif Davis, Davis, CA 95616 USA.
[Denning, David W.] Univ Manchester, Univ South Manchester Hosp, Natl Aspergillosis Ctr, Manchester M13 9PL, Lancs, England.
[Fishman, Jay A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fishman, Jay A.] Harvard Med Sch, Boston, MA USA.
[Hadley, Susan] Tufts Med Ctr, Boston, MA USA.
[Herbrecht, Raoul] Univ Strasbourg, Strasbourg, France.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Marr, Kieren A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Marr, Kieren A.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Morrison, Vicki A.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Morrison, Vicki A.; Young, Jo-Anne H.] Univ Minnesota, Minneapolis, MN USA.
[Nguyen, M. Hong] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Segal, Brahm H.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.
[Segal, Brahm H.] Roswell Pk Canc Inst, New York, NY USA.
[Steinbach, William J.] Duke Univ, Med Ctr, Durham, NC USA.
[Stevens, David A.] Calif Inst Med Res, San Jose, CA 95128 USA.
[Walsh, Thomas J.] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA.
[Wingard, John R.] Univ Florida, Gainesville, FL USA.
[Bennett, John E.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio Ctr Med Mycol, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA.
EM patterson@uthscsa.edu
OI Herbrecht, Raoul/0000-0002-9381-4876
FU IDSA
FX Support for this guideline was provided by the IDSA.
NR 657
TC 27
Z9 27
U1 10
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2016
VL 63
IS 4
BP E1
EP E60
DI 10.1093/cid/ciw326
PG 60
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QU
UT WOS:000383202400001
PM 27365388
ER
PT J
AU Eitan, E
Petralia, RS
Wang, YX
Indig, FE
Mattson, MP
Yao, PJ
AF Eitan, Erez
Petralia, Ronald S.
Wang, Ya-Xian
Indig, Fred E.
Mattson, Mark P.
Yao, Pamela J.
TI Probing extracellular Sonic hedgehog in neurons
SO BIOLOGY OPEN
LA English
DT Article
DE Sonic hedgehog; Hippocampal neurons; Extracellular vesicle; Filopodia
ID HIPPOCAMPAL-NEURONS; CAENORHABDITIS-ELEGANS; NMDA RECEPTORS; BRAIN;
PROLIFERATION; CYCLOPAMINE; INHIBITION; CEREBELLUM; ASTROCYTES;
EXPRESSION
AB The bioactivity of Sonic hedgehog (Shh) depends on specific lipid modifications; a palmitate at its N-terminus and a cholesterol at its C-terminus. This dual-lipid modification makes Shh molecules lipophilic, which prevents them from diffusing freely in extracellular space. Multiple lines of evidence indicate that Shh proteins are carried by various forms of extracellular vesicles (EVs). It also has been shown, for instance, that in some tissues Shh proteins are transported to neighboring cells directly via filopodia. We have previously reported that Shh proteins are expressed in hippocampal neurons. In this study we show that, in the hippocampus and cerebellum of postnatal day (P)2 rats, Shh is mostly found near or on the membrane surface of small neurites or filopodia. We also examined cultured hippocampal neurons where we observed noticeable and widespread Shh-immunolabeled vesicles located outside neurons. Through immunoelectron microscopy and biochemical analysis, we find Shh-containing EVs with a wide range of sizes. Unlike robust Shh activity in EVs isolated from cells overexpressing an N-terminal Shh fragment construct, we did not detect measurable Shh activity in EVs purified from the medium of cultured hippocampal neurons. These results suggest the complexity of the transcellular Shh signaling mechanisms in neurons.
C1 [Eitan, Erez; Mattson, Mark P.; Yao, Pamela J.] NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.
[Petralia, Ronald S.; Wang, Ya-Xian] NIDCD, Adv Imaging Core, NIH, Bethesda, MD 20892 USA.
[Indig, Fred E.] NIA, Adv Imaging Core, Clin Invest Lab, Intramural Res Program, Baltimore, MD 21224 USA.
RP Yao, PJ (reprint author), NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.
EM yaopa@grc.nia.nih.gov
FU Intramural Research Programs of National Institute on Aging - National
Institutes of Health; National Institute on Deafness and Other
Communication Disorders - National Institutes of Health
FX This study was supported by the Intramural Research Programs of National
Institute on Aging - National Institutes of Health and National
Institute on Deafness and Other Communication Disorders - National
Institutes of Health.
NR 50
TC 2
Z9 2
U1 2
U2 2
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 2046-6390
J9 BIOL OPEN
JI Biol. Open
PD AUG 15
PY 2016
VL 5
IS 8
BP 1086
EP 1092
DI 10.1242/bio.019422
PG 7
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DU6DQ
UT WOS:000382304400009
PM 27387534
ER
PT J
AU Bellad, RM
Bang, A
Carlo, WA
McClure, EM
Meleth, S
Goco, N
Goudar, SS
Derman, RJ
Hibberd, PL
Patel, A
Esamai, F
Bucher, S
Gisore, P
Wright, LL
AF Bellad, Roopa M.
Bang, Akash
Carlo, Waldemar A.
McClure, Elizabeth M.
Meleth, Sreelatha
Goco, Norman
Goudar, Shivaprasad S.
Derman, Richard J.
Hibberd, Patricia L.
Patel, Archana
Esamai, Fabian
Bucher, Sherri
Gisore, Peter
Wright, Linda L.
CA HBB Study Grp
TI A pre-post study of a multi-country scale up of resuscitation training
of facility birth attendants: does Helping Babies Breathe training save
lives?
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
ID MIDDLE-INCOME COUNTRIES; MORTALITY; ETHIOPIA; WOMEN
AB Background: Whether facility-based implementation of Helping Babies Breathe (HBB) reduces neonatal mortality at a population level in low and middle income countries (LMIC) has not been studied. Therefore, we evaluated HBB implementation in this context where our study team has ongoing prospective outcome data on all pregnancies regardless of place of delivery.
Methods: We compared outcomes of birth cohorts in three sites in India and Kenya pre-post implementation of a facility-based intervention, using a prospective, population-based registry in 52 geographic clusters. Our hypothesis was that HBB implementation would result in a 20 % decrease in the perinatal mortality rate (PMR) among births >= 1500 g.
Results: We enrolled 70,704 births during two 12-month study periods. Births within each site did not differ pre-post intervention, except for an increased proportion of <2500 g newborns and deliveries by caesarean section in the post period. There were no significant differences in PMR among all registry births; however, a post-hoc analysis stratified by birthweight documented improvement in <2500 g mortality in Belgaum in both registry and in HBB-trained facility births. No improvement in <2500 g mortality measures was noted in Nagpur or Kenya and there was no improvement in normal birth weight survival.
Conclusions: Rapid scale up of HBB training of facility birth attendants in three diverse sites in India and Kenya was not associated with consistent improvements in mortality among all neonates >= 1500 g; however, differential improvements in <2500 g survival in Belgaum suggest the need for careful implementation of HBB training with attention to the target population, data collection, and ongoing quality monitoring activities.
C1 [Bellad, Roopa M.; Goudar, Shivaprasad S.] KLE Univ Jawaharlal Nehru Med Coll, Belgaum, Karnataka, India.
[Bang, Akash] Mahatma Gandhi Inst Med Sci, Sevagram, Maharashtra, India.
[Carlo, Waldemar A.] Univ Alabama Birmingham, Birmingham, AL USA.
[McClure, Elizabeth M.; Meleth, Sreelatha; Goco, Norman] RTI Int, Durham, NC USA.
[Derman, Richard J.] Christiana Care Hlth Syst, Dept Obstet & Gynecol, Newark, DE USA.
[Hibberd, Patricia L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Patel, Archana] Lata Med Res Fdn, Nagpur, Maharashtra, India.
[Patel, Archana] Indira Gandhi Govt Med Coll, Nagpur, Maharashtra, India.
[Esamai, Fabian; Gisore, Peter] Moi Univ Sch Med, Dept Child Hlth & Paediat, Eldoret, Kenya.
[Bucher, Sherri] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Wright, Linda L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA.
[Wright, Linda L.] 5800 Nicholson Lane,1206, Rockville, MD 20852 USA.
RP Wright, LL (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA.; Wright, LL (reprint author), 5800 Nicholson Lane,1206, Rockville, MD 20852 USA.
EM lindawright.md@gmail.com
OI Somannavar, Manjunath/0000-0002-8871-5072
FU Norad; Laerdal Foundation; Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD)
FX The study was funded by grants from Norad, Laerdal Foundation and the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD). NICHD staff had input into the study design, data
interpretation and writing of the report. RTI staff had access to all
the study data. The corresponding author wrote the first draft of the
manuscript and had final responsibility for the decision to submit for
publication.
NR 17
TC 1
Z9 1
U1 6
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD AUG 15
PY 2016
VL 16
AR 222
DI 10.1186/s12884-016-0997-6
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT4UL
UT WOS:000381476500001
PM 27527831
ER
PT J
AU Gerfen, CR
Sawchenko, PE
AF Gerfen, Charles R.
Sawchenko, Paul E.
TI An anterograde neuroanatomical tracing method that shows the detailed
morphology of neurons, their axons and terminals: Immunohistochemical
localization of an axonally transported plant lectin, Phaseolus
vulgaris-leucoagglutinin (PHA-L)
SO BRAIN RESEARCH
LA English
DT Review
DE Neuroanatomy; Axonal tract tracing
ID CENTRAL-NERVOUS-SYSTEM; NEUROENDOCRINE STRESS-RESPONSE; SUPRAOPTIC
NUCLEI; NEURAL CIRCUITS; ORGANIZATION; HYPOTHALAMUS; INHIBITION; INPUTS;
BRAIN; RAT
AB A new neuroanatomical method for tracing connections in the central nervous system based on the anterograde axonal transport of the kidney bean lectin, Phaseolus vulgaris-leucoagglutinin (PHA-L) is described. The method, for which a detailed protocol is presented, offers several advantages over present techniques. First, when the lectin is delivered iontophoretically, PHA-L injection sites as small as 50200 mu m in diameter can be produced, and are clearly demarcated since the neurons within the labeled zone are completely filled. Second, many morphological features of such filled neurons are clearly demonstrated including their cell bodies, axons, dendritic arbors and even dendritic spines. Third, there is some evidence to suggest that only the neurons at the injection site that are filled transport demonstrable amounts of the tracer, raising the possibility that the effective injection site can be defined quite precisely. Fourth, even with the most restricted injections, the morphology of the labeled axons and axon terminals is clearly demonstrated; this includes boutons en passant, fine collateral branches, and various terminal specialization, all of which can be visualized as well as in the best rapid Golgi preparations. Fifth, when introduced iontophoretically, PHA-L appears to be transported preferentially in the anterograde direction; only rarely is it transported retrogradely. Sixth, PHA-L does not appear to be taken up and transported effectively by fibers of passage. Seventh, there is no discernible degradation of the transported PHA-L with survival times of up to 17 days. Finally, since the transported marker can be demonstrated with either peroxidase or fluorescent antibody techniques, it may be used in conjunction with other neuroanatomical methods. For example, double anterograde labeling experiments can be done using the autoradiographic method along with immunoperoxidase localization of PHA-L, and the retrogradely transported fluorescent dyes can be visualized in the same tissue sections as PHA-L localized with immunofluorescence techniques. 1984.
This article is part of a Special Issue entitled SI:50th Anniversary Issue. Published by Elsevier B.V.
C1 [Gerfen, Charles R.] NIMH, Lab Syst Neurosci, Bethesda, MD 20892 USA.
[Sawchenko, Paul E.] Salk Inst Biol Studies, Lab Neuronal Struct & Funct, La Jolla, CA USA.
RP Gerfen, CR (reprint author), NIMH, Lab Syst Neurosci, Bethesda, MD 20892 USA.
EM gerfenc@mail.nih.gov
NR 19
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD AUG 15
PY 2016
VL 1645
SI SI
BP 42
EP 45
DI 10.1016/j.brainres.2015.12.040
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA DT5QJ
UT WOS:000381537400014
PM 26790346
ER
PT J
AU Madlala, P
Singh, R
An, P
Werner, L
Mlisana, K
Karim, SSA
Winkler, CA
Ndung'u, T
AF Madlala, Paradise
Singh, Ravesh
An, Ping
Werner, Lise
Mlisana, Koleka
Karim, Salim S. Abdool
Winkler, Cheryl A.
Ndung'u, Thumbi
TI Association of Polymorphisms in the Regulatory Region of the Cyclophilin
a Gene (PPIA) with Gene Expression and HIV/AIDS Disease Progression
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE SNP; CypA; PPIA; HIV-1; mRNA expression
ID HIV-1 INFECTION; SUSCEPTIBILITY; DETERMINANTS; VIRIONS
AB Background:Human cyclophilin A (CypA) encoded by peptidyl prolyl isomerase A gene (PPIA), enhances HIV-1 replication by aiding capsid uncoating. The association of genetic variation in the PPIA regulatory region with susceptibility to HIV-1 infection, disease progression, and gene expression among black South Africans at risk for infection or infected with HIV-1 is unknown.Methods:We genotyped 539 participants from 2 longitudinal study cohorts of black South Africans at high risk for infection or infected with HIV-1 for PPIA regulatory single nucleotide polymorphisms by polymerase chain reaction-restriction fragment length polymorphism.Results:Minor allele (G) of SNP rs6850 (rs6850 G) significantly associated with higher viral loads (mean 4.85 versus 4.46 log copies/mL, P = 0.0006) and lower CD4(+) T-cell counts (mean 506 versus 557 cells/L, P = 0.0256) during the acute phase of infection in the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 cohort. Consistently, rs6850 G significantly associated with higher viral loads (mean 4.49 versus 4.01 log copies/mL, P < 0.0001) and lower CD4(+) T-cell counts (mean 442 versus 494 cells/L, P = 0.0002) during the early chronic phase of infection in the CAPRISA 002 cohort; rs6850 G further associated significantly with rapid CD4(+) T-cell decline in the CAPRISA 002 cohort (P = 0.0481) and Sinikithemba chronic infection cohort (P = 0.0156). Interestingly, rs6850 G significantly associated with elevated CypA mRNA levels in HIV-1-positive individuals (P = 0.0061).Conclusions:These data suggest that rs6850 G enhances HIV-1 replication through upregulation of CypA expression following HIV-1 infection. The data support ongoing efforts to develop anti-HIV-1 drugs that block interaction of HIV-1 and cellular proteins.
C1 [Madlala, Paradise; Singh, Ravesh; Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, Durban, South Africa.
[Werner, Lise; Mlisana, Koleka; Karim, Salim S. Abdool] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Nelson R Mandela Sch Med, Durban, South Africa.
[An, Ping; Winkler, Cheryl A.] NCI, Basic Res Lab, Ctr Canc Res, Leidos Biomed Res Inc,Frederick Natl Lab Canc Res, Frederick, MD 21701 USA.
[Ndung'u, Thumbi] Univ KwaZulu Natal, KwaZulu Natal Res Inst TB & HIV, Nelson R Mandela Sch Med, Durban, South Africa.
RP Ndung'u, T (reprint author), Univ KwaZulu Natal, HIV Pathogenesis Programme, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, Level 1,Room 117, ZA-4013 Durban, South Africa.
EM ndungu@ukzn.ac.za
OI Abdool Karim, Salim/0000-0002-4986-2133
FU seventh framework programme (FP7) of the European Commission (THINC)
[HEALTH-F3-2008-201032]; South African Department of Science and
Technology/National Research Foundation Research Chairs Initiative;
Victor Daitz Foundation; Howard Hughes Medical Institute International
Early Career Scientist award; National Cancer Institute, National
Institutes of Health [HHSN261200800001E]; Intramural Research Program of
the NIH, National Cancer Institute, Center for Cancer Research
FX Supported by the seventh framework programme (FP7) of the European
Commission (THINC, HEALTH-F3-2008-201032). Additional funding was
provided by the South African Department of Science and
Technology/National Research Foundation Research Chairs Initiative and
the Victor Daitz Foundation. Part of the work was funded by the Howard
Hughes Medical Institute International Early Career Scientist award to
TN. This project has been funded in part with federal funds from the
National Cancer Institute, National Institutes of Health, under contract
HHSN261200800001E. This Research was supported in part by the Intramural
Research Program of the NIH, National Cancer Institute, Center for
Cancer Research. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the US Government.
NR 22
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2016
VL 72
IS 5
BP 465
EP 473
DI 10.1097/QAI.0000000000001028
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DT3KC
UT WOS:000381378700002
PM 27088296
ER
PT J
AU Smith, SJ
Pauly, GT
Akram, A
Melody, K
Ambrose, Z
Schneider, JP
Hughes, SH
AF Smith, Steven J.
Pauly, Gary T.
Akram, Aamir
Melody, Kevin
Ambrose, Zandrea
Schneider, Joel P.
Hughes, Stephen H.
TI Rilpivirine and Doravirine Have Complementary Efficacies Against
NNRTI-Resistant HIV-1 Mutants
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; antiviral activity; susceptibility; potency; resistance;
non-nucleoside reverse transcriptase inhibitor
ID REVERSE-TRANSCRIPTASE INHIBITORS; NONNUCLEOSIDE INHIBITORS; POSITIONAL
ADAPTABILITY; HIV-1-INFECTED PATIENTS; DOUBLE-BLIND; WILD-TYPE; DRUG;
MECHANISM; PHASE-3; TMC278
AB Background:Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 angstrom from the polymerase active site of reverse transcriptase (RT). Although NNRTIs potently inhibit the replication of wild-type HIV-1, the binding site is not conserved, and mutations arise in the binding pocket. Doravirine (DOR) is a new NNRTI in phase III clinical trials.Methods:Using a single round HIV-1 infection assay, we tested RPV and DOR against a broad panel of NNRTI-resistant mutants to determine their respective activities. We also used molecular modeling to determine if the susceptibility profile of each compound was related to how they bind RT.Results:Several mutants displayed decreased susceptibility to DOR. However, with the exception of E138K, our data suggest that the mutations that reduce the potency of DOR and RPV are non-overlapping. Thus, these 2 NNRTIs have the potential to be used together in combination therapy. We also show that the location at which DOR and RPV bind with the NNRTI binding pocket of RT correlates with the differences in their respective susceptibility to the panel of NNRTI-resistance mutations.Conclusions:This shows that (1) DOR is susceptible to a number of well-known NNRTI resistance mutations and (2) an understanding of the mutational susceptibilities and binding interactions of NNRTIs with RT could be used to develop pairs of compounds with non-overlapping mutational susceptibilities.
C1 [Smith, Steven J.; Akram, Aamir; Hughes, Stephen H.] NCI, HIV Dynam & Replicat Program, NIH, POB B 1050 Boyles St,539-130, Frederick, MD 21702 USA.
[Pauly, Gary T.; Schneider, Joel P.] NCI, Biol Chem Lab, NIH, Frederick, MD 21701 USA.
[Melody, Kevin; Ambrose, Zandrea] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
[Ambrose, Zandrea] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
RP Hughes, SH (reprint author), NCI, HIV Dynam & Replicat Program, NIH, POB B 1050 Boyles St,539-130, Frederick, MD 21702 USA.
EM hughesst@mail.nih.gov
FU Intramural Research Programs of the National Cancer Institute;
Intramural AIDS Targeted Antiviral Program (IATAP); NIH [R01 AI080290,
T32 AI065380]
FX Supported by the Intramural Research Programs of the National Cancer
Institute and the Intramural AIDS Targeted Antiviral Program (IATAP) and
NIH grants R01 AI080290 (Z.A.) and T32 AI065380 (K.M.).
NR 27
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 15
PY 2016
VL 72
IS 5
BP 485
EP 491
DI 10.1097/QAI.0000000000001031
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DT3KC
UT WOS:000381378700004
PM 27124362
ER
PT J
AU Huang, B
Wang, Q
Deng, CS
Wang, JH
Yang, T
Huang, SG
Su, XZ
Liu, YJ
Pan, LH
Li, GM
Li, D
Zhang, HY
Bacar, A
Abdallah, KS
Attoumane, R
Mliva, AMSA
Zheng, SQ
Xu, Q
Lu, FL
Guan, YZ
Song, JP
AF Huang, Bo
Wang, Qi
Deng, Changsheng
Wang, Jianhua
Yang, Tao
Huang, Shiguang
Su, Xin-zhuan
Liu, Yajun
Pan, Longhua
Li, Guoming
Li, Di
Zhang, Hongying
Bacar, Afane
Abdallah, Kamal Said
Attoumane, Rachad
Mliva, Ahamada M. S. A.
Zheng, Shaoqin
Xu, Qin
Lu, Fangli
Guan, Yezhi
Song, Jianping
TI Prevalence of crt and mdr-1 mutations in Plasmodium falciparum isolates
from Grande Comore island after withdrawal of chloroquine
SO MALARIA JOURNAL
LA English
DT Article
DE Comoros; Plasmodium falciparum; Chloroquine resistance; pfcrt; pfmdr-1
ID GENE HAPLOTYPE SVMNT; DRUG-RESISTANCE; ARTEMETHER-LUMEFANTRINE;
MOLECULAR MARKER; TRANSPORTER GENE; TREATMENT POLICY; COPY NUMBER;
IN-VIVO; MALARIA; PFCRT
AB Background: In Comoros, the widespread of chloroquine (CQ)-resistant Plasmodium falciparum populations was a major obstacle to malaria control, which led to the official withdrawal of CQ in 2004. Continuous monitoring of CQ-resistant markers of the P. falciparum CQ resistant transporter (pfcrt) and the P. falciparum multiple drug resistance 1 (pfmdr-1) is necessary inder to obtain first-hand information on CQ susceptibility of parasite populations in the field. The objective of this study is to assess the prevalence and evolution of CQ-resistance in the P. falciparum populations on the Comoros' Grande Comore island after withdrawal of CQ.
Methods: A total of 207 P. falciparum clinical isolates were collected from the island, including 118 samples from 2006 to 2007 and 89 samples from 2013 to 2014. Nucleotide substitutions in the pfcrt and pfmdr-1 genes linked to CQ response in parasite isolates were assessed using nested PCR and DNA sequencing.
Results: From the pfcrt gene segment sequenced, we detected C72S, M74I, N75E, and K76T substitutions in the parasite isolates collected from both 2006-2007 to 2013-2014 periods. Significant decline of pfcrt resistant alleles at C72S (42.6 to 6.9 %), M74I (39.1 to 14.9 %), N75E (63.5 to 18.3 %), and K76T (72.2 to 19.5 %) from 2006-2007 to 2013-2014 were observed, and the frequency of pfcrt wild type allele was significantly increased from 19.1 % in 2006-2007 to 75.8 % in 2013-2014. Sequence analysis of pfmdr-1 also detected point mutations at codons N86Y, Y184F, and D1246Y, but not S1034C and N1042D, in the isolates collected from both examined periods. An increasing trend in the prevalence of the pfmdr-1 wild type allele (NYD, 4.3 % in 2006-2007; and 28.7 % in 2013-2014), and a decreasing trend for pfmdr-1 N86Y mutation (87.0 % in 2006-2007; and 40.2 % in 2013-2014) were observed in our samples.
Conclusions: The present data indicate that the prevalence and patterns of mutant pfcrt and pfmdr-1 dramatically decreased in the Grande Comore isolates from 2006 to 2014, suggesting that the CQ-sensitive P. falciparum strains have returned after the withdrawal of CQ. The data also suggests that the parasites with wild type pfcrt/pfdmr-1 genes may have growth and/or transmission advantages over the mutant parasites. The information obtained from this study will be useful for developing and updating anti-malarial treatment policy in Grande Comore island.
C1 [Huang, Bo; Wang, Qi; Deng, Changsheng; Wang, Jianhua; Yang, Tao; Zhang, Hongying; Zheng, Shaoqin; Guan, Yezhi; Song, Jianping] Guangzhou Univ Chinese Med, Sci & Technol Pk, Guangzhou 510006, Guangdong, Peoples R China.
[Huang, Shiguang] Jinan Univ, Sch Med, Guangzhou 510632, Guangdong, Peoples R China.
[Su, Xin-zhuan] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
[Su, Xin-zhuan] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.
[Liu, Yajun] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510006, Guangdong, Peoples R China.
[Pan, Longhua; Li, Guoming; Li, Di] Guangdong Newsouth Artepharm Co Ltd, Guangzhou 510405, Guangdong, Peoples R China.
[Bacar, Afane; Abdallah, Kamal Said; Attoumane, Rachad] Natl Malaria Control Programme, BP 500 Moroni, Moroni, Comoros.
[Mliva, Ahamada M. S. A.] Minist Hlth Comoros, BP 500 Moroni, Moroni, Comoros.
[Xu, Qin] Guangzhou Univ Chinese Med, Res Inst Trop Med, Guangzhou 510006, Guangdong, Peoples R China.
[Lu, Fangli] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Parasitol, Guangzhou 510080, Guangdong, Peoples R China.
RP Guan, YZ; Song, JP (reprint author), Guangzhou Univ Chinese Med, Sci & Technol Pk, Guangzhou 510006, Guangdong, Peoples R China.
EM gyz111@hotmail.com; songjpgz@sina.com
OI Su, Xinzhuan/0000-0003-3246-3248
FU Natural Science Foundation of China [81273643]; Guangdong Provincial
Science and Technology Program [2014B050502013]; China Postdoctoral
Science Foundation [2015M570699, 2016T90773]; Guangdong Provincial
Science Foundation [2015A030310107]; Guangdong Provincial Medicine
Science Foundation [A2016315]; Foundation of Traditional Chinese
Medicine Bureau of Guangdong Province [20141074]; Science and Technology
Program of Guangzhou [2014J4500037]; Division of Intramural Research,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health
FX This work was supported in part by grants from Natural Science
Foundation of China [Grant Number 81273643] and Guangdong Provincial
Science and Technology Program [Grant Number 2014B050502013] to JS,
China Postdoctoral Science Foundation [Grant Number 2015M570699 and
2016T90773], Guangdong Provincial Science Foundation [Grant Number
2015A030310107], and Guangdong Provincial Medicine Science Foundation
[Grant Number A2016315] to BH, Foundation of Traditional Chinese
Medicine Bureau of Guangdong Province [Grant Number 20141074] to QW,
Science and Technology Program of Guangzhou [2014J4500037] to YG, and by
the Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health (XzS). The funds had
no role in the study design, data collection and analysis, decision to
publish, or the preparation of the manuscript.
NR 52
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 15
PY 2016
VL 15
AR 414
DI 10.1186/s12936-016-1474-4
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DT3CQ
UT WOS:000381358500004
PM 27527604
ER
PT J
AU Wu, SP
Pfeiffer, RM
Ahn, IE
Mailankody, S
Sonneveld, P
van Duin, M
Munshi, NC
Walker, BA
Morgan, G
Landgren, O
AF Wu, S. Peter
Pfeiffer, Ruth M.
Ahn, Inhye E.
Mailankody, Sham
Sonneveld, Pieter
van Duin, Mark
Munshi, Nikhil C.
Walker, Brian A.
Morgan, Gareth
Landgren, Ola
TI Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of
Non-MMSET Myeloma Patients
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID RISK MULTIPLE-MYELOMA; BREAST-CANCER RISK; T(4/14) MYELOMA; CELL-CYCLE;
C-MYC; PLASMA-CELLS; EXPRESSION; PREDICTION; TRANSLOCATION; TRANSCRIPTS
AB Purpose: The poor prognosis of multiple myeloma with t(4;14) is driven by the fusion of genes encoding multiple myeloma SET domain (MMSET) and immunoglobulin heavy chain. Specific genes affected by MMSET and their clinical implications in non-MMSET myeloma remain undetermined.
Experimental Design: We obtained gene expression profiles of 1,032 newly diagnosed myeloma patients enrolled in Total Therapy 2, Total Therapy 3, Myeloma IX, and HOVON65-GMMGHD4 trials and 156 patients from Multiple Myeloma Resource Collection. Probes that correlated most with MMSET myeloma were selected on the basis of a multivariable linear regression and Bonferroni correction and refined on the basis of the strength of association with survival in non-MMSET patients.
Results: Ten MMSET-like probes were associated with poor survival in non-MMSET myeloma. Non-MMSET myeloma patients in the highest quartile of the 10-gene signature (MMSET-like myeloma) had 5-year overall survival similar to that of MMSET myeloma [highest quartile vs. lowest quartile HR = 2.0; 95% confidence interval (CI), 1.5-2.8 in MMSET-like myeloma; HR = 2.3; 95% CI, 1.6-3.3 in MMSET myeloma]. Analyses of MMSET-like gene signature suggested the involvement of p53 and MYC pathways.
Conclusions: MMSET-like gene signature captures a subset of high-risk myeloma patients underrepresented by conventional risk stratification platforms and defines a distinct biologic subtype. (C) 2016 AACR.
C1 [Wu, S. Peter; Ahn, Inhye E.] NCI, Multiple Myeloma Sect, NIH, Bethesda, MD 20892 USA.
[Pfeiffer, Ruth M.] NCI, Dept Canc Epidemiol & Genet, Biostat Branch, NIH, Rockville, MD USA.
[Mailankody, Sham; Landgren, Ola] Mem Sloan Kettering Canc Ctr, Myeloma Serv, New York, NY 10021 USA.
[Sonneveld, Pieter; van Duin, Mark] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands.
[Munshi, Nikhil C.] Harvard Med Sch, Lebow Inst Myeloma Therapeut, Boston, MA USA.
[Munshi, Nikhil C.] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA USA.
[Walker, Brian A.] Inst Canc Res, Sect Haematooncol, London, England.
[Morgan, Gareth] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
RP Landgren, O (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM landgrec@mskcc.org
OI Walker, Brian/0000-0002-8615-6254
FU NIH; NIH Medical Research Scholars Program
FX This work was supported by the intramural research program of the NIH.
Research support for S.P. Wu was made possible through the NIH Medical
Research Scholars Program, a public-private partnership supported
jointly by the NIH and generous contributions to the Foundation for the
NIH from Pfizer Inc., The Leona M. and Harry B. Helmsley Charitable
Trust, and the Howard Hughes Medical Institute, as well as other private
donors. For a complete list, please visit the Foundation website at
http://www.fnih.org/work/programs-development/medical-research-scholars-
program.
NR 35
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2016
VL 22
IS 16
BP 4039
EP 4044
DI 10.1158/1078-0432.CCR-15-2366
PG 6
WC Oncology
SC Oncology
GA DU5QH
UT WOS:000382265900009
PM 26847058
ER
PT J
AU Osgood, CL
Maloney, N
Kidd, CG
Kitchen-Goosen, S
Segars, L
Gebregiorgis, M
Woldemichael, GM
He, M
Sankar, S
Lessnick, SL
Kang, M
Smith, M
Turner, L
Madaj, ZB
Winn, ME
Nunez, LE
Gonzalez-Sabin, J
Helman, LJ
Moris, F
Grohar, PJ
AF Osgood, Christy L.
Maloney, Nichole
Kidd, Christopher G.
Kitchen-Goosen, Susan
Segars, Laura
Gebregiorgis, Meti
Woldemichael, Girma M.
He, Min
Sankar, Savita
Lessnick, Stephen L.
Kang, Min
Smith, Malcolm
Turner, Lisa
Madaj, Zachary B.
Winn, Mary E.
Nunez, Luz-Elena
Gonzalez-Sabin, Javier
Helman, Lee J.
Moris, Francisco
Grohar, Patrick J.
TI Identification of Mithramycin Analogues with Improved Targeting of the
EWS-FLI1 Transcription Factor
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CHILDRENS ONCOLOGY GROUP; LOCALIZED EWING SARCOMA; IN-VIVO;
COMBINATORIAL BIOSYNTHESIS; ONCOGENIC TRANSCRIPTION; NEUROECTODERMAL
TUMOR; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; GROWTH; EWS/FLI
AB Purpose: The goal of this study was to identify second-generation mithramycin analogues that better target the EWS-FLI1 transcription factor for Ewing sarcoma. We previously established mithramycin as an EWS-FLI1 inhibitor, but the compound's toxicity prevented its use at effective concentrations in patients.
Experimental Design: We screened a panel of mithralogs to establish their ability to inhibit EWS-FLI1 in Ewing sarcoma. We compared the IC50 with the MTD established in mice to determine the relationship between efficacy and toxicity. We confirmed the suppression of EWS-FLI1 at the promoter, mRNA, gene signature, and protein levels. We established an improved therapeutic window by using time-lapse microscopy to model the effects on cellular proliferation in Ewing sarcoma cells relative to HepG2 control cells. Finally, we established an improved therapeutic window using a xenograft model of Ewing sarcoma.
Results: EC-8105 was found to be the most potent analogue and was able to suppress EWS-FLI1 activity at concentrations nontoxic to other cell types. EC-8042 was substantially less toxic than mithramycin in multiple species but maintained suppression of EWS-FLI1 at similar concentrations. Both compounds markedly suppressed Ewing sarcoma xenograft growth and inhibited EWS-FLI1 in vivo.
Conclusions: These results provide a basis for the continued development of EC-8042 and EC-8105 as EWS-FLI1 inhibitors for the clinic. (C) 2016 AACR.
C1 [Osgood, Christy L.; Maloney, Nichole; Kidd, Christopher G.; Segars, Laura; Grohar, Patrick J.] Vanderbilt Univ, Sch Med, Div Pediat Hematol Oncol, Nashville, TN 37212 USA.
[Kitchen-Goosen, Susan; Turner, Lisa; Madaj, Zachary B.; Winn, Mary E.; Grohar, Patrick J.] Van Andel Res Inst, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.
[Segars, Laura; Gebregiorgis, Meti; Smith, Malcolm; Helman, Lee J.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Woldemichael, Girma M.] Frederick Natl Lab Canc Res, Basic Sci Program, Leidos Biomed Res Lab Inc, Mol Targets Lab, Frederick, MD USA.
[He, Min; Smith, Malcolm] NCI, Dev Therapeut Program, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
[Sankar, Savita] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA.
[Lessnick, Stephen L.] Ohio State Univ, Nationwide Childrens Hosp, Div Pediat Hematol Oncol BMT, Ctr Childhood Canc & Blood Disorders, Columbus, OH 43210 USA.
[Kang, Min] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79430 USA.
[Nunez, Luz-Elena; Gonzalez-Sabin, Javier; Moris, Francisco] EntreChem SL, Oviedo, Spain.
[Grohar, Patrick J.] Helen De Vos Childrens Hosp, Grand Rapids, MI USA.
[Grohar, Patrick J.] Michigan State Univ, Sch Med, Dept Pediat, E Lansing, MI 48824 USA.
RP Grohar, PJ (reprint author), Van Andel Res Inst, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.
EM patrick.grohar@vai.org
FU Hyundai Hope on Wheels Program; T32 training grant; Vanderbilt Clinical
Oncology Research Career Development K12; Vanderbilt University
Department of Pediatrics; Lily's Garden Foundation; Frederick National
Laboratory for Cancer Research, National Institutes of Health
[HHSN261200800001E]
FX The majority of the funding for this work was from the Hyundai Hope on
Wheels Program (to P.J. Grohar, C.G. Kidd, and N. Maloney). Funding was
also provided by the T32 training grant conducting research in pediatric
oncology (Principal Investigator, D. Friedman) as well as the Vanderbilt
Clinical Oncology Research Career Development K12 both for C.L. Osgood
(Principal Investigator, D. Friedman). Additional internal funds were
provided by the Vanderbilt University Department of Pediatrics (to P.J.
Grohar, C.L. Osgood, and N. Maloney). Immunofluorescent assay
development was supported by the Alex's Lemonade Stand Reach Award (to
P.J. Grohar). Additional funding was provided by the Lily's Garden
Foundation (to P.J. Grohar and L. Segars). EntreChem thanks Mariam
Hermosilla and Patricia Oro for superior technical assistance. This
project has also been funded in part with federal funds from the
Frederick National Laboratory for Cancer Research, National Institutes
of Health under contract HHSN261200800001E (to G.M. Woldemichael).
NR 49
TC 3
Z9 3
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 15
PY 2016
VL 22
IS 16
BP 4105
EP 4118
DI 10.1158/1078-0432.CCR-15-2624
PG 14
WC Oncology
SC Oncology
GA DU5QH
UT WOS:000382265900016
PM 26979396
ER
PT J
AU Dellibovi-Ragheb, T
Altan-Bonnet, N
AF Dellibovi-Ragheb, Teegan
Altan-Bonnet, Nihal
TI Cloud storage for endosomes
SO EMBO JOURNAL
LA English
DT Editorial Material
AB Coordinated regulation of vesicle trafficking is critical for the proper functioning of a cell. The bulk of cellular transport vesicles are sequestered in a "perinuclear cloud", with only a small fraction released to the cell periphery. Jongsma et al (2016) found that the ER-associated E3 ubiquitin ligase RNF26 is responsible for establishing and maintaining the architecture of the perinuclear cloud and that this spatiotemporal positioning is critical for effective regulation of the endocytic and exocytic systems.
C1 [Dellibovi-Ragheb, Teegan; Altan-Bonnet, Nihal] NHLBI, Lab Host Pathogen Dynam, Cell Biol & Physiol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Altan-Bonnet, N (reprint author), NHLBI, Lab Host Pathogen Dynam, Cell Biol & Physiol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM nihal.altan-bonnet@nih.gov
NR 7
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD AUG 15
PY 2016
VL 35
IS 16
BP 1724
EP 1725
DI 10.15252/embj.201695080
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DU6II
UT WOS:000382317500002
PM 27378788
ER
PT J
AU Kehrl, JH
AF Kehrl, John H.
TI The impact of RGS and other G-protein regulatory proteins on G
alpha(i)-mediated signaling in immunity
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE G-protein; RGS proteins; Chemokine receptors; Sphingosine 1-phosphate;
Cell trafficking
ID G-ALPHA-I; HETEROTRIMERIC G-PROTEINS; RECEPTOR-INDEPENDENT ACTIVATORS;
T-LYMPHOCYTE MIGRATION; ELEGANS NERVOUS-SYSTEM; G-BETA-GAMMA; NEUTROPHIL
CHEMOTAXIS; PERTUSSIS-TOXIN; COUPLED RECEPTORS; CELL-DIVISION
AB Leukocyte chemoattractant receptors are members of the G-protein coupled receptor (GPCR) family. Signaling downstream of these receptors directs the localization, positioning and homeostatic trafficking of leukocytes; as well as their recruitment to, and their retention at, inflammatory sites. Ligand induced changes in the molecular conformation of chemoattractant receptors results in the engagement of heterotrimeric G-proteins, which promotes alpha subunits to undergo GTP/GDP exchange. This results in the functional release of B gamma subunits from the heterotrimers, thereby activating downstream effector molecules, which initiate leukocyte polarization, gradient sensing, and directional migration. Pertussis toxin ADP ribosylates G alpha(i) subunits and prevents chemoattractant receptors from triggering G alpha(i) nucleotide exchange. The use of pertussis toxin revealed the essential importance of G alpha(i) subunit nucleotide exchange for chemoattractant receptor signaling. More recent studies have identified a range of regulatory mechanisms that target these receptors and their associated heterotrimeric G-proteins, thereby helping to control the magnitude, kinetics, and duration of signaling. A failure in these regulatory pathways can lead to impaired receptor signaling and immunopathology. The analysis of mice with targeted deletions of G alpha(i) isoforms as well as some of these G-protein regulatory proteins is providing insights into their roles in chemoattractant receptor signaling. Published by Elsevier Inc.
C1 [Kehrl, John H.] NIAID, Immunoregulat Lab, NIH, Bldg 10,Room 11B08,10 Ctr Dr MSC 1876, Bethesda, MD 20892 USA.
RP Kehrl, JH (reprint author), NIAID, Immunoregulat Lab, NIH, Bldg 10,Room 11B08,10 Ctr Dr MSC 1876, Bethesda, MD 20892 USA.
EM jkehrl@niaid.nih.gov
FU intramural program of the National Institutes of Allergy and Infectious
Diseases
FX The author would like to thank the members of his laboratory that
contributed to some of the studies described in this review and thank
Dr. Anthony Fauci for his long standing support. The intramural program
of the National Institutes of Allergy and Infectious Diseases supported
some of the research described in this review.
NR 154
TC 1
Z9 1
U1 7
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD AUG 15
PY 2016
VL 114
SI SI
BP 40
EP 52
DI 10.1016/j.bcp.2016.04.005
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DT1KK
UT WOS:000381241000005
PM 27071343
ER
PT J
AU Kersey, RK
Brodigan, TM
Fukushige, T
Krause, MW
AF Kersey, Rossio K.
Brodigan, Thomas M.
Fukushige, Tetsunari
Krause, Michael W.
TI Regulation of UNC-130/FOXD-mediated mesodermal patterning in C-elegans
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Forkhead; FOXD; UNC-130; UNC-129; Embryogenesis; Transcriptional
regulation
ID FORKHEAD TRANSCRIPTION FACTORS; CAENORHABDITIS-ELEGANS; DNA-BINDING;
GENETIC INTERFERENCE; MUSCLE DEVELOPMENT; FEEDBACK LOOP; BOX PROTEINS;
TGF-BETA; EXPRESSION; GENOME
AB Spatial polarity cues in animals are used repeatedly during development for many processes, including cell fate determination, cell migration, and axon guidance. In Caenorhabditis elegans, the body wall muscle extends the length of the animal in four distinct quadrants and generates an UNC-129/TGF-beta-related signal that is much higher in the dorsal two muscle quadrants compared to their ventral counterparts. This pattern of unc-129 expression requires the activity of the proposed transcriptional repressor UNC-130/FOXD whose body wall muscle activity is restricted to the ventral two body wall muscle quadrants. To understand how these dorsal-ventral differences in UNC-130 activity are established and maintained, we have analyzed the regulation of unc-130 expression and the distribution of UNC-130 protein. We have identified widespread, cis-acting elements in the unc-130 promoter that function to positively regulate ventral body wall muscle expression and negatively regulate dorsal body wall muscle expression. We have defined the temporal distribution of UNC-130 protein in body wall muscle cells during embryogenesis, demonstrated that this pattern is required to establish the dorsal-ventral polarity of UNC-129/TGF-beta, and shown that UNC-130 is not required post-embryonically to maintain the asymmetry of body wall muscle unc-129 expression. Finally, we have tested the impact of the depletion of a variety of transcription factors, repressors, and signaling molecules to identify additional regulators of body wall muscle UNC-130 polarity. Our results confirm and extend earlier studies to clarify the mechanisms by which UNC-130 is controlled and affects the pattern of unc-129 expression in body wall muscle. These results further our understanding of the transcriptional logic behind the generation of polarity cues involving this poorly understood subclass of Forkhead factors. Published by Elsevier Inc.
C1 [Kersey, Rossio K.; Brodigan, Thomas M.; Fukushige, Tetsunari; Krause, Michael W.] NIDDK, Mol Biol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Krause, MW (reprint author), NIDDK, Mol Biol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM michaelkr@niddk.nih.gov
OI Krause, Michael/0000-0001-6127-3940
FU NIH Office of Research Infrastructure Programs [P40 OD010440];
Intramural Research Program of the NIH, The National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK)
FX Our thanks to Lyn Noordam for help with the text and figures, Andy
Golden, Harold Smith, and Jim McGhee for plasmids, Harald Hutter for
strains, Piali Sengupta and Michel Labouesse for antibodies, Jun "Kelly"
Liu for reagents and comments on the manuscript, Ward Odenwald for help
with EvoPrinter-based identifications of conserved promoter sequences,
and WormBase as a resource. Some strains were provided by the CGC, which
is funded by NIH Office of Research Infrastructure Programs (P40
OD010440). This work was supported by the Intramural Research Program of
the NIH, The National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK).
NR 51
TC 0
Z9 0
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0012-1606
EI 1095-564X
J9 DEV BIOL
JI Dev. Biol.
PD AUG 15
PY 2016
VL 416
IS 2
BP 300
EP 311
DI 10.1016/j.ydbio.2016.06.029
PG 12
WC Developmental Biology
SC Developmental Biology
GA DT9QE
UT WOS:000381836600005
PM 27341757
ER
PT J
AU Peer, CJ
Strope, JD
Beedie, S
Ley, AM
Holly, A
Calis, K
Farkas, R
Parepally, J
Men, A
Fadiran, EO
Scott, P
Jenkins, M
Theodore, WH
Sissung, TM
AF Peer, Cody J.
Strope, Jonathan D.
Beedie, Shaunna
Ley, Ariel M.
Holly, Alesia
Calis, Karim
Farkas, Ronald
Parepally, Jagan
Men, Angela
Fadiran, Emmanuel O.
Scott, Pamela
Jenkins, Marjorie
Theodore, William H.
Sissung, Tristan M.
TI Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related
Differences in Clearance of Zolpidem in Rats
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE zolpidem; drug metabolism; pharmacokinetics; testosterone
ID ETHANOL-METABOLISM; HUMAN LIVER; PHARMACOKINETICS; EXPRESSION;
MECHANISM; GENDER; BRAIN; MUCOSA; ADULTS; AGE
AB Objectives: The recommended zolpidem starting dose was lowered in females (5 mg vs. 10 mg) since side effects were more frequent and severe than those of males; the mechanism underlying sex differences in pharmacokinetics (PK) is unknown. We hypothesized that such differences were caused by known sex-related variability in alcohol dehydrogenase (ADH) expression.
Methods: Male, female, and castrated male rats were administered 2.6 mg/kg zolpidem, +/- disulfiram (ADH/ALDH pathway inhibitor) to compare PK changes induced by sex and gonadal hormones. PK analyses were conducted in rat plasma and rat brain.
Key findings: Sex differences in PK were evident: females had a higher C-MAX (112.4 vs. 68.1 ug/L) and AUG (537.8 vs. 231.8 h*ug/L) than uncastrated males. Castration induced an earlier T-MAX (0.25 vs. 1 h), greater C-MAX (109.1 vs. 68.1 ug/L), and a corresponding AUG increase (339.7 vs. 231.8 h*ug/L). Administration of disulfiram caused more drastic C-MAX and T-MAX changes in male vs. female rats that mirrored the effects of castration on first-pass metabolism, suggesting that the observed PK differences may be caused by ADH/ALDH expression. Brain concentrations paralleled plasma concentrations.
Conclusion: These findings indicate that sex differences in zolpidem PK are influenced by variation in the expression of ADH/ALDH due to gonadal androgens.
C1 [Peer, Cody J.; Sissung, Tristan M.] NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA.
[Strope, Jonathan D.; Beedie, Shaunna; Ley, Ariel M.; Holly, Alesia] NCI, Mol Pharmacol Program, NIH, Bethesda, MD 20892 USA.
[Calis, Karim] Food & Drug Adm, Ctr Drug Evaluat & Res, Off Med Policy, Silver Spring, MD USA.
[Farkas, Ronald] Food & Drug Adm, Ctr Drug Evaluat & Res, Div Neurol Prod, Off New Drugs, Silver Spring, MD USA.
[Parepally, Jagan; Men, Angela] Food & Drug Adm, Ctr Drug Evaluat & Res, Off Translat Sci, Off Clin Pharmacol, Silver Spring, MD USA.
[Fadiran, Emmanuel O.; Scott, Pamela; Jenkins, Marjorie] Food & Drug Adm, Off Commissioner, Off Womens Hlth, Silver Spring, MD USA.
[Theodore, William H.] NINDS, Clin Epilepsy Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Sissung, TM (reprint author), NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA.
EM sissungt@mail.nih.gov
FU National Cancer Institute (National Institutes of Health); Intramural
Research Program of the NIH, National Cancer Institute; Office of
Women's Health, Food, and Drug Administration; Food Drug Administration
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute (National Institutes of Health) and the
Food Drug Administration. This work was supported by the Intramural
Research Program of the NIH, National Cancer Institute, and the Office
of Women's Health, Food, and Drug Administration.
NR 44
TC 1
Z9 1
U1 3
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 15
PY 2016
VL 7
AR 260
DI 10.3380/fphar.2016.00260
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DT2ZU
UT WOS:000381351100001
PM 27574509
ER
PT J
AU Lau, MWL
Ferre-D'Amare, AR
AF Lau, Matthew W. L.
Ferre-D'Amare, Adrian R.
TI In vitro evolution of coenzyme-independent variants from the glmS
ribozyme structural scaffold
SO METHODS
LA English
DT Article
DE SELEX; Catalytic RNA; Divalent cation; Riboswitch; Mercury-thiol
affinity chromatography
ID SMALL MOLECULES; INTERVENING SEQUENCE; GENE-EXPRESSION; RNA;
TETRAHYMENA; RIBOSWITCH; COFACTOR; BINDING; GLUCOSAMINE-6-PHOSPHATE;
TRANSCRIPTION
AB Uniquely among known natural ribozymes that cleave RNA sequence-specifically, the glmS ribozyme-riboswitch employs a small molecule, glucosamine-6-phosphate (GlcN6P) as a catalytic cofactor. In vitro selection was employed to search for coenzyme-independent variants of this ribozyme. In addition to shedding light on the catalytic mechanism of the ribozyme, such variants could resemble the evolutionary ancestors of the modern, GlcN6P-regulated ribozyme-riboswitch. A mutant pool was constructed such that the secondary structure elements, which define the triply-pseudoknotted global fold of the ribozyme, was preserved. A stringent selection scheme that relies on thiol-mercury affinity chromatography for separating active and inactive sequences ultimately yielded a triple mutant with a cleavage rate exceeding 3 min(-1) that only requires divalent cations for activity. Mutational analysis demonstrated that a point reversion of the variant toward the wild-type sequence was sufficient to partially restore GlcN6P-dependence, suggesting that coenzyme dependence can be readily be acquired by RNA5 that adopt the glmS ribozyme fold. The methods employed to perform this selection experiment are described in detail in this review. Published by Elsevier Inc.
C1 [Lau, Matthew W. L.; Ferre-D'Amare, Adrian R.] NHLBI, 50 South Dr,MSC 8012, Bethesda, MD 20892 USA.
RP Ferre-D'Amare, AR (reprint author), NHLBI, 50 South Dr,MSC 8012, Bethesda, MD 20892 USA.
EM adrian.ferre@nih.gov
FU Intramural Program of the National Heart, Lung and Blood Institute, NIH
FX We thank S. Bachas, N. Baird, M. Chen, J. Hogg, C. Jones, J. Posakony,
R. Trachman, K. Warner, and J. Zhang for discussions. M.W.L. was a
Croucher Foundation Postdoctoral Fellow. This work was supported in part
by the Intramural Program of the National Heart, Lung and Blood
Institute, NIH.
NR 41
TC 2
Z9 2
U1 5
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD AUG 15
PY 2016
VL 106
BP 76
EP 81
DI 10.1016/j.ymeth.2016.04.027
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DT9PZ
UT WOS:000381836100011
PM 27130889
ER
PT J
AU Hoinka, J
Przytycka, T
AF Hoinka, Jan
Przytycka, Teresa
TI AptaPLEX - A dedicated, multithreaded demultiplexer for HT-SELEX data
SO METHODS
LA English
DT Article
DE Aptamers; HT-SELEX; Demultiplexing; Quality control
AB Aptamers, short and synthetic RNA/DNA molecules binding distinct targets with high affinity and specificity, are identified via Systematic Evolution of Ligands by Exponential Enrichment (SELEX), an in vitro procedure that, starting from a pool of random ssDNA/RNA sequences, selects sequences by amplifying target-affine species through a series of selection cycles. This versatile protocol has recently been combined with high throughput sequencing, allowing arbitrary stages of the selection to be sequenced and analyzed in silico. As a prerequisite, these data require extensive preprocessing by means of quality controls, error correction and demultiplexing, all while taking into account the specific design of aptamers. Existing solutions addressing this task are currently present only as integrated components in larger pipelines, limiting their applicability in independent software solutions.
Here we present AptaPLEX, a standalone and platform independent demultiplexer specifically designed for HT-SELEX data. Given the multiplexed data from one or multiple HT-SELEX experiments, AptaPLEX extracts and restores aptamers into the original selection cycles by identifying the barcode and primer regions in each read. AptaPLEX is capable of fuzzy matching for both the barcode and primers, and automatically corrects mismatches between forward and reverse reads for paired-end data. Our software provides a rich set of additional features and can easily be integrated into existing analysis automation pipelines on multiple platforms ranging from desktop machines to cloud based solutions. (C) 2016 Published by Elsevier Inc.
C1 [Hoinka, Jan; Przytycka, Teresa] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
RP Hoinka, J (reprint author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
EM jan.hoinka@nih.gov
FU Intramural Research Program of the NIH, National Library of Medicine
FX This work was supported by the Intramural Research Program of the NIH,
National Library of Medicine.
NR 18
TC 2
Z9 2
U1 3
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD AUG 15
PY 2016
VL 106
BP 82
EP 85
DI 10.1016/j.ymeth.2016.04.011
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DT9PZ
UT WOS:000381836100012
PM 27080809
ER
PT J
AU Billeskov, R
Tan, EV
Cang, M
Abalos, RM
Burgos, J
Pedersen, BV
Christensen, D
Agger, EM
Andersen, P
AF Billeskov, Rolf
Tan, Esterlina V.
Cang, Marjorie
Abalos, Rodolfo M.
Burgos, Jasmin
Pedersen, Bo Vestergaard
Christensen, Dennis
Agger, Else Marie
Andersen, Peter
TI Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a
BCG-Booster in a Non-Human Primate Model of Tuberculosis
SO PLOS ONE
LA English
DT Article
ID BACILLUS-CALMETTE-GUERIN; T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS;
PROTECTIVE IMMUNITY; CYNOMOLGUS MACAQUES; INTERFERON-GAMMA; RHESUS
MACAQUES; INFECTION; MEMORY; FREQUENCY
AB The search for new and improved tuberculosis (TB) vaccines has focused on IFN-gamma both for selecting antigens and for evaluating vaccine delivery strategies. The essential role of IFN-gamma in endogenous host protection is well established, but it is still uncertain whether this also holds true for vaccine protection. Here we evaluate the H56 fusion protein vaccine as a BCG booster in a non-human primate (NHP) model of TB that closely recapitulates human TB pathogenesis. To date, only a handful of novel adjuvants have been tested in the NHP model of TB, and therefore we administered H56 in 3 novel cationic liposome adjuvants of increasing immunogenicity (CAF01, CAF04, CAF05) and compared them to H56 in the IC31 (R) adjuvant previously reported to promote protection in this model. The individual clinical parameters monitored during infection (weight, ESR, X-ray) all correlated with survival, and boosting BCG with H56 in all adjuvants resulted in better survival rates compared to BCG alone. The adjuvants promoted IFN-gamma responses of increasing intensity as measured by ELISPOT in the peripheral blood, but the level of vaccine-specific IFN-gamma production did not correlate with or predict disease outcome. This study's main outcome underscores the importance of the choice of adjuvant for TB subunit vaccines, and secondly it highlights the need for better correlates of protection in preclinical models of TB.
C1 [Billeskov, Rolf; Christensen, Dennis; Agger, Else Marie; Andersen, Peter] Statens Serum Inst, Dept Infect Dis Immunol, Copenhagen, Denmark.
[Billeskov, Rolf] NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Tan, Esterlina V.; Cang, Marjorie; Abalos, Rodolfo M.; Burgos, Jasmin] Leonard Wood Mem LWM Ctr Leprosy Res, Cebu, Philippines.
[Pedersen, Bo Vestergaard] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark.
RP Billeskov, R; Andersen, P (reprint author), Statens Serum Inst, Dept Infect Dis Immunol, Copenhagen, Denmark.; Billeskov, R (reprint author), NCI, Vaccine Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM rob@ssi.dk; pa@ssi.dk
OI Christensen, Dennis/0000-0003-2382-8639; Billeskov,
Rolf/0000-0003-4533-7304
FU European Commission [FP7-HEALTH-2011.1.4-4-280873]; National Institutes
of Health [AI 105422]
FX The parts of this work that was performed at the SSI was funded by the
European Commission [contract number FP7-HEALTH-2011.1.4-4-280873
(ADITEC)], and National Institutes of Health [grant number AI 105422].
The funders had no role in design of studies or preparation of the
manuscript.
NR 43
TC 1
Z9 1
U1 5
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2016
VL 11
IS 8
AR e0161217
DI 10.1371/journal.pone.0161217
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT4SL
UT WOS:000381471100043
PM 27525651
ER
PT J
AU Desai, A
Krynitsky, J
Pohida, TJ
Zhao, HY
Schuck, P
AF Desai, Abhiksha
Krynitsky, Jonathan
Pohida, Thomas J.
Zhao, Huaying
Schuck, Peter
TI 3D-Printing for Analytical Ultracentrifugation
SO PLOS ONE
LA English
DT Article
ID VELOCITY ANALYTICAL ULTRACENTRIFUGATION; SEDIMENTATION EQUILIBRIUM;
PROTEIN INTERACTIONS; QUANTITATION; PRECISION; ACCURACY; DENSITY; SIZE
AB Analytical ultracentrifugation (AUC) is a classical technique of physical biochemistry providing information on size, shape, and interactions of macromolecules from the analysis of their migration in centrifugal fields while free in solution. A key mechanical element in AUC is the centerpiece, a component of the sample cell assembly that is mounted between the optical windows to allow imaging and to seal the sample solution column against high vacuum while exposed to gravitational forces in excess of 300,000 g. For sedimentation velocity it needs to be precisely sector-shaped to allow unimpeded radial macromolecular migration. During the history of AUC a great variety of centerpiece designs have been developed for different types of experiments. Here, we report that centerpieces can now be readily fabricated by 3D printing at low cost, from a variety of materials, and with customized designs. The new centerpieces can exhibit sufficient mechanical stability to withstand the gravitational forces at the highest rotor speeds and be sufficiently precise for sedimentation equilibrium and sedimentation velocity experiments. Sedimentation velocity experiments with bovine serum albumin as a reference molecule in 3D printed centerpieces with standard double-sector design result in sedimentation boundaries virtually indistinguishable from those in commercial double-sector epoxy centerpieces, with sedimentation coefficients well within the range of published values. The statistical error of the measurement is slightly above that obtained with commercial epoxy, but still below 1%. Facilitated by modern open-source design and fabrication paradigms, we believe 3D printed centerpieces and AUC accessories can spawn a variety of improvements in AUC experimental design, efficiency and resource allocation.
C1 [Desai, Abhiksha; Zhao, Huaying; Schuck, Peter] Natl Inst Biomed Imaging & Bioengn, Dynam Macromol Assembly Sect, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA.
[Krynitsky, Jonathan; Pohida, Thomas J.] NIH, Div Computat Biosci, Ctr Informat Technol, Bethesda, MD 20892 USA.
RP Schuck, P (reprint author), Natl Inst Biomed Imaging & Bioengn, Dynam Macromol Assembly Sect, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA.
EM schuckp@mail.nih.gov
FU Intramural Research Program of the National Institute of Biomedical
Imaging and Bioengineering, National Institutes of Health, United States
[ZIA EB000051-09 LCIM]
FX This work was supported by the Intramural Research Program of the
National Institute of Biomedical Imaging and Bioengineering, National
Institutes of Health, United States (ZIA EB000051-09 LCIM to PS). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 61
TC 0
Z9 0
U1 12
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2016
VL 11
IS 8
AR e0155201
DI 10.1371/journal.pone.0155201
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT4SL
UT WOS:000381471100001
PM 27525659
ER
PT J
AU Ofori, E
Zhu, XY
Etukala, JR
Peprah, K
Jordan, KR
Adkins, AA
Bricker, BA
Kang, HJ
Huang, XP
Roth, BL
Ablordeppey, SY
AF Ofori, Edward
Zhu, Xue Y.
Etukala, Jagan R.
Peprah, Kwakye
Jordan, Kamanski R.
Adkins, Adia A.
Bricker, Barbara A.
Kang, Hye J.
Huang, Xi-Ping
Roth, Bryan L.
Ablordeppey, Seth Y.
TI Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Dual receptor ligands; Multi-receptor targeting; CNS ligands; Serotonin
receptors; 5-HT1A receptor and 5-HT7 receptor ligands
ID ATYPICAL ANTIPSYCHOTIC-DRUG; SEROTONIN RECEPTORS; ROBUST PHARMACOLOGY;
NEGATIVE SYMPTOMS; PARTIAL AGONIST; DOPAMINE D-3; ARIPIPRAZOLE;
CARIPRAZINE; SCHIZOPHRENIA; ANTAGONIST
AB 5-HT1A and 5-HT7 receptors have been at the center of discussions recently due in part to their major role in the etiology of major central nervous system diseases such as depression, sleep disorders, and schizophrenia. As part of our search to identify dual targeting ligands for these receptors, we have carried out a systematic modification of a selective 5HT(7) receptor ligand culminating in the identification of several dual 5-HT1A and 5-HT7 receptor ligands. Compound 16, a butyrophenone derivative of tetrahydroisoquinoline (THIQ), was identified as the most potent agent with low nanomolar binding affinities to both receptors. Interestingly, compound 16 also displayed moderate affinity to other clinically relevant dopamine receptors. Thus, it is anticipated that compound 16 may serve as a lead for further exploitation in our quest to identify new ligands with the potential to treat diseases of CNS origin. Published by Elsevier Ltd.
C1 [Ofori, Edward; Zhu, Xue Y.; Etukala, Jagan R.; Peprah, Kwakye; Jordan, Kamanski R.; Adkins, Adia A.; Bricker, Barbara A.; Ablordeppey, Seth Y.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Div Basic Pharmaceut Sci, Tallahassee, FL 32307 USA.
[Kang, Hye J.; Huang, Xi-Ping; Roth, Bryan L.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
[Kang, Hye J.; Huang, Xi-Ping; Roth, Bryan L.] Univ North Carolina Chapel Hill, Sch Med, NIMH PDSP, Chapel Hill, NC 27599 USA.
[Roth, Bryan L.] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA.
RP Ablordeppey, SY (reprint author), Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Div Basic Pharmaceut Sci, Tallahassee, FL 32307 USA.
FU NIH/NIGMS SCORE grant [2SC1GM116724]; RCMI grant from NIMHD [G12 RR
03020]; Pharmaceutical Research Center NIH/NCRR [1C06-RR12512-01];
National Institute of Mental Health's Psychoactive Drug Screening
Program [HHSN-271-2013-00017-C]; Title III Grant
FX This work would not have been possible without the continuing financial
support of the NIH/NIGMS SCORE grant number 2SC1GM116724, RCMI grant
number G12 RR 03020 from NIMHD and a Title III Grant to Florida A&M
University. The work was also supported in part by the Pharmaceutical
Research Center NIH/NCRR 1C06-RR12512-01 Grant. Ki
determinations and receptor binding profiles were generously provided by
the National Institute of Mental Health's Psychoactive Drug Screening
Program, Contract # HHSN-271-2013-00017-C (NIMH PDSP). The NIMH PDSP is
directed by Bryan L. Roth MD, PhD at the University of North Carolina at
Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD,
USA. Funding sources acknowledged had no involvement in the study
design, data collection and interpretation, or article preparation and
submission of this manuscript.
NR 42
TC 1
Z9 1
U1 5
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 15
PY 2016
VL 24
IS 16
BP 3464
EP 3471
DI 10.1016/j.bmc.2016.05.053
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA DS2AF
UT WOS:000380515700015
PM 27312422
ER
PT J
AU Etukala, JR
Zhu, XY
Eyunni, SVK
Onyameh, EK
Ofori, E
Bricker, BA
Kang, HJ
Huang, P
Roth, BL
Ablordeppey, SY
AF Etukala, Jagan R.
Zhu, Xue Y.
Eyunni, Suresh V. K.
Onyameh, Edem K.
Ofori, Edward
Bricker, Barbara A.
Kang, Hye J.
Huang, Ping
Roth, Bryan L.
Ablordeppey, Seth Y.
TI Development of CNS multi-receptor ligands: Modification of known D-2
pharmacophores
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Multi-receptor targeting; Dopamine receptor ligands; Antipsychotic;
Pharmacophore; CNS receptor
ID REVERSES MK-801-INDUCED IMPAIRMENT; INDUCED DOPAMINE RELEASE; SIGMA(2)
BINDING-SITE; ANTIPSYCHOTIC AGENT; PREFRONTAL CORTEX; BIPOLAR
DEPRESSION; WEIGHT-GAIN; HALOPERIDOL; DRUG; LURASIDONE
AB Several known D-2 pharmacophores have been explored as templates for identifying ligands with multiple binding affinities at dopamine and serotonin receptors considered as clinically relevant receptors in the treatment of neuropsychiatric diseases. This approach has resulted in the identification of ligands that target multiple CNS receptors while avoiding others associated with deleterious effects. In particular, compounds 11, 15 and 22 may have potential for further development as antipsychotic agents as they favorably interact with the clinically relevant receptors including D2R, 5-HT1AR, and 5-HT7R. We have also identified the pair of compounds 11 and 10 as high affinity D2R ligands with and without SERT binding affinities, respectively. These differential binding profiles endow the pair with the potential for evaluating SERT contributions to antipsychotic drug activity in animal behavioral models. In addition, compound 11 has no significant affinity for 5-HT2CR and binds only moderately to the H1R, suggesting it may not induce weight gain or sedation when used clinically. Taken together, compound 11 displays an interesting pharmacological profile that necessitates the evaluation of its functional and in vivo effects in animal models which are currently ongoing. Published by Elsevier Ltd.
C1 [Etukala, Jagan R.; Zhu, Xue Y.; Eyunni, Suresh V. K.; Onyameh, Edem K.; Ofori, Edward; Bricker, Barbara A.; Ablordeppey, Seth Y.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Div Basic Pharmaceut Sci, Tallahassee, FL 32307 USA.
[Kang, Hye J.; Huang, Ping; Roth, Bryan L.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
[Kang, Hye J.; Huang, Ping; Roth, Bryan L.] Univ North Carolina Chapel Hill, Sch Med, NIMH PDSP, Chapel Hill, NC 27599 USA.
[Roth, Bryan L.] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA.
RP Ablordeppey, SY (reprint author), Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Div Basic Pharmaceut Sci, Tallahassee, FL 32307 USA.
EM seth.ablordeppey@famu.edu
FU NIH/NIGMS SCORE grant [2SC1GM116724]; NIMHD RCMI grant [G12 RR03020];
Title III Grant; Pharmaceutical Research Center NIH/NCRR [1C06RR12512];
National Institute of Mental Health's Psychoactive Drug Screening
Program [HHSN-271-2013-00017-C]
FX This work would not have been possible without the continuing financial
support of the NIH/NIGMS SCORE grant number 2SC1GM116724, NIMHD RCMI
grant number G12 RR03020 and a Title III Grant to Florida A&M
University. The work was also supported in part by the Pharmaceutical
Research Center NIH/NCRR grant number 1C06RR12512. Ki
determinations and receptor binding profiles were generously provided by
the National Institute of Mental Health's Psychoactive Drug Screening
Program, Contract #HHSN-271-2013-00017-C (NIMH PDSP). The NIMH PDSP is
directed by Bryan L. Roth MD, PhD at the University of North Carolina at
Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD,
USA. Funding sources acknowledged had no involvement in the study
design, data collection and interpretation, or article preparation and
submission of this manuscript.
NR 49
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 15
PY 2016
VL 24
IS 16
BP 3671
EP 3679
DI 10.1016/j.bmc.2016.06.011
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA DS2AF
UT WOS:000380515700038
PM 27364609
ER
PT J
AU Kosa, P
Ghazali, D
Tanigawa, M
Barbour, C
Cortese, I
Kelley, W
Snyder, B
Ohayon, J
Fenton, K
Lehky, T
Wu, TX
Greenwood, M
Nair, G
Bielekova, B
AF Kosa, Peter
Ghazali, Danish
Tanigawa, Makoto
Barbour, Chris
Cortese, Irene
Kelley, William
Snyder, Blake
Ohayon, Joan
Fenton, Kaylan
Lehky, Tanya
Wu, Tianxia
Greenwood, Mark
Nair, Govind
Bielekova, Bibiana
TI Development of a sensitive Outcome for economical Drug screening for
Progressive Multiple sclerosis Treatment
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE multiple sclerosis; clinical trial; outcome measure; composite scale;
progressive MS; disability scale; quantitative MRI
ID MAGNETIZATION-TRANSFER RATIO; CLINICAL-TRIALS; DIFFUSION MRI;
DOUBLE-BLIND; MATTER; BRAIN; NEUROPROTECTION; DISABILITY; ROBUST; MSFC
AB Therapeutic advance in progressive multiple sclerosis (MS) has been very slow. Based on the transformative role magnetic resonance imaging (MRI) contrast-enhancing lesions had on drug development for relapsing-remitting MS, we consider the lack of sensitive outcomes to be the greatest barrier for developing new treatments for progressive MS. The purpose of this study was to compare 58 prospectively acquired candidate outcomes in the real-world situation of progressive MS trials to select and validate the best-performing outcome. The 1-year pre-treatment period of adaptively designed IPPoMS (ClinicalTrials. gov #NCT00950248) and RIVITaLISe (ClinicalTrials. gov #NCT01212094) Phase II trials served to determine the primary outcome for the subsequent blinded treatment phase by comparing 8 clinical, 1 electrophysiological, 1 optical coherence tomography, 7 MRI volumetric, 9 quantitative T1 MRI, and 32 diffusion tensor imaging MRI outcomes. Fifteen outcomes demonstrated significant progression over 1 year (Delta) in the predetermined analysis and seven out of these were validated in two independent cohorts. Validated MRI outcomes had limited correlations with clinical scales, relatively poor signal-to-noise ratios (SNR) and recorded overlapping values between healthy subjects and MS patients with moderate-severe disability. Clinical measures correlated better, even though each reflects a somewhat different disability domain. Therefore, using machine-learning techniques, we developed a combinatorial weight-adjusted disability score (CombiWISE) that integrates four clinical scales: expanded disability status scale (EDSS), Scripps neurological rating scale, 25 foot walk and 9 hole peg test. CombiWISE outperformed all clinical scales (Delta = 9.10%; p = 0.0003) and all MRI outcomes. CombiWISE recorded no overlapping values between healthy subjects and disabled MS patients, had high SNR, and predicted changes in EDSS in a longitudinal assessment of 98 progressive MS patients and in a cross-sectional cohort of 303 untreated subjects. One point change in EDSS corresponds on average to 7.50 point change in CombiWISE with a standard error of 0.10. The novel validated clinical outcome, CombiWISE, outperforms the current broadly utilized MRI brain atrophy outcome and more than doubles sensitivity in detecting clinical deterioration in progressive MS in comparison to the scale traditionally used for regulatory approval, EDSS.
C1 [Kosa, Peter; Ghazali, Danish; Tanigawa, Makoto; Barbour, Chris; Kelley, William; Snyder, Blake; Bielekova, Bibiana] NINDS, Neuroimmunol Dis Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Barbour, Chris; Greenwood, Mark] Montana State Univ, Dept Math Sci, Bozeman, MT 59717 USA.
[Cortese, Irene; Ohayon, Joan; Fenton, Kaylan; Nair, Govind] NINDS, Neuroimmunol Clin, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Lehky, Tanya] NINDS, EMG Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Wu, Tianxia] NINDS, Clin Trials Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Bielekova, B (reprint author), NINDS, Neuroimmunol Dis Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
EM bibi.bielekova@nih.gov
FU Intramural Research Program of National Institute of Neurological
Disorders and Stroke, National Institutes of Health [NS003055-08,
NS003056-08]
FX Intramural Research Program of National Institute of Neurological
Disorders and Stroke, National Institutes of Health (NS003055-08,
NS003056-08).
NR 40
TC 2
Z9 2
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD AUG 15
PY 2016
VL 7
AR 131
DI 10.3389/fneur.2016.00131
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DT3HD
UT WOS:000381370700001
PM 27574516
ER
PT J
AU Bai, RL
Hamel, E
AF Bai, Ruoli
Hamel, Ernest
TI (-)-Rhazinilam and the diphenylpyridazinone NSC 613241: Two compounds
inducing the formation of morphologically similar tubulin spirals but
binding apparently to two distinct sites on tubulin
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Diphenylpyridazinone derivatives; NSC 613241; (-)-Rhazinilam; Tubulin
polymer of aberrant morphology; Inhibition of tubulin assembly;
Glutaraldehyde-fixed microtubules
ID MICROTUBULE-ASSOCIATED PROTEINS; AMINO-ACID-SEQUENCE; ANTIMITOTIC
AGENTS; STRUCTURAL BASIS; PORCINE BRAIN; BETA-TUBULIN; TAXOID SITE;
VINBLASTINE; LAULIMALIDE; RHAZINILAM
AB The most potent microtubule assembly inhibitor of newer diphenylpyridazinone derivatives examined was NSC 613241. Because NSC 613241 and (-)-rhazinilam also induce the formation of similar 2-filament spirals, these aberrant reactions were compared. Spiral formation with both compounds was enhanced by GTP and inhibited by GDP and by 15 other inhibitors of microtubule assembly. Similarly, microtubule assembly induced by paclitaxel or laulimalide is enhanced by GTP and inhibited by GDP and assembly inhibitors, but neither [H-3]NSC 613241 nor [H-3](-)-rhazinilam bound to microtubules or inhibited the binding of [H-3]paclitaxel or [H-3]peloruside A to microtubules. Differences in the pitch of aberrant polymers were found: NSC 613241-induced and (-)-rhazinilam-induced spirals had average repeats of 85 and 79-80 nm, respectively. We found no binding of [H-3]NSC 613241 or [H-3](-)-rhazinilam to alpha beta-tubulin dimer, but both compounds were incorporated into the polymers they induced in substoichiometric reactions, with as little as 0.1-0.2 mol compound/mal of tubulin, and no cross-inhibition by NSC 613241 or (-)-rhazinilam into spirals occurred. Under reaction conditions where neither compound induced spiral formation, both compounds together synergistically induced substantial spiral formation. We conclude that (-)-rhazinilam and NSC 613241 bind to different sites on tubulin that differ from binding sites for other antitubulin agents. Published by Elsevier Inc.
C1 [Bai, Ruoli; Hamel, Ernest] NCI, Screening Technol Branch, Dev Therapeut Program,NIH, Div Canc Treatment & Diag,Frederick Natl Lab Canc, Frederick, MD 21702 USA.
RP Hamel, E (reprint author), Frederick Natl Lab Canc Res, Bldg 322,Room 102, Frederick, MD 21702 USA.
EM hamele@mail.nih.gov
FU Intramural NIH HHS [Z99 CA999999]
NR 43
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD AUG 15
PY 2016
VL 604
BP 63
EP 73
DI 10.1016/j.abb.2016.06.008
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DS2PY
UT WOS:000380627200008
PM 27311615
ER
PT J
AU Li, SS
Sun, YF
Huang, CY
Follmann, DA
Krause, R
AF Li, Shanshan
Sun, Yifei
Huang, Chiung-Yu
Follmann, Dean A.
Krause, Richard
TI Recurrent event data analysis with intermittently observed time-varying
covariates
SO STATISTICS IN MEDICINE
LA English
DT Article
DE estimating equations; kernel smoothing; partial likelihood; recurrent
events; survival analysis
ID SEMIPARAMETRIC ANALYSIS; SURVIVAL ANALYSIS; REGRESSION-MODEL; CASE
SERIES
AB Although recurrent event data analysis is a rapidly evolving area of research, rigorous studies on estimation of the effects of intermittently observed time-varying covariates on the risk of recurrent events have been lacking. Existing methods for analyzing recurrent event data usually require that the covariate processes are observed throughout the entire follow-up period. However, covariates are often observed periodically rather than continuously. We propose a novel semiparametric estimator for the regression parameters in the popular proportional rate model. The proposed estimator is based on an estimated score function where we kernel smooth the mean covariate process. We show that the proposed semiparametric estimator is asymptotically unbiased, normally distributed, and derives the asymptotic variance. Simulation studies are conducted to compare the performance of the proposed estimator and the simple methods carrying forward the last covariates. The different methods are applied to an observational study designed to assess the effect of group A streptococcus on pharyngitis among school children in India. Copyright (c) 2016 John Wiley & Sons, Ltd.
C1 [Li, Shanshan] Indiana Univ Fairbanks, Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46202 USA.
[Sun, Yifei; Huang, Chiung-Yu] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA.
[Huang, Chiung-Yu] Johns Hopkins Univ, Div Biostat & Bioinformat, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
[Follmann, Dean A.; Krause, Richard] NIAID, Natl Inst Hlth, Bethesda, MD 20817 USA.
RP Huang, CY (reprint author), Johns Hopkins Univ, Div Biostat & Bioinformat, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
EM cyhuang@jhu.edu
FU National Cancer Institute [R01CA193888]
FX The authors are grateful to the editor, associate editor, and referees
for their comments that helped improve this paper. This research was
supported by the National Cancer Institute grant R01CA193888.
NR 30
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD AUG 15
PY 2016
VL 35
IS 18
BP 3049
EP 3065
DI 10.1002/sim.6901
PG 17
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA DR6PZ
UT WOS:000380025100002
PM 26887664
ER
PT J
AU Begre, L
Rohner, E
Mbulaiteye, SM
Egger, M
Bohlius, J
AF Begre, Lorin
Rohner, Eliane
Mbulaiteye, Sam M.
Egger, Matthias
Bohlius, Julia
TI Is human herpesvirus 8 infection more common in men than in women?
Systematic review and meta-analysis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Review
DE human herpesvirus 8; Kaposi sarcoma; seroprevalence; gender;
meta-analysis
ID SARCOMA-ASSOCIATED HERPESVIRUS; SEXUALLY-TRANSMITTED-DISEASES;
MOTHER-TO-CHILD; KAPOSIS-SARCOMA; RISK-FACTORS; GENERAL-POPULATION;
ENDEMIC POPULATION; UNITED-STATES; TRANSMISSION; SEROPREVALENCE
AB All forms of Kaposi sarcoma (KS) are more common in men than in women. It is unknown if this is due to a higher prevalence of human herpesvirus 8 (HHV-8), the underlying cause of KS, in men compared to women. We did a systematic review and meta-analysis to examine the association between HHV-8 seropositivity and gender in the general population. Studies in selected populations like for example, blood donors, hospital patients and men who have sex with men were excluded. We searched Medline and Embase from January 1994 to February 2015. We included observational studies that recruited participants from the general population and reported HHV-8 seroprevalence for men and women or boys and girls. We used random-effects meta-analysis to pool odds ratios (OR) of the association between HHV-8 and gender. We used meta-regression to identify effect modifiers, including age, geographical region and type of HHV-8 antibody test. We included 22 studies, with 36,175 participants. Men from sub-Saharan Africa (SSA) [OR 1.21, 95% confidence interval (CI) 1.09-1.34], but not men from elsewhere (OR 0.94, 95% CI 0.83-1.06), were more likely to be HHV-8 seropositive than women (p value for interaction = 0.010). There was no difference in HHV-8 seroprevalence between boys and girls from SSA (OR 0.90, 95% CI 0.72-1.13). The type of HHV-8 assay did not affect the overall results. A higher HHV-8 seroprevalence in men than women in SSA may partially explain why men have a higher KS risk in this region.
C1 [Begre, Lorin; Rohner, Eliane; Egger, Matthias; Bohlius, Julia] Univ Bern, ISPM, Finkenhubelweg 11, CH-3012 Bern, Switzerland.
[Mbulaiteye, Sam M.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Egger, Matthias] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa.
RP Bohlius, J (reprint author), Univ Bern, ISPM, Finkenhubelweg 11, CH-3012 Bern, Switzerland.
EM julia.bohlius@ispm.unibe.ch
OI Rohner, Eliane/0000-0002-0554-2875
FU National Institute of Allergy and Infectious Diseases of the National
Institutes of Health [U01AI069924]; National Cancer Institute
[5U01A1069924-05]; Swiss National Science Foundation [Ambizione-PROSPER
PZ00P3_160407]
FX Grant sponsor: National Institute of Allergy and Infectious Diseases of
the National Institutes of Health; Grant number: U01AI069924 to M.E.;
Grant sponsor: National Cancer Institute; Grant number: 5U01A1069924-05
to M.E.; Grant sponsor: Swiss National Science Foundation; Grant number:
Ambizione-PROSPER PZ00P3_160407 to J.B.
NR 41
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 15
PY 2016
VL 139
IS 4
BP 776
EP 783
DI 10.1002/ijc.30129
PG 8
WC Oncology
SC Oncology
GA DP3TM
UT WOS:000378418300013
PM 27062038
ER
PT J
AU Hare, DJ
Raven, EP
Roberts, BR
Bogeski, M
Portbury, SD
McLean, CA
Masters, CL
Connor, JR
Bush, AI
Crouch, PJ
Doble, PA
AF Hare, Dominic J.
Raven, Erika P.
Roberts, Blaine R.
Bogeski, Mirjana
Portbury, Stuart D.
McLean, Catriona A.
Masters, Colin L.
Connor, James R.
Bush, Ashley I.
Crouch, Peter J.
Doble, Philip A.
TI Laser ablation-inductively coupled plasma-mass spectrometry imaging of
white and gray matter iron distribution in Alzheimer's disease frontal
cortex
SO NEUROIMAGE
LA English
DT Article
ID NON-HAEMIN IRON; LA-ICP-MS; BRAIN IRON; IN-VIVO; SUBSTANTIA-NIGRA; MRI
CONTRAST; PARKINSONS-DISEASE; TRANSITION-METALS; CEREBRAL-CORTEX; TISSUE
AB Iron deposition in the brain is a feature of normal aging, though in several neurodegenerative disorders, including Alzheimer's disease, the rate of iron accumulation is more advanced than in age-matched controls. Using laser ablation-inductively coupled plasma-mass spectrometry imaging we present here a pilot study that quantitatively assessed the iron content of white and gray matter in paraffin-embedded sections from the frontal cortex of Alzheimer's and control subjects. Using the phosphorus image as a confirmed proxy for the white/gray matter boundary, we found that increased intrusion of iron into gray matter occurs in the Alzheimer's brain compared to controls, which may be indicative of either a loss of iron homeostasis in this vulnerable brain region, or provide evidence of increased inflammatory processes as a response to chronic neurodegeneration. We also observed a trend of increasing iron within the white matter of the frontal cortex, potentially indicative of disrupted iron metabolism preceding loss of myelin integrity. Considering the known potential toxicity of excessive iron in the brain, our results provide supporting evidence for the continuous development of novel magnetic resonance imaging approaches for assessing white and gray matter iron accumulation in Alzheimer's disease. Crown Copyright (C) 2016 Published by Elsevier Inc. All rights reserved.
C1 [Hare, Dominic J.; Doble, Philip A.] Univ Technol Sydney, Elemental Bioimaging Facil, Sydney, NSW 2007, Australia.
[Hare, Dominic J.; Roberts, Blaine R.; Bogeski, Mirjana; Portbury, Stuart D.; Masters, Colin L.; Bush, Ashley I.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic 3010, Australia.
[Raven, Erika P.] Georgetown Univ, Ctr Funct & Mol Imaging, Med Ctr, Washington, DC 20057 USA.
[Raven, Erika P.] NINDS, Adv Magnet Resonance Imaging Sect, Lab Funct & Mol Imaging, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[McLean, Catriona A.] Alfred Hosp, Dept Anat Pathol, Melbourne, Vic, Australia.
[McLean, Catriona A.] Monash Univ, Dept Med, Cent Clin Sch, Clayton, Vic 3800, Australia.
[Connor, James R.] Penn State Hershey Med Ctr, Dept Neural & Behav Sci, Hershey, PA USA.
[Connor, James R.] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA.
[Crouch, Peter J.] Univ Melbourne, Dept Pathol, Sch Biomed Sci, Melbourne, Vic 3010, Australia.
RP Hare, DJ; Doble, PA (reprint author), Univ Technol Sydney, POB 123, Sydney, NSW 2007, Australia.
EM dominic.hare@uts.edu.au; philip.doble@uts.edu.au
FU Australian Research Council Linkage Project [LP120200081, LP140100095];
ESI Ltd.; Agilent Technologies; National Science Foundation Graduate
Research Fellowship [DGE-1444316]; National Health and Medical Research
Council [1005651, 1061550]; Victorian Government's Operational
Infrastructure Support Program; Victorian Brain Bank Network
FX The authors would like to thank Dr. Ian Birchall and Dr. Jeff Duyn for
their helpful advice, and Ms. Fairlie Hilton of the Victorian Brain Bank
Network for her assistance with case notes. D.J.H. and P.A.D. are
supported by funds from Australian Research Council Linkage Project
(LP120200081) in conjunction with ESI Ltd. and Agilent Technologies.
D.J.H. and B.R.R. are additionally supported through Australian Research
Council Linkage Project (LP140100095) with Agilent Technologies. E.P.R.
is supported by the National Science Foundation Graduate Research
Fellowship under Grant No. DGE-1444316. P.J.C. is supported by funds
from the National Health and Medical Research Council (1005651 and
1061550). We gratefully acknowledge the support of the Victorian
Government's Operational Infrastructure Support Program and the
Victorian Brain Bank Network.
NR 74
TC 1
Z9 1
U1 20
U2 46
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD AUG 15
PY 2016
VL 137
BP 124
EP 131
DI 10.1016/j.neuroimage.2016.05.057
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DO8QO
UT WOS:000378048700013
PM 27233149
ER
PT J
AU Zavala, B
Tan, HL
Ashkan, K
Foltynie, T
Limousin, P
Zrinzo, L
Zaghloul, K
Brown, P
AF Zavala, Baltazar
Tan, Huiling
Ashkan, Keyoumars
Foltynie, Thomas
Limousin, Patricia
Zrinzo, Ludvic
Zaghloul, Kareem
Brown, Peter
TI Human subthalamic nucleus-medial frontal cortex theta phase coherence is
involved in conflict and error related cortical monitoring
SO NEUROIMAGE
LA English
DT Article
DE Conflict; Subthalamic nucleus; Theta; Coherence; Errors
ID ANTERIOR CINGULATE CORTEX; DEEP BRAIN-STIMULATION; PARKINSONS-DISEASE;
COGNITIVE CONTROL; DECISION-MAKING; RESPONSE CONFLICT; TASK-DIFFICULTY;
DYNAMICS; OSCILLATIONS; RESOLUTION
AB The medial prefrontal cortex (mPFC) is thought to control the shift from automatic to controlled action selection when conflict is present or when mistakes have been recently committed. Growing evidence suggests that this process involves frequency specific communication in the theta (4-8 Hz) band between the mPFC and the subthalamic nucleus (STN), which is the main target of deep brain stimulation (DBS) for Parkinson's disease. Key in this hypothesis is the finding that DBS can lead to impulsivity by disrupting the correlation between higher mPFC oscillations and slower reaction times during conflict. In order to test whether theta band coherence between the mPFC and the STN underlies adjustments to conflict and to errors, we simultaneously recorded mPFC and STN electrophysiological activity while DBS patients performed an arrowed flanker task. These recordings revealed higher theta phase coherence between the two sites during the high conflict trials relative to the low conflict trials. These differences were observed soon after conflicting arrows were displayed, but before a response was executed. Furthermore, trials that occurred after an error was committed showed higher phase coherence relative to trials that followed a correct trial, suggesting that mPFC-STN connectivity may also play a role in error related adjustments in behavior. Interestingly, the phase coherence we observed occurred before increases in theta power, implying that the theta phase and power may influence behavior at separate times during cortical monitoring. Finally, we showed that pre-stimulus differences in STN theta power were related to the reaction time on a given trial, which may help adjust behavior based on the probability of observing conflict during a task. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Zavala, Baltazar; Tan, Huiling; Brown, Peter] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurol, Oxford OX3 9DU, England.
[Zavala, Baltazar; Zaghloul, Kareem] NIH, Surg Neurol Branch, 10 Ctr Dr,3D20, Bethesda, MD 20814 USA.
[Tan, Huiling; Brown, Peter] Univ Oxford, Med Res Council, Brain Network Dynam Unit, Mansfield Rd, Oxford OX1 3TH, England.
[Ashkan, Keyoumars] Kings Coll Hosp London, Dept Neurosurg, Kings Coll, London SE5 9RS, England.
[Foltynie, Thomas; Limousin, Patricia; Zrinzo, Ludvic] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1 3BG, England.
RP Zavala, B (reprint author), Natl Inst Neurol Dis & Stroke, Surg Neurol Branch, Bldg 10,Room 3D20,10 Ctr Dr, Bethesda, MD 20892 USA.
EM zarzavala@gmail.com
OI Zavala, Baltazar/0000-0002-7284-7994; Brown, Peter/0000-0002-5201-3044;
Tan, Huiling /0000-0001-8038-3029
FU National Institutes of Health Oxford-Cambridge fellowship; Department of
Health National Institute for Health Research UCL Biomedical Research
Center; Monument Trust; Parkinson's Appeal for Deep Brain Stimulation;
Medical Research Council; Department of Health National Institute for
Health Research Oxford Biomedical Research Centre
FX B.Z. is supported by the National Institutes of Health Oxford-Cambridge
fellowship. T.F. and L.Z. are funded by the Department of Health
National Institute for Health Research UCL Biomedical Research Center,
The Monument Trust, and Parkinson's Appeal for Deep Brain Stimulation.
P.B. and H.T. are funded by the Medical Research Council, and P.B. is
further funded by the Department of Health National Institute for Health
Research Oxford Biomedical Research Centre.
NR 50
TC 2
Z9 2
U1 10
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD AUG 15
PY 2016
VL 137
BP 178
EP 187
DI 10.1016/j.neuroimage.2016.05.031
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA DO8QO
UT WOS:000378048700018
PM 27181763
ER
PT J
AU Scuteri, A
Morrell, CH
Orru, M
AlGhatrif, M
Saba, PS
Terracciano, A
Ferreli, LAP
Loi, F
Marongiu, M
Pilia, MG
Delitala, A
Tarasov, KV
Schlessinger, D
Ganau, A
Cucca, F
Lakatta, EG
AF Scuteri, Angelo
Morrell, Christopher H.
Orru, Marco
AlGhatrif, Majid
Saba, Pier Sergio
Terracciano, Antonio
Ferreli, Liana Anna Pina
Loi, Francesco
Marongiu, Michele
Pilia, Maria Grazia
Delitala, Alessandro
Tarasov, Kirill V.
Schlessinger, David
Ganau, Antonello
Cucca, Francesco
Lakatta, Edward G.
TI Gender specific profiles of white coat and masked hypertension impacts
on arterial structure and function in the SardiNIA study
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Arterial stiffness; Pulse wave velocity; Carotid thickness; Arterial
aging; Masked hypertension; White coat hypertension; 24 hour blood
pressure monitoring
ID PULSE-WAVE VELOCITY; AMBULATORY BLOOD-PRESSURE; LONG-TERM RISK;
SUSTAINED HYPERTENSION; COGNITIVE IMPAIRMENT; METABOLIC SYNDROME; ORGAN
DAMAGE; METAANALYSIS; STIFFNESS; STROKE
AB Background: There is no definite consensus on the CV burden associated to Masked hypertension (MH) or White Coat Hypertension (WCH) - conditions that can be detected by out-of-office blood pressure measurements (24 hour Ambulatory Blood Pressure Monitoring, 24 h ABPM).
Methods: We investigated the association of WCH and MH with arterial aging, indexed by a range of parameters of large artery structure and function in 2962 subjects, taking no antihypertensive medications, who are participating in a large community-based population of both men and women over a broad age range (14-102 years).
Results: The overall prevalence of WCH was 9.5% and was 5.0% for MH, with 54.9% of subjects classified as true normotensive and 30.6% as true hypertensive. Both WCH and MH were associated with a stiffer aorta, a less distensible and thicker common carotid artery, and greater central BP than true normotensive subjects. Notably, the profile of arterial alterations in WCH and MH did not significantly differ from what was observed in true hypertensive subjects. The arterial changes accompanying WCH and MH differed in men and women, with women showing a greater tendency towards concentric remodeling, greater parietal wall stress, and PWV than men.
Conclusion: Both WCH, and MH are associated with early arterial aging, and therefore, neither can be regarded as innocent conditions. Future studies are required to establish whether measurement of arterial aging parameters in subjects with WCH or MH will identify subjects at higher risk of CV events and cognitive impairment, who may require more clinical attention and pharmacological intervention. (C) 2016 Published by Elsevier Ireland Ltd.
C1 [Morrell, Christopher H.; AlGhatrif, Majid; Tarasov, Kirill V.; Schlessinger, David; Lakatta, Edward G.] NIA, NIH, Baltimore, MD 21224 USA.
[Orru, Marco; Ferreli, Liana Anna Pina; Loi, Francesco; Marongiu, Michele; Pilia, Maria Grazia; Delitala, Alessandro; Cucca, Francesco] Cittadella Univ Monserrato, Ist Ric Genet & Biomed, CNR, Cagliari, Italy.
[Saba, Pier Sergio; Ganau, Antonello] Univ Sassari, I-07100 Sassari, Italy.
[Terracciano, Antonio] Florida State Univ, Coll Med, Tallahassee, FL 32306 USA.
[Morrell, Christopher H.] Loyola Univ Maryland, Baltimore, MD USA.
[Orru, Marco] Presidio Osped A Businco, Unita Operat Complessa Cardiol, Cagliari, Italy.
RP Scuteri, A (reprint author), Policlin Tor Vergata, Hypertens Ctr, Hypertens & Nephrol Unit, Rome, Italy.
EM angeloelefante@interfree.it
RI Delitala, Alessandro/L-3194-2016
OI Delitala, Alessandro/0000-0003-1729-8969
FU NIA [NO1-AG-1-2109]; Intramural Research Program of the NIH, U.S.
National Institute on Aging
FX The SardiNIA team was supported by Contract NO1-AG-1-2109 from the NIA.
This research was supported in part by the Intramural Research Program
of the NIH, U.S. National Institute on Aging.
NR 31
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD AUG 15
PY 2016
VL 217
BP 92
EP 98
DI 10.1016/j.ijcard.2016.04.172
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DO5OO
UT WOS:000377832700014
PM 27179214
ER
PT J
AU Metcalf, CJE
Farrar, J
Cutts, FT
Basta, NE
Graham, AL
Lessler, J
Ferguson, NM
Burke, DS
Grenfell, BT
AF Metcalf, C. Jessica E.
Farrar, Jeremy
Cutts, Felicity T.
Basta, Nicole E.
Graham, Andrea L.
Lessler, Justin
Ferguson, Neil M.
Burke, Donald S.
Grenfell, Bryan T.
TI Use of serological surveys to generate key insights into the changing
global landscape of infectious disease
SO LANCET
LA English
DT Editorial Material
ID INFLUENZA; TRANSMISSION; DYNAMICS; ANTIBODY; MODEL
C1 [Metcalf, C. Jessica E.; Graham, Andrea L.; Grenfell, Bryan T.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
[Metcalf, C. Jessica E.; Basta, Nicole E.; Graham, Andrea L.; Grenfell, Bryan T.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
[Farrar, Jeremy] Wellcome Trust Res Labs, Gibbs Bldg, London, England.
[Cutts, Felicity T.] London Sch Hyg & Trop Med, London, England.
[Basta, Nicole E.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Lessler, Justin] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Ferguson, Neil M.] Imperial Coll London, Dept Med, Sch Publ Hlth, London, England.
[Burke, Donald S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
RP Metcalf, CJE (reprint author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
EM cmetcalf@princeton.edu
RI Graham, Andrea/A-8808-2010;
OI Graham, Andrea/0000-0002-6580-2755; Lessler, Justin/0000-0002-9741-8109;
/0000-0002-5704-8094
FU Medical Research Council [, MR/K010174/1]; NICHD NIH HHS [P2C HD047879];
NIH HHS [DP5 OD009162]
NR 14
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 13
PY 2016
VL 388
IS 10045
BP 728
EP 730
DI 10.1016/S0140-6736(16)30164-7
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DT1UX
UT WOS:000381268700033
PM 27059886
ER
PT J
AU Verma, A
Verma, SS
Pendergrass, SA
Crawford, DC
Crosslin, DR
Kuivaniemi, H
Bush, WS
Bradford, Y
Kullo, I
Bielinski, SJ
Li, RL
Denny, JC
Peissig, P
Hebbring, S
De Andrade, M
Ritchie, MD
Tromp, G
AF Verma, Anurag
Verma, Shefali S.
Pendergrass, Sarah A.
Crawford, Dana C.
Crosslin, David R.
Kuivaniemi, Helena
Bush, William S.
Bradford, Yuki
Kullo, Iftikhar
Bielinski, Suzette J.
Li, Rongling
Denny, Joshua C.
Peissig, Peggy
Hebbring, Scott
De Andrade, Mariza
Ritchie, Marylyn D.
Tromp, Gerard
TI eMERGE Phenome-Wide Association Study (PheWAS) identifies clinical
associations and pleiotropy for stop-gain variants
SO BMC MEDICAL GENOMICS
LA English
DT Article; Proceedings Paper
CT 5th Translational Bioinformatics Conference (TBC)
CY NOV 07-09, 2015
CL Tokyo, JAPAN
ID ELECTRONIC MEDICAL-RECORDS; GENETIC-VARIANTS; GENOME; SUSCEPTIBILITY;
POLYMORPHISMS; DISEASE; HYPOTHYROIDISM; ANNOTATION; CHALLENGES;
DISPERSION
AB Background: We explored premature stop-gain variants to test the hypothesis that variants, which are likely to have a consequence on protein structure and function, will reveal important insights with respect to the phenotypes associated with them. We performed a phenome-wide association study (PheWAS) exploring the association between a selected list of functional stop-gain genetic variants (variation resulting in truncated proteins or in nonsense-mediated decay) and an extensive group of diagnoses to identify novel associations and uncover potential pleiotropy.
Results: In this study, we selected 25 stop-gain variants: 5 stop-gain variants with previously reported phenotypic associations, and a set of 20 putative stop-gain variants identified using dbSNP. For the PheWAS, we used data from the electronic MEdical Records and GEnomics (eMERGE) Network across 9 sites with a total of 41,057 unrelated patients. We divided all these samples into two datasets by equal proportion of eMERGE site, sex, race, and genotyping platform. We calculated single effect associations between these 25 stop-gain variants and ICD-9 defined case-control diagnoses. We also performed stratified analyses for samples of European and African ancestry. Associations were adjusted for sex, site, genotyping platform and the first three principal components to account for global ancestry. We identified previously known associations, such as variants in LPL associated with hyperglyceridemia indicating that our approach was robust. We also found a total of three significant associations with p < 0.01 in both datasets, with the most significant replicating result being LPL SNP rs328 and ICD-9 code 272. 1 "Disorder of Lipoid metabolism" (p(discovery) = 2.59x10-6, p(replicating) = 2.7x10-4). The other two significant replicated associations identified by this study are: variant rs1137617 in KCNH2 gene associated with ICD-9 code category 244 "Acquired Hypothyroidism" (p(discovery) = 5.31x103, p(replicating) = 1.15x10-3) and variant rs12060879 in DPT gene associated with ICD-9 code category 996 "Complications peculiar to certain specified procedures" (p(discovery) = 8. 65x103, p(replicating) = 4.16x10-3).
Conclusion: In conclusion, this PheWAS revealed novel associations of stop-gained variants with interesting phenotypes (ICD-9 codes) along with pleiotropic effects.
C1 [Verma, Anurag; Verma, Shefali S.; Bradford, Yuki; Ritchie, Marylyn D.] Penn State Univ, Ctr Syst Genom, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.
[Verma, Anurag; Verma, Shefali S.; Pendergrass, Sarah A.; Ritchie, Marylyn D.] Geisinger Hlth Syst, Biomed & Translat Informat, Danville, PA USA.
[Kuivaniemi, Helena; Tromp, Gerard] Univ Stellenbosch, Fac Med & Hlth Sci, Dept Biomed Sci, Div Mol Biol & Human Genet, ZA-7505 Tygerberg, South Africa.
[Crawford, Dana C.; Bush, William S.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Crosslin, David R.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Denny, Joshua C.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Peissig, Peggy; Hebbring, Scott] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA.
[De Andrade, Mariza] Mayo Clin, Rochester, MN USA.
[Li, Rongling] NHGRI, Bethesda, MD 20892 USA.
RP Verma, A; Verma, SS (reprint author), Penn State Univ, Ctr Syst Genom, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.
EM anurag.verma@psu.edu; szs14@psu.edu
OI Kuivaniemi, Helena/0000-0001-5753-8766
FU NCATS NIH HHS [UL1 TR000427]; NHGRI NIH HHS [U01 HG006388, U01 HG004424,
U01 HG004438, U01 HG006375, U01 HG006378, U01 HG006379, U01 HG006380,
U01 HG006382, U01 HG006385, U01 HG006389, U01 HG006828, U01 HG006830,
U01 HG008657, U01 HG008684, U01 HG008701]
NR 52
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD AUG 12
PY 2016
VL 9
SU 1
AR 32
DI 10.1186/s12920-016-0191-8
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA DT2OH
UT WOS:000381319300005
PM 27535653
ER
PT J
AU Goodman, PJ
Tangen, CM
Darke, AK
Arnold, KB
Hartline, J
Yee, M
Anderson, K
Caban-Holt, A
Christen, WG
Cassano, PA
Lance, P
Klein, EA
Crowley, JJ
Minasian, LM
Meyskens, FL
AF Goodman, Phyllis J.
Tangen, Catherine M.
Darke, Amy K.
Arnold, Kathryn B.
Hartline, JoAnn
Yee, Monica
Anderson, Karen
Caban-Holt, Allison
Christen, William G.
Cassano, Patricia A.
Lance, Peter
Klein, Eric A.
Crowley, John J.
Minasian, Lori M.
Meyskens, Frank L.
TI Opportunities and challenges in incorporating ancillary studies into a
cancer prevention randomized clinical trial
SO TRIALS
LA English
DT Article
DE Prostate cancer; Ancillary studies; Randomized controlled trial; Study
implementation
ID VITAMIN-E; ALZHEIMERS-DISEASE; PROSTATE-CANCER; SELENIUM; SELECT;
DEMENTIA; RISK
AB Background: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a randomized, double-blind, placebo-controlled, prostate cancer prevention study funded by the National Cancer Institute and conducted by SWOG (Southwest Oncology Group). A total of 35,533 men were assigned randomly to one of four treatment groups (vitamin E + placebo, selenium + placebo, vitamin E + selenium, placebo + placebo). At the time of the trial's development, NIH had invested substantial resources in evaluating the potential benefits of these antioxidants. To capitalize on the knowledge gained from following a large cohort of healthy, aging males on the effects of selenium and/or vitamin E, ancillary studies with other disease endpoints were solicited.
Methods: Four ancillary studies were added. Each drew from the same population but had independent objectives and an endpoint other than prostate cancer. These studies fell into two categories: those prospectively enrolling and following participants (studies of Alzheimer's disease and respiratory function) and those requiring a retrospective medical record review after a reported event (cataracts/age-related macular degeneration and colorectal screening). An examination of the challenges and opportunities of adding ancillary studies is provided. The impact of the ancillary studies on adherence to SELECT was evaluated using a Cox proportional hazards model.
Results: While the addition of ancillary studies appears to have improved participant adherence to the primary trial, this did not come without added complexity. Activation of the ancillary studies happened after the SELECT randomizations had begun resulting in accrual problems to some of the studies. Study site participation in the ancillary trials varied greatly and depended on the interest of the study site principal investigator. Procedures for each were integrated into the primary trial and all monitoring was done by the SELECT Data and Safety Monitoring Committee. The impact of the early closure of the primary trial was different for each of the ancillary trials.
Conclusions: The ancillary studies allowed study sites to broaden the research opportunities for their participants. Their implementation was efficient because of the established infrastructure of the primary trial. Implementation of these ancillary trials took substantial planning and coordination but enriched the overall primary trial.
C1 [Goodman, Phyllis J.; Tangen, Catherine M.; Darke, Amy K.; Arnold, Kathryn B.] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1100 Fairview Ave N,M3-C102, Seattle, WA 98109 USA.
[Hartline, JoAnn; Yee, Monica; Anderson, Karen; Crowley, John J.] SWOG Stat Ctr, Canc Res & Biostat, Seattle, WA USA.
[Caban-Holt, Allison] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.
[Christen, William G.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA.
[Cassano, Patricia A.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.
[Lance, Peter] Univ Arizona, Arizona Canc Ctr, Phoenix, AZ USA.
[Klein, Eric A.] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA.
[Minasian, Lori M.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
[Meyskens, Frank L.] Univ Calif Irvine, Orange, CA 92668 USA.
RP Goodman, PJ (reprint author), Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1100 Fairview Ave N,M3-C102, Seattle, WA 98109 USA.
EM pgoodman@fredhutch.org
FU Public Health Service - National Cancer Institute, National Institutes
of Health, Department of Health and Human Services [CA37429, UM1
CA182883]; National Center for Complementary and Alternative Medicine
(National Institutes of Health); NIA [R01 AG19241]; NEI [EY014418];
NHLBI [RO1HL071022]; NCI [R01CA124862]
FX This work was supported in part by Public Health Service Cooperative
Agreement grant CA37429 and UM1 CA182883 awarded by the National Cancer
Institute, National Institutes of Health, Department of Health and Human
Services, and in part by the National Center for Complementary and
Alternative Medicine (National Institutes of Health). It was also
supported in part by NIA R01 AG19241 (PREADVISE), NEI EY014418 (SEE),
NHLBI (RO1HL071022) (RAS) and NCI R01CA124862 (ACP). Study agents and
packaging were provided by Perrigo Company (Allegan, MI, USA), Sabinsa
Corporation (Piscataway, NJ, USA), Tishcon Corporation (Westbury, NY,
USA) and DSM Nutritional Products Inc. (Parsipanny, NJ, USA).
NR 12
TC 0
Z9 0
U1 6
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD AUG 12
PY 2016
VL 17
AR 400
DI 10.1186/s13063-016-1524-9
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DT2ZE
UT WOS:000381349500001
PM 27519183
ER
PT J
AU Bucher, S
Konana, O
Liechty, E
Garces, A
Gisore, P
Marete, I
Tenge, C
Shipala, E
Wright, L
Esamai, F
AF Bucher, Sherri
Konana, Olive
Liechty, Edward
Garces, Ana
Gisore, Peter
Marete, Irene
Tenge, Constance
Shipala, Evelyn
Wright, Linda
Esamai, Fabian
TI Self-reported practices among traditional birth attendants surveyed in
western Kenya: a descriptive study
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Traditional birth attendant; Maternal-newborn health; Delivery
practices; Africa; Kenya; Health policy
ID NEWBORN HEALTH REGISTRY; HELPING BABIES BREATHE; PREVENT POSTPARTUM
HEMORRHAGE; RESOURCE-LIMITED SETTINGS; IN-HOME BIRTHS; MATERNAL HEALTH;
GLOBAL-NETWORK; NEONATAL-MORTALITY; INCOME COUNTRIES; CONTROLLED-TRIAL
AB Background: The high rate of home deliveries conducted by unskilled birth attendants in resource-limited settings is an important global health issue because it is believed to be a significant contributing factor to maternal and newborn mortality. Given the large number of deliveries that are managed by unskilled or traditional birth attendants outside of health facilities, and the fact that there is on-going discussion regarding the role of traditional birth attendants in the maternal newborn health (MNH) service continuum, we sought to ascertain the practices of traditional birth attendants in our catchment area. The findings of this descriptive study might help inform conversations regarding the roles that traditional birth attendants can play in maternal-newborn health care.
Methods: A structured questionnaire was used in a survey that included one hundred unskilled birth attendants in western Kenya. Descriptive statistics were employed.
Results: Inappropriate or outdated practices were reported in relation to some obstetric complications and newborn care. Encouraging results were reported with regard to positive relationships that traditional birth attendants have with their local health facilities. Furthermore, high rates of referral to health facilities was reported for many common obstetric emergencies and similar rates for reporting of pregnancy outcomes to village elders and chiefs.
Conclusions: Potentially harmful or outdated practices with regard to maternal and newborn care among traditional birth attendants in western Kenya were revealed by this study. There were high rates of traditional birth attendant referrals of pregnant mothers with obstetric complications to health facilities. Policy makers may consider re-educating and re-defining the roles and responsibilities of traditional birth attendants in maternal and neonatal health care based on the findings of this survey.
C1 [Bucher, Sherri; Konana, Olive; Liechty, Edward] Indiana Univ Sch Med, Sect Neonatal Perinatal Med, Dept Pediat, 699 Riley Hosp Dr,RR208, Indianapolis, IN 46202 USA.
[Garces, Ana] INSALUD, Guatemala City, Guatemala.
[Gisore, Peter; Marete, Irene; Tenge, Constance; Esamai, Fabian] Moi Univ, Sch Med, Dept Paediat & Child Hlth, Eldoret, Kenya.
[Shipala, Evelyn] Moi Teaching & Referral Hosp, Eldoret, Kenya.
[Wright, Linda] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Ctr Res Mothers & Children, Bethesda, MD USA.
RP Bucher, S (reprint author), Indiana Univ Sch Med, Sect Neonatal Perinatal Med, Dept Pediat, 699 Riley Hosp Dr,RR208, Indianapolis, IN 46202 USA.
EM shbucher@iu.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development of the National Institutes of Health [U01 HD058326, U01
HD040657, U01 HD040636]; Bill & Melinda Gates Foundation
FX This study was funded by the Eunice Kennedy Shriver National Institute
of Child Health and Human Development of the National Institutes of
Health under Award Numbers U01 HD058326 (Kenya), U01 HD040657
(Guatemala), and U01 HD040636 (RTI). This study was supported in part by
a grant from the Bill & Melinda Gates Foundation. The investigators were
solely responsible for the study design, data collection, analysis,
interpretation of the data, and writing of the manuscript, without
influence from the funding agencies.
NR 55
TC 0
Z9 0
U1 6
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD AUG 12
PY 2016
VL 16
AR 219
DI 10.1186/s12884-016-1007-8
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DT4UK
UT WOS:000381476400002
PM 27514379
ER
PT J
AU Toombes, GES
Swartz, KJ
AF Toombes, Gilman E. S.
Swartz, Kenton J.
TI Twists and turns in gating ion channels with voltage The EAG potassium
channel may use an alternative voltage-dependent gating mechanism
SO SCIENCE
LA English
DT Editorial Material
ID CRYSTAL-STRUCTURE; DOMAINS
C1 [Toombes, Gilman E. S.; Swartz, Kenton J.] NINDS, Mol Physiol & Biophys Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Swartz, KJ (reprint author), NINDS, Mol Physiol & Biophys Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.
EM kenton.swartz@nih.gov
NR 15
TC 0
Z9 0
U1 5
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 12
PY 2016
VL 353
IS 6300
BP 646
EP 647
DI 10.1126/science.aah4194
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5ZC
UT WOS:000381561200018
PM 27516583
ER
PT J
AU Hoenen, T
Groseth, A
Safronetz, D
Wollenberg, K
Feldmann, H
AF Hoenen, Thomas
Groseth, Allison
Safronetz, David
Wollenberg, Kurt
Feldmann, Heinz
TI Response to Comment on "Mutation rate and genotype variation of Ebola
virus from Mali case sequences"
SO SCIENCE
LA English
DT Editorial Material
ID SIERRA-LEONE; OUTBREAK; TRANSMISSION; MACAQUES; DISEASE; STRAIN
AB Rambaut et al. show that the erratum to our report on Ebola virus Makona evolution not only corrected sample dates modified by others in GenBank but also corrected an additional transcriptional error in our original analysis. We agree with their observation that both factors contributed to our revised evolutionary rate estimate but continue to stand by our revised estimate and conclusions.
C1 [Hoenen, Thomas; Groseth, Allison; Safronetz, David; Feldmann, Heinz] NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT USA.
[Wollenberg, Kurt] NIAID, Bioinformat & Computat Biosci Branch, NIH, Bethesda, MD USA.
RP Feldmann, H (reprint author), NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT USA.
EM feldmannh@niaid.nih.gov
OI Hoenen, Thomas/0000-0002-5829-6305
FU Intramural NIH HHS
NR 13
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 12
PY 2016
VL 353
IS 6300
DI 10.1126/science.aaf4561
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5ZC
UT WOS:000381561200030
PM 27516593
ER
PT J
AU Enose-Akahata, Y
Caruso, B
Haner, B
Charlip, E
Nair, G
Massoud, R
Billioux, BJ
Ohayon, J
Switzer, WM
Jacobson, S
AF Enose-Akahata, Yoshimi
Caruso, Breanna
Haner, Benjamin
Charlip, Emily
Nair, Govind
Massoud, Raya
Billioux, Bridgette J.
Ohayon, Joan
Switzer, William M.
Jacobson, Steven
TI Development of neurologic diseases in a patient with primate T
lymphotropic virus type 1 (PTLV-1)
SO RETROVIROLOGY
LA English
DT Article
DE HTLV; PTLV; STLV; HAM/TSP
ID TROPICAL SPASTIC PARAPARESIS; I-ASSOCIATED MYELOPATHY; HTLV-I;
NONHUMAN-PRIMATES; PERIPHERAL-BLOOD; MOLECULAR EPIDEMIOLOGY;
CEREBROSPINAL-FLUID; HAM/TSP PATIENTS; CENTRAL-AFRICA; COTE-DIVOIRE
AB Background: Virus transmission from various wild and domestic animals contributes to an increased risk of emerging infectious diseases in human populations. HTLV-1 is a human retrovirus associated with acute T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 originated from ancient zoonotic transmission from nonhuman primates, although cases of zoonotic infections continue to occur. Similar to HTLV-1, the simian counterpart, STLV-1, causes chronic infection and leukemia and lymphoma in naturally infected monkeys, and combined are called primate T-lymphotropic viruses (PTLV-1). However, other clinical syndromes typically seen in humans such as a chronic progressive myelopathy have not been observed in nonhuman primates. Little is known about the development of neurologic and inflammatory diseases in human populations infected with STLV-1-like viruses following nonhuman primate exposure.
Results: We performed detailed laboratory analyses on an HTLV-1 seropositive patient with typical HAM/TSP who was born in Liberia and now resides in the United States. Using a novel droplet digital PCR for the detection of the HTLV-1 tax gene, the proviral load in PBMC and cerebrospinal fluid cells was 12.98 and 51.68 %, respectively; however, we observed a distinct difference in fluorescence amplitude of the positive droplet population suggesting possible mutations in proviral DNA. A complete PTLV-1 proviral genome was amplified from the patient's PBMC DNA using an overlapping PCR strategy. Phylogenetic analysis of the envelope and LTR sequences showed the virus was highly related to PTLV-1 from sooty mangabey monkeys (smm) and humans exposed via nonhuman primates in West Africa.
Conclusions: These results demonstrate the patient is infected with a simian variant of PTLV-1, suggesting for the first time that PTLV-1smm infection in humans may be associated with a chronic progressive neurologic disease.
C1 [Enose-Akahata, Yoshimi; Caruso, Breanna; Haner, Benjamin; Charlip, Emily; Massoud, Raya; Billioux, Bridgette J.; Ohayon, Joan; Jacobson, Steven] NINDS, Viral Immunol Sect, Neuroimmunol Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 5C-103, Bethesda, MD 20892 USA.
[Nair, Govind] NINDS, Translat Neuroradiol Unit, Neuroimmunol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA.
RP Jacobson, S (reprint author), NINDS, Viral Immunol Sect, Neuroimmunol Branch, NIH, 9000 Rockville Pike,Bldg 10 Room 5C-103, Bethesda, MD 20892 USA.
EM jacobsons@ninds.nih.gov
FU Intramural Research Program of the NINDS, NIH
FX This research was supported by the Intramural Research Program of the
NINDS, NIH.
NR 45
TC 1
Z9 1
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD AUG 12
PY 2016
VL 13
AR 56
DI 10.1186/s12977-016-0290-9
PG 13
WC Virology
SC Virology
GA DT1RX
UT WOS:000381260900001
PM 27519553
ER
PT J
AU Eveland, M
Brokamp, GA
Lue, CH
Harbison, ST
Leips, J
De Luca, M
AF Eveland, Matthew
Brokamp, Gabrielle A.
Lue, Chia-Hua
Harbison, Susan T.
Leips, Jeff
De Luca, Maria
TI Knockdown expression of Syndecan in the fat body impacts nutrient
metabolism and the organismal response to environmental stresses in
Drosophila melanogaster
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Fat body; Syndecans; Metabolism; Survival; AKT; ERK1/2
ID EXTENDS LIFE-SPAN; ENERGY-METABOLISM; GENE-EXPRESSION; CROSS-TALK;
OBESITY; LOCALIZATION; TOLERANCE; PATHWAYS; BEHAVIOR; WEIGHT
AB The heparan sulfate proteoglycan syndecans are transmembrane proteins involved in multiple physiological processes, including cell-matrix adhesion and inflammation. Recent evidence from model systems and humans suggest that syndecans have a role in energy balance and nutrient metabolism regulation. However, much remains to be learned about the mechanisms through which syndecans influence these phenotypes. Previously, we reported that Drosophila melanogaster Syndecan (Sdc) mutants had reduced metabolic activity compared to controls. Here, we knocked down endogenous Sdc expression in the fat body (the functional equivalent of mammalian adipose tissue and liver) to investigate whether the effects on metabolism originate from this tissue. We found that knocking down Sdc in the fat body leads to flies with higher levels of glycogen and fat and that survive longer during starvation, likely due to their extra energy reserves and an increase in gluconeogenesis. However, compared to control flies, they are also more sensitive to environmental stresses (e.g. bacterial infection and cold) and have reduced metabolic activity under normal feeding conditions. Under the same conditions, fat-body Sdc reduction enhances expression of genes involved in glyceroneogenesis and gluconeogenesis and induces a drastic decrease in phosphorylation levels of AI CT and extracellular signal regulated kinase 1/2 (ERK1/2). Altogether, these findings strongly suggest that Drosophila fat body Sdc is involved in a mechanism that shifts resources to different physiological functions according to nutritional status. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Eveland, Matthew; Brokamp, Gabrielle A.; De Luca, Maria] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Lue, Chia-Hua; Leips, Jeff] Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21228 USA.
[Harbison, Susan T.] NHLBI, Lab Syst Genet, Bldg 10, Bethesda, MD 20892 USA.
[Eveland, Matthew] Columbia Univ, Dept Biochem & Mol Biophys, Med Ctr, New York, NY 10032 USA.
RP De Luca, M (reprint author), Univ Alabama Birmingham, Webb 451-1530 3rd Ave S, Birmingham, AL 35294 USA.
EM mdeluca2@uab.edu
RI Harbison, Susan/P-2577-2016
OI Harbison, Susan/0000-0001-7233-0947
FU National Institutes of Health [R01 DK084219]; UAB Diabetes Research
Center Pilot & Feasibility Program [P30 DK079626]
FX We are grateful to Michael Crowley and David K. Crossman at the UAB
Heflin Center for Genomic Sciences for performing RNA sequencing
analysis. This work was supported by the National Institutes of Health
(R01 DK084219) and UAB Diabetes Research Center Pilot & Feasibility
Program (P30 DK079626) grants to MD.
NR 31
TC 1
Z9 1
U1 5
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 12
PY 2016
VL 477
IS 1
BP 103
EP 108
DI 10.1016/j.bbrc.2016.06.027
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DS0OQ
UT WOS:000380297000016
PM 27289019
ER
PT J
AU Yeo, S
Hodgkinson, CA
Zhou, ZF
Jung, J
Leung, M
Yuan, QP
Goldman, D
AF Yeo, Seungeun
Hodgkinson, Colin A.
Zhou, Zhifeng
Jung, Jeesun
Leung, Ming
Yuan, Qiaoping
Goldman, David
TI The abundance of cis-acting loci leading to differential allele
expression in F1 mice and their relationship to loci harboring genes
affecting complex traits
SO BMC GENOMICS
LA English
DT Article
DE RNA-Seq; Differential allelic expression; cis-acting loci; Quantitative
trait loci
ID INBRED MOUSE STRAINS; IMPRINTED GENES; MONOALLELIC EXPRESSION; VOLUNTARY
CONSUMPTION; RNA-SEQ; MICE; IDENTIFICATION; BRAIN; PHENOTYPES; ETHANOL
AB Background: Genome-wide surveys have detected cis-acting quantitative trait loci altering levels of RNA transcripts (RNA-eQTLs) by associating SNV alleles to transcript levels. However, the sensitivity and specificity of detection of cis- expression quantitative trait loci (eQTLs) by genetic approaches, reliant as it is on measurements of transcript levels in recombinant inbred strains or offspring from arranged crosses, is unknown, as is their relationship to QTL's for complex phenotypes.
Results: We used transcriptome-wide differential allele expression (DAE) to detect cis-eQTLs in forebrain and kidney from reciprocal crosses between three mouse inbred strains, 129S1/SvlmJ, DBA/2J, and CAST/EiJ and C57BL/6 J. Two of these crosses were previously characterized for cis-eQTLs and QTLs for various complex phenotypes by genetic analysis of recombinant inbred (RI) strains. 5.4 %, 1.9 % and 1.5 % of genes assayed in forebrain of B6/129SF1, B6/DBAF1, and B6/CASTF1 mice, respectively, showed differential allelic expression, indicative of cis-acting alleles at these genes. Moreover, the majority of DAE QTLs were observed to be tissue-specific with only a small fraction showing cis-effects in both tissues. Comparing DAE QTLs in F1 mice to cis-eQTLs previously mapped in RI strains we observed that many of the cis-eQTLs were not confirmed by DAE. Additionally several novel DAE-QTLs not identified as cis-eQTLs were identified suggesting that there are differences in sensitivity and specificity for QTL detection between the two methodologies. Strain specific DAE QTLs in B6/DBAF1 mice were located in excess at candidate genes for alcohol use disorders, seizures, and angiogenesis previously implicated by genetic linkage in C57BL/6J x DBA/2JF2 mice or BXD RI strains.
Conclusions: Via a survey for differential allele expression in F1 mice, a substantial proportion of genes were found to have alleles altering expression in cis-acting fashion. Comparing forebrain and kidney, many or most of these alleles were tissue-specific in action. The identification of strain specific DAE QTLs, can assist in assessment of candidate genes located within the large intervals associated with trait QTLs.
C1 [Yeo, Seungeun; Hodgkinson, Colin A.; Zhou, Zhifeng; Leung, Ming; Yuan, Qiaoping; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20852 USA.
[Jung, Jeesun] NIAAA, Lab Epidemiol & Biometry, NIH, Bethesda, MD 20852 USA.
RP Goldman, D (reprint author), NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20852 USA.
EM davidgoldman@mail.nih.gov
FU National Institutes of Health [AA000301]
FX Financial support was provided by the National Institutes of Health
(AA000301)
NR 51
TC 1
Z9 1
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 11
PY 2016
VL 17
AR 620
DI 10.1186/s12864-016-2922-9
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DX0JP
UT WOS:000384047900012
PM 27515598
ER
PT J
AU Wolfe, GI
Kaminski, HJ
Aban, IB
Minisman, G
Kuo, HC
Marx, A
Strobel, P
Mazia, C
Oger, J
Cea, JG
Heckmann, JM
Evoli, A
Nix, W
Ciafaloni, E
Antonini, G
Witoonpanich, R
King, JO
Beydoun, SR
Chalk, CH
Barboi, AC
Amato, AA
Shaibani, AI
Katirji, B
Lecky, BRF
Buckley, C
Vincent, A
Dias-Tosta, E
Yoshikawa, H
Waddington-Cruz, M
Pulley, MT
Rivner, MH
Kostera-Pruszczyk, A
Pascuzzi, RM
Jackson, CE
Ramos, GSG
Verschuuren, JJGM
Massey, JM
Kissel, JT
Werneck, LC
Benatar, M
Barohn, RJ
Tandan, R
Mozaffar, T
Conwit, R
Odenkirchen, J
Sonett, JR
Jaretzki, A
Newsom-Davis, J
Cutter, GR
AF Wolfe, G. I.
Kaminski, H. J.
Aban, I. B.
Minisman, G.
Kuo, H-C
Marx, A.
Strobel, P.
Mazia, C.
Oger, J.
Cea, J. G.
Heckmann, J. M.
Evoli, A.
Nix, W.
Ciafaloni, E.
Antonini, G.
Witoonpanich, R.
King, J. O.
Beydoun, S. R.
Chalk, C. H.
Barboi, A. C.
Amato, A. A.
Shaibani, A. I.
Katirji, B.
Lecky, B. R. F.
Buckley, C.
Vincent, A.
Dias-Tosta, E.
Yoshikawa, H.
Waddington-Cruz, M.
Pulley, M. T.
Rivner, M. H.
Kostera-Pruszczyk, A.
Pascuzzi, R. M.
Jackson, C. E.
Ramos, G. S. Garcia
Verschuuren, J. J. G. M.
Massey, J. M.
Kissel, J. T.
Werneck, L. C.
Benatar, M.
Barohn, R. J.
Tandan, R.
Mozaffar, T.
Conwit, R.
Odenkirchen, J.
Sonett, J. R.
Jaretzki, A., III
Newsom-Davis, J.
Cutter, G. R.
CA MGTX Study Grp
TI Randomized Trial of Thymectomy in Myasthenia Gravis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID EXTENDED THYMECTOMY; THORACOSCOPIC THYMECTOMY; MYCOPHENOLATE-MOFETIL;
FOLLOW-UP; PREDNISONE; STANDARDS; SCORE
AB BACKGROUND
Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial comparing thymectomy plus prednisone with prednisone alone.
METHODS
We compared extended transsternal thymectomy plus alternate-day prednisone with alternate-day prednisone alone. Patients 18 to 65 years of age who had generalized nonthymomatous myasthenia gravis with a disease duration of less than 5 years were included if they had Myasthenia Gravis Foundation of America clinical class II to IV disease (on a scale from I to V, with higher classes indicating more severe disease) and elevated circulating concentrations of acetylcholine-receptor antibody. The primary outcomes were the time-weighted average Quantitative Myasthenia Gravis score (on a scale from 0 to 39, with higher scores indicating more severe disease) over a 3-year period, as assessed by means of blinded rating, and the time-weighted average required dose of prednisone over a 3-year period.
RESULTS
A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P < 0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P < 0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P < 0.001) or were hospitalized for exacerbations (9% vs. 37%, P < 0.001). The number of patients with treatment-associated complications did not differ significantly between groups (P = 0.73), but patients in the thymectomy group had fewer treatment-associated symptoms related to immunosuppressive medications (P < 0.001) and lower distress levels related to symptoms (P = 0.003).
CONCLUSIONS
Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis. (Funded by the National Institute of Neurological Disorders and Stroke and others; MGTX ClinicalTrials.gov number, NCT00294658.)
C1 [Wolfe, G. I.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurol, 100 High St, Buffalo, NY 14203 USA.
[Ciafaloni, E.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14627 USA.
[Sonett, J. R.; Jaretzki, A., III] Columbia Univ, Sect Gen Thorac Surg, Med Ctr, New York, NY USA.
[Kaminski, H. J.] George Washington Univ, Dept Neurol, Sch Med & Hlth Sci, Washington, DC USA.
[Aban, I. B.; Minisman, G.; Kuo, H-C; Cutter, G. R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Marx, A.] Heidelberg Univ, Inst Pathol, Univ Med Ctr Mannheim, Mannheim, Germany.
[Strobel, P.] Univ Gottingen, Inst Pathol, Gottingen, Germany.
[Nix, W.] Johannes Gutenberg Univ Mainz, Dept Neurol, Mainz, Germany.
[Mazia, C.] Univ Buenos Aires, Dept Neurol, Buenos Aires, DF, Argentina.
[Oger, J.] Univ British Columbia, Div Neurol, Vancouver, BC, Canada.
[Chalk, C. H.] McGill Univ, Dept Neurol, Montreal, PQ, Canada.
[Cea, J. G.] Univ Chile, Dept Neurol, Santiago, Chile.
[Heckmann, J. M.] Univ Cape Town, Div Neurol, Dept Med, Cape Town, South Africa.
[Evoli, A.] Catholic Univ, Dept Neurol, Rome, Italy.
[Antonini, G.] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs, Rome, Italy.
[Witoonpanich, R.] Mahidol Univ, Div Neurol, Ramathibodi Hosp, Bangkok, Thailand.
[King, J. O.] Univ Melbourne, Dept Neurol, Melbourne, Vic, Australia.
[Beydoun, S. R.] Univ Southern Calif, Dept Neurol, Los Angeles, CA USA.
[Mozaffar, T.] Univ Calif Irvine, Dept Neurol, Med Ctr, Orange, CA 92668 USA.
[Barboi, A. C.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.
[Amato, A. A.] Harvard Med Sch, Dept Neurol, Boston, MA USA.
[Shaibani, A. I.] Nerve & Muscle Ctr Texas, Houston, TX USA.
[Jackson, C. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.
[Katirji, B.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA.
[Kissel, J. T.] Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA.
[Lecky, B. R. F.] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England.
[Buckley, C.; Vincent, A.; Newsom-Davis, J.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.
[Dias-Tosta, E.] Univ Brasilia, Neurol Unit, Brasilia, DF, Brazil.
[Waddington-Cruz, M.] Fed Univ, Dept Neurol, Rio De Janeiro, Brazil.
[Werneck, L. C.] Univ Fed Parana, Dept Neurol, Curitiba, Parana, Brazil.
[Yoshikawa, H.] Kanazawa Univ, Dept Neurol, Kanazawa, Ishikawa, Japan.
[Pulley, M. T.] Univ Florida, Dept Neurol, Jacksonville, FL USA.
[Benatar, M.] Univ Miami, Dept Neurol, Miami, FL USA.
[Rivner, M. H.] Georgia Regents Univ, Dept Neurol, Augusta, GA USA.
[Kostera-Pruszczyk, A.] Med Univ Warsaw, Dept Neurol, Warsaw, Poland.
[Pascuzzi, R. M.] Indiana Sch Med, Dept Neurol, Indianapolis, IN USA.
[Ramos, G. S. Garcia] Inst Nacl Nutr, Dept Neurol & Psychiat, Tlalpan, Mexico.
[Verschuuren, J. J. G. M.] Leiden Univ Med Ctr, Dept Neurol, Leiden, Netherlands.
[Massey, J. M.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA.
[Barohn, R. J.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
[Tandan, R.] Univ Vermont, Coll Med, Dept Neurol Sci, Burlington, VT USA.
[Conwit, R.; Odenkirchen, J.] NINDS, Div Extramural Res, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Wolfe, GI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurol, 100 High St, Buffalo, NY 14203 USA.
EM gilwolfe@buffalo.edu
OI Heckmann, Jeannine/0000-0002-8999-718X; Venuta,
Federico/0000-0001-9296-877X
FU National Institute of Neurological Disorders and Stroke
FX Funded by the National Institute of Neurological Disorders and Stroke
and others; MGTX ClinicalTrials.gov number, NCT00294658.
NR 32
TC 19
Z9 19
U1 7
U2 7
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 11
PY 2016
VL 375
IS 6
BP 511
EP 522
DI 10.1056/NEJMoa1602489
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU4OT
UT WOS:000382193100004
PM 27509100
ER
PT J
AU Silva, NCS
Vale, VF
Franco, PF
Gontijo, NF
Valenzuela, JG
Pereira, MH
Sant'Anna, MRV
Rodrigues, DS
Lima, WS
Fux, B
Araujo, RN
AF Silva, Naylene C. S.
Vale, Vladimir F.
Franco, Paula F.
Gontijo, Nelder F.
Valenzuela, Jesus G.
Pereira, Marcos H.
Sant'Anna, Mauricio R. V.
Rodrigues, Daniel S.
Lima, Walter S.
Fux, Blima
Araujo, Ricardo N.
TI Saliva of Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) inhibits
classical and alternative complement pathways
SO PARASITES & VECTORS
LA English
DT Article
DE Rhipicephalus (Boophilus) microplus; Saliva; Complement inhibition;
Classical pathway; Alternative pathway
ID MANNOSE-BINDING LECTIN; IXODES-DAMMINI; ANTICOMPLEMENT PROTEINS; C3
CONVERTASE; TICK; CALRETICULIN; SYSTEM; CATTLE; ACTIVATION; MECHANISM
AB Background: Rhipicephalus (Boophilus) microplus is the main ectoparasite affecting livestock worldwide. For a successful parasitism, ticks need to evade several immune responses of their hosts, including the activation of the complement system. In spite of the importance of R. microplus, previous work only identified one salivary molecule that blocks the complement system. The current study describes complement inhibitory activities induced by R. microplus salivary components and mechanisms elicited by putative salivary proteins on both classical and alternative complement pathways.
Results: We found that R. microplus saliva from fully-and partially engorged females was able to inhibit both pathways. Saliva acts strongly at the initial steps of both complement activation pathways. In the classical pathway, the saliva blocked C4 cleavage, and hence, deposition of C4b on the activation surface, suggesting that the inhibition occurs at some point between C1q and C4. In the alternative pathway, saliva acts by binding to initial components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and reducing C3b production and deposition as well as cleavage of factor B. Saliva has no effect on formation or decay of the C6 to C8 components of the membrane attack complex.
Conclusion: The saliva of R. microplus is able to inhibit the early steps of classical and alternative pathways of the complement system. Saliva acts by blocking C4 cleavage and deposition of C4b on the classical pathway activation surface and, in the alternative pathway, saliva bind to initial components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and the production and deposition of additional C3b.
C1 [Silva, Naylene C. S.; Vale, Vladimir F.; Franco, Paula F.; Gontijo, Nelder F.; Pereira, Marcos H.; Sant'Anna, Mauricio R. V.; Lima, Walter S.; Araujo, Ricardo N.] Univ Fed Minas Gerais, Dept Parasitol, Lab Fisiol Insetos Hematofagos, Belo Horizonte, MG, Brazil.
[Vale, Vladimir F.] Fiocruz MS, Inst Oswaldo Cruz, Lab Simulideos & Oncocercose, Rio De Janeiro, RJ, Brazil.
[Gontijo, Nelder F.; Pereira, Marcos H.] Inst Nacl Ciencia & Tecnol Entomol Mol, BR-21941591 Rio De Janeiro, Brazil.
[Valenzuela, Jesus G.] NIAID, Vector Mol Biol Sect, LMVR, NIH, Rockville, MD USA.
[Rodrigues, Daniel S.] Empresa Pesquisa Agr Minas Gerais, Rodovia MG 424 Km 64,Caixa Postal 295, BR-35701970 Prudente De Morais, MG, Brazil.
[Fux, Blima] Univ Fed Espirito Santo, Dept Patol, Vitoria, MG, Brazil.
RP Araujo, RN (reprint author), Univ Fed Minas Gerais, Dept Parasitol, Lab Fisiol Insetos Hematofagos, Belo Horizonte, MG, Brazil.
EM rnaraujo@icb.ufmg.br
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG);
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
INCT- Entomologia Molecular
FX The work was supported by Fundacao de Amparo a Pesquisa do Estado de
Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Cientifico
e Tecnologico (CNPq) and INCT- Entomologia Molecular.
NR 55
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD AUG 11
PY 2016
VL 9
AR 445
DI 10.1186/s13071-016-1726-8
PG 14
WC Parasitology
SC Parasitology
GA DW7NJ
UT WOS:000383837500001
PM 27515662
ER
PT J
AU Horvath, S
Gurven, M
Levine, ME
Trumble, BC
Kaplan, H
Allayee, H
Ritz, BR
Chen, B
Lu, AT
Rickabaugh, TM
Jamieson, BD
Sun, D
Li, SX
Chen, W
Quintana-Murci, L
Fagny, M
Kobor, MS
Tsao, PS
Reiner, AP
Edlefsen, KL
Absher, D
Assimes, TL
AF Horvath, Steve
Gurven, Michael
Levine, Morgan E.
Trumble, Benjamin C.
Kaplan, Hillard
Allayee, Hooman
Ritz, Beate R.
Chen, Brian
Lu, Ake T.
Rickabaugh, Tammy M.
Jamieson, Beth D.
Sun, Dianjianyi
Li, Shengxu
Chen, Wei
Quintana-Murci, Lluis
Fagny, Maud
Kobor, Michael S.
Tsao, Philip S.
Reiner, Alexander P.
Edlefsen, Kerstin L.
Absher, Devin
Assimes, Themistocles L.
TI An epigenetic clock analysis of race/ethnicity, sex, and coronary heart
disease
SO GENOME BIOLOGY
LA English
DT Article
DE DNA methylation; Epigenetic clock; Race; Gender; Aging; Coronary heart
disease; Hispanic paradox; Black/white mortality cross-over
ID DNA METHYLATION AGE; HUMAN BRAIN; ALZHEIMERS-DISEASE; TELOMERE LENGTH;
PARKINSONS-DISEASE; AFRICAN-AMERICANS; UNITED-STATES; HUMAN TISSUES;
ALL-CAUSE; T-CELLS
AB Background: Epigenetic biomarkers of aging (the "epigenetic clock") have the potential to address puzzling findings surrounding mortality rates and incidence of cardio-metabolic disease such as: (1) women consistently exhibiting lower mortality than men despite having higher levels of morbidity; (2) racial/ethnic groups having different mortality rates even after adjusting for socioeconomic differences; (3) the black/white mortality cross-over effect in late adulthood; and (4) Hispanics in the United States having a longer life expectancy than Caucasians despite having a higher burden of traditional cardio-metabolic risk factors.
Results: We analyzed blood, saliva, and brain samples from seven different racial/ethnic groups. We assessed the intrinsic epigenetic age acceleration of blood (independent of blood cell counts) and the extrinsic epigenetic aging rates of blood (dependent on blood cell counts and tracks the age of the immune system). In blood, Hispanics and Tsimane Amerindians have lower intrinsic but higher extrinsic epigenetic aging rates than Caucasians. African-Americans have lower extrinsic epigenetic aging rates than Caucasians and Hispanics but no differences were found for the intrinsic measure. Men have higher epigenetic aging rates than women in blood, saliva, and brain tissue.
Conclusions: Epigenetic aging rates are significantly associated with sex, race/ethnicity, and to a lesser extent with CHD risk factors, but not with incident CHD outcomes. These results may help elucidate lower than expected mortality rates observed in Hispanics, older African-Americans, and women.
C1 [Horvath, Steve; Levine, Morgan E.; Lu, Ake T.] Univ Calif Los Angeles, David Geffen Sch Med, Human Genet, Los Angeles, CA 90095 USA.
[Horvath, Steve] Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA.
[Gurven, Michael; Trumble, Benjamin C.] Univ Calif Santa Barbara, Dept Anthropol, Santa Barbara, CA 93106 USA.
[Kaplan, Hillard] Univ New Mexico, Dept Anthropol, Albuquerque, NM 87131 USA.
[Allayee, Hooman] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Allayee, Hooman] Univ Southern Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA.
[Ritz, Beate R.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.
[Chen, Brian] NIA, Longitudinal Studies Sect, Translat Gerontol Branch, NIH, Baltimore, MD 21224 USA.
[Rickabaugh, Tammy M.; Jamieson, Beth D.] Univ Calif Los Angeles, AIDS Inst, Dept Med, Div Hematol Oncol, Los Angeles, CA USA.
[Sun, Dianjianyi; Li, Shengxu; Chen, Wei] Tulane Univ, Dept Epidemiol, New Orleans, LA 70112 USA.
[Quintana-Murci, Lluis] CNRS, Inst Pasteur, URA3012, URA3012,Unit Human Evolutionary Genet, F-75015 Paris, France.
[Fagny, Maud] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Fagny, Maud] Dana Farber Canc Inst, Dept Computat Biol & Biostat, Boston, MA 02115 USA.
[Kobor, Michael S.] Univ British Columbia, Ctr Mol Med & Therapeut, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada.
[Kobor, Michael S.] Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada.
[Tsao, Philip S.; Assimes, Themistocles L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
[Tsao, Philip S.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Reiner, Alexander P.] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Epidemiol, Seattle, WA 98109 USA.
[Edlefsen, Kerstin L.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
[Absher, Devin] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.
RP Horvath, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Human Genet, Los Angeles, CA 90095 USA.; Horvath, S (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA.
EM shorvath@mednet.ucla.edu
RI Assimes, Themistocles/D-9696-2015;
OI Assimes, Themistocles/0000-0003-2349-0009; Horvath,
Steve/0000-0002-4110-3589; Fagny, Maud/0000-0002-7740-2521
FU NIH/NHLBI [60442456 BAA23]; National Institutes of Health NIH/NIA
[1U34AG051425-01]; National Heart, Lung, and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services
[HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; NIEHS
[RO1ES10544, R21 ES024356]; NIH/NIA [R01AG024119, R56AG02411];
[P30AG10161]; [R01AG17917]; [RF1AG15819]; [R01AG36042]
FX This study was supported by NIH/NHLBI 60442456 BAA23 (Assimes, Absher,
Horvath), National Institutes of Health NIH/NIA 1U34AG051425-01
(Horvath). The WHI program is funded by the National Heart, Lung, and
Blood Institute, National Institutes of Health, U.S. Department of
Health and Human Services through contracts HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C. The PEG data were supported by
NIEHS RO1ES10544 (Ritz) and NIEHS R21 ES024356 (Horvath, Ritz). Gurven
and Trumble were funded by NIH/NIA R01AG024119 and R56AG02411. The
Religious Order study and Rush Memory and Aging Project (brain dataset
6) were funded by P30AG10161, R01AG17917, RF1AG15819, and R01AG36042.
NR 89
TC 4
Z9 4
U1 18
U2 27
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD AUG 11
PY 2016
VL 17
AR 171
DI 10.1186/s13059-016-1030-0
PG 22
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DT8EH
UT WOS:000381721400001
PM 27511193
ER
PT J
AU Boritz, EA
Darko, S
Swaszek, L
Wolf, G
Wells, D
Wu, XL
Henry, AR
Laboune, F
Hu, JF
Ambrozak, D
Hughes, MS
Hoh, R
Casazza, JP
Vostal, A
Bunis, D
Nganou-Makamdop, K
Lee, JS
Migueles, SA
Koup, RA
Connors, M
Moir, S
Schacker, T
Maldarelli, F
Hughes, SH
Deeks, SG
Douek, DC
AF Boritz, Eli A.
Darko, Samuel
Swaszek, Luke
Wolf, Gideon
Wells, David
Wu, Xiaolin
Henry, Amy R.
Laboune, Farida
Hu, Jianfei
Ambrozak, David
Hughes, Marybeth S.
Hoh, Rebecca
Casazza, Joseph P.
Vostal, Alexander
Bunis, Daniel
Nganou-Makamdop, Krystelle
Lee, James S.
Migueles, Stephen A.
Koup, Richard A.
Connors, Mark
Moir, Susan
Schacker, Timothy
Maldarelli, Frank
Hughes, Stephen H.
Deeks, Steven G.
Douek, Daniel C.
TI Multiple Origins of Virus Persistence during Natural Control of HIV
Infection
SO CELL
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; ELITE SUPPRESSORS; LATENT
RESERVOIR; IN-VIVO; REPLICATION; PROLIFERATION; TYPE-1; LYMPHOCYTES;
ACTIVATION
AB Targeted HIV cure strategies require definition of the mechanisms that maintain the virus. Here, we tracked HIV replication and the persistence of infected CD4 T cells in individuals with natural virologic control by sequencing viruses, T cell receptor genes, HIV integration sites, and cellular transcriptomes. Our results revealed three mechanisms of HIV persistence operating within distinct anatomic and functional compartments. In lymph node, we detected viruses with genetic and transcriptional attributes of active replication in both T follicular helper (T-FH) cells and non-T-FH memory cells. In blood, we detected inducible proviruses of archival origin among highly differentiated, clonally expanded cells. Linking the lymph node and blood was a small population of circulating cells harboring inducible proviruses of recent origin. Thus, HIV replication in lymphoid tissue, clonal expansion of infected cells, and recirculation of recently infected cells act together to maintain the virus in HIV controllers despite effective antiviral immunity.
C1 [Boritz, Eli A.; Darko, Samuel; Swaszek, Luke; Wolf, Gideon; Henry, Amy R.; Laboune, Farida; Hu, Jianfei; Bunis, Daniel; Nganou-Makamdop, Krystelle; Lee, James S.; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Wells, David; Wu, Xiaolin] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
[Ambrozak, David; Casazza, Joseph P.; Koup, Richard A.] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Hughes, Marybeth S.] NCI, Thorac & Gastrointestinal Oncol Branch, NIH, Bethesda, MD 20892 USA.
[Hoh, Rebecca; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA.
[Migueles, Stephen A.; Connors, Mark; Moir, Susan] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Maldarelli, Frank; Hughes, Stephen H.] NCI, HIV Dynam & Replicat Program, NIH, Frederick, MD 21702 USA.
[Schacker, Timothy] Univ Minnesota, Dept Med, Program HIV Med, Minneapolis, MN 55455 USA.
RP Douek, DC (reprint author), NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
EM ddouek@mail.nih.gov
OI Jianfei, Hu/0000-0001-8458-6683
FU NIH Intramural Research Program; NIAID Division of AIDS; NIH Office of
AIDS Research; AIDS Vaccine Discovery grant from the Bill and Melinda
Gates Foundation [OPP1032325]; Delaney AIDS Research Enterprise
[AI096109]; NIAID [AI069994]; UCSF/Gladstone Institute of Virology &
Immunology CFAR [P30 AI027763]; NCI
FX We thank the study participants for their involvement in the study. We
thank S. Kosakovsky-Pond for help with phylogenetic analysis and C.
Petrovas for helpful discussions. D.C.D. and E.A.B. are funded by the
NIH Intramural Research Program. D.C.D. is also funded by the NIAID
Division of AIDS and the NIH Office of AIDS Research. Additional funding
came from AIDS Vaccine Discovery grant OPP1032325 from the Bill and
Melinda Gates Foundation (to R.A.K.), the Delaney AIDS Research
Enterprise (AI096109 to S.G.D.), NIAID K24 (AI069994 to S.G.D.), the
UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763 to
S.G.D.), and federal funds from the NCI (to F.M. and S.H.H.).
NR 40
TC 9
Z9 9
U1 11
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 11
PY 2016
VL 166
IS 4
BP 1004
EP 1015
DI 10.1016/j.cell.2016.06.039
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DU5NO
UT WOS:000382258700021
PM 27453467
ER
PT J
AU Zhao, HY
Fernandez, E
Dowd, KA
Speer, SD
Platt, DJ
Gorman, MJ
Govero, J
Nelson, CA
Pierson, TC
Diamond, MS
Fremont, DH
AF Zhao, Haiyan
Fernandez, Estefania
Dowd, Kimberly A.
Speer, Scott D.
Platt, Derek J.
Gorman, Matthew J.
Govero, Jennifer
Nelson, Christopher A.
Pierson, Theodore C.
Diamond, Michael S.
Fremont, Daved H.
TI Structural Basis of Zika Virus-Specific Antibody Protection
SO CELL
LA English
DT Article
ID WEST-NILE-VIRUS; CROSS-REACTIVE ANTIBODIES; TICK-BORNE ENCEPHALITIS;
DENGUE VIRUS; MONOCLONAL-ANTIBODY; ENVELOPE PROTEIN; DOMAIN-III;
FUSION-LOOP; NEUTRALIZATION; INFECTION
AB Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C' loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV.
C1 [Zhao, Haiyan; Gorman, Matthew J.; Nelson, Christopher A.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Fernandez, Estefania; Platt, Derek J.; Govero, Jennifer; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Diamond, Michael S.; Fremont, Daved H.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
[Fremont, Daved H.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.
[Nelson, Christopher A.; Diamond, Michael S.; Fremont, Daved H.] Washington Univ, Sch Med, Ctr Human Immunol & Immunotherapy Programs, St Louis, MO 63110 USA.
[Dowd, Kimberly A.; Speer, Scott D.; Pierson, Theodore C.] NIAID, Viral Pathogenesis Sect, NIH, Bethesda, MD 20892 USA.
RP Diamond, MS (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Diamond, MS (reprint author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Diamond, MS; Fremont, DH (reprint author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Fremont, DH (reprint author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.; Diamond, MS; Fremont, DH (reprint author), Washington Univ, Sch Med, Ctr Human Immunol & Immunotherapy Programs, St Louis, MO 63110 USA.
EM diamond@borcim.wustl.edu; fremont@wustl.edu
FU NIH [R01 AI073755, R01 AI104972, T32 AI007163]; NIAID
[HHSN272201400018C, HHSN272201200026C]; NIH Research Education Program
[R25 HG006687]; NIAID
FX This work was supported by NIH grants R01 AI073755 (to M.S.D. and D.H.F)
and R01 AI104972 (to M.S.D.), and NIAID contracts HHSN272201400018C (to
D.H.F. and M.S.D) and HHSN272201200026C (CSGID; to D.H.F.). E.F. and
D.J.P. were supported by an NIH Pre-doctoral training grant award (T32
AI007163) and the NIH Research Education Program (R25 HG006687),
respectively. K.A.D., S.D.S., and T.C.P. were funded by the intramural
program of NIAID. We acknowledge Jay Nix (MBC 4.2.2 beamline at ALS
Berkeley) for aid in remote data collection. M.S.D. consults for Inbios,
Visterra, Sanofi, and Takeda Pharmaceuticals, is on the Scientific
Advisory Boards of Moderna and OraGene, and has received research grants
from Moderna, Sanofi, and Visterra.
NR 53
TC 22
Z9 24
U1 23
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 11
PY 2016
VL 166
IS 4
BP 1016
EP 1027
DI 10.1016/j.cell.2016.07.020
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DU5NO
UT WOS:000382258700022
PM 27475895
ER
PT J
AU Lee, SM
Wu, CK
Plieskatt, J
McAdams, DH
Miura, K
Ockenhouse, C
King, CR
AF Lee, Shwu-Maan
Wu, Chia-Kuei
Plieskatt, Jordan
McAdams, David H.
Miura, Kazutoyo
Ockenhouse, Chris
King, C. Richter
TI Assessment of Pfs25 expressed from multiple soluble expression platforms
for use as transmission-blocking vaccine candidates
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Pfs25; Plasmodium falciparum; Transmission blocking vaccine;
Baculovirus; Pichia; Glycosylation; Recombinant protein
ID PLASMODIUM-FALCIPARUM; PICHIA-PASTORIS; LINKED GLYCOSYLATION; MALARIA
VACCINES; SEXUAL STAGE; PROTEIN; ANTIBODIES; PEPTIDES; SEQUENCE;
CRYSTALLIZATION
AB Background: Transmission-blocking vaccines (TBVs) have become a focus of strategies to control and eventually eliminate malaria as they target the entry of sexual stage into the Anopheles stephensi mosquito thereby preventing transmission, an essential component of the parasite life cycle. Such vaccines are envisioned as complements to vaccines that target human infection, such as RTS, S as well as drug treatment, and vector control strategies. A number of conserved proteins, including Pfs25, have been identified as promising TBV targets in research or early stage development. Pfs25 is a 25 kDa protein of Plasmodium falciparum expressed on the surface of zygotes and ookinetes. Its complex tertiary structure, including numerous cysteines, has led to difficulties in the expression of a recombinant protein that is homogeneous, with proper conformation, and free of glycosylation, a phenomenon not found in native parasite machinery.
Methods: While the expression and purification of Pfs25 in various systems, has been previously independently reported, here a parallel analysis of Pfs25 is presented to inform on the biochemical features of Pfs25 and their impact on functionality. Three scalable expression systems were used to express, purify, and evaluate Pfs25 both in vitro and in vivo, including the ability of each protein to produce functional antibodies through the standard membrane feeding assay.
Results: Through numerous attempts, soluble, monomeric Pfs25 derived from Escherichia coli was not achieved, while Pichia pastoris presented Pfs25 as an inhomogeneous product with glycosylation. In comparison, baculovirus produced a pure, monomeric protein free of glycosylation. The glycosylation present for Pichia produced Pfs25, showed no notable decrease in the ability to elicit transmission reducing antibodies in functional evaluation, while a reduced and alkylated Pfs25 (derived from plant and used as a control) was found to have significantly decreased transmission reducing activity, emphasizing the importance of ensuring correct disulfide stabilized conformation during vaccine design and production.
Conclusions: In this study, the biochemical features of Pfs25, produced from different expression systems, are described along with their impact on the ability of the protein to elicit functional antibodies. Pfs25 expressed using baculovirus and Pichia showed promise as candidates for vaccine development.
C1 [Lee, Shwu-Maan; Wu, Chia-Kuei; Plieskatt, Jordan; Ockenhouse, Chris; King, C. Richter] PATH Malaria Vaccine Initiat MVI, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
[McAdams, David H.] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
[Miura, Kazutoyo] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
RP Lee, SM (reprint author), PATH Malaria Vaccine Initiat MVI, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
EM smlee@path.org
OI Lee, Shwu-Maan/0000-0003-0819-0569
FU Bill & Melinda Gates Foundation
FX The work presented here was funded in whole or part by a grant from the
Bill & Melinda Gates Foundation. The views expressed herein are solely
those of the authors and do not necessarily reflect the views of the
Foundation.
NR 35
TC 2
Z9 2
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 11
PY 2016
VL 15
AR 405
DI 10.1186/s12936-016-1464-6
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DT3CI
UT WOS:000381357700004
PM 27515826
ER
PT J
AU Bennett, WD
Ivins, S
Alexis, NE
Wu, JH
Bromberg, PA
Brar, SS
Travlos, G
London, SJ
AF Bennett, William D.
Ivins, Sally
Alexis, Neil E.
Wu, Jihong
Bromberg, Philip A.
Brar, Sukhdev S.
Travlos, Gregory
London, Stephanie J.
TI Effect of Obesity on Acute Ozone-Induced Changes in Airway Function,
Reactivity, and Inflammation in Adult Females
SO PLOS ONE
LA English
DT Article
ID BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; HUMAN-LUNG; RESPONSES;
ASTHMA; MICE; METHACHOLINE; DECREMENTS; MECHANISMS; CHALLENGE
AB We previously observed greater ozone-induced lung function decrements in obese than non-obese women. Animal models suggest that obesity enhances ozone-induced airway reactivity and inflammation. In a controlled exposure study, we compared the acute effect of randomized 0.4ppm ozone and air exposures (2 h with intermittent light exercise) in obese (N= 20) (30 < BMI < 40Kg/m2) vs. non- obese (N= 20) (BMI < 25Kg/m2) non- smoking 18-35 year old women. We measured spirometry and bronchial reactivity to inhaled methacholine (3h post-exposure). Inflammation and obesity markers were assessed in the blood (pre, 4h post, and 20h post exposures) and induced-sputum (4h post-exposures and on 24h preexposure training day, no exercise): measures of C reactive protein (CRP) (blood only), leptin (blood only), adiponectin, interleukins IL-6, IL-1b, and IL-8, and tumor necrosis factor alpha, and sputum cell differential cell counts. The pre-topost-exposure decrease in forced vital capacity after ozone (adjusted for the change after air exposure) was significantly greater in the obese group (12.5+/-7.5vs.8.0+/-5.8%,p < 0.05). Post ozone exposure, 6 obese and 6 non-obese subjects responded to methacholine at <= 10mg/ml ( the maximum dose); the degree of hyperresponsiveness was similar for the two groups. Both BMI groups showed similar and significant ozone-induced increases in sputum neutrophils. Plasma IL-6 was increased by exercise (4 hr post air exposure vs. pre) only in the obese but returned to pre-air exposure levels at 20hr post-exposure. Plasma IL-6 was significantly increased at 4hr post ozone exposure in both groups and returned to pre-exposure levels by 20h postexposure. These results confirm our previous findings of greater post-ozone spirometric decrements in obese young women. However, acute ozone-induced airway reactivity to methacholine and airway inflammation did not differ by obesity at the exposure and exercise levels used.
C1 [Bennett, William D.; Ivins, Sally; Alexis, Neil E.; Wu, Jihong; Bromberg, Philip A.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.
[Brar, Sukhdev S.; Travlos, Gregory; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.
RP Bennett, WD (reprint author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.
EM William_Bennett@med.unc.edu
OI London, Stephanie/0000-0003-4911-5290
FU National Institutes of Health, National Institute of Environmental
Health Sciences, USEPA [CR 83578501, CR 83346301]
FX This study was supported by the Intramural Research Program of the
National Institutes of Health, National Institute of Environmental
Health Sciences, USEPA cooperative agreement #CR 83578501, USEPA
cooperative agreement #CR 83346301.
NR 30
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2016
VL 11
IS 8
AR e0160030
DI 10.1371/journal.pone.0160030
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3KY
UT WOS:000381381100023
PM 27513854
ER
PT J
AU La Porta, J
Matus-Nicodemos, R
Valentin-Acevedo, A
Covey, LR
AF La Porta, James
Matus-Nicodemos, Rodrigo
Valentin-Acevedo, Anibal
Covey, Lori R.
TI The RNA-Binding Protein, Polypyrimidine Tract-Binding Protein 1 (PTBP1)
Is a Key Regulator of CD4 T Cell Activation
SO PLOS ONE
LA English
DT Article
ID KINASE MESSENGER-RNA; GENE-EXPRESSION; CYCLIN D1; LIGAND EXPRESSION;
POSTTRANSCRIPTIONAL REGULATION; LYMPHOCYTE DEVELOPMENT;
GLUCOSE-METABOLISM; DEPENDENT MANNER; IN-VIVO; B-CELLS
AB We have previously shown that the RNA binding protein, polypyrimidine tract-binding protein (PTBP1) plays a critical role in regulating the expression of CD40L in activated CD4 T cells. This is achieved mechanistically through message stabilization at late times of activation as well as by altered distribution of CD40L mRNA within distinct cellular compartments. PTBP1 has been implicated in many different processes, however whether PTBP1 plays a broader role in CD4 T cell activation is not known. To examine this question, experiments were designed to introduce shRNA into primary human CD4 T cells to achieve decreased, but not complete ablation of PTBP1 expression. Analyses of shPTB-expressing CD4 T cells revealed multiple processes including cell proliferation, activation-induced cell death and expression of activation markers and cytokines that were regulated in part by PTBP1 expression. Although there was an overall decrease in the steady-state level of several activation genes, only IL-2 and CD40L appeared to be regulated by PTBP1 at the level of RNA decay suggesting that PTBP1 is critical at different regulatory steps of expression that is gene-specific. Importantly, even though the IL-2 protein levels were reduced in cells with lowered PTBP1, the steady-state level of IL-2 mRNA was significantly higher in these cells suggesting a block at the translational level. Evaluation of T cell activation in shPTBexpressing T cells revealed that PTBP1 was linked primarily to the activation of the PLC.1/ ERK1/2 and the NF-.B pathways. Overall, our results reveal the importance of this critical RNA binding protein in multiple steps of T cell activation.
C1 [La Porta, James; Matus-Nicodemos, Rodrigo; Valentin-Acevedo, Anibal; Covey, Lori R.] Rutgers State Univ, Dept Cell Biol & Neurosci, New Brunswick, NJ 08903 USA.
[Matus-Nicodemos, Rodrigo] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD USA.
[Valentin-Acevedo, Anibal] Univ Puerto Rico, Dept Nat Sci, Aguadilla, PR USA.
RP Covey, LR (reprint author), Rutgers State Univ, Dept Cell Biol & Neurosci, New Brunswick, NJ 08903 USA.
EM covey@biology.rutgers.edu
FU National Institutes of Health/National Institute of Allergy and
Infectious Disease [R03 AI107811-01, PO1 AI-57596]
FX This work was funded in part by R03 AI107811-01 and PO1 AI-57596
(project #2) (National Institutes of Health/National Institute of
Allergy and Infectious Disease)(https://www.niaid.nih.gov) to LRC.
NR 76
TC 1
Z9 1
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2016
VL 11
IS 8
AR e0158708
DI 10.1371/journal.pone.0158708
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3KY
UT WOS:000381381100011
PM 27513449
ER
PT J
AU Louis, JM
Baber, JL
Ghirlando, R
Aniana, A
Bax, A
Roche, J
AF Louis, John M.
Baber, James L.
Ghirlando, Rodolfo
Aniana, Annie
Bax, Ad
Roche, Julien
TI Insights into the Conformation of the Membrane Proximal Regions Critical
to the Trimerization of the HIV-1 gp41 Ectodomain Bound to Dodecyl
Phosphocholine Micelles
SO PLOS ONE
LA English
DT Article
ID FUSION-ACTIVE CONFORMATION; ENVELOPE GLYCOPROTEIN; NEUTRALIZING
ANTIBODY; PROTEIN GP41; SEDIMENTATION-VELOCITY; ATOMIC-STRUCTURE;
MEDIATED FUSION; EXTERNAL REGION; VIRAL MEMBRANE; INTERMEDIATE
AB The transitioning of the ectodomain of gp41 from a pre-hairpin to a six-helix bundle conformation is a crucial aspect of virus-cell fusion. To gain insight into the intermediary steps of the fusion process we have studied the pH and dodecyl phosphocholine (DPC) micelle dependent trimer association of gp41 by systematic deletion analysis of an optimized construct termed 17-172 (residues 528 to 683 of Env) that spans the fusion peptide proximal region (FPPR) to the membrane proximal external region (MPER) of gp41, by sedimentation velocity and double electron-electron resonance (DEER) EPR spectroscopy. Trimerization at pH 7 requires the presence of both the FPPR and MPER regions. However, at pH 4, the protein completely dissociates to monomers. DEER measurements reveal a partial fraying of the C-terminal MPER residues in the 17-172 trimer while the other regions, including the FPPR, remain compact. In accordance, truncating nine C-terminal MPER residues (675-683) in the 17-172 construct does not shift the trimer-monomer equilibrium significantly. Thus, in the context of the gp41 ectodomain spanning residues 17-172, trimerization is clearly dependent on FPPR and MPER regions even when the terminal residues of MPER unravel. The antibody Z13e1, which spans both the 2F5 and 4E10 epitopes in MPER, binds to 17-172 with a K-d of 1 +/- 0.12 mu M. Accordingly, individual antibodies 2F5 and 4E10 also recognize the 17-172 trimer/DPC complex. We propose that binding of the C-terminal residues of MPER to the surface of the DPC micelles models a correct positioning of the trimeric transmembrane domain anchored in the viral membrane.
C1 [Louis, John M.; Baber, James L.; Aniana, Annie; Bax, Ad; Roche, Julien] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
[Ghirlando, Rodolfo] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
[Roche, Julien] Iowa State Univ, Roy J Carver Dept Biochem Biophys & Mol Biol, Ames, IA USA.
RP Louis, JM; Roche, J (reprint author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.; Roche, J (reprint author), Iowa State Univ, Roy J Carver Dept Biochem Biophys & Mol Biol, Ames, IA USA.
EM johnl@niddk.nih.gov; julien.roche@nih.gov
FU Intramural Research Program of the NIDDK; National Institutes of Health;
NIH
FX This research was supported by the Intramural Research Program of the
NIDDK, National Institutes of Health and the Intramural AIDS-Targeted
Antiviral Program of the Office of the Director, NIH.
NR 55
TC 0
Z9 0
U1 11
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 11
PY 2016
VL 11
IS 8
AR e0160597
DI 10.1371/journal.pone.0160597
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3KY
UT WOS:000381381100047
PM 27513582
ER
PT J
AU Cobos, AJ
Nelson, CG
Jehn, M
Viboud, C
Chowell, G
AF Cobos, April J.
Nelson, Clinton G.
Jehn, Megan
Viboud, Cecile
Chowell, Gerardo
TI Mortality and transmissibility patterns of the 1957 influenza pandemic
in Maricopa County, Arizona
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE 1957 influenza; H2N2 virus; Asian influenza; Mathematical epidemiology;
Mortality rates; Transmissibility; Reproduction number; Maricopa County;
Arizona
ID EXCESS MORTALITY; REPRODUCTION NUMBER; EPIDEMIC INFLUENZA; WAVE; REGIONS
AB Background: While prior studies have quantified the mortality burden of the 1957 H2N2 influenza pandemic at broad geographic regions in the United States, little is known about the pandemic impact at a local level. Here we focus on analyzing the transmissibility and mortality burden of this pandemic in Arizona, a setting where the dry climate was promoted as reducing respiratory illness transmission yet tuberculosis prevalence was high.
Methods: Using archival death certificates from 1954 to 1961, we quantified the age-specific seasonal patterns, excess-mortality rates, and transmissibility patterns of the 1957 H2N2 pandemic in Maricopa County, Arizona. By applying cyclical Serfling linear regression models to weekly mortality rates, the excess-mortality rates due to respiratory and all-causes were estimated for each age group during the pandemic period. The reproduction number was quantified from weekly data using a simple growth rate method and assumed generation intervals of 3 and 4 days. Local newspaper articles published during 1957-1958 were also examined.
Results: Excess-mortality rates varied between waves, age groups, and causes of death, but overall remained low. From October 1959-June 1960, the most severe wave of the pandemic, the absolute excess-mortality rate based on respiratory deaths per 10,000 population was 16.59 in the elderly (>= 65 years). All other age groups exhibit very low excess-mortality and the typical U-shaped age-pattern was absent. However, the standardized mortality ratio was greatest (4.06) among children and young adolescents (5-14 years) from October 1957-March 1958, based on mortality rates of respiratory deaths. Transmissibility was greatest during the same 1957-1958 period, when the mean reproduction number was estimated at 1.08-1.11, assuming 3- or 4-day generation intervals with exponential or fixed distributions.
Conclusions: Maricopa County exhibited very low mortality impact associated with the 1957 influenza pandemic. Understanding the relatively low excess-mortality rates and transmissibility in Maricopa County during this historic pandemic may help public health officials prepare for and mitigate future outbreaks of influenza.
C1 [Cobos, April J.; Nelson, Clinton G.; Jehn, Megan; Chowell, Gerardo] Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ 85281 USA.
[Cobos, April J.; Nelson, Clinton G.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA.
[Cobos, April J.] Arizona State Univ, Barrett Honors Coll, Tempe, AZ USA.
[Viboud, Cecile; Chowell, Gerardo] NIH, Div Int Epidemiol & Populat Studies, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
[Chowell, Gerardo] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA.
RP Chowell, G (reprint author), Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ 85281 USA.; Chowell, G (reprint author), NIH, Div Int Epidemiol & Populat Studies, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
EM gchowell@gsu.edu
FU Multinational Influenza Seasonal Mortality Study (MISMS)
FX We would like to thank the undergraduate students who assisted in
collecting the raw data. April Cobos would like to thank Melinda Jenner
for advice on mathematical modeling tools. This work was partially
supported by the Multinational Influenza Seasonal Mortality Study
(MISMS), an on-going international collaborative effort to understand
influenza epidemiological and evolutionary patterns, led by the Fogarty
International Center, National Institutes of Health
(http://www.origem.info/misms/index.php).
NR 44
TC 0
Z9 0
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 11
PY 2016
VL 16
AR 405
DI 10.1186/s12879-016-1716-7
PG 14
WC Infectious Diseases
SC Infectious Diseases
GA DT2YP
UT WOS:000381348000006
PM 27516082
ER
PT J
AU Stavreva, DA
Varticovski, L
Levkova, L
George, AA
Davis, L
Pegoraro, G
Blazer, V
Iwanowicz, L
Hager, GL
AF Stavreva, Diana A.
Varticovski, Lyuba
Levkova, Ludmila
George, Anuja A.
Davis, Luke
Pegoraro, Gianluca
Blazer, Vicki
Iwanowicz, Luke
Hager, Gordon L.
TI Novel cell-based assay for detection of thyroid receptor
beta-interacting environmental contaminants
SO TOXICOLOGY
LA English
DT Article
DE EDCs; TR beta; High-throughput cell assay; BPA; TBBPA
ID ENDOCRINE-DISRUPTING CHEMICALS; GREEN FLUORESCENT PROTEIN; REPORTER GENE
ASSAY; IN-VITRO; HORMONE DISRUPTION; REPRODUCTIVE HEALTH; NUCLEAR
RECEPTORS; LIVING CELLS; BISPHENOL-A; TRANSLOCATION
AB Even though the presence of endocrine disrupting chemicals (EDCs) with thyroid hormone (TH)-like activities in the environment is a major health concern, the methods for their efficient detection and monitoring are still limited. Here we describe a novel cell assay, based on the translocation of a green fluorescent protein (GFP) tagged chimeric molecule of glucocorticoid receptor (GR) and the thyroid receptor beta (TR beta) from the cytoplasm to the nucleus in the presence of TR ligands. Unlike the constitutively nuclear TR beta, this GFP-GR-TR beta chimera is cytoplasmic in the absence of hormone while translocating to the nucleus in a time- and concentration-dependent manner upon stimulation with triiodothyronine (T3) and thyroid hormone analogue, TRIAC, while the reverse triiodothyronine (3,3',5'-triiodothyronine, or rT3) was inactive. Moreover, GFP-GR-TR beta chimera does not show any cross reactivity with the GR-activating hormones, thus providing a clean system for the screening of TR beta interacting EDCs. Using this assay, we demonstrated that Bisphenol A (BPA) and 3,3',5,5'-Tetrabromobisphenol (TBBPA) induced GFP-GR-TR beta translocation at micro molar concentrations. We screened over 100 concentrated water samples from different geographic locations in the United States and detected a low, but reproducible contamination in 53% of the samples. This system provides a novel high throughput approach for screening for endocrine disrupting chemicals (EDCs) interacting with TR beta. Published by Elsevier Ireland Ltd.
C1 [Stavreva, Diana A.; Varticovski, Lyuba; George, Anuja A.; Davis, Luke; Pegoraro, Gianluca; Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, NIH, Bldg 41,B602,41 Lib Dr, Bethesda, MD 20892 USA.
[Levkova, Ludmila] Univ Utah, Dept Phys & Astron, Phys & Astron, Salt Lake City, UT USA.
[Blazer, Vicki; Iwanowicz, Luke] US Geol Survey, Leetown Sci Ctr, Natl Fish Hlth Res Lab, 11649 Leetown Rd, Kearneysville, WV 25430 USA.
[George, Anuja A.] Rutgers Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.
[Davis, Luke] Tulane Univ, 6823 St Charles Ave, New Orleans, LA 70118 USA.
RP Stavreva, DA; Hager, GL (reprint author), NCI, Lab Receptor Biol & Gene Express, NIH, Bldg 41,B602,41 Lib Dr, Bethesda, MD 20892 USA.
EM stavrevd@mail.nih.gov; hagerg@exchange.nih.gov
RI George, Anuja/C-5963-2017;
OI George, Anuja/0000-0003-2643-6307; Iwanowicz, Luke/0000-0002-1197-6178
FU Intramural Research Program of the NIH, Center for Cancer Research,
National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; NCI High Throughput Facility
FX This study has been funded in whole or in part with Federal funds from
the Intramural Research Program of the NIH, Center for Cancer Research,
National Cancer Institute, National Institutes of Health, under Contract
No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services. The use of trade, firm, or product names is for
descriptive purposes only and does not imply endorsement by the U.S.
Government. We acknowledge the support of the NCI High Throughput
Facility. We also acknowledge the assistance of Tatiana Karpova, LRBGE
Fluorescence Imaging Facility.
NR 46
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD AUG 10
PY 2016
VL 368
BP 69
EP 79
DI 10.1016/j.tox.2016.08.012
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA EB2NO
UT WOS:000387199300008
PM 27528272
ER
PT J
AU Shenai, S
Ronacher, K
Malherbe, S
Stanley, K
Kriel, M
Winter, J
Peppard, T
Barry, CE
Wang, J
Dodd, LE
Via, LE
Barry, CE
Walzl, G
Alland, D
AF Shenai, Shubhada
Ronacher, Katharina
Malherbe, Stefanus
Stanley, Kim
Kriel, Magdalena
Winter, Jill
Peppard, Thomas
Barry, Charles E.
Wang, Jing
Dodd, Lori E.
Via, Laura E.
Barry, Clifton E., III
Walzl, Gerhard
Alland, David
TI Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of
Culture Conversion and Bacteriological Cure in Pulmonary TB
SO PLOS ONE
LA English
DT Article
ID TUBERCULOSIS TREATMENT; MYCOBACTERIUM-TUBERCULOSIS; RIFAMPIN RESISTANCE;
TREATMENT RESPONSE; CLINICAL-TRIALS; TIME; BIOMARKERS; RELAPSE; LIQUID;
RISK
AB Introduction
Biomarkers are needed to monitor tuberculosis (TB) treatment and predict treatment outcomes. We evaluated the Xpert MTB/RIF (Xpert) assay as a biomarker for TB treatment during and at the end of the 24 weeks therapy.
Methods
Sputum from 108 HIV-negative, culture-positive pulmonary TB patients was analyzed using Xpert at time points before and during anti-TB therapy. Results were compared against culture. Direct Xpert cycle-threshold (Ct), a change in the Ct (delta Ct), or a novel "percent closing of baseline Ct deficit" (percent closing) were evaluated as classifiers of same-day and end-of-treatment culture and therapeutic outcomes.
Results
Xpert was positive in 29/95 (30.5%) of subjects at week 24; and positive one year after treatment in 8/64 (12.5%) successfully-treated patients who remained free of tuberculosis. We identified a relationship between initial bacterial load measured by baseline Xpert Ct and time to culture conversion (hazard ratio 1.06, p = 0.0023), and to the likelihood of being among the 8 treatment failures at week 24 (AUC = 72.8%). Xpert Ct was even more strongly associated with culture conversion on the day the test was performed with AUCs 96.7%, 99.2%, 86.0% and 90.2%, at Day 7, Week 4, 8 and 24, respectively. Compared to baseline Ct measures alone, a combined measure of baseline Ct plus either Delta Ct or percent closing improved the classification of treatment failure status to a 75% sensitivity and 88.9% specificity.
Conclusions
Genome loads measured by Xpert provide a potentially-useful biomarker for classifying same day culture status and predicting response to therapy.
C1 [Shenai, Shubhada; Alland, David] Rutgers Biomed & Hlth Sci, Rutgers New Jersey Med Sch, Div Infect Dis, 185 South Orange Ave, Newark, NJ 07103 USA.
[Ronacher, Katharina; Malherbe, Stefanus; Stanley, Kim; Kriel, Magdalena; Walzl, Gerhard] Univ Stellenbosch, Fac Med & Hlth Sci, DST NRF Ctr Excellence Biomed TB Res, Cape Town, South Africa.
[Ronacher, Katharina; Malherbe, Stefanus; Stanley, Kim; Kriel, Magdalena; Walzl, Gerhard] Univ Stellenbosch, Fac Med & Hlth Sci, MRC Ctr TB Res, Div Mol Biol & Human Genet,Dept Biomed Sci, Cape Town, South Africa.
[Winter, Jill] Catalysis Fdn Hlth, Emeryville, CA 94608 USA.
[Peppard, Thomas] Certara LP, Greater Detroit Area, Detroit, MI 48226 USA.
[Barry, Charles E.] Brown Univ, Providence, RI 02912 USA.
[Wang, Jing] Leidos Biomed Res Inc, Clin Monitoring Res Program, Clin Res Directorate, NCI Campus Frederick, Frederick, MD USA.
[Dodd, Lori E.] NIAID, Biostat Res Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Via, Laura E.; Barry, Clifton E., III] NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Via, Laura E.; Barry, Clifton E., III] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7701 Rondebosch, South Africa.
[Via, Laura E.; Barry, Clifton E., III] Univ Cape Town, Fac Hlth Sci, Dept Clin Lab Sci, ZA-7701 Rondebosch, South Africa.
RP Alland, D (reprint author), Rutgers Biomed & Hlth Sci, Rutgers New Jersey Med Sch, Div Infect Dis, 185 South Orange Ave, Newark, NJ 07103 USA.
EM allandda@njms.rutgers.edu
RI Ronacher, Katharina/N-9603-2016
OI Ronacher, Katharina/0000-0002-6371-1462
FU Catalysis Foundation for Health; Intramural Research Program of the
NIAID, National Institutes of Health; Intramural Research program of the
NIAID, NIH [OPP51919]; National Cancer Institute, National Institutes of
Health [HHSN261200800001E]
FX This work was supported the Catalysis Foundation for Health and by the
Intramural Research Program of the NIAID, National Institutes of Health
(CEB), by the Intramural Research program of the NIAID, NIH (CEB) Grant
No - OPP51919, and with federal funds from the National Cancer
Institute, National Institutes of Health, under Contract No.
HHSN261200800001E. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.; We thank all patients for participation in this study and
the clinic and Laboratory staff from the Stellenbosch University, Cape
Town, South Africa for technical assistance. This work was supported by
the Catalysis Foundation for Health and by the Intramural Research
Program of the NIAID, National Institutes of Health (CEB), by the
Intramural Research program of the NIAID, NIH (CEB) Grant No-OPP51919,
and with federal funds from the National Cancer Institute, National
Institutes of Health, under Contract No. HHSN261200800001E. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 25
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 10
PY 2016
VL 11
IS 8
AR e0160062
DI 10.1371/journal.pone.0160062
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3KR
UT WOS:000381380400020
PM 27508390
ER
PT J
AU Shin, SY
Kim, S
Wilbur, WJ
Kwon, D
AF Shin, Soo-Yong
Kim, Sun
Wilbur, W. John
Kwon, Dongseop
TI BioC viewer: a web-based tool for displaying and merging annotations in
BioC
SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION
LA English
DT Article
AB BioC is an XML-based format designed to provide interoperability for text mining tools and manual curation results. A challenge of BioC as a standard format is to align annotations from multiple systems. Ideally, this should not be a major problem if users follow guidelines given by BioC key files. Nevertheless, the misalignment between text and annotations happens quite often because different systems tend to use different software development environments, e.g. ASCII vs. Unicode. We first implemented the BioC Viewer to assist BioGRID curators as a part of the BioCreative V BioC track (Collaborative Biocurator Assistant Task). For the BioC track, the BioC Viewer helped curate protein-protein interaction and genetic interaction pairs appearing in full-text articles. Here, we describe the BioC Viewer itself as well as improvements made to the BioC Viewer since the BioCreative V Workshop to address the misalignment issue of BioC annotations. While uploading BioC files, a BioC merge process is offered when there are files from the same full-text article. If there is a mismatch between an annotated offset and text, the BioC Viewer adjusts the offset to correctly align with the text. The BioC Viewer has a user-friendly interface, where most operations can be performed within a few mouse clicks. The feedback from BioGRID curators has been positive for the web interface, particularly for its usability and learnability.
C1 [Shin, Soo-Yong] Asan Med Ctr, Dept Biomed Informat, Seoul 05505, South Korea.
[Kim, Sun; Wilbur, W. John] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
[Kwon, Dongseop] Myongji Univ, Deptartment Comp Engn, Yongin 17058, Gyeonggi Do, South Korea.
RP Kwon, D (reprint author), Myongji Univ, Deptartment Comp Engn, Yongin 17058, Gyeonggi Do, South Korea.
EM dongseop@mju.ac.kr
FU Myongji University; Genome Program for Fostering New Post-Genome
Industry of National Research Foundation (NRF) - Korean government
(MSIP) [NRF-2014M3C9A3064706]; Asan Institute for Life Sciences
[2013-7205]; Intramural Research Program of National Institutes of
Health, National Library of Medicine
FX The 2007 Research Fund of Myongji University to D.K.; The Genome Program
for Fostering New Post-Genome Industry of the National Research
Foundation (NRF) funded by the Korean government (MSIP)
(NRF-2014M3C9A3064706) to D.K.; The grant (2013-7205) from the Asan
Institute for Life Sciences to S.Y.S.; Intramural Research Program of
the National Institutes of Health, National Library of Medicine to S.K.
and W.J.W.
NR 15
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1758-0463
J9 DATABASE-OXFORD
JI Database
PD AUG 10
PY 2016
AR baw106
DI 10.1093/database/baw106
PG 7
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA DT5KI
UT WOS:000381521700001
ER
PT J
AU Schmidt, MK
Hogervorst, F
van Hien, R
Cornelissen, S
Broeks, A
Adank, MA
Meijers, H
Waisfisz, Q
Hollestelle, A
Schutte, M
van den Ouweland, A
Hooning, M
Andrulis, IL
Anton-Culver, H
Antonenkova, NN
Antoniou, AC
Arndt, V
Bermisheva, M
Bogdanova, NV
Bolla, MK
Brauch, H
Brenner, H
Bruning, T
Burwinkel, B
Chang-Claude, J
Chenevix-Trench, G
Couch, FJ
Cox, A
Cross, SS
Czene, K
Dunning, AM
Fasching, PA
Figueroa, J
Fletcher, O
Flyger, H
Galle, E
Garcia-Closas, M
Giles, GG
Haeberle, L
Hall, P
Hillemanns, P
Hopper, JL
Jakubowska, A
John, EM
Jones, M
Khusnutdinova, E
Knight, JA
Kosma, VM
Kristensen, V
Lee, A
Lindblom, A
Lubinski, J
Mannermaa, A
Margolin, S
Meindl, A
Milne, RL
Muranen, TA
Newcomb, PA
Offit, K
Park-Simon, TW
Peto, J
Pharoah, PDP
Robson, M
Rudolph, A
Sawyer, EJ
Schmutzler, RK
Seynaeve, C
Soens, J
Southey, MC
Spurdle, AB
Surowy, H
Swerdlow, A
Tollenaar, RAEM
Tomlinson, I
Trentham-Dietz, A
Vachon, C
Wang, Q
Whittemore, AS
Ziogas, A
van der Kolk, L
Nevanlinna, H
Dork, T
Bojesen, S
Easton, DF
AF Schmidt, Marjanka K.
Hogervorst, Frans
van Hien, Richard
Cornelissen, Sten
Broeks, Annegien
Adank, Muriel A.
Meijers, Hanne
Waisfisz, Quinten
Hollestelle, Antoinette
Schutte, Mieke
van den Ouweland, Ans
Hooning, Maartje
Andrulis, Irene L.
Anton-Culver, Hoda
Antonenkova, Natalia N.
Antoniou, Antonis C.
Arndt, Volker
Bermisheva, Marina
Bogdanova, Natalia V.
Bolla, Manjeet K.
Brauch, Hiltrud
Brenner, Hermann
Bruning, Thomas
Burwinkel, Barbara
Chang-Claude, Jenny
Chenevix-Trench, Georgia
Couch, Fergus J.
Cox, Angela
Cross, Simon S.
Czene, Kamila
Dunning, Alison M.
Fasching, Peter A.
Figueroa, Jonine
Fletcher, Olivia
Flyger, Henrik
Galle, Eva
Garcia-Closas, Montserrat
Giles, Graham G.
Haeberle, Lothar
Hall, Per
Hillemanns, Peter
Hopper, John L.
Jakubowska, Anna
John, Esther M.
Jones, Michael
Khusnutdinova, Elza
Knight, Julia A.
Kosma, Veli-Matti
Kristensen, Vessela
Lee, Andrew
Lindblom, Annika
Lubinski, Jan
Mannermaa, Arto
Margolin, Sara
Meindl, Alfons
Milne, Roger L.
Muranen, Taru A.
Newcomb, Polly A.
Offit, Kenneth
Park-Simon, Tjoung-Won
Peto, Julian
Pharoah, Paul D. P.
Robson, Mark
Rudolph, Anja
Sawyer, Elinor J.
Schmutzler, Rita K.
Seynaeve, Caroline
Soens, Julie
Southey, Melissa C.
Spurdle, Amanda B.
Surowy, Harald
Swerdlow, Anthony
Tollenaar, Rob A. E. M.
Tomlinson, Ian
Trentham-Dietz, Amy
Vachon, Celine
Wang, Qin
Whittemore, Alice S.
Ziogas, Argyrios
van der Kolk, Lizet
Nevanlinna, Heli
Doerk, Thilo
Bojesen, Stig
Easton, Douglas F.
TI Age- and Tumor Subtype Specific Breast Cancer Risk Estimates for
CHEK2*1100delC Carriers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID WOMEN; MUTATION; 1100DELC; CHEK2; SUSCEPTIBILITY; PREDICTION; CHK2;
KINASES; SURGERY; BRCA1
AB Purpose
CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC.
Patients and Methods
CHEK71100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (ORs) for CHEK71100delC carriers versus noncarriers were estimated by using logistic regression and adjusted for study (categorical) and age. Main analyses included patients with invasive breast cancer from population- and hospital-based studies.
Results
Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer from population- and hospital-based studies, and in patients with breast cancer from familial- and clinical genetics center based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 x 10(-20)). The OR was higher for estrogen receptor (ER) positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.9 x 10(-21)]) than it was for ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 x 10(-4)). The OR significantly declined with attained age for breast cancer overall (P = .001) and for ER-positive tumors (P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general population of the United Kingdom.
Conclusion
These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up. J Clin Oncol 34:2750-2760. (C) 2016 by American Society of Clinical Oncology
C1 [Schmidt, Marjanka K.; Hogervorst, Frans; van Hien, Richard; Cornelissen, Sten; Broeks, Annegien; van der Kolk, Lizet] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
[Adank, Muriel A.; Meijers, Hanne; Waisfisz, Quinten] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
[Hollestelle, Antoinette; Schutte, Mieke; Hooning, Maartje; Seynaeve, Caroline] Erasmus MC, Inst Canc, Rotterdam, Netherlands.
[van den Ouweland, Ans] Erasmus MC, Rotterdam, Netherlands.
[Tollenaar, Rob A. E. M.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Andrulis, Irene L.; Knight, Julia A.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, New York, NY USA.
[Andrulis, Irene L.; Knight, Julia A.] Univ Toronto, Toronto, ON, Canada.
[Anton-Culver, Hoda; Ziogas, Argyrios] Univ Calif Irvine, Irvine, CA USA.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[John, Esther M.] Canc Prevent Inst Calif, Fremont, CA USA.
[John, Esther M.; Whittemore, Alice S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Antonenkova, Natalia N.] NN Alexandrov Res Inst Oncol & Med Radiol, Minsk, Byelarus.
[Antoniou, Antonis C.; Bolla, Manjeet K.; Dunning, Alison M.; Lee, Andrew; Pharoah, Paul D. P.; Wang, Qin; Easton, Douglas F.] Univ Cambridge, Cambridge CB2 1TN, England.
[Cox, Angela; Cross, Simon S.] Univ Sheffield, Sheffield, S Yorkshire, England.
[Fletcher, Olivia; Jones, Michael; Swerdlow, Anthony] Kings Coll London, Inst Canc Res, London WC2R 2LS, England.
[Peto, Julian] Kings Coll London, London Sch Hyg & Trop Med, London WC2R 2LS, England.
[Sawyer, Elinor J.] Kings Coll London, London WC2R 2LS, England.
[Figueroa, Jonine] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland.
[Tomlinson, Ian] Univ Oxford, Oxford, England.
[Arndt, Volker; Brauch, Hiltrud; Brenner, Hermann; Burwinkel, Barbara; Chang-Claude, Jenny; Rudolph, Anja; Surowy, Harald] German Canc Res Ctr, Heidelberg, Germany.
[Burwinkel, Barbara; Surowy, Harald] Heidelberg Univ, Bergheimer Str 58, D-69115 Heidelberg, Germany.
[Bogdanova, Natalia V.; Hillemanns, Peter; Park-Simon, Tjoung-Won; Doerk, Thilo] Hannover Med Sch, Hannover, Germany.
[Brauch, Hiltrud] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
[Brauch, Hiltrud] Univ Tubingen, Tubingen, Germany.
[Bruning, Thomas] Inst Ruhr Univ Bochum, German Social Accid Insurance, Bochum, Germany.
[Chang-Claude, Jenny] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
Friedrich Alexander Univ Erlangen Nuremberg, Comprehens Canc Ctr Erlangen EMN, Univ Hosp Erlangen, Erlangen, Germany.
[Meindl, Alfons] Tech Univ Munich, Munich, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Cologne, Germany.
[Schmutzler, Rita K.] Univ Cologne, Cologne, Germany.
[Bermisheva, Marina] Russian Acad Sci, Ufa Sci Ctr, Moscow, Russia.
[Khusnutdinova, Elza] Bashkir State Univ, Ufa, Russia.
[Chenevix-Trench, Georgia; Spurdle, Amanda B.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
[Giles, Graham G.; Milne, Roger L.] Canc Council Victoria, Melbourne, Vic, Australia.
[Giles, Graham G.; Hopper, John L.; Milne, Roger L.; Southey, Melissa C.] Univ Melbourne, Melbourne, Vic, Australia.
[Couch, Fergus J.; Vachon, Celine] Mayo Clin, Rochester, MN USA.
[Czene, Kamila; Hall, Per; Lindblom, Annika; Margolin, Sara] Karolinska Inst, Stockholm, Sweden.
[Figueroa, Jonine; Garcia-Closas, Montserrat] NCI, Rockville, MD USA.
[Flyger, Henrik; Bojesen, Stig] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Herlev, Denmark.
[Bojesen, Stig] Univ Copenhagen, Copenhagen, Denmark.
[Galle, Eva] Univ Leuven, Leuven, Belgium.
[Galle, Eva] Vesalius Res Ctr, Leuven, Belgium.
[Soens, Julie] Univ Hosp Gasthuisberg, Leuven, Belgium.
[Jakubowska, Anna; Lubinski, Jan] Pomeranian Med Univ, Szczecin, Poland.
[Kosma, Veli-Matti; Mannermaa, Arto] Univ Eastern Finland, Joensuu, Finland.
[Kosma, Veli-Matti; Mannermaa, Arto] Kuopio Univ Hosp, Kuopio, Finland.
[Muranen, Taru A.; Nevanlinna, Heli] Univ Helsinki, Helsinki, Finland.
[Kristensen, Vessela] Radiumhosp, Oslo Univ Hosp, Oslo, Norway.
[Kristensen, Vessela] Univ Oslo, Oslo, Norway.
[Newcomb, Polly A.; Trentham-Dietz, Amy] Univ Wisconsin, Madison, WI USA.
[Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Offit, Kenneth; Robson, Mark] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
RP Schmidt, MK (reprint author), Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.; Schmidt, MK (reprint author), Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM mk.schmidt@nki.nl
RI Knight, Julia/A-6843-2012; Bruning, Thomas/G-8120-2015; Dork,
Thilo/J-8620-2012; Khusnutdinova, Elza/A-4810-2013; Brenner,
Hermann/B-4627-2017;
OI Bruning, Thomas/0000-0001-9560-5464; Brenner,
Hermann/0000-0002-6129-1572; Muranen, Taru/0000-0002-5895-1808; Dunning,
Alison Margaret/0000-0001-6651-7166
FU Cancer Research UK [10118, 10119, 10124, 11174]; NCI NIH HHS [P50
CA116201, K07 CA092044, R01 CA047147, R01 CA047305, R01 CA058860, R01
CA069664, R01 CA116167, R01 CA176785, R01 CA192393, U01 CA058860, U01
CA116167, UM1 CA164920]
NR 28
TC 4
Z9 4
U1 8
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 10
PY 2016
VL 34
IS 23
BP 2750
EP +
DI 10.1200/JCO.2016.66.5844
PG 25
WC Oncology
SC Oncology
GA DU8MF
UT WOS:000382467000012
PM 27269948
ER
PT J
AU Lopatina, N
McDannald, MA
Styer, CV
Peterson, JF
Sadacca, BF
Cheer, JF
Schoenbaum, G
AF Lopatina, Nina
McDannald, Michael A.
Styer, Clay V.
Peterson, Jacob F.
Sadacca, Brian F.
Cheer, Joseph F.
Schoenbaum, Geoffrey
TI Medial Orbitofrontal Neurons Preferentially Signal Cues Predicting
Changes in Reward during Unblocking
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE orbitofrontal; Pavlovian; rat; single unit
ID VENTROMEDIAL PREFRONTAL CORTEX; DECISION-MAKING; ECONOMIC VALUE;
REINFORCER DEVALUATION; BASOLATERAL AMYGDALA; GOAL VALUES;
REPRESENTATION; BRAIN
AB The orbitofrontal cortex (OFC) has been broadly implicated in the ability to use the current value of expected outcomes to guide behavior. Although value correlates have been prominently reported in lateral OFC, they are more often associated with more medial areas. Further, recent studies in primates have suggested a dissociation in which the lateral OFC is involved in credit assignment and representation of reward identity and more medial areas are critical to representing value. Previously, we used unblocking to test more specifically what information about outcomes is represented by OFC neurons in rats; consistent with the proposed dichotomy between the lateral and medial OFC, we found relatively little linear value coding in the lateral OFC (Lopatina et al., 2015). Here we have repeated this experiment, recording in the medial OFC, to test whether such value signals might be found there. Neurons were recorded in an unblocking task as rats learned about cues that signaled either more, less, or the same amount of reward. We found that medial OFC neurons acquired responses to these cues; however, these responses did not signal different reward values across cues. Surprisingly, we found that cells developed responses to cues predicting a change, particularly a decrease, in reward value. This is consistent with a special role for medial OFC in representing current value to support devaluation/revaluation sensitive changes in behavior.
C1 [Lopatina, Nina; Styer, Clay V.; Peterson, Jacob F.; Sadacca, Brian F.; Schoenbaum, Geoffrey] Natl Inst Drug Abuse, Intramural Res Program, Baltimore, MD 21224 USA.
[McDannald, Michael A.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02467 USA.
[Lopatina, Nina] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA.
[Cheer, Joseph F.; Schoenbaum, Geoffrey] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA.
[Schoenbaum, Geoffrey] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA.
RP Schoenbaum, G (reprint author), Behav Neurophysiol Res Sect, Cellular Neurobiol Res Branch, 251 Bayview Blvd,Suite 200,Bldg BRC,Room 06A705, Baltimore, MD 21224 USA.
EM geoffrey.schoenbaum@nih.gov
OI Sadacca, Brian/0000-0003-1425-6077
FU Intramural Research Program at the National Institute on Drug Abuse
FX This work was supported by the Intramural Research Program at the
National Institute on Drug Abuse. The opinions expressed in this article
are the authors' own and do not reflect the view of the National
Institutes of Health/Department of Health and Human Services.
NR 26
TC 0
Z9 0
U1 5
U2 5
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 10
PY 2016
VL 36
IS 32
BP 8416
EP 8424
DI 10.1523/JNEUROSCI.1101-16.2016
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA DU6GQ
UT WOS:000382312700012
PM 27511013
ER
PT J
AU Tran, TM
Jones, MB
Ongoiba, A
Bijker, EM
Schats, R
Venepally, P
Skinner, J
Doumbo, S
Quinten, E
Visser, LG
Whalen, E
Presnell, S
O'Connell, EM
Kayentao, K
Doumbo, OK
Chaussabel, D
Lorenzi, H
Nutman, TB
Ottenhoff, THM
Haks, MC
Traore, B
Kirkness, EF
Sauerwein, RW
Crompton, PD
AF Tran, Tuan M.
Jones, Marcus B.
Ongoiba, Aissata
Bijker, Else M.
Schats, Remko
Venepally, Pratap
Skinner, Jeff
Doumbo, Safiatou
Quinten, Edwin
Visser, Leo G.
Whalen, Elizabeth
Presnell, Scott
O'Connell, Elise M.
Kayentao, Kassoum
Doumbo, Ogobara K.
Chaussabel, Damien
Lorenzi, Hernan
Nutman, Thomas B.
Ottenhoff, Tom H. M.
Haks, Marielle C.
Traore, Boubacar
Kirkness, Ewen F.
Sauerwein, Robert W.
Crompton, Peter D.
TI Transcriptomic evidence for modulation of host inflammatory responses
during febrile Plasmodium falciparum malaria
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIFFERENTIAL EXPRESSION ANALYSIS; ACQUIRED-IMMUNITY; GENE-EXPRESSION;
PERIPHERAL-BLOOD; PROTECTION; INFECTION; CHILDREN; COHORT
AB Identifying molecular predictors and mechanisms of malaria disease is important for understanding how Plasmodium falciparum malaria is controlled. Transcriptomic studies in humans have so far been limited to retrospective analysis of blood samples from clinical cases. In this prospective, proof-of-principle study, we compared whole-blood RNA-seq profiles at pre- and post-infection time points from Malian adults who were either asymptomatic (n = 5) or febrile (n = 3) during their first seasonal PCR-positive P. falciparum infection with those from malaria-naive Dutch adults after a single controlled human malaria infection (n = 5). Our data show a graded activation of pathways downstream of pro-inflammatory cytokines, with the highest activation in malaria-naive Dutch individuals and significantly reduced activation in malaria-experienced Malians. Newly febrile and asymptomatic infections in Malians were statistically indistinguishable except for genes activated by pro-inflammatory cytokines. The combined data provide a molecular basis for the development of a pyrogenic threshold as individuals acquire immunity to clinical malaria.
C1 [Tran, Tuan M.; Skinner, Jeff; Crompton, Peter D.] NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
[Tran, Tuan M.] Indiana Univ Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN 46202 USA.
[Jones, Marcus B.; Venepally, Pratap; Kirkness, Ewen F.] J Craig Venter Inst, Genom Med Grp, Rockville, MD USA.
[Ongoiba, Aissata; Doumbo, Safiatou; Kayentao, Kassoum; Doumbo, Ogobara K.; Traore, Boubacar] Univ Sci Tech & Technol Bamako, Mali Int Ctr Excellence Res, Bamako, Mali.
[Bijker, Else M.; Sauerwein, Robert W.] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands.
[Schats, Remko; Quinten, Edwin; Visser, Leo G.; Ottenhoff, Tom H. M.; Haks, Marielle C.] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
[Whalen, Elizabeth; Presnell, Scott; Chaussabel, Damien] Benaroya Res Inst, Syst Immunol Div, Seattle, WA USA.
[O'Connell, Elise M.; Nutman, Thomas B.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD USA.
[Chaussabel, Damien] Sidra Med & Res Ctr, Doha, Qatar.
[Lorenzi, Hernan] J Craig Venter Inst, Infect Dis Grp, Bethesda, MD USA.
RP Tran, TM (reprint author), NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.; Tran, TM (reprint author), Indiana Univ Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN 46202 USA.
EM tuantran@iu.edu
RI Crompton, Peter/N-1130-2016;
OI Chaussabel, Damien/0000-0002-6131-7242; Skinner,
Jeff/0000-0001-5697-0442
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services
[HHSN272200900007C]; Division of Intramural Research; Netherlands
Organization for Health Research and Development (ZonMw) [m95110086];
Dioraphte Foundation [12010100]
FX We thank the residents of Kalifabougou, Mali and the Dutch volunteers
for participating in this study. This project was supported with federal
funds from the National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Department of Health and Human Services
under contract number HHSN272200900007C and the Division of Intramural
Research. The CHMI trial was supported by The Netherlands Organization
for Health Research and Development (ZonMw) (projectm95110086) and the
Dioraphte Foundation (project 12010100).
NR 41
TC 0
Z9 0
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 10
PY 2016
VL 6
AR 31291
DI 10.1038/srep31291
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS9VP
UT WOS:000381131900002
PM 27506615
ER
PT J
AU Gill, KP
Hung, SSC
Sharov, A
Lo, CY
Needham, K
Lidgerwood, GE
Jackson, S
Crombie, DE
Nayagam, BA
Cook, AL
Hewitt, AW
Pebay, A
Wong, RCB
AF Gill, Katherine P.
Hung, Sandy S. C.
Sharov, Alexei
Lo, Camden Y.
Needham, Karina
Lidgerwood, Grace E.
Jackson, Stacey
Crombie, Duncan E.
Nayagam, Bryony A.
Cook, Anthony L.
Hewitt, Alex W.
Pebay, Alice
Wong, Raymond C. B.
TI Enriched retinal ganglion cells derived from human embryonic stem cells
SO Scientific Reports
LA English
DT Article
ID HEREDITARY OPTIC NEUROPATHY; HUMAN MULLER GLIA; IN-VITRO;
GENE-EXPRESSION; MACULAR DEGENERATION; NEURAL PROGENITORS; HUMAN
BLASTOCYSTS; BRN-3 FAMILY; HUMAN ESCS; GENERATION
AB Optic neuropathies are characterised by a loss of retinal ganglion cells (RGCs) that lead to vision impairment. Development of cell therapy requires a better understanding of the signals that direct stem cells into RGCs. Human embryonic stem cells (hESCs) represent an unlimited cellular source for generation of human RGCs in vitro. In this study, we present a 45-day protocol that utilises magnetic activated cell sorting to generate enriched population of RGCs via stepwise retinal differentiation using hESCs. We performed an extensive characterization of these stem cell-derived RGCs by examining the gene and protein expressions of a panel of neural/RGC markers. Furthermore, whole transcriptome analysis demonstrated similarity of the hESC-derived RGCs to human adult RGCs. The enriched hESC-RGCs possess long axons, functional electrophysiological profiles and axonal transport of mitochondria, suggestive of maturity. In summary, this RGC differentiation protocol can generate an enriched population of functional RGCs from hESCs, allowing future studies on disease modeling of optic neuropathies and development of cell therapies.
C1 [Gill, Katherine P.; Hung, Sandy S. C.; Lidgerwood, Grace E.; Jackson, Stacey; Crombie, Duncan E.; Hewitt, Alex W.; Pebay, Alice; Wong, Raymond C. B.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
[Gill, Katherine P.; Hung, Sandy S. C.; Lidgerwood, Grace E.; Jackson, Stacey; Crombie, Duncan E.; Hewitt, Alex W.; Pebay, Alice; Wong, Raymond C. B.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic 3010, Australia.
[Sharov, Alexei] NIA, NIH, Bethesda, MD 20892 USA.
[Lo, Camden Y.] Monash Univ, Monash Micro Imaging, Clayton, Vic 3800, Australia.
[Needham, Karina] Univ Melbourne, Dept Otolaryngol, Melbourne, Vic 3010, Australia.
[Needham, Karina] Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia.
[Needham, Karina] Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
[Nayagam, Bryony A.] Univ Melbourne, Dept Audiol & Speech Pathol, Melbourne, Vic 3010, Australia.
[Nayagam, Bryony A.] Univ Melbourne, Dept Ophthalmol, Melbourne, Vic 3010, Australia.
[Cook, Anthony L.] Univ Tasmania, Wicking Dementia Res & Educ Ctr, Hobart, Tas 7001, Australia.
[Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Sch Med, Hobart, Tas 7001, Australia.
RP Pebay, A; Wong, RCB (reprint author), Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.; Pebay, A; Wong, RCB (reprint author), Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic 3010, Australia.
EM apebay@unimelb.edu.au; wongcb@unimelb.edu.au
OI Cook, Anthony/0000-0003-1770-7910
FU National Health and Medical Research Council [1084256]; Bright Focus
Foundation; University of Melbourne; Retina Australia; Ophthalmic
Research Institute of Australia; National Stem Cell Foundation of
Australia; Clifford Craig Medical Research Trust [133]; NHMRC Career
Development Fellowship [1004164]; NHMRC Early Career Fellowship;
NHMRC-CSL Gustav Nossal postgraduate research scholarship; Australian
Research Council Future Fellowship [FT140100047]; Cranbourne Foundation
Fellowship; Australian Postgraduate Award; Garnett Passe and Rodney
Williams Memorial Foundation Research Fellowship; Senior Wagstaff
Fellowship in Otolaryngology; Intramural Research Program of the
National Institute on Aging
FX This work was supported by grants from the National Health and Medical
Research Council (RCBW, 1084256), Bright Focus Foundation (AWH, AP), the
University of Melbourne (RCBW, AP), Retina Australia (RCBW, SSCH, AWH,
AP) the Ophthalmic Research Institute of Australia (RCBW, SSCH, AWH,
AP), National Stem Cell Foundation of Australia (AP), Clifford Craig
Medical Research Trust (#133, ALC, AWH, AP), a NHMRC Career Development
Fellowship (AP, 1004164), a NHMRC Early Career Fellowship (AWH), a
NHMRC-CSL Gustav Nossal postgraduate research scholarship (DEC), an
Australian Research Council Future Fellowship (AP, FT140100047), a
Cranbourne Foundation Fellowship (RCBW), an Australian Postgraduate
Award (KPG), a Garnett Passe and Rodney Williams Memorial Foundation
Research Fellowship (BAN), a Senior Wagstaff Fellowship in
Otolaryngology (KN), Intramural Research Program of the National
Institute on Aging (AS) and operational infrastructure support from the
Victorian Government.
NR 67
TC 0
Z9 0
U1 4
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 10
PY 2016
VL 6
AR 30552
DI 10.1038/srep30552
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS9RL
UT WOS:000381120900001
PM 27506453
ER
PT J
AU Nagmetova, G
Yagofarova, A
Berdimuratova, K
Kurmanbayev, A
AF Nagmetova, Gulden
Yagofarova, Almira
Berdimuratova, Kalysh
Kurmanbayev, Askar
TI Evaluating the performance of electrogenic strains of bacteria in
microbial fuel cells
SO JOURNAL OF BIOTECHNOLOGY
LA English
DT Meeting Abstract
CT European Biotechnology Conference
CY MAY 05-07, 2016
CL LATVIA
C1 [Nagmetova, Gulden] LN Gumilyov Eurasian Natl Univ, Fac Nat Sci, Astana, Kazakhstan.
[Yagofarova, Almira; Berdimuratova, Kalysh; Kurmanbayev, Askar] Natl Biotechnol Ctr, Lab Ecol Biotechnol, Astana, Kazakhstan.
EM solnce30-04@mail.ru
NR 0
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1656
EI 1873-4863
J9 J BIOTECHNOL
JI J. Biotechnol.
PD AUG 10
PY 2016
VL 231
SU S
BP S74
EP S74
DI 10.1016/j.jbiotec.2016.05.270
PG 1
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DR9TZ
UT WOS:000380240300231
ER
PT J
AU Duplat-Bermudez, L
Ruiz-Medrano, R
Landsman, D
Marino-Ramirez, L
Xoconostle-Cazares, B
AF Duplat-Bermudez, L.
Ruiz-Medrano, R.
Landsman, D.
Marino-Ramirez, L.
Xoconostle-Cazares, B.
TI Transcriptomic analysis of Arabidopsis overexpressing flowering locus T
driven by a meristem-specific promoter that induces early flowering
SO GENE
LA English
DT Article
DE Arabidopsis; Flowering locus T; RNA-seq analysis; Plant development;
Transgenic plants
ID LARGE GENE LISTS; RNA-SEQ; FLORAL INDUCTION; FT PROTEIN; PHYSIOLOGICAL
ANALYSIS; EXPRESSION ANALYSIS; PATHWAY INTEGRATOR; LIGHT QUALITY;
SEASONAL CUES; THALIANA
AB Here we analyzed in leaves the effect of FT overexpression driven by meristem-specific KNAT1 gene homolog of Arabidopsis thaliana (Lincoln et al., 1994; Long et al., 1996) on the transcriptomic response during plant development. Our results demonstrated that meristematic FT overexpression generates a phenotype with an early flowering independent of photoperiod when compared with wild type (WT) plants. Arabidopsis FT-overexpressor lines (AtFTOE) did not show significant differences compared with WT lines neither in leaf number nor in rosette diameter up to day 21, when AtFTOE flowered. After this period AtFTOE plants started flower production and no new rosette leaves were produced. Additionally, WT plants continued on vegetative stage up to day 40, producing 12-14 rosette leaves before flowering. Transcriptomic analysis of rosette leaves studied by sequencing lllumina RNA-seq allowed us to determine the differential expression in mature leaf rosette of 3652 genes, being 626 of them up-regulated and 3026 down-regulated. Overexpressed genes related with flowering showed up-regulated transcription factors such as MADS-box that are known as flowering markers in meristem and which overexpression has been related with meristem identity preservation and the transition from vegetative to floral stage. Genes related with sugar transport have shown a higher demand of monosaccharides derived from the hydrolysis of sucrose to glucose and probably fructose, which can also be influenced by reproductive stage of AtFTOE plants. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Duplat-Bermudez, L.; Ruiz-Medrano, R.; Xoconostle-Cazares, B.] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biotecnol & Bioingn, Av IPN 2508 San Pedro Zacatenco, Mexico City 07360, DF, Mexico.
[Landsman, D.; Marino-Ramirez, L.] NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.
RP Xoconostle-Cazares, B (reprint author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Av IPN 2508 San Pedro Zacatenco, Mexico City 07360, DF, Mexico.
EM bxoconos@cinvestav.mx
OI Marino-Ramirez, Leonardo/0000-0002-5716-8512; Landsman,
David/0000-0002-9819-6675
FU CINVESTAV-IPN; CONACyT [156162, 105985, 388937]; SENASICA-SAGARPA grant;
Intramural Research Program of the NIH, NLM, NCBI
FX This work was supported by departmental funds from CINVESTAV-IPN, by
CONACyT grant nos. 156162 to RR-M and 105985 to BX-C, and a
SENASICA-SAGARPA grant to BX-C and RR-M. LD-B was supported by a
doctoral fellowship from CONACyT no 388937. This research was partially
supported by the Intramural Research Program of the NIH, NLM, NCBI. We
are grateful to the members of the laboratory of Plant Biotechnology for
critical comments to this manuscript.
NR 79
TC 0
Z9 0
U1 14
U2 51
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD AUG 10
PY 2016
VL 587
IS 2
BP 120
EP 131
DI 10.1016/j.gene.2016.04.060
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA DO5MQ
UT WOS:000377827600002
PM 27154816
ER
PT J
AU Bhattacharyya, T
Jha, S
Wang, HY
Kastner, DL
Remmers, EF
AF Bhattacharyya, Timothy
Jha, Smita
Wang, Hongying
Kastner, Daniel L.
Remmers, Elaine F.
TI Hypophosphatasia and the risk of atypical femur fractures: a
case-control study
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID BISPHOSPHONATE USE; FEMORAL FRACTURES; DIAPHYSEAL FRACTURES; STRESS;
SHAFT
AB Background: Case reports have linked adult hypophosphatasia as a possible cause of atypical femur fractures (AFF) associated with bisphosphonate use. Adult hypophosphatasia is an asymptomatic genetic condition which results in low alkaline phosphatase and elevated pyridoxal phosphate. We conducted a case- control study to assess the role of hypophosphatasia and atypical femur fracture.
Methods: We recruited 13 control patients who took long term bisphosphonates without complication and 10 patients who sustained atypical femur fractures (mean bisphosphonate use, 9 years both cohorts). Patients underwent clinical exam and measurement of alkaline phosphatase and pyridoxal phosphate (PLP) levels. In addition, DNA was extracted and the ALPL gene was sequenced in both cohorts.
Results: Low alkaline phosphatase levels (< 55 U/L) were seen in 5/10 AFF patients and 5/13 control patients. Two control patients demonstrated low alkaline phosphatase levels and elevated PLP. The alkaline phosphatase (ALPL) gene exons and intron splice sites were sequenced in the atypical femur fracture and control cohorts and no coding mutations were identified in any subjects. Atypical femur fracture patients demonstrated more varus hip alignment (p < 0.048) with no significant difference in mechanical axis.
Conclusions: We found no evidence of hypophosphatasia as a risk factor for atypical femur fractures. Laboratory findings of mildly low alkaline phosphatase activity were equally common in atypical and control cohorts and may be due to long term bisphosphonate use.
C1 [Bhattacharyya, Timothy] NIAMSD, NIH, 10 Ctr Dr,Mail Code 1468, Bethesda, MD 20892 USA.
[Jha, Smita] Natl Inst Child Hlth & Human Dev NICHD, NIH, Bethesda, MD USA.
[Wang, Hongying; Kastner, Daniel L.; Remmers, Elaine F.] NHGRI, Inflammatory Dis Sect, Med Genet Branch, NIH, Bethesda, MD 20892 USA.
RP Bhattacharyya, T (reprint author), NIAMSD, NIH, 10 Ctr Dr,Mail Code 1468, Bethesda, MD 20892 USA.
EM timothy.bhattacharyya@nih.gov
FU Intramural Research Programs of the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, National Human Genome Research
Institute
FX The study was funded by the Intramural Research Programs of the National
Institute of Arthritis and Musculoskeletal and Skin Diseases, National
Human Genome Research Institute. The funding bodies had no role in the
collection of data or review of the manuscript.
NR 18
TC 1
Z9 1
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 9
PY 2016
VL 17
AR 332
DI 10.1186/s12891-016-1191-8
PG 4
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA EM0OC
UT WOS:000395016600001
PM 27507156
ER
PT J
AU Nakamura, Y
Harada, T
Nagaya, T
Sato, K
Okuyama, S
Choyke, PL
Kobayashi, H
AF Nakamura, Yuko
Harada, Toshiko
Nagaya, Tadanobu
Sato, Kazuhide
Okuyama, Shuhei
Choyke, Peter L.
Kobayashi, Hisataka
TI Dynamic fluorescent imaging with the activatable probe, gamma-glutamyl
hydroxymethyl rhodamine green in the detection of peritoneal cancer
metastases: Overcoming the problem of dilution when using a sprayable
optical probe
SO ONCOTARGET
LA English
DT Article
DE kinetic map; green emitting probe; autofluorescence;
gamma-glutamyltranspeptidase; peritoneal cancer metastases
ID KILLER-REPORTER ADENOVIRUS; IN-VIVO; GUIDED SURGERY; MOLECULAR PROBES;
DRUG-RESISTANCE; LIVE MOUSE; TUMORS; TRANSFERASE; EXPRESSION; CELLS
AB Optical fluorescence-guided imaging is increasingly used to guide surgery and endoscopic procedures. Activatable probes are particularly useful because of high target-to-background ratios that increase sensitivity for tiny cancer foci. However, green fluorescent activatable probes suffer from interference from autofluorescence found in biological tissue. The purpose of this study was to determine if dynamic imaging can be used to differentiate specific fluorescence arising from an activated probe in a tumor from autofluorescence in background tissues especially when low concentrations of the dye are applied. Serial fluorescence imaging was performed using various concentrations of gamma-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) which was sprayed on the peritoneal surface with tiny implants of SHIN3-DsRed ovarian cancer tumors. Temporal differences in signal between specific green fluorescence in cancer foci and non-specific autofluorescence in background tissue were measured at 5, 10, 20 and 30 min after application of gGlu-HMRG and were processed into three kinetic maps reflecting maximum fluorescence signal (MF), wash-in rate (WIR), and area under the curve (AUC), respectively. Using concentrations up to 10 mu M of gGlu-HMRG, the fluorescence intensity of cancer foci was significantly higher than that of small intestine but only at 30 min. However, on kinetic maps derived from dynamic fluorescence imaging, the signal of cancer foci was significantly higher than that of small intestine after only 5 min even at concentrations as low as 2.5 mu M of gGlu-HMRG (p < 0.01). At lower concentrations, kinetic maps derived from dynamic fluorescence imaging were superior to unprocessed images for cancer detection.
C1 [Nakamura, Yuko; Harada, Toshiko; Nagaya, Tadanobu; Sato, Kazuhide; Okuyama, Shuhei; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Kobayashi, H (reprint author), NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA.
EM kobayash@mail.nih.gov
FU Intramural Research Program of the National Institute of Health,
National Cancer Institute, Center for Cancer Research
FX This research was supported by the Intramural Research Program of the
National Institute of Health, National Cancer Institute, Center for
Cancer Research.
NR 42
TC 0
Z9 0
U1 4
U2 4
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 9
PY 2016
VL 7
IS 32
BP 51124
EP 51137
DI 10.18632/oncotarget.9898
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY9CC
UT WOS:000385429100030
PM 27286461
ER
PT J
AU Earl, LA
Subramaniam, S
AF Earl, Lesley A.
Subramaniam, Sriram
TI Cryo-EM of viruses and vaccine design
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Editorial Material
ID HUMAN RHINOVIRUS C; CRYOELECTRON MICROSCOPY; ELECTRON CRYOMICROSCOPY;
CHILDREN; PROTEIN
C1 [Earl, Lesley A.; Subramaniam, Sriram] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
RP Subramaniam, S (reprint author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM ss1@nih.gov
NR 20
TC 1
Z9 1
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 9
PY 2016
VL 113
IS 32
BP 8903
EP 8905
DI 10.1073/pnas.1609721113
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT2EJ
UT WOS:000381293300036
PM 27482113
ER
PT J
AU Aksoyoglu, MA
Podgornik, R
Bezrukov, SM
Gurnev, PA
Muthukumar, M
Parsegian, VA
AF Aksoyoglu, M. Alphan
Podgornik, Rudolf
Bezrukov, Sergey M.
Gurnev, Philip A.
Muthukumar, Murugappan
Parsegian, V. Adrian
TI Size-dependent forced PEG partitioning into channels: VDAC, OmpC, and
alpha-hemolysin
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE beta-barrel pores; nanopore-based sensing; polymer confinement; polymer
transport; macromolecular crowding
ID MOLECULE MASS-SPECTROMETRY; ACCESS RESISTANCE; FLEXIBLE POLYMERS;
PROTEIN STABILITY; ION-CHANNEL; PORE; NANOPORE; CONDUCTIVITY;
CONDUCTANCE; MEMBRANE
AB Nonideal polymer mixtures of PEGs of different molecular weights partition differently into nanosize protein channels. Here, we assess the validity of the recently proposed theoretical approach of forced partitioning for three structurally different beta-barrel channels: voltage-dependent anion channel from outer mitochondrial membrane VDAC, bacterial porin OmpC (outer membrane protein C), and bacterial channel-forming toxin alpha-hemolysin. Our interpretation is based on the idea that relatively less-penetrating polymers push the more easily penetrating ones into nanosize channels in excess of their bath concentration. Comparison of the theory with experiments is excellent for VDAC. Polymer partitioning data for the other two channels are consistent with theory if additional assumptions regarding the energy penalty of pore penetration are included. The obtained results demonstrate that the general concept of "polymers pushing polymers" is helpful in understanding and quantification of concrete examples of size-dependent forced partitioning of polymers into protein nanopores.
C1 [Aksoyoglu, M. Alphan; Podgornik, Rudolf; Gurnev, Philip A.; Parsegian, V. Adrian] Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA.
[Podgornik, Rudolf] Univ Ljubljana, Dept Phys, Fac Math & Phys, Ljubljana 1000, Slovenia.
[Podgornik, Rudolf] J Stefan Inst, Dept Theoret Phys, Ljubljana 1000, Slovenia.
[Bezrukov, Sergey M.; Gurnev, Philip A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Mol Transport, NIH, Bethesda, MD 20892 USA.
[Muthukumar, Murugappan] Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA.
RP Podgornik, R (reprint author), Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA.; Podgornik, R (reprint author), Univ Ljubljana, Dept Phys, Fac Math & Phys, Ljubljana 1000, Slovenia.; Podgornik, R (reprint author), J Stefan Inst, Dept Theoret Phys, Ljubljana 1000, Slovenia.; Bezrukov, SM (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Mol Transport, NIH, Bethesda, MD 20892 USA.
EM rudolf.podgornik@ijs.si; bezrukos@mail.nih.gov
FU US Department of Energy, Office of Basic Energy Sciences, Division of
Materials Sciences and Engineering Award [DE-SC0008176]; Intramural
Research Program of the NIH, Eunice Kennedy Shriver National Institute
of Child Health and Human Development; National Science Foundation EAGER
Award [1249199]; National Science Foundation [DMR-1504265]; Air Force
Office of Scientific Research Grant [FA9550-14-1-0164]; NIH
[R01HG002776-11]
FX This work was supported by US Department of Energy, Office of Basic
Energy Sciences, Division of Materials Sciences and Engineering Award
DE-SC0008176 (to M.A.A., V.A.P., and R.P.); the Intramural Research
Program of the NIH, Eunice Kennedy Shriver National Institute of Child
Health and Human Development (S.M.B. and P.A.G.); National Science
Foundation EAGER Award 1249199 (to P.A.G.); and National Science
Foundation Grant DMR-1504265, Air Force Office of Scientific Research
Grant FA9550-14-1-0164, and NIH Grant R01HG002776-11 (all to M.M.).
NR 40
TC 2
Z9 2
U1 6
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 9
PY 2016
VL 113
IS 32
BP 9003
EP 9008
DI 10.1073/pnas.1602716113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT2EJ
UT WOS:000381293300053
PM 27466408
ER
PT J
AU Won, S
Incontro, S
Nicoll, RA
Roche, KW
AF Won, Sehoon
Incontro, Salvatore
Nicoll, Roger A.
Roche, Katherine W.
TI PSD-95 stabilizes NMDA receptors by inducing the degradation of STEP61
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE PSD-95; NMDA receptor; STEP; ubiquitination
ID PROTEIN-TYROSINE-PHOSPHATASE; D-ASPARTATE RECEPTOR; LONG-TERM
POTENTIATION; DISEASE MOUSE MODEL; ALZHEIMERS-DISEASE; MOLECULAR
CHARACTERIZATION; GLUTAMATE RECEPTORS; SYNAPTIC PLASTICITY; C-TERMINUS;
SUBUNIT
AB Phosphorylation regulates surface and synaptic expression of NMDA receptors (NMDARs). Both the tyrosine kinase Fyn and the tyrosine phosphatase striatal-enriched protein tyrosine phosphatase (STEP) are known to target the NMDA receptor subunit GluN2B on tyrosine 1472, which is a critical residue that mediates NMDAR endocytosis. STEP reduces the surface expression of NMDARs by promoting dephosphorylation of GluN2B Y1472, whereas the synaptic scaffolding protein postsynaptic density protein 95 (PSD-95) stabilizes the surface expression of NMDARs. However, nothing is known about a potential functional interaction between STEP and PSD-95. We now report that STEP61 binds to PSD-95 but not to other PSD-95 family members. We find that PSD-95 expression destabilizes STEP61 via ubiquitination and degradation by the proteasome. Using subcellular fractionation, we detect low amounts of STEP61 in the PSD fraction. However, STEP61 expression in the PSD is increased upon knockdown of PSD-95 or in vivo as detected in PSD-95-KO mice, demonstrating that PSD-95 excludes STEP61 from the PSD. Importantly, only extrasynaptic NMDAR expression and currents were increased upon STEP knockdown, as is consistent with low STEP61 localization in the PSD. Our findings support a dual role for PSD-95 in stabilizing synaptic NMDARs by binding directly to GluN2B but also by promoting synaptic exclusion and degradation of the negative regulator STEP61.
C1 [Won, Sehoon; Roche, Katherine W.] NINDS, Receptor Biol Sect, NIH, Bethesda, MD 20892 USA.
[Incontro, Salvatore; Nicoll, Roger A.] Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94158 USA.
[Nicoll, Roger A.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.
RP Roche, KW (reprint author), NINDS, Receptor Biol Sect, NIH, Bethesda, MD 20892 USA.; Nicoll, RA (reprint author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94158 USA.; Nicoll, RA (reprint author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.
EM rochek@ninds.nih.gov; nicoll@cmp.ucsf.edu
OI Roche, Katherine/0000-0001-7282-6539
FU NINDS Intramural Research Program; National Institute of Mental Health
Grant [MH-38256]
FX We thank John D. Badger II for technical assistance and the National
Institute of Neurological Disorders and Stroke (NINDS) imaging facility
for their assistance. This research was supported by the NINDS
Intramural Research Program (S.W. and K.W.R.) and by National Institute
of Mental Health Grant MH-38256 (S.I. and R.A.N.).
NR 53
TC 1
Z9 1
U1 5
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 9
PY 2016
VL 113
IS 32
BP E4736
EP E4744
DI 10.1073/pnas.1609702113
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT2EJ
UT WOS:000381293300022
PM 27457929
ER
PT J
AU Maurer, CW
LaFaver, K
Ameli, R
Epstein, SA
Hallett, M
Horovitz, SG
AF Maurer, Carine W.
LaFaver, Kathrin
Ameli, Rezvan
Epstein, Steven A.
Hallett, Mark
Horovitz, Silvina G.
TI Impaired self-agency in functional movement disorders A resting-state
fMRI study
SO NEUROLOGY
LA English
DT Article
ID CONVERSION DISORDER; CONNECTIVITY; EXPERIENCE; SENSE; FLUCTUATIONS;
DEPRESSION; NEUROLOGY; STRATEGY; CORTEX; TREMOR
AB Objective: To investigate the neural mechanisms underlying impaired self-agency in patients with functional movement disorders using resting-state functional MRI (fMRI).
Methods: We obtained resting-state fMRI on 35 patients with clinically definite functional movement disorders and 35 age-and sex-matched healthy controls. Between-group differences in functional connectivity from the right temporo-parietal junction (TPJ), a region previously demonstrated to play a critical role in self-agency by comparing internal predictions of movement with actual external events, were assessed using t tests. All participants were screened for psychiatric diagnoses using a structured clinical interview and completed the Beck Depression Inventory and Childhood Trauma Questionnaire.
Results: Compared to the healthy controls, patients with functional movement disorders showed decreased functional connectivity between the right TPJ and the right sensorimotor cortex, cerebellar vermis, bilateral supplementary motor area, and right insula. These findings were independent of depression, anxiety, and childhood trauma scores included in our assessment as covariates.
Conclusions: The decreased functional connectivity between the right TPJ and bilateral sensorimotor regions observed in patients with functional movement disorders supports a model whereby impaired motor feed-forward together with altered sensory feedback from sensorimotor regions and areas of sensorimotor integration to the right TPJ contributes to patients' impaired sense of self-agency.
C1 [Maurer, Carine W.; LaFaver, Kathrin; Hallett, Mark; Horovitz, Silvina G.] Natl Inst Neurol Disorders & Stroke, Human Motor Control Sect, Med Neurol Branch, Bethesda, MD 20824 USA.
[Ameli, Rezvan] NIMH, Expt Therapeut & Pathophysiol Branch, NIH, Bethesda, MD 20892 USA.
[LaFaver, Kathrin] Univ Louisville, Dept Neurol, Louisville, KY 40292 USA.
[Epstein, Steven A.] Georgetown Univ, Dept Psychiat, Washington, DC USA.
RP Maurer, CW (reprint author), Natl Inst Neurol Disorders & Stroke, Human Motor Control Sect, Med Neurol Branch, Bethesda, MD 20824 USA.
EM carine.maurer@nih.gov
FU National Institute of Neurological Disorders and Stroke Intramural
Research Program
FX Supported by the National Institute of Neurological Disorders and Stroke
Intramural Research Program.
NR 35
TC 2
Z9 2
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 9
PY 2016
VL 87
IS 6
BP 564
EP 570
DI 10.1212/WNL.0000000000002940
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6LT
UT WOS:000382327000009
PM 27385746
ER
PT J
AU Chen, KY
Cypess, AM
Laughlin, MR
Haft, CR
Hu, HH
Bredella, MA
Enerback, S
Kinahan, PE
Lichtenbelt, WV
Lin, FI
Sunderland, JJ
Virtanen, KA
Wahl, RL
AF Chen, Kong Y.
Cypess, Aaron M.
Laughlin, Maren R.
Haft, Carol R.
Hu, Houchun Harry
Bredella, Miriam A.
Enerback, Sven
Kinahan, Paul E.
Lichtenbelt, Wouter van Marken
Lin, Frank I.
Sunderland, John J.
Virtanen, Kirsi A.
Wahl, Richard L.
TI Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0):
Recommendations for Standardized FDG-PET/CT Experiments in Humans
SO CELL METABOLISM
LA English
DT Review
ID POSITRON-EMISSION-TOMOGRAPHY; TYPE-2 DIABETES-MELLITUS; ADULT HUMANS;
F-18-FDG PET/CT; ENERGY-EXPENDITURE; OXIDATIVE-METABOLISM; INSULIN
SENSITIVITY; COMPUTED-TOMOGRAPHY; TISSUE ACTIVITY; COLD-EXPOSURE
AB Human brown adipose tissue (BAT) presence, metabolic activity, and estimated mass are typically measured by imaging [18F]fluorodeoxyglucose (FDG) uptake in response to cold exposure in regions of the body expected to contain BAT, using positron emission tomography combined with X-ray computed tomography (FDG-PET/CT). Efforts to describe the epidemiology and biology of human BAT are hampered by diverse experimental practices, making it difficult to directly compare results among laboratories. An expert panel was assembled by the National Institute of Diabetes and Digestive and Kidney Diseases on November 4, 2014 to discuss minimal requirements for conducting FDG-PET/CT experiments of human BAT, data analysis, and publication of results. This resulted in Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0). Since there are no fully validated best practices at this time, panel recommendations are meant to enhance comparability across experiments, but not to constrain experimental design or the questions that can be asked.
C1 [Chen, Kong Y.; Cypess, Aaron M.; Laughlin, Maren R.; Haft, Carol R.] NIDDK, NIH, Bethesda, MD 20892 USA.
[Hu, Houchun Harry] Phoenix Childrens Hosp, Phoenix, AZ 85016 USA.
[Bredella, Miriam A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bredella, Miriam A.] Harvard Med Sch, Boston, MA 02114 USA.
[Enerback, Sven] Univ Gothenburg, S-40530 Gothenburg, Sweden.
[Kinahan, Paul E.] Univ Washington, Seattle, WA 98105 USA.
[Lichtenbelt, Wouter van Marken] Maastricht Univ, NL-6211 LK Maastricht, Netherlands.
[Lin, Frank I.] NCI, NIH, Bethesda, MD 20892 USA.
[Sunderland, John J.] Univ Iowa, Iowa City, IA 52242 USA.
[Virtanen, Kirsi A.] Turku Univ Hosp, Turku 20500, Finland.
[Virtanen, Kirsi A.] Univ Turku, SF-20500 Turku, Finland.
[Wahl, Richard L.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA.
RP Chen, KY; Cypess, AM; Laughlin, MR (reprint author), NIDDK, NIH, Bethesda, MD 20892 USA.
EM kong.chen@nih.gov; aaron.cypess@nih.gov; maren.laughlin@nih.gov
OI Chen, Kong/0000-0002-0306-1904
FU Intramural Research Program of the NIH; National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK); National Cancer Institute
(NCI)
FX This research was supported in part by the Intramural Research Program
of the NIH, The National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), and the National Cancer Institute (NCI).
NR 74
TC 4
Z9 4
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD AUG 9
PY 2016
VL 24
IS 2
BP 210
EP 222
DI 10.1016/j.cmet.2016.07.014
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA DT3PH
UT WOS:000381392800010
PM 27508870
ER
PT J
AU Cox, PJ
Kirk, T
Ashmore, T
Willerton, K
Evans, R
Smith, A
Murray, AJ
Stubbs, B
West, J
McLure, SW
King, MT
Dodd, MS
Holloway, C
Neubauer, S
Drawer, S
Veech, RL
Griffin, JL
Clarke, K
AF Cox, Pete J.
Kirk, Tom
Ashmore, Tom
Willerton, Kristof
Evans, Rhys
Smith, Alan
Murray, Andrew J.
Stubbs, Brianna
West, James
McLure, Stewart W.
King, M. Todd
Dodd, Michael S.
Holloway, Cameron
Neubauer, Stefan
Drawer, Scott
Veech, Richard L.
Griffin, Julian L.
Clarke, Kieran
TI Nutritional Ketosis Alters Fuel Preference and Thereby Endurance
Performance in Athletes
SO CELL METABOLISM
LA English
DT Article
ID HUMAN METABOLIC RESPONSE; HUMAN SKELETAL-MUSCLE; FATTY-ACID CYCLE;
KETONE-BODIES; PROLONGED EXERCISE; CALORIC RESTRICTION;
INSULIN-RESISTANCE; OXIDATION RATES; KETOGENIC DIET; NICOTINIC-ACID
AB Ketosis, the metabolic response to energy crisis, is a mechanism to sustain life by altering oxidative fuel selection. Often overlooked for its metabolic potential, ketosis is poorly understood outside of starvation or diabetic crisis. Thus, we studied the biochemical advantages of ketosis in humans using a ketone ester-based form of nutrition without the unwanted milieu of endogenous ketone body production by caloric or carbohydrate restriction. In five separate studies of 39 high-performance athletes, we show how this unique metabolic state improves physical endurance by altering fuel competition for oxidative respiration. Ketosis decreased muscle glycolysis and plasma lactate concentrations, while providing an alternative substrate for oxidative phosphorylation. Ketosis increased intramuscular triacylglycerol oxidation during exercise, even in the presence of normal muscle glycogen, co-ingested carbohydrate and elevated insulin. These findings may hold clues to greater human potential and a better understanding of fuel metabolism in health and disease.
C1 [Cox, Pete J.; Kirk, Tom; Willerton, Kristof; Evans, Rhys; Stubbs, Brianna; McLure, Stewart W.; Dodd, Michael S.; Holloway, Cameron; Clarke, Kieran] Univ Oxford, Dept Physiol Anat & Genet, S Parks Rd, Oxford OX1 3PT, England.
[Cox, Pete J.; Holloway, Cameron; Neubauer, Stefan] Univ Oxford, Dept Cardiovasc Med, Oxford OX3 9DU, England.
[Ashmore, Tom; West, James; Griffin, Julian L.] Univ Cambridge, Dept Biochem, Oxford CB1 9NL, England.
[Ashmore, Tom; West, James; Griffin, Julian L.] Univ Cambridge, Cambridge Syst Biol Ctr, Oxford CB1 9NL, England.
[Ashmore, Tom; West, James; Griffin, Julian L.] MRC Human Nutr Res, Oxford CB1 9NL, England.
[Smith, Alan; Drawer, Scott] UK Sport, 40 Bernard St, London WC1N 1ST, England.
[Murray, Andrew J.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.
[King, M. Todd; Veech, Richard L.] NIAAA, Lab Metab Control, NIH, Rockville, MD 20852 USA.
RP Cox, PJ (reprint author), Univ Oxford, Dept Physiol Anat & Genet, S Parks Rd, Oxford OX1 3PT, England.; Cox, PJ (reprint author), Univ Oxford, Dept Cardiovasc Med, Oxford OX3 9DU, England.
EM petejcox456@gmail.com
FU Defence Advanced Research Projects Agency (DARPA); UK Sport
FX The authors thank Dr. R. Stillion, Dr. O. Faull, E. Carter, Dr. N
Boehlke, and Y Green for their excellent assistance with these studies.
The authors thank the Defence Advanced Research Projects Agency (DARPA)
and UK Sport for funding this work.
NR 47
TC 8
Z9 8
U1 41
U2 51
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD AUG 9
PY 2016
VL 24
IS 2
BP 256
EP 268
DI 10.1016/j.cmet.2016.07.010
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA DT3PH
UT WOS:000381392800014
PM 27475046
ER
PT J
AU Moon, HY
Becke, A
Berron, D
Becker, B
Sah, N
Benoni, G
Janke, E
Lubejko, ST
Greig, NH
Mattison, JA
Duzel, E
van Praag, H
AF Moon, Hyo Youl
Becke, Andreas
Berron, David
Becker, Benjamin
Sah, Nirnath
Benoni, Galit
Janke, Emma
Lubejko, Susan T.
Greig, Nigel H.
Mattison, Julie A.
Duzel, Emrah
van Praag, Henriette
TI Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory
Function
SO CELL METABOLISM
LA English
DT Article
ID HIPPOCAMPAL NEUROGENESIS; PHYSICAL-EXERCISE; ALZHEIMER-DISEASE;
SKELETAL-MUSCLE; IMPROVE MEMORY; ANNEXIN A2; BRAIN; MICE; NEURONS; CELLS
AB Peripheral processes that mediate beneficial effects of exercise on the brain remain sparsely explored. Here, we show that a muscle secretory factor, cathepsin B (CTSB) protein, is important for the cognitive and neurogenic benefits of running. Proteomic analysis revealed elevated levels of CTSB in conditioned medium derived from skeletal muscle cell cultures treated with AMP-kinase agonist AICAR. Consistently, running increased CTSB levels in mouse gastrocnemius muscle and plasma. Furthermore, recombinant CTSB application enhanced expression of brain-derived neurotrophic factor (BDNF) and doublecortin (DCX) in adult hippocampal progenitor cells through a mechanism dependent on the multifunctional protein P11. In vivo, in CTSB knockout (KO) mice, running did not enhance adult hippocampal neurogenesis and spatial memory function. Interestingly, in Rhesus monkeys and humans, treadmill exercise elevated CTSB in plasma. In humans, changes in CTSB levels correlated with fitness and hippocampus-dependent memory function. Our findings suggest CTSB as a mediator of effects of exercise on cognition.
C1 [Moon, Hyo Youl; Becker, Benjamin; Sah, Nirnath; Benoni, Galit; Janke, Emma; Lubejko, Susan T.; van Praag, Henriette] NIA, Neuroplast & Behav Unit, Lab Neurosci, Baltimore, MD 21224 USA.
[Becke, Andreas; Berron, David; Duzel, Emrah] Univ Magdeburg, Inst Cognit Neurol & Dementia Res, Leipziger Str 44, D-39120 Magdeburg, Germany.
[Duzel, Emrah] German Ctr Neurodegenerat Dis DZNE, Leipziger Str 44, D-39120 Magdeburg, Germany.
[Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Baltimore, MD 21224 USA.
[Mattison, Julie A.] NIA, Nonhuman Primate Core, Translat Gerontol Branch, Baltimore, MD 21224 USA.
RP van Praag, H (reprint author), NIA, Neuroplast & Behav Unit, Lab Neurosci, Baltimore, MD 21224 USA.
EM vanpraag17@gmail.com
RI van Praag, Henriette/F-3939-2015
OI van Praag, Henriette/0000-0002-5727-434X
FU BMBF (EnergI Project); National Institute on Aging, Intramural Research
Program; Korean Visiting Scientist Training Award [HI13C1149]; Deutsche
Forschungs Gemeinschaft [SFB 779 TP A7]
FX This work was supported in part by the BMBF (EnergI Project), the
National Institute on Aging, Intramural Research Program, the Korean
Visiting Scientist Training Award (HI13C1149 to H.Y.M.), and the
Deutsche Forschungs Gemeinschaft (SFB 779 TP A7). We thank Drs. Young Ah
Goo and Hyung Won Choi for proteomic analysis, Yang An for statistical
advice, Linda R. Kitabayashi for image preparation, and Bryan Christie
Design for illustration.
NR 41
TC 4
Z9 4
U1 14
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD AUG 9
PY 2016
VL 24
IS 2
BP 332
EP 340
DI 10.1016/j.cmet.2016.05.025
PG 9
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA DT3PH
UT WOS:000381392800020
PM 27345423
ER
PT J
AU Dowd, KA
DeMaso, CR
Pelc, RS
Speer, SD
Smith, ARY
Goo, L
Platt, DJ
Mascola, JR
Graham, BS
Mulligan, MJ
Diamond, MS
Ledgerwood, JE
Pierson, TC
AF Dowd, Kimberly A.
DeMaso, Christina R.
Pelc, Rebecca S.
Speer, Scott D.
Smith, Alexander R. Y.
Goo, Leslie
Platt, Derek J.
Mascola, John R.
Graham, Barney S.
Mulligan, Mark J.
Diamond, Michael S.
Ledgerwood, Julie E.
Pierson, Theodore C.
TI Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a
Single Viral Serotype
SO CELL REPORTS
LA English
DT Article
ID ANTIBODY-MEDIATED NEUTRALIZATION; DENGUE VIRUS; CLINICAL-TRIAL;
DOUBLE-BLIND; PHASE-III; INFECTION; FLAVIVIRUSES; VACCINES;
IMMUNOGENICITY; ENHANCEMENT
AB Recent epidemics of Zika virus (ZIKV) have been associated with congenital malformation during pregnancy and Guillain-Barre syndrome. There are two ZIKV lineages (African and Asian) that share >95% amino acid identity. Little is known regarding the ability of neutralizing antibodies elicited against one lineage to protect against the other. We investigated the breadth of the neutralizing antibody response following ZIKV infection by measuring the sensitivity of six ZIKV strains to neutralization by ZIKV-confirmed convalescent human serum or plasma samples. Contemporary Asian and early African ZIKV strains were similarly sensitive to neutralization regardless of the cellular source of virus. Furthermore, mouse immune serum generated after infection with African or Asian ZIKV strains was capable of neutralizing homologous and heterologous ZIKV strains equivalently. Because our study only defines a single ZIKV serotype, vaccine candidates eliciting robust neutralizing antibody responses should inhibit infection of both ZIKV lineages, including strains circulating in the Americas.
C1 [Dowd, Kimberly A.; DeMaso, Christina R.; Pelc, Rebecca S.; Speer, Scott D.; Smith, Alexander R. Y.; Goo, Leslie; Pierson, Theodore C.] NIAID, Viral Pathogenesis Sect, NIH, Bethesda, MD 20892 USA.
[Platt, Derek J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Platt, Derek J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
[Platt, Derek J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Platt, Derek J.; Diamond, Michael S.] Washington Univ, Sch Med, Ctr Human Immunol, St Louis, MO 63110 USA.
[Platt, Derek J.; Diamond, Michael S.] Washington Univ, Sch Med, Immunotherapy Programs, St Louis, MO 63110 USA.
[Mascola, John R.; Graham, Barney S.; Ledgerwood, Julie E.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Mulligan, Mark J.] Emory Univ, Sch Med, Dept Med, Hope Clin,Emory Vaccine Ctr,Div Infect Dis, Decatur, GA 30030 USA.
RP Pierson, TC (reprint author), NIAID, Viral Pathogenesis Sect, NIH, Bethesda, MD 20892 USA.
EM piersontc@mail.nih.gov
FU National Institute of Allergy and Infectious Disease; Emory University
School of Medicine; Georgia Research Alliance; Moderna; Sanofi;
Visterra; [R01AI073755]
FX This work was funded by the intramural program of the National Institute
of Allergy and Infectious Disease to the Division of Intramural Research
and the Vaccine Research Center and extramural grant R01AI073755 to
M.S.D. M.J.M. was supported by funds from the Emory University School of
Medicine and the Georgia Research Alliance. We thank X. de Lamballerie
(Emergence des Pathologies Virales, Aix-Marseille Universite) and the
European Virus Archive Goes Global (EVAg) for providing the H/PF/2013
ZIKV strain and Stephen S. Whitehead (NIAID) for the Brazil Paraiba/2015
virus. We are grateful to the subjects for providing research samples
and to Ingelise Gordon (VRC), Pamela Costner (VRC), Adam Dezure (VRC),
Lilin Lai (Emory), Natalie Thornburg (Emory), Henry Wu (Emory), Srilatha
Edupuganti (Emory), Allison Beck, (Emory), Sree Aramgam (Emory), and
Pamela Lankford-Turner (Emory) for assistance with ZIKV patients and the
collection of samples. We also thank Amanda Feldpausch (Georgia
Department of Health), Jennifer Govero (Washington University), and
Estefania Fernandez (Washington University) for their help with these
studies. M.S.D. is a consultant for Inbios, Visterra, Sanofi, and Takeda
Pharmaceuticals, is on the Scientific Advisory Boards of Moderna and
OraGene, and is a recipient of research grants from Moderna, Sanofi, and
Visterra.
NR 39
TC 13
Z9 15
U1 14
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD AUG 9
PY 2016
VL 16
IS 6
BP 1485
EP 1491
DI 10.1016/j.celrep.2016.07.049
PG 7
WC Cell Biology
SC Cell Biology
GA DT3ID
UT WOS:000381373400001
PM 27481466
ER
PT J
AU Liu, JC
Liu, J
Holmstrom, KM
Menazza, S
Parks, RJ
Fergusson, MM
Yu, ZX
Springer, DA
Halsey, C
Liu, C
Murphy, E
Finkel, T
AF Liu, Julia C.
Liu, Jie
Holmstrom, Kira M.
Menazza, Sara
Parks, Randi J.
Fergusson, Maria M.
Yu, Zu-Xi
Springer, Danielle A.
Halsey, Charles
Liu, Chengyu
Murphy, Elizabeth
Finkel, Toren
TI MICU1 Serves as a Molecular Gatekeeper to Prevent In Vivo Mitochondrial
Calcium Overload
SO CELL REPORTS
LA English
DT Article
ID RAT-KIDNEY MITOCHONDRIA; CA2+ UPTAKE; ENDOPLASMIC-RETICULUM; CELL-DEATH;
UNIPORTER; STRESS; MCU; ACTIVATION; PROTEIN; HEART
AB MICU1 is a component of the mitochondrial calcium uniporter, a multiprotein complex that also includes MICU2, MCU, and EMRE. Here, we describe a mouse model of MICU1 deficiency. MICU1(-/-) mitochondria demonstrate altered calcium uptake, and deletion of MICU1 results in significant, but not complete, perinatal mortality. Similar to afflicted patients, viable MICU1(-/-) mice manifest marked ataxia and muscle weakness. Early in life, these animals display a range of biochemical abnormalities, including increased resting mitochondrial calcium levels, altered mitochondrial morphology, and reduced ATP. Older MICU1(-/-) mice show marked, spontaneous improvement coincident with improved mitochondrial calcium handling and an age-dependent reduction in EMRE expression. Remarkably, deleting one allele of EMRE helps normalize calcium uptake while simultaneously rescuing the high perinatal mortality observed in young MICU1(-/-) mice. Together, these results demonstrate that MICU1 serves as a molecular gatekeeper preventing calcium overload and suggests that modulating the calcium uniporter could have widespread therapeutic benefits.
C1 [Liu, Julia C.; Liu, Jie; Holmstrom, Kira M.; Fergusson, Maria M.; Finkel, Toren] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA.
[Menazza, Sara; Parks, Randi J.; Murphy, Elizabeth] NHLBI, Syst Biol Ctr, NIH, Bethesda, MD 20892 USA.
[Yu, Zu-Xi] NHLBI, Pathol Core, NIH, Bethesda, MD 20892 USA.
[Springer, Danielle A.] NHLBI, Murine Phenotyping Core, NIH, Bethesda, MD 20892 USA.
[Halsey, Charles] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA.
[Liu, Chengyu] NHLBI, Transgen Core, NIH, Bethesda, MD 20892 USA.
RP Finkel, T (reprint author), NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA.
EM finkelt@nih.gov
OI Holmstrom, Kira/0000-0001-6434-7909
FU Intramural NIH funds; Leducq Transatlantic Network grant; PRAT
postdoctoral fellowship from NIGMS
FX We are grateful to Michele Allen for help with mouse phenotyping; Erin
Stempinski, Camron Keshavarz, and Christopher Bleck for help with
electron microscopic analysis; and Jeffrey Culver at the Sanford-Burnham
Orlando Metabolomics Core for skeletal muscle lactate measurements. This
work was supported by Intramural NIH funds, a Leducq Transatlantic
Network grant (to T.F.), and a PRAT postdoctoral fellowship from NIGMS
(to J.C.L.).
NR 46
TC 5
Z9 5
U1 4
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD AUG 9
PY 2016
VL 16
IS 6
BP 1561
EP 1573
DI 10.1016/j.celrep.2016.07.011
PG 13
WC Cell Biology
SC Cell Biology
GA DT3ID
UT WOS:000381373400009
PM 27477272
ER
PT J
AU Lee, SH
Le Pichon, CE
Adolfsson, O
Gafner, V
Pihlgren, M
Lin, H
Solanoy, H
Brendza, R
Ngu, H
Foreman, O
Chan, R
Ernst, JA
DiCara, D
Hotzel, I
Srinivasan, K
Hansen, DV
Atwal, J
Lu, YM
Bumbaca, D
Pfeifer, A
Watts, RJ
Muhs, A
Scearce-Levie, K
Ayalon, G
AF Lee, Seung-Hye
Le Pichon, Claire E.
Adolfsson, Oskar
Gafner, Valerie
Pihlgren, Maria
Lin, Han
Solanoy, Hilda
Brendza, Robert
Ngu, Hai
Foreman, Oded
Chan, Ruby
Ernst, James A.
DiCara, Danielle
Hotzel, Isidro
Srinivasan, Karpagam
Hansen, David V.
Atwal, Jasvinder
Lu, Yanmei
Bumbaca, Daniela
Pfeifer, Andrea
Watts, Ryan J.
Muhs, Andreas
Scearce-Levie, Kimberly
Ayalon, Gai
TI Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector
Function and Microglial Engagement
SO CELL REPORTS
LA English
DT Article
ID ALZHEIMERS-DISEASE; TRANSGENIC MICE; PASSIVE-IMMUNIZATION; MOUSE MODEL;
PROTEIN; PATHOLOGY; BRAIN; NEURONS; PHOSPHORYLATION; PROPAGATION
AB The spread of tau pathology correlates with cognitive decline in Alzheimer's disease. In vitro, tau antibodies can block cell-to-cell tau spreading. Although mechanisms of anti-tau function in vivo are unknown, effector function might promote microglia-mediated clearance. In this study, we investigated whether antibody effector function is required for targeting tau. We compared efficacy in vivo and in vitro of two versions of the same tau antibody, with and without effector function, measuring tau pathology, neuron health, and microglial function. Both antibodies reduced accumulation of tau pathology in Tau-P301L transgenic mice and protected cultured neurons against extracellular tau-induced toxicity. Only the full-effector antibody enhanced tau uptake in cultured microglia, which promoted release of proinflammatory cytokines. In neuron-microglia cocultures, only effectorless anti-tau protected neurons, suggesting full-effector tau antibodies can induce indirect toxicity via microglia. We conclude that effector function is not required for efficacy, and effectorless tau antibodies may represent a safer approach to targeting tau.
C1 [Lee, Seung-Hye; Le Pichon, Claire E.; Lin, Han; Solanoy, Hilda; Brendza, Robert; Ngu, Hai; Foreman, Oded; Chan, Ruby; Ernst, James A.; DiCara, Danielle; Hotzel, Isidro; Srinivasan, Karpagam; Hansen, David V.; Atwal, Jasvinder; Lu, Yanmei; Bumbaca, Daniela; Watts, Ryan J.; Scearce-Levie, Kimberly; Ayalon, Gai] Genentech Inc, San Francisco, CA 94080 USA.
[Adolfsson, Oskar; Gafner, Valerie; Pihlgren, Maria; Pfeifer, Andrea; Muhs, Andreas] AC Immune SA, CH-1015 Lausanne, Switzerland.
[Le Pichon, Claire E.] NINDS, NIH, Bethesda, MD 20892 USA.
[Chan, Ruby] Gilead Sci, Foster City, CA 94404 USA.
RP Scearce-Levie, K; Ayalon, G (reprint author), Genentech Inc, San Francisco, CA 94080 USA.; Muhs, A (reprint author), AC Immune SA, CH-1015 Lausanne, Switzerland.
EM andreas.muhs@acimmune.com; kscearcelevie@gmail.com; ayalon.gai@gene.com
NR 37
TC 1
Z9 1
U1 5
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD AUG 9
PY 2016
VL 16
IS 6
BP 1690
EP 1700
DI 10.1016/j.celrep.2016.06.099
PG 11
WC Cell Biology
SC Cell Biology
GA DT3ID
UT WOS:000381373400019
PM 27475227
ER
PT J
AU Jourdain, G
Ngo-Giang-Huong, N
Cressey, TR
Hua, L
Harrison, L
Tierney, C
Salvadori, N
Decker, L
Traisathit, P
Sirirungsi, W
Khamduang, W
Bowonwatanuwong, C
Puthanakit, T
Siberry, GK
Watts, DH
Murphy, TV
Achalapong, J
Hongsiriwon, S
Klinbuayaem, V
Thongsawat, S
Chung, RT
Pol, S
Chotivanich, N
AF Jourdain, Gonzague
Ngo-Giang-Huong, Nicole
Cressey, Tim R.
Hua, Lei
Harrison, Linda
Tierney, Camlin
Salvadori, Nicolas
Decker, Luc
Traisathit, Patrinee
Sirirungsi, Wasna
Khamduang, Woottichai
Bowonwatanuwong, Chureeratana
Puthanakit, Thanyawee
Siberry, George K.
Watts, Diane Heather
Murphy, Trudy V.
Achalapong, Jullapong
Hongsiriwon, Suchat
Klinbuayaem, Virat
Thongsawat, Satawat
Chung, Raymond T.
Pol, Stanislas
Chotivanich, Nantasak
TI Prevention of mother-to-child transmission of hepatitis B virus: a phase
III, placebo-controlled, double-blind, randomized clinical trial to
assess the efficacy and safety of a short course of tenofovir disoproxil
fumarate in women with hepatitis B virus e-antigen
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID PERINATAL TRANSMISSION; INFANT TRANSMISSION; SURFACE-ANTIGEN; INFECTION;
PREGNANCY; METAANALYSIS
AB Background: Chronic hepatitis B virus (HBV) infection is complicated by cirrhosis and liver cancer. In Thailand, 6-7 % of adults are chronically infected with HBV. The risk of mother-to-child transmission (MTCT) of HBV has been estimated to be about 12 % when mothers have a high hepatitis B viral load, even if infants receive passive-active prophylaxis with HBV immunoglobulin (HBIg) and initiate the hepatitis B vaccine series at birth. We designed a study to assess the efficacy and safety of a short course of maternal tenofovir disoproxil fumarate (TDF) among women with a marker of high viral load for the prevention of MTCT of HBV.
Methods: The study is a phase III, multicenter (17 sites in Thailand), placebo-controlled, double-blind, randomized 1: 1, two-arm clinical trial of TDF 300 mg once daily versus placebo among pregnant women from 28 weeks' gestation through 2-month post-partum. All infants receive HBIg at birth, and a hepatitis B (HB) vaccination series according to Thai guidelines: birth, and age 1, 2, 4 and 6 months. Participant women at study entry must be age >= 18 years, hepatitis B surface antigen (HBsAg) and e-antigen (HBeAg) positive, have alanine aminotransferase (ALT) level < 30 IU/L at screening (confirmed < 60 IU/L pre-entry), negative hepatitis C serology, creatinine clearance > 50 mL/min, and no history of anti-HBV antiviral treatment.
The target sample size of 328 mother/infant pairs assumed 156 evaluable cases per arm to detect a >= 9 % difference in MTCT transmission (3 % experimental arm versus 12 % placebo arm) with 90 % power. Mothers and infants are followed until 12 months after delivery. The primary infant endpoint is detection of HBsAg, confirmed by detection of HBV DNA at six months of age. Secondary endpoints are maternal and infant adverse events, acute exacerbations of maternal hepatitis B disease (ALT > 300 IU/ L, defined as a "flare") following discontinuation of study treatment, infant HBV infection status and growth up to 12 months of age.
Discussion: The results of this randomized trial will clarify the efficacy and safety of a short course of antiviral treatment to prevent mother-to-child transmission of HBV and inform international guidelines.
C1 [Jourdain, Gonzague; Ngo-Giang-Huong, Nicole; Cressey, Tim R.; Salvadori, Nicolas; Decker, Luc] Inst Rech Dev IRD France, PHPT, UMI 174, 187-10 Changklan Rd, Chiang Mai 50100, Thailand.
[Jourdain, Gonzague; Ngo-Giang-Huong, Nicole; Cressey, Tim R.; Salvadori, Nicolas; Decker, Luc; Sirirungsi, Wasna; Khamduang, Woottichai] Chiang Mai Univ, Fac Associated Med Sci, 110 Intawaroroj Rd, Chiang Mai 50200, Thailand.
[Jourdain, Gonzague; Ngo-Giang-Huong, Nicole; Cressey, Tim R.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, 677 Huntington Ave, Boston, MA 02115 USA.
[Cressey, Tim R.] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
[Hua, Lei; Harrison, Linda; Tierney, Camlin] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res CBAR, 677 Huntington Ave, Boston, MA 02115 USA.
[Bowonwatanuwong, Chureeratana; Chotivanich, Nantasak] Chonburi Hosp, 69 M-2,Sukhumvit Rd, Muang 20000, Chonburi, Thailand.
[Puthanakit, Thanyawee] Chulalongkorn Univ, Fac Med, 1873 Rama 4 Rd, Bangkok 10330, Thailand.
[Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, 6100 Execut Blvd, Bethesda, MD 20892 USA.
[Watts, Diane Heather] US Dept State, Off Global AIDS Coordinator, SA-22,2201 C St NW, Washington, DC 20522 USA.
[Murphy, Trudy V.] Ctr Dis Control & Prevent, DHHS CDC NCHHSTP DVH Vaccine Unit, Bldg Corp SQ 12,Room 3111, Atlanta, GA 30329 USA.
[Achalapong, Jullapong] Chiangrai Prachanukroh Hosp, Dept Obstet & Gynecol, 1039 Sathan Phayaban Rd, Muang 57000, Chiang Rai, Thailand.
[Hongsiriwon, Suchat] Chonburi Hosp, Dept Pediat, 69 M-2,Sukhumvit Rd, Muang 20000, Chonburi, Thailand.
[Klinbuayaem, Virat] Sanpatong Hosp, Dept Med, 149 M-15 Yuhwa, Chiang Mai 50120, Thailand.
[Traisathit, Patrinee] Chiang Mai Univ, Dept Stat, Fac Sci, 239 Huaykaew Rd, Chiang Mai 50200, Thailand.
[Thongsawat, Satawat] Chiang Mai Univ, Dept Internal Med, Fac Med, Chiang Mai 50200, Thailand.
[Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, GI Unit, WRN 1007C,55 Fruit St, Boston, MA 02114 USA.
[Pol, Stanislas] Cochin Univ Hosp, Dept Hepatogastroenterol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.
RP Jourdain, G (reprint author), Inst Rech Dev IRD France, PHPT, UMI 174, 187-10 Changklan Rd, Chiang Mai 50100, Thailand.; Jourdain, G (reprint author), Chiang Mai Univ, Fac Associated Med Sci, 110 Intawaroroj Rd, Chiang Mai 50200, Thailand.
EM gonzague.jourdain@ird.fr
FU Eunice Kennedy Shriver National Institute of Child Health & Human
Development (NICHD) [U01HD071889]
FX The study activities are supported by a grant from the Eunice Kennedy
Shriver National Institute of Child Health & Human Development (NICHD)
(U01HD071889) under a cooperative agreement between NICHD, the Centers
for Disease Control and Prevention, United States of America, and
Institut de recherche pour le developpement, France.
NR 12
TC 1
Z9 1
U1 8
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD AUG 9
PY 2016
VL 16
AR 393
DI 10.1186/s12879-016-1734-5
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA DT2YM
UT WOS:000381347700010
PM 27506549
ER
PT J
AU Ordonez, AE
Ranney, R
Schwartz, M
Mathews, CA
Satre, DD
AF Ordonez, Anna E.
Ranney, Rachel
Schwartz, Maxine
Mathews, Carol A.
Satre, Derek D.
TI Hazardous drinking among young adults seeking outpatient mental health
services
SO Addiction Science & Clinical Practice
LA English
DT Article
DE Alcohol; Hazardous drinking; Cannabis; Depression; Mental health; Young
adults
ID ALCOHOL-USE DISORDERS; RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE
DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; DRUG-USE; PSYCHIATRIC-SERVICES;
BRIEF INTERVENTION; COMORBIDITY; CONSUMPTION; PREVALENCE
AB Background: Alcohol use can have a significant negative impact on young adults in mental health treatment. This cross-sectional study examined prevalence and factors associated with hazardous drinking among young adults seeking outpatient mental health services, rate of alcohol use disorders (AUDs), and the relationship between hazardous drinking and other types of substance use.
Methods: Participants were 487 young adults ages 18-25 who completed self-administered computerized screening questions for alcohol and drug use. Alcohol use patterns were assessed and predictors of hazardous drinking (>= 5 drinks on one or more occasions in the past year) were identified using logistic regression.
Results: Of the 487 participants, 79.8 % endorsed prior-year alcohol use, 52.3 % reported one or more episodes of hazardous drinking in the prior year and 8.2 % were diagnosed with an AUD. Rates of recent and lifetime alcohol, tobacco and marijuana use were significantly greater in those with prior-year hazardous drinking. In logistic regression, prior-year hazardous drinking was associated with lifetime marijuana use (OR 3.30, p < 0.001; 95 % CI 2.05, 5.28), lifetime tobacco use (OR 1.88, p = 0.004; 95 % CI 1.22, 2.90) and older age (OR 1.18 per year, p < 0.001; 95 % CI 1.08, 1.29).
Conclusions: In an outpatient mental health setting, high rates of hazardous drinking were identified, and drinking was associated with history of other substance use. Results highlight patient characteristics associated with hazardous drinking that mental health providers should be aware of in treating young adults, especially older age and greater use of tobacco and marijuana.
C1 [Ordonez, Anna E.; Ranney, Rachel; Schwartz, Maxine; Mathews, Carol A.; Satre, Derek D.] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.
[Ordonez, Anna E.; Ranney, Rachel; Schwartz, Maxine; Mathews, Carol A.; Satre, Derek D.] Univ Calif San Francisco, UCSF Weill Inst Neurosci, 401 Parnassus Ave, San Francisco, CA 94143 USA.
[Satre, Derek D.] Kaiser Permanente Northern Calif Reg, Div Res, 2000 Broadway,3rd Floor, Oakland, CA 94612 USA.
[Ordonez, Anna E.] NIMH, Off Clin Res, 6001 Execut Blvd MSC 9669, Bethesda, MD 20892 USA.
[Mathews, Carol A.] Univ Florida, Dept Psychiat, 100 S Newell Dr, Gainesville, FL 32610 USA.
RP Ordonez, AE (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.; Ordonez, AE (reprint author), Univ Calif San Francisco, UCSF Weill Inst Neurosci, 401 Parnassus Ave, San Francisco, CA 94143 USA.; Ordonez, AE (reprint author), NIMH, Off Clin Res, 6001 Execut Blvd MSC 9669, Bethesda, MD 20892 USA.
EM anna.ordonez@nih.gov
FU NIAAA NIH HHS [R01 AA020463]; NIDA NIH HHS [T32 DA007250]; NIMH NIH HHS
[R25 MH060482]
NR 30
TC 0
Z9 0
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1940-0640
J9 ADDICT SCI CLIN PRAC
JI Addict. Sci. Clin. Pract.
PD AUG 9
PY 2016
VL 11
AR 12
DI 10.1186/s13722-016-0060-y
PG 7
WC Substance Abuse
SC Substance Abuse
GA DS9RR
UT WOS:000381121500001
PM 27506832
ER
PT J
AU Gach, JS
Gorlani, A
Dotsey, EY
Becerra, JC
Anderson, CTM
Berzins, B
Felgner, PL
Forthal, DN
Deeks, SG
Wilkin, TJ
Casazza, JP
Koup, RA
Katlama, C
Autran, B
Murphy, RL
Achenbach, CJ
AF Gach, Johannes S.
Gorlani, Andrea
Dotsey, Emmanuel Y.
Becerra, Juan C.
Anderson, Chase T. M.
Berzins, Baiba
Felgner, Philip L.
Forthal, Donald N.
Deeks, Steven G.
Wilkin, Timothy J.
Casazza, Joseph P.
Koup, Richard A.
Katlama, Christine
Autran, Brigitte
Murphy, Robert L.
Achenbach, Chad J.
TI HIV-1-Specific Antibody Response and Function after DNA Prime and
Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects
SO PLOS ONE
LA English
DT Article
ID DEPENDENT CELLULAR CYTOTOXICITY; IMMUNODEFICIENCY-VIRUS TYPE-1;
NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODY; EFFICACY TRIAL;
ANTIRETROVIRAL THERAPY; MEDIATED CYTOTOXICITY; LONGITUDINAL ANALYSIS;
ENVELOPE PROTEINS; EPITOPES
AB Little is known about the humoral immune response against DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine among HIV-infected patients on long-term suppressive antiretroviral therapy (ART). Previous studies emphasized cellular immune responses; however, current research suggests both cellular and humoral responses are likely required for a successful therapeutic vaccine. Thus, we aimed to understand antibody response and function induced by vaccination of ART-treated HIV-1-infected patients with immune recovery. All subjects participated in EraMune 02, an open-label randomized clinical trial of ART intensification followed by a six plasmid DNA prime (envA, envB, envC, gagB, polB, nefB) and rAd5 boost HIV vaccine with matching inserts. Antibody binding levels were determined with a recently developed microarray approach. We also analyzed neutralization efficiency and antibody-dependent cellular cytotoxicity (ADCC). We found that the DNA prime-rAd5 boost vaccine induced a significant cross-clade HIV-specific antibody response, which correlated with antibody neutralization efficiency. However, despite the increase in antibody binding levels, the vaccine did not significantly stimulate neutralization or ADCC responses. This finding was also reflected by a lack of change in total CD4+ cell associated HIV DNA in those who received the vaccine. Our results have important implications for further therapeutic vaccine design and administration, especially in HIV-1 infected patients, as boosting of preexisting antibody responses are unlikely to lead to clearance of latent proviruses in the HIV reservoir.
C1 [Gach, Johannes S.; Gorlani, Andrea; Dotsey, Emmanuel Y.; Becerra, Juan C.; Felgner, Philip L.; Forthal, Donald N.] Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine, CA 92717 USA.
[Anderson, Chase T. M.; Berzins, Baiba; Murphy, Robert L.; Achenbach, Chad J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Infect Dis,Ctr Global Hlth, Chicago, IL 60611 USA.
[Deeks, Steven G.] San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94110 USA.
[Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wilkin, Timothy J.] Weill Cornell Med Coll, Div Infect Dis, New York, NY USA.
[Casazza, Joseph P.; Koup, Richard A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Katlama, Christine] Hop La Pitie Salpetriere, Dept Infect Dis, Paris, France.
[Autran, Brigitte] Hop La Pitie Salpetriere, Dept Immunol, Paris, France.
[Gorlani, Andrea] ModiQuest Res, Oss, Netherlands.
RP Gach, JS (reprint author), Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine, CA 92717 USA.; Achenbach, CJ (reprint author), Northwestern Univ, Dept Med, Feinberg Sch Med, Div Infect Dis,Ctr Global Hlth, Chicago, IL 60611 USA.
EM jgach@uci.edu; c-achenbach@northwestern.edu
OI Gach, Johannes/0000-0002-5043-5710
FU Objectif Recherche Vaccin SIDA (ORVACS)
FX Objectif Recherche Vaccin SIDA (ORVACS) provided all funding for this
study. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 56
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2016
VL 11
IS 8
AR e0160341
DI 10.1371/journal.pone.0160341
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3IE
UT WOS:000381373500020
PM 27500639
ER
PT J
AU Hong, CS
Singh, LN
Mullikin, JC
Biesecker, LG
AF Hong, Celine S.
Singh, Larry N.
Mullikin, James C.
Biesecker, Leslie G.
TI Assessing the reproducibility of exome copy number variations
predictions
SO GENOME MEDICINE
LA English
DT Article
DE Copy number variations (CNV); Exomes; CNV predictions; Reproducibility
ID SEQUENCING DATA; DISCOVERY; VARIANTS; TOOLS; DEPTH
AB Background: Reproducibility is receiving increased attention across many domains of science and genomics is no exception. Efforts to identify copy number variations (CNVs) from exome sequence (ES) data have been increasing. Many algorithms have been published to discover CNVs from exomes and a major challenge is the reproducibility in other datasets. Here we test exome CNV calling reproducibility under three conditions: data generated by different sequencing centers; varying sample sizes; and varying capture methodology.
Methods: Four CNV tools were tested: eXome Hidden Markov Model (XHMM), Copy Number Inference From Exome Reads (CoNIFER), EXCAVATOR, and Copy Number Analysis for Targeted Resequencing (CONTRA). To examine the reproducibility, we ran the callers on four datasets, varying sample sizes of N = 10, 30, 75, 100, 300, and data with different capture methodology. We examined the false negative (FN) calls and false positive (FP) calls for potential limitations of the CNV callers. The positive predictive value (PPV) was measured by checking the CNV call concordance against single nucleotide polymorphism array.
Results: Using independently generated datasets, we examined the PPV for each dataset and observed wide range of PPVs. The PPV values were highly data dependent (p < 0.001). For the sample sizes and capture method analyses, we tested the callers in triplicates. Both analyses resulted in wide ranges of PPVs, even for the same test. Interestingly, negative correlations between the PPV and the sample sizes were observed for CoNIFER (rho = - 0.80). Further examination of FN calls showed that 44 % of these were missed by all callers and were attributed to the CNV size (46 % spanned = 3 exons). Overlap of the FP calls showed that FPs were unique to each caller, indicative of algorithm dependency.
Conclusions: Our results demonstrate that further improvements in CNV callers are necessary to improve reproducibility and to include wider spectrum of CNVs (including the small CNVs). These CNV callers should be evaluated on multiple independent, heterogeneously generated datasets of varying size to increase robustness and utility. These approaches to the evaluation of exome CNV are essential to support wide utility and applicability of CNV discovery in exome studies.
C1 [Hong, Celine S.; Singh, Larry N.; Biesecker, Leslie G.] NHGRI, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA.
[Mullikin, James C.; Biesecker, Leslie G.] NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20852 USA.
[Mullikin, James C.] NHGRI, Comparat Genom Anal Unit, Canc Genet & Comparat Genom Branch, NIH, Bethesda, MD 20852 USA.
RP Biesecker, LG (reprint author), NHGRI, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA.; Biesecker, LG (reprint author), NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20852 USA.
EM lesb@mail.nih.gov
FU Intramural Research Program of the National Human Genome Research
Institute, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Human Genome Research Institute, National Institutes of Health.
NR 28
TC 1
Z9 1
U1 3
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD AUG 8
PY 2016
VL 8
AR 82
DI 10.1186/s13073-016-0336-6
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA DT2XL
UT WOS:000381345000001
PM 27503473
ER
PT J
AU Elwyn, G
Frosch, DL
Kobrin, S
AF Elwyn, Glyn
Frosch, Dominick L.
Kobrin, Sarah
TI Implementing shared decision-making: consider all the consequences
SO IMPLEMENTATION SCIENCE
LA English
DT Article
DE Collaborative deliberation; Shared decision making; Patient-centered
care; Implementation; Practice improvement; Quality improvement;
Multilevel; Conceptual model; Measurement
ID SUPPORT INTERVENTIONS; HEALTH-CARE; MULTILEVEL FACTORS;
CLINICAL-PRACTICE; PATIENT; AIDS; SATISFACTION; METAANALYSIS; ADHERENCE;
OUTCOMES
AB Background: The ethical argument that shared decision-making is "the right" thing to do, however laudable, is unlikely to change how healthcare is organized, just as evidence alone will be an insufficient factor: practice change is governed by factors such as cost, profit margin, quality, and efficiency. It is helpful, therefore, when evaluating new approaches such as shared decision-making to conceptualize potential consequences in a way that is broad, long-term, and as relevant as possible to multiple stakeholders. Yet, so far, evaluation metrics for shared decision-making have been mostly focused on short-term outcomes, such as cognitive or affective consequences in patients. The goal of this article is to hypothesize a wider set of consequences, that apply over an extended time horizon, and include outcomes at interactional, team, organizational and system levels, and to call for future research to study these possible consequences.
Main argument: To date, many more studies have evaluated patient decision aids rather than other approaches to shared decision-making, and the outcomes measured have typically been focused on short-term cognitive and affective outcomes, for example knowledge and decisional conflict. From a clinicians perspective, the shared decision-making process could be viewed as either intrinsically rewarding and protective, or burdensome and impractical, yet studies have not focused on the impact on professionals, either positive or negative. At interactional levels, group, team, and microsystem, the potential long-term consequences could include the development of a culture where deliberation and collaboration are regarded as guiding principles, where patients are coached to assess the value of interventions, to trade-off benefits versus harms, and assess their burdens-in short, to new social norms in the clinical workplace. At organizational levels, consistent shared decision-making might boost patient experience evaluations and lead to fewer complaints and legal challenges. In the long-term, shared decision-making might lead to changes in resource utilization, perhaps to reductions in cost, and to modification of workforce composition. Despite the gradual shift to value-based payment, some organizations, motivated by continued income derived from achieving high volumes of procedures and contacts, will see this as a negative consequence.
Conclusion: We suggest that a broader conceptualization and measurement of shared decision-making would provide a more substantive evidence base to guide implementation. We outline a framework which illustrates a hypothesized set of proximal, distal, and distant consequences that might occur if collaboration and deliberation could be achieved routinely, proposing that well-informed preference- based patient decisions might lead to safer, more cost-effective healthcare, which in turn might result in reduced utilization rates and improved health outcomes.
C1 [Elwyn, Glyn] Dartmouth Inst Hlth Policy & Clin Practice, 37 Dewey Field Rd, Hanover, NH 03755 USA.
[Frosch, Dominick L.] Palo Alto Med Fdn, Res Inst, 795 El Camino Real, Palo Alto, CA 94301 USA.
[Frosch, Dominick L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Kobrin, Sarah] NCI, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
RP Elwyn, G (reprint author), Dartmouth Inst Hlth Policy & Clin Practice, 37 Dewey Field Rd, Hanover, NH 03755 USA.
EM glynelwyn@gmail.com
NR 45
TC 3
Z9 3
U1 12
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD AUG 8
PY 2016
VL 11
AR 114
DI 10.1186/s13012-016-0480-9
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA DT7KJ
UT WOS:000381665200002
PM 27502770
ER
PT J
AU Bissinger, R
Lang, E
Ghashghaeinia, M
Singh, Y
Zelenak, C
Fehrenbacher, B
Honisch, S
Chen, H
Fakhri, H
Umbach, AT
Liu, GL
Rexhepaj, R
Liu, GX
Schaller, M
Mack, AF
Lupescu, A
Birnbaumer, L
Lang, F
Qadri, SM
AF Bissinger, Rosi
Lang, Elisabeth
Ghashghaeinia, Mehrdad
Singh, Yogesh
Zelenak, Christine
Fehrenbacher, Birgit
Honisch, Sabina
Chen, Hong
Fakhri, Hajar
Umbach, Anja T.
Liu, Guilai
Rexhepaj, Rexhep
Liu, Guoxing
Schaller, Martin
Mack, Andreas F.
Lupescu, Adrian
Birnbaumer, Lutz
Lang, Florian
Qadri, Syed M.
TI Blunted apoptosis of erythrocytes in mice deficient in the
heterotrimeric G-protein subunit G alpha i2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IN-VITRO; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; SUICIDAL DEATH;
CELL-DEATH; RED-CELLS; ACTIVATION; ERYPTOSIS; STIMULATION; SURVIVAL
AB Putative functions of the heterotrimeric G-protein subunit G alpha i2-dependent signaling include ion channel regulation, cell differentiation, proliferation and apoptosis. Erythrocytes may, similar to apoptosis of nucleated cells, undergo eryptosis, characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine (PS) exposure. Eryptosis may be triggered by increased cytosolic Ca2+ activity and ceramide. In the present study, we show that G alpha i2 is expressed in both murine and human erythrocytes and further examined the survival of erythrocytes drawn from G alpha i2-deficient mice (G alpha i2(-/-)) and corresponding wild-type mice (G alpha i(2+/+)). Our data show that plasma erythropoietin levels, erythrocyte maturation markers, erythrocyte counts, hematocrit and hemoglobin concentration were similar in G alpha i2(-/-) and G alpha i(2+/+) mice but the mean corpuscular volume was significantly larger in G alpha i2(-/-) mice. Spontaneous PS exposure of circulating G alpha i2(-/-) erythrocytes was significantly lower than that of circulating G alpha i(2+/+) erythrocytes. PS exposure was significantly lower in G alpha i2(-/-) than in G alpha i(2+/+) erythrocytes following ex vivo exposure to hyperosmotic shock, bacterial sphingomyelinase or C6 ceramide. Erythrocyte G alpha i2 deficiency further attenuated hyperosmotic shock-induced increase of cytosolic Ca2+ activity and cell shrinkage. Moreover, G alpha i2(-/-) erythrocytes were more resistant to osmosensitive hemolysis as compared to G alpha i(2+/+) erythrocytes. In conclusion, G alpha i2 deficiency in erythrocytes confers partial protection against suicidal cell death.
C1 [Bissinger, Rosi; Ghashghaeinia, Mehrdad; Singh, Yogesh; Honisch, Sabina; Chen, Hong; Fakhri, Hajar; Umbach, Anja T.; Liu, Guilai; Rexhepaj, Rexhep; Liu, Guoxing; Lupescu, Adrian; Lang, Florian; Qadri, Syed M.] Univ Tubingen, Inst Cardiol Vasc Med & Physiol, Tubingen, Germany.
[Lang, Elisabeth] Univ Duesseldorf, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany.
[Zelenak, Christine] Charite, Dept Internal Med, Berlin, Germany.
[Fehrenbacher, Birgit; Schaller, Martin] Univ Tubingen, Dept Dermatol, Tubingen, Germany.
[Rexhepaj, Rexhep] Univ Bonn, Inst Biochem & Mol Biol, Bonn, Germany.
[Mack, Andreas F.] Univ Tubingen, Inst Anat, Tubingen, Germany.
[Birnbaumer, Lutz] NIEHS, Neurobiol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
[Qadri, Syed M.] Catholic Univ Argentina, Sch Med Sci, Inst Biomed Res BIOMED, Buenos Aires, DF, Argentina.
[Qadri, Syed M.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
RP Lang, F (reprint author), Univ Tubingen, Inst Cardiol Vasc Med & Physiol, Tubingen, Germany.
EM florian.lang@uni-tuebingen.de
FU Deutsche Forschungsgemeinschaft [La 315/13-3]; NIH [Z01-ES-101643]
FX The authors thank Prof. Bernd Nurnberg and members of his laboratory
(Institute of Experimental and Clinical Pharmacology and Toxicology,
University of Tubingen, Germany) for their valuable suggestions and for
providing blood from G alpha i2-/- mice. The authors
acknowledge the meticulous preparation of the manuscript by Tanja Loch
and the technical assistance of Efi Faber and Annette Knoblich. This
study was supported by Deutsche Forschungsgemeinschaft (Nr. La 315/13-3)
and the Intramural Research Program of the NIH (project Z01-ES-101643 to
LB).
NR 60
TC 1
Z9 1
U1 5
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 8
PY 2016
VL 6
AR 30925
DI 10.1038/srep30925
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT4NF
UT WOS:000381457200001
PM 27499046
ER
PT J
AU Hirschman, L
Fort, K
Boue, S
Kyrpides, N
Dogan, RI
Cohen, KB
AF Hirschman, Lynette
Fort, Karen
Boue, Stephanie
Kyrpides, Nikos
Dogan, Rezarta Islamaj
Cohen, Kevin Bretonnel
TI Crowdsourcing and curation: perspectives from biology and natural
language processing
SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION
LA English
DT Article
ID ANNOTATION; RETRIEVAL; NETWORKS; IMPROVER; GENE; TEXT
AB Crowdsourcing is increasingly utilized for performing tasks in both natural language processing and biocuration. Although there have been many applications of crowdsourcing in these fields, there have been fewer high-level discussions of the methodology and its applicability to biocuration. This paper explores crowdsourcing for biocuration through several case studies that highlight different ways of leveraging 'the crowd'; these raise issues about the kind(s) of expertise needed, the motivations of participants, and questions related to feasibility, cost and quality. The paper is an outgrowth of a panel session held at BioCreative V (Seville, September 9-11, 2015). The session consisted of four short talks, followed by a discussion. In their talks, the panelists explored the role of expertise and the potential to improve crowd performance by training; the challenge of decomposing tasks to make them amenable to crowdsourcing; and the capture of biological data and metadata through community editing.
C1 [Hirschman, Lynette] Mitre Corp, Burlington Rd, Bedford, MA 01730 USA.
[Fort, Karen] Univ Paris 04, STIH Team, Paris, France.
[Boue, Stephanie] Philip Morris Prod SA, Philip Morris Int R&D, Neuchatel, Switzerland.
[Kyrpides, Nikos] Joint Genome Inst, Creek, CA USA.
[Dogan, Rezarta Islamaj] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA.
[Cohen, Kevin Bretonnel] Univ Colorado, Sch Med, Denver, CO USA.
RP Hirschman, L (reprint author), Mitre Corp, Burlington Rd, Bedford, MA 01730 USA.
EM lynette@mitre.org
RI Kyrpides, Nikos/A-6305-2014
OI Kyrpides, Nikos/0000-0002-6131-0462
FU NIH/NIGMS [R13GM109648-01A1]; National Institutes of Health Intramural
Research Program, National Library of Medicine; DOE [DE-SC0010838];
Inria; French Ministry of Culture through a DGLFLF grant; Philip Morris
International; NIH [2R01 LM008111-09A1 NIH 2R01, LM009254-09 NIH,
1R01MH096906-01A1]; NSF [IIS-1207592]; MITRE Corporation
FX BioCreative has been partially funded by NIH/NIGMS R13GM109648-01A1, by
the National Institutes of Health Intramural Research Program, National
Library of Medicine and by DOE grant DE-SC0010838. ZombiLingo is funded
by Inria and by the French Ministry of Culture through a DGLFLF grant to
KF. sbv IMPROVER is funded by Philip Morris International. KBC's work
was supported by grants NIH 2R01 LM008111-09A1 NIH 2R01 and LM009254-09
NIH to Lawrence E. Hunter, 1R01MH096906-01A1 to Tal Yarkoni, and NSF
IIS-1207592 to Lawrence E. Hunter and Barbara Grimpe. Funding for open
access charge: The MITRE Corporation.
NR 34
TC 0
Z9 0
U1 4
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1758-0463
J9 DATABASE-OXFORD
JI Database
PD AUG 7
PY 2016
AR baw115
DI 10.1093/database/baw115
PG 11
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA DT5KS
UT WOS:000381522700001
ER
PT J
AU Abudayyeh, OO
Gootenberg, JS
Konermann, S
Joung, J
Slaymaker, IM
Cox, DBT
Shmakov, S
Makarova, KS
Semenova, E
Minakhin, L
Severinov, K
Regev, A
Lander, ES
Koonin, EV
Zhang, F
AF Abudayyeh, Omar O.
Gootenberg, Jonathan S.
Konermann, Silvana
Joung, Julia
Slaymaker, Ian M.
Cox, David B. T.
Shmakov, Sergey
Makarova, Kira S.
Semenova, Ekaterina
Minakhin, Leonid
Severinov, Konstantin
Regev, Aviv
Lander, Eric S.
Koonin, Eugene V.
Zhang, Feng
TI C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR
effector
SO SCIENCE
LA English
DT Article
ID ADAPTIVE BACTERIAL IMMUNITY; ESCHERICHIA-COLI;
STREPTOCOCCUS-THERMOPHILUS; CRYSTAL-STRUCTURE; CAS IMMUNITY;
THERMUS-THERMOPHILUS; SURVEILLANCE COMPLEX; PYROCOCCUS-FURIOSUS; SPACER
ACQUISITION; BINDING PROTEINS
AB The clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated genes (Cas) adaptive immune system defends microbes against foreign genetic elements via DNA or RNA-DNA interference. We characterize the class 2 type VI CRISPR-Cas effector C2c2 and demonstrate its RNA-guided ribonuclease function. C2c2 from the bacterium Leptotrichia shahii provides interference against RNA phage. In vitro biochemical analysis shows that C2c2 is guided by a single CRISPR RNA and can be programmed to cleave single-stranded RNA targets carrying complementary protospacers. In bacteria, C2c2 can be programmed to knock down specific mRNAs. Cleavage is mediated by catalytic residues in the two conserved Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains, mutations of which generate catalytically inactive RNA-binding proteins. These results broaden our understanding of CRISPR-Cas systems and suggest that C2c2 can be used to develop new RNA-targeting tools.
C1 [Abudayyeh, Omar O.; Cox, David B. T.; Zhang, Feng] MIT, Dept Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Abudayyeh, Omar O.; Gootenberg, Jonathan S.; Konermann, Silvana; Joung, Julia; Slaymaker, Ian M.; Cox, David B. T.; Regev, Aviv; Lander, Eric S.; Zhang, Feng] Broad Inst & Harvard, Cambridge, MA 02142 USA.
[Abudayyeh, Omar O.; Gootenberg, Jonathan S.; Konermann, Silvana; Joung, Julia; Slaymaker, Ian M.; Cox, David B. T.; Zhang, Feng] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Abudayyeh, Omar O.; Gootenberg, Jonathan S.; Konermann, Silvana; Joung, Julia; Slaymaker, Ian M.; Cox, David B. T.; Zhang, Feng] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Abudayyeh, Omar O.; Gootenberg, Jonathan S.; Konermann, Silvana; Joung, Julia; Slaymaker, Ian M.; Cox, David B. T.; Zhang, Feng] MIT, Dept Biomol Engn, Cambridge, MA 02139 USA.
[Gootenberg, Jonathan S.; Lander, Eric S.] Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA.
[Cox, David B. T.; Regev, Aviv; Lander, Eric S.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Shmakov, Sergey] Skolkovo Inst Sci & Technol, Skolkovo 143025, Russia.
[Shmakov, Sergey; Makarova, Kira S.; Koonin, Eugene V.] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
[Semenova, Ekaterina; Minakhin, Leonid; Severinov, Konstantin] State Univ New Jersey, Rutgers, Waksman Inst Microbiol, Piscataway, NJ 08854 USA.
[Severinov, Konstantin] Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia.
RP Zhang, F (reprint author), MIT, Dept Hlth Sci & Technol, Cambridge, MA 02139 USA.; Zhang, F (reprint author), Broad Inst & Harvard, Cambridge, MA 02142 USA.; Zhang, F (reprint author), MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.; Zhang, F (reprint author), MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.; Zhang, F (reprint author), MIT, Dept Biomol Engn, Cambridge, MA 02139 USA.; Koonin, EV (reprint author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
EM koonin@ncbi.nlm.nih.gov; zhang@broadinstitute.org
FU Paul and Daisy Soros Fellowship; Friends of the McGovern Institute
Fellowship; Poitras Center for Affective Disorders; U.S. Department of
Energy (DOE); graduate program of Skoltech Data-Intensive Biomedicine
and Biotechnology Center for Research, Education, and Innovation; Simons
Center for the Social Brain; National Institute of General Medical
Sciences [T32GM007753]; U.S. Department of Health and Human Services;
NIH [GM10407]; Russian Science Foundation [14-14-00988]; Skoltech; NIH
through the National Institute of Mental Health [5DP1-MH100706,
1R01-MH110049]; NSF; New York Stem Cell Foundation; Simons, Paul G.
Allen Family Foundation; Vallee Foundation
FX We thank P. Boutz, J. Doench, P. Sharp, and B. Zetsche for helpful
discussions and insights; R. Belliveau for overall research support; J.
Francis and D. O'Connell for generous MiSeq instrument access; D.
Daniels and C. Garvie for providing bacterial incubation space for
protein purification; R. Macrae for critical reading of the manuscript;
and the entire Zhang laboratory for support and advice. We thank N. Ranu
for generously providing plasmid pRFP and D. Daniels for providing
6-His-MBP-TEV. O.O.A. is supported by a Paul and Daisy Soros Fellowship,
a Friends of the McGovern Institute Fellowship, and the Poitras Center
for Affective Disorders. J.S.G. is supported by a U.S. Department of
Energy (DOE) Computational Science Graduate Fellowship. S.S. is
supported by the graduate program of Skoltech Data-Intensive Biomedicine
and Biotechnology Center for Research, Education, and Innovation. I.M.S.
is supported by the Simons Center for the Social Brain. D.B.T.C. is
supported by award T32GM007753 from the National Institute of General
Medical Sciences. K.S.M., E.V.K., and, in part, S.S. are supported by
the intramural program of the U.S. Department of Health and Human
Services (to the National Library of Medicine). K.S. is supported by NIH
grant GM10407, Russian Science Foundation grant 14-14-00988, and
Skoltech. F.Z. is a New York Stem Cell Foundation Robertson
Investigator. F.Z. is supported by the NIH through the National
Institute of Mental Health (5DP1-MH100706 and 1R01-MH110049), NSF, the
New York Stem Cell, Simons, Paul G. Allen Family, and Vallee
Foundations; and J. Poitras, P. Poitras, R. Metcalfe, and D. Cheng. A.
R. is a member of the scientific advisory board for Syros
Pharmaceuticals and Thermo Fisher. O.O.A., J.S.G., J.J., E.V.K., S.K.,
E.S.L., K.S.M., L.M., E.S., K.S., S.S., and F.Z. are inventors on
provisional patent application 62/181,675 applied for by the Broad
Institute, MIT, Harvard, NIH, Skoltech, and Rutgers that covers the C2c2
proteins described in this paper. Deep sequencing data are available at
Sequence Read Archive under BioProject accession no. PRJNA318890. The
authors plan to make the reagents widely available to the academic
community through Addgene subject to a materials transfer agreement and
to provide software tools via the Zhang laboratory website
(www.genome-engineering.org) and GitHub
(https://github.com/fengzhanglab).
NR 50
TC 45
Z9 46
U1 12
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 5
PY 2016
VL 353
IS 6299
AR aaf5573
DI 10.1126/science.aaf5573
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5YZ
UT WOS:000381560900032
PM 27256883
ER
PT J
AU Mohanraju, P
Makarova, KS
Zetsche, B
Zhang, F
Koonin, EV
van der Oost, J
AF Mohanraju, Prarthana
Makarova, Kira S.
Zetsche, Bernd
Zhang, Feng
Koonin, Eugene V.
van der Oost, John
TI Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas
systems
SO SCIENCE
LA English
DT Review
ID GUIDED SURVEILLANCE COMPLEX; ADAPTIVE IMMUNE-SYSTEMS; GENOME-EDITING
SPECIFICITY; RNA-SILENCING COMPLEX; HUMAN-CELLS; SPACER ACQUISITION;
CRYSTAL-STRUCTURE; FOREIGN DNA; ESCHERICHIA-COLI; STRUCTURAL BASIS
AB Adaptive immunity had been long thought of as an exclusive feature of animals. However, the discovery of the CRISPR-Cas defense system, present in almost half of prokaryotic genomes, proves otherwise. Because of the everlasting parasite-host arms race, CRISPR-Cas has rapidly evolved through horizontal transfer of complete loci or individual modules, resulting in extreme structural and functional diversity. CRISPR-Cas systems are divided into two distinct classes that each consist of three types and multiple subtypes. We discuss recent advances in CRISPR-Cas research that reveal elaborate molecular mechanisms and provide for a plausible scenario of CRISPR-Cas evolution. We also briefly describe the latest developments of a wide range of CRISPR-based applications.
C1 [Mohanraju, Prarthana; van der Oost, John] Wageningen Univ, Dept Agrotechnol & Food Sci, Microbiol Lab, NL-6703 HB Wageningen, Netherlands.
[Makarova, Kira S.; Koonin, Eugene V.] Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA.
[Zetsche, Bernd; Zhang, Feng] Broad Inst & Harvard, Cambridge, MA 02142 USA.
RP van der Oost, J (reprint author), Wageningen Univ, Dept Agrotechnol & Food Sci, Microbiol Lab, NL-6703 HB Wageningen, Netherlands.
EM john.vanderoost@wur.nl
FU U.S. Department of Health and Human Services; NWO/TOP [714.015.001]; NIH
through NIMH [5DP1-MH100706, 1R01-MH110049]; NIH through NIDDK
[5R01DK097768-03]; New York Stem Cell Foundation; Paul G. Allen Family
Foundation; Vallee Foundation
FX E.V.K. and K.S.M. are supported by the intramural program of the U.S.
Department of Health and Human Services (to the National Library of
Medicine). J.v.d.O. and P.M. are supported by the NWO/TOP grant
714.015.001. F.Z. is a New York Stem Cell Foundation-Robertson
Investigator. F.Z. is supported by the NIH through NIMH (5DP1-MH100706
and 1R01-MH110049) and NIDDK (5R01DK097768-03), the New York Stem Cell,
Simons, Paul G. Allen Family, and Vallee Foundations, and D. R. Cheng,
T. Harriman, and R. Metcalfe. F.Z. is a founder of Editas Medicine and
scientific advisor for Editas Medicine and Horizon Discovery.
NR 166
TC 21
Z9 21
U1 10
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 5
PY 2016
VL 353
IS 6299
AR aad5147
DI 10.1126/science.aad5147
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT5YZ
UT WOS:000381560900031
PM 27493190
ER
PT J
AU Chou, HC
Pruitt, MM
Bastin, BR
Schneider, SQ
AF Chou, Hsien-Chao
Pruitt, Margaret M.
Bastin, Benjamin R.
Schneider, Stephan Q.
TI A transcriptional blueprint for a spiral-cleaving embryo
SO BMC GENOMICS
LA English
DT Article
DE Spiral cleavage; Lophotrochozoan; Annelid; Transcriptome; Maternal
contribution; Zygotic transcription
ID ANNELID PLATYNEREIS-DUMERILII; RNA-SEQ DATA; TO-ZYGOTIC TRANSITION;
CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; COMMON ORIGIN; ANIMAL
PHYLOGENY; GATA FACTORS; STEM-CELLS; GENOME
AB Background: The spiral cleavage mode of early development is utilized in over one-third of all animal phyla and generates embryonic cells of different size, position, and fate through a conserved set of stereotypic and invariant asymmetric cell divisions. Despite the widespread use of spiral cleavage, regulatory and molecular features for any spiral-cleaving embryo are largely uncharted. To address this gap we use RNA-sequencing on the spiralian model Platynereis dumerilii to capture and quantify the first complete genome-wide transcriptional landscape of early spiral cleavage.
Results: RNA-sequencing datasets from seven stages in early Platynereis development, from the zygote to the protrochophore, are described here including the de novo assembly and annotation of similar to 17,200 Platynereis genes. Depth and quality of the RNA-sequencing datasets allow the identification of the temporal onset and level of transcription for each annotated gene, even if the expression is restricted to a single cell. Over 4000 transcripts are maternally contributed and cleared by the end of the early spiral cleavage phase. Small early waves of zygotic expression are followed by major waves of thousands of genes, demarcating the maternal to zygotic transition shortly after the completion of spiral cleavages in this annelid species.
Conclusions: Our comprehensive stage-specific transcriptional analysis of early embryonic stages in Platynereis elucidates the regulatory genome during early spiral embryogenesis and defines the maternal to zygotic transition in Platynereis embryos. This transcriptome assembly provides the first systems-level view of the transcriptional and regulatory landscape for a spiral-cleaving embryo.
C1 [Chou, Hsien-Chao; Pruitt, Margaret M.; Bastin, Benjamin R.; Schneider, Stephan Q.] Iowa State Univ, Dept Genet Dev & Cell Biol, 503 Sci Hall 2, Ames, IA 50011 USA.
[Chou, Hsien-Chao] NCI, US Natl Inst Hlth, Bethesda, MD 20892 USA.
[Pruitt, Margaret M.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.
RP Schneider, SQ (reprint author), Iowa State Univ, Dept Genet Dev & Cell Biol, 503 Sci Hall 2, Ames, IA 50011 USA.
EM sqs@iastate.edu
FU Roy J. Carver Charitable Trust; National Science Foundation [1455185]
FX Funding for this work was provided by the Roy J. Carver Charitable Trust
and the National Science Foundation (Award ID 1455185) to SQS.
NR 102
TC 0
Z9 0
U1 6
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 5
PY 2016
VL 17
AR 552
DI 10.1186/s12864-016-2860-6
PG 25
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DT1EY
UT WOS:000381225700003
PM 27496340
ER
PT J
AU Lu, XW
Kovac, P
AF Lu, Xiaowei
Kovac, Pavol
TI Chemical Synthesis of the Galacturonic Acid Containing Pentasaccharide
Antigen of the O-Specific Polysaccharide of Vibrio cholerae O139 and Its
Five Fragments
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID SYNONYM BENGAL; PHOSPHORYLATED DISACCHARIDE; CAPSULAR POLYSACCHARIDE;
CONJUGATION-READY; OLIGOSACCHARIDES; DERIVATIVES; GLYCOSYLATION;
TRISACCHARIDE; DONORS; GALACTOSYLATION
AB Three pentasaccharides, two tetrasaccharides, and a trisaccharide fragment of the O-specific antigen of Vibrio cholerae O139 were synthesized by applying 1 + 1, 2 + 1, 3 + 1, and 4 + 1 coupling strategies. The most challenging tasks involved were the synthesis of the 1,2-cis-glycosidic linkage between galactose and the linker (spacer) molecule and final purification of the target multicharged substances. Difficulties with final deprotection by hydrogenation/hydrogenolysis caused by the presence of galacturonic acid were overcome by protecting the acid with a group inert to the treatment with hydrogen. Some intermediates described previously as incompletely characterized amorphous materials were obtained in the crystalline condition and were fully characterized for the first time.
C1 [Lu, Xiaowei; Kovac, Pavol] NIDDK, Sect Carbohydrates, Bioorgan Chem Lab, NIH, 8 Ctr Dr, Bethesda, MD 20892 USA.
RP Kovac, P (reprint author), NIDDK, Sect Carbohydrates, Bioorgan Chem Lab, NIH, 8 Ctr Dr, Bethesda, MD 20892 USA.
EM kpn@helix.nih.gov
FU Intramural Research Program of the National Institutes of Health (NIH);
National Institute of Diabetes and Digestive and Kidney Diseases
[DK059701]
FX This research was supported by the Intramural Research Program of the
National Institutes of Health (NIH) and National Institute of Diabetes
and Digestive and Kidney Diseases (DK059701).
NR 58
TC 0
Z9 0
U1 9
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD AUG 5
PY 2016
VL 81
IS 15
BP 6374
EP 6394
DI 10.1021/acs.joc.6b01019
PG 21
WC Chemistry, Organic
SC Chemistry
GA DT1IX
UT WOS:000381236000024
PM 27452084
ER
PT J
AU Bhattacharjee, A
Yang, HJ
Duffy, M
Robinson, E
Conrad-Antoville, A
Lu, YW
Capps, T
Braiterman, L
Wolfgang, M
Murphy, MP
Yi, L
Kaler, SG
Lutsenko, S
Ralle, M
AF Bhattacharjee, Ashima
Yang, Haojun
Duffy, Megan
Robinson, Emily
Conrad-Antoville, Arianrhod
Lu, Ya-Wen
Capps, Tony
Braiterman, Lelita
Wolfgang, Michael
Murphy, Michael P.
Yi, Ling
Kaler, Stephen G.
Lutsenko, Svetlana
Ralle, Martina
TI The Activity of Menkes Disease Protein ATP7A Is Essential for Redox
Balance in Mitochondria
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID EARLY COPPER THERAPY; TX-J MOUSE; WILSON-DISEASE; HYDROGEN-PEROXIDE;
OXIDATIVE STRESS; MURINE HOMOLOG; IN-VIVO; MODEL; CELLS; MICE
AB Copper-transporting ATPase ATP7A is essential for mammalian copper homeostasis. Loss of ATP7A activity is associated with fatal Menkes disease and various other pathologies. In cells, ATP7A inactivation disrupts copper transport from the cytosol into the secretory pathway. Using fibroblasts from Menkes disease patients and mouse 3T3-L1 cells with a CRISPR/Cas9-inactivated ATP7A, we demonstrate that ATP7A dysfunction is also damaging to mitochondrial redox balance. In these cells, copper accumulates in nuclei, cytosol, and mitochondria, causing distinct changes in their redox environment. Quantitative imaging of live cells using GRX1-roGFP2 and HyPer sensors reveals highest glutathione oxidation and elevation of H2O2 in mitochondria, whereas the redox environment of nuclei and the cytosol is much less affected. Decreasing the H2O2 levels in mitochondria with MitoQ does not prevent glutathione oxidation; i.e. elevated copper and not H2O2 is a primary cause of glutathione oxidation. Redox misbalance does not significantly affect mitochondrion morphology or the activity of respiratory complex IV but markedly increases cell sensitivity to even mild glutathione depletion, resulting in loss of cell viability. Thus, ATP7A activity protects mitochondria from excessive copper entry, which is deleterious to redox buffers. Mitochondrial redox misbalance could significantly contribute to pathologies associated with ATP7A inactivation in tissues with paradoxical accumulation of copper (i.e. renal epithelia).
C1 [Bhattacharjee, Ashima; Yang, Haojun; Lu, Ya-Wen; Lutsenko, Svetlana] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.
[Braiterman, Lelita] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.
[Wolfgang, Michael] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.
[Duffy, Megan; Robinson, Emily; Conrad-Antoville, Arianrhod; Capps, Tony; Ralle, Martina] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
[Murphy, Michael P.] MRC, Mitochondrial Biol Unit, Cambridge CB2 0XY, England.
[Yi, Ling; Kaler, Stephen G.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Translat Neurosci, NIH, Bethesda, MD 20892 USA.
RP Lutsenko, S (reprint author), 725 N Wolfe St, Baltimore, MD 21205 USA.; Ralle, M (reprint author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM Lutsenko@jhmi.edu; rallem@ohsu.edu
FU Department of Energy, Office of Science, Office of Basic Energy Sciences
[DE-AC02-06CH11357]
FX We thank Dr Ann Hubbard (Johns Hopkins University School of Medicine)
for XS and YS cells, Dr. Tobias P. Dick (German Cancer Research Center
(DKFZ), Heidelberg, Germany) for the GRX1-roGFP2 construct, and Dr.
Vadim Gladyshev (Brigham and Women's Hospital, Harvard Medical School)
for the HyPer constructs. The Elemental Analysis Core at Oregon Health
and Science University performed ICP-MS measurements. We acknowledge use
of the Advanced Photon Source at Argonne National Laboratory, supported
by the Department of Energy, Office of Science, Office of Basic Energy
Sciences, under contract no. DE-AC02-06CH11357. We thank the staff of
Johns Hopkins School of Medicine MicFac facility for help with EM sample
sectioning and staining.
NR 52
TC 3
Z9 3
U1 3
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 5
PY 2016
VL 291
IS 32
BP 16644
EP 16658
DI 10.1074/jbc.M116.727248
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DS5MQ
UT WOS:000380826700023
PM 27226607
ER
PT J
AU Erbil, S
Oral, O
Mitou, G
Kig, C
Durmaz-Timucin, E
Guven-Maiorov, E
Gulacti, F
Gokce, G
Dengjel, J
Sezerman, OU
Gozuacik, D
AF Erbil, Secil
Oral, Ozlem
Mitou, Geraldine
Kig, Cenk
Durmaz-Timucin, Emel
Guven-Maiorov, Emine
Gulacti, Ferah
Gokce, Gokcen
Dengjel, Jorn
Sezerman, Osman Ugur
Gozuacik, Devrim
TI RACK1 Is an Interaction Partner of ATG5 and a Novel Regulator of
Autophagy
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MOLECULAR-DYNAMICS; PROTEIN; COMPLEX; MTOR; PHOSPHORYLATION;
IDENTIFICATION; MECHANISMS; PROTEOMICS; CONJUGATE; FIELDS
AB Autophagy is biological mechanism allowing recycling of long-lived proteins, abnormal protein aggregates, and damaged organelles under cellular stress conditions. Following sequestration in double-or multimembrane autophagic vesicles, the cargo is delivered to lysosomes for degradation. ATG5 is a key component of an E3-like ATG12-ATG5-ATG16 protein complex that catalyzes conjugation of the MAP1LC3 protein to lipids, thus controlling autophagic vesicle formation and expansion. Accumulating data indicate that ATG5 is a convergence point for autophagy regulation. Here, we describe the scaffold protein RACK1 (receptor activated C-kinase 1, GNB2L1) as a novel ATG5 interactor and an autophagy protein. Using several independent techniques, we showed that RACK1 interacted with ATG5. Importantly, classical autophagy inducers (starvation or mammalian target of rapamycin blockage) stimulated RACK1-ATG5 interaction. Knockdown of RACK1 or prevention of its binding to ATG5 using mutagenesis blocked autophagy activation. Therefore, the scaffold protein RACK1 is a new ATG5-interacting protein and an important and novel component of the autophagy pathways.
C1 [Erbil, Secil; Oral, Ozlem; Mitou, Geraldine; Kig, Cenk; Durmaz-Timucin, Emel; Gulacti, Ferah; Gokce, Gokcen; Gozuacik, Devrim] Sabanci Univ, Mol Biol Genet & Bioengn Program, TR-34956 Istanbul, Turkey.
[Guven-Maiorov, Emine] Koc Univ, Dept Chem & Biol Engn, TR-34450 Istanbul, Turkey.
[Guven-Maiorov, Emine] Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey.
[Dengjel, Jorn] Univ Fribourg, Dept Biol, Chemin Musee 10, CH-1700 Fribourg, Switzerland.
[Sezerman, Osman Ugur] Acibadem Univ, Sch Med, Dept Biostat & Med Informat, TR-34752 Istanbul, Turkey.
[Oral, Ozlem] Sabanci Univ, Nanotechnol Res & Applicat Ctr, TR-34956 Istanbul, Turkey.
[Mitou, Geraldine] Inserm UMR1037 CRCT, F-31000 Toulouse, France.
[Guven-Maiorov, Emine] NCI, Ctr Canc Res, NIH, Bldg 542,Rm 603, Frederick, MD 21702 USA.
[Gulacti, Ferah] Duzce Ataturk Publ Hosp, Aziziye Str, TR-81010 Duzce, Turkey.
[Gokce, Gokcen] Santa Farma Drug Co, Borucicegi Str 16, TR-34382 Istanbul, Turkey.
RP Gozuacik, D (reprint author), Sabanci Univ, Mol Biol Genet & Bioengn Program, TR-34956 Istanbul, Turkey.
EM dgozuacik@sabanciuniv.edu
OI Guven Maiorov, Emine/0000-0002-7388-9811
FU Scientific and Technological Research Council of Turkey (TUBITAK)
[107T153]; Sabanci University; Swiss National Science Foundation
[31003A-166482/1]; TUBITAK [BIDEB 2211]; IKU Prof. Onder Oztunali
Science Award; TGC Sedat Simavi Health Sciences Award; Elginkan
Foundation Technology Award
FX This work was supported in part by Scientific and Technological Research
Council of Turkey (TUBITAK) 1001 Grant 107T153, the Sabanci University
(to D. G.), and Swiss National Science Foundation Grant 31003A-166482/1
(to J. D.). The authors declare that they have no conflicts of interest
with the contents of this article.; Supported by a TUBITAK BIDEB 2211
Scholarship for Ph.D. studies.; Recipient of IKU Prof. Onder Oztunali
Science Award, TGC Sedat Simavi Health Sciences Award, and Elginkan
Foundation Technology Award. To whom correspondence should be addressed.
Tel.: 90-216-4839617; E-mail: dgozuacik@sabanciuniv.edu.
NR 39
TC 1
Z9 1
U1 5
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 5
PY 2016
VL 291
IS 32
BP 16753
EP 16765
DI 10.1074/jbc.M115.708081
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DS5MQ
UT WOS:000380826700032
PM 27325703
ER
PT J
AU Kim, JH
Wahyudi, LD
Kim, KK
Gonzalez, FJ
AF Kim, Jung-Hwan
Wahyudi, Lilik Duwi
Kim, Kee K.
Gonzalez, Frank J.
TI PPAR alpha activation drives demethylation of the CpG islands of the
Gadd45b promoter in the mouse liver
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Gadd45b; PPAR alpha; CpG methylation
ID OXIDATIVE STRESS; GENE; RECEPTORS
AB Growth arrest and DNA damage-inducible beta (GADD45b) plays a pivotal role in many intracellular events in both cell survival- and cell death-related signaling. To date, the study of GADD35b has mainly focused on investigation of its function, as well as interacting molecules. However, studies of Gadd45b gene regulation are limited. In this study, we investigated the transcriptional regulation mechanism of Gadd45b. Since Gadd45b mRNA is highly induced by the PPAR alpha agonist Wy-14,643 in the mouse liver, we analyzed the Gadd45b promoter using an in vivo reporter assay. Interestingly, the naked Gadd45b-luciferase construct strongly induced luciferase activity without any stimulant in our in vivo system. Therefore, we investigated the epigenetic changes in the Gadd45b promoter region using mouse liver genomic DNA, the methylation-specific restriction enzyme (HpaII), and disulfide conversion. Our results showed that two possible CpG methylation sites were methylated and demethylated by Wy-14,643 treatment. This study indicates that epigenetic change at the Gadd45b promoter is critical for Gadd45b induction. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Kim, Jung-Hwan; Wahyudi, Lilik Duwi] Gyeongsang Natl Univ, Inst Hlth Sci, Sch Med, Dept Pharmacol, Jinju 52727, South Korea.
[Kim, Kee K.] Chungnam Natl Univ, Dept Biochem, Daejeon 34134, South Korea.
[Gonzalez, Frank J.] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Kim, JH (reprint author), Gyeongsang Natl Univ, Inst Hlth Sci, Sch Med, Dept Pharmacol, Jinju 52727, South Korea.
EM junghwan.kim@gnu.ac.kr
FU National Research Foundation of Korea (NRF) grant - Korea government
(MEST) [NRF-2015R1A5A2008833]; Fund for New Professor Research
Foundation Program, Gyeongsang National University [2014-04-007];
Institute of Health Sciences [HIS GNU-2014-2]; National Cancer Institute
Intramural Research Program
FX This work was supported by the National Research Foundation of Korea
(NRF) grant funded by the Korea government (MEST)
(NRF-2015R1A5A2008833), the Fund for New Professor Research Foundation
Program, Gyeongsang National University (2014-04-007), the grant of
Institute of Health Sciences (HIS GNU-2014-2), and the National Cancer
Institute Intramural Research Program.
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 5
PY 2016
VL 476
IS 4
BP 293
EP 298
DI 10.1016/j.bbrc.2016.05.115
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DR4QE
UT WOS:000379886500018
PM 27233605
ER
PT J
AU Yamashita, S
Tanaka, M
Sato, T
Ida, C
Ohta, N
Hamada, T
Uetsuki, T
Nishi, Y
Moss, J
Miwa, M
AF Yamashita, Sachiko
Tanaka, Masakazu
Sato, Teruaki
Ida, Chieri
Ohta, Narumi
Hamada, Takashi
Uetsuki, Taichi
Nishi, Yoshisuke
Moss, Joel
Miwa, Masanao
TI Effect of mild temperature shift on poly(ADP-ribose) and gamma H2AX
levels in cultured cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Thermal environment; DNA double-strand break; DNA single-strand break;
gamma H2AX; Poly(ADP-ribose); DNA repair
ID STRAND BREAKS; HISTONE H2AX; MAMMALIAN-CELLS; DNA; HYPERTHERMIA; REPAIR;
PHOSPHORYLATION; DAMAGE
AB Poly (ADP-ribose) (PAR) is rapidly synthesized by PAR polymerases (PARPs) upon activation by DNA single- and double-strand breaks. In this study, we examined the quantitative amount of PAR in HeLa cells cultured within the physiological temperatures below 41 degrees C for verification of the effect of shifting up or -down the temperature from 37.0 degrees C on the DNA breaks, whether the temperature-shift caused breaks that could be monitored by the level of PAR. While PAR level did not change significantly when HeLa cells were cultured at 33.5 degrees C or 37.0 degrees C, it was significantly increased 2- and 3-fold when cells were cultured for 12 h and 24 h, respectively, at 40.5 degrees C as compared to 37.0 degrees C. Similar to the results with HeLa cells, PAR level was increased 2-fold in CHO-K1 cells cultured at 40.5 degrees C for 24 h as compared to 37.0 degrees C. As the cellular levels of PAR polymerasel (PARP1) and PAR glycohydrolase (PARG), a major degradation enzyme for PAR, did not seem to change significantly, this increase could be caused by activation of PARP1 by DNA strand breaks. In fact, gamma H2AX, claimed to be a marker of DNA double-strand breaks, was found in cell extracts of HeLa cells and CHO-Kl cells at elevated temperature vs. 37.0 degrees C, and these gamma H2AX signals were intensified in the presence of 3-aminobenzamide, a PARP inhibitor. The gamma H2AX immunohistochemistry results in HeLa cells were consistent with Western blot analyses. In HeLa cells, proliferation was significantly suppressed at 40.5 degrees C in 72 h-continuous cultures and decreased viabilities were also observed after 24-72 h at 40.5 degrees C. Flow cytometric analyses showed that the HeLa cells were arrested at G2/M after temperature shift-up to 40.5 degrees C. These physiological changes were potentiated in the presence of 3-aminobenzamide. Decrease in growth rates, increased cytotoxicity and G2/M arrest, were associated with the temperature-shift to 40.5 degrees C and are indirect evidence of DNA breaks. In addition to gamma H2AX, PAR could be a sensitive marker for DNA single- and double-strand breaks. These two molecular markers provide evidence of physiological changes occurring within cells. (C) 2016 Published by Elsevier Inc.
C1 [Yamashita, Sachiko; Sato, Teruaki; Ohta, Narumi; Hamada, Takashi; Uetsuki, Taichi; Nishi, Yoshisuke; Miwa, Masanao] Nagahama Inst Biosci & Technol, Fac Biosci, 1266 Tamura, Nagahama, Shiga 5260829, Japan.
[Tanaka, Masakazu] Kansai Med Univ, Dept Microbiol, 2-5-1 Shin Machi, Hirakata, Osaka 5731010, Japan.
[Ida, Chieri] Coll Nagoya Womens Univ, Dept Appl Life Studies, Mizuho Ku, 3-40 Shioji Cho, Nagoya, Aichi 4678610, Japan.
[Moss, Joel] NHLBI, Cardiovasc & Pulm Branch, NIH, Bethesda, MD 20892 USA.
RP Miwa, M (reprint author), Nagahama Inst Biosci & Technol, Fac Biosci, 1266 Tamura, Nagahama, Shiga 5260829, Japan.
EM m_miwa@nagahama-i-bio.ac.jp
FU Japan Society for the Promotion of Science [23590350]; Intramural
Research Program (National Institutes of Health [NIH], National Heart,
Lung, and Blood Institute [NHLBI])
FX This work was supported in part by Grants-in-Aid for Scientific Research
(23590350) from the Japan Society for the Promotion of Science. J.M. was
supported by the Intramural Research Program (National Institutes of
Health [NIH], National Heart, Lung, and Blood Institute [NHLBI]).
NR 26
TC 0
Z9 0
U1 5
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 5
PY 2016
VL 476
IS 4
BP 594
EP 599
DI 10.1016/j.bbrc.2016.06.001
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DR4QE
UT WOS:000379886500064
PM 27262441
ER
PT J
AU Tabakoff, B
Ren, W
Vanderlinden, L
Snell, LD
Matheson, CJ
Wang, ZJ
Levinson, R
Smothers, CT
Woodward, JJ
Honse, Y
Lovinger, D
Rush, AM
Sather, WA
Gustafson, DL
Hoffman, PL
AF Tabakoff, Boris
Ren, Wenhua
Vanderlinden, Lauren
Snell, Lawrence D.
Matheson, Christopher J.
Wang, Ze-Jun
Levinson, Rock
Smothers, C. Thetford
Woodward, John J.
Honse, Yumiko
Lovinger, David
Rush, Anthony M.
Sather, William A.
Gustafson, Daniel L.
Hoffman, Paula L.
TI A novel substituted aminoquinoline selectively targets voltage-sensitive
sodium channel isoforms and NMDA receptor subtypes and alleviates
chronic inflammatory and neuropathic pain
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Chronic pain; NMDA; GluN2B; Na(v)1.8; Na(v)1.7; Substituted
aminoquinoline
ID DORSAL-ROOT GANGLION; D-ASPARTATE RECEPTORS; OF-HEALTH PATHWAYS; NERVE
INJURY; OPIOID RECEPTOR; SPINAL-CORD; ELECTROPHYSIOLOGICAL PROPERTIES;
MECHANICAL HYPERALGESIA; GLUTAMATE RECEPTORS; DIABETIC-NEUROPATHY
AB Recent understanding of the systems that mediate complex disease states, has generated a search for molecules that simultaneously modulate more than one component of a pathologic pathway. Chronic pain syndromes are etiologically connected to functional changes (sensitization) in both peripheral sensory neurons and in the central nervous system (CNS). These functional changes involve modifications of a significant number of components of signal generating, signal transducing and signal propagating pathways. Our analysis of disease-related changes which take place in sensory neurons during sensitization led to the design of a molecule that would simultaneously inhibit peripheral NMDA receptors and voltage sensitive sodium channels. In the current report, we detail the selectivity of N,N(diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline (DCUKA) for action at NMDA receptors composed of different subunit combinations and voltage sensitive sodium channels having different alpha subunits. We show that DCUKA is restricted to the periphery after oral administration, and that circulating blood levels are compatible with its necessary concentrations for effects at the peripheral cognate receptors/channels that were assayed in vitro. Our results demonstrate that DCUKA, at concentrations circulating in the blood after oral administration, can modulate systems which are upregulated during peripheral sensitization, and are important for generating and conducting pain information to the CNS. Furthermore, we demonstrate that DCUKA ameliorates the hyperalgesia of chronic pain without affecting normal pain responses in neuropathic and inflammation-induced chronic pain models. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Tabakoff, Boris; Ren, Wenhua; Snell, Lawrence D.] Lohocla Res Corporat, Colorado Biosci Bldg,12635 East Montview Blvd, Aurora, CO 80045 USA.
[Tabakoff, Boris; Vanderlinden, Lauren; Matheson, Christopher J.] Univ Colorado Anschutz Med Campus, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Campus Box C238 12850,E Montview Blvd, Aurora, CO 80045 USA.
[Levinson, Rock] Univ Colorado Anschutz Med Campus, Dept Physiol & Biophys, 12800 E 19th Ave, Aurora, CO 80045 USA.
[Smothers, C. Thetford; Woodward, John J.] Med Univ S Carolina, Dept Neurosci, 171 Ashley Ave, Charleston, SC 29425 USA.
[Smothers, C. Thetford; Woodward, John J.] Med Univ S Carolina, Dept Psychiat, 171 Ashley Ave, Charleston, SC 29425 USA.
[Honse, Yumiko; Lovinger, David] NIAAA, Clin & Biol Res Unit, 12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.
[Rush, Anthony M.] Neurosolut Ltd, Coventry CV4 7ZS, W Midlands, England.
[Sather, William A.; Hoffman, Paula L.] Univ Colorado Anschutz Med Campus, Dept Pharmacol, 12800 E 19 Ave, Aurora, CO 80045 USA.
[Gustafson, Daniel L.] Colorado State Univ, Vet Teaching Hosp, UCCC Pharmacol Shared Resource, A CC246,300 West Drake Rd, Ft Collins, CO 80023 USA.
[Ren, Wenhua] Univ Colorado Denver, Genom & Microarray Core Lab, Campus Box C272,12700 E 19th Ave, Aurora, CO 80045 USA.
[Snell, Lawrence D.] Colorado Neurol Inst, 701 E Hampden Ave, Englewood, CO 80113 USA.
[Wang, Ze-Jun] Howard Univ, Coll Med, Dept Anat, 520 W Str NW, Washington, DC 20059 USA.
[Rush, Anthony M.] Metrion Biosci Ltd, B501 Babraham Res Campus, Cambridge CB22 3AT, England.
RP Tabakoff, B (reprint author), Univ Colorado Anschutz Med Campus, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Campus Box C238 12850,E Montview Blvd, Aurora, CO 80045 USA.
EM boris.tabakoff@Lohocla.com; wenhua.ren@ucdenver.edu;
lauren.vanderlinden@ucdenver.edu; LDSnell56@gmail.com;
chris.matheson@ucdenver.edu; zwang@Howard.edu;
rock.levinson@ucdenver.edu; corigan3@aim.com; woodward@musc.edu;
honseymk@hotmail.com; lovindav@mail.nih.gov;
tony.rush@metrionbiosciences.com; william.sather@ucdenver.edu;
daniel.gustafson@ColoState.edu; paula.hoffman@ucdenver.edu
FU Banbury Fund; NIH/NIAAA (SBIR grant) [R44AA009930]; NIH/NHLBI
[R01HL088548]; University of Colorado Cancer Center Support Grant
[P30CA046934]; National Institute of Mental Health's Psychoactive Drug
Screening Program [HHSN-271-2013-00017-C]
FX This work was supported in part by the Banbury Fund and NIH/NIAAA (SBIR
grant R44AA009930) to B.T. and NIH/NHLBI (R01HL088548) to W.A.S.
Pharmacokinetic analysis was performed in the Pharmacology Shared
Resource (D.L.G.) with support from a University of Colorado Cancer
Center Support Grant (P30CA046934). Receptor binding profiles were
generously provided by the National Institute of Mental Health's
Psychoactive Drug Screening Program, Contract # HHSN-271-2013-00017-C
(NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD at the
University of North Carolina at Chapel Hill and Project Officer Jamie
Driscoll at NIMH, Bethesda MD, USA. The sponsors had no role in study
design; collection, analysis and interpretation of data; writing of the
manuscript; or decision to submit the manuscript for publication.
NR 92
TC 0
Z9 0
U1 5
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 5
PY 2016
VL 784
BP 1
EP 14
DI 10.1016/j.ejphar.2016.05.006
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DR1GI
UT WOS:000379653600001
PM 27158117
ER
PT J
AU Moaddel, R
Sanghvi, M
Ramamoorthy, A
Jozwiak, K
Singh, N
Green, C
O'Loughlin, K
Torjman, M
Wainer, IW
AF Moaddel, R.
Sanghvi, M.
Ramamoorthy, A.
Jozwiak, K.
Singh, N.
Green, C.
O'Loughlin, K.
Torjman, M.
Wainer, I. W.
TI Subchronic administration of (R,S)-ketamine induces ketamine ring
hydroxylation in Wistar rats
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Neuropathic pain; Complex Regional Pain Syndrome;
(2S,6R)-hydroxynorketamine
ID REGIONAL PAIN SYNDROME; MAJOR DEPRESSION; SERINE RACEMASE; METABOLITES;
EXPRESSION; PHARMACOLOGY; NORKETAMINE; INDUCTION; INFUSION; PLASMA
AB Subchronic administration of (R,S)-ketamine, (R,S)-Ket, is used in the treatment of neuropathic pain, in particular Complex Regional Pain Syndrome, but the effect of this protocol on the metabolism of (R,S)-Ket is unknown. In this study, daily administration of a low dose of (R,S)-Ket for 14-days to Wistar rats was conducted to determine the impact of sub-chronic dosing on the pharmacokinetics of (R,S)-Ket and its major metabolites. The data indicate that, relative to a single administration of (R,S)-Ket, subchronic administration resulted in increased clearance of (R,S)-Ket and the N-demethylated metabolite norketamine measured as elimination half-life (t(1/2)) and decreased plasma concentrations of these compounds. Subchronic administration produced a slight decrease in t(1/2) and an increase in plasma concentration of the major metabolite, (2S,6S;2R,6R)-hydroxynorketamine, and produced significant increases in the plasma concentrations of the (2S,6R;2R,6S)-hydroxynorketamine and (2S,4R;2R,4S)-hydroxynorketamine metabolites. The metabolism of (R,S)-Ket predominately occurs via two microsomal enzyme-mediated pathways: (R,S)-Ket double right arrow (RS)-norketamine double right arrow (2S,6S;2R,6R)-hydroxynorketamine and (2S,4R;2R,4S)-hydroxynorketamine and the (R,S)-Ket double right arrow (2S,6R;2R,6S)-hydroxyketamine double right arrow (2S,6R;2R,6S)-hydroxynorketamine and (2S,6S;2R,6R)-hydroxynorketamine. The results indicate that the activity of both metabolic pathways are increased by subchronic administration of (R,S)-Ket producing new metabolite patterns and potential differences in clinical effects. Published by Elsevier B.V.
C1 [Moaddel, R.; Sanghvi, M.; Ramamoorthy, A.; Singh, N.; Wainer, I. W.] NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA.
[Jozwiak, K.] Med Univ Lublin, Dept Biopharm, Lublin, Poland.
[Green, C.; O'Loughlin, K.] SRI Int, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.
[Torjman, M.] Cooper Univ Hosp, Robert Wood Johnson Med Sch, UMDNJ, Dept Anesthesiol, Camden, NJ 08103 USA.
[Wainer, I. W.] Mitchell Woods Pharmaceut, Shelton, CT USA.
RP Wainer, IW (reprint author), Mitchell Woods Pharmaceut Inc, 4 Corp Dr,Suite 287, Shelton, CT 06484 USA.
EM iwwainer@mitchellwoods.com
RI Singh, Nagendra/K-8966-2015
FU Intramural Research Program of the National Institute on Aging/NIH and
NIA [HHSN271201000008I]
FX This work was supported by funding from the Intramural Research Program
of the National Institute on Aging/NIH and NIA Contract no.
HHSN271201000008I.
NR 29
TC 1
Z9 1
U1 7
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731-7085
EI 1873-264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD AUG 5
PY 2016
VL 127
SI SI
BP 3
EP 8
DI 10.1016/j.jpba.2016.03.030
PG 6
WC Chemistry, Analytical; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DP8PL
UT WOS:000378760000002
PM 27017097
ER
PT J
AU Marszall, MP
Sroka, WD
Sikora, A
Chelminiak, D
Ziegler-Borowska, M
Siodmiak, T
Moaddel, R
AF Marszall, Michal Piotr
Sroka, Wiktor Dariusz
Sikora, Adam
Chelminiak, Dorota
Ziegler-Borowska, Marta
Siodmiak, Tomasz
Moaddel, Ruin
TI Ligand fishing using new chitosan based functionalized Androgen Receptor
magnetic particles
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Androgen receptor; Antiandrogens; Chitosan; Ligand fishing; Magnetic
beads
ID HUMAN SERUM-ALBUMIN; PROSTATE-CANCER; BINDING ASSAY; NANOPARTICLES;
PROTEIN; BEADS; IMMOBILIZATION; TARGET; IDENTIFICATION; DISCOVERY
AB Superparamagnetic nanoparticles with chemically modified chitosan has been proposed as a potential support for the immobilization of the androgen receptor (AR). The study involved comparison of different AR carriers like commercially available magnetic beads coated with silica (BcMag) and chitosan coated nanoparticles with different amount of amino groups. The immobilization was carried out through covalent immobilization of the AR through the terminal amino group or through available carboxylic acids. The initial characterization of the AR coated magnetic beads was carried out with dihydrotestosterone, a known AR ligand. Subsequently, chitosan modified nanporticles with long-distanced primary amino groups (Fe3O4CS-(NH2)(3)) (upto 8.34 mM/g) were used for further study to isolate known AR ligands (bicalutamide, flutamide, hydroxyflutamide and levonogestrel) from a mixture of tested compounds in ammonium acetate buffer [10mM, pH 7.4]. The results showed that the selected nanoparticles are a promising semi-quantitative tool for the identification of high affinity compounds to AR and might be of special importance in the identification of novel agonists or antiandrogens. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Marszall, Michal Piotr; Sroka, Wiktor Dariusz; Sikora, Adam; Siodmiak, Tomasz] Nicolaus Copernicus Univ Torun, Ludwik Rydygier Coll Med Bydgoszcz, Dept Med Chem, Ul Jurasza 2, PL-85089 Bydgoszcz, Poland.
[Chelminiak, Dorota; Ziegler-Borowska, Marta] Nicolaus Copernicus Univ Torun, Fac Chem, Gagarina 7, PL-87100 Torun, Poland.
[Moaddel, Ruin] NIA, Lab Clin Invest, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
RP Marszall, MP (reprint author), Nicolaus Copernicus Univ Torun, Ludwik Rydygier Coll Med Bydgoszcz, Dept Med Chem, Ul Jurasza 2, PL-85089 Bydgoszcz, Poland.
EM mmars@cm.umk.pl
RI Ziegler-Borowska, Marta/O-5764-2015; Marszall, Michal/G-8936-2014;
Sroka, Wiktor/H-7860-2014; Chelminiak-Dudkiewicz, Dorota/O-5864-2015
FU National Science Centre [DEC-2011/03/D/NZ7/02296]; NIA Intramural
Research Program
FX The project was supported by research grant: National Science Centre:
DEC-2011/03/D/NZ7/02296. This work was also supported in part by funds
from the NIA Intramural Research Program (RM).
NR 28
TC 1
Z9 1
U1 11
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731-7085
EI 1873-264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD AUG 5
PY 2016
VL 127
SI SI
BP 129
EP 135
DI 10.1016/j.jpba.2016.04.013
PG 7
WC Chemistry, Analytical; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DP8PL
UT WOS:000378760000016
PM 27156644
ER
PT J
AU Fuchsberger, C
Flannick, J
Teslovich, TM
Mahajan, A
Agarwala, V
Gaulton, KJ
Ma, C
Fontanillas, P
Moutsianas, L
McCarthy, DJ
Rivas, MA
Perry, JRB
Sim, X
Blackwell, TW
Robertson, NR
Rayner, NW
Cingolani, P
Locke, AE
Tajes, JF
Highland, HM
Dupuis, J
Chines, PS
Lindgren, CM
Hartl, C
Jackson, AU
Chen, H
Huyghe, JR
van de Bunt, M
Pearson, RD
Kumar, A
Muller-Nurasyid, M
Grarup, N
Stringham, HM
Gamazon, ER
Lee, J
Chen, YH
Scott, RA
Below, JE
Chen, P
Huang, J
Go, MJ
Stitzel, ML
Pasko, D
Parker, SCJ
Varga, TV
Green, T
Beer, NL
Day-Williams, AG
Ferreira, T
Fingerlin, T
Horikoshi, M
Hu, C
Huh, I
Ikram, MK
Kim, BJ
Kim, Y
Kim, YJ
Kwon, MS
Lee, J
Lee, S
Lin, KH
Maxwell, TJ
Nagai, Y
Wang, X
Welch, RP
Yoon, J
Zhang, W
Barzilai, N
Voight, BF
Han, BG
Jenkinson, CP
Kuulasmaa, T
Kuusisto, J
Manning, A
Ng, MCY
Palmer, ND
Balkau, B
Stancakova, A
Abboud, HE
Boeing, H
Giedraitis, V
Prabhakaran, D
Gottesman, O
Scott, J
Carey, J
Kwan, P
Grant, G
Smith, JD
Neale, BM
Purcell, S
Butterworth, AS
Howson, JMM
Lee, HM
Lu, YC
Kwak, SH
Zhao, W
Danesh, J
Lam, VKL
Park, KS
Saleheen, D
So, WY
Tam, CHT
Afzal, U
Aguilar, D
Arya, R
Aung, T
Chan, E
Navarro, C
Cheng, CY
Palli, D
Correa, A
Curran, JE
Rybin, D
Farook, VS
Fowler, SP
Freedman, BI
Griswold, M
Hale, DE
Hicks, PJ
Khor, CC
Kumar, S
Lehne, B
Thuillier, D
Lim, WY
Liu, J
van der Schouw, YT
Loh, M
Musani, SK
Puppala, S
Scott, WR
Yengo, L
Tan, ST
Taylor, HA
Thameem, F
Wilson, G
Wong, TY
Njolstad, PR
Levy, JC
Mangino, M
Bonnycastle, LL
Schwarzmayr, T
Fadista, J
Surdulescu, GL
Herder, C
Groves, CJ
Wieland, T
Bork-Jensen, J
Brandslund, I
Christensen, C
Koistinen, HA
Doney, ASF
Kinnunen, L
Esko, T
Farmer, AJ
Hakaste, L
Hodgkiss, D
Kravic, J
Lyssenko, V
Hollensted, M
Jorgensen, ME
Jorgensen, T
Ladenvall, C
Justesen, JM
Karajamaki, A
Kriebel, J
Rathmann, W
Lannfelt, L
Lauritzen, T
Narisu, N
Linneberg, A
Melander, O
Milani, L
Neville, M
Orho-Melander, M
Qi, L
Qi, QB
Roden, M
Rolandsson, O
Swift, A
Rosengren, AH
Stirrups, K
Wood, AR
Mihailov, E
Blancher, C
Carneiro, MO
Maguire, J
Poplin, R
Shakir, K
Fennell, T
DePristo, M
de Angelis, MH
Deloukas, P
Gjesing, AP
Jun, G
Nilsson, P
Murphy, J
Onofrio, R
Thorand, B
Hansen, T
Meisinger, C
Hu, FB
Isomaa, B
Karpe, F
Liang, LM
Peters, A
Huth, C
O'Rahilly, SP
Palmer, CNA
Pedersen, O
Rauramaa, R
Tuomilehto, J
Salomaa, V
Watanabe, RM
Syvanen, AC
Bergman, RN
Bharadwaj, D
Bottinger, EP
Cho, YS
Chandak, GR
Chan, JCN
Chia, KS
Daly, MJ
Ebrahim, SB
Langenberg, C
Elliott, P
Jablonski, KA
Lehman, DM
Jia, WP
Ma, RCW
Pollin, TI
Sandhu, M
Tandon, N
Froguel, P
Barroso, I
Teo, YY
Zeggini, E
Loos, RJF
Small, KS
Ried, JS
DeFronzo, RA
Grallert, H
Glaser, B
Metspalu, A
Wareham, NJ
Walker, M
Banks, E
Gieger, C
Ingelsson, E
Im, HK
Illig, T
Franks, PW
Buck, G
Trakalo, J
Buck, D
Prokopenko, I
Magi, R
Lind, L
Farjoun, Y
Owen, KR
Gloyn, AL
Strauch, K
Tuomi, T
Kooner, JS
Lee, JY
Park, T
Donnelly, P
Morris, AD
Hattersley, AT
Bowden, DW
Collins, FS
Atzmon, G
Chambers, JC
Spector, TD
Laakso, M
Strom, TM
Bell, GI
Blangero, J
Duggirala, R
Tai, ES
McVean, G
Hanis, CL
Wilson, JG
Seielstad, M
Frayling, TM
Meigs, JB
Cox, NJ
Sladek, R
Lander, ES
Gabriel, S
Burtt, NP
Mohlke, KL
Meitinger, T
Groop, L
Abecasis, G
Florez, JC
Scott, LJ
Morris, AP
Kang, HM
Boehnke, M
Altshuler, D
McCarthy, MI
AF Fuchsberger, Christian
Flannick, Jason
Teslovich, Tanya M.
Mahajan, Anubha
Agarwala, Vineeta
Gaulton, Kyle J.
Ma, Clement
Fontanillas, Pierre
Moutsianas, Loukas
McCarthy, Davis J.
Rivas, Manuel A.
Perry, John R. B.
Sim, Xueling
Blackwell, Thomas W.
Robertson, Neil R.
Rayner, N. William
Cingolani, Pablo
Locke, Adam E.
Tajes, Juan Fernandez
Highland, Heather M.
Dupuis, Josee
Chines, Peter S.
Lindgren, Cecilia M.
Hartl, Christopher
Jackson, Anne U.
Chen, Han
Huyghe, Jeroen R.
van de Bunt, Martijn
Pearson, Richard D.
Kumar, Ashish
Mueller-Nurasyid, Martina
Grarup, Niels
Stringham, Heather M.
Gamazon, Eric R.
Lee, Jaehoon
Chen, Yuhui
Scott, Robert A.
Below, Jennifer E.
Chen, Peng
Huang, Jinyan
Go, Min Jin
Stitzel, Michael L.
Pasko, Dorota
Parker, Stephen C. J.
Varga, Tibor V.
Green, Todd
Beer, Nicola L.
Day-Williams, Aaron G.
Ferreira, Teresa
Fingerlin, Tasha
Horikoshi, Momoko
Hu, Cheng
Huh, Iksoo
Ikram, Mohammad Kamran
Kim, Bong-Jo
Kim, Yongkang
Kim, Young Jin
Kwon, Min-Seok
Lee, Juyoung
Lee, Selyeong
Lin, Keng-Han
Maxwell, Taylor J.
Nagai, Yoshihiko
Wang, Xu
Welch, Ryan P.
Yoon, Joon
Zhang, Weihua
Barzilai, Nir
Voight, Benjamin F.
Han, Bok-Ghee
Jenkinson, Christopher P.
Kuulasmaa, Teemu
Kuusisto, Johanna
Manning, Alisa
Ng, Maggie C. Y.
Palmer, Nicholette D.
Balkau, Beverley
Stancakova, Alena
Abboud, Hanna E.
Boeing, Heiner
Giedraitis, Vilmantas
Prabhakaran, Dorairaj
Gottesman, Omri
Scott, James
Carey, Jason
Kwan, Phoenix
Grant, George
Smith, Joshua D.
Neale, Benjamin M.
Purcell, Shaun
Butterworth, Adam S.
Howson, Joanna M. M.
Lee, Heung Man
Lu, Yingchang
Kwak, Soo-Heon
Zhao, Wei
Danesh, John
Lam, Vincent K. L.
Park, Kyong Soo
Saleheen, Danish
So, Wing Yee
Tam, Claudia H. T.
Afzal, Uzma
Aguilar, David
Arya, Rector
Aung, Tin
Chan, Edmund
Navarro, Carmen
Cheng, Ching-Yu
Palli, Domenico
Correa, Adolfo
Curran, Joanne E.
Rybin, Denis
Farook, Vidya S.
Fowler, Sharon P.
Freedman, Barry I.
Griswold, Michael
Hale, Daniel Esten
Hicks, Pamela J.
Khor, Chiea-Chuen
Kumar, Satish
Lehne, Benjamin
Thuillier, Dorothee
Lim, Wei Yen
Liu, Jianjun
van der Schouw, Yvonne T.
Loh, Marie
Musani, Solomon K.
Puppala, Sobha
Scott, William R.
Yengo, Loic
Tan, Sian-Tsung
Taylor, Herman A., Jr.
Thameem, Farook
Wilson, Gregory, Sr.
Wong, Tien Yin
Njolstad, Pal Rasmus
Levy, Jonathan C.
Mangino, Massimo
Bonnycastle, Lori L.
Schwarzmayr, Thomas
Fadista, Joao
Surdulescu, Gabriela L.
Herder, Christian
Groves, Christopher J.
Wieland, Thomas
Bork-Jensen, Jette
Brandslund, Ivan
Christensen, Cramer
Koistinen, Heikki A.
Doney, Alex S. F.
Kinnunen, Leena
Esko, Tonu
Farmer, Andrew J.
Hakaste, Liisa
Hodgkiss, Dylan
Kravic, Jasmina
Lyssenko, Valeriya
Hollensted, Mette
Jorgensen, Marit E.
Jorgensen, Torben
Ladenvall, Claes
Justesen, Johanne Marie
Karajamaki, Annemari
Kriebel, Jennifer
Rathmann, Wolfgang
Lannfelt, Lars
Lauritzen, Torsten
Narisu, Narisu
Linneberg, Allan
Melander, Olle
Milani, Lili
Neville, Matt
Orho-Melander, Marju
Qi, Lu
Qi, Qibin
Roden, Michael
Rolandsson, Olov
Swift, Amy
Rosengren, Anders H.
Stirrups, Kathleen
Wood, Andrew R.
Mihailov, Evelin
Blancher, Christine
Carneiro, Mauricio O.
Maguire, Jared
Poplin, Ryan
Shakir, Khalid
Fennell, Timothy
DePristo, Mark
de Angelis, Martin Hrabe
Deloukas, Panos
Gjesing, Anette P.
Jun, Goo
Nilsson, Peter
Murphy, Jacquelyn
Onofrio, Robert
Thorand, Barbara
Hansen, Torben
Meisinger, Christa
Hu, Frank B.
Isomaa, Bo
Karpe, Fredrik
Liang, Liming
Peters, Annette
Huth, Cornelia
O'Rahilly, Stephen P.
Palmer, Colin N. A.
Pedersen, Oluf
Rauramaa, Rainer
Tuomilehto, Jaakko
Salomaa, Veikko
Watanabe, Richard M.
Syvanen, Ann-Christine
Bergman, Richard N.
Bharadwaj, Dwaipayan
Bottinger, Erwin P.
Cho, Yoon Shin
Chandak, Giriraj R.
Chan, Juliana C. N.
Chia, Kee Seng
Daly, Mark J.
Ebrahim, Shah B.
Langenberg, Claudia
Elliott, Paul
Jablonski, Kathleen A.
Lehman, Donna M.
Jia, Weiping
Ma, Ronald C. W.
Pollin, Toni I.
Sandhu, Manjinder
Tandon, Nikhil
Froguel, Philippe
Barroso, Ines
Teo, Yik Ying
Zeggini, Eleftheria
Loos, Ruth J. F.
Small, Kerrin S.
Ried, Janina S.
DeFronzo, Ralph A.
Grallert, Harald
Glaser, Benjamin
Metspalu, Andres
Wareham, Nicholas J.
Walker, Mark
Banks, Eric
Gieger, Christian
Ingelsson, Erik
Im, Hae Kyung
Illig, Thomas
Franks, Paul W.
Buck, Gemma
Trakalo, Joseph
Buck, David
Prokopenko, Inga
Magi, Reedik
Lind, Lars
Farjoun, Yossi
Owen, Katharine R.
Gloyn, Anna L.
Strauch, Konstantin
Tuomi, Tiinamaija
Kooner, Jaspal Singh
Lee, Jong-Young
Park, Taesung
Donnelly, Peter
Morris, Andrew D.
Hattersley, Andrew T.
Bowden, Donald W.
Collins, Francis S.
Atzmon, Gil
Chambers, John C.
Spector, Timothy D.
Laakso, Markku
Strom, Tim M.
Bell, Graeme I.
Blangero, John
Duggirala, Ravindranath
Tai, E. Shyong
McVean, Gilean
Hanis, Craig L.
Wilson, James G.
Seielstad, Mark
Frayling, Timothy M.
Meigs, James B.
Cox, Nancy J.
Sladek, Rob
Lander, Eric S.
Gabriel, Stacey
Burtt, Noel P.
Mohlke, Karen L.
Meitinger, Thomas
Groop, Leif
Abecasis, Goncalo
Florez, Jose C.
Scott, Laura J.
Morris, Andrew P.
Kang, Hyun Min
Boehnke, Michael
Altshuler, David
McCarthy, Mark I.
TI The genetic architecture of type 2 diabetes
SO NATURE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; PROTEIN INTERACTION NETWORKS; SUSCEPTIBILITY
LOCI; LOW-FREQUENCY; SEQUENCING ASSOCIATION; COMPLEX TRAITS; RARE
VARIANTS; HUMAN-DISEASE; RISK; HERITABILITY
AB The genetic architecture of common traits, including the number, frequency, and effect sizes of inherited variants that contribute to individual risk, has been long debated. Genome-wide association studies have identified scores of common variants associated with type 2 diabetes, but in aggregate, these explain only a fraction of the heritability of this disease. Here, to test the hypothesis that lower-frequency variants explain much of the remainder, the GoT2D and T2D-GENES consortia performed whole-genome sequencing in 2,657 European individuals with and without diabetes, and exome sequencing in 12,940 individuals from five ancestry groups. To increase statistical power, we expanded the sample size via genotyping and imputation in a further 111,548 subjects. Variants associated with type 2 diabetes after sequencing were overwhelmingly common and most fell within regions previously identified by genome-wide association studies. Comprehensive enumeration of sequence variation is necessary to identify functional alleles that provide important clues to disease pathophysiology, but large-scale sequencing does not support the idea that lower-frequency variants have a major role in predisposition to type 2 diabetes.
C1 [Fuchsberger, Christian; Teslovich, Tanya M.; Ma, Clement; Sim, Xueling; Blackwell, Thomas W.; Locke, Adam E.; Jackson, Anne U.; Huyghe, Jeroen R.; Stringham, Heather M.; Lin, Keng-Han; Welch, Ryan P.; Kwan, Phoenix; Jun, Goo; Abecasis, Goncalo; Scott, Laura J.; Kang, Hyun Min; Boehnke, Michael] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Fuchsberger, Christian] Med Univ Innsbruck, Dept Med Genet Mol & Clin Pharmacol, Div Genet Epidemiol, Innsbruck, Austria.
[Fuchsberger, Christian] Univ Lubeck, European Acad Bolzano Bozen EURAC, Ctr Biomed, Bolzano, Italy.
[Flannick, Jason; Agarwala, Vineeta; Fontanillas, Pierre; Lindgren, Cecilia M.; Hartl, Christopher; Green, Todd; Manning, Alisa; Carey, Jason; Grant, George; Neale, Benjamin M.; Purcell, Shaun; Esko, Tonu; Carneiro, Mauricio O.; Maguire, Jared; Poplin, Ryan; Shakir, Khalid; Fennell, Timothy; DePristo, Mark; Murphy, Jacquelyn; Onofrio, Robert; Banks, Eric; Gabriel, Stacey; Burtt, Noel P.; Florez, Jose C.; Altshuler, David] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Flannick, Jason; Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Mahajan, Anubha; Gaulton, Kyle J.; Moutsianas, Loukas; McCarthy, Davis J.; Rivas, Manuel A.; Perry, John R. B.; Robertson, Neil R.; Rayner, N. William; Tajes, Juan Fernandez; Lindgren, Cecilia M.; van de Bunt, Martijn; Pearson, Richard D.; Kumar, Ashish; Chen, Yuhui; Ferreira, Teresa; Horikoshi, Momoko; Ingelsson, Erik; Prokopenko, Inga; Gloyn, Anna L.; Donnelly, Peter; McVean, Gilean; Morris, Andrew P.; McCarthy, Mark I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Med, Oxford, England.
[Agarwala, Vineeta] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[McCarthy, Davis J.; Donnelly, Peter] Univ Oxford, Dept Stat, Oxford, England.
[Perry, John R. B.; Pasko, Dorota; Wood, Andrew R.; Frayling, Timothy M.] Univ Exeter, Sch Med, Genet Complex Traits, Exeter, Devon, England.
[Perry, John R. B.; Scott, Robert A.; Langenberg, Claudia; Wareham, Nicholas J.] Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.
[Perry, John R. B.; Mangino, Massimo; Surdulescu, Gabriela L.; Hodgkiss, Dylan; Small, Kerrin S.; Spector, Timothy D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
[Robertson, Neil R.; Rayner, N. William; van de Bunt, Martijn; Beer, Nicola L.; Horikoshi, Momoko; Levy, Jonathan C.; Groves, Christopher J.; Neville, Matt; Karpe, Fredrik; Prokopenko, Inga; Owen, Katharine R.; Gloyn, Anna L.; McCarthy, Mark I.] Univ Oxford, Radcliffe Dept Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Rayner, N. William; Day-Williams, Aaron G.; Danesh, John; Stirrups, Kathleen; Sandhu, Manjinder; Barroso, Ines; Zeggini, Eleftheria] Wellcome Trust Sanger Inst, Dept Human Genet, Hinxton, Cambs, England.
[Cingolani, Pablo] McGill Univ, Sch Comp Sci, Montreal, PQ, Canada.
[Cingolani, Pablo; Nagai, Yoshihiko; Sladek, Rob] McGill Univ, Montreal, PQ, Canada.
[Cingolani, Pablo; Nagai, Yoshihiko; Sladek, Rob] Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
[Highland, Heather M.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Grad Sch Biomed Sci Houston, Human Genet Ctr, Houston, TX 77030 USA.
[Dupuis, Josee; Chen, Han; Rybin, Denis] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Chines, Peter S.; Bonnycastle, Lori L.; Narisu, Narisu; Swift, Amy; Collins, Francis S.] NHGRI, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA.
[Chen, Han; Liang, Liming] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Kumar, Ashish] Univ Basel, Swiss Trop & Publ Hlth Inst, Chron Dis Epidemiol, Basel, Switzerland.
[Mueller-Nurasyid, Martina; Ried, Janina S.; Gieger, Christian; Strauch, Konstantin] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
[Mueller-Nurasyid, Martina] Univ Munich, Univ Hosp Grosshadern, Dept Med 1, Munich, Germany.
[Mueller-Nurasyid, Martina; Strauch, Konstantin] Univ Munich, Chair Genet Epidemiol, Inst Med Informat Biometry & Epidemiol, Munich, Germany.
[Mueller-Nurasyid, Martina; Peters, Annette] Munich Heart Alliance, DZHK German Ctr Cardiovasc Res, Munich, Germany.
[Grarup, Niels; Bork-Jensen, Jette; Hollensted, Mette; Justesen, Johanne Marie; Gjesing, Anette P.; Hansen, Torben; Pedersen, Oluf] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark.
[Gamazon, Eric R.; Im, Hae Kyung; Cox, Nancy J.] Univ Chicago, Dept Med, Med Genet Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.
[Lee, Jaehoon; Huh, Iksoo; Kim, Yongkang; Lee, Selyeong; Park, Taesung] Seoul Natl Univ, Dept Stat, Seoul, South Korea.
[Below, Jennifer E.; Maxwell, Taylor J.; Jun, Goo; Hanis, Craig L.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Human Genet Ctr, Houston, TX 77030 USA.
[Chen, Peng; Wang, Xu; Cheng, Ching-Yu; Khor, Chiea-Chuen; Lim, Wei Yen; Liu, Jianjun; Chia, Kee Seng; Teo, Yik Ying; Tai, E. Shyong] Natl Univ Hlth Syst, Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
[Huang, Jinyan; Hu, Frank B.; Liang, Liming] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Go, Min Jin; Kim, Bong-Jo; Kim, Young Jin; Lee, Juyoung; Han, Bok-Ghee; Lee, Jong-Young] Korea Natl Inst Hlth, Ctr Genome Sci, Cheongju, Chungcheongbuk, South Korea.
[Stitzel, Michael L.] Jackson Lab Genom Med, Farmington, CT USA.
[Parker, Stephen C. J.] Univ Michigan, Dept Computat Med, Ann Arbor, MI USA.
[Parker, Stephen C. J.] Univ Michigan, Dept Bioinformat & Human Genet, Ann Arbor, MI USA.
[Varga, Tibor V.; Franks, Paul W.] Lund Univ, Genet & Mol Epidemiol Unit, Lund Univ Diabet Ctr, Dept Clin Sci, Malmo, Sweden.
[Fingerlin, Tasha] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
[Hu, Cheng; Jia, Weiping] Shanghai Jiao Tong Univ, Peoples Hosp 6, Shanghai Diabet Inst, Dept Endocrinol & Metab, Shanghai, Peoples R China.
[Ikram, Mohammad Kamran; Aung, Tin; Cheng, Ching-Yu; Khor, Chiea-Chuen; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
[Ikram, Mohammad Kamran; Aung, Tin; Cheng, Ching-Yu; Khor, Chiea-Chuen; Wong, Tien Yin] Natl Univ Hlth Syst, Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
[Ikram, Mohammad Kamran; Aung, Tin; Cheng, Ching-Yu; Wong, Tien Yin] Duke NUS Grad Med Sch, Eye Acad Clin Programme, Singapore, Singapore.
[Kwon, Min-Seok; Yoon, Joon; Park, Taesung] Seoul Natl Univ, Interdisciplinary Program Bioinformat, Seoul, South Korea.
[Nagai, Yoshihiko; Sladek, Rob] McGill Univ, Dept Human Genet, Montreal, PQ, Canada.
[Nagai, Yoshihiko] McGill Univ Hlth Ctr, Res Inst, Montreal, PQ, Canada.
[Zhang, Weihua; Afzal, Uzma; Lehne, Benjamin; Loh, Marie; Scott, William R.; Elliott, Paul; Chambers, John C.] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England.
[Zhang, Weihua; Tan, Sian-Tsung; Kooner, Jaspal Singh; Chambers, John C.] Ealing Hosp NHS Trust, Dept Cardiol, Southall, Middx, England.
[Barzilai, Nir; Atzmon, Gil] Albert Einstein Coll Med, Dept Med, New York, NY USA.
[Barzilai, Nir; Atzmon, Gil] Albert Einstein Coll Med, Dept Genet, New York, NY USA.
[Voight, Benjamin F.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.
[Voight, Benjamin F.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
[Jenkinson, Christopher P.; Abboud, Hanna E.; Fowler, Sharon P.; Thameem, Farook; Lehman, Donna M.; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Jenkinson, Christopher P.] South Texas Vet Hlth Care Syst, Res, San Antonio, TX USA.
[Kuulasmaa, Teemu; Kuusisto, Johanna; Stancakova, Alena; Laakso, Markku] Univ Eastern Finland, Internal Med, Inst Clin Med, Fac Hlth Sci, Kuopio, Finland.
[Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, Kuopio, Finland.
[Ng, Maggie C. Y.; Palmer, Nicholette D.; Hicks, Pamela J.; Bowden, Donald W.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA.
[Ng, Maggie C. Y.; Palmer, Nicholette D.; Hicks, Pamela J.; Bowden, Donald W.] Wake Forest Sch Med, Ctr Diabet Res, Winston Salem, NC USA.
[Palmer, Nicholette D.; Hicks, Pamela J.; Bowden, Donald W.] Wake Forest Sch Med, Dept Biochem, Winston Salem, NC USA.
[Balkau, Beverley] INSERM, Ctr Res Epidemiol & Populat Hlth, U1018, Villejuif, France.
[Boeing, Heiner] German Inst Human Nutr Potsdam Rehbrucke, Nuthetal, Germany.
[Giedraitis, Vilmantas; Lannfelt, Lars] Uppsala Univ, Geriatr, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.
[Prabhakaran, Dorairaj; Ebrahim, Shah B.] Ctr Chron Dis Control, New Delhi, India.
[Gottesman, Omri; Lu, Yingchang; Bottinger, Erwin P.; Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA.
[Scott, James; Tan, Sian-Tsung; Kooner, Jaspal Singh] Univ London Imperial Coll Sci Technol & Med, Cardiovasc Sci, Natl Heart & Lung Inst, Hammersmith Campus, London, England.
[Smith, Joshua D.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA.
[Neale, Benjamin M.; Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Neale, Benjamin M.; Purcell, Shaun; Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Ctr Human Genet Res, Boston, MA 02114 USA.
[Purcell, Shaun] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, Dept Psychiat, New York, NY 10029 USA.
[Butterworth, Adam S.; Howson, Joanna M. M.; Danesh, John; Sandhu, Manjinder] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
[Lee, Heung Man; Lam, Vincent K. L.; So, Wing Yee; Tam, Claudia H. T.; Chan, Juliana C. N.; Ma, Ronald C. W.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
[Kwak, Soo-Heon; Park, Kyong Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
[Zhao, Wei] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Danesh, John] Univ Cambridge, Dept Publ Hlth & Primary Care, NIHR Blood & Transplant Res Unit Donor Hlth & Gen, Cambridge, England.
[Park, Kyong Soo] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.
[Park, Kyong Soo] Seoul Natl Univ, Coll Med, Seoul, South Korea.
[Saleheen, Danish] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Saleheen, Danish] Ctr Noncommunicable Dis, Karachi, Pakistan.
[Aguilar, David] Baylor Coll Med, Div Cardiovasc, Houston, TX 77030 USA.
[Arya, Rector; Hale, Daniel Esten] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
[Chan, Edmund; Tai, E. Shyong] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
[Navarro, Carmen] IMIB Arrixaca, Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain.
[Navarro, Carmen] Univ Murcia, CIBERESP, Murcia, Spain.
[Navarro, Carmen] Univ Murcia, Sch Med, Unit Prevent Med & Publ Hlth, E-30001 Murcia, Spain.
[Palli, Domenico] Canc Res & Prevent Inst ISPO, Florence, Italy.
[Correa, Adolfo; Taylor, Herman A., Jr.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
[Curran, Joanne E.; Kumar, Satish; Blangero, John] Univ Texas Rio Grande Valley, Reg Acad Hlth Ctr, South Texas Diabet & Obes Inst, Brownsville, TX USA.
[Farook, Vidya S.; Puppala, Sobha; Duggirala, Ravindranath] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Freedman, Barry I.] Wake Forest Sch Med, Nephrol Sect, Dept Internal Med, Winston Salem, NC USA.
[Griswold, Michael] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA.
[Khor, Chiea-Chuen] Natl Univ Singapore, Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Paediat, Singapore, Singapore.
[Khor, Chiea-Chuen; Liu, Jianjun] ASTAR, Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
[Thuillier, Dorothee; Yengo, Loic; Froguel, Philippe] Univ Lille, Lille Pasteur Inst, CNRS UMR8199, Lille, France.
[van der Schouw, Yvonne T.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
[Loh, Marie] Univ Oulu, Inst Hlth Sci, Oulu, Finland.
[Loh, Marie] ASTAR, TLGM, Singapore, Singapore.
[Musani, Solomon K.] Univ Mississippi, Med Ctr, Jackson Heart Study, Jackson, MS 39216 USA.
[Wilson, Gregory, Sr.] Jackson State Univ, Coll Publ Serv, Jackson, MS USA.
[Njolstad, Pal Rasmus] Univ Bergen, Dept Clin Sci, KG Jebsen Ctr Diabet Res, Bergen, Norway.
[Njolstad, Pal Rasmus] Haukeland Hosp, Dept Pediat, Bergen, Norway.
[Schwarzmayr, Thomas; Wieland, Thomas; Strom, Tim M.; Meitinger, Thomas] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Human Genet, Neuherberg, Germany.
[Fadista, Joao; Kravic, Jasmina; Lyssenko, Valeriya; Ladenvall, Claes; Rosengren, Anders H.; Groop, Leif] Lund Univ, Ctr Diabet, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden.
[Herder, Christian; Roden, Michael] Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany.
[Herder, Christian; Kriebel, Jennifer; Roden, Michael; de Angelis, Martin Hrabe; Thorand, Barbara; Meisinger, Christa; Peters, Annette; Huth, Cornelia; Grallert, Harald] German Ctr Diabet Res DZD, Neuherberg, Germany.
[Brandslund, Ivan] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark.
[Brandslund, Ivan] Vejle Hosp, Dept Clin Biochem, Vejle, Denmark.
[Christensen, Cramer] Vejle Hosp, Dept Internal Med & Endocrinol, Vejle, Denmark.
[Koistinen, Heikki A.; Kinnunen, Leena; Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Dept Hlth, Helsinki, Finland.
[Koistinen, Heikki A.; Hakaste, Liisa; Tuomi, Tiinamaija] Univ Helsinki, Abdominal Ctr Endocrinol, Helsinki, Finland.
[Koistinen, Heikki A.; Hakaste, Liisa; Tuomi, Tiinamaija] Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Koistinen, Heikki A.] Minerva Fdn, Helsinki, Finland.
[Koistinen, Heikki A.] Univ Helsinki, Dept Med, Helsinki, Finland.
[Doney, Alex S. F.] Ninewells Hosp & Med Sch, Med Res Inst, Div Cardiovasc & Diabet Med, Dundee, Scotland.
[Esko, Tonu; Milani, Lili; Mihailov, Evelin; Metspalu, Andres; Magi, Reedik; Morris, Andrew P.] Univ Tartu, Estonian Genome Ctr, Tartu, Estonia.
[Esko, Tonu; Altshuler, David] Harvard Med Sch, Dept Genet, Boston, MA USA.
[Esko, Tonu] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA.
[Farmer, Andrew J.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.
[Hakaste, Liisa; Isomaa, Bo; Tuomi, Tiinamaija] Folkhalsan Res Ctr, Helsinki, Finland.
[Hakaste, Liisa; Tuomi, Tiinamaija] Univ Helsinki, Res Programs Unit, Diabet & Obes, Helsinki, Finland.
[Jorgensen, Marit E.] Steno Diabet Ctr, Gentofte, Denmark.
[Jorgensen, Torben; Linneberg, Allan] Capital Reg Denmark, Res Ctr Prevent & Hlth, Glostrup, Denmark.
[Jorgensen, Torben] Univ Copenhagen, Inst Hlth Sci, Dept Publ Hlth, Copenhagen, Denmark.
[Jorgensen, Torben] Aalborg Univ, Med, Aalborg, Denmark.
[Karajamaki, Annemari] Vaasa Cent Hosp, Dept Primary Hlth Care, Vaasa, Finland.
[Karajamaki, Annemari] Vaasa Hlth Care Ctr, Ctr Diabet, Vaasa, Finland.
[Kriebel, Jennifer; Thorand, Barbara; Meisinger, Christa; Peters, Annette; Huth, Cornelia; Grallert, Harald; Gieger, Christian] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 2, Neuherberg, Germany.
[Kriebel, Jennifer; Grallert, Harald; Gieger, Christian; Illig, Thomas] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Res Unit Mol Epidemiol, Neuherberg, Germany.
[Rathmann, Wolfgang] Univ Dusseldorf, Leibniz Ctr Diabet Res, German Diabet Ctr, Inst Biometr & Epidemiol, Dusseldorf, Germany.
[Lauritzen, Torsten] Aarhus Univ, Sect Gen Practice, Dept Publ Hlth, Aarhus, Denmark.
[Linneberg, Allan] Rigshosp, Dept Clin Expt Res, Glostrup, Denmark.
[Linneberg, Allan] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark.
[Melander, Olle] Lund Univ, Dept Clin Sci Hypertens & Cardiovasc, Malmo, Sweden.
[Neville, Matt; Karpe, Fredrik; Owen, Katharine R.; Gloyn, Anna L.; McCarthy, Mark I.] Oxford Univ Hosp Trust, Oxford NIHR Biomed Res Ctr, Oxford, England.
[Orho-Melander, Marju] Lund Univ, Dept Clin Sci Diabet & Cardiovasc Dis, Genet Epidemiol, Malmo, Sweden.
[Qi, Lu; Qi, Qibin; Hu, Frank B.; Franks, Paul W.] Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[Qi, Lu] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Qi, Lu] Harvard Med Sch, Boston, MA USA.
[Qi, Qibin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, New York, NY USA.
[Roden, Michael] Univ Dusseldorf, Fac Med, Dept Endocrinol & Diabetol, Dusseldorf, Germany.
[Rolandsson, Olov; Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Blancher, Christine; Buck, Gemma; Trakalo, Joseph; Buck, David] Univ Oxford, Nuffield Dept Med, Oxford Genom Ctr, High Throughput Genom,Wellcome Trust Ctr Human Ge, Oxford, England.
[de Angelis, Martin Hrabe] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Expt Genet, Neuherberg, Germany.
[de Angelis, Martin Hrabe] Tech Univ Munich, Ctr Life & Food Sci Weihenstephan, Freising Weihenstephan, Germany.
[Deloukas, Panos] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England.
[Deloukas, Panos] King Abdulaziz Univ, Princess Al Jawhara Al Brahim Ctr Excellence Res, Jeddah, Saudi Arabia.
[Nilsson, Peter] Lund Univ, Dept Clin Sci, Med, Malmo, Sweden.
[Hansen, Torben] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark.
[Isomaa, Bo] Dept Social Serv & Hlth Care, Pietarsaari, Finland.
[O'Rahilly, Stephen P.; Barroso, Ines] Univ Cambridge, Inst Metab Sci, Metab Res Labs, Cambridge, England.
[Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Pat Macpherson Ctr Pharmacogenet & Pharmacogen, Dundee, Scotland.
[Rauramaa, Rainer] Kuopio Res Inst Exercise Med, Fdn Res Hlth Exercise & Nutr, Kuopio, Finland.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Diabet Res Grp, Jeddah, Saudi Arabia.
[Tuomilehto, Jaakko] Autonomous Univ Madrid, Univ Hosp LaPaz, Inst Invest Sanitaria Hosp Univ LaPaz IdiPAZ, Madrid, Spain.
[Tuomilehto, Jaakko; Salomaa, Veikko] Natl Inst Hlth & Welf, Helsinki, Finland.
[Watanabe, Richard M.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
[Watanabe, Richard M.] Univ Southern Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA USA.
[Watanabe, Richard M.] Univ Southern Calif, Keck Sch Med, Dabet & Obes Res Inst, Los Angeles, CA USA.
[Syvanen, Ann-Christine] Uppsala Univ, Mol Med & Sci Life Lab, Dept Med Sci, Uppsala, Sweden.
[Bergman, Richard N.] Cedars Sinai Diabet & Obes Res Inst, Los Angeles, CA USA.
[Bharadwaj, Dwaipayan] CSIR IGIB, Funct Genom Unit, New Delhi, India.
[Cho, Yoon Shin] Hallym Univ, Dept Biomed Sci, Chunchon, South Korea.
[Chandak, Giriraj R.] CSIR Ctr Cellular & Mol Biol, Hyderabad, Telangana, India.
[Chan, Juliana C. N.; Ma, Ronald C. W.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
[Chan, Juliana C. N.; Ma, Ronald C. W.] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Hong Kong, Peoples R China.
[Elliott, Paul] Imperial Coll London, MRC PHE Ctr Environm & Hlth, London, England.
[Jablonski, Kathleen A.] George Washington Univ, Biostat Ctr, Rockville, MD USA.
[Pollin, Toni I.] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA.
[Pollin, Toni I.] Univ Maryland, Sch Med, Program Personalized & Genom Med, Baltimore, MD 21201 USA.
[Tandon, Nikhil] All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, India.
[Froguel, Philippe; Prokopenko, Inga] Imperial Coll London, Sch Publ Hlth, Dept Genom Common Dis, London, England.
[Teo, Yik Ying] Natl Univ Singapore, Inst Life Sci, Singapore, Singapore.
[Teo, Yik Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore, Singapore.
[Glaser, Benjamin] Hadassah Hebrew Univ Med Ctr, Endocrinol & Metab Serv, Jerusalem, Israel.
[Walker, Mark] Newcastle Univ, Inst Cellular Med, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England.
[Ingelsson, Erik] Uppsala Univ, Mol Epidemiol & Sci Life Lab, Dept Med Sci, Uppsala, Sweden.
[Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, NH, Germany.
[Illig, Thomas] Hannover Med Sch, Inst Human Genet, Hannover, NH, Germany.
[Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[Farjoun, Yossi] Broad Inst, Data Sci & Data Engn, Cambridge, MA USA.
[Tuomi, Tiinamaija; Groop, Leif] Univ Helsinki, FIMM, Helsinki, Finland.
[Kooner, Jaspal Singh; Chambers, John C.] Imperial Coll London, Imperial Coll Healthcare NHS Trust, London, England.
[Morris, Andrew D.] Ninewells Hosp & Med Sch, Ctr Mol Med, Clin Res Ctr, Dundee, Scotland.
[Morris, Andrew D.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
[Hattersley, Andrew T.] Univ Exeter, Sch Med, Exeter, Devon, England.
[Atzmon, Gil] Univ Haifa, Dept Nat Sci, Haifa, Israel.
[Strom, Tim M.; Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, Munich, Germany.
[Bell, Graeme I.] Univ Chicago, Dept Med Genet, Chicago, IL 60637 USA.
[Bell, Graeme I.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
[Tai, E. Shyong] Duke NUS Med Sch Singapore, Cardiovasc & Metab Disorders Program, Singapore, Singapore.
[McVean, Gilean] Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, England.
[Wilson, James G.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA.
[Seielstad, Mark] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
[Seielstad, Mark] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
[Seielstad, Mark] Blood Syst Res Inst, San Francisco, CA USA.
[Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Meigs, James B.] Harvard Med Sch, Dept Med, Boston, MA USA.
[Sladek, Rob] McGill Univ, Dept Med, Div Endocrinol & Metab, Montreal, PQ, Canada.
[Lander, Eric S.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Florez, Jose C.; Altshuler, David] Harvard Med Sch, Dept Med, Boston, MA USA.
[Florez, Jose C.; Altshuler, David] Massachusetts Gen Hosp, Dept Med, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA.
[Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England.
[Altshuler, David] MIT, Dept Biol, Cambridge, MA USA.
RP Boehnke, M (reprint author), Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.; McCarthy, MI (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Med, Oxford, England.; McCarthy, MI (reprint author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
EM boehnke@umich.edu; mark.mccarthy@drl.ox.ac.uk
RI Hrabe de Angelis, Martin/F-5531-2012; Jun, Goo/F-1941-2017; Kinnunen,
Leena/B-7059-2012; van der Schouw, Yvonne/F-8327-2014; Ma,
Ronald/C-2788-2009; Yengo, Loic/D-2692-2017; Palmer, Colin/C-7053-2008;
Chan, Juliana /B-7918-2016; Peters, Annette/A-6117-2011; Park, Kyong
Soo/C-2265-2008; Justesen, Johanne Marie/L-6023-2015; Deloukas,
Panos/B-2922-2013; Hu, Cheng/C-3346-2008; Grallert, Harald/B-3424-2013;
Grarup, Niels/K-2807-2015
OI Varga, Tibor/0000-0002-2383-699X; Tai, E Shyong/0000-0003-2929-8966;
Hattersley, Andrew/0000-0001-5620-473X; Linneberg,
Allan/0000-0002-0994-0184; Hrabe de Angelis, Martin/0000-0002-7898-2353;
Jun, Goo/0000-0003-0891-0204; Gieger, Christian/0000-0001-6986-9554;
Kinnunen, Leena/0000-0001-8739-4812; mangino,
massimo/0000-0002-2167-7470; Koistinen, Heikki/0000-0001-7870-070X;
Meisinger, Christa/0000-0002-9026-6544; Chen, Han/0000-0002-9510-4923;
Tuomi, Tiinamaija/0000-0002-8306-6202; Small,
Kerrin/0000-0003-4566-0005; Khor, Chiea Chuen/0000-0002-1128-4729; van
der Schouw, Yvonne/0000-0002-4605-435X; Ma, Ronald/0000-0002-1227-803X;
Yengo, Loic/0000-0002-4272-9305; Palmer, Colin/0000-0002-6415-6560;
Chan, Juliana /0000-0003-1325-1194; Park, Kyong Soo/0000-0003-3597-342X;
Justesen, Johanne Marie/0000-0002-0484-8522; Deloukas,
Panos/0000-0001-9251-070X; Grarup, Niels/0000-0001-5526-1070
FU British Heart Foundation [RG/14/5/30893, SP/04/002, SP/09/002]; CIHR;
Medical Research Council [G0601261, G0601966, G0700931, G0800270,
G0900747-‐91070, MC_UU_12012/5, MC_UU_12015/1, MR/K002414/1,
MR/L01341X/1]; NCI NIH HHS [K12CA139160]; NHGRI NIH HHS [U01 HG005773,
U01HG005773, U54 HG003067, U54HG003067]; NHLBI NIH HHS
[HHSN268201300046C, HHSN268201300047C, HHSN268201300048C,
HHSN268201300049C, HHSN268201300050C, R01 HL102830, R01HL102830]; NIA
NIH HHS [1R01AG042188, P01 AG027734, P01AG027734, P30 AG038072,
P30AG038072, R01 AG042188, R01 AG046949, R01AG046949]; NIDDK NIH HHS
[1RC2DK088389, DK072193, DK085501, DK085524, DK085526, DK085545,
DK085584, DK088389, DK093757, DK098032, K24 DK080140, K24DK080140, P30
DK020595, P30DK020595, P60 DK020595, P60DK20595, R00 DK092251, R00
DK099240, R00DK092251, R01 DK066358, R01 DK072193, R01 DK073541, R01
DK093757, R01 DK098032, R01 DK101478, R01 DK106236, R01DK062370,
R01DK066358, R01DK073541, R01DK098032, RC2 DK088389, RC2-‐DK088389,
RC2DK088389, U01 DK062370, U01 DK078616, U01 DK085501, U01 DK085524, U01
DK085526, U01 DK085545, U01 DK085584, U01DK085501, U01DK085526]; NIGMS
NIH HHS [T32 GM007753, T32GM007753]; NIMH NIH HHS [R01MH101820, R01
MH090937, R01 MH101820, R01MH090937]; NIMHD NIH HHS [U54 MD007588]; PHS
HHS [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C,
HHSN268201300049C, HHSN268201300050C]; Wellcome Trust [064890, 083948,
084723, 085475, 086596, 090367, 090532, 092447, 095101, 095552, 098017,
098051, 098381, 100956]
NR 68
TC 34
Z9 34
U1 40
U2 41
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 4
PY 2016
VL 536
IS 7614
BP 41
EP +
DI 10.1038/nature18642
PG 29
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS7YM
UT WOS:000380999200026
PM 27398621
ER
PT J
AU Montezuma-Rusca, JM
Powers, JH
Follmann, D
Wang, J
Sullivan, B
Williamson, PR
AF Montezuma-Rusca, Jairo M.
Powers, John H.
Follmann, Dean
Wang, Jing
Sullivan, Brigit
Williamson, Peter R.
TI Early Fungicidal Activity as a Candidate Surrogate Endpoint for
All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of
the Evidence
SO PLOS ONE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; LIPOSOMAL AMPHOTERICIN-B; HIGH-DOSE
FLUCONAZOLE; COMBINATION ANTIFUNGAL THERAPY; PLUS FLUCYTOSINE;
CLINICAL-TRIALS; AIDS PATIENTS; HIV; METAANALYSES; ASSOCIATION
AB Background
Cryptococcal meningitis ( CM) is a leading cause of HIV-associated mortality. In clinical trials evaluating treatments for CM, biomarkers of early fungicidal activity (EFA) in cerebrospinal fluid (CSF) have been proposed as candidate surrogate endpoints for all-cause mortality (ACM). However, there has been no systematic evaluation of the group-level or trial-level evidence for EFA as a candidate surrogate endpoint for ACM.
Methods
We conducted a systematic review of randomized trials in treatment of CM to evaluate available evidence for EFA measured as culture negativity at 2 weeks/10 weeks and slope of EFA as candidate surrogate endpoints for ACM. We performed sensitivity analysis on superiority trials and high quality trials as determined by Cochrane measures of trial bias.
Results
Twenty-seven trials including 2854 patients met inclusion criteria. Mean ACM was 15.8% at 2 weeks and 27.0% at 10 weeks with no overall significant difference between test and control groups. There was a statistically significant group-level correlation between average EFA and ACM at 10 weeks but not at 2 weeks. There was also no statistically significant group-level correlation between CFU culture negativity at 2weeks/10weeks or average EFA slope at 10 weeks. A statistically significant trial-level correlation was identified between EFA slope and ACM at 2 weeks, but is likely misleading, as there was no treatment effect on ACM.
Conclusions
Mortality remains high in short time periods in CM clinical trials. Using published data and Institute of Medicine criteria, evidence for use of EFA as a surrogate endpoint for ACM is insufficient and could provide misleading results from clinical trials. ACM should be used as a primary endpoint evaluating treatments for cryptococcal meningitis.
C1 [Montezuma-Rusca, Jairo M.] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Powers, John H.; Wang, Jing] Leidos Biomed Res Inc, Clin Res Directorate, Clin Monitoring Res Program, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Follmann, Dean] NIAID, Math Statisticians, Biostat Res Branch, NIH, Bethesda, MD 20892 USA.
[Sullivan, Brigit] NIH, Natl Inst Hlth Lib, Off Res Serv, Bethesda, MD 20892 USA.
[Williamson, Peter R.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
RP Williamson, PR (reprint author), NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM williamsonpr@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; Intramural Research Program of the NIH, National
Institutes of Allergy and Infectious Diseases [NIH AI001123,
AI001124-PRW]; Leidos Biomedical Research under the FFRDC
FX JHP works for Leidos Biomedical Research under the FFRDC contract and
receives compensation in the form of salary. Leidos Biomedical Research
is a FFRDC (Federally Funded Research and Development Contractor) to NIH
and is a fully separate subsidiary of corporate Leidos Inc. This project
has been funded in whole or in part with federal funds from the National
Cancer Institute, National Institutes of Health (Contract No.
HHSN261200800001E). The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U.S. Government. This project was
also supported by the Intramural Research Program of the NIH, National
Institutes of Allergy and Infectious Diseases (NIH AI001123,
AI001124-PRW). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 49
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 4
PY 2016
VL 11
IS 8
AR e0159727
DI 10.1371/journal.pone.0159727
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GL
UT WOS:000381368900015
PM 27490100
ER
PT J
AU Vleurinck, C
Raub, S
Sturgill, D
Oliver, B
Beye, M
AF Vleurinck, Christina
Raub, Stephan
Sturgill, David
Oliver, Brian
Beye, Martin
TI Linking Genes and Brain Development of Honeybee Workers: A
Whole-Transcriptome Approach
SO PLOS ONE
LA English
DT Article
ID DIVISION-OF-LABOR; COLONY INTEGRATION; APIS-MELLIFERA; BEE;
DIFFERENTIATION; DROSOPHILA; BEHAVIOR; VISUALIZATION; EXPRESSION; QUEEN
AB Honeybees live in complex societies whose capabilities far exceed those of the sum of their single members. This social synergism is achieved mainly by the worker bees, which form a female caste. The worker bees display diverse collaborative behaviors and engage in different behavioral tasks, which are controlled by the central nervous system (CNS). The development of the worker brain is determined by the female sex and the worker caste determination signal. Here, we report on genes that are controlled by sex or by caste during differentiation of the worker's pupal brain. We sequenced and compared transcriptomes from the pupal brains of honeybee workers, queens and drones. We detected 333 genes that are differently expressed and 519 genes that are differentially spliced between the sexes, and 1760 genes that are differentially expressed and 692 genes that are differentially spliced between castes. We further found that 403 genes are differentially regulated by both the sex and caste signals, providing evidence of the integration of both signals through differential gene regulation. In this gene set, we found that the molecular processes of restructuring the cell shape and cell-to-cell signaling are overrepresented. Our approach identified candidate genes that may be involved in brain differentiation that ensures the various social worker behaviors.
C1 [Vleurinck, Christina; Beye, Martin] Univ Dusseldorf, Inst Evolutionary Genet, Dusseldorf, Germany.
[Raub, Stephan] Univ Dusseldorf, Ctr Informat & Media Technol, Dusseldorf, Germany.
[Sturgill, David; Oliver, Brian] NIDDK, Lab Cellular & Dev Biol, Bethesda, MD 20892 USA.
[Sturgill, David] NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA.
RP Beye, M (reprint author), Univ Dusseldorf, Inst Evolutionary Genet, Dusseldorf, Germany.
EM martin.beye@hhu.de
FU Deutsche Forschungsgemeinschaft
FX The project was funded by Deutsche Forschungsgemeinschaft
(http://www.dfg.de/). MB received the funding. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 37
TC 0
Z9 0
U1 8
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 4
PY 2016
VL 11
IS 8
AR e0157980
DI 10.1371/journal.pone.0157980
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT3GL
UT WOS:000381368900003
PM 27490820
ER
PT J
AU Polfus, LM
Khajuria, RK
Schick, UM
Pankratz, N
Pazoki, R
Brody, JA
Chen, MH
Auer, PL
Floyd, JS
Huang, J
Lange, L
van Rooij, FJA
Gibbs, RA
Metcalf, G
Muzny, D
Veeraraghavan, N
Walter, K
Chen, L
Yanek, L
Becker, LC
Peloso, GM
Wakabayashi, A
Kals, M
Metspalu, A
Esko, T
Fox, K
Wallace, R
Franceschini, N
Matijevic, N
Rice, KM
Bartz, TM
Lyytikainen, LP
Kahonen, M
Lehtimaki, T
Raitakari, OT
Li-Gao, R
Mook-Kanamori, DO
Lettre, G
van Duijn, CM
Franco, OH
Rich, SS
Rivadeneira, F
Hofman, A
Uitterlinden, AG
Wilson, JG
Psaty, BM
Soranzo, N
Dehghan, A
Boerwinkle, E
Zhang, XL
Johnson, AD
O'Donnell, CJ
Johnsen, JM
Reiner, AP
Ganesh, SK
Sankaran, VG
AF Polfus, Linda M.
Khajuria, Rajiv K.
Schick, Ursula M.
Pankratz, Nathan
Pazoki, Raha
Brody, Jennifer A.
Chen, Ming-Huei
Auer, Paul L.
Floyd, James S.
Huang, Jie
Lange, Leslie
van Rooij, Frank J. A.
Gibbs, Richard A.
Metcalf, Ginger
Muzny, Donna
Veeraraghavan, Narayanan
Walter, Klaudia
Chen, Lu
Yanek, Lisa
Becker, Lewis C.
Peloso, Gina M.
Wakabayashi, Aoi
Kals, Mart
Metspalu, Andres
Esko, Tonu
Fox, Keolu
Wallace, Robert
Franceschini, Nora
Matijevic, Nena
Rice, Kenneth M.
Bartz, Traci M.
Lyytikainen, Leo-Pekka
Kahonen, Mika
Lehtimaki, Terho
Raitakari, Olli T.
Li-Gao, Ruifang
Mook-Kanamori, Dennis O.
Lettre, Guillaume
van Duijn, Cornelia M.
Franco, Oscar H.
Rich, Stephen S.
Rivadeneira, Fernando
Hofman, Albert
Uitterlinden, Andre G.
Wilson, James G.
Psaty, Bruce M.
Soranzo, Nicole
Dehghan, Abbas
Boerwinkle, Eric
Zhang, Xiaoling
Johnson, Andrew D.
O'Donnell, Christopher J.
Johnsen, Jill M.
Reiner, Alexander P.
Ganesh, Santhi K.
Sankaran, Vijay G.
TI Whole-Exome Sequencing Identifies Loci Associated with Blood Cell Traits
and Reveals a Role for Alternative GFI1B Splice Variants in Human
Hematopoiesis
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DIAMOND-BLACKFAN ANEMIA; GRAY PLATELET SYNDROME; HEMATOLOGICAL TRAITS;
GENETIC-VARIATION; GFI-1B; DIFFERENTIATION; METAANALYSIS; CONSORTIUM;
MUTATIONS; DISORDER
AB Circulating blood cell counts and indices are important indicators of hematopoietic function and a number of clinical parameters, such as blood oxygen-carrying capacity, inflammation, and hemostasis. By performing whole-exome sequence association analyses of hematologic quantitative traits in 15,459 community-dwelling individuals, followed by in silico replication in up to 52,024 independent samples, we identified two previously undescribed coding variants associated with lower platelet count: a common missense variant in CPS1 (rs1047891, MAF=0.33, discovery + replication p=6.38 x 10(-10)) and a rare synonymous variant in GFI1B (rs150813342, MAF=0.009, discovery + replication p=1.79 x 10(-27)). By performing CRISPR/Cas9 genome editing in hematopoietic cell lines and follow-up targeted knockdown experiments in primary human hematopoietic stem and progenitor cells, we demonstrate an alternative splicing mechanism by which the GFI1B rs150813342 variant suppresses formation of a GFI1B isoform that preferentially promotes megakaryocyte differentiation and platelet production. These results demonstrate how unbiased studies of natural variation in blood cell traits can provide insight into the regulation of human hematopoiesis.
C1 [Polfus, Linda M.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.
[Khajuria, Rajiv K.; Wakabayashi, Aoi; Sankaran, Vijay G.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Khajuria, Rajiv K.; Wakabayashi, Aoi; Sankaran, Vijay G.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Khajuria, Rajiv K.; Wakabayashi, Aoi; Sankaran, Vijay G.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Khajuria, Rajiv K.] Charite, Berlin Brandenburg Sch Regenerat Therapies, D-13353 Berlin, Germany.
[Schick, Ursula M.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA.
[Pankratz, Nathan] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55454 USA.
[Pazoki, Raha; van Rooij, Frank J. A.; Franco, Oscar H.; Dehghan, Abbas] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 DR Rotterdam, Netherlands.
[Brody, Jennifer A.; Floyd, James S.; Rice, Kenneth M.; Bartz, Traci M.; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Brody, Jennifer A.; Floyd, James S.; Rice, Kenneth M.; Bartz, Traci M.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Chen, Ming-Huei] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Auer, Paul L.] Univ Wisconsin Milwaukee, Sch Publ Hlth, Milwaukee, WI 53205 USA.
[Huang, Jie; Walter, Klaudia; Chen, Lu; Soranzo, Nicole] Wellcome Trust Sanger Inst, Human Genet, Hinxton CB10 1HH, England.
[Lange, Leslie] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Gibbs, Richard A.; Metcalf, Ginger; Muzny, Donna; Veeraraghavan, Narayanan] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Chen, Lu; Soranzo, Nicole] Univ Cambridge, Dept Haematol, Cambridge CB2 0AH, England.
[Yanek, Lisa; Becker, Lewis C.] Johns Hopkins Univ, Sch Med, Dept Med, GeneSTAR Res Program,Div Gen Internal Med, Baltimore, MD 21205 USA.
[Peloso, Gina M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kals, Mart; Metspalu, Andres; Esko, Tonu] Univ Tartu, Estonian Genome Ctr, EE-51010 Tartu, Estonia.
[Fox, Keolu] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Wallace, Robert] Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA.
[Franceschini, Nora] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA.
[Matijevic, Nena] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA.
[Lyytikainen, Leo-Pekka; Lehtimaki, Terho] Fimlab Labs, Dept Clin Chem, Tampere 33520, Finland.
[Lyytikainen, Leo-Pekka; Lehtimaki, Terho] Univ Tampere, Sch Med, Tampere 33520, Finland.
[Kahonen, Mika] Tampere Univ Hosp, Dept Clin Physiol, Tampere 33521, Finland.
[Kahonen, Mika] Univ Tampere, Sch Med, Tampere 33521, Finland.
[Raitakari, Olli T.] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, Turku 20520, Finland.
[Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku 20520, Finland.
[Li-Gao, Ruifang; Mook-Kanamori, Dennis O.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RA Leiden, Netherlands.
[Mook-Kanamori, Dennis O.] King Faisal Specialist Hosp & Res Ctr, Dept Biostat, Epidemiol, Epidemiol Sect, Riyadh 11211, Saudi Arabia.
[Mook-Kanamori, Dennis O.] King Faisal Specialist Hosp & Res Ctr, Dept Comp Sci, Riyadh 11211, Saudi Arabia.
[Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Lettre, Guillaume] Univ Montreal, Montreal, PQ H1T 1C8, Canada.
[van Duijn, Cornelia M.; Rivadeneira, Fernando; Hofman, Albert; Uitterlinden, Andre G.] Erasmus Univ, Med Ctr, Dept Internal Med, NL-3000 DR Rotterdam, Netherlands.
[Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA.
[Wilson, James G.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Zhang, Xiaoling] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Zhang, Xiaoling] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.
[Zhang, Xiaoling] Boston Univ, Sch Publ Hlth, Dept Med, Boston, MA 02118 USA.
[Zhang, Xiaoling] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
[Johnson, Andrew D.] NHLBI, Cardiovasc Epidemiol & Human Genom Branch, Framingham Heart Study, Framingham, MA 01702 USA.
[O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Johnsen, Jill M.] Bloodworks Northwest, Seattle, WA 98102 USA.
[Reiner, Alexander P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Womens Hlth Initiat Clin Coordinating Ctr, Seattle, WA 98109 USA.
[Ganesh, Santhi K.] Univ Michigan, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
[Ganesh, Santhi K.] Univ Michigan, Dept Human Genet, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
RP Sankaran, VG (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.; Sankaran, VG (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.; Sankaran, VG (reprint author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
EM sankaran@broadinstitute.org
RI Floyd, James/G-7563-2015; Johnson, Andrew/G-6520-2013
FU NIH [HL122684, DK103794, HL120791]; Wellcome Trust [WT098051, WT091310];
EU [257082, HEALTH-F5-2011-282510]; NIH Research (NIHR) Blood and
Transplant Research Unit (BTRU) in Donor Health and Genomics at the
University of Cambridge; NHS Blood and Transplant (NHSBT)
FX The work described in this manuscript was supported in part by NIH
grants HL122684 to S.K.G. and DK103794 and HL120791 to V.G.S. N.S. is
supported by the Wellcome Trust (grant codes WT098051 and WT091310), the
EU 7th Framework Programme (EPIGENESYS grant code 257082 and BLUEPRINT
grant code HEALTH-F5-2011-282510) and the NIH Research (NIHR) Blood and
Transplant Research Unit (BTRU) in Donor Health and Genomics at the
University of Cambridge in partnership with NHS Blood and Transplant
(NHSBT).
NR 33
TC 5
Z9 5
U1 2
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD AUG 4
PY 2016
VL 99
IS 2
BP 481
EP 488
DI 10.1016/j.ajhg.2016.06.016
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA DT6TO
UT WOS:000381617200020
PM 27486782
ER
PT J
AU Mulligan, N
Schalkwijk, S
Best, BM
Colbers, A
Wang, JJ
Capparelli, EV
Molto, J
Stek, AM
Taylor, G
Smith, E
Tenorio, CH
Chakhtoura, N
van Kasteren, M
Fletcher, CV
Mirochnick, M
Burger, D
AF Mulligan, Nikki
Schalkwijk, Stein
Best, Brookie M.
Colbers, Angela
Wang, Jiajia
Capparelli, Edmund V.
Molto, Jose
Stek, Alice M.
Taylor, Graham
Smith, Elizabeth
Tenorio, Carmen Hidalgo
Chakhtoura, Nahida
van Kasteren, Marjo
Fletcher, Courtney V.
Mirochnick, Mark
Burger, David
CA PANNA Network
IMPAACT 1026s Study Teams
TI Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
SO Frontiers in Pharmacology
LA English
DT Article
DE etravirine; pregnancy; HIV; pharmacokinetics; perinatal transmission
ID TRANSPLACENTAL PASSAGE; NEGATIVE VOLUNTEERS; SAFETY; DARUNAVIR;
DARUNAVIR/RITONAVIR; PHARMACODYNAMICS; COMBINATION; RESISTANCE;
EFFICACY; WOMAN
AB Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.
Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women. Intensive steady-state 12-h pharmacokinetic profiles were performed from 2nd trimester through postpartum. Etravirine was measured at two labs using validated ultra performance liquid chromatography (detection limits: 0.020 and 0.026 mcg/mL).
Results: Fifteen women took etravirine 200 mg twice-daily. Etravirine AUC(0-12) was higher in the 3rd trimester compared to paired postpartum data by 34% (median 8.3 vs. 5.3 mcg*h/mL, p = 0.068). Etravirine apparent oral clearance was significantly lower in the 3rd trimester of pregnancy compared to paired postpartum data by 52% (median 24 vs. 38 L/h, p = 0.025). The median ratio of cord blood to maternal plasma concentration at delivery was 0.52 (range: 0.19-4.25) and no perinatal transmission occurred.
Conclusion: Etravirine apparent oral clearance is reduced and exposure increased during the third trimester of pregnancy. Based on prior dose-ranging and safety data, no dose adjustment is necessary for maternal health but the effects of etravirine in utero are unknown. Maternal health and infant outcomes should be closely monitored until further infant safety data are available.
C1 [Mulligan, Nikki; Best, Brookie M.; Capparelli, Edmund V.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
[Schalkwijk, Stein; Colbers, Angela; Burger, David] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands.
[Wang, Jiajia] Harvard Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA.
[Molto, Jose] Hosp Badalona Germans Trias & Pujol, Fdn Lluita Contra Sida, Badalona, Spain.
Univ Southern Calif, Maternal Child & Adolescent Adult Ctr, Sch Med, Los Angeles, CA USA.
[Taylor, Graham] Imperial Coll Healthcare Natl Hlth Serv Trust, London, England.
[Smith, Elizabeth] NIAID, Maternal Adolescent & Pediat Res Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Tenorio, Carmen Hidalgo] Hosp Univ Virgen Nieves Granada, Granada, Spain.
[Chakhtoura, Nahida] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, Bethesda, MD USA.
[van Kasteren, Marjo] St Elizabeth Hosp, Dept Internal Med, Tilburg, Netherlands.
[Fletcher, Courtney V.] Univ Nebraska Med Ctr, Coll Pharm, Antiviral Pharmacol Lab, Omaha, NE USA.
[Mirochnick, Mark] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA.
RP Best, BM (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
EM brookie@ucsd.edu
RI Colbers, A./L-4248-2015
FU National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health (NIH) [UM1AI068632, UM1AI068616,
UM1AI106716]; Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD); National Institute of Mental Health
(NIMH); "European AIDS Treatment Network (NEAT)" under the European
Commission, DG Research, 6th Framework program [LSHP-CT-2006-037570];
"Pediatric European Network for Treatment of AIDS (PENTA)" under the
European Commission, DG Research, 5th Framework program
[QLK2-CT-2000-00150]; 6th Framework program [LSHP-CT-2006-018865]; Merck
Sharp Dohme Corp; Bristol Myers Squibb; Janssen Research; ViiV
Healthcare
FX Overall support for the International Maternal Pediatric Adolescent AIDS
Clinical Trials Group (IMPAACT) was provided by the National Institute
of Allergy and Infectious Diseases (NIAID) of the National Institutes of
Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616
(IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD) and the National Institute of Mental Health (NIMH).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH. Overall support for
the "Pharmacokinetics of newly developed antiretroviral agents in
HIV-infected pregnant women (PANNA)" network is financially supported by
the "European AIDS Treatment Network (NEAT)" under the European
Commission, DG Research, 6th Framework program, contract
LSHP-CT-2006-037570 and the "Pediatric European Network for Treatment of
AIDS (PENTA)" under the European Commission, DG Research, 5th Framework
program, contract QLK2-CT-2000-00150 and 6th Framework program, contract
LSHP-CT-2006-018865, with co-funding from Merck Sharp & Dohme Corp,
Bristol Myers Squibb, Janssen Research and ViiV Healthcare.
NR 30
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 4
PY 2016
VL 7
DI 10.3389/fphar.2016.00239
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DS3ET
UT WOS:000380666600001
ER
PT J
AU Carreras-Torres, R
Haycock, PC
Relton, CL
Martin, RM
Smith, GD
Kraft, P
Gao, C
Tworoger, S
Le Marchand, L
Wilkens, LR
Park, SL
Haiman, C
Field, JK
Davies, M
Marcus, M
Liu, G
Caporaso, NE
Christiani, DC
Wei, YY
Chen, C
Doherty, JA
Severi, G
Goodman, GE
Hung, RJ
Amos, CI
McKay, J
Johansson, M
Brennan, P
AF Carreras-Torres, Robert
Haycock, Philip C.
Relton, Caroline L.
Martin, Richard M.
Smith, George Davey
Kraft, Peter
Gao, Chi
Tworoger, Shelley
Le Marchand, Loic
Wilkens, Lynne R.
Park, Sungshim L.
Haiman, Christopher
Field, John K.
Davies, Michael
Marcus, Michael
Liu, Geoffrey
Caporaso, Neil E.
Christiani, David C.
Wei, Yongyue
Chen, Chu
Doherty, Jennifer A.
Severi, Gianluca
Goodman, Gary E.
Hung, Rayjean J.
Amos, Christopher I.
McKay, James
Johansson, Mattias
Brennan, Paul
TI The causal relevance of body mass index in different histological types
of lung cancer: A Mendelian randomization study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RISK; METAANALYSIS; ASSOCIATION; POPULATION; VARIANTS; INSIGHTS; OBESITY
AB Body mass index (BMI) is inversely associated with lung cancer risk in observational studies, even though it increases the risk of several other cancers, which could indicate confounding by tobacco smoking or reverse causality. We used the two-sample Mendelian randomization (MR) approach to circumvent these limitations of observational epidemiology by constructing a genetic instrument for BMI, based on results from the GIANT consortium, which was evaluated in relation to lung cancer risk using GWAS results on 16,572 lung cancer cases and 21,480 controls. Results were stratified by histological subtype, smoking status and sex. An increase of one standard deviation (SD) in BMI (4.65 Kg/m(2)) raised the risk for lung cancer overall (OR = 1.13; P = 0.10). This was driven by associations with squamous cell (SQ) carcinoma (OR = 1.45; P = 1.2 x 10(-3)) and small cell (SC) carcinoma (OR = 1.81; P = 0.01). An inverse trend was seen for adenocarcinoma (AD) (OR = 0.82; P = 0.06). In stratified analyses, a 1 SD increase in BMI was inversely associated with overall lung cancer in never smokers (OR = 0.50; P = 0.02). These results indicate that higher BMI may increase the risk of certain types of lung cancer, in particular SQ and SC carcinoma.
C1 [Carreras-Torres, Robert; McKay, James; Johansson, Mattias; Brennan, Paul] IARC, Genet Sect, Lyon, France.
[Haycock, Philip C.; Relton, Caroline L.; Martin, Richard M.; Smith, George Davey] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
[Martin, Richard M.] Univ Hosp Bristol NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Unit Nutr Diet & Lifestyle, Bristol BS2 8AE, Avon, England.
[Martin, Richard M.] Univ Bristol, Bristol BS2 8AE, Avon, England.
[Kraft, Peter; Gao, Chi; Tworoger, Shelley; Christiani, David C.; Wei, Yongyue] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Tworoger, Shelley] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Tworoger, Shelley] Harvard Med Sch, Boston, MA USA.
[Le Marchand, Loic; Wilkens, Lynne R.] Univ Hawaii, Ctr Canc, Epidemiol Program, Honolulu, HI 96822 USA.
[Park, Sungshim L.; Haiman, Christopher] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
[Field, John K.; Davies, Michael; Marcus, Michael] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Canc Med, Roy Castle Lung Canc Res Programme,Canc Res Ctr, Liverpool, Merseyside, England.
[Liu, Geoffrey] Princess Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON, Canada.
[Caporaso, Neil E.] NCI, Genet Epidemiol Branch, DCEG, NIH, Rockville, MD USA.
[Christiani, David C.; Wei, Yongyue] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA.
[Christiani, David C.; Wei, Yongyue] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA.
[Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1124 Columbia St, Seattle, WA 98104 USA.
[Doherty, Jennifer A.] Dartmouth Coll, Geisel Sch Med, Dept Epidemiol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
[Severi, Gianluca] Human Genet Fdn HuGeF, Turin, Italy.
[Goodman, Gary E.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Hung, Rayjean J.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
[Amos, Christopher I.] Dartmouth Coll, Geisel Sch Med, Dept Biomed Data Sci, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
RP Brennan, P (reprint author), IARC, Genet Sect, Lyon, France.
EM gep@iarc.fr
RI Liu, Geoffrey/N-4421-2016; Hung, Rayjean/A-7439-2013; Davey Smith,
George/A-7407-2013
OI Davey Smith, George/0000-0002-1407-8314
FU Cancer Research UK [C18281/A19169, C52724/A20138]; National Institute
for Health Research (NIHR) Bristol Nutritional Biomedical Research Unit
at University Hospitals Bristol NHS Foundation Trust; University of
Bristol; MRC Integrative Epidemiology Unit at the University of Bristol
[MC_UU_12013/1, MC_UU_12013/2]; NCI [UM1 CA186107, P01 CA87969, R01
CA49449, UM1 CA167552]
FX RCT, PCH, CLR, RMM, GDS, MJ, and PB are investigators or researchers on
a Cancer Research UK (C18281/A19169) Programme Grant (the Integrative
Cancer Epidemiology Programme). RMM is supported by the National
Institute for Health Research (NIHR) Bristol Nutritional Biomedical
Research Unit based at University Hospitals Bristol NHS Foundation Trust
and the University of Bristol. CLR and GDS are supported by funding from
the MRC Integrative Epidemiology Unit at the University of Bristol
(MC_UU_12013/1, MC_UU_12013/2). PCH is supported by a Cancer Research UK
Population Research Postdoctoral Fellowship (C52724/A20138). The views
expressed are those of the authors and not necessarily those of the NHS,
the NIHR, or the Department of Health. NCI grants: UM1 CA186107, P01
CA87969, R01 CA49449, UM1 CA167552. We would like to thank the
participants and staff of the NHS and HPFS for their valuable
contributions as well as the following state cancer registries for their
help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME,
MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA,
WA, WY. The authors assume full responsibility for analyses and
interpretation of these data.
NR 24
TC 1
Z9 1
U1 3
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 4
PY 2016
VL 6
AR 31121
DI 10.1038/srep31121
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS7MB
UT WOS:000380966500001
PM 27487993
ER
PT J
AU Nishio, A
Ito, T
Cheng, H
Fitzgerald, TS
Wangemann, P
Griffith, AJ
AF Nishio, Ayako
Ito, Taku
Cheng, Hui
Fitzgerald, Tracy S.
Wangemann, Philine
Griffith, Andrew J.
TI Slc26a4 EXPRESSION PREVENTS FLUCTUATION OF HEARING IN A MOUSE MODEL OF
LARGE VESTIBULAR AQUEDUCT SYNDROME
SO NEUROSCIENCE
LA English
DT Article
DE deafness; DFNB4; EVA; fluctuation; gene therapy; SLC26A4
ID STRIA VASCULARIS; PENDRED-SYNDROME; CELLS; DEGENERATION; DEAFNESS;
INSIGHT; PDS
AB SLC26A4 mutations cause fluctuating and progressive hearing loss associated with enlargement of the vestibular aqueduct (EVA). SLC26A4 encodes a transmembrane anion exchanger called pendrin expressed in nonsensory epithelial cells of the lateral wall of cochlea, vestibular organs and endolymphatic sac. We previously described a transgenic mouse model of EVA with doxycycline (dox)-inducible expression of Slc26a4 in which administration of dox from conception to embryonic day 17.5 (DE17.5) resulted in hearing fluctuation between 1 and 3 months of age. In the present study, we hypothesized that Slc26a4 is required to stabilize hearing in DE17.5 ears between 1 and 3 months of age. We tested our hypothesis by evaluating the effect of postnatal re-induction of Slc26a4 expression on hearing. Readministration of dox to DE17.5 mice at postnatal day 6 (P6), but not at 1 month of age, resulted in reduced click-evoked auditory brainstem response (ABR) thresholds, less fluctuation of hearing and a higher surface density of pendrin expression in spindle-shaped cells of the stria vascularis. Pendrin expression in spindle-shaped cells was inversely correlated with ABR thresholds. These findings suggest that stabilization of hearing by readministration of dox at P6 is mediated by pendrin expression in spindle-shaped cells. We conclude that early re-induction of Slc26a4 expression can prevent fluctuation of hearing in our Slc26a4-insufficient mouse model. Restoration of SLC26A4 expression and function could reduce or prevent fluctuation of hearing in EVA patients. Published by Elsevier Ltd on behalf of IBRO.
C1 [Nishio, Ayako; Ito, Taku; Griffith, Andrew J.] Natl Inst Deafness & Other Commun Disorders, Otolaryngol Branch, NIH, 35A Convent Dr,Room GF-103, Bethesda, MD 20892 USA.
[Cheng, Hui] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA.
[Fitzgerald, Tracy S.] Natl Inst Deafness & Other Commun Disorders, Mouse Auditory Testing Core Facil, NIH, Bethesda, MD 20892 USA.
[Wangemann, Philine] Kansas State Univ, Dept Anat & Physiol, Manhattan, KS 66506 USA.
RP Griffith, AJ (reprint author), Natl Inst Deafness & Other Commun Disorders, Otolaryngol Branch, NIH, 35A Convent Dr,Room GF-103, Bethesda, MD 20892 USA.
EM griffita@nidcd.nih.gov
FU NIH [Z01-DC000060, Z01-DC000080, R01-DC012151]; JSPS
FX This work was supported by NIH intramural research funds Z01-DC000060
and Z01-DC000080. A.N. was supported in part by a JSPS Research
Fellowship for Japanese Biomedical and Behavioral Researchers at NIH.
P.W. was supported by NIH grant R01-DC012151. We thank Wade Chien, Keiji
Honda, Meghan Drummond and our NIDCD colleagues for helpful suggestions
and advice, Ken Kitamura for support, and Tom Friedman and Doris Wu for
critical reading of the manuscript.
NR 20
TC 1
Z9 1
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD AUG 4
PY 2016
VL 329
BP 74
EP 82
DI 10.1016/j.neuroscience.2016.04.042
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA DO6ZW
UT WOS:000377933000007
PM 27155149
ER
PT J
AU Verheij, MMM
Vendruscolo, LF
Caffino, L
Giannotti, G
Cazorla, M
Fumagalli, F
Riva, MA
Homberg, JR
Koob, GF
Contet, C
AF Verheij, Michel M. M.
Vendruscolo, Leandro F.
Caffino, Lucia
Giannotti, Giuseppe
Cazorla, Maxime
Fumagalli, Fabio
Riva, Marco A.
Homberg, Judith R.
Koob, George F.
Contet, Candice
TI Systemic Delivery of a Brain-Penetrant TrkB Antagonist Reduces Cocaine
Self-Administration and Normalizes TrkB Signaling in the Nucleus
Accumbens and Prefrontal Cortex
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE BDNF; brain-derived neurotrophic factor; cocaine; cyclotraxin-B;
dopamine system; TrkB signaling
ID MESOLIMBIC DOPAMINE SYSTEM; D-3 RECEPTOR EXPRESSION; VENTRAL TEGMENTAL
AREA; NEUROTROPHIC FACTOR; BDNF EXPRESSION; REINFORCING EFFICACY;
PROTEIN-LEVELS; RATS; WITHDRAWAL; REWARD
AB Cocaine exposure alters brain-derived neurotrophic factor (BDNF) expression in the brain. BDNF signaling through TrkB receptors differentially modulates cocaine self-administration, depending on the brain regions involved. In the present study, we determined how brain-wide inhibition of TrkB signaling affects cocaine intake, the motivation for the drug, and reinstatement of drug taking after extinction. To overcome the inability of TrkB ligands to cross the blood-brain barrier, the TrkB antagonist cyclotraxin-B was fused to the nontoxic transduction domain of the tat protein from human immunodeficiency virus type 1 (tat-cyclotraxin-B). Intravenous injection of tat-cyclotraxin-B dose-dependently reduced cocaine intake, motivation for cocaine (as measured under a progressive ratio schedule of reinforcement), and reinstatement of cocaine taking in rats allowed either short or long access to cocaine self-administration. In contrast, the treatment did not affect operant responding for a highly palatable sweet solution, demonstrating that the effects of tat-cyclotraxin-B are specific for cocaine reinforcement. Cocaine self-administration increased TrkB signaling and activated the downstream Akt pathway in the nucleus accumbens, and had opposite effects in the prefrontal cortex. Pretreatment with tat-cyclotraxin-B normalized protein levels in these two dopamine-innervated brain regions. Cocaine self-administration also increased TrkB signaling in the ventral tegmental area, where the dopaminergic projections originate, but pretreatment with tat-cyclotraxin-B did not alter this effect. Altogether, our data show that systemic administration of a brain-penetrant TrkB antagonist leads to brain region-specific effects and may be a potential pharmacological strategy for the treatment of cocaine addiction.
C1 [Verheij, Michel M. M.; Homberg, Judith R.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, NL-6500 HB Nijmegen, Netherlands.
[Verheij, Michel M. M.; Vendruscolo, Leandro F.; Koob, George F.; Contet, Candice] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA.
[Vendruscolo, Leandro F.; Koob, George F.] NIDA, Neurobiol Addict Sect, NIH, Baltimore, MD 21224 USA.
[Caffino, Lucia; Giannotti, Giuseppe; Fumagalli, Fabio; Riva, Marco A.] Univ Milan, Dept Pharmacol & Biomol Sci, I-20133 Milan, Italy.
[Caffino, Lucia; Giannotti, Giuseppe; Fumagalli, Fabio] Presidency Council Ministers, Collaborat Ctr Dept Antidrug Policies, I-00187 Rome, Italy.
[Cazorla, Maxime] Univ Grenoble Alpes, GIN, F-38000 Grenoble, France.
[Cazorla, Maxime] INSERM, U1216, F-38000 Grenoble, France.
RP Verheij, MMM (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Cognit Neurosci CNS, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM M.Verheij@cns.umcn.nl
RI koob, george/P-8791-2016; Homberg, Judith/D-2473-2010;
OI Riva, Marco Andrea/0000-0002-1699-5060; Fumagalli,
Fabio/0000-0002-8814-7706; Giannotti, Giuseppe/0000-0003-0629-4882
FU Zardi-Gori Foundation; National Institutes of Health [AA020913,
AA024198]; Netherlands Organization for Scientific Research [31180005];
U.S. National Institute on Drug Abuse (NIDA) Project [31180005];
European College of Neuropsychopharmacology Research Grant; NIDA INVEST
Drug Abuse Research Fellowship; NIDA Intramural Research Program
FX This research was supported by the Zardi-Gori Foundation (to F.F.) and
National Institutes of Health Grants AA020913 and AA024198 (to C.C.).
M.M.M.V., J.R.H., G.F.K., and C.C. were supported by a joint program of
the Netherlands Organization for Scientific Research and U.S. National
Institute on Drug Abuse (NIDA) Project 31180005. M.M.M.V. was supported
by a European College of Neuropsychopharmacology Research Grant for
Young Scientists and a NIDA INVEST Drug Abuse Research Fellowship.
L.F.V. and G.F.K. were supported by the NIDA Intramural Research
Program. We thank Kiki Rink and Famke Ouwerkerk (Department of Cognitive
Neuroscience, Radboud University Nijmegen, Nijmegen, The Netherlands)
for technical assistance.
NR 49
TC 0
Z9 0
U1 4
U2 4
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD AUG 3
PY 2016
VL 36
IS 31
BP 8149
EP 8159
DI 10.1523/JNEUROSCI.2711-14.2016
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA DU6DM
UT WOS:000382304000013
PM 27488635
ER
PT J
AU Yong, KJ
Basseres, DS
Welner, RS
Zhang, WC
Yang, H
Yan, B
Alberich-Jorda, M
Zhang, JY
de Figueiredo-Pontes, LL
Battelli, C
Hetherington, CJ
Ye, M
Zhang, H
Maroni, G
O'Brien, K
Magli, MC
Borczuk, AC
Varticovski, L
Kocher, O
Zhang, P
Moon, YC
Sydorenko, N
Cao, LX
Davis, TW
Thakkar, BM
Soo, RA
Iwama, A
Lim, B
Halmos, B
Neuberg, D
Tenen, DG
Levantini, E
AF Yong, Kol Jia
Basseres, Daniela S.
Welner, Robert S.
Zhang, Wen Cai
Yang, Henry
Yan, Benedict
Alberich-Jorda, Meritxell
Zhang, Junyan
de Figueiredo-Pontes, Lorena Lobo
Battelli, Chiara
Hetherington, Christopher J.
Ye, Min
Zhang, Hong
Maroni, Giorgia
O'Brien, Karen
Magli, Maria Cristina
Borczuk, Alain C.
Varticovski, Lyuba
Kocher, Olivier
Zhang, Pu
Moon, Young-Choon
Sydorenko, Nadiya
Cao, Liangxian
Davis, Thomas W.
Thakkar, Bhavin M.
Soo, Ross A.
Iwama, Atsushi
Lim, Bing
Halmos, Balazs
Neuberg, Donna
Tenen, Daniel G.
Levantini, Elena
TI Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas
with low CEBP alpha expression
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID CCAAT/ENHANCER-BINDING-PROTEIN; ACUTE MYELOID-LEUKEMIA;
FACTOR-C/EBP-ALPHA; POSTTRANSCRIPTIONAL CONTROL; ADJUVANT CHEMOTHERAPY;
CELL-PROLIFERATION; DOWN-REGULATION; DRUG DISCOVERY; GENE SIGNATURE;
SELF-RENEWAL
AB Lung cancer is the most common cause of cancer deaths. The expression of the transcription factor C/EBP alpha (CCAAT/enhancer binding protein a) is frequently lost in non-small cell lung cancer, but the mechanisms by which C/EBP alpha suppresses tumor formation are not fully understood. In addition, no pharmacological therapy is available to specifically target C/EBP alpha expression. We discovered a subset of pulmonary adenocarcinoma patients in whom negative/low C/EBP alpha expression and positive expression of the oncogenic protein BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) have prognostic value. We also generated a lung-specific mouse model of C/EBP alpha deletion that develops lung adenocarcinomas, which are prevented by Bmi1 haploinsufficiency. BMI1 activity is required for both tumor initiation and maintenance in the C/EBP alpha-null background, and pharmacological inhibition of BMI1 exhibits antitumor effects in both murine and human adenocarcinoma lines. Overall, we show that C/EBP alpha is a tumor suppressor in lung cancer and that BMI1 is required for the oncogenic process downstream of C/EBP alpha loss. Therefore, anti-BMI1 pharmacological inhibition may offer a therapeutic benefit for lung cancer patients with low expression of C/EBP alpha and high BMI1.
C1 [Yong, Kol Jia; Yang, Henry; Thakkar, Bhavin M.; Soo, Ross A.; Tenen, Daniel G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117599, Singapore.
[Basseres, Daniela S.] Univ Sao Paulo, Inst Chem, Biochem Dept, BR-05508 Sao Paulo, Brazil.
[Basseres, Daniela S.; Welner, Robert S.; Zhang, Wen Cai; Alberich-Jorda, Meritxell; Zhang, Junyan; de Figueiredo-Pontes, Lorena Lobo; Battelli, Chiara; Hetherington, Christopher J.; Ye, Min; Zhang, Hong; O'Brien, Karen; Kocher, Olivier; Zhang, Pu; Lim, Bing; Levantini, Elena] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Basseres, Daniela S.; Welner, Robert S.; Zhang, Wen Cai; Alberich-Jorda, Meritxell; Zhang, Junyan; de Figueiredo-Pontes, Lorena Lobo; Battelli, Chiara; Hetherington, Christopher J.; Ye, Min; Zhang, Hong; O'Brien, Karen; Kocher, Olivier; Zhang, Pu; Lim, Bing; Tenen, Daniel G.; Levantini, Elena] Harvard Med Sch, Boston, MA 02215 USA.
[Basseres, Daniela S.; Welner, Robert S.; Alberich-Jorda, Meritxell; Zhang, Junyan; de Figueiredo-Pontes, Lorena Lobo; Hetherington, Christopher J.; Ye, Min; Zhang, Hong; O'Brien, Karen; Zhang, Pu; Tenen, Daniel G.; Levantini, Elena] Harvard Stem Cell Inst, Boston, MA 02215 USA.
[Welner, Robert S.] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL 35233 USA.
[Zhang, Wen Cai; Lim, Bing] Genome Inst Singapore, Stem Cell & Dev Biol, Singapore 138672, Singapore.
[Yan, Benedict] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore 119074, Singapore.
[Alberich-Jorda, Meritxell] ASCR, Inst Mol Genet, Prague 14200, Czech Republic.
[de Figueiredo-Pontes, Lorena Lobo] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Hematol Div, BR-14020 Sao Paulo, Brazil.
[Maroni, Giorgia; Magli, Maria Cristina; Levantini, Elena] Natl Res Council CNR, Inst Biomed Technol, I-56124 Pisa, Italy.
[Borczuk, Alain C.] Weill Cornell Univ, Med Ctr, Dept Pathol, New York, NY 10065 USA.
[Varticovski, Lyuba] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20817 USA.
[Moon, Young-Choon; Sydorenko, Nadiya; Cao, Liangxian; Davis, Thomas W.] PTC Therapeut, 100 Corp Court, South Plainfield, NJ 07080 USA.
[Soo, Ross A.] Univ Western Australia, Dept Hematol Oncol, Crawley, WA 6009, Australia.
[Iwama, Atsushi] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba 2608670, Japan.
[Halmos, Balazs] Montefiore Hosp, Div Hematol Oncol, Bronx, NY 10461 USA.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Battelli, Chiara] New England Canc Specialists, Scarborough, ME 04074 USA.
[O'Brien, Karen] Novartis Inst BioMed Res Inc, Cambridge, MA 02176 USA.
[Lim, Bing] Merck Res Labs, Translat Med Res Ctr, Singapore 138665, Singapore.
RP Tenen, DG (reprint author), Natl Univ Singapore, Canc Sci Inst, Singapore 117599, Singapore.; Levantini, E (reprint author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.; Tenen, DG; Levantini, E (reprint author), Harvard Med Sch, Boston, MA 02215 USA.; Tenen, DG; Levantini, E (reprint author), Harvard Stem Cell Inst, Boston, MA 02215 USA.; Levantini, E (reprint author), Natl Res Council CNR, Inst Biomed Technol, I-56124 Pisa, Italy.
EM csidgt@nus.edu.sg; elevanti@bidmc.harvard.edu
RI Basseres, Daniela/C-6623-2013
OI Basseres, Daniela/0000-0001-7745-3567
FU NIH/NCI (National Cancer Institute) Project 2 grant [P50 CA90578]; NCIS
(National University Cancer Institute of Singapore) Yong Siew Yoon
Research grant; Singapore Ministry of Health's National Medical Research
Council under its Singapore Translational Research (STaR) Investigator
Award; National Research Foundation of Singapore; Singapore Ministry of
Education under its Research Centres of Excellence initiative Project 3
[PO1 CA66996, 1R35CA197697]; FAMRI (Flight Attendant Medical Research
Institute) YCSA (Young Clinical Scientist Award) [052409]; FAMRI CIA
(Clinical Innovator Awards) [103063]; FAMRI YCSA [072165]; Doctors
Cancer Foundation Award; IASLC (International Association for the Study
of Lung Cancer) Award; MIUR (Ministry of Education, University and
Research) Flagship InterOmics Project; MSMT Navrat grant [LK21307]; Jose
Carreras fellowship [FIJC-10]; NCI [T32/K12/R25]; Agency for Science,
Technology and Research (A*STAR), Singapore; National Medical Research
Council of Singapore [NMRC/CG/NCIS/2010]; Dana-Farber/Harvard Cancer
Center support grant [5P30 CA006516]
FX This work was funded by NIH/NCI (National Cancer Institute) P50 CA90578
Project 2 grant (to D.G.T. and B.H.); the NCIS (National University
Cancer Institute of Singapore) Yong Siew Yoon Research grant through
donations from the Yong Loo Lin Trust, the Singapore Ministry of
Health's National Medical Research Council under its Singapore
Translational Research (STaR) Investigator Award, and the National
Research Foundation of Singapore and the Singapore Ministry of Education
under its Research Centres of Excellence initiative and PO1 CA66996
Project 3 and 1R35CA197697 grants (to D.G.T.); FAMRI (Flight Attendant
Medical Research Institute) YCSA (Young Clinical Scientist Award) 052409
and FAMRI CIA (Clinical Innovator Awards) 103063 (to E.L.); FAMRI YCSA
072165 (to D.S.B.); Doctors Cancer Foundation Award (to E.L.); IASLC
(International Association for the Study of Lung Cancer) Award (to
E.L.); MIUR (Ministry of Education, University and Research) Flagship
InterOmics Project (to E.L. and M.C.M.); and MSMT Navrat grant LK21307
(to M.-A.J.). R.S.W. was supported by a Jose Carreras fellowship,
FIJC-10. C.B. was supported by an NCI T32/K12/R25 award. W.C.Z. and
B.L.'s work was supported by Agency for Science, Technology and Research
(A*STAR), Singapore. R.A.S. was supported by the National Medical
Research Council of Singapore (NMRC/CG/NCIS/2010). D.N. was supported by
Dana-Farber/Harvard Cancer Center support grant 5P30 CA006516.
NR 50
TC 1
Z9 1
U1 4
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 3
PY 2016
VL 8
IS 350
AR 350ra104
DI 10.1126/scitranslmed.aad6066
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA DS4VP
UT WOS:000380780000006
PM 27488898
ER
PT J
AU Ulloa, A
Horwitz, B
AF Ulloa, Antonio
Horwitz, Barry
TI Embedding Task-Based Neural Models into a Connectome-Based Model of the
Cerebral Cortex
SO Frontiers in Neuroinformatics
LA English
DT Article
DE computational modeling; neural networks; visual object processing; The
Virtual Brain; fMRI; human; brain
ID STATE FUNCTIONAL CONNECTIVITY; COMMON BRAIN SPACE; LARGE-SCALE MODEL;
WORKING-MEMORY; BALLOON MODEL; VIRTUAL BRAIN; FMRI DATA; INTEGRATION;
OBJECT; ATTENTION
AB A number of recent efforts have used large-scale, biologically realistic, neural models to help understand the neural basis for the patterns of activity observed in both resting state and task-related functional neural imaging data. An example of the former is The Virtual Brain (TVB) software platform, which allows one to apply large-scale neural modeling in a whole brain framework. TVB provides a set of structural connectomes of the human cerebral cortex, a collection of neural processing units for each connectome node, and various forward models that can convert simulated neural activity into a variety of functional brain imaging signals. In this paper, we demonstrate how to embed a previously or newly constructed task-based large-scale neural model into the TVB platform. We tested our method on a previously constructed large-scale neural model (LSNM) of visual object processing that consisted of interconnected neural populations that represent, primary and secondary visual, inferotemporal, and prefrontal cortex. Some neural elements in the original model were "non-task-specific" (NS) neurons that served as noise generators to "task-specific" neurons that processed shapes during a delayed match-to-sample (DMS) task. We replaced the NS neurons with an anatomical TVB connectome model of the cerebral cortex comprising 998 regions of interest interconnected by white matter fiber tract weights. We embedded our LSNM of visual object processing into corresponding nodes within the TVB connectome. Reciprocal connections between TVB nodes and our task-based modules were included in this framework. We ran visual object processing simulations and showed that the TVB simulator successfully replaced the noise generation originally provided by NS neurons: i.e., the DMS tasks performed with the hybrid LSNM/TVB simulator generated equivalent neural and fMRI activity to that of the original task-based models. Additionally, we found partial agreement between the functional connectivities using the hybrid LSNWTVB model and the original LSNM. Our framework thus presents a way to embed task-based neural models into the TVB platform, enabling a better comparison between empirical and computational data, which in turn can lead to a better understanding of how interacting neural populations give rise to human cognitive behaviors.
C1 [Ulloa, Antonio; Horwitz, Barry] Natl Inst Deafness & Other Commun Disorders, Sect Brain Imaging & Modeling, NIH, Bethesda, MD 20892 USA.
[Ulloa, Antonio] Neural Bytes LLC, Washington, DC USA.
RP Horwitz, B (reprint author), Natl Inst Deafness & Other Commun Disorders, Sect Brain Imaging & Modeling, NIH, Bethesda, MD 20892 USA.
EM horwitzb@mail.nih.gov
OI Ulloa, Antonio/0000-0002-7554-4542
FU Division of Intramural Research of the NIDCD
FX We wish to thank Pearce Decker, Paul Corbitt, Qin Liu, and John Gilbert
for useful comments concerning numerous aspects of this paper, and for
testing simulations using various aspects of our combined model. We also
thank the staff of The Virtual Brain for technical help in working with
their software. This research was funded by the Division of Intramural
Research of the NIDCD.
NR 51
TC 0
Z9 0
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1662-5196
J9 FRONT NEUROINFORM
JI Front. Neuroinformatics
PD AUG 3
PY 2016
VL 10
AR 32
DI 10.3389/fninf.2016.00032
PG 15
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA DS3FN
UT WOS:000380668600002
PM 27536235
ER
PT J
AU Lee, J
Seong, S
Kim, JH
Kim, K
Kim, I
Jeong, BC
Nam, KI
Kim, KK
Hennighausen, L
Kim, N
AF Lee, Jongwon
Seong, Semun
Kim, Jung Ha
Kim, Kabsun
Kim, Inyoung
Jeong, Byung-chul
Nam, Kwang-Il
Kim, Kyung Keun
Hennighausen, Lothar
Kim, Nacksung
TI STAT5 is a key transcription factor for IL-3-mediated inhibition of
RANKL-induced osteoclastogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GRANULOCYTE-MACROPHAGE; CELL-PROLIFERATION; RECEPTOR ACTIVATOR;
GENE-EXPRESSION; BONE-RESORPTION; NUCLEAR-FACTOR; IMMUNE-SYSTEM;
KAPPA-B; DIFFERENTIATION; IL-3
AB Among the diverse cytokines involved in osteoclast differentiation, interleukin (IL)-3 inhibits RANKL-induced osteoclastogenesis. However, the mechanism underlying IL-3-mediated inhibition of osteoclast differentiation is not fully understood. Here we demonstrate that the activation of signal transducers and activators of transcription 5 (STAT5) by IL-3 inhibits RANKL-induced osteoclastogenesis through the induction of the expression of Id genes. We found that STAT5 overexpression inhibited RANKL-induced osteoclastogenesis. However, RANKL did not regulate the expression or activation of STAT5 during osteoclast differentiation. STAT5 deficiency prevented IL-3-mediated inhibition of osteoclastogenesis, suggesting a key role of STAT5 in IL-3-mediated inhibition of osteoclast differentiation. In addition, IL-3-induced STAT5 activation upregulated the expression of Id1 and Id2, which are negative regulators of osteoclastogenesis. Overexpression of ID1 or ID2 in STAT5-deficient cells reversed osteoclast development recovered from IL-3-mediated inhibition. Importantly, microcomputed tomography and histomorphometric analysis revealed that STAT5 conditional knockout mice showed reduced bone mass, with an increased number of osteoclasts. Furthermore, IL-3 inhibited RANKL-induced osteoclast differentiation less effectively in the STAT5 conditional knockout mice than in the wild-type mice after RANKL injection. Taken together, our findings indicate that STAT5 contributes to the remarkable IL-3-mediated inhibition of RANKL-induced osteoclastogenesis by activating Id genes and their associated pathways.
C1 [Lee, Jongwon; Seong, Semun; Kim, Jung Ha; Kim, Kabsun; Kim, Inyoung; Jeong, Byung-chul; Kim, Kyung Keun; Kim, Nacksung] Chonnam Natl Univ, Sch Med, Dept Pharmacol, Gwangju 61469, South Korea.
[Seong, Semun; Jeong, Byung-chul; Kim, Nacksung] Chonnam Natl Univ, Sch Med, Dept Biomed Sci, Gwangju 61469, South Korea.
[Nam, Kwang-Il] Chonnam Natl Univ, Sch Med, Dept Anat, Gwangju 61469, South Korea.
[Hennighausen, Lothar] NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20814 USA.
RP Kim, N (reprint author), Chonnam Natl Univ, Sch Med, Dept Pharmacol, Gwangju 61469, South Korea.; Kim, N (reprint author), Chonnam Natl Univ, Sch Med, Dept Biomed Sci, Gwangju 61469, South Korea.
EM nacksung@jnu.ac.kr
OI Nam, Kwang Il/0000-0001-5380-6815
FU Basic Science Research Program through the National Research Foundation
of Korea (NRF) - Ministry of Science, ICT and Future Planning (MRC)
[2011-0030132, NRF-2014R1A2A2A01003966]; IRP of the NIDDK/NIH
FX This research was supported by grants from the Basic Science Research
Program through the National Research Foundation of Korea (NRF) funded
by the Ministry of Science, ICT and Future Planning (MRC, 2011-0030132
and NRF-2014R1A2A2A01003966). LH was supported by the IRP of the
NIDDK/NIH.
NR 27
TC 1
Z9 1
U1 5
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 3
PY 2016
VL 6
AR 30977
DI 10.1038/srep30977
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS2UE
UT WOS:000380638300001
PM 27485735
ER
PT J
AU Weidmann, CA
Qiu, C
Arvola, RM
Lou, TF
Killingsworth, J
Campbell, ZT
Hall, TMT
Goldstrohm, AC
AF Weidmann, Chase A.
Qiu, Chen
Arvola, Rene M.
Lou, Tzu-Fang
Killingsworth, Jordan
Campbell, Zachary T.
Hall, Traci M. Tanaka
Goldstrohm, Aaron C.
TI Drosophila Nanos acts as a molecular clamp that modulates the
RNA-binding and repression activities of Pumilio
SO ELIFE
LA English
DT Article
DE Nanos; Pumilio; translational repression; cooperative RNA binding
ID HUNCHBACK MESSENGER-RNA; BRAIN-TUMOR; TRANSLATIONAL REGULATION;
CAENORHABDITIS-ELEGANS; CRYSTAL-STRUCTURE; HOMOLOGY DOMAIN; PROTEIN;
PUF; SPECIFICITY; SEQUENCE
AB Collaboration among the multitude of RNA-binding proteins (RBPs) is ubiquitous, yet our understanding of these key regulatory complexes has been limited to single RBPs. We investigated combinatorial translational regulation by Drosophila Pumilio (Pum) and Nanos (Nos), which control development, fertility, and neuronal functions. Our results show how the specificity of one RBP (Pum) is modulated by cooperative RNA recognition with a second RBP (Nos) to synergistically repress mRNAs. Crystal structures of Nos-Pum-RNA complexes reveal that Nos embraces Pum and RNA, contributes sequence-specific contacts, and increases Pum RNA-binding affinity. Nos shifts the recognition sequence and promotes repression complex formation on mRNAs that are not stably bound by Pum alone, explaining the preponderance of sub-optimal Pum sites regulated in vivo. Our results illuminate the molecular mechanism of a regulatory switch controlling crucial gene expression programs, and provide a framework for understanding how the partnering of RBPs evokes changes in binding specificity that underlie regulatory network dynamics.
C1 [Weidmann, Chase A.; Arvola, Rene M.; Killingsworth, Jordan; Goldstrohm, Aaron C.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.
[Goldstrohm, Aaron C.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
[Qiu, Chen; Hall, Traci M. Tanaka] NIEHS, Epigenet & Stem Cell Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
[Lou, Tzu-Fang; Campbell, Zachary T.] Univ Texas Richardson, Dept Biol Sci, Richardson, TX 75080 USA.
RP Goldstrohm, AC (reprint author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.; Goldstrohm, AC (reprint author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.; Hall, TMT (reprint author), NIEHS, Epigenet & Stem Cell Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
EM hall4@niehs.nih.gov; agoldstr@umn.edu
FU NIGMS [R01GM105707]; NIH [NRSA 5T32GM007544]; American Cancer Society
[RSG-13-080-01-RMC]; NSF [DGE 1256260]; Intramural Research Program of
the National Institutes of Health, National Institute of Environmental
Health Sciences (TMTH); US Department of Energy, Office of Science,
Office of Basic Energy Sciences [W-31-109-Eng-38]
FX We thank L. Pedersen and the staff of the Southeast Regional
Collaborative Access Team beamlines for assistance with X-ray data
collection and Drs. P. Blackshear, K. McCann, R. Trievel, and P.
Freddolino for comments on the manuscript. This research was supported
in part by NIGMS R01GM105707 (A.C.G); NIH NRSA 5T32GM007544 (C.W. and R.
A.); a Research Scholar Grant, RSG-13-080-01-RMC, from the American
Cancer Society (A.C.G.); a Graduate Research Fellowship, DGE 1256260,
from NSF (R.M.A.) and the Intramural Research Program of the National
Institutes of Health, National Institute of Environmental Health
Sciences (TMTH). The Advanced Photon Source used for this study is
supported by the US Department of Energy, Office of Science, Office of
Basic Energy Sciences, under contract no. W-31-109-Eng-38.
NR 69
TC 1
Z9 1
U1 3
U2 3
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD AUG 2
PY 2016
VL 5
AR e17096
DI 10.7554/eLife.17096
PG 57
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DS6XV
UT WOS:000380927700001
ER
PT J
AU Ji, J
Qin, YF
Zhou, R
Zang, RJ
Huang, ZY
Zhang, Y
Chen, MJ
Wu, W
Song, L
Ling, XF
Shen, HB
Hu, ZB
Xia, YK
Lu, CC
Wang, XR
AF Ji, Juan
Qin, Yufeng
Zhou, Ran
Zang, Rujin
Huang, Zhenyao
Zhang, Yan
Chen, Minjian
Wu, Wei
Song, Ling
Ling, Xiufeng
Shen, Hongbing
Hu, Zhibin
Xia, Yankai
Lu, Chuncheng
Wang, Xinru
TI X chromosome-wide identification of SNVs in microRNA genes and
non-obstructive azoospermia risk in han chinese population
SO ONCOTARGET
LA English
DT Article
DE X-linked miRNAs; non-obstructive azoospermia
ID C-ELEGANS; BIOGENESIS; CANCER; SPERMATOGENESIS; DUPLICATIONS;
INACTIVATION; ASSOCIATION; EXPRESSION; VARIANTS; PATHWAY
AB Human X chromosome has higher densities of microRNAs (miRNAs) compared to the average densities on autosomes. Given that numbers of X-linked miRNAs can escape from meiotic sex chromosome inactivation (MSCI) silencing, it is proposed that X-linked miRNAs may play critical roles in the process of spermatogenesis. To test the hypothesis, we performed DNA capture sequencing of human X-linked miRNAs, which was followed by a two-stage case-control study to identify the non-obstructive azoospermia (NOA) related single nucleotide variants (SNVs) in 1107 NOA cases and 1191 fertile healthy controls. Eventually, we found rs5951785, located near hsami-RNA-506/507, increased the risk of NOA, while rs1447393, near hsa-miRNA-510, decreased the risk of NOA. Functional analysis revealed that rs5951785 significantly inhibited cell proliferation and induced cell apoptosis. Taken together, our results demonstrated that X-linked miRNAs played important roles in the pathogenesis of NOA.
C1 [Ji, Juan; Zhou, Ran; Huang, Zhenyao; Zhang, Yan; Chen, Minjian; Wu, Wei; Song, Ling; Shen, Hongbing; Hu, Zhibin; Xia, Yankai; Lu, Chuncheng; Wang, Xinru] Nanjing Med Univ, Inst Toxicol, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.
[Ji, Juan; Zhou, Ran; Huang, Zhenyao; Zhang, Yan; Chen, Minjian; Wu, Wei; Song, Ling; Shen, Hongbing; Hu, Zhibin; Xia, Yankai; Lu, Chuncheng; Wang, Xinru] Nanjing Med Univ, Sch Publ Hlth, Key Lab Modern Toxicol, Minist Educ, Nanjing 210029, Jiangsu, Peoples R China.
[Qin, Yufeng] NIEHS, Epigenet & Stem Cell Biol Lab, Res Triangle Pk, NC 27709 USA.
[Ji, Juan; Ling, Xiufeng] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Children Hlth Care, Nanjing 210029, Jiangsu, Peoples R China.
[Zang, Rujin] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Pediat Surg, State Key Lab Reprod Med, Nanjing 210008, Jiangsu, Peoples R China.
[Shen, Hongbing; Hu, Zhibin] Nanjing Med Univ, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
RP Lu, CC; Wang, XR (reprint author), Nanjing Med Univ, Inst Toxicol, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.; Lu, CC; Wang, XR (reprint author), Nanjing Med Univ, Sch Publ Hlth, Key Lab Modern Toxicol, Minist Educ, Nanjing 210029, Jiangsu, Peoples R China.
EM chunchenglu@njmu.edu.cn; xrwang@njmu.edu.cn
FU National Basic Research Program of China (973 Program) [2012CBA01306];
National Natural Science Foundation of China [81471500, 81330067,
81322039]; Distinguished Young Scholars of Jiangsu Province
[BK20130041]; Priority Academic Program for the Development of Jiangsu
Higher Education Institutions (Public Health and Preventive Medicine)
FX We thank all the research staff and students who took part in this work.
Funding was provided by grants from National Basic Research Program of
China (973 Program, 2012CBA01306), the National Natural Science
Foundation of China (81471500, 81330067 and 81322039), Distinguished
Young Scholars of Jiangsu Province (BK20130041) and the Priority
Academic Program for the Development of Jiangsu Higher Education
Institutions (Public Health and Preventive Medicine).
NR 32
TC 0
Z9 0
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 2
PY 2016
VL 7
IS 31
BP 49122
EP 49129
DI 10.18632/oncotarget.8759
PG 8
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY8ZS
UT WOS:000385422000024
PM 27107421
ER
PT J
AU Szasz, AM
Lanczky, A
Nagy, A
Forster, S
Hark, K
Green, JE
Boussioutas, A
Busuttil, R
Szabo, A
Gyorffy, B
AF Szasz, A. Marcell
Lanczky, Andrs
Nagy, Adm
Foerster, Susann
Hark, Kim
Green, Jeffrey E.
Boussioutas, Alex
Busuttil, Rita
Szabo, Andras
Gyorffy, Balazs
TI Cross-validation of survival associated biomarkers in gastric cancer
using transcriptomic data of 1,065 patients
SO ONCOTARGET
LA English
DT Article
DE gastric cancer; survival; meta-analysis
ID GROWTH-FACTOR RECEPTOR; PROGNOSTIC VALUE; BREAST-CANCER; POOR-PROGNOSIS;
THERAPEUTIC TARGET; EXPRESSION; METAANALYSIS; SIRT1; CARCINOMA;
CLASSIFICATION
AB Introduction: Multiple gene expression based prognostic biomarkers have been repeatedly identified in gastric carcinoma. However, without confirmation in an independent validation study, their clinical utility is limited. Our goal was to establish a robust database enabling the swift validation of previous and future gastric cancer survival biomarker candidates.
Results: The entire database incorporates 1,065 gastric carcinoma samples, gene expression data. Out of 29 established markers, higher expression of BECN1 (HR = 0.68, p = 1.5E-05), CASP3 (HR = 0.5, p = 6E-14), COX2 (HR = 0.72, p = 0.0013), CTGF (HR = 0.72, p = 0.00051), CTNNB1 (HR = 0.47, p = 4.3E-15), MET (HR = 0.63, p = 1.3E-05), and SIRT1 (HR = 0.64, p = 2.2E-07) correlated to longer OS. Higher expression of BIRC5 (HR = 1.45, p = 1E-04), CNTN1 (HR = 1.44, p = 3.5E-05), EGFR (HR = 1.86, p = 8.5E-11), ERCC1 (HR = 1.36, p = 0.0012), HER2 (HR = 1.41, p = 0.00011), MMP2 (HR = 1.78, p = 2.6E-09), PFKB4 (HR = 1.56, p = 3.2E-07), SPHK1 (HR = 1.61, p = 3.1E-06), SP1 (HR = 1.45, p = 1.6E-05), TIMP1 (HR = 1.92, p = 2.2E-10) and VEGF (HR = 1.53, p = 5.7E-06) were predictive for poor OS.
Materials and Methods: We integrated samples of three major cancer research centers (Berlin, Bethesda and Melbourne datasets) and publicly available datasets with available follow-up data to form a single integrated database. Subsequently, we performed a literature search for prognostic markers in gastric carcinomas (PubMed, 2012-2015) and re-validated their findings predicting first progression (FP) and overall survival (OS) using uni- and multivariate Cox proportional hazards regression analysis.
Conclusions: The major advantage of our analysis is that we evaluated all genes in the same set of patients thereby making direct comparison of the markers feasible. The best performing genes include BIRC5, CASP3, CTNNB1, TIMP-1, MMP-2, SIRT, and VEGF.
C1 [Szasz, A. Marcell; Lanczky, Andrs; Nagy, Adm; Gyorffy, Balazs] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary.
[Szasz, A. Marcell] Semmelweis Univ, Dept Pathol 2, Budapest, Hungary.
[Foerster, Susann] Max Delbruck Ctr Mol Med, Berlin, Germany.
[Hark, Kim; Green, Jeffrey E.] NCI, Transgen Oncogenesis & Genom Sect, Lab Canc Biol & Genet, Bethesda, MD 20892 USA.
[Boussioutas, Alex; Busuttil, Rita] Peter MacCallum Canc Ctr, Canc Genet & Genom Lab, East Melbourne, Australia.
[Boussioutas, Alex; Busuttil, Rita] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia.
[Boussioutas, Alex; Busuttil, Rita] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Australia.
[Szabo, Andras; Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary.
RP Gyorffy, B (reprint author), MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary.; Gyorffy, B (reprint author), Semmelweis Univ, Dept Pediat 2, Budapest, Hungary.
EM gyorffy.balazs@ttk.mta.hu
OI Boussioutas, Alex/0000-0002-8109-6897
FU OTKA [K108655]; Hungarian Academy of Sciences
FX BG was supported by the OTKA K108655 grant. AMSz was supported by a
Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences.
NR 50
TC 9
Z9 9
U1 3
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 2
PY 2016
VL 7
IS 31
BP 49322
EP 49333
DI 10.18632/oncotarget.10337
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY8ZS
UT WOS:000385422000040
PM 27384994
ER
PT J
AU Yang, W
Cho, H
Shin, HY
Chung, JY
Kang, ES
Lee, EJ
Kim, JH
AF Yang, Wookyeom
Cho, Hanbyoul
Shin, Ha-Yeon
Chung, Joon-Yong
Kang, Eun Suk
Lee, Eun-Ju
Kim, Jae-Hoon
TI Accumulation of cytoplasmic Cdk1 is associated with cancer growth and
survival rate in epithelial ovarian cancer
SO ONCOTARGET
LA English
DT Article
DE Cdk1; cytoplasmic accumulation; epithelial ovarian cancer; RO-3306
ID PREDICTS POOR-PROGNOSIS; KINASE 1 CDK1; CELL-CYCLE; BRCA1 MUTATION;
BREAST-CANCER; EXPRESSION; PROLIFERATION; PHOSPHORYLATION;
OVEREXPRESSION; APOPTOSIS
AB Cyclin dependent kinase 1 (Cdk1) have previously reported correlation with cancer growth and a key regulator for cell cycle. Mostly, Cdk1' s function of nucleus for cell cycle is well known to be associated with cancer, but cytoplasmic Cdk1's traits are not clearly identified, yet. We revealed that tissue microarray blocks of epithelial ovarian cancer (n = 249) showed increased level of cytoplasmic Cdk1 (p < 0.001), but not in nucleus (p = 0.192) of histologic cell type independently. On survival analysis, Cdk1 overexpression conferred a significantly worse prognosis in 5-year overall survival (Log-rank p = 0.028, Hazard ratio = 2.016, 95% CI = 1.097 to 4.635). Also, the expression of Cdk1 was increased in ovarian cancer cell lines and Gene Expression Omnibus datasets. When the expression and activity of Cdk1 were inhibited by si-Cdk1 or RO-3306 which is a potent Cdk1 inhibitor, the growth of ovarian cancer was diminished. Moreover, combined treatment with RO-3306 and cisplatin in ovarian cancer significantly elevated anti-cancer effects than single-agent treatment. In conclusion, cytoplasmic Cdk1 expression which was elevated in ovarian cancer predicts a poor overall survival. The inhibition of Cdk1 expression and activity reduced ovarian cancer growth.
C1 [Yang, Wookyeom; Cho, Hanbyoul; Shin, Ha-Yeon; Lee, Eun-Ju; Kim, Jae-Hoon] Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Gangnam Severance Hosp, Seoul, South Korea.
[Yang, Wookyeom; Cho, Hanbyoul; Shin, Ha-Yeon; Lee, Eun-Ju; Kim, Jae-Hoon] Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Seoul, South Korea.
[Chung, Joon-Yong] NCI, Tissue Array Res Program, Pathol Lab, NIH, Bethesda, MD 20892 USA.
[Kang, Eun Suk] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med, Seoul, South Korea.
RP Kim, JH (reprint author), Yonsei Univ, Coll Med, Dept Obstet & Gynecol, Gangnam Severance Hosp, Seoul, South Korea.; Kim, JH (reprint author), Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Seoul, South Korea.
EM jaehoonkim@yuhs.ac
OI Chung, Joon-Yong/0000-0001-5041-5982
FU Basic Science Research Program through the National Research Foundation
of Korea (NRF) - Ministry of Education [NRF-2014R1A1A2057882]
FX This research was supported by Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded by the Ministry
of Education (NRF-2014R1A1A2057882).
NR 31
TC 1
Z9 1
U1 1
U2 1
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 2
PY 2016
VL 7
IS 31
BP 49481
EP 49497
DI 10.18632/oncotarget.10373
PG 17
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA DY8ZS
UT WOS:000385422000052
PM 27385216
ER
PT J
AU Chen, X
Randles, L
Shi, K
Tarasov, SG
Aihara, H
Walters, KJ
AF Chen, Xiang
Randles, Leah
Shi, Ke
Tarasov, Sergey G.
Aihara, Hideki
Walters, Kylie J.
TI Structures of Rpn1 T1:Rad23 and hRpn13:hPLIC2 Reveal Distinct Binding
Mechanisms between Substrate Receptors and Shuttle Factors of the
Proteasome
SO STRUCTURE
LA English
DT Article
ID UBIQUITIN-LIKE DOMAIN; DEUBIQUITINATING ENZYME UCH37; AMYLOID PRECURSOR
PROTEIN; EXCISION-REPAIR PATHWAY; 26 S PROTEASOME; UBA DOMAIN;
SACCHAROMYCES-CEREVISIAE; GENETIC POLYMORPHISMS; QUANTITATIVE-ANALYSIS;
AMPLIFICATION TARGET
AB Three receptors (Rpn1/S2/PSMD2, Rpn10/S5a, Rpn13/Adrm1) in the proteasome bind substrates by interacting with conjugated ubiquitin chains and/or shuttle factors (Rad23/HR23, Dsk2/PLIC/ubiquilin, Ddi1) that carry ubiquitinated substrates to proteasomes. We solved the structure of two such receptors with their preferred shuttle factor, namely hRpn13(Pru):hPLIC2(UBL) and scRpn1 T1:scRad23(UBL). We find that ubiquitin folds in Rad23 and Dsk2 are fine-tuned by residue substitutions to achieve high affinity for Rpn1 and Rpn13, respectively. A single substitution in hPLIC2 yields enhanced interactions with the Rpn13 ubiquitin contact surface and sterically blocks hRpn13 binding to its preferred ubiquitin chain type, K48-linked chains. Rpn1 T1 binds two ubiquitins in tandem and we find that Rad23 binds exclusively to the higher-affinity Helix28/Helix30 site. Rad23 contacts at Helix28/Helix30 are optimized compared to ubiquitin by multiple conservative amino acid substitutions. Thus, shuttle factors deliver substrates to proteasomes through fine-tuned ubiquitin-like surfaces.
C1 [Chen, Xiang; Randles, Leah; Walters, Kylie J.] NCI, Prot Proc Sect, Struct Biophys Lab, Ctr Canc Res, Frederick, MD 21702 USA.
[Shi, Ke; Aihara, Hideki] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
[Tarasov, Sergey G.] NCI, Biophys Resource, Struct Biophys Lab, Ctr Canc Res, Frederick, MD 21702 USA.
RP Walters, KJ (reprint author), NCI, Prot Proc Sect, Struct Biophys Lab, Ctr Canc Res, Frederick, MD 21702 USA.
EM kylie.walters@nih.gov
FU Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research; NIH [GM095558]; NIGMS [P41 GM103403]; US
Department of Energy Office of Science User Facility [DE-AC02-06CH11357]
FX This research was funded by the Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research to K.J.W. and a
grant from the NIH to H.A. (GM095558). X-ray data were collected at the
Advanced Photon Source (APS) NE-CAT beamlines, which are supported by
the NIGMS (P41 GM103403). APS is a US Department of Energy Office of
Science User Facility operated by Argonne National Laboratory under
Contract DE-AC02-06CH11357.
NR 96
TC 1
Z9 1
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD AUG 2
PY 2016
VL 24
IS 8
BP 1257
EP 1270
DI 10.1016/j.str.2016.05.018
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DV9FC
UT WOS:000383244600007
PM 27396824
ER
PT J
AU Shin, S
Lee, J
Yoo, S
Kulikowicz, T
Bohr, VA
Ahn, B
Hohng, S
AF Shin, Soochul
Lee, Jinwoo
Yoo, Sangwoon
Kulikowicz, Tomasz
Bohr, Vilhelm A.
Ahn, Byungchan
Hohng, Sungchul
TI Active Control of Repetitive Structural Transitions between Replication
Forks and Holliday Junctions by Werner Syndrome Helicase
SO STRUCTURE
LA English
DT Article
ID SYNDROME PROTEIN WRN; BRANCH MIGRATION; SINGLE-MOLECULE;
DNA-REPLICATION; GENOME STABILITY; MAMMALIAN-CELLS; STRANDED-DNA; HUMAN
HLTF; REGRESSION; REPAIR
AB The reactivation of stalled DNA replication via fork regression invokes Holliday junction formation, branch migration, and the recovery of the replication fork after DNA repair or error-free DNA synthesis. The coordination mechanism for these DNA structural transitions by molecular motors, however, remains unclear. Here we perform single-molecule fluorescence experiments with Werner syndrome protein (WRN) and model replication forks. The Holliday junction is readily formed once the lagging arm is unwound, and migrated unidirectionally with 3.2 +/- 0.03 bases/s velocity. The recovery of the replication fork was controlled by branch migration reversal of WRN, resulting in repetitive fork regression. The Holliday junction formation, branch migration, and migration direction reversal are all ATP dependent, revealing that WRN uses the energy of ATP hydrolysis to actively coordinate the structural transitions of DNA.
C1 [Shin, Soochul; Lee, Jinwoo; Yoo, Sangwoon; Hohng, Sungchul] Seoul Natl Univ, Dept Phys & Astron, Seoul 08826, South Korea.
[Shin, Soochul; Lee, Jinwoo; Yoo, Sangwoon; Hohng, Sungchul] Seoul Natl Univ, Inst Appl Phys, Seoul 08826, South Korea.
[Shin, Soochul; Lee, Jinwoo; Yoo, Sangwoon; Hohng, Sungchul] Seoul Natl Univ, Natl Ctr Creat Res Initiat, Seoul 08826, South Korea.
[Hohng, Sungchul] Seoul Natl Univ, Dept Biophys & Chem Biol, Seoul 08826, South Korea.
[Kulikowicz, Tomasz; Bohr, Vilhelm A.] NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA.
[Ahn, Byungchan] Univ Ulsan, Dept Life Sci, Ulsan 680749, South Korea.
RP Hohng, S (reprint author), Seoul Natl Univ, Dept Phys & Astron, Seoul 08826, South Korea.; Hohng, S (reprint author), Seoul Natl Univ, Inst Appl Phys, Seoul 08826, South Korea.; Hohng, S (reprint author), Seoul Natl Univ, Natl Ctr Creat Res Initiat, Seoul 08826, South Korea.; Hohng, S (reprint author), Seoul Natl Univ, Dept Biophys & Chem Biol, Seoul 08826, South Korea.; Ahn, B (reprint author), Univ Ulsan, Dept Life Sci, Ulsan 680749, South Korea.
EM bbccahn@mail.ulsan.ac.kr; shohng@snu.ac.kr
FU Creative Research Initiatives [2009-0081562]; Priority Research Center
Program through NRF [2009-0094050]; Intramural Program of the National
Institute on Aging, National Institutes of Health USA
FX This work was supported by the Creative Research Initiatives
(2009-0081562) to S.H., Priority Research Center Program through NRF
(2009-0094050) to B.A., and funds from the Intramural Program of the
National Institute on Aging, National Institutes of Health USA to V.A.B.
Funding for open access charge: Creative Research Initiatives.
NR 46
TC 0
Z9 0
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD AUG 2
PY 2016
VL 24
IS 8
BP 1292
EP 1300
DI 10.1016/j.str.2016.06.004
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DV9FC
UT WOS:000383244600010
PM 27427477
ER
PT J
AU Davenport, TM
Gorman, J
Joyce, MG
Zhou, TQ
Soto, C
Guttman, M
Moquin, S
Yang, YP
Zhang, BS
Doria-Rose, NA
Hu, SL
Mascola, JR
Kwong, PD
Lee, KK
AF Davenport, Thaddeus M.
Gorman, Jason
Joyce, M. Gordon
Zhou, Tongqing
Soto, Cinque
Guttman, Miklos
Moquin, Stephanie
Yang, Yongping
Zhang, Baoshan
Doria-Rose, Nicole A.
Hu, Shiu-Lok
Mascola, John R.
Kwong, Peter D.
Lee, Kelly K.
TI Somatic Hypermutation-Induced Changes in the Structure and Dynamics of
HIV-1 Broadly Neutralizing Antibodies
SO STRUCTURE
LA English
DT Article
ID EXCHANGE MASS-SPECTRA; AFFINITY MATURATION; PROTEIN DYNAMICS;
HYDROGEN-EXCHANGE; COMBINING SITE; BINDING-SITE; EVOLUTION; ANTIGEN;
GP120; RECOGNITION
AB Antibody somatic hypermutation (SHM) and affinity maturation enhance antigen recognition by modifying antibody paratope structure to improve its complementarity with the target epitope. SHM-induced changes in paratope dynamics may also contribute to antibody maturation, but direct evidence of this is limited. Here, we examine two classes of HIV-1 broadly neutralizing antibodies (bNAbs) for SHM-induced changes in structure and dynamics, and delineate the effects of these changes on interactions with the HIV-1 envelope glycoprotein (Env). In combination with new and existing structures of unmutated and affinity matured antibody Fab fragments, we used hydrogen/deuterium exchange with mass spectrometry to directly measure Fab structural dynamics. Changes in antibody structure and dynamics were positioned to improve complementarity with Env, with changes in dynamics primarily observed at the paratope peripheries. We conclude that SHM optimizes paratope complementarity to conserved HIV-1 epitopes and restricts the mobility of paratope-peripheral residues to minimize clashes with variable features on HIV-1 Env.
C1 [Davenport, Thaddeus M.; Guttman, Miklos; Lee, Kelly K.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.
[Gorman, Jason; Joyce, M. Gordon; Zhou, Tongqing; Soto, Cinque; Moquin, Stephanie; Yang, Yongping; Zhang, Baoshan; Doria-Rose, Nicole A.; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Hu, Shiu-Lok] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Lee, KK (reprint author), Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.
EM kklee@uw.edu
RI Zhou, Tongqing/A-6880-2010
OI Zhou, Tongqing/0000-0002-3935-4637
FU NIH [R01-GM099989, R21-AI112389, T32-AI7509]; Bill and Melinda Gates
Foundation Collaboration for AIDS Vaccine Discovery (CAVD) grant
[OPP1033102]; Intramural Research Program of the Vaccine Research
Center, National Institute of Allergy and Infectious Diseases, NIH; US
Department of Energy, Basic Energy Sciences, Office of Science
[W-31-109-Eng-38]
FX We thank members of the Structural Biology Section, VRC, for comments on
the manuscript. This work was supported by NIH grants R01-GM099989 and
R21-AI112389 (K.K.L.), T32-AI7509 (T.M.D.), and the Bill and Melinda
Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) grant
OPP1033102 (K.K.L., S.L.H.). Support was also provided by the Intramural
Research Program of the Vaccine Research Center, National Institute of
Allergy and Infectious Diseases, NIH (J.R.M., P.D.K.). Use of insertion
device 22 (SER-CAT) at the Advanced Photon Source was supported by the
US Department of Energy, Basic Energy Sciences, Office of Science, under
contract W-31-109-Eng-38.
NR 51
TC 1
Z9 1
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD AUG 2
PY 2016
VL 24
IS 8
BP 1346
EP 1357
DI 10.1016/j.str.2016.06.012
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DV9FC
UT WOS:000383244600015
ER
PT J
AU Shehadah, A
Franklin, GM
Benson, RT
AF Shehadah, Amjad
Franklin, Gary M.
Benson, Richard T.
TI Global disparities in stroke and why we should care
SO NEUROLOGY
LA English
DT Editorial Material
C1 [Shehadah, Amjad] NINDS, Stroke Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Franklin, Gary M.] Univ Washington, Seattle, WA 98195 USA.
[Benson, Richard T.] Medstar Washington Hosp Ctr, Washington, DC 20010 USA.
RP Benson, RT (reprint author), Medstar Washington Hosp Ctr, Washington, DC 20010 USA.
EM richard.benson@nih.gov
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 2
PY 2016
VL 87
IS 5
BP 450
EP 451
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU6LO
UT WOS:000382326500005
PM 27371491
ER
PT J
AU Li, KG
Liu, DP
Haynie, D
Gee, B
Chaurasia, A
Seo, DC
Iannotti, RJ
Simons-Morton, BG
AF Li, Kaigang
Liu, Danping
Haynie, Denise
Gee, Benjamin
Chaurasia, Ashok
Seo, Dong-Chul
Iannotti, Ronald J.
Simons-Morton, Bruce G.
TI Individual, social, and environmental influences on the transitions in
physical activity among emerging adults
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Moderate and vigorous physical activity; Emerging adults; Transition
model; Physical activity planning; Peer physical activity
ID ADOLESCENTS; BEHAVIOR; HEALTH; STUDENTS; COLLEGE; YOUTH; PEER;
RELIABILITY; UNIVERSITY; PATTERNS
AB Background: Youth's physical activity (PA) may change across developmental periods. Although previous studies have observed a decline in levels of PA during adolescence, few studies have explored trends in PA during the transition from adolescence to young adulthood and what factors may impact the transitional change. The purpose of this study was to examine changes and predictors of change over time in PA from 10th grade to post-high school.
Methods: The NEXT Generation Health Study recruited a nationally-representative cohort of US 10th-graders, and administered longitudinal surveys in four waves (years) to follow up the participants to their first year after high school. Using transition models, the self-reported outcomes, moderate-to-vigorous PA (MVPA) and vigorous PA (VPA) each of which was repeatedly measured by one question, were modelled in association with wave-4 environmental-status variables and time-varying covariates.
Results: There was a continuous decline in the proportion of respondents who met or exceeded the minimum recommended level for either MVPA (from 55.97 to 34.33 %) or VPA (from 65.96 to 54.90 %) from W1 to W4. Higher scores of peer PA, family support and VPA planning were prospectively associated with higher likelihood of meeting the MVPA/VPA recommendations. At wave 4, compared to those not working, attending 4-year colleges, or living on campus, participants working full/part time, not attending school or attending community-college level schools, and living at home or in own place were more likely to engage in MVPA.
Conclusions: Peer PA, family support, self-regulatory skills, and environmental status after high school are critical factors that can promote MVPA/VPA among adolescents and emerging adults.
C1 [Li, Kaigang] Colorado State Univ, Dept Hlth & Exercise Sci, B 215E Moby Complex, Ft Collins, CO 80523 USA.
[Liu, Danping; Haynie, Denise; Gee, Benjamin; Simons-Morton, Bruce G.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, 6100 Execut Blvd, Bethesda, MD 20892 USA.
[Chaurasia, Ashok] Univ Waterloo, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
[Seo, Dong-Chul] Indiana Univ, Sch Publ Hlth, Bloomington, IN 47405 USA.
[Iannotti, Ronald J.] CDM Grp, 7500 Old Georgetown Rd, Bethesda, MD 20814 USA.
RP Li, KG (reprint author), Colorado State Univ, Dept Hlth & Exercise Sci, B 215E Moby Complex, Ft Collins, CO 80523 USA.
EM kaigang.li@colostate.edu
OI Seo, Dong-Chul/0000-0002-1972-6237; Simons-Morton,
Bruce/0000-0003-1099-6617; Haynie, Denise/0000-0002-8270-6079
FU intramural research program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development [HHSN275201200001I];
National Heart, Lung and Blood Institute; National Institute on Alcohol
Abuse and Alcoholism; National Institute on Drug Abuse; Maternal and
Child Health Bureau of the Health Resources and Services Administration
FX This project (contract # HHSN275201200001I) was supported in part by the
intramural research program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, and the National Heart,
Lung and Blood Institute, the National Institute on Alcohol Abuse and
Alcoholism, and Maternal, the National Institute on Drug Abuse, and the
Maternal and Child Health Bureau of the Health Resources and Services
Administration.
NR 50
TC 1
Z9 1
U1 6
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD AUG 2
PY 2016
VL 16
AR 682
DI 10.1186/s12889-016-3368-3
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DS8AG
UT WOS:000381004300002
PM 27485724
ER
PT J
AU Lee, SA
Bacchetti, P
Chomont, N
Fromentin, R
Lewin, SR
O'Doherty, U
Palmer, S
Richman, DD
Siliciano, JD
Yukl, SA
Deeks, SG
Burbelo, PD
AF Lee, Sulggi A.
Bacchetti, Peter
Chomont, Nicolas
Fromentin, Remi
Lewin, Sharon R.
O'Doherty, Una
Palmer, Sarah
Richman, Douglas D.
Siliciano, Janet D.
Yukl, Steven A.
Deeks, Steven G.
Burbelo, Peter D.
TI Anti-HIV Antibody Responses and the HIV Reservoir Size during
Antiretroviral Therapy
SO PLOS ONE
LA English
DT Article
ID INFECTED-CELLS; INTEGRATION; REPLICATION; PCR; PERSISTENCE; PLASMA;
ASSAY
AB Background
A major challenge to HIV eradication strategies is the lack of an accurate measurement of the total burden of replication-competent HIV (the "reservoir"). We assessed the association of anti-HIV antibody responses and the estimated size of the reservoir during antiretroviral therapy (ART).
Methods
We evaluated anti-HIV antibody profiles using luciferase immunoprecipitation systems (LIPS) assay in relation to several blood-based HIV reservoir measures: total and 2-LTR DNA (rtPCR or droplet digital PCR); integrated DNA (Alu PCR); unspliced RNA (rtPCR), multiply-spliced RNA (TILDA), residual plasma HIV RNA (single copy PCR), and replication- competent virus (outgrowth assay). We also assessed total HIV DNA and RNA in gut-associated lymphoid tissue (rtPCR). Spearman correlations and linear regressions were performed using log-transformed blood-or tissue-based reservoir measurements as predictors and log-transformed antibody levels as outcome variables.
Results
Among 51 chronically HIV-infected ART-suppressed participants (median age = 57, nadir CD4+ count = 196 cells/mm3, ART duration = 9 years), the most statistically significant associations were between antibody responses to integrase and HIV RNA in gut-associated lymphoid tissue (1.17 fold-increase per two-fold RNA increase, P = 0.004) and between antibody responses to matrix and integrated HIV DNA in resting CD4+ T cells (0.35 fold-decrease per two-fold DNA increase, P = 0.003). However, these associations were not statistically significant after a stringent Bonferroni-adjustment of P<0.00045. Multivariate models including age and duration of ART did not markedly alter results.
Conclusions
Our findings suggest that anti-HIV antibody responses may reflect the size of the HIV reservoir during chronic treated HIV disease, possibly via antigen recognition in reservoir sites. Larger, prospective studies are needed to validate the utility of antibody levels as a measure of the total body burden of HIV during treatment.
C1 [Lee, Sulggi A.; Bacchetti, Peter; Yukl, Steven A.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Chomont, Nicolas; Fromentin, Remi] Univ Montreal, CR CHUM, Montreal, PQ, Canada.
[Chomont, Nicolas; Fromentin, Remi] Univ Montreal, Dept Microbiol Infect Dis & Immunol, Montreal, PQ, Canada.
[Lewin, Sharon R.] Univ Melbourne, Peter Doherty Infect & Immun, Melbourne, Vic, Australia.
[Lewin, Sharon R.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
[Lewin, Sharon R.] Monash Univ, Dept Infect Dis, Melbourne, Vic, Australia.
[Lewin, Sharon R.] Alfred Hosp, Melbourne, Vic, Australia.
[O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Palmer, Sarah] Univ Sydney, Westmead Inst Med Res, Ctr Virus Res, Sydney, NSW, Australia.
[Richman, Douglas D.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Richman, Douglas D.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
[Richman, Douglas D.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Siliciano, Janet D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Yukl, Steven A.] Vet Affairs San Francisco Healthcare Syst, San Francisco, CA USA.
[Burbelo, Peter D.] Natl Inst Dent & Craniofacial Res, Dent Clin Res Core, Bethesda, MD USA.
[Lee, Sulggi A.] Univ Calif San Francisco, Dept Med, Div HIV AIDS, San Francisco, CA 94143 USA.
RP Lee, SA (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Lee, SA (reprint author), Univ Calif San Francisco, Dept Med, Div HIV AIDS, San Francisco, CA 94143 USA.
EM sulggi.lee@ucsf.edu
OI Lewin, Sharon Ruth/0000-0002-0330-8241
FU National Institutes of Health [1K23GM112526, 1R01DK108349]; DARE
Collaboratory [U19 AI096109]; CARE Collaboratory [U19 AI096113];
Division of Intramural Research of the National Institutes, the National
Institute of Dental and Craniofacial Research; National Health and
Medical Research Council of Australia; amfAR Research Consortium on HIV
Eradication a.k.a. ARCHE [108072-50-RGRL]; Department of Veterans
Affairs [IK2 CX000520]; UCSD Center for AIDS Research [P30 AI36214];
James B. Pendleton Charitable Trust
FX This work was supported in part by the National Institutes of Health
(1K23GM112526, 1R01DK108349, the DARE Collaboratory [U19 AI096109], the
CARE Collaboratory [U19 AI096113]), the Division of Intramural Research
of the National Institutes, the National Institute of Dental and
Craniofacial Research, and the National Health and Medical Research
Council of Australia. This work was also supported by the amfAR Research
Consortium on HIV Eradication a.k.a. ARCHE (108072-50-RGRL), the
Department of Veterans Affairs (IK2 CX000520), the UCSD Center for AIDS
Research (P30 AI36214), and the James B. Pendleton Charitable Trust. The
funders had no role in the study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 21
TC 0
Z9 0
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 2
PY 2016
VL 11
IS 8
AR e0160192
DI 10.1371/journal.pone.0160192
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS9NS
UT WOS:000381110700027
PM 27483366
ER
PT J
AU Lau, E
Watson, KE
Ping, PP
AF Lau, Edward
Watson, Karol E.
Ping, Peipei
TI Connecting the Dots From Big Data to Healthy Heart
SO CIRCULATION
LA English
DT Editorial Material
DE bioinformatics; data mining; dataset
ID MEDICINE
C1 [Lau, Edward; Watson, Karol E.; Ping, Peipei] Univ Calif Los Angeles, NIH, Ctr Excellence Biomed Comp BD2K, 675 Charles E Young Dr S,MRL 1-619, Los Angeles, CA 90095 USA.
[Lau, Edward; Ping, Peipei] Univ Calif Los Angeles, Dept Physiol, 675 Charles E Young Dr S,MRL 1-619, Los Angeles, CA 90095 USA.
[Watson, Karol E.; Ping, Peipei] Univ Calif Los Angeles, Dept Med Cardiol, 675 Charles E Young Dr S,MRL 1-619, Los Angeles, CA 90095 USA.
[Ping, Peipei] Univ Calif Los Angeles, Dept Bioinformat, 675 Charles E Young Dr S,MRL 1-619, Los Angeles, CA 90095 USA.
RP Ping, PP (reprint author), Univ Calif Los Angeles, 675 Charles E Young Dr S,MRL 1-619, Los Angeles, CA 90095 USA.
EM peipeiping@earthlink.net
FU NIGMS NIH HHS [U54 GM114833]
NR 4
TC 2
Z9 2
U1 5
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 2
PY 2016
VL 134
IS 5
BP 362
EP 364
DI 10.1161/CIRCULATIONAHA.116.021892
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DS2NB
UT WOS:000380612600004
PM 27481999
ER
PT J
AU Abdel-Gadir, A
Vorasettakarnkij, Y
Ngamkasem, H
Nordin, S
Ako, EA
Tumkosit, M
Sucharitchan, P
Uaprasert, N
Kellman, P
Piechnik, SK
Fontana, M
Fernandes, JL
Manisty, C
Westwood, M
Porter, JB
Walker, JM
Moon, JC
AF Abdel-Gadir, Amna
Vorasettakarnkij, Yongkasem
Ngamkasem, Hataichanok
Nordin, Sabrina
Ako, Emmanuel A.
Tumkosit, Monravee
Sucharitchan, Pranee
Uaprasert, Noppacharn
Kellman, Peter
Piechnik, Stefan K.
Fontana, Marianna
Fernandes, Juliano L.
Manisty, Charlotte
Westwood, Mark
Porter, John B.
Walker, J. Malcolm
Moon, James C.
TI Ultrafast Magnetic Resonance Imaging for Iron Quantification in
Thalassemia Participants in the Developing World The TIC-TOC Study
(Thailand and UK International Collaboration in Thalassaemia Optimising
Ultrafast CMR)
SO CIRCULATION
LA English
DT Article
DE cardiomyopathies; diagnosis; iron overload; magnetic resonance imaging
C1 [Abdel-Gadir, Amna; Nordin, Sabrina; Ako, Emmanuel A.; Manisty, Charlotte; Westwood, Mark; Moon, James C.] Barts Heart Ctr, London EC1A 7BE, England.
[Abdel-Gadir, Amna; Nordin, Sabrina; Ako, Emmanuel A.; Fontana, Marianna; Manisty, Charlotte; Walker, J. Malcolm; Moon, James C.] UCL, Inst Cardiovasc Sci, London WC1E 6BT, England.
[Vorasettakarnkij, Yongkasem; Tumkosit, Monravee; Sucharitchan, Pranee; Uaprasert, Noppacharn] Chulalongkorn Univ, Fac Med, Bangkok, Thailand.
[Vorasettakarnkij, Yongkasem; Tumkosit, Monravee; Sucharitchan, Pranee; Uaprasert, Noppacharn] King Chulalongkorn Mem Hosp, Bangkok, Thailand.
[Ngamkasem, Hataichanok] Queen Savang Vadhana Mem Hosp, Sriracha, Thailand.
[Kellman, Peter] NHLBI, Med Signal & Image Proc Program, Bldg 10, Bethesda, MD 20892 USA.
[Piechnik, Stefan K.] Univ Oxford, Radcliffe Dept Med, Ctr Clin Magnet Resonance Res, Div Cardiovasc Med, Oxford OX1 2JD, England.
[Fontana, Marianna] Royal Free Hosp, Natl Amyloidosis Ctr, London, England.
[Fernandes, Juliano L.] Jose Michel Kalaf Res Inst, Cardiovasc Imaging Ctr, Sao Paulo, Brazil.
[Porter, John B.] Univ Coll London Hosp, Dept Haematol, London, England.
[Walker, J. Malcolm] Univ Coll Hosp, Hatter Cardiovasc Inst, London, England.
RP Abdel-Gadir, A (reprint author), Barts Heart Ctr, London EC1A 7BE, England.
EM a.abdel-gadir@ucl.ac.uk
FU Rosetrees Trust; UK Thalassaemia Society; Ratchadapiseksompotch Fund,
Faculty of Medicine, Chulalongkorn University [RA58/058]; British
Research Council; National Institute for Health Research Oxford
Biomedical Research Center based at The Oxford University Hospitals
Trust at the University of Oxford; UK National Institute for Health
Research Biomedical Research Center
FX Dr Abdel-Gadir is supported by the Rosetrees Trust and UK Thalassaemia
Society. Drs Vorasettakarnkij, Ngamkasem, Tumkosit, Sucharitchan, and
Uaprasert are supported by the Ratchadapiseksompotch Fund, Faculty of
Medicine, Chulalongkorn University (grant RA58/058). Dr Porter is
supported by the British Research Council. Dr Piechnik is supported by
the National Institute for Health Research Oxford Biomedical Research
Center based at The Oxford University Hospitals Trust at the University
of Oxford. Drs Moon and Manisty are supported by the UK National
Institute for Health Research Biomedical Research Center funding scheme.
NR 4
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD AUG 2
PY 2016
VL 134
IS 5
BP 432
EP +
DI 10.1161/CIRCULATIONAHA.116.022803
PG 4
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DS2NB
UT WOS:000380612600011
PM 27482005
ER
PT J
AU Margulies, KB
Hernandez, AF
Redfield, MM
Givertz, MM
Oliveira, GH
Cole, R
Mann, DL
Whellan, DJ
Kiernan, MS
Felker, GM
McNulty, SE
Anstrom, KJ
Shah, MR
Braunwald, E
Cappola, TP
AF Margulies, Kenneth B.
Hernandez, Adrian F.
Redfield, Margaret M.
Givertz, Michael M.
Oliveira, Guilherme H.
Cole, Robert
Mann, Douglas L.
Whellan, David J.
Kiernan, Michael S.
Felker, G. Michael
McNulty, Steven E.
Anstrom, Kevin J.
Shah, Monica R.
Braunwald, Eugene
Cappola, Thomas P.
CA NHLBI Heart Failure Clinical Res
TI Effects of Liraglutide on Clinical Stability Among Patients With
Advanced Heart Failure and Reduced Ejection Fraction A Randomized
Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID GLUCAGON-LIKE PEPTIDE-1; CARDIOVASCULAR OUTCOMES; INSULIN-RESISTANCE;
MORTALITY; DESIGN
AB IMPORTANCE Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.
OBJECTIVE To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.
DESIGN, SETTING, AND PARTICIPANTS Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites.
INTERVENTIONS The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
MAIN OUTCOMES AND MEASURES The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events.
RESULTS Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25%[IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively).
CONCLUSIONS AND RELEVANCE Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation.
C1 [Margulies, Kenneth B.; Cappola, Thomas P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hernandez, Adrian F.; McNulty, Steven E.; Anstrom, Kevin J.] Duke Clin Res Inst, Durham, NC USA.
[Redfield, Margaret M.] Mayo Clin, Rochester, MN USA.
[Givertz, Michael M.; Braunwald, Eugene] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Oliveira, Guilherme H.] Univ Hosp, Case Med Ctr, Cleveland, OH USA.
[Cole, Robert] Emory Univ, Atlanta, GA 30322 USA.
[Mann, Douglas L.] Washington Univ, Sch Med, St Louis, MO USA.
[Whellan, David J.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Kiernan, Michael S.] Tufts Univ, Boston, MA 02111 USA.
[Felker, G. Michael] Duke Univ, Sch Med, Durham, NC USA.
[Felker, G. Michael] Duke Heart Ctr, Durham, NC USA.
[Shah, Monica R.] NHLBI, Bldg 10, Bethesda, MD 20892 USA.
RP Margulies, KB (reprint author), Smilow Ctr Translat Res, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM ken.margulies@uphs.upenn.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [U10 HL084904, U01
HL084861, U10 HL110312, U10 HL110337, U10 HL110342, U10 HL110262, U10
HL110297, U10 HL110302, U10 HL110309, U10 HL110336, U10 HL110338]
FX This research was supported by grants U10 HL084904 (awarded to the
coordinating center) and U01 HL084861, U10 HL110312, U10 HL110337, U10
HL110342, U10 HL110262, U10 HL110297, U10 HL110302, U10 HL110309, U10
HL110336, and U10 HL110338 (awarded to the regional clinical centers)
from the National Heart, Lung, and Blood Institute (NHLBI). The study
drug (liraglutide) and matching placebo injections were supplied by
NovoNordisk Inc.
NR 22
TC 16
Z9 16
U1 3
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 2
PY 2016
VL 316
IS 5
BP 500
EP 508
DI 10.1001/jama.2016.10260
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS9AU
UT WOS:000381075000016
PM 27483064
ER
PT J
AU Hannah-Shmouni, F
Demidowich, A
Stratakis, CA
AF Hannah-Shmouni, Fady
Demidowich, Andrew
Stratakis, Constantine A.
TI Cortisol in the Evaluation of Adrenal Insufficiency
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID DIAGNOSIS
C1 [Hannah-Shmouni, Fady; Demidowich, Andrew; Stratakis, Constantine A.] NICHHD, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA.
RP Stratakis, CA (reprint author), NICHD, SEGEN, PDEGEN, NIH, 9000 Rockville Pk,Bldg 10,CRC,Room 1-3330,MSC1103, Bethesda, MD 20892 USA.
EM stratakc@mail.nih.gov
NR 6
TC 0
Z9 0
U1 5
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 2
PY 2016
VL 316
IS 5
BP 535
EP 536
DI 10.1001/jama.2016.8360
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DS9AU
UT WOS:000381075000021
PM 27483068
ER
PT J
AU Orfano, AS
Nacif-Pimenta, R
Duarte, APM
Villegas, LM
Rodrigues, NB
Pinto, LC
Campos, KMM
Pinilla, YT
Chaves, B
Guerra, MGVB
Monteiro, WM
Smith, RC
Molina-Cruz, A
Lacerda, MVG
Secundino, NFC
Jacobs-Lorena, M
Barillas-Mury, C
Pimenta, PFP
AF Orfano, Alessandra S.
Nacif-Pimenta, Rafael
Duarte, Ana P. M.
Villegas, Luis M.
Rodrigues, Nilton B.
Pinto, Luciana C.
Campos, Keillen M. M.
Pinilla, Yudi T.
Chaves, Barbara
Guerra, Maria G. V. Barbosa
Monteiro, Wuelton M.
Smith, Ryan C.
Molina-Cruz, Alvaro
Lacerda, Marcus V. G.
Secundino, Nagila F. C.
Jacobs-Lorena, Marcelo
Barillas-Mury, Carolina
Pimenta, Paulo F. P.
TI Species-specific escape of Plasmodium sporozoites from oocysts of avian,
rodent, and human malarial parasites
SO MALARIA JOURNAL
LA English
DT Article
DE Sporozoite escape; Oocyst; Mosquito vector; Plasmodium; Human; Murine;
Avian
ID MOSQUITO SALIVARY-GLAND; HOST-CELL INVASION; ANOPHELES-GAMBIAE;
SPOROGONIC DEVELOPMENT; CIRCUMSPOROZOITE PROTEIN; APICOMPLEXAN
PARASITES; LABORATORY MODELS; GLIDING MOTILITY; MAMMALIAN HOST;
FINE-STRUCTURE
AB Background: Malaria is transmitted when an infected mosquito delivers Plasmodium sporozoites into a vertebrate host. There are many species of Plasmodium and, in general, the infection is host-specific. For example, Plasmodium gallinaceum is an avian parasite, while Plasmodium berghei infects mice. These two parasites have been extensively used as experimental models of malaria transmission. Plasmodium falciparum and Plasmodium vivax are the most important agents of human malaria, a life-threatening disease of global importance. To complete their life cycle, Plasmodium parasites must traverse the mosquito midgut and form an oocyst that will divide continuously. Mature oocysts release thousands of sporozoites into the mosquito haemolymph that must reach the salivary gland to infect a new vertebrate host. The current understanding of the biology of oocyst formation and sporozoite release is mostly based on experimental infections with P. berghei, and the conclusions are generalized to other Plasmodium species that infect humans without further morphological analyses.
Results: Here, it is described the microanatomy of sporozoite escape from oocysts of four Plasmodium species: the two laboratory models, P. gallinaceum and P. berghei, and the two main species that cause malaria in humans, P. vivax and P. falciparum. It was found that sporozoites have species-specific mechanisms of escape from the oocyst. The two model species of Plasmodium had a common mechanism, in which the oocyst wall breaks down before sporozoites emerge. In contrast, P. vivax and P. falciparum sporozoites show a dynamic escape mechanism from the oocyst via polarized propulsion.
Conclusions: This study demonstrated that Plasmodium species do not share a common mechanism of sporozoite escape, as previously thought, but show complex and species-specific mechanisms. In addition, the knowledge of this phenomenon in human Plasmodium can facilitate transmission-blocking studies and not those ones only based on the murine and avian models.
C1 [Orfano, Alessandra S.; Nacif-Pimenta, Rafael; Duarte, Ana P. M.; Villegas, Luis M.; Rodrigues, Nilton B.; Pinto, Luciana C.; Chaves, Barbara; Secundino, Nagila F. C.; Pimenta, Paulo F. P.] Ctr Pesquisas Rene Rachou Fiocruz, Belo Horizonte, MG, Brazil.
[Duarte, Ana P. M.; Campos, Keillen M. M.; Pinilla, Yudi T.; Chaves, Barbara; Guerra, Maria G. V. Barbosa; Monteiro, Wuelton M.; Lacerda, Marcus V. G.; Pimenta, Paulo F. P.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, AM, Brazil.
[Lacerda, Marcus V. G.] Inst Leonidas & Maria Deane Fiocruz, Manaus, AM, Brazil.
[Smith, Ryan C.] Iowa State Univ, Dept Entomol, Ames, IA USA.
[Smith, Ryan C.; Jacobs-Lorena, Marcelo] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
[Molina-Cruz, Alvaro; Barillas-Mury, Carolina] NIH, Lab Malaria & Vector Res, Rockville, MD USA.
RP Pimenta, PFP (reprint author), Ctr Pesquisas Rene Rachou Fiocruz, Belo Horizonte, MG, Brazil.
EM pimenta@cpqrr.fiocruz.br
OI Smith, Ryan/0000-0003-0245-2265
FU Bill and Melinda Gates Foundation (TransEpi Study); National Institutes
of Health [R01AI031478]; Foundation of the Institute Oswaldo Cruz
(FIOCRUZ); Strategic Programme for Supporting Health Research (PAPES V);
Brazilian Council for Scientific and Technological Development (CNPq);
Minas Gerais State Research Support Foundation (FAPEMIG); Amazonas State
Research Support Foundation (FAPEAM)
FX This study was partially funded by Bill and Melinda Gates Foundation
(TransEpi Study), by grant from the National Institutes of Health
R01AI031478 and by the following Brazilian agencies: Foundation of the
Institute Oswaldo Cruz (FIOCRUZ), Strategic Programme for Supporting
Health Research (PAPES V), Brazilian Council for Scientific and
Technological Development (CNPq), Minas Gerais State Research Support
Foundation (FAPEMIG) and Amazonas State Research Support Foundation
(FAPEAM). ASO, RNP, KMMC, YTP and BC received Ph.D. scholarships from
one of the following Brazilian agencies: FAPEAM, FIOCRUZ, CNPq and
CAPES. APMD, LMV, NBR and LCP received pos-doctoral scholarships from
CNPq or CAPES. PFPP, NFCS, MGVB and MVGL are senior fellows from CNPq.
NR 61
TC 1
Z9 1
U1 2
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 2
PY 2016
VL 15
AR 394
DI 10.1186/s12936-016-1451-y
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DS3BN
UT WOS:000380658000001
PM 27480269
ER
PT J
AU Imamichi, H
Dewar, RL
Adelsberger, JW
Rehm, CA
O'Doherty, U
Paxinos, EE
Fauci, AS
Lane, HC
AF Imamichi, Hiromi
Dewar, Robin L.
Adelsberger, Joseph W.
Rehm, Catherine A.
O'Doherty, Una
Paxinos, Ellen E.
Fauci, Anthony S.
Lane, H. Clifford
TI Defective HIV-1 proviruses produce novel protein-coding RNA species in
HIV-infected patients on combination antiretroviral therapy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE HIV-1; provirus; activation; latency
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELLS; REPLICATION-COMPETENT; VIRAL
GENOMES; IDENTIFICATION; RESERVOIR; PROLIFERATION; EXPRESSION;
SEQUENCES; ALIGNMENT
AB Despite years of plasma HIV-RNA levels <40 copies per milliliter during combination antiretroviral therapy (cART), the majority of HIV-infected patients exhibit persistent seropositivity to HIV-1 and evidence of immune activation. These patients also show persistence of proviruses of HIV-1 in circulating peripheral blood mononuclear cells. Many of these proviruses have been characterized as defective and thus thought to contribute little to HIV-1 pathogenesis. By combining 5'LTR-to-3'LTR single-genome amplification and direct amplicon sequencing, we have identified the presence of "defective" proviruses capable of transcribing novel unspliced HIV-RNA (usHIV-RNA) species in patients at all stages of HIV-1 infection. Although these novel usHIV-RNA transcripts had exon structures that were different from those of the known spliced HIV-RNA variants, they maintained translationally competent ORFs, involving elements of gag, pol, env, rev, and nef to encode a series of novel HIV-1 chimeric proteins. These novel usHIV-RNAs were detected in five of five patients, including four of four patients with prolonged viral suppression of HIV-RNA levels <40 copies per milliliter for more than 6 y. Our findings suggest that the persistent defective proviruses of HIV-1 are not "silent," but rather may contribute to HIV-1 pathogenesis by stimulating host-defense pathways that target foreign nucleic acids and proteins.
C1 [Imamichi, Hiromi; Rehm, Catherine A.; Fauci, Anthony S.; Lane, H. Clifford] NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Dewar, Robin L.; Adelsberger, Joseph W.] Leidos Biomed Res Inc, Appl & Dev Res Directorate, Clin Serv Program, Frederick, MD 21072 USA.
[O'Doherty, Una] Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA.
[Paxinos, Ellen E.] Pacif Biosci, Applicat & Collaborat, Menlo Pk, CA 94025 USA.
RP Fauci, AS (reprint author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM afauci@niaid.nih.gov
FU intramural research program of the National Institute of Allergy and
Infectious Diseases of the National Institutes of Health; National
Cancer Institute, National Institutes of Health [HHSN261200800001E]
FX We thank R. Davey, C. Hadigan, J. Kovacs, F. Maldarelli, A. Pau, M.
Sneller, and M. Wright for providing patient specimens; A. Ober, G.
Roby, and C. Seamon for coordinating patient visits; H. Highbarger, A.
Shah, and I. Davis for running the Abbott HIV-1 assay; D.-W. Huang, R.
Lempicki, and D. Liang for running the MiSeq assay; M. Brown, Y. Guo,
and C. Ludka for performing the PacBio sequencing; and S. Hughes, T.
Imamichi, and L. Dodd for helpful discussion. This work was funded
through the intramural research program of the National Institute of
Allergy and Infectious Diseases of the National Institutes of Health,
and in part with federal funds from the National Cancer Institute,
National Institutes of Health, under Contract HHSN261200800001E.
NR 42
TC 6
Z9 6
U1 3
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 2
PY 2016
VL 113
IS 31
BP 8783
EP 8788
DI 10.1073/pnas.1609057113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS2HH
UT WOS:000380586600065
PM 27432972
ER
PT J
AU Hsu, LM
Liang, X
Gu, H
Brynildsen, JK
Stark, JA
Ash, JA
Lin, CP
Lu, HB
Rapp, PR
Stein, EA
Yang, YH
AF Hsu, Li-Ming
Liang, Xia
Gu, Hong
Brynildsen, Julia K.
Stark, Jennifer A.
Ash, Jessica A.
Lin, Ching-Po
Lu, Hanbing
Rapp, Peter R.
Stein, Elliot A.
Yang, Yihong
TI Constituents and functional implications of the rat default mode network
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE default mode network; functional connectivity; modularity; rat brain;
aging
ID POSTERIOR PARIETAL CORTEX; STATE BRAIN ACTIVITY; RESTING-STATE;
STRUCTURAL CONNECTIVITY; HIPPOCAMPAL FORMATION; COMMUNITY STRUCTURE;
ALZHEIMERS-DISEASE; MRI; ORGANIZATION; ARCHITECTURE
AB The default mode network (DMN) has been suggested to support a variety of self-referential functions in humans and has been fractionated into subsystems based on distinct responses to cognitive tasks and functional connectivity architecture. Such subsystems are thought to reflect functional hierarchy and segregation within the network. Because preclinical models can inform translational studies of neuropsychiatric disorders, partitioning of the DMN in nonhuman species, which has previously not been reported, may inform both physiology and pathophysiology of the human DMN. In this study, we sought to identify constituents of the rat DMN using resting-state functional MRI (rs-fMRI) and diffusion tensor imaging. After identifying DMN using a group-level independent-component analysis on the rs-fMRI data, modularity analyses fractionated the DMN into an anterior and a posterior subsystem, which were further segregated into five modules. Diffusion tensor imaging tractography demonstrates a close relationship between fiber density and the functional connectivity between DMN regions, and provides anatomical evidence to support the detected DMN subsystems. Finally, distinct modulation was seen within and between these DMN subcomponents using a neurocognitive aging model. Taken together, these results suggest that, like the human DMN, the rat DMN can be partitioned into several subcomponents that may support distinct functions. These data encourage further investigation into the neurobiological mechanisms of DMN processing in preclinical models of both normal and disease states.
C1 [Hsu, Li-Ming; Liang, Xia; Gu, Hong; Brynildsen, Julia K.; Stark, Jennifer A.; Lu, Hanbing; Stein, Elliot A.; Yang, Yihong] NIDA, Neuroimaging Res Branch, Baltimore, MD 21224 USA.
[Hsu, Li-Ming; Lin, Ching-Po] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan.
[Ash, Jessica A.; Rapp, Peter R.] NIA, Lab Behav Neurosci, Biomed Res Ctr, Baltimore, MD 21224 USA.
[Liang, Xia] Harbin Inst Technol, Res Ctr Basic Space Sci, Harbin 150080, Peoples R China.
[Brynildsen, Julia K.] Univ Penn, Perelman Sch Med, Neurosci Grad Grp, Philadelphia, PA 19104 USA.
[Stark, Jennifer A.] Univ Maryland, Maryland Neuroimaging Ctr, College Pk, MD 20742 USA.
[Ash, Jessica A.] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.
RP Yang, YH (reprint author), NIDA, Neuroimaging Res Branch, Baltimore, MD 21224 USA.
EM yihongyang@intra.nida.nih.gov
FU Food and Drug Administration Center for Tobacco Products; Intramural
Research Programs of the National Institute on Drug Abuse, National
Institutes of Health; National Institute on Aging, National Institutes
of Health
FX This study was supported by the Intramural Research Programs of the
National Institute on Drug Abuse and National Institute on Aging,
National Institutes of Health, and a grant from the Food and Drug
Administration Center for Tobacco Products.
NR 64
TC 1
Z9 1
U1 4
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 2
PY 2016
VL 113
IS 31
BP E4541
EP E4547
DI 10.1073/pnas.1601485113
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS2HH
UT WOS:000380586600017
PM 27439860
ER
PT J
AU Kahle, KT
Flores, B
Bharucha-Goebel, D
Zhang, JW
Donkervoort, S
Hegde, M
Hussain, G
Duran, D
Liang, B
Sun, DD
Bonnemann, CG
Delpire, E
AF Kahle, Kristopher T.
Flores, Bianca
Bharucha-Goebel, Diana
Zhang, Jinwei
Donkervoort, Sandra
Hegde, Madhuri
Hussain, Gulnaz
Duran, Daniel
Liang, Bo
Sun, Dandan
Bonnemann, Carsten G.
Delpire, Eric
TI Peripheral motor neuropathy is associated with defective kinase
regulation of the KCC3 cotransporter
SO Science Signaling
LA English
DT Article
ID CATION-CHLORIDE COTRANSPORTERS; CONDITIONAL MOUSE MODEL; CELL-VOLUME
HOMEOSTASIS; K+-CL-COTRANSPORTER; CORPUS-CALLOSUM; MISSENSE MUTATIONS;
ANDERMANN-SYNDROME; HEREDITARY MOTOR; DISEASE; MICE
AB Using exome sequencing, we identified a de novo mutation (c.2971A>G; T991A) in SLC12A6, the gene encoding the K+-Cl(-)cotransporter KCC3, in a patient with an early-onset, progressive, and severe peripheral neuropathy primarily affecting motor neurons. Normally, the WNK kinase-dependent phosphorylation of T-991 tonically inhibits KCC3; however, cell swelling triggers Thr(991) dephosphorylation to activate the transporter and restore cell volume. KCC3 (T991A) mutation in patient cells abolished Thr(991) phosphorylation, resulted in constitutive KCC3 activity, and compromised cell volume homeostasis. KCC3(T991A/T991A) mutant mice exhibited constitutive KCC3 activity and recapitulated aspects of the clinical, electrophysiological, and histopathological findings of the patient. These results suggest that the function of the peripheral nervous system depends on finely tuned, kinase-regulated KCC3 activity and implicate abnormal cell volume homeostasis as a previously unreported mechanism of axonal degeneration.
C1 [Kahle, Kristopher T.; Zhang, Jinwei; Duran, Daniel] Yale Sch Med, Ctr Mendelian Genom, Dept Neurosurg, New Haven, CT 06510 USA.
[Kahle, Kristopher T.; Zhang, Jinwei; Duran, Daniel] Yale Sch Med, Ctr Mendelian Genom, Dept Pediat & Cellular & Mol Physiol, New Haven, CT 06510 USA.
[Flores, Bianca; Delpire, Eric] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA.
[Bharucha-Goebel, Diana; Donkervoort, Sandra; Bonnemann, Carsten G.] NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, Neurogenet Branch, Bethesda, MD 20814 USA.
[Bharucha-Goebel, Diana] Childrens Natl Hlth Syst, Dept Neurol, Washington, DC 20010 USA.
[Zhang, Jinwei] Univ Dundee, Coll Life Sci, Prot Phosphorylat & Ubiquitylat Unit, MRC, Dundee DD15EH, Scotland.
[Hegde, Madhuri] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA.
[Hussain, Gulnaz; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.
[Hussain, Gulnaz; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA 15240 USA.
[Liang, Bo] Harvard Med Sch, Dept MicroBiol, Boston, MA 02114 USA.
[Liang, Bo] Harvard Med Sch, Dept Immunobiol, Boston, MA 02114 USA.
RP Delpire, E (reprint author), Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA.; Bonnemann, CG (reprint author), NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, Neurogenet Branch, Bethesda, MD 20814 USA.
EM carsten.bonnemann@nih.gov; eric.delpire@vanderbilt.edu
OI Duran, Daniel/0000-0001-6888-252X; Zhang, Jinwei/0000-0001-8683-509X
FU NIH [GM74771, 2T32MH064913-11A1, T32-AR056993]; Harvard-Massachusetts
Institute of Technology Neuroscience Grant; Manton Center for Orphan
Disease Research at Harvard Medical School; March of Dimes Basil
O'Connor Award; NINDS
FX This work was supported by NIH research grant GM74771 (E.D.). K.T.K. was
supported by a Harvard-Massachusetts Institute of Technology
Neuroscience Grant, the Manton Center for Orphan Disease Research at
Harvard Medical School, and the March of Dimes Basil O'Connor Award.
C.G.B. is supported by intramural funds of the NINDS. B.F. and D.B.G.
received support from NIH grants 2T32MH064913-11A1 and T32-AR056993,
respectively.
NR 51
TC 2
Z9 2
U1 1
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD AUG 2
PY 2016
VL 9
IS 439
AR ra77
DI 10.1126/scisignal.aae0546
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA DS4VJ
UT WOS:000380779400001
PM 27485015
ER
PT J
AU Jorgensen, JT
Norregaard, K
Tian, PF
Bendix, PM
Kjaer, A
Oddershede, LB
AF Jorgensen, Jesper Tranekjaer
Norregaard, Kamilla
Tian, Pengfei
Bendix, Poul Martin
Kjaer, Andreas
Oddershede, Lene B.
TI Single Particle and PET-based Platform for Identifying Optimal Plasmonic
Nano-Heaters for Photothermal Cancer Therapy
SO Scientific Reports
LA English
DT Article
ID CONJUGATED GOLD NANOPARTICLES; POSITRON-EMISSION-TOMOGRAPHY; NANOSHELLS;
TUMORS; RESONANCE; NANOCAGES; DELIVERY; NANOMATRYOSHKAS; NANOSTRUCTURES;
NANOMEDICINE
AB Plasmonic nanoparticle-based photothermal cancer therapy is a promising new tool to inflict localized and irreversible damage to tumor tissue by hyperthermia, without harming surrounding healthy tissue. We developed a single particle and positron emission tomography (PET)-based platform to quantitatively correlate the heat generation of plasmonic nanoparticles with their potential as cancer killing agents. In vitro, the heat generation and absorption cross-section of single irradiated nanoparticles were quantified using a temperature sensitive lipid-based assay and compared to their theoretically predicted photo-absorption. In vivo, the heat generation of irradiated nanoparticles was evaluated in human tumor xenografts in mice using 2-deoxy-2-[F-18] fluoro-D-glucose (F-18-FDG) PET imaging. To validate the use of this platform, we quantified the photothermal efficiency of near infrared resonant silica-gold nanoshells (AuNSs) and benchmarked this against the heating of colloidal spherical, solid gold nanoparticles (AuNPs). As expected, both in vitro and in vivo the heat generation of the resonant AuNSs performed superior compared to the non-resonant AuNPs. Furthermore, the results showed that PET imaging could be reliably used to monitor early treatment response of photothermal treatment. This multidisciplinary approach provides a much needed platform to benchmark the emerging plethora of novel plasmonic nanoparticles for their potential for photothermal cancer therapy.
C1 [Jorgensen, Jesper Tranekjaer; Norregaard, Kamilla; Kjaer, Andreas] Rigshosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark.
[Jorgensen, Jesper Tranekjaer; Norregaard, Kamilla; Kjaer, Andreas] Univ Copenhagen, DK-1168 Copenhagen, Denmark.
[Norregaard, Kamilla; Tian, Pengfei; Bendix, Poul Martin; Oddershede, Lene B.] Univ Copenhagen, Niels Bohr Inst, DK-1168 Copenhagen, Denmark.
[Tian, Pengfei] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Oddershede, LB (reprint author), Univ Copenhagen, Niels Bohr Inst, DK-1168 Copenhagen, Denmark.
EM oddershede@nbi.ku.dk
OI Kjaer, Andreas/0000-0002-2706-5547
FU Lundbeckfonden [506800-50-34062]; Novo Nordisk Foundation
[NNF14OC0011361]
FX The research was made possible through financial support from
Lundbeckfonden (506800-50-34062) and from the Novo Nordisk Foundation
(NNF14OC0011361).
NR 55
TC 1
Z9 1
U1 16
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 2
PY 2016
VL 6
AR 30076
DI 10.1038/srep30076
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DS2RS
UT WOS:000380631900001
PM 27481537
ER
PT J
AU Sampson, UKA
Kaplan, RM
Cooper, RS
Roux, AVD
Marks, JS
Engelgau, MM
Peprah, E
Mishoe, H
Boulware, LE
Felix, KL
Califf, RM
Flack, JM
Cooper, LA
Gracia, JN
Henderson, JA
Davidson, KW
Krishnan, JA
Lewis, TT
Sanchez, E
Luban, NL
Vaccarino, V
Wong, WF
Wright, JT
Meyers, D
Ogedegbe, OG
Presley-Cantrell, L
Chambers, DA
Belis, D
Bennett, GC
Boyington, JE
Creazzo, TL
de Jesus, JM
Krishnamurti, C
Lowden, MR
Punturieri, A
Shero, ST
Young, NS
Zou, S
Mensah, GA
AF Sampson, Uchechukwu K. A.
Kaplan, Robert M.
Cooper, Richard S.
Roux, Ana V. Diez
Marks, James S.
Engelgau, Michael M.
Peprah, Emmanuel
Mishoe, Helena
Boulware, L. Ebony
Felix, Kaytura L.
Califf, Robert M.
Flack, John M.
Cooper, Lisa A.
Gracia, J. Nadine
Henderson, Jeffrey A.
Davidson, Karina W.
Krishnan, Jerry A.
Lewis, Tene T.
Sanchez, Eduardo
Luban, Naomi L.
Vaccarino, Viola
Wong, Winston F.
Wright, Jackson T., Jr.
Meyers, David
Ogedegbe, Olugbenga G.
Presley-Cantrell, Letitia
Chambers, David A.
Belis, Deshiree
Bennett, Glen C.
Boyington, Josephine E.
Creazzo, Tony L.
de Jesus, Janet M.
Krishnamurti, Chitra
Lowden, Mia R.
Punturieri, Antonello
Shero, Susan T.
Young, Neal S.
Zou, Shimian
Mensah, George A.
TI Reducing Health Inequities in the US Recommendations From the NHLBI's
Health Inequities Think Tank Meeting
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Review
DE health information exchange; health policy; health services
accessibility; social determinants of health; T4 research; translation
research
ID CHILDHOOD; DISPARITIES; DESIGN; ATHEROSCLEROSIS; IMPLEMENTATION;
EXPERIENCES; PREVENTION; OBJECTIVES; ENGLAND; DISEASE
AB The National, Heart, Lung, and Blood Institute convened a Think Tank meeting to obtain insight and recommendations regarding the objectives and design of the next generation of research aimed at reducing health inequities in the United States. The panel recommended several specific actions, including: 1) embrace broad and inclusive research themes; 2) develop research platforms that optimize the ability to conduct informative and innovative research, and promote systems science approaches; 3) develop networks of collaborators and stakeholders, and launch transformative studies that can serve as benchmarks; 4) optimize the use of new data sources, platforms, and natural experiments; and 5) develop unique transdisciplinary training programs to build research capacity. Confronting health inequities will require engaging multiple disciplines and sectors (including communities), using systems science, and intervening through combinations of individual, family, provider, health system, and community-targeted approaches. Details of the panel's remarks and recommendations are provided in this report. (C) 2016 by the American College of Cardiology Foundation.
C1 [Sampson, Uchechukwu K. A.; Engelgau, Michael M.; Peprah, Emmanuel; Mishoe, Helena; Belis, Deshiree; Bennett, Glen C.; de Jesus, Janet M.; Krishnamurti, Chitra; Shero, Susan T.; Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Kaplan, Robert M.; Meyers, David] US Agcy Healthcare Res & Qual, Rockville, MD USA.
[Cooper, Richard S.] Loyola Univ, Dept Publ Hlth, Chicago, IL 60611 USA.
[Roux, Ana V. Diez] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA.
[Marks, James S.] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA.
[Boulware, L. Ebony] Duke Univ, Div Gen Internal Med, Durham, NC USA.
[Felix, Kaytura L.] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA.
[Califf, Robert M.] US FDA, Off Med Prod & Tobacco, Silver Spring, MD USA.
[Flack, John M.] Southern Illinois Univ, Dept Internal Med, Springfield, IL USA.
[Cooper, Lisa A.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
[Gracia, J. Nadine] US Dept Hlth & Human Serv, Off Minor Hlth, Rockville, MD USA.
[Henderson, Jeffrey A.] Black Hills Ctr Amer Indian Hlth, Rapid City, SD USA.
[Davidson, Karina W.] Columbia Univ, Dept Med, Ctr Behav Cardiovasc Hlth, New York, NY USA.
[Davidson, Karina W.] New York Presbyterian Hosp, Value Inst, New York, NY USA.
[Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA.
[Lewis, Tene T.; Vaccarino, Viola] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
[Sanchez, Eduardo] Amer Hlth Assoc, Dallas, TX USA.
[Luban, Naomi L.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA.
[Wong, Winston F.] Kaiser Permanente, Los Angeles, CA USA.
[Wright, Jackson T., Jr.] Univ Hosp Case Med Ctr, Cleveland, OH USA.
[Ogedegbe, Olugbenga G.] NYU, Div Hlth Behav, New York, NY USA.
[Presley-Cantrell, Letitia] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA.
[Chambers, David A.] NCI, NIH, Div Canc Control & Populat Sci, Rockville, MD USA.
[Boyington, Josephine E.] NHLBI, NIH, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
[Creazzo, Tony L.] NHLBI, NIH, Div Extramural Res Activ, Bldg 10, Bethesda, MD 20892 USA.
[Lowden, Mia R.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Punturieri, Antonello] NHLBI, NIH, Div Lung Dis, Bldg 10, Bethesda, MD 20892 USA.
[Young, Neal S.] NHLBI, NIH, Div Intramural Res, Bldg 10, Bethesda, MD 20892 USA.
[Zou, Shimian] NHLBI, NIH, Div Blood Dis & Resources, Bldg 10, Bethesda, MD 20892 USA.
RP Sampson, UKA (reprint author), NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM uchechukwu.sampson@nih.gov
FU Medtronic; Bayer; GlaxoSmithKline
FX The views expressed in this article are those of the authors and do not
necessarily represent the views of the National Heart, Lung, and Blood
Institute, National Institutes of Health, or the U.S. Department of
Health and Human Services. Dr. Flack has been a consultant for
Medtronic, Back Beat Medical, Lundbeck, Forrest, Bayer, Sanofi, and
Regeneron; and has received research grants from Medtronic, Bayer, and
GlaxoSmithKline. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
NR 25
TC 3
Z9 3
U1 7
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD AUG 2
PY 2016
VL 68
IS 5
BP 517
EP 524
DI 10.1016/j.jacc.2016.04.059
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DR7VO
UT WOS:000380108000012
PM 27470459
ER
PT J
AU Yuan, C
Jurgensen, HJ
Engelholm, LH
Li, R
Liu, M
Jiang, LG
Luo, ZP
Behrendt, N
Huang, MD
AF Yuan, Cai
Jurgensen, Henrik J.
Engelholm, Lars H.
Li, Rui
Liu, Min
Jiang, Longguang
Luo, Zhipu
Behrendt, Niels
Huang, Mingdong
TI Crystal structures of the ligand-binding region of uPARAP: effect of
calcium ion binding
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE crystal structure; C-type lectin-like domain; endocytic collagen
receptor; ligand-binding region; long loop region; receptor
structure-function; uPARAP/Endo180
ID RECEPTOR-ASSOCIATED PROTEIN; PLASMINOGEN-ACTIVATOR-RECEPTOR;
CARBOHYDRATE-RECOGNITION DOMAIN; MANNOSE RECEPTOR; COLLAGEN DEGRADATION;
MATRIX TURNOVER; ENDO180; EXPRESSION; FAMILY; UPARAP/ENDO180
AB The proteins of the mannose receptor (MR) family share a common domain organization and have a broad range of biological functions. Urokinase plasminogen activator receptor-associated protein (uPARAP) (or Endo180) is a member of this family and plays an important role in extracellular matrix remodelling through interaction with its ligands, including collagens and urokinase plasminogen activator receptor (uPAR). We report the crystal structures of the first four domains of uPARAP (also named the ligand-binding region, LBR) at pH 7.4 in Ca2+-bound and Ca2+-free forms. The first domain (cysteine-rich or CysR domain) folds into a new and unique conformation different from the beta-trefoil fold of typical CysR domains. The so-called long loop regions (LLRs) of the C-type lectin-like domain (CTLD) 1 and 2 (the third and fourth domain) mediate the direct contacts between these domains. These LLRs undergo a Ca2+ dependent conformational change, and this is likely to be the key structural determinant affecting the overall conformation of uPARAP. Our results provide a molecular mechanism to support the structural flexibility of uPARAP, and shed light on the structural flexibility of other members of the MR family.
C1 [Yuan, Cai; Li, Rui; Liu, Min; Jiang, Longguang; Luo, Zhipu; Huang, Mingdong] Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Peoples R China.
[Yuan, Cai] Fuzhou Univ, Coll Biosci & Biotechnol, Fuzhou 350108, Peoples R China.
[Jurgensen, Henrik J.; Engelholm, Lars H.; Behrendt, Niels] Rigshosp, Finsen Lab, Biotech Res & Innovat Ctr, DK-2200 Copenhagen, Denmark.
[Engelholm, Lars H.] NIDCR, Proteases & Tissue Remodeling Sect, NIH, Bethesda, MD 20892 USA.
[Jiang, Longguang; Huang, Mingdong] Fuzhou Univ, Coll Chem & Chem Engn, Fuzhou 350108, Peoples R China.
RP Huang, MD (reprint author), Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Peoples R China.; Huang, MD (reprint author), Fuzhou Univ, Coll Chem & Chem Engn, Fuzhou 350108, Peoples R China.
EM mhuang@fjirsm.ac.cn
OI Engelholm, Lars/0000-0002-6616-1232
FU National Natural Science Foundation of China [31570745, 31370737,
31400637, U1405229]; Danish Cancer Society [R90-A5823-14-S2]; Danish
Medical Research Council; Danish Cancer Research Foundation; Lundbeck
Foundation [R118-A11578]; Novo Nordisk Foundation; Danish National
Research Foundation (Danish-Chinese Center for Proteases and Cancer);
CAS/SAFEA International Partnership Program for Creative Research Teams
[XDA09030307]; Scientific Research Foundation for the Returned Overseas
Chinese Scholars, State Education Ministry [2013-693]
FX This work was supported by the National Natural Science Foundation of
China [grant numbers 31570745, 31370737, 31400637 and U1405229]; the
Danish Cancer Society [grant number R90-A5823-14-S2]; the Danish Medical
Research Council; the Danish Cancer Research Foundation; the Lundbeck
Foundation [grant number R118-A11578]; the Novo Nordisk Foundation; the
Danish National Research Foundation (Danish-Chinese Center for Proteases
and Cancer); the CAS/SAFEA International Partnership Program for
Creative Research Teams [grant number XDA09030307]; and the Scientific
Research Foundation for the Returned Overseas Chinese Scholars, State
Education Ministry [grant number 2013-693].
NR 46
TC 0
Z9 0
U1 5
U2 5
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD AUG
PY 2016
VL 473
BP 2359
EP 2368
DI 10.1042/BCJ20160276
PN 15
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA EK1VD
UT WOS:000393713000007
PM 27247422
ER
PT J
AU Zulkifli, M
Yadav, S
Thakur, A
Singla, S
Sharma, M
Bachhawat, AK
AF Zulkifli, Mohammad
Yadav, Shambhu
Thakur, Anil
Singla, Shiffalli
Sharma, Monika
Bachhawat, Anand Kumar
TI Substrate specificity and mapping of residues critical for transport in
the high-affinity glutathione transporter Hgt1p
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE membrane transport; oligopeptide transporter (OPT) family; Saccharomyces
cerevisiae; site-directed mutagenesis; substrate specificity;
transmembrane domain
ID PROTEIN-STRUCTURE PREDICTION; TRANSMEMBRANE DOMAIN 9; TOPOLOGY
PREDICTION; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; RECOGNITION;
THIOREDOXIN; HELICES; FAMILY; GROWTH
AB The high-affinity glutathione transporterHgt1p of Saccharomyces cerevisiae belongs to a relatively new and structurally uncharacterized oligopeptide transporter (OPT) family. To understand the structural features required for interaction with Hgt1p, a quantitative investigation of substrate specificity of Hgt1p was carried out. Hgt1p showed a higher affinity for reduced glutathione (GSH), whereas it transported oxidized glutathione (GSSG) and other glutathione conjugates with lower affinity. To identify the residues of Hgt1p critical for substrate binding and translocation, all amino acid residues of the 13 predicted transmembrane domains (TMDs) have been subjected to mutagenesis. Functional evaluation of these 269 mutants by growth and biochemical assay followed by kinetic analysis of the severely defective mutants including previous mutagenic studies on this transporter have led to the identification of N124 (TMD1), V185 (TMD3), Q222, G225 and Y226 (TMD4), P292 (TMD5), Y374 (TMD6), L429 (TMD7) and F523 and Q526 (TMD9) as critical for substrate binding with at least 3-fold increase in K-m upon mutagenesis to alanine. In addition residues Y226 and Y374 appeared to be important for differential substrate specificity. An ab initio model of Hgt1p was built and refined using these mutagenic data that yielded a helical arrangement that includes TMD3, TMD4, TMD5, TMD6, TMD7, TMD9 and TMD13 as pore-lining helices with the functionally important residues in a channel-facing orientation. Taken together the results of this study provides the first mechanistic insights into glutathione transport by a eukaryotic high-affinity glutathione transporter.
C1 [Zulkifli, Mohammad; Yadav, Shambhu; Thakur, Anil; Singla, Shiffalli; Bachhawat, Anand Kumar] Indian Inst Sci Educ & Res, Dept Biol Sci, Sas Nagar 140306, Punjab, India.
[Sharma, Monika] Indian Inst Sci Educ & Res, Dept Chem Sci, Sas Nagar 140306, Punjab, India.
[Thakur, Anil] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.
[Singla, Shiffalli] PGGC, Dept Biotechnol, Sect 11, Chandigarh 160011, Punjab, India.
RP Bachhawat, AK (reprint author), Indian Inst Sci Educ & Res, Dept Biol Sci, Sas Nagar 140306, Punjab, India.
EM anand@iisermohali.ac.in
OI Sharma, Monika/0000-0001-9864-3298
FU Council for Scientific and Industrial Research; Department of
Biotechnology; DST [002950]; Department of Science and Technology
[015611, SR/S2/JCB-98/2011, SB/SO/BB-017/2014]
FX This work was supported by a Council for Scientific and Industrial
Research Fellowship (to M.Z. and A.T.); the Department of Biotechnology
for Research Associateship [DBT-RA (to S.S.)]; the DST INSPIRE
Fellowship [grant number 002950 (to S.Y.)]; the Department of Science
and Technology INSPIRE Faculty Fellowship [grant number 015611 (to
M.S.)]; the Department of Science and Technology JC Bose National
Fellowship [grant number SR/S2/JCB-98/2011 (to A.K.B.)]; and the
Department of Science and Technology [grant number SB/SO/BB-017/2014 (to
A.K.B.)].
NR 35
TC 0
Z9 0
U1 1
U2 1
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD AUG
PY 2016
VL 473
BP 2369
EP 2382
DI 10.1042/BCJ20160231
PN 15
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA EK1VD
UT WOS:000393713000008
PM 27252386
ER
PT J
AU Aon, MA
Cortassa, S
Juhaszova, M
Sollott, SJ
AF Aon, Miguel A.
Cortassa, Sonia
Juhaszova, Magdalena
Sollott, Steven J.
TI Mitochondrial health, the epigenome and healthspan
SO CLINICAL SCIENCE
LA English
DT Article
DE acetylation; aging; autophagy; biogenesis; caloric restriction;
cardiovascular disease; diet; epigenetic modification; histones;
chromatin; mitochondrial fusion-fission; mitophagy
ID ENDOPLASMIC-RETICULUM STRESS; CORONARY-HEART-DISEASE; DIABETIC HUMAN
HEART; REDOX-OPTIMIZED ROS; REACTIVE OXYGEN; DNA METHYLATION;
INSULIN-RESISTANCE; CARDIAC MYOCYTES; OXIDATIVE STRESS; SKELETAL-MUSCLE
AB Food nutrients and metabolic supply-demand dynamics constitute environmental factors that interact with our genome influencing health and disease states. These gene-environment interactions converge at the metabolic-epigenome-genome axis to regulate gene expression and phenotypic outcomes. Mounting evidence indicates that nutrients and lifestyle strongly influence genome-metabolic functional interactions determining disease via altered epigenetic regulation. The mitochondrial network is a central player of the metabolic-epigenome-genome axis, regulating the level of key metabolites [NAD+, AcCoA (acetyl CoA), ATP] acting as substrates/cofactors for acetyl transferases, kinases (e.g. protein kinase A) and deacetylases (e.g. sirtuins, SIRTs). The chromatin, an assembly of DNA and nucleoproteins, regulates the transcriptional process, acting at the epigenomic interface between metabolism and the genome. Within this framework, we review existing evidence showing that preservation of mitochondrial network function is directly involved in decreasing the rate of damage accumulation thus slowing aging and improving healthspan.
C1 [Aon, Miguel A.; Cortassa, Sonia; Juhaszova, Magdalena; Sollott, Steven J.] NIA, Lab Cardiovasc Sci, NIH, Baltimore, MD 21224 USA.
RP Aon, MA (reprint author), NIA, Lab Cardiovasc Sci, NIH, Baltimore, MD 21224 USA.
EM miguel.aon@nih.gov
RI Aon, Miguel/A-6564-2008;
OI Aon, Miguel/0000-0002-4355-5431; Cortassa, Sonia/0000-0001-7224-9858
FU National Institutes of Health, National Institute on Aging
FX This work was supported by the Intramural Research Program of the
National Institutes of Health, National Institute on Aging.
NR 224
TC 2
Z9 2
U1 2
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD AUG 1
PY 2016
VL 130
IS 15
BP 1285
EP 1305
DI 10.1042/CS20160002
PG 21
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EK2MR
UT WOS:000393761900001
PM 27358026
ER
PT J
AU Szabo, R
Lantsman, T
Peters, DE
Bugge, TH
AF Szabo, Roman
Lantsman, Taliya
Peters, Diane E.
Bugge, Thomas H.
TI Delineation of proteolytic and non-proteolytic functions of the
membrane-anchored serine protease prostasin
SO DEVELOPMENT
LA English
DT Article
DE Cell surface proteolysis; Serine protease; Epithelial development;
Placental labyrinth
ID GROWTH-FACTOR ACTIVATOR; EPIDERMAL BARRIER FUNCTION; NEURAL-TUBE
CLOSURE; MATRIPTASE-ACTIVATION; PLACENTAL DEVELOPMENT; EPITHELIAL-CELLS;
SODIUM-CHANNEL; CAP1/PRSS8; INHIBITOR; ZYMOGEN
AB The membrane-anchored serine proteases prostasin (PRSS8) and matriptase (ST14) initiate a cell surface proteolytic pathway essential for epithelial function. Mice expressing only catalytically inactive prostasin are viable, unlike prostasin null mice, indicating that at least some prostasin functions are non-proteolytic. Here we used knock-in mice expressing catalytically inactive prostasin (Prss8(Ki)/(Ki)) to show that the physiological and pathological functions of prostasin vary in their dependence on its catalytic activity. Whereas prostasin null mice exhibited partial embryonic and complete perinatal lethality, Prss8(Ki)/(Ki) mice displayed normal prenatal and postnatal survival. Unexpectedly, catalytically inactive prostasin caused embryonic lethality in mice lacking its cognate inhibitors HAI-1 (SPINT1) or HAI-2 (SPINT2). Proteolytically inactive prostasin, unlike the wild-type protease, was unable to activate matriptase during placentation. Surprisingly, all essential functions of prostasin in embryonic and postnatal development were compensated for by loss of HAI-1, indicating that prostasin is only required for mouse development and overall viability in the presence of this inhibitor. This study expands our knowledge of non-proteolytic functions of membrane-anchored serine proteases and provides unexpected new data on the mechanistic interactions between matriptase and prostasin in the context of epithelial development.
C1 [Szabo, Roman; Lantsman, Taliya; Peters, Diane E.; Bugge, Thomas H.] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, NIH, Bethesda, MD 20892 USA.
[Peters, Diane E.] Tufts Univ, Sch Med, Program Pharmacol & Expt Therapeut, Boston, MA 02110 USA.
RP Bugge, TH (reprint author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, NIH, Bethesda, MD 20892 USA.
EM thomas.bugge@nih.gov
FU National Institutes of Health/NIDCR Intramural Research Program
FX Supported by the National Institutes of Health/NIDCR Intramural Research
Program. Deposited in PMC for release after 12 months.
NR 40
TC 1
Z9 1
U1 0
U2 0
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD AUG
PY 2016
VL 143
IS 15
BP 2818
EP 2828
DI 10.1242/dev.137968
PG 11
WC Developmental Biology
SC Developmental Biology
GA EJ5UV
UT WOS:000393285000014
PM 27385010
ER
PT J
AU Nelson, SC
Stilp, AM
Papanicolaou, GJ
Taylor, KD
Rotter, JI
Thornton, TA
Laurie, CC
AF Nelson, Sarah C.
Stilp, Adrienne M.
Papanicolaou, George J.
Taylor, Kent D.
Rotter, Jerome I.
Thornton, Timothy A.
Laurie, Cathy C.
TI Improved imputation accuracy in Hispanic/Latino populations with larger
and more diverse reference panels: applications in the Hispanic
Community Health Study/Study of Latinos (HCHS/SOL)
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENOTYPE-IMPUTATION; ADMIXED POPULATIONS; RARE
VARIANTS; LOW-FREQUENCY; ANCESTRY; DISEASE; SETS
AB Imputation is commonly used in genome-wide association studies to expand the set of genetic variants available for analysis. Larger and more diverse reference panels, such as the final Phase 3 of the 1000 Genomes Project, hold promise for improving imputation accuracy in genetically diverse populations such as Hispanics/Latinos in the USA. Here, we sought to empirically evaluate imputation accuracy when imputing to a 1000 Genomes Phase 3 versus a Phase 1 reference, using participants from the Hispanic Community Health Study/Study of Latinos. Our assessments included calculating the correlation between imputed and observed allelic dosage in a subset of samples genotyped on a supplemental array. We observed that the Phase 3 reference yielded higher accuracy at rare variants, but that the two reference panels were comparable at common variants. At a sample level, the Phase 3 reference improved imputation accuracy in Hispanic/Latino samples from the Caribbean more than for Mainland samples, which we attribute primarily to the additional reference panel samples available in Phase 3. We conclude that a 1000 Genomes Project Phase 3 reference panel can yield improved imputation accuracy compared with Phase 1, particularly for rare variants and for samples of certain genetic ancestry compositions. Our findings can inform imputation design for other genome-wide association studies of participants with diverse ancestries, especially as larger and more diverse reference panels continue to become available.
C1 [Nelson, Sarah C.; Stilp, Adrienne M.; Thornton, Timothy A.; Laurie, Cathy C.] Univ Washington, Dept Biostat, POB 359461, Seattle, WA 98195 USA.
[Papanicolaou, George J.] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Taylor, Kent D.; Rotter, Jerome I.] Harbor UCLA Med Ctr, Inst Translat Genom & Populat Sci, Los Angeles Biomed Res, Inst & Dept Pediat, Torrance, CA 90509 USA.
RP Nelson, SC (reprint author), Univ Washington, Dept Biostat, POB 359461, Seattle, WA 98195 USA.
EM sarahcn@uw.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC65233,
N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; National Institute
on Minority Health and Health Disparities; National Institute on
Deafness and Other Communication Disorders; National Institute of Dental
and Craniofacial Research (NIDCR); National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK); National Institute of
Neurological Disorders and Stroke; NIH Institution-Office of Dietary
Supplements; NHLBI; NIDCR [HHSN268201300005C AM03, MOD03]; National
Center for Advancing Translational Science Clinical Translational
Science Institute [UL1TR000124]; NIDDK Diabetes Research Center
[DK063491]
FX The baseline examination of HCHS/SOL was carried out as a collaborative
study supported by contracts from the National Heart, Lung, and Blood
Institute (NHLBI) to the University of North Carolina (N01-HC65233),
University of Miami (N01-HC65234), Albert Einstein College of Medicine
(N01-HC65235), Northwestern University (N01-HC65236), and San Diego
State University (N01-HC65237). The following Institutes/Centers/Offices
contribute to the HCHS/SOL through a transfer of funds to the NHLBI:
National Institute on Minority Health and Health Disparities, National
Institute on Deafness and Other Communication Disorders, National
Institute of Dental and Craniofacial Research (NIDCR), National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
National Institute of Neurological Disorders and Stroke, NIH
Institution-Office of Dietary Supplements. The Genetic Analysis Center
at University of Washington was supported by NHLBI and NIDCR contracts
(HHSN268201300005C AM03 and MOD03). Genotyping efforts were supported by
NHLBI HSN 26220/20054C, National Center for Advancing Translational
Science Clinical Translational Science Institute grant UL1TR000124, and
NIDDK Diabetes Research Center grant DK063491.
NR 30
TC 0
Z9 0
U1 79
U2 79
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2016
VL 25
IS 15
BP 3245
EP 3254
DI 10.1093/hmg/ddw174
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EJ2YK
UT WOS:000393077300009
PM 27346520
ER
PT J
AU Hou, LP
Bergen, SE
Akula, N
Song, J
Hultman, CM
Landen, M
Adli, M
Alda, M
Ardau, R
Arias, B
Aubry, JM
Backlund, L
Badner, JA
Barrett, TB
Bauer, M
Baune, BT
Bellivier, F
Benabarre, A
Bengesser, S
Berrettini, WH
Bhattacharjee, AK
Biernacka, JM
Birner, A
Bloss, CS
Brichant-Petitjean, C
Bui, ET
Byerley, W
Cervantes, P
Chillotti, C
Cichon, S
Colom, F
Coryell, W
Craig, DW
Cruceanu, C
Czerski, PM
Davis, T
Dayer, A
Degenhardt, F
Del Zompo, M
DePaulo, JR
Edenberg, HJ
Etain, B
Falkai, P
Foroud, T
Forstner, AJ
Frisen, L
Frye, MA
Fullerton, JM
Gard, S
Garnham, JS
Gershon, ES
Goes, FS
Greenwood, TA
Grigoroiu-Serbanescu, M
Hauser, J
Heilbronner, U
Heilmann-Heimbach, S
Herms, S
Hipolito, M
Hitturlingappa, S
Hoffmann, P
Hofmann, A
Jamain, S
Jimenez, E
Kahn, JP
Kassem, L
Kelsoe, JR
Kittel-Schneider, S
Kliwicki, S
Koller, DL
Konig, B
Lackner, N
Laje, G
Lang, M
Lavebratt, C
Lawson, WB
Leboyer, M
Leckband, SG
Liu, CY
Maaser, A
Mahon, PB
Maier, W
Maj, M
Manchia, M
Martinsson, L
McCarthy, MJ
McElroy, SL
McInnis, MG
McKinney, R
Mitchell, PB
Mitjans, M
Mondimore, FM
Monteleone, P
Muhleisen, TW
Nievergelt, CM
Nothen, MM
Novak, T
Nurnberger, JI
Nwulia, EA
Osby, U
Pfennig, A
Potash, JB
Propping, P
Reif, A
Reininghaus, E
Rice, J
Rietschel, M
Rouleau, GA
Rybakowski, JK
Schalling, M
Scheftner, WA
Schofield, PR
Schork, NJ
Schulze, TG
Schumacher, J
Schweizer, BW
Severino, G
Shekhtman, T
Shilling, PD
Simhandl, C
Slaney, CM
Smith, EN
Squassina, A
Stamm, T
Stopkova, P
Streit, F
Strohmaier, J
Szelinger, S
Tighe, SK
Tortorella, A
Turecki, G
Vieta, E
Volkert, J
Witt, SH
Wright, A
Zandi, PP
Zhang, P
Zollner, S
McMahon, FJ
AF Hou, Liping
Bergen, Sarah E.
Akula, Nirmala
Song, Jie
Hultman, Christina M.
Landen, Mikael
Adli, Mazda
Alda, Martin
Ardau, Raffaella
Arias, Barbara
Aubry, Jean-Michel
Backlund, Lena
Badner, Judith A.
Barrett, Thomas B.
Bauer, Michael
Baune, Bernhard T.
Bellivier, Frank
Benabarre, Antonio
Bengesser, Susanne
Berrettini, Wade H.
Bhattacharjee, Abesh Kumar
Biernacka, Joanna M.
Birner, Armin
Bloss, Cinnamon S.
Brichant-Petitjean, Clara
Bui, Elise T.
Byerley, William
Cervantes, Pablo
Chillotti, Caterina
Cichon, Sven
Colom, Francesc
Coryell, William
Craig, David W.
Cruceanu, Cristiana
Czerski, Piotr M.
Davis, Tony
Dayer, Alexandre
Degenhardt, Franziska
Del Zompo, Maria
DePaulo, J. Raymond
Edenberg, Howard J.
Etain, Bruno
Falkai, Peter
Foroud, Tatiana
Forstner, Andreas J.
Frisen, Louise
Frye, Mark A.
Fullerton, Janice M.
Gard, Sebastien
Garnham, Julie S.
Gershon, Elliot S.
Goes, Fernando S.
Greenwood, Tiffany A.
Grigoroiu-Serbanescu, Maria
Hauser, Joanna
Heilbronner, Urs
Heilmann-Heimbach, Stefanie
Herms, Stefan
Hipolito, Maria
Hitturlingappa, Shashi
Hoffmann, Per
Hofmann, Andrea
Jamain, Stephane
Jimenez, Esther
Kahn, Jean-Pierre
Kassem, Layla
Kelsoe, John R.
Kittel-Schneider, Sarah
Kliwicki, Sebastian
Koller, Daniel L.
Koenig, Barbara
Lackner, Nina
Laje, Gonzalo
Lang, Maren
Lavebratt, Catharina
Lawson, William B.
Leboyer, Marion
Leckband, Susan G.
Liu, Chunyu
Maaser, Anna
Mahon, Pamela B.
Maier, Wolfgang
Maj, Mario
Manchia, Mirko
Martinsson, Lina
McCarthy, Michael J.
McElroy, Susan L.
McInnis, Melvin G.
McKinney, Rebecca
Mitchell, Philip B.
Mitjans, Marina
Mondimore, Francis M.
Monteleone, Palmiero
Muehleisen, Thomas W.
Nievergelt, Caroline M.
Noethen, Markus M.
Novak, Tomas
Nurnberger, John I., Jr.
Nwulia, Evaristus A.
Osby, Urban
Pfennig, Andrea
Potash, James B.
Propping, Peter
Reif, Andreas
Reininghaus, Eva
Rice, John
Rietschel, Marcella
Rouleau, Guy A.
Rybakowski, Janusz K.
Schalling, Martin
Scheftner, William A.
Schofield, Peter R.
Schork, Nicholas J.
Schulze, Thomas G.
Schumacher, Johannes
Schweizer, Barbara W.
Severino, Giovanni
Shekhtman, Tatyana
Shilling, Paul D.
Simhandl, Christian
Slaney, Claire M.
Smith, Erin N.
Squassina, Alessio
Stamm, Thomas
Stopkova, Pavla
Streit, Fabian
Strohmaier, Jana
Szelinger, Szabolcs
Tighe, Sarah K.
Tortorella, Alfonso
Turecki, Gustavo
Vieta, Eduard
Volkert, Julia
Witt, Stephanie H.
Wright, Adam
Zandi, Peter P.
Zhang, Peng
Zollner, Sebastian
McMahon, Francis J.
TI Genome-wide association study of 40,000 individuals identifies two novel
loci associated with bipolar disorder
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TO-CASE RATIO; X-CHROMOSOME; GENETIC ASSOCIATION; STATISTICAL POWER;
SPECTRUM DISORDER; LITHIUM TREATMENT; COMPLEX TRAITS; RISK LOCI;
SCHIZOPHRENIA; POPULATION
AB Bipolar disorder (BD) is a genetically complex mental illness characterized by severe oscillations of mood and behaviour. Genome-wide association studies (GWAS) have identified several risk loci that together account for a small portion of the heritability. To identify additional risk loci, we performed a two-stage meta-analysis of >9 million genetic variants in 9,784 bipolar disorder patients and 30,471 controls, the largest GWAS of BD to date. In this study, to increase power we used similar to 2,000 lithium-treated cases with a long-term diagnosis of BD from the Consortium on Lithium Genetics, excess controls, and analytic methods optimized for markers on the X-chromosome. In addition to four known loci, results revealed genome-wide significant associations at two novel loci: an intergenic region on 9p21.3 (rs12553324, P = 5.87 x 10(-9); odds ratio (OR) = 1.12) and markers within ERBB2 (rs2517959, P = 4.53 x 10(-9); OR = 1.13). No significant X-chromosome associations were detected and X-linked markers explained very little BD heritability. The results add to a growing list of common autosomal variants involved in BD and illustrate the power of comparing well-characterized cases to an excess of controls in GWAS.
C1 [Hou, Liping; Akula, Nirmala; Bui, Elise T.; Kassem, Layla; Laje, Gonzalo; Schulze, Thomas G.; McMahon, Francis J.] NIMH, Intramural Res Program, NIH, US Dept HHS, Bethesda, MD 20892 USA.
[Bergen, Sarah E.; Song, Jie; Hultman, Christina M.; Landen, Mikael] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Bergen, Sarah E.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA.
[Landen, Mikael] Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden.
[Adli, Mazda; Stamm, Thomas] Charite, Campus Charite Mitte, Dept Psychiat & Psychotherapy, Berlin, Germany.
[Alda, Martin; Garnham, Julie S.; Slaney, Claire M.] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada.
[Ardau, Raffaella; Chillotti, Caterina] Hosp Univ Agcy Cagliari, Clin Pharmacol Unit, Cagliari, Italy.
[Arias, Barbara; Mitjans, Marina] Univ Barcelona, CIBERSAM, Dept Biol Anim, Unitat Antropol Dp Biol Anim,Fac Biol, Barcelona, Spain.
[Arias, Barbara; Mitjans, Marina] Univ Barcelona, CIBERSAM, Inst Biomed IBUB, Barcelona, Spain.
[Aubry, Jean-Michel; Dayer, Alexandre] Univ Hosp Geneva, Mood Disorders Unit, Dept Mental Hlth & Psychiat, Geneva, Switzerland.
[Backlund, Lena; Lavebratt, Catharina; Schalling, Martin] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
[Backlund, Lena; Lavebratt, Catharina; Osby, Urban; Schalling, Martin] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden.
[Badner, Judith A.; Gershon, Elliot S.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
[Barrett, Thomas B.] Portland VA Med Ctr, Portland, OR USA.
[Bauer, Michael; Pfennig, Andrea] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Dresden, Germany.
[Baune, Bernhard T.; Davis, Tony; Hitturlingappa, Shashi] Univ Adelaide, Discipline Psychiat, Adelaide, SA, Australia.
[Bellivier, Frank; Brichant-Petitjean, Clara] Univ Paris Diderot, INSERM UMR S 1144, Pole Psychiat, Grp Hosp Lariboisiere F Widal,AP HP, Paris, France.
[Benabarre, Antonio; Colom, Francesc; Jimenez, Esther; Vieta, Eduard] Univ Barcelona, IDIBAPS, CIBERSAM, Bipolar Disorder Program,Inst Neurosci,Hosp Clin, Barcelona, Spain.
[Bengesser, Susanne; Birner, Armin; Lackner, Nina; Reininghaus, Eva] Med Univ Graz, Special Outpatient Ctr Bipolar Affect Disorder, Graz, Austria.
[Berrettini, Wade H.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Bhattacharjee, Abesh Kumar; Greenwood, Tiffany A.; Kelsoe, John R.; McKinney, Rebecca; Nievergelt, Caroline M.; Shekhtman, Tatyana; Shilling, Paul D.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Biernacka, Joanna M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Biernacka, Joanna M.; Frye, Mark A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA.
[Bloss, Cinnamon S.; Schork, Nicholas J.; Smith, Erin N.] Scripps Translat Sci Inst, La Jolla, CA USA.
[Byerley, William] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Cervantes, Pablo] McGill Univ, Ctr Hlth, Disorders Program, Montreal, PQ, Canada.
[Cichon, Sven; Degenhardt, Franziska; Forstner, Andreas J.; Heilmann-Heimbach, Stefanie; Herms, Stefan; Hoffmann, Per; Hofmann, Andrea; Maaser, Anna; Muehleisen, Thomas W.; Noethen, Markus M.; Propping, Peter; Schumacher, Johannes] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Cichon, Sven; Degenhardt, Franziska; Forstner, Andreas J.; Heilmann-Heimbach, Stefanie; Herms, Stefan; Hoffmann, Per; Hofmann, Andrea; Maaser, Anna; Muehleisen, Thomas W.; Noethen, Markus M.; Schumacher, Johannes] Univ Bonn, Life Brain Ctr, Dept Genom, Bonn, Germany.
[Cichon, Sven; Hoffmann, Per; Muehleisen, Thomas W.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany.
[Cichon, Sven; Herms, Stefan; Hoffmann, Per] Univ Basel, Div Med Genet, Basel, Switzerland.
[Cichon, Sven; Herms, Stefan; Hoffmann, Per] Univ Basel, Dept Biomed, Basel, Switzerland.
[Coryell, William] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
[Craig, David W.; Szelinger, Szabolcs] Translat Genom Res Inst, Phoenix, AZ USA.
[Cruceanu, Cristiana; Turecki, Gustavo] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada.
[Czerski, Piotr M.; Hauser, Joanna] Poznan Univ Med Sci, Psychiat Genet Unit, Poznan, Poland.
[Del Zompo, Maria; Manchia, Mirko; Severino, Giovanni; Squassina, Alessio] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy.
[DePaulo, J. Raymond; Goes, Fernando S.; Mahon, Pamela B.; Mondimore, Francis M.; Schulze, Thomas G.; Schweizer, Barbara W.] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA.
[Edenberg, Howard J.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
[Etain, Bruno; Jamain, Stephane; Leboyer, Marion] Univ Paris Est Creteil, INSERM U955, Psychiat Translat, Pole Psychiat & Addictol,Hop Univ Henri Mondor, Creteil, France.
[Falkai, Peter] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Munich, Germany.
[Foroud, Tatiana; Koller, Daniel L.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Frisen, Louise; Martinsson, Lina] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
[Frisen, Louise] Child & Adolescent Psychiat Res Ctr, Stockholm, Sweden.
[Fullerton, Janice M.] Neurosci Res Australia, Psychiat Genet, Sydney, NSW, Australia.
[Fullerton, Janice M.; Schofield, Peter R.] Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia.
[Gard, Sebastien] Hop Charles Perrens, Psychiat Serv, Bordeaux, France.
[Grigoroiu-Serbanescu, Maria] Alexandru Obregia Clin Psychiat Hosp, Biometr Psychiat Genet Res Unit, Bucharest, Romania.
[Heilbronner, Urs; Schulze, Thomas G.] Ludwig Maximilians Univ Munchen, Inst Psychiat Phen & Genom, Munich, Germany.
[Heilbronner, Urs; Schulze, Thomas G.] Georg August Univ Gottingen, Univ Med Ctr, Dept Psychiat & Psychotherapy, Gottingen, Germany.
[Hipolito, Maria; Lawson, William B.; Nwulia, Evaristus A.] Howard Univ Hosp, Dept Psychiat & Behav Sci, Washington, DC USA.
[Kahn, Jean-Pierre] Univ Lorraine, Ctr Psychotherap Nancy, Serv Psychiat & Psychol Clin, Nancy, France.
[Kittel-Schneider, Sarah; Reif, Andreas; Volkert, Julia] Univ Hosp Frankfurt, Dept Psychiat Psychosomat Med & Psychotherapy, Frankfurt, Germany.
[Kliwicki, Sebastian; Rybakowski, Janusz K.] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland.
[Koenig, Barbara] Landesklinikum Neunkirchen, Dept Psychiat & Psychotherapeuth Med, Neunkirchen, Austria.
[Lang, Maren; Rietschel, Marcella; Schulze, Thomas G.; Streit, Fabian; Strohmaier, Jana; Witt, Stephanie H.] Heidelberg Univ, Dept Genet Epidemiol Psychiat, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany.
[Leckband, Susan G.] VA San Diego Healthcare Syst, Dept Pharm, San Diego, CA USA.
[Liu, Chunyu] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA.
[Maier, Wolfgang] Univ Bonn, Dept Psychiat, Bonn, Germany.
[Maj, Mario; Monteleone, Palmiero; Tortorella, Alfonso] Univ Naples SUN, Dept Psychiat, Naples, Italy.
[Manchia, Mirko] Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada.
[McCarthy, Michael J.] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA.
[McElroy, Susan L.] Univ Cincinnati, Coll Med, Lindner Ctr HOPE, Mason, OH USA.
[McInnis, Melvin G.; Zhang, Peng; Zollner, Sebastian] Univ Michigan, Dept Psychiat, Ann Arbor, MI USA.
[Mitchell, Philip B.; Wright, Adam] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia.
[Mitchell, Philip B.; Wright, Adam] Black Dog Inst, Sydney, NSW, Australia.
[Monteleone, Palmiero] Univ Salerno, Dept Med & Surg, Neurosci Sect, Salerno, Italy.
[Novak, Tomas; Stopkova, Pavla] Natl Inst Mental Hlth, Klecany, Czech Republic.
[Nurnberger, John I., Jr.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA.
[Nurnberger, John I., Jr.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden.
[Potash, James B.; Tighe, Sarah K.] Univ Iowa, Sch Med, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
[Rice, John] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Rouleau, Guy A.] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada.
[Scheftner, William A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Schofield, Peter R.] Neurosci Res Australia, Mental Illness, Sydney, NSW, Australia.
[Simhandl, Christian] Bipolar Ctr Wiener Neustadt, Wiener Neustadt, Austria.
[Zandi, Peter P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
RP McMahon, FJ (reprint author), NIMH, Human Genet Branch, Intramural Res Program, 35 Convent Dr,Rm 1A201, Bethesda, MD 20892 USA.
EM mcmahonf@mail.nih.gov
OI Mitjans, Marina/0000-0001-5543-7320; Novak, Tomas/0000-0001-9156-9654;
Squassina, Alessio/0000-0001-7415-7607; Maaser,
Anna/0000-0002-9440-0712; Dayer, Alexandre/0000-0002-4490-9780
FU National Institute of Mental Health (NIMH) [ZIA-MH00284311]; NARSAD
Young Investigator Award
FX This work was supported by the National Institute of Mental Health
(NIMH) Intramural Research Program (ZIA-MH00284311; NCT00001174) and a
NARSAD Young Investigator Award to L.H.
NR 62
TC 3
Z9 3
U1 4
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2016
VL 25
IS 15
BP 3383
EP 3394
DI 10.1093/hmg/ddw181
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EJ2YK
UT WOS:000393077300018
PM 27329760
ER
PT J
AU Ferrucci, L
AF Ferrucci, Luigi
TI Commentary: Life course epidemiology embraces geroscience
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID AGE-RELATED DISEASES; DNA METHYLATION AGE; CAPACITY; MODELS; BLOOD
C1 [Ferrucci, Luigi] NIA, Intramural Res Program, NIH, 251 Bayview Blvd, Baltimore, MD 21224 USA.
RP Ferrucci, L (reprint author), NIA, Intramural Res Program, NIH, 251 Bayview Blvd, Baltimore, MD 21224 USA.
EM Ferruccilu@mail.nih.gov
FU Intramural Research Program of the National Institutes of Health;
National Institute on Aging
FX This research was supported entirely by the Intramural Research Program
of the National Institutes of Health, National Institute on Aging.
NR 33
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2016
VL 45
IS 4
BP 1015
EP 1019
DI 10.1093/ije/dyw104
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ4JD
UT WOS:000393182000011
PM 27880694
ER
PT J
AU Abraham, S
Collins, G
Nordsieck, M
AF Abraham, Sidney
Collins, Gretchen
Nordsieck, Marie
TI Relationship of childhood weight status to morbidity in adults
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID BODY-WEIGHT; INTERRELATIONSHIP; OBESITY; DISEASE; HEART
AB A cohort of white males who had attended elementary schools in Hagerstown, Md., between 1923 and 1928, and whose height-weight records for those years were available, was examined during 1961-63. A study of their childhood relative weight at ages 913, and of their adult relative weight 35-40 years later, was made in relation to selected physiological variables and diagnosed morbidity.
Essential findings were as follows:
Childhood relative weight at ages 9-13 had no significant relationship to adult levels of fasting blood sugar, serum cholesterol, beta-lipoprotein, or blood pressure, or to cardiovascular renal disease.
Childhood relative weight at ages 9-13 was significantly related to hypertensive vascular disease. The below average weight group experienced a higher prevalence than observed in either average or moderately overweight childhood groups.
Approximately 30 percent of the below average weight children became average weight adults and 21 percent became overweight adults. Of the average weight children, approximately 40 percent became overweight adults. Overweight children tended to remain overweight as adults.
Adult relative weight of the same cohort, viewed 35-40 years later, was significantly associated with fasting blood sugar, beta-lipoprotein, and systolic and diastolic blood pressure. Elevated levels of each of these variables occurred with greater frequency in the overweight child. Adult relative weight was significantly associated with hypertensive vascular disease and cardiovascular renal disease; the higher prevalence occurred in the overweight adults. The highest risk for hypertensive vascular and cardiovascular renal disease was associated with the persons who acquired their overweight status as adults. The higher prevalence of these diseases among the overweight adults was largely attributable to the adults who moved from a below average childhood weight category to an overweight adult group. The moderately or markedly overweight adults who was similarly classified as a child did not appear to be at greater risk than the average weight adult who had been an average weight child.
C1 [Abraham, Sidney; Collins, Gretchen; Nordsieck, Marie] Publ Hlth Serv, Heart Dis Program, Reg Med Programs Serv, Washington, DC USA.
[Abraham, Sidney] Natl Ctr Hlth Stat, Nutr Stat Branch, Div Hlth Examinat Stat, Hyattsville, MD USA.
[Collins, Gretchen] Ctr Dis Control, Demonstrat & Tech Serv Branch, Nutr Program, Atlanta, GA 30333 USA.
[Nordsieck, Marie] NIAID, Rockville, MD USA.
RP Abraham, S (reprint author), Room 8A-44,Parklawn Bldg,5600 Fishers Lane, Rockville, MD 20852 USA.
NR 20
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2016
VL 45
IS 4
BP 1020
EP 1031
DI 10.1093/ije/dyw171
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EJ4JD
UT WOS:000393182000012
PM 27498297
ER
PT J
AU Rubio, FJ
Li, X
Liu, QR
Cimbro, R
Hope, BT
AF Rubio, F. Javier
Li, Xuan
Liu, Qing-Rong
Cimbro, Raffaello
Hope, Bruce T.
TI Fluorescence Activated Cell Sorting (FACS) and Gene Expression Analysis
of Fos-expressing Neurons from Fresh and Frozen Rat Brain Tissue
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Neuroscience; Issue 114; Cell types; neurons; glia; antibody; mRNA; FACS
ID ENSEMBLES
AB The study of neuroplasticity and molecular alterations in learned behaviors is switching from the study of whole brain regions to the study of specific sets of sparsely distributed activated neurons called neuronal ensembles that mediate learned associations. Fluorescence Activated Cell Sorting (FACS) has recently been optimized for adult rat brain tissue and allowed isolation of activated neurons using antibodies against the neuronal marker NeuN and Fos protein, a marker of strongly activated neurons. Until now, Fos-expressing neurons and other cell types were isolated from fresh tissue, which entailed long processing days and allowed very limited numbers of brain samples to be assessed after lengthy and complex behavioral procedures. Here we found that yields of Fos-expressing neurons and Fos mRNA from dorsal striatum were similar between freshly dissected tissue and tissue frozen at -80 degrees C for 3 - 21 days. In addition, we confirmed the phenotype of the NeuN-positive and NeuN-negative sorted cells by assessing gene expression of neuronal (NeuN), astrocytic (GFAP), oligodendrocytic (Oligo2) and microgial (Iba1) markers, which indicates that frozen tissue can also be used for FACS isolation of glial cell types. Overall, it is possible to collect, dissect and freeze brain tissue for multiple FACS sessions. This maximizes the amount of data obtained from valuable animal subjects that have often undergone long and complex behavioral procedures.
C1 [Rubio, F. Javier; Li, Xuan; Liu, Qing-Rong; Hope, Bruce T.] NIDA, Behav Neurosci Res Branch, Intramural Res Program, NIH,DHHS, Bethesda, MD 20892 USA.
[Cimbro, Raffaello] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21218 USA.
RP Hope, BT (reprint author), NIDA, Behav Neurosci Res Branch, Intramural Res Program, NIH,DHHS, Bethesda, MD 20892 USA.
EM Bhope@intra.nida.nih.gov
RI Hope, Bruce/A-9223-2010;
OI Hope, Bruce/0000-0001-5804-7061; Cimbro, Raffaello/0000-0002-6251-5160
FU NIDA Intramural Research Program; NIDA Research Participation Program -
National Institutes of Health; Becas-Chile scholarship; Universidad de
los Andes, Santiago, Chile; National Institute of Arthritis and
Musculoskeletal and Skin Diseases of the National Institute of Health
[P30AR053503]
FX This work was supported by the NIDA Intramural Research Program (Bruce
T. Hope, Yavin Shaham). F.J.R. was supported by an appointment to the
NIDA Research Participation Program sponsored by the National Institutes
of Health and administered by the Oak Ridge Institute for Science and
Education, and received additional financial support from a Becas-Chile
scholarship managed by CONICYT and the Universidad de los Andes,
Santiago, Chile. The Johns Hopkins FACS Core facility was supported by
Award P30AR053503 from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases of the National Institute of Health.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD AUG
PY 2016
IS 114
AR e54358
DI 10.3791/54358
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH4LM
UT WOS:000391742700075
ER
PT J
AU Benjamin, LA
Bryer, A
Lucas, S
Stanley, A
Allain, TJ
Joekes, E
Emsley, H
Turnbull, I
Downey, C
Toh, CH
Brown, K
Brown, D
Ison, C
Smith, C
Corbett, EL
Nath, A
Heyderman, RS
Connor, MD
Solomon, T
AF Benjamin, Laura A.
Bryer, Alan
Lucas, Sebastian
Stanley, Alan
Allain, Theresa J.
Joekes, Elizabeth
Emsley, Hedley
Turnbull, Ian
Downey, Colin
Toh, Cheng-Hock
Brown, Kevin
Brown, David
Ison, Catherine
Smith, Colin
Corbett, Elizabeth L.
Nath, Avindra
Heyderman, Robert S.
Connor, Myles D.
Solomon, Tom
TI Arterial ischemic stroke in HIV Defining and classifying etiology for
research studies
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL VESSEL DISEASE;
CENTRAL-NERVOUS-SYSTEM; ANTIPHOSPHOLIPID SYNDROME; NEUROSYPHILIS
DIAGNOSIS; CONSENSUS CONFERENCE; CEREBROSPINAL-FLUID; PRIMARY ANGIITIS;
RISK-FACTORS; INFECTION
AB HIV infection, and potentially its treatment, increases the risk of an arterial ischemic stroke. Multiple etiologies and lack of clear case definitions inhibit progress in this field. Several etiologies, many treatable, are relevant to HIV-related stroke. To fully understand the mechanisms and the terminology used, a robust classification algorithm to help ascribe the various etiologies is needed. This consensus paper considers the strengths and limitations of current case definitions in the context of HIV infection. The case definitions for the major etiologies in HIV-related strokes were refined (e.g., varicella zoster vasculopathy and antiphospholipid syndrome) and in some instances new case definitions were described (e.g., HIV-associated vasculopathy). These case definitions provided a framework for an algorithm to help assign a final diagnosis, and help classify the subtypes of HIV etiology in ischemic stroke.
C1 [Benjamin, Laura A.; Corbett, Elizabeth L.; Heyderman, Robert S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
[Benjamin, Laura A.; Allain, Theresa J.] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi.
[Benjamin, Laura A.; Emsley, Hedley; Solomon, Tom] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
[Benjamin, Laura A.; Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
[Bryer, Alan; Stanley, Alan] Univ Cape Town, Div Neurol, Groote Schuur Hosp, Dept Med, ZA-7700 Rondebosch, South Africa.
[Lucas, Sebastian] St Thomas Hosp, Dept Histopathol, London, England.
[Joekes, Elizabeth] Royal Liverpool Hospital, Dept Radiol, London, England.
[Downey, Colin; Toh, Cheng-Hock] Royal Liverpool Hospital, Dept Haematol, London, England.
[Emsley, Hedley] Preston Hosp, London, England.
[Turnbull, Ian] North Manchester Gen Hosp, London, England.
[Brown, Kevin; Brown, David] Publ Hlth England, Reference Dept, London, England.
[Ison, Catherine] Publ Hlth England, Syphilis Reference Dept, London, England.
[Smith, Colin] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
[Connor, Myles D.] Univ Edinburgh, Div Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland.
[Corbett, Elizabeth L.] London Sch Hyg & Trop Med, Dept Clin Res, London, England.
[Nath, Avindra] NIH, Bldg 10, Bethesda, MD 20892 USA.
[Heyderman, Robert S.] UCL, Div Infect & Immun, London WC1E 6BT, England.
[Connor, Myles D.] NHS Borders, Melrose, Scotland.
[Connor, Myles D.] Univ Witwatersrand, Sch Publ Hlth, ZA-2050 Johannesburg, South Africa.
[Solomon, Tom] Natl Inst Hlth Res Hlth Protect, Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
RP Benjamin, LA (reprint author), Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.; Benjamin, LA (reprint author), Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi.; Benjamin, LA (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.; Benjamin, LA (reprint author), Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
EM l.benjamin@liverpool.ac.uk
FU Wellcome Trust; NIHR Health Protection Research Unit in Emerging and
Zoonotic Infections at Liverpool
FX L.B. was supported by the Wellcome Trust. T.S. was supported by the NIHR
Health Protection Research Unit in Emerging and Zoonotic Infections at
Liverpool.
NR 60
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD AUG
PY 2016
VL 3
IS 4
AR e254
DI 10.1212/NXI.0000000000000254
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA EG6PR
UT WOS:000391168900016
PM 27386505
ER
PT J
AU Brady, RO
AF Brady, Roscoe O.
TI CLAUDE NICOLAU AND THE BIOTECHNOLOGY INDUSTRY
SO REVUE ROUMAINE DE CHIMIE
LA English
DT Editorial Material
C1 [Brady, Roscoe O.] NIH, Bethesda, MD 20892 USA.
RP Brady, RO (reprint author), NIH, Bethesda, MD 20892 USA.
EM BradyR@ninds.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 0035-3930
J9 REV ROUM CHIM
JI Rev. Roum. Chim.
PD AUG-SEP
PY 2016
VL 61
IS 8-9
BP 629
EP 630
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA EF8YQ
UT WOS:000390618300002
ER
PT J
AU Pitcher, D
Handwerker, D
Ianni, G
Bandettini, P
Ungerleider, L
AF Pitcher, David
Handwerker, Daniel
Ianni, Geena
Bandettini, Peter
Ungerleider, Leslie
TI Combined TMS and fMRI demonstrates a Double dissociation between face
and motor functional brain networks
SO PERCEPTION
LA English
DT Meeting Abstract
C1 [Pitcher, David] Univ York, Psychol, York, N Yorkshire, England.
[Handwerker, Daniel; Ianni, Geena; Bandettini, Peter; Ungerleider, Leslie] NIMH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0301-0066
EI 1468-4233
J9 PERCEPTION
JI Perception
PD AUG
PY 2016
VL 45
SU 2
MA 1P050
BP 26
EP 26
PG 1
WC Ophthalmology; Psychology; Psychology, Experimental
SC Ophthalmology; Psychology
GA EF3HR
UT WOS:000390215900051
ER
PT J
AU Welsh, KJ
Hermane, AT
Zhao, Z
AF Welsh, Kerry J.
Hermane, Allison T.
Zhao, Zhen
TI Is This Patient Pregnant?
SO CLINICAL CHEMISTRY
LA English
DT Editorial Material
C1 [Welsh, Kerry J.; Hermane, Allison T.; Zhao, Zhen] NIH, Dept Lab Med, Clin Chem Serv, 10 Ctr Dr,Bldg 10,Room 2C306, Bethesda, MD 20814 USA.
RP Zhao, Z (reprint author), NIH, Dept Lab Med, Clin Chem Serv, 10 Ctr Dr,Bldg 10,Room 2C306, Bethesda, MD 20814 USA.
EM zhen.zhao@nih.gov
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD AUG
PY 2016
VL 62
IS 8
BP 1163
EP 1164
DI 10.1373/clinchem.2015.253039
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA EF2DH
UT WOS:000390134300023
PM 27471249
ER
PT J
AU Ladeiras-Lopes, R
Turin-Moreira, H
Bettencourt, N
Fontes-Carvalho, R
Sampaio, F
Ambale-Venkatesh, B
Wu, C
Liu, K
Bertoni, A
Ouyang, P
Bluemke, D
Lima, J
AF Ladeiras-Lopes, R.
Turin-Moreira, H.
Bettencourt, N.
Fontes-Carvalho, R.
Sampaio, F.
Ambale-Venkatesh, B.
Wu, C.
Liu, K.
Bertoni, A.
Ouyang, P.
Bluemke, D.
Lima, J.
TI Metabolic syndrome is associated with increased cardiac fibrosis and
impaired diastolic function: a potential role for inflammation
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Ladeiras-Lopes, R.; Fontes-Carvalho, R.; Sampaio, F.] Gaia Hosp Ctr, Dept Cardiol, Vila Nova De Gaia, Portugal.
[Turin-Moreira, H.; Ambale-Venkatesh, B.; Ouyang, P.; Lima, J.] Johns Hopkins Univ Baltimore, Baltimore, MD USA.
[Bettencourt, N.] Univ Porto, Fac Med, Oporto, Portugal.
[Wu, C.; Bluemke, D.] NIH, Bldg 10, Bethesda, MD 20892 USA.
[Liu, K.] Northwestern Univ, Chicago, IL 60611 USA.
[Bertoni, A.] Wake Forest Univ, Winston Salem, NC 27109 USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA 1893
BP 399
EP 399
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869502012
ER
PT J
AU Malliou, F
Andreadou, I
Gonzalez, FJ
Lazou, A
Xepapadaki, E
Vallianou, I
Lambrinidis, G
Mikros, E
Marselos, M
Skaltsounis, L
Konstandi, M
AF Malliou, F.
Andreadou, I.
Gonzalez, F. J.
Lazou, A.
Xepapadaki, E.
Vallianou, I.
Lambrinidis, G.
Mikros, E.
Marselos, M.
Skaltsounis, L.
Konstandi, M.
TI The olive constituent oleuropein markedly reduces serum triglycerides
via PPARalpha activation
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Malliou, F.; Marselos, M.; Konstandi, M.] Univ Ioannina, Dept Pharmacol, Sch Med, Ioannina, Greece.
[Andreadou, I.; Lambrinidis, G.; Mikros, E.; Skaltsounis, L.] Univ Athens, Fac Pharm, Athens, Greece.
[Gonzalez, F. J.] NCI, NIH, Lab Metab, Bethesda, MD 20892 USA.
[Lazou, A.; Vallianou, I.] Aristotle Univ Thessaloniki, Sch Biol, Physiol Anim Lab, Thessaloniki, Greece.
[Xepapadaki, E.] Univ Patras, Sch Med, Dept Pharmacol, Patras, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA P2740
BP 553
EP 553
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869502507
ER
PT J
AU Christophersen, IE
Magnani, JW
Yin, X
Barnard, J
Chung, M
Lubitz, SA
Benjamin, EJ
Ellinor, PT
AF Christophersen, I. E.
Magnani, J. W.
Yin, X.
Barnard, J.
Chung, M.
Lubitz, S. A.
Benjamin, E. J.
Ellinor, P. T.
CA CHARGE Investigators
TI Meta-analyses in > 44,000 individuals identify fifteen genetic loci
associated with the electrocardiographic P-wave
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Christophersen, I. E.; Lubitz, S. A.; Ellinor, P. T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Magnani, J. W.; Benjamin, E. J.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Yin, X.] NHLBI, Framingham, MA USA.
[Yin, X.] Boston Univ, Framingham Heart Study, Framingham, MA USA.
[Barnard, J.; Chung, M.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Barnard, J.; Chung, M.] Cleveland Clin, Dept Cellular & Mol Med, Cleveland, OH 44106 USA.
[Barnard, J.; Chung, M.] Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA P4313
BP 841
EP 841
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869504173
ER
PT J
AU Wong, ND
Zhao, Y
Quek, RGW
Blumenthal, RS
Budoff, MJ
Cushman, M
Garg, P
Sandfort, V
Tsai, M
Lopez, JA
AF Wong, N. D.
Zhao, Y.
Quek, R. G. W.
Blumenthal, R. S.
Budoff, M. J.
Cushman, M.
Garg, P.
Sandfort, V.
Tsai, M.
Lopez, J. A.
TI Residual atherosclerotic cardiovascular disease risk in statin-treated
adults: the multi-ethnic study of atherosclerosis
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Wong, N. D.; Zhao, Y.] Univ Calif Irvine, Heart Dis Prevent Program, Div Cardiol, Irvine, CA USA.
[Quek, R. G. W.; Lopez, J. A.] Amgen Inc, Thousand Oaks, CA 91320 USA.
[Blumenthal, R. S.] Johns Hopkins Univ Baltimore, Baltimore, MD USA.
[Budoff, M. J.] Los Angeles Biomed Res Inst, Torrance, CA USA.
[Cushman, M.] Univ Vermont, Burlington, VT USA.
[Garg, P.] Univ Southern Calif, Los Angeles, CA USA.
[Sandfort, V.] NIH, Bldg 10, Bethesda, MD 20892 USA.
[Tsai, M.] Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA P4991
BP 1014
EP 1014
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869505085
ER
PT J
AU Higgins, AY
Shanbhag, SM
Bandettini, WP
Rogers, T
Ratnayaka, K
Arai, AE
Lederman, RJ
Chen, MY
AF Higgins, A. Y.
Shanbhag, S. M.
Bandettini, W. P.
Rogers, T.
Ratnayaka, K.
Arai, A. E.
Lederman, R. J.
Chen, M. Y.
TI Novel cardiac CT method accurately measures shunt flow in patients with
atrial or ventricular septal defects
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Higgins, A. Y.; Shanbhag, S. M.; Bandettini, W. P.; Rogers, T.; Ratnayaka, K.; Arai, A. E.; Lederman, R. J.; Chen, M. Y.] NHLBI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA P5214
BP 1046
EP 1046
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869505185
ER
PT J
AU Yoneyama, K
Venkatexh, BA
Wu, C
Mewton, N
Gjesdal, O
Kishi, S
McClelland, R
Bluemke, D
Lima, J
AF Yoneyama, K.
Venkatexh, B. A.
Wu, C.
Mewton, N.
Gjesdal, O.
Kishi, S.
McClelland, R.
Bluemke, D.
Lima, J.
CA Multi-Ethnic Study Atherosclerosis
TI Diabetes mellitus and insulin resistance associate with left ventricular
remodeling and function by cardiac magnetic resonance imaging from the
Multi-Ethnic Study of Atherosclerosis
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Yoneyama, K.; Venkatexh, B. A.; Mewton, N.; Kishi, S.; Lima, J.] Johns Hopkins Univ Baltimore, Cardiol, Baltimore, MD USA.
[Wu, C.] NHLBI, Off Biostat Res, Bldg 10, Bethesda, MD 20892 USA.
[Gjesdal, O.] Oslo Univ Hosp, Cardiol, Oslo, Norway.
[McClelland, R.] Univ Washington, Biostat, Seattle, WA 98195 USA.
[Bluemke, D.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA 5867
BP 1196
EP 1196
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869506020
ER
PT J
AU Ohyama, Y
Ambale-Venkatesh, B
Yoneyama, K
Nwabuo, C
Noda, C
Tura, GT
Redheuil, A
Gomes, A
Hundley, G
Nakamura, T
Bluemke, D
Lima, J
AF Ohyama, Y.
Ambale-Venkatesh, B.
Yoneyama, K.
Nwabuo, C.
Noda, C.
Teixido Tura, G.
Redheuil, A.
Gomes, A.
Hundley, G.
Nakamura, T.
Bluemke, D.
Lima, J.
TI Impact of aortic size and function assessed by MRI on incident
hypertension and blood pressure progression: the multi-ethnic study of
atherosclerosis
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Ohyama, Y.; Ambale-Venkatesh, B.; Yoneyama, K.; Nwabuo, C.; Noda, C.; Lima, J.] Johns Hopkins Univ, Cardiol, Baltimore, MD USA.
[Teixido Tura, G.] Univ Hosp Vall dHebron, Cardiol, Barcelona, Spain.
[Redheuil, A.] Univ Pierre & Marie Curie Paris VI, Paris, France.
[Gomes, A.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Hundley, G.] Wake Forest Univ, Cardiol, Winston Salem, NC 27109 USA.
[Nakamura, T.] Gunma Univ, Sch Med, Cardiol, Maebashi, Gumma, Japan.
[Bluemke, D.] NIH, Radiol, Bldg 10, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA P5888
BP 1203
EP 1203
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869506041
ER
PT J
AU Hsu, PF
Cheng, HM
Sung, SH
Chuang, SY
Yin, F
Lakatta, ED
Chou, P
Chen, CH
AF Hsu, P. F.
Cheng, H. M.
Sung, S. H.
Chuang, S. Y.
Yin, F.
Lakatta, E. D.
Chou, P.
Chen, C. H.
TI Serum uric acid levels and 20-year cardiovascular mortality: dual
pathways of hemodynamics and renal function
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT Congress of the European-Society-of-Cardiology (ESC)
CY AUG 27-31, 2016
CL Rome, ITALY
SP European Soc Cardiol
C1 [Hsu, P. F.; Cheng, H. M.; Sung, S. H.; Chen, C. H.] Taipei Vet Gen Hosp, Taipei, Taiwan.
[Chuang, S. Y.] Natl Hlth Res Inst, Miaoli, Taiwan.
[Yin, F.] Washington Univ, Dept Biomed Engn, St Louis, MO USA.
[Lakatta, E. D.] NIA, Baltimore, MD 21224 USA.
[Chou, P.] Natl Yang Ming Univ, Taipei, Taiwan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG 1
PY 2016
VL 37
SU 1
MA P6395
BP 1333
EP 1333
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW7YL
UT WOS:000383869506453
ER
PT J
AU Mackesy-Amiti, ME
Strand, L
Nance, R
Chandler, R
Cunningham, W
Riley, E
Mehta, S
Altice, F
Wechsberg, W
Cunningham, C
Cleland, C
Metsch, L
Feaster, D
del Rio, C
Beckwith, C
Kurth, A
Kuo, I
Kruszka, B
Springer, S
AF Mackesy-Amiti, Mary-Ellen
Strand, Lauren
Nance, Robin
Chandler, Redonna
Cunningham, William
Riley, Elise
Mehta, Shruti
Altice, Frederick
Wechsberg, Wendee
Cunningham, Chinazo
Cleland, Charles
Metsch, Lisa
Feaster, Daniel
del Rio, Carlos
Beckwith, Curt
Kurth, Ann
Kuo, Irene
Kruszka, Bridget
Springer, Sandra
TI An Example of Exposure Heterogeneity When Pooling Epidemiologic Studies
for Meta-Analysis of Antiretroviral Medication Adherence
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Mackesy-Amiti, Mary-Ellen] Univ Illinois, Sch Publ Hlth, Chicago, IL USA.
[Strand, Lauren; Nance, Robin; Kruszka, Bridget] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Chandler, Redonna] NIDA, Rockville, MD USA.
[Cunningham, William] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Riley, Elise] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Mehta, Shruti] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
[Altice, Frederick] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Wechsberg, Wendee] Res Triangle Inst Int, Res Triangle Pk, NC USA.
[Cunningham, Chinazo] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Cleland, Charles; Kurth, Ann] NYU, Coll Nursing, New York, NY USA.
[Metsch, Lisa; Feaster, Daniel] Columbia Univ, Sch Publ Hlth, New York, NY USA.
[Feaster, Daniel] Univ Miami, Sch Med, Miami, FL USA.
[del Rio, Carlos] Emory Univ, Sch Med, Atlanta, GA USA.
[Beckwith, Curt] Miriam Hosp, Providence, RI 02906 USA.
[Kuo, Irene] George Washington Sch Publ Hlth, Washington, DC USA.
[Altice, Frederick; Springer, Sandra] Yale Sch Med, New Haven, CT USA.
[Cunningham, William] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[del Rio, Carlos] Emory Univ, Sch Publ Hlth, Atlanta, GA USA.
RI del Rio, Carlos/B-3763-2012
OI del Rio, Carlos/0000-0002-0153-3517
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 87
BP 55
EP 56
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483501087
ER
PT J
AU Chodick, G
Trabert, B
Shalev, V
McGlynn, KA
AF Chodick, Gabriel
Trabert, Britton
Shalev, Varda
McGlynn, Katherine A.
TI Assisted Reproductive Technologies and the Risk of Cryptorchidism and
Hypospadias: Population-Based Study
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Chodick, Gabriel; Shalev, Varda] MaccabiTech, Maccabi Healthcare Serv, Tel Aviv, Israel.
[Trabert, Britton; McGlynn, Katherine A.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Chodick, Gabriel; Shalev, Varda] Tel Aviv Univ, Fac Med, Tel Aviv, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 574
BP 334
EP 335
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483502206
ER
PT J
AU Bradley, MC
Zhou, G
Freedman, AN
Haque, R
Yood, MU
Van den Eeden, SK
Potosky, AL
AF Bradley, Marie C.
Zhou, Grace
Freedman, Andrew N.
Haque, Reina
Yood, Marianne Ulcickas
Van den Eeden, Stephen K.
Potosky, Arnold L.
TI The Association Between Diabetic Complications and Androgen Deprivation
Therapy Used for Clinically Localized Prostate Cancer
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Bradley, Marie C.; Freedman, Andrew N.] NCI, Clin & Translat Epidemiol Branch, DCCPS, Rockville, MD USA.
[Zhou, Grace; Potosky, Arnold L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Haque, Reina] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA.
[Yood, Marianne Ulcickas] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Van den Eeden, Stephen K.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 665
BP 389
EP 389
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483502297
ER
PT J
AU Tsai, HT
Pfeiffer, R
Philips, G
Barac, A
Fu, AZ
Zhou, GY
Potosky, A
AF Tsai, Huei-Ting
Pfeiffer, Ruth
Philips, George
Barac, Ana
Fu, Alex Z.
Zhou, Grace Y.
Potosky, Arnold
TI Population-Based Comparison of the Risks of Serious Adverse Events from
Intermittent versus Continuous Androgen Deprivation Therapy in Advanced
Prostate Cancer Patients
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Tsai, Huei-Ting; Fu, Alex Z.; Zhou, Grace Y.; Potosky, Arnold] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
[Pfeiffer, Ruth] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Philips, George] Georgetown Univ Hosp, Washington, DC 20007 USA.
[Barac, Ana] MedStar Washington Hosp Ctr, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 914
BP 532
EP 532
PG 1
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483503177
ER
PT J
AU Strand, LN
Young, RL
Delaney, JA
Bertoni, AG
Bluemke, DA
Burke, GL
Lima, JA
Sotoodehnia, N
Psaty, BM
Heckbert, SR
McClelland, RL
AF Strand, Lauren N.
Young, Rebekah L.
Delaney, Joseph A.
Bertoni, Alain G.
Bluemke, David A.
Burke, Gregory L.
Lima, Joao A.
Sotoodehnia, Nona
Psaty, Bruce M.
Heckbert, Susan R.
McClelland, Robyn L.
TI New Statin Use And Left Ventricular Structure: Estimating Long-Term
Associations In The Multi-Ethnic Study of Atherosclerosis (MESA)
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Meeting Abstract
C1 [Strand, Lauren N.; Young, Rebekah L.; Delaney, Joseph A.; Psaty, Bruce M.; Heckbert, Susan R.; McClelland, Robyn L.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Bertoni, Alain G.; Burke, Gregory L.] Wake Forest Sch Med, Winston Salem, NC USA.
[Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Bluemke, David A.] Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA.
[Lima, Joao A.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Lima, Joao A.] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
[Sotoodehnia, Nona; Psaty, Bruce M.] Univ Washington, Sch Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-8569
EI 1099-1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD AUG
PY 2016
VL 25
SU S3
MA 977
BP 568
EP 569
PG 2
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA DY9VP
UT WOS:000385483503238
ER
PT J
AU Willcox, BJ
Tranah, GJ
Chen, R
Morris, BJ
Masaki, KH
He, QM
Willcox, DC
Allsopp, RC
Moisyadi, S
Poon, LW
Rodriguez, B
Newman, AB
Harris, TB
Cummings, SR
Liu, YM
Parimi, N
Evans, DS
Davy, P
Gerschenson, M
Donlon, TA
AF Willcox, Bradley J.
Tranah, Gregory J.
Chen, Randi
Morris, Brian J.
Masaki, Kamal H.
He, Qimei
Willcox, D. Craig
Allsopp, Richard C.
Moisyadi, Stefan
Poon, Leonard W.
Rodriguez, Beatriz
Newman, Anne B.
Harris, Tamara B.
Cummings, Steven R.
Liu, Yongmei
Parimi, Neeta
Evans, Daniel S.
Davy, Phil
Gerschenson, Mariana
Donlon, Timothy A.
TI The FoxO3 gene and cause-specific mortality
SO AGING CELL
LA English
DT Article
DE FOXO3; heart disease; longevity; mortality
ID HUMAN LONGEVITY; TRANSCRIPTION FACTORS; LIFE-SPAN; ASSOCIATION;
CENTENARIANS; INDIVIDUALS; MAINTENANCE; SURVIVAL; PATHWAY; DISEASE
AB The G allele of the FOXO3 single nucleotide polymorphism (SNP) rs2802292 exhibits a consistently replicated genetic association with longevity in multiple populations worldwide. The aims of this study were to quantify the mortality risk for the longevity-associated genotype and to discover the particular cause(s) of death associated with this allele in older Americans of diverse ancestry. It involved a 17-year prospective cohort study of 3584 older American men of Japanese ancestry from the Honolulu Heart Program cohort, followed by a 17-year prospective replication study of 1595 white and 1056 black elderly individuals from the Health Aging and Body Composition cohort. The relation between FOXO3 genotype and cause-specific mortality was ascertained for major causes of death including coronary heart disease (CHD), cancer, and stroke. Age-adjusted and multivariable Cox proportional hazards models were used to compute hazard ratios (HRs) for all-cause and cause-specific mortality. We found G allele carriers had a combined (Japanese, white, and black populations) risk reduction of 10% for total (all-cause) mortality (HR = 0.90; 95% CI, 0.84-0.95; P = 0.001). This effect size was consistent across populations and mostly contributed by 26% lower risk for CHD death (HR = 0.74; 95% CI, 0.64-0.86; P = 0.00004). No other causes of death made a significant contribution to the survival advantage for G allele carriers. In conclusion, at older age, there is a large risk reduction in mortality for G allele carriers, mostly due to lower CHD mortality. The findings support further research on FOXO3 and FoxO3 protein as potential targets for therapeutic intervention in aging-related diseases, particularly cardiovascular disease.
C1 [Willcox, Bradley J.; Chen, Randi; Morris, Brian J.; Masaki, Kamal H.; He, Qimei; Willcox, D. Craig; Rodriguez, Beatriz; Donlon, Timothy A.] Kuakini Med Ctr, Dept Res, Honolulu, HI 96817 USA.
[Willcox, Bradley J.; Morris, Brian J.; Masaki, Kamal H.; Willcox, D. Craig; Rodriguez, Beatriz] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96817 USA.
[Tranah, Gregory J.; Cummings, Steven R.; Parimi, Neeta; Evans, Daniel S.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA.
[Morris, Brian J.] Univ Sydney, Sch Med Sci, Sydney, NSW 2006, Australia.
[Morris, Brian J.] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia.
[Willcox, D. Craig] Okinawa Int Univ, Dept Human Welf, Ginowan, Okinawa 9012701, Japan.
[Allsopp, Richard C.; Moisyadi, Stefan; Davy, Phil] Univ Hawaii, Inst Biogenesis Res, Honolulu, HI 96813 USA.
[Poon, Leonard W.] Univ Georgia, Inst Gerontol, Athens, GA 30602 USA.
[Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Harris, Tamara B.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA.
[Liu, Yongmei] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA.
[Gerschenson, Mariana] Univ Hawaii, Dept Cell & Mol Biol, Honolulu, HI 96813 USA.
RP Willcox, BJ (reprint author), Kuakini Med Ctr, 347 North Kuakini St,HPM-9, Honolulu, HI 96817 USA.
EM willcox@hawaii.edu
FU Kuakini Medical Center; US National Institutes of Health [N01-AG-4-2149,
5 U01 AG019349-05, 5R01AG027060, 5R01AG038707]; National Heart, Lung,
and Blood Institute [N01-HC-05102]; National Institutes of Aging
[N01AG62101, N01AG62103, N01AG62106]; Intramural Research Program of the
NIH, National Institute on Aging (Health ABC); NIA [1R01AG032098-01A1];
National Institutes of Health [HHSN268200782096C]
FX The work in Honolulu was funded by the Kuakini Medical Center, the US
National Institutes of Health (contract N01-AG-4-2149, Grants 5 U01
AG019349-05, 5R01AG027060 [Kuakini Hawaii Lifespan Study], 5R01AG038707
[Kuakini Hawaii Healthspan Study]), contract N01-HC-05102 from the
National Heart, Lung, and Blood Institute, and Kuakini Medical Center.
We acknowledge the expert assistance of the Hawaii State Department of
Health, particularly for supplying death certificate data. Research
involving the Health ABC study was supported by National Institutes of
Aging contracts N01AG62101, N01AG62103, and N01AG62106 and in part by
the Intramural Research Program of the NIH, National Institute on Aging
(Health ABC study). The Health ABC genomewide association study was
funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health
Sciences, and genotyping services were provided by the Center for
Inherited Disease Research (CIDR). CIDR is fully funded through a
federal contract (number HHSN268200782096C) from the National Institutes
of Health to The Johns Hopkins University. We thank all study
participants and their families for their cooperation and the Hawaii
State Department of Health for death certificate data. We thank Dr.
Eunjung Lim for assistance with statistical analysis.
NR 40
TC 2
Z9 2
U1 5
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2016
VL 15
IS 4
BP 617
EP 624
DI 10.1111/acel.12452
PG 8
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA DW5WN
UT WOS:000383718400003
PM 27071935
ER
PT J
AU Mohamad, M
Mitchell, SJ
Wu, LE
White, MY
Cordwell, SJ
Mach, J
Solon-Biet, SM
Boyer, D
Nines, D
Das, A
Li, SYC
Warren, A
Hilmer, SN
Fraser, R
Sinclair, DA
Simpson, SJ
de Cabo, R
Le Couteur, DG
Cogger, VC
AF Mohamad, Mashani
Mitchell, Sarah Jayne
Wu, Lindsay Edward
White, Melanie Yvonne
Cordwell, Stuart James
Mach, John
Solon-Biet, Samantha Marie
Boyer, Dawn
Nines, Dawn
Das, Abhirup
Li, Shi-Yun Catherine
Warren, Alessandra
Hilmer, Sarah Nicole
Fraser, Robin
Sinclair, David Andrew
Simpson, Stephen James
de Cabo, Rafael
Le Couteur, David George
Cogger, Victoria Carroll
TI Ultrastructure of the liver microcirculation influences hepatic and
systemic insulin activity and provides a mechanism for age-related
insulin resistance
SO AGING CELL
LA English
DT Article
DE ageing; aging; fenestrations; fenestrae; endothelium; hyperinsulinemia
ID PERFUSED-RAT-LIVER; SINUSOIDAL ENDOTHELIUM; INTERACTION NETWORKS;
DIABETES-MELLITUS; ADIPOSE-TISSUE; POLOXAMER 407; FATTY LIVER; OLD-AGE;
CLEARANCE; ATHEROSCLEROSIS
AB While age-related insulin resistance and hyperinsulinemia are usually considered to be secondary to changes in muscle, the liver also plays a key role in whole-body insulin handling and its role in age-related changes in insulin homeostasis is largely unknown. Here, we show that patent pores called 'fenestrations' are essential for insulin transfer across the liver sinusoidal endothelium and that age-related loss of fenestrations causes an impaired insulin clearance and hyperinsulinemia, induces hepatic insulin resistance, impairs hepatic insulin signaling, and deranges glucose homeostasis. To further define the role of fenestrations in hepatic insulin signaling without any of the long-term adaptive responses that occur with aging, we induced acute defenestration using poloxamer 407 (P407), and this replicated many of the age-related changes in hepatic glucose and insulin handling. Loss of fenestrations in the liver sinusoidal endothelium is a hallmark of aging that has previously been shown to cause deficits in hepatic drug and lipoprotein metabolism and now insulin. Liver defenestration thus provides a new mechanism that potentially contributes to age-related insulin resistance.
C1 [Mohamad, Mashani; Solon-Biet, Samantha Marie; Warren, Alessandra; Le Couteur, David George; Cogger, Victoria Carroll] Univ Sydney, Ageing & Alzheimers Inst, Ctr Educ & Res Ageing, Sydney, NSW, Australia.
[Mohamad, Mashani; Solon-Biet, Samantha Marie; Warren, Alessandra; Le Couteur, David George] Concord Hosp, Sydney, NSW, Australia.
[Mohamad, Mashani; Solon-Biet, Samantha Marie; Warren, Alessandra; Le Couteur, David George; Cogger, Victoria Carroll] Univ Sydney, ANZAC Res Inst, Sydney, NSW, Australia.
[Mohamad, Mashani] Univ Teknol MARA, Fac Pharm, Selangor, Malaysia.
[Mitchell, Sarah Jayne; Boyer, Dawn; Nines, Dawn; de Cabo, Rafael] NIA, Translat Gerontol Branch, NIH, Baltimore, MD 21224 USA.
[Wu, Lindsay Edward; Das, Abhirup; Li, Shi-Yun Catherine; Sinclair, David Andrew] Univ New South Wales, Sch Med Sci, Lab Ageing Res, Sydney, NSW, Australia.
[White, Melanie Yvonne; Cordwell, Stuart James; Solon-Biet, Samantha Marie; Simpson, Stephen James; Le Couteur, David George; Cogger, Victoria Carroll] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia.
[Mach, John; Hilmer, Sarah Nicole] Royal North Shore Hosp, Kolling Inst Med Res, Sydney, NSW, Australia.
[Mach, John; Hilmer, Sarah Nicole] Univ Sydney, Sydney, NSW, Australia.
[Fraser, Robin] Univ Otago, Dept Pathol, Christchurch, New Zealand.
[Sinclair, David Andrew] Harvard Med Sch, Dept Genet, Boston, MA USA.
RP Cogger, VC (reprint author), Concord Hosp, ANZAC Res Inst, Gate 3,Hosp Rd, Sydney, NSW 2139, Australia.
EM victoria.cogger@sydney.edu.au
OI de Cabo, Rafael/0000-0002-3354-2442; , rafael/0000-0003-2830-5693
FU Ageing and Alzheimer's Research Foundation; National Institute on Aging,
National Institutes of Health
FX We acknowledge the financial support from the Ageing and Alzheimer's
Research Foundation. This study was funded in part by the National
Institute on Aging, National Institutes of Health, and facilitated by
the Sydney Mass Spectrometry Core Facility (MSCF).
NR 47
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2016
VL 15
IS 4
BP 706
EP 715
DI 10.1111/acel.12481
PG 10
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA DW5WN
UT WOS:000383718400011
PM 27095270
ER
PT J
AU Yaniv, Y
Ahmet, I
Tsutsui, K
Behar, J
Moen, JM
Okamoto, Y
Guiriba, TR
Liu, J
Bychkov, R
Lakatta, EG
AF Yaniv, Yael
Ahmet, Ismayil
Tsutsui, Kenta
Behar, Joachim
Moen, Jack M.
Okamoto, Yosuke
Guiriba, Toni-Rose
Liu, Jie
Bychkov, Rostislav
Lakatta, Edward G.
TI Deterioration of autonomic neuronal receptor signaling and mechanisms
intrinsic to heart pacemaker cells contribute to age-associated
alterations in heart rate variability in vivo
SO AGING CELL
LA English
DT Article
DE autonomic neural impulses; chaotic systems; heart rate variability;
intrinsic heart rate; pacemaker cells; sinoatrial nodal
ID SINOATRIAL NODE; HEALTHY POPULATION; CONDUCTION; DYNAMICS; SYSTEMS;
DEMAND; RABBIT
AB We aimed to determine how age-associated changes in mechanisms extrinsic and intrinsic to pacemaker cells relate to basal beating interval variability (BIV) reduction in vivo. Beating intervals (BIs) were measured in aged (23-25 months) and adult (3-4 months) C57BL/6 male mice (i) via ECG in vivo during light anesthesia in the basal state, or in the presence of 0.5 mg mL(-1) atropine + 1 mg mL(-1) propranolol (in vivo intrinsic conditions), and (ii) via a surface electrogram, in intact isolated pacemaker tissue. BIV was quantified in both time and frequency domains using linear and nonlinear indices. Although the average basal BI did not significantly change with age under intrinsic conditions in vivo and in the intact isolated pacemaker tissue, the average BI was prolonged in advanced age. In vivo basal BIV indices were found to be reduced with age, but this reduction diminished in the intrinsic state. However, in pacemaker tissue BIV indices increased in advanced age vs. adults. In the isolated pacemaker tissue, the sensitivity of the average BI and BIV in response to autonomic receptor stimulation or activation of mechanisms intrinsic to pacemaker cells by broad-spectrum phosphodiesterase inhibition declined in advanced age. Thus, changes in mechanisms intrinsic to pacemaker cells increase the average BIs and BIV in the mice of advanced age. Autonomic neural input to pacemaker tissue compensates for failure of molecular intrinsic mechanisms to preserve average BI. But this compensation reduces the BIV due to both the imbalance of autonomic neural input to the pacemaker cells and altered pacemaker cell responses to neural input.
C1 [Yaniv, Yael; Behar, Joachim] Technion IIT, Biomed Engn Fac, IL-32000003 Haifa, Israel.
[Ahmet, Ismayil; Tsutsui, Kenta; Moen, Jack M.; Okamoto, Yosuke; Guiriba, Toni-Rose; Liu, Jie; Bychkov, Rostislav; Lakatta, Edward G.] NIA, Lab Cardiovasc Sci, Biomed Res Ctr, Intramural Res Program,NIH, Baltimore, MD 21224 USA.
RP Yaniv, Y (reprint author), Technion IIT, Biomed Engn Fac, IL-32000003 Haifa, Israel.; Lakatta, EG (reprint author), NIA, NIH, 251 Bayview Blvd, Baltimore, MD 21224 USA.
EM yaely@bm.technion.ac.il; lakattae@grc.nia.nih.gov
FU Intramural Research Program of the NIH, National Institute on Aging;
Glenn Foundation Cube Award; Technion V.P.R Fund-Mallat Family Research
Fund; Ministry of Science; NSFC-ISF joint research program [398/14]
FX This research was partially supported by the Intramural Research Program
of the NIH, National Institute on Aging, sponsored in part by a Glenn
Foundation Cube Award for research on mechanisms of biologic aging
(E.G.L)., by Technion V.P.R Fund-Mallat Family Research Fund (Y.Y.),
Ministry of Science (Y.Y), and by NSFC-ISF joint research program, No.
398/14 (Y.Y).
NR 38
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD AUG
PY 2016
VL 15
IS 4
BP 716
EP 724
DI 10.1111/acel.12483
PG 9
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA DW5WN
UT WOS:000383718400012
PM 27168363
ER
PT J
AU Scadding, G
Calderon, M
Shamji, MH
Penagos, M
Eifan, A
Phippard, D
Harris, KM
Chani, E
Qin, T
Tchao, N
Togias, A
Bahnson, HT
Sever, ML
Lawson, K
Wurtzen, PA
Durham, SR
AF Scadding, G.
Calderon, M.
Shamji, M. H.
Penagos, M.
Eifan, A.
Phippard, D.
Harris, K. M.
Chani, E.
Qin, T.
Tchao, N.
Togias, A.
HT, Bahnson
Sever, M. L.
Lawson, K.
Wurtzen, P. A.
Durham, S. R.
TI Grass pollen subcutaneous and sublingual immunotherapy inhibit
allergen-induced nasal responses and local Th2 cytokines: a randomised
controlled trial
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Scadding, G.; Calderon, M.; Shamji, M. H.; Penagos, M.; Eifan, A.; Durham, S. R.] Imperial Coll London, Allergy, London, England.
[Phippard, D.; Harris, K. M.; Chani, E.; Qin, T.] Immune Tolerance Network, Bethesda, MD USA.
[Tchao, N.] UCSF, Immune Tolerance Network, San Francisco, CA USA.
[Togias, A.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[HT, Bahnson; Sever, M. L.] Rho Fed Syst Div, Chapel Hill, NC USA.
[Wurtzen, P. A.] Alk Abello, Horsholm, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 2
BP 3
EP 3
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679800003
ER
PT J
AU Koplin, J
Peters, RL
Dharmage, SC
Gurrin, L
Tang, ML
Ponsonby, AL
Matheson, M
Togias, A
Lack, G
Allen, KJ
AF Koplin, J.
Peters, R. L.
Dharmage, S. C.
Gurrin, L.
Tang, M. L.
Ponsonby, A-L
Matheson, M.
Togias, A.
Lack, G.
Allen, K. J.
CA HealthNuts, Study
TI Understanding the feasibility and implications of implementing early
peanut introduction for prevention of peanut allergy
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Koplin, J.; Peters, R. L.; Tang, M. L.; Ponsonby, A-L; Allen, K. J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
[Dharmage, S. C.; Gurrin, L.; Matheson, M.] Univ Melbourne, Sch Populat & Global Hlth, Parkville, Vic, Australia.
[Togias, A.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Lack, G.] Kings Coll London, London, England.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 121
BP 62
EP 62
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679800121
ER
PT J
AU Scadding, G
Calderon, M
Shamji, M
Penagos, M
Eifan, A
Phippard, D
Harris, KM
Tchao, N
Lim, N
Togias, A
Bahnson, HT
Sever, ML
Lawson, K
Durham, SR
AF Scadding, G.
Calderon, M.
Shamji, M.
Penagos, M.
Eifan, A.
Phippard, D.
Harris, K. M.
Tchao, N.
Lim, N.
Togias, A.
Bahnson, H. T.
Sever, M. L.
Lawson, K.
Durham, S. R.
TI Grass pollen subcutaneous immunotherapy results in faster and greater
suppression of allergen-induced skin responses compared to sublingual
immunotherapy: a randomised controlled trial
SO ALLERGY
LA English
DT Meeting Abstract
CT Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology
CY JUN 11-15, 2016
CL Vienna, AUSTRIA
SP European Acad Allergy & Clin Immunol
C1 [Scadding, G.; Calderon, M.; Shamji, M.; Penagos, M.; Eifan, A.; Durham, S. R.] Imperial Coll London, Allergy, London, England.
[Phippard, D.; Harris, K. M.; Lim, N.] Immune Tolerance Network, Bethesda, MD USA.
[Tchao, N.] UCSF, Immune Tolerance Network, San Francisco, CA USA.
[Togias, A.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Bahnson, H. T.; Sever, M. L.; Lawson, K.] Rho Fed Syst Div, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD AUG
PY 2016
VL 71
SU 102
SI SI
MA 333
BP 172
EP 172
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA DW5JI
UT WOS:000383679801141
ER
PT J
AU Gulyani, S
Salas, R
Mari, Z
Choi, S
Mahajan, A
Gamaldo, C
AF Gulyani, S.
Salas, R.
Mari, Z.
Choi, S.
Mahajan, A.
Gamaldo, C.
TI Evaluating and managing sleep disorders in the parkinson's disease
clinic
SO Basal Ganglia
LA English
DT Review
ID RESTLESS LEGS SYNDROME; EXCESSIVE DAYTIME SLEEPINESS; DEEP
BRAIN-STIMULATION; BEHAVIOR DISORDER; REM-SLEEP; PRACTICE PARAMETERS;
DOPAMINE AGONIST; DOUBLE-BLIND; INSOMNIA; TRIAL
AB Parkinson's disease is a multi-systems neurodegenerative disorder that is characterized by a combination of motor and non-motor symptoms. Non-motor symptoms of Parkinson's disease comprise a variety of cognitive, neuropsychiatric, autonomic, sensory, and sleep complaints. Although sleep disruption represents one of the most common non-motor symptom complaints among Parkinson's disease patients, recommendations regarding effective evaluation and management strategies for this specific population remain limited. Published by Elsevier GmbH.
C1 [Gulyani, S.] NIA, Human Neurosci Unit, NIH, Baltimore, MD 21224 USA.
[Salas, R.; Mari, Z.; Choi, S.; Gamaldo, C.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA.
[Mahajan, A.] Henry Ford Hosp, Detroit, MI 48202 USA.
RP Gulyani, S (reprint author), NIA, Human Neurosci Unit, NIH, Baltimore, MD 21224 USA.
EM seema.gulyani@nih.gov
FU Intramural NIH HHS [Z99 AG999999]
NR 77
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2210-5336
EI 2210-5344
J9 BASAL GANGLIA
JI Basal Ganglia
PD AUG
PY 2016
VL 6
IS 3
BP 165
EP 172
DI 10.1016/j.baga.2016.05.001
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA EE3WS
UT WOS:000389532300008
PM 27818912
ER
PT J
AU Williams, PM
Conley, BA
AF Williams, P. Mickey
Conley, Barbara A.
TI Clinical Application of Liquid Biopsies
SO JAMA ONCOLOGY
LA English
DT Editorial Material
ID LUNG-CANCER
C1 [Williams, P. Mickey] Frederick Natl Lab Canc Res, Charter Mol Genet Lab, Mol Characterizat Lab, Federick, MA USA.
[Conley, Barbara A.] NCI, Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Conley, BA (reprint author), NIH, 9609 Med Ctr Dr, Room 4W426,MSC 9730, Bethesda, MD 20892 USA.
EM conleyba@mail.nih.gov
NR 8
TC 2
Z9 2
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD AUG
PY 2016
VL 2
IS 8
BP 1003
EP 1005
DI 10.1001/jamaoncol.2016.0240
PG 4
WC Oncology
SC Oncology
GA DW5RN
UT WOS:000383704700008
PM 27054513
ER
PT J
AU Freedman, DM
Pfeiffer, RM
AF Freedman, D. Michal
Pfeiffer, Ruth M.
TI Associations Between Parkinson Disease and Cancer in US Asian Americans
SO JAMA ONCOLOGY
LA English
DT Letter
ID TAIWAN; RISK
C1 [Freedman, D. Michal; Pfeiffer, Ruth M.] NCI, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr 7E538, Rockville, MD 20850 USA.
RP Freedman, DM (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr 7E538, Rockville, MD 20850 USA.
EM freedmam@mail.nih.gov
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD AUG
PY 2016
VL 2
IS 8
BP 1093
EP 1094
DI 10.1001/jamaoncol.2016.0729
PG 2
WC Oncology
SC Oncology
GA DW5RN
UT WOS:000383704700024
PM 27196082
ER
PT J
AU Mirigian, LS
Makareeva, E
Mertz, EL
Omari, S
Roberts-Pilgrim, AM
Oestreich, AK
Phillips, CL
Leikin, S
AF Mirigian, Lynn S.
Makareeva, Elena
Mertz, Edward L.
Omari, Shakib
Roberts-Pilgrim, Anna M.
Oestreich, Arin K.
Phillips, Charlotte L.
Leikin, Sergey
TI Osteoblast Malfunction Caused by Cell Stress Response to Procollagen
Misfolding in alpha 2(I)-G610C Mouse Model of Osteogenesis Imperfecta
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOGENESIS IMPERFECTA; PROCOLLAGEN; OSTEOBLAST; AUTOPHAGY; CELL STRESS
ID COLLAGEN TRIPLE-HELIX; GROWTH-FACTOR-BETA; I COLLAGEN;
EXTRACELLULAR-MATRIX; ENDOPLASMIC-RETICULUM; BONE; MUTATIONS; MECHANISM;
AUTOPHAGY; CULTURES
AB Glycine (Gly) substitutions in collagen Gly-X-Y repeats disrupt folding of type I procollagen triple helix and cause severe bone fragility and malformations (osteogenesis imperfecta [OI]). However, these mutations do not elicit the expected endoplasmic reticulum (ER) stress response, in contrast to other protein-folding diseases. Thus, it has remained unclear whether cell stress and osteoblast malfunction contribute to the bone pathology caused by Gly substitutions. Here we used a mouse with a Gly610 to cysteine (Cys) substitution in the procollagen alpha 2(I) chain to show that misfolded procollagen accumulation in the ER leads to an unusual form of cell stress, which is neither a conventional unfolded protein response (UPR) nor ER overload. Despite pronounced ER dilation, there is no upregulation of binding immunoglobulin protein (BIP) expected in the UPR and no activation of NF-kappa B signaling expected in the ER overload. Altered expression of ER chaperones alpha B crystalline and HSP47, phosphorylation of EIF2 alpha, activation of autophagy, upregulation of general stress response protein CHOP, and osteoblast malfunction reveal some other adaptive response to the ER disruption. We show how this response alters differentiation and function of osteoblasts in culture and in vivo. We demonstrate that bone matrix deposition by cultured osteoblasts is rescued by activation of misfolded procollagen autophagy, suggesting a new therapeutic strategy for OI. (C) 2016 American Society for Bone and Mineral Research.
C1 [Mirigian, Lynn S.; Makareeva, Elena; Mertz, Edward L.; Omari, Shakib; Roberts-Pilgrim, Anna M.; Leikin, Sergey] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Phys Biochem, NIH, Bethesda, MD USA.
[Mirigian, Lynn S.] Univ Texas Med Branch, Dept Cell Biol, Galveston, TX 77555 USA.
[Oestreich, Arin K.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.
[Phillips, Charlotte L.] Univ Missouri, Dept Biochem, Columbia, MO USA.
RP Leikin, S (reprint author), NIH, Bldg 9,Room 1E-127, Bethesda, MD 20892 USA.
EM leikins@mail.nih.gov
RI Leikin, Sergey/A-5518-2008
OI Leikin, Sergey/0000-0001-7095-0739
FU NICHD
FX This work was funded in part by the Intramural Research Program of
NICHD. Electron microscopy was performed at the NICHD Microscopy and
Imaging core with the assistance of Dr Louis (Chip) Dye.
NR 38
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2016
VL 31
IS 8
BP 1608
EP 1616
DI 10.1002/jbmr.2824
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DW5WC
UT WOS:000383717200017
PM 26925839
ER
PT J
AU Daviglus, ML
Pirzada, A
Durazo-Arvizu, R
Chen, JS
Allison, M
Aviles-Santa, L
Cai, JW
Gonzalez, HM
Kaplan, RC
Schneiderman, N
Sorlie, PD
Talavera, GA
Wassertheil-Smoller, S
Stamler, J
AF Daviglus, Martha L.
Pirzada, Amber
Durazo-Arvizu, Ramon
Chen, Jinsong
Allison, Matthew
Aviles-Santa, Larissa
Cai, Jianwen
Gonzalez, Hector M.
Kaplan, Robert C.
Schneiderman, Neil
Sorlie, Paul D.
Talavera, Gregory A.
Wassertheil-Smoller, Sylvia
Stamler, Jeremiah
TI Prevalence of Low Cardiovascular Risk Profile Among Diverse
Hispanic/Latino Adults in the United States by Age, Sex, and Level of
Acculturation: The Hispanic Community Health Study/Study of Latinos
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE cardiovascular disease prevention; cardiovascular disease risk factors;
low risk
ID MEXICAN-AMERICANS; MIDDLE-AGE; DISEASE PREVENTION; MEDICARE COSTS;
HEART-DISEASE; MORTALITY; LIFE; WOMEN; PARADOX; DESIGN
AB Background-Favorable levels of all readily measurable major cardiovascular disease risk factors (ie, low risk [LR]) are associated with lower risks of cardiovascular disease morbidity and mortality. Data are not available on LR prevalence among Hispanic/Latino adults of diverse ethnic backgrounds. This study aimed to describe the prevalence of a low cardiovascular disease risk profile among Hispanic/Latino adults in the United States and to examine cross-sectional associations of LR with measures of acculturation.
Methods and Results-The multicenter, prospective, population-based Hispanic Community Health Study/Study of Latinos examined 16 415 men and women aged 18 to 74 years at baseline (2008-2011) with diverse Hispanic/Latino backgrounds. Analyses involved 14 757 adults (mean age 41.3 years; 60.6% women). LR was defined using national guidelines for favorable levels of serum cholesterol, blood pressure, and body mass index and by not having diabetes mellitus and not currently smoking. Age-adjusted LR prevalence was low (8.4% overall; 5.1% for men, 11.2% for women) and varied by background (4.2% in men of Mexican heritage versus 15.0% in women of Cuban heritage). Lower acculturation (assessed using proxy measures) was significantly associated with higher odds of a LR profile among women only: Age-adjusted odds ratios of having LR were 1.64 (95% CI 1.24-2.17) for foreign-born versus US-born women and 1.96 (95% CI 1.49-2.58) for women residing in the United States <10 versus >= 10 years.
Conclusions-Among diverse US Hispanic/Latino adults, the prevalence of a LR profile is low. Lower acculturation is associated with higher odds of a LR profile among women but not men. Comprehensive public health strategies are needed to improve the cardiovascular health of US Hispanic/Latino adults.
C1 [Daviglus, Martha L.; Pirzada, Amber; Durazo-Arvizu, Ramon; Chen, Jinsong] Univ Illinois, Inst Minor Hlth Res, 1819 W Polk St,Suite 246, Chicago, IL 60612 USA.
[Daviglus, Martha L.; Chen, Jinsong] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA.
[Durazo-Arvizu, Ramon] Loyola Univ, Dept Publ Hlth Sci, Chicago, IL 60611 USA.
[Allison, Matthew] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Aviles-Santa, Larissa; Sorlie, Paul D.] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Chen, Jinsong] Univ N Carolina, Collaborat Studies Coordinating Ctr, Dept Biostat, Chapel Hill, NC USA.
[Gonzalez, Hector M.] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
[Kaplan, Robert C.; Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, Dept Epidemiol & Biostat, Bronx, NY 10467 USA.
[Schneiderman, Neil] Univ Miami, Behav Med Res Ctr, Dept Psychol, Coral Gables, FL 33124 USA.
[Talavera, Gregory A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA.
RP Daviglus, ML (reprint author), Univ Illinois, Inst Minor Hlth Res, 1819 W Polk St,Suite 246, Chicago, IL 60612 USA.
EM daviglus@uic.edu
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC65233,
N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237]; National Center on
Minority Health and Health Disparities; National Institute of Deafness
and Other Communications Disorders; National Institute of Dental and
Craniofacial Research; National Institute of Diabetes and Digestive and
Kidney Diseases; National Institute of Neurological Disorders and
Stroke; Office of Dietary Supplements
FX The Hispanic Community Health Study/Study of Latinos was carried out as
a collaborative study supported by contracts from the National Heart,
Lung, and Blood Institute (NHLBI) to the University of North Carolina
(N01-HC65233), University of Miami (N01-HC65234), Albert Einstein
College of Medicine (N01-HC65235), Northwestern University
(N01-HC65236), and San Diego State University (N01-HC65237). The
following Institutes/Centers/Offices contribute to the HCHS/SOL through
a transfer of funds to the NHLBI: National Center on Minority Health and
Health Disparities, the National Institute of Deafness and Other
Communications Disorders, the National Institute of Dental and
Craniofacial Research, the National Institute of Diabetes and Digestive
and Kidney Diseases, the National Institute of Neurological Disorders
and Stroke, and the Office of Dietary Supplements.
NR 34
TC 1
Z9 1
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD AUG
PY 2016
VL 5
IS 8
AR e003929
DI 10.1161/JAHA.116.003929
PG 19
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EA6DE
UT WOS:000386714900043
ER
PT J
AU Nikitskaya, E
Lebedeva, A
Ivanova, O
Maryukhnich, E
Shpektor, A
Grivel, JC
Margolis, L
Vasilieva, E
AF Nikitskaya, Elizaveta
Lebedeva, Anna
Ivanova, Oxana
Maryukhnich, Elena
Shpektor, Alexander
Grivel, Jean-Charles
Margolis, Leonid
Vasilieva, Elena
TI Cytomegalovirus-Productive Infection Is Associated With Acute Coronary
Syndrome
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE acute coronary syndrome; atherosclerosis; human herpesvirus; immune
system; myocardial infarction; polymerase chain reaction; virus
ID HERPES-SIMPLEX-VIRUS; C-REACTIVE PROTEIN; TIME PCR ASSAY; T-CELLS;
MYOCARDIAL-INFARCTION; HEART-DISEASE; CARDIOVASCULAR-DISEASE;
ARTERY-DISEASE; ESC GUIDELINES; RISK-FACTOR
AB Background-Although an association between human herpesvirus (HHV) infection and atherosclerosis has been suggested, the data supporting such an association are controversial and, in most cases, are based on serological evidence or on the presence of cell-associated HHV DNA, which do not report about actual viral replication. We quantified the DNA of all 8 types of HHVs in plasma, in which their presence is evidence of viral replication.
Methods and Results-Using quantitative real-time polymerase chain reaction, we evaluated the presence of HHV DNA in blood samples obtained at the time of hospitalization from 71 patients with acute coronary syndrome, 26 patients with stable coronary artery disease, and 53 healthy volunteers and in atherosclerotic plaques of 22 patients with peripheral artery disease who underwent endarterectomy. HHV-5 (cytomegalovirus [CMV]) was the only HHV with a level that was higher in acute coronary syndrome patients than in the control group and that correlated with the level of high-sensitivity C-reactive protein. The numbers of effector memory T cells positively correlated with the numbers of CMV genome copies in carotid arteries plaques, whereas the numbers of central memory T cells negatively correlated with CMV copy numbers.
Conclusions-Of all HHV levels, only CMV was higher in patients with stable coronary artery disease and acute coronary syndrome than in the healthy group, and its load correlated with the level of high-sensitivity C-reactive protein. The level of CMV in atherosclerotic plaques correlated with the state of immunoactivation of lymphocytes in plaques, suggesting that the reactivation of CMV may contribute to the immune activation associated with the progression of atherosclerosis.
C1 [Lebedeva, Anna; Grivel, Jean-Charles; Margolis, Leonid] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Intercellular Interact, NIH, Bethesda, MD USA.
[Nikitskaya, Elizaveta; Lebedeva, Anna; Ivanova, Oxana; Maryukhnich, Elena; Shpektor, Alexander; Vasilieva, Elena] Moscow State Univ Med & Dent, Lab Atherothrombosis, Dept Cardiol, 11 Yauzskaya St, Moscow 109240, Russia.
RP Lebedeva, A (reprint author), Moscow State Univ Med & Dent, Lab Atherothrombosis, Dept Cardiol, 11 Yauzskaya St, Moscow 109240, Russia.; Margolis, L (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA.
EM asisiajka@gmail.com; margolil@mail.nih.govand
OI Ivanova, Oxana/0000-0002-8477-9706
FU Russian Federation Government grant [14.B25.31.0016]; Intramural Program
of National Institute of Child Health and Human Development
FX This work of Nikitskaya, Lebedeva, Ivanova, Maryukhnich, Shpektor, and
Vasilieva was supported by Russian Federation Government grant
#14.B25.31.0016. The work of Margolis and Grivel was supported by the
Intramural Program of National Institute of Child Health and Human
Development.
NR 50
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD AUG
PY 2016
VL 5
IS 8
AR e003759
DI 10.1161/JAHA.116.003759
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EA6DE
UT WOS:000386714900030
ER
PT J
AU Phelps, DL
Ward, RM
Williams, RL
Nolen, TL
Watterberg, KL
Oh, W
Goedecke, M
Ehrenkranz, RA
Fennell, T
Poindexter, BB
Cotten, CM
Hallman, M
Frantz, ID
Faix, RG
Zaterka-Baxter, KM
Das, A
Ball, MB
Lacy, CB
Walsh, MC
Carlo, WA
Sanchez, PJ
Bell, EF
Shankaran, S
Carlton, DP
Chess, PR
Higgins, RD
AF Phelps, Dale L.
Ward, Robert M.
Williams, Rick L.
Nolen, Tracy L.
Watterberg, Kristi L.
Oh, William
Goedecke, Michael
Ehrenkranz, Richard A.
Fennell, Timothy
Poindexter, Brenda B.
Cotten, C. Michael
Hallman, Mikko
Frantz, Ivan D., III
Faix, Roger G.
Zaterka-Baxter, Kristin M.
Das, Abhik
Ball, M. Bethany
Lacy, Conra Backstrom
Walsh, Michele C.
Carlo, Waldemar A.
Sanchez, Pablo J.
Bell, Edward F.
Shankaran, Seetha
Carlton, David P.
Chess, Patricia R.
Higgins, Rosemary D.
CA Eunice Kennedy Shriver Natl Inst
Human Dev Neonatal Res Network
TI Safety and pharmacokinetics of multiple dose myo-inositol in preterm
infants
SO PEDIATRIC RESEARCH
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; INOSITOL SUPPLEMENTATION; PREMATURITY;
RETINOPATHY
AB Background: Preterm infants with respiratory distress syndrome (RDS) given inositol had reduced bronchopulmonary dysplasia (BPD), death and severe retinopathy of prematurity (ROP). We assessed the safety and pharmacokinetics of daily inositol to select a dose providing serum levels previously associated with benefit, and to learn if accumulation occurred when administered throughout the normal period of retinal vascularization.
Methods: Infants <= 29 wk GA (n = 122, 14 centers) were randomized and treated with placebo or inositol at 10, 40, or 80 mg/kg/d. Intravenous administration converted to enteral when feedings were established, and continued to the first of 10 wk, 34 wk postmenstrual age (PMA) or discharge. Serum collection employed a sparse sampling population pharmacokinetics design. Inositol urine losses and feeding intakes were measured. Safety was prospectively monitored.
Results: At 80 mg/kg/d mean serum levels reached 140 mg/l, similar to Hallman's findings. Levels declined after 2 wk, converging in all groups by 6 wk. Analyses showed a mean volume of distribution 0.657 l/kg, clearance 0.058 l/kg/h, and half-life 7.90 h. Adverse events and comorbidities were fewer in the inositol groups, but not significantly so.
Conclusion: Multiple dose inositol at 80 mg/kg/d was not associated with increased adverse events, achieves previously effective serum levels, and is appropriate for investigation in a phase III trial.
C1 [Phelps, Dale L.; Chess, Patricia R.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA.
[Ward, Robert M.; Faix, Roger G.] Univ Utah, Sch Med, Dept Pediat & Pediat Pharmacol, Salt Lake City, UT USA.
[Williams, Rick L.; Nolen, Tracy L.; Goedecke, Michael; Zaterka-Baxter, Kristin M.] RTI Int, Social Stat & Environm Sci Unit, Res Triangle Pk, NC USA.
[Watterberg, Kristi L.; Lacy, Conra Backstrom] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
[Oh, William] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA.
[Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
[Fennell, Timothy] RTI Int, Pharmacol & Toxicol Div, Res Triangle Pk, NC USA.
[Poindexter, Brenda B.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
[Cotten, C. Michael] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
[Hallman, Mikko] PEDEGO Res Ctr, Oulu, Finland.
[Hallman, Mikko] MRC Oulu, Oulu, Finland.
[Hallman, Mikko] Oulu Univ Hosp, Oulu, Finland.
[Frantz, Ivan D., III] Floating Hosp Children, Tufts Med Ctr, Dept Pediat, Boston, MA USA.
[Das, Abhik] RTI Int, Social Stat & Environm Sci Unit, Rockville, MD USA.
[Ball, M. Bethany] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA.
[Ball, M. Bethany] Lucile Packard Childrens Hosp, Palo Alto, CA USA.
[Walsh, Michele C.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA.
[Carlo, Waldemar A.] Univ Alabama Birmingham, Div Neonatol, Dept Pediat, Birmingham, AL USA.
[Sanchez, Pablo J.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA.
[Bell, Edward F.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
[Shankaran, Seetha] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA.
[Carlton, David P.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
[Carlton, David P.] Childrens Healthcare Atlanta, Atlanta, GA USA.
[Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Phelps, DL (reprint author), Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA.
EM dale_phelps@urmc.rochester.edu
OI Hallman, Mikko/0000-0002-8172-729X
FU National Eye Institute; National Center for Research Resources; National
Center for Advancing Translational Sciences, Bethesda, MD, USA; Alpert
Medical School of Brown University and Women & Infants Hospital of Rhode
Island [U10 HD27904]; Case Western Reserve University, Rainbow Babies &
Children's Hospital [U10 HD21364, M01 RR80]; Duke University School of
Medicine, University Hospital [U10 HD40492, M01 RR30]; Durham Regional
Hospital [U10 HD40492, M01 RR30]; Emory University, Children's
Healthcare of Atlanta [U10 HD27851, M01 RR39, UL1 TR454]; Grady Memorial
Hospital [U10 HD27851, M01 RR39, UL1 TR454]; Emory University Hospital
Midtown [U10 HD27851, M01 RR39, UL1 TR454]; Wishard Health Services [U10
HD27856, M01 RR750]; Stanford University [U10 HD27880]; Tufts Medical
Center, Floating Hospital for Children [U10 HD53119, M01 RR54];
University of Alabama at Birmingham Health System and Children's
Hospital of Alabama [U10 HD34216, M01 RR32]; University of Iowa [U10
HD53109, M01 RR59, UL1 TR442]; University of New Mexico Health Sciences
Center [U10 HD53089, M01 RR997]; University of Rochester Medical Center,
Golisano Children's Hospital [U10 HD40521, M01 RR44]; Children's Medical
Center Dallas [U10 HD40689, M01 RR633]; Primary Children's Medical
Center [U10 HD53124, U10 HD45986, M01 RR64]; Children's Hospital of
Michigan [U10 HD21385, U10 HD37261]; Yale University, Yale-New Haven
Children's Hospital [U10 HD27871, UL1 RR24139, M01 RR125]
FX The National Institutes of Health and the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD)
Neonatal Research Network and the Pediatric Pharmacology Research Units
Network, with cofunding from the National Eye Institute provided grant
support for this trial, with additional support from the National Center
for Research Resources, and the National Center for Advancing
Translational Sciences, Bethesda, MD, USA. The following NRNetwork
Centers and Institutions (with grant numbers) participated in the
Inositol Multidose Study: Alpert Medical School of Brown University and
Women & Infants Hospital of Rhode Island (U10 HD27904); Case Western
Reserve University, Rainbow Babies & Children's Hospital (U10 HD21364,
M01 RR80); Duke University School of Medicine, University Hospital, and
Durham Regional Hospital (U10 HD40492, M01 RR30); Emory University,
Children's Healthcare of Atlanta, Grady Memorial Hospital, and Emory
University Hospital Midtown (U10 HD27851, M01 RR39, and UL1 TR454);
Indiana University, University Hospital, Methodist Hospital, Riley
Hospital for Children at Indiana University Health, and Wishard Health
Services (U10 HD27856, M01 RR750); Stanford University (U10 HD27880);
Tufts Medical Center, Floating Hospital for Children (U10 HD53119, M01
RR54); University of Alabama at Birmingham Health System and Children's
Hospital of Alabama (U10 HD34216, M01 RR32); University of Iowa (U10
HD53109, M01 RR59, UL1 TR442); University of New Mexico Health Sciences
Center (U10 HD53089, M01 RR997); University of Rochester Medical Center,
Golisano Children's Hospital (U10 HD40521, M01 RR44); University of
Texas Southwestern Medical Center, Parkland Health & Hospital System,
and Children's Medical Center Dallas (U10 HD40689, M01 RR633);
University of Utah Medical Center, Intermountain Medical Center, LDS
Hospital, and Primary Children's Medical Center (U10 HD53124, U10
HD45986, and M01 RR64); Wayne State University, Hutzel Women's Hospital
and Children's Hospital of Michigan (U10 HD21385, U10 HD37261); Yale
University, Yale-New Haven Children's Hospital (U10 HD27871, UL1
RR24139, M01 RR125).
NR 25
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD AUG
PY 2016
VL 80
IS 2
BP 209
EP 217
DI 10.1038/pr.2016.97
PG 9
WC Pediatrics
SC Pediatrics
GA EA6EO
UT WOS:000386719200008
PM 27074126
ER
PT J
AU Cole-Lewis, H
Perotte, A
Galica, K
Dreyer, L
Griffith, C
Schwarz, M
Yun, C
Patrick, H
Coa, K
Augustson, E
AF Cole-Lewis, Heather
Perotte, Adler
Galica, Kasia
Dreyer, Lindy
Griffith, Christopher
Schwarz, Mary
Yun, Christopher
Patrick, Heather
Coa, Kisha
Augustson, Erik
TI Social Network Behavior and Engagement Within a Smoking Cessation
Facebook Page
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE social network analysis; smoking cessation; Facebook; social support;
Web-based communities; social media; communication
ID INTERVENTIONS; SITES
AB Background: Social media platforms are increasingly being used to support individuals in behavior change attempts, including smoking cessation. Examining the interactions of participants in health-related social media groups can help inform our understanding of how these groups can best be leveraged to facilitate behavior change.
Objective: The aim of this study was to analyze patterns of participation, self-reported smoking cessation length, and interactions within the National Cancer Institutes' Facebook community for smoking cessation support.
Methods: Our sample consisted of approximately 4243 individuals who interacted (eg, posted, commented) on the public Smokefree Women Facebook page during the time of data collection. In Phase 1, social network visualizations and centrality measures were used to evaluate network structure and engagement. In Phase 2, an inductive, thematic qualitative content analysis was conducted with a subsample of 500 individuals, and correlational analysis was used to determine how participant engagement was associated with self-reported session length.
Results: Between February 2013 and March 2014, there were 875 posts and 4088 comments from approximately 4243 participants. Social network visualizations revealed the moderator's role in keeping the community together and distributing the most active participants. Correlation analyses suggest that engagement in the network was significantly inversely associated with cessation status (Spearman correlation coefficient = -0.14, P=.03, N=243). The content analysis of 1698 posts from 500 randomly selected participants identified the most frequent interactions in the community as providing support (43%, n=721) and announcing number of days smoke free (41%, n=689).
Conclusions: These findings highlight the importance of the moderator for network engagement and provide helpful insights into the patterns and types of interactions participants are engaging in. This study adds knowledge of how the social network of a smoking cessation community behaves within the confines of a Facebook group.
C1 [Cole-Lewis, Heather; Galica, Kasia; Coa, Kisha] ICF Int, Rockville, MD USA.
[Perotte, Adler] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY USA.
[Dreyer, Lindy] ICF Int, Washington, DC USA.
[Griffith, Christopher; Schwarz, Mary; Yun, Christopher] ICF Int, Fairfax, VA USA.
[Patrick, Heather] Envolve PeopleCare, Appl Behav Change Sci Sci & Prod, Bethesda, MD USA.
[Augustson, Erik] NCI, Tobacco Control Res Branch, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
RP Augustson, E (reprint author), NCI, Tobacco Control Res Branch, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
EM augustse@mail.nih.gov
OI Coa, Kisha/0000-0001-5637-259X
NR 19
TC 0
Z9 0
U1 11
U2 11
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD AUG
PY 2016
VL 18
IS 8
AR e205
DI 10.2196/jmir.5574
PG 11
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA EC9WT
UT WOS:000388495700014
PM 27485315
ER
PT J
AU Fothergill, E
Guo, JE
Howard, L
Kerns, JC
Knuth, ND
Brychta, R
Chen, KY
Skarulis, MC
Walter, M
Walter, PJ
Hall, KD
AF Fothergill, Erin
Guo, Juen
Howard, Lilian
Kerns, Jennifer C.
Knuth, Nicolas D.
Brychta, Robert
Chen, Kong Y.
Skarulis, Monica C.
Walter, Mary
Walter, Peter J.
Hall, Kevin D.
TI Persistent Metabolic Adaptation 6 Years After "The Biggest Loser"
Competition
SO OBESITY
LA English
DT Article
ID RESTING ENERGY-EXPENDITURE; MASSIVE WEIGHT-LOSS; FAT-FREE MASS; ADAPTIVE
THERMOGENESIS; BODY-COMPOSITION; OBESE WOMEN; INDIVIDUALS; HUMANS;
REGAIN; ASSOCIATION
AB Objective: To measure long-term changes in resting metabolic rate (RMR) and body composition in participants of "The Biggest Loser" competition.
Methods: Body composition was measured by dual energy X-ray absorptiometry, and RMR was determined by indirect calorimetry at baseline, at the end of the 30-week competition and 6 years later. Metabolic adaptation was defined as the residual RMR after adjusting for changes in body composition and age.
Results: Of the 16 "Biggest Loser" competitors originally investigated, 14 participated in this follow-up study. Weight loss at the end of the competition was (mean +/- SD) 58.3 +/- 24.9 kg (P < 0.0001), and RMR decreased by 610 +/- 483 kcal/day (P = 0.0004). After 6 years, 41.0 +/- 31.3 kg of the lost weight was regained (P = 0.0002), while RMR was 704 +/- 427 kcal/day below baseline (P < 0.0001) and metabolic adaptation was -499 +/- 207 kcal/day (P < 0.0001). Weight regain was not significantly correlated with metabolic adaptation at the competition's end (r = 20.1, P = 0.75), but those subjects maintaining greater weight loss at 6 years also experienced greater concurrent metabolic slowing (r = 0.59, P = 0.025).
Conclusions: Metabolic adaptation persists over time and is likely a proportional, but incomplete, response to contemporaneous efforts to reduce body weight.
C1 [Fothergill, Erin; Guo, Juen; Howard, Lilian; Brychta, Robert; Chen, Kong Y.; Skarulis, Monica C.; Walter, Mary; Walter, Peter J.; Hall, Kevin D.] NIDDK, NIH, Bethesda, MD 20892 USA.
[Kerns, Jennifer C.] Washington DC Vet Affairs Med Ctr, Hospitalist Sect, Washington, DC USA.
[Knuth, Nicolas D.] Towson Univ, Dept Kinesiol, Baltimore, MD USA.
RP Hall, KD (reprint author), NIDDK, NIH, Bethesda, MD 20892 USA.
EM kevinh@niddk.nih.gov
OI Chen, Kong/0000-0002-0306-1904
FU Intramural Research Program of the NIH, National Institute of Diabetes
and Digestive and Kidney Diseases
FX This research was supported by the Intramural Research Program of the
NIH, National Institute of Diabetes and Digestive and Kidney Diseases.
NR 38
TC 28
Z9 28
U1 5
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD AUG
PY 2016
VL 24
IS 8
BP 1612
EP 1619
DI 10.1002/oby.21538
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EC6VP
UT WOS:000388275100004
PM 27136388
ER
PT J
AU Keadle, SK
McKinnon, R
Graubard, BI
Troiano, RP
AF Keadle, Sarah Kozey
McKinnon, Robin
Graubard, Barry I.
Troiano, Richard P.
TI Prevalence and trends in physical activity among older adults in the
United States: A comparison across three national surveys
SO PREVENTIVE MEDICINE
LA English
DT Article
ID SEDENTARY BEHAVIORS; TIME SPENT; US ADULTS; ACCELEROMETER
AB This paper examined how many older adults (65 + years) are meeting physical activity (PA) Guidelines (PAG; 150 min/week of moderate-to-vigorous PA) using data from three leading national surveys (NHANES, BRFSS and NHIS). The proportion of individuals meeting aerobic PAG was determined for the most recent cycle available for each survey (NHANES 2011-12, NHIS and BRFSS 2013). We also assessed whether PAG adherence has changed over time. Predicted margins from multinomial logistic regression were computed after adjusting for age, race/ethnicity and gender and sample weights. The proportion of older adults meeting PAG was 27.3% for NHANES, 35.8% for NHIS and 44.3% for BRFSS. Across all surveys, men reported higher levels of activity than women, Non-Hispanic whites reported higher levels than Non-Hispanic blacks and Hispanics, activity declined with age and was lower in those with functional limitations, all P < 0.05. The proportion of older adults meeting PAG in the NHIS survey, the only survey where PA questions remained the same over time, increased from 25.7% in 1998 to 35.8% in 2013 (P < 0.01). Point-estimates for activity levels are different between surveys but they consistently identify sub-groups who are less active. Although older adults are reporting more activity over time, adherence to aerobic and strength training PAG remains low in this population and there is a need for effective interventions to prevent age-related declines in PA and address health disparities among older adults. Published by Elsevier Inc.
C1 [Keadle, Sarah Kozey] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Keadle, Sarah Kozey] NCI, Canc Prevent Fellowship Program, Canc Prevent Div, Bethesda, MD 20892 USA.
[McKinnon, Robin; Troiano, Richard P.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[McKinnon, Robin] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA.
[Graubard, Barry I.] NCI, Biostat Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Keadle, SK (reprint author), NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.; Keadle, SK (reprint author), NCI, Canc Prevent Fellowship Program, Canc Prevent Div, Bethesda, MD 20892 USA.
EM Sarah.keadle@nih.gov
FU Intramural Research Program at National Cancer Institute
FX The authors would like to thank Lisa Kahle for her programming
assistance. This work is funded in part by the Intramural Research
Program at the National Cancer Institute.
NR 28
TC 2
Z9 2
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD AUG
PY 2016
VL 89
BP 37
EP 43
DI 10.1016/j.ypmed.2016.05.009
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA EC7KJ
UT WOS:000388316700006
PM 27196146
ER
PT J
AU Tota, JE
Isidean, SD
Franco, EL
AF Tota, Joseph E.
Isidean, Sandra D.
Franco, Eduardo L.
TI Should we lower the age for routine HPV vaccination in the United
States?
SO PREVENTIVE MEDICINE
LA English
DT Editorial Material
DE Human papillomavirus; Vaccination; Age
ID HPV-16/18 AS04-ADJUVANTED VACCINE; HUMAN-PAPILLOMAVIRUS VACCINE;
IMMUNIZATION PRACTICES ACIP; INTRAEPITHELIAL NEOPLASIA;
ADVISORY-COMMITTEE; QUADRIVALENT VACCINE; SUSTAINED EFFICACY; LONG-TERM;
FOLLOW-UP; RECOMMENDATIONS
C1 [Tota, Joseph E.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Tota, Joseph E.; Isidean, Sandra D.; Franco, Eduardo L.] McGill Univ, Div Canc Epidemiol, Montreal, PQ, Canada.
RP Tota, JE (reprint author), NCI, Div Canc Epidemiol & Genet, Infect & Immunoepidemiol Branch, 9609 Med Ctr Dr,Room 6E228, Rockville, MD 20850 USA.
EM joseph.tota@nih.gov
OI Franco, Eduardo/0000-0002-4409-8084
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD AUG
PY 2016
VL 89
BP 334
EP 336
DI 10.1016/j.ypmed.2016.05.027
PG 3
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA EC7KJ
UT WOS:000388316700045
PM 27240451
ER
PT J
AU Cucinotta, FA
Hamada, N
Little, MP
AF Cucinotta, Francis A.
Hamada, Nobuyuki
Little, Mark P.
TI No evidence for an increase in circulatory disease mortality in
astronauts following space radiation exposures
SO LIFE SCIENCES IN SPACE RESEARCH
LA English
DT Editorial Material
DE Space radiation; Apollo missions; Cardiovascular disease; Circulatory
disease; Astronauts; Galactic cosmic rays; Healthy worker effects
ID CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK; MODELS; COHORT
AB Previous analysis has shown that astronauts have a significantly lower standardized mortality ratio for circulatory disease mortality compared to the U.S. population, which is consistent with the rigorous selection process and healthy lifestyles of astronauts, and modest space radiation exposures from past space missions. However, a recent report by Delp et al. estimated the proportional mortality ratio for ages of 55-64 y of Apollo lunar mission astronauts to claim a high risk of cardiovascular disease due to space radiation compared to the U.S. population or to non-flight astronauts. In this Commentary we discuss important deficiencies in the methods and assumptions on radiation exposures used by Delp et al. that we judge cast serious doubt on their conclusions. (C) 2016 The Committee on Space Research (COSPAR). Published by Elsevier Ltd. All rights reserved.
C1 [Cucinotta, Francis A.] Univ Nevada, Dept Diagnost Sci & Hlth Phys, Box 453037, Las Vegas, NV 89154 USA.
[Hamada, Nobuyuki] CRIEPI, Nucl Technol Res Lab, Radiat Safety Res Ctr, 2-11-1 Iwado Kita, Komae, Tokyo 2018511, Japan.
[Little, Mark P.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, HHS, 9609 Med Ctr Dr, Bethesda, MD 20892 USA.
RP Cucinotta, FA (reprint author), Univ Nevada, Dept Diagnost Sci & Hlth Phys, Box 453037, Las Vegas, NV 89154 USA.
EM francis.cucinotta@unlv.edu
NR 27
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2214-5524
EI 2214-5532
J9 LIFE SCI SPACE RES
JI Life Sci. Space Res.
PD AUG
PY 2016
VL 10
BP 53
EP 56
DI 10.1016/j.lssr.2016.08.002
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC3GU
UT WOS:000388015100007
PM 27662788
ER
PT J
AU Schiller, JT
AF Schiller, John T.
TI The Potential Benefits of HPV Vaccination in Previously Infected Women
SO EBIOMEDICINE
LA English
DT Editorial Material
ID HUMAN-PAPILLOMAVIRUS; MEMORY B; ANTIBODIES; RESPONSES
C1 [Schiller, John T.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Schiller, JT (reprint author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM Schillej@mail.nih.gov
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2016
VL 10
BP 5
EP 6
DI 10.1016/j.ebiom.2016.08.005
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA8IE
UT WOS:000386877700003
PM 27515688
ER
PT J
AU Cimbro, R
Peterson, FC
Liu, QB
Guzzo, C
Zhang, P
Miao, HY
Van Ryk, D
Ambroggio, X
Hurt, DE
De Gioia, L
Volkman, BF
Dolan, MA
Lusso, P
AF Cimbro, Raffaello
Peterson, Francis C.
Liu, Qingbo
Guzzo, Christina
Zhang, Peng
Miao, Huiyi
Van Ryk, Donald
Ambroggio, Xavier
Hurt, Darrell E.
De Gioia, Luca
Volkman, Brian F.
Dolan, Michael A.
Lusso, Paolo
TI Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor
mimicry
SO EBIOMEDICINE
LA English
DT Article
DE HIV-1; Envelope; Trimer; Coreceptors; Molecular mimicry; Peptides;
Inhibitors; Immune evasion
ID GP120 ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; CRYOELECTRON
MICROSCOPY; STRUCTURAL BASIS; VARIABLE LOOPS; V1/V2 DOMAIN; N-TERMINUS;
CD4; RECOGNITION; TRIMER
AB Tyrosine sulfation is a post-translational modification that facilitates protein-protein interaction. Two sulfated tyrosines (Tys173 and Tys177) were recently identified within the second variable (V2) loop of the major HIV-1 envelope glycoprotein, gp120, and shown to contribute to stabilizing the intramolecular interaction between V2 and the third variable (V3) loop. Here, we report that tyrosine-sulfated peptides derived from V2 act as structural and functional mimics of the CCR5 N-terminus and potently block HIV-1 infection. Nuclear magnetic and surface plasmon resonance analyses indicate that a tyrosine-sulfated V2 peptide (pV2a-Tys) adopts a CCR5-like helical conformation and directly interacts with gp120 in a CD4-dependent fashion, competing with a CCR5 N-terminal peptide. Sulfated V2 mimics, but not their non-sulfated counterparts, inhibit HIV-1 entry and fusion by preventing coreceptor utilization, with the highly conserved C-terminal sulfotyrosine, Tys177, playing a dominant role. Unlike CCR5 N-terminal peptides, V2 mimics inhibit a broad range of HIV-1 strains irrespective of their coreceptor tropism, highlighting the overall structural conservation of the coreceptor-binding site in gp120. These results document the use of receptor mimicry by a retrovirus to occlude a key neutralization target site and provide leads for the design of therapeutic strategies against HIV-1. Published by Elsevier B.V.
C1 [Cimbro, Raffaello; Liu, Qingbo; Guzzo, Christina; Zhang, Peng; Miao, Huiyi; Van Ryk, Donald; Lusso, Paolo] NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Peterson, Francis C.; Volkman, Brian F.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
[Ambroggio, Xavier; Hurt, Darrell E.; Dolan, Michael A.] NIAID, Bioinformat & Computat Biosci Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[De Gioia, Luca] Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.
[Cimbro, Raffaello] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD 21224 USA.
[Ambroggio, Xavier] Rosetta Design Grp LLC, 47 Maple St, Burlington, VT 05401 USA.
RP Lusso, P (reprint author), NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM plusso@niaid.nih.gov
OI Cimbro, Raffaello/0000-0002-6251-5160
FU NIAID NIH HHS [R01 AI058072]
NR 49
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2016
VL 10
BP 45
EP 54
DI 10.1016/j.ebiom.2016.06.037
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA8IE
UT WOS:000386877700015
PM 27389109
ER
PT J
AU Gallo, A
Jang, SI
Ong, HL
Perez, P
Tandon, M
Ambudkar, I
Illei, G
Alevizos, I
AF Gallo, Alessia
Jang, Shyh-Ing
Ong, Hwei Ling
Perez, Paola
Tandon, Mayank
Ambudkar, Indu
Illei, Gabor
Alevizos, Ilias
TI Targeting the Ca2+ Sensor STIM1 by Exosomal Transfer of
Ebv-miR-BART13-3p is Associated with Sjogren's Syndrome
SO EBIOMEDICINE
LA English
DT Article
DE Sjoren's syndrome; microRNA; Exosomes; STIM1; Salivary gland dysfunction
ID EPSTEIN-BARR-VIRUS; SALIVARY-GLAND BIOPSIES; POLYMERASE-CHAIN-REACTION;
AUTOIMMUNE-DISEASES; MICRORNA EXPRESSION; DNA; LYMPHOCYTES;
IDENTIFICATION; HYBRIDIZATION; REPLICATION
AB Primary Sjogren's syndrome (pSS) is a systemic autoimmune disease that is associated with inflammation and dysfunction of salivary and lacrimal glands. The molecular mechanism(s) underlying this exocrinopathy is not known, although the syndrome has been associated with viruses, such as the Epstein Barr Virus (EBV). We report herein that an EBV-specific microRNA (ebv-miR-BART13-3p) is significantly elevated in salivary glands (SGs) of pSS patients and we show that it targets stromal interacting molecule 1 (STIM1), a primary regulator of the store-operated Ca2+ entry (SOCE) pathway that is essential for SG function, leading to loss of SOCE and Ca2+-dependent activation of NFAT. Although EBV typically infects B cells and not salivary epithelial cells, ebv-miR-BART-13-3p is present in both cell types in pSS SGs. Importantly, we further demonstrate that ebv-miRBART13-3p can be transferred from B cells to salivary epithelial cells through exosomes and it recapitulates its functional effects on calcium signaling in a model system. Published by Elsevier B.V.
C1 [Gallo, Alessia; Jang, Shyh-Ing; Perez, Paola; Tandon, Mayank; Illei, Gabor; Alevizos, Ilias] Natl Inst Dent & Craniofacial Res, Sjogrens Syndrome & Salivary Gland Dysfunct Unit, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA.
[Ong, Hwei Ling; Ambudkar, Indu] Natl Inst Dent & Craniofacial Res, Secretory Physiol Sect, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA.
RP Alevizos, I (reprint author), NIDCR, Sjogrens Syndrome & Salivary Gland Dysfunct Unit, NIH, 10 Ctr Dr,Bld 10,Rm 1N110, Bethesda, MD USA.
EM alevizosi@nidcr.nih.gov
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2016
VL 10
BP 216
EP 226
DI 10.1016/j.ebiom.2016.06.041
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA8IE
UT WOS:000386877700032
PM 27381477
ER
PT J
AU Keutgen, XM
Babic, B
Nilubol, N
AF Keutgen, Xavier M.
Babic, Bruna
Nilubol, Naris
TI Management of pancreatic neuroendocrine tumors
SO INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY
LA English
DT Review
DE liver-directed therapy; pancreatic neuroendocrine tumor; systemic
therapy
ID RECEPTOR RADIONUCLIDE THERAPY; LAPAROSCOPIC RADIOFREQUENCY ABLATION;
LIVER-DIRECTED THERAPIES; ISLET-CELL CARCINOMA; ENDOCRINE TUMORS;
SURGICAL-TREATMENT; SINGLE INSTITUTION; CONSENSUS GUIDELINES;
CLINICAL-OUTCOMES; UNKNOWN PRIMARY
AB Pancreatic neuroendocrine tumors (pNETs) are rare tumors that have a better prognosis than their exocrine counterpart, but frequently present with advanced disease. Management of pNETs has evolved considerably over the past decade. Surgical resection remains the only potentially curative option for patients with pNETs. Patients who have locoregionally advanced and/or metastatic pNETs require additional treatments. These include liver-directed (transarterial (chemo)-embolization, selective intraarterial radio therapy) and systemic therapies (somatostatin analogs, targeted therapy such as tyrosine-kinase inhibitors and mammalian target of rapamycin inhibitor, peptide receptor radionuclide therapy and cytotoxic chemotherapy). The aim of this article is to review the current treatment options as well as potential future therapeutic perspectives for patients with pNETs.
C1 [Keutgen, Xavier M.; Babic, Bruna; Nilubol, Naris] NCI, Endocrine Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Nilubol, N (reprint author), NCI, Endocrine Oncol Branch, NIH, Bethesda, MD 20892 USA.
EM niluboln@mail.nih.gov
NR 89
TC 0
Z9 0
U1 1
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 2045-0869
EI 2045-0877
J9 INT J ENDOCR ONCOL
JI Int. J. Endocr. Oncol.
PD AUG
PY 2016
VL 3
IS 3
BP 267
EP 277
DI 10.2217/ije-2016-0002
PG 11
WC Oncology
SC Oncology
GA EB6NO
UT WOS:000387501100008
ER
PT J
AU Scelo, G
Hofmann, JN
Banks, RE
Bigot, P
Bhatt, RS
Cancel-Tassin, G
Chew, SK
Creighton, CJ
Cussenot, O
Davis, IJ
Escudier, B
Frayling, TM
Haggstrom, C
Hildebrandt, MAT
Holcatova, I
Johansson, M
Linehan, WM
McDermott, DF
Nathanson, KL
Ogawa, S
Perlman, EJ
Purdue, MP
Stattin, P
Swanton, C
Vasudev, NS
Wu, X
Znaor, A
Brennan, P
Chanock, SJ
AF Scelo, G.
Hofmann, J. N.
Banks, R. E.
Bigot, P.
Bhatt, R. S.
Cancel-Tassin, G.
Chew, S. K.
Creighton, C. J.
Cussenot, O.
Davis, I. J.
Escudier, B.
Frayling, T. M.
Haggstrom, C.
Hildebrandt, M. A. T.
Holcatova, I.
Johansson, M.
Linehan, W. M.
McDermott, D. F.
Nathanson, K. L.
Ogawa, S.
Perlman, E. J.
Purdue, M. P.
Stattin, P.
Swanton, C.
Vasudev, N. S.
Wu, X.
Znaor, A.
Brennan, P.
Chanock, S. J.
TI International cancer seminars: a focus on kidney cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE kidney cancer; genomics; epidemiology; clinical research
ID RENAL-CELL CARCINOMA; GENOME-WIDE ASSOCIATION; GENETIC-BASIS;
HETEROGENEITY; LANDSCAPE; DISEASE; TUMOR; RISK
AB Recent years have seen important advances in our understanding of the etiology, biology and genetics of kidney cancer. To summarize important achievements and identify prominent research questions that remain, a workshop was organized by IARC and the US NCI. A series of 'difficult questions' were formulated, which should be given future priority in the areas of population, genomic and clinical research.Recent years have seen important advances in our understanding of the etiology, biology and genetics of kidney cancer. To summarize important achievements and identify prominent research questions that remain, a workshop was organized by IARC and the US NCI. A series of 'difficult questions' were formulated, which should be given future priority in the areas of population, genomic and clinical research.
C1 [Scelo, G.; Johansson, M.; Znaor, A.; Brennan, P.] Int Agcy Res Canc, Sect Genet, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
[Hofmann, J. N.; Purdue, M. P.; Chanock, S. J.] NCI, Div Canc Epidemiol & Genet, US Dept HHS, NIH, Bethesda, MD 20892 USA.
[Banks, R. E.; Vasudev, N. S.] St James Univ Hosp, Leeds Inst Canc Studies & Pathol, Canc Res UK Ctr, Clin & Biomed Prote Grp, Leeds, W Yorkshire, England.
[Bigot, P.] CHU Angers, Dept Urol, Angers, France.
[Bhatt, R. S.; McDermott, D. F.] Dana Farber Harvard Canc Ctr, Kidney Canc Program, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA.
[Cancel-Tassin, G.; Cussenot, O.] CeRePP, Grp Rech GRC UPMC 5, Paris, France.
[Chew, S. K.] UCL, UCL Canc Inst, Translat Canc Therapeut Lab, London, England.
[Creighton, C. J.] Baylor Coll Med, Duncan Canc Center Biostat, Houston, TX 77030 USA.
[Davis, I. J.] UNC, Sch Med, Dept Genet, Chapel Hill, NC USA.
[Escudier, B.] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France.
[Frayling, T. M.] Univ Exeter, Sch Med, Exeter, Devon, England.
[Haggstrom, C.; Stattin, P.] Umea Univ, Dept Surg & Perioperat Sci Urol & Androl, Umea, Sweden.
[Haggstrom, C.] Umea Univ, Dept Biobank Res, Umea, Sweden.
[Hildebrandt, M. A. T.] Univ Texas MD Anderson Canc Ctr, Canc Prevent & Populat Sci, Div OVP, Dept Epidemiol, Houston, TX 77030 USA.
[Holcatova, I.] Charles Univ Prague, Fac Med 2, Inst Publ Hlth & Prevent Med, Prague, Czech Republic.
[Linehan, W. M.] NCI, Urol Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Nathanson, K. L.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Ogawa, S.] Univ Tokyo, Grad Sch Med, Tokyo, Japan.
[Perlman, E. J.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Swanton, C.] UCL, Hosp & Canc Inst, London, England.
[Wu, X.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
RP Brennan, P (reprint author), Int Agcy Res Canc, Sect Genet, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM brennanp@iarc.fr
OI Cancel-Tassin, Geraldine/0000-0002-9583-6382
FU International Agency for Research on Cancer (IARC); Division of Cancer
Epidemiology and Genetics (DCEG) of the US National Cancer Institute
FX Organization of production of this seminar was funded jointly by the
International Agency for Research on Cancer (IARC) and the Division of
Cancer Epidemiology and Genetics (DCEG) of the US National Cancer
Institute (no grant number applicable).
NR 31
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD AUG
PY 2016
VL 27
IS 8
BP 1382
EP 1385
DI 10.1093/annonc/mdw186
PG 4
WC Oncology
SC Oncology
GA DV8JH
UT WOS:000383182800008
PM 27130845
ER
PT J
AU Hashim, D
Sartori, S
Brennan, P
Curado, MP
Wunsch, V
Divaris, K
Olshan, AF
Zevallos, JP
Winn, DM
Franceschi, S
Castellsague, X
Lissowska, J
Rudnai, P
Matsuo, K
Morgenstern, H
Chen, C
Vaughan, TL
Hofmann, JN
D'Souza, G
Haddad, RI
Wu, H
Lee, YC
Hashibe, M
La Vecchia, C
Boffetta, P
AF Hashim, D.
Sartori, S.
Brennan, P.
Curado, M. P.
Wunsch-Filho, V.
Divaris, K.
Olshan, A. F.
Zevallos, J. P.
Winn, D. M.
Franceschi, S.
Castellsague, X.
Lissowska, J.
Rudnai, P.
Matsuo, K.
Morgenstern, H.
Chen, C.
Vaughan, T. L.
Hofmann, J. N.
D'Souza, G.
Haddad, R. I.
Wu, H.
Lee, Y. -C.
Hashibe, M.
La Vecchia, C.
Boffetta, P.
TI The role of oral hygiene in head and neck cancer: results from
International Head and Neck Cancer Epidemiology (INHANCE) consortium
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE head and neck neoplasms; oral neoplasms; pharyngeal neoplasms; oral
hygiene; pooled analyses
ID SQUAMOUS-CELL CARCINOMA; ILL-FITTING DENTURES; RISK-FACTORS;
PERIODONTAL-DISEASE; DIABETES-MELLITUS; POOLED ANALYSIS; TOOTH LOSS;
HEALTH; COHORT; ALCOHOL
AB This pooled analysis describes the largest and most comprehensive assessment of the association between oral hygiene indicators and HNCs to date, including oral cavity, laryngeal, hypopharyngeal, and oropharyngeal cancers. We found good oral hygiene is associated with lower risk of HNC. Improvements in oral hygiene by increasing oral hygiene literacy, particularly for annual dentist visits and daily tooth brushing, may be protective against HNC.Poor oral hygiene has been proposed to contribute to head and neck cancer (HNC) risk, although causality and independency of some indicators are uncertain. This study investigates the relationship of five oral hygiene indicators with incident HNCs.
In a pooled analysis of 8925 HNC cases and 12 527 controls from 13 studies participating in the International Head and Neck Cancer Epidemiology Consortium, comparable data on good oral hygiene indicators were harmonized. These included: no denture wear, no gum disease (or bleeding), < 5 missing teeth, tooth brushing at least daily, and visiting a dentist a parts per thousand yenonce a year. Logistic regression was used to estimate the effects of each oral hygiene indicator and cumulative score on HNC risk, adjusting for tobacco smoking and alcohol consumption.
Inverse associations with any HNC, in the hypothesized direction, were observed for < 5 missing teeth [odds ratio (OR) = 0.78; 95% confidence interval (CI) 0.74, 0.82], annual dentist visit (OR = 0.82; 95% CI 0.78, 0.87), daily tooth brushing (OR = 0.83, 95% CI 0.79, 0.88), and no gum disease (OR = 0.94; 95% CI 0.89, 0.99), and no association was observed for wearing dentures. These associations were relatively consistent across specific cancer sites, especially for tooth brushing and dentist visits. The population attributable fraction for a parts per thousand currency sign 2 out of 5 good oral hygiene indicators was 8.9% (95% CI 3.3%, 14%) for oral cavity cancer.
Good oral hygiene, as characterized by few missing teeth, annual dentist visits, and daily tooth brushing, may modestly reduce the risk of HNC.
C1 [Sartori, S.; Wu, H.; Boffetta, P.] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA.
[Brennan, P.; Franceschi, S.] Int Agcy Res Canc, Lyon, France.
[Curado, M. P.] CIPE ACCAMARGO, Epidemiol, Sao Paulo, Brazil.
[Wunsch-Filho, V.] Univ Sao Paulo, Sch Publ Hlth, Sao Paulo, Brazil.
[Divaris, K.] Univ N Carolina, Sch Publ Hlth, Dept Pediat Dent, Chapel Hill, NC USA.
[Olshan, A. F.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
[Zevallos, J. P.] Univ N Carolina, Dept Otolaryngol Head & Neck Surg, Chapel Hill, NC USA.
[Winn, D. M.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Castellsague, X.] Catalan Inst Oncol ICO IDIBELL, Lhospitalet De Llobregat, Spain.
[Castellsague, X.] CIBERESP, Madrid, Spain.
[Lissowska, J.] M Sklasodowska Curie Mem Canc Ctr & Inst Oncol, Dept Canc Epidemiol & Prevent, Warsaw, Poland.
[Rudnai, P.] Natl Publ Hlth Ctr, Budapest, Hungary.
[Matsuo, K.] Aichi Canc Ctr Res Inst, Div Mol Med, Nagoya, Aichi, Japan.
[Morgenstern, H.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Morgenstern, H.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA.
[Chen, C.; Vaughan, T. L.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Hofmann, J. N.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[D'Souza, G.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Haddad, R. I.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA.
[Lee, Y. -C.; Hashibe, M.] Univ Utah, Sch Med, Dept Family & Prevent Med, Div Publ Hlth, Salt Lake City, UT 84112 USA.
[Lee, Y. -C.; Hashibe, M.] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA.
[La Vecchia, C.] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
[Boffetta, P.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
RP Hashim, D (reprint author), Icahn Sch Med Mt Sinai, Dept Prevent Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM dana.hashim@mssm.edu
RI Castellsague Pique, Xavier/N-5795-2014; Kowalski, Luiz/D-1701-2012;
Curado, Maria Paula/M-6200-2013; Divaris, Kimon/E-4706-2011;
OI Castellsague Pique, Xavier/0000-0002-0802-3595; Kowalski,
Luiz/0000-0001-5865-9308; Curado, Maria Paula/0000-0001-8172-2483;
Divaris, Kimon/0000-0003-1290-7251; La Vecchia,
Carlo/0000-0003-1441-897X
FU NIH [NCI R03CA113157, R01CA061188, P50CA090388, R01DA011386,
R03CA077954, T32CA009142, U01CA096134, R21ES011667, R01CA048996,
R01DE012609, R01CA030022, DE016631, R01CA051845]; NIDCR [R03DE016611];
Latin America: Fondo para la Investigacion Cientifica y Tecnologica
(FONCYT) Argentina; IMIM (Barcelona); Fundaco de Amparo a Pesquisa no
Estado de Sao Paulo (FAPESP) [01/01768-2]; European Commission
[IC18-CT97-0222]; National Institute of Environmental Health Sciences
[P30ES010126]; NCI, NIH, United States; Fondo de Investigaciones
Sanitarias (FIS) of the Spanish Government [FIS 97/0024, FIS 97/0662,
BAE 01/5013]; International Union Against Cancer (UICC);
Yamagiwa-Yoshida Memorial International Cancer Study Grant; European
Commission INCO-COPERNICUS Program [IC15-CT98-0332]; Alper Research
Program for Environmental Genomics of the UCLA Jonsson Comprehensive
Cancer Center; Ministry of Education, Science, Sports, Culture and
Technology of Japan [17015052]; Ministry of Health, Labour and Welfare
of Japan [H20-002]
FX The INHANCE Consortium was supported by NIH grants NCI R03CA113157 and
NIDCR R03DE016611. Studies participating in the pooled analysis were
supported by: Latin America: Fondo para la Investigacion Cientifica y
Tecnologica (FONCYT) Argentina, IMIM (Barcelona), Fundaco de Amparo a
Pesquisa no Estado de Sao Paulo (FAPESP) (No. 01/01768-2), and European
Commission (IC18-CT97-0222). North Carolina (1994-1997): NIH
(R01CA061188), and in part by a grant from the National Institute of
Environmental Health Sciences (P30ES010126). US multicenter: The
Intramural Program of the NCI, NIH, United States (No grant number
applicable). International Multicenter study: Fondo de Investigaciones
Sanitarias (FIS) of the Spanish Government (FIS 97/0024, FIS 97/0662,
BAE 01/5013), International Union Against Cancer (UICC), and
Yamagiwa-Yoshida Memorial International Cancer Study Grant. Central
Europe study: World Cancer Research Fund and the European Commission
INCO-COPERNICUS Program (Contract No. IC15-CT98-0332). Los Angeles
study: NIH (P50CA090388, R01DA011386, R03CA077954, T32CA009142,
U01CA096134, R21ES011667) and the Alper Research Program for
Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center.
Japan study: Scientific Research grant from the Ministry of Education,
Science, Sports, Culture and Technology of Japan (17015052) and a grant
for the ThirdTerm Comprehensive 10-Year Strategy for Cancer Control from
the Ministry of Health, Labour and Welfare of Japan (H20-002). Seattle
study (1985-1995): NIH (R01CA048996, R01DE012609). Seattle-LEO study:
NIH (R01CA030022). Puerto Rico study: jointly funded by National
Institutes of Health NCI and NIDCR intramural programs (No grant number
applicable). Baltimore: NIH (DE016631). Memorial Sloan Kettering Cancer
Center, New York, USA: NIH (R01CA051845). HOTSPOT: Johns Hopkins Richard
Gelb Cancer Prevention Award (no grant number applicable).
NR 38
TC 1
Z9 1
U1 4
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD AUG
PY 2016
VL 27
IS 8
BP 1619
EP 1625
DI 10.1093/annonc/mdw224
PG 7
WC Oncology
SC Oncology
GA DV8JH
UT WOS:000383182800034
PM 27234641
ER
PT J
AU Barrett, J
AF Barrett, John
TI Expanding the antigenic repertoire of CAR-T cells with "TCR-like"
antibody specificity
SO CYTOTHERAPY
LA English
DT Editorial Material
C1 [Barrett, John] NHLBI, Hematol Branch, NIH, CRC Rm 3-5330,10 Ctr Dr, Bethesda, MD 20892 USA.
RP Barrett, J (reprint author), NHLBI, Hematol Branch, NIH, CRC Rm 3-5330,10 Ctr Dr, Bethesda, MD 20892 USA.
EM cytotherapyjournal@gmail.com
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465-3249
EI 1477-2566
J9 CYTOTHERAPY
JI Cytotherapy
PD AUG
PY 2016
VL 18
IS 8
BP 929
EP 930
DI 10.1016/j.jcyt.2016.06.007
PG 2
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology; Hematology; Medicine, Research & Experimental
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
& Experimental Medicine
GA EA5OX
UT WOS:000386671700001
PM 27378341
ER
PT J
AU Balbus, JM
Tart, KGT
Dilworth, CH
Birnbaum, LS
AF Balbus, John M.
Tart, Kimberly G. Thigpen
Dilworth, Caroline H.
Birnbaum, Linda S.
TI Changing the Climate of Respiratory Clinical Practice Insights from the
2016 Climate and Health Assessment of the US Global Change Research
Program
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Editorial Material
C1 [Balbus, John M.; Tart, Kimberly G. Thigpen; Dilworth, Caroline H.; Birnbaum, Linda S.] NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA.
RP Balbus, JM (reprint author), 31 Ctr Dr,Room B1C02, Bethesda, MD 20814 USA.
EM John.balbus@nih.gov
OI Thigpen Tart, Kimberly/0000-0003-1633-1624
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD AUG
PY 2016
VL 13
IS 8
BP 1202
EP 1204
DI 10.1513/AnnalsATS.201607-535ED
PG 3
WC Respiratory System
SC Respiratory System
GA DZ8JV
UT WOS:000386117600003
PM 27509146
ER
PT J
AU Lau, CY
Mihalek, AD
Wang, J
Dodd, LE
Perkins, K
Price, S
Webster, S
Pittaluga, S
Folio, LR
Rao, VK
Olivier, KN
AF Lau, Chuen-Yen
Mihalek, Andrew D.
Wang, Jing
Dodd, Lori E.
Perkins, Katie
Price, Susan
Webster, Sharon
Pittaluga, Stefania
Folio, Les R.
Rao, V. Koneti
Olivier, Kenneth N.
TI Pulmonary Manifestations of the Autoimmune Lymphoproliferative Syndrome
A Retrospective Study of a Unique Patient Cohort
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
AB Rationale: Patients with autoimmune lymphoproliferative syndrome (ALPS), a disorder of impaired lymphocyte apoptosis, often undergo radiographic chest imaging to evaluate the presence and progression of lymphadenopathy. These images often lead to parenchymal and interstitial lung findings of unclear clinical significance.
Objectives: To characterize the pulmonary findings associated with ALPS and to determine if lung abnormalities present on computed tomographic (CT) imaging of the chest correlate with infection or functional status.
Methods: Patients with lung abnormalities observed on chest CT scans were retrospectively identified from the largest known ALPS cohort. Lung computed tomography findings were characterized and correlated with medical records, bronchoalveolar lavage, biopsy, and lung function.
Measurements and Main Results: CT images of the chest were available for 234 (92%) of 255 of the patients with ALPS. Among patients with a chest CT scan, 18 (8%) had lung abnormalities on at least one CT scan. Fourteen (78%) of those 18 were classified as having ALPS with undetermined genetic defect. Most patients (n = 16 [89%]) with lung lesions were asymptomatic. However, two (11%) of them had associated dyspnea and/or desaturation on room air. Immunosuppressive treatment was administered for lung disease in nine (50%) cases, and all were followed for clinical outcomes.
Conclusions: Patients with ALPS can develop chest radiographic findings with protean manifestations that may mimic pulmonary infection. Management of patients with ALPS with incidental lung lesions identified by CT imaging should be guided by clinical correlation. Symptomatic patients may benefit from chest CT imaging and lesion biopsy to exclude infection and guide administration of immunosuppressive therapy.
C1 [Lau, Chuen-Yen] NIAID, Collaborat Clin Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Dodd, Lori E.] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Perkins, Katie; Price, Susan; Webster, Sharon; Rao, V. Koneti] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Mihalek, Andrew D.; Olivier, Kenneth N.] NHLBI, Cardiovasc & Pulm Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Perkins, Katie] NCI, Leidos Biomed Res Inc, Frederick Natl Lab, NIH, Frederick, MD 21701 USA.
[Wang, Jing] NCI, Clin Monitoring Res Program, Leidos Biomed Res Inc, NIH, Frederick, MD 21701 USA.
[Pittaluga, Stefania] NCI, Pathol Lab, NIH, Frederick, MD 21701 USA.
[Folio, Les R.] NIH, Ctr Clin, Radiol & Imaging Sci, Bethesda, MD 20892 USA.
[Mihalek, Andrew D.] Univ Virginia, Div Pulm & Crit Care Med, Charlottesville, VA USA.
[Mihalek, Andrew D.] Lovelace Resp Res Inst, Albuquerque, NM USA.
RP Olivier, KN (reprint author), NHLBI, Cardiovasc & Pulm Branch, 10 Ctr Dr,MSC 1454,Bldg 10 CRC,Room 6-3130, Bethesda, MD 20892 USA.
EM olivierk@nhlbi.nih.gov
FU intramural research programs at the National Institute of Allergy and
Infectious Diseases; National Heart, Lung, and Blood Institute; National
Institutes of Health Clinical Center
FX This work is supported by the intramural research programs at the
National Institute of Allergy and Infectious Diseases; the National
Heart, Lung, and Blood Institute; and the National Institutes of Health
Clinical Center. The authors are gratefully indebted to the patients and
the families of patients who have participated in the ALPS Natural
History Study. The authors also thank Fred Gill, Helen Su, Joie Davis,
and Gulbu Uzel for their valuable contributions to this research.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD AUG
PY 2016
VL 13
IS 8
BP 1279
EP 1288
DI 10.1513/AnnalsATS.201601-079OC
PG 10
WC Respiratory System
SC Respiratory System
GA DZ8JV
UT WOS:000386117600018
PM 27268092
ER
PT J
AU Leigh, MW
Ferkol, TW
Davis, SD
Lee, HS
Rosenfeld, M
Dell, SD
Sagel, SD
Milla, C
Olivier, KN
Sullivan, KM
Zariwala, MA
Pittman, JE
Shapiro, AJ
Carson, JL
Krischer, J
Hazucha, MJ
Knowles, MR
AF Leigh, Margaret W.
Ferkol, Thomas W.
Davis, Stephanie D.
Lee, Hye-Seung
Rosenfeld, Margaret
Dell, Sharon D.
Sagel, Scott D.
Milla, Carlos
Olivier, Kenneth N.
Sullivan, Kelli M.
Zariwala, Maimoona A.
Pittman, Jessica E.
Shapiro, Adam J.
Carson, Johnny L.
Krischer, Jeffrey
Hazucha, Milan J.
Knowles, Michael R.
TI Clinical Features and Associated Likelihood of Primary Ciliary
Dyskinesia in Children and Adolescents
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
AB Rationale: Primary ciliary dyskinesia (PCD), a genetically heterogeneous, recessive disorder of motile cilia, is associated with distinct clinical features. Diagnostic tests, including ultrastructural analysis of cilia, nasal nitric oxide measurements, and molecular testing for mutations in PCD genes, have inherent limitations.
Objectives: To define a statistically valid combination of systematically defined clinical features that strongly associates with PCD in children and adolescents.
Methods: Investigators at seven North American sites in the Genetic Disorders of Mucociliary Clearance Consortium prospectively and systematically assessed individuals (aged 0-18 yr) referred due to high suspicion for PCD. The investigators defined specific clinical questions for the clinical report form based on expert opinion. Diagnostic testing was performed using standardized protocols and included nasal nitric oxide measurement, ciliary biopsy for ultrastructural analysis of cilia, and molecular genetic testing for PCD-associated genes. Final diagnoses were assigned as "definite PCD" (hallmark ultrastructural defects and/or two mutations in a PCD-associated gene), "probable/possible PCD" (no ultrastructural defect or genetic diagnosis, but compatible clinical features and nasal nitric oxide level in PCD range), and "other diagnosis or undefined." Criteria were developed to define early childhood clinical features on the basis of responses to multiple specific queries. Each defined feature was tested by logistic regression. Sensitivity and specificity analyses were conducted to define the most robust set of clinical features associated with PCD.
Measurements and Main Results: From 534 participants 18 years of age and younger, 205 were identified as having "definite PCD" (including 164 with two mutations in a PCD-associated gene), 187 were categorized as "other diagnosis or undefined," and 142 were defined as having "probable/possible PCD." Participants with "definite PCD" were compared with the "other diagnosis or undefined" group. Four criteria-defined clinical features were statistically predictive of PCD: laterality defect; unexplained neonatal respiratory distress; early-onset, year-round nasal congestion; and early-onset, year-round wet cough (adjusted odds ratios of 7.7, 6.6, 3.4, and 3.1, respectively). The sensitivity and specificity based on the number of criteria-defined clinical features were four features, 0.21 and 0.99, respectively; three features, 0.50 and 0.96, respectively; and two features, 0.80 and 0.72, respectively.
Conclusions: Systematically defined early clinical features could help identify children, including infants, likely to have PCD.
C1 [Leigh, Margaret W.; Shapiro, Adam J.; Carson, Johnny L.] UNC Sch Med, Dept Pediat, 450 MacNider,CB 7217, Chapel Hill, NC 27599 USA.
[Leigh, Margaret W.; Sullivan, Kelli M.; Zariwala, Maimoona A.; Knowles, Michael R.] UNC Sch Med, Marsico Lung Inst, Chapel Hill, NC USA.
[Sullivan, Kelli M.; Hazucha, Milan J.] UNC Sch Med, Dept Med, Chapel Hill, NC USA.
[Zariwala, Maimoona A.] UNC Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA.
[Carson, Johnny L.; Hazucha, Milan J.] UNC Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA.
[Ferkol, Thomas W.; Pittman, Jessica E.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
[Davis, Stephanie D.] Indiana Univ Sch Med, Dept Pediat, Riley Childrens Hosp, Indianapolis, IN 46202 USA.
[Lee, Hye-Seung; Krischer, Jeffrey] Univ S Florida, Dept Pediat, Tampa, FL USA.
[Rosenfeld, Margaret] Seattle Childrens Hosp, Seattle, WA USA.
[Dell, Sharon D.] Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON, Canada.
[Dell, Sharon D.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Sagel, Scott D.] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO USA.
[Milla, Carlos] Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA.
[Olivier, Kenneth N.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Leigh, MW (reprint author), UNC Sch Med, Dept Pediat, 450 MacNider,CB 7217, Chapel Hill, NC 27599 USA.
EM mleigh@med.unc.edu
FU National Institutes of Health (NIH) - Office of Rare Diseases Research
(ORDR) of the National Center for Advancing Translational Sciences
(NCATS) [5 U54 HL09640958-11, 5R01 HL071798]; National Heart, Lung, and
Blood Institute (NHLBI); Clinical and Translational Science Awards
(CTSA) NIH/NCATS [UNC ULTR000083]; CTSA NIH/NCATS Colorado
[UL1TR000154]; Intramural Research Program of the NHLBI, NIH; NIH ORDR
at the NCATS [5 U54HL096458]; NIH NHLBI [5 U54HL096458]
FX Supported by (1) National Institutes of Health (NIH) grants 5 U54
HL09640958-11 and 5R01 HL071798, funded by the Office of Rare Diseases
Research (ORDR) of the National Center for Advancing Translational
Sciences (NCATS), and by the National Heart, Lung, and Blood Institute
(NHLBI); (2) Clinical and Translational Science Awards (CTSA) NIH/NCATS
UNC ULTR000083; (3) CTSA NIH/NCATS Colorado UL1TR000154; and (4) the
Intramural Research Program of the NHLBI, NIH. The Genetic Disorders of
Mucociliary Clearance Consortium (5 U54HL096458) is a part of the NIH
Rare Disease Clinical Research Network (RDCRN), supported through
collaboration between the NIH ORDR at the NCATS, and the NIH NHLBI. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH.
NR 0
TC 7
Z9 7
U1 1
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD AUG
PY 2016
VL 13
IS 8
BP 1305
EP 1313
DI 10.1513/AnnalsATS.201511-748OC
PG 9
WC Respiratory System
SC Respiratory System
GA DZ8JV
UT WOS:000386117600022
PM 27070726
ER
PT J
AU Khan, RJ
Riestra, P
Gebreab, SY
Wilson, JG
Gaye, A
Xu, R
Davis, SK
AF Khan, Rumana J.
Riestra, Pia
Gebreab, Samson Y.
Wilson, James G.
Gaye, Amadou
Xu, Ruihua
Davis, Sharon K.
TI Vitamin D Receptor Gene Polymorphisms Are Associated with Abdominal
Visceral Adipose Tissue Volume and Serum Adipokine Concentrations but
Not with Body Mass Index or Waist Circumference in African Americans:
The Jackson Heart Study
SO JOURNAL OF NUTRITION
LA English
DT Article
DE vitamin D receptor gene; single-nucleotide polymorphisms; visceral
adipose tissue; subcutaneous adipose tissue; adiponectin; leptin;
African Americans
ID TYPE-2 DIABETES-MELLITUS; METABOLIC SYNDROME; 25-HYDROXYVITAMIN D;
INSULIN-RESISTANCE; RISK-FACTORS; OBESITY; ADIPONECTIN; DISEASE;
POPULATION; ADIPOGENESIS
AB Background: The biological actions of vitamin D are mediated through the vitamin D receptor (VDR). Single-nucleotide polymorphisms (SNPs) in the VDR gene have been previously associated with adiposity traits. However, to our knowledge, few studies have included direct measures of adiposity and adipokine concentrations.
Objective: We examined the association of tagging SNPs in the VDR gene with multiple adiposity measures, including waist circumference (WC), body mass index (BMI), body fat percentage, subcutaneous and visceral adipose tissue (VAT) volume, and serum adipokine (adiponectin and leptin) concentrations in adult African Americans (AAs).
Methods: Data from 3020 participants (61.9% women; mean age, 54.6 y) from the Jackson Heart Study were used for this analysis. Forty-five tag SNPs were chosen with the use of genotype data from the International HapMap project. We used linear regression to test the associations of imputed VDR SNPs with each of the traits, adjusted for age, sex, educational status, physical activity, smoking, alcohol intake, serum vitamin D concentration, European ancestry, and multiple testing.
Results: The G allele of the SNP rs4328262 remained associated with increased VAT volume after multiple testing correction (beta = 45.7; P < 0.001). The A allele of another SNP (rs11574070) was nominally associated with body fat percentage (beta = 0.96; P = 0.002). None of the VDR SNPs analyzed showed any link with WC or BMI. The A allele of rs2228570 (beta = 0.08; P = 0.001) for men and the T allele of rs2853563 (beta = 0.04; P < 0.001) for women remained positively associated with serum adiponectin concentrations after multiple testing correction.
Conclusion: Although we did not find any association for anthropometric measures, we did observe associations of VDR variants with serum adipokines and with the more metabolically active fat, VAT. Therefore, our findings demonstrate a possible role of VDR variants in regulating adipose tissue activity and adiposity among AAs.
C1 [Khan, Rumana J.; Riestra, Pia; Gebreab, Samson Y.; Gaye, Amadou; Xu, Ruihua; Davis, Sharon K.] NHGRI, Cardiovasc Sect, Metab Cardiovasc & Inflammatory Dis Genom Branch, NIH, Bethesda, MD 20892 USA.
[Wilson, James G.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA.
RP Khan, RJ (reprint author), NHGRI, Cardiovasc Sect, Metab Cardiovasc & Inflammatory Dis Genom Branch, NIH, Bethesda, MD 20892 USA.
EM rumana.khan@nih.gov
OI Gaye, Amadou/0000-0002-1180-2792
FU NIH Intramural Research Program; National Heart, Lung, and Blood
Institute [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C,
HHSN268201300049C, HHSN268201300050C]; National Institute on Minority
Health and Health Disparities
FX Supported by the NIH Intramural Research Program. The Jackson Heart
Study is supported by contracts HHSN268201300046C, HHSN268201300047C,
HHSN268201300048C, HHSN268201300049C, and HHSN268201300050C from the
National Heart, Lung, and Blood Institute and the National Institute on
Minority Health and Health Disparities.
NR 56
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD AUG
PY 2016
VL 146
IS 8
BP 1476
EP 1482
DI 10.3945/jn.116.229963
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA DZ8OT
UT WOS:000386130900002
PM 27358421
ER
PT J
AU Brown, P
AF Brown, Patricia
TI A word from OLAW
SO LAB ANIMAL
LA English
DT Editorial Material
C1 [Brown, Patricia] NIH, OLAW, OER, OD,HHS, Bldg 10, Bethesda, MD 20892 USA.
RP Brown, P (reprint author), NIH, OLAW, OER, OD,HHS, Bldg 10, Bethesda, MD 20892 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0093-7355
EI 1548-4475
J9 LAB ANIMAL
JI Lab Anim.
PD AUG
PY 2016
VL 45
IS 8
BP 288
EP 288
DI 10.1038/laban.1080
PG 1
WC Veterinary Sciences
SC Veterinary Sciences
GA DZ8SW
UT WOS:000386142800015
PM 27439095
ER
PT J
AU Colloca, L
Enck, P
DeGrazia, D
AF Colloca, Luana
Enck, Paul
DeGrazia, David
TI Relieving pain using dose-extending placebos: a scoping review
SO PAIN
LA English
DT Review
DE Clinical outcomes; Enhancement; Expectancy; Learning; Pain; Placebo
effects; Partial reinforcement; Pharmacological conditioning; Opioids
ID OPEN-LABEL USE; CLINICAL-PRACTICE; QUESTIONNAIRE SURVEY; ANALGESIA;
ETHICS; INTERVENTIONS; PHYSICIANS; RESPONSES; MECHANISMS; ATTITUDES
AB Placebos are often used by clinicians, usually deceptively and with little rationale or evidence of benefit, making their use ethically problematic. In contrast with their typical current use, a provocative line of research suggests that placebos can be intentionally exploited to extend analgesic therapeutic effects. Is it possible to extend the effects of drug treatments by interspersing placebos? We reviewed a database of placebo studies, searching for studies that indicate that placebos given after repeated administration of active treatments acquire medication-like effects. We found a total of 22 studies in both animals and humans hinting of evidence that placebos may work as a sort of dose extender of active painkillers. Wherever effective in relieving clinical pain, such placebo use would offer several advantages. First, extending the effects of a painkiller through the use of placebos may reduce total drug intake and side effects. Second, dose-extending placebos may decrease patient dependence. Third, using placebos along with active medication, for part of the course of treatment, should limit dose escalation and lower costs. Provided that nondisclosure is preauthorized in the informed consent process and that robust evidence indicates therapeutic benefit comparable to that of standard full-dose therapeutic regimens, introducing dose-extending placebos into the clinical arsenal should be considered. This novel prospect of placebo use has the potential to change our general thinking about painkiller treatments, the typical regimens of painkiller applications, and the ways in which treatments are evaluated.
C1 [Colloca, Luana] Univ Maryland, Sch Nursing, Dept Pain Translat Symptom Sci, 655 W Lombard St,Room 729A, Baltimore, MD 21201 USA.
[Colloca, Luana] Univ Maryland, Sch Med, Dept Anesthesiol, 655 W Lombard St,Room 729A, Baltimore, MD 21201 USA.
[Colloca, Luana] Univ Maryland, Ctr Adv Chron Pain Res, 655 W Lombard St,Room 729A, Baltimore, MD 21201 USA.
[Enck, Paul] Univ Tubingen Hosp, Dept Internal Med Psychosomat Med & Psychotherapy, Tubingen, Germany.
[DeGrazia, David] NIH, Dept Bioeth, Bldg 10, Bethesda, MD 20892 USA.
[DeGrazia, David] George Washington Univ, Dept Philosophy, Washington, DC USA.
RP Colloca, L (reprint author), Univ Maryland, Sch Nursing, 655 W Lombard St,Room 729A, Baltimore, MD 21201 USA.
EM colloca@son.umaryland.edu
FU National Institute of Dental and Craniofacial Research
[LCR01DE025946-01]; Clinical Center at the National Institutes of Health
FX This research was supported by funds from the National Institute of
Dental and Craniofacial Research (LCR01DE025946-01) and the Clinical
Center at the National Institutes of Health (DD). The funding agencies
have no roles in the study. The views expressed here are the authors'
own and do not reflect the position or policy of the National Institutes
of Health or any other part of the federal government.
NR 81
TC 2
Z9 2
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD AUG
PY 2016
VL 157
IS 8
BP 1590
EP 1598
DI 10.1097/j.pain.0000000000000566
PG 9
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA DZ7AB
UT WOS:000386014000006
PM 27023425
ER
PT J
AU Low, LA
Bauer, LC
Pitcher, MH
Bushnell, MC
AF Low, Lucie A.
Bauer, Lucy C.
Pitcher, Mark H.
Bushnell, M. Catherine
TI Restraint training for awake functional brain scanning of rodents can
cause long-lasting changes in pain and stress responses
SO PAIN
LA English
DT Article
DE MRI habituation; Rat; Restraint; Stress; Pain; Amygdala
ID PLASMA-CORTICOSTERONE LEVELS; CEREBRAL-BLOOD-FLOW; RESTING-STATE FMRI;
ANESTHETIZED RATS; SEX-DIFFERENCES; CONSCIOUS RATS; FEMALE RATS;
COMPUTATIONAL ANALYSIS; SOMATOSENSORY CORTEX; HOUSING CONDITIONS
AB With the increased interest in longitudinal brain imaging of awake rodents, it is important to understand both the short-term and long-term effects of restraint on sensory and emotional processing in the brain. To understand the effects of repeated restraint on pain behaviors and stress responses, we modeled a restraint protocol similar to those used to habituate rodents for magnetic resonance imaging scanning, and studied sensory sensitivity and stress hormone responses over 5 days. To uncover lasting effects of training, we also looked at responses to the formalin pain test 2 weeks later. We found that while restraint causes acute increases in the stress hormone corticosterone, it can also cause lasting reductions in nociceptive behavior in the formalin test, coupled with heightened corticosterone levels and increased activation of the "nociceptive" central nucleus of the amygdala, as seen by Fos protein expression. These results suggest that short-term repeated restraint, similar to that used to habituate rats for awake functional brain scanning, could potentially cause long-lasting changes in physiological and brain responses to pain stimuli that are stress-related, and therefore could potentially confound the functional activation patterns seen in awake rodents in response to pain stimuli.
C1 [Low, Lucie A.; Bauer, Lucy C.; Pitcher, Mark H.; Bushnell, M. Catherine] NIH, Lab Pain & Integrat Neurosci, Natl Ctr Complementary & Integrat Hlth, Bldg 10, Bethesda, MD 20892 USA.
RP Low, LA (reprint author), NIH, Natl Ctr Complementary & Integrat Hlth, Room 1D-802,35 Ctr Dr, Bethesda, MD 20892 USA.
EM lucie.low@nih.gov
OI Low, Lucie/0000-0001-6082-8625
FU Intramural Research program of the National Center; Integrative Health
(NCCIH) at the National Institutes for Health
FX This work was funded by the Intramural Research program of the National
Center for Complementary and Integrative Health (NCCIH) at the National
Institutes for Health.
NR 76
TC 3
Z9 3
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD AUG
PY 2016
VL 157
IS 8
BP 1761
EP 1772
DI 10.1097/j.pain.0000000000000579
PG 12
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA DZ7AB
UT WOS:000386014000024
PM 27058679
ER
PT J
AU Decker, LM
Cignetti, F
Hunt, N
Potter, JF
Stergiou, N
Studenski, SA
AF Decker, Leslie M.
Cignetti, Fabien
Hunt, Nathaniel
Potter, Jane F.
Stergiou, Nicholas
Studenski, Stephanie A.
TI Effects of aging on the relationship between cognitive demand and step
variability during dual-task walking
SO AGE
LA English
DT Article
DE Aging; Gait; Cognitive control; Step variability; Resource competition
ID LOCAL DYNAMIC STABILITY; HEALTHY OLDER-ADULTS; GAIT VARIABILITY;
POSTURAL CONTROL; YOUNG-ADULTS; EXPLICIT PRIORITIZATION; SENSORY
INTEGRATION; PARKINSONS-DISEASE; EXECUTIVE FUNCTION; TREADMILL WALKING
AB A U-shaped relationship between cognitive demand and gait control may exist in dual-task situations, reflecting opposing effects of external focus of attention and attentional resource competition. The purpose of the study was twofold: to examine whether gait control, as evaluated from step-to-step variability, is related to cognitive task difficulty in a U-shaped manner and to determine whether age modifies this relationship. Young and older adults walked on a treadmill without attentional requirement and while performing a dichotic listening task under three attention conditions: non-forced (NF), forced-right (FR), and forced-left (FL). The conditions increased in their attentional demand and requirement for inhibitory control. Gait control was evaluated by the variability of step parameters related to balance control (step width) and rhythmic stepping pattern (step length and step time). A U-shaped relationship was found for step width variability in both young and older adults and for step time variability in older adults only. Cognitive performance during dual tasking was maintained in both young and older adults. The U-shaped relationship, which presumably results from a trade-off between an external focus of attention and competition for attentional resources, implies that higher-level cognitive processes are involved in walking in young and older adults. Specifically, while these processes are initially involved only in the control of (lateral) balance during gait, they become necessary for the control of (fore-aft) rhythmic stepping pattern in older adults, suggesting that attentional resources turn out to be needed in all facets of walking with aging. Finally, despite the cognitive resources required by walking, both young and older adults spontaneously adopted a "posture second" strategy, prioritizing the cognitive task over the gait task.
C1 [Decker, Leslie M.] INSERM, UMR S COMETE Mobilites Attent Orientat Chronobiol, 2 Rue Rochambelles, F-14032 Caen 5, France.
[Decker, Leslie M.] Univ Caen Normandie, Pole Format & Rech Sante, 2 Rue Rochambelles, F-14032 Caen 5, France.
[Decker, Leslie M.; Stergiou, Nicholas] Univ Nebraska, Biomech Res Bldg,6160 Univ Dr, Omaha, NE 68182 USA.
[Cignetti, Fabien] CNRS, UMR 7291, 3 Pl Victor Hugo, F-13331 Marseille 3, France.
[Cignetti, Fabien] Aix Marseille Univ, 3 Pl Victor Hugo, F-13331 Marseille 3, France.
[Hunt, Nathaniel] Univ Calif Berkeley, Dept Integrat Biol, 3040 Valley Life Sci Bldg 3140, Berkeley, CA 94720 USA.
[Potter, Jane F.] Univ Nebraska Med Ctr, Div Geriatr & Gerontol, 986155 Nebraska Med Ctr, Omaha, NE 68198 USA.
[Studenski, Stephanie A.] NIA, Translat Gerontol Branch, Longitudinal Studies Sect, 251 Bayview Blvd,Suite 100,Rm 04B316, Baltimore, MD 21224 USA.
RP Decker, LM (reprint author), INSERM, UMR S COMETE Mobilites Attent Orientat Chronobiol, 2 Rue Rochambelles, F-14032 Caen 5, France.; Decker, LM (reprint author), Univ Caen Normandie, Pole Format & Rech Sante, 2 Rue Rochambelles, F-14032 Caen 5, France.
EM leslie.decker@unicaen.fr
FU National Institute on Aging at the National Institutes of Health
[1K99AG033684]
FX This study was supported by the National Institute on Aging at the
National Institutes of Health (1K99AG033684). The authors are very
grateful to Sharon Lynn Salhi, Ph.D., for presubmission editorial
assistance.
NR 76
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD AUG
PY 2016
VL 38
IS 4
BP 363
EP 375
DI 10.1007/s11357-016-9941-y
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA DY8SJ
UT WOS:000385400700010
PM 27488838
ER
PT J
AU Toepfer, CN
Sikkel, MB
Caorsi, V
Vydyanath, A
Torre, I
Copeland, O
Lyon, AR
Marston, SB
Luther, PK
Macleod, KT
West, TG
Ferenczi, MA
AF Toepfer, Christopher N.
Sikkel, Markus B.
Caorsi, Valentina
Vydyanath, Anupama
Torre, Iratxe
Copeland, O'Neal
Lyon, Alexander R.
Marston, Steven B.
Luther, Pradeep K.
Macleod, Kenneth T.
West, Timothy G.
Ferenczi, Michael A.
TI A post-MI power struggle: adaptations in cardiac power occur at the
sarcomere level alongside MyBP-C and RLC phosphorylation
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE contractile function; infarction; regulatory light chain; myosin binding
protein-C; contractile apparatus
ID BINDING-PROTEIN-C; REGULATORY LIGHT-CHAIN; HUMAN HEART-MUSCLE; IN-VITRO
MOTILITY; CHRONIC MYOCARDIAL-INFARCTION; TROPONIN-I; THICK FILAMENTS;
RAT-HEART; CONTRACTILE FUNCTION; CALCIUM SENSITIVITY
AB Myocardial remodeling in response to chronic myocardial infarction (CMI) progresses through two phases, hypertrophic "compensation" and congestive "decompensation." Nothing is known about the ability of uninfarcted myocardium to produce force, velocity, and power during these clinical phases, even though adaptation in these regions likely drives progression of compensation. We hypothesized that enhanced cross-bridge-level contractility underlies mechanical compensation and is controlled in part by changes in the phosphorylation states of myosin regulatory proteins. We induced CMI in rats by left anterior descending coronary artery ligation. We then measured mechanical performance in permeabilized ventricular trabecula taken distant from the infarct zone and assayed myosin regulatory protein phosphorylation in each individual trabecula. During full activation, the compensated myocardium produced twice as much power and 31% greater isometric force compared with noninfarcted controls. Isometric force during submaximal activations was raised >2.4-fold, while power was 2-fold greater. Electron and confocal microscopy demonstrated that these mechanical changes were not a result of increased density of contractile protein and therefore not an effect of tissue hypertrophy. Hence, sarcomere-level contractile adaptations are key determinants of enhanced trabecular mechanics and of the overall cardiac compensatory response. Phosphorylation of myosin regulatory light chain (RLC) increased and remained elevated post-MI, while phosphorylation of myosin binding protein-C (MyBP-C) was initially depressed but then increased as the hearts became decompensated. These sensitivities to CMI are in accordance with phosphorylation-dependent regulatory roles for RLC and MyBP-C in crossbridge function and with compensatory adaptation in force and power that we observed in post-CMI trabeculae.
C1 [Toepfer, Christopher N.; Caorsi, Valentina; Vydyanath, Anupama; Torre, Iratxe; Luther, Pradeep K.; Ferenczi, Michael A.] Imperial Coll London, Natl Heart & Lung Inst, Mol Med Sect, London, England.
[Toepfer, Christopher N.] Natl Heart & Lung Inst, Lab Mol Physiol, NIH, Bethesda, MD USA.
[Sikkel, Markus B.; Copeland, O'Neal; Lyon, Alexander R.; Marston, Steven B.; Macleod, Kenneth T.] Imperial Coll London, Natl Heart & Lung Inst, Dept Cardiac Med, London, England.
[Caorsi, Valentina] Inst Curie, UMR168, Lab Physicochim, Paris, France.
[Lyon, Alexander R.] Royal Brompton Hosp, Nationa Inst Hlth Res, Cardiovasc Biomed Res Unit, London, England.
[West, Timothy G.] Royal Vet Coll London, Struct & Mot Lab, N Mymms, England.
[Ferenczi, Michael A.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
RP Toepfer, CN (reprint author), Harvard Med Sch, Dept Genet, NRB Room 256,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM christopher_toepfer@HMS.harvard.edu
RI Ferenczi, Michael/F-9510-2015;
OI Ferenczi, Michael/0000-0002-0349-331X; Toepfer,
Christopher/0000-0003-4671-2030
FU Wellcome Trust [091460/Z/10/Z, 092852/Z/10/Z]; Biotechnology and
Biological Sciences Research Council [BB/I019448/1]
FX The work presented herein was supported by Wellcome Trust Grants
091460/Z/10/Z and 092852/Z/10/Z and Biotechnology and Biological
Sciences Research Council Grant BB/I019448/1.
NR 68
TC 0
Z9 0
U1 3
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD AUG
PY 2016
VL 311
IS 2
BP H465
EP H475
DI 10.1152/ajpheart.00899.2015
PG 11
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA DY3DK
UT WOS:000384970800016
PM 27233767
ER
PT J
AU Schliep, KC
Mumford, SL
Johnstone, EB
Peterson, CM
Sharp, HT
Stanford, JB
Chen, Z
Backonja, U
Wallace, ME
Louis, GMB
AF Schliep, K. C.
Mumford, Sunni L.
Johnstone, Erica B.
Peterson, C. Matthew
Sharp, Howard T.
Stanford, Joseph B.
Chen, Zhen
Backonja, Uba
Wallace, Maeve E.
Louis, Germaine M. Buck
TI Sexual and physical abuse and gynecologic disorders
SO HUMAN REPRODUCTION
LA English
DT Article
DE physical abuse; sexual abuse; epidemiology; endometriosis; pelvic
adhesions
ID INTIMATE PARTNER VIOLENCE; CHRONIC PELVIC PAIN; ENDOMETRIOSIS; HEALTH;
WOMEN; RELIABILITY; CHILDHOOD; DIAGNOSIS; ADHESIONS; EXPOSURE
AB Is sexual and/or physical abuse history associated with incident endometriosis diagnosis or other gynecologic disorders among premenopausal women undergoing diagnostic and/or therapeutic laparoscopy or laparotomy regardless of clinical indication?
No association was observed between either a history of sexual or physical abuse and risk of endometriosis, ovarian cysts or fibroids; however, a history of physical abuse was associated with a higher likelihood of adhesions after taking into account important confounding and mediating factors.
Sexual and physical abuse may alter neuroendocrine-immune processes leading to a higher risk for endometriosis and other noninfectious gynecologic disorders, but few studies have assessed abuse history prior to diagnosis.
The study population for these analyses includes the ENDO Study (2007-2009) operative cohort: 473 women, ages 18-44 years, who underwent a diagnostic and/or therapeutic laparoscopy or laparotomy at 1 of the 14 surgical centers located in Salt Lake City, UT, USA or San Francisco, CA, USA. Women with a history of surgically confirmed endometriosis were excluded.
Prior to surgery, women completed standardized abuse questionnaires. Relative risk (RR) of incident endometriosis, uterine fibroids, adhesions or ovarian cysts by abuse history were estimated, adjusting for age, race/ethnicity, education, marital status, smoking, gravidity and recruitment site. We assessed whether a history of chronic pelvic pain, depression, or STIs explained any relationships via mediation analyses.
43 and 39% of women reported experiencing sexual and physical abuse. No association was observed between either a history of sexual or physical abuse, versus no history, and risk of endometriosis (aRR: 1.00 [95% confidence interval (CI): 0.80-1.25]); aRR: 0.83 [95% CI: 0.65-1.06]), ovarian cysts (aRR: 0.67 [95% CI: 0.39-1.15]); aRR: 0.60 [95% CI: 0.34-1.09]) or fibroids (aRR: 1.25 [95% CI: 0.85-1.83]); aRR: 1.36 [95% CI: 0.92-2.01]). Conversely, a history of physical abuse, versus no history, was associated with higher risk of adhesions (aRR: 2.39 [95% CI: 1.18-4.85]). We found no indication that the effect of abuse on women's adhesion risk could be explained by a history of chronic pelvic pain, depression or STIs.
Limitations to our study include inquiries on childhood physical but not sexual abuse. Additionally, we did not inquire about childhood or adulthood emotional support systems, found to buffer the negative impact of stress on gynecologic health.
Abuse may be associated with some but not all gynecologic disorders with neuroendocrine-inflammatory origin. High prevalence of abuse reporting supports the need for care providers to screen for abuse and initiate appropriate follow-up.
Supported by the Intramural Research Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (contracts NO1-DK-6-3428, NO1-DK-6-3427, and 10001406-02). The authors have no potential competing interests.
C1 [Schliep, K. C.; Stanford, Joseph B.] Univ Utah, Sch Med, Dept Family & Prevent Med, Salt Lake City, UT 84108 USA.
[Schliep, K. C.; Mumford, Sunni L.; Chen, Zhen; Louis, Germaine M. Buck] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, Rockville, MD USA.
[Johnstone, Erica B.; Peterson, C. Matthew; Sharp, Howard T.] Univ Utah, Sch Med, Dept Obstet & Gynecol, Salt Lake City, UT 84108 USA.
[Backonja, Uba] Univ Washington, Sch Med, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA.
[Wallace, Maeve E.] Tulane Univ, Mary Amelia Womens Ctr, New Orleans, LA 70118 USA.
RP Schliep, KC (reprint author), Univ Utah, Div Publ Hlth, 375 Chipeta Way,Suite A, Salt Lake City, UT 84108 USA.
EM karen.schliep@utah.edu
OI Buck Louis, Germaine/0000-0002-1774-4490
FU Intramural Research Program, Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD) [NO1-DK-6-3428,
NO1-DK-6-3427, 10001406-02]; National Institutes of Health Graduate
Partnership Program; National Institutes of Health, National Library of
Medicine (NLM) Biomedical and Health Informatics Training Program at the
University ofWashington [T15LM007442]
FX Funded by the Intramural Research Program, Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD;
contracts NO1-DK-6-3428; NO1-DK-6-3427; 10001406-02). Ethicon
Endo-Surgery LLC donated shears and scalpel blades through a signed
Materials Transfer Agreement with the University of Utah and the NICHD.
U.B. was funded through the National Institutes of Health Graduate
Partnership Program and is currently funded in part by the National
Institutes of Health, National Library of Medicine (NLM) Biomedical and
Health Informatics Training Program at the University ofWashington
(Grant Nr. T15LM007442).
NR 35
TC 0
Z9 0
U1 3
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2016
VL 31
IS 8
BP 1904
EP 1912
DI 10.1093/humrep/dew153
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DV9GE
UT WOS:000383247700030
PM 27334336
ER
PT J
AU Forman, EJ
Franasiak, JM
Patounakis, G
Scott, RT
AF Forman, Eric J.
Franasiak, Jason M.
Patounakis, George
Scott, Richard T.
TI Why abandoning sustained implantation rate may be throwing the baby out
with the bathwater
SO HUMAN REPRODUCTION
LA English
DT Letter
C1 [Forman, Eric J.; Franasiak, Jason M.; Scott, Richard T.] Reprod Med Associates New Jersey, Basking Ridge, NJ 07920 USA.
[Patounakis, George] NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Franasiak, JM (reprint author), Reprod Med Associates New Jersey, Basking Ridge, NJ 07920 USA.
EM jfranasiak@rmanj.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2016
VL 31
IS 8
BP 1926
EP 1927
DI 10.1093/humrep/dew138
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DV9GE
UT WOS:000383247700032
PM 27301363
ER
PT J
AU Aarons, GA
Sommerfeld, DH
Chi, BH
Ezeanolue, EE
Sturke, R
Guay, L
Siberry, GK
AF Aarons, Gregory A.
Sommerfeld, David H.
Chi, Benjamin H.
Ezeanolue, Echezona E.
Sturke, Rachel
Guay, Laura
Siberry, George K.
TI Concept Mapping of PMTCT Implementation Challenges and Solutions Across
6 sub-Saharan African Countries in the NIH-PEPFAR PMTCT Implementation
Science Alliance
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE implementation; mixed methods; HIV
ID HEALTH-SERVICES RESEARCH; FRAMEWORK; DISSEMINATION; TRANSMISSION;
PREVENTION; CONTEXT
AB Objective: Although tremendous gains have been made to reduce mother-to-child HIV transmission (MTCT) globally, evidence-based practice implementation remains inconsistent in sub-Saharan Africa. We sought to identify the key domains for effective prevention of MTCT (PMTCT) implementation, using a participatory mixed-methods approach.
Methods: Participants were members of the NIH-PEPFAR PMTCT Implementation Science Alliance (ISA), a platform of researchers, public-health practitioners, policymakers, and donors supported through NIH/PEPFAR. We used concept mapping to identify priority areas for PMTCT implementation science. Participants responded to the focus question: "In your experience, what factors have facilitated or hindered implementation of PMTCT interventions?" Responses were consolidated into discrete statements, grouped together based on similarity, and rated for importance, changeability, and extent to which ISA participation enhanced the capacity to influence/change the factor.
Results: Using multidimensional scaling and cluster analysis, we identified 12 key domains of PMTCT implementation. Two domains (Governmental Commitment and Data Measurement & Collection) were consistently ranked at or near the top for overall importance, perceived changeability, and enhanced ability to address through ISA participation.
Discussion: Through a stakeholder-based, participatory approach, we identified key domains for that should be considered for future PMTCT implementation research in sub-Saharan Africa.
C1 [Aarons, Gregory A.; Sommerfeld, David H.] Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,0812, San Diego, CA 92103 USA.
[Chi, Benjamin H.] Univ North Carolina Chapel Hill, Dept Obstet & Gynecol, Chapel Hill, NC USA.
[Ezeanolue, Echezona E.] Univ Nevada, Sch Community Hlth Sci, Las Vegas, NV 89154 USA.
[Sturke, Rachel] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
[Guay, Laura] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
[Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Aarons, GA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,0812, San Diego, CA 92103 USA.
EM gaarons@ucsd.edu
FU National Institutes of Health Fogarty International Center (FIC); Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD); [R01 MH072961]; [R01 DA038466]; [K24 AI120796]; [R01
HD075131]; [R01 HD075050]
FX Supported by R01 MH072961 and R01 DA038466 (G.A.A.), K24 AI120796 and
R01 HD075131 (B.H.C.), and R01 HD075050 (E.E.E.). Overall support for
the PMTCT Implementation Science Alliance was provided by the National
Institutes of Health Fogarty International Center (FIC) and the Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD).
NR 29
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2016
VL 72
SU 2
BP S202
EP S206
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YG
UT WOS:000385275100016
PM 27355510
ER
PT J
AU Ezeanolue, EE
Powell, BJ
Patel, D
Olutola, A
Obiefune, M
Dakum, P
Okonkwo, P
Gobir, B
Akinmurele, T
Nwandu, A
Torpey, K
Oyeledum, B
Aina, M
Eyo, A
Oleribe, O
Ibanga, I
Oko, J
Anyaike, C
Idoko, J
Aliyu, MH
Sturke, R
Watts, H
Siberry, G
AF Ezeanolue, Echezona E.
Powell, Byron J.
Patel, Dina
Olutola, Ayodotun
Obiefune, Michael
Dakum, Patrick
Okonkwo, Prosper
Gobir, Bola
Akinmurele, Timothy
Nwandu, Anthea
Torpey, Kwasi
Oyeledum, Bolanle
Aina, Muyiwa
Eyo, Andy
Oleribe, Obinna
Ibanga, Ikoedem
Oko, John
Anyaike, Chukwuma
Idoko, John
Aliyu, Muktar H.
Sturke, Rachel
Watts, Heather
Siberry, George
CA Nigeria Implementation Sci
TI Identifying and Prioritizing Implementation Barriers, Gaps, and
Strategies Through the Nigeria Implementation Science Alliance: Getting
to Zero in the Prevention of Mother-to-Child Transmission of HIV
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE barriers; gaps; implementation strategies; implementation research;
Nigeria
ID HEALTH
AB Background: In 2013, Nigeria accounted for 15% of the 1.3 million pregnant women living with HIV in sub-Saharan Africa and 26% of new infections among children worldwide. Despite this, less than 20% of pregnant women in Nigeria received an HIV test during pregnancy, and only 23% of HIV-infected pregnant women received appropriate intervention following HIV diagnosis. This article reports findings from 2 structured group exercises conducted at the first Nigeria Implementation Science Alliance Conference to identify (1) barriers and research gaps related to prevention of mother-to-child transmission (PMTCT) and (2) potential strategies and interventions that could address PMTCT challenges.
Methods: Two 1-hour structured group exercises were conducted with 10 groups of 14-15 individuals (n = 145), who were asked to brainstorm barriers and strategies and to rank their top 3 in each category. Data analysis eliminated duplicate responses and categorized each of the priorities along the HIV care continuum: HIV diagnosis, linkage to care, or retention in care.
Results: Participating stakeholders identified 20 unique barriers and research gaps related to PMTCT across the HIV continuum. Twenty-five unique interventions and implementation strategies were identified. Similar to the barriers and research gaps, these interventions and strategies were distributed across the HIV care continuum.
Conclusions: The barriers and strategies identified in this study represent important pathways to progress addressing MTCT. The deliberate involvement of state and federal policy makers, program implementers, and researchers helps ensure that they are relevant and actionable.
C1 [Ezeanolue, Echezona E.; Patel, Dina] Univ Nevada, Div Hlth Sci, Dept Epidemiol & Biostat, Global Hlth Initiat, Las Vegas, NV 89154 USA.
[Ezeanolue, Echezona E.; Patel, Dina] Univ Nevada, Div Hlth Sci, Dept Epidemiol & Biostat, Implementat Res Initiat, Las Vegas, NV 89154 USA.
[Ezeanolue, Echezona E.; Patel, Dina] HealthySunrise Fdn, Enugu, Nigeria.
[Powell, Byron J.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Olutola, Ayodotun] Ctr Clin Care & Clin Res, Abuja, Nigeria.
[Obiefune, Michael] Partners Prevent Educ Training Treatment & Res, Abuja, Nigeria.
[Obiefune, Michael; Nwandu, Anthea] Univ Maryland, Inst Human Virol, Div Epidemiol & Prevent, Baltimore, MD 21201 USA.
[Dakum, Patrick] Inst Human Virol, Abuja, Nigeria.
[Okonkwo, Prosper] AIDS Prevent Initiat, Abuja, Nigeria.
[Okonkwo, Prosper] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
[Gobir, Bola; Nwandu, Anthea] Maryland Global Initiatives Corp, Baltimore, MD USA.
[Akinmurele, Timothy] Enhanced Hlth Access Initiat, Abuja, Nigeria.
[Torpey, Kwasi] Family Hlth Int, Abuja, Nigeria.
[Oyeledum, Bolanle] Ctr Integrated Hlth Programs, Abuja, Nigeria.
[Aina, Muyiwa] Solina Hlth, Abuja, Nigeria.
[Eyo, Andy] Excellence Community Educ Welf Scheme, Abuja, Nigeria.
[Oleribe, Obinna] Excellence & Friends Management Consult, Abuja, Nigeria.
[Ibanga, Ikoedem] ProHlth Int, Abuja, Nigeria.
[Oko, John] Catholic Caritas Fdn Nigeria, Abuja, Nigeria.
[Anyaike, Chukwuma] Federal Minist Hlth, Abuja, Nigeria.
[Idoko, John] Natl Agcy Control AIDS, Abuja, Nigeria.
[Aliyu, Muktar H.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Global Hlth, Nashville, TN USA.
[Sturke, Rachel] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
[Watts, Heather] US Dept State, Off US Global AIDS Coordinator, Washington, DC 20520 USA.
[Siberry, George] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Ezeanolue, EE (reprint author), Univ Nevada, Sch Community Hlth Sci, Global Hlth Initiat, 4505 S Maryland Pkwy,POB 454009, Las Vegas, NV 89154 USA.
EM echezona.ezeanolue@unlv.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development; National Institute of Mental Health; President's Emergency
Plan for AIDS Relief (PEPFAR) [R01HD075050]; Nigeria Implementation
Science Alliance
FX Funding for the first National Implementation Science Conference was
provided by members of the Nigeria Implementation Science Alliance
(member organization listed below). E.E.E. received funding from the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, the National Institute of Mental Health, the President's
Emergency Plan for AIDS Relief (PEPFAR), award number R01HD075050.
NR 26
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2016
VL 72
SU 2
BP S161
EP S166
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YG
UT WOS:000385275100010
PM 27355504
ER
PT J
AU Glass, RI
Birx, DL
AF Glass, Roger I.
Birx, Deborah L.
TI Advancing PMTCT Implementation Through Scientific Research: A Vital
Agenda for Combating the Global AIDS Epidemic in Low- and Middle-Income
Countries
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Editorial Material
C1 [Glass, Roger I.] NIH, Fogarty Int Ctr, 31 Ctr Dr,Room B2C02, Bethesda, MD 20892 USA.
[Birx, Deborah L.] US Dept State, Off US Global AIDS Coordinator, Washington, DC 20520 USA.
RP Glass, RI (reprint author), NIH, Fogarty Int Ctr, 31 Ctr Dr,Room B2C02, Bethesda, MD 20892 USA.
EM roger.glass@nih.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2016
VL 72
SU 2
BP S101
EP S101
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YG
UT WOS:000385275100001
PM 27355495
ER
PT J
AU Price, JT
Wheeler, SB
Stranix-Chibanda, L
Hosek, SG
Watts, DH
Siberry, GK
Spiegel, HML
Stringer, JS
Chi, BH
AF Price, Joan T.
Wheeler, Stephanie B.
Stranix-Chibanda, Lynda
Hosek, Sybil G.
Watts, D. Heather
Siberry, George K.
Spiegel, Hans M. L.
Stringer, Jeffrey S.
Chi, Benjamin H.
TI Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and
Breastfeeding in Sub-Saharan Africa
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE pre-exposure prophylaxis; HIV prevention; pregnancy; breastfeeding;
sub-Saharan Africa; cost-effectiveness
ID TENOFOVIR DISOPROXIL FUMARATE; RANDOMIZED CLINICAL-TRIAL; TO-CHILD
TRANSMISSION; ANTIRETROVIRAL THERAPY; POOLED ANALYSIS; SOUTH-AFRICA;
DISABILITY WEIGHTS; UNINFECTED INFANTS; INFECTED CHILDREN; INCOME
COUNTRIES
AB Introduction: Antiretroviral pre-exposure prophylaxis (PrEP) for the prevention of HIV acquisition is cost-effective when delivered to those at substantial risk. Despite a high incidence of HIV infection among pregnant and breastfeeding women in sub-Saharan Africa (SSA), a theoretical increased risk of preterm birth on PrEP could outweigh the HIV prevention benefit.
Methods: We developed a decision analytic model to evaluate a strategy of daily oral PrEP during pregnancy and breastfeeding in SSA. We approached the analysis from a health care system perspective across a lifetime time horizon. Model inputs were derived from existing literature and local sources. The incremental cost-effectiveness ratio (ICER) of PrEP versus no PrEP was calculated in 2015 U. S. dollars per disability-adjusted life year (DALY) averted. We evaluated the effect of uncertainty in baseline estimates through one-way and probabilistic sensitivity analyses.
Results: PrEP administered to pregnant and breastfeeding women in SSA was cost-effective. In a base case of 10,000 women, the administration of PrEP averted 381 HIV infections but resulted in 779 more preterm births. PrEP was more costly per person ($450 versus $117), but resulted in fewer disability-adjusted life years (DALYs) (3.15 versus 3.49). The incremental cost-effectiveness ratio of $965/DALY averted was below the recommended regional threshold for cost-effectiveness of $6462/DALY. Probabilistic sensitivity analyses demonstrated robustness of the model.
Conclusions: Providing PrEP to pregnant and breastfeeding women in SSA is likely cost-effective, although more data are needed about adherence and safety. For populations at high risk of HIV acquisition, PrEP may be considered as part of a broader combination HIV prevention strategy.
C1 [Price, Joan T.; Stringer, Jeffrey S.; Chi, Benjamin H.] Univ North Carolina Chapel Hill, Div Global Womens Hlth, Dept Obstet & Gynecol, Chapel Hill, NC USA.
[Wheeler, Stephanie B.] Univ North Carolina Chapel Hill, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Stranix-Chibanda, Lynda] Univ Zimbabwe, Dept Pediat & Child Hlth, Coll Hlth Sci, Harare, Zimbabwe.
[Hosek, Sybil G.] John H Stroger Jr Hosp Cook Cty, Dept Psychiat, Chicago, IL USA.
[Watts, D. Heather] US Dept State, Off Global AIDS Coordinator & Hlth Diplomacy, Washington, DC 20520 USA.
[Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
[Spiegel, Hans M. L.] NIAID, Kelly Govt Serv, Prevent Sci Program, Div Aids,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Price, JT (reprint author), Univ North Carolina Chapel Hill, Div Global Womens Hlth, CB 7577, Chapel Hill, NC 27599 USA.
EM joan_price@med.unc.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD) [R01HD075131, T32HD075731]; National Institute of
Allergy and Infectious Diseases (NIAID) [K24AI120796]; International
Maternal Pediatric Adolescent AIDS Clinical Trials Network [UM1AI068632,
UM1AI068616, UM1AI067616]; NIAID; NICHD; National Institute of Mental
Health; Gilead Foundation
FX Investigator and trainee support for this study was provided by the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD; R01HD075131 and T32HD075731) and the National
Institute of Allergy and Infectious Diseases (NIAID; K24AI120796).
Additional support was provided by the International Maternal Pediatric
Adolescent AIDS Clinical Trials Network (UM1AI068632, UM1AI068616, and
UM1AI067616); funded by NIAID, NICHD, and the National Institute of
Mental Health.; BHC received grant funding from the Gilead Foundation to
support global health research training. The remaining authors have no
conflicts of interest to disclose.
NR 91
TC 4
Z9 4
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2016
VL 72
SU 2
BP S145
EP S153
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YG
UT WOS:000385275100008
PM 27355502
ER
PT J
AU Sturke, R
Siberry, G
Mofenson, L
Watts, DH
McIntyre, JA
Brouwers, P
Guay, L
AF Sturke, Rachel
Siberry, George
Mofenson, Lynne
Watts, D. Heather
McIntyre, James A.
Brouwers, Pim
Guay, Laura
CA NIH-PEPFAR PMTCT Implementation
TI Creating Sustainable Collaborations for Implementation Science: The Case
of the NIH-PEPFAR PMTCT Implementation Science Alliance
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV/AIDS; implementation science; PMTCT; PEPFAR
C1 [Sturke, Rachel] NIH, Div Int Sci Policy Planning & Evaluat, 16 Ctr Dr, Bethesda, MD 20892 USA.
[Sturke, Rachel] NIH, Ctr Global Hlth Studies, Fogarty Int Ctr, 16 Ctr Dr, Bethesda, MD 20892 USA.
[Siberry, George] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
[Mofenson, Lynne] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA.
[Watts, D. Heather; Guay, Laura] US Dept State, Off US Global AIDS Coordinator, Washington, DC 20520 USA.
[McIntyre, James A.] Univ Cape Town, Anova Hlth Inst, Johannesburg, South Africa.
[McIntyre, James A.] Univ Cape Town, Sch Publ Hlth & Family Med, Johannesburg, South Africa.
[Brouwers, Pim] NIMH, NIH, Bethesda, MD 20892 USA.
RP Sturke, R (reprint author), NIH, Div Int Sci Policy Planning & Evaluat, 16 Ctr Dr, Bethesda, MD 20892 USA.; Sturke, R (reprint author), NIH, Ctr Global Hlth Studies, Fogarty Int Ctr, 16 Ctr Dr, Bethesda, MD 20892 USA.
EM rachel.sturke@nih.gov
NR 11
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD AUG 1
PY 2016
VL 72
SU 2
BP S102
EP S107
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY6YG
UT WOS:000385275100002
PM 27355496
ER
PT J
AU Johnson, RF
Hammoud, DA
Perry, DL
Solomon, J
Moore, IN
Lackemeyer, MG
Bohannon, JK
Sayre, PJ
Minai, M
Papaneri, AB
Hagen, KR
Janosko, KB
Jett, C
Cooper, K
Blaney, JE
Jahrling, PB
AF Johnson, Reed F.
Hammoud, Dima A.
Perry, Donna L.
Solomon, Jeffrey
Moore, Ian N.
Lackemeyer, Matthew G.
Bohannon, Jordan K.
Sayre, Philip J.
Minai, Mahnaz
Papaneri, Amy B.
Hagen, Katie R.
Janosko, Krisztina B.
Jett, Catherine
Cooper, Kurt
Blaney, Joseph E.
Jahrling, Peter B.
TI Exposure of rhesus monkeys to cowpox virus Brighton Red by
large-particle aerosol droplets results in an upper respiratory tract
disease
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID CYNOMOLGUS MACAQUES; ECTROMELIA VIRUS; SMALLPOX VIRUS; INFECTION;
IDENTIFICATION; INOCULATION; OUTBREAK; PROTEIN; LAVAGE; MODEL
AB We previously demonstrated that small-particle (0.5-3.0 mu m) aerosol infection of rhesus monkeys (Macaca mulatta) with cowpox virus (CPXV)-Brighton Red (BR) results in fulminant respiratory tract disease characterized by severe lung parenchymal pathology but only limited systemic virus dissemination and limited classic epidermal pox-like lesion development (Johnson et al., 2015). Based on these results, and to further develop CPXV as an improved model of human smallpox, we evaluated a novel large-particle aerosol (7.0-9.0 mu m) exposure of rhesus monkeys to CPXV-BR and monitored for respiratory tract disease by serial computed tomography (CT). As expected, the upper respiratory tract and large airways were the major sites of virus-induced pathology following large-particle aerosol exposure. Large-particle aerosol CPXV exposure of rhesus macaques resulted in severe upper airway and large airway pathology with limited systemic dissemination.
C1 [Johnson, Reed F.; Papaneri, Amy B.; Jahrling, Peter B.] NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD 21702 USA.
[Hammoud, Dima A.] NIH, Ctr Infect Dis Imaging Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA.
[Perry, Donna L.; Lackemeyer, Matthew G.; Bohannon, Jordan K.; Sayre, Philip J.; Hagen, Katie R.; Janosko, Krisztina B.; Jett, Catherine; Cooper, Kurt; Jahrling, Peter B.] NIAID, Integrated Res Facil, NIH, Frederick, MD 21702 USA.
[Solomon, Jeffrey] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Clin Res Directorate, Clin Monitoring Res Program, Frederick, MD 21702 USA.
[Moore, Ian N.; Minai, Mahnaz] NIAID, Infect Dis Pathogenesis Sect, NIH, Bethesda, MD 20892 USA.
[Blaney, Joseph E.] NIAID, Off Sci Director, NIH, Bethesda, MD 20892 USA.
RP Johnson, RF (reprint author), NIAID, Emerging Viral Pathogens Sect, NIH, Frederick, MD 21702 USA.
EM johnsonreed@mail.nih.gov
FU US National Institute of Allergy and Infectious Diseases (NIAID)
Division of Intramural Research; Battelle Memorial Institute's prime
contract; NIAID [HHSN272200700016I]; federal funds from National Cancer
Institute, National Institutes of Health [HHSN261200800001E]
FX This work was supported by the US National Institute of Allergy and
Infectious Diseases (NIAID) Division of Intramural Research. We are
grateful to Marisa St. Claire (Integrated Research Facility, Division of
Clinical Research, NIAID), Russell Byrum (Integrated Research Facility,
Division of Clinical Research NIAID), Dan Ragland (Integrated Research
Facility, Division of Clinical Research, NIAID), and the entire EVPS and
IRF team for their contributions to these studies. We thank Jiro Wada
for his contribution to the preparation of this manuscript. The content
of this publication does not necessarily reflect the views or policies
of the US Department of Health and Human Services (DHHS) or of the
institutions and companies affiliated with the authors. This work was
funded in part through Battelle Memorial Institute's prime contract with
the NIAID under contract no. HHSN272200700016I. K. B. J. and K. J. B.
performed this work as employees of Battelle Memorial Institute.
Subcontractors to Battelle Memorial Institute who performed this work
are: C. J., an employee of Tunnell Government Services, Inc.; D. L. P.
and K. C., employees of Charles River Laboratories; K. R. H. an employee
of MRI Global; and P. J. S. an employee of MedRelief. This project has
been funded in whole or in part with federal funds from the National
Cancer Institute, National Institutes of Health, under contract no.
HHSN261200800001E. The content of this publication does not necessarily
reflect the views or policies of the DHHS, nor does mention of trade
names, commercial products, or organization imply endorsement by the US
Government.
NR 40
TC 0
Z9 0
U1 0
U2 0
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD AUG
PY 2016
VL 97
BP 1942
EP 1954
DI 10.1099/jgv.0.000501
PN 8
PG 13
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA DY7DB
UT WOS:000385288500022
PM 27166137
ER
PT J
AU Tanaka, M
Fujiwara, A
Suzuki, A
Yamasaki, T
Hasebe, R
Masujin, K
Horiuchi, M
AF Tanaka, Misaki
Fujiwara, Ai
Suzuki, Akio
Yamasaki, Takeshi
Hasebe, Rie
Masujin, Kentaro
Horiuchi, Motohiro
TI Comparison of abnormal isoform of prion protein in prion-infected cell
lines and primary-cultured neurons by PrPSc-specific immunostaining
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID MOUSE NEUROBLASTOMA-CELLS; SCRAPIE-ASSOCIATED FORM; MONOCLONAL-ANTIBODY;
ELECTRON-MICROSCOPY; NORMAL BRAIN; DISEASE; LOCALIZATION; CONVERSION;
SURFACE; STRAIN
AB We established abnormal isoform of prion protein (PrPSc)-specific double immunostaining using mAb 132, which recognizes aa 119-127 of the PrP molecule, and novel PrPSc-specific mAb 8D5, which recognizes the N-terminal region of the PrP molecule. Using the PrPSc-specific double immunostaining, we analysed PrPSc in immortalized neuronal cell lines and primary cerebral-neuronal cultures infected with prions. The PrPSc-specific double immunostaining showed the existence of PrPSc positive for both mAbs 132 and 8D5, as well as those positive only for either mAb 132 or mAb 8D5. This indicated that double immunostaining detects a greater number of PrPSc species than single immunostaining. Double immunostaining revealed cell-type-dependent differences in PrPSc staining patterns. In the 22 L prion strain-infected Neuro2a (N2a)-3 cells, a subclone of N2a neuroblastoma cell line, or GT1-7, a subclone of the GT1 hypothalamic neuronal cell line, granular PrPSc stains were observed at the perinuclear regions and cytoplasm, whereas unique string-like PrPSc stains were predominantly observed on the surface of the 22 L strain-infected primary cerebral neurons. Only 14% of PrPSc in the 22 L strain-infected N2a-3 cells were positive for mAb 8D5, indicating that most of the PrPSc in N2a-3 lack the N-terminal portion. In contrast, nearly half PrPSc detected in the 22 L strain-infected primary cerebral neurons were positive for mAb 8D5, suggesting the abundance of full-length PrPSc that possesses the N-terminal portion of PrP. Further analysis of prion-infected primary neurons using PrPSc-specific immunostaining will reveal the neuron-specific mechanism for prion propagation.
C1 [Tanaka, Misaki; Fujiwara, Ai; Suzuki, Akio; Yamasaki, Takeshi; Hasebe, Rie; Horiuchi, Motohiro] Hokkaido Univ, Grad Sch Vet Med, Lab Vet Hyg, Kita Ku, Kita 18,Nishi 9, Sapporo, Hokkaido 0600818, Japan.
[Masujin, Kentaro] Natl Agr Food Res Org NARO, 3-1-5 Kannondai, Tsukuba, Ibaraki 3050856, Japan.
[Masujin, Kentaro] NIAID, Lab Persistent Viral Dis, Rocky Mt Labs, NIH, Hamilton, MT USA.
RP Horiuchi, M (reprint author), Hokkaido Univ, Grad Sch Vet Med, Lab Vet Hyg, Kita Ku, Kita 18,Nishi 9, Sapporo, Hokkaido 0600818, Japan.
EM horiuchi@vetmed.hokudai.ac.jp
FU Program for Leading Graduate Schools [F01]; Japan Initiative for Global
Research Network on Infectious Diseases (J-GRID); Ministry of Education,
Culture, Sports, Science and Technology, Japan; Ministry of Health,
Labour and Welfare of Japan; Intramural Research Program of NIAID;
[15H02475]
FX This work was supported by a Grant-in-Aid for Science Research (A)
(grant no. 15H02475), a grant from the Program for Leading Graduate
Schools (F01), and the Japan Initiative for Global Research Network on
Infectious Diseases (J-GRID), from the Ministry of Education, Culture,
Sports, Science and Technology, Japan. This work was also supported by
grants for TSE research (H26-Shokuhin-Ippan-004) and Research on
Measures for Intractable Diseases from the Ministry of Health, Labour
and Welfare of Japan. We thank Zensho Co. Ltd., for the BSL3 facility.
This work was also supported in part by the Intramural Research Program
of NIAID.
NR 47
TC 0
Z9 0
U1 2
U2 2
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD AUG
PY 2016
VL 97
BP 2030
EP 2042
DI 10.1099/jgv.0.000514
PN 8
PG 13
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA DY7DB
UT WOS:000385288500030
PM 27267758
ER
PT J
AU Hammoud, DA
AF Hammoud, Dima A.
TI Molecular Imaging of Inflammation: Current Status
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE inflammation; molecular imaging; PET; MRI; iron oxide nanoparticles
ID POSITRON-EMISSION-TOMOGRAPHY; IRON-OXIDE; FDG PET/CT; CAROTID
ATHEROSCLEROSIS; DISEASE-ACTIVITY; NANOPARTICLES; MRI; RADIOLIGANDS;
MACROPHAGES; DIAGNOSIS
AB The ability to image inflammation in vivo can improve our understanding of the pathophysiology underlying various disease etiologies, including cancer, atherosclerosis, and neurodegeneration. A great wealth of preclinical and translational research has been and is currently being developed to decipher the involvement of the immune system in disease pathophysiology, quantify the course of a disease, and visualize the potential detrimental effects of excessive inflammation. Down the road, the ultimate goal is to have clinical noninvasive in vivo imaging biomarkers of inflammation that will help diagnose disease, establish prognosis, and gauge response to preventative and therapeutic strategies.
C1 [Hammoud, Dima A.] NIH, Ctr Infect Dis Imaging Radiol & Imaging Sci, Bldg 10, Bethesda, MD 20892 USA.
RP Hammoud, DA (reprint author), NIH, Ctr Clin, 10 Ctr Dr,Room 1C368, Bethesda, MD 20814 USA.
EM hammoudd@cc.nih.gov
NR 40
TC 0
Z9 0
U1 3
U2 3
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD AUG 1
PY 2016
VL 57
IS 8
BP 1161
EP 1165
DI 10.2967/jnumed.115.161182
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DY6UJ
UT WOS:000385263600006
PM 27173159
ER
PT J
AU Szabo, R
Samson, AL
Lawrence, DA
Medcalf, RL
Bugge, TH
AF Szabo, R.
Samson, A. L.
Lawrence, D. A.
Medcalf, R. L.
Bugge, T. H.
TI Passenger mutations and aberrant gene expression in congenic tissue
plasminogen activator-deficient mouse strains
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE brain; congenic mice; gene targeting; mutation; tissue plasminogen
activator
ID LONG-TERM POTENTIATION; ANXIETY-LIKE BEHAVIOR; HOMOLOGOUS RECOMBINATION;
MICE LACKING; HUMAN-BRAIN; RECEPTOR; SYSTEM; GENOME; GENERATION;
THROMBOSIS
AB Background The ability to generate defined null mutations in mice revolutionized the analysis of gene function in mammals. However, gene-deficient mice generated by using 129-derived embryonic stem cells may carry large segments of 129 DNA, even when extensively backcrossed to reference strains, such as C57BL/6J, and this may confound interpretation of experiments performed in these mice. Tissue plasminogen activator (tPA), encoded by the PLAT gene, is a fibrinolytic serine protease that is widely expressed in the brain. A number of neurological abnormalities have been reported in tPA-deficient mice.
Objectives To study genetic contamination of tPA-deficient mice.
Materials and methods Whole genome expression array analysis, RNAseq expression profiling, low- and high-density single nucleotide polymorphism (SNP) analysis, bioinformatics and genome editing were used to analyze gene expression in tPA-deficient mouse brains.
Results and conclusions Genes differentially expressed in the brain of Plat(-/-) mice from two independent colonies highly backcrossed onto the C57BL/6J strain clustered near Plat on chromosome 8. SNP analysis attributed this anomaly to about 20 Mbp of DNA flanking Plat being of 129 origin in both strains. Bioinformatic analysis of these 129-derived chromosomal segments identified a significant number of mutations in genes co-segregating with the targeted Plat allele, including several potential null mutations. Using zinc finger nuclease technology, we generated novel passenger mutation'-free isogenic C57BL/6J-Plat(-/-) and FVB/NJ-Plat(-/-) mouse strains by introducing an 11 bp deletion into the exon encoding the signal peptide. These novel mouse strains will be a useful community resource for further exploration of tPA function in physiological and pathological processes.
C1 [Szabo, R.; Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 320, Bethesda, MD 20892 USA.
[Samson, A. L.; Medcalf, R. L.] Monash Univ, Australian Ctr Blood Dis, Alfred Med Res & Educ Precinct, Melbourne, Vic, Australia.
[Lawrence, D. A.] Univ Michigan, Sch Med, Div Cardiovasc Med, Internal Med, Ann Arbor, MI USA.
RP Bugge, TH (reprint author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 320, Bethesda, MD 20892 USA.
EM thomas.bugge@nih.gov
FU NIDCR; National Institutes of Health [HL055374, NS079639]
FX We thank K. Mann and M. Warnock for excellent technical assistance, R.
McEachin of the University of Michigan Bioinformatics Core for
Bioinformatics analysis of the RNAseq data, K. Shedden of the University
of Michigan Center for Statistical Consultation and Research (CSCAR) for
statistical analysis, and M. J. Danton for critically reviewing this
manuscript. This study was supported by the NIDCR Intramural Research
Program (T.H.B) and National Institutes of Health Grants HL055374 and
NS079639 (D. A. L.). Bethesda C57BL/6J-Plat-/- mice and
Bethesda FVB/NJ-Plat-/- mice can be obtained by contacting
Thomas Bugge (Thomas.bugge@nih.gov).
NR 47
TC 2
Z9 2
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD AUG
PY 2016
VL 14
IS 8
BP 1618
EP 1628
DI 10.1111/jth.13338
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DW4HS
UT WOS:000383604400017
PM 27079292
ER
PT J
AU Ghazizadeh, A
Griggs, W
Hikosaka, O
AF Ghazizadeh, Ali
Griggs, Whitney
Hikosaka, Okihide
TI Object-finding skill created by repeated reward experience
SO JOURNAL OF VISION
LA English
DT Article
DE object search; reward; long-term memory; skill
ID BASAL GANGLIA CIRCUITS; NIGRA PARS RETICULATA; FRONTAL EYE FIELD;
VISUAL-SEARCH; SUPERIOR COLLICULUS; SUBSTANTIA-NIGRA; RHESUS-MONKEY;
ATTENTION; FAMILIARITY; MEMORY
AB For most animals, survival depends on rapid detection of rewarding objects, but search for an object surrounded by many others is known to be difficult and time consuming. However, there is neuronal evidence for robust and rapid differentiation of objects based on their reward history in primates (Hikosaka, Kim, Yasuda, & Yamamoto, 2014). We hypothesized that such robust coding should support efficient search for high-value objects, similar to a pop-out mechanism. To test this hypothesis, we let subjects (n = 4, macaque monkeys) view a large number of complex objects with consistently biased rewards with variable training durations (1, 5, or 30+ days). Following training, subjects searched for a high-value object (Good) among a variable number of low-value objects (Bad). Consistent with our hypothesis, we found that Good objects were accurately and quickly targeted, often by a single and direct saccade with a very short latency (<200 ms). The dependence of search times on display size reduced significantly with longer reward training, giving rise to a more efficient search (40 ms/item to 16 ms/item). This object-finding skill showed a large capacity for value-biased objects and was maintained in the long-term memory with no interference from reward learning with other objects. Such object-finding skill, and in particular its large capacity and long term retention, would be crucial for maximizing rewards and biological fitness throughout life where many objects are experienced continuously and/or intermittently.
C1 [Ghazizadeh, Ali; Griggs, Whitney; Hikosaka, Okihide] NEI, Sensorimotor Res Lab, NIH, Bethesda, MD 20892 USA.
[Hikosaka, Okihide] NIDA, NIH, Bethesda, MD 20892 USA.
RP Ghazizadeh, A (reprint author), NEI, Sensorimotor Res Lab, NIH, Bethesda, MD 20892 USA.
EM alieghazizadeh@gmail.com
FU Intramural Research Program at the National Eye Institute
FX This work was supported by the Intramural Research Program at the
National Eye Institute. We thank members of Hikosaka lab for valuable
discussions and Simon Hong for providing technical assistance. The
authors do not have any financial or non-financial conflict of interest
to declare.
NR 43
TC 0
Z9 0
U1 5
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PD AUG
PY 2016
VL 16
IS 10
AR 17
DI 10.1167/16.10.17
PG 13
WC Ophthalmology
SC Ophthalmology
GA DZ3NQ
UT WOS:000385755200017
PM 27564993
ER
PT J
AU Sheliga, BM
Quaia, C
FitzGibbon, EJ
Cumming, BG
AF Sheliga, B. M.
Quaia, C.
FitzGibbon, E. J.
Cumming, B. G.
TI Human short-latency ocular vergence responses produced by interocular
velocity differences
SO JOURNAL OF VISION
LA English
DT Article
DE motion in depth; interocular velocity difference; binocular disparity;
vergence eye movements
ID MOTION-IN-DEPTH; RANDOM-DOT STEREOGRAMS; EYE-MOVEMENTS; RHESUS-MONKEY;
BINOCULAR CUES; AREA MT; DISPARITY; SPEED; PERCEPTION; CORTEX
AB We studied human short-latency vergence eye movements to a novel stimulus that produces interocular velocity differences without a changing disparity signal. Sinusoidal luminance gratings moved in opposite directions (left vs. right; up vs. down) in the two eyes. The grating seen by each eye underwent 1/4-wavelength shifts with each image update. This arrangement eliminated changing disparity cues, since the phase difference between the eyes alternated between 0 degrees and 180 degrees. We nevertheless observed robust short-latency vergence responses (VRs), whose sign was consistent with the interocular velocity differences (IOVDs), indicating that the IOVD cue in isolation can evoke short-latency VRs. The IOVD cue was effective only when the images seen by the two eyes overlapped in space. We observed equally robust VRs for opposite horizontal motions (left in one eye, right in the other) and opposite vertical motions (up in one eye, down in the other). Whereas the former are naturally generated by objects moving in depth, the latter are not part of our normal experience. To our knowledge, this is the first demonstration of a behavioral consequence of vertical IOVD. This may reflect the fact that some neurons in area MT are sensitive to these motion signals (Czuba, Huk, Cormack, & Kohn, 2014). VRs were the strongest for spatial frequencies in the range of 0.35-1 c/degrees, much higher than the optimal spatial frequencies for evoking ocular-following responses observed during frontoparallel motion. This suggests that the two motion signals are detected by different neuronal populations. We also produced IOVD using moving uncorrelated one-dimensional white-noise stimuli. In this case the most effective stimuli have low speed, as predicted if the drive originates in neurons tuned to high spatial frequencies (Sheliga, Quaia, FitzGibbon, & Cumming, 2016).
C1 [Sheliga, B. M.; Quaia, C.; FitzGibbon, E. J.; Cumming, B. G.] NEI, Sensorimotor Res Lab, NIH, Bethesda, MD 20892 USA.
RP Sheliga, BM (reprint author), NIH, Sensorimotor Res Lab, Bldg 10, Bethesda, MD 20892 USA.
EM bms@nei.nih.gov
FU Intramural Program of the National Eye Institute at the NIH
FX This research was supported by the Intramural Program of the National
Eye Institute at the NIH.
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PD AUG
PY 2016
VL 16
IS 10
AR 11
DI 10.1167/16.10.11
PG 13
WC Ophthalmology
SC Ophthalmology
GA DZ3NQ
UT WOS:000385755200011
PM 27548089
ER
PT J
AU Rastegar, N
Riele, ASJMT
James, CA
Bhonsale, A
Murray, B
Tichnell, C
Calkins, H
Tandri, H
Bluemke, DA
Kamel, IR
Zimmerman, SL
AF Rastegar, Neda
Riele, Anneline S. J. M. Te
James, Cynthia A.
Bhonsale, Aditya
Murray, Brittney
Tichnell, Crystal
Calkins, Hugh
Tandri, Harikrishna
Bluemke, David A.
Kamel, Ihab R.
Zimmerman, Stefan L.
TI Fibrofatty Changes: Incidence at Cardiac MR Imaging in Patients with
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
SO RADIOLOGY
LA English
DT Article
ID TASK-FORCE CRITERIA; MAGNETIC-RESONANCE; MYOCARDIAL FIBROSIS; FAT
DETECTION; CARDIOMYOPATHY; DYSPLASIA; ARVD/C; EXPERIENCE; DIAGNOSIS;
INSIGHTS
AB Purpose: To determine the incidence of ventricular fatty replacement and late gadolinium enhancement (LGE) at cardiac magnetic resonance (MR) imaging in patients with arrhythmogenic right ventricular (RV) dysplasia/cardiomyopathy (ARVD/C) and the relationship of these findings to disease severity.
Materials and Methods: This was a retrospective institutional review board-approved HIPAA-compliant study. All subjects provided written informed consent. Seventy-six patients with ARVD/C were enrolled from 2002 to 2012. Quantitative and qualitative cardiac MR imaging analyses of the RV and the left ventricle (LV) were performed to determine cardiac MR imaging-specific Task Force Criteria (TFC) and non-TFC features (ARVD/C-type pattern of fatty infiltration and/or nonischemic pattern LGE). Patients were separated into four groups on the basis of cardiac MR imaging TFC: (a) patients with major cardiac MR imaging criteria, (b) patients with minor criteria, (c) patients with partial criteria, and (d) patients with no criterion. Continuous variables were compared by using the independent Student t test and analysis of variance. Categoric variables were compared by using the Fisher exact test.
Results: Of 76 patients (mean age, 34.2 years +/- 14 [standard deviation]; 51.3% men), 42 met major cardiac MR imaging criteria, seven met minor criteria, seven met partial criteria, and 20 met no criterion. Most probands (36 [80.0%] of 45) met major or minor cardiac MR imaging criteria. Only 13 (41.9%) of 31 family members met any cardiac MR imaging criterion. The most common non-TFC MR imaging features were RV fatty infiltration (28.9%) and LV LGE (35.5%). Non-TFC cardiac MR imaging features were seen in 88.1% of subjects with major criteria, in 28.6% of those with minor criteria, in 71.4% of those with partial criteria, and in 10.0% of those with no criteria.
Conclusion: In this large cohort of patients with ARVD/C, non-TFC findings of ventricular fatty infiltration and LGE were frequent and were most often found in those who met major cardiac MR imaging criteria and in probands. (C) RSNA, 2016
C1 [Rastegar, Neda; Kamel, Ihab R.; Zimmerman, Stefan L.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, 733 N Broadway, Baltimore, MD 21205 USA.
[Riele, Anneline S. J. M. Te; James, Cynthia A.; Bhonsale, Aditya; Murray, Brittney; Tichnell, Crystal; Calkins, Hugh; Tandri, Harikrishna] Johns Hopkins Univ, Sch Med, Div Cardiol, 733 N Broadway, Baltimore, MD 21205 USA.
[Bluemke, David A.] NIH, Dept Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Riele, Anneline S. J. M. Te] Univ Med Ctr Utrecht, Div Cardiol, Utrecht, Netherlands.
RP Zimmerman, SL (reprint author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, 733 N Broadway, Baltimore, MD 21205 USA.
EM stefan.zimmerman@jhmi.edu
FU Dr Francis P. Chiaramonte Private Foundation; St Jude Medical;
Medtronic; Leyla Erkan Family Fund for ARVD Research; Bogle Foundation;
Healing Hearts Foundation; Campanella family; Patrick J. Harrison
Family; Peter French Memorial Foundation; Wilmerding Endowments; Dr
Satish, Rupal, and Robin Shah ARVD Fund at Johns Hopkins
FX H.C. supported by the Dr Francis P. Chiaramonte Private Foundation, St
Jude Medical, and Medtronic. There was no industry support specifically
for this study. The Johns Hopkins ARVD/C Program is supported by the
Leyla Erkan Family Fund for ARVD Research, the Dr Satish, Rupal, and
Robin Shah ARVD Fund at Johns Hopkins, the Bogle Foundation, the Healing
Hearts Foundation, the Campanella family, the Patrick J. Harrison
Family, the Peter French Memorial Foundation, and the Wilmerding
Endowments. D.A.B. is an employee of the National Institutes of Health
Clinical Center.
NR 25
TC 0
Z9 0
U1 4
U2 4
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD AUG
PY 2016
VL 280
IS 2
BP 405
EP 412
DI 10.1148/radiol.2016150988
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DY6UW
UT WOS:000385265200008
PM 26967143
ER
PT J
AU Palant, CE
Chawla, LS
Faselis, C
Li, P
Pallone, TL
Kimmel, PL
Amdur, RL
AF Palant, Carlos E.
Chawla, Lakhmir S.
Faselis, Charles
Li, Ping
Pallone, Thomas L.
Kimmel, Paul L.
Amdur, Richard L.
TI High serum creatinine nonlinearity: a renal vital sign?
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE serum creatinine concentration variability; chronic kidney disease
progression; acute kidney injury
ID KIDNEY-DISEASE PROGRESSION; MYOGENIC RESPONSIVENESS; CKD PROGRESSION;
HEART-FAILURE; RISK; VARIABILITY; RAT; AUTOREGULATION; AKI
AB Patients with chronic kidney disease (CKD) may have nonlinear serum creatinine concentration (SC) trajectories, especially as CKD progresses. Variability in SC is associated with renal failure and death. However, present methods for measuring SC variability are unsatisfactory because they blend information about SC slope and variance. We propose an improved method for defining and calculating a patient's SC slope and variance so that they are mathematically distinct, and we test these methods in a large sample of US veterans, examining the correlation of SC slope and SC nonlinearity (SCNL) and the association of SCNL with time to stage 4 CKD (CKD4) and death. We found a strong correlation between SCNL and rate of CKD progression, time to CKD4, and time to death, even in patients with normal renal function. We therefore argue that SCNL may be a measure of renal autoregulatory dysfunction that provides an early warning sign for CKD progression.
C1 [Palant, Carlos E.; Chawla, Lakhmir S.; Faselis, Charles; Li, Ping; Amdur, Richard L.] Vet Affairs Med Ctr, Dept Med, 50 Irving St NW, Washington, DC 20422 USA.
[Amdur, Richard L.] Vet Affairs Med Ctr, Biostat Core, 50 Irving St NW, Washington, DC 20422 USA.
[Palant, Carlos E.; Chawla, Lakhmir S.; Li, Ping; Kimmel, Paul L.] George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA.
[Chawla, Lakhmir S.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA.
[Pallone, Thomas L.] Univ Maryland, Dept Med, Baltimore, MD 21201 USA.
[Kimmel, Paul L.] NIDDK, NIH, Bethesda, MD USA.
[Amdur, Richard L.] George Washington Univ, Sch Med & Hlth Sci, Dept Surg, Washington, DC 20052 USA.
RP Amdur, RL (reprint author), Med Fac Associates, Dept Surg, 2150 Penn Ave NW, Washington, DC 20037 USA.
EM amdur@gwu.edu
FU NIDDK NIH HHS [R01 DK042495]
NR 24
TC 2
Z9 2
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD AUG 1
PY 2016
VL 311
IS 2
BP F305
EP F309
DI 10.1152/ajprenal.00025.2016
PG 5
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA DY3FP
UT WOS:000384976500007
PM 27194712
ER
PT J
AU Masika, LS
Zhao, Z
Soldin, SJ
AF Masika, Likhona Siphe
Zhao, Zhen
Soldin, Steven John
TI Is measurement of TT3 by immunoassay reliable at low concentrations? A
comparison of the Roche Cobas 6000 vs. LC-MSMS
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Immunoassay; Mass spectrometry; FDA
ID TANDEM MASS-SPECTROMETRY; THYROID-STIMULATING HORMONE; FREE-THYROXINE;
HYPOTHYROIDISM; THERAPY; TRIIODOTHYRONINE; POLYMORPHISMS; ASSOCIATION;
REPLACEMENT; GENES
AB Objectives: Thyroid dysfunction is a common medical condition affecting an estimated 30 million people in the US alone. Employing gold standard Liquid chromatography-tandem mass spectrometry (LC-MSMS) methods we have examined the extent of inaccuracy of immunoassay (IA) measurement for total T3 (TT3) at low, normal and high concentrations.
Design and Methods: 268 TT3 Roche Cobas 6000 immunoassay TT3 values (covering the low, normal, and high ranges) were compared with LC-MSMS results.
Results: At TT3 concentrations between 50 and 113 ng/dL (conversion factor for TT3 to SI Units is ng/ dL x 0.0154 = nmol/L), n = 122, LC-MSMS values were lower than immunoassay with 72% found to be below the 2.5th percentile by LC-MSMS compared to 27% for immunoassay. Strikingly 45% of the patients classified as normal TT3 by immunoassay were defined as lower than the 2.5th percentile by LC-MSMS. Only 38 of the 122 patients with low T3's were not receiving T4. In this latter group all of whom had TSH's N 3.7 mIU/L, 74% of results by LC-MSMS were below the 2.5th percentile while only 21% were below the 2.5th percentile by IA. The clinical consequences of these inaccuracies may affect whether dosing with T4 or combination of T4 with T3 is selected for treatment. Finally the correlation of TT3 with TSH was far superior when TT3 was measured by LC-MSMS. A typical case which demonstrates our message is included.
Conclusion: T3 being the active hormone needs to be reliably measured and if the patient has low TT3 and hypothyroid symptoms persist; treatment with T3 should be considered. A typical case report is included to illustrate the problems of inaccurate immunoassay results for TT3.
Measurement of TT3 by immunoassay at low concentrations is less than optimal and often provides the clinician with a normal result when the LC-MSMS method and the patient's clinical condition suggests that supplementation with T3 (as in combination therapy) may be required to optimize patient care. The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
C1 [Masika, Likhona Siphe; Zhao, Zhen; Soldin, Steven John] NIH, Dept Lab Med, 10 Ctr Dr, Bethesda, MD 20892 USA.
[Soldin, Steven John] Georgetown Univ, Dept Med, 3900 Reservoir Rd NW, Washington, DC USA.
RP Soldin, SJ (reprint author), NIH, Dept Lab Med, 10 Ctr Dr, Bethesda, MD 20892 USA.
EM soldinsj@cc.nih.gov
FU Intramural Research Program of the National Institutes of Health
FX This research was supported by the Intramural Research Program of the
National Institutes of Health.
NR 20
TC 3
Z9 3
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD AUG
PY 2016
VL 49
IS 12
BP 846
EP 849
DI 10.1016/j.clinbiochem.2016.02.004
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA DX9VI
UT WOS:000384744700002
PM 26879528
ER
PT J
AU Deleage, C
Turkbey, B
Estes, JD
AF Deleage, Claire
Turkbey, Baris
Estes, Jacob D.
TI Imaging lymphoid tissues in nonhuman primates to understand SIV
pathogenesis and persistence
SO CURRENT OPINION IN VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; T-CELL
DEPLETION; RHESUS MACAQUES; IMMUNE ACTIVATION; HIV-1 INFECTION;
MICROBIAL TRANSLOCATION; GASTROINTESTINAL-TRACT; COLLAGEN DEPOSITION;
DENDRITIC CELLS
AB CD4+ T cells are the primary HIV-1 target cell, with the vast majority of these cells residing within lymphoid tissue compartments throughout the body. Predictably, HIV-1 infection, replication, localization, reservoir establishment and persistence, as well as associated host immune and inflammatory responses and disease pathology principally take place within the tissues of the immune system. By virture of the fact that the virus-host struggle is played out within lymphoid and additional tissues compartments in HIV-1 infected individuals it is critical to understand HIV-1 infection and disease within these relevant tissue sites; however, there are obvious limitations to studying these dynamic processes in humans. Nonhuman primate (NHP) research has provided a vital bridge between basic and preclinical research and clinical studies, with experimental SIV infection of NHP models offering unique opportunities to understand key processes of HIV-1 infection and disease that are either not practically feasible or ethical in HIV-1 infected humans. In this review we will discuss current approaches to studying the tissue based immunopathogenesis of AIDS virus infection in NHPs, including both analyses of tissues obtained at biopsy or necropsy and complementary non-invasive imaging approaches that may have practical utility in monitoring HIV-1 disease in the clinical setting.
C1 [Deleage, Claire; Estes, Jacob D.] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, BG 535,POB B, Frederick, MD 21702 USA.
[Turkbey, Baris] NCI, Mol Imaging Program, Bldg 10,Room B3B69F, Bethesda, MD 20814 USA.
RP Estes, JD (reprint author), Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, BG 535,POB B, Frederick, MD 21702 USA.
EM estesj@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX We would like to thank Jeffrey D. Lifson for his careful reading and
thoughtful comments in the preparation of this review. This project has
been funded with federal funds from the National Cancer Institute,
National Institutes of Health, under Contract No. HHSN261200800001E. The
content of this publication does not necessarily reflect the views or
policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government.
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1879-6257
J9 CURR OPIN VIROL
JI Curr. Opin. Virol.
PD AUG
PY 2016
VL 19
BP 77
EP 84
DI 10.1016/j.coviro.2016.07.002
PG 8
WC Virology
SC Virology
GA DY6JL
UT WOS:000385212100016
PM 27490446
ER
PT J
AU Wohlfarth, A
Scheidweiler, KB
Pang, S
Zhu, MS
Castaneto, M
Kronstrand, R
Huestis, MA
AF Wohlfarth, Ariane
Scheidweiler, Karl B.
Pang, Shaokun
Zhu, Mingshe
Castaneto, Marisol
Kronstrand, Robert
Huestis, Marilyn A.
TI Metabolic characterization of AH-7921, a synthetic opioid designer drug:
in vitro metabolic stability assessment and metabolite identification,
evaluation of in silico prediction, and in vivo confirmation
SO DRUG TESTING AND ANALYSIS
LA English
DT Article
DE high resolution mass spectrometry; human hepatocytes; metabolism;
synthetic opioids; in silico prediction
ID MASS-SPECTROMETRY
AB AH-7921 (3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl] benzamide) is a new synthetic opioid and has led to multiple nonfatal and fatal intoxications. To comprehensively study AH-7921 metabolism, we assessed human liver microsome (HLM) metabolic stability, determined AH-7921's metabolic profile after human hepatocytes incubation, confirmed our findings in a urine case specimen, and compared results to in silico predictions. For metabolic stability, 1 mu mol/L AH-7921 was incubated with HLM for up to 1 h; for metabolite profiling, 10 mu mol/L was incubated with pooled human hepatocytes for up to 3 h. Hepatocyte samples were analyzed by liquid chromatography quadrupole/time-of-flight high-resolution mass spectrometry (MS). High-resolution full scan MS and information-dependent acquisition MS/MS data were analyzed with MetabolitePilot (TM) (SCIEX) using multiple data processing algorithms. The presence of AH-7921 and metabolites was confirmed in the urine case specimen. In silico prediction of metabolite structures was performed with MetaSite (TM) (Molecular Discovery). AH-7921 in vitro half-life was 13.5 +/- 0.4 min. We identified 12 AH-7921 metabolites after hepatocyte incubation, predominantly generated by demethylation, less dominantly by hydroxylation, and combinations of different biotransformations. Eleven of 12 metabolites identified in hepatocytes were found in the urine case specimen. One metabolite, proposed to be di-demethylated, N-hydroxylated and glucuronidated, eluted after AH-7921 and was the most abundant metabolite in non-hydrolyzed urine. MetaSite (TM) correctly predicted the two most abundant metabolites and the majority of observed biotransformations. The two most dominant metabolites after hepatocyte incubation (also identified in the urine case specimen) were desmethyl and di-desmethyl AH-7921. Together with the glucuronidated metabolites, these are likely suitable analytical targets for documenting AH-7921 intake. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Wohlfarth, Ariane; Scheidweiler, Karl B.; Castaneto, Marisol; Huestis, Marilyn A.] NIDA, Chem & Drug Metab, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
[Pang, Shaokun] SCIEX Ltd, Redwood City, CA 94404 USA.
[Zhu, Mingshe] Bristol Myers Squibb Res & Dev, Dept Biotransformat, Princeton, NJ 08543 USA.
[Kronstrand, Robert] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden.
[Kronstrand, Robert] Linkoping Univ, Dept Drug Res, S-58185 Linkoping, Sweden.
RP Huestis, MA (reprint author), NIDA, Chem & Drug Metab, Intramural Res Program, 251 Bayview Blvd,Suite 200,Room 05A-721, Baltimore, MD 21224 USA.
EM mhuestis@intra.nida.nih.gov
FU Intramural Research Program of the National Institute on Drug Abuse,
National Institutes of Health
FX This research was supported by the Intramural Research Program of the
National Institute on Drug Abuse, National Institutes of Health. We also
thank the Drug Enforcement Administration for generously donating
AH-7921 and Molecular Discovery for kindly providing the MetaSite (TM)
software.
NR 26
TC 5
Z9 5
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1942-7603
EI 1942-7611
J9 DRUG TEST ANAL
JI Drug Test. Anal.
PD AUG
PY 2016
VL 8
IS 8
BP 779
EP 791
DI 10.1002/dta.1856
PG 13
WC Biochemical Research Methods; Chemistry, Analytical; Pharmacology &
Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA DY0RY
UT WOS:000384805100003
PM 26331297
ER
PT J
AU Kilianski, A
Roth, PA
Liem, AT
Hill, JM
Willis, KL
Rossmaier, RD
Marinich, AV
Maughan, MN
Karavis, MA
Kuhn, JH
Honko, AN
Rosenzweig, CN
AF Kilianski, Andy
Roth, Pierce A.
Liem, Alvin T.
Hill, Jessica M.
Willis, Kristen L.
Rossmaier, Rebecca D.
Marinich, Andrew V.
Maughan, Michele N.
Karavis, Mark A.
Kuhn, Jens H.
Honko, Anna N.
Rosenzweig, C. Nicole
TI Use of Unamplified RNA/cDNA-Hybrid Nanopore Sequencing for Rapid
Detection and Characterization of RNA Viruses
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID EBOLA-VIRUS; REAL-TIME; TRANSMISSION; OUTBREAK; IDENTIFICATION;
SURVEILLANCE
AB Nanopore sequencing, a novel genomics technology, has potential applications for routine biosurveillance, clinical diagnosis, and outbreak investigation of virus infections. Using rapid sequencing of unamplified RNA/cDNA hybrids, we identified Venezuelan equine encephalitis virus and Ebola virus in 3 hours from sample receipt to data acquisition, demonstrating a fieldable technique for RNA virus characterization.
C1 [Kilianski, Andy; Roth, Pierce A.; Liem, Alvin T.; Hill, Jessica M.; Willis, Kristen L.; Rossmaier, Rebecca D.; Marinich, Andrew V.; Maughan, Michele N.; Karavis, Mark A.; Rosenzweig, C. Nicole] US Army, Edgewood Chem Biol Ctr, Aberdeen Proving Ground, MD USA.
[Willis, Kristen L.] Def Threat Reduct Agcy, Ft Belvoir, VA USA.
[Kuhn, Jens H.; Honko, Anna N.] NIH, Frederick, MD USA.
RP Rosenzweig, CN (reprint author), Edgewood Chem Biol Ctr, BioSci Div, BioDef Branch, Aberdeen Proving Ground, MD 21010 USA.
EM carolyn.n.rosenzweig.civ@mail.mil
OI Kilianski, Andy/0000-0002-2350-0142; Honko, Anna/0000-0001-9165-148X
FU United States Army; Edgewood Chemical Biological Center Innovative
Project [219]; US National Academy of Science; US Defense Threat
Reduction Agency as a National Research Council fellow; prime contract
of Battelle Memorial Institute, Columbus, Ohio; US National Institute of
Allergy and Infectious Diseases [HHSN272200700016I]
FX This project was funded through the United States Army and Edgewood
Chemical Biological Center 219 Innovative Project initiative to A.K.
A.K. is also supported by the US National Academy of Science and the US
Defense Threat Reduction Agency as a National Research Council fellow.
A.K. is part of the Oxford Nanopore MinION Access Program, and has
received free materials for this research. This work was funded in part
through the prime contract of Battelle Memorial Institute, Columbus,
Ohio, with the US National Institute of Allergy and Infectious Diseases
under Contract no. HHSN272200700016I. A subcontractor to Battelle
Memorial Institute who performed this work is: J.H.K., an employee of
Tunnell Government Services, Inc, Bethesda, MD. Information in this
report is cleared for public release and distribution is unlimited.
NR 15
TC 3
Z9 3
U1 3
U2 3
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2016
VL 22
IS 8
BP 1448
EP 1451
DI 10.3201/eid2208.160270
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DY2PM
UT WOS:000384934500017
PM 27191483
ER
PT J
AU Zhao, WS
Zheng, J
Dong, LX
Liang, F
Hu, Y
Wang, LW
Wang, GF
Zhou, QF
AF Zhao, Wen-Sheng
Zheng, Jie
Dong, Linxi
Liang, Feng
Hu, Yue
Wang, Luwen
Wang, Gaofeng
Zhou, Qifa
TI High-Frequency Modeling of On-Chip Coupled Carbon Nanotube Interconnects
for Millimeter-Wave Applications
SO IEEE TRANSACTIONS ON COMPONENTS PACKAGING AND MANUFACTURING TECHNOLOGY
LA English
DT Article
DE Effective complex conductivity; equivalent circuit model; on-chip
coupled carbon nanotube (CNT) interconnects; partial element equivalent
circuit (PEEC) method; temperature effect
ID NEXT-GENERATION INTERCONNECTS; THROUGH-SILICON VIAS; BUNDLES; SYSTEMS
AB This paper presents a high-frequency equivalent circuit model for on-chip coupled carbon nanotube (CNT) interconnects up to 100 GHz. By simplifying the circuit model, the S-parameters of on-chip coupled interconnects can be acquired and validated by comparing with the full-wave electromagnetic simulations. By virtue of effective complex conductivity, the high-frequency behaviors of coupled CNT interconnects are captured and studied, with the impacts of kinetic inductance treated appropriately.
C1 [Zhao, Wen-Sheng; Zheng, Jie; Dong, Linxi; Hu, Yue; Wang, Luwen; Wang, Gaofeng] Hangzhou Dianzi Univ, Key Lab RF Circuits & Syst, Minist Educ, Zhejiang Prov Key Lab LSI Design,Microelect CAD C, Hangzhou 310018, Zhejiang, Peoples R China.
[Liang, Feng] Univ Elect Sci & Technol China, Sch Phys Elect, Chengdu 610054, Peoples R China.
[Zhou, Qifa] Univ Southern Calif, Resource Ctr Med Ultrason Transducer Technol, Dept Biomed Engn, NIH, Los Angeles, CA 90089 USA.
RP Wang, GF (reprint author), Hangzhou Dianzi Univ, Key Lab RF Circuits & Syst, Minist Educ, Zhejiang Prov Key Lab LSI Design,Microelect CAD C, Hangzhou 310018, Zhejiang, Peoples R China.
EM gaofeng@hdu.edu.cn
FU National Natural Science Foundation of China [61504033, 61411136003,
61204041, 61404040]; Zhejiang Provincial Natural Science Foundation of
China [LQ14F010010, LZ14F040001, LQ15F040006]
FX This work was supported in part by the National Natural Science
Foundation of China under Grants 61504033, 61411136003, 61204041, and
61404040, and the Zhejiang Provincial Natural Science Foundation of
China under Grants LQ14F010010, LZ14F040001, and LQ15F040006.
Recommended for publication by Associate Editor A. Maffucci upon
evaluation of reviewers' comments.
NR 25
TC 0
Z9 0
U1 7
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2156-3950
EI 2156-3985
J9 IEEE T COMP PACK MAN
JI IEEE Trans. Compon. Pack. Manuf. Technol.
PD AUG
PY 2016
VL 6
IS 8
BP 1226
EP 1232
DI 10.1109/TCPMT.2016.2580592
PG 7
WC Engineering, Manufacturing; Engineering, Electrical & Electronic;
Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA DX8NZ
UT WOS:000384647100009
ER
PT J
AU Simon, N
Antignani, A
Sarnovsky, R
Hewitt, SM
FitzGerald, D
AF Simon, Nathan
Antignani, Antonella
Sarnovsky, Robert
Hewitt, Stephen M.
FitzGerald, David
TI Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor
Receptor in Triple-Negative Breast Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID CHIMERIC ANTIGEN RECEPTOR; RECOMBINANT IMMUNOTOXIN; TRASTUZUMAB
EMTANSINE; MEDIATED APOPTOSIS; LOW IMMUNOGENICITY; TUMOR XENOGRAFTS;
CELL EPITOPES; EGFR MUTATION; PHASE-II; ANTIBODY
AB Background: Triple-negative breast cancers (TNBCs) are typically more aggressive and result in poorer outcomes than other breast cancers because treatment options are limited due to lack of hormone receptors or amplified human epidermal growth factor receptor 2 (HER2). Many TNBCs overexpress the epidermal growth factor receptor (EGFR) or manifest amplification of the EGFR gene, supporting EGFR as a therapeutic target. While EGFR-directed small molecule inhibitors have shown limited effectiveness in clinical settings, use of EGFR as a mechanism of delivering enzymatic cytotoxins to TNBC has not been demonstrated.
Methods: Using the single-chain variable fragment (scFv) of the 806 antibody that binds only cells with overexpressed, misfolded, or mutant variants of the EGFR, a recombinant immunotoxin was engineered through gene fusion with Pseudomonas aeruginosa Exotoxin A (806-PE38). The potency of 806-PE38 on reducing TNBC cell growth in vitro and in xenograft models (n >= 6) was examined for six TNBC cell lines. All statistical tests were two-sided.
Results: 806-PE38 statistically significantly reduced the viability of all tested TNBC lines, with IC50 values below 10 ng/mL for three of six cell lines, while not affecting cells with wild-type EGFR (IC50 > 300 ng/mL). Systemic treatments with 806-PE38 vs vehicle resulted in statistically significantly reduced tumor burdens (806-PE38 mean = 128 mm(3) [SD = 46 mm(3)] vs vehicle mean = 749 mm(3) [SD = 395 mm(3)], P = .001) and increased median survival (806-PE38 median = 82 days vs vehicle median = 50 days, P = .01) in a MDA-MB-468 TNBC mouse xenograft. Deletion of the catalytic residue eliminated both cytotoxic activity in vitro and the reduction in tumor burden and survival (P = .52).
Conclusions: These data support the further development of the 806-PE38 immunotoxin as a therapeutic agent for the treatment of patients with EGFR-positive TNBC. Follow-up experiments with combination therapies will be attempted to achieve full remissions.
C1 [Simon, Nathan; Antignani, Antonella; Sarnovsky, Robert; FitzGerald, David] NCI, Biotherapy Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
[Hewitt, Stephen M.] NCI, Expt Pathol Lab, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
RP FitzGerald, D (reprint author), NCI, Biotherapy Sect, Mol Biol Lab, Ctr Canc Res,NIH, 9000 Rockville Pike,37-S124, Bethesda, MD 20892 USA.
EM fitzgerd@helix.nih.gov
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research
FX This work was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute, Center for
Cancer Research.
NR 52
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD AUG
PY 2016
VL 108
IS 8
AR djw028
DI 10.1093/jnci/djw028
PG 8
WC Oncology
SC Oncology
GA DY3UD
UT WOS:000385019300021
ER
PT J
AU Rulli, T
Wendler, D
AF Rulli, Tina
Wendler, David
TI The Duty to Take Rescue Precautions
SO JOURNAL OF APPLIED PHILOSOPHY
LA English
DT Article
ID SCOPE
AB There is much philosophical literature on the duty to rescue. Individuals who encounter and could save, at relatively little cost to themselves, a person at risk of losing life or limb are morally obligated to do so. Yet little has been said about the other side of the issue. There are cases in which the need for rescue could have been reasonably avoided by the rescuee. We argue for a duty to take rescue precautions, providing an account of the circumstances in which it arises. This novel duty has important implications for public policy. We apply it to the situation of some of the uninsured in the United States. Given the US clinician's duty to provide emergency care to all people regardless of ability to pay, some of the uninsured have a moral duty to purchase health insurance. We defend the duty against objections, including the possibility that a right to rescue can be waived, thus undermining a duty to take rescue precautions, that the duty of many professionals is voluntarily incurred, and that a distinction between actively assumed and passively assumed risks matters morally.
C1 [Rulli, Tina] UC Davis Philosophy Dept, Social Sci & Humanities 1240, One Shields Ave, Davis, CA 95616 USA.
[Wendler, David] NIH, Dept Bioeth, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA.
RP Rulli, T (reprint author), UC Davis Philosophy Dept, Social Sci & Humanities 1240, One Shields Ave, Davis, CA 95616 USA.
EM trulli@ucdavis.edu; dwendler@nih.gov
NR 39
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0264-3758
EI 1468-5930
J9 J APPL PHILOS
JI J. Appl. Philos.
PD AUG
PY 2016
VL 33
IS 3
BP 240
EP 258
DI 10.1111/japp.12115
PG 19
WC Ethics; Philosophy
SC Social Sciences - Other Topics; Philosophy
GA DY2DJ
UT WOS:000384903000002
ER
PT J
AU Du Toit, J
AF Du Toit, Jessica
TI Is Having Pets Morally Permissible?
SO JOURNAL OF APPLIED PHILOSOPHY
LA English
DT Article
ID USELESS CONCEPT; DIGNITY
AB In this article, I consider the question of whether having pets is morally permissible. However, I do so indirectly by considering three objections to the practice of having pets - what I shall call the 'restriction of freedom objection', the 'property objection', and the 'dependency objection'. The restriction of freedom objection is dismissed relatively easily. The property objection also fails to show that having pets is morally impermissible. However, my consideration of this second objection does lead to the conclusion that we ought to aim at changing existing legal systems and the majority of people's attitudes towards pets such that they (pets) are no longer considered to be the personal property of the humans in whose homes they are kept. But, while it is clear that we ought to aim at ending the practice of owning pets, it is not clear whether we ought to aim at ending the practice of keeping pets. Indeed, I do not to reach a definitive conclusion about the cogency of the dependency objection. However, I argue that this lack of clarity is of little concern at this time as our present moral obligations to pets are quite clear.
C1 [Du Toit, Jessica] NIH, Dept Bioeth, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA.
[Du Toit, Jessica] Univ Cape Town, Dept Philosophy, Private Bag X3, ZA-7701 Rondebosch, South Africa.
RP Du Toit, J (reprint author), NIH, Dept Bioeth, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA.; Du Toit, J (reprint author), Univ Cape Town, Dept Philosophy, Private Bag X3, ZA-7701 Rondebosch, South Africa.
EM jess.dutoit@gmail.com
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0264-3758
EI 1468-5930
J9 J APPL PHILOS
JI J. Appl. Philos.
PD AUG
PY 2016
VL 33
IS 3
BP 327
EP 343
DI 10.1111/japp.12106
PG 17
WC Ethics; Philosophy
SC Social Sciences - Other Topics; Philosophy
GA DY2DJ
UT WOS:000384903000008
ER
PT J
AU Wu, D
Dean, J
AF Wu, Di
Dean, Jurrien
TI BTG4, a maternal mRNA cleaner
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Editorial Material
C1 [Wu, Di; Dean, Jurrien] Natl Inst Diabet & Digest & Kidney Dis, Lab Cellular & Dev Biol, NIH, Bethesda, MD 20892 USA.
RP Dean, J (reprint author), Natl Inst Diabet & Digest & Kidney Dis, Lab Cellular & Dev Biol, NIH, Bethesda, MD 20892 USA.
EM jurrien.dean@nih.gov
NR 8
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
EI 1759-4685
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD AUG
PY 2016
VL 8
IS 4
BP 369
EP 370
DI 10.1093/jmcb/mjw031
PG 2
WC Cell Biology
SC Cell Biology
GA DY1JE
UT WOS:000384849900010
PM 27339058
ER
PT J
AU Naimark, DMJ
Grams, ME
Matsushita, K
Black, C
Drion, I
Fox, CS
Inker, LA
Ishani, A
Jee, SH
Kitamura, A
Lea, JP
Nally, J
Peralta, CA
Rothenbacher, D
Ryu, S
Tonelli, M
Yatsuya, H
Coresh, J
Gansevoort, RT
Warnock, DG
Woodward, M
de Jong, PE
AF Naimark, David M. J.
Grams, Morgan E.
Matsushita, Kunihiro
Black, Corri
Drion, Iefke
Fox, Caroline S.
Inker, Lesley A.
Ishani, Areef
Jee, Sun Ha
Kitamura, Akihiko
Lea, Janice P.
Nally, Joseph
Peralta, Carmen Alicia
Rothenbacher, Dietrich
Ryu, Seungho
Tonelli, Marcello
Yatsuya, Hiroshi
Coresh, Josef
Gansevoort, Ron T.
Warnock, David G.
Woodward, Mark
de Jong, Paul E.
CA CKD Prognosis Consortium
TI Past Decline Versus Current eGFR and Subsequent Mortality Risk
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE;
COLLABORATIVE METAANALYSIS; POPULATION COHORTS; HIGHER ALBUMINURIA;
ALL-CAUSE; CARDIOVASCULAR-DISEASE; DEATH; EQUATION
AB A single determination of eGFR associates with subsequent mortality risk. Prior decline in eGFR indicates loss of kidney function, but the relationship to mortality risk is uncertain. We conducted an individual-level meta-analysis of the risk of mortality associated with antecedent eGFR slope, adjusting for established risk factors, including last eGFR, among 1.2 million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3-year antecedent period, 12% of participants in the CKD cohorts and 11% in the other cohorts had an eGFR slope, <-5 ml/min per 1.73 m(2) per year, whereas 7% and 4% had a slope >5 ml/min per 1.73 m(2) per year, respectively. Compared with a slope of 0 ml/min per 1.73 m(2) per year, a slope of -6 ml/min per 1.73 m(2) per year associated with adjusted hazard ratios for all-cause mortality of 1.25 (95% confidence interval [95% CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95% CI, 1.01 to 1.31) among other cohorts during a follow-up of 3.2 years. A slope of +6 ml/min per 1.73 m(2) per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95% CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus <3 years). We conclude that prior decline or rise in eGFR associates with an increased risk of mortality, independent of current eGFR.
C1 [Naimark, David M. J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Nephrol, Toronto, ON, Canada.
[Naimark, David M. J.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
[Grams, Morgan E.; Matsushita, Kunihiro; Coresh, Josef; Woodward, Mark] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Grams, Morgan E.] Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD USA.
[Black, Corri] Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen, Scotland.
[Drion, Iefke] Isala Clin, Ctr Diabet, Zwolle, Netherlands.
[Fox, Caroline S.] NHLBI, Framingham Heart Study, Ctr Populat Studies, Framingham, MA USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, 75 Francis St, Boston, MA 02115 USA.
[Fox, Caroline S.] Harvard Med Sch, Boston, MA USA.
[Inker, Lesley A.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
[Ishani, Areef] Minneapolis Vet Affairs Hlth Care Syst, Nephrol Sect, Minneapolis, MN USA.
[Jee, Sun Ha] Yonsei Univ, Inst Hlth Promot, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul, South Korea.
[Kitamura, Akihiko] Osaka Ctr Canc & Cardiovasc Dis Prevent, Osaka, Japan.
[Lea, Janice P.] Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA.
[Nally, Joseph] Glickman Urol & Kidney Inst, Dept Hypertens & Nephrol, Cleveland, OH USA.
[Peralta, Carmen Alicia] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Peralta, Carmen Alicia] San Francisco VA Med Ctr, San Francisco, CA USA.
[Rothenbacher, Dietrich] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Rothenbacher, Dietrich] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany.
[Ryu, Seungho] Sunkgyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Seoul, South Korea.
[Tonelli, Marcello] Univ Calgary, Dept Med, Calgary, AB, Canada.
[Yatsuya, Hiroshi] Fujita Hlth Univ, Dept Publ Hlth, Toyoake, Aichi, Japan.
[Gansevoort, Ron T.; de Jong, Paul E.] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands.
[Warnock, David G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Woodward, Mark] Univ Oxford, Nuffield Dept Populat Hlth, George Inst Global Hlth, Oxford, England.
[Woodward, Mark] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia.
RP Coresh, J (reprint author), Chron Kidney Dis Prognosis Consortium, Data Coordinating Ctr, 2024 East Monument St, Baltimore, MD 21287 USA.
EM ckdpc@jhmi.edu
RI Tonelli, Marcello/B-3028-2009; Brenner, Hermann/B-4627-2017
OI Brenner, Hermann/0000-0002-6129-1572
FU US National Kidney Foundation; National Institute of Diabetes and
Digestive and Kidney Diseases [R01DK100446-01]; National Institutes of
Health
FX The Chronic Kidney Disease Prognosis Consortium (CKD-PC) Data
Coordinating Center is funded, in part, by a program grant from the US
National Kidney Foundation (funding sources include AbbVie and Amgen,
Inc.) and National Institute of Diabetes and Digestive and Kidney
Diseases Grant R01DK100446-01. A variety of sources have supported
enrollment and data collection, including laboratory measurements, as
well as follow-up in the collaborating cohorts of the CKD-PC. These
funding sources include government agencies, such as the National
Institutes of Health, and medical research councils as well as
foundations and industry sponsors, and they are listed in Supplemental
Appendix 3. Individual cohort and collaborator support is listed in
Supplemental Appendix 3.
NR 29
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD AUG
PY 2016
VL 27
IS 8
BP 2456
EP 2466
DI 10.1681/ASN.2015060688
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA DY3PM
UT WOS:000385006100025
PM 26657865
ER
PT J
AU Tin, A
Grams, ME
Ashar, FN
Lane, JA
Rosenberg, AZ
Grove, ML
Boerwinkle, E
Selvin, E
Coresh, J
Pankratz, N
Arking, DE
AF Tin, Adrienne
Grams, Morgan E.
Ashar, Foram N.
Lane, John A.
Rosenberg, Avi Z.
Grove, Megan L.
Boerwinkle, Eric
Selvin, Elizabeth
Coresh, Josef
Pankratz, Nathan
Arking, Dan E.
TI Association between Mitochondrial DNA Copy Number in Peripheral Blood
and Incident CKD in the Atherosclerosis Risk in Communities Study
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; RENAL-CELL CARCINOMA; OXIDATIVE STRESS;
DIABETIC-NEPHROPATHY; RENOVASCULAR DISEASE; DYSFUNCTION; DAMAGE;
PATHOPHYSIOLOGY; PATHOGENESIS; MECHANISMS
AB Mitochondrial dysfunction in kidney cells has been implicated in the pathogenesis of CKD. Mitochondrial DNA (mtDNA) copy number is a surrogate measure of mitochondrial function, and higher mtDNA copy number in peripheral blood has been associated with lower risk of two important risk factors for CKD progression, diabetes and microalbuminuria. We evaluated whether mtDNA copy number in peripheral blood associates with incident CKD in a population-based cohort of middle-aged adults. We estimated mtDNA copy number using 25 high-quality mitochondrial single nucleotide polymorphisms from the Affymetrix 6.0 array. Among 9058 participants, those with higher mtDNA copy number had a lower rate of prevalent diabetes and lower C-reactive protein levels and white blood cell counts. Baseline eGFR did not differ significantly by mtDNA copy number. Over a median follow-up of 19.6 years, 1490 participants developed CKD. Higher mtDNA copy number associated with lower risk of incident CKD (highest versus lowest quartile: hazard ratio 0.65; 95% confidence interval, 0.56 to 0.75; P < 0.001) after adjusting for age, sex, and race. After adjusting for additional risk factors of CKD, including prevalent diabetes, hypertension, C-reactive protein level, and white blood cell count, this association remained significant (highest versus lowest quartile: hazard ratio 0.75; 95% confidence interval, 0.64 to 0.87; P < 0.001). In conclusion, higher mtDNA copy number associated with lower incidence of CKD independent of traditional risk factors and inflammation biomarker levels in this cohort. Further research on modifiable factors influencing mtDNA copy number may lead to improvement in the prevention and treatment of CKD.
C1 [Tin, Adrienne; Selvin, Elizabeth; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Grams, Morgan E.] Johns Hopkins Sch Med, Div Nephrol, Baltimore, MD USA.
[Ashar, Foram N.; Arking, Dan E.] Johns Hopkins Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Ashar, Foram N.; Arking, Dan E.] Johns Hopkins Sch Med, Dept Med, Div Cardiol, Baltimore, MD USA.
[Lane, John A.; Pankratz, Nathan] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Rosenberg, Avi Z.] NCI, Pathol Lab, Ctr Canc Res, Frederick, MD USA.
[Rosenberg, Avi Z.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Grove, Megan L.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA.
RP Tin, A (reprint author), Johns Hopkins Univ, Dept Epidemiol, 339 Homeland Southway,Apt 3B, Baltimore, MD 21212 USA.; Tin, A (reprint author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 339 Homeland Southway,Apt 3B, Baltimore, MD 21212 USA.
EM atin1@jhu.edu
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) Renal Disease Epidemiology
Training Grant [T32DK007732]; National Heart, Lung, and Blood Institute
[HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, HHSN268201100012C]; NIDDK [R01 DK089174]
FX A.T. was supported by National Institutes of Health/National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK) Renal Disease
Epidemiology Training Grant T32DK007732. The Atherosclerosis Risk in
Communities Study is carried out as a collaborative study supported by
National Heart, Lung, and Blood Institute contracts (HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C,
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and
HHSN268201100012C).; Reagent for C-reactive protein was donated by Roche
Diagnostics. Reagent for serum albumin was donated by Asahi Kasei
Corporation. Assays of C-reactive protein and serum albumin were
supported by NIDDK R01 DK089174.
NR 43
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD AUG
PY 2016
VL 27
IS 8
BP 2467
EP 2473
DI 10.1681/ASN.2015060661
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA DY3PM
UT WOS:000385006100026
PM 26794963
ER
PT J
AU Magsi, S
Khoja, A
Rameez, MAM
AF Magsi, Shahvaiz
Khoja, Adeel
Rameez, Mansoor Ali Merchant
TI Standard post-stroke care: Far from reality in Pakistan
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Letter
ID STROKE
C1 [Magsi, Shahvaiz] Baqai Med Univ, Karachi, Pakistan.
[Khoja, Adeel] Natl Inst Hlth, Fogarty Int Ctr, Int Cerebrovasc Translat Clin Res Training Progra, Karachi, Pakistan.
[Khoja, Adeel] Aga Khan Univ, Karachi, Pakistan.
[Rameez, Mansoor Ali Merchant] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan.
RP Rameez, MAM (reprint author), Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan.
EM rameezmerchant@ymail.com
NR 7
TC 0
Z9 0
U1 0
U2 0
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD AUG
PY 2016
VL 66
IS 8
BP 1044
EP 1044
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA DY2KI
UT WOS:000384921100032
PM 27524549
ER
PT J
AU Guo, LH
Derbyshire, JA
Herzka, DA
AF Guo, Liheng
Derbyshire, J. Andrew
Herzka, Daniel A.
TI Pseudo-Projection-Driven, Self-Gated Cardiac Cine Imaging Using
Cartesian Golden Step Phase Encoding
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE golden step; self-navigation; self-gating; respiratory motion; motion
tracking; pseudo-projections; cardiac imaging
ID STATE FREE PRECESSION; HEART CORONARY MRA; REAL-TIME; MOTION CORRECTION;
RETROSPECTIVE RECONSTRUCTION; FLOATING NAVIGATOR; RESPIRATORY MOTION;
FLOW ARTIFACTS; BALANCED SSFP; EDDY-CURRENTS
AB Purpose: To develop and evaluate a novel two-dimensional self-gated imaging technique for free-breathing cardiac cine MRI that is free of motion-detection overhead and requires minimal planning for motion tracking.
Methods: Motion along the readout direction was extracted solely from normal Cartesian imaging readouts near k(y) = 0. During imaging, the readouts below a certain vertical bar k(y)vertical bar threshold were scaled in magnitude and filtered in time to form "pseudo-projections," enabling projection-based motion tracking along readout without frequently acquiring the central phase encode. A discrete golden step phase encode scheme allowed the vertical bar k(y)vertical bar threshold to be freely set after the scan while maintaining uniform motion sampling.
Results: The pseudo-projections stream displayed sufficient spatiotemporal resolution for both cardiac and respiratory tracking, allowing retrospective reconstruction of free-breathing nonelectrocardiogram (ECG) cines. The technique was tested on healthy subjects, and the resultant image quality, measured by blood-myocardium boundary sharpness, myocardial mass, and single-slice ejection fraction was found to be comparable to standard breath-hold ECG-gated cines.
Conclusion: The use of pseudo-projections for motion tracking was found feasible for cardiorespiratory self-gated imaging. Despite some sensitivity to flow and eddy currents, the simplicity of acquisition makes the proposed technique a valuable tool for self-gated cardiac imaging. (C) 2015 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
C1 [Guo, Liheng; Herzka, Daniel A.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, 720 Rutland Ave,Suite 726,Ross Bldg, Baltimore, MD 21205 USA.
[Derbyshire, J. Andrew] NIMH, Funct MRI Facil, NIH, Bethesda, MD 20892 USA.
RP Herzka, DA (reprint author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, 720 Rutland Ave,Suite 726,Ross Bldg, Baltimore, MD 21205 USA.
EM daniel.herzka@jhu.edu
OI Herzka, Daniel/0000-0002-9400-7814
NR 58
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
EI 1522-2594
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD AUG
PY 2016
VL 76
IS 2
BP 417
EP 429
DI 10.1002/mrm.25834
PG 13
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DY3MR
UT WOS:000384997900006
PM 26519940
ER
PT J
AU Ngo, TM
Fung, GSK
Han, S
Chen, M
Prince, JL
Tsui, BMW
McVeigh, ER
Herzka, DA
AF Ngo, Tri M.
Fung, George S. K.
Han, Shuo
Chen, Min
Prince, Jerry L.
Tsui, Benjamin M. W.
McVeigh, Elliot R.
Herzka, Daniel A.
TI Realistic Analytical Polyhedral MRI Phantoms
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE analytical phantom; magnetic resonance imaging; simulation; Fourier
transform
ID MAGNETIC-RESONANCE; IMAGING RESEARCH; HEART PHANTOM; SIMULATOR;
EVOLUTION; XCAT
AB Purpose: Analytical phantoms have closed form Fourier transform expressions and are used to simulate MRI acquisitions. Existing three-dimensional (3D) analytical phantoms are unable to accurately model shapes of biomedical interest. The goal of this study was to demonstrate that polyhedral analytical phantoms have closed form Fourier transform expressions and can accurately represent 3D biomedical shapes.
Methods: The Fourier transform of a polyhedron was implemented and its accuracy in representing faceted and smooth surfaces was characterized. Realistic anthropomorphic polyhedral brain and torso phantoms were constructed and their use in simulated 3D and two-dimensional (2D) MRI acquisitionswas described.
Results: Using polyhedra, the Fourier transform of faceted shapes can be computed to within machine precision. Smooth surfaces can be approximated with increasing accuracy by increasing the number of facets in the polyhedron; the additional accumulated numerical imprecision of the Fourier transform of polyhedra with many faces remained small. Simulations of 3D and 2D brain and 2D torso cine acquisitions produced realistic reconstructions free of high frequency edge aliasing compared with equivalent voxelized/rasterized phantoms.
Conclusion: Analytical polyhedral phantoms are easy to construct and can accurately simulate shapes of biomedical interest. (C) 2015 Wiley Periodicals, Inc.
C1 [Ngo, Tri M.; Han, Shuo; Prince, Jerry L.; McVeigh, Elliot R.; Herzka, Daniel A.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
[Fung, George S. K.; Tsui, Benjamin M. W.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Div Med Imaging Phys, 600 N Wolfe St, Baltimore, MD 21205 USA.
[Chen, Min] Johns Hopkins Univ, Dept Elect & Comp Engn, Image Anal & Commun Lab, Baltimore, MD 21218 USA.
[Chen, Min] NINDS, Translat Neuroradiol Unit, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Prince, Jerry L.] Johns Hopkins Univ, Dept Elect & Comp Engn, Baltimore, MD 21218 USA.
RP Herzka, DA (reprint author), 720 Rutland Ave,726 Ross Bldg, Baltimore, MD 21205 USA.
EM daniel.herzka@jhu.edu
OI Herzka, Daniel/0000-0002-9400-7814
FU American Heart Association [11SDG5280025]; National Institutes of Health
[EB-010021]
FX Grant sponsor: American Heart Association; Grant number: 11SDG5280025;
Grant sponsor: National Institutes of Health; Grant number: NIH T32
training grant EB-010021.
NR 25
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
EI 1522-2594
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD AUG
PY 2016
VL 76
IS 2
BP 663
EP 678
DI 10.1002/mrm.25888
PG 16
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA DY3MR
UT WOS:000384997900028
PM 26479724
ER
PT J
AU Galletta, BJ
Fagerstrom, CJ
Schoborg, TA
McLamarrah, TA
Ryniawec, JM
Buster, DW
Slep, KC
Rogers, GC
Rusan, NM
AF Galletta, Brian J.
Fagerstrom, Carey J.
Schoborg, Todd A.
McLamarrah, Tiffany A.
Ryniawec, John M.
Buster, Daniel W.
Slep, Kevin C.
Rogers, Gregory C.
Rusan, Nasser M.
TI A centrosome interactome provides insight into organelle assembly and
reveals a non-duplication role for Plk4
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PROTEIN-INTERACTION MAP; PERICENTRIOLAR MATERIAL; CENTRIOLE DUPLICATION;
DROSOPHILA-MELANOGASTER; STRUCTURE PREDICTION; REGULATES CENTRIOLE;
SCALE MAP; NETWORK; SCAFFOLD; CELLS
AB The centrosome is the major microtubule-organizing centre of many cells, best known for its role in mitotic spindle organization. How the proteins of the centrosome are accurately assembled to carry out its many functions remains poorly understood. The non-membranebound nature of the centrosome dictates that protein-protein interactions drive its assembly and functions. To investigate this massive macromolecular organelle, we generated a `domain-level' centrosome interactome using direct protein-protein interaction data from a focused yeast two-hybrid screen. We then used biochemistry, cell biology and the model organism Drosophila to provide insight into the protein organization and kinase regulatory machinery required for centrosome assembly. Finally, we identified a novel role for Plk4, the master regulator of centriole duplication. We show that Plk4 phosphorylates Cep135 to properly position the essential centriole component Asterless. This interaction landscape affords a critical framework for research of normal and aberrant centrosomes.
C1 [Galletta, Brian J.; Fagerstrom, Carey J.; Schoborg, Todd A.; Rusan, Nasser M.] NHLBI, Cell Biol & Physiol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
[McLamarrah, Tiffany A.; Ryniawec, John M.; Buster, Daniel W.; Rogers, Gregory C.] Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.
[Slep, Kevin C.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.
RP Rusan, NM (reprint author), NHLBI, Cell Biol & Physiol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM Nasser@nih.gov
RI Rusan, Nasser/P-3511-2016
FU Division of Intramural Research at the NIH/NHLBI [1ZIAHL006104];
NIH/NIGMS [R01GM110166, R01GM094415]; NSF [MCB1158151]
FX We thank the NHLBI light microscopy core for assistance with SIM
experiments; the NHLBI proteomics core for performing MS analysis;
Rodrigo Guillen for cloning assistance; and Alexander Kelly, Susan
Harbison and Clare Waterman for insightful discussions. This work was
supported by the Division of Intramural Research at the NIH/NHLBI
(1ZIAHL006104) to N.M.R., NIH/NIGMS R01GM110166 and NSF MCB1158151 to
G.C.R. and NIH/NIGMS R01GM094415 to K.C.S.
NR 70
TC 0
Z9 0
U1 4
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG
PY 2016
VL 7
AR 12476
DI 10.1038/ncomms12476
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW4XP
UT WOS:000383646600001
PM 27558293
ER
PT J
AU Stuart, DI
Subramaniam, S
Abrescia, NGA
AF Stuart, David I.
Subramaniam, Sriram
Abrescia, Nicola G. A.
TI The democratization of cryo-EM
SO NATURE METHODS
LA English
DT Letter
ID MICROSCOPY
C1 [Stuart, David I.] Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Instruct, Oxford, England.
[Stuart, David I.] Diamond Light Source Ltd, Diamond House,Harwell Sci & Innovat Campus, Didcot, Oxon, England.
[Subramaniam, Sriram] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
[Abrescia, Nicola G. A.] CIBERehd, Struct Biol Unit, CICbioGUNE, Derio, Spain.
[Abrescia, Nicola G. A.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain.
RP Stuart, DI (reprint author), Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Instruct, Oxford, England.
EM dave@strubi.ox.ac.uk; ss1@nih.gov; nabrescia@cicbiogune.es
OI Abrescia, Nicola GA/0000-0001-5559-1918
FU Medical Research Council [G1100525, MR/N00065X/1]
NR 6
TC 0
Z9 0
U1 8
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1548-7091
EI 1548-7105
J9 NAT METHODS
JI Nat. Methods
PD AUG
PY 2016
VL 13
IS 8
BP 607
EP 608
DI 10.1038/nmeth.3946
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA DY6AT
UT WOS:000385188700008
PM 27467721
ER
PT J
AU Liew, SL
Rana, M
Cornelsen, S
de Barros, MF
Birbaumer, N
Sitaram, R
Cohen, LG
Soekadar, SR
AF Liew, Sook-Lei
Rana, Mohit
Cornelsen, Sonja
de Barros Filho, Marcos Fortunato
Birbaumer, Niels
Sitaram, Ranganatha
Cohen, Leonardo G.
Soekadar, Surjo R.
TI Improving Motor Corticothalamic Communication After Stroke Using
Real-Time fMRI Connectivity-Based Neurofeedback
SO NEUROREHABILITATION AND NEURAL REPAIR
LA English
DT Article
DE stroke; real-time functional magnetic resonance imaging (rtfMRI);
neurofeedback; connectivity; brain-machine interface (BMI)
AB Background. Two thirds of stroke survivors experience motor impairment resulting in long-term disability. The anatomical substrate is often the disruption of cortico-subcortical pathways. It has been proposed that reestablishment of cortico-subcortical communication relates to functional recovery. Objective. In this study, we applied a novel training protocol to augment ipsilesional cortico-subcortical connectivity after stroke. Chronic stroke patients with severe motor impairment were provided online feedback of blood-oxygenation level dependent signal connectivity between cortical and subcortical regions critical for motor function using real-time functional magnetic resonance imaging neurofeedback. Results. In this proof of principle study, 3 out of 4 patients learned to voluntarily modulate cortico-subcortical connectivity as intended. Conclusions. Our results document for the first time the feasibility and safety for patients with chronic stroke and severe motor impairment to self-regulate and augment ipsilesional cortico-subcortical connectivity through neurofeedback using real-time functional magnetic resonance imaging.
C1 [Liew, Sook-Lei; Cohen, Leonardo G.] NINDS, Human Cort Physiol & Neurorehabil Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Liew, Sook-Lei] Univ Southern Calif, Chan Div Occupat Sci & Occupat Therapy, Div Phys Therapy & Biokinesiol, Dept Neurol, Los Angeles, CA USA.
[Rana, Mohit; Sitaram, Ranganatha] Pontificia Univ Catolica Chile, Inst Med & Biol Engn, Santiago, Chile.
[Rana, Mohit; Sitaram, Ranganatha] Pontificia Univ Catolica Chile, Dept Psychiat, Santiago, Chile.
[Rana, Mohit; Sitaram, Ranganatha] Pontificia Univ Catolica Chile, Dept Psychiat, Santiago, Chile.
[Rana, Mohit; Sitaram, Ranganatha] Pontificia Univ Catolica Chile, Sect Neurosci, Sch Engn, Santiago, Chile.
[Rana, Mohit; Sitaram, Ranganatha] Pontificia Univ Catolica Chile, Sect Neurosci, Sch Med, Santiago, Chile.
[Rana, Mohit; Sitaram, Ranganatha] Pontificia Univ Catolica Chile, Sect Neurosci, Sch Biol, Santiago, Chile.
[Rana, Mohit; Birbaumer, Niels; Sitaram, Ranganatha; Soekadar, Surjo R.] Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Tubingen, Germany.
[Rana, Mohit; Sitaram, Ranganatha] Univ Florida, Dept Biomed Engn, Gainesville, FL USA.
[Cornelsen, Sonja] Univ Tubingen, Hertie Inst Clin Brain Res, Div Neuropsychol, Ctr Neurol, Tubingen, Germany.
[de Barros Filho, Marcos Fortunato; Soekadar, Surjo R.] Univ Tubingen Hosp, Dept Psychiat & Psychotherapy, Appl Neurotechnol Lab, Tubingen, Germany.
[Birbaumer, Niels] Osped San Camillo, IRCSS, Venice, Italy.
RP Liew, SL (reprint author), USC Neural Plast & Neurorehabil Lab, 1540 Alcazar St,CHP 133 MC 9003, Los Angeles, CA 90089 USA.; Soekadar, SR (reprint author), Univ Tubingen Hosp, Appl Neurotechnol Lab, Calwerstr 14, D-72076 Tubingen, Germany.
EM sliew@usc.edu; surjo.soekadar@uni-tuebingen.de
FU Intramural Research Program (IRP) of the National Institute of
Neurological Disorders and Stroke (NINDS), USA; DAAD Research Grant; NIH
[K12 HD055929]; German Federal Ministry of Education and Research (BMBF)
[01GQ0831, 16SV5838K]; Deutsche Forschungsgemeinschaft (DFG) [SO932-2];
European Commission under the project WAY [288551]; Volkswagenstiftung
(VW); Baden-Wurttemberg Stiftung, Germany; New INDIGO Research Grant
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the Intramural Research Program (IRP) of the National
Institute of Neurological Disorders and Stroke (NINDS), USA; the DAAD
Research Grant (to SLL); NIH K12 HD055929 (to SLL); the German Federal
Ministry of Education and Research (BMBF, Grant Numbers 01GQ0831 and
16SV5838K to SRS and NB); the Deutsche Forschungsgemeinschaft (DFG,
Grant Number SO932-2 to SRS and Koselleck support to NB); the European
Commission under the project WAY (Grant Number 288551 to SRS and NB);
the Volkswagenstiftung (VW); the Baden-Wurttemberg Stiftung, Germany;
and the New INDIGO Research Grant (to RS).
NR 13
TC 3
Z9 3
U1 5
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1545-9683
EI 1552-6844
J9 NEUROREHAB NEURAL RE
JI Neurorehabil. Neural Repair
PD AUG
PY 2016
VL 30
IS 7
BP 671
EP 675
DI 10.1177/1545968315619699
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA DS7BN
UT WOS:000380937600007
PM 26671217
ER
PT J
AU Bontemps-Gallo, S
Lawrence, K
Gherardini, FC
AF Bontemps-Gallo, Sebastien
Lawrence, Kevin
Gherardini, Frank C.
TI Two Different Virulence-Related Regulatory Pathways in Borrelia
burgdorferi Are Directly Affected by Osmotic Fluxes in the Blood Meal of
Feeding Ixodes Ticks
SO PLOS PATHOGENS
LA English
DT Article
ID LYME-DISEASE SPIROCHETE; OUTER-SURFACE PROTEIN; ESCHERICHIA-COLI;
DERMACENTOR-ANDERSONI; GENE-EXPRESSION; WATER-BALANCE; TRANSCRIPTIONAL
ACTIVATOR; RESPONSE REGULATOR; SALIVARY SECRETION; HOST ADAPTATION
AB Lyme disease, caused by Borrelia burgdorferi, is a vector-borne illness that requires the bacteria to adapt to distinctly different environments in its tick vector and various mammalian hosts. Effective colonization (acquisition phase) of a tick requires the bacteria to adapt to tick midgut physiology. Successful transmission (transmission phase) to a mammal requires the bacteria to sense and respond to the midgut environmental cues and up-regulate key virulence factors before transmission to a new host. Data presented here suggest that one environmental signal that appears to affect both phases of the infective cycle is osmolarity. While constant in the blood, interstitial fluid and tissue of a mammalian host (300 mOsm), osmolarity fluctuates in the midgut of feeding Ixodes scapularis. Measured osmolarity of the blood meal isolated from the midgut of a feeding tick fluctuates from an initial osmolarity of 600 mOsm to blood-like osmolarity of 300 mOsm. After feeding, the midgut osmolarity rebounded to 600 mOsm. Remarkably, these changes affect the two independent regulatory networks that promote acquisition (Hk1-Rrp1) and transmission (Rrp2-RpoN-RpoS) of B. burgdorferi. Increased osmolarity affected morphology and motility of wild-type strains, and lysed Hk1 and Rrp1 mutant strains. At low osmolarity, Borrelia cells express increased levels of RpoN-RpoS-dependent virulence factors (OspC, DbpA) required for the mammalian infection. Our results strongly suggest that osmolarity is an important part of the recognized signals that allow the bacteria to adjust gene expression during the acquisition and transmission phases of the infective cycle of B. burgdorferi.
C1 [Bontemps-Gallo, Sebastien; Lawrence, Kevin; Gherardini, Frank C.] NIAID, Lab Zoonot Pathogens, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.
RP Gherardini, FC (reprint author), NIAID, Lab Zoonot Pathogens, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.
EM Fgherardini@niaid.nih.gov
OI bontemps-gallo, sebastien/0000-0002-1834-5416
FU Intramural Research Program of the National Institute for Allergy and
Infectious Diseases, National Institutes of Health
FX This study was supported by the Intramural Research Program of the
National Institute for Allergy and Infectious Diseases, National
Institutes of Health. The funders were not involved in the study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 74
TC 1
Z9 1
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2016
VL 12
IS 8
AR e1005791
DI 10.1371/journal.ppat.1005791
PG 25
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA DW1AV
UT WOS:000383376000029
ER
PT J
AU Judson, SD
Fischer, R
Judson, A
Munster, VJ
AF Judson, Seth D.
Fischer, Robert
Judson, Andrew
Munster, Vincent J.
TI Ecological Contexts of Index Cases and Spillover Events of Different
Ebolaviruses
SO PLOS PATHOGENS
LA English
DT Article
ID EBOLA HEMORRHAGIC-FEVER; RESTON-EBOLAVIRUS; VIRUS-DISEASE; FRUIT BATS;
GEOGRAPHIC-DISTRIBUTION; CONGO; OUTBREAKS; FILOVIRIDAE; UGANDA; GABON
AB Ebola virus disease afflicts both human and animal populations and is caused by four ebola-viruses. These different ebolaviruses may have distinct reservoir hosts and ecological contexts that determine how, where, and when different ebolavirus spillover events occur. Understanding these virus-specific relationships is important for preventing transmission of ebolaviruses from wildlife to humans. We examine the ecological contexts surrounding 34 human index case infections of ebolaviruses from 1976-2014. Determining possible sources of spillover from wildlife, characterizing the environment of each event, and creating ecological niche models to estimate habitats suitable for spillover, we find that index case infections of two ebolaviruses, Ebola virus and Sudan virus, have occurred under different ecological contexts. The index cases of Ebola virus infection are more associated with tropical evergreen broadleaf forests and consuming bushmeat than the cases of Sudan virus. Given these differences, we emphasize caution when generalizing across different ebolaviruses and that location and virus-specific ecological knowledge will be essential to unravelling how human and animal behavior lead to the emergence of Ebola virus disease.
C1 [Judson, Seth D.; Fischer, Robert; Munster, Vincent J.] NIAID, Virus Ecol Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT 59840 USA.
[Judson, Seth D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Judson, Andrew] Square Inc, San Francisco, CA USA.
RP Munster, VJ (reprint author), NIAID, Virus Ecol Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT 59840 USA.
EM Vincent.munster@nih.gov
OI Munster, Vincent/0000-0002-2288-3196
FU Intramural Research Program of the National Institute of Allergy and
Infectious Diseases, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 70
TC 0
Z9 0
U1 9
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2016
VL 12
IS 8
AR e1005780
DI 10.1371/journal.ppat.1005780
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA DW1AV
UT WOS:000383376000021
ER
PT J
AU Meliopoulos, VA
Van de Velde, LA
Van de Velde, NC
Karlsson, EA
Neale, G
Vogel, P
Guy, C
Sharma, S
Duan, S
Surman, SL
Jones, BG
Johnson, MDL
Bosio, C
Jolly, L
Jenkins, RG
Hurwitz, JL
Rosch, JW
Sheppard, D
Thomas, PG
Murray, PJ
Schultz-Cherry, S
AF Meliopoulos, Victoria A.
Van de Velde, Lee-Ann
Van de Velde, Nicholas C.
Karlsson, Erik A.
Neale, Geoff
Vogel, Peter
Guy, Cliff
Sharma, Shalini
Duan, Susu
Surman, Sherri L.
Jones, Bart G.
Johnson, Michael D. L.
Bosio, Catharine
Jolly, Lisa
Jenkins, R. Gisli
Hurwitz, Julia L.
Rosch, Jason W.
Sheppard, Dean
Thomas, Paul G.
Murray, Peter J.
Schultz-Cherry, Stacey
TI An Epithelial Integrin Regulates the Amplitude of Protective Lung
Interferon Responses against Multiple Respiratory Pathogens
SO PLOS PATHOGENS
LA English
DT Article
ID INFLUENZA-VIRUS INFECTION; TGF-BETA ACTIVATION; GROWTH-FACTOR-BETA;
ALVEOLAR MACROPHAGES; DISTRESS-SYNDROME; EXPRESSION PROFILES; LATENT
TGF-BETA-1; INNATE IMMUNITY; MOUSE MODEL; GM-CSF
AB The healthy lung maintains a steady state of immune readiness to rapidly respond to injury from invaders. Integrins are important for setting the parameters of this resting state, particularly the epithelial-restricted alpha V beta 6 integrin, which is upregulated during injury. Once expressed, alpha V beta 6 moderates acute lung injury (ALI) through as yet undefined molecular mechanisms. We show that the upregulation of beta 6 during influenza infection is involved in disease pathogenesis. beta 6-deficient mice (beta 6 KO) have increased survival during influenza infection likely due to the limited viral spread into the alveolar spaces leading to reduced ALI. Although the beta 6 KO have morphologically normal lungs, they harbor constitutively activated lung CD11b+ alveolar macrophages (AM) and elevated type I IFN signaling activity, which we traced to the loss of beta 6-activated transforming growth factor-beta (TGF-beta). Administration of exogenous TGF-beta to beta 6 KO mice leads to reduced numbers of CD11b(+) AMs, decreased type I IFN signaling activity and loss of the protective phenotype during influenza infection. Protection extended to other respiratory pathogens such as Sendai virus and bacterial pneumonia. Our studies demonstrate that the loss of one epithelial protein, alpha V beta 6 integrin, can alter the lung microenvironment during both homeostasis and respiratory infection leading to reduced lung injury and improved survival.
C1 [Meliopoulos, Victoria A.; Van de Velde, Lee-Ann; Van de Velde, Nicholas C.; Karlsson, Erik A.; Surman, Sherri L.; Jones, Bart G.; Johnson, Michael D. L.; Hurwitz, Julia L.; Rosch, Jason W.; Murray, Peter J.; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Van de Velde, Lee-Ann; Van de Velde, Nicholas C.; Guy, Cliff; Sharma, Shalini; Duan, Susu; Thomas, Paul G.; Murray, Peter J.] St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Neale, Geoff] St Jude Childrens Res Hosp, Hartwell Ctr, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Vogel, Peter] St Jude Childrens Res Hosp, Dept Vet Pathol Core, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Bosio, Catharine] NIAID, Rocky Mt Lab, NIH, Hamilton, MT 59840 USA.
[Jolly, Lisa; Jenkins, R. Gisli] Univ Nottingham, Div Resp Med, Nottingham, England.
[Sheppard, Dean] UCSF Med Ctr, Dept Med, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA USA.
RP Murray, PJ; Schultz-Cherry, S (reprint author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.; Murray, PJ (reprint author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM peter.murray@stjude.org; Stacey.Schultz-Cherry@stjude.org
OI Thomas, Paul G./0000-0001-7955-0256; Johnson,
Michael/0000-0002-6347-0208
FU Hartwell Foundation; St. Jude Children's Research Hospital Children's
Infection Defense Center; ALSAC, NIAID [HHSN272201400006C]; NHLBI
[HL108794, HL53949]; NIAID [R01 AI 088729]; NCI [P30 CA21765]; Asthma UK
[10-020]; Wellcome Trust [085350]; MRC MICA grant [G0901226]
FX These studies were supported by The Hartwell Foundation (SSC and PJM),
St. Jude Children's Research Hospital Children's Infection Defense
Center (SSC and PJM), ALSAC, NIAID HHSN272201400006C (SSC), NHLBI
HL108794 and NHLBI HL53949 (DS), NIAID R01 AI 088729 (JLH), NCI P30
CA21765, Asthma UK (10-020, RGJ), Wellcome Trust (085350, RGJ) and MRC
MICA grant (G0901226, RGJ). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 68
TC 2
Z9 2
U1 3
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2016
VL 12
IS 8
AR e1005804
DI 10.1371/journal.ppat.1005804
PG 30
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA DW1AV
UT WOS:000383376000035
PM 27505057
ER
PT J
AU Driessen, J
Baik, SH
Zhang, YT
AF Driessen, Julia
Baik, Seo Hyon
Zhang, Yuting
TI Trends in Off-Label Use of Second-Generation Antipsychotics in the
Medicare Population From 2006 to 2012
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID SCHIZOPHRENIA; DRUGS
AB Objective: The study evaluated trends in the off-label use of second-generation antipsychotics in the Medicare population, a practice that has been identified as lacking adequate supporting evidence for many indications.
Methods: Medicare claims data from 2006 to 2012 were used to identify beneficiaries who filled at least one prescription for any second-generation antipsychotic. Any use that was not associated with a medical claim for an approved indication in a given year was classified as off-label use. Rates of off-label use and of diagnoses associated with off-label use were compared over time. Fill counts standardized for 30-day supply and costs were compared by type of use.
Results: On the basis of a sample of 490,314 patient-years, the rate of off-label use among beneficiaries prescribed a second-generation antipsychotic declined from 51% to 45%. Fill counts were 16% lower for off-label users compared with on-label users. Off-label users had higher out-of-pocket costs but lower total costs for second-generation antipsychotics. Off-label users most commonly had claims related to dementia, minor depression, anxiety disorders, and other psychosis. The proportion of off-label users without any claims for the most common off-label uses of second-generation antipsychotics declined from 45% in 2006 to 30% in 2012.
Conclusions: Off-label use of second-generation antipsychotics has declined, especially among persons without any of the common off-label conditions. The diagnoses accompanying off-label use did not systematically reflect changes in the evidence base for the use of these drugs, suggesting a mismatch between evidence supporting the use of off-label second-generation antipsychotics and prescribing practices.
C1 [Driessen, Julia; Zhang, Yuting] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA.
[Baik, Seo Hyon] Natl Lib Med, Lister Hill Natl Ctr Biomed Commun, Bethesda, MD USA.
RP Driessen, J (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA.
EM driessen@pitt.edu
FU National Institute of Mental Health [R21 MH100721, RC1 MH088510];
Commonwealth Fund; Institute of Medicine
FX The authors acknowledge funding from the National Institute of Mental
Health (R21 MH100721 and RC1 MH088510), the Commonwealth Fund, and the
Institute of Medicine.
NR 14
TC 0
Z9 0
U1 1
U2 3
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD AUG 1
PY 2016
VL 67
IS 8
BP 898
EP 903
DI 10.1176/appi.ps.201500316
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA DT7OC
UT WOS:000381675100020
PM 27079991
ER
PT J
AU Parchment, RE
Doroshow, JH
AF Parchment, Ralph E.
Doroshow, James H.
TI Theory and practice of clinical pharmacodynamics in oncology drug
development
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE Assay fitness-for-purpose; Biopsy sample quality; Reagent quality
control; Biopsy surrogate tissues
ID REFRACTORY SOLID TUMORS; ADP-RIBOSE POLYMERASE; PHASE-I; INHIBITOR
ABT-888; CANCER; COMBINATION; TRIALS; BIOMARKERS; THERAPY; BIOPSY
AB The clinical development of molecularly targeted cancer therapies is enhanced by proof of mechanism of action as well as proof of concept, which relate molecular pharmacodynamics to efficacy via changes in cancer cell biology and physiology resulting from drug action on its intended target. Here, we present an introduction to the field of clinical pharmacodynamics, its medical and laboratory aspects, and its practical incorporation into clinical trials. We also describe key success factors that are useful for judging the quality of clinical pharmacodynamic studies, including biopsy quality and suitability, specimen handling, assay fitness-for-purpose, and reagent quality control. This introduction provides not only context for the following articles in this issue, but also an appreciation of the role of well-conducted clinical pharmacodynamic studies in oncology drug development. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Parchment, Ralph E.] Leidos Biomed Res Inc, Clin Pharmacodynam Program, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Parchment, RE (reprint author), NCI, 1050 Boyles St,POB 1050,Bldg 425, Frederick, MD 20702 USA.
EM parchmentr@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 54
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 427
EP 435
DI 10.1053/j.seminoncol.2016.07.001
PG 9
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100001
PM 27663474
ER
PT J
AU Kummar, S
Do, K
Coyne, GO
Chen, A
Ji, JP
Rubinstein, L
Doroshow, JH
AF Kummar, Shivaani
Khanh Do
Coyne, Geraldine O'Sullivan
Chen, Alice
Ji, Jiuping
Rubinstein, Larry
Doroshow, James H.
TI Establishing proof of mechanism: Assessing target modulation in
early-phase clinical trials
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE Pharmacodynamics; Biomarkers; Biopsy surrogate tissues; Phase I; Drug
evaluation
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; RESEARCH-RELATED BIOPSIES;
ADP-RIBOSE POLYMERASE; ANAPLASTIC LYMPHOMA; EMISSION-TOMOGRAPHY;
ANTITUMOR-ACTIVITY; BREAST-CANCER; SOLID TUMORS; I TRIALS
AB Since modulation of the putative target and the observed anti-tumor effects form the basis for the clinical development of a molecularly targeted therapy, early-phase clinical trials should be designed to demonstrate proof-of-mechanism in tissues of interest. In addition to establishing safety and the maximum tolerated dose, first-in-human clinical trials should be designed to demonstrate target modulation, define the proposed mechanism of action, and evaluate pharmacokinetic-pharmacodynamic relationships of a new anti-cancer agent. Assessing target modulation in paired tumor biopsies in patients with solid tumors presents multiple challenges, including procedural issues such as patient safety, ethical considerations, and logistics of sample handling and processing. In addition, the availability of qualified biomarker assay technologies, resources to conduct such studies, and real-time analysis of samples to detect inter-species differences that may affect the determination of optimal sampling time points must be taken into account. This article provides a discussion of the challenges that confront the practical application of pharmacodynamic studies in early-phase clinical trials of anti-cancer agents. (C) 2016 Published by Elsevier Inc.
C1 [Kummar, Shivaani; Khanh Do; Coyne, Geraldine O'Sullivan; Chen, Alice; Rubinstein, Larry; Doroshow, James H.] NCI, NIH, Bethesda, MD 20892 USA.
[Ji, Jiuping] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
[Kummar, Shivaani] 780 Welch Rd,Room CJ250L, Palo Alto, CA 94304 USA.
RP Kummar, S (reprint author), NCI, NIH, Bethesda, MD 20892 USA.; Kummar, S (reprint author), 780 Welch Rd,Room CJ250L, Palo Alto, CA 94304 USA.
EM skummar@stanford.edu
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX We thank Dr Andrea Regier Voth, Leidos Biomedical Research, Inc, for
medical writing support in the preparation of this manuscript. This
project has been funded in whole or in part with federal funds from the
National Cancer Institute, National Institutes of Health, under Contract
No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 41
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 446
EP 452
DI 10.1053/j.seminoncol.2016.06.002
PG 7
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100003
PM 27663476
ER
PT J
AU Wang, LH
Balasubramanian, P
Chen, AP
Kummar, S
Evrard, YA
Kinders, RJ
AF Wang, Lihua
Balasubramanian, Priya
Chen, Alice P.
Kummar, Shivaani
Evrard, Yvonne A.
Kinders, Robert J.
TI Promise and limits of the CellSearch platform for evaluating
pharmacodynamics in circulating tumor cells
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE CTCs; Assay validation; Surrogate endpoint; Pharmacodynamics
ID RESISTANT PROSTATE-CANCER; METASTATIC BREAST-CANCER; PROGRESSION-FREE
SURVIVAL; PREDICTIVE BIOMARKER; ABIRATERONE ACETATE; OVARIAN-CANCER;
LUNG-CANCER; PHASE-I; VELIPARIB; BLOOD
AB Circulating tumor cells (CTCs), which are captured from blood with anti-epithelial cell adhesion molecule (EpCAM) antibodies, have established prognostic value in specific epithelial cancers, but less is known about their utility for assessing patient response to molecularly targeted agents via measurement of pharmacodynamic (PD) endpoints. We discuss the use of CellSearch (Janssen Diagnostics, LLC, Raritan, NJ) CTC isolation technology for monitoring PD response in early phase trials. We present representative data from three clinical trials with the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) suggesting that CTCs can be used to measure PD effects. However, while often leading to hypothesis generating information, our experience points to the difficulty in obtaining sufficient EpCAM-expressing CTCs from patients with advanced disease to reach statistically significant conclusions about PD effects from each trial. Overall, the level of phenotypic heterogeneity observed in specimens from patients with advanced carcinomas suggests caution in the use of cell-surface differentiation marker-based methods for isolating CTCs. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Wang, Lihua; Balasubramanian, Priya; Evrard, Yvonne A.; Kinders, Robert J.] Leidos Biomed Res Inc, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Chen, Alice P.; Kummar, Shivaani] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
RP Kinders, RJ (reprint author), Leidos Biomed Res Inc, Pharmacodynam Assay Dev & Implementat Sect, Lab Human Toxicol & Pharmacol, Appl Dev Res Directorate, Frederick, MD 21702 USA.
EM kindersr@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX We thank Dr Andrea Regier Voth, Leidos Biomedical Research, Inc, for
medical writing support in the preparation of the manuscript. This
project has been funded in whole or in part with federal funds from the
National Cancer Institute, National Institutes of Health, under Contract
No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 34
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 464
EP 475
DI 10.1053/j.seminoncol.2016.06.004
PG 12
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100005
PM 27663478
ER
PT J
AU Ferry-Galow, KV
Makhlouf, HR
Wilsker, DF
Lawrence, SM
Pfister, TD
Marrero, AM
Bigelow, KM
Yutzy, WH
Ji, JPJ
Butcher, DO
Gouker, BA
Kummar, S
Chen, AP
Kinders, RJ
Parchment, RE
Doroshow, JH
AF Ferry-Galow, Katherine V.
Makhlouf, Hala R.
Wilsker, Deborah F.
Lawrence, Scott M.
Pfister, Thomas D.
Marrero, Allison M.
Bigelow, Kristina M.
Yutzy, William H.
Ji, Jiuping J.
Butcher, Donna O.
Gouker, Brad A.
Kummar, Shivaani
Chen, Alice P.
Kinders, Robert J.
Parchment, Ralph E.
Doroshow, James H.
TI The root causes of pharmacodynamic assay failure
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE Tumor biopsy; Reagent qualification; Assay quality control
ID CLINICAL-TRIALS; PROTEIN BIOMARKERS; METHOD VALIDATION; DRUG
DEVELOPMENT; TUMOR-BIOPSIES; IMPLEMENTATION; IMMUNOASSAY; GAMMA-H2AX;
SUPPORT; CELLS
AB Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reagent and specimen quality are two major contributors to this problem. Minimizing all potential sources of variability in procedures for specimen collection, processing, and assay measurements is essential for meaningful comparison of pharmacodynamic biomarkers across sample time points. This is especially true in the evaluation of pre- and post-dose tumor biopsies, which suffer from high levels of tumor insufficiency due to variations in biopsy collection techniques and significant specimen heterogeneity within and across patients. Developing methods to assess heterogeneous biopsies is necessary in order to evaluate a majority of tumor biopsies collected for pharmacodynamic biomarker studies. Improved collection devices and standardization of methods are being sought in order to improve the tumor content and quality of tumor biopsies. In terms of reagent variability, we have found that stringent initial reagent qualification and quality control of R&D-grade reagents is critical to minimize lot-to-lot variability and prevent assay failures, especially for clinical pharmacodynamic questions, which often demand assay performance that meets or exceeds clinical diagnostic assay standards. Rigorous reagent specifications and use of appropriate assay quality control methodologies help to ensure consistency between assay runs, laboratories and trials to provide much needed pharmacodynamic insights into the activity of investigational agents. (C) 2016 Published by Elsevier Inc.
C1 [Ferry-Galow, Katherine V.; Wilsker, Deborah F.; Lawrence, Scott M.; Pfister, Thomas D.; Yutzy, William H.; Ji, Jiuping J.; Kinders, Robert J.; Parchment, Ralph E.] Leidos Biomed Res Inc, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Makhlouf, Hala R.] Div Canc Treatment & Diag, Canc Diag Program, Rockville, MD USA.
[Marrero, Allison M.] MedImmune LLC, Gaithersburg, MD USA.
[Bigelow, Kristina M.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
[Butcher, Donna O.; Gouker, Brad A.] Leidos Biomed Res, Pathol Histotechnol Lab, Anim Sci Program, Frederick Natl Labs, Frederick, MD USA.
[Kummar, Shivaani] Stanford Univ, Dept Oncol, Sch Med, Stanford, CA USA.
[Chen, Alice P.] NCI DCTD Early Clin Trials Dev Program, Bethesda, MD USA.
[Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Ferry-Galow, KV (reprint author), Leidos Biomed Res Inc, Clin Pharmacodynam Biomarkers Program, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
EM Katherine.FerryGalow@nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX We thank Dr. Andrea Regier Voth, Leidos Biomedical Research, Inc., for
medical writing support in the preparation of this manuscript. This
project has been funded in whole or in part with federal funds from the
National Cancer Institute, National Institutes of Health, under Contract
No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 23
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 484
EP 491
DI 10.1053/j.seminoncol.2016.06.006
PG 8
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100007
PM 27663480
ER
PT J
AU Ferry-Galow, KV
Ji, JP
Kinders, RJ
Zhang, YP
Czambel, RK
Schmitz, JC
Herzog, J
Evrard, YA
Parchment, RE
AF Ferry-Galow, Katherine V.
Ji, Jiuping
Kinders, Robert J.
Zhang, Yiping
Czambel, R. Kenneth
Schmitz, John C.
Herzog, Josef
Evrard, Yvonne A.
Parchment, Ralph E.
TI Pharmacodynamic analyses in a multi-laboratory network: lessons from the
poly(ADP-ribose) assay
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE Poly(ADP-ribose), PAR; Reagent qualification; Assay quality control
ID ADP-RIBOSE POLYMERASE; 0 CLINICAL-TRIAL; DRUG DEVELOPMENT;
QUALIFICATION; BIOMARKERS; INHIBITOR; ABT-888
AB Clinical pharmacodynamic assays need to meet higher criteria for sensitivity, precision, robustness, and reproducibility than those expected for research-grade assays because of the long duration of clinical trials and the potentially unpredictable number of laboratories running the assays. This report describes the process of making an immunoassay based on commercially available reagents "clinically ready". The assay was developed to quantify poly(ADP-ribose) (PAR) levels as a marker of PAR polymerase inhibitor activity for a proof-of-concept phase 0 clinical trial at the National Cancer Institute (NCI) and subsequent clinical trials. In this publication, we retrospectively examine the measures taken to validate the published PAR immunoassay and outline key lessons learned during the development and implementation of these procedures at both internal and external clinical trial sites; these measures included optimizing PAR measurements in tumor biopsies and peripheral blood mononuclear cells (PBMCs), reagent qualification, analytical validation and assay quality control, instrument qualification and method quality control, and support for external laboratories. (C) 2016 Published by Elsevier Inc.
C1 [Ferry-Galow, Katherine V.; Ji, Jiuping; Kinders, Robert J.; Zhang, Yiping; Evrard, Yvonne A.; Parchment, Ralph E.] Leidos Biomed Res Inc, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Czambel, R. Kenneth; Schmitz, John C.] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA.
[Herzog, Josef] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA USA.
RP Ferry-Galow, KV (reprint author), Leidos Biomed Res Inc, Clin Pharmacodynam Biomarkers Program, Appl Dev Res Directorate, Natl Lab Canc Res, Frederick, MD 21702 USA.
EM Katherine.FerryGalow@nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 15
TC 1
Z9 1
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 492
EP 500
DI 10.1053/j.seminoncol.2016.06.007
PG 9
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100008
PM 27663481
ER
PT J
AU Parchment, RE
Voth, AR
Doroshow, JH
Berzofsky, JA
AF Parchment, Ralph E.
Voth, Andrea Regier
Doroshow, James H.
Berzofsky, Jay A.
TI Immuno-pharmacodynamics for evaluating mechanism of action and
developing immunotherapy combinations
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE Pharmacodynamic biomarkers; Cellular landscape; Immune checkpoints; PD1;
Combination immunotherapy
ID REGULATORY T-CELLS; MHC CLASS-I; TUMOR VACCINE EFFICACY; BREAST-CANCER;
LUNG-CANCER; DENDRITIC CELLS; TYROSINE PHOSPHORYLATION; CELLULAR
CYTOTOXICITY; MONOCLONAL-ANTIBODY; SUPPRESSOR-CELLS
AB Immunotherapy has become a major modality of cancer treatment, with multiple new classes of immunotherapeutics recently entering the clinic and obtaining market approval from regulatory agencies. While the promise of these therapies is great, so is the number of possible combinations not only with each other but also with small molecule therapeutics. Furthermore, the observation of unusual dose-response relationships suggests a critical dependency of drug effectiveness on the dosage regimen (dose and schedule). Clinical pharmacodynamic (PD) biomarkers will be useful endpoints for confirming drug mechanism of action, evaluating combination therapies for synergy or antagonism, and identifying optimal dosage regimens. In contrast to conventional PD in which drug action occurs entirely within a single target cell (ie, is self-contained within the malignant cell), immunotherapy involves a complex mechanism of action with sequential steps that propagate through multiple cell types, both normal and malignant. Its intercellular pharmacology begins with molecular target engagement either on an immune effector cell or a malignant cell, followed by stimulatory biochemical and biological signals in immune effector cells, and then finally ends with activation of cell death mechanisms in malignant cells lying within a certain distance from the activated effector cells (immune cell tumor cell proximity). Evaluating such "trans cellular pharmacology," in which different steps of drug action are distributed across multiple cell types, requires novel microscopy and image analysis tools capable of quantifying PD-biomarker responses, mapping the responses onto the cellular geography of the tumor using phenotypic biomarkers to identify specific cell types, and finally analyzing the spatial relationships between biomarkers in the context of each cell's biological role. We have termed this form of nearest neighbor image analysis of drug action "proximity PD microscopy," to indicate the importance of the location of the PD-biomarker response within the cellular landscape of a tumor specimen. We discuss herein the major modes of immunotherapy, and lay out a blueprint for using PD assessment to optimize dosage regimens of single agents and guide development of combination immunotherapy regimens, using PD1/PD-L1 immune checkpoint inhibition as a case study. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Parchment, Ralph E.; Voth, Andrea Regier] Leidos Biomed Res Inc, Clin Pharmacodynam Program, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, POB B, Frederick, MD 21702 USA.
[Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
[Berzofsky, Jay A.] NCI, Vaccine Branch, Bethesda, MD 20892 USA.
RP Parchment, RE (reprint author), Leidos Biomed Res Inc, Clin Pharmacodynam Program, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, POB B, Frederick, MD 21702 USA.
EM parchmentr@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 100
TC 0
Z9 0
U1 7
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 501
EP 513
DI 10.1053/j.seminoncol.2016.06.008
PG 13
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100009
PM 27663482
ER
PT J
AU Parchment, RE
Doroshow, JH
AF Parchment, Ralph E.
Doroshow, James H.
TI Pharmacodynamic endpoints as clinical trial objectives to answer
important questions in oncology drug development
SO SEMINARS IN ONCOLOGY
LA English
DT Review
DE Pharmacodynamics; Cancer drug development; Proof-of-mechanism trials
ID ADP-RIBOSE POLYMERASE; COLD ISCHEMIC TIME; TYROSINE KINASE;
PREANALYTICAL VARIABLES; COMBINATION THERAPY; PARP INHIBITORS; PHASE-0
TRIALS; FFPE TISSUE; CANCER; ACTIVATION
AB Analyzing the molecular interplay between malignancies and therapeutic agents is rarely a straightforward process, but we hope that this special issue of Seminars has highlighted the clinical value of such endeavors as well as the relevant theoretical and practical considerations. Here, we conclude with both an overview of the various high-value applications of clinical pharmacodynamics (PD) in developmental therapeutics and an outline of the framework for incorporating PD analyses into the design of clinical trials. Given the increasingly recognized importance of determining and administering the biologically effective dose (BED) and schedule of targeted agents, we explain how clinical PD biomarkers specific to the agent mechanism of action (MOA) can be used for the development of pharmacodynamics-guided biologically effective dosage regimens (PD-BEDR) to maximize the efficacy and minimize the toxicity of targeted therapies. In addition, we discuss how MOA-based PD biomarker analyses can be used both as patient selection diagnostic tools and for designing novel drug combinations targeting the specific mutational signature of a given malignancy. We also describe the role of PD analyses in clinical trials, including for MOA confirmation and dosage regimen optimization during phase 0 trials as well as for correlating molecular changes with clinical efficacy when establishing proof-of-concept in phase trials. Finally, we outline the critical technological developments that are needed to enhance the quality and quantity of future clinical PD data collection, broaden the types of molecular questions that can be answered in the clinic, and, ultimately, improve patient outcomes. Published by Elsevier Inc.
C1 [Parchment, Ralph E.] Leidos Biomed Res Inc, Clin Pharmacodynam Program, Appl Dev Res Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
RP Doroshow, JH (reprint author), NCI, Div Canc Treatment & Diag, NIH, Bldg 31,Room 3A-44,31 Ctr Dr, Bethesda, MD 20892 USA.
EM doroshoj@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
NR 55
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
EI 1532-8708
J9 SEMIN ONCOL
JI Semin. Oncol.
PD AUG
PY 2016
VL 43
IS 4
BP 514
EP 525
DI 10.1053/j.seminoncol.2016.07.002
PG 12
WC Oncology
SC Oncology
GA DY1QS
UT WOS:000384870100010
PM 27663483
ER
PT J
AU Noda, C
Venkatesh, BA
Ohyama, Y
Liu, CY
Chamera, E
Redheuil, A
Teixido-Tura, G
Chugh, AR
Wu, CO
Hundley, GW
Bluemke, DA
Lima, JAC
AF Noda, Chikara
Venkatesh, Bharath Ambale
Ohyama, Yoshiaki
Liu, Chia-Ying
Chamera, Elzbieta
Redheuil, Alban
Teixido-Tura, Gisela
Chugh, Atul R.
Wu, Colin O.
Hundley, Gregory W.
Bluemke, David A.
Lima, Joao A. C.
TI Reproducibility of functional aortic analysis using magnetic resonance
imaging: the MESA
SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
LA English
DT Article
DE aorta; reproducibility; pulse wave velocity; strain; MRI; phase contrast
ID PULSE-WAVE VELOCITY; CONTRAST MR-IMAGES; ARTERIAL STIFFNESS;
HYPERTENSIVE PATIENTS; ATHEROSCLEROSIS MESA; GENERAL-POPULATION;
HEART-FAILURE; DISTENSIBILITY; DISEASE; RISK
AB Aims To assess the test-retest, intra- and inter-reader reliability of thoracic aorta measurements by magnetic resonance imaging (MRI).
Methods and results Twenty-five participants underwent aortic MRI twice over 13 +/- 7 days. All aortic variables from baseline and repeat MR were analysed using a semi-automated method by the ARTFUN software. To assess the inter-study reproducibility of aortic variables, we calculated intraclass correlation coefficient (ICC) for individual aortic measurements. Intra-and inter-observer variability was also assessed using the baseline MR data. Mean ascending aortic strain had moderate inter-study reproducibility (11.53 +/- 6.44 vs. 10.55 +/- 6.64, P = 0.443, ICC = 0.53, P < 0.01). Mean descending aortic strain and arch pulse wave velocity (PWV) had good inter-study reproducibility (descending aortic strain: 8.65 +/- 5.30 vs. 8.35 +/- 5.26, P = 0.706, ICC = 0.74, P < 0.001; PWV: 9.92 +/- 4.18 vs. 9.94 +/- 4.55, P = 0.968, ICC = 0.77, P < 0.001, respectively). All aortic variables had excellent intra-and inter-observer reproducibility (intra-: ICC range, 0.87-0.99, inter-: ICC range, 0.56-0.99, respectively).
Conclusion Inter-study reproducibility of all aortic variables was acceptable. Intra-and inter-observer reproducibility of all aortic variables was excellent. MRI can provide a repeatable method of measuring aortic structural and functional parameters.
C1 [Noda, Chikara; Ohyama, Yoshiaki; Chamera, Elzbieta; Lima, Joao A. C.] Johns Hopkins Univ, Dept Cardiol, Baltimore, MD 21287 USA.
[Venkatesh, Bharath Ambale] Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21287 USA.
[Liu, Chia-Ying; Bluemke, David A.] NIH, Ctr Clin, Radiol & Imaging Sci, Bethesda, MD 20892 USA.
[Redheuil, Alban] UPMC, Sorbonne Univ, Grp Hosp La Pitie Salpetriere, Paris, France.
[Redheuil, Alban] ICAN Imaging Core Lab, Lab Dimagerie Fonct LIB INSERM UMR S 1146, Paris, France.
[Teixido-Tura, Gisela] Vall Hebron Hosp, Barcelona, Spain.
[Chugh, Atul R.] Jewish Hosp, Dept Cardiol, Louisville, KY 40202 USA.
[Wu, Colin O.] NHLBI, Off Biostat Res, NIH, Bethesda, MD 20892 USA.
[Hundley, Gregory W.] Wake Forest Univ Hlth Sci, Dept Internal Med Cardiol, Winston Salem, NC 27157 USA.
[Lima, Joao A. C.] Johns Hopkins Univ Hosp, Dept Med & Radiol, 600 North Wolfe St,Blalock 524D1, Baltimore, MD 21287 USA.
RP Lima, JAC (reprint author), Johns Hopkins Univ, Dept Cardiol, Baltimore, MD 21287 USA.; Lima, JAC (reprint author), Johns Hopkins Univ Hosp, Dept Med & Radiol, 600 North Wolfe St,Blalock 524D1, Baltimore, MD 21287 USA.
EM jlima@jhmi.edu
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160,
N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165,
N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; NCRR
[UL1-RR-024156, UL1-RR-025005]
FX This study was supported by contracts N01-HC-95159 through N01-HC-95169
from the National Heart, Lung, and Blood Institute and by grants
UL1-RR-024156 and UL1-RR-025005 from NCRR. The authors thank the other
investigators, staff, and participants of the MESA for their valuable
contributions. A full list of participating MESA investigators and
institutions can be found at http://www.mesa-nhlbi.org.
NR 25
TC 3
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2047-2404
EI 2047-2412
J9 EUR HEART J-CARD IMG
JI Eur. Heart J.-Cardiovasc. Imaging
PD AUG 1
PY 2016
VL 17
IS 8
BP 909
EP 917
DI 10.1093/ehjci/jev215
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DX9OW
UT WOS:000384726000016
PM 26358693
ER
PT J
AU Leng, Y
Wang, JY
Wang, ZF
Liao, HM
Wei, M
Leeds, P
Chuang, DM
AF Leng, Yan
Wang, Junyu
Wang, Zhifei
Liao, Hsiao-Mei
Wei, Monica
Leeds, Peter
Chuang, De-Maw
TI Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression
and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE FGF21; HDAC inhibitors; valproic acid; glial cells; cell processes
ID GROWTH-FACTOR 21; HISTONE DEACETYLASE INHIBITION; MOOD STABILIZERS
LITHIUM; AMYOTROPHIC-LATERAL-SCLEROSIS; FOCAL CEREBRAL-ISCHEMIA;
BLOOD-BRAIN-BARRIER; IN-VIVO; BIPOLAR DISORDER; SODIUM-BUTYRATE;
PPAR-ALPHA
AB Fibroblast growth factor 21, a novel regulator of glucose and lipid metabolism, has robust protective properties in neurons. However, its expression and function in glia are unknown. Valproic acid, a mood stabilizer and anticonvulsant, is a histone deacetylase inhibitor and a dynamic gene regulator. We investigated whether histone deacetylase inhibition by valproic acid and other inhibitors upregulates fibroblast growth factor 21 expression and, if so, sought to identify the histone deacetylase isoform(s) involved and their role in altering glial cell morphology.
C6 glioma or primary cortical glial cultures were treated with histone deacetylase inhibitors, and fibroblast growth factor 21 levels and length of cell processes were subsequently measured. Histone deacetylase 1, 2, or 3 was also knocked down to detect which isoform was involved in regulating fibroblast growth factor 21 mRNA levels. Finally, knockdown and overexpression of fibroblast growth factor 21 were performed to determine whether it played a role in regulating cell process length.
Treatment of C6 cells or primary glial cultures with valproic acid elevated fibroblast growth factor 21 mRNA levels, extended cell process length, and markedly increased acetylated histone-H3 levels. Other histone deacetylase inhibitors including pan- and class I-specific inhibitors, or selective knockdown of histone deacetylase 2 or 3 isoform produced similar effects. Knockdown or overexpression of fibroblast growth factor 21 significantly decreased or increased C6 cell process length, respectively.
In glial cell line and primary glia, using pharmacological inhibition and selective gene silencing of histone deacetylases to boost fibroblast growth factor 21 mRNA levels results in elongation of cell processes. Our study provides a new mechanism via which histone deacetylase 2 and 3 participate in upregulating fibroblast growth factor 21 transcription and extending process outgrowth in glia.
C1 [Leng, Yan; Wang, Junyu; Wang, Zhifei; Liao, Hsiao-Mei; Wei, Monica; Leeds, Peter; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.
RP Leng, Y; Chuang, DM (reprint author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.
EM lengy@mail.nih.gov; chuang@mail.nih.gov
FU National Institute of Mental Health, National Institutes of Health
[1ZIAMH002468-25]
FX This study was supported by the Intramural Research Program of the
National Institute of Mental Health, National Institutes of Health
(1ZIAMH002468-25). This work was written as part of the authors'
official duties as Government employees (affiliated with Annual Report
ZIAMH002468). The views expressed in this article do not necessarily
represent the views of the NIMH, NIH, HHS, or the United States
Government.
NR 101
TC 0
Z9 0
U1 7
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD AUG
PY 2016
VL 19
IS 8
DI 10.1093/ijnp/pyw035
PG 13
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DX8QP
UT WOS:000384654200011
ER
PT J
AU Wang, TY
Lee, SY
Chen, SL
Chung, YL
Li, CL
Chang, YH
Wang, LJ
Chen, PS
Chen, SH
Chu, CH
Huang, SY
Tzeng, NS
Hsieh, TH
Chiu, YC
Lee, IH
Chen, KC
Yang, YK
Hong, JS
Lu, RB
AF Wang, Tzu-Yun
Lee, Sheng-Yu
Chen, Shiou-Lan
Chung, Yi-Lun
Li, Chia-Ling
Chang, Yun-Hsuan
Wang, Liang-Jen
Chen, Po See
Chen, Shih-Heng
Chu, Chun-Hsien
Huang, San-Yuan
Tzeng, Nian-Sheng
Hsieh, Tsai-Hsin
Chiu, Yen-Chu
Lee, I. Hui
Chen, Kao-Chin
Yang, Yen Kuang
Hong, Jau-Shyong
Lu, Ru-Band
TI The Differential Levels of Inflammatory Cytokines and BDNF among Bipolar
Spectrum Disorders
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE bipolar spectrum disorder; bipolar I disorder; bipolar II disorder;
subthreshold bipolarity; cytokines; BDNF
ID COMORBIDITY SURVEY REPLICATION; MAJOR DEPRESSIVE DISORDER; NEUROTROPHIC
FACTOR; SUBTHRESHOLD BIPOLARITY; II DISORDER; DIAGNOSTIC-CRITERIA;
RATING-SCALE; TGF-BETA; HYPOMANIA; METAANALYSIS
AB Emerging evidence suggests that inflammation and neurodegeneration underlies bipolar disorder. To investigate biological markers of cytokines and brain-derived neurotrophic factor between bipolar I, bipolar II, and other specified bipolar disorder with short duration hypomania may support the association with inflammatory dysregulation and bipolar disorder and, more specifically, provide evidence for other specified bipolar disorder with short duration hypomania patients were similar to bipolar II disorder patients from a biological marker perspective.
We enrolled patients with bipolar I disorder (n=234), bipolar II disorder (n=260), other specified bipolar disorder with short duration hypomania (n=243), and healthy controls (n=140). Their clinical symptoms were rated using the Hamilton Depression Rating Scale and Young Mania Rating Scale. Inflammatory cytokine (tumor necrosis factor-alpha, C-reactive protein, transforming growth factor-beta 1, and interleukin-8) and brain-derived neurotrophic factor levels were measured in each group. Multivariate analysis of covariance and linear regression controlled for possible confounders were used to compare cytokine and brain-derived neurotrophic factor levels among the groups.
Multivariate analysis of covariance adjusted for age and sex and a main effect of diagnosis was significant (P <.001). Three of the 5 measured biomarkers (tumor necrosis factor-alpha, transforming growth factor-beta 1, and interleukin-8) were significantly (P=.006, .01, and <.001) higher in all bipolar disorder patients than in controls. Moreover, covarying for multiple associated confounders showed that bipolar I disorder patients had significantly higher IL-8 levels than did bipolar II disorder and other specified bipolar disorder with short duration hypomania patients in multivariate analysis of covariance (P=.03) and linear regression (P=.02) analyses. Biomarkers differences between bipolar II disorder and other specified bipolar disorder with short duration hypomania patients were nonsignificant.
The immunological disturbance along the bipolar spectrum was most severe in bipolar I disorder patients. Other specified bipolar disorder with short duration hypomania patients and bipolar II disorder patients did not differ in these biological markers.
C1 [Wang, Tzu-Yun; Lee, Sheng-Yu; Chen, Shiou-Lan; Chung, Yi-Lun; Li, Chia-Ling; Chang, Yun-Hsuan; Chen, Po See; Hsieh, Tsai-Hsin; Lee, I. Hui; Chen, Kao-Chin; Yang, Yen Kuang; Lu, Ru-Band] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Psychiat, Tainan, Taiwan.
[Yang, Yen Kuang; Lu, Ru-Band] Natl Cheng Kung Univ, Inst Behav Med, Coll Med, Tainan, Taiwan.
[Chang, Yun-Hsuan; Lu, Ru-Band] Natl Cheng Kung Univ, Inst Allied Hlth Sci, Coll Med, Tainan, Taiwan.
[Chen, Po See; Lee, I. Hui; Chen, Kao-Chin; Yang, Yen Kuang; Lu, Ru-Band] Natl Cheng Kung Univ, Addict Res Ctr, Tainan, Taiwan.
[Lee, Sheng-Yu] Kaohsiung Vet Gen Hosp, Dept Psychiat, Kaohsiung, Taiwan.
[Chen, Shiou-Lan] KMU, Grad Inst Med, Coll Med, Lipid Sci & Aging Res Ctr, Kaohsiung, Taiwan.
Natl Def Med Ctr, Triserv Gen Hosp, Dept Psychiat, Sch Med, Taipei, Taiwan.
[Tzeng, Nian-Sheng] Natl Def Med Ctr, Student Counseling Ctr, Taipei, Taiwan.
[Huang, San-Yuan] Natl Def Med Ctr, Taipei, Taiwan.
[Wang, Liang-Jen] Kaohsiung Chang Gung Mem Hosp, Dept Child & Adolescent Psychiat, Kaohsiung, Taiwan.
[Wang, Liang-Jen] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
[Yang, Yen Kuang] Natl Cheng Kung Univ Hosp, Dou Liou Branch, Dept Psychiat, Yunlin, Taiwan.
[Lu, Ru-Band] Natl Hlth Res Inst, Ctr Neuropsychiat Res, Miaoli, Taiwan.
[Chen, Shih-Heng; Hong, Jau-Shyong] NIEHS, Neurobiol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
[Chang, Yun-Hsuan] Asia Univ, Deprtment Psychol, Taichung, Taiwan.
[Chu, Chun-Hsien] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan.
[Chung, Yi-Lun] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.
[Chiu, Yen-Chu] Kaohsiung Med Univ, Sch Life Sci, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan.
RP Lu, RB (reprint author), Natl Cheng Kung Univ, Coll Med & Hosp, Dept Psychiat, Inst Behav Med, 138 Sheng Li Rd, Tainan 70428, Taiwan.
EM rblu@mail.ncku.edu.tw
FU Taiwan National Science Council [NSC98-2314-B-006-022-MY3,
NSC102-2622-B-006-002-CC2, NSC100-2314-B-075B-010-MY3]; Taiwan
Department of Health [DOH 95-TD-M-113-055]; Taiwan National Health
Research Institute [NHRI-EX-97-9738NI]; National Cheng Kung University
Project for Promoting Academic Excellence and Developing World Class
Research Centers
FX This work was supported in part by grant NSC98-2314-B-006-022-MY3,
NSC102-2622-B-006-002-CC2 (to R.-B.L.) and grant
NSC100-2314-B-075B-010-MY3 (to S.-Y.L.) from the Taiwan National Science
Council, grant DOH 95-TD-M-113-055 (to R.-B.L.) from the Taiwan
Department of Health, grant NHRI-EX-97-9738NI (to R.-B.L.) from the
Taiwan National Health Research Institute, and the National Cheng Kung
University Project for Promoting Academic Excellence and Developing
World Class Research Centers.
NR 62
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD AUG
PY 2016
VL 19
IS 8
DI 10.1093/ijnp/pyw012
PG 8
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DX8QP
UT WOS:000384654200001
ER
PT J
AU Subramanian, S
Krishna, MC
AF Subramanian, Sankaran
Krishna, Murali C.
TI Electron Paramagnetic Resonance Imaging 2. Radiofrequency FT-EPR Imaging
SO RESONANCE-JOURNAL OF SCIENCE EDUCATION
LA English
DT Article
DE FT-EPR; Hahn-echo; acquisition delay; single-point imaging (SPI);
gradient-echo; k-space; echo-SPI; carbogen; oxygen relaxivity; T-2* T-2-
and T-1-based oximetry; co-registration; cycling hypoxia; blood volume;
angiogram; Warburg effect; metabolic imaging
ID RESOLUTION
AB In this part we shall outline the challenges one faces while developing time-domain radiofrequency ( RF) EPR imaging spectrometer for in vivo studies. Time-domain or FT-EPR is quite a different animal compared to the CW modality. The evolution of FT-EPR instrumentation at the National Cancer Institute, NIH, USA and representative examples of application in cancer research are outlined in this article.
C1 [Subramanian, Sankaran] IIT Madras, Chem, Madras 600036, Tamil Nadu, India.
[Krishna, Murali C.] NCI, Biophys Spect & Imaging Sect, NIH, Bethesda, MD 20892 USA.
RP Subramanian, S (reprint author), Indian Inst Technol, Madras 600036, Tamil Nadu, India.; Krishna, MC (reprint author), NCI, Radiat Biol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM subukannan@gmail.com; cherukum@mail.nih.gov
NR 8
TC 0
Z9 0
U1 4
U2 4
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0971-8044
EI 0973-712X
J9 RESONANCE
JI Resonance
PD AUG
PY 2016
VL 21
IS 8
BP 717
EP 740
PG 24
WC Education, Scientific Disciplines
SC Education & Educational Research
GA DX7YA
UT WOS:000384604100005
ER
PT J
AU Roda, RH
FitzGibbon, EJ
Boucekkine, H
Schindler, AB
Blackstone, C
AF Roda, Ricardo H.
FitzGibbon, Edmond J.
Boucekkine, Houda
Schindler, Alice B.
Blackstone, Craig
TI Neurologic syndrome associated with homozygous mutation at MAG sialic
acid binding site
SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
LA English
DT Article
ID MYELIN-ASSOCIATED GLYCOPROTEIN; INHIBITION SITE; MICE DEFICIENT;
NEUROPATHY; ABNORMALITIES; SUPERFAMILY; DISTINCT; DISEASE; GROWTH
AB The MAG gene encodes myelin-associated glycoprotein (MAG), an abundant protein involved in axon-glial interactions and myelination during nerve regeneration. Several members of a consanguineous family with a clinical syndrome reminiscent of Pelizaeus-Merzbacher disease and demyelinating leukodystrophy on brain MRI were recently found to harbor a homozygous missense p.Ser133Arg MAG mutation. Here, we report two brothers from a nonconsanguineous family afflicted with progressive cognitive impairment, neuropathy, ataxia, nystagmus, and gait disorder. Exome sequencing revealed the homozygous missense mutation p.Arg118His in MAG. This Arg118 residue in immunoglobulin domain 1 is critical for sialic acid binding, providing a compelling mechanistic basis for disease pathogenesis.
C1 [Roda, Ricardo H.] Johns Hopkins Univ, Sch Med, Dept Neurol, Neuromuscular Med, Baltimore, MD 21205 USA.
[Roda, Ricardo H.; Boucekkine, Houda; Schindler, Alice B.; Blackstone, Craig] NINDS, Neurogenet Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[FitzGibbon, Edmond J.] NEI, Sensorimotor Res Lab, NIH, Bethesda, MD 20892 USA.
RP Roda, RH (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurol, Meyer 5-119A,600 N Wolfe St, Baltimore, MD 21287 USA.
EM rroda1@jhmi.edu
NR 20
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2328-9503
J9 ANN CLIN TRANSL NEUR
JI Ann. Clin. Transl. Neurol.
PD AUG
PY 2016
VL 3
IS 8
BP 650
EP 654
DI 10.1002/acn3.329
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DX1JT
UT WOS:000384123900007
PM 27606346
ER
PT J
AU Chang, W
Brohl, AS
Patidar, R
Sindiri, S
Shern, JF
Wei, JS
Song, YK
Yohe, ME
Gryder, B
Zhang, SL
Calzone, KA
Shivaprasad, N
Wen, XY
Badgett, TC
Miettinen, M
Hartman, KR
League-Pascual, JC
Trahair, TN
Widemann, BC
Merchant, MS
Kaplan, RN
Lin, JC
Khan, J
AF Chang, Wendy
Brohl, Andrew S.
Patidar, Rajesh
Sindiri, Sivasish
Shern, Jack F.
Wei, Jun S.
Song, Young K.
Yohe, Marielle E.
Gryder, Berkley
Zhang, Shile
Calzone, Kathleen A.
Shivaprasad, Nityashree
Wen, Xinyu
Badgett, Thomas C.
Miettinen, Markku
Hartman, Kip R.
League-Pascual, James C.
Trahair, Toby N.
Widemann, Brigitte C.
Merchant, Melinda S.
Kaplan, Rosandra N.
Lin, Jimmy C.
Khan, Javed
TI MultiDimensional ClinOmics for Precision Therapy of Children and
Adolescent Young Adults with Relapsed and Refractory Cancer: A Report
from the Center for Cancer Research
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID INCIDENTAL FINDINGS; GERMLINE MUTATIONS; GENOMIC LANDSCAPE; EWING
SARCOMA; GENE; FUSION; TUMOR; RHABDOMYOSARCOMA; NEUROBLASTOMAS;
ASSOCIATION
AB Purpose: We undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers to determine the feasibility of genome-guided precision therapy.
Experimental Design: Patients with non-central nervous system solid tumors underwent a combination of whole exome sequencing (WES), whole transcriptome sequencing (WTS), and high-density single-nucleotide polymorphism array analysis of the tumor, with WES of matched germline DNA. Clinically actionable alterations were identified as a reportable germline mutation, a diagnosis change, or a somatic event (including a single nucleotide variant, an indel, an amplification, a deletion, or a fusion gene), which could be targeted with drugs in existing clinical trials or with FDA-approved drugs.
Results: Fifty-nine patients in 20 diagnostic categories were enrolled from 2010 to 2014. Ages ranged from 7 months to 25 years old. Seventy-three percent of the patients had prior chemotherapy, and the tumors from these patients with relapsed or refractory cancers had a higher mutational burden than that reported in the literature. Thirty patients (51% of total) had clinically actionable mutations, of which 24 (41%) had a mutation that was currently targetable in a clinical trial setting, 4 patients (7%) had a change in diagnosis, and 7 patients (12%) had a reportable germline mutation.
Conclusions: We found a remarkably high number of clinically actionable mutations in 51% of the patients, and 12% with significant germline mutations. We demonstrated the clinical feasibility of next-generation sequencing in a diverse population of relapsed and refractory pediatric solid tumors. (C) 2016 AACR.
C1 [Chang, Wendy; Brohl, Andrew S.; Patidar, Rajesh; Sindiri, Sivasish; Shern, Jack F.; Wei, Jun S.; Song, Young K.; Yohe, Marielle E.; Gryder, Berkley; Zhang, Shile; Shivaprasad, Nityashree; Wen, Xinyu; Badgett, Thomas C.; Lin, Jimmy C.; Khan, Javed] NCI, Oncogen Sect, Genet Branch, Ctr Canc Res,NIH, 37 Convent Dr,Room 2016B, Bethesda, MD 20892 USA.
[Chang, Wendy; Shern, Jack F.; Yohe, Marielle E.; League-Pascual, James C.; Widemann, Brigitte C.; Merchant, Melinda S.; Kaplan, Rosandra N.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Chang, Wendy] Columbia Univ, Dept Pediat, Med Ctr, Mol Genet, New York, NY 10027 USA.
[Brohl, Andrew S.] H Lee Moffitt Canc Ctr & Res Inst, Sarcoma Dept, Tampa, FL USA.
[Calzone, Kathleen A.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Badgett, Thomas C.] Kentucky Childrens Hosp, Pediat Hematol Oncol, Lexington, KY USA.
[Miettinen, Markku] NCI, Pathol Lab, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.
[Hartman, Kip R.; League-Pascual, James C.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
[Hartman, Kip R.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
[Trahair, Toby N.] Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW, Australia.
RP Khan, J (reprint author), NCI, Oncogen Sect, Genet Branch, Ctr Canc Res,NIH, 37 Convent Dr,Room 2016B, Bethesda, MD 20892 USA.
EM khanjav@mail.nih.gov
RI Khan, Javed/P-9157-2014;
OI Khan, Javed/0000-0002-5858-0488; Trahair, Toby/0000-0002-3295-228X
FU Intramural NIH HHS [ZIA BC010998-04, ZIA BC010998-05, ZIA BC010998-06,
ZIA BC010998-07, ZIA BC010998-08, ZIA BC011002-07, ZIA BC011002-08]
NR 48
TC 2
Z9 2
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2016
VL 22
IS 15
BP 3810
EP 3820
DI 10.1158/1078-0432.CCR-15-2717
PG 11
WC Oncology
SC Oncology
GA DU5QE
UT WOS:000382265600014
PM 26994145
ER
PT J
AU Kobayashi, H
Choyke, PL
Ogawa, M
AF Kobayashi, Hisataka
Choyke, Peter L.
Ogawa, Mikako
TI Monoclonal antibody-based optical molecular imaging probes;
considerations and caveats in chemistry, biology and pharmacology
SO CURRENT OPINION IN CHEMICAL BIOLOGY
LA English
DT Review
ID GROWTH-FACTOR RECEPTOR; ENGINEERING ANTIBODIES; CANCER; FRAGMENTS;
THERAPY; FLUOROPHORES; LINKERS; DOMAINS
AB The monoclonal antibody (mAb) has proven to be a good platform for designing specific molecular imaging probes due to its superior binding specificity. Several optical imaging probes have been developed for surgical navigation in patients and are in early phase clinical trials. However, an inherent limitation of using the mAb is its pharmacokinetics which result in a prolonged circulating half-life and slow clearance from the body. This results in undesirable target to background ratios during imaging. In this review, we first describe the mAb as a platform material for optical probe design and then discuss optimizing the design of monoclonal antibody-based optical molecular imaging probes by focusing on chemistry, biology and pharmacology.
C1 [Kobayashi, Hisataka; Choyke, Peter L.] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Ogawa, Mikako] Hokkaido Univ, Lab Bioanal & Mol Imaging, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan.
RP Kobayashi, H (reprint author), NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM Kobayash@mail.nih.gov
FU Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research
FX This research was supported by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research.
NR 37
TC 3
Z9 3
U1 12
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1367-5931
EI 1879-0402
J9 CURR OPIN CHEM BIOL
JI Curr. Opin. Chem. Biol.
PD AUG
PY 2016
VL 33
BP 32
EP 38
DI 10.1016/j.cbpa.2016.05.015
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DW8WW
UT WOS:000383937200007
PM 27281509
ER
PT J
AU Gorka, AP
Schnermann, MJ
AF Gorka, Alexander P.
Schnermann, Martin J.
TI Harnessing cyanine photooxidation: from slowing photobleaching to
near-IR uncaging
SO CURRENT OPINION IN CHEMICAL BIOLOGY
LA English
DT Review
ID PHOTOREMOVABLE PROTECTING GROUPS; ENHANCED PHOTOSTABILITY; ORGANIC
FLUOROPHORES; VISIBLE-LIGHT; IN-VIVO; INTRAMOLECULAR PHOTOSTABILIZATION;
BIOORTHOGONAL CHEMISTRY; COMBRETASTATIN A-4; INDOCYANINE GREEN; GUIDED
SURGERY
AB Light provides a uniquely powerful stimulus to help visualize and/or perturb biological systems. The use of tissue penetrant near-IR wavelengths enables in vivo applications, however the design of molecules that function in this range remains a substantial challenge. Heptamethine cyanine fluorophores are already important tools for near-IR optical imaging. These molecules are susceptible to photobleaching through a photooxidative cleavage reaction. This review details efforts to define the mechanism of this reaction and two emerging fields closely tied to this process. In the first, efforts that slow photooxidation enable the creation of photobleaching resistant fluorophores. In the second, cyanine photooxidation has recently been employed as the cornerstone of a near-IR uncaging strategy. This review seeks to highlight the utility of mechanistic organic chemistry insights to help tailor cyanine scaffolds for new, and previously intractable, biological applications.
C1 [Gorka, Alexander P.; Schnermann, Martin J.] Natl Canc Inst, Ctr Canc Res, Biol Chem Lab, Frederick, MD 21702 USA.
RP Schnermann, MJ (reprint author), Natl Canc Inst, Ctr Canc Res, Biol Chem Lab, Frederick, MD 21702 USA.
EM martin.schnermann@nih.gov
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Center for Cancer Research
FX Dr. Roger Nani is thanked for helpful discussions and comments. This
work was supported by the Intramural Research Program of the National
Institutes of Health, National Cancer Institute, Center for Cancer
Research.
NR 71
TC 1
Z9 1
U1 28
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1367-5931
EI 1879-0402
J9 CURR OPIN CHEM BIOL
JI Curr. Opin. Chem. Biol.
PD AUG
PY 2016
VL 33
BP 117
EP 125
DI 10.1016/j.cbpa.2016.05.022
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DW8WW
UT WOS:000383937200018
PM 27348157
ER
PT J
AU Lack, JB
Yassin, A
Sprengelmeyer, QD
Johanning, EJ
David, JR
Pool, JE
AF Lack, Justin B.
Yassin, Amir
Sprengelmeyer, Quentin D.
Johanning, Evan J.
David, Jean R.
Pool, John E.
TI Life history evolution and cellular mechanisms associated with increased
size in high-altitude Drosophila
SO ECOLOGY AND EVOLUTION
LA English
DT Article
DE Cell; Drosophila; egg; life history; size; wing
ID SPRUCE BUDWORM LEPIDOPTERA; BODY-SIZE; EGG SIZE; DEVELOPMENTAL TIME;
THERMAL EVOLUTION; WING SIZE; MORPHOLOGICAL TRAITS; NATURAL-POPULATIONS;
LATITUDINAL CLINES; LARVAL DEVELOPMENT
AB Understanding the physiological and genetic basis of growth and body size variation has wide-ranging implications, from cancer and metabolic disease to the genetics of complex traits. We examined the evolution of body and wing size in high-altitude Drosophila melanogaster from Ethiopia, flies with larger size than any previously known population. Specifically, we sought to identify life history characteristics and cellular mechanisms that may have facilitated size evolution. We found that the large-bodied Ethiopian flies laid significantly fewer but larger eggs relative to lowland, smaller-bodied Zambian flies. The highland flies were found to achieve larger size in a similar developmental period, potentially aided by a reproductive strategy favoring greater provisioning of fewer offspring. At the cellular level, cell proliferation was a strong contributor to wing size evolution, but both thorax and wing size increases involved important changes in cell size. Nuclear size measurements were consistent with elevated somatic ploidy as an important mechanism of body size evolution. We discuss the significance of these results for the genetic basis of evolutionary changes in body and wing size in Ethiopian D. melanogaster.
C1 [Lack, Justin B.; Yassin, Amir; Sprengelmeyer, Quentin D.; Johanning, Evan J.; Pool, John E.] Univ Wisconsin, Genet Lab, 425-G Henry Mall, Madison, WI 53706 USA.
[David, Jean R.] Univ Paris Saclay, Univ Paris 11, Lab Evolut Genomes Comportement Ecol EGCE, CNRS,IRD, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.
[Lack, Justin B.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Lack, JB (reprint author), Univ Wisconsin, 425-G Henry Mall, Madison, WI 53706 USA.
EM jpool@wisc.edu
FU National Institute of General Medical Sciences [F32 GM106594, R01
GM111797]
FX National Institute of General Medical Sciences (Grant/Award Number: "F32
GM106594", "R01 GM111797").
NR 72
TC 1
Z9 1
U1 6
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7758
J9 ECOL EVOL
JI Ecol. Evol.
PD AUG
PY 2016
VL 6
IS 16
BP 5893
EP 5906
DI 10.1002/ece3.2327
PG 14
WC Ecology; Evolutionary Biology
SC Environmental Sciences & Ecology; Evolutionary Biology
GA DT6FF
UT WOS:000381578400027
PM 27547363
ER
PT J
AU Masson, F
Xin, A
Liao, Y
Preston, S
Guan, T
Gloury, R
Olshansky, M
Lin, JX
Li, P
Speed, TP
Smyth, GK
Ernst, M
Leonard, WJ
Pellegrini, M
Kaech, S
Nutt, SL
Shi, W
Belz, GT
Kallies, A
AF Masson, F.
Xin, A.
Liao, Y.
Preston, S.
Guan, T.
Gloury, R.
Olshansky, M.
Lin, J-X
Li, P.
Speed, T. P.
Smyth, G. K.
Ernst, M.
Leonard, W. J.
Pellegrini, M.
Kaech, S.
Nutt, S. L.
Shi, W.
Belz, G. T.
Kallies, A.
TI A combinatorial threshold model for effector differentiation of CD8(+) T
cells mediated by Blimp-1 and T-bet
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Masson, F.; Ernst, M.] Olivia Newton Jonh Canc Res Inst, Canc Inflammat Lab, Heidelberg, Vic, Australia.
[Masson, F.; Xin, A.; Liao, Y.; Preston, S.; Gloury, R.; Olshansky, M.; Speed, T. P.; Smyth, G. K.; Pellegrini, M.; Nutt, S. L.; Shi, W.; Belz, G. T.; Kallies, A.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.
[Masson, F.; Xin, A.; Liao, Y.; Preston, S.; Gloury, R.; Pellegrini, M.; Nutt, S. L.; Belz, G. T.; Kallies, A.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.
[Guan, T.; Kaech, S.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
[Olshansky, M.] Univ Melbourne, Dept Comp & Informat Syst, Parkville, Vic, Australia.
[Lin, J-X; Li, P.; Leonard, W. J.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Speed, T. P.; Smyth, G. K.; Shi, W.] Univ Melbourne, Dept Math & Stat, Parkville, Vic, Australia.
[Ernst, M.] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia.
[Kaech, S.] Howard Hughes Med Inst, Chavy Chase, MD USA.
RI Smyth, Gordon/B-5276-2008
OI Smyth, Gordon/0000-0001-9221-2892
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 768
BP 5
EP 5
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400010
ER
PT J
AU Kurotaki, D
Nakabayashi, J
Nishiyama, A
Sasaki, H
Kaneko, N
Ozato, K
Suzuki, Y
Tamura, T
AF Kurotaki, D.
Nakabayashi, J.
Nishiyama, A.
Sasaki, H.
Kaneko, N.
Ozato, K.
Suzuki, Y.
Tamura, T.
TI Hierarchical regulation of enhancer establishment and gene expression by
transcription factors during mononuclear phagocyte development
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Kurotaki, D.; Nishiyama, A.; Sasaki, H.; Kaneko, N.; Tamura, T.] Yokohama City Univ, Grad Sch Med, Dept Immunol, Yokohama, Kanagawa, Japan.
[Nakabayashi, J.] Yokohama City Univ, Adv Med Res Ctr, Yokohama, Kanagawa, Japan.
[Ozato, K.] NICHD, NIH, Bethesda, MD USA.
[Suzuki, Y.] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol, Chiba, Japan.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1387
BP 6
EP 6
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400013
ER
PT J
AU Butt, D
Chan, T
Bourne, K
Hermes, J
Strasser, A
Tangye, S
Phan, T
Rao, VK
Brink, R
AF Butt, D.
Chan, T.
Bourne, K.
Hermes, J.
Strasser, A.
Tangye, S.
Phan, T.
Rao, V. K.
Brink, R.
TI Rogue germinal center B cells: unconventional lymphocytes released by
FAS inactivation that drive IgE and autoantibody production
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Butt, D.; Chan, T.; Bourne, K.; Hermes, J.; Tangye, S.; Phan, T.; Brink, R.] Garvan Inst Med Res, Sydney, NSW, Australia.
[Strasser, A.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.
[Rao, V. K.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 2907
BP 25
EP 26
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400052
ER
PT J
AU Meylan, F
Hayes, E
Ferdinand, J
Farley, T
Richoz, N
Gabay, O
Siegel, R
AF Meylan, F.
Hayes, E.
Ferdinand, J.
Farley, T.
Richoz, N.
Gabay, O.
Siegel, R.
TI Role of the TNF-family cytokine TL1A and its receptor DR3 in systemic
autoimmunity and glomerulonephritis
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Meylan, F.; Hayes, E.; Ferdinand, J.; Farley, T.; Richoz, N.; Gabay, O.; Siegel, R.] NIAMS, NIH, Immunoregulat Grp, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 4108
BP 28
EP 29
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400058
ER
PT J
AU Darrah, P
Roederer, M
Flynn, J
Scanga, C
Coleman, MT
DiFazio, R
Lin, P
Evans, T
Laddy, D
Anantha, R
Limbach, MP
Temmerman, S
Demoitie, MA
Seder, R
AF Darrah, P.
Roederer, M.
Flynn, J.
Scanga, C.
Coleman, M. T.
DiFazio, R.
Lin, P.
Evans, T.
Laddy, D.
Anantha, R.
Limbach, M. P.
Temmerman, S.
Demoitie, M-A
Seder, R.
TI Protective efficacy of tuberculosis-specific T Cell immunity in the lung
after aerosol delivery of adenoviral vaccines in nonhuman primates
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Darrah, P.; Roederer, M.; Seder, R.] NIAID, NIH, Vaccine Res Ctr, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Flynn, J.; Scanga, C.; Coleman, M. T.; DiFazio, R.; Lin, P.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Evans, T.; Laddy, D.; Anantha, R.; Limbach, M. P.] Aeras, Rockville, MD USA.
[Temmerman, S.; Demoitie, M-A] GlaxoSmithKline, Rixensart, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 2847
BP 31
EP 31
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400063
ER
PT J
AU Sui, Y
Dzutsev, A
Venzon, D
Frey, B
Trinchieri, G
Berzofsk, J
AF Sui, Y.
Dzutsev, A.
Venzon, D.
Frey, B.
Trinchieri, G.
Berzofsk, J.
TI Gut microbiome and immune activation in mucosal SHIV transmission
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Sui, Y.; Dzutsev, A.; Venzon, D.; Frey, B.; Trinchieri, G.; Berzofsk, J.] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 950
BP 74
EP 75
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400149
ER
PT J
AU Le Saout, C
Luckey, M
Villarino, A
Smith, M
Myers, T
Hasley, R
Park, JH
Jj, O
Lane, HC
Catalfamo, M
AF Le Saout, C.
Luckey, M.
Villarino, A.
Smith, M.
Myers, T.
Hasley, R.
Park, J. -H
Jj, O.
Lane, H. C.
Catalfamo, M.
TI Overexpression of total-STAT1 during lymphopenia-induced proliferation
leads to diminished CD4 T cell survival: implications in HIV infection
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Le Saout, C.; Smith, M.; Hasley, R.; Lane, H. C.; Catalfamo, M.] NIAID, NIH, CMRS, Immunoregulat Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Luckey, M.; Park, J. -H] NIAMS, NIH, Bethesda, MD USA.
[Villarino, A.; Jj, O.] NCI, NIH, CCR, Expt Immunol Branch, Bethesda, MD 20892 USA.
[Myers, T.] NIAID, NIH, Genom Technol Sect, Res Technol Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 4117
BP 75
EP 76
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400151
ER
PT J
AU Freeman, M
Panigrahi, S
Mudd, J
Sieg, S
Funderburg, N
Lederman, M
Zidar, D
AF Freeman, M.
Panigrahi, S.
Mudd, J.
Sieg, S.
Funderburg, N.
Lederman, M.
Zidar, D.
TI CX3CR1+CD8 T cells promote monocyte activation and cardiovascular risk
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Freeman, M.; Panigrahi, S.; Mudd, J.; Sieg, S.; Lederman, M.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Mudd, J.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Funderburg, N.] Ohio State Univ, Columbus, OH 43210 USA.
[Zidar, D.] Univ Hosp Cleveland, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1552
BP 76
EP 77
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400153
ER
PT J
AU Luo, Z
Martin, L
Kilby, JM
Liu, H
Jin, P
Stroncek, D
Jiang, W
AF Luo, Z.
Martin, L.
Kilby, J. M.
Liu, H.
Jin, P.
Stroncek, D.
Jiang, W.
TI Influenza vaccine induces anti-nuclear and anti-double strand DNA IgG
antibodies and their relates to levels of microbial translocation in
antiretroviral-treated aviremic HIV-infected patients
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Luo, Z.; Martin, L.; Kilby, J. M.; Jiang, W.] Med Univ South Carolina, Chareleston, SC USA.
[Liu, H.; Jin, P.; Stroncek, D.] NIH, Bldg 10, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1124
BP 91
EP 91
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400181
ER
PT J
AU Jandl, C
Liu, SM
Nieto, PFD
Warren, J
Hughes, WE
Vogelzang, A
Webster, K
Craig, M
Uzel, G
Tangye, S
Dent, A
Vinuesa, C
Sprent, J
King, C
AF Jandl, C.
Liu, S. M.
Nieto, Fernandez De Cantete P.
Warren, J.
Hughes, W. E.
Vogelzang, A.
Webster, K.
Craig, M.
Uzel, G.
Tangye, S.
Dent, A.
Vinuesa, C.
Sprent, J.
King, C.
TI Interleukin-21 limits regulatory T cell populations by modulating
responsiveness to Interleukin-2
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Jandl, C.; Liu, S. M.; Warren, J.; Hughes, W. E.; Vogelzang, A.; Webster, K.; Tangye, S.; Sprent, J.; King, C.] Garvan Inst Med Res, Div Immunol, Sydney, NSW, Australia.
[Jandl, C.; Liu, S. M.; Vogelzang, A.; Webster, K.; Tangye, S.; Sprent, J.; King, C.] UNSW Australia, Dept Med, St Vincents Clin Sch, Sydney, NSW, Australia.
[Nieto, Fernandez De Cantete P.; Vinuesa, C.] Austalian Natl Univ, John Curtin Sch Med Res, Div Immunol, Canberra, ACT, Australia.
[Craig, M.] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Sydney, NSW, Australia.
[Uzel, G.] NIAID, NIH, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Dent, A.] Indiana Univ Sch Dent, Dept Microbiol & Immunol, Indianapolis, IN USA.
RI Vogelzang, Alexis/C-5440-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 3878
BP 102
EP 102
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400203
ER
PT J
AU Kato, S
Pasquet, L
Adams, T
Sharrow, S
Davies-Hill, T
Jaffe, E
Xia, Z
Suzuki, M
Kovalovsky, D
Berzofsky, J
Terabe, M
AF Kato, S.
Pasquet, L.
Adams, T.
Sharrow, S.
Davies-Hill, T.
Jaffe, E.
Xia, Z.
Suzuki, M.
Kovalovsky, D.
Berzofsky, J.
Terabe, M.
TI Characterization of sulfatide-reactive type II NKT cells in mouse lungs
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Kato, S.; Pasquet, L.; Adams, T.; Sharrow, S.; Davies-Hill, T.; Jaffe, E.; Xia, Z.; Kovalovsky, D.; Berzofsky, J.; Terabe, M.] NCI, NIH, Bethesda, MD 20892 USA.
[Suzuki, M.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 134
BP 183
EP 183
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400368
ER
PT J
AU Wang, H
Yin, S
Li, J
Gao, B
AF Wang, H.
Yin, S.
Li, J.
Gao, B.
TI Myeloid STAT3 promotes hepatocarcinogenesis by inactivating natural
killer T cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Wang, H.] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei, Peoples R China.
[Yin, S.] Anhui Med Univ, Affiliated Prov Hosp, Dept Geriatr, Hefei, Peoples R China.
[Li, J.] Anhui Med Univ, Inst Liver Dis, Hefei, Peoples R China.
[Gao, B.] NIAAA, NIH, Rockville, MD 20852 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 173
BP 202
EP 202
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400407
ER
PT J
AU Restifo, NP
AF Restifo, N. P.
TI Novel mediators of immune suppression within the tumor microenvironment
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Restifo, N. P.] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
BP 246
EP 246
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400498
ER
PT J
AU Huang, Y
Mao, K
Chen, X
Kawabe, T
Zhu, J
Urban, JF
Germain, RN
Paul, WE
AF Huang, Y.
Mao, K.
Chen, X.
Kawabe, T.
Zhu, J.
Urban, Jr J. F.
Germain, R. N.
Paul, W. E.
TI Tissue-resident ILC2 and inflammatory ILC2: two distinct ILC populations
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Huang, Y.; Chen, X.; Kawabe, T.; Zhu, J.; Paul, W. E.] NIAID, NIH, Immunol Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Mao, K.; Germain, R. N.] NIAID, NIH, Lab Syst Biol, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Urban, Jr J. F.] ARS, Beltsville Human Nutr Res Ctr, USDA, Genom & Immunol Lab, Beltsville, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 4728
BP 297
EP 297
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400599
ER
PT J
AU Deplanche, M
Filho, RAEA
Semenovskaya, K
Alekseeva, L
Jardin, J
Henry, G
Azevedo, V
Germon, P
Rainard, P
Dessauge, F
Finot, L
Laurent, F
Lina, G
Vandenesch, F
Le Loir, Y
Smith, D
Otto, M
Gotz, F
Berkova, NN
AF Deplanche, M.
Filho, R. A. E. -A
Semenovskaya, K.
Alekseeva, L.
Jardin, J.
Henry, G.
Azevedo, V
Germon, P.
Rainard, P.
Dessauge, F.
Finot, L.
Laurent, F.
Lina, G.
Vandenesch, F.
Le Loir, Y.
Smith, D.
Otto, M.
Goetz, F.
Berkova, N. N.
TI Phenol-soluble modulins alpha induce G2/M phase transition delay and
impair immune response of eukaryotic cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Deplanche, M.; Filho, R. A. E. -A; Semenovskaya, K.; Alekseeva, L.; Jardin, J.; Henry, G.; Le Loir, Y.; Berkova, N. N.] INRA, UMR 1253, STLO, Rennes, France.
[Deplanche, M.; Semenovskaya, K.; Jardin, J.; Henry, G.; Le Loir, Y.; Berkova, N. N.] Agrocampus Ouest, UMR 1253, STLO, Rennes, France.
[Filho, R. A. E. -A; Azevedo, V] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
[Alekseeva, L.] Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia.
[Germon, P.; Rainard, P.] Univ Tours, Nouzilly, France.
[Dessauge, F.; Finot, L.] INRA, St Gilles, France.
[Laurent, F.; Lina, G.; Vandenesch, F.] Univ Lyon, INSERM, U1111, Lyon, France.
[Smith, D.] Univ Glasgow, Glasgow, Lanark, Scotland.
[Otto, M.] US Natl Inst Hlth, Bethesda, MD USA.
[Goetz, F.] Univ Tubingen, Tubingen, Germany.
RI vasco, azevedo/F-4315-2011
OI vasco, azevedo/0000-0002-4775-2280
NR 0
TC 0
Z9 0
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1425
BP 351
EP 351
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400706
ER
PT J
AU Blatt, A
Saggu, G
Cortes, C
Herbert, A
Kavanagh, D
Ricklin, D
Lambris, J
Valenzuela, J
Ferreira, V
AF Blatt, A.
Saggu, G.
Cortes, C.
Herbert, A.
Kavanagh, D.
Ricklin, D.
Lambris, J.
Valenzuela, J.
Ferreira, V
TI Role of factor H and effects of C-terminal mutations on control of human
platelet/granulocyte aggregate formation
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Blatt, A.; Saggu, G.; Ferreira, V] Univ Toledo, Dept Med Microbiol & Immunol, Coll Med, 2801 W Bancroft St, Toledo, OH 43606 USA.
[Cortes, C.] Oakland Univ, William Beaumont Sch Med, Dept Biomed Sci, Rochester, MI 48063 USA.
[Herbert, A.] Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland.
[Kavanagh, D.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne, Tyne & Wear, England.
[Ricklin, D.; Lambris, J.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA.
[Valenzuela, J.] NIAID, NIH, Vector Mol Biol Sect, Rockville, MD USA.
RI Kavanagh, David/E-8498-2011
OI Kavanagh, David/0000-0003-4718-0072
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 270
BP 366
EP 367
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400736
ER
PT J
AU Myles, I
AF Myles, I
TI Therapeutic bacterial transplantation for atopic dermatitis
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Myles, I] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 454
BP 455
EP 455
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401108
ER
PT J
AU Dutta, M
Robertson, S
Okumura, A
Rasmussen, A
Chang, J
Weiss, JM
Katze, MG
Best, S
AF Dutta, M.
Robertson, S.
Okumura, A.
Rasmussen, A.
Chang, J.
Weiss, J. M.
Katze, M. G.
Best, S.
TI A systems approach to understanding the role of MAVS in Ebola
pathogenesis in murine models of infection
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Dutta, M.; Rasmussen, A.; Chang, J.; Weiss, J. M.; Katze, M. G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
[Robertson, S.; Okumura, A.; Best, S.] NIAID, Rocky Mt Lab, NIH, Hamilton, MT 59840 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 2389
BP 526
EP 526
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401250
ER
PT J
AU Sullivan, NJ
AF Sullivan, N. J.
TI Protective monotherapy against lethal ebola virus infection: structural
and molecular basis of potent neutralization
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Sullivan, N. J.] NIAID, NIH, Vaccine Res Ctr, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 3670
BP 528
EP 528
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401255
ER
PT J
AU Arbore, G
West, E
Robertson, A
Klos, A
Rheinheimer, C
Dutow, P
Woodruff, T
O'Neill, L
Coll, R
Sher, A
Leonard, W
Kohl, J
Monk, P
Cooper, M
Arno, M
Afzali, B
Lachmann, H
Cope, A
Mayer-Barber, K
Kemper, C
AF Arbore, G.
West, E.
Robertson, A.
Klos, A.
Rheinheimer, C.
Dutow, P.
Woodruff, T.
O'Neill, L.
Coll, R.
Sher, A.
Leonard, W.
Koehl, J.
Monk, P.
Cooper, M.
Arno, M.
Afzali, B.
Lachmann, H.
Cope, A.
Mayer-Barber, K.
Kemper, C.
TI Autocrine NLRP3 inflammasome activity is critical to normal adaptive
immunity via regulation of IFN-gamma in CD4+T cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Arbore, G.; Afzali, B.; Kemper, C.] Kings Coll London, DTIMB, London, England.
[West, E.; Leonard, W.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Robertson, A.; Woodruff, T.; Coll, R.; Cooper, M.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.
[Klos, A.; Rheinheimer, C.; Dutow, P.] Hannover Med Sch, Inst Med Microbiol, Hannover, Germany.
[O'Neill, L.] Univ Dublin, Sch Biochem & Immunol, Trinity Coll Dublin, Dublin, Ireland.
[Sher, A.; Mayer-Barber, K.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Koehl, J.] Univ Lubeck, Inst System Inflammat Res, Lubeck, Germany.
[Koehl, J.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Koehl, J.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Monk, P.] Univ Sheffield, Dept Infect & Immun, Sheffield, S Yorkshire, England.
[Arno, M.] Kings Coll London, Genom Ctr, Fac Life Sci & Med, London, England.
[Afzali, B.] NIAMS, NIH, Bethesda, MD USA.
[Lachmann, H.] UCL, UK Natl Amyloidosis Ctr, London, England.
[Cope, A.] Kings Coll London, DIIID, London, England.
RI Monk, Peter/C-6155-2008
OI Monk, Peter/0000-0003-4637-3059
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 2450
BP 534
EP 535
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401267
ER
PT J
AU Jankovic, D
Tosh, K
Mittereder, L
Sher, A
AF Jankovic, D.
Tosh, K.
Mittereder, L.
Sher, A.
TI The IL-12 response to Toxoplasma gondii in humans involves a pathogen
sensing mechanism and myeloid cell subsets distinct from those utilized
by mice
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Jankovic, D.; Tosh, K.; Mittereder, L.; Sher, A.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1558
BP 560
EP 560
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401318
ER
PT J
AU Jegaskanda, S
Mason, R
Andrews, S
Wheatley, A
Zhang, R
Abambrozak, D
Santos, C
Luke, C
Matsuoka, Y
Brenchley, J
Talaat, K
Permar, S
Liao, HX
Koup, R
Roederer, M
McDermott, A
Subbarao, K
AF Jegaskanda, S.
Mason, R.
Andrews, S.
Wheatley, A.
Zhang, R.
Abambrozak, D.
Santos, C.
Luke, C.
Matsuoka, Y.
Brenchley, J.
Talaat, K.
Permar, S.
Liao, H-X
Koup, R.
Roederer, M.
McDermott, A.
Subbarao, K.
TI Intranasal live-attenuated vaccine primes influenza-specific B cells in
local lymph nodes that are rapidly recalled with parental inactivated
subunit vaccine boost
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Jegaskanda, S.; Santos, C.; Luke, C.; Matsuoka, Y.; Subbarao, K.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Jegaskanda, S.] Univ Melbourne, Melbourne, Vic, Australia.
[Jegaskanda, S.] Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
[Mason, R.; Andrews, S.; Wheatley, A.; Abambrozak, D.; Koup, R.; Roederer, M.; McDermott, A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Zhang, R.; Permar, S.; Liao, H-X] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27706 USA.
[Brenchley, J.] NIAID, NIH, Mol Microbiol Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Talaat, K.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1527
BP 594
EP 594
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401384
ER
PT J
AU Singh, OP
Ansari, N
Kumar, R
Nylen, S
Rai, M
Sacks, D
Sundar, S
AF Singh, O. P.
Ansari, N.
Kumar, R.
Nylen, S.
Rai, M.
Sacks, D.
Sundar, S.
TI IL-17 is associated with protection in human visceral leishmaniasis
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Singh, O. P.; Kumar, R.; Rai, M.; Sundar, S.] Banaras Hindu Univ, Med, Varanasi, Uttar Pradesh, India.
[Ansari, N.; Sacks, D.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Nylen, S.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 639
BP 666
EP 666
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401528
ER
PT J
AU Germain, RN
Laemmermann, T
Uderhardt, S
Liu, Z
Rudensky, AY
Levine, AG
Li, W
Radtke, A
Yu, W
Baptista, APD
Gerner, MY
AF Germain, R. N.
Laemmermann, T.
Uderhardt, S.
Liu, Z.
Rudensky, A. Y.
Levine, A. G.
Li, W.
Radtke, A.
Yu, W.
Baptista, Pires da Silva A.
Gerner, M. Y.
TI Imaging Immunity: Developing a Spatiotemporal Understanding of Host
Defense and Disease
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Germain, R. N.; Laemmermann, T.; Uderhardt, S.; Liu, Z.; Li, W.; Radtke, A.; Yu, W.; Baptista, Pires da Silva A.; Gerner, M. Y.] NIAID, Lab Syst Biol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Laemmermann, T.] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany.
[Rudensky, A. Y.; Levine, A. G.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.
[Rudensky, A. Y.; Levine, A. G.] Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.
[Gerner, M. Y.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
BP 751
EP 751
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401703
ER
PT J
AU Pasquet, L
Kato, S
Xia, M
Berzofsky, JA
Terabe, M
AF Pasquet, L.
Kato, S.
Xia, M.
Berzofsky, J. A.
Terabe, M.
TI Activity of sulfatide-reactive type II NKT cells from mouse lung
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Pasquet, L.; Kato, S.; Xia, M.; Berzofsky, J. A.; Terabe, M.] NCI, NIH, Vaccine Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 2377
BP 759
EP 760
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401721
ER
PT J
AU Pillay, B
Gray, P
Ziegler, JB
Smart, JM
Choo, S
Peake, J
Arkwright, PD
Hambleton, S
Reyes, SOL
Freeman, AF
Uzel, G
Su, HC
Casanova, JL
Tangye, SG
Ma, CS
AF Pillay, B.
Gray, P.
Ziegler, J. B.
Smart, J. M.
Choo, S.
Peake, J.
Arkwright, P. D.
Hambleton, S.
Lugo Reyes, Oswaldo S.
Freeman, A. F.
Uzel, G.
Su, H. C.
Casanova, J-L
Tangye, S. G.
Ma, C. S.
TI DOCK8-deficient CD4(+) T cells are biased to a Th2 effector fate at the
expense of Th1 and Th17 cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Pillay, B.; Tangye, S. G.; Ma, C. S.] Garvan Inst Med Res, Sydney, NSW, Australia.
[Pillay, B.; Tangye, S. G.; Ma, C. S.] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia.
[Gray, P.; Ziegler, J. B.] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia.
[Smart, J. M.; Choo, S.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia.
[Peake, J.] Royal Childrens Hosp Brisbane, Dept Paediat & Child Hlth, Brisbane, Qld, Australia.
[Arkwright, P. D.; Hambleton, S.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester, Lancs, England.
[Lugo Reyes, Oswaldo S.] Immunodeficiencies Res Unit, Mexico City, DF, Mexico.
[Lugo Reyes, Oswaldo S.] Natl Inst Pediat, Mexico City, DF, Mexico.
[Freeman, A. F.; Uzel, G.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Su, H. C.] NIAID, Host Def Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Casanova, J-L] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1211
BP 781
EP 781
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401764
ER
PT J
AU Kamphorst, AO
Wieland, A
Yang, S
Nasti, T
Zhang, R
Barber, DL
Konieczny, BT
Koenig, L
Yu, K
Sica, G
Owonikoko, TK
Sharpe, AH
Freeman, GJ
Blazar, BR
Turka, LA
Pillai, R
Ramalingam, SS
Araki, K
Ahmed, R
AF Kamphorst, A. O.
Wieland, A.
Yang, S.
Nasti, T.
Zhang, R.
Barber, D. L.
Konieczny, B. T.
Koenig, L.
Yu, K.
Sica, G.
Owonikoko, T. K.
Sharpe, A. H.
Freeman, G. J.
Blazar, B. R.
Turka, L. A.
Pillai, R.
Ramalingam, S. S.
Araki, K.
Ahmed, R.
TI Rescue of exhausted CD8 T cells by PD-1 targeted therapies is
CD28-dependent
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Kamphorst, A. O.; Wieland, A.; Yang, S.; Nasti, T.; Konieczny, B. T.; Araki, K.; Ahmed, R.] Emory Univ, Sch Med, Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA USA.
[Yang, S.] Cent S Univ, Xiangya Sch Med, Changsha, Hunan, Peoples R China.
[Zhang, R.; Turka, L. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Zhang, R.; Turka, L. A.] Harvard Med Sch, Dept Surg, Boston, MA USA.
[Barber, D. L.] NIAID, Parasit Dis Lab, Bethesda, MD USA.
[Koenig, L.; Yu, K.; Owonikoko, T. K.; Pillai, R.; Ramalingam, S. S.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA.
[Sica, G.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
[Sharpe, A. H.] Harvard Med Sch, Boston, MA USA.
[Freeman, G. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Blazar, B. R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA.
NR 0
TC 0
Z9 0
U1 5
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 963
BP 793
EP 793
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610401788
ER
PT J
AU Chiramel, A
Meyerson, N
McNally, K
Mendes-Solis, O
Montoya, V
Robertson, S
Sturdevant, G
Sawyer, S
Best, S
AF Chiramel, A.
Meyerson, N.
McNally, K.
Mendes-Solis, O.
Montoya, V
Robertson, S.
Sturdevant, G.
Sawyer, S.
Best, S.
TI Human TRIM5 is a functional restriction factor for tick-borne
flaviviruses
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Chiramel, A.; McNally, K.; Mendes-Solis, O.; Montoya, V; Robertson, S.; Sturdevant, G.; Best, S.] NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.
[Meyerson, N.; Sawyer, S.] Univ Colorado, Mol Cellular & Dev Biol, Boulder, CO 80309 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 2392
BP 816
EP 816
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402031
ER
PT J
AU Slaney, CY
Von Scheidt, B
Beavis, PA
Davenport, AJ
Westwood, JA
Mardiana, S
Tscharke, DC
Restifo, NP
Darcy, PK
Kershaw, MH
AF Slaney, C. Y.
Von Scheidt, B.
Beavis, P. A.
Davenport, A. J.
Westwood, J. A.
Mardiana, S.
Tscharke, D. C.
Restifo, N. P.
Darcy, P. K.
Kershaw, M. H.
TI Dual-specific T cells and oncolytic virus eradicate large solid tumors
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Slaney, C. Y.; Von Scheidt, B.; Beavis, P. A.; Davenport, A. J.; Westwood, J. A.; Mardiana, S.; Darcy, P. K.; Kershaw, M. H.] Peter MacCallum Canc Ctr, Canc Immunol Program, East Melbourne, Australia.
[Slaney, C. Y.; Von Scheidt, B.; Beavis, P. A.; Davenport, A. J.; Westwood, J. A.; Mardiana, S.; Darcy, P. K.; Kershaw, M. H.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia.
[Tscharke, D. C.] Australian Natl Univ, Res Sch Biol, Canberra, ACT, Australia.
[Restifo, N. P.] NCI, NIH, Ctr Canc Res, Bethesda, MD 20892 USA.
[Darcy, P. K.; Kershaw, M. H.] Monash Univ, Dept Immunol, Clayton, Vic, Australia.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1607
BP 829
EP 829
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402057
ER
PT J
AU Arenas-Hernandez, M
Romero, R
Balancio, A
Mial, T
Hassan, S
Sanchez-Torres, C
Gomez-Lopez, N
AF Arenas-Hernandez, M.
Romero, R.
Balancio, A.
Mial, T.
Hassan, S.
Sanchez-Torres, C.
Gomez-Lopez, N.
TI The depletion of regulatory T cells in the third trimester increases the
susceptibility for LPS-induced preterm birth and causes adverse neonatal
outcomes
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Arenas-Hernandez, M.; Balancio, A.; Mial, T.; Hassan, S.; Gomez-Lopez, N.] Wayne State Univ, OB GYN, Detroit, MI USA.
[Arenas-Hernandez, M.; Romero, R.; Gomez-Lopez, N.] NIH, Perinatol Res Branch, Detroit, MI USA.
[Sanchez-Torres, C.] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City, DF, Mexico.
RI Sanchez-Torres, Carmen/K-4713-2014
OI Sanchez-Torres, Carmen/0000-0003-0045-8233
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 826
BP 877
EP 877
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402155
ER
PT J
AU Weng, NP
AF Weng, N-P
TI Characterization of human TCR repertoire of CD4(+) and CD8(+) T cells
and its implications in evaluation of T cell immunity and aging
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Weng, N-P] NIA, NIH, Baltimore, MD 21224 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 829
BP 878
EP 878
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402158
ER
PT J
AU Edwards, ESJ
Cole, T
Wong, M
Uzel, G
Tangye, SG
AF Edwards, E. S. J.
Cole, T.
Wong, M.
Uzel, G.
Tangye, S. G.
TI Effect of gain-of-function mutations in PI3 kinase p110d on the
phenotype and function of EBV-specific CD8(+) T-cells
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Edwards, E. S. J.; Tangye, S. G.] Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW, Australia.
[Edwards, E. S. J.; Tangye, S. G.] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia.
[Cole, T.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia.
[Wong, M.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia.
[Uzel, G.] NIAID, NIH, Immunopathogenesis Sect, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1040
BP 980
EP 981
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402365
ER
PT J
AU Ranasinghe, S
Lamothe-Molina, P
Soghoian, D
Kaizer, S
Shalek, A
Cole, M
Yosef, N
Jones, B
White, J
Crawford, F
Sidney, J
Sette, A
Carrington, M
Streeck, H
Kaufmann, D
Picker, L
Kappler, J
Walker, BD
AF Ranasinghe, S.
Lamothe-Molina, P.
Soghoian, D.
Kaizer, S.
Shalek, A.
Cole, M.
Yosef, N.
Jones, B.
White, J.
Crawford, F.
Sidney, J.
Sette, A.
Carrington, M.
Streeck, H.
Kaufmann, D.
Picker, L.
Kappler, J.
Walker, B. D.
TI Non-classical CD8(+) T cells restricted by HLA class II DRB1 emerge in
HIV infection and show antiviral efficacy and atypical TCR usage
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Ranasinghe, S.; Lamothe-Molina, P.; Soghoian, D.; Kaizer, S.; Shalek, A.; Walker, B. D.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
[Cole, M.; Yosef, N.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[Jones, B.] George Washington Univ, Washington, DC USA.
[White, J.; Crawford, F.; Kappler, J.] Natl Jewish Hlth, Denver, CO USA.
[Sidney, J.; Sette, A.] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
[Carrington, M.] NCI, NIH, Frederick, MD 21701 USA.
[Streeck, H.] Univ Duisburg Essen, Essen, Germany.
[Kaufmann, D.] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada.
[Picker, L.] Oregon Hlth & Sci Univ, Portland, OR USA.
[Kappler, J.; Walker, B. D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1051
BP 985
EP 986
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402376
ER
PT J
AU Watkins, TS
McGuire, H
Darko, S
Haigh, O
Ransier, A
Santner-Nanan, B
Nanan, R
Douek, DC
Miles, JJ
AF Watkins, T. S.
McGuire, H.
Darko, S.
Haigh, O.
Ransier, A.
Santner-Nanan, B.
Nanan, R.
Douek, D. C.
Miles, J. J.
TI Dissecting T cell repertories at the human placenta by fusing high
definition gene profiling with TCR massive parallel sequencing
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Watkins, T. S.; Haigh, O.; Miles, J. J.] QIMR Berghofer Med Res Inst, Human Immun, Brisbane, Qld, Australia.
[McGuire, H.] Centenary Inst, Sydney, NSW, Australia.
[Darko, S.; Ransier, A.; Douek, D. C.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Santner-Nanan, B.; Nanan, R.] Sydney Med Sch, Nepean Ctr Perinatal Care, Sydney, NSW, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1053
BP 986
EP 987
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402378
ER
PT J
AU Pillay, BA
Ma, CS
Casanova, JL
Uzel, G
Tangye, SG
AF Pillay, B. A.
Ma, C. S.
Casanova, J. L.
Uzel, G.
Tangye, S. G.
TI Using immunodeficiency patient cells in in vitro cultures to provide
insight into T-helper cell differentiation
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Pillay, B. A.; Ma, C. S.; Tangye, S. G.] Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW, Australia.
[Pillay, B. A.; Ma, C. S.; Tangye, S. G.] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia.
[Casanova, J. L.] Rockefeller Univ, Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA.
[Uzel, G.] NIAID, NIH, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1057
BP 988
EP 989
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402382
ER
PT J
AU Rodriguez, JG
Meylan, F
Handon, R
Hayes, E
Anderson, S
Kirby, M
Siegel, R
Schwartzberg, P
AF Rodriguez, Gomez J.
Meylan, F.
Handon, R.
Hayes, E.
Anderson, S.
Kirby, M.
Siegel, R.
Schwartzberg, P.
TI Itk is required for Th9 differentiation via TCR-mediated induction of
IL-2 and IRF4
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Rodriguez, Gomez J.; Handon, R.; Anderson, S.; Kirby, M.; Schwartzberg, P.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Meylan, F.; Hayes, E.; Siegel, R.] NIAMS, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1062
BP 991
EP 991
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402387
ER
PT J
AU Berzofsky, JA
Terabe, M
Wood, LV
AF Berzofsky, J. A.
Terabe, M.
Wood, L., V
TI Cancer immunotherapy: translation from mice to human clinical trials
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Berzofsky, J. A.; Terabe, M.; Wood, L., V] NCI, NIH, Vaccine Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1152
BP 1008
EP 1008
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402423
ER
PT J
AU Zhong, C
Yagi, R
Northrup, D
Cui, K
Wilhelm, C
Bouladoux, N
Hu, G
Mao, K
Belkaid, Y
Zhao, K
Zhu, J
AF Zhong, C.
Yagi, R.
Northrup, D.
Cui, K.
Wilhelm, C.
Bouladoux, N.
Hu, G.
Mao, K.
Belkaid, Y.
Zhao, K.
Zhu, J.
TI GATA3 regulates the development and functions of innate lymphoid cell
subsets at multiple stages
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Zhong, C.; Yagi, R.; Zhu, J.] NIAID, Immunol Lab, Mol & Cellular Immunoregulat Unit, Bldg 10, Bethesda, MD 20892 USA.
[Northrup, D.; Cui, K.; Hu, G.; Zhao, K.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Wilhelm, C.; Bouladoux, N.; Mao, K.; Belkaid, Y.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1168
BP 1069
EP 1070
PG 2
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402547
ER
PT J
AU Saethang, T
Payne, M
Pisitkun, T
AF Saethang, T.
Payne, M.
Pisitkun, T.
TI AbDesigner3D
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Saethang, T.; Payne, M.; Pisitkun, T.] Chulalongkorn Univ, Syst Biol Ctr, Fac Med, Res Affairs, Bangkok, Thailand.
[Pisitkun, T.] NHLBI, Epithelial Syst Biol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1210
BP 1166
EP 1166
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402744
ER
PT J
AU Kapnick, S
Ritter, A
Stinchcombe, J
Lippincott-Schwartz, J
Griffiths, G
Schwartzberg, P
AF Kapnick, S.
Ritter, A.
Stinchcombe, J.
Lippincott-Schwartz, J.
Griffiths, G.
Schwartzberg, P.
TI Inducible T cell kinase regulates late stages of CD8+T lymphocyte
effector function
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Kapnick, S.; Ritter, A.; Lippincott-Schwartz, J.; Schwartzberg, P.] NIH, Bldg 10, Bethesda, MD 20892 USA.
[Stinchcombe, J.; Griffiths, G.] Cambridge Inst Med Res, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1273
BP 1197
EP 1197
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402807
ER
PT J
AU Stevenson, PG
Yunis, J
AF Stevenson, P. G.
Yunis, J.
TI A murine cytomegalovirus vaccine vector protects against murine gamma
herpesvirus 68
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Stevenson, P. G.] Univ Queensland, Sch Chem & Mol Biosci, Viral Immunol Res Lab, St Lucia, Qld, Australia.
[Stevenson, P. G.] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia.
[Stevenson, P. G.] Ctr Childrens Hlth Res, South Brisbane, Australia.
[Stevenson, P. G.] NIH, Bldg 10, Bethesda, MD 20892 USA.
[Stevenson, P. G.] Australian Res Council, Canberra, ACT, Australia.
[Yunis, J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 1339
BP 1228
EP 1228
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610402872
ER
PT J
AU Chen, HL
AF Chen, Honglei
TI Are We Ready for a Potential Increase in Parkinson Incidence?
SO JAMA NEUROLOGY
LA English
DT Editorial Material
ID DISEASE; SMOKING; RISK
C1 [Chen, Honglei] Natl Inst Environm Hlth Sci, Epidemiol Branch, 111 TW Alexander Dr,POB 12233,Mail Drop A3-05, Res Triangle Pk, NC 27709 USA.
RP Chen, HL (reprint author), Natl Inst Environm Hlth Sci, Epidemiol Branch, 111 TW Alexander Dr,POB 12233,Mail Drop A3-05, Res Triangle Pk, NC 27709 USA.
EM chenh2@niehs.nih.gov
OI Chen, Honglei/0000-0003-3446-7779
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD AUG
PY 2016
VL 73
IS 8
BP 919
EP 921
DI 10.1001/jamaneurol.2016.1599
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA DX2MS
UT WOS:000384204900009
PM 27322659
ER
PT J
AU Carbone, M
Kanodia, S
Chao, A
Miller, A
Wali, A
Weissman, D
Adjei, A
Baumann, F
Boffetta, P
Buck, B
de Perrot, M
Dogan, AU
Gavett, S
Gualtieri, A
Hassan, R
Hesdorffer, M
Hirsch, FR
Larson, D
Mao, WM
Masten, S
Pass, HI
Peto, J
Pira, E
Steele, I
Tsao, A
Woodard, GA
Yang, HN
Malik, S
AF Carbone, Michele
Kanodia, Shreya
Chao, Ann
Miller, Aubrey
Wali, Anil
Weissman, David
Adjei, Alex
Baumann, Francine
Boffetta, Paolo
Buck, Brenda
de Perrot, Marc
Dogan, A. Umran
Gavett, Steve
Gualtieri, Alessandro
Hassan, Raffit
Hesdorffer, Mary
Hirsch, Fred R.
Larson, David
Mao, Weimin
Masten, Scott
Pass, Harvey I.
Peto, Julian
Pira, Enrico
Steele, Ian
Tsao, Anne
Woodard, Gavitt Alida
Yang, Haining
Malik, Shakun
TI Consensus Report of the 2015 Weinman International Conference on
Mesothelioma
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Mesothelioma; BAP1; Asbestos; Erionite; Biomarkers; Genetics; Therapy
ID MALIGNANT-PLEURAL-MESOTHELIOMA; GERMLINE BAP1 MUTATIONS; PHASE-II TRIAL;
NATURALLY-OCCURRING ASBESTOS; SERUM OSTEOPONTIN LEVELS; EXTRAPLEURAL
PNEUMONECTOMY; NEOADJUVANT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY;
TRIMODALITY THERAPY; TUMOR-SUPPRESSOR
AB On November 9 and 10, 2015, the International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of Hawaii Cancer Center in Honolulu, Hawaii. The meeting was cosponsored by the International Association for the Study of Lung Cancer, and the agenda was designed with significant input from staff at the U.S. National Cancer Institute and National Institute of Environmental Health Sciences. A multidisciplinary group of participants presented updates reflecting a range of disciplinary perspectives, including mineralogy, geology, epidemiology, toxicology, biochemistry, molecular biology, genetics, public health, and clinical oncology. The group identified knowledge gaps that are barriers to preventing and treating malignant mesothelioma (MM) and the required next steps to address barriers. This manuscript reports the group's efforts and focus on strategies to limit risk to the population and reduce the incidence of MM. Four main topics were explored: genetic risk, environmental exposure, biomarkers, and clinical interventions. Genetics plays a critical role in MM when the disease occurs in carriers of germline BRCA1 associated protein 1 mutations. Moreover, it appears likely that, in addition to BRCA1 associated protein 1, other yet unknown genetic variants may also influence the individual risk for development of MM, especially after exposure to asbestos and related mineral fibers. MM is an almost entirely preventable malignancy as it is most often caused by exposure to commercial asbestos or mineral fibers with asbestos-like health effects, such as erionite. In the past in North America and in Europe, the most prominent source of exposure was related to occupation. Present regulations have reduced occupational exposure in these countries; however, some people continue to be exposed to previously installed asbestos in older construction and other settings. Moreover, an increasing number of people are being exposed in rural areas that contain noncommercial asbestos, erionite, and other mineral fibers in soil or rock (termed naturally occurring asbestos [NOA]) and are being developed. Public health authorities, scientists, residents, and other affected groups must work together in the areas where exposure to asbestos, including NOA, has been documented in the environment to mitigate or reduce this exposure. Although a blood biomarker validated to be effective for use in screening and identifying MM at an early stage in asbestos/NOA-exposed populations is not currently available, novel biomarkers presented at the meeting, such as high mobility group box 1 and fibulin-3, are promising. There was general agreement that current treatment for MM, which is based on surgery and standard chemotherapy, has a modest effect on the overall survival (OS), which remains dismal. Additionally, although much needed novel therapeutic approaches for MM are being developed and explored in clinical trials, there is a critical need to invest in prevention research, in which there is a great opportunity to reduce the incidence and mortality from MM. 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Carbone, Michele; Kanodia, Shreya; Larson, David; Yang, Haining] Univ Hawaii, Thorac Oncol, Ctr Canc, Honolulu, HI 96822 USA.
[Kanodia, Shreya] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
[Kanodia, Shreya] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.
[Chao, Ann] NCI, Ctr Global Hlth, NIH, Bethesda, MD 20892 USA.
[Miller, Aubrey] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
[Wali, Anil] NCI, Ctr Reduce Canc Hlth Dispar, NIH, Bethesda, MD 20892 USA.
[Weissman, David] NIOSH, Resp Hlth Div, Ctr Dis Control & Prevent, Morgantown, WV USA.
[Adjei, Alex] Mayo Clin, Rochester, MN USA.
[Baumann, Francine] Univ New Caledonia, ERIM, Noumea, New Caledonia.
[Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA.
[Buck, Brenda] Univ Nevada, Dept Geosci, Las Vegas, NV 89154 USA.
[de Perrot, Marc] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Dogan, A. Umran] Univ Iowa, Chem & Biochem Engn Dept, Iowa City, IA USA.
[Dogan, A. Umran] Univ Iowa, Ctr Global & Reg Environm Res, Iowa City, IA USA.
[Gavett, Steve] US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USA.
[Gualtieri, Alessandro] Univ Modena, Chem Earth Sci Dept, Modena, Italy.
[Hassan, Raffit] NIH, Thorac Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.
[Hesdorffer, Mary] Mesothelioma Appl Res Fdn, Alexandria, VA USA.
[Hirsch, Fred R.] Univ Colorado, Ctr Canc, Denver, CO 80202 USA.
[Mao, Weimin] Zhejiang Canc Hosp, Canc Res Inst, Hangzhou, Zhejiang, Peoples R China.
[Mao, Weimin] Key Lab Diag & Treatment Technol Thorac Oncol Zhe, Hangzhou, Zhejiang, Peoples R China.
[Masten, Scott] NIEHS, Natl Toxicol Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
[Pass, Harvey I.] NYU, Langone Med Ctr, Cardiothorac Surg, New York, NY USA.
[Peto, Julian] London Sch Hyg & Trop Med, Canc Res UK, London, England.
[Pira, Enrico] Univ Turin, Dept Publ Hlth & Pediat, Turin, Italy.
[Steele, Ian] Notre Dame Univ, Notre Dame Integrated Imaging Facil, Notre Dame, IN USA.
[Tsao, Anne] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Div Canc Med, Houston, TX 77030 USA.
[Woodard, Gavitt Alida] Univ Calif San Francisco, Thorac Surg, San Francisco, CA 94143 USA.
[Malik, Shakun] NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA.
RP Carbone, M (reprint author), Univ Hawaii, Ctr Canc, 701 Ilalo St,Room 437, Honolulu, HI 96813 USA.
EM mcarbone@cc.hawaii.edu
RI masten, scott/R-1403-2016
OI masten, scott/0000-0002-7847-181X
FU Jack Mishkin Discovery Fund for Mesothelioma Research from the Tower
Cancer Research Foundation; Bureau of Land Management of the U.S.
Department of the Interior [L13AC00237]
FX The meeting was made possible by a generous donation from the Barry and
Virginia Weinman Foundation and the International Association for the
Study of Lung Cancer. Dr. Kanodia is funded by the Jack Mishkin
Discovery Fund for Mesothelioma Research from the Tower Cancer Research
Foundation. Dr. Buck has a grant funded by the Bureau of Land Management
of the U.S. Department of the Interior to study NOA in Nevada (no.
L13AC00237). The findings and conclusions in this report are those of
the authors and do not necessarily represent the views of any part of
the U.S. Government.
NR 140
TC 7
Z9 7
U1 14
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD AUG
PY 2016
VL 11
IS 8
BP 1246
EP 1262
DI 10.1016/j.jtho.2016.04.028
PG 17
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA DS8XW
UT WOS:000381067300008
PM 27453164
ER
PT J
AU Alberobello, AT
Wang, YS
Beerkens, FJ
Conforti, F
McCutcheon, JN
Rao, GH
Raffeld, M
Liu, J
Rahhal, R
Zhang, YW
Giaccone, G
AF Alberobello, Anna Teresa
Wang, Yisong
Beerkens, Frans Joseph
Conforti, Fabio
McCutcheon, Justine N.
Rao, Guanhua
Raffeld, Mark
Liu, Jing
Rahhal, Raneen
Zhang, Yu-Wen
Giaccone, Giuseppe
TI PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Thymic epithelial tumor; PI3K; Mutation; PI3K inhibitor
ID PHOSPHOINOSITIDE 3-KINASES; HIGH-FREQUENCY; BREAST-CANCER; HUMAN
THYMOMA; CARCINOMA; MUTATIONS; ESTABLISHMENT; INHIBITOR; GDC-0941;
RESISTANCE
AB Introduction: Thymic epithelial tumors (TETs) are rare tumors originating from the epithelium of the thymus with limited therapeutic options beyond surgery. The pathogenesis of TETs is poorly understood, and the scarcity of model systems for these rare tumors makes the study of their biology very challenging.
Methods: A new cell line (MP57) was established from a thymic carcinoma specimen and characterized using standard biomarker analysis, as well as next-generation sequencing (NGS) and functional assays. Sanger sequencing was used to confirm the mutations identified by NGS.
Results: MP57 possesses all the tested thymic epithelial markers and is deemed a bona fide thymic carcinoma cell line. NGS analysis of MP57 identified a mutation in the gene PIK3R2, which encodes a regulatory subunit of PI3K. Further analysis identified different mutations in multiple PI3K subunit genes in another cell line and several primary thymic carcinoma samples, including two catalytic subunits (PIK3CA and PIK3CG) and another regulatory subunit (PIK3R4). Inhibiting PI3K with GDC-0941 resulted in in vitro antitumor activity in TET cells carrying mutant PI3K subunits.
Conclusions: Alterations of PI3K due to mutations in its catalytic or regulatory subunits are observed in a subgroup of TETs, in particular, thymic carcinomas. Targeting PI3K may be an effective strategy to treat these tumors. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
C1 [Alberobello, Anna Teresa; Wang, Yisong; Beerkens, Frans Joseph; Conforti, Fabio; McCutcheon, Justine N.; Rao, Guanhua; Liu, Jing; Rahhal, Raneen; Zhang, Yu-Wen; Giaccone, Giuseppe] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
[Raffeld, Mark] NCI, Lab Pathol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Giaccone, G (reprint author), Res Bldg,Room W503B,3970 Reservoir Rd, Washington, DC 20007 USA.
EM gg496@georgetown.edu
RI Giaccone, Giuseppe/E-8297-2017
OI Giaccone, Giuseppe/0000-0002-5023-7562
FU Lombardi Comprehensive Cancer Center core grant
FX Funding support was provided by a Lombardi Comprehensive Cancer Center
core grant.
NR 52
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD AUG
PY 2016
VL 11
IS 8
BP 1345
EP 1356
DI 10.1016/j.jtho.2016.04.013
PG 12
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA DS8XW
UT WOS:000381067300018
PM 27117832
ER
PT J
AU Evensen, CT
Treadwell, MJ
Keller, S
Levine, R
Hassell, KL
Werner, EM
Smith, WR
AF Evensen, Christian T.
Treadwell, Marsha J.
Keller, San
Levine, Roger
Hassell, Kathryn L.
Werner, Ellen M.
Smith, Wally R.
TI Quality of care in sickle cell disease: Cross-sectional study and
development of a measure for adults reporting on ambulatory and
emergency department care
SO MEDICINE
LA English
DT Article
DE access to care; ambulatory care; emergency medicine; health care
delivery; quality of care; sickle cell disease
ID CAHPS(R) HOSPITAL SURVEY; PNEUMOCOCCAL CONJUGATE VACCINE; ANALGESIC
MANAGEMENT; CONSUMER ASSESSMENT; YOUNG-ADULTS; HEALTH-CARE; PAIN;
EXPERIENCES; LIFE; CHILDREN
AB Documented deficiencies in adult sickle cell disease (SCD) care include poor access to knowledgeable providers and inadequate treatment in emergency departments (EDs).The aim of this study was to create patient-reported outcome measures of the quality of ambulatory and ED care for adults with SCD.We developed and pilot tested SCD quality of care questions consistent with Consumer Assessments of Healthcare Providers and Systems surveys. We applied psychometric methods to develop scores and evaluate reliability and validity.The participants of this study were adults with SCD (n=556)63% aged 18 to 34 years; 64% female; 64% SCD-SSat 7 US sites.The measure used was Adult Sickle Cell Quality of Life Measurement information system Quality of Care survey.Most participants (90%) reported at least 1 severe pain episode (pain intensity 7.82.3, 0-10 scale) in the past year. Most (81%) chose to manage pain at home rather than the ED, citing negative ED experiences (83%). Using factor analysis, we identified Access, Provider Interaction, and ED Care composites with reliable scores (Cronbach 0.70-0.83) and construct validity (r=0.32-0.83 correlations with global care ratings). Compared to general adult Consumer Assessments of Healthcare Providers and Systems scores, adults with SCD had worse care, adjusted for age, education, and general health.Results were consistent with other research reflecting deficiencies in ED care for adults with SCD. The Adult Sickle Cell Quality of Life Measurement Quality of Care measure is a useful self-report measure for documenting and tracking disparities in quality of SCD care.
C1 [Evensen, Christian T.; Keller, San] Amer Inst Res, Chapel Hill, NC USA.
[Treadwell, Marsha J.] Univ Calif San Francisco, Dept Hematol Oncol, Benioff Childrens Hosp, Oakland, CA USA.
[Hassell, Kathryn L.] Univ Colorado, Div Hematol, Aurora, CO USA.
[Werner, Ellen M.] NHLBI, Blood Epidemiol & Clin Therapeut Branch, Div Blood Dis & Resources, Bldg 10, Bethesda, MD 20892 USA.
[Smith, Wally R.] Virginia Commonwealth Univ, Div Gen Internal Med, Richmond, VA USA.
RP Treadwell, MJ (reprint author), UCSF Benioff Childrens Hosp Oakland, 747 52nd St, Oakland, CA 94609 USA.
EM mtreadwell@mail.cho.org
FU National Heart, Lung, and Blood Institute, National Institutes of Health
[HHSN-268-2005-74264C]
FX This research was funded by a contract from the National Heart, Lung,
and Blood Institute, National Institutes of Health, to the American
Institutes for Research, contract no. HHSN-268-2005-74264C.
NR 56
TC 0
Z9 0
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2016
VL 95
IS 35
AR e4528
DI 10.1097/MD.0000000000004528
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DX0HC
UT WOS:000384041400022
PM 27583862
ER
PT J
AU Loeffler, DA
LeWitt, PA
Camp, DM
AF Loeffler, David A.
LeWitt, Peter A.
Camp, Dianne M.
TI Nocardia asteroides-Induced movement abnormalities in mice: Relevance
for Parkinson's disease?
SO MOVEMENT DISORDERS
LA English
DT Article
ID ALPHA-SYNUCLEIN; BRAIN SPECIMENS; UP-REGULATION; PC12 CELLS; MPTP;
DOPAMINE; GUH-2; PATHOGENICITY; EXPOSURE; MODEL
C1 [Loeffler, David A.] Beaumont Hlth, Beaumont Hosp Royal Oak, Dept Neurol, Royal Oak, MI USA.
[LeWitt, Peter A.] Henry Ford West Bloomfield Hosp, Dept Neurol, W Bloomfield, MI USA.
[LeWitt, Peter A.] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA.
[Camp, Dianne M.] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Loeffler, DA (reprint author), Beaumont Hlth, Beaumont Hosp Royal Oak, Dept Neurol, Neurol Res Lab, 3601 West Thirteen Mile Rd, Royal Oak, MI 48073 USA.
EM DLoeffler@beaumont.edu
FU Public Health Service (PHS) [R01-ES010793]; National Parkinson
Foundation Center of Excellence grant; Parkinson's Disease and Movement
Disorders Program
FX D.A.L.'s support for his Nocardia research reported in this manuscript
came from Public Health Service (PHS) grant R01-ES010793 (P.L., P.I.)
and a National Parkinson Foundation Center of Excellence grant (to
P.A.L.). He serves without compensation on the editorial board of the
Journal of Neuroinflammation. He declares no potential conflicts of
interest. P.A.L.'s Nocardia research reported in this manuscript was
supported by Public Health Service (PHS) grant R01-ES010793 and a
National Parkinson Foundation Center of Excellence grant. In the past
year, he served as a consultant or advisor for Acorda, Biogen Idec,
Britannia, Insightec, Intec, Kyowa Hakko, Lundbeck, Luye, NeuroDerm,
Pfizer, ProStrakan, Prothena, SynAgile, Teva, Union chemique belge (UCB)
Pharma, and USWorldMeds, and received speaker honoraria from Acadia, The
International Parkinson's and Movement Disorders Society, Lundbeck, and
USWorldMeds. He is compensated for services as Editor-in-Chief of
Clinical Neuropharmacology and serves without compensation on the
editorial boards of Journal of Neural Transmission, Translational
Neurodegeneration, Journal of Parkinson's Disease, and Neurology
Reviews. The Parkinson's Disease and Movement Disorders Program that Dr.
LeWitt directs has received clinical research grant support (for
conducting clinical trials and other research) from AbbVie, Acorda,
Adamas, Biotie, Kyowa Hakko, The Michael J. Fox Foundation for
Parkinson's Research, the Parkinson Study Group, Pharma 2B, and
USWorldMeds. He declares no potential conflicts of interest. D.M.C. has
no potentially competing financial interests to declare.
NR 39
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD AUG
PY 2016
VL 31
IS 8
BP 1134
EP 1138
DI 10.1002/mds.26711
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU9ST
UT WOS:000382558800009
PM 27411508
ER
PT J
AU West, AB
Cookson, MR
AF West, Andrew B.
Cookson, Mark R.
TI Identification of bona-fide LRRK2 kinase substrates
SO MOVEMENT DISORDERS
LA English
DT Editorial Material
ID AUTOPHOSPHORYLATION
C1 [West, Andrew B.] Univ Alabama Birmingham, Dept Neurol, Ctr Neurodegenerat & Expt Therapeut, Birmingham, AL USA.
[Cookson, Mark R.] NIA, Cell Biol & Gene Express Sect, Neurogenet Lab, Bethesda, MD 20892 USA.
RP West, AB (reprint author), Univ Alabama Birmingham, Dept Neurol, Ctr Neurodegenerat & Expt Therapeut, Birmingham, AL USA.
FU NINDS NIH HHS [R01 NS064934, U18 NS082132]
NR 5
TC 0
Z9 0
U1 4
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD AUG
PY 2016
VL 31
IS 8
BP 1140
EP 1141
DI 10.1002/mds.26647
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA DU9ST
UT WOS:000382558800011
PM 27126091
ER
PT J
AU Kumar, A
Christensen, R
Guo, M
Chandris, P
Duncan, W
Wu, YC
Santella, A
Moyle, M
Winter, PW
Colon-Ramos, D
Bao, ZR
Shroff, H
AF Kumar, Abhishek
Christensen, Ryan
Guo, Min
Chandris, Panos
Duncan, William
Wu, Yicong
Santella, Anthony
Moyle, Mark
Winter, Peter W.
Colon-Ramos, Daniel
Bao, Zhirong
Shroff, Hari
TI Using Stage- and Slit-Scanning to Improve Contrast and Optical
Sectioning in Dual-View Inverted Light Sheet Microscopy (diSPIM)
SO BIOLOGICAL BULLETIN
LA English
DT Article
ID PLANE ILLUMINATION MICROSCOPY; CAENORHABDITIS-ELEGANS; FLUORESCENCE
MICROSCOPY; CELL LINEAGE; RESOLUTION; RECONSTRUCTION; BIOLOGY; EMBRYOS;
BRAIN; IMAGE
AB Dual-view inverted selective plane illumination microscopy (diSPIM) enables high-speed, long-term, four dimensional (4D) imaging with isotropic spatial resolution. It is also compatible with conventional sample mounting on glass coverslips. However, broadening of the light sheet at distances far from the beam waist and sample-induced scattering degrades diSPIM contrast and optical sectioning. We describe two simple improvements that address both issues and entail no additional hardware modifications to the base diSPIM. First, we demonstrate improved diSPIM sectioning by keeping the light sheet and detection optics stationary, and scanning the sample through the stationary light sheet (rather than scanning the broadening light sheet and detection plane through the stationary sample, as in conventional diSPIM). This stage-scanning approach allows a thinner sheet to be used when imaging laterally extended samples, such as fixed microtubules or motile mitochondria in cell monolayers, and produces finer contrast than does conventional diSPIM. We also used stage-scanning diSPIM to obtain high-quality, 4D nuclear datasets derived from an uncompressed nematode embryo, and performed lineaging analysis to track 97% of cells until twitching. Second, we describe the improvement of contrast in thick, scattering specimens by synchronizing light-sheet synthesis with the rolling, electronic shutter of our scientific complementary metal-oxide-semiconductor (sCMOS) detector. This maneuver forms a virtual confocal slit in the detection path, partially removing out-of-focus light. We demonstrate the applicability of our combined stage-and slit-scanning-methods by imaging pollen grains and nuclear and neuronal structures in live nematode embryos. All acquisition and analysis code is freely available online.
C1 [Kumar, Abhishek; Christensen, Ryan; Guo, Min; Chandris, Panos; Duncan, William; Wu, Yicong; Winter, Peter W.; Shroff, Hari] Natl Inst Biomed Imaging & Bioengn, Sect High Resolut Opt Imaging, NIH, Bethesda, MD 20892 USA.
[Santella, Anthony; Bao, Zhirong] Sloan Kettering Inst, Dev Biol Program, New York, NY 10065 USA.
[Moyle, Mark; Colon-Ramos, Daniel] Yale Univ, Dept Cell Biol, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06511 USA.
RP Kumar, A (reprint author), Natl Inst Biomed Imaging & Bioengn, Sect High Resolut Opt Imaging, NIH, Bethesda, MD 20892 USA.
EM abhishk@gmail.com
FU National Natural Science Foundation of China [61427807, 61271083,
61525106]; Shenzhen Innovation Funding [SGLH20131010110119871,
GJHZ20140415152115754]; Zhejiang Province Science and Technology
Projects [2015C33061]; Intramural Research Programs of the National
Institute of Biomedical Imaging and Bioengineering; NIH [U01 HD075602,
R24OD016474]
FX We thank Jim Sims, Patrick Gregorio, and Shelley Brankner (Hamamatsu
Corporation) for help in integrating the sCMOS slit-scanning function
with our LabVIEW program; Jon Daniels and Gary Rondeau (Applied
Scientific Instrumentation) for useful discussions on stage-scanning;
William Mohler (University of Connecticut Health Center) for
encouragement; William Gandler (NIH Center for Information Technology)
for help with MIPAV; Nicole Tashakkori and John Joseph for acquiring
embryo data used for lineaging; and Hank Eden and Talley Lambert for
their comments on the manuscript. We also thank the Research Center for
Minority Institutions program and the Institute of Neurobiology at the
University of Puerto Rico for providing a meeting and brainstorming
platform. MG acknowledges funding from the National Natural Science
Foundation of China (grants no. 61427807, 61271083, and 61525106);
Shenzhen Innovation Funding (grants no. SGLH20131010110119871 and
GJHZ20140415152115754); and Zhejiang Province Science and Technology
Projects (grant no. 2015C33061). Much of this work was conducted at the
Marine Biological Laboratory at Woods Hole, either through the Whitman
Program (DAC-R and HS) or a Grass Foundation Fellowship (to AK). Support
for this work was provided by the Intramural Research Programs of the
National Institute of Biomedical Imaging and Bioengineering, and by NIH
grants no. U01 HD075602 and R24OD016474.
NR 34
TC 1
Z9 1
U1 6
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0006-3185
EI 1939-8697
J9 BIOL BULL-US
JI Biol. Bull.
PD AUG
PY 2016
VL 231
IS 1
BP 26
EP 39
PG 14
WC Biology; Marine & Freshwater Biology
SC Life Sciences & Biomedicine - Other Topics; Marine & Freshwater Biology
GA DW9JB
UT WOS:000383973100005
PM 27638693
ER
PT J
AU Ferrer, RA
Padgett, L
Ellis, EM
AF Ferrer, Rebecca A.
Padgett, Lynne
Ellis, Erin M.
TI Extending Emotion and Decision-Making Beyond the Laboratory: The Promise
of Palliative Care Contexts
SO EMOTION
LA English
DT Article
DE emotion; decision-making; palliative care
ID POSITIVE AFFECT; CONTROLLED-TRIAL; ADVANCED CANCER; BREAST-CANCER;
UNITED-STATES; COMMUNICATION; SATISFACTION; METAANALYSIS; INFORMATION;
CAREGIVERS
AB Although laboratory-based research on emotion and decision-making holds the distinct advantage of rigorous experimental control conditions that allow causal inferences, the question of how findings in a laboratory generalize to real-world settings remains. Identifying ecologically valid, real-world opportunities to extend laboratory findings is a valuable means of advancing this field. Palliative care-or care intended to provide relief from serious illness and aging-related complications during treatment or at the end of life-provides a particularly rich opportunity for such work. Here, we present an overview of palliative care, summarize existing research on emotion and palliative care decision-making, highlight challenges associated with conducting such research, outline examples of collaborative projects leveraging palliative care as a context for generating fundamental knowledge about emotion and decision-making, and describe the resources and collaborations necessary to conduct this type of research. In sum, palliative care holds unique promise as an emotionally laden context in which to answer fundamental questions about emotion and decision-making that extends our theoretical understanding of the role of emotion in high-stakes decision-making while simultaneously generating knowledge that can improve palliative care implementation.
C1 [Ferrer, Rebecca A.] NCI, Basic Biobehav & Psychol Sci Branch, Behav Res Program, 9609 Med Ctr Dr, Rockville, MD 20852 USA.
[Padgett, Lynne] Amer Canc Soc, Atlanta, GA 30329 USA.
[Ellis, Erin M.] NCI, Canc Prevent Fellowship Program, Basic Biobehav & Psychol Sci Branch, Behav Res Program, Rockville, MD USA.
RP Ferrer, RA (reprint author), NCI, Basic Biobehav & Psychol Sci Branch, Behav Res Program, 9609 Med Ctr Dr, Rockville, MD 20852 USA.
EM ferrerra@mail.nih.gov
NR 42
TC 0
Z9 0
U1 4
U2 4
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1528-3542
EI 1931-1516
J9 EMOTION
JI Emotion
PD AUG
PY 2016
VL 16
IS 5
BP 581
EP 586
PG 6
WC Psychology, Experimental
SC Psychology
GA DV7ER
UT WOS:000383099500003
PM 27018611
ER
PT J
AU Miguelez, C
Navailles, S
Delaville, C
Marquis, L
Lagiere, M
Benazzouz, A
Ugedo, L
De Deurwaerdere, P
AF Miguelez, Cristina
Navailles, Sylvia
Delaville, Claire
Marquis, Loise
Lagiere, Melanie
Benazzouz, Abdelhamid
Ugedo, Luisa
De Deurwaerdere, Philippe
TI L-DOPA elicits non-vesicular releases of serotonin and dopamine in
hemiparkinsonian rats in vivo
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Intracerebral micro dialysis; Prefrontal cortex; Hippocampus;
Exocytosis; Tissue measurement Electrophysiology
ID HIGH-FREQUENCY STIMULATION; EXOGENOUS L-DOPA; PARKINSONS-DISEASE;
EXTRACELLULAR DOPAMINE; SUBTHALAMIC NUCLEUS; SUBSTANTIA-NIGRA; INDUCED
DYSKINESIA; NEURONAL-ACTIVITY; BASAL GANGLIA; UPTAKE SITES
AB The control of the secretory activity of serotonergic neurons has been pointed out to reduce motor and non-motor side effects of the antiparkinsonian drug L-DOPA. This strategy deserves further investigation because it is presently unclear whether L-DOPA promotes a non-vesicular release of dopamine and serotonin from serotonergic neurons. To get a full neurochemical picture compatible with the existence of such a mechanism, we combined multisite intracerebral microdialysis, post mortem tissue measurement and single unit extracellular recordings in the dorsal raphe nucleus from hemiparkinsonian rats. L-DOPA (3-100 mg/kg, ip.) non-homogeneously decreased extracellular serotonin levels in the striatum, substantia nigra pars reticulata, hippocampus and prefrontal cortex and homogenously serotonin tissue content in the striatum, cortex and cerebellum. L-DOPA (12 mg/kg) did not modify the firing rate or pattern of serotonergic-like neurons recorded in the dorsal raphe nucleus. When focusing on serotonin release in the prefrontal cortex and the hippocampus, we found that L-DOPA (12 or 100 mg/kg) enhanced serotonin extracellular levels in both regions upon Cat removal. Concomitantly, L-DOPA-stimulated dopamine release partly persisted in the absence of Ca2+ in a region-dependent manner. Local application of the serotonin reuptake inhibitor citalopram (1 mu M) blunted the responses to L-DOPA (3-12 mg/kg), measured as extracellular dopamine levels, most prominently in the hippocampus. These data stress that L-DOPA, already at low to moderate doses, promotes non-vesicular releases of serotonin and dopamine in a region dependent manner. (C) 2016 Elsevier B.V. and ECNP. All rights reserved.
C1 [Miguelez, Cristina; Ugedo, Luisa] Univ Basque Country, UPV EHU, Fac Med & Dent, Dept Pharmacol, Leioa 48940, Spain.
[Miguelez, Cristina] Univ Basque Country, UPV EHU, Fac Pharm, Dept Pharmacol, Vitoria 01006, Spain.
[Navailles, Sylvia; Delaville, Claire; Marquis, Loise; Lagiere, Melanie; Benazzouz, Abdelhamid; De Deurwaerdere, Philippe] Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, 146 Rue Leo Saignat, F-33000 Bordeaux, France.
[Navailles, Sylvia; Delaville, Claire; Marquis, Loise; Lagiere, Melanie; Benazzouz, Abdelhamid; De Deurwaerdere, Philippe] CNRS, Inst Malad Neurodegenerat, UMR 5293, F-33000 Bordeaux, France.
[Delaville, Claire] NINDS, Neurophysiol Pharmacol Sect, NIH, Bethesda, MD 20892 USA.
[Lagiere, Melanie] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands.
RP De Deurwaerdere, P (reprint author), Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, 146 Rue Leo Saignat, F-33000 Bordeaux, France.
EM deurwaer@u-bordeaux2.fr
OI De Deurwaerdere, Philippe/0000-0002-1226-3516; Miguelez,
Cristina/0000-0001-6624-2932
FU Fondation de France; FIS [PI 12/00613]; University of the Basque Country
[UFI 11/32, IT 747-13]
FX The project was funded by the Fondation de France and by FIS PI 12/00613
and the University of the Basque Country (UFI 11/32 and IT 747-13). None
of the funding sources had no further role in the design, in the
collection, analysis and interpretation of the data; in the writing or
the report; and in decision to submit the paper for publication.
NR 62
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
EI 1873-7862
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD AUG
PY 2016
VL 26
IS 8
BP 1297
EP 1309
DI 10.1016/j.euroneuro.2016.05.004
PG 13
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA DW0OU
UT WOS:000383340800005
PM 27234917
ER
PT J
AU Plummer, NW
de Marchena, J
Jensen, P
AF Plummer, Nicholas W.
de Marchena, Jacqueline
Jensen, Patricia
TI A knock-in allele of En1 expressing dre recombinase
SO GENESIS
LA English
DT Article
DE Dre; rox; mouse; midbrain; hindbrain; recombination
ID SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; MAMMALIAN-CELLS;
TRANSGENIC MICE; MOUSE; CRE; BOUNDARIES; DIVERSITY; DELETION; LINEAGE
AB Engrailed 1 (En1) is a homeobox-containing transcription factor expressed during development in diverse tissues, including the embryonic midbrain and anterior hindbrain. To facilitate investigation of genetic and developmental heterogeneity among cells with a history of En1 expression, we have generated En1(Dre), a knock-in allele expressing Dre recombinase. En1(Dre) can be used with existing Cre and Flp recombinase lines for genetic intersectional labeling, fate mapping, and functional manipulation of subpopulations of cells characterized by transient expression of En1. To avoid disrupting En1 function, the Dre cDNA is inserted at the 3 end of the En1 coding sequence, together with a viral 2A peptide to mediate translation of separate EN1 and Dre proteins. Consequently, viable and fertile En1(Dre) homozygotes can be used to increase the proportion of useful genotypes produced in complex crosses. The pattern of Dre expression from En1(Dre) is indistinguishable from wild-type En1 expression in mid-gestation mouse embryos, and En1(Dre) controls Dre-responsive indicator alleles by efficiently recombining rox sites in vivo. Through the application of genetic tools that allow manipulation of cells based on combinatorial expression of multiple distinct recombinases, En1(Dre) will significantly extend the ability to target important subpopulations of neurons and other cells within the broader En1 expression domain. genesis 54:447-454, 2016. Published 2016. This article is a US Government work and is in the public domain in the USA.
C1 [Plummer, Nicholas W.; de Marchena, Jacqueline; Jensen, Patricia] NIEHS, Neurobiol Lab, NIH, US Dept HHS, POB 12233, Res Triangle Pk, NC 27709 USA.
[de Marchena, Jacqueline] Impact Pharmaceut Serv, Durham, NC 27709 USA.
RP Jensen, P (reprint author), 111 TW Alexander Driver,Box F1-11, Res Triangle Pk, NC 27709 USA.
EM Patricia.jensen@nih.gov
FU Intramural Research Program of the US National Institutes of Health,
National Institute of Environmental Health Sciences [ES102805]
FX Contract grant sponsor: Intramural Research Program of the US National
Institutes of Health, National Institute of Environmental Health
Sciences, Contract grant number: ES102805
NR 30
TC 1
Z9 1
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-954X
EI 1526-968X
J9 GENESIS
JI Genesis
PD AUG
PY 2016
VL 54
IS 8
BP 447
EP 454
DI 10.1002/dvg.22954
PG 8
WC Developmental Biology; Genetics & Heredity
SC Developmental Biology; Genetics & Heredity
GA DW1ES
UT WOS:000383386400004
PM 27313055
ER
PT J
AU Ellis, EM
Collins, RL
Homish, GG
Parks, KA
Kiviniemi, MT
AF Ellis, Erin M.
Collins, R. Lorraine
Homish, Gregory G.
Parks, Kathleen A.
Kiviniemi, Marc T.
TI Perceived Controllability of Condom Use Shifts Reliance on Implicit
Versus Explicit Affect
SO HEALTH PSYCHOLOGY
LA English
DT Article
DE dual processes; affect/emotions; condom use
ID POISSON REGRESSION APPROACH; ATTITUDES; PROTECTION; BEHAVIOR
AB Objectives: This study integrated the framework of the behavioral affective associations model with dual process theories to investigate whether feelings about condoms operate at both implicit and explicit levels to influence condom use. We then tested whether 2 factors related to the perceived controllability of condom use (perceived behavioral control and past experience losing control in the heat of the moment) moderated the reliance on implicit versus explicit affect. Method: Sexually active young adults (N = 54) completed measures of implicit and explicit affect surrounding condoms, perceived behavioral control, and whether they attributed their prior unprotected sex to getting lost in the heat of the moment. They then completed 30 daily reports of their sexual activity and condom use. Multiple moderation analysis using generalized estimating equation (GEE) models tested the relative influence of implicit and explicit affect on condom use at varying levels of perceived controllability. Results: Both perceived behavioral control and past unprotected sex because of getting lost in the heat of the moment moderated the effects of both implicit and explicit affect on behavior, ps < .05. Only implicit affect predicted condom use among participants who had gotten lost in the heat of the moment and who had low perceived behavioral control. Only explicit affect predicted condom use among participants without a history of getting lost in the heat of the moment and who had high perceived behavioral control. Conclusion: Feelings about condoms predicted condom use at either an implicit or explicit level, depending on perceived controllability, suggesting this is an important moderator of whether implicit processes drive condom use.
C1 [Ellis, Erin M.] NCI, Canc Prevent Fellowship Program, Behav Res Program, Rockville, MD USA.
[Collins, R. Lorraine; Homish, Gregory G.; Kiviniemi, Marc T.] SUNY Buffalo, Dept Community Hlth & Hlth Behav, Buffalo, NY USA.
[Parks, Kathleen A.] SUNY Buffalo, Res Inst Addict, Buffalo, NY USA.
RP Ellis, EM (reprint author), NCI, Behav Res Program, 9609 Med Ctr Dr,Room 3E-626, Rockville, MD 20850 USA.
EM erin.ellis@nih.gov
NR 27
TC 1
Z9 1
U1 4
U2 4
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0278-6133
EI 1930-7810
J9 HEALTH PSYCHOL
JI Health Psychol.
PD AUG
PY 2016
VL 35
IS 8
SI SI
BP 842
EP 846
DI 10.1037/hea0000336
PG 5
WC Psychology, Clinical; Psychology
SC Psychology
GA DV7FQ
UT WOS:000383102200010
PM 27505204
ER
PT J
AU Kessels, LTE
Harris, PR
Ruiter, RAC
Klein, WMP
AF Kessels, Loes T. E.
Harris, Peter R.
Ruiter, Robert A. C.
Klein, William M. P.
TI Attentional Effects of Self-Affirmation in Response to Graphic
Antismoking Images
SO HEALTH PSYCHOLOGY
LA English
DT Article
DE self-affirmation; anti-smoking images; attention; eye-movements
ID CIGARETTE WARNING LABELS; THREATENING HEALTH INFORMATION; EYE-MOVEMENTS;
NEUROSCIENTIFIC EVIDENCE; RISK INFORMATION; FEAR APPEALS; MESSAGES;
PSYCHOLOGY; SMOKERS; MODEL
AB Objective: Self-affirmation has been shown to reduce defensive responding to threatening information. However, little is known about the cognitive and attentional processes underlying these effects. In the current eye-movement study, the authors explored whether self-affirmation affects attention allocation (i. e., number of fixations) among those for whom a threatening health message is self-relevant. Methods: After a self-affirmation manipulation, 47 smokers and 52 nonsmokers viewed a series of cigarette packs displaying high or low threat smoking-related images accompanied by a brief smoking message containing risk, coping or neutral textual information. Results: Self-affirmed smokers made more fixations to the cigarette packs than did nonaffirmed smokers (across both high and low threat images), whereas self-affirmed nonsmokers made fewer fixations to the cigarette packs than did nonaffirmed nonsmokers (again across both image types). The textual information did not moderate responses. Conclusions: Findings indicate attention-increasing effects of self-affirmation among those for whom the information is self-relevant (smokers) and attention-decreasing effects of self-affirmation among those for whom the information is not self-relevant (nonsmokers). Such findings are consistent with the calibration model of self-affirmation (Griffin & Harris, 2011) in which self-affirmation increases sensitivity to the self-relevance of health-risk information. The use of an implicit measure of visual orienting informs our understanding of the working mechanisms of self-affirmation when encoding health information, and may also hold practical implications for the design and delivery of graphic warning labels.
C1 [Kessels, Loes T. E.; Ruiter, Robert A. C.] Maastricht Univ, Dept Work & Social Psychol, Fac Psychol & Neurosci, POB 616, NL-6200 MD Maastricht, Netherlands.
[Harris, Peter R.] Univ Sussex, Sch Psychol, Brighton BN1 9RH, E Sussex, England.
[Klein, William M. P.] NCI, Rockville, MD USA.
[Klein, William M. P.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
RP Kessels, LTE (reprint author), Maastricht Univ, Dept Work & Social Psychol, Fac Psychol & Neurosci, POB 616, NL-6200 MD Maastricht, Netherlands.
EM Lte.kessels@maastrichtuniversity.nl
FU National Science Foundation [BCS-0924387]
FX This material is based upon work supported by the National Science
Foundation under Grant BCS-0924387. Any opinions, findings, and
conclusions or recommendations expressed in this material are those of
the author(s) and do not necessarily reflect the views of the National
Science Foundation and the National Institutes of Health.
NR 50
TC 1
Z9 1
U1 16
U2 17
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0278-6133
EI 1930-7810
J9 HEALTH PSYCHOL
JI Health Psychol.
PD AUG
PY 2016
VL 35
IS 8
SI SI
BP 891
EP 897
DI 10.1037/hea0000366
PG 7
WC Psychology, Clinical; Psychology
SC Psychology
GA DV7FQ
UT WOS:000383102200018
PM 27505212
ER
PT J
AU Mesa, R
Tyagi, M
Harocopos, G
Vollman, D
Bassnett, S
AF Mesa, Rosana
Tyagi, Manoj
Harocopos, George
Vollman, David
Bassnett, Steven
TI Somatic Variants in the Human Lens Epithelium: A Preliminary Assessment
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE somatic mutation; cataract risk factors; genomics
ID INTEGRATIVE GENOMICS VIEWER; ATOMIC-BOMB SURVIVORS; AGE-RELATED
CATARACT; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; ANTERIOR EYE;
MUTATIONS; OPACITIES; LIGHT; RISK
AB PURPOSE. We hypothesize that somatic mutations accumulate in cells of the human lens and may contribute to the development of cortical or posterior sub-capsular cataracts. Here, we used a Next-generation sequencing (NGS) strategy to screen for low-allelic frequency variants in DNA extracted from human lens epithelial samples.
METHODS. Next-Generation sequencing of 151 cancer-related genes (WUCaMP2 panel) was performed on DNA extracted from post-mortem or surgical specimens obtained from 24 individuals. Usually, pairwise comparisons were made between two or more ocular samples from the same individual, allowing putative somatic variants detected in lens samples to be differentiated from germline variants.
RESULTS. Use of a targeted hybridization approach enabled high sequence coverage (> 1000-fold) of the WUCaMP2 genes. In addition to high-frequency variants (corresponding to homozygous or heterozygous SNPs and Indels), somatic variants with allelic frequencies of 14% were detected in the lens epithelial samples. The presence of one such variant, a T > C point substitution at position 32907082 in BRCA2, was verified subsequently using droplet digital PCR.
CONCLUSIONS. Low-allelic fraction variants are present in the human lens epithelium, at frequencies consistent with the presence of millimeter-sized clones.
C1 [Mesa, Rosana; Harocopos, George; Vollman, David; Bassnett, Steven] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
[Tyagi, Manoj] Washington Univ, Sch Med, Dept Genet, Genome Technol Access Ctr, St Louis, MO 63110 USA.
[Harocopos, George] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Tyagi, Manoj] NCI, Bethesda, MD 20892 USA.
RP Bassnett, S (reprint author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM bassnett@vision.wustl.edu
FU National Cancer Institute Cancer Center [P30 CA91842]; Clinical and
Translational Science Award (CTSA) from the National Center for Research
Resources, a component of the National Institutes of Health (NIH) [UL1
TR000448]; NIH Roadmap for Medical Research; NIH grant National Eye
Institute [R01 EY09852, P30 EY02687]; Research to Prevent Blindness
FX The Genome Technology Access Center is partially supported by National
Cancer Institute Cancer Center Support Grant P30 CA91842 to the Siteman
Cancer Center and by Clinical and Translational Science Award (CTSA)
Grant UL1 TR000448 from the National Center for Research Resources, a
component of the National Institutes of Health (NIH), and NIH Roadmap
for Medical Research. This work was also supported by NIH grant National
Eye Institute R01 EY09852 (SB), core grant for vision research P30
EY02687, and an unrestricted grant to the Department of Ophthalmology
and Visual Sciences from Research to Prevent Blindness.
NR 52
TC 1
Z9 1
U1 2
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2016
VL 57
IS 10
BP 4063
EP 4075
DI 10.1167/iovs.16-19726
PG 13
WC Ophthalmology
SC Ophthalmology
GA DW9LR
UT WOS:000383981600014
PM 27537255
ER
PT J
AU Knickelbein, JE
Liu, BY
Arakelyan, A
Zicari, S
Hannes, S
Chen, P
Li, ZY
Grivel, JC
Chaigne-Delalande, B
Sen, HN
Margolis, L
Nussenblatt, RB
AF Knickelbein, Jared E.
Liu, Baoying
Arakelyan, Anush
Zicari, Sonia
Hannes, Susan
Chen, Ping
Li, Zhiyu
Grivel, Jean-Charles
Chaigne-Delalande, Benjamin
Sen, H. Nida
Margolis, Leonid
Nussenblatt, Robert B.
TI Modulation of Immune Responses by Extracellular Vesicles From Retinal
Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE extracellular vesicles; retinal pigment epithelium; monocytes; T cells;
immune privilege
ID COLLAGEN-INDUCED ARTHRITIS; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
DENDRITIC CELLS; EXOSOMES; ACTIVATION; MONOCYTES; PRIVILEGE; APOPTOSIS;
EYE
AB PURPOSE. Extracellular vesicles (EV), such as exosomes, are important mediators of intercellular communication and have been implicated in modulation of the immune system. We investigated if EV released from retinal pigment epithelium (RPE) modulate immune responses in vitro.
METHODS. Extracellular vesicles were isolated from ARPE-19 cultures stimulated or not with the inflammatory cytokines IL-1 beta, IFN-gamma, and TNF-alpha. Isolated EV were characterized by nanoparticle flow and Western blot analyses. Retinal pigment epithelium-derived EV were cultured with human peripheral blood mononuclear cells, which were assayed for T-cell proliferation by H-3-thymidine incorporation. Retinal pigment epithelium-derived EV were also independently cultured with enriched lymphocytes or monocytes. Cell phenotype and cell death were evaluated by flow cytometric analysis. Cytokine levels were assayed in culture supernatants by multiplex bead analysis.
RESULTS. The concentration of ARPE-derived EV from cytokine-stimulated cultures was slightly higher than from nonstimulated cultures. The size of EV was approximately 100 nm in both groups. Extracellular vesicles from both nonstimulated and cytokine-stimulated ARPE-19 significantly inhibited T-cell proliferation without affecting T-cell viability. Culture of EV from nonstimulated ARPE-19 with undifferentiated human monocytes induced an immunoregulatory phenotype with a significantly higher percentage of CD14(++)CD16(+) monocytes and upregulation of TGF-beta 1. Culture of EV from cytokine-stimulated ARPE-19 cells with human monocytes induced upregulation of several proinflammatory cytokines and monocyte death.
CONCLUSIONS. Retinal pigment epithelium cells constitutively secrete EV in the size range of exosomes, with increased release from RPE cells stimulated with inflammatory cytokines. Extracellular vesicles from both nonstimulated and cytokine-stimulated RPE inhibited T-cell stimulation. Extracellular vesicles from nonstimulated ARPE-19 cells promoted an immunoregulatory CD14(++)CD16(+) phenotype in human monocytes, while EV from cytokine-stimulated ARPE-19 cells caused human monocyte death. These findings suggest that RPE cells use EV to induce a downregulatory immune environment under homeostatic conditions. In an inflammatory milieu, RPE-derived EV may mitigate a potentially harmful inflammatory response through killing of monocytes.
C1 [Knickelbein, Jared E.; Liu, Baoying; Hannes, Susan; Chen, Ping; Li, Zhiyu; Chaigne-Delalande, Benjamin; Sen, H. Nida; Nussenblatt, Robert B.] NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Arakelyan, Anush; Zicari, Sonia; Grivel, Jean-Charles; Margolis, Leonid] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Intercellular Interact, Bethesda, MD USA.
[Grivel, Jean-Charles] Sidra Med & Res Ctr, Doha, Qatar.
RP Margolis, L (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Intercellular Interact, NIH, Bldg 10,Room 9D58,10 Ctr Dr, Bethesda, MD 20892 USA.
EM margolis@helix.nih.gov
FU National Eye Institute; Eunice Kennedy-Shriver National Institute of
Child Health and Human Development (National Institutes of Health,
Bethesda, MD, USA)
FX Supported by Intramural funds from the National Eye Institute and Eunice
Kennedy-Shriver National Institute of Child Health and Human Development
(National Institutes of Health, Bethesda, MD, USA).
NR 25
TC 0
Z9 0
U1 8
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2016
VL 57
IS 10
BP 4101
EP 4107
DI 10.1167/iovs.15-18353
PG 7
WC Ophthalmology
SC Ophthalmology
GA DW9LR
UT WOS:000383981600018
PM 27537259
ER
PT J
AU Tam, J
Liu, JF
Dubra, A
Fariss, R
AF Tam, Johnny
Liu, Jianfei
Dubra, Alfredo
Fariss, Robert
TI In Vivo Imaging of the Human Retinal Pigment Epithelial Mosaic Using
Adaptive Optics Enhanced Indocyanine Green Ophthalmoscopy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE adaptive optics; indocyanine green; ophthalmoscopy; retinal imaging;
retinal pigment epithelium
ID SCANNING LASER OPHTHALMOSCOPY; TARGETED STIMULUS DELIVERY; COHERENCE
TOMOGRAPHY; MACULAR DEGENERATION; PARAFOVEAL CAPILLARIES; LIGHT
OPHTHALMOSCOPE; ADVERSE REACTIONS; ANGIOGRAPHY; AUTOFLUORESCENCE; CONE
AB PURPOSE. The purpose of this study was to establish that retinal pigment epithelial (RPE) cells take up indocyanine green (ICG) dye following systemic injection and that adaptive optics enhanced indocyanine green ophthalmoscopy (AO-ICG) enables direct visualization of the RPE mosaic in the living human eye.
METHODS. A customized adaptive optics scanning light ophthalmoscope (AOSLO) was used to acquire high-resolution retinal fluorescence images of residual ICG dye in human subjects after intravenous injection at the standard clinical dose. Simultaneously, multimodal AOSLO images were also acquired, which included confocal reflectance, nonconfocal split detection, and darkfield. Imaging was performed in 6 eyes of three healthy subjects with no history of ocular or systemic diseases. In addition, histologic studies in mice were carried out.
RESULTS. The AO-ICG channel successfully resolved individual RPE cells in human subjects at various time points, including 20 minutes and 2 hours after dye administration. Adaptive optics-ICG images of RPE revealed detail which could be correlated with AO dark-field images of the same cells. Interestingly, there was a marked heterogeneity in the fluorescence of individual RPE cells. Confirmatory histologic studies in mice corroborated the specific uptake of ICG by the RPE layer at a late time point after systemic ICG injection.
CONCLUSIONS. Adaptive optics-enhanced imaging of ICG dye provides a novel way to visualize and assess the RPE mosaic in the living human eye alongside images of the overlying photoreceptors and other cells.
C1 [Tam, Johnny; Liu, Jianfei] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
[Dubra, Alfredo] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
[Dubra, Alfredo] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.
[Dubra, Alfredo] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.
[Fariss, Robert] NEI, Biol Imaging Core, NIH, Bethesda, MD 20892 USA.
RP Tam, J (reprint author), Ophthalm Genet & Visual Funct Branch, 10 Ctr Dr,Room 10N226,MSC1860, Bethesda, MD 20892 USA.
EM johnny@nih.gov
FU US National Institutes of Health/National Eye Institute [U01 EY025477];
NIH Intramural Research Program; Glaucoma Research Foundation Catalyst
for a Cure Initiative
FX Supported by US National Institutes of Health/National Eye Institute
award U01 EY025477, NIH Intramural Research Program, and Glaucoma
Research Foundation Catalyst for a Cure Initiative. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
NR 57
TC 1
Z9 1
U1 2
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2016
VL 57
IS 10
BP 4376
EP 4384
DI 10.1167/iovs.16-19503
PG 9
WC Ophthalmology
SC Ophthalmology
GA DW9LR
UT WOS:000383981600056
PM 27564519
ER
PT J
AU Kelly, JP
Dunning, A
Schulte, PJ
Fiuzat, M
Leifer, ES
Fleg, JL
Cooper, LS
Keteyian, SJ
Kitzman, DW
Pina, IL
Kraus, WE
Whellan, DJ
O'Connor, CM
Mentz, RJ
AF Kelly, Jacob P.
Dunning, Allison
Schulte, Phillip J.
Fiuzat, Mona
Leifer, Eric S.
Fleg, Jerome L.
Cooper, Lawton S.
Keteyian, Steven J.
Kitzman, Dalane W.
Pina, Ileana L.
Kraus, William E.
Whellan, David J.
O'Connor, Christopher M.
Mentz, Robert J.
TI Statins and Exercise Training Response in Heart Failure Patients
Insights From HF-ACTION
SO JACC-HEART FAILURE
LA English
DT Article
DE chronic heart failure; exercise training; heart failure with reduced
ejection fraction; statins
ID TRIAL INVESTIGATING OUTCOMES; RANDOMIZED CONTROLLED-TRIAL;
SKELETAL-MUSCLE FUNCTION; TASK-FORCE; ATORVASTATIN; MITOCHONDRIA;
MEDICATIONS; ADAPTATIONS; DYSFUNCTION; GUIDELINES
AB OBJECTIVES The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response.
BACKGROUND Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF).
METHODS HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction <= 35% who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates.
RESULTS Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05).
CONCLUSIONS In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437) (C) 2016 by the American College of Cardiology Foundation.
C1 [Kelly, Jacob P.; Fiuzat, Mona; Kraus, William E.; O'Connor, Christopher M.; Mentz, Robert J.] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.
[Kelly, Jacob P.; Dunning, Allison; Fiuzat, Mona; O'Connor, Christopher M.; Mentz, Robert J.] Duke Clin Res Inst, Durham, NC USA.
[Schulte, Phillip J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Leifer, Eric S.; Fleg, Jerome L.; Cooper, Lawton S.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
[Keteyian, Steven J.] Henry Ford Hosp, Div Cardiovasc Med, Detroit, MI 48202 USA.
[Kitzman, Dalane W.] Wake Forest Univ, Dept Internal Med, Cardiol Sect, Winston Salem, NC USA.
[Pina, Ileana L.] Albert Einstein Coll Med, Dept Med, Div Cardiol, New York, NY USA.
[Kraus, William E.] Duke Mol Physiol Inst, Durham, NC USA.
[Whellan, David J.] Thomas Jefferson Univ, Div Cardiol, Philadelphia, PA 19107 USA.
RP Kelly, JP (reprint author), Duke Univ, Dept Med, Med Ctr, 2301 Erwin Rd, Durham, NC 27710 USA.
EM Jacob.kelly@duke.edu
FU NHLBI NIH HHS [T32 HL007101]
NR 32
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1779
EI 2213-1787
J9 JACC-HEART FAIL
JI JACC-Heart Fail.
PD AUG
PY 2016
VL 4
IS 8
BP 617
EP 624
DI 10.1016/j.jchf.2016.05.006
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DW1ME
UT WOS:000383406500002
PM 27395348
ER
PT J
AU White, SF
Tyler, PM
Erway, AK
Botkin, ML
Kolli, V
Meffert, H
Pope, K
Blair, JR
AF White, Stuart F.
Tyler, Patrick M.
Erway, Anna K.
Botkin, Mary L.
Kolli, Venkata
Meffert, Harma
Pope, Kayla
Blair, James R.
TI Dysfunctional representation of expected value is associated with
reinforcement-based decision-making deficits in adolescents with conduct
problems
SO JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY
LA English
DT Article
DE Conduct problems; decision-making; anterior insula; expected value;
prediction error
ID CALLOUS-UNEMOTIONAL TRAITS; VENTROMEDIAL PREFRONTAL CORTEX; DISRUPTIVE
BEHAVIOR DISORDERS; RESPONSE REVERSAL; AMYGDALA RESPONSE; REWARD;
PSYCHOPATHY; CHILDREN; BRAIN; FEAR
AB Background: Previous work has shown that patients with conduct problems (CP) show impairments in reinforcement-based decision-making. However, studies with patients have not previously demonstrated any relationships between impairment in any of the neurocomputations underpinning reinforcement-based decision-making and specific symptom sets [e.g. level of CP and/or callous-unemotional (CU) traits]. Methods: Seventy-two youths [20 female, mean age = 13.81 (SD = 2.14), mean IQ = 102.34 (SD = 10.99)] from a residential treatment program and the community completed a passive avoidance task while undergoing functional MRI. Results: Greater levels of CP were associated with poorer task performance. Reduced representation of expected values (EV) when making avoidance responses within bilateral anterior insula cortex/inferior frontal gyrus (AIC/iFG) and striatum was associated with greater levels of CP but not CU traits. Conclusions: The current data indicate that difficulties in the use of value information to motivate decisions to avoid suboptimal choices are associated with increased levels of CP (though not severity of CU traits). Moreover, they account for the behavioral deficits observed during reinforcement-based decision-making in youth with CP. In short, an individual's relative failure to utilize value information within AIC/iFG to avoid bad choices is associated with elevated levels of CP.
C1 [White, Stuart F.; Meffert, Harma; Blair, James R.] NIMH, Sect Affect Cognit Neurosci, NIH, 9000 Rockville Pike,Bldg 15k,Room 204,MSC 2670, Bethesda, MD 20892 USA.
[White, Stuart F.; Tyler, Patrick M.; Erway, Anna K.; Botkin, Mary L.; Pope, Kayla] Boys Town Natl Res Hosp, Ctr Neurobehav Res, Boys Town, NE USA.
[Kolli, Venkata] Creighton Univ, Sch Med, Omaha, NE USA.
RP White, SF (reprint author), NIMH, Sect Affect Cognit Neurosci, NIH, 9000 Rockville Pike,Bldg 15k,Room 204,MSC 2670, Bethesda, MD 20892 USA.
EM stuart.white@boystown.org
FU Intramural Research Program of the National Institute of Mental Health,
National Institutes of Health [1-ZIA-MH002860]
FX This work was supported by the Intramural Research Program of the
National Institute of Mental Health, National Institutes of Health
(1-ZIA-MH002860), J.R.B. principal investigator. This study was
conducted under protocol number 05-M-0105, with ClinicalTrials.gov
Identifier NCT00104039. S.W. and J.R.B. had full access to the data and
take responsibility for the integrity of the data and the accuracy of
the data analysis. The authors have declared that they have no conflict
of interests in relation to this article.
NR 41
TC 3
Z9 3
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9630
EI 1469-7610
J9 J CHILD PSYCHOL PSYC
JI J. Child Psychol. Psychiatry
PD AUG
PY 2016
VL 57
IS 8
BP 938
EP 946
DI 10.1111/jcpp.12557
PG 9
WC Psychology, Developmental; Psychiatry; Psychology
SC Psychology; Psychiatry
GA DW1JH
UT WOS:000383398900007
PM 27062170
ER
PT J
AU Eccleston, JL
Su, H
Ling, A
Heller, T
Koh, C
AF Eccleston, J. L.
Su, H.
Ling, A.
Heller, T.
Koh, C.
TI Gastrointestinal: Adult presentation of intestinal malrotation
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
C1 [Eccleston, J. L.; Heller, T.; Koh, C.] NIDDK, Liver Dis Branch, Bethesda, MD 20892 USA.
[Su, H.] NIDDK, Human Immunol Dis Unit, Bethesda, MD 20892 USA.
[Ling, A.] NIH, Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
RP Eccleston, JL (reprint author), NIDDK, Liver Dis Branch, Bethesda, MD 20892 USA.
FU Intramural NIH HHS [Z99 DK999999]
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD AUG
PY 2016
VL 31
IS 8
BP 1382
EP 1382
DI 10.1111/jgh.13401
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA DW6QX
UT WOS:000383777100002
PM 27060900
ER
PT J
AU Shiono, H
Matsui, T
Okada, T
Ito, Y
AF Shiono, Hiroyuki
Matsui, Takuya
Okada, Tadashi
Ito, Yoichiro
TI Single-step enrichment of basophils from human peripheral blood by a
novel method using a Percoll density gradient
SO JOURNAL OF SEPARATION SCIENCE
LA English
DT Article
DE Basophils; Cell separation; Centrifugation; Density gradient; Human
peripheral blood
ID CELL-SEPARATION METHOD; UMBILICAL-CORD BLOOD; HUMAN MAST-CELLS;
BONE-MARROW; ALLERGIC INFLAMMATION; BUFFY COAT; PURIFICATION;
CENTRIFUGATION; HOMOGENEITY; RESPONSES
AB We have developed a novel continuous flow-through cell separation method using a Percoll density gradient. This method can continuously separate a large number of cells into five fractions according to their densities. To apply this method to the separation of basophils, Percoll density gradients were modified to improve basophil enrichment. When a set of Percoll density gradients was prepared (1.071, 1.075, 1.080, 1.084, and 1.090 g/mL) the basophils in a healthy volunteer were enriched by an average of 23.1 and 63.5% at Percoll densities of 1.075 (fraction 3) and 1.080 g/mL (fraction 4), respectively. On average, the yield of basophils was 1.66 x 10(5) cells in fraction 3 and 1.61 x 10(5) cells in fraction 4 from 9 mL of peripheral blood. The expression of CD203c (cluster of differentiation 203c) on separated basophils was upregulated by anti-immunoglobulin E stimulation similar to basophils in whole blood. Histamine release induced by calcium ionophore was also observed in the separated basophils. The present method will be useful for basophil enrichment since it preserves their function without using counterflow elutriation and immunological reagents, and this method will be effective as a preparative separation for cell purification by flow cytometry.
C1 [Shiono, Hiroyuki; Matsui, Takuya; Okada, Tadashi] Aichi Med Univ, Sch Med, Dept Physiol, 1-1 Karimata, Nagakute, Aichi 4801195, Japan.
[Ito, Yoichiro] NHLBI, Bioseparat Technol Lab, Biochem & Biophys Ctr, NIH, Bethesda, MD USA.
RP Shiono, H (reprint author), Aichi Med Univ, Sch Med, Dept Physiol, 1-1 Karimata, Nagakute, Aichi 4801195, Japan.
EM shiono-h@aichi-med-u.ac.jp
FU Intramural NIH HHS [ZIA HL001053-07]
NR 38
TC 1
Z9 1
U1 5
U2 5
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1615-9306
EI 1615-9314
J9 J SEP SCI
JI J. Sep. Sci.
PD AUG
PY 2016
VL 39
IS 15
BP 3062
EP 3071
DI 10.1002/jssc.201600329
PG 10
WC Chemistry, Analytical
SC Chemistry
GA DW0VD
UT WOS:000383360200021
PM 27293108
ER
PT J
AU Schanz, O
Bageac, D
Braun, L
Traynor, BJ
Lehky, TJ
Floeter, MK
AF Schanz, Olivia
Bageac, Devin
Braun, Laura
Traynor, Bryan J.
Lehky, Tanya J.
Floeter, Mary Kay
TI CORTICAL HYPEREXCITABILITY IN PATIENTS WITH C9ORF72 MUTATIONS:
RELATIONSHIP TO PHENOTYPE
SO MUSCLE & NERVE
LA English
DT Article
DE ALS; amyotrophic lateral sclerosis; C9orf72; cortical hyperexcitability;
cortical silent period; frontotemporal dementia; transcranial magnetic
stimulation
ID AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSCRANIAL MAGNETIC STIMULATION;
MOTOR-NEURON DYSFUNCTION; GGGGCC REPEAT EXPANSION; FRONTOTEMPORAL
DEMENTIA; CORTICOMOTOR THRESHOLD; HEXANUCLEOTIDE REPEAT; BEHAVIORAL
VARIANT; PTDP-43 PATHOLOGY; CORTEX INHIBITION
AB Introduction: Patients with mutations in C9orf72 can have amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or ALS-FTD. The goals were to establish whether cortical hyperexcitability occurs in C9orf72 patients with different clinical presentations. Methods: Cortical thresholds and silent periods were measured in thenar muscles in 19 participants with C9orf72 expansions and 21 healthy controls using transcranial magnetic stimulation (TMS). El Escorial and Rascovsky criteria were used to diagnose ALS and FTD. Fourteen participants with C9orf72 expansions were re-tested 6 months later. Correlations with finger-tapping speed, timed peg test, the ALS functional rating scale, and Dementia Rating Scale were examined. Results: Most participants with C9orf72 expansions had normal or low cortical thresholds. Among them, ALS patients had the lowest thresholds and significantly shorter silent periods. Thresholds correlated with timed peg-test scores. TMS did not correlate with the Dementia Rating Scale. Conclusions: TMS measures of cortical excitability may serve as non-invasive biomarkers of ALS disease activity.
C1 [Schanz, Olivia; Bageac, Devin; Braun, Laura; Floeter, Mary Kay] NIH, Motor Neuron Disorders Unit, Bldg 10, Bethesda, MD 20892 USA.
[Traynor, Bryan J.] NIA, Neurogenet Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA.
[Lehky, Tanya J.] Natl Inst Neurol Disorders, EMG Sect, NIH, Bethesda, MD USA.
RP Floeter, MK (reprint author), 10 Ctr Dr,MSC 1404, Bethesda, MD 20892 USA.
EM floeterm@ninds.nih.gov
FU National Institute of Health, NINDS; NIA [Z01 NS002976]
FX This study was supported by the intramural program of the National
Institute of Health, NINDS, and NIA (Z01 NS002976).
NR 46
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD AUG
PY 2016
VL 54
IS 2
BP 264
EP 269
DI 10.1002/mus.25047
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA DW2IP
UT WOS:000383466400013
PM 26799151
ER
PT J
AU Ang, R
Abramowitz, J
Birnbaumer, L
Gourine, AV
Tinker, A
AF Ang, Richard
Abramowitz, Joel
Birnbaumer, Lutz
Gourine, Alexander V.
Tinker, Andrew
TI The role of G(alpha O)-mediated signaling in the rostral ventrolateral
medulla oblongata in cardiovascular reflexes and control of cardiac
ventricular excitability
SO PHYSIOLOGICAL REPORTS
LA English
DT Article
DE Autonomic nervous system; blood pressure; cardiac excitability; G
proteins; rostral ventral lateral medulla
ID 5-HT1A RECEPTORS; BRAIN-STEM; C1 NEURONS; G-PROTEINS; ACTIVATION; RATS;
HEART; MICE; HYPOTHALAMUS; PRESSURE
AB The heart is controlled by the sympathetic and parasympathetic limbs of the autonomic nervous system with inhibitory signaling mechanisms recruited in both limbs. The aim of this study was to determine the role of inhibitory heterotrimeric G proteins in the central nervous mechanisms underlying autonomic control of the heart and its potential role in arrhythmogenesis. Mice with conditional deletion of the inhibitory heterotrimeric G protein GaO in the presympathetic area of the rostral ventral lateral medulla (RVLM) were generated to determine the role of GaO-mediated signalling in autonomic control and electrophysiological properties of the heart. GaO deletion within the RVLM was not associated with changes in heart rate (HR) or the arterial blood pressure at rest (home cage, normal behavior). However, exposure to stressful conditions (novel environment, hypoxia, or hypercapnia) in these mice was associated with abnormal HR responses and an increased baroreflex gain when assessed under urethane anesthesia. This was associated with shortening of the ventricular effective refractory period. This phenotype was reversed by systemic beta-adrenoceptor blockade, suggesting that GaO depletion in the RVLM increases central sympathetic drive. The data obtained support the hypothesis that GaO-mediated signaling within the presympathetic circuits of the RVLM contributes to the autonomic control of the heart. GaO deficiency in the RVLM has a significant impact on cardiovascular responses to stress, cardiovascular reflexes and electrical properties of the heart.
C1 [Ang, Richard; Gourine, Alexander V.] Barts & London Queen Marys Sch Med & Dent, William Harvey Heart Ctr, London EC1M 6BQ, England.
[Ang, Richard; Tinker, Andrew] UCL, Dept Neurosci Physiol & Pharmacol, London, England.
[Abramowitz, Joel; Birnbaumer, Lutz] NIEHS, Div Intramural Res, POB 12233, Res Triangle Pk, NC 27709 USA.
RP Tinker, A (reprint author), Barts & London Queen Marys Sch Med & Dent, William Harvey Heart Ctr, London EC1M 6BQ, England.
EM a.tinker@qmul.ac.uk
NR 43
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2051-817X
J9 PHYSIOL REP
JI PHYSIOL. REP.
PD AUG
PY 2016
VL 4
IS 15
AR e12860
DI 10.14814/phy2.12860
PG 13
WC Physiology
SC Physiology
GA DW1ZE
UT WOS:000383441900001
ER
PT J
AU Karchin, R
Nussinov, R
AF Karchin, Rachel
Nussinov, Ruth
TI Genome Landscapes of Disease: Strategies to Predict the Phenotypic
Consequences of Human Germline and Somatic Variation
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Editorial Material
C1 [Karchin, Rachel] Johns Hopkins Inst, Dept Biomed Engn, Baltimore, MD 21218 USA.
[Karchin, Rachel] Johns Hopkins Inst, Inst Computat Med, Dept Oncol, Canc Biol Program, Baltimore, MD 21218 USA.
[Nussinov, Ruth] NCI, Canc & Inflammat Program, Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA.
[Nussinov, Ruth] Tel Aviv Univ, Sackler Inst Mol Med, Dept Human Genet & Mol Med, Sackler Sch Med, Tel Aviv, Israel.
RP Karchin, R (reprint author), Johns Hopkins Inst, Dept Biomed Engn, Baltimore, MD 21218 USA.; Karchin, R (reprint author), Johns Hopkins Inst, Inst Computat Med, Dept Oncol, Canc Biol Program, Baltimore, MD 21218 USA.
EM rachel.karchin@gmail.com; NussinoR@helix.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD AUG
PY 2016
VL 12
IS 8
AR e1005043
DI 10.1371/journal.pcbi.1005043
PG 3
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA DW0QL
UT WOS:000383346100014
ER
PT J
AU Guo, Y
Andersen, SW
Shu, XO
Michailidou, K
Bolla, MK
Wang, Q
Garcia-Closas, M
Milne, RL
Schmidt, MK
Chang-Claude, J
Dunning, A
Bojesen, SE
Ahsan, H
Aittomaki, K
Andrulis, IL
Anton-Culver, H
Arndt, V
Beckmann, MW
Beeghly-Fadiel, A
Benitez, J
Bogdanova, NV
Bonanni, B
Borresen-Dale, AL
Brand, J
Brauch, H
Brenner, H
Bruning, T
Burwinkel, B
Casey, G
Chenevix-Trench, G
Couch, FJ
Cox, A
Cross, SS
Czene, K
Devilee, P
Dork, T
Dumont, M
Fasching, PA
Figueroa, J
Flesch-Janys, D
Fletcher, O
Flyger, H
Fostira, F
Gammon, M
Giles, GG
Guenel, P
Haiman, CA
Hamann, U
Hooning, MJ
Hopper, JL
Jakubowska, A
Jasmine, F
Jenkins, M
John, EM
Johnson, N
Jones, ME
Kabisch, M
Kibriya, M
Knight, JA
Koppert, LB
Kosma, VM
Kristensen, V
Le Marchand, L
Lee, E
Li, JM
Lindblom, A
Luben, R
Lubinski, J
Malone, KE
Mannermaa, A
Margolin, S
Marme, F
McLean, C
Meijers-Heijboer, H
Meindl, A
Neuhausen, SL
Nevanlinna, H
Neven, P
Olson, JE
Perez, JIA
Perkins, B
Peterlongo, P
Phillips, KA
Pylkas, K
Rudolph, A
Santella, R
Sawyer, EJ
Schmutzler, RK
Seynaeve, C
Shah, M
Shrubsole, MJ
Southey, MC
Swerdlow, AJ
Toland, AE
Tomlinson, I
Torres, D
Truong, T
Ursin, G
Van Der Luijt, RB
Verhoef, S
Whittemore, AS
Winqvist, R
Zhao, H
Zhao, SL
Hall, P
Simard, J
Kraft, P
Pharoah, P
Hunter, D
Easton, DF
Zheng, W
AF Guo, Yan
Andersen, Shaneda Warren
Shu, Xiao-Ou
Michailidou, Kyriaki
Bolla, Manjeet K.
Wang, Qin
Garcia-Closas, Montserrat
Milne, Roger L.
Schmidt, Marjanka K.
Chang-Claude, Jenny
Dunning, Allison
Bojesen, Stig E.
Ahsan, Habibul
Aittomaki, Kristiina
Andrulis, Irene L.
Anton-Culver, Hoda
Arndt, Volker
Beckmann, Matthias W.
Beeghly-Fadiel, Alicia
Benitez, Javier
Bogdanova, Natalia V.
Bonanni, Bernardo
Borresen-Dale, Anne-Lise
Brand, Judith
Brauch, Hiltrud
Brenner, Hermann
Bruening, Thomas
Burwinkel, Barbara
Casey, Graham
Chenevix-Trench, Georgia
Couch, Fergus J.
Cox, Angela
Cross, Simon S.
Czene, Kamila
Devilee, Peter
Doerk, Thilo
Dumont, Martine
Fasching, Peter A.
Figueroa, Jonine
Flesch-Janys, Dieter
Fletcher, Olivia
Flyger, Henrik
Fostira, Florentia
Gammon, Marilie
Giles, Graham G.
Guenel, Pascal
Haiman, Christopher A.
Hamann, Ute
Hooning, Maartje J.
Hopper, John L.
Jakubowska, Anna
Jasmine, Farzana
Jenkins, Mark
John, Esther M.
Johnson, Nichola
Jones, Michael E.
Kabisch, Maria
Kibriya, Muhammad
Knight, Julia A.
Koppert, Linetta B.
Kosma, Veli-Matti
Kristensen, Vessela
Le Marchand, Loic
Lee, Eunjung
Li, Jingmei
Lindblom, Annika
Luben, Robert
Lubinski, Jan
Malone, Kathi E.
Mannermaa, Arto
Margolin, Sara
Marme, Frederik
McLean, Catriona
Meijers-Heijboer, Hanne
Meindl, Alfons
Neuhausen, Susan L.
Nevanlinna, Heli
Neven, Patrick
Olson, Janet E.
Perez, Jose I. A.
Perkins, Barbara
Peterlongo, Paolo
Phillips, Kelly-Anne
Pylkas, Katri
Rudolph, Anja
Santella, Regina
Sawyer, Elinor J.
Schmutzler, Rita K.
Seynaeve, Caroline
Shah, Mitul
Shrubsole, Martha J.
Southey, Melissa C.
Swerdlow, Anthony J.
Toland, Amanda E.
Tomlinson, Ian
Torres, Diana
Truong, Therese
Ursin, Giske
Van Der Luijt, Rob B.
Verhoef, Senno
Whittemore, Alice S.
Winqvist, Robert
Zhao, Hui
Zhao, Shilin
Hall, Per
Simard, Jacques
Kraft, Peter
Pharoah, Paul
Hunter, David
Easton, Douglas F.
Zheng, Wei
TI Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian
Randomization Analyses of Data from 145,000 Women of European Descent
SO PLOS MEDICINE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HORMONE-RECEPTOR STATUS; GENOTYPE IMPUTATION;
PROSPECTIVE COHORT; FAT DISTRIBUTION; RELATIVE WEIGHT; OBESITY; LOCI;
SIZE; METAANALYSIS
AB Background
Observational epidemiological studies have shown that high body mass index (BMI) is associated with a reduced risk of breast cancer in premenopausal women but an increased risk in postmenopausal women. It is unclear whether this association is mediated through shared genetic or environmental factors.
Methods
We applied Mendelian randomization to evaluate the association between BMI and risk of breast cancer occurrence using data from two large breast cancer consortia. We created a weighted BMI genetic score comprising 84 BMI-associated genetic variants to predicted BMI. We evaluated genetically predicted BMI in association with breast cancer risk using individual-level data from the Breast Cancer Association Consortium (BCAC) (cases = 46,325, controls = 42,482). We further evaluated the association between genetically predicted BMI and breast cancer risk using summary statistics from 16,003 cases and 41,335 controls from the Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) Project. Because most studies measured BMI after cancer diagnosis, we could not conduct a parallel analysis to adequately evaluate the association of measured BMI with breast cancer risk prospectively.
Results
In the BCAC data, genetically predicted BMI was found to be inversely associated with breast cancer risk (odds ratio [OR] = 0.65 per 5 kg/m(2) increase, 95% confidence interval [CI]: 0.56-0.75, p = 3.32 x 10(-10)). The associations were similar for both premenopausal (OR = 0.44, 95% CI: 0.31-0.62, p = 9.91x10(-8)) and postmenopausal breast cancer (OR = 0.57, 95% CI: 0.46-0.71, p = 1.88x10(-8)). This association was replicated in the data from the DRIVE consortium (OR = 0.72, 95% CI: 0.60-0.84, p = 1.64 x 10(-7)). Single marker analyses identified 17 of the 84 BMI-associated single nucleotide polymorphisms (SNPs) in association with breast cancer risk at p < 0.05; for 16 of them, the allele associated with elevated BMI was associated with reduced breast cancer risk.
Conclusions
BMI predicted by genome-wide association studies (GWAS)-identified variants is inversely associated with the risk of both pre- and postmenopausal breast cancer. The reduced risk of postmenopausal breast cancer associated with genetically predicted BMI observed in this study differs from the positive association reported from studies using measured adult BMI. Understanding the reasons for this discrepancy may reveal insights into the complex relationship of genetic determinants of body weight in the etiology of breast cancer.
C1 [Guo, Yan; Zhao, Shilin] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Andersen, Shaneda Warren; Shu, Xiao-Ou; Beeghly-Fadiel, Alicia; Shrubsole, Martha J.; Zheng, Wei] Vanderbilt Univ, Sch Med, Dept Med, Div Epidemiol,Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
[Michailidou, Kyriaki; Bolla, Manjeet K.; Wang, Qin; Pharoah, Paul; Easton, Douglas F.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England.
[Garcia-Closas, Montserrat; Jones, Michael E.; Swerdlow, Anthony J.] Inst Canc Res, Div Genet & Epidemiol, London, England.
[Garcia-Closas, Montserrat; Fletcher, Olivia; Johnson, Nichola] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London, England.
[Milne, Roger L.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[Milne, Roger L.; Giles, Graham G.; Hopper, John L.; Jenkins, Mark] Univ Melbourne, Ctr Epidemiol & Biostat, Sch Populat & Global Hlth, Melbourne, Vic, Australia.
[Schmidt, Marjanka K.; Verhoef, Senno] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
[Chang-Claude, Jenny; Rudolph, Anja] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Chang-Claude, Jenny] Univ Ulm, Dept Obstet & Gynecol, Ulm, Germany.
[Dunning, Allison; Cross, Simon S.] Univ Sheffield, Dept Neurosci, Acad Unit Pathol, Sheffield, S Yorkshire, England.
[Bojesen, Stig E.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
[Bojesen, Stig E.] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, Herlev, Denmark.
[Bojesen, Stig E.] Copenhagen Univ Hosp, Herlev Hosp, Copenhagen Gen Populat Study, Herlev, Denmark.
[Ahsan, Habibul; Beckmann, Matthias W.; Jasmine, Farzana; Kibriya, Muhammad] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA.
[Aittomaki, Kristiina] Univ Helsinki, Helsinki Univ Hosp, Dept Clin Genet, Helsinki, Finland.
[Andrulis, Irene L.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
[Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Anton-Culver, Hoda] Univ Calif Irvine, Dept Epidemiol, Irvine, CA 92697 USA.
[Arndt, Volker; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Benitez, Javier] Spanish Natl Canc Res Ctr, Human Canc Genet Program, Madrid, Spain.
[Benitez, Javier] Ctr Invest Red Enfermedades Raras, Valencia, Spain.
[Bogdanova, Natalia V.] Hannover Med Sch, Dept Radiat Oncol, Hannover, Germany.
[Bonanni, Bernardo] Ist Europeo Oncol, Div Canc Prevent & Genet, Milan, Italy.
[Borresen-Dale, Anne-Lise; Kristensen, Vessela] Oslo Univ Hosp, Radiumhosp, Dept Genet, Inst Canc Res, Oslo, Norway.
[Borresen-Dale, Anne-Lise; Kristensen, Vessela] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
[Brand, Judith; Czene, Kamila; Li, Jingmei; Hall, Per] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Brauch, Hiltrud; Brenner, Hermann] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.
[Brauch, Hiltrud] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
[Brauch, Hiltrud] Univ Tubingen, Tubingen, Germany.
[Brenner, Hermann] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.
[Bruening, Thomas] Ruhr Univ Bochum, German Social Accid Insurance, Inst Prevent & Occupat Med, Bochum, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Div Mol Genet Epidemiol, Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, Heidelberg, Germany.
[Casey, Graham; Haiman, Christopher A.; Lee, Eunjung] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Dept Genet, Brisbane, Qld, Australia.
[Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
[Cox, Angela] Univ Sheffield, Sheffield Canc Res, Dept Oncol, Sheffield, S Yorkshire, England.
[Devilee, Peter] Leiden Univ, Dept Human Genet, Med Ctr, Leiden, Netherlands.
[Doerk, Thilo] Hannover Med Sch, Gynaecol Res Unit, Hannover, Germany.
[Dumont, Martine; Simard, Jacques] Univ Laval, Ctr Hosp Univ Quebec Res Ctr, Quebec City, PQ, Canada.
[Fasching, Peter A.] Univ Erlangen Nurnberg, Dept Obstet & Gynaecol, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Figueroa, Jonine] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20850 USA.
[Flesch-Janys, Dieter] Univ Med Ctr Hamburg Eppendorf, Inst Med Biometr & Epidemiol, Hamburg, Germany.
[Flesch-Janys, Dieter] Univ Med Ctr Hamburg Eppendorf, Dept Canc Epidemiol, Clin Canc Registry, Hamburg, Germany.
[Flyger, Henrik] Copenhagen Univ Hosp, Herlev Hosp, Dept Breast Surg, Herlev, Denmark.
[Fostira, Florentia] Natl Ctr Sci Res Demokritos, IRRP, Mol Diagnost Lab, Athens, Greece.
[Gammon, Marilie] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[Guenel, Pascal; Truong, Therese] INSERM, Environm Epidemiol Canc, Ctr Res Epidemiol & Populat Hlth, Villejuif, France.
[Guenel, Pascal; Truong, Therese] Univ Paris Sud, Villejuif, France.
[Hamann, Ute; Kabisch, Maria; Torres, Diana] German Canc Res Ctr, Mol Genet Breast Canc, Heidelberg, Germany.
[Hooning, Maartje J.; Koppert, Linetta B.; Seynaeve, Caroline] Erasmus Univ, Dept Surg Oncol, Med Ctr, Rotterdam, Netherlands.
[Jakubowska, Anna; Lubinski, Jan] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland.
[John, Esther M.] Canc Prevent Inst Calif, Dept Epidemiol, Fremont, CA USA.
[John, Esther M.; Whittemore, Alice S.] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA.
[Knight, Julia A.] Mt Sinai Hosp, Prosserman Ctr Hlth Res, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
[Knight, Julia A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada.
[Kosma, Veli-Matti; Mannermaa, Arto] Kuopio Univ Hosp, Dept Clin Pathol, Imaging Ctr, Kuopio, Finland.
[Kosma, Veli-Matti; Mannermaa, Arto] Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, Kuopio, Finland.
[Kosma, Veli-Matti; Mannermaa, Arto] Univ Eastern Finland, Canc Ctr Eastern Finland, Kuopio, Finland.
[Kristensen, Vessela] Univ Oslo, Oslo Univ Hosp, Dept Clin Mol Biol, Oslo, Norway.
[Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
[Lindblom, Annika] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
[Luben, Robert] Univ Cambridge, Dept Publ Hlth & Primary Care, Clin Gerontol, Cambridge, England.
[Malone, Kathi E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
[Margolin, Sara] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
[Marme, Frederik] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany.
[Marme, Frederik] Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany.
[McLean, Catriona] Alfred Hosp, Anat Pathol, Melbourne, Vic, Australia.
[Meijers-Heijboer, Hanne] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
[Meindl, Alfons] Tech Univ Munich, Div Gynaecol & Obstet, Munich, Germany.
[Neuhausen, Susan L.] Beckman Res Inst City Hope, Duarte, CA 91010 USA.
[Nevanlinna, Heli] Univ Helsinki, Helsinki Univ Hosp, Dept Obstet & Gynecol, Helsinki, Finland.
[Neven, Patrick] Univ Hosp Gasthuisberg, Dept Oncol, Leuven, Belgium.
[Olson, Janet E.; Shah, Mitul] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
[Perez, Jose I. A.] Hosp Monte Naranco, Serv Cirugia Gen & Especialidades, Oviedo, Spain.
[Perkins, Barbara; Pharoah, Paul; Easton, Douglas F.] Univ Cambridge, Dept Oncol, Ctr Canc Genet Epidemiol, Cambridge, England.
[Peterlongo, Paolo] Fdn Ist FIRC Italian Fdn Canc Res Oncol Mol, IFOM, Milan, Italy.
[Phillips, Kelly-Anne] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Phillips, Kelly-Anne] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.
[Phillips, Kelly-Anne] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia.
[Pylkas, Katri; Ursin, Giske; Winqvist, Robert] Univ Oulu, Dept Clin Chem, Lab Canc Genet & Tumor Biol, Oulu, Finland.
[Pylkas, Katri; Ursin, Giske; Winqvist, Robert] Univ Oulu, Bioctr Oulu, Oulu, Finland.
[Santella, Regina] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY 10027 USA.
[Santella, Regina] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10027 USA.
[Sawyer, Elinor J.] Kings Coll London, Guys Hosp, Res Oncol, London, England.
[Schmutzler, Rita K.] Univ Hosp Cologne, Dept Obstet & Gynaecol, Div Mol Gynecooncol, Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Ctr Mol Med, Cologne, Germany.
[Schmutzler, Rita K.] Univ Hosp Cologne, Ctr Familial Breast & Ovarian Canc, Cologne, Germany.
[Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
[Swerdlow, Anthony J.] Inst Canc Res, Div Breast Canc Res, London, England.
[Toland, Amanda E.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
[Tomlinson, Ian] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Tomlinson, Ian] Univ Oxford, Oxford Biomed Res Ctr, Oxford, England.
[Ursin, Giske] Univ Oslo, Dept Nutr, Inst Basic Med Sci, Oslo, Norway.
[Van Der Luijt, Rob B.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
[Winqvist, Robert] Northern Finland Lab Ctr NordLab, Lab Canc Genet & Tumor Biol, Oulu, Finland.
[Zhao, Hui] Vesalius Res Ctr, Leuven, Belgium.
[Zhao, Hui] Univ Leuven, Dept Oncol, Lab Translat Genet, Leuven, Belgium.
[Kraft, Peter; Hunter, David] Harvard Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Boston, MA USA.
[Kraft, Peter; Hunter, David] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Zheng, W (reprint author), Vanderbilt Univ, Sch Med, Dept Med, Div Epidemiol,Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
EM wei.zheng@vanderbilt.edu
RI Knight, Julia/A-6843-2012; Zheng, Wei/O-3351-2013; Bruning,
Thomas/G-8120-2015; Dork, Thilo/J-8620-2012; Li, Jingmei/I-2904-2012;
Brenner, Hermann/B-4627-2017;
OI Zheng, Wei/0000-0003-1226-070X; Bruning, Thomas/0000-0001-9560-5464; Li,
Jingmei/0000-0001-8587-7511; Brenner, Hermann/0000-0002-6129-1572;
Dunning, Alison Margaret/0000-0001-6651-7166
FU National Cancer Institute [R37CA070867, R25CA160056]
FX The work conducted for this project at Vanderbilt University is
supported primarily by National Cancer Institute research grants
(R37CA070867 and R25CA160056) and endowment funds for the Ingram
Professorship and Anne Potter Wilson Chair. JF is a volunteer for the
NCI in the Epidemiology and Biostatistics Program and has no role in
funding decisions. A complete funding statement is available in the
Supporting Information. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 46
TC 1
Z9 1
U1 8
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2016
VL 13
IS 8
AR e1002105
DI 10.1371/journal.pmed.1002105
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW0UD
UT WOS:000383357400022
PM 27551723
ER
PT J
AU Kilmarx, PH
Simbi, R
AF Kilmarx, Peter H.
Simbi, Raiva
TI Progress and Challenges in Scaling Up Laboratory Monitoring of HIV
Treatment
SO PLOS MEDICINE
LA English
DT Editorial Material
ID CASCADE
C1 [Kilmarx, Peter H.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
[Simbi, Raiva] Minist Hlth & Child Care, Harare, Zimbabwe.
RP Kilmarx, PH (reprint author), NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
EM peter.kilmarx@nih.gov
OI Kilmarx, Peter/0000-0001-6464-3345
NR 15
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2016
VL 13
IS 8
AR e1002089
DI 10.1371/journal.pmed.1002089
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DW0UD
UT WOS:000383357400014
PM 27551962
ER
PT J
AU Kullenberg, T
Lofqvist, M
Leinonen, M
Goldbach-Mansky, R
Olivecrona, H
AF Kullenberg, Torbjorn
Lofqvist, Malin
Leinonen, Mika
Goldbach-Mansky, Raphaela
Olivecrona, Hans
TI Long-term safety profile of anakinra in patients with severe
cryopyrin-associated periodic syndromes
SO RHEUMATOLOGY
LA English
DT Article
DE adverse event (AE); anakinra; clinical trial; cryopyrin-associated
periodic syndromes ( CAPS); neonatal-onset multisystem inflammatory
disease (NOMID); safety; injection site reactions (ISR); infections;
headache
ID INTERLEUKIN-1 RECEPTOR ANTAGONIST; PLACEBO-CONTROLLED TRIAL;
RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; METHOTREXATE; MULTICENTER; DISEASES
AB Objective. Anakinra is approved for the treatment of RA and cryopyrin-associated periodic syndromes (CAPS). While the anakinra safety profile is well established in RA, the long-term safety profile in severe CAPS is less well documented and will therefore be discussed in this report.
Methods. A prospective, open-label, single centre, clinical cohort study was conducted at the National Institutes of Health in the USA, from 2003 to 2010, investigating the efficacy and safety of anakinra treatment for up to 5 years in 43 patients with CAPS. Safety was evaluated using adverse event (AE) reports, laboratory assessments, vital signs and diary reports.
Results. In total, 1233 AEs were reported during the study, with a yearly rate of 7.7 AEs per patient. The event rate decreased over time, and dose escalation during the study did not affect AE frequency. Anakinra had similar safety profiles in adults and children. The most frequently reported AEs were typical CAPS disease symptoms such as headache and arthralgia. Injection site reactions occurred mainly during the first month of anakinra treatment. In total, 14 patients experienced 24 serious AEs (SAEs), all of which resolved during the study period. The most common types of SAEs were infections such as pneumonia and gastroenteritis. There were no permanent discontinuations of treatment due to AEs.
Conclusion. In this study anakinra treatment of patients with severe CAPS for up to 5 years was safe and well tolerated both in paediatric and adult patients, with most AEs emerging during the first months after treatment initiation.
C1 [Kullenberg, Torbjorn; Lofqvist, Malin; Leinonen, Mika; Olivecrona, Hans] Sobi, Dev & Med, Stockholm, Sweden.
[Leinonen, Mika] 4Pharma AB, Dept Stat, Stockholm, Sweden.
[Goldbach-Mansky, Raphaela] NIAMSD, Translat Autoinflammatory Dis Sect, NIH, Bethesda, MD 20892 USA.
RP Kullenberg, T (reprint author), Swedish Orphan Biovitrum Sobi, Dev & Med, SE-11276 Stockholm, Sweden.
EM torbjorn.kullenberg@sobi.com
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health; Swedish Orphan Biovitrum AB
FX This work was supported by the Intramural Research Program of the
National Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health and Swedish Orphan Biovitrum AB (publ).
NR 18
TC 1
Z9 2
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD AUG
PY 2016
VL 55
IS 8
BP 1499
EP 1506
DI 10.1093/rheumatology/kew208
PG 8
WC Rheumatology
SC Rheumatology
GA DW7QX
UT WOS:000383847200020
PM 27143789
ER
PT J
AU Zhu, CQ
Yang, CX
Wang, YH
Lin, G
Yang, YH
Wang, XY
Zhu, J
Chen, XY
Lu, X
Liu, G
Xia, HP
AF Zhu, Congqing
Yang, Caixia
Wang, Yongheng
Lin, Gan
Yang, Yuhui
Wang, Xiaoyong
Zhu, Jun
Chen, Xiaoyuan
Lu, Xin
Liu, Gang
Xia, Haiping
TI CCCCC pentadentate chelates with planar Mobius aromaticity and unique
properties
SO SCIENCE ADVANCES
LA English
DT Article
ID PINCER COMPLEXES; TRANSITION-METAL; DENSITY; THERAPY; DELOCALIZATION;
OSMAPENTALENE; MOLECULES; CHEMISTRY; CATALYSTS; SWITCHES
AB The coordinating atoms in polydentate chelates are primarily heteroatoms. We present the first examples of pentadentate chelates with all binding atoms of the chelating agent being carbon atoms, denoted as CCCCC chelates. Having up to five metal-carbon bonds in the equatorial plane has not been previously observed in transition metal chemistry. Density functional theory calculations showed that the planar metallacycle has extended Craig-Mobius aromaticity arising from 12-center-12-electron d(pi)-p(pi) pi-conjugation. These planar chelates have broad absorption in the ultraviolet-visible-near-infrared region and, thus, notable photothermal performance upon irradiation by an 808-nm laser, indicating that these chelates have potential applications in photothermal therapy. The combination of facile synthesis, high stability, and broad absorption of these complexes could make the polydentate carbon chain a novel building block in coordination chemistry.
C1 [Zhu, Congqing; Wang, Yongheng; Yang, Yuhui; Zhu, Jun; Lu, Xin; Xia, Haiping] Xiamen Univ, Collaborat Innovat Ctr Chem Energy Mat iChEM, Coll Chem & Chem Engn, State Key Lab Phys Chem Solid Surfaces, Xiamen 361005, Peoples R China.
[Yang, Caixia; Lin, Gan; Wang, Xiaoyong; Liu, Gang] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361005, Peoples R China.
[Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
RP Lu, X; Xia, HP (reprint author), Xiamen Univ, Collaborat Innovat Ctr Chem Energy Mat iChEM, Coll Chem & Chem Engn, State Key Lab Phys Chem Solid Surfaces, Xiamen 361005, Peoples R China.; Liu, G (reprint author), Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361005, Peoples R China.
EM xinlu@xmu.edu.cn; gangliu.cmitm@xmu.edu.cn; hpxia@xmu.edu.cn
NR 50
TC 2
Z9 2
U1 15
U2 15
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD AUG
PY 2016
VL 2
IS 8
AR e1601031
DI 10.1126/sciadv.1601031
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW6CP
UT WOS:000383734300046
ER
PT J
AU Crawford, DW
Blakeley, BD
Chen, PH
Sherpa, C
Le Grice, SFJ
Laird-Offringa, IA
McNaughton, BR
AF Crawford, David W.
Blakeley, Brett D.
Chen, Po-Han
Sherpa, Chringma
Le Grice, Stuart F. J.
Laird-Offringa, Ite A.
McNaughton, Brian R.
TI An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TAR-Dependent
Transcription
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID HAIRPIN-II RNA; PROTEIN TRANSDUCTION DOMAIN; MYOTONIC-DYSTROPHY TYPE-1;
YEAST SURFACE DISPLAY; CELLS IN-VITRO; TAR RNA; SMALL MOLECULES;
MAMMALIAN-CELLS; TARGETING RNA; U1A PROTEIN
AB Potent and selective recognition and modulation of disease-relevant RNAs remain a daunting challenge. We previously examined the utility of the U1A N-terminal RNA recognition motif as a scaffold for tailoring new RNA hairpin recognition and showed that as few as one or two mutations can result in moderate affinity (low mu M dissociation constant) for the human immunodeficiency virus (HIV) trans-activation response element (TAR) RNA, an RNA hairpin controlling transcription of the human immunodeficiency virus (HIV) genome. Here, we use yeast display and saturation mutagenesis of established RNA-binding regions in U1A to identify new synthetic proteins that potently and selectively bind TAR RNA. Our best candidate has truly altered, not simply broadened, RNA-binding selectivity; it binds TAR with subnanomolar affinity (apparent dissociation constant of similar to 0.5 nM) but does not appreciably bind the original U1A RNA target (U1hpII). It specifically recognizes the TAR RNA hairpin in the context of the HIV-1 5'-untranslated region, inhibits the interaction between TAR RNA and an HIV trans-activator of transcription (Tat)-derived peptide, and suppresses Tat/TAR-dependent transcription. Proteins described in this work are among the tightest TAR RNA-binding reagentssmall molecule, nucleic acid, or proteinreported to date and thus have potential utility as therapeutics and basic research tools. Moreover, our findings demonstrate how a naturally occurring RNA recognition motif can be dramatically resurfaced through mutation, leading to potent and selective recognitionand modulationof disease-relevant RNA.
C1 [Crawford, David W.; Blakeley, Brett D.; McNaughton, Brian R.] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.
[McNaughton, Brian R.] Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.
[Chen, Po-Han; Laird-Offringa, Ite A.] Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90033 USA.
[Chen, Po-Han; Laird-Offringa, Ite A.] Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
[Sherpa, Chringma; Le Grice, Stuart F. J.] NCI, Basic Res Lab, Frederick, MD 21702 USA.
RP McNaughton, BR (reprint author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.; McNaughton, BR (reprint author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.
EM brian.mcnaughton@colostate.edu
FU NIH/NIGMS [R01GM107520]; NIH/NCI [P30 CA014089]; Intramural Research
Program of the National Cancer Institute, National Institutes of Health,
Department of Health and Social Services
FX This work is supported by the NIH/NIGMS (R01GM107520, B.R.M.) and
NIH/NCI P30 CA014089 (I.A.L-O.). We thank A. Chapman for assistance with
isothermal titration calorimetry experiments as well as valuable
discussions. The authors are grateful to J.T. Sczepanski (Texas A&M) for
supplying plasmid pLAI-BS used in transcription assays and for helpful
discussions. S.L.G. and C.S. are supported by the Intramural Research
Program of the National Cancer Institute, National Institutes of Health,
Department of Health and Social Services.
NR 65
TC 0
Z9 0
U1 5
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD AUG
PY 2016
VL 11
IS 8
BP 2206
EP 2215
DI 10.1021/acschembio.6b00145
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DT9UL
UT WOS:000381847700016
PM 27253715
ER
PT J
AU Sarathy, JP
Zuccotto, F
Hsinpin, H
Sandberg, L
Via, LE
Marriner, GA
Masquelin, T
Wyatt, P
Ray, P
Dartois, V
AF Sarathy, Jansy P.
Zuccotto, Fabio
Hsinpin, Ho
Sandberg, Lars
Via, Laura E.
Marriner, Gwendolyn A.
Masquelin, Thierry
Wyatt, Paul
Ray, Peter
Dartois, Veronique
TI Prediction of Drug Penetration in Tuberculosis Lesions
SO ACS INFECTIOUS DISEASES
LA English
DT Article
DE Mycobacterium tuberculosis; granuloma; caseum; drug penetration; in
vitro assay; principle component analysis
ID PLASMA-PROTEIN-BINDING; MYCOBACTERIUM-TUBERCULOSIS; ANTITUBERCULOSIS
DRUGS; C3HEB/FEJ MICE; EQUILIBRIUM DIALYSIS; MOLECULAR-STRUCTURE;
PYRAZINAMIDE; BRAIN; MODEL; MACROPHAGES
AB The penetration of antibiotics in necrotic tuberculosis lesions is heterogeneous and drug-specific, but the factors underlying such differential partitioning are unknown. We hypothesized that drug binding to macromolecules in necrotic foci (or caseum) prevents passive drug diffusion through avascular caseum, a critical site of infection. Using a caseum binding assay and MALDI mass spectrometry imaging of tuberculosis drugs, we showed that binding to caseum inversely correlates with passive diffusion into the necrotic core. We developed a high-throughput assay relying on rapid equilibrium dialysis and a caseum surrogate designed to mimic the composition of native caseum. A set of 279 compounds was profiled in this assay to generate a large data set and explore the physicochemical drivers of free diffusion into caseum. Principle component analysis and modeling of the data set delivered an in silico signature predictive of caseum binding, combining 69 molecular descriptors. Among the major positive drivers of binding were high lipophilicity and poor solubility. Determinants of molecular shape such as the number of rings, particularly aromatic rings, number of sp(2) carbon counts, and volume-to-surface ratio negatively correlated with the free fraction, indicating that low-molecular-weight nonflat compounds are more likely to exhibit low caseum binding properties and diffuse effectively through caseum. To provide simple guidance in the property-based design of new compounds, a rule of thumb was derived whereby the sum of the hydrophobicity (clogP) and aromatic ring count is proportional to caseum binding. These tools can be used to ensure desirable lesion partitioning and guide the selection of optimal regimens against tuberculosis.
C1 [Sarathy, Jansy P.; Hsinpin, Ho; Dartois, Veronique] Univ Med & Dent New Jersey, Publ Hlth Res Inst Ctr, 225 Warren St, Newark, NJ 07103 USA.
[Zuccotto, Fabio; Sandberg, Lars; Wyatt, Paul; Ray, Peter] Univ Dundee, Div Biol Chem & Drug Discovery, Sir James Black Ctr, Drug Discovery Unit, Dow St, Dundee DD1 5EH, Scotland.
[Via, Laura E.; Marriner, Gwendolyn A.] NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Masquelin, Thierry] Eli Lilly & Co, Lilly Corp Ctr, Discovery Chem Res, 893 S Delaware,MC-87-02-203 G17, Indianapolis, IN 46285 USA.
RP Sarathy, JP (reprint author), Univ Med & Dent New Jersey, Publ Hlth Res Inst Ctr, 225 Warren St, Newark, NJ 07103 USA.
EM sarathja@njms.rutgers.edu
RI Zuccotto, Fabio/E-7144-2017
OI Zuccotto, Fabio/0000-0002-3888-7423
FU Bill and Melinda Gates Foundation [OPP1044966, OPP1024050]; NIH
[S10OD018072]; Bill and Melinda Gates Foundation; Wellcome Trust
FX We thank Johnson & Johnson, the TB Alliance, Astra Zeneca, Rib-X, and
Trius Therapeutics for providing bedaquiline, PA-824 (pretomanid),
AZD5847, radezolid, and tedizolid, respectively. Brendan Prideaux,
Matthew Zimmerman, Stephen Juzwin, Emma Rey-Jurado, Nancy Ruel, Leyan
Li, and Danielle Weiner provided support with MALDI analysis,
bioanalytical methods, preparation of the caseum surrogate, chemical
synthesis, and isolation of rabbit caseum. We thank the members of the
TB Drug Accelerator consortium and the University of Dundee/NIH HIT-TB
consortium for selecting and sharing the compound series. We are
grateful to Peter Warner and James Metz for stimulating discussions.
This work was conducted with funding from the Bill and Melinda Gates
Foundation, award nos. OPP1044966 and OPP1024050 to V.D., NIH Shared
Instrumentation Grant S10OD018072, as well as joint funding from the
Bill and Melinda Gates Foundation and Wellcome Trust for A Centre of
Excellence for Lead Optimization for Diseases of the Developing World to
P.W.
NR 41
TC 3
Z9 3
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373-8227
J9 ACS INFECT DIS
JI ACS Infect. Dis.
PD AUG
PY 2016
VL 2
IS 8
BP 552
EP 563
DI 10.1021/acsinfecdis.6b00051
PG 12
WC Chemistry, Medicinal; Infectious Diseases
SC Pharmacology & Pharmacy; Infectious Diseases
GA DT6HI
UT WOS:000381584900004
PM 27626295
ER
PT J
AU Lee, JY
Yu, KR
Kim, HS
Kang, I
Kim, JJ
Lee, BC
Choi, SW
Shin, JH
Seo, Y
Kang, KS
AF Lee, Jin Young
Yu, Kyung-Rok
Kim, Hyung-Sik
Kang, Insung
Kim, Jae-Jun
Lee, Byung-Chul
Choi, Soon Won
Shin, Ji-Hee
Seo, Yoojin
Kang, Kyung-Sun
TI BMI1 inhibits senescence and enhances the immunomodulatory properties of
human mesenchymal stem cells via the direct suppression of MKP-1/DUSP1
SO AGING-US
LA English
DT Article
DE hMSCs; Hypoxia; BMI1; immunomodulation; aging; MKP-1
ID STROMAL CELLS; IN-VIVO; REPLICATIVE SENESCENCE; ENDOTHELIAL-CELLS;
NITRIC-OXIDE; LIFE-SPAN; HYPOXIA; PROLIFERATION; EXPRESSION; OXYGEN
AB For the application of mesenchymal stem cells (MSCs) as clinical therapeutics, the regulation of cellular aging is important to protect hMSCs from an age-associated decline in their function. In this study, we evaluated the effects of hypoxia on cellular senescence and the immunomodulatory abilities of hUCB-MSCs. Hypoxic-cultured hUCB-MSCs showed enhanced proliferation and had increased immunosuppressive effects on mitogen-induced mononuclear cell proliferation. We found that BMI1, a member of the polycomb repressive complex protein group, showed increased expression in hypoxic-cultured hUCB-MSCs, and the further knock-down of BMI1 in hypoxic cells induced decreased proliferative and immunomodulatory abilities in hUCB-MSCs, along with COX-2/PGE(2) down-regulation. Furthermore, the expression of phosphorylated p38 MAP kinase increased in response to the over-expression of BMI1 in normoxic conditions, suggesting that BMI1 regulates the immunomodulatory properties of hUCB-MSCs via p38 MAP kinase-mediated COX-2 expression. More importantly, we identified BMI1 as a direct repressor of MAP kinase phosphatase-1 (MKP-1)/DUSP1, which suppresses p38 MAP kinase activity. In conclusion, our results demonstrate that BMI1 plays a key role in the regulation of the immunomodulatory properties of hUCB-MSCs, and we suggest that these findings might provide a strategy to enhance the functionality of hUCB-MSCs for use in therapeutic applications.
C1 [Lee, Jin Young; Yu, Kyung-Rok; Kang, Insung; Kim, Jae-Jun; Lee, Byung-Chul; Choi, Soon Won; Shin, Ji-Hee; Seo, Yoojin; Kang, Kyung-Sun] Seoul Natl Univ, Coll Vet Med, Adult Stem Cell Res Ctr, Seoul 151742, South Korea.
[Lee, Jin Young; Yu, Kyung-Rok; Kang, Insung; Kim, Jae-Jun; Lee, Byung-Chul; Choi, Soon Won; Shin, Ji-Hee; Seo, Yoojin; Kang, Kyung-Sun] Seoul Natl Univ, Vet Med Res Inst, Coll Vet Med, Seoul 151742, South Korea.
[Yu, Kyung-Rok] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Kim, Hyung-Sik] Pusan Natl Univ, Sch Med, Busan 49241, South Korea.
[Kim, Hyung-Sik] Pusan Natl Univ Hosp, Biomed Res Inst, Busan 49241, South Korea.
RP Kang, KS (reprint author), Seoul Natl Univ, Coll Vet Med, Adult Stem Cell Res Ctr, Seoul 151742, South Korea.; Kang, KS (reprint author), Seoul Natl Univ, Vet Med Res Inst, Coll Vet Med, Seoul 151742, South Korea.
EM kangpub@snu.ac.kr
FU Korea Health Technology R&D Project through the Korea Health Industry
Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
of Korea [HI14C3301]; Bio & Medical Technology Development Program of
the National Research Foundation (NRF) - Korean government
[2012M3A9C6049716]; Research Institute for Veterinary Science, Seoul
National University (SNU, Republic of Korea)
FX This research was supported by a grant of the Korea Health Technology
R&D Project through the Korea Health Industry Development Institute
(KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
(grant number : HI14C3301), by the Bio & Medical Technology Development
Program of the National Research Foundation (NRF) funded by the Korean
government (No. 2012M3A9C6049716) and partially by the Research
Institute for Veterinary Science, Seoul National University (SNU,
Republic of Korea).
NR 53
TC 0
Z9 0
U1 2
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG
PY 2016
VL 8
IS 8
BP 1670
EP 1689
DI 10.18632/aging.101000
PG 20
WC Cell Biology
SC Cell Biology
GA DV9UI
UT WOS:000383287300010
PM 27454161
ER
PT J
AU Kusiak, JW
Somerman, M
AF Kusiak, John W.
Somerman, Martha
TI Data science at the National Institute of Dental and Craniofacial
Research Changing dental practice
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
C1 [Kusiak, John W.; Somerman, Martha] Natl Inst Dent & Craniofacial Res, NIH, Bldg 31,Room 2C-39, Bethesda, MD 20892 USA.
RP Kusiak, JW (reprint author), Natl Inst Dent & Craniofacial Res, NIH, Bldg 31,Room 2C-39, Bethesda, MD 20892 USA.
EM kusiakj@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2016
VL 24
IS 8
BP 597
EP 599
DI 10.1016/j.adaj.2016.06.005
PG 3
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DV2NM
UT WOS:000382757300001
ER
PT J
AU Wright, JT
Tampi, MP
Graham, L
Estrich, C
Crall, JJ
Fontana, M
Gillette, EJ
Novy, BB
Dhar, V
Donly, K
Hewlett, ER
Quinonez, RB
Chaffin, J
Crespin, M
Iafolla, T
Siegal, MD
Carrasco-Labra, A
AF Wright, John T.
Tampi, Malavika P.
Graham, Laurel
Estrich, Cameron
Crall, James J.
Fontana, Margherita
Gillette, E. Jane
Novy, Brian B.
Dhar, Vineet
Donly, Kevin
Hewlett, Edmond R.
Quinonez, Rocio B.
Chaffin, Jeffrey
Crespin, Matt
Iafolla, Timothy
Siegal, Mark D.
Carrasco-Labra, Alonso
TI Sealants for preventing and arresting pit-and-fissure occlusal caries in
primary and permanent molars A systematic review of randomized
controlled trials-a report of the American Dental Association and the
American Academy of Pediatric Dentistry
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Glass ionomer sealants; resin-based sealants; caries prevention; caries
arrest; pit-and-fissure sealants; systematic review
ID GLASS-IONOMER; CLINICAL-EVALUATION; FLUORIDE VARNISH; RESIN SEALANT;
LOW-RISK; RETENTION
AB Background. National Health and Nutrition Examination Survey 2011-2012 data indicated that, in the United States, nearly one-fourth of children and over one-half of adolescents experienced dental caries in their permanent teeth. The purpose of this review was to summarize the available clinical evidence regarding the effect of dental sealants for the prevention and management of pit-and-fissure occlusal carious lesions in primary and permanent molars, compared with a control without sealants, with fluoride varnishes, or with other head-to head comparisons.
Type of Studies Reviewed. The authors included parallel and split-mouth randomized controlled trials that included at least 2 years of follow-up, which they identified using MEDLINE (via PubMed), Embase, LILACS, the Cochrane Central Register of Controlled Trials, and registers of ongoing trials. Pairs of reviewers independently conducted the selection of studies, data extraction, risk of bias assessments, and quality of the evidence assessments by using the Grading of Recommendations Assessment, Development and Evaluation approach.
Results. Of 2,869 records screened, the authors determined that 24 articles (representing 23 studies) proved eligible. Moderate-quality evidence suggested that participants who received sealants had a reduced risk of developing carious lesions in occlusal surfaces of permanent molars compared with those who did not receive sealants (odds ratio [OR], 0.15; 95% confidence interval [CI], 0.08-0.27) after 7 or more years of follow-up. When the authors compared studies whose investigators had compared sealants with fluoride varnishes, they found that sealants reduced the incidence of carious lesions after 7 or more years of follow-up (OR, 0.19; 95% CI, 0.07-0.51); however, this finding was supported by low-quality evidence. On the basis of the evidence, the authors could not provide a hierarchy of effectiveness among the studies whose investigators had conducted head-to-head comparisons. The investigators of 2 trials provided information about adverse events, but they did not report any adverse events.
Conclusions and Practical Implications. Available evidence suggests that sealants are effective and safe to prevent or arrest the progression of noncavitated carious lesions compared with a control without sealants or fluoride varnishes. Further research is needed to provide information about the relative merits of the different types of sealant materials.
C1 [Wright, John T.] Univ North Carolina Chapel Hill, Sch Dent, Dept Pediat Dent, Pediat Dent, Chapel Hill, NC USA.
[Wright, John T.] Univ North Carolina Chapel Hill, Sch Dent, Dept Pediat Dent, Strateg Initiat, Chapel Hill, NC USA.
[Tampi, Malavika P.] Amer Dent Assoc, Ctr Evidence Based Dent, Inst Sci, 211 E Chicago Ave, Chicago, IL 60611 USA.
[Graham, Laurel] Amer Acad Pediat Dent, Chicago, IL USA.
[Estrich, Cameron] Amer Dent Assoc, Inst Sci, Sci Informat, Chicago, IL USA.
[Crall, James J.] Univ Calif Los Angeles, Sch Dent, Div Publ Hlth & Community Dent, Los Angeles, CA 90024 USA.
[Fontana, Margherita] Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA.
[Novy, Brian B.] DentaQuest Inst, Practice Improvement, Westborough, MA USA.
[Dhar, Vineet] Univ Maryland, Sch Dent, Div Pediat Dent, Baltimore, MD 21201 USA.
[Donly, Kevin] Univ Texas Hlth Sci Ctr, Sch Dent, Dept Dev Dent, San Antonio, TX USA.
[Hewlett, Edmond R.] Univ Calif Los Angeles, Sch Dent, Sect Restorat Dent, Los Angeles, CA 90024 USA.
[Quinonez, Rocio B.] Univ North Carolina Chapel Hill, Sch Dent, Dept Pediat Dent & Pediat, Chapel Hill, NC USA.
[Chaffin, Jeffrey] Delta Dent Iowa, Des Moines, IA USA.
[Chaffin, Jeffrey] AT Still Univ, Coll Grad Hlth Studies, Mesa, AZ USA.
[Chaffin, Jeffrey] Assoc State & Territorial Dent Directors, Reno, NV USA.
[Crespin, Matt] Childrens Hosp Wisconsin, Childrens Hlth Alliance Wisconsin, Milwaukee, WI 53201 USA.
[Iafolla, Timothy] Natl Inst Dent & Craniofacial Res, Program Anal & Reports Branch, NIH, Bethesda, MD USA.
[Siegal, Mark D.] Amer Assoc Publ Hlth Dent, Springfield, IL USA.
[Carrasco-Labra, Alonso] Amer Dent Assoc, Ctr Evidence Based Dent, Chicago, IL USA.
[Carrasco-Labra, Alonso] Univ Chile, Evidence Based Dent Unit, Santiago, Chile.
[Carrasco-Labra, Alonso] Univ Chile, Dept Oral & Maxillofacial Surg, Fac Dent, Santiago, Chile.
[Carrasco-Labra, Alonso] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
RP Tampi, MP (reprint author), Amer Dent Assoc, Ctr Evidence Based Dent, Inst Sci, 211 E Chicago Ave, Chicago, IL 60611 USA.
EM tampim@ada.org
FU American Academy of Pediatric Dentistry
FX The American Dental Association's Council on Scientific Affairs
commissioned this work, and the American Academy of Pediatric Dentistry
partly funded this project.
NR 46
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2016
VL 24
IS 8
BP 631
EP +
DI 10.1016/j.adaj.2016.06.003
PG 33
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DV2NM
UT WOS:000382757300011
ER
PT J
AU Wright, JT
Crall, JJ
Fontana, M
Gillette, EJ
Novy, BB
Dhar, V
Donly, K
Hewlett, ER
Quinonez, RB
Chaffin, J
Crespin, M
Iafolla, T
Siegal, MD
Tampi, MP
Graham, L
Estrich, C
Carrasco-Labra, A
AF Wright, John T.
Crall, James J.
Fontana, Margherita
Gillette, E. Jane
Novy, Brian B.
Dhar, Vineet
Donly, Kevin
Hewlett, Edmond R.
Quinonez, Rocio B.
Chaffin, Jeffrey
Crespin, Matt
Iafolla, Timothy
Siegal, Mark D.
Tampi, Malavika P.
Graham, Laurel
Estrich, Cameron
Carrasco-Labra, Alonso
TI Evidence-based clinical practice guideline for the use of
pit-and-fissure sealants A report of the American Dental Association and
the American Academy of Pediatric Dentistry
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Pit-and-fissure sealants; clinical recommendations; guideline; occlusal
caries; caries prevention; caries arresting
ID GLASS-IONOMER; CARIES PREVENTION; SCIENTIFIC AFFAIRS; FLUORIDE VARNISH;
RANDOMIZED-TRIAL; PERMANENT MOLARS; OCCLUSAL CARIES; RESIN SEALANT;
LOW-RISK; RECOMMENDATIONS
AB Background. This article presents evidence-based clinical recommendations for the use of pit-and-fissure sealants on the occlusal surfaces of primary and permanent molars in children and adolescents. A guideline panel convened by the American Dental Association (ADA) Council on Scientific Affairs and the American Academy of Pediatric Dentistry conducted a systematic review and formulated recommendations to address clinical questions in relation to the efficacy, retention, and potential side effects of sealants to prevent dental caries; their efficacy compared with fluoride varnishes; and a head-to-head comparison of the different types of sealant material used to prevent caries on pits and fissures of occlusal surfaces.
Types of Studies Reviewed. This is an update of the ADA 2008 recommendations on the use of pit-and-fissure sealants on the occlusal surfaces of primary and permanent molars. The authors conducted a systematic search in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and other sources to identify randomized controlled trials reporting on the effect of sealants (available on the US market) when applied to the occlusal surfaces of primary and permanent molars. The authors used the Grading of Recommendations Assessment, Development, and Evaluation approach to assess the quality of the evidence and to move from the evidence to the decisions.
Results. The guideline panel formulated 3 main recommendations. They concluded that sealants are effective in preventing and arresting pit-and-fissure occlusal carious lesions of primary and permanent molars in children and adolescents compared with the nonuse of sealants or use of fluoride varnishes. They also concluded that sealants could minimize the progression of noncavitated occlusal carious lesions (also referred to as initial lesions) that receive a sealant. Finally, based on the available limited evidence, the panel was unable to provide specific recommendations on the relative merits of 1 type of sealant material over the others.
Conclusions and Practical Implications. These recommendations are designed to inform practitioners during the clinical decision-making process in relation to the prevention of occlusal carious lesions in children and adolescents. Clinicians are encouraged to discuss the information in this guideline with patients or the parents of patients. The authors recommend that clinicians reorient their efforts toward increasing the use of sealants on the occlusal surfaces of primary and permanent molars in children and adolescents.
C1 [Wright, John T.] Univ North Carolina Chapel Hill, Pediat Dent, Chapel Hill, NC USA.
[Wright, John T.] Univ North Carolina Chapel Hill, Sch Dent, Dept Pediat Dent, Strateg Initiat, Chapel Hill, NC USA.
[Tampi, Malavika P.] Amer Dent Assoc, Inst Sci, Ctr Evidence Based Dent, 211 E Chicago Ave, Chicago, IL 60611 USA.
[Graham, Laurel] Amer Acad Pediat Dent, Chicago, IL USA.
[Estrich, Cameron] Amer Dent Assoc, Inst Sci, Sci Informat, 211 E Chicago Ave, Chicago, IL 60611 USA.
[Crall, James J.] Univ Calif Los Angeles, Sch Dent, Div Publ Hlth & Community Dent, Los Angeles, CA 90024 USA.
[Fontana, Margherita] Univ Michigan, Sch Dent, Dept Cariol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA.
[Novy, Brian B.] DentaQuest Inst, Practice Improvement, Westborough, MA USA.
[Dhar, Vineet] Univ Maryland, Sch Dent, Div Pediat Dent, Baltimore, MD 21201 USA.
[Donly, Kevin] Univ Texas Hlth Sci Ctr San Antonio, Sch Dent, Dept Dev Dent, San Antonio, TX 78229 USA.
[Hewlett, Edmond R.] Univ Calif Los Angeles, Sch Dent, Sect Restorat Dent, Los Angeles, CA 90024 USA.
[Quinonez, Rocio B.] Univ North Carolina Chapel Hill, Sch Dent, Dept Pediat Dent & Pediat, Chapel Hill, NC USA.
[Chaffin, Jeffrey] Delta Dent Iowa, Des Moines, IA USA.
[Chaffin, Jeffrey] AT Still Univ, Coll Grad Hlth Studies, Mesa, AZ USA.
[Crespin, Matt] Childrens Hosp Wisconsin, Childrens Hlth Alliance Wisconsin, Milwaukee, WI 53201 USA.
[Iafolla, Timothy] Natl Inst Dent & Craniofacial Res, Program Anal & Reports Branch, NIH, Bethesda, MD USA.
[Siegal, Mark D.] Amer Assoc Publ Hlth Dent, Springfield, IL USA.
[Carrasco-Labra, Alonso] Amer Dent Assoc, Ctr Evidence Based Dent, Chicago, IL USA.
[Carrasco-Labra, Alonso] Univ Chile, Evidence Based Dent Unit, Santiago, Chile.
[Carrasco-Labra, Alonso] Univ Chile, Dept Oral & Maxillofacial Surg, Fac Dent, Santiago, Chile.
[Carrasco-Labra, Alonso] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
RP Tampi, MP (reprint author), Amer Dent Assoc, Inst Sci, Ctr Evidence Based Dent, 211 E Chicago Ave, Chicago, IL 60611 USA.
EM tampim@ada.org
FU American Academy of Pediatric Dentistry
FX The American Dental Association Council on Scientific Affairs
commissioned this work and the American Academy of Pediatric Dentistry
partly funded this project.
NR 57
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD AUG
PY 2016
VL 24
IS 8
BP 672
EP +
DI 10.1016/j.adaj.2016.06.001
PG 23
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA DV2NM
UT WOS:000382757300016
ER
PT J
AU Friesen, MC
Lan, Q
Ge, C
Locke, SJ
Hosgood, D
Fritschi, L
Sadkowsky, T
Chen, YC
Wei, H
Xu, J
Lam, TH
Kwong, YL
Chen, KX
Xu, CG
Su, YC
Chiu, BCH
Ip, KMD
Purdue, MP
Bassig, BA
Rothman, N
Vermeulen, R
AF Friesen, Melissa C.
Lan, Qing
Ge, Calvin
Locke, Sarah J.
Hosgood, Dean
Fritschi, Lin
Sadkowsky, Troy
Chen, Yu-Cheng
Wei, Hu
Xu, Jun
Lam, Tai Hing
Kwong, Yok Lam
Chen, Kexin
Xu, Caigang
Su, Yu-Chieh
Chiu, Brian C. H.
Ip, Kai Ming Dennis
Purdue, Mark P.
Bassig, Bryan A.
Rothman, Nat
Vermeulen, Roel
TI Evaluation of Automatically Assigned Job-Specific Interview Modules
SO ANNALS OF OCCUPATIONAL HYGIENE
LA English
DT Article
DE case-control studies; epidemiologic studies; occupational exposure;
solvents
ID DIESEL EXHAUST EXPOSURE; OCCUPATIONAL-EXPOSURE; INFORMATION; AUSTRALIA;
CANCER
AB In community-based epidemiological studies, job- and industry-specific 'modules' are often used to systematically obtain details about the subject's work tasks. The module assignment is often made by the interviewer, who may have insufficient occupational hygiene knowledge to assign the correct module. We evaluated, in the context of a case-control study of lymphoid neoplasms in Asia ('AsiaLymph'), the performance of an algorithm that provided automatic, real-time module assignment during a computer-assisted personal interview.
AsiaLymph's occupational component began with a lifetime occupational history questionnaire with free-text responses and three solvent exposure screening questions. To assign each job to one of 23 study-specific modules, an algorithm automatically searched the free-text responses to the questions 'job title' and 'product made or services provided by employer' using a list of module-specific keywords, comprising over 5800 keywords in English, Traditional and Simplified Chinese. Hierarchical decision rules were used when the keyword match triggered multiple modules. If no keyword match was identified, a generic solvent module was assigned if the subject responded 'yes' to any of the three solvent screening questions. If these question responses were all 'no', a work location module was assigned, which redirected the subject to the farming, teaching, health professional, solvent, or industry solvent modules or ended the questions for that job, depending on the location response. We conducted a reliability assessment that compared the algorithm-assigned modules to consensus module assignments made by two industrial hygienists for a subset of 1251 (of 11409) jobs selected using a stratified random selection procedure using module-specific strata. Discordant assignments between the algorithm and consensus assignments (483 jobs) were qualitatively reviewed by the hygienists to evaluate the potential information lost from missed questions with using the algorithm-assigned module (none, low, medium, high).
The most frequently assigned modules were the work location (33%), solvent (20%), farming and food industry (19%), and dry cleaning and textile industry (6.4%) modules. In the reliability subset, the algorithm assignment had an exact match to the expert consensus-assigned module for 722 (57.7%) of the 1251 jobs. Overall, adjusted for the proportion of jobs in each stratum, we estimated that 86% of the algorithm-assigned modules would result in no information loss, 2% would have low information loss, and 12% would have medium to high information loss. Medium to high information loss occurred for < 10% of the jobs assigned the generic solvent module and for 21, 32, and 31% of the jobs assigned the work location module with location responses of 'someplace else', 'factory', and 'don't know', respectively. Other work location responses had a parts per thousand currency sign8% with medium to high information loss because of redirections to other modules. Medium to high information loss occurred more frequently when a job description matched with multiple keywords pointing to different modules (29-69%, depending on the triggered assignment rule).
These evaluations demonstrated that automatically assigned modules can reliably reproduce an expert's module assignment without the direct involvement of an industrial hygienist or interviewer. The feasibility of adapting this framework to other studies will be language- and exposure-specific.
C1 [Friesen, Melissa C.; Lan, Qing; Locke, Sarah J.; Chen, Yu-Cheng; Wei, Hu; Purdue, Mark P.; Bassig, Bryan A.; Rothman, Nat] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr, North Bethesda, MD 20980 USA.
[Ge, Calvin; Vermeulen, Roel] Univ Utrecht, Utrecht, Netherlands.
[Hosgood, Dean] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Fritschi, Lin] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia.
[Sadkowsky, Troy] Data Scientists Pty Ltd, Sunshine Coast, Qld, Australia.
[Chen, Yu-Cheng] Natl Hlth Res Inst, Environm Hlth Res Ctr, Zhunan, Taiwan.
[Xu, Jun; Lam, Tai Hing; Ip, Kai Ming Dennis] Univ Hong Kong, Sch Publ Hlth, Div Community Med & Publ Hlth Practice, Hong Kong, Hong Kong, Peoples R China.
[Kwong, Yok Lam] Queen Mary Hosp, Bone Marrow Transplant Unit, Hong Kong, Hong Kong, Peoples R China.
[Kwong, Yok Lam] Univ Hong Kong, Dept Med, Div Haematol Oncol & Bone Marrow Transplantat, Hong Kong, Hong Kong, Peoples R China.
[Chen, Kexin] Tianjin Med Univ, Canc Inst & Hosp, Dept Epidemiol & Biostat, Tianjin, Peoples R China.
[Xu, Caigang] Sichuan Univ, West China Hosp, Dept Hematol Hematol Res Lab & Pathol, Chengdu, Sichuan, Peoples R China.
[Su, Yu-Chieh] Buddhist Dalin Tzu Chi Gen Hosp, Dept Internal Med, Div Hematol Oncol, Chiayi, Taiwan.
[Su, Yu-Chieh] Tzu Chi Univ, Sch Med, Hualien, Taiwan.
[Chiu, Brian C. H.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA.
RP Friesen, MC (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr, North Bethesda, MD 20980 USA.
EM friesenmc@mail.nih.gov
RI Friesen, Melissa/A-5362-2009; Vermeulen, Roel/F-8037-2011
OI Vermeulen, Roel/0000-0003-4082-8163
FU Intramural Research Program of the Division of Cancer Epidemiology and
Genetics, NCI, NIH; National Health and Medical Research Council of
Australia
FX This project was funded by the Intramural Research Program of the
Division of Cancer Epidemiology and Genetics, NCI, NIH. LF is supported
by a fellowship from the National Health and Medical Research Council of
Australia. The authors report no conflicts of interest. The authors wish
to acknowledge the study interviewers, local industrial hygienists, all
other study staff, and the patients that participated in the study.
NR 12
TC 1
Z9 1
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0003-4878
EI 1475-3162
J9 ANN OCCUP HYG
JI Ann. Occup. Hyg.
PD AUG
PY 2016
VL 60
IS 7
BP 885
EP 899
DI 10.1093/annhyg/mew029
PG 15
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA DV8JE
UT WOS:000383182500009
PM 27250109
ER
PT J
AU Paik, JJ
Mammen, AL
Wigley, FM
Shah, AA
Hummers, LK
Polydefkis, M
AF Paik, Julie J.
Mammen, Andrew L.
Wigley, Fredrick M.
Shah, Ami A.
Hummers, Laura K.
Polydefkis, Michael
TI Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in
Scleroderma
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID SYSTEMIC-SCLEROSIS SCLERODERMA; CLASSIFICATION CRITERIA;
SJOGRENS-SYNDROME; NERVE-FIBERS; THRESHOLDS; DEGENERATION; INVOLVEMENT;
DYSFUNCTION; SPECTRUM; DISEASE
AB Objective. To determine the prevalence of peripheral neuropathy in scleroderma.
Methods. The prevalence of length-dependent peripheral neuropathy was rigorously assessed using signs and symptoms of neuropathy derived from the Total Neuropathy Score (TNS), and standardized nerve conduction study (NCS). All subjects underwent TNS and NCS. Those who were symptomatic or had NCS evidence of peripheral neuropathy underwent laboratory evaluation for secondary causes of neuropathy.
Results. A total of 130 subjects were approached for participation and 60 enrolled. Of the 60 subjects, 50 (83.3%) were female and 37 (61.7%) were of the limited cutaneous subtype. The mean +/- SD age was 55 +/- 11.1 years, and mean +/- SD disease duration was 15.3 +/- 10.1 years. A total of 17 of 60 (28%) had evidence of a peripheral neuropathy as defined by the presence of neuropathic symptoms on the TNS (12 of 60) and/or electrophysiologic evidence of neuropathy (5 subjects with neuropathic symptoms and 5 without neuropathic symptoms). Subjects with neuropathy were more likely to be male (60% versus 40%; P=0.02), African American (41% versus 4.6%; P=0.001), have diabetes mellitus (17.7% versus 0%; P=0.02), have limited cutaneous scleroderma (82.3% versus 53.5%; P=0.04), and have anti-U1 RNP antibodies (23.5% versus 0%; P=0.009) than those without neuropathy. A potential nonscleroderma etiology for the peripheral neuropathy such as diabetes mellitus was found in 82.3% (14 of 17) of subjects with neuropathy.
Conclusion. While symptoms or objective evidence of peripheral neuropathy are common among patients with scleroderma, the cause may often be attributed to comorbid nonscleroderma-related conditions.
C1 [Paik, Julie J.; Mammen, Andrew L.; Wigley, Fredrick M.; Shah, Ami A.; Hummers, Laura K.; Polydefkis, Michael] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Mammen, Andrew L.] NIAMSD, NIH, Bethesda, MD 20892 USA.
RP Paik, JJ (reprint author), 5200 Eastern Ave,MFL Ctr Tower,Suite 4500, Baltimore, MD 21224 USA.
EM jpaik1@jhmi.edu
FU Scleroderma Research Foundation; Arthritis Foundation Clinical to
Research Transition Award; National Institute of Arthritis and
Musculoskeletal and Skin Diseases/NIH; NIH [K23-AR-0-61439]; Donald B.
and Dorothy L. Stabler Foundation
FX Supported by the Scleroderma Research Foundation. Dr. Paik's work was
supported by an Arthritis Foundation Clinical to Research Transition
Award. Dr. Mammen's work was supported by the Intramural Research
Program of the National Institute of Arthritis and Musculoskeletal and
Skin Diseases/NIH. Dr. Shah's work was supported by the NIH (grant
K23-AR-0-61439). Dr. Hummers' work was supported by the Donald B. and
Dorothy L. Stabler Foundation.
NR 33
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD AUG
PY 2016
VL 68
IS 8
BP 1150
EP 1157
DI 10.1002/acr.22818
PG 8
WC Rheumatology
SC Rheumatology
GA DW2WG
UT WOS:000383501900012
PM 26663579
ER
PT J
AU Weiss, PF
Colbert, RA
AF Weiss, Pamela F.
Colbert, Robert A.
TI Are the Assessment of Spondyloarthritis international Society
classification criteria useful in juvenile spondyloarthritis? Comment on
the article by Weiss et al Reply
SO ARTHRITIS CARE & RESEARCH
LA English
DT Letter
ID IDIOPATHIC ARTHRITIS
C1 [Weiss, Pamela F.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Colbert, Robert A.] NIAMSD, NIH, Bethesda, MD 20892 USA.
RP Weiss, PF (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.; Weiss, PF (reprint author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
FU Intramural NIH HHS [ZIA AR041184-07]; NIAMS NIH HHS [K23 AR059749, R03
AR062665]
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD AUG
PY 2016
VL 68
IS 8
BP 1213
EP 1214
DI 10.1002/acr.22885
PG 3
WC Rheumatology
SC Rheumatology
GA DW2WG
UT WOS:000383501900024
PM 26991095
ER
PT J
AU Figueroa, JD
Pfeiffer, RM
Brinton, LA
Palakal, MM
Degnim, AC
Radisky, D
Hartmann, LC
Frost, MH
Mann, MLS
Papathomas, D
Gierach, GL
Hewitt, SM
Duggan, MA
Visscher, D
Sherman, ME
AF Figueroa, Jonine D.
Pfeiffer, Ruth M.
Brinton, Louise A.
Palakal, Maya M.
Degnim, Amy C.
Radisky, Derek
Hartmann, Lynn C.
Frost, Marlene H.
Mann, Melody L. Stallings
Papathomas, Daphne
Gierach, Gretchen L.
Hewitt, Stephen M.
Duggan, Maire A.
Visscher, Daniel
Sherman, Mark E.
TI Standardized measures of lobular involution and subsequent breast cancer
risk among women with benign breast disease: a nested case-control study
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Lobular involution; Breast cancer risk
ID FACTOR BINDING PROTEIN-3; GROWTH-FACTOR-I; UNIT INVOLUTION; MAMMOGRAPHIC
DENSITY; NURSES HEALTH; AGE; PROGRESSION; PREVENTION; ORIGIN
AB Lesser degrees of terminal duct-lobular unit (TDLU) involution predict higher breast cancer risk; however, standardized measures to quantitate levels of TDLU involution have only recently been developed. We assessed whether three standardized measures of TDLU involution, with high intra/inter pathologist reproducibility in normal breast tissue, predict subsequent breast cancer risk among women in the Mayo benign breast disease (BBD) cohort. We performed a masked evaluation of biopsies from 99 women with BBD who subsequently developed breast cancer (cases) after a median of 16.9 years and 145 age-matched controls. We assessed three metrics inversely related to TDLU involution: TDLU count/mm(2), median TDLU span (microns, which approximates acini content), and median category of acini counts/TDLU (0-10; 11-20; 21-30; 31-50; > 50). Associations with subsequent breast cancer risk for quartiles (or categories of acini counts) of each of these measures were assessed with multivariable conditional logistic regression to estimate odds ratios (ORs) and 95 % confidence intervals (CI). In multivariable models, women in the highest quartile compared to the lowest quartiles of TDLU counts and TDLU span measures were significantly associated with subsequent breast cancer diagnoses; TDLU counts quartile4 versus quartile1, OR = 2.44, 95 %CI 0.96-6.19, p-trend = 0.02; and TDLU spans, quartile4 versus quartile1, OR = 2.83, 95 %CI = 1.13-7.06, p-trend = 0.03. Significant associations with categorical measures of acini counts/TDLU were also observed: compared to women with median category of < 10 acini/TDLU, women with > 25 acini counts/TDLU were at significantly higher risk, OR = 3.40, 95 %CI 1.03-11.17, p-trend = 0.032. Women with TDLU spans and TDLU count measures above the median were at further increased risk, OR = 3.75 (95 %CI 1.40-10.00, p-trend = 0.008), compared with women below the median for both of these metrics. Similar results were observed for combinatorial metrics of TDLU acini counts/TDLU, and TDLU count. Standardized quantitative measures of TDLU counts and acini counts approximated by TDLU span measures or visually assessed in categories are independently associated with breast cancer risk. Visual assessment of TDLU numbers and acini content, which are highly reproducible between pathologists, could help identify women at high risk for subsequent breast cancer among the million women diagnosed annually with BBD in the US.
C1 [Figueroa, Jonine D.; Pfeiffer, Ruth M.; Brinton, Louise A.; Palakal, Maya M.; Papathomas, Daphne; Gierach, Gretchen L.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Figueroa, Jonine D.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
[Degnim, Amy C.; Radisky, Derek; Hartmann, Lynn C.; Frost, Marlene H.; Mann, Melody L. Stallings; Visscher, Daniel] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Hewitt, Stephen M.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Duggan, Maire A.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada.
[Sherman, Mark E.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
RP Figueroa, JD (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.; Figueroa, JD (reprint author), Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
EM jonine.figueroa@ed.ac.uk; Pfeiffer@mail.nih.gov; brintonl@mail.nih.gov;
palakalm@mail.nih.gov; Degnim.Amy@mayo.edu; Radisky.Derek@mayo.edu;
hartmann.lynn@mayo.edu; frost.marlene@mayo.edu;
StallingsMann.Melody@mayo.edu; dcp448@gmail.com; gierachg@mail.nih.gov;
hewitts@mail.nih.gov; duggan@ucalgary.ca; visscher.daniel@mayo.edu;
shermanm@mail.nih.gov
RI Gierach, Gretchen/E-1817-2016
OI Gierach, Gretchen/0000-0002-0165-5522
FU Mayo Clinic Breast Specialized Programs of Research Excellence Grant NCI
[CA116201]; Jimmy V Foundation; Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research and Division of
Cancer Epidemiology and Genetics; [ROI CA132879]
FX This research was supported by Mayo Clinic Breast Specialized Programs
of Research Excellence Grant NCI CA116201 (D.W.V., D.C.R., and L.C.H.),
the Jimmy V Foundation (D.C.R. and L.C.H.), and ROI CA132879 (MHF). This
research was supported in part by the Intramural Research Program of the
NIH, National Cancer Institute, Center for Cancer Research and Division
of Cancer Epidemiology and Genetics.
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2016
VL 159
IS 1
BP 163
EP 172
DI 10.1007/s10549-016-3908-7
PG 10
WC Oncology
SC Oncology
GA DV3UA
UT WOS:000382847800015
PM 27488681
ER
PT J
AU Qian, DC
Han, YH
Byun, JY
Shin, HR
Hung, RJ
McLaughlin, JR
Landi, MT
Seminara, D
Amos, CI
AF Qian, David C.
Han, Younghun
Byun, Jinyoung
Shin, Hae Ri
Hung, Rayjean J.
McLaughlin, John R.
Landi, Maria Teresa
Seminara, Daniela
Amos, Christopher I.
TI A Novel Pathway-Based Approach Improves Lung Cancer Risk Prediction
Using Germline Genetic Variations
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID SUSCEPTIBILITY LOCUS; INDIVIDUAL RISK; COMPLEX TRAITS; VARIANTS; MODEL;
SNPS; CRITERIA; SMOKERS; 15Q25.1; SMOKING
AB Background: Although genome-wide association studies (GWAS) have identified many genetic variants that are strongly associated with lung cancer, these variants have low penetrance and serve as poor predictors of lung cancer in individuals. We sought to increase the predictive value of germline variants by considering their cumulative effects in the context of biologic pathways.
Methods: For individuals in the Environment and Genetics in Lung Cancer Etiology study (1,815 cases/1,971 controls), we computed pathway-level susceptibility effects as the sum of relevant SNP variant alleles weighted by their log-additive effects from a separate lung cancer GWAS meta-analysis (7,766 cases/37,482 controls). Logistic regression models based on age, sex, smoking, genetic variants, and principal components of pathway effects and pathway-smoking interactions were trained and optimized in cross-validation and further tested on an independent dataset (556 cases/830 controls). We assessed prediction performance using area under the receiver operating characteristic curve (AUC).
Results: Compared with typical binomial prediction models that have epidemiologic predictors (AUC = 0.607) in addition to top GWAS variants (AUC = 0.617), our pathway-based smoking-interactive multinomial model significantly improved prediction performance in external validation (AUC = 0.656, P < 0.0001).
Conclusions: Our biologically informed approach demonstrated a larger increase in AUC over nongenetic counterpart models relative to previous approaches that incorporate variants.
Impact: This model is the first of its kind to evaluate lung cancer prediction using subtype-stratified genetic effects organized into pathways and interacted with smoking. We propose pathway-exposure interactions as a potentially powerful new contributor to risk inference. (C) 2016 AACR.
C1 [Qian, David C.; Han, Younghun; Byun, Jinyoung; Shin, Hae Ri; Amos, Christopher I.] Dartmouth Geisel Sch Med, Dept Biomed Data Sci, Lebanon, NH USA.
[Hung, Rayjean J.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
[McLaughlin, John R.] Univ Toronto, Dalla Lana Sch Publ Hlth Univ, Toronto, ON, Canada.
[Landi, Maria Teresa; Seminara, Daniela] NCI, NIH, Bethesda, MD 20892 USA.
RP Amos, CI (reprint author), Dartmouth Geisel Sch Med, 1 Med Ctr Dr,Williamson Translat Res Bldg, Lebanon, NH 03756 USA.
EM Christopher.I.Amos@dartmouth.edu
FU NIH [P30CA023108, U19CA148127, R01CA149462, P20GM103534]; National
Science Foundation Graduate Fellowship [K12]; Kimball Union Academy
[DGE-0947790]
FX This research was supported by the NIH (P30CA023108, U19CA148127,
R01CA149462, and P20GM103534; to C.I. Amos) and the National Science
Foundation Graduate-K12 Fellowship in collaboration with Kimball Union
Academy (DGE-0947790; to D.C. Qian).
NR 51
TC 1
Z9 1
U1 3
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD AUG
PY 2016
VL 25
IS 8
BP 1208
EP 1215
DI 10.1158/1055-9965.EPI-15-1318
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA DV6JV
UT WOS:000383042300003
PM 27222311
ER
PT J
AU Prickett, TD
Crystal, JS
Cohen, CJ
Pasetto, A
Parkhurst, MR
Gartner, JJ
Yao, X
Wang, R
Gros, A
Li, YF
El-Gamil, M
Trebska-McGowan, K
Rosenberg, SA
Robbins, PF
AF Prickett, Todd D.
Crystal, Jessica S.
Cohen, Cyrille J.
Pasetto, Anna
Parkhurst, Maria R.
Gartner, Jared J.
Yao, Xin
Wang, Rong
Gros, Alena
Li, Yong F.
El-Gamil, Mona
Trebska-McGowan, Kasia
Rosenberg, Steven A.
Robbins, Paul F.
TI Durable Complete Response from Metastatic Melanoma after Transfer of
Autologous T Cells Recognizing 10 Mutated Tumor Antigens
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID TRANSFER THERAPY; CANCER REGRESSION; CTLA-4 BLOCKADE; CUTTING EDGE;
GENE-THERAPY; LUNG-CANCER; LYMPHOCYTES; IMMUNOTHERAPY; PATIENT;
PERSISTENCE
AB Immunotherapy treatment of patients with metastatic cancer has assumed a prominent role in the clinic. Durable complete response rates of 20% to 25% are achieved in patients with metastatic melanoma following adoptive cell transfer of T cells derived from metastatic lesions, responses that appear in some patients to be mediated by T cells that predominantly recognize mutated antigens. Here, we provide a detailed analysis of the reactivity of T cells administered to a patient with metastatic melanoma who exhibited a complete response for over 3 years after treatment. Over 4,000 nonsynonymous somatic mutations were identified by whole-exome sequence analysis of the patient's autologous normal and tumor cell DNA. Autologous B cells transfected with 720 mutated minigenes corresponding to the most highly expressed tumor cell transcripts were then analyzed for their ability to stimulate the administered T cells. Autologous tumor-infiltrating lymphocytes recognized 10 distinct mutated gene products, but not the corresponding wild-type products, each of which was recognized in the context of one of three different MHC class I restriction elements expressed by the patient. Detailed clonal analysis revealed that 9 of the top 20 most prevalent clones present in the infused T cells, comprising approximately 24% of the total cells, recognized mutated antigens. Thus, we have identified and enriched mutation-reactive T cells and suggest that such analyses may lead to the development of more effective therapies for the treatment of patients with metastatic cancer. (C) 2016 AACR.
C1 [Prickett, Todd D.; Crystal, Jessica S.; Pasetto, Anna; Parkhurst, Maria R.; Gartner, Jared J.; Yao, Xin; Gros, Alena; Li, Yong F.; El-Gamil, Mona; Trebska-McGowan, Kasia; Rosenberg, Steven A.; Robbins, Paul F.] NCI, NIH, Surg Branch, Bethesda, MD 20892 USA.
[Cohen, Cyrille J.] Bar Ilan Univ, Lab Tumor Immunol & Immunotherapy, Ramat Gan, Israel.
[Wang, Rong] US FDA, Bethesda, MD 20014 USA.
RP Prickett, TD (reprint author), NCI, Ctr Canc Res, 10 Ctr Dr,Bldg 10,Room 3W-3864, Bethesda, MD 20892 USA.
EM prickettt@mail.nih.gov
OI Gros, Alena/0000-0002-1207-1880
FU Intramural NIH HHS [Z01 BC010984-01, Z99 CA999999]
NR 38
TC 4
Z9 4
U1 4
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD AUG
PY 2016
VL 4
IS 8
BP 669
EP 678
DI 10.1158/2326-6066.CIR-15-0215
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA DV6NE
UT WOS:000383052800005
PM 27312342
ER
PT J
AU Ambudkar, IS
Muallem, S
AF Ambudkar, Indu S.
Muallem, Shmuel
TI ROS and Ca2+-Partners in sickness and in health
SO CELL CALCIUM
LA English
DT Editorial Material
ID ENDOPLASMIC-RETICULUM; CALCIUM; MITOCHONDRIA; CHANNELS; MECHANISMS;
MICRODOMAINS; DISEASES; SENSORS; DEATH
C1 [Ambudkar, Indu S.; Muallem, Shmuel] Natl Inst Dent & Craniofacial Res, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD 20892 USA.
RP Ambudkar, IS (reprint author), Natl Inst Dent & Craniofacial Res, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD 20892 USA.
EM iambudkar@dir.nidcr.nih.gov
NR 47
TC 0
Z9 0
U1 5
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
EI 1532-1991
J9 CELL CALCIUM
JI Cell Calcium
PD AUG
PY 2016
VL 60
IS 2
SI SI
BP 51
EP 54
DI 10.1016/j.ceca.2016.06.003
PG 4
WC Cell Biology
SC Cell Biology
GA DV5YZ
UT WOS:000383007900001
PM 27474448
ER
PT J
AU Kiselyov, K
Muallem, S
AF Kiselyov, Kirill
Muallem, Shmuel
TI ROS and intracellular ion channels
SO CELL CALCIUM
LA English
DT Review
DE Reactive oxygen species; Oxidative stress; Calcium; Transition metals;
Ion channels; Endoplasmic reticulum; Lysosomes
ID MUCOLIPIDOSIS TYPE-IV; TRAUMATIC BRAIN-INJURY; INOSITOL
1,4,5-TRISPHOSPHATE RECEPTOR; DIVALENT METAL TRANSPORTER-1; INTESTINAL
EPITHELIAL-CELLS; ATPASE ATP7A GENE; OXIDATIVE STRESS;
MOLECULAR-MECHANISMS; RYANODINE RECEPTORS; ENDOTHELIAL-CELLS
AB Oxidative stress is a well-known driver of numerous pathological processes involving protein and lipid peroxidation and DNA damage. The resulting increase of pro-apoptotic pressure drives tissue damage in a host of conditions, including ischemic stroke and reperfusion injury, diabetes, death in acute pancreatitis and neurodegenerative diseases. Somewhat less frequently discussed, but arguably as important, is the signaling function of oxidative stress stemming from the ability of oxidative stress to modulate ion channel activity. The evidence for the modulation of the intracellular ion channels and transporters by oxidative stress is constantly emerging and such evidence suggests new regulatory and pathological circuits that can be explored towards new treatments for diseases in which oxidative stress is an issue. In this review we summarize the current knowledge on the effects of oxidative stress on the intracellular ion channels and transporters and their role in cell function. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Kiselyov, Kirill; Muallem, Shmuel] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
[Kiselyov, Kirill; Muallem, Shmuel] NIDCR, Epithelial Signaling & Transport Sect, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD 20892 USA.
RP Kiselyov, K (reprint author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.; Muallem, S (reprint author), NIDCR, Epithelial Signaling & Transport Sect, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD 20892 USA.
EM kiselyov@pitt.edu; shmuel.muallem@nih.gov
FU NICHD NIH HHS [R01 HD058577]; NIEHS NIH HHS [R21 ES016782]
NR 137
TC 5
Z9 5
U1 20
U2 22
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4160
EI 1532-1991
J9 CELL CALCIUM
JI Cell Calcium
PD AUG
PY 2016
VL 60
IS 2
SI SI
BP 108
EP 114
DI 10.1016/j.ceca.2016.03.004
PG 7
WC Cell Biology
SC Cell Biology
GA DV5YZ
UT WOS:000383007900007
PM 26995054
ER
PT J
AU Eitan, E
Braverman, C
Tichon, A
Gitler, D
Hutchison, ER
Mattson, MP
Priel, E
AF Eitan, Erez
Braverman, Carmel
Tichon, Ailone
Gitler, Daniel
Hutchison, Emmette R.
Mattson, Mark P.
Priel, Esther
TI Excitotoxic and Radiation Stress Increase TERT Levels in the
Mitochondria and Cytosol of Cerebellar Purkinje Neurons
SO CEREBELLUM
LA English
DT Article
DE Telomerase; TERT; Cerebellum; Purkinje neurons; Excitotoxicity
ID TELOMERASE REVERSE-TRANSCRIPTASE; DNA-DAMAGE RESPONSES; CATALYTIC
SUBUNIT; TOPOISOMERASE-I; BRAIN-INJURY; CELLS; EXPRESSION; GLUTAMATE;
SURVIVAL; MICE
AB Telomerase reverse transcriptase (TERT) is the catalytic subunit of telomerase, an enzyme that elongates telomeres at the ends of chromosomes during DNA replication. Recently, it was shown that TERT has additional roles in cell survival, mitochondrial function, DNA repair, and Wnt signaling, all of which are unrelated to telomeres. Here, we demonstrate that TERT is enriched in Purkinje neurons, but not in the granule cells of the adult mouse cerebellum. TERT immunoreactivity in Purkinje neurons is present in the nucleus, mitochondria, and cytoplasm. Furthermore, TERT co-localizes with mitochondrial markers, and immunoblot analysis of protein extracts from isolated mitochondria and synaptosomes confirmed TERT localization in mitochondria. TERT expression in Purkinje neurons increased significantly in response to two stressors: a sublethal dose of X-ray radiation and exposure to a high glutamate concentration. While X-ray radiation increased TERT levels in the nucleus, glutamate exposure elevated TERT levels in mitochondria. Our findings suggest that in mature Purkinje neurons, TERT is present both in the nucleus and in mitochondria, where it may participate in adaptive responses of the neurons to excitotoxic and radiation stress.
C1 [Eitan, Erez; Braverman, Carmel; Tichon, Ailone; Priel, Esther] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol Immunol & Genet, IL-84105 Beer Sheva, Israel.
[Gitler, Daniel] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Fac Hlth Sci, Dept Physiol & Cell Biol, IL-84105 Beer Sheva, Israel.
[Eitan, Erez; Hutchison, Emmette R.; Mattson, Mark P.] NIA, Lab Neurosci, Intramural Res Program, Baltimore, MD 21224 USA.
RP Eitan, E (reprint author), Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol Immunol & Genet, IL-84105 Beer Sheva, Israel.; Eitan, E (reprint author), NIA, Lab Neurosci, Intramural Res Program, Baltimore, MD 21224 USA.
EM erez.eitan@nih.gov
OI Gitler, Daniel/0000-0001-9544-3610
FU Intramural NIH HHS [Z99 AG999999]
NR 44
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1473-4222
EI 1473-4230
J9 CEREBELLUM
JI Cerebellum
PD AUG
PY 2016
VL 15
IS 4
BP 509
EP 517
DI 10.1007/s12311-015-0720-6
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA DV4XG
UT WOS:000382928400012
PM 26374457
ER
PT J
AU Habibi, M
Samiei, S
Venkatesh, BA
Opdahl, A
Helle-Valle, TM
Zareian, M
Almeida, ALC
Choi, EY
Wu, CL
Alonso, A
Heckbert, SR
Bluemke, DA
Lima, JAC
AF Habibi, Mohammadali
Samiei, Sanaz
Venkatesh, Bharath Ambale
Opdahl, Anders
Helle-Valle, Thomas M.
Zareian, Mytra
Almeida, Andre L. C.
Choi, Eui-Young
Wu, Colin
Alonso, Alvaro
Heckbert, Susan R.
Bluemke, David A.
Lima, Joao A. C.
TI Cardiac Magnetic Resonance-Measured Left Atrial Volume and Function and
Incident Atrial Fibrillation Results From MESA (Multi-Ethnic Study of
Atherosclerosis)
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE atrial fibrillation; atrial function, left; cardiovascular diseases;
heart atria; magnetic resonance imaging
ID DELAYED-ENHANCEMENT MRI; HEART-FAILURE; CATHETER ABLATION; RISK;
ASSOCIATION; FIBROSIS; STROKE; STRAIN; AGE; ECHOCARDIOGRAPHY
AB Background-Early detection of structural changes in left atrium (LA) before atrial fibrillation (AF) development could be helpful in identification of those at higher risk for AF. Using cardiac magnetic resonance imaging, we examined the association of LA volume and function, and incident AF in a multiethnic population free of clinical cardiovascular diseases.
Methods and Results-In a case-cohort study embedded in MESA (Multi-Ethnic Study of Atherosclerosis), baseline LA size and function assessed by cardiac magnetic resonance feature-tracking were compared between 197 participants with incident AF and 322 participants randomly selected from the whole MESA cohort. Participants were followed up for 8 years. Incident AF cases had a larger LA volume and decreased passive, active, and total LA emptying fractions and peak global LA longitudinal strain (peak LA strain) at baseline. In multivariable analysis, elevated LA maximum volume index (hazard ratio, 1.38 per SD; 95% confidence interval, 1.01-1.89) and decreased peak LA strain (hazard ratio, 0.68 per SD; 95% confidence interval, 0.48-0.96), and passive and total LA emptying fractions (hazard ratio for passive LA emptying fractions, 0.55 per SD; 95% confidence interval, 0.40-0.75 and hazard ratio for active LA emptying fractions, 0.70 per SD; 95% confidence interval, 0.52-0.95), but not active LA emptying fraction, were associated with incident AF.
Conclusions-Elevated LA volumes and decreased passive and total LA emptying fractions were independently associated with incident AF in an asymptomatic multiethnic population. Including LA functional variables along with other risk factors of AF may help to better risk stratify individuals at risk of AF development.
C1 [Habibi, Mohammadali] Montefiore Med Ctr, Albert Einstein Coll Med, Div Cardiol, Bronx, NY 10467 USA.
[Habibi, Mohammadali; Venkatesh, Bharath Ambale; Almeida, Andre L. C.; Choi, Eui-Young; Lima, Joao A. C.] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA.
[Samiei, Sanaz; Zareian, Mytra] Erasmus MC, Dept Cardiol, Rotterdam, Netherlands.
[Opdahl, Anders; Helle-Valle, Thomas M.] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway.
[Almeida, Andre L. C.] Univ Estadual Feira de Santana, Salvador, BA, Brazil.
[Choi, Eui-Young] Yonsei Univ, Coll Med, Seoul, South Korea.
[Wu, Colin] NHLBI, Off Biostat, Bldg 10, Bethesda, MD 20892 USA.
[Alonso, Alvaro] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA.
[Bluemke, David A.] NIH, Dept Radiol & Imaging Sci, Bldg 10, Bethesda, MD 20892 USA.
RP Lima, JAC (reprint author), Johns Hopkins Univ Hosp, Blalock 524D,600 N Wolfe St, Baltimore, MD 21287 USA.
EM jlima@jhmi.edu
RI Alonso, Alvaro/A-4917-2010
OI Alonso, Alvaro/0000-0002-2225-8323
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160,
N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165,
N01-HC-95166, N01-HC-95168]; National Center for Research Resources,
National Institutes of Health [UL1-RR-024156, UL1-RR-025005]
FX This research was supported by contracts N01-HC-95159 through
N01-HC-95166, and N01-HC-95168 from the National Heart, Lung, and Blood
Institute; and UL1-RR-024156 and UL1-RR-025005 from National Center for
Research Resources, National Institutes of Health.
NR 40
TC 3
Z9 3
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD AUG
PY 2016
VL 9
IS 8
AR e004299
DI 10.1161/CIRCIMAGING.115.004299
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DU5FF
UT WOS:000382236900002
ER
PT J
AU Jordan, JH
Vasu, S
Morgan, TM
D'Agostino, RB
Melendez, GC
Hamilton, CA
Arai, AE
Liu, ST
Liu, CY
Lima, JAC
Bluemke, DA
Burke, GL
Hundley, WG
AF Jordan, Jennifer H.
Vasu, Sujethra
Morgan, Timothy M.
D'Agostino, Ralph B., Jr.
Melendez, Giselle C.
Hamilton, Craig A.
Arai, Andrew E.
Liu, Songtao
Liu, Chia-Ying
Lima, Joao A. C.
Bluemke, David A.
Burke, Gregory L.
Hundley, W. Gregory
TI Anthracycline-Associated T1 Mapping Characteristics Are Elevated
Independent of the Presence of Cardiovascular Comorbidities in Cancer
Survivors
SO CIRCULATION-CARDIOVASCULAR IMAGING
LA English
DT Article
DE cardiotoxicity; cardiovascular magnetic resonance imaging; extracellular
volume; myocardial fibrosis; T1 mapping
ID MAGNETIC-RESONANCE; HEART-FAILURE; EXTRACELLULAR VOLUME; MYOCARDIAL
FIBROSIS; EJECTION FRACTION; CHILDHOOD-CANCER; ATHEROSCLEROSIS;
CARDIOMYOPATHY; CHEMOTHERAPY; THERAPY
AB Background-Cardiovascular magnetic resonance T1 mapping characteristics are elevated in adult cancer survivors; however, it remains unknown whether these elevations are related to age or presence of coincident cardiovascular comorbidities.
Methods and Results-We performed blinded cardiovascular magnetic resonance analyses of left ventricular T1 and extracellular volume (ECV) fraction in 327 individuals (65% women, aged 64 +/- 12 years). Thirty-seven individuals had breast cancer or a hematologic malignancy but had not yet initiated their treatment, and 54 cancer survivors who received either anthracycline-based (n=37) or nonanthracycline-based (n=17) chemotherapy 2.8 +/- 1.3 years earlier were compared with 236 cancer-free participants. Multivariable analyses were performed to determine the association between T1/ECV measures and variables associated with myocardial fibrosis. Age-adjusted native T1 was elevated pre-(1058 +/- 7 ms) and post-(1040 +/- 7 ms) receipt of anthracycline chemotherapy versus comparators (965 +/- 3 ms; P<0.0001 for both). Age-adjusted ECV, a marker of myocardial fibrosis, was elevated in anthracycline-treated cancer participants (30.4 +/- 0.7%) compared with either pretreatment cancer (27.8V0.7%; P<0.01) or cancer-free comparators (26.9 +/- 0.2%; P<0.0001). T1 and ECV of nonanthracycline survivors were no different than pretreatment survivors (P=0.17 and P=0.16, respectively). Native T1 and ECV remained elevated in cancer survivors after accounting for demographics (including age), myocardial fibrosis risk factors, and left ventricular ejection fraction or myocardial mass index (P<0.0001 for all).
Conclusions-Three years after anthracycline-based chemotherapy, elevations in myocardial T1 and ECV occur independent of underlying cancer or cardiovascular comorbidities, suggesting that imaging biomarkers of interstitial fibrosis in cancer survivors are related to prior receipt of a potentially cardiotoxic cancer treatment regimen.
C1 [Jordan, Jennifer H.; Vasu, Sujethra; Melendez, Giselle C.; Hundley, W. Gregory] Wake Forest Sch Med, Dept Internal Med, Sect Cardiovasc Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Morgan, Timothy M.; D'Agostino, Ralph B., Jr.; Burke, Gregory L.] Wake Forest Sch Med, Dept Publ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Melendez, Giselle C.] Wake Forest Sch Med, Dept Pathol, Comparat Med Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Hamilton, Craig A.] Wake Forest Sch Med, Dept Biomed Engn, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Hundley, W. Gregory] Wake Forest Sch Med, Dept Radiol Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Arai, Andrew E.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Liu, Songtao] NIH, Radiol & Imaging Sci, Bldg 10, Bethesda, MD 20892 USA.
[Liu, Chia-Ying; Lima, Joao A. C.; Bluemke, David A.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA.
RP Hundley, WG (reprint author), Wake Forest Sch Med, Dept Internal Med, Sect Cardiovasc Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM ghundley@wakehealth.edu
RI Dagostino Jr, Ralph/C-4060-2017;
OI Dagostino Jr, Ralph/0000-0002-3550-8395; Bluemke,
David/0000-0002-8323-8086
FU National Heart, Lung, and Blood Institute [N01-HC-95165, N01-HC-95168];
NCRR [UL1-TR-000040, UL1-TR-001079]; National Institutes of Health (NIH)
[R33CA12196, R01HL118740, R01CA167821, P30CA012197]; Susan G. Komen
Foundation [BCTR07007769]; NIH [UG1CA189824]
FX This research was supported by contracts N01-HC-95165 and N01-HC-95168
from the National Heart, Lung, and Blood Institute and by grants
UL1-TR-000040 and UL1-TR-001079 from NCRR. Additionally, this work was
supported in part by National Institutes of Health (NIH) grants
R33CA12196, R01HL118740, R01CA167821, and P30CA012197 and the Susan G.
Komen Foundation (BCTR07007769). The Wake Forest NCI Community Oncology
Research Program (NCORP) is supported in part by NIH grant UG1CA189824.
NR 35
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-9651
EI 1942-0080
J9 CIRC-CARDIOVASC IMAG
JI Circ.-Cardiovasc. Imaging
PD AUG
PY 2016
VL 9
IS 8
AR e004325
DI 10.1161/CIRCIMAGING.115.004325
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA DU5FF
UT WOS:000382236900003
ER
PT J
AU Lienhardt, C
Kraigsley, AM
Sizemore, CF
AF Lienhardt, Christian
Kraigsley, Alison M.
Sizemore, Christine F.
TI Driving the Way to Tuberculosis Elimination: The Essential Role of
Fundamental Research
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE tuberculosis; elimination; biomedical; research; global health
ID TB DRUG DEVELOPMENT; MYCOBACTERIUM-TUBERCULOSIS; INFECTIOUS-DISEASES;
LATENT TUBERCULOSIS; RESISTANCE; MOXIFLOXACIN; REGIMENS; VACCINES;
MODELS; KEY
AB Tuberculosis has impacted human health for millennia. The World Health Organization estimated that, in 2014, 9.6 million people developed tuberculosis and 1.5 million people died from the disease. In May 2014, the World Health Assembly endorsed the new "End TB Strategy" that presents a pathway to tuberculosis elimination. The strategy outlines 3 areas of emphasis, one of which is intensified research and innovation. In this article we highlight the essential role for fundamental tuberculosis research in the future of tuberculosis diagnostics, treatment, and prevention. To maximize the impact of fundamental research, we must foster collaboration among all stakeholders engaged in tuberculosis research and control to facilitate open dialogue to assure that critical gaps in outcome-oriented science are identified and addressed. We present here a framework for future discussions among scientists, physicians, research and development specialists, and public health managers for the reinforcement of national and international strategies toward tuberculosis elimination.
C1 [Lienhardt, Christian] World Hlth Org, Global TB Programme, Geneva, Switzerland.
[Kraigsley, Alison M.] Amer Assoc Advancement Sci, Washington, DC USA.
[Kraigsley, Alison M.; Sizemore, Christine F.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Lienhardt, C (reprint author), World Hlth Org, Res TB Eliminat, Global TB Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM lienhardtc@who.int
NR 46
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 370
EP 375
DI 10.1093/cid/ciw250
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900012
PM 27270671
ER
PT J
AU Wong, KK
Davey, RT
Hewlett, AL
Kraft, CS
Mehta, AK
Mulligan, MJ
Beck, A
Dorman, W
Kratochvil, CJ
Lai, LL
Palmore, TN
Rogers, S
Smith, P
Suffredini, AF
Wolcott, M
Stroher, U
Uyeki, TM
AF Wong, Karen K.
Davey, Richard T., Jr.
Hewlett, Angela L.
Kraft, Colleen S.
Mehta, Aneesh K.
Mulligan, Mark J.
Beck, Allison
Dorman, William
Kratochvil, Christopher J.
Lai, Lilin
Palmore, Tara N.
Rogers, Susan
Smith, PhilipW.
Suffredini, Anthony F.
Wolcott, Mark
Stroher, Ute
Uyeki, Timothy M.
TI Use of Postexposure Prophylaxis After Occupational Exposure to Zaire
ebolavirus
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Ebola virus; postexposure prophylaxis; vesicular stomatitis virus;
TKM-Ebola
ID VIRUS DISEASE; UNITED-STATES; VACCINATION; MANAGEMENT
AB From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease.
C1 [Wong, Karen K.; Stroher, Ute; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Kraft, Colleen S.; Mehta, Aneesh K.; Mulligan, Mark J.; Beck, Allison; Lai, Lilin; Rogers, Susan] Emory Univ, Atlanta, GA 30322 USA.
[Davey, Richard T., Jr.; Palmore, Tara N.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
[Suffredini, Anthony F.] NIH, Crit Care Med Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
[Dorman, William; Wolcott, Mark] US Army, Med Res Inst Infect Dis, Frederick, MD USA.
[Hewlett, Angela L.; Kratochvil, Christopher J.; Smith, PhilipW.] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Wong, KK (reprint author), 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM kwong@cdc.gov
FU CDC; National Center for Advancing Translational Sciences of the NIH
[UL1TR000454]; NIAID
FX This work was supported by the CDC. The care of patients at the Emory
Serious Communicable Diseases Unit was supported in part by the National
Center for Advancing Translational Sciences of the NIH (award
UL1TR000454). The care of patients at the NIH Clinical Center was funded
by the NIAID.
NR 15
TC 2
Z9 2
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 376
EP 379
DI 10.1093/cid/ciw256
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900013
PM 27118786
ER
PT J
AU Jackson, BR
Tarr, C
Strain, E
Jackson, KA
Conrad, A
Carleton, H
Katz, LS
Stroika, S
Gould, LH
Mody, RK
Silk, BJ
Beal, J
Chen, Y
Timme, R
Doyle, M
Fields, A
Wise, M
Tillman, G
Defibaugh-Chavez, S
Kucerova, Z
Sabol, A
Roache, K
Trees, E
Simmons, M
Wasilenko, J
Kubota, K
Pouseele, H
Klimke, W
Besser, J
Brown, E
Allard, M
Gerner-Smidt, P
AF Jackson, Brendan R.
Tarr, Cheryl
Strain, Errol
Jackson, Kelly A.
Conrad, Amanda
Carleton, Heather
Katz, Lee S.
Stroika, Steven
Gould, L. Hannah
Mody, Rajal K.
Silk, Benjamin J.
Beal, Jennifer
Chen, Yi
Timme, Ruth
Doyle, Matthew
Fields, Angela
Wise, Matthew
Tillman, Glenn
Defibaugh-Chavez, Stephanie
Kucerova, Zuzana
Sabol, Ashley
Roache, Katie
Trees, Eija
Simmons, Mustafa
Wasilenko, Jamie
Kubota, Kristy
Pouseele, Hannes
Klimke, William
Besser, John
Brown, Eric
Allard, Marc
Gerner-Smidt, Peter
TI Implementation of Nationwide Real-time Whole-genome Sequencing to
Enhance Listeriosis Outbreak Detection and Investigation
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE Listeria monocytogenes; DNA sequencing; outbreaks; foodborne diseases
ID UNITED-STATES; FOODBORNE LISTERIOSIS; MONOCYTOGENES; SURVEILLANCE;
PATHOGENS; STRAINS; CLONES; FOOD
AB Listeria monocytogenes (Lm) causes severe foodborne illness (listeriosis). Previous molecular subtyping methods, such as pulsed-field gel electrophoresis (PFGE), were critical in detecting outbreaks that led to food safety improvements and declining incidence, but PFGE provides limited genetic resolution. A multiagency collaboration began performing real-time, whole-genome sequencing (WGS) on all US Lm isolates from patients, food, and the environment in September 2013, posting sequencing data into a public repository. Compared with the year before the project began, WGS, combined with epidemiologic and product trace-back data, detected more listeriosis clusters and solved more outbreaks (2 outbreaks in pre-WGS year, 5 in WGS year 1, and 9 in year 2). Whole-genome multilocus sequence typing and single nucleotide polymorphism analyses provided equivalent phylogenetic relationships relevant to investigations; results were most useful when interpreted in context of epidemiological data. WGS has transformed listeriosis outbreak surveillance and is being implemented for other foodborne pathogens.
C1 [Jackson, Brendan R.; Tarr, Cheryl; Jackson, Kelly A.; Conrad, Amanda; Carleton, Heather; Katz, Lee S.; Stroika, Steven; Gould, L. Hannah; Mody, Rajal K.; Silk, Benjamin J.; Wise, Matthew; Kucerova, Zuzana; Sabol, Ashley; Roache, Katie; Trees, Eija; Besser, John; Gerner-Smidt, Peter] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
[Strain, Errol; Beal, Jennifer; Chen, Yi; Timme, Ruth; Doyle, Matthew; Fields, Angela; Brown, Eric; Allard, Marc] US FDA, College Pk, MD USA.
[Tillman, Glenn; Simmons, Mustafa; Wasilenko, Jamie] US Food Safety & Inspect Serv, USDA, Athens, GA USA.
[Defibaugh-Chavez, Stephanie] US Food Safety & Inspect Serv, USDA, Washington, DC 20250 USA.
[Kubota, Kristy] Assoc Publ Hlth Labs, Silver Spring, MD USA.
[Pouseele, Hannes] Appl Maths, Sint Martens Latem, Belgium.
[Klimke, William] Natl Inst Biotechnol Informat, NIH, Bethesda, MD USA.
RP Jackson, BR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA.
EM brjackson1@cdc.gov
FU CDC's Advanced Molecular Detection Initiative; CDC [U60HM000803]; FDA;
USDA-FSIS; National Institute for Biotechnology Information; NIH,
National Library of Medicine
FX This work was supported by CDC, including CDC's Advanced Molecular
Detection Initiative and Cooperative Agreement number U60HM000803; FDA;
USDA-FSIS; National Institute for Biotechnology Information; and the
Intramural Research Program of the NIH, National Library of Medicine. H.
P. is an employee of Applied Maths.
NR 30
TC 17
Z9 17
U1 16
U2 19
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2016
VL 63
IS 3
BP 380
EP 386
DI 10.1093/cid/ciw242
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DV8QP
UT WOS:000383201900014
PM 27090985
ER
EF